



Effective Health Care Program

Comparative Effectiveness Review
Number 36

Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Comparative Effectiveness Review

Number 36

Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2007-10064-I

Prepared by:

Minnesota Evidence-based Practice Center
Minneapolis, Minnesota

Investigators:

Tatyana Shamliyan, M.D., M.S.
Jean Wyman, Ph.D.
Robert L. Kane, M.D.

**AHRQ Publication No. 11(12)-EHC074-EF
April 2012**

This report is based on research conducted by the Minnesota Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHS 290-2007-10064-I). The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation: Shamliyan T, Wyman J, Kane RL. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Comparative Effectiveness Review No. 36. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. HHS 290-2007-10064-I.) AHRQ Publication No. 11(12)-EHC074-EF. Rockville, MD. Agency for Healthcare Research and Quality. April 2012. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Preface

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting Comparative Effectiveness Reviews (CERs) of medications, devices, and other relevant interventions, including strategies for how these items and services can best be organized, managed, and delivered.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm.

AHRQ expects that CERs will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. In addition, AHRQ is committed to presenting information in different formats so that consumers who make decisions about their own and their family's health can benefit from the evidence.

Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input. Comparative Effectiveness Reviews will be updated regularly.

We welcome comments on this CER. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director and Task Order Officer
Evidence-based Practice Program
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Acknowledgments

The authors gratefully acknowledge the following individuals for their contributions to this project. We would like to thank the librarians, Judy Stanke, M.A., and Delbert Reed, Ph.D., for their contributions to the literature search; Rema Ramakrishnan, M.P.H., and Shiyi Wang, M.D., for their assistance with the literature search and data abstraction; Jeannine Ouellette for her help in writing the report; Marilyn Eells for editing and formatting the report; and Nancy Russell, M.L.S., Yaminah Oliver, Christa Prodzinski, and Michele Rockne for assistance with data entry, quality control, and formatting tables. We would like to thank Dr. Trikalinos, M.D., Ph.D., and Dr. Rücker, PhD., for their statistical help in arcsine transformation of the data.

Key Informants

Alan M. Adelman, M.D., M.S.
Penn State University
Hershey, PA

Apostolos Panagiotis Dallas, M.D.
Carilion Roanoke Memorial Hospital
Roanoke, VA

Catherine DuBeau, M.D.
UMass Memorial Medical Center
Worcester, MA

Mary Forciea, M.D., FACP
University of Pennsylvania
Philadelphia, PA

Jessica Griffin, M.S.
Oregon Evidence-based Practice Center
Portland, OR

Leah Hole-Curry, J.D.
Washington Health Care Authority
Olympia, WA

Lore Joplin
Oregon Health & Science University
Portland, OR

Kay Mattson, M.S.W., M.P.H.
Oregon Health and Science University
Portland, OR

Diane Newman, R.N.C., M.S.N., CRNP
FAAN
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania

Ingrid Nygaard, M.D.
University of Utah School of Medicine
Salt Lake City, UT

Mary Patrick, R.N.
Department of Public Health & Human
Services
Helena, MT

Suzanne Pope, M.B.A.
American Urological Association
Linthicum, MD

Amir Qaseem, M.D., Ph.D., M.H.A., FACP
American College of Physicians
Philadelphia, PA

Kenneth G. Schellhase, M.D., M.P.H.
Medical College of Wisconsin
Milwaukee, WI

Paul Shekelle, M.D.
RAND Corporation
Santa Monica, CA

J. Christian Winters, M.D., FACS
LSU Health Sciences Center
Metairie, LA

Technical Expert Panel

In designing the study questions and methodology at the outset of this report, we consulted several technical and content experts. Broad expertise and perspectives are sought. Divergent and conflicted opinions are common and perceived as health scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, and/or methodologic approaches do not necessarily represent the views of individual technical and content experts.

Alan M. Adelman, M.D., M.S.
Penn State University
Hershey, PA

Amir Qaseem, M.D., Ph.D., M.H.A., FACP
American College of Physicians
Philadelphia, PA

Apostolos Panagiotis Dallas, M.D.
Carilion Roanoke Memorial Hospital
Roanoke, VA

Kenneth G. Schellhase, M.D., M.P.H.
Medical College of Wisconsin
Milwaukee, WI

Catherine DuBeau, M.D.
UMass Memorial Medical Center
Worcester, MA

Paul Shekelle, M.D.
RAND Corporation
Santa Monica, CA

Mary Forciea, M.D., FACP
University of Pennsylvania
Philadelphia, PA

J. Christian Winters, M.D., FACS
LSU Health Sciences Center
Metairie, LA

Leah Hole-Curry, J.D.
Washington Health Care Authority
Olympia, WA

Diane Newman, R.N.C., M.S.N., CRNP,
FAAN
University of Pennsylvania Medical Center
Philadelphia, PA

Ingrid Nygaard, M.D.
University of Utah School of Medicine
Salt Lake City, UT

Mary Patrick, R.N.
Department of Public Health & Human
Services
Helena, MT

Suzanne Pope, M.B.A.
American Urological Association
Linthicum, MD

Peer Reviewers

We considered peer reviewer comments on a preliminary draft of this report in the preparation of this final report. Synthesis of the scientific literature presented here does not necessarily represent the views of individual reviewers.

Matthew Barber, M.D.
Cleveland Clinic
Cleveland, OH

Eric Rovner, M.D. Medical University of
South Carolina
Charleston, SC

Sandra Engberg, Ph.D., R.N., CRNP
University of Pittsburgh
Pittsburgh, PA

David Thom, M.D. M.P.H., Ph.D.
San Francisco General Hospital
San Francisco, CA

Ingrid Nygaard, M.D.
University of Utah School of Medicine
Salt Lake City, UT

Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness

Structured Abstract

Objectives. Our objectives were to assess methods to diagnose urinary incontinence (UI) and monitor treatment effectiveness in community-dwelling adult women, and to assess clinical efficacy and comparative effectiveness of pharmacological and nonsurgical treatments for UI.

Data Sources. We searched major electronic bibliographic databases, the FDA (Food and Drug Administration) reviews, trial registries, and research grant databases up to December 30, 2011.

Review Methods. A systematic review of diagnostic studies and therapeutic randomized and nonrandomized studies published in English was performed to synthesize diagnostic accuracy; minimally clinically important differences in validated tools for diagnosing UI; and rates of continence, improvements in UI, and harms of examined treatments. We calculated pooled absolute risk differences to estimate the number needed to treat (NNT) to achieve continence or avoid harms with random effects models.

Results. From a total of 905 eligible references, 99 studies showed minimal diagnostic value of tests to distinguish urodynamic stress or urgency UI; 57 studies suggested specific ranges of improvement in UI frequency (based on voiding diaries) that women considered important, as well as the value of quality-of-life assessment with validated checklists or scales. Pretreatment urodynamic diagnoses were not associated with better predictions of nonsurgical treatment outcomes. Continence was achieved in one woman with urgency UI for every eight women treated with fesoterodine (NNT 8, 95 percent CI [confidence interval], 5 to 17), 12 with tolterodine (NNT=12, 95 percent CI, 8 to 25), nine with oxybutynin (NNT=9, 95 percent CI, 6 to 16), nine with solifenacin (NNT=9, 95 percent CI, 6 to 17), and nine with tiroprium (NNT=9, 95 percent CI, 7 to 12). Discontinuation of treatment due to adverse effects occurred in one woman for every 33 treated with fesoterodine (NNT=33, 95 percent CI, 18 to 102), 16 with oxybutynin (NNT=16, 95 percent CI, 8 to 86), 56 with tiroprium (NNT=56, 95 percent CI, 30 to 228), and 78 with solifenacin (NNT=78, 95 percent CI, 39 to 823). Discontinuation due to adverse effects occurred more often with fesoterodine or oxybutynin than with tolterodine. Continence was achieved in one woman for every three treated with pelvic floor muscle training (NNT=3, 95 percent CI, 2 to 5), six with pelvic floor muscle training combined with bladder training (NNT=6, 95 percent CI, 4 to 16), and six with intravaginal electrical stimulations (NNT=6, 95 percent CI, 4 to 16). Weight loss improved UI in obese women. Improvement in UI and quality of life were examined using different definitions, which hampered the synthesis of evidence. Evidence was insufficient from which to conclude prediction of treatment effects by age, race, baseline severity of UI, and comorbidities.

Conclusions. Clinical evaluation with validated tools for diagnosis of UI, its type, frequency, severity, and impact on quality of life informs nonsurgical treatment decisions. Women determine treatment satisfaction and success according to clinically important reductions in UI frequency as recorded in voiding diaries and with clinically important improvements on

condition-specific quality-of-life scales. Benefits from pelvic floor muscle training, bladder training, and electrical stimulation are large, and adverse effects are uncommon. Benefits from drugs are small. Drugs for urgency UI have comparable effectiveness. Evidence about long-term adherence to and safety of all available treatments is insufficient.

Contents

Executive Summary	ES-1
Introduction	1
Measuring Outcomes of UI Treatment	2
Methods	7
Input From Stakeholders	7
Literature Search Strategy and Eligibility Criteria	7
Search Strategy	7
Eligibility	8
Quality Assessment	9
Grading the Evidence for Each Key Question	10
Applicability	11
Data Extraction	11
Data Synthesis	11
Results	14
Study Flow	14
Key Question 1. What Constitutes an Adequate Diagnostic Evaluation in the Ambulatory Care Setting on Which To Base Treatment of Urinary Incontinence (UI)?	15
Diagnostic Evaluation for UI	16
Minimal Clinically Important Differences in Diagnostic Tools To Monitor Effectiveness of the Treatments	20
Association Between Methods of Diagnosis and Prediction of Patient Outcomes	22
Key Question 2. How Effective Is the Pharmacological Treatment of UI in Women?	44
Pharmacological Treatments for Stress UI	44
Pharmacological Treatments for Urgency UI	46
Comparative Effectiveness of Pharmacological Treatments	66
The Role of Patient Characteristics on Patient Outcomes With Pharmacological Treatments	82
Key Question 3. How Effective Is the Nonpharmacological Treatment of UI?	95
Efficacy of Nonpharmacological Treatments for Stress UI	95
Efficacy of Nonpharmacological Treatments for Urgency UI	100
Comparative Effectiveness of Nonpharmacological Treatments	103
Comparative Effectiveness of Nonpharmacological Treatments for Stress UI	104
Comparative Effectiveness of Nonpharmacological Treatments for Urgency UI	107
Comparative Effectiveness of Nonpharmacological Treatments for Mixed UI	107
Discussion	120
Key Findings	120
Diagnosis	120
Measuring Treatment Success	120
Pharmacological Treatments	120
Nonpharmacological Treatments	121
UI Diagnosis	121
UI Treatment	122
Future Research	124
References	130
Abbreviations	171

Tables

Table A. Diagnostic Value of the Test for Urinary Incontinence (UI) in Women (Pooled With Random Effects Models and Bivariate Pooling)	ES-19
Table B. Clinical Outcomes With Treatments for UI (Pooled With Random Effects Estimates From Head-to-Head RCTs).....	ES-21
Table 1. Definitions of Urinary Incontinence (UI) and Treatment Outcomes.....	5
Table 2. Overall Ranking of Evidence.....	10
Table 3. Diagnostic Value of the Test for UI in Women (Pooled With Random Effects Models and Bivariate Pooling)	24
Table 4. Predictive Value of Diagnostic Tests for Different Types of UI by Age Subgroups	36
Table 5. Diagnostic Tools To Assess Clinical Importance and Monitor Effectiveness of Treatments of UI.....	37
Table 6. Clinical Outcomes With Duloxetine Treatments (Pooled With Random Effects Estimates From Head-to-Head RCTs)	57
Table 7. Continence, Improvement in UI, Treatment Failure, and Adverse Effects With Pharmacological Interventions Compared to Placebo (Pooled With Random Effects Estimates From Head-to-Head RCTs)	59
Table 8. Rates of Adverse Effects After Drugs Vs. Placebo (Significant Differences Only, Pooled With Random Effects Estimates From Head-to-Head RCTs)	64
Table 9. Discontinuation Due to Adverse Effects With Pharmacological Treatments for Urgency UI (Pooled With Random Effects Estimates From Head-to-Head RCTs)	73
Table 10. Continence With Pharmacological Treatments for Urgency UI.....	74
Table 11. Continence With 60 Mg Once Daily of Trospium Vs. Placebo in Obese and Nonobese Adults With Overactive Bladder (Pooled Results From RCTs Using the WHO Criteria for Obesity)	95
Table 12. Continence With Nonpharmacological Treatments Compared to No Active Treatment (Pooled With Random Effects Estimates From Head-to-Head RCTs).....	113
Table 13. Improvement in Severity of Incontinence and Quality of Life With Nonpharmacological Treatments Compared to No Active Treatment	114
Table 14. Continence With Nonpharmacological Treatments (Insufficient Evidence).....	115
Table 15. Continence Rates Compared Between Nonpharmacological Treatments (Pooled With Random Effects Estimates From Head-to-Head RCTs)	117
Table 16. Continence With Pharmacological Treatments Compared to Nonpharmacological Treatments or Combined Modalities	119
Table 17. Conclusions About Diagnosis of UI in Women	125
Table 18. Conclusions About Management of UI in Women	126
Table 19. Future Research Recommendations.....	128

Figures

Figure 1. Analytic Framework of Diagnosis and Comparative Effectiveness of Treatments for Urinary Incontinence (UI) in Adult Women	7
Figure 2. Study Flow.....	15
Figure 3. Accuracy of Diagnostic Methods for Female UI (Pooled With Random Effects Model Results)	34
Figure 4. Diagnostic Odds Ratio of Diagnostic Methods for Female UI (Pooled With Random Effects Model Results).....	35

Figure 5. Comparative Effectiveness of Oxybutynin Vs. Tolterodine (Pooled Results From Individual RCTs).....	75
Figure 6. Continence With Drugs for Overactive Bladder When Compared to Placebo (Pooled With Random Effects Estimates From Head-to-Head RCTs)	76
Figure 7. Continence Rates (%) With Drugs Vs. Placebo (Pooled Results From RCTs).....	77
Figure 8. Discontinuation of Treatments Due to Adverse Effects (%) With Drugs Vs. Placebo (Pooled Results From RCTs).....	78
Figure 9. Dry Mouth Rates (%) With Drugs Vs. Placebo (Pooled Results From RCTs).....	79
Figure 10. Rates (%) of the Most Common (>10%) Adverse Effects With Drugs Vs. Placebo (Pooled Results From RCTs).....	80
Figure 11. Treatment Persistence During 1 Year of Followup of the Drugs for UI.....	81
Figure 12. Clinical Outcomes With Duloxetine Vs. Placebo in Age Subgroups (Pooled Analysis of Individual Data on Women From Four RCTs).....	86
Figure 13. Urinary Continence With Solifenacin When Compared to Placebo (Pooled Analysis of Individual Patient Data From Four RCTs)	87
Figure 14. Clinical Outcomes With Tolterodine Vs. Placebo in Age Subgroups (Individual RCTs).....	88
Figure 15. Clinical Outcomes With Duloxetine in Racial Subgroups of Women With Stress UI, DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic Populations)	89
Figure 16. Continence With Solifenacin Compared to Placebo in Patients With Mixed or Pure Urgency UI (Pooled Analyses of Individual Patient Data).....	90
Figure 17. Complete Continence With Tolterodine, Extended Release of 4 Mg/Day Vs. Placebo in Groups With Different Baseline Frequency UI (Episodes/Week).....	91
Figure 18. Adverse Effects of Fesoterodine Compared to Placebo in Subgroups With Different Baseline Frequency of Urgency UI (Pooled Analysis of Four RCTs).....	92
Figure 19. Continence With Solifenacin Vs. Placebo in Subgroup by Response to the Previous Treatment With Antimuscarinic Medications (Pooled Analysis of RCT).....	93
Figure 20. Patient Global Impression of Improvement Rating as “Better” With Duloxetine When Compared to Placebo in Subgroups With Different Comorbidity Status (Duloxetine Urinary Incontinence Study Group).....	94
Figure 21. Continence With Nonpharmacological Treatments for UI When Compared to No Active Treatment (Pooled With Random Effects Estimates From Head-to-Head RCTs).....	118

Appendixes

- Appendix A. Search Strings
- Appendix B. Excluded Studies
- Appendix C. Analysis of Results From Ongoing Studies
- Appendix D. Analytical Framework
- Appendix E. Abstraction Forms
- Appendix F. Evidence Tables and Evidence Figures

Executive Summary

Background

Urinary incontinence (UI) is the involuntary loss of urine.¹ About 25 percent of young women,² 44 to 57 percent of middle-aged and postmenopausal women,³ and about 75 percent of older women experience some involuntary urine loss.⁴ UI can affect women's physical, psychological, and social well-being, and sometimes imposes significant lifestyle restrictions. The effects of UI range from slightly bothersome to debilitating.

The cost of incontinence care in the United States averaged \$19.5 billion in 2004.⁵ Six percent of nursing home admissions of older women are attributable to UI,⁵ and by one estimate, the annualized cost of women's nursing home admissions due to UI was \$3 billion.⁶

Nonpharmacological therapies target strengthening the pelvic floor and changing behaviors that influence bladder function, whereas pharmacological therapies address innervating the bladder and sphincter. The etiology of incontinence is multifactorial; risk factors include age, pregnancy, pelvic floor trauma after vaginal delivery, menopause, hysterectomy, obesity, urinary tract infections, functional and/or cognitive impairment, chronic cough, and constipation.⁷ Assessments of women complaining of UI begin with exclusion of underlying causes such as pelvic organ prolapse, urinary tract infection, and poor bladder emptying,⁸ all of which are beyond the scope of this review, as is neurogenic UI associated with spinal cord injury or stroke.⁹ We focus specifically on women with stress UI associated with sphincter function, and with urgency UI, often associated with overactive bladder (Table 1 in the full report).

Incontinence types are distinguished by their baseline mechanisms. Stress incontinence is associated with impaired sphincter function, and results in an inability to retain urine during coughing or sneezing.⁹ Urgency incontinence is defined as involuntary loss of urine associated with the sensation of a sudden compelling urge to void that is difficult to defer.⁹ Mixed UI is the term applied when both stress and urgency UI are present. These definitions reflect the consensus definitions developed by the International Urogynecological Association/International Continence Society.⁹ Overactive bladder is defined as urinary urgency with or without incontinence, usually accompanied by frequency and nocturia (the need to urinate at night).⁹ Approximately one-third of women with overactive bladder also experience urgency UI.

The types of UI imply different attendant risk factors and recommended treatments; however, UI etiology is frequently mixed.⁸ Stress UI is more common in younger women in association with pelvic floor trauma and uterine prolapse, both of which are often related to vaginal delivery and may require surgical treatments.⁷ Urgency and mixed UI are more common in older women in association with overactive bladders with or without sphincter dysfunction.^{1,7}

Although UI can be diagnosed based on patients' reports of involuntary urine leakage,⁷ researchers have also proposed clinical methods for objective diagnosis of different UI types. Urodynamic diagnosis of pure stress UI without detrusor overactivity has demonstrated usefulness for women undergoing surgery for stress UI.⁹ Diagnostic studies use multichannel urodynamics as a reference standard test to compare with noninvasive tests applicable to ambulatory care. However, researchers disagree on whether urodynamic examination represents the gold standard for UI diagnosis.⁸ Furthermore, urodynamic examination is not possible in ambulatory primary care. Previously published systematic reviews have reported a weak association between urodynamic test results and self-reported symptoms,¹⁰ but these reviews did not focus on the most appropriate methods to distinguish different types of UI in ambulatory care

settings. The role of invasive diagnostic methods in predicting which patients will benefit from specific treatments for UI remains unclear.

Standard UI treatments for women include lifestyle changes, pelvic floor muscle training, and, for predominant stress UI, surgical treatments.¹ In addition, several drugs have been approved for adults with overactive bladder, with or without urgency UI.¹ Clinical interventions to reduce the frequency of UI episodes in women have been extensively reviewed in recent years,^{8,11} but the reviews did not emphasize continence or women's perceptions of treatment success and satisfaction. Continence (complete voluntary control of the bladder) has been considered a primary goal in UI treatment^{8,12} and is the most important outcome associated with quality of life in women with UI;¹³ yet, it is rarely examined as a primary outcome in syntheses of evidence.¹⁴ Thus, we focus on continence and quality of life as primary outcomes for this Comparative Effectiveness Review.

While definitions of continence are similar, the definitions most commonly applied to improvement in UI vary and include different degrees of change in frequency and severity of symptoms.¹⁵ Furthermore, improvement in UI has been viewed very differently by women and by researchers. Women define improvement according to reduced lifestyle restrictions or improved overall perception of bladder symptoms, especially resolution of urine leakage, whereas researchers define improvement as a decrease in the amount of lost urine during pad tests, or any statistically significant decrease in the frequency of UI episodes.¹⁵ Treatments for overactive bladder aim to decrease the frequency and intensity of urgency sensations, as well as the frequency of urgency UI episodes. Previous reviews of treatments for overactive bladder have considered clinical success as any statistically significant decrease in the frequency of UI episodes and voiding, irrespective of whether women perceived improvement.¹⁴ Measurement of treatment outcomes should be patient centered and based on factors important to women, rather than on the results of invasive tests.¹² Thus, treatment success and failure should be evaluated according to what women report in validated questionnaires or scales. Ultimately, discussions of UI are complicated by the wide variety of measures used to describe the problem and its treatment outcomes. This review examines improvement thresholds of clinical importance in validated scales and checklists that can be applied to judge UI treatment success according to women's own perceptions.

This report synthesizes published evidence about diagnosis and management of UI in adult women. We focused on adult women in ambulatory care settings and on nonsurgical nonpharmacological treatments and pharmacological agents available in the United States. This report is intended as a companion piece to an earlier Evidence-based Practice Center report⁷ that examined a wide range of treatment alternatives, including surgery. We focus on techniques appropriate to primary care ambulatory practice and nonsurgical interventions for women with refractory UI.

Our report also addresses the role of urodynamic testing, which is not typically performed in primary care. We include it here primarily as background information for primary care practitioners, and because it raises a conundrum. As we have emphasized, the primary outcome for UI should be patient-centered reports of the UI experience, especially the presence or absence of UI. Although we typically think of physiological testing as more objective than patient reports, these results are, at best, akin to intermediate outcomes. In the diagnostic context, physiological testing can inform in one of three ways: (1) establishing a diagnosis, (2) determining an etiology with therapeutic implications, and (3) generating a prognosis. In the case of UI, it is unclear whether physiological measures represent a gold standard against which

other measures can be compared, or whether they should be viewed as information that may predict key patient-centered outcomes. Hence, we may be more interested in levels of agreement between physiological measures and patient outcomes but hard pressed to interpret differences between them. We examine the role of urodynamic testing in diagnosing and treating UI to provide insight into this conundrum.

Our systematic review is intended to help clinicians, consumers, and policymakers make clinical recommendations and informed decisions based on synthesized evidence and other relevant factors.

Objectives

We present a comprehensive synthesis of evidence regarding valid methods to diagnose UI in adult women and to monitor treatment benefits and harms. We evaluated the clinical efficacy and comparative effectiveness of pharmacological and nonsurgical treatments for UI in adult women following the principles from the Methods Guide for Effectiveness and Comparative Effectiveness Reviews from the Agency for Healthcare Research and Quality (AHRQ) (www.effectivehealthcare.ahrq.gov). We examined the following questions:

Key Question 1. What constitutes an adequate diagnostic evaluation for women in the ambulatory care setting on which to base treatment of urinary incontinence?

1. What are the diagnostic values of different methods—questionnaires, checklists, scales, self-reports of UI during a clinical examination, pad tests, and ultrasound—when compared with multichannel urodynamics?
2. What are the diagnostic values of different methods—questionnaires, checklists, scales, self-reports of UI during a clinical examination, pad tests, and ultrasound—when compared with a bladder diary?
3. What are the diagnostic values of the methods listed above for different types of UI, including stress, urgency, and mixed incontinence?
4. What is the association between patient outcomes (continence, severity and frequency of UI, quality of life) and UI diagnostic methods?

Key Question 2. How effective is the pharmacological treatment of UI in women?

1. How do pharmacologic treatments affect continence, severity and frequency of UI, and quality of life when compared with no active treatment or with combined treatment modalities?
2. What is the comparative effectiveness of pharmacological treatments when compared with each other or with nonpharmacological treatments of UI?
3. What are the harms from pharmacological treatments when compared with no active treatment?
4. What are the harms from pharmacological treatments when compared with each other or with nonpharmacological treatments of UI?
5. Which patient characteristics, including age, type of UI, severity of UI, baseline disease that affects UI, adherence to treatment recommendations, and comorbidities, can modify the effects of the pharmacological treatments on patient outcomes, including continence, quality of life, and harms?

Key Question 3. How effective is the nonpharmacological treatment of UI in women?

1. How do nonpharmacological treatments affect incontinence, UI severity and frequency, and quality of life when compared with no active treatment?
2. How do combined modalities of nonpharmacological treatments with drugs affect incontinence, UI severity and frequency, and quality of life when compared with no active treatment or with monotherapy?
3. What is the comparative effectiveness of nonpharmacological treatments when compared with each other?
4. What are the harms from nonpharmacological treatments when compared with no active treatment?
5. What are the harms from nonpharmacological treatments when compared with each other?
6. Which patient characteristics, including age, type of UI, severity of UI, baseline disease that affects UI, adherence to treatment recommendations, and comorbidities, can modify the effects of the nonpharmacological treatments on patient outcomes, including continence, quality of life, and harms?

Methods

Input From Stakeholders

We developed research questions and an analytic framework after discussions with key informants and technical experts. Research questions for the systematic review were posted for public comment, based on which we identified interventions eligible for this review. Stakeholders recommended a focus on patient-centered outcomes and interventions most relevant for ambulatory care and not evaluated in previous systematic reviews. Stakeholders also recommended reviewing nonsurgical interventions relevant to women with refractory UI. Comprehensive information about all nonsurgical treatment choices can lead to evidence-based referral practices for women with refractory UI.

Candidates to serve as key informants, technical experts, and peer reviewers were approved by the Task Order Officer from AHRQ after disclosure of conflicts of interest. The protocol was developed with input from the Technical Expert Panel.

Data Sources and Selection

We sought studies from MEDLINE[®] via OVID and via PubMed[®], the Cochrane Library, SCIRUS, Google Scholar, other databases, and manual searches of reference lists from systematic reviews. We identified studies published in English from 1990 through December 30, 2011.

Study Selection

Three investigators independently determined the eligibility of the studies. For Key Question 1, we included studies that evaluated different methods to diagnose UI in women that are applicable to ambulatory care settings. Index methods that are applicable to ambulatory care settings were compared in eligible studies with urodynamic or clinical diagnosis of UI made by investigators in specialized clinics.

For Key Questions 2 and 3, we included randomized controlled trials (RCTs) that combined men and women if they reported outcomes in women separately or included more than 75 percent women. We excluded studies of men, children, or residents of long-term care facilities. We excluded studies of surgical treatments for UI or urogenital prolapse and studies of drugs not available in the United States. We analyzed harms regardless of how authors perceived the causality of treatments. We included observational studies with adjusted treatment estimates. We included observational studies of treatments not examined in RCTs.

Data Extraction

Evaluations of the studies, data extraction, and quality control were conducted by four researchers using a standardized form. We abstracted minimum datasets for diagnostic and therapeutic studies. We abstracted inclusion of minorities, inclusion of women who failed prior therapy for UI, inclusion of mixed UI, baseline daily UI, and presence of urogenital prolapse or hysterectomy in female participants. We focused on urgency UI in women with overactive bladder and did not analyze urgency, voiding frequency, or nocturia.

Quality Assessment

We evaluated the quality of studies and classified them by their designs. We evaluated studies for Key Question 1 with predefined criteria for assessing the quality of the diagnostic accuracy of studies. We evaluated the quality of therapeutic studies using predefined criteria to assess the risk of bias, which included randomization, adequacy of randomization and allocation concealment, masking of the treatment status, and intention-to-treat analyses. We examined sponsorship and conflict of interest but did not downgrade quality using this information. We incorporated quality in the synthesis of evidence, conducting meta-regression, subgroup, and sensitivity analysis for each quality criterion rather than for the overall quality score. Well-designed RCTs are believed to have a low risk of bias. We defined studies as having a medium or high risk of bias if one or more quality criteria were not met.

Applicability of the population was estimated by evaluating the selection of women in observational studies and clinical trials. For each study, we examined settings, including ambulatory care or specialized clinics, recruitment in the clinical settings or in the community, inclusion age and type of UI, and exclusion criteria.

Data Synthesis and Analysis

For Key Question 1, results of individual studies were summarized to analyze sensitivity, specificity, predictive values, diagnostic odds ratios, and predictive likelihood ratios for correct diagnosis of any, stress, and urgency UI. We focused on the predictive likelihood ratios of UI in women examined with index tests when compared to women who had urodynamic or clinical diagnosis. Ratios of 1 indicated that the tests likely do not provide accurate UI diagnosis. Ratios of more than 10 provided large and often conclusive increases in the likelihood of UI. We pooled diagnostic test data with random effects models using an inverse variance weighting method with Meta-Analyst software. Random effects meta-analyses incorporate heterogeneity by assuming a normal distribution of underlying effects. In cases of heterogeneity, we used bivariate pooling methods.

Following guidelines and recommendations from key informants and members of our Technical Expert Panel, we focused on patient-centered outcomes, including continence,

improvement in UI, quality of life, adverse effects, and discontinuation due to adverse effects. Voiding frequency in women with overactive bladder had been reviewed previously and was outside of our scope. The methods to assess harms were not assessed for validity. For Key Questions 2 and 3, we calculated relative risk, absolute risk differences, number needed to treat, and the number of events attributable to active treatment per 1,000 persons treated for binary outcomes. We assessed missing data across studies, including loss to followup and dropout patterns, and forced intention-to-treat analyses using the number of randomized subjects for all calculations.

Meta-analysis was conducted when clinical populations, interventions, and outcomes were deemed sufficiently similar. We chose the random-effects inverse variance weights model to incorporate in the pooled analysis differences across trials in patient populations, baseline rates of the outcomes, dosage of drugs, and other factors. We analyzed adverse effects with drugs for urgency UI using double arcsine transformations of the event rates. We examined consistency in results across studies with Chi square tests and I square statistics. Using a standard preplanned algorithm, we explored heterogeneity with meta-regression, subgroup, and sensitivity analysis by clinical diversity, treatment dose and duration, and quality criteria of individual studies, and whether conflict of interest was disclosed by study authors. When exploring heterogeneity, we did not use subject-level variables to avoid an ecological fallacy. We calculated Bayesian odds ratios with 95 percent credible intervals. All calculations were performed using Meta-Analyst and STATA (Statistics/Data analysis, 10.1) software at 95 percent confidence limits. We assumed publication bias, and did conduct formal statistical tests.

We assessed strength of evidence and judged it according to the domains of risk of bias, consistency, directness, and precision for each major outcome. We defined evidence as strong when several well-designed RCTs with a low risk of bias demonstrated consistent treatment effects. Significant dose-response association or large magnitude of treatment effects increased the level of evidence. We defined evidence as insufficient when only a single study examined treatment effects or associations.

Results

We identified and retrieved 5,185 references. We included 905 references for this review.

Diagnosis of UI

For Key Question 1, 99 studies of 81,043 women provided information on different methods for diagnosing UI. Described use of urodynamic testing as a reference standard test was very similar across the studies. Diagnostic methods to establish a clinical diagnosis of UI were described with different levels of detail and included patient history, physical and pelvic examination, urine culture, and other instrumental measures.

The majority of studies demonstrated that the tests had only small diagnostic value in distinguishing women with urodynamic stress or urgency UI (Table A). The diagnostic values were similar after random effects versus bivariate pooling methods. The quality of the studies did not explain statistical heterogeneity in pooled estimates.

Measuring Treatment Success

Urodynamic evaluation, which was used as a reference method in many diagnostic studies, detects the presence of UI but not the frequency and severity of UI episodes. Validated tools to

measure UI treatment success based on meaningful changes in symptoms and quality of life for women include the Incontinence Severity Index; Patient Global Impression of Improvement and of Severity; Patient Perception of Bladder Condition; Urogenital Distress Inventory; Bladder Self-Assessment Questionnaire; International Consultation on Incontinence Modular Questionnaire-SF; Incontinence Impact Questionnaire; Urinary Incontinence-Specific Quality of Life Instrument; King's Health Questionnaire; and Protection, Amount, Frequency, Adjustment, Body Image assessment tool.

A reduction in UI episode frequency assessed with a 3- to 7-day diary was the most common primary outcome in the included RCTs. Importantly, women with daily stress UI perceived important clinical benefit at reductions of approximately 50 percent and important incremental clinical value at reductions of 75 percent and 90 to 100 percent. Women reported improved quality of life and clinical success only when they experienced a greater than 70 percent reduction in urinary episode frequency assessed by a voiding diary. Smaller decreases (20 to 40 percent) in UI episode frequency were not clinically important when the results from a voiding diary were analyzed in association with the validated Incontinence Quality of Life questionnaire. The quality-of-life impact was similar for stress UI episode reductions of >40 percent to <70 percent. In the case of women with persistent urge, stress, or mixed UI, more than 60 percent reported complete treatment satisfaction on the Global Perception of Improvement and Incontinence Impact Questionnaire when they experienced more than 70 percent reduction in UI episodes according to voiding diaries.

The few RCTs that analyzed differences in outcomes depending on baseline urodynamic diagnosis versus self-reported symptoms of stress, urgency, or mixed UI suggested no advantage with urodynamic diagnosis. However, baseline urodynamic evaluation resulted in better prediction of harms from surgery for stress UI refractory to conservative treatments.

Evidence was insufficient for the superiority of urodynamic evaluation's prediction of nonsurgical treatment outcomes compared to diagnosis based on self-reported symptoms. Women's perceptions of treatment success depend upon clinically important differences in their voiding diaries, scales, questionnaires, and impressions of global improvement.

Efficacy of Pharmacological Treatments

We synthesized the evidence of efficacy and comparative effectiveness of the drugs for predominant stress UI (including topical estrogen and serotonin-noradrenalin uptake inhibitors) and drugs for overactive bladder. Table B demonstrates how many studies were examined for each outcome, how many subjects participated in the studies, and what percentage of subjects experienced the outcomes. The last column indicates our level of confidence that the evidence reflects the true effect of the treatment and that future research is unlikely to change the estimate of effect (Appendix Table F1 in the full report). Drugs were more effective than placebo in achieving continence and improving UI, but the magnitude of effect was low. The absolute risk difference in continence was less than 20 percent for all drugs. Pharmacological treatments resulted in fewer than 200 cases of continence attributable to the drugs per 1,000 treated. The studies had good quality with low risk of bias. Individual quality criteria and disclosure of conflict of interest were not associated with differences in the results.

Stress UI

Estrogen

Individual RCTs indicated greater continence and improvement in UI with vaginal estrogen formulations and worsening of UI with transdermal patches.

Duloxetine

Duloxetine did not resolve stress UI when compared to placebo (Table B). The risk of adverse effects was significantly higher with duloxetine than with placebo. Duloxetine resulted in improved UI in 75-140 women per 1,000 treated, while 129 women per 1,000 treated stopped taking duloxetine because of adverse effects.

Urgency UI

Oxybutynin

Oxybutynin increased continence rates and improved UI more often than placebo but also resulted in treatment discontinuation due to adverse effects. Oxybutynin resolved UI in 114 women per 1,000 treated (95% CI, 64 to 163), while 63 women per 1,000 treated (95% CI, 12 to 127) discontinued oxybutynin because of adverse effects.

Tolterodine

Tolterodine increased continence rates and significantly improved UI more often than placebo. Tolterodine resolved UI in 85 women per 1,000 treated (95% CI, 40 to 129), while 83 women per 1,000 treated (95% CI, 47 to 120) experienced adverse effects. Discontinuation of treatment due to adverse effects did not differ between tolterodine and placebo.

Darifenacin

Darifenacin significantly improved urgency UI and several domains of quality of life more often than placebo. Darifenacin improved UI in 117 women per 1,000 treated (95% CI 57 to 177), while 190 women per 1,000 treated (95% CI, 118 to 260) experienced adverse effects. Treatment discontinuation rates due to adverse effects did not differ between darifenacin and placebo.

Solifenacin

Solifenacin increased continence rates; higher doses resulted in greater benefits. Treatment discontinuation due to adverse effects was more common with solifenacin than with placebo. Solifenacin resolved UI in 107 women per 1,000 treated (95% CI, 58 to 156), while 13 women per 1,000 (95% CI, 1 to 26) discontinued treatment because of adverse effects.

Fesoterodine

Fesoterodine increased continence rates. Significant improvement in UI with fesoterodine compared to placebo was dose responsive. Fesoterodine resulted in higher rates of adverse effects and discontinuation of treatment due to adverse effects than placebo. Fesoterodine resolved UI in 130 women per 1,000 treated (95 percent CI, 58 to 202), while 31 women per 1,000 (95 percent CI, 10 to 56) stopped treatment due to adverse effects.

Trospium

Trospium increased continence rates more often than placebo. Risk of adverse effects was greater with trospium than with placebo. Trospium resolved UI in 114 women per 1,000 treated (95% CI, 83 to 144), while 18 women per 1,000 (95% CI, 4 to 33) stopped treatment because of harmful adverse effects.

Comparative Effectiveness of Pharmacological Treatments

Evidence of the comparative effectiveness of different drugs was insufficient for the majority of comparisons. Oxybutynin and tolterodine had the same benefits, but tolterodine was safer. The numbers needed to treat (NNT) to achieve continence in one woman were similar across drugs. Treatment discontinuation due to adverse effects was greater than with placebo for all drugs, excluding darifenacin and tolterodine; NNT to achieve discontinuation due to adverse effects was highest with solifenacin (NNT=78) and lowest with oxybutynin (NNT=16). Several retrospective observational studies analyzed the long-term comparative effectiveness and safety of pharmacological treatments for UI. The evidence-based cost utility analysis reported that more than half of patients stop taking drugs for UI after 1 year of treatment. The lowest rates of treatment discontinuation were with 5 mg of solifenacin.¹⁶

Role of Patient Characteristics on Outcomes of Pharmacological Treatments

Age

Treatment response was similar across age groups. Solifenacin increased continence rates more often than placebo, regardless of age.

Oxybutynin, trospium, and darifenacin improved UI in older women. Oxybutynin reduced UI frequency and produced subjective benefits compared to placebo in frail community-dwelling older people. Darifenacin improved UI when compared to placebo in older women. The drug needed to be given to eight older patients to achieve more than a 50 percent reduction in UI episodes in one person. Cognitive function changes did not differ between darifenacin and placebo in short-term (2-week) treatment. Trospium improved UI and quality of life in older subjects with overactive bladder. Solifenacin caused serious adverse effects less often than oxybutynin in older patients, with no differences between the drugs in younger patients.

Race

We found limited evidence about treatment responses in race subgroups. Only one study, of duloxetine, examined clinical outcomes in different race groups. Evidence was inconclusive about racial differences in the treatment effects of duloxetine in women with stress UI.

Comorbidities

One RCT examined the role of comorbidities. Duloxetine was no better than placebo in women with depression, diabetes, and chronic lung diseases. Trospium was effective in resolving UI regardless of body mass index in obese and normal weight women.

Baseline UI

Evidence was limited from which to conclude any differences in benefits by baseline frequency and severity of UI. Studies found no differences in outcomes between tolterodine and solifenacin in subjects with baseline mixed or pure urgency UI. Subjects with mixed UI may require a larger dose and longer treatment than women with urgency UI to achieve clinical benefits from solifenacin. Inclusion of women with mixed UI did not significantly modify the treatment benefits from oxybutynin and solifenacin across the studies in meta-regression and subgroup analyses.

The baseline frequency of UI did not dramatically modify the effects of the drugs on clinical outcomes. Subjects with more frequent UI had slightly greater benefits with solifenacin or fesoterodine than with placebo. In contrast, trospium was better than placebo at resolving UI only in subjects with fewer than five UI episodes per day. Trospium did not resolve UI in subgroups with more than five episodes of UI per day (relative risk [RR] 1.2, 95% CI, 0.93 to 1.56).

Prior Treatment Response

Solifenacin was effective regardless of the response to previous treatments; however, poor responders did not benefit from increasing the dose of the drug. We could not examine differences in the treatment response to other drugs among those who failed prior treatments because the studies provided neither subgroup analyses within trials nor consistent reporting of the percentage of nonresponders for subgroup analyses across the trials.

Concomitant Treatments

Trospium reduced the number of urgency UI episodes irrespective of concomitant medications. Adverse effects were more common in those taking seven or more concomitant medications.

Efficacy of Nonpharmacological Treatments

Nonpharmacological treatments were better than no active treatment in achieving continence and improving UI, according to RCTs (Table B). The magnitude of effect was large. The majority of the studies included women with mixed UI. Inclusion of women with mixed UI did not dramatically modify the treatment effects in meta-regression and subgroup analyses. We examined the effects of the interventions on predominant stress or urgency UI when the authors reported that information. A summary of the evidence of effectiveness of all treatments, including strength of evidence, is found in Table B.

Stress UI

Pelvic Floor Muscle Training

Pelvic floor muscle training (PFMT) increased continence rates and improved UI more often than usual care. PFMT combined with bladder training increased continence rates and improved mixed UI. PFMT with biofeedback improved UI.

Vaginal Cones

Evidence was insufficient from which to draw valid conclusions. Uncontrolled high risk of bias studies of other intravaginal and intraurethral devices demonstrated that they improved UI but also resulted in high discontinuation rates and adverse effects.

Intravaginal Electrical Stimulation

Intravaginal electrical stimulation increased continence rates and improved UI more often than sham stimulation.

Magnetic Stimulation

Magnetic stimulation improved UI but did not increase continence more than sham stimulation.

Urgency UI

Bladder Training

Bladder training improved UI when compared to usual care.

Percutaneous Tibial Nerve Stimulation

Percutaneous tibial nerve stimulation improved UI. Individual RCTs indicated no difference in adverse effects and treatment discontinuation with active or sham stimulation.

Mixed UI

Specialized Continence Services

Studies indicated no consistently greater benefits for continence or improvement of UI with continence services implemented by specialized providers compared to usual care. Comparison across studies was difficult because of the variety of interventions that constituted complex continence services.

Weight Loss

Weight loss and exercise improved UI in obese women without evident harms.

Comparative Effectiveness of Nonpharmacological Treatments

Clinical outcomes of one nonpharmacological treatment versus another were reported in 54 RCTs, but these trials rarely compared the same treatment effects, which decreased the strength of evidence to low.

We found no differences in UI between supervised PFMT combined with bladder training and self-administered PFMT. Continence did not differ between bladder training combined with PFMT and bladder training alone.

Indirect comparison indicated the comparable effectiveness of nonpharmacological treatments on continence. Cases of continence achieved per 1,000 treated were 299 for PFMT, 162 for electrical stimulation, and 166 for PFMT combined with bladder training. Rates of continence were comparable with different treatments: 38 percent of women became continent with PFMT, 23 percent became continent with electrical stimulation, and 21 percent became continent with PFMT combined with bladder training.

Discussion

Our findings agree with those of previously published systematic reviews of diagnosis and treatment of UI by AHRQ, the Cochrane Collaborative Group, and the International Consultation on Incontinence. Our report offers a comprehensive analysis of patient-centered outcomes, including continence, improvement in UI, and harms from nonsurgical treatments for female UI that are available in the United States.

Diagnosis of predominant stress or urgency UI in ambulatory care settings includes clinical history and evaluation, voiding diary, and validated scales.¹⁷ Urodynamic diagnosis is more invasive and not applicable to ambulatory settings. Although it more sensitively distinguishes UI mechanisms, including detrusor overactivity, this added sensitivity did not better predict treatment benefits for patients undergoing nonsurgical UI treatments. It did, however, better predict harms from surgery for women with refractory UI by identifying women with detrusor overactivity, which is associated with greater risk of postsurgical urgency UI, an important quality-of-life outcome.¹⁸ Studies of pharmacological treatments for urgency UI included women treated surgically for stress UI but did not distinguish treatment effects within this subpopulation.¹⁹

Outcome evaluations for treatments of female UI address issues that women consider important: continence, 50 to 70 percent or more reduction in UI episode frequency, meaningful changes in scales measuring quality of life, and treatment satisfaction.²⁰ However, previous reviews of drugs for overactive bladder have focused on other outcomes, such as reduction in frequency of both urgency micturition and urgency UI episodes.^{14,21,22} The majority of drug RCTs were designed to test differences in the frequency of UI episodes. Medical and statistical reviews by the Food and Drug Administration also focused on reduction in the frequency of UI. Based on women's definitions of clinical success, we focused on clinical outcomes, including continence and quality of life.

Policymakers should consider patient-centered outcomes when making regulatory decisions. Research based on patient-centered outcomes provides patients and clinicians the necessary information for effective and informed decisions about health care services.²³ Prescription drugs for UI all demonstrated more effectiveness than placebo in some women. The magnitude of the association was not strong, with fewer than 200 attributable cases of continence per 1,000 patients treated. Adverse effects were common with all drugs and varied between the drugs. Nonpharmacological treatments for UI showed clinically significant benefit with a large magnitude of effect and very few adverse effects.

Direct evidence for the comparative effectiveness of nonpharmacological treatments and drugs was insufficient. However, the few RCTs that compared clinical outcomes between nonpharmacological treatments and drugs found similar effectiveness but better safety with nondrug interventions. This finding is significant, considering that side effects from drugs were common and frequently bothersome enough to negatively affect treatment compliance and continuation. The synthesis of evidence was hampered by differences in definitions of improvement in UI, quality of life, and treatment-related adverse effects. Valid comparisons of benefits and harms with different treatments were possible only for studies that used similar definitions of the outcomes.

While the comparative safety of UI drugs could inform clinical decisions, information on long-term comparative safety was rarely available in RCTs, despite high discontinuation rates suggesting that there were adverse effects. Continuous monitoring of the drugs' adverse effects in clinical practice could provide information about long-term comparative safety. For example,

continuous prescription-event monitoring as a part of postmarketing surveillance has provided valuable information about the unfavorable long-term effects of tolterodine, which has been shown to have a significantly higher risk of hallucinations than 10 drugs of other therapeutic classes.²⁴

Additionally, RCTs have not yet examined the role of concurrent treatments, but postmarketing surveillance could address the long-term safety of UI drugs when combined with other medications. For instance, relative risks of ventricular arrhythmias (adjusted RR 5.5, 95 percent CI, 1.3 to 22.3) or sudden death (adjusted RR 21.5, 95 percent CI, 5.2 to 88.3) were very high among older people using UI medications in combination with antihistamine/cytochrome inhibitors.²⁵

Meanwhile, very few studies provided evidence for individualized treatment decisions. Evidence of aggregate treatment effects may not be applicable to individuals with specific characteristics.²⁶ An average treatment effect in a clinically diverse population may not reflect the actual effect for a specific group.²⁷ Yet few existing studies examined the role of clinical predictors of treatment failure and success in patient subpopulations.²⁸ Patient comorbidity and baseline severity of UI were associated with differences in treatment benefits. The direction and magnitude of the association varied. Benefits from solifenacin and fesoterodine were greater in those with more than two or three daily episodes of UI; trospium was not better than placebo in those with frequent baseline UI (>5 episodes/day). Which factors are associated with differences in harms remains unclear.

Adherence to UI treatments is poor. Treatment discontinuation due to adverse effects of drugs is common. Yet, very few studies have addressed adherence to treatment, pharmacological or nonpharmacological. Observational economic drug evaluations^{29,30} have demonstrated greater absolute rates of treatment discontinuation due to adverse effects or treatment failure than have been demonstrated in RCTs. One possible explanatory factor for poor adherence is that polypharmacy or previous use of the drugs for urinary tract infections was associated with adherence to the drugs for overactive bladder in California Medicaid program beneficiaries.³¹ Cost-effectiveness analyses^{29,32} that should incorporate comparative effectiveness, safety, and adherence to treatments were beyond the scope of our review. High discontinuation rates also apply to nonpharmacologic treatments such as PFMT and bladder training. Reasons for poor adherence are not well established.

The nonsurgical treatments included in this review are applicable to ambulatory care settings. Appropriately trained continence nurses and physical therapists can provide high quality UI care for women; women were satisfied with care provided by continence nurses.³³⁻³⁵ A large cross-sectional community survey by mail of women with UI in France, Germany, Spain, and the United Kingdom found that many women actually prefer to be treated for UI by primary care providers, despite easy access to specialized services.³⁶ However, adherence to evidence-based recommendations by ambulatory care providers is not satisfactory and should be improved.^{37,38}

The quality of most drug RCTs was good. The majority of drug studies were double blind with adequate randomization and clear reporting of planned intention-to-treat analysis. Benefits and harms with drugs did not differ by individual quality criteria. We concluded that there was a low risk of bias in the drug studies.

Most nonpharmacological RCTs had good quality. Baseline data demonstrated the adequacy of randomization in the majority of RCTs. Double or single blinding was reported in approximately half of the RCTs. The quality of the studies, including intention-to-treat analysis and adequacy of allocation concealment, did not demonstrate significant modification of the

association between treatments and patient outcomes. We concluded that there was a moderate risk of bias in the nonpharmacological studies.

Our review has limitations. We restricted our review to English-language studies published in journals, presented at scientific meetings, reviewed by the Food and Drug Administration,³⁹ or reported on the ClinicalTrials.gov Web site. Even after such an exhaustive review of evidence, we do not know how many funded and unregistered studies we missed in our review. Evidence was insufficient for individualized treatment recommendations by age, race, comorbidity, and baseline UI. Evidence was also insufficient regarding women whose prior treatments had failed. However, previous research has demonstrated that women with stress UI whose conservative treatments failed may benefit from a tension-free vaginal tape procedure.⁴⁰ For women with urgency UI whose conservative treatments failed, percutaneous tibial nerve stimulation,⁴¹ sacral neuromodulation,⁴² and botulinum toxin injections⁴³ may be of benefit. Invasive treatments, including midurethral slings, sacral nerve stimulation, and radiofrequency ablation, were beyond our scope. We were unable to explain why drug efficacy studies reported substantially different outcome rates for the same comparator placebo treatments. Therefore, we avoided making indirect comparisons of drugs never tested in head-to-head RCTs.

Our report has implications for future research. Such research should clarify which characteristics of women, including age, race, genitourinary characteristics, and comorbidities, are associated with greater treatment benefits and adherence and fewer adverse events. Future studies should assess treatment success with primary outcomes centered on women, including long-term continence, reduction of 50 to 70 percent or more in UI episodes, and clinically important improvement in scales of severity and quality of life. All harms should be analyzed, regardless of investigator judgment about possible association with tested treatments. Nonsurgical treatments for predominant stress UI are limited to PFMT, with very few ongoing studies of bulking agents and devices. Future research should explore new treatment options for women with stress UI. The results from all studies, including 25 closed and 124 ongoing registered studies, should be made available for future reviews of evidence. A comparison of different methods of delivery of nonpharmacological interventions—Internet-based, group-based, and self-management—is also a possible area of future research, with great applicability for ambulatory care populations. Future research should address which factors might increase adherence to UI treatments. Finally, the preventive effects of PFMT, bladder training, and electrical stimulation in premenopausal women should be examined, and future large well-designed head-to-head randomized trials should examine whether combined drug and nonpharmacological treatment modalities are superior to mono-drug therapy.

Key Findings

Diagnosis

- Clinical evaluation with validated tools for diagnosis of UI, its type, frequency, severity, and impact on quality of life informs nonsurgical treatment decisions.
- Compared with diagnosis by patients' symptom reports, multichannel urodynamics did not better predict which patients would benefit from nonsurgical treatments.

Measuring Treatment Success

- Women with daily stress UI perceived important clinical benefit from reductions of approximately 50 percent in UI frequency and important incremental clinical value from reductions of 75 percent and 90 to 100 percent.
- Women reported improved quality of life and clinical success only when they experienced a greater than 70 percent reduction in UI episode frequency assessed by a voiding diary.
- More than 60 percent of women with persistent urgency, stress, or mixed UI reported complete treatment satisfaction when they experienced more than 70 percent reduction of UI episodes. Validated tools have been used to assess threshold values of clinical importance for evaluating treatment success in women.

Pharmacological Treatments

- All anticholinergic medications were more effective than placebo in achieving continence and improving UI, but the degree of benefit was low for all drugs, with fewer than 200 cases of continence attributable to treatment per 1,000 patients treated (absolute risk difference with placebo <20 percent).
- Treatment benefits, including continence, were achieved with antimuscarinic drugs, including trospium, solifenacin, fesoterodine, tolterodine, and oxybutynin.
- Drugs for urgency UI demonstrated similar effectiveness. Treatment discontinuation due to adverse effects was most common with oxybutynin and least common with solifenacin.
- Pharmacological treatments for stress UI, including off-label use of low-dose topical estrogen formulations, may improve stress UI in postmenopausal women.
- Duloxetine has an unfavorable balance between improvement in stress UI and treatment discontinuation due to adverse effects.
- Compliance rates for prescription drugs are low; discontinuation due to side effects is common. Dry mouth, constipation, and blurred vision were among the most frequent adverse effects.
- Evidence is insufficient for the long-term safety of pharmacological treatments.
- Women with urgency UI whose prior treatments failed may benefit from solifenacin; however, poor responders would not benefit from increasing the dose of the drug.
- Oxybutynin, trospium, and darifenacin improved UI in older women.

Nonpharmacological Treatments

- Nonpharmacological treatments result in significant clinical benefit with a low risk of adverse effects. The magnitude of benefit is large, with more than 100 percent relative difference in continence rates.
- Women with stress UI can achieve continence performing PFMT. Continence rates are similar between those who undergo PFMT with and without biofeedback.

Glossary

AHRQ	Agency for Healthcare Research and Quality
CI	Confidence interval

NNT	Number needed to treat
PFMT	Pelvic floor muscle training
RCT	Randomized controlled trial
RR	Relative risk
UI	Urinary incontinence

References

- Abrams P. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008. 4th ed. [Paris]: Health Publications Ltd. 2009, Committee 1 Epidemiology of Urinary (UI) and Fecal (FI) Incontinence and Pelvic Organ Prolapse (POP).
- Carls C. The prevalence of stress urinary incontinence in high school and college-age female athletes in the midwest: implications for education and prevention. *Urol Nurs* 2007 Feb;27(1):21-4, 39. PMID 17390923.
- Kinchen KS, Lee J, Fireman B, et al. The prevalence, burden, and treatment of urinary incontinence among women in a managed care plan. *J Womens Health (Larchmt)* 2007 Apr;16(3):415-22. PMID 17439386.
- Boyington JE, Howard DL, Carter-Edwards L, et al. Differences in resident characteristics and prevalence of urinary incontinence in nursing homes in the southeastern United States. *Nurs Res* 2007;56:97-107. PMID 17356440.
- Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. *Value Health* 2006 Jul-Aug;9(4):272-4. PMID 16903997.
- Anger JT, Saigal CS, Madison R, et al. Increasing costs of urinary incontinence among female Medicare beneficiaries. *J Urol* 2006 Jul;176(1):247-51; discussion 51. PMID 16753411.
- Shamliyan T, Wyman J, Bliss DZ, et al. Prevention of urinary and fecal incontinence in adults. *Evid Rep Technol Assess (Full Rep)* 2007 Dec(161):1-379. PMID 18457475.
- Abrams P. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008. 4th ed. [Paris]: Health Publications Ltd.; 2009.
- Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn* 2010;29(1):4-20. PMID 19941278.
- Holroyd-Leduc JM, Tannenbaum C, Thorpe KE, et al. What type of urinary incontinence does this woman have? *JAMA* 2008 Mar 26;299(12):1446-56. PMID 18364487.
- Abrams P. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008: Health Publications Ltd: 2009. Committee 12. Adult Conservative Management.
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, et al. Draft Guidance for Industry and FDA Staff - Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence. Rockville, MD. Available at: www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070852.htm. Accessed August 2009.
- Coyne KS, Sexton CC, Kopp ZS, et al. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. *BJU Int* 2011 Mar 3. PMID 21371240.
- Hartmann KE, McPheeters ML, Biller DH, et al. Treatment of overactive bladder in women. *Evid Rep Technol Assess (Full Rep)* 2009 Aug(187):1-120, v. PMID 19947666.
- Shamliyan TA, Kane RL, Wyman J, et al. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. *Ann Intern Med* 2008 Mar 18;148(6):459-73. PMID 18268288.

16. Cardozo L, Thorpe A, Warner J, et al. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. *BJU Int* 2010 Feb 3. PMID 20132203.
17. Martin JL, Williams KS, Sutton AJ, et al. Systematic review and meta-analysis of methods of diagnostic assessment for urinary incontinence. *Neurourol Urodyn* 2006;25:674-83. PMID 17016795.
18. Dmochowski RR, Blaivas JM, Gormley EA, et al. Update of AUA guideline on the surgical management of female stress urinary incontinence. *J Urol* 2010 May;183(5):1906-14. PMID 20303102.
19. National Collaborating Centre for Women's and Children's Health. Urinary incontinence: The management of urinary incontinence in women Commissioned by the National Institute for Health and Clinical Excellence. Available at: www.nice.org.uk/nicemedia/pdf/CG40NICEguideline.pdf. Accessed October 2006.
20. Ghoniem G, Stanford E, Kenton K, et al. Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice. *International Urogynecology Journal* 2008 Jan;19(1):5-33. PMID 21118. PMID: 18026681.
21. Campbell JD, Gries KS, Watanabe JH, et al. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. *BMC Urol* 2009;9:18. PMID 19930578.
22. McDonagh MS, Selover D, Santa J, et al. Drug class review on agents for overactive bladder: Final report Oregon Health & Science University. Dec 2005.
23. Agency for Healthcare Research and Quality. HHS Awards \$473 Million in Patient-Centered Outcomes Research Funding. Rockville, MD; 2010.
24. Layton D, Pearce GL, Shakir SA. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. *Drug Saf* 2001;24(9):703-13. PMID 11522122.
25. Wang PS, Levin R, Zhao SZ, et al. Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients. *J Am Geriatr Soc* 2002 Jan;50(1):117-24. PMID 12028256.
26. Ioannidis JPA, Lau J. Heterogeneity of the baseline risk within patient populations of = clinical trials: a proposed evaluation algorithm. *Am J Epidemiol* 1998;148:1117-26.
27. Arends LR, Hoes AW, Lubsen J, et al. Baseline risk as predictor of treatment benefit: three clinical = meta-re-analyses. *Stat Med* 2000;19:3497-518.
28. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. *BMJ* 1994;309:1351-5.
29. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. *Pharmacotherapy* 2006 Dec;26(12):1694-702. PMID 17125433.
30. Prescribing antimuscarinics for overactive bladder; how many chances do we have to get it right? *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010:29.
31. Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. *Value Health* 2005 Jul-Aug;8(4):495-505. PMID 16091027.
32. Perfetto EM, Subedi P, Jumadilova Z. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. *Am J Manag Care* 2005 Jul;11(4 Suppl):S150-7. PMID 16161388.
33. Laurant M, Reeves D, Hermens R, et al. Substitution of doctors by nurses in primary care. *Cochrane Database Syst Rev* 2005(2):CD001271. PMID 15846614.

34. Festen L, Duggan P, Coates D. Improved quality of life in women treated for urinary incontinence by an authorised continence nurse practitioner. *Int Urogynecol J Pelvic Floor Dysfunct* 2008 Apr;19(4):567-71. PMID 17898919.
35. Jeffery S, Doumouchtsis SK, Fynes M. Patient satisfaction with nurse-led telephone follow-up in women with lower urinary tract symptoms. *J Telemed Telecare* 2007;13(7):369-73. PMID 17958940.
36. O'Donnell M, Viktrup L, Hunskaar S. The role of general practitioners in the initial management of women with urinary incontinence in France, Germany, Spain and the UK. *Eur J Gen Pract* 2007;13(1):20-6. PMID 17366290.
37. Steel N, Bachmann M, Maisey S, et al. Self reported receipt of care consistent with 32 quality indicators: national population survey of adults aged 50 or more in England. *BMJ* 2008;337:a957. PMID 18703659.
38. Wagg A, Potter J, Peel P, et al. National audit of continence care for older people: management of urinary incontinence. *Age Ageing* 2008 Jan;37(1):39-44. PMID 18033776.
39. Wieseler B, McGauran N, Kaiser T. Finding studies on reboxetine: a tale of hide and seek. *BMJ* 2010;341:c4942. PMID 20940211.
40. Imamura M, Abrams P, Bain C, et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. *Health Technol Assess* 2010 Aug;14(40):1-188, iii-iv. PMID 20738930.
41. National Institute for Health and Clinical Excellence. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome: guidance. Available at: www.nice.org.uk/nicemedia/live/12412/51304/51304.pdf. Accessed October 27, 2010.
42. Goode PS, Burgio KL, Richter HE, et al. Incontinence in older women. *JAMA* 2010 Jun 2;303(21):2172-81. PMID 20516418.
43. Thuroff JW, Abrams P, Andersson KE, et al. EAU Guidelines on Urinary Incontinence. *Eur Urol* 2011 Mar;59(3):387-400. PMID 21130559.

Table A. Diagnostic value of the test for urinary incontinence (UI) in women (pooled with random effects models and bivariate pooling)

Type of incontinence	Method index	Reference standard	# of studies # of subjects	Sensitivity/ bivariate pooling	Specificity/ bivariate pooling	Positive likelihood ratio ¹	Negative likelihood ratio ¹	Positive predictive value	Negative predictive value
Urodynamic stress UI	Symptoms of stress UI	Urodynamic test	27 5,780	0.93 ² (0.90 to 0.95) 0.94 (0.91 to 0.96)	0.41 ² (0.34 to 0.49) 0.41 (0.31 to 0.51)	1.54 (1.40 to 1.7)	0.20 (0.14 to 0.27)	0.74 (0.68 to 0.80)	0.74 (0.67 to 0.81)
Detrusor overactivity	Symptoms of urgency UI	Urodynamic test	23 5,485	0.82 ² (0.76 to 0.87) 0.82 (0.75 to 0.88)	0.51 ² (0.44 to 0.59) 0.52 (0.40 to 0.65)	1.54 (1.38 to 1.73)	0.39 (0.30 to 0.50)	0.56 (0.48 to 0.63)	0.80 (0.73 to 0.86)
Detrusor overactivity	Symptoms of urgency	Urodynamic test	9 6,418	0.84 ² (0.59 to 0.95) 0.82 (0.70 to 0.92)	0.39 ² (0.17 to 0.67) 0.39 (0.24 to 0.55)	1.36 (1.18 to 1.58)	0.47 (0.33 to 0.67)	0.48 (0.39 to 0.57)	0.75 (0.67 to 0.81)
Detrusor overactivity ³	Symptoms of urgency UI	Urodynamic test	17 3,924	0.84 ² (0.78 to 0.89) 0.84 (0.79 to 0.90)	0.43 ² (0.36 to 0.50) 0.44 (0.34 to 0.54)	1.48 (1.31 to 1.66)	0.40 (0.29 to 0.54)	0.33 (0.26 to 0.41)	0.89 (0.83 to 0.93)
Detrusor overactivity ³	Symptoms of urgency	Urodynamic test	6 1,598	0.86 (0.83 to 0.89) 0.86 (0.80 to 0.90)	0.31 ² (0.24 to 0.39) 0.31 (0.20 to 0.45)	1.21 (1.11 to 1.32)	0.523 (0.41 to 0.67)	0.27 (0.17 to 0.40)	0.86 (0.76 to 0.93)
Mixed UI	Symptoms of stress and urgency UI	Urodynamic test	11 2,767	0.73 ² (0.61 to 0.82) 0.72 (0.58 to 0.83)	0.53 ² (0.40 to 0.66) 0.53 (0.34 to 0.72)	1.45 (1.27 to 1.67)	0.61 (0.52 to 0.71)	0.26 (0.20 to 0.34)	0.89 (0.85 to 0.92)
Urodynamic stress UI	Pad test	Urodynamic test	3 574	0.84 (0.76 to 0.90) 0.83 (0.75 to 0.91)	0.77 (0.72 to 0.82) 0.77 (0.17 to 0.97)	3.62 (2.88 to 4.57)	0.22 (0.15 to 0.32)	0.82 (0.77 to 0.86)	0.78 (0.73 to 0.83)
Detrusor overactivity	Pad	Urodynamic test	2 469	0.72 ² (0.30 to 0.94)	0.56 ² (0.38 to 0.72)	1.56 (0.62 to 3.90)	0.47 (0.10 to 2.33)	0.32 (0.04 to 0.83)	0.88 (0.83 to 0.91)

**Table A. Diagnostic value of the test for urinary incontinence (UI) in women (pooled with random effects models and bivariate pooling)
(continued)**

Type of incontinence	Method index	Reference standard	# of studies # of subjects	Sensitivity/ bivariate pooling	Specificity/ bivariate pooling	Positive likelihood ratio ¹	Negative likelihood ratio ¹	Positive predictive value	Negative predictive value
Urodynamic stress UI	Symptoms of stress UI	Clinical diagnosis	5 947	0.88 ² (0.68 to 0.96) 0.86 (0.70 to 0.96)	0.67 ² (0.54 to 0.78) 0.67 (0.51 to 0.81)	2.35 (1.97 to 2.81)	0.19 (0.09 to 0.41)	0.80 (0.66 to 0.89)	0.75 (0.58 to 0.87)
Detrusor overactivity	Symptoms of urgency UI	Clinical diagnosis	4 735	0.82 ² (0.73 to 0.89) 0.82 (0.73 to 0.90)	0.67 ² (0.53 to 0.79) 0.67 (0.45 to 0.86)	2.52 (1.81 to 3.50)	0.26 (0.18 to 0.38)	0.72 (0.48 to 0.88)	0.79 (0.54 to 0.92)
Mixed UI	Symptoms of stress and urgency UI	Clinical diagnosis	3 654	0.65 ² (0.36 to 0.86) 0.64 (0.38 to 0.85)	0.54 ² (0.21 to 0.84) 0.52 (0.06 to 0.94)	1.57 (0.68 to 3.59)	0.74 (0.28 to 1.95)	0.36 (0.27 to 0.47)	0.80 (0.43 to 0.96)
Urodynamic stress UI	Q-tip test	Urodynamic test	3 267	0.62 (0.53 to 0.70) 0.62 (0.49 to 0.74)	0.60 ² (0.40 to 0.78) 0.58 (0.00 to 1.00)	1.70 (0.89 to 3.23)	0.60 (0.31 to 1.17)	0.58 (0.26 to 0.85)	0.67 (0.34 to 0.89)

¹Clinical interpretations of likelihood ratios:

Likelihood ratio Interpretation

>10 Large and often conclusive increase in the likelihood of disease

5-10 Moderate increase in the likelihood of disease

2-5 Small increase in the likelihood of disease

1-2 Minimal increase in the likelihood of disease

1 No change in the likelihood of disease

²Significant heterogeneity

³Pure type

Table B. Clinical outcomes with treatments for UI (pooled with random effects estimates from head-to-head RCTs)

Treatments	Outcomes	Number of studies	Patients	Rate, % active/control	Relative risk (95% CI)	Absolute risk difference* (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Effect in relative/absolute scale	Evidence
Pharmacological treatments for stress UI										
Duloxetine vs. placebo	Continence	2	736	38/40	0.92 (0.86 to 0.99)	-0.03 (-0.12 to 0.06)			↓/NS	Low
Duloxetine vs. placebo	Improved UI	4	1,138	37/29	1.68 (0.94 to 3.00)	0.08 (0.01 to 0.14)	13 (7 to 143)	75 (7 to 142)	NS/↑	High
Duloxetine vs. placebo	Discontinuation due to adverse effects	9	3,252	16/3	4.4 (3.24 to 5.86)	0.13 (0.06 to 0.19)	8 (5 to 16)	129 (64 to 193)	↑	High
Pharmacological treatments for urgency UI										
Darifenacin vs. placebo	Improved UI	3	1,011	48/33	1.3 (1.2 to 1.5)	0.12 (0.06 to 0.17)	9 (6 to 18)	117 (57 to 177)	↑	High
Darifenacin vs. placebo	Discontinuation due to adverse effects	7	3,138	5/3	1.2 (0.8 to 1.8)	0.00 (-0.01 to 0.02)			NS	High
Darifenacin vs. placebo	Discontinuation due to failure	4	1,280	1/2	0.6 (0.2 to 1.7)	-0.01 (-0.02 to 0.01)			NS	Moderate
Fesoterodine vs. placebo	Continence	2	2,465	61/48	1.3 (1.1 to 1.5)	0.13 (0.06 to 0.20)	8 (5 to 17)	130 (58 to 202)	↑	Low
Fesoterodine vs. placebo	Improved UI	2	1,896	42/32	1.3 (1.2 to 1.5)	0.10 (0.06 to 0.15)	10 (7 to 18)	100 (56 to 145)	↑	High
Fesoterodine vs. placebo	Adverse effects	4	4,145	51/38	1.4 (1.2 to 1.6)	0.16 (0.11 to 0.20)	6 (5 to 9)	156 (112 to 200)	↑	High
Fesoterodine vs. placebo	Discontinuation due to adverse effects	4	4,433	6/3	2.0 (1.3 to 3.1)	0.03 (0.01 to 0.06)	33 (18 to 102)	31 (10 to 56)	↑	High
Fesoterodine vs. placebo	Discontinuation due to failure	2	1,896	2/3	0.6 (0.2;2.5)	-0.01 (-0.03 to 0.02)			NS	Moderate
Oxybutynin vs. placebo	Continence	4	992	27/16	1.7 (1.3 to 2.1)	0.11 (0.06 to 0.16)	9 (6 to 16)	114 (64 to 163)	↑	High
Oxybutynin vs. placebo	Improved UI	9	1,244	53/32	1.5 (1.2 to 1.9)	0.17 (0.10 to 0.24)	6 (4 to 11)	167 (95 to 240)	↑	Moderate
Oxybutynin vs. placebo	Discontinuation due to adverse effects	5	1,483	10/5	1.7 (1.1 to 2.5)	0.06 (0.01 to 0.13)	16 (8 to 86)	63 (12 to 127)	↑	High

Table B. Clinical outcomes with treatments for UI (pooled with random effects estimates from head-to-head RCTs) (continued)

Treatments	Outcomes	Number of studies	Patients	Rate, % active/control	Relative risk (95% CI)	Absolute risk difference* (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Effect in relative/absolute scale	Evidence
Propiverine vs. placebo	Continenence	2	691	53/37	1.4 (1.2 to 1.7)	0.16 (0.09 to 0.24)	6 (4 to 12)	163 (86 to 239)	↑	Low
Propiverine vs. placebo	Improved UI	3	985	55/35	1.6 (1.3 to 2.0)	0.19 (0.13 to 0.25)	5 (4 to 8)	192 (132 to 252)	↑	Moderate
Propiverine vs. placebo	Discontinuation due to adverse effects	2	1,401	5/2	2.6 (1.4 to 5.00)	0.03 (0.01 to 0.06)	29 (16 to 77)	34 (13 to 61)	↑	Low
Solifenacin vs. placebo	Continenence	5	6,304	39/28	1.5 (1.4 to 1.6)	0.11 (0.06 to 0.16)	9 (6 to 17)	107 (58 to 156)	↑	High
Solifenacin vs. placebo	Improved UI	2	1,507	60/42	1.5 (1.0 to 2.1)	0.18 (0.10 to 0.26)	6 (4 to 10)	180 (97 to 263)	↑	Low
Solifenacin vs. placebo	Adverse effects	3	1,713	52/36	1.7 (1.2 to 2.4)	0.18 (0.09 to 0.27)	6 (4 to 12)	177 (85 to 267)	↑	High
Solifenacin vs. placebo	Discontinuation due to adverse effects	7	9,080	5/4	1.3 (1.1 to 1.7)	0.01 (0.00 to 0.03)	78 (39 to 823)	13 (1 to 26)	↑	High
Solifenacin vs. placebo	Discontinuation due to failure	4	2,812	2/1	1.0 (0.5 to 1.8)	0.00 (-0.01 to 0.01)			NS	Moderate
Tolterodine vs. placebo	Continenence	4	3,404	53/44	1.2 (1.1 to 1.4)	0.09 (0.04 to 0.13)	12 (8 to 25)	85 (40 to 129)	↑	High
Tolterodine vs. placebo	Improved UI	7	6,119	45/37	1.3 (1.1 to 1.4)	0.10 (0.04 to 0.15)	10 (7 to 24)	96 (42 to 149)	↑	High
Tolterodine vs. placebo	Adverse effects	12	4,162	45/38	1.2 (1.1 to 1.3)	0.08 (0.05 to 0.12)	12 (8 to 21)	83 (47 to 120)	↑	High
Tolterodine vs. placebo	Discontinuation due to adverse effects	10	4,466	4/3	1.0 (0.6 to 1.7)	0.01 (-0.01 to 0.03)			NS	High
Tolterodine vs. placebo	Discontinuation due to failure	5	4,049	1/2	0.5 (0.2 to 0.9)	-0.01 (-0.01 to 0.00)			NS	High
Trospium vs. placebo	Continenence	4	2,677	28/17	1.7 (1.5 to 2.0)	0.11 (0.08 to 0.14)	9 (7 to 12)	114 (83 to 144)	↑	High
Trospium vs. placebo	Improved UI	2	1,176	32/25	1.1 (0.6 to 2.0)	0.08 (-0.10 to 0.25)			NS	Low
Trospium vs. placebo	Adverse effects	5	2,967	41/29	1.4 (1.2 to 1.7)	0.12 (0.09 to 0.16)	8 (6 to 11)	123 (88 to 159)	↑	Moderate

Table B. Clinical outcomes with treatments for UI (pooled with random effects estimates from head-to-head RCTs) (continued)

Treatments	Outcomes	Number of studies	Patients	Rate, % active/control	Relative risk (95% CI)	Absolute risk difference* (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Effect in relative/absolute scale	Evidence
Trospium vs. placebo	Discontinuation due to adverse effects	6	3,936	6/4	1.5 (1.1 to 1.9)	0.02 (0.00 to 0.03)	56 (30 to 228)	18 (4 to 33)	↑	High
Fesoterodine vs. tolterodine	Continence	2	3,312	61/56	1.10 (1.04 to 1.16)	0.06 (0.02 to 0.09)	18 (11 to 48)	55 (21 to 88)	↑	Low
Fesoterodine vs. tolterodine	Improved UI	3	4,425	44/35	1.06 (1; 1.2)	0.03 (0; 0.06)	36 (17 to 1000)	28 (1 to 57)	↑/↑	High
Fesoterodine vs. tolterodine	Discontinuation due to adverse effects	4	4,440	5/4	1.54 (1.21 to 1.97)	0.02 (0.01 to 0.03)	58 (33 to 206)	17 (5 to 31)	↑	Moderate
Oxybutynin vs. tolterodine	Improved UI	3	947	50/45	1.11 (0.94 to 1.31)	0.05 (-0.03 to 0.13)			NS	Moderate
Oxybutynin vs. tolterodine	Discontinuation due to adverse effects	6	2,323	13/6	1.9 (1.1 to 3.3)	0.07 (0.01 to 0.15)	14 (7 to 145)	72 (7 to 154)	↑	High
Solifenacin vs. tolterodine	Discontinuation due to adverse effects	3	2,755	4/3	1.28 (0.86 to 1.91)	0.01 (0.00 to 0.03)			NS	Moderate
Trospium vs. oxybutynin	Discontinuation due to adverse effects	2	2,015	5/7	0.75 (0.52; 1.1)	0.00 (-0.03 to 0.05)			NS	Low
Nonpharmacological treatments										
Bladder training vs. no active treatment	Improved UI	2	283	61.4/19.2	3.22 (2.25 to 4.60)	0.43 (0.28 to 0.59)	2 (2 to 4)	430 (275 to 585)	↑	Low
Continence service vs. no active treatment	Continence	3	3,939	29/20	1.6 (1.1 to 2.3)	0.30 (-0.01 to 0.60)			↑/NS	Moderate
Continence service vs. no active treatment	Improved UI	2	4,038	62.6/53.5	1.33 (1.06 to 1.68)	0.20 (-0.01 to 0.41)			↑/NS	Low

Table B. Clinical outcomes with treatments for UI (pooled with random effects estimates from head-to-head RCTs) (continued)

Treatments	Outcomes	Number of studies	Patients	Rate, % active/control	Relative risk (95% CI)	Absolute risk difference* (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Effect in relative/absolute scale	Evidence
Electrical stimulation vs. no active treatment	Continence	7	420	23/8	2.9 (1.6 to 5.2)	0.16 (0.06 to 0.26)	6 (4 to 16)	162 (64 to 259)	↑	High
Electrical stimulation vs. no active treatment	Improved UI	8	582	31.7/15.1	2.01 (1.28 to 3.15)	0.16 (0.08 to 0.23)	6 (4 to 12)	156 (84 to 228)	↑	High
Magnetic stimulation vs. no active treatment	Improved UI	3	153	46.8/21.2	2.30 (1.43 to 3.71)	0.27 (0.11 to 0.42)	4 (2 to 9)	265 (112 to 417)	↑	Moderate
Magnetic stimulation vs. no active treatment	Continence	3	171	30.7/17.8	1.22 (0.78 to 1.88)	0.09 (-0.01 to 0.18)			NS	Moderate
Percutaneous electrical stimulation vs. no active treatment	Improved UI	3	405	40/20	1.9 (1.1 to 3.2)	0.31 (0.04 to 0.58)	3 (2 to 25)	308 (40 to 577)	↑	Moderate
PFMT vs. no active treatment	Continence	10	959	38/12	3.8 (2.1 to 6.8)	0.30 (0.19 to 0.41)	3 (2 to 5)	299 (188 to 410)	↑	High
PFMT vs. no active treatment	Improved UI	6	510	56.9/14.7	5.44 (1.57 to 18.83)	0.41 (0.17 to 0.65)	2 (2 to 6)	412 (174 to 649)	↑	High
PFMT with bladder training vs. no active treatment	Continence	5	1,369	21/12	3.8 (1.5 to 9.3)	0.17 (0.06 to 0.27)	6 (4 to 16)	166 (63 to 268)	↑	High
PFMT with bladder training vs. no active treatment	Improved UI	4	1,171	53.3/22.5	4.13 (1.58 to 10.78)	0.39 (0.17 to 0.60)	3 (2 to 6)	387 (171 to 603)	↑	High

Table B. Clinical outcomes with treatments for UI (pooled with random effects estimates from head-to-head RCTs) (continued)

Treatments	Outcomes	Number of studies	Patients	Rate, % active/control	Relative risk (95% CI)	Absolute risk difference* (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Effect in relative/absolute scale	Evidence
PFMT with biofeedback vs. no active treatment	Continence	2	185	42/2	11.2 (2.2 to 56.4)	0.49 (-0.10 to 1.08)			↑/NS	Low
PFMT with biofeedback vs. no active treatment	Improved UI	4	383	60.1/18.6	3.93 (1.00 to 15.49)	0.39 (0.17 to 0.61)	3 (2 to 6)	390 (170 to 610)	↑	High
Weight Loss vs. no active treatment	Improved UI	2	386	42.8/20.8	2.17 (1.26 to 3.76)	0.27 (0.06 to 0.50)	4 (2 to 18)	273 (57 to 490)	↑	Moderate
PFMT + bladder training vs. bladder training	Continence	2	271	21/21	1 (0.4 to 2.8)	0.001 (-0.2 to 0.2)			NS	High
PFMT vs. electrical stimulation	Continence	3	99	24/29	0.85 (0.45 to 1.61)	-0.04 (-0.20 to 0.11)			NS	Moderate
PFMT vs. electrical stimulation	Improved UI	4	136	31/45	0.97 (0.62 to 1.51)	-0.01 (-0.17 to 0.16)			NS	Moderate
PFMT vs. vaginal cone	Continence	3	320	22/27	0.78 (0.58 to 1.06)	-0.11 (-0.26 to 0.04)			NS	Moderate
PFMT vs. vaginal cone	Improved UI	4	440	41/41	1.02 (0.91 to 1.14)	0.01 (-0.08 to 0.09)			NS	Moderate
PFMT with biofeedback vs. PFMT	Continence	6	542	30/25	1.27 (0.88 to 1.85)	0.08 (-0.03 to 0.19)			NS	High
Supervised PFMT vs. self-PFMT	Continence	4	300	35/22	1.92 (0.87 to 4.23)	0.20 (-0.03 to 0.43)			NS	High
Supervised PFMT vs. self-PFMT	Improved UI	4	283	50/33	1.51 (0.85 to 2.67)	0.14 (-0.05 to 0.32)			NS	Moderate

Note: CI=confidence interval; PFMT=pelvic floor muscle training; NS=not significant; RCT=randomized controlled trial; UI=urinary incontinence; ↑=effect of active drug is greater than control; ↓=effect of active drug is lower than control. * Risk differences for drug adverse effects were calculated using arcsine transformation

Introduction

Urinary incontinence (UI) is the involuntary loss of urine.¹ UI affects a significant number of women in the United States and other countries.¹ About 25 percent of young women,² 44 to 57 percent of middle-aged and post-menopausal women,^{3,4} and about 75 percent of older women experience some involuntary urine loss.⁵ The impact of UI can be serious, affecting women's physical, psychological, and social wellbeing, and sometimes imposing significant lifestyle restrictions. The effects of UI on an individual may range from slightly bothersome to debilitating.

The cost of UI care in the United States averaged \$19.5 billion in 2004.⁶ Six percent of nursing home admissions of older women is attributable to UI⁶ and, by one estimate, the annualized cost of nursing home admissions of elderly women due to UI was \$3 billion.^{7,8}

Voluntary voiding requires a balance between sphincter activity and bladder function. UI in women is related to actions of the bladder and the urinary sphincter. Stress incontinence is a sphincter failure attributed to intra-abdominal pressure. Urgency incontinence is attributable to sphincter failure with or without overactive bladder contractions. Conversely, an inactive bladder may result in overflow incontinence, whereby urine is retained until bladder capacity is exceeded. In many women, stress and urgency occur together in what is called mixed incontinence. Sphincter failure in women is often associated with weakness of the pelvic floor muscles.

The etiology of incontinence is multifactorial. Known risk factors include age, pregnancy, pelvic floor trauma after vaginal delivery, menopause, hysterectomy, obesity, urinary tract infections, functional and/or cognitive impairment, chronic cough, and constipation.⁹ Assessments of women complaining of UI begin with exclusion of underlying causes such as pelvic organ prolapse, urinary tract infection, and poor bladder emptying,¹ all of which are conditions beyond the scope of this review. We focus specifically on women with stress UI associated with sphincter function, and with urgency UI, often associated with overactive bladder.

Incontinence types are distinguished by their baseline mechanisms. Stress incontinence is associated with sphincter function, and results in an inability to retain urine when coughing or sneezing.¹⁰ Urgency incontinence is defined as involuntary loss of urine associated with the sensation of a sudden, compelling urge to void that is difficult to defer.¹⁰ Mixed UI is the term applied when both stress and urgency UI are present. These definitions reflect the consensus definitions developed by the International Urogynecological Association (IUGA)/International Continence Society (ICS)¹⁰ (Table 1).

Overactive bladder is defined as urinary urgency with or without incontinence, usually accompanied by frequency and nocturia (the need to urinate at night).¹⁰ Approximately one-third of women with overactive bladder also experience urgency UI. Other diagnoses for female pelvic floor dysfunction beyond the scope of our review include poor bladder emptying, voiding dysfunction, pelvic organ prolapse, and recurrent urinary tract infections, as well as neurogenic UI associated with spinal cord injury or stroke.¹⁰

Stress incontinence was the most prevalent type in women 19 to 44 years of age (31 percent)¹¹⁻²⁴ and in those 45 to 64 years of age (33 percent).^{3,11,13,14,16,18,19,21,24-49} The prevalence of urgency UI gradually increased from 13 percent in younger women^{11-19,21-24,50} to 17 percent in women 45 to 64 years of age^{11,13,14,25-35} and to 25 percent in women older than 65.^{13,14,18,19,21,23,24,27,30,34,51-68} Older women suffer from both types, and so-called mixed UI; 33 percent of older women^{13,14,18,19,24,30,52,54,56-60,62,63,66-68} reported mixed UI.^{13,30,56}

The types of UI imply different attendant risk factors and recommended treatments; however, UI etiology is frequently mixed. Stress UI is associated with pelvic floor trauma and uterine prolapse (both of which are conditions associated with vaginal delivery that often require surgical treatments).⁹ Urgency and mixed UI are associated with overactive bladder with or without sphincter dysfunction and may benefit from nonsurgical treatments, including pharmacological and nonpharmacological options.^{1,9}

Although diagnosis of UI can be made based on patients' reports of involuntary urine leakage,⁹ researchers have also proposed instrumental methods for objective diagnosis of different types of UI. Urodynamic evaluation may help to distinguish pure stress UI without urgency UI for women undergoing surgery for stress UI.¹⁰ Diagnostic studies use multichannel urodynamics as a reference standard test to compare with noninvasive tests. However, researchers disagree over whether urodynamic examination represents the gold standard for UI diagnosis.⁶⁹⁻⁷¹ Previously published systematic reviews reported a weak association between urodynamic results and self-reported symptoms,^{72,73} however, previous reviews did not focus on the most appropriate methods to distinguish different types of UI in ambulatory care clinical settings.⁷⁴⁻⁷⁷ The role of invasive diagnostic methods in better predicting treatment outcomes for UI remains unclear.

Our report also addresses the role of urodynamic testing, which is not typically performed in primary care. We include it here primarily as background information for primary care practitioners and because it raises a conundrum. As we have emphasized, the primary outcome for UI should be patient-centered reports of the UI experience, especially the presence or absence of UI. Although we typically think of physiological testing as more objective than patient reports, these results are, at best, akin to intermediate outcomes. In the diagnostic context, physiological testing can inform in one of three ways: (1) establishing a diagnosis; (2) determining an etiology with therapeutic implications; and (3) generating a prognosis. In the case of UI, it is unclear whether physiological measures represent a gold standard against which other measures can be compared or whether they should be viewed as information that may predict key patient-centered outcomes. Hence, we may be more interested in levels of agreement between physiological measures and patient outcomes but hard pressed to interpret differences between them. We examine the role of urodynamic testing in diagnosing and treating UI to provide insight into this conundrum.

Measuring Outcomes of UI Treatment

The variations in definitions of UI complicate evaluation of treatment success. Standard UI treatment for women includes lifestyle changes, pelvic floor muscle training (PFMT), and surgical treatments for stress UI.¹ In addition, several drugs have been approved for adults with overactive bladder with or without urgency UI.¹ Clinical interventions to reduce the frequency of UI episodes in women have been extensively reviewed in recent years,^{69,78-107} but reviews have not emphasized outcomes of continence or women's perceptions of treatment success and satisfaction. However, continence has been considered a primary goal in UI treatment.^{69,108} Continence is also the most important outcome associated with quality of life in women with UI,¹⁰⁹⁻¹¹¹ but it is rarely examined as a primary outcome in syntheses of evidence.¹¹² Thus, we focus on continence and quality of life as primary outcomes for this comparative effectiveness review.¹¹²

While continence is similarly defined across studies, the definitions most often applied to improvement of UI vary and include different degrees of change in frequency and severity of

symptoms.¹¹³ The Food and Drug Administration (FDA) clinical reviews defined treatment success as a significant reduction in daily UI episodes.^{112,114,115} An average effect was a significant reduction by two UI episodes per day.¹¹² Clinical importance of this reduction was not clear. Women with severe UI may not even notice this reduction, let alone judge it as a treatment success. Other studies and reviews defined treatment success differently. In addition to varied definitions across studies, improvement in UI has been judged by researchers and women very differently. Researchers have defined improvement as a decrease in the amount of lost urine during pad tests or any statistically significant decrease in the frequency of UI episodes,¹¹³ whereas women have defined improvement according to reduced restrictions in lifestyle or improved overall perception of bladder symptoms, especially resolution of urine leakage. Measurement of treatment outcomes should be patient-centered and based on factors important to women, rather than on the results of invasive tests.¹⁰⁸ Thus, treatment success and failure should be evaluated according to what women report in validated questionnaires or scales. However, meaningful differences in questionnaires or scales have not been systematically reviewed. Ultimately, discussions of UI are complicated by the wide variety of measures used to describe the problem and its treatment outcomes. We focus on continence as the primary outcome for this comparative effectiveness review.^{69,108}

Clinical interventions to reduce the progression of UI have been extensively reviewed during recent years by the Agency for Healthcare Research and Quality (AHRQ),^{79,80} the Cochrane Collaborative Group,^{81-88,90-107,116,117} the International Consultation on Incontinence (ICI),^{69,78} and the National Institute for Health and Clinical Excellence.¹¹⁸ However, the comparative effectiveness of different UI treatments, including pharmacological therapies and their effects on patient morbidity¹¹⁹ and quality of life,¹²⁰ were beyond the scope of previously published evidence-based reports.¹²¹ In addition, previously published reports did not include pharmacological treatments for urgency UI.^{9,81} Systemic estrogens have been associated with increased risk of UI.⁹ Selective estrogen receptor modulators did not demonstrate consistent benefits for UI prevention.^{122,123} Based on discussions with key informants and Technical Expert Panel members, we excluded systemic estrogen treatments from our review.

Pharmacological agents to treat urgency UI act as muscarinic antagonists.¹²⁴⁻¹²⁶ The drugs bind to muscarinic receptors but do not activate them, thereby blocking the actions of acetylcholine, the endogenous neurostimulator of urinary bladder tone. Such blocking leads to less frequent urination and thus potential improvement in UI. However, antimuscarinic drugs also block many other effects of acetylcholine, including secretions of the respiratory tract, gastrointestinal system, and salivary glands, and actions on the central nervous system, the iris and ciliary muscle of the eye, heart, and blood vessels. Acetylcholine blocking leads to adverse effects, including dry mouth, dry eye, constipation, confusion, headache, blurred vision, and others.^{124,127-129} Previously published advocacy reviews did not focus on comparative safety of these drugs in adult women.¹³⁰⁻¹³⁷ Moreover, many recently published studies have not yet been synthesized into clinical recommendations for physicians.

Comprehensive and up-to-date reviews of treatment options for women with UI are necessary in order to develop evidence-based guidelines and recommendations for patients, clinicians, and policymakers.^{8,138-140}

This report synthesizes published evidence about diagnosis and management of UI in adult women. We focused on adult women and on nonsurgical, nonpharmacological treatments appropriate to primary care ambulatory practice, as well as pharmacological agents available in

the United States. This report is intended as a companion piece to an earlier Evidence-based Practice Center report⁹ that examined a wide range of treatment alternatives, including surgery.

Our systematic review is intended to help clinicians, consumers, and policymakers make clinical recommendations and informed decisions based on synthesized evidence and other relevant factors.

We examined the following questions:

Key Question 1. What constitutes an adequate diagnostic evaluation for women in the ambulatory care setting on which to base treatment of urinary incontinence?

1. What are the diagnostic values of different methods—questionnaires, checklists, scales, self-reports of UI during a clinical examination, pad tests, and ultrasound—when compared with multichannel urodynamics?
2. What are the diagnostic values of different methods—questionnaires, checklists, scales, self-reports of UI during a clinical examination, pad tests, and ultrasound—when compared with a bladder diary?
3. What are the diagnostic values of the methods listed above for different types of UI, including stress, urgency, and mixed incontinence?
4. What is the association between patient outcomes (continence, severity and frequency of UI, quality of life) and UI diagnostic methods?

Key Question 2. How effective is the pharmacological treatment of UI in women?

1. How do pharmacologic treatments affect continence, severity and frequency of UI, and quality of life when compared with no active treatment or with combined treatment modalities?
2. What is the comparative effectiveness of pharmacological treatments when compared with each other or with nonpharmacological treatments of UI?
3. What are the harms from pharmacological treatments when compared with no active treatment?
4. What are the harms from pharmacological treatments when compared with each other or with nonpharmacological treatments of UI?
5. Which patient characteristics, including age, type of UI, severity of UI, baseline disease that affects UI, adherence to treatment recommendations, and comorbidities, can modify the effects of the pharmacological treatments on patient outcomes, including continence, quality of life, and harms?

Key Question 3. How effective is the nonpharmacological treatment of UI in women?

1. How do nonpharmacological treatments affect incontinence, UI severity and frequency, and quality of life when compared with no active treatment?
2. How do combined modalities of nonpharmacological treatments with drugs affect incontinence, UI severity and frequency, and quality of life when compared with no active treatment or with monotherapy?
3. What is the comparative effectiveness of nonpharmacological treatments when compared with each other?
4. What are the harms from nonpharmacological treatments when compared with no active treatment?

5. What are the harms from nonpharmacological treatments when compared with each other?
6. Which patient characteristics, including age, type of UI, severity of UI, baseline disease that affects UI, adherence to treatment recommendations, and comorbidities, can modify the effects of the nonpharmacological treatments on patient outcomes, including continence, quality of life, and harms?

Table 1. Definitions of urinary incontinence (UI) and treatment outcomes⁹

Outcome	Definition
Symptoms of UI ¹⁴¹ Signs of UI	Complaint of involuntary loss of urine Observation of involuntary loss of urine on examination; may be urethral or extraurethral
Transient UI ^{142,143}	Potentially reversible incontinence resulting from conditions that may resolve if the underlying cause is managed: delirium/confusional state; urinary tract infection (symptomatic); atrophic urethritis/vaginitis; use of pharmaceuticals; psychological conditions, especially depression; excessive urine output related to another medical condition (e.g., congestive heart failure, hyperglycemia); restricted mobility; stool impaction
Established UI ^{142,143}	UI that is attributed to bladder or urethral dysfunction, such as detrusor overactivity, detrusor underactivity, urethral obstruction, urethral incompetence
Stress UI Pure (urodynamic) stress UI	Complaint of involuntary loss of urine on effort or physical exertion (or on sneezing or coughing) The finding of involuntary leakage during filling cystometry, associated with increased intra-abdominal pressure (stress test), in the absence of a detrusor contraction
Urgency UI ¹⁰ Pure (urodynamic) detrusor overactivity	Complaint of involuntary loss of urine associated with urgency Observation of involuntary leakage from the urethra synchronous with the sensation of a sudden compelling desire to void that is difficult to defer; involuntary detrusor muscle contractions occur during filling cystometry
Overactive bladder ¹⁴⁴	Urinary urgency, usually accompanied by frequency and nocturia, with or without urgency UI, in the absence of urinary tract infection or other obvious pathology. Treatment effectiveness is judged based on decreased voiding and urgency frequency and urgency UI
UI associated with poor bladder emptying ¹⁴⁵	UI associated with: bladder over distention; a contractile detrusor; hypotonic or underactive detrusor, occurring secondarily to drugs, fecal impaction, diabetes, lower spinal cord injury, or disruption of the motor innervations of the detrusor muscle
Mixed UI ¹⁴¹ Predominant stress UI Predominant urgency UI	Complaint of involuntary loss of urine associated with urgency and also with effort or physical exertion or on sneezing or coughing Mixed UI with predominant, more frequent symptoms of stress UI Mixed UI with predominant, more frequent symptoms of urgency UI
Postural UI Continuous UI Coital incontinence	Complaint of involuntary loss of urine associated with change of body position, for example, rising from a seated or lying position Complaint of continuous involuntary loss of urine Complaint of involuntary loss of urine with coitus; this symptom might be further divided into that occurring with penetration or intromission and that occurring at orgasm
Insensible UI Nocturnal enuresis	Complaint of UI where the woman has been unaware of how it occurred Complaint of involuntary urine loss that occurs during sleep
Acute UI ¹⁴⁶ Chronic UI	Sudden onset of symptoms related to an illness, treatment, or medication Persistent UI, including disorders of storage (stress and urgency) and of emptying (overflow) and functional and mixed incontinence

Table 1. Definitions of urinary incontinence (UI) and treatment outcomes⁹ (continued)

Outcome	Definition
Severity of UI	Measured as incontinent episodes/unit time, pad changes/unit time, pad weight/unit time, number of micturitions/unit time, urine loss on a pad test; also indicated by urodynamically diagnosed detrusor overactivity, urodynamic stress incontinence
Outcomes to examine treatment effectiveness	
Continence	Absence of any involuntary leakage of urine Author's reports of cure, absence of incontinent episodes in bladder diaries, negative pad stress, or no abnormalities noted on urodynamics
Resolved stress UI	No involuntary urine leakage on physical exertion or effort or with sneezing or coughing
Resolved urgency UI	No involuntary leakage accompanied by or immediately preceded by urgency
Resolved mixed UI	No involuntary leakage associated with urgency or with exertion, effort, sneezing, or coughing
Improvement in UI	Reduction in frequency and severity of incontinence episodes by >50% Reduction in pad stress test by >50% Reduction in restrictions of daily activities due to incontinence Women's perception of improvement in their bladder condition
Treatment failure	Progression of incontinence: increase in frequency and severity of incontinence episodes Increase in restrictions of daily activities because of incontinence Continence not achieved No reduction in the frequency and severity of incontinent episodes
Discontinuation of treatment	Subject refusal to continue treatment
Discontinuation of treatment due to adverse effect	Subject refusal to continue treatment due to adverse effects or physician decision to withdraw treatment due to adverse effects
Discontinuation of treatment due to treatment failure	Subject refusal to continue treatment due to lack of efficacy
Quality of life	Subject's reports about emotional, physical, and social wellbeing
Adverse effects	Any harmful and undesired effect in treated subjects


Methods

Input From Stakeholders

We developed research questions and an analytic framework (Figure 1) after discussions with key informants and technical experts. Research questions for the systematic review were posted for public comment, based on which we identified interventions eligible for this review. Stakeholders recommended a focus on patient-centered outcomes and interventions most relevant for ambulatory care and not evaluated in previous systematic reviews. Stakeholders also recommended reviewing nonsurgical interventions relevant to women with refractory UI. Comprehensive information about all nonsurgical treatment choices can lead to evidence-based referral practices for women with refractory UI.

Candidates to serve as key informants, technical experts, and peer reviewers were approved by the Task Order Officer from AHRQ after disclosure of conflicts of interest. The protocol was developed with input from the Technical Expert Panel.

Figure 1. Analytic framework of diagnosis and comparative effectiveness of treatments for urinary incontinence (UI) in adult women



Literature Search Strategy and Eligibility Criteria

Search Strategy

We sought studies from a wide variety of sources, including MEDLINE® via OVID and via PubMed®, the Cochrane Library, SCIRUS, Google Scholar, and manual searches of reference lists from systematic reviews, the proceedings of the ICS, and systematic reviews by the ICI. We also reviewed grey literature packets from the Scientific Resource Center (SRC) (Appendix Table A1). This search included regulatory documents and conducted clinical trials. The regulatory documents included medical and statistical reviews from the U.S. FDA, Health

Canada - Drug Monographs, and Authorized Medicines for the European Union - Scientific Discussions. We searched the Web site www.ClinicalTrials.gov on May 20, 2010, to find closed studies of urinary incontinence or overactive bladder. In addition, the following clinical trial registries were searched for completed trials related to the key questions: Current Controlled Trials (United Kingdom), Clinical Study Results (Pharmaceutical Research and Manufacturers of America), and World Health Organization Clinical Trials (International). Scopus and Physical Education Index was searched for conference papers and abstracts related to UI. We identified ongoing studies in [ClinicalTrials.gov](http://www.ClinicalTrials.gov) and the National Institutes of Health Research Portfolio Online Reported Tools (report) <http://report.nih.gov/index.aspx> Web sites.

The search strategies for the three research questions are described in Appendix A. Exact search strategies were developed through consultation with qualified librarians and guided by the SRC. We developed an a priori search strategy based on relevant medical subject headings (MeSH) terms, text words, and weighted word frequency algorithms to identify related articles. We documented each recommended, included, and excluded study in the master library. We identified studies published in English from 1990 until December 30, 2011.

Excluded references are shown in Appendix B. Our analysis of the results from ongoing studies is presented in Appendix C. The protocol was developed with input from the Technical Expert Panel.

Eligibility

Three investigators independently determined the eligibility of the studies according to recommendations from the Cochrane Manual for Systematic Reviews.¹⁴⁷ The algorithm to define study eligibility was developed for each research question (Appendix Table D1). We followed the Comparative Effectiveness Manual to select evidence from controlled trials and observational studies.¹⁴⁸ We defined the target population, eligible independent and dependent variables, outcomes, time, and setting following the PICOS framework (Appendix Table D2). We formulated a list of eligible interventions following the discussion with key informants and technical experts, and after considering public comments (Appendix Table D3). We included nonsurgical, nonpharmacological treatments for UI. We included the drugs available in the United States for predominant stress UI (topical estrogens and antidepressants) and those approved by the FDA for overactive bladder (Appendix Table D4). We excluded systemic estrogens⁹ and selective estrogen receptor modulators^{122,123} that failed to prevent or improve UI. We included bulking agents and ingestible neurotoxins to review all nonsurgical treatment options for women with refractory UI. We reviewed abstracts to exclude news, reviews, letters, comments, and case reports. Then we confirmed eligible target populations of adult women residing in the community.

Inclusion Criteria

- Studies published in English after 1989.
- Studies that examined eligible interventions of drug therapies or nonsurgical treatments for women with UI (Appendix D).
- Studies that examined eligible outcomes of UI (total, mixed, stress, urgency), quality of life in women with UI, and harms of the treatments.

We included all RCTs, pooled individual patient data from RCTs, nonrandomized multicenter clinical trials, and observational studies that used strategies to reduce bias (adjustment, stratification, matching, or propensity scores).

For Key Question 1 we included studies that evaluated different diagnostic methods for UI in women that are applicable to ambulatory care settings. We applied criteria for assessing whether a body of study data was sufficient to answer the question of diagnostic methods.¹⁴⁹ We included any observational studies that reported true and false positive and negative cases, sensitivity, and specificity of diagnostic methods for different types of female UI.

For Key Questions 2 and 3 we defined efficacy and effectiveness trials following criteria from the CER manual.¹⁴⁹ We compared the results from observational studies and RCTs on positive clinical outcomes and harms.¹⁴⁹ We included randomized controlled trials (RCTs) that combined men and women if they reported outcomes in women separately or included more than 75 percent women. We examined unpublished RCTs from the medical and statistical reviews that were conducted by the FDA. We included observational studies of treatments that were not examined in RCTs.

Exclusion Criteria

- Studies of children, adolescents, or men.
- Studies of incontinence caused by neurological disease.
- Studies of dual fecal and UI.
- Studies of surgical treatments for UI or urogenital prolapsed.
- Studies of drugs not available in the United States.
- Studies with no clinical outcomes relevant to UI.
- Case series with fewer than 100 subjects that reported short-term (less than 4 weeks) crude rates of the outcomes and/or did not use strategies to reduce bias.
- Secondary data analysis, nonsystematic reviews, letters, or comments.
- Studies that reported absolute values of the diagnostic tests in incontinent women.
- Studies that did not report true and false positive and negative cases of diagnostic tests.

To assess harms of the treatments we followed the recommendations from the CER manual^{149,150} and reviewed published and unpublished evidence of the adverse effects of eligible drugs and nonsurgical treatments for female urinary incontinence including:

- Randomized controlled trials.
- Unpublished supplemental trials data from the Web site <http://www.clinicalstudyresults.org>.
- Observational cohort and case control studies.
- Observational studies based on patient registries or large databases.
- Case reports and post-marketing surveillance.

We defined harms as the totality of all possible adverse consequences of an intervention.¹⁵⁰ We analyzed harms regardless of how authors perceived the causality of treatments.

We did not contact the investigators of the primary studies.

Quality Assessment

We rated the quality of studies according to recommendations from the Methods Guide for Effectiveness and Comparative Effectiveness Review.¹⁴⁹ We classified the studies by design to

distinguish randomized and nonrandomized controlled clinical trials from observational studies. We evaluated reporting and methodological quality of the studies for Key Question 1 with predefined criteria for assessing the quality of diagnostic accuracy studies.¹⁵¹⁻¹⁵⁶ We evaluated the quality of therapeutic studies using predefined criteria, which included randomization, adequacy of randomization and allocation concealment, masking of the treatment status, intention to treat principles, and justification of the sample size.¹⁴⁷ We evaluated disclosure of conflict of interest by the authors of individual studies and funding sources but did not use this information to downgrade quality of individual studies. We did not downgrade methodological quality of poorly reported studies. We did synthesize evidence from poorly reported studies separately.

We defined well-designed RCTs with adequate allocation concealment, intention to treat principles in analysis, and appropriate measurements of clinically important outcomes as studies with low risk of bias.

We defined studies as having a medium risk of bias if they were susceptible to some bias but not sufficient bias to invalidate the results. Examples of studies with medium risk of bias include open label RCTs, RCTs with unclear allocation concealment, RCTs with a short term of followup, and crossover RCTs without assessment of carryover effect.

We defined studies as having a high risk of bias if they had significant flaws that imply biases of various types that may invalidate the results, including nonrandom treatment allocation, no strategies to reduce bias, and ignoring randomization in analysis.

Grading the Evidence for Each Key Question

We assessed strength of evidence following the guidelines in the CER Manual.¹⁵⁷ We judged the strength of evidence according to the domains of risk of bias, consistency, directness, and precision for each major outcome.¹⁴⁹ When appropriate, we also included dose response association, presence of confounders that would diminish an observed effect, and strength of association. We evaluated strength of the association defining a priori large effect when relative risk was >2 or <0.5) and very large effect when relative risk was >5 or <0.2 .¹⁴⁷ We defined low magnitude of the effect when relative risk was significant but less than 2.

We defined evidence as strong when several well-designed RCTs with a low risk of bias demonstrated consistent treatment effects. These are findings for which future research would be very unlikely to change the estimate of effect. We assigned a moderate level of evidence when RCTs with medium risk of bias reported consistent treatment effects or large observational studies reported consistent associations. We assigned a low level of evidence to data from RCTs with serious flaws in design/analysis, and from post hoc subgroup analysis; these are findings for which further research is likely to change the estimate. We defined insufficient evidence when a single study examined treatment effects or associations. We graded the level of evidence for primary outcomes across studies as illustrated in Table 2.

Table 2. Overall ranking of evidence

Grade	Definition
High	High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
Moderate	Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
Low	Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.
Insufficient	Evidence either is unavailable or does not permit a conclusion.

Applicability

Applicability of the population was estimated by evaluating the female population from which samples have been selected in observational studies and clinical trials.¹⁵⁸ We examined settings of the studies including ambulatory care or specialized clinics, recruitment in clinical settings or in the community, inclusion age and type of UI, and exclusion criteria for each study. The studies that recruited women from the population had better applicability.

We assumed the presence of publication bias and did not use statistical tests for bias defined as the tendency to publish positive results.¹⁵⁹⁻¹⁶² We used several strategies to reduce bias, including a comprehensive literature search of published and unpublished evidence in several databases, reference lists of systematic reviews, proceedings of scientific meetings, contacts with experts for additional references, and agreement on the eligibility status by several investigators.

Data Extraction

Four researchers manually and independently performed evaluations of the studies and data extraction. The data abstraction forms are shown in Appendix E. We did multiple quality controls of all data from RCTs and in a 30 percent random sample of observational studies. Errors in data extractions were assessed by a comparison with the established ranges for each variable and the data charts with the original articles. Any discrepancies were detected and discussed. We abstracted the number of positive (true and false) and negative (true and false) after index diagnostic tests when compared to multichannel urodynamics or diary. We abstracted descriptive information about populations, interventions, controls, outcomes, settings, and time to measure outcomes in relation to the randomization or beginning of the treatment. We abstracted the number randomized into active and control treatments, doses of the drugs, events or rates, or means and standard deviations after active and control treatments. We abstracted sponsorship of the studies, sponsor participation in design and data analysis and presentation, and conflict of interest by the authors of the studies. We abstracted inclusion of minorities in the studies, inclusion of women who failed prior therapy for UI, inclusion of mixed UI, baseline daily UI, and presence of urogenital prolapse or hysterectomy in women who participated in the studies. Adjustments for age, race, comorbidities, socioeconomic status, previous treatments, and baseline severity of UI were extracted from observational studies.

Data Synthesis

For Key Question 1 results of individual studies were summarized in evidence tables to analyze sensitivity, specificity, predictive values, diagnostic odds ratios, and predictive likelihood ratios for correct diagnosis of any, stress, and urgency UI (Appendix Table D5). We focused on the predictive likelihood ratios of UI in women examined with index tests when compared to women who had urodynamic or clinical diagnosis.¹⁶³⁻¹⁶⁶ Ratios of 1 indicated that the tests likely do not provide accurate UI diagnosis.¹⁶⁷ Ratios of more than 10 provided large and often conclusive increases in the likelihood of UI.¹⁶⁷ Tabulation was performed for each article regarding symptoms or results of diagnostic tests and the diagnosis of stress incontinence or detrusor overactivity, using either urodynamic testing or clinical final diagnosis separately as the criterion standard. Specifically, the diagnostic value of history of three symptoms was evaluated: symptoms of stress incontinence for stress UI and symptoms of urgency incontinence and urgency for detrusor overactivity. We pooled diagnostic test data with random effects

models using Meta-Analyst software.¹⁶⁸ In cases of heterogeneity, we used bivariate pooling methods.^{166,169,170}

Urodynamic evaluation detects a presence of UI but not severity and frequency of UI. However, doctors need information about frequency and severity of UI to make treatment decisions and evaluate treatment effectiveness. To address the diagnostic methods of frequency and severity of UI we synthesized content and applicability of checklists and scales to assess symptom frequency and bothersomeness, quality of life, and women's satisfaction with treatments. We evaluated validation, reliability, and the proposed minimal important differences in total scores when this information was available.

For Key Questions 2 and 3 we calculated relative risk, absolute risk differences, number needed to treat (NNT), and the number of events attributable to active treatment per 1,000 persons treated for binary outcomes. We used the number of randomized subjects forcing intention to treat principles independent of the ambulatory studies analyses. We calculated mean differences from the reported means and standard deviations among randomized to active and control treatments. We used correction coefficients, forced intention to treat, and recommended calculations for missing data.¹⁴⁷ We used Meta-Analyst¹⁶⁸ and STATA (Statistics/Data analysis, 10.1) software to calculate individual study estimates with a 95 percent confidence interval (CI).

Following guidelines^{69,108} and recommendations from key informants and Technical Expert Panel members we focused on patient-centered outcomes including continence, improvement in UI, quality of life, adverse effects, and discontinuation due to adverse effects. We used the definitions of signs and symptoms of UI promoted by the IUGA/ICS (Appendix Table D2), including mixed, stress, and urgency UI.¹⁰ We defined continence when the authors reported cure, absence of incontinent episodes in bladder diaries, or negative pad or stress tests (Table 1). We defined improvement in UI when the authors reported reduction by more than 50 percent in frequency of UI in diaries or patient-reported significant improvement in UI. We defined failure when frequency of UI did not change or became worse in diaries or according to patient reported worsening of UI. We relied on patient outcomes rather than continuous measures of UI episodes or urine loss.¹⁰⁸ We analyzed discontinuation rates independent of investigator judgments about association with tested drugs. We analyzed adverse effects as reported by the authors.

Pooling criteria included the same operational definitions of clinical populations, incontinence outcomes, the same clinical interventions, and the time of the assessment of the outcomes.¹⁷¹ Meta-analysis was used to assess the consistency of the association between treatments and incontinence outcomes with random effects models using an inverse variance weighting method (Appendix Table D5).^{168,172} We chose the random effects model to incorporate in the pooled analysis differences across trials in patient populations, baseline rates of the outcomes, dosage of drugs, and other factors.¹⁷³ For pooled relative risks (RR) and absolute risk difference (ARD) we excluded trials with no events in both groups and added a correction coefficient of 0.5 in the trials with no events only in one group.¹⁷³ We used pooled ARD to calculate the number needed to treat and the number of events attributable to active treatment per 1,000 persons treated.^{174,175} We calculated means and 95 percent CI for the number needed to treat as reciprocal to pooled ARD when ARD was significant.¹⁷⁶ We calculated means and 95 percent CI for treatment events per 1,000 treated, multiplying pooled absolute risk difference by 1,000.^{168,172,174-176} We assessed missing data across studies, including loss to followup and dropout patterns, and forced intention-to-treat analysis using the number of randomized subjects for all calculations. We also used maximum likelihood method for pooling continence, clinically important improvement in UI, and treatment discontinuation due to adverse effects.¹⁶⁸We

calculated split placebo sample sizes and events in multi-arm drug trials proportionally to the randomization ratio to avoid double counting control groups. We synthesized sparse data defined as rates less than 2 percent by calculating fixed Mantel-Haenszel relative risk, and Peto odds ratio.¹⁷⁷ We analyzed adverse effects with drugs for urgency UI using double arcsine transformation for event rates. When studies had no events with active, control, or both treatments, we used correction coefficients and calculated odds ratios from random-effects generalized nonlinear mixed-effect models.^{168,178-181}

We examined the association between age, race, obesity, comorbidities, UI type, baseline severity, and response to prior treatments with clinical outcomes as reported by the authors of the original studies. We synthesized the evidence by the baseline type of UI as pure or predominant stress, pure or predominant urgency, and mixed UI. We compared clinical outcomes by the type of UI within each study and across the studies. We evaluated inclusion and exclusion criteria and baseline characteristics of the subject to determine whether all or a proportion of the subjects had mixed UI. Then we conducted quantitative meta-regression and subgroup analysis to determine treatment effects by baseline type of UI. When exploring heterogeneity, we did not use subject level variables to avoid an ecological fallacy.


We examined consistency in results across the studies with Chi square tests and I square statistics.^{182,183} We explored heterogeneity with meta-regression, subgroup, and sensitivity analysis and reported the results from random effects models only.¹⁷³ Using a standard preplanned algorithm, we explored heterogeneity by clinical diversity, comprised of the proportion of women, proportion of minority population, age of women, severity of UI, failure after prior treatments, concomitant treatments, inclusion of women with urogenital prolapse, and inclusion of women with mixed UI.¹⁷³ We explored heterogeneity by dose (when applicable), by duration of the treatments, and by control rate of the outcomes. We explored heterogeneity by quality criteria of individual studies and by whether conflict of interest was disclosed by study authors.¹⁷³ We explored heterogeneity by each quality criterion rather than the global quality score.^{184,185} We calculated pooled relative risk, absolute risk difference with 95 percent CI, and Bayesian odds ratios with 95 percent credible intervals using STATA 10.1 and Meta-Analyst software.^{168,174} We analyzed the probability that active treatments increased the chances of continence, improvements of UI, or adverse effects with the Bayesian approach using noninformative prior probability of the events.¹⁶⁸ The analytic framework and algorithms for the meta-analysis are shown in Appendix Table D5.

Results

Study Flow

We identified and retrieved 5,185 references (Figure 2). We excluded 3,452 references (Appendix B). We included 905 references for this review. Abstracted data is available at https://netfiles.umn.edu/xythoswfs/webui/_xy-17667196_1-t_lUjda8AM. Eligible references presented the results from individual studies, several publications of the same study, pooled analyses of the aggregate data, pooled analyses of the individual patient data, or statistical analyses of several studies with strength of evidence (Appendix Table F1). As an example of the latter, the FDA medical and statistical reviews contained 43 eligible studies (Appendix Table F2).

Figure 2. Study flow



Key Question 1. What constitutes an adequate diagnostic evaluation in the ambulatory care setting on which to base treatment of urinary incontinence (UI)?

Reporting quality of the studies precluded definitive conclusions about methodological quality (Appendix Table F3).^{151,166} We did not identify the studies that reported sensitivity or specificity of different methods when compared to bladder diaries.

We identified 99 studies that provided diagnostic values of different methods for UI (Appendix Table F4).^{3,32,186-278}

The studies included a total of 81,043 women. The sample size of individual studies varied from the largest study of 42,724 Australian women²⁶³ to the small studies of fewer than 100 women^{186,189,190,198,201,204,205,211,213,215,230,233,240,241,245,251,268-270,278} (Appendix Figure F1).

We summarized diagnostic values of diagnostic methods to differentiate stress, urgency, and mixed UI when compared to multichannel urodynamics or to clinical diagnosis. Described use of urodynamic testing as a reference standard test was very similar across the studies. Diagnostic methods to establish a clinical diagnosis of UI were described with different levels of detail and included history, physical examination, pelvic examination, urine culture, Q-tip test, diary, cytometry,²¹⁸ cough stress test, 48-hour home pad test,²⁵⁹ evaluation of sacral nerves 2 to 4 (deep tendon reflexes, anal wink, perineal sensation), and measurement of postvoid residual volume (by catheter or ultrasonography).

Diagnostic Evaluation for UI

Diagnostic Value of the Symptoms of Stress UI To Distinguish Urodynamic Stress UI Was Low

The diagnostic value of symptoms of stress incontinence compared to multichannel urodynamics for stress UI was examined in 27 studies of 5,780 patients (Appendix Table F5).^{188,189,191,193,195,197,200,202,203,206,207,209,213,217,228,229,238,244,246,251,253,273,279-283} Sensitivity was more than 70 percent, while specificity varied from 10 to 13 percent^{213,273,280} to 79 to 88 percent.^{197,238}

Pooled sensitivity was 93 percent (95 percent CI, 90 to 95 percent) (Appendix Figure F2). The test was not specific with pooled specificity of 41 percent (95 percent CI, 34 to 49 percent) (Appendix Figure F3). Positive predictive likelihood ratio was small at 1.5 (95 percent CI, 1.4 to 1.7) (Appendix Table F6).

Diagnostic Value of Urgency Symptoms of UI To Distinguish Urodynamic Detrusor Overactivity Was Low

The diagnostic value of the symptoms of urgency UI compared to multichannel urodynamics to distinguish detrusor overactivity was examined in 23 studies of 5,485 patients (Appendix Table F7).^{188,191,195,200,202,203,213,216,217,228,229,238,244,246,251,273,279-281,284} Sensitivity varied across the individual studies from 14 percent²⁸⁰ to more than 90 percent.^{188,216,244,251,279,284} Specificity varied across the individual studies from 21 percent²⁰⁷ to more than 90 percent.^{203,280} Pooled sensitivity was 82 percent (95 percent CI, 76 to 87 percent) (Appendix Figure F4) for any detrusor overactivity while pooled specificity was as low as 51 percent (95 percent CI, 44 to 59 percent) (Appendix Figure F5). The positive predictive likelihood ratio was small at 1.5 (95 percent CI, 1.4 to 1.7).

Urgency Symptoms of UI Had a Low Diagnostic Value To Distinguish Pure Detrusor Overactivity

The diagnostic value of the symptoms of urgency UI compared to multichannel urodynamics to distinguish pure detrusor overactivity was examined in 17 studies of 3,924 subjects^{191,195,200,203,206,207,209,211-213,217,228,229,244,251,273,279} (Appendix Table F8). Pooled sensitivity was 84 percent (95 percent CI, 78 to 89 percent) (Appendix Figure F6). Pooled specificity was as small as 43 percent (95 percent CI, 36 to 50 percent) (Appendix Figure F7). The positive predictive likelihood ratio was small at 1.5 (95 percent CI, 1.3 to 1.7) (Appendix Table F9).

Urgency Symptoms Alone, With, or Without UI Had a Minimal Diagnostic Value in Distinguishing Detrusor Overactivity in Women

The diagnostic value of urgency symptoms with or without UI compared to multichannel urodynamics to distinguish detrusor overactivity was examined in nine studies of 6,418 patients^{202,206,209,213,217,229,247,279,284} (Appendix Table F10). Pooled sensitivity was 84 percent (95 percent CI, 59 to 95 percent) (Appendix Figure F8). Pooled specificity was as low as 39 percent (95 percent CI, 17 to 67 percent) with substantial heterogeneity across the studies (Appendix Figure F9). The positive likelihood ratio was also low at 1.36 (95 percent CI, 1.2 to 1.6) (Appendix Table F11).

Urgency Symptoms Had Minimal Diagnostic Value to Distinguish Pure Detrusor Overactivity in Women

The diagnostic value of urgency symptoms with or without UI compared to multichannel urodynamics to distinguish pure detrusor overactivity was examined in six studies of 1,598 subjects^{206,209,213,217,229,279} (Appendix Table F12). Pooled sensitivity was 86 percent (95 percent CI, 83 to 89 percent) (Appendix Figure F10). Pooled specificity was as low as 31 percent (95 percent CI, 24 to 39 percent) (Appendix Figure F11). The positive likelihood ratio was also low at 1.21 (95 percent CI, 1.1 to 1.3) (Appendix Table F13).

Mixed Symptoms Had Minimal Diagnostic Value for Urodynamic Criteria of Mixed UI

The diagnostic value of mixed UI symptoms compared to multichannel urodynamics for mixed UI was examined in 11 studies of 2,767 subjects^{191,195,199,200,203,207,228,244,246,251,273} (Appendix Table F14). Pooled sensitivity was 73 percent (95 percent CI, 61 to 82 percent) (Appendix Figure F12). Pooled specificity was as low as 53 percent (95 percent CI, 40 to 66 percent) (Appendix Figure F13). Positive likelihood ratio was also low at 1.5 (95 percent CI, 1.3 to 1.7) (Appendix Table F15). Sensitivity and specificity differed across individual studies. Quality of the studies was not associated with differences in sensitivity or specificity. The results were similar after pooling with random effects models that incorporated heterogeneity across the studies in pooled estimates and bivariate pooling as recommended in cases of detected heterogeneity (Table 3).

Diagnostic Value of Pad Tests Compared to Multichannel Urodynamics

The diagnostic value of a 1-hour pad test compared to multichannel urodynamics for stress UI was examined in three studies of 574 women^{207,271,275} (Appendix Table F16). Pooled sensitivity was 84 percent (95 percent CI, 76 to 90 percent) (Appendix Figure F14). Pooled specificity was 77 percent (95 percent CI, 72 to 82 percent) (Appendix Figure F15). The positive likelihood ratio was below 5 (3.6, 95 percent CI, 2.9 to 4.6), pointing out a small increase in the likelihood of urodynamic stress UI in women with positive pad tests (Appendix Table F17).

The diagnostic value of a 1-hour pad test compared to multichannel urodynamics for detrusor overactivity was examined in two studies of 469 subjects. Sensitivity varied in studies with pooled estimates of 72 percent (95 percent CI, 30 to 94 percent)^{271,275} (Appendix Figure F16). Pooled specificity was as low as 56 percent (95 percent CI, 38 to 72 percent) (Appendix Figure F17). The positive likelihood ratio was as small as 1.56 (95 percent CI, 0.6 to 3.9) (Appendix Table F18).

Diagnostic Value of Symptoms of UI to Clinical Diagnosis

Clinical diagnosis of UI was based on history, physical examination, pelvic examination, urine culture, Q-tip test, diary, cytometry,²¹⁸ cough stress test, 48-hour home pad test,²⁵⁹ and measurement of postvoid residual volume (by catheter or ultrasonography).^{223,266}

Women With Urgency Symptoms Had a Small Likelihood of a Clinical Diagnosis of Detrusor Overactivity

The diagnostic value of urgency UI symptoms compared to clinical diagnosis for any detrusor overactivity was examined in four studies of 735 subjects^{218,223,259,266} (Appendix Table F19). Pooled sensitivity was 82 percent (95 percent CI, 73 to 89 percent) (Appendix Figure F18). Pooled specificity was 67 percent (95 percent CI, 53 to 79 percent) (Appendix Figure F19). The positive likelihood ratio was above 2 (2.5, 95 percent CI, 1.8 to 3.5) (Appendix Table F20).

Women With Symptoms of Stress UI Had a Minimal Likelihood of a Clinical Diagnosis of Stress UI

The diagnostic value of symptoms of stress UI compared to a clinical diagnosis of stress UI was examined in five studies of 947 subjects^{218,223,259,266,285} (Appendix Table F19). Pooled sensitivity was 88 percent (95 percent CI, 68 to 96 percent) (Appendix Figure F20). Pooled specificity was 67 percent (95 percent CI, 54 to 78 percent) (Appendix Figure F21). The positive likelihood ratio was above 2 (2.4, 95 percent CI, 2.0 to 2.8) (Appendix Table F21). The diagnostic value of symptoms of mixed UI compared to clinical diagnosis of mixed UI was examined in three studies of 654 subjects. Pooled sensitivity was 65 percent (95 percent CI, 36 to 86 percent) (Appendix Figure F22). Pooled specificity was 54 percent (95 percent CI, 21 to 84 percent) (Appendix Figure F23). The positive likelihood ratio was as small as 1.6 (95 percent CI, 0.7 to 3.6) (Appendix Table F22).

Women With Urgency Symptoms Had a Minimal Likelihood of Having a Clinical Diagnosis of Pure Detrusor Overactivity

The diagnostic value of urgency UI symptoms compared to clinical diagnosis for pure detrusor overactivity was examined in two studies of 551 women (Appendix Table F23). Pooled sensitivity was 70 percent (95 percent CI, 43 to 88 percent) (Appendix Figure F24). Pooled specificity was 55 percent (95 percent CI, 28 to 79 percent) (Appendix Figure F25). The positive likelihood ratio was as small as 1.6 (95 percent CI, 0.6 to 4.2) (Appendix Table F24).

Individual studies reported diagnostic values of the tests that did not meet pooling criteria (Table 3). One study of 488 women analyzed diagnostic value of the symptoms reported in mailed questionnaires compared to multichannel urodynamics.²⁵⁸ Questionnaires had a minimal diagnostic value for stress (positive likelihood ratio=1.8) and urgency (positive likelihood ratio=1.8) UI.

Diagnostic Value of Complex Clinical Algorithms

The diagnostic values of complex clinical algorithms were high and varied depending on components of algorithms and reference methods to diagnose UI.

Diagnostic Value of a Clinical Algorithm Versus Urodynamics

Diagnostic value of complex clinical algorithms for UI was high when compared to urodynamic evaluation. Two studies examined diagnostic value of algorithms for stress UI. One

study of 1,455 women examined diagnostic value of a clinical algorithm versus urodynamics. Included subjects had predominant symptoms of stress UI with more than four episodes of UI per week, normal diurnal and nocturnal frequency, a bladder capacity of 400 ml or greater, and a positive cough stress (sign of stress UI) and stress pad test.²⁵⁴ The authors reported positive predictive values of 90.2 percent for urodynamic stress UI and 76.9 percent for pure urodynamic stress UI.²⁵⁴ Diagnostic accuracy was the same across age categories and among those with previous surgery for stress UI.²⁵⁴ The authors did not report positive predictive likelihood of the clinical algorithm. Another study of 652 women examined the diagnostic value of a clinical algorithm that required the presence of a predominant complaint of stress UI, positive cough stress test results, postvoid residual urine volume of no more than 50 ml, and a functional bladder capacity of at least 400 ml as determined by a completed 24-hour frequency volume chart.²³⁰ This study also used urodynamics as a reference standard test. The algorithm had a positive predictive value of 97 percent when compared to multichannel urodynamics to diagnose stress UI.²³⁰

One study examined diagnostic value of algorithms for urgency UI. The diagnosis of pure detrusor overactivity was accurate when compared to urodynamics in scoring frequency, urgency, nocturia, and self-reported urgency UI.^{276,277} The algorithm demonstrated good diagnostic value with a positive predictive likelihood ratio of 12.6 and a diagnostic odds ratio of 27.3. The same study proposed scoring of urodynamic stress UI based on self-reported frequency of incontinent episodes and the amount of protection.^{276,277} The diagnostic value of such composite scores was moderate with a positive predictive likelihood ratio of 3.8 and a diagnostic odds ratio of 11.

Diagnostic Value of Clinical Algorithms Based on the Epidemiology of a Pelvic Organ Prolapse and Incontinence Questionnaire When Compared to Clinical Diagnosis

This comparison was tested in one study of 110 women.²⁶² The questionnaire had a moderate likelihood of identifying women with detrusor overactivity (positive likelihood ratio=7.7) and a large likelihood of identifying women with stress UI (positive likelihood ratio=19).²⁶² One study demonstrated moderate diagnostic value of the Three Incontinence Questions Questionnaire (3IQ) when compared to clinical diagnosis in 301 women to detect those with stress or urgency UI.²⁶⁶

Diagnostic Values of Individual Tests When Compared to Urodynamics

In individual studies, other examined tests using urodynamics as a reference standard, including the Q-tip test,^{208,286} UDI-6,^{244,287} questionnaire for urinary incontinence diagnosis (QUID) stress score,²⁸⁸ or Bristol Female Lower Urinary Tract Symptoms Questionnaire,²⁵³ demonstrated minimal diagnostic value for UI with positive predictive likelihood ratios less than 2 (Table 3). The studies of the Gaudenz questionnaire reported different results depending on the country where the study was conducted.^{220,238}

Diagnostic Values of Ultrasound Versus Urodynamics as a Reference Standard

The diagnostic values of ultrasound using urodynamics as a reference standard were examined in five studies of 540 women.²⁸⁹⁻²⁹³ Perineal ultrasound had a small diagnostic value

with a positive predictive likelihood ratio of 3 for urodynamic stress UI.²⁸⁹ Vaginal ultrasound had a moderate diagnostic value with a positive predictive likelihood ratio of 5.3 for urodynamic stress UI.²⁹³ Transrectal ultrasound that detected a decreased angle of UV junction demonstrated a large and conclusive increase in the likelihood of urodynamic stress UI.^{291,292}

Comparison of Diagnostic Values of Different Tests

The majority of studies demonstrated that the tests had only small diagnostic value in distinguishing women with urodynamic stress or urgency UI. Complex clinical algorithms demonstrated better diagnostic performance. Individual studies suggested a good diagnostic value of the epidemiology of prolapse and incontinence questionnaires. Post-test probability of mixed or urgency UI increased in aging women.²⁹⁴

We compared the accuracy of diagnostic tests for different types of UI across studies (Table 3). Urodynamic stress UI was accurately diagnosed in 80 percent of women using 1-hour pad test, and in 75 percent of women using self-reported symptoms of stress UI (Figure 3). Urge symptoms accurately diagnosed urodynamic urgency UI in 66 percent of women. Pad tests accurately diagnosed urodynamic urgency UI in 61 percent of women. Accuracy of the symptoms of mixed UI to diagnose urodynamic stress UI combined with detrusor overactivity was low (56 percent). Clinical diagnosis of stress UI was accurately detected with self-reported symptoms of stress UI in 80 percent of women. Clinical diagnosis of detrusor overactivity was accurately detected with self-reported symptoms of urgency UI in 73 percent. The pooled diagnostic odds ratio demonstrated the same pattern with the best discriminatory performance of symptoms of stress UI and pad test when compared to urodynamic diagnosis of stress UI (Figure 4). The diagnostic odds ratio was the more than 10 for the symptoms for stress and urgency UI when compared to a clinical diagnosis.

We also compared predictive values of diagnostic tests for different type of UI across the studies (Table 4). The predictive values in ambulatory settings depend on prevalence of UI in community dwelling women.¹⁶⁷ Positive predictive values were less than 50 percent for most comparisons while negative predictive values were larger than 90 percent. Positive predictive value of the symptoms of mixed UI and urgency UI increased with age. The majority of women without symptoms of UI did not have clinical diagnosis of UI.

Minimal Clinically Important Differences in Diagnostic Tools To Monitor Effectiveness of Treatments

Women considered a reduction of 50 percent or more in UI episode frequency a clinical success.²⁹⁵ Quality of life was improved with more than 70 percent reduction in UI episode frequency. However, clinical trials and the FDA reviews did not define women centered outcomes as primary outcomes.

Clinically important differences have been determined for several questionnaires and scales. Among validated diagnostic questionnaires, The Leicester Urinary Symptom Questionnaire (LUSQ)²⁹⁶ and Medical, Epidemiological, and Social Aspects of Aging Questionnaire (MESA)²⁹⁷ provided information about presence and severity of UI in categorical terms. Other tools suggested scoring of the symptoms of any UI^{259,298} or urgency UI.²⁶⁴ The overall score varied for different tools (Table 5). The Bladder Self-Assessment Questionnaire and Bladder Control Self-Assessment Questionnaires defined minimal important differences in scores that can be used to detect treatment success in clinical settings.²⁹⁹

A variety of validated tools are available to monitor quality of life in women with UI and with different UI types. Several tools that define clinically important differences in scores can be used to assess treatment success in clinical settings.

Patient satisfaction can be assessed with several validated tools, including the Overactive Bladder Symptom Score,³⁰⁰ the Benefit, Satisfaction with Treatment, and Willingness,³⁰¹ the Estimated Percent Improvement,³²⁸ or the Global Perception of Improvement³⁰² (Table 5). Some tools focused on satisfaction with treatments in women with urgency UI,^{300,301,303} while other tools were proposed for any UI type. These instruments are brief and do not require much time to complete. Clinical importance of different responses is self-explanatory. Patient satisfaction measures define treatment success but do not provide many details to explain treatment failure.

We analyzed validity and reliability of the tools and sought literature to find definitions of the minimum important differences in continuous measures of severity of UI, bothersomeness, or quality of life (Table 5). We evaluated the scales and questionnaires recommended by the ICI for diagnosis, monitoring of treatment, and assessment of quality of life in women with UI.³⁰⁴

Effectiveness of treatments in randomized controlled clinical trials was assessed with 3 to 7 day diaries. A reduction in UI episode frequency was the most common primary outcome that RCTs were designed to examine.^{115,305-326} Medical and statistical reviews conducted by the FDA focused on the same primary outcomes that RCTs were designed to examine—absolute changes in UI episode frequency.^{115,306,307,327-330} Some RCTs further categorized treatment success as any reduction in UI episode frequency or reduction by 50, 75, or 90 percent in UI episode frequency.

One pooled analysis of individual data of 1,913 women with predominant stress UI who participated in four RCTs examined what reduction in UI episode frequency was important for the patients.²⁹⁵ The authors examined the relationship between relative reduction in UI episode frequency and improvement meaningful for women in the Incontinence Quality of Life questionnaire.²⁹⁵ Women with daily stress UI perceived important clinical benefit at reductions of approximately 50 percent and important incremental clinical value at reductions of 75 percent and 90 to 100 percent. The study concluded that women noticed improvement in quality of life when UI episode frequency was reduced by more than 70 percent.²⁹⁵ Small changes of 20 to 40 percent in incontinence episode frequency were not important to women when the results from a voiding diary were analyzed in association with the validated Incontinence Quality of Life (I-QOL) questionnaire. The quality of life impact was similar for stress UI episode reductions of >40 percent to <70 percent.²⁹⁵ In the case of women with persistent urge, stress or mixed urinary incontinence, more than 60 percent reported complete treatment satisfaction using the Global Perception of Improvement of Incontinence Impact Questionnaire when they experienced a more than 70 percent reduction in UI episode.³⁰² No studies examined clinically important reduction in UI episode frequency for women with predominant urgency UI.

All tools to assess symptom bother have been validated. Tools that distinguish symptom bother for stress UI include Patient Global Impression of Improvement PGI-I,³³¹ PGI-S Patient Global Impression of Improvement and Severity,³³¹ or Symptom Severity Index and Symptom Impact Index for stress UI in women.³³² The Primary OAB Symptom Questionnaire provided four scales to assess symptom bother for urgency UI.³³³ Other tools evaluated symptom bother for any type of UI (Table 5). The Incontinence Severity Index,^{334,335} Patient Global Impression of Improvement and of Severity,³³¹ Urogenital Distress Inventory,^{222,336,337} and Patient Perception of Bladder Condition^{333,338,339} developed definitions of minimum important differences in any UI that can be used to define treatment success in clinical settings. The Urogenital Distress Inventory stress subscale also can distinguish minimum important differences in stress UI.³³⁶

Women reported improvement in UI when the incontinence episode frequency was reduced by ≥ 63 percent.³³¹

Several tools have been validated to assess quality of life in women with UI (Table 5). All tools provided scoring for different domains of quality of life and overall total scores that varied by direction and magnitude across the scales. Comparing efficacy of the tools was difficult because of such variability in content and psychometric properties. Few tools addressed quality of life depending on the type of incontinence.

Association Between Methods of Diagnosis and Prediction of Patient Outcomes

We found no evidence that outcomes of conservative treatments were better predicted by urodynamic diagnosis.

However, women who failed conservative treatments and/or decided to have surgery for stress UI may benefit from a multichannel urodynamic evaluation. In all cases, a diagnostic algorithm assumes adequate assessment of baseline conditions that may result in UI, including pelvic organ prolapse, urinary tract infection, or pelvic floor trauma.

A few studies tested the effect of baseline urodynamic examination in association with better prediction of treatment outcomes. The studies generally showed that urodynamic findings did not better predict response to conservative treatments. One extension of RCTs of conservative treatment concluded that continence (RR 1.24, 95 percent CI, 0.30 to 5.23), improvement in UI (RR 0.85, 95 percent CI, 0.55 to 1.31), or treatment failure with worsening of UI (RR 1.24, 95 percent CI, 0.47 to 3.29) did not differ between women who did or did not have a baseline urodynamic evaluation.³⁴⁰ The second RCT randomized women to conservative treatments depending on baseline urodynamics or clinical symptoms.³⁴¹ Treatments included fluid management, physical therapy, and drugs, depending on urodynamic or clinical diagnosis. Quality of life measured with King's Health Questionnaire and the frequency of UI episodes measured with voiding diary did not differ between randomized groups.³⁴¹ The authors concluded that baseline urodynamic diagnosis was not associated with better predicting outcomes.

Drug studies showed that in women with severe stress UI, duloxetine versus placebo decreased the frequency of UI episodes independent of baseline urodynamic findings.³¹⁹ Women with intrinsic sphincter deficiency experienced more than a 50 percent decrease in daily UI (RR 6.15, 95 percent CI, 1.54 to 24.54), as did women without intrinsic sphincter deficiency (RR 4.20, 95 percent CI, 1.81 to 9.76). The RCT, however, was not designed to detect differences in duloxetine effect by using a baseline urodynamic evaluation. One multicenter RCT examined clinical outcomes with fesoterodine in subgroups by urodynamic findings of detrusor overactivity.³⁴² Treatment response, discontinuation rate, and adverse effects did not differ between individuals with versus without urodynamic diagnosis of detrusor overactivity (Appendix Table F25).³⁴² One RCT that compared clinical outcomes with tolterodine-ER versus placebo also did not demonstrate differences in treatment effects in women with and without urodynamic detrusor overactivity.³⁴³ Baseline urodynamic examination did not better predict treatment outcomes. Case series also found no differences in treatment response with oxybutynin between those with versus without urodynamically verified symptoms (Appendix Table F26).³⁴⁴

In contrast, one large analysis of 6,276 women with UI from the United Kingdom suggested that urodynamic evaluation is essential to predict outcomes, but only with surgery for UI.³⁴⁵ The authors examined the accuracy of the history of pure stress UI in predicting only urodynamic

stress UI compared to the NICE guidance and found very low sensitivity of 11 percent and good specificity of 98 percent (NICE, 83 percent; 95 percent CI, 49 to 92 percent). The study suggested that a multichannel urodynamic evaluation is indicated for women whose conservative treatments failed and who decided to have surgery for stress UI.³⁴⁵ A recent study also concluded that all women whose conservative treatments failed and who undergo surgery for stress UI should have multichannel urodynamic evaluation.³⁴⁶

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Urodynamic stress UI	Symptoms of stress UI/ Urodynamic test	27 ^{188,189,191,193,195,197,200,202,203,206,207,209,213,217,228,229,238,244,246,251,253,273,279-283} 5,780	0.93 [^] (0.90 to 0.95) 0.94 (0.91 to 0.96)	0.41 [^] (0.34 to 0.49) 0.41 (0.31 to 0.51)	1.54 (1.40 to 1.7)	0.20 (0.14 to 0.27)	0.74 (0.68 to 0.80)	0.74 (0.67 to 0.81)
Detrusor overactivity	Symptoms of urgency UI/ Urodynamic test	23 ^{188,191,195,200,202,203,206,207,209,213,216,217,228,229,238,244,246,251,273,279-281,284} 5,485	0.82 [^] (0.76 to 0.87) 0.82 (0.75 to 0.88)	0.51 [^] (0.44 to 0.59) 0.52 (0.40 to 0.65)	1.54 (1.38 to 1.73)	0.39 (0.30 to 0.50)	0.56 (0.48 to 0.63)	0.80 (0.73 to 0.86)
Detrusor overactivity	Symptoms of urgency/ Urodynamic test	9 ^{202,206,209,213,217,229,247,279,284} 6,418	0.84 [^] (0.59 to 0.95) 0.82 (0.70 to 0.92)	0.39 [^] (0.17 to 0.67) 0.39 (0.24 to 0.55)	1.36 (1.18 to 1.58)	0.47 (0.33 to 0.67)	0.48 (0.39 to 0.57)	0.75 (0.67 to 0.81)
Detrusor overactivity*	Symptoms of urgency UI/ Urodynamic test	17 ^{191,195,200,203,206,207,209,211-213,217,228,229,244,251,273,279} 3,924	0.84 [^] (0.78 to 0.89) 0.84 (0.79 to 0.90)	0.43 [^] (0.36 to 0.50) 0.44 (0.34 to 0.54)	1.48 (1.31 to 1.66)	0.40 (0.29 to 0.54)	0.33 (0.26 to 0.41)	0.89 (0.83 to 0.93)
Detrusor overactivity*	Symptoms of urgency/ Urodynamic test	6 ^{206,209,213,217,229,279} 1,598	0.86 (0.83 to 0.89) 0.86 (0.80 to, 0.90)	0.31 [^] (0.24 to 0.39) 0.31 (0.20 to 0.45)	1.21 (1.11 to 1.32)	0.523 (0.41 to 0.67)	0.27 (0.17 to 0.40)	0.86 (0.76 to 0.93)
Mixed UI	Symptoms of stress and urgency UI/ Urodynamic test	11 ^{191,195,199,200,203,207,228,244,246,251,273} 2,767	0.73 [^] (0.61 to 0.82) 0.72 (0.58 to 0.83)	0.53 [^] (0.40 to 0.66) 0.53 (0.34 to 0.72)	1.45 (1.27 to 1.67)	0.61 (0.52 to 0.71)	0.26 (0.20 to 0.34)	0.89 (0.85 to 0.92)
Urodynamic stress UI	Pad test/ Urodynamic test	3 ^{225,271,275} 574	0.84 (0.76 to 0.90) 0.83 (0.75 to 0.91)	0.77 (0.72 to 0.82) 0.77 (0.17 to 0.97)	3.62 (2.88 to 4.57)	0.22 (0.15 to 0.32)	0.82 (0.77 to 0.86)	0.78 (0.73 to 0.83)
Detrusor overactivity	Pad test/ Urodynamic test	2 ^{271,275} 469	0.72 [^] (0.30 to 0.94)	0.56 [^] (0.38 to 0.72)	1.56 (0.62 to 3.90)	0.47 (0.10 to 2.33)	0.32 (0.04 to 0.83)	0.88 (0.83 to 0.91)

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling) (continued)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Urodynamic stress UI	Symptoms of predominant stress UI/clinical diagnosis	5 ^{218,223,259,266,285} 947	0.88^ (0.68 to 0.96) 0.86 (0.70 to 0.96)	0.67^ (0.54 to 0.78) 0.67 (0.51 to 0.81)	2.35 (1.97 to 2.81)	0.19 (0.09 to 0.41)	0.80 (0.66 to 0.89)	0.75 (0.58 to 0.87)
Detrusor overactivity	Symptoms of predominant urgency UI/clinical diagnosis	4 ^{218,223,259,266} 735	0.82^ (0.73 to 0.89) 0.82 (0.73 to 0.90)	0.67^ (0.53 to 0.79) 0.67 (0.45 to 0.86)	2.52 (1.81 to 3.50)	0.26 (0.18 to 0.38)	0.72 (0.48 to 0.88)	0.79 (0.54 to 0.92)
Mixed UI	Symptoms of stress and urgency UI/clinical diagnosis	3 ^{223,259,266} 654	0.65^ (0.36 to 0.86) 0.64 (0.38 to 0.85)	0.54^ (0.21 to 0.84) 0.52 (0.06 to 0.94)	1.57 (0.68 to 3.59)	0.74 (0.28 to 1.95)	0.36 (0.27 to 0.47)	0.80 (0.43 to 0.96)
Urodynamic stress UI	Logistic regression model/ Urodynamic test	1 ²⁵⁸ 488	0.77	0.56	1.76	0.41	0.68	0.65
Detrusor overactivity	Logistic regression model/ Urodynamic test	1 ²⁵⁸ 488	0.63	0.65	1.81	0.57	0.63	0.67
Urodynamic stress UI	Clinical algorithm/ Urodynamic test	1 ²⁵⁴ 173					0.90 (0.85 to 0.94)	
Urodynamic stress UI	Clinical algorithm/ Urodynamic test	1 ²³⁰ 74					0.97	
Urodynamic stress UI	Clinical algorithm based on EPIQ/Clinical diagnosis	1 ²⁶² 110	0.80	0.92	10.00	0.22	0.88	0.87
Detrusor overactivity	Clinical algorithm based on EPIQ/Clinical diagnosis	1 ²⁶² 110	0.77	0.90	7.70	0.26	0.77	0.90

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling) (continued)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Detrusor overactivity	Clinical algorithm based on OAB-V8/Clinical diagnosis	1 ²⁶⁴ 1,260	0.98	0.83	5.66	0.02	0.44	1.00
Urodynamic stress UI	Q-tip test/ Urodynamic test	3 ^{208,286,291} 267	0.62 (0.53 to 0.70)	0.60 [^] (0.40 to 0.78)	1.70 (0.89 to 3.23)	0.60 (0.31 to 1.17)	0.58 (0.26 to 0.85)	0.67 (0.34 to 0.89)
Detrusor overactivity	Q-tip test/ Urodynamic test	1 ²⁰⁸ 100	0.40	0.40	0.66	1.50	0.33	0.47
Urodynamic stress UI	UDI-6 question 3 score ≥2/ Urodynamic test**	1 ²³⁴ 128	0.85	0.63	2.32	0.24		
Urodynamic stress UI	UDI-6 question 3 score ≥2/ Urodynamic test**	1 ²⁴⁴ 202	0.88	0.55	1.97	0.21	0.86	0.60
Urodynamic stress UI	DIS	1 ²⁰⁸ 250	0.60	0.77	2.61	0.52	0.82	0.52
Detrusor overactivity	UDI-6 question 1 score ≥2/ Urodynamic test	1 ²³⁴ 128	0.83	0.50	1.67	0.33		
Detrusor overactivity	UDI-6 question 2 score ≥2/ Urodynamic test	1 ²³⁴ 128	0.75	0.33	1.11	0.77		
Detrusor overactivity	UDI-6 question 1 and 2 score ≥2/ Urodynamic test	1 ²³⁴ 128	0.69	0.64	1.90	0.49		
Urodynamic stress UI	QUID stress score ≥4/Clinical diagnosis	1 ²⁵⁹ 117	0.85	0.71	2.93	0.21	0.90	0.61

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling) (continued)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Detrusor overactivity	QUID urge score ≥6/Clinical diagnosis	1 ²⁵⁹ 117	0.79	0.79	3.76	0.27	0.95	0.43
Detrusor overactivity	BIDI from diary/ Urodynamic test	1 ²⁸⁸ 217	0.88	0.83	5.12	0.14	0.41	0.98
Detrusor overactivity	Logistic regression model/ Urodynamic test	1 ²⁷⁷ 200	0.81	0.72	2.89	0.26	0.74	0.79
Detrusor overactivity*	Logistic regression model/ Urodynamic test	1 ²⁷⁶ 207	0.56	0.96	12.56	0.46	0.80	0.87
Urodynamic stress UI	Gaudenz-Incontinence-questionnaire predominant stress UI symptoms/ Urodynamic test	1 ²²⁰ 1,911	0.56	0.45	1.01	0.99	0.88	0.18
Detrusor overactivity	Gaudenz-Incontinence-questionnaire predominant urgency UI symptoms/ Urodynamic test	1 ²²⁰ 1,911	0.62	0.56	1.40	0.69	0.03	0.99
Urodynamic stress UI*	Logistic regression/ Urodynamic test	1 ²⁷⁶ 207	0.95	0.43	1.66	0.13	0.48	0.93
Urodynamic stress UI	Logistic regression/ Urodynamic test	1 ²⁷⁷ 200	0.72	0.81	3.79	0.35	0.79	0.74

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling) (continued)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Urodynamic stress UI*	Clinical algorithm based on I-QOL/ Urodynamic test	1 ²⁵⁰ 86					0.76	
Urodynamic stress UI	Clinical algorithm based on I-QOL/ Urodynamic test	1 ²⁵⁰ 86					0.92	
Urodynamic stress UI*	Clinical algorithm/ Urodynamic test	1 ²⁵⁴ 173					0.77 (0.7 to 0.83)	
Urodynamic stress UI	Clinical algorithm/clinical diagnosis	1 ²⁵⁴ 173					0.98 (0.95 to 1.00)	
Urodynamic stress UI*	Clinical algorithm/clinical diagnosis	1 ²⁵⁴ 173					0.85 (0.79 to 0.90)	
Urodynamic stress UI*	Clinical algorithm/ Urodynamic test	1 ²³⁰ 74					0.82	
Urodynamic stress UI*	Clinical algorithm retrospective/ Urodynamic test	1 ²³² 57	0.90	1.00		0.10	1.00	0.82
Urodynamic stress UI*	Clinical algorithm prospective/ Urodynamic test	1 ²³² 19	0.62	1.00		0.38	1.00	0.55
Urodynamic stress UI*	Clinical algorithm combining retrospective and prospective/ Urodynamic test	1 ²³² 76	0.83	1.00		0.17	1.00	0.73

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling) (continued)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Urodynamic stress UI*	Q-tip test/ Urodynamic test	1 ²⁰⁸ 100	0.38	0.44	0.67	1.42	0.22	0.63
Detrusor overactivity*	Q-tip test/ Urodynamic test	1 ²⁰⁸ 100	0.63	0.56	1.45	0.65	0.47	0.71
Urodynamic stress UI	Self reported questionnaire/Urodynamic test	1 ¹⁹⁷ 161	0.68	0.79	3.23	0.40	0.82	0.63
Detrusor overactivity	Self reported questionnaire/UD	1 ¹⁹⁷ 166	0.67	0.66	1.94	0.51	0.13	0.96
Detrusor overactivity	Bristol Female Lower Urinary Tract Symptoms Questionnaire, interview/ Urodynamic test	1 ²⁵³ 72	0.85	0.16	1.01	0.94		
Detrusor overactivity	Bristol Female Lower Urinary Tract Symptoms Questionnaire, self report/ Urodynamic test	1 ²⁵³ 72	0.81	0.12	0.92	1.58		
Urodynamic stress UI	Bristol Female Lower Urinary Tract Symptoms Questionnaire, interview/ Urodynamic test	1 ²⁵³ 72	0.89	0.30	1.27	0.37		

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling) (continued)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Urodynamic stress UI	Bristol Female Lower Urinary Tract Symptoms Questionnaire, self report/ Urodynamic test	1 ²⁵³ 72	0.88	0.29	1.24	0.41		
Urodynamic stress UI	Discriminant score/ Urodynamic test	1 ²⁵³ 252	0.78	0.84	4.97	0.26	0.81	0.81
Urodynamic stress UI*	Gaudenz-Incontinence-questionnaire score predominant stress UI symptoms/ Urodynamic test	1 ²⁵³ 198	0.83	0.92	10.12	0.18	0.95	0.76
Urodynamic stress UI*	3IQ predominant stress UI symptoms/clinical diagnosis	1 ²⁶⁶ 301	0.77	0.79	3.63	0.29	0.74	0.82
Urodynamic stress UI*	Clinical algorithm of predominant stress UI symptoms based on UITN/ Urodynamic test	1 ²⁶⁷ 655	0.91					
Detrusor overactivity*	3IQ predominant stress UI symptoms/ clinical diagnosis	1 ²³⁸ 301	0.57	0.87	4.52	0.49	0.75	0.76
Urodynamic stress UI	3IQ predominant stress UI symptoms/clinical diagnosis	1 ²³⁸ 301	0.68	0.85	4.57	0.37	0.86	0.66

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling) (continued)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Detrusor overactivity	3IQ predominant stress UI symptoms/ clinical diagnosis	1 ²³⁸ 301	0.48	0.91	5.22	0.57	0.86	0.60
Detrusor overactivity*	Gaudenz-Incontinence-questionnaire score predominant urgency UI symptoms/ Urodynamic test	1 ²³⁸ 198	0.86	0.96	24.28	0.14	0.81	0.98
Mixed UI	Gaudenz-Incontinence-questionnaire score mixed UI symptoms/ Urodynamic test	1 ²³⁸ 198	0.61	0.87	4.56	0.45	0.54	0.89
Urodynamic stress UI	Gaudenz-Incontinence-questionnaire score predominant stress UI symptoms/ Urodynamic test	1 ²³⁸ 198	0.98	0.55	2.18	0.03	0.79	0.95
Detrusor overactivity	Gaudenz-Incontinence-questionnaire score predominant urgency UI symptoms/ Urodynamic test	1 ²³⁸ 198	0.90	0.70	2.97	0.15	0.34	0.98

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling) (continued)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Urodynamic stress UI	Symptoms, Q-tip, and cough test/ Urodynamic test	1 ³⁴⁷ 87	0.94	0.84	5.85	0.08	0.94	0.84
Detrusor overactivity	Symptoms, Q-tip, and cough test/ Urodynamic test	1 ³⁴⁷ 87	0.78	0.87	5.98	0.25	0.84	0.82
Urodynamic stress UI*	Symptoms, Q-tip, and cough test/ Urodynamic test	1 ³⁴⁷ 87	0.92	0.45	1.67	0.18	0.56	0.88
Detrusor overactivity*	Symptoms, Q-tip, and cough test/ Urodynamic test	1 ³⁴⁷ 87	0.88	0.67	2.69	0.18	0.39	0.96
Mixed UI	Symptoms, Q-tip, and cough test/ Urodynamic test	1 ³⁴⁷ 87	0.67	0.89	6.00	0.38	0.70	0.88
Urodynamic stress UI	Ultrasound (perineal, BND)/ Urodynamic test	1 ²⁸⁹ 102	0.73	0.77	3.16	0.35	0.64	0.83
Urodynamic stress UI	Ultrasound (perineal, BND)/ Urodynamic test	1 ²⁹⁰ 38	0.72					
Urodynamic stress UI	Ultrasound (transrectal, drop of UV junction)/ Urodynamic test	1 ²⁹¹ 91	0.86	0.96	20.30	0.14	0.95	0.88
Urodynamic stress UI	Ultrasound (transrectal, drop of UV junction)/ Urodynamic test	1 ²⁹² 85	0.94	0.87	7.10	0.07	0.81	0.96

Table 3. Diagnostic value of the test for UI in women (pooled with random effects models and bivariate pooling) (continued)

Type of incontinence	Method index/ Reference Standard	Number of studies References Number of subjects in analyses	Sensitivity/ Bivariate pooling	Specificity/ Bivariate pooling	Positive likelihood ratio†	Negative likelihood ratio†	Positive predictive value	Negative predictive value
Urodynamic stress UI	Ultrasound (vaginal, opening of bladder neck/proximal urethral with leakage during cough)/ Urodynamic test	1 ²⁹³ 124	0.96	0.82	5.33	0.05		
Detrusor overactivity	Symptoms and pad test/ Urodynamic test	1 ³⁴⁸ 100	0.88					

* pure type

** not pooled because of poor reporting quality

68% women and 32% men, the golden standard was not clearly defined

^ significant heterogeneity

† Clinical interpretations of likelihood ratios¹⁹⁷

Likelihood Ratio	Interpretation
>10	Large and often conclusive increase in the likelihood of disease
5 - 10	Moderate increase in the likelihood of disease
2 - 5	Small increase in the likelihood of disease
1 - 2	Minimal increase in the likelihood of disease
1	No change in the likelihood of disease

Figure 3. Accuracy of diagnostic methods for female UI (pooled with random effects model results)




Figure 4. Diagnostic odds ratio of diagnostic methods for female UI (pooled with random effects model results)




Table 4. Predictive value of diagnostic tests for different types of UI by age subgroups

Age groups	Prevalence of UI,%	Symptoms of mixed UI compared to clinical diagnosis for mixed UI		Symptoms of mixed UI compared to urodynamic diagnosis of stress UI	
	Mixed UI	PPV+, %	PPV-, %	PPV+, %	PPV-, %
19-44	21.6	28.0	84.8	30.0	87.7
45-64	20.2	26.4	85.9	28.3	88.6
65+	33.4	41.4	75.5	43.7	79.7
80+	32.8	40.8	76.0	43.1	80.1
		Symptoms of stress incontinence compared to clinical diagnosis for stress UI		Symptoms of stress incontinence compared to urodynamic stress UI	
	Stress UI	PPV+, %	PPV-, %	PPV+, %	PPV-, %
19-44	30.6	50.3	94.5	40.9	93.0
45-64	33.4	53.6	93.7	44.2	92.1
65+	28.6	47.9	94.9	38.7	93.6
80+	25.1	43.5	95.7	34.6	94.6
		Symptoms of urgency UI compared to clinical diagnosis for detrusor overactivity		Symptoms of urgency UI compared to urodynamic diagnosis of detrusor overactivity	
	Urgency UI	PPV+, %	PPV-, %	PPV+, %	PPV-, %
19-44	13.2	27.5	96.1	20.3	94.9
45-64	17.4	34.3	94.7	26.0	93.1
65+	25.4	45.8	91.6	36.3	89.3
80+	24.7	45.0	91.9	35.5	89.6

Table 5. Diagnostic tools to assess clinical importance and monitor effectiveness of treatments of UI

Tools*	References (all that mentioned)	Conditions	Domain	Minimal important differences	Worst to best	Validity/ reliability
Symptom Bother ISI	Sandvik, 1993 ³³⁴ Sandvik, 2000 ³³⁵	Any/not specified	Frequency Severity	1993 version* 6-8 as severe UI (pad test mean 56-63g/24 hours) 3-4 as moderate UI (pad test 17g/24 hours) 2000 version 8-9 as severe UI(pad test mean 52g/24 hours) 12 as very severe UI (pad test mean 122g/24 hrs)	1993 version 8 to 1 2000 version 12 to 1	Yes/No
Symptom Bother PGI-I	Yalcin, 2003 ³³¹	Stress UI	1 item for improvement	Change incontinence episode frequency* -92% in very much better group -63% in much better group	7 to 1 for improvement	Yes/No
Symptom Bother PGI-S	Yalcin, 2003 ³³¹	Stress UI	1 item for severity	Mean incontinence episode frequency* 32.8 per week for severe cases	4 to 1 for severity	Yes/No
Symptom Bother POSQ	Matza, 2005 ³³³	Urgency UI or OAB	4 bother scales for OAB symptoms 1 item to indicate the most bother symptom	Not available	5 to 1 for first 4 items	Yes/Yes
Symptom Bother PPBC	Coyne, 2005 ³³⁸ Capo, 2008 ³³⁹ Matza, 2005 ³³³	Any/not specified	Single-Item Global Measure	Incontinence episodes/7days diary* 7.4 in many severe cases 3.3 in very severe cases 2.0 in moderate severe cases	6 to 1	Yes/Yes
Symptom Bother SSI/SII	Black, 1996 ³³⁸	Stress UI	Severity Incontinence impact	Not available	20 to 0 for SSI 16 to 0 for SII	Yes/Yes
Symptom Bother SUIQQ	Kulseng-Hanssen, 2003 ²⁵²	Stress UI or Urgency UI (OAB)	Total QoL	Not available	12 to 0 for the stress incontinence index 8 to 0 for the urgency incontinence index 16 to 0 for the QoL index	Yes/Yes
Symptom Bother UDI	Uebersax, 1995 ³³⁶ Shumaker, 1994 ²²² Barber, 2009 ³³⁷ Dyer, 2010 ³⁴⁹	Stress UI or Urgency UI (OAB)	Symptom: irritative, stress, obstructive	-6.4 to -22.4 -35 to -43 (anchor-based) or -10 to -25 (distribution-based) for UUI -4.6 to -16.5 for UDI-stress subscale	100 to 0 for each subscale	Yes/Yes
Symptom Bother UDI-6	Uebersax, 1995 ³³⁶	Any/not specified	Symptom: irritative, stress, obstructive	Not available	18 to 0	Yes/Yes
Screening 3IQ	Brown, 2006 ²⁶⁶	Any/not specified	3 questions to classify UUI and SUI	Not available	Categorical variables	No/No

Table 5. Diagnostic tools to assess clinical importance and monitor effectiveness of treatments of UI (continued)

Tools*	References (all that mentioned)	Conditions	Domain	Minimal important differences	Worst to best	Validity/ reliability
Screening B-SAQ	Basra, 2007 ²⁹⁹	Any/not specified	Symptoms Bother	Symptom score 7-9: significant problem* Symptom score 10-12: very significant problem Bother score 7-9: significant problem Bother score 10-12: major problem	12 to 0	Yes/Yes
Screening ISQ	Gunthorpe, 2000 ²⁴⁰	Any/not specified	Five items for predicting UI Three items for concerns	Not available	Algorism for predicting UI 12 to 3 for concerns of UI	Yes/Yes
Screening LUSQ	Shaw, 2002 ²⁹⁶	Any/not specified	Presence of incontinence Severity Urgency Frequency Nocturia	Not available	Categorical variables	Yes/Yes
Screening MESA	Diokno, 1986 ²⁹⁷	Any/not specified	General medical Urological: severity (frequency and quantity) and nature (stress, urge, or mixed) Social Mental health	Not available	Categorical variables	Yes/Yes
Screening OAB-V8	Yalcin, 2003 ³³¹	Urgency UI or OAB	8 items for screening	Not available	40 to 0	Yes/No
Screening QUID	Bradley, 2005 ²⁵⁹	Any/not specified	Stress score Urge score	Not available	15 to 0 for each score	Yes/Yes
Screening USP	Haab, 2008 ²⁹⁸	Any/not specified	Stress urinary incontinence Overactive bladder Low stream	Not available	9 to 0 for SUI 21 to 0 for OAB 9 to 0 for low stream	Yes/Yes
Quality of Life BFLUTS-SF	Jackson, 1996 ²²⁷ Brookes, 2004 ³⁵⁰ Reid, 2007 ³⁵¹	Any/not specified	Symptom Severity Bothersome Sexual function Total QoL	Not available	20 to 0 for the incontinence score 12 to 0 for the voiding score 15 to 0 for the filling score 6 to 0 for the sexual function score 18 to 0 for the QoL score	Yes/Yes

Table 5. Diagnostic tools to assess clinical importance and monitor effectiveness of treatments of UI (continued)

Tools*	References (all that mentioned)	Conditions	Domain	Minimal important differences	Worst to best	Validity/ reliability
Quality of Life CONTLIFE	Amarenco, 2003 ²⁴⁸	Any/not specified	Global health and quality of life Daily Activities Emotions Sexual function Effort Activities Self-Image Well-Being	-7 to -20 (graph only), depending on the domain, in improved population defined by decrease of at least 50% in the number of urinary leaks under treatment	0 to 100	Yes/Yes
Quality of Life EPIQ	Lukacz, 2005 ²⁶²	Any/not specified	QoL Defecatory dysfunction Pelvic organ prolapse Stress urinary incontinence Overactive bladder Pain and difficult voiding Anal incontinence	Not available	Not available	Yes/Yes
Quality of Life IBS	Abdel-Fattah, 2007 ³⁵²	Any/not specified	Simple visual analogue scale	Not available	100 to 0	No/No
Quality of Life ICIQ	Avery, 2004 ³⁵³	Any/not specified	Frequency Severity Bothersome Social limitation Sexual function Interference with everyday life Total QoL	Not available	21 to 0	Yes/Yes
Quality of Life ICIQ-SF	Klovning, 2009 ³⁵⁴	Any/not specified	Frequency Severity Total QoL	With QoL* Mean 16.3 for very severe UI (defined by 2000 ISI) 12.3 for severe UI Without QoL 9.4 for very severe UI 6.8 for severe UI	21 to 0 with QoL 11 to 0 without QoL	Yes/Yes

Table 5. Diagnostic tools to assess clinical importance and monitor effectiveness of treatments of UI (continued)

Tools*	References (all that mentioned)	Conditions	Domain	Minimal important differences	Worst to best	Validity/ reliability
Quality of Life ICS	Stothers, 2004 ³⁵⁵	Any/not specified	Global health and quality of life Social interaction Sexual function Financial impact Satisfaction Personal strain	Not available	45 to 0	Yes/Yes
Quality of Life IHI	Rai, 1994 ³⁵⁶	Urgency UI or OAB	Health/function Emotion	Not available	68 to 0	Yes/No
Quality of Life IIQ	Shumaker, 1994 ²²² Uebersax, 1995 ³³⁶ Hagen, 2002 ³⁵⁷ Barber, 2009 ³³⁷ Dyer, 2010 ³⁴⁹	Any/not specified	Travel Physical activity Social Emotional Total QoL	-6.5 to -22 for stress UI -18 to -50 for UUI	100 to 0 for each domain	Yes/Yes
Quality of Life IIQ-7	Uebersax, 1995 ³³⁶	Any/not specified	Travel Physical activity Social Emotional Total QoL	Not available	21 to 0	Yes/No
Quality of Life IOQ	Bjelic-Radusic, 2007 ³⁵⁸	Stress UI	Symptom Complication Satisfaction QoL	Not available	2100 to 0	Yes/Yes
Quality of Life I-QOL	Patrick, 1999 ³⁵⁹ Bushnell, 2005 ³⁶⁰ Wagner, 1996 ³⁶¹ Oh, 2007 ³⁶² Schurch, 2007 ³⁶³ Yalcin, 2006 ³⁶⁴ Yalcin, 2010 ³²¹ Hollingworth, 2010 ³⁶⁵	Any/not specified Neurogenic UI	Avoidance and Limiting behavior Psychological impact Social embarrassment Total QoL	2 to 5 for UI 6.3 for the within-group MCID: Patients appear to recognize important clinical value at reductions of 50-70% or more incontinence episode frequency 2.5 for the between-group MCID 4 to 11 for neurogenic UI A ≥10-point increase was associated with a 0.05 SF- 6D increase in patients with neurogenic UI	0 to 100	Yes/Yes

Table 5. Diagnostic tools to assess clinical importance and monitor effectiveness of treatments of UI (continued)

Tools*	References (all that mentioned)	Conditions	Domain	Minimal important differences	Worst to best	Validity/ reliability
Quality of Life KHQ	Kelleher, 1997 ³⁶⁶ Reese, 2003 ³⁶⁷ Sand, 2007 ³⁶⁸ Kelleher, 2004 ³⁶⁹ Mostafa, 2010 ³⁷⁰	Any/not specified Urgency UI or OAB	Severity Incontinence impact Role limitation Physical limitation Social limitation Personal relationship Emotions Sleep and energy General health	-3 to -4 for general health and severity domains -5 to -6 for other domains “Very Much improved or Much improved” in PGI-I corresponds to a mean change in KHQ of 46 & 35 points (Range 17 – 60 points) with clear demarcation from those reporting “no change and/or worse condition” (mean 2 & -21; Range -25 – 10)*	100 to 0 for each domain	Yes/Yes
Quality of Life LIS	Shaw, 2004 ³⁷¹	Any/not specified	Impact on activities Impact on feelings	Not available	22 to 0 for activities 20 to 10 on feelings	Yes/Yes
Quality of Life Quality of Life OAB-q	Coyne, 2002 ³⁷² Coyne, 2006 ³⁷³	Urgency UI or OAB	Bothersome Social interaction Sleep and energy Concern/worry Coping Total QoL	Bothersome: 16-19 Social interaction: 4.5-9.3 Sleep and energy: 13-20) Concern/worry: 12-19 Coping: 11-19 Total QoL: 12-16 (within-treatment	0 to 100 for bother score 100 to 0 for QoL	Yes/Yes
Quality of Life PISQ	Rogers, 2001 ³⁷⁴	Any/not specified	Behavioral/emotive Physical activity Partner-related Total score	Not available	0 to 125	Yes/Yes
Quality of Life PRAFAB	Hendriks, 2007 ³⁷⁵ Hendriks, 2008 ³⁷⁶ Hendriks, 2008 ³⁷⁷	Any/not specified	Protection Amount Frequency Adjustment Body image	>14 points for severe UI (>2 g/hour urine loss)* SUI: 2.5-3.1 Urgency UI: 3.0-4.0	20 to 5. 4 points/item (1–4) with a total PRAFAB-Q score of 20 points	Yes/Yes
Quality of Life UISS	Stach-Lempinen, 2001 ²⁴⁵	Any/not specified	The amount of leakage the degree to which UI affects aspects of women’s daily lives	>11.02 points for severe UI (>30 g/24 hour urine loss)*	100 to 0	Yes/Yes

Table 5. Diagnostic tools to assess clinical importance and monitor effectiveness of treatments of UI (continued)

Tools*	References (all that mentioned)	Conditions	Domain	Minimal important differences	Worst to best	Validity/ reliability
Quality of Life UQ	Matza, 2005 ³³³	Stress UI or Urgency UI (OAB)	15 Likert-scale items nocturia Fear of incontinence Time to control urge Impact on daily activities 4 visual analog scales Urinary urgency's severity Intensity Impact Discomfort	Not available	1 (or 5) to 5 (or 1) for Likert-scale 10 to 1 for visual analog scales	Yes/Yes
Quality of Life YIPS	Lee, 1995 ³⁷⁸	Any/not specified	Eight-item seven-point rating scales a unidimensional measure Three single-item measures of self-perceptions of change in continence status, health status, amount of leakage	Not available	0 to 7 for eight rating scales Categorical variables for three single-item measures	Yes/Yes
Patient Satisfaction OAB-SS	Blaivas, 2007 ³⁰⁰	Urgency UI or OAB	5 items for urgency 2 items for frequency	Not available	5 points Likert scales	Yes/Yes
Satisfaction BSW	Pleil, 2005 ³⁰¹	Urgency UI or OAB	Benefit Satisfaction Willingness to continue	-2.21 mean number of incontinence episodes per 24 hours for much benefit population	Categorized for each domain	Yes/No
Satisfaction EPI	Burgio, 2006 ³⁰²	Any/not specified	One item for estimated percent improvement	Not available	0 to 100	Yes/No
Satisfaction GPI	Burgio, 2006 ³⁰²	Any/not specified	One item for global perception of improvement	Not available	5 categories	Yes/No
Satisfaction PSQ	Burgio, 2006 ³⁰²	Any/not specified	One item for patient satisfaction	A 70% improvement in the frequency of incontinence episodes on bladder diary as a critical threshold	3 categories	Yes/No

Table 5. Diagnostic tools to assess clinical importance and monitor effectiveness of treatments of UI (continued)

Tools*	References (all that mentioned)	Conditions	Domain	Minimal important differences	Worst to best	Validity/ reliability
Satisfaction TBS	Colman, 2008 ³⁰³	Urgency UI or OAB	One item for patient- reported benefits	UUI episodes/24 hours +1.31 in “4” group -0.52 in “3” group -1.62 in “2” group -2.38 in “1” group	4 to 1	Yes/Yes

Abbreviations: ***3IQ:** Three Incontinence Questions Questionnaire; **BFLUTS:** Bristol Female Lower Urinary Tract Symptoms Questionnaire; **B-SAQ:** Bladder Self-Assessment Questionnaire or Bladder Control Self-Assessment Questionnaire (BCSQ); **BSW:** Benefit, Satisfaction with treatment, and Willingness; **Contilife:** Quality of Life Assessment Questionnaire Concerning Urinary Incontinence; **EPI:** Estimated Percent Improvement; **EPIQ:** Epidemiology of Prolapse and Incontinence Questionnaire; **GPI:** Global Perception of Improvement; **IBS:** Incontinence Bothersome Scale; **ICIQ:** International Consultation on Incontinence Modular Questionnaire; **ICS:** Incontinence Classification System; **IHI:** Urinary Incontinence Handicap Inventory; **IIQ:** Incontinence Impact Questionnaire; **IIQ-7:** Incontinence Impact Questionnaire - short form; **IOQ:** Incontinence Outcome Questionnaire; **I-QOL:** Urinary Incontinence- Specific Quality of Life Instrument; **ISI:** Incontinence Severity Index; **ISQ:** Incontinence Screening Questionnaire; **KHQ:** King’s Health Questionnaire; **LIS:** Leicester Impact Scale; **LUSQ:** The Leicester Urinary Symptom Questionnaire; **MESA:** Medical, Epidemiological, and Social Aspects of Aging Questionnaire; **OAB-q:** Overactive Bladder Questionnaire; **OAB-S:** Overactive Bladder Satisfaction Questionnaire; **OAB-SS:** Overactive Bladder Symptom Score; **OAB-V8:** OAB Awareness Tool; **PGI-I and PGI-S:** Patient Global Impression of Improvement and of Severity; **PISQ:** Pelvic Organ Prolapse–Urinary Incontinence Sexual Function Questionnaire; **POSQ:** Primary OAB Symptom Questionnaire; **PPBC:** Patient Perception of Bladder Condition; **PRAFAB:** Protection, Amount, Frequency, Adjustment, Body image tool; **PSQ:** Patient Satisfaction Question; **PUF:** patient symptom scale (Pelvic Pain, Urgency, and Frequency); **QUID:** Questionnaire for Urinary Incontinence Diagnosis; **SF:** Short Form; **SSI and SII:** Symptom Severity Index and Symptom Impact Index for stress incontinence in women; **SUIQQ:** Stress and Urge Incontinence and Quality of Life Questionnaire; **TBS:** Treatment Benefit Scale; **UDI:** Urogenital Distress Inventory; **UDI-6:** Urogenital Distress Inventory-6; **UISS:** Urinary Incontinence Severity Score; **UI:** Urinary Incontinence Score; **UQ:** Urgency Questionnaire; **USP:** Urinary Symptom Profile; **YIPS:** York Incontinence perceptions scale. *clinically important cut-off values

Key Question 2. How effective is the pharmacological treatment of UI in women?

We synthesized evidence of efficacy and comparative effectiveness of the drugs for stress UI, including topical estrogen and serotonin-noradrenalin uptake inhibitors and drugs used in the treatment of overactive bladder.⁶⁹ We integrated information about inclusion, exclusion criteria, sponsorship, conflict of interest (Appendix Table F27) and quality of the studies (Appendix Table F28) in the synthesis of evidence. We report here study characteristics that could influence the treatment effects of drugs for UI.

Pharmacological Treatments for Stress UI

Clinical Effectiveness of Topical Estrogen Therapy

Evidence from individual RCTs indicated greater continence and improvement in UI with vaginal estrogen formulations and worsening of UI with transdermal patches (Appendix Table F29). Evidence was insufficient to draw conclusions about clinical efficacy of different topical estrogen treatments for UI.

Four RCTs of 640 women examined the effects of topical estrogen formulations compared to placebo on UI (Appendix Table F27). The studies enrolled postmenopausal women with urodynamic stress,^{379,380} clinical symptoms of any UI,³⁸¹ clinical symptoms of any UI,³⁸¹ or with urge syndrome.³⁸² Estrogen was administered in vaginal tablets, gel,³⁷⁹ subcutaneous implants,³⁸² intravaginal ovules,³⁸⁰ or transdermal patches.^{380,381} The length of treatment varied from 6 months³⁷⁹ to 2 years.³⁸¹ Three studies aimed to treat UI.^{379,380,382} One study examined very low dose transdermal estrogen formulation proposed for prevention of osteoporosis in postmenopausal women.³⁸¹

Continence

Two RCTs examined urinary continence^{379,382} (Appendix Table F30). Vaginal estrogen tablets increased continence rates more often than placebo (RR 20.68, 95 percent CI, 1.23 to 346.46).³⁷⁹ The authors needed to treat five women with estrogen tablets to achieve continence in one woman (NNT 5, 95 percent CI, 3 to 12).³⁷⁹ In contrast, 25 mg 17 beta-estradiol implant did not resolve stress or urgency UI compared to placebo.³⁸²

Improvement in UI

Improvement in UI was significantly greater than placebo with vaginal estrogen tablets³⁷⁹ and vaginal ovules³⁸⁰ (Appendix Table F31). Women complained of stress UI less frequently with intravaginal estrogen formulations than with placebo.³⁸⁰ Unchanged incontinence was less frequent with intravaginal estrogen than with placebo.³⁷⁹ In contrast, transdermal patches with very low doses of estrogen worsened any UI and stress UI at 2 years³⁸¹ (Appendix Table F32). Adjusted for clinical site odds ratios of worsened UI demonstrated increases in odds of stress UI at 4 months (OR 2.05, 95 percent CI, 1.09 to 3.85) but not 4 years. In addition to worsening of UI, women experienced vaginal bleeding with estradiol implants more often than with placebo.³⁸²

Clinical Effectiveness of Duloxetine

A high level of evidence indicated significant improvement in stress UI with duloxetine, while a low level of evidence suggested that duloxetine did not resolve stress UI when compared to placebo. A low level of evidence suggested improvement in quality of life in women with UI. Evidence was insufficient to conclude benefits of duloxetine in women with urgency UI. The risk of adverse effects was significantly higher with duloxetine than with placebo. Duloxetine resulted in improved UI in 75 to 140 women per 1,000 treated,^{319,364,383-387} while 129 women per 1,000 treated stopped taking duloxetine because of adverse effects.

The 24 publications that reported clinical outcomes with duloxetine^{250,319,364,383-404} included six primary RCTs of 4,292 women,^{319,383,386,387,401,402} collaborative publications from the DESIRE Study group (3,983 subjects),³⁸⁸ Duloxetine Dose Escalation Study Group (516 subjects),³⁸⁹ Duloxetine OAB Study Group (306 subjects),³⁸⁵ Duloxetine Urinary Incontinence Study Group (2,741 patients),^{250,384,390-392} Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group (201 subjects), pooled analyses of individual patient data (52,891 subjects),^{364,396-400,404} safety evaluation using pooled analysis of 42 placebo-controlled clinical trials of 8,504 patients⁴⁰³ (Appendix Table F27), and nonrandomized prospective observational studies^{394,395} (Appendix Table F33).

Continence

Two studies of 736 women demonstrated greater continence with placebo than with duloxetine (pooled RR 0.92, 95 percent CI, 0.86 to 0.99)^{384,390} (Appendix Table F34). One publication from the Duloxetine Urinary Incontinence Study Group did not find significant dose response increase in continence with 40 mg of the drug versus 20 mg/day³⁹⁰ (Appendix Table F35).

Improvement in UI

Women experienced more than a 50 percent reduction in the frequency of UI episodes with duloxetine^{319,364,384,386,387} (Appendix Table F36). More women perceived an improvement in UI as either much better or better with duloxetine than with placebo^{319,383-385} (Appendix Table F36). Seven women had to take duloxetine to achieve a 50 percent reduction in UI episodes in one woman (Table 6). Thirteen women (NNT 13, 95 percent CI, 7 to 143) needed to be treated so one woman would perceive an improvement as either much better or better. Improvement in UI was greater with 40 mg/day compared to 20 mg/day³⁹⁰ (Appendix Table F37). Treatment failure did not differ between duloxetine and placebo^{319,383,385,402} (Appendix Table F38).

Improvement in quality of life measures with duloxetine was inconsistent across the studies. Quality of life was examined in eight studies of 5,001 women^{319,364,384-386,390,391,398} (Appendix Table F39). Pooled analysis of two RCTs of 1,133 women with predominant stress UI demonstrated improved Incontinence Quality of Life scores using 80 mg of duloxetine.³⁶⁴ The Multinational Duloxetine UI Study Group found significant improvement in quality of life in North American women,³⁹¹ with no benefit for women in other continents.³⁸⁴ One study indicated significant dose response improvements in the Incontinence Quality of Life questionnaire with 40 mg compared to 20 mg of duloxetine/day.³⁹⁰ Women with severe stress UI³¹⁹ and women with overactive bladder did not experience better quality of life with duloxetine³⁸⁵ compared to placebo.

Adverse Effects

Adverse effects with duloxetine versus placebo were examined in 15 studies with 26,703 subjects.^{319,383-387,389-393,397,401,402,404} Results demonstrated the importance of definitions and measurements of harms. Studies of any adverse effects or treatment-related adverse effects (as judged by investigators) reported less relative harm from the drug than studies of individual adverse effects. For example, the relative increase in treatment-related adverse effects (as judged by investigators) was 36 percent (pooled RR 1.36, 95 percent CI, 1.28 to 1.44)^{319,383-387,391,392,401} (Appendix Table F40). At the same time, the relative increase in several harms was much larger. For instance, relative increase in somnolence was 761 percent (pooled RR 8.61, 95 percent CI, 4.58 to 16.20).^{319,383-387,389,391-393,397,401,402} Nausea (NNT 5, 95 percent CI, 4 to 7),^{319,384,390,392,393,397,401} dry mouth (NNT 9, 95 percent CI, 7 to 11),^{319,383-387,389-393,397,401,402} and fatigue (NNT 13, 95 percent CI, 10 to 19)^{319,383-387,390-392,397,401,402} were among the most common adverse effects of duloxetine when compared to placebo (Appendix Table F41).

The studies did not show consistent dose response associations between duloxetine and adverse effects (Appendix Table F42). The Duloxetine Dose Escalation study reported lower risks of adverse effects at a starting dose of 20 mg with slow escalation to 80 mg/day.³⁸⁹ Large pooled analysis that examined cardiovascular adverse effects of duloxetine⁴⁰³ demonstrated electrocardiographic abnormalities that were statistically but not clinically significant.

Women stopped taking duloxetine because of adverse effects more often than placebo (Appendix Table F43). The relative increase in discontinuation of duloxetine treatment for any adverse effects was 340 percent (pooled RR 4.4, 95 percent CI, 3.24 to 5.86).^{319,383,384,386,389-392,394,402}

Discontinuation rates differed across the studies. We explored heterogeneity by women's age, prior treatments, and concurrent medications for UI, and baseline type and severity of UI (Appendix Table F44) and did not find significant association with the outcome (Appendix Table F45). We explored heterogeneity by study quality (Appendix Table F46) and did not find significant association with the outcome (Appendix Table F45).

Among individual adverse effects leading to treatment discontinuation, every tenth woman stopped taking duloxetine because of effects such as nausea,^{384,386,389-393,397,402} somnolence,^{386,390,391,393,397,402} insomnia,^{384,386,389,391-393,397} dizziness,^{384,386,389-393,397} headache,^{389,390,402} fatigue,^{389,391,397,402} diarrhea,^{397,402} and constipation,^{393,397} which were the most common adverse effects leading to treatment discontinuation (Appendix Table F41).

Pharmacological Treatments for Urgency UI

Clinical Effectiveness of Oxybutynin

A high level of evidence indicated that oxybutynin increased continence rates and improved UI more often than placebo but also resulted in treatment discontinuation due to adverse effects (see Table ES2 in the Executive Summary). Dry mouth was the most common adverse effect. Oxybutynin resulted in resolved UI in 114 women per 1,000 treated, while 63 women per 1,000 treated stopped taking oxybutynin because of adverse effects. Evidence was insufficient to conclude improved quality of life with oxybutynin. A low level of evidence indicated greater rates of adverse effects and dry mouth with immediate release oxybutynin than with controlled release oral or transdermal oxybutynin. A low level of evidence indicated that larger versus lower doses of extended oxybutynin resulted in greater improvement in UI and the same rates of dry mouth, but greater treatment withdrawal.

We identified 15 publications of individual RCTs,^{115,310,322,405-416} one RCT of intravesicular injection of oxybutynin in 52 women,⁴¹⁷ one post hoc analysis of RCTs,⁴¹⁸ and 10 RCTs that compared different doses and formulations of oxybutynin⁴¹⁹⁻⁴²⁸ (Appendix Table F27). We also reviewed a noncontrolled Ditropan XL study of 256 women,⁴²⁹ a Multicentre Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin (MATRIX) study of 2,888 women, pooled analysis of dosing studies,^{323,430,431} and five observational studies of harms and discontinuation rates of oxybutynin therapy⁴³²⁻⁴³⁶ (Appendix Table F33).

Continence

Urinary continence was greater with oxybutynin than with placebo^{409,413,416,437,438} (Appendix Table F47). Pooled results were consistent with nonsignificant heterogeneity across the studies despite differences in populations and doses of the drug. The pooled results, however, were sensitive to one multicenter study at 76 clinics in the United States that demonstrated significant increase in resolved UI with oxybutynin.⁴¹³ The drug needed to be given to nine women to achieve continence in one woman (Table 7).

Improvement in UI

Oxybutynin improved UI more often than placebo^{322,406,415,416,418,437-443} (Appendix Table F47). The drug needed to be given to six women to improve UI in one woman (Table 7). The magnitude of the effect varied across the studies with significant heterogeneity in pooled estimates. Dose of the drug did not explain heterogeneity (p value for meta-regression >0.5). Differences in definitions of improved UI may contribute to heterogeneity. The studies that defined improvement as a reduction of 75 percent in UI episodes^{415,437} reported similar relative risk and absolute risk difference. In contrast, the studies that did not quantify improvement in UI tended to demonstrate very large benefits from oxybutynin compared to placebo (Appendix Table F47).

We explored heterogeneity by characteristics of women, treatment, and study and found no significant association with the outcomes (Appendix Table F48).

Change in quality of life was inconsistent within and across the studies^{407,410,437,442,444} (Appendix Tables F49 and F50). Transdermal oxybutynin did not improve quality of life and did not result in treatment satisfaction compared to placebo in women with overactive bladder (OAB).⁴⁴⁵

Treatment failure with unchanged or worsened UI was less common with oxybutynin than with placebo^{415,437,439,441,443} (Appendix Table F47).

Adverse Effects

Discontinuation of treatments did not differ between oxybutynin and placebo^{406,413,437,439,446} (Appendix Table F47). However, discontinuation of treatment due to adverse effects was greater with active drugs than with placebo (Appendix Table F47).^{87,412,413,441,442,446} Among every 16 treated, one woman stopped taking the drug because of adverse effects. Interestingly, the relative increase in total adverse effects^{411,439,441} or serious adverse effects^{411,413,441} did not differ from placebo (Appendix Table F47). The differences across the studies in definitions and methods to assess harms may contribute to discrepancies.

Dry mouth was the most common adverse effect^{322,405,406,410,413,416,437,441,442,446} (Appendix Table F47). Oxybutynin caused dry mouth on one woman for every three treated (NNT 3, 95 percent CI, 2 to 6) (Table 7).

Several studies compared formulations and doses of oxybutynin (Appendix Table F51). The Uromax Study demonstrated greater improvement in UI with larger doses of extended oxybutynin (15 mg versus 5 or 10 mg).⁴²⁷ The larger doses, however, resulted in greater treatment withdrawal for 15 versus 5 mg/day.⁴²⁷

The Transdermal Oxybutynin Study found that severe dry mouth and constipation were less common with transdermal than with oral immediate-release oxybutynin.⁴²³ Adverse effects were less common with once-daily, controlled-release formulation oxybutynin than with immediate-release oxybutynin.⁴⁴⁷ Dry mouth was less common with transdermal versus oral immediate-release oxybutynin,⁴²³ with controlled versus immediate-release oxybutynin,⁴¹⁹ and with lower versus larger doses of controlled-release oxybutynin.⁴²⁷

Clinical Effectiveness of Tolterodine

A high level of evidence indicated increased continence rates and significant improvement in UI with tolterodine treatments than with placebo in women with UI (see Table ES2 in the Executive Summary). A low level of evidence indicated improvement in quality of life with tolterodine treatment. Adverse effects including autonomic nervous system disorders, abdominal pain, dry mouth, dyspepsia, and fatigue were significantly more common with tolterodine than with placebo. Per 1,000 women treated, tolterodine resulted in resolved UI in 85 women, and resulted in adverse effects in 83 women. Discontinuation of the treatment and stopping treatment due to adverse effects did not differ between tolterodine and placebo.

We identified 24 RCTs that examined clinical outcomes with tolterodine versus placebo,^{309,312,314,317,321,343,448-465} publications of secondary data analyses,^{87,466-468} multicenter nonrandomized clinical trials,⁴⁶⁹ including the IMPACT study (Appendix Table F27)⁴⁷⁰⁻⁴⁷² and several noncontrolled observational studies of harms with tolterodine treatments (Appendix Table 33).⁴⁷³⁻⁴⁷⁶

Continence

Urinary continence was achieved more often with tolterodine than with placebo in pooled analysis (pooled RR 1.2, 95 percent CI, 1.1 to 1.4)^{309,312,313,343} (Appendix Table F47). The drug had to be given to 12 women to achieve continence in one woman (NNT 12, 95 percent CI, 8 to 25) (Table 7).

Improvement in UI

Tolterodine improved UI more often than placebo^{88,309,313,454,456,461,463,464} (Appendix Table F47). The drug needed to be given to 10 women to achieve improvement in UI in one (Table 7). The magnitude of the association differed across the studies, probably because of different definitions of improvement. Women's characteristics, treatment dose and duration, and study quality were not associated with the outcome (Appendix Table F48).

Secondary data analyses demonstrated that 4mg/day of tolterodine, but not 2 mg/day, improved subjects' perceptions of their bladder condition (Appendix Table F52).^{87,88,456} Women evaluated treatment success as "much better" more often with 4 mg/day of tolterodine than with placebo⁴⁵⁶ (Appendix Table F52). One pooled analysis reported a greater decrease in the urgency perception scale score with 4 mg of tolterodine daily than with placebo.⁴⁵⁶ An evidence-based report about treatment of overactive bladder in women showed a significant decrease in the frequency of UI episodes with immediate release (weighted mean difference 1.45, 95 percent CI, 1.24 to 1.66) and with controlled release tolterodine (weighted mean difference 1.75, 95 percent

CI, 1.65 to 1.85).¹¹² One nonrandomized study reported that 79 percent of subjects experience improvement in UI after 12 weeks of tolterodine.⁴⁷⁰⁻⁴⁷²

Adverse Effects

Adverse effects were more common with tolterodine than with placebo^{309,312,321,322,343,449,450,453,457,460,465,477} (Appendix Table F47). Active drugs needed to be given to 12 women in order cause adverse effects in one woman (Table 7). Half of the women experienced adverse effects with 4 mg/day of tolterodine in the IMPACT noncontrolled study.⁴⁷⁰⁻⁴⁷² According to pooled analysis of the aggregate data,^{309,448,450-452} and one pooled analysis of individual patient data, women did not have serious adverse effects more often with tolterodine than with placebo.⁸⁷ The same pooled analysis, however, reported that dose reduction in the case of intolerance was more common with 2 mg twice/day of tolterodine than with placebo⁸⁷ (Appendix Table F52). The rates of all^{449,453} or serious adverse effects with different doses and formulations of tolterodine did not differ^{451,452} (Appendix Table F53).

Among individual adverse effects, tolterodine significantly increased rates of autonomic nervous system disorders,⁴⁴⁸⁻⁴⁵⁰ constipation,^{321,449,451-453,455,457,458,477,478} dyspepsia,^{309,322,343,451,452,455,457} and fatigue^{309,460,463} (Table 8). Tolterodine also increased rates of abdominal pain.^{309,451-453,455,457} Pooled analysis of individual patient data demonstrated greater rates of abdominal pain,⁴⁵⁶ autonomic nervous system disorder,⁸⁷ fatigue,^{88,468} and dry mouth^{88,456,468} (Appendix Table F52). Autonomic nervous system disorder was less common with 1 mg twice daily versus 2 mg daily.^{87,448} Differences in adverse effects of different doses and formulations of tolterodine were not consistent across the individual studies and pooled data from individual patients (Appendix Table F53). Tolterodine caused dry mouth in one woman among seven treated according to our pooled analysis (Table 7).^{309,312,313,321,322,343,451,453,460,461,463,465,477,478} Increases in the rates of dry mouth were not greater with higher doses of tolterodine (p value for meta-regression >0.5).

Treatment discontinuation rates^{309,450,451,454,458,460-462,477,478} and treatment discontinuation due to adverse effects did not differ between tolterodine and placebo^{309,313,321,322,450,452,453,457,458,460,461,463,478} (Table 7). Pooled analyses also demonstrated no differences in discontinuation rates between 2 mg of tolterodine twice daily⁸⁷ and 4 mg of tolterodine once daily⁴⁶⁸ (Appendix Table F52). One pooled analysis reported that treatment discontinuation was lower with 1 mg twice daily than with 2 mg daily of tolterodine (Appendix Table F53). Treatment discontinuation due to adverse effects did not differ in individual RCTs⁴⁵³ and in pooled analyses of individual patient data from RCTs that examined 2 mg of tolterodine twice^{450,452,453} or 4 mg daily^{457,458,460} (Appendix Table F54).

Clinical Effectiveness of Darifenacin

A high level of evidence indicated significant improvement in urgency UI episodes and several domains of quality of life with 7.5 and 15 mg of darifenacin compared to placebo. Adverse effects were more common with darifenacin than with placebo. Darifenacin increased rates of constipation, dry mouth, dyspepsia, and headache. Darifenacin improved UI in 117 women per 1,000 treated while 190 women per 1,000 treated experienced various adverse effects. Evidence was insufficient from which to conclude better benefits with 30 mg of darifenacin/day. The largest dose, however, resulted in greater rates of adverse effects. Treatment discontinuation rates due to adverse effects were the same between darifenacin and placebo.

Seven RCTs reported clinical outcomes of darifenacin versus placebo^{306,307,311,479-483} and several publications of secondary data analyses⁴⁸⁴⁻⁴⁸⁹ (Appendix Tables F27 and F28).

Continence

Urinary continence outcomes were not examined with darifenacin treatment. One pooled analysis demonstrated that women did not experience continence for more than 7 consecutive days more often with 15 mg of darifenacin than with placebo⁴⁸⁶ (Appendix Table F55). The rates of more than 3 dry days/week were greater than placebo with 7.5 mg of darifenacin (RR 1.47, 95 percent CI, 1.02 to 2.13) and with 15 mg of darifenacin (RR 1.48, 95 percent CI, 1.04 to 2.09).⁴⁸⁶ The drug had to be given to 17 women to achieve 3 dry days/week in one woman.⁴⁸⁶

Improvement in UI

Darifenacin improved UI more often than placebo^{479,481,482} (Appendix Table F47). Darifenacin needed to be given to nine women in order to improve UI in one woman (Table 7). Pooled individual patient data from three RCTs also indicated a significant reduction of more than 90 percent in UI episodes more often with 7.5 mg and 15 mg of darifenacin than with placebo⁴⁸⁶ (Appendix Table F55). Women experienced reductions of more than 50 percent^{479,481,482} or more than 70 percent^{479,482} in UI episodes more often with darifenacin than with placebo.

Adverse Effects

Adverse effects were more common with 7.5^{479,482} and 15 mg/day of darifenacin than with placebo.^{482,483} Adverse effects were experienced by one woman among every five treated with darifenacin^{479,482,483} (Table 7). The Darifenacin Study found a significant dose response association with a greater rate of adverse effects with larger doses of darifenacin (Appendix Tables F56 and F57). The rates of serious adverse effects did not differ between darifenacin and placebo.^{482,483}

Rates of individual adverse effects did not demonstrate a consistent dose response association with darifenacin (Appendix Table F57). Among individual adverse effects, darifenacin increased rates of constipation.^{479,480,482,483,489} The association was not dose responsive because constipation with 15 mg/day did not differ from placebo.^{480,482,483,489} Dry mouth was more common with 7.5 mg darifenacin than with placebo.^{479,480,482,483,489} Much less expected was the fact that rates of dry mouth did not differ from placebo, even with larger doses of darifenacin of 15 mg^{480,482,483,489} or 30 mg/day.^{482,489} Dyspepsia was more common with darifenacin than with placebo^{480,482,483,489} (Table 8).

One RCT examined short-term effects of darifenacin controlled release (3.75, 7.5, or 15 mg once daily), darifenacin immediate-release (5 mg three times daily), or placebo on cognitive function in elderly volunteers without clinical dementia.⁴⁸⁰ The authors did not find statistically significant differences, except increased memory scanning speed, with 7.5 and 15 mg of darifenacin.⁴⁸⁰

Treatment discontinuation rates^{483,489} and discontinuation because of adverse effects did not differ between darifenacin and placebo^{306,307,479,481-483,489} (Table 7). The Darifenacin Study Group reported a significant dose response association with greater rates of withdrawals due to adverse effects with 30 mg than with 7.5 mg of darifenacin/day⁴⁸² (Appendix Table F57).

Clinical Effectiveness of Solifenacin

A high level of evidence suggested that solifenacin increased continence rates with greater benefits with the larger dose of the drug in women with urgency and mixed UI. Evidence was insufficient that solifenacin improved quality of life. A high level of evidence suggested greater risk of dry mouth, constipation, and blurred vision with the drug. A high level of evidence suggested that 10 mg of solifenacin increased the risk of severe dry mouth and constipation. Treatment discontinuation due to adverse effects was more common with solifenacin than with placebo. Solifenacin resolved UI in 107 women per 1,000 treated, while 13 women per 1,000 treated stopped taking the drug because of adverse effects.

We identified nine publications of individual RCTs^{477,478,490-496} and pooled analysis of individual patient data from four RCTs⁴⁹⁷⁻⁴⁹⁹ that examined clinical outcomes with solifenacin compared to placebo (Appendix Table F27). We also reviewed the results from the nonrandomized VOLT flexible-dosing trial (VESIcare Open-Label Trial) that examined quality of life in subjects with OAB and urgency UI at 207 centers in the United States.^{500,501}

Continence

Solifenacin resolved UI more often than placebo (pooled RR 1.5, 95 percent CI, 1.4 to 1.6)^{492,494,496,497,499} (Appendix Table F47). Solifenacin needed to be given to nine women to achieve continence in one woman (Table 7). The effect was consistent across the studies. Complete urinary continence was greater with 10 mg of solifenacin than with placebo in two pooled analyses of individual patient data with a relative increase of 43 percent⁴⁹⁹ to 53 percent⁴⁹⁷ (Appendix Table F58). One pooled analysis of individual patient data from four RCTs demonstrated significant dose response increase in continence with better effect with 10 versus 5 mg of solifenacin in women with mixed UI⁴⁹⁹ (Appendix Table F59). Another previously published pooled analysis of individual patient data, however, did not find better continence rates with the larger dose of the drug in women with urgency UI.⁴⁹⁷

Improvement in UI

Solifenacin improved UI more often than placebo^{492,495} (Table 7). The drug needed to be given to six women to achieve improvement in one woman.^{492,495}

Solifenacin in a dose of 5 mg/day improved all examined domains of quality of life measured with King's Health Questionnaire in one RCT.⁴⁹⁹ The largest improvement was in role limitations (mean difference -10.92, 95 percent CI, -11.25 to -10.59), coping/severity measures (mean difference -8.21, 95 percent CI, -8.48 to -7.94), emotions (mean difference -7.84, 95 percent CI, -8.18 to -7.51), and physical limitations (mean difference -7.54, 95 percent CI, -7.88 to -7.21). The VOLT study found that 80.4 percent of the subjects reported improvement in their Patient Perception of Bladder Condition.⁵⁰¹ The VESIcare Investigation of Bother and Quality of Life in Subjects With OAB VIBRANT study reported greater perceived benefit (RR 1.78, 95 percent CI, 1.48 to 2.14), satisfaction (RR 1.42, 95 percent CI 1.26 to 1.61), and willingness to continue (RR 1.39, 95 percent CI, 1.23 to 1.57) with flexible 5 to 10 mg doses of solifenacin⁴⁹² (Appendix Table F60).

Adverse Effects

Adverse effects were more common with solifenacin than with placebo^{477,494-496} (Table 7). The association was significant but not dose responsive (p value for meta-regression >0.5). Among individual adverse effects, dry mouth was the most common with both doses of

solifenacin.^{477,492-495,497,499,502} Pooled analysis of individual patient data reported significant positive dose response association between dry mouth and the larger dose of the drug^{497,499} (Appendix Table F59). The larger dose of the drug caused blurred vision and mild blurred vision more often than placebo (Appendix Table F58).^{497,499} Constipation and severe constipation were more common with 10 mg of solifenacin than with placebo.^{497,499}

Adverse effects leading to discontinuation were more common with solifenacin than with placebo (Table 7).^{478,493-497,499,502} Every 78th woman discontinued the treatment with solifenacin because of adverse effects. Much less expected was the fact that two pooled analyses of individual patient data demonstrated no difference in treatment discontinuation with 5 or 10 mg of solifenacin than with placebo^{497,499} (Appendix Table F58). One pooled analysis of individual patient data of four RCTs reported that women with mixed UI stopped treatment because of adverse effects more often with 10 mg of solifenacin than with 5 mg of the drug⁴⁹⁹ (Appendix Table F59).

Clinical Effectiveness of Fesoterodine

A low level of evidence indicated a significant increase in continence with fesoterodine. A high level of evidence indicated a significant improvement in urgency UI with fesoterodine compared to placebo, with a better response with 8 mg versus 4 mg. Evidence was low that fesoterodine improved quality of life in women with urgency UI. Fesoterodine treatment resulted in higher rates of adverse effects and related discontinuation of treatment than placebo. Adverse effects were more common with 8 mg than with 4 mg of fesoterodine. Women experienced dry mouth and severe dry mouth with fesoterodine more often than with placebo, with a greater risk with the larger dose of the drug. Fesoterodine resolved UI in 130 women per 1,000 treated, while 31 women per 1,000 treated stopped taking the drug because of adverse effects.

Nine publications of RCTs^{309,313,316,460,461,503-506} and four publications of individual patient data analyses^{88,468,507,508} reported clinical outcomes with fesoterodine compared to placebo (Appendix Table F27). All RCTs were double blinded (Appendix Table F28).

Continence

Continence was greater with fesoterodine than with placebo in two RCTs^{309,313} (Appendix Table F47).

Improvement in UI

Fesoterodine improved UI more often than placebo.^{309,461,503,505} The drug needed to be given to 10 women to achieve improvement in UI in one (Table 7). One pooled analysis of individual patient data from two RCTs found that the proportion of women indicating that their condition greatly improved or improved was significantly larger with 4 or 8 mg of fesoterodine than with placebo⁸⁸ (Appendix Table F61). Treatment response was significantly better with the higher dose of the drug⁸⁸ (Appendix Table F62). An evidence-based report about treatment of OAB in women found a significant reduction in daily UI episodes with fesoterodine (weighted mean difference 2.03, 95 percent CI, 1.74 to 2.31).¹¹²

Adverse Effects

Adverse effects were more common with fesoterodine than with placebo (Appendix Table F47).^{309,460,505,506} One pooled analysis of individual patient data from two RCTs also demonstrated increased rates of adverse effects with fesoterodine than with placebo, showing

that the drug given to six to ten women results in adverse effects in one woman.⁵⁰⁸ The risk of adverse effects was dose responsive with significantly higher rates with 8 mg than with 4 mg of the drug (Appendix Table F62).^{460,506} Dry mouth was the most common adverse effect with fesoterodine^{309,313,316,460,461,503,505,506} (Appendix Table F47). An increased risk of dry mouth was dose responsive with greater rates with 8 mg than with 4 mg of the drug^{460,506,507} (Appendix Table F62).

Among other adverse effects, individual RCTs (Appendix Table F47), pooled analyses of aggregate (Table 7), and pooled analyses of individual patient data (Appendix Table F61),^{88,468,507} found higher rates of constipation with fesoterodine than with placebo.^{309,313,316,460,461,503,505,506} Increased risk of urinary tract infection was small but significant with fesoterodine versus placebo in one RCT⁴⁶¹ while pooled analysis of individual patient data did not show statistically significant differences in the rates of urinary tract infection between 4 or 8 mg of darifenacin and placebo⁵⁰⁸ (Appendix Table F63).

Discontinuation due to adverse effects was more common with fesoterodine than with placebo^{309,313,316,461,503,505} (Appendix Table F47). The drug given to 33 women resulted in discontinuation of treatment due to adverse effects in one woman (Table 7). One pooled analysis of individual patient data from two RCTs⁵⁰⁷ examined withdrawal rates due to adverse effects with fesoterodine and placebo (Appendix Table F61). Discontinuation rates due to adverse effects did not differ between 4 mg of fesoterodine and placebo but were significantly higher with 8 mg of darifenacin than with placebo.⁵⁰⁷

Clinical Effectiveness of Trospium

A high level of evidence indicated increased continence rates with trospium compared to placebo. Individual RCTs found that trospium improved quality of life. Women experienced dry mouth, dry eye, dry skin, and constipation more often with the drug than with placebo. Adverse effects resulted in treatment discontinuation with the drug more often than with placebo. Trospium resolved UI in 114 women per 1,000 treated, while 18 women per 1,000 treated stopped taking the drug because of adverse effects.

Eight publications of RCTs,^{308,325,329,330,509-512} two publications of the Trospium Study Group,^{513,514} and one pooled analysis of individual patient data from two RCTs⁵¹² examined the effects of trospium on clinical outcomes compared to placebo (Appendix Table F27).

Continence

Trospium increased continence rates more often than placebo^{325,512-514} (Appendix Table F47). The drug needed to be given to nine women to achieve continence in one woman⁵¹⁵ (Table 7). Trospium increased rates of a complete response defined as continence and normal voiding in a pooled analysis of individual subject data from two RCTs.⁵¹⁵ The drug had to be given to 11 women (95 percent CI, 8 to 20) to achieve complete response in one woman.⁵¹⁵

Improvement in UI

Trospium improved UI more often than placebo.^{509,513} The Trospium Study Group demonstrated a significant improvement in UI, defined as a greater than 50 percent decrease in the number of incontinent episodes per 24 hours.⁵¹³

An evidence-based report about treatments for overactive bladder in women demonstrated a significant reduction in urgency UI by 2.45 episodes per day (mean difference 2.45, 95 percent CI, 2.19 to 2.7).¹¹²

Adverse Effects

Adverse effects were more common with tiroprium than with placebo^{325,465,510,512,514} (Appendix Table F47). The drug had to be given to eight women to observe an adverse effect in one woman (Table 7). Constipation rates were greater with tiroprium than with placebo.^{325,510,512-514}

Women using tiroprium experienced dry eye,^{512,514} dry mouth,^{325,465,510,512-514} and dry skin^{512,514} more often than those using a placebo.⁵¹⁵ The most common adverse effect was dry mouth, experienced by one woman of every nine treated (Table 7). Discontinuation rates due to adverse effects were also higher with tiroprium than with placebo^{329,330,510,512-514} (Table 7).

Clinical Effectiveness of Propiverine

A low level of evidence indicated that propiverine resolved UI. A moderate level of evidence indicated that propiverine improved urgency UI and increased the risk of adverse effects, including abnormal vision, constipation, and dry mouth in a dose responsive manner. Propiverine resolved UI in 163 women per 1,000 treated, while 34 women per 1,000 treated stopped taking the drug because of adverse effects.

Five RCTs examined clinical outcomes of propiverine compared to placebo or to different doses of the drug^{320,502,516-518} (Appendix Tables F27 and F28).

Continence

Propiverine increased continence rates more often than placebo^{320,516} (Appendix Table F47). The drug had to be given to six women to achieve continence in one. One study concluded higher rates of continence with immediate- than with extended-release propiverine (RR 1.3, 95 percent CI, 1.1 to 1.6).³²⁰

Improvement in UI

Propiverine improved UI more often than placebo^{320,516,518} (Appendix Table F47). The drug was effective in resolving symptoms of urgency but not UI in older women with mixed UI (Appendix Table F64).⁵¹⁶ One study compared immediate- versus extended-release propiverine and concluded an opposite association depending on the definition of improvement.³²⁰ Investigators rated better overall efficacy with the extended-release drug. In contrast, patients reported better overall efficacy with the immediate-release drug.³²⁰

Adverse Effects

Propiverine caused adverse effects more often than placebo^{320,517,518} (Appendix Table F47). Propiverine caused adverse effects in one woman of every six treated. Rates of adverse effects were relatively higher with 20 mg of propiverine and 45 mg/day of propiverine than with placebo.⁵¹⁷ Treatment discontinuation due to adverse effects was more common with propiverine than with placebo^{320,502} (Appendix Table F47).

Clinical Effectiveness of Botulinum Toxin

A high level of evidence suggested a reduction in UI episodes due to treatment with botulinum toxin, with an increased risk of elevated post-void residual in patients with severe urgency UI refractory to antimuscarinic drugs.

Four RCTs of 185 subjects reported clinical outcomes after intravesicular injection of botulinum toxin^{315,519-521} (Appendix Table F27). We found one systematic review of the literature about the efficacy and safety of botulinum toxin in the management of OAB.⁵²²

Continence

Two RCTs demonstrated that botulinum injections resolved urgency UI. A single published RCT randomized 313 adults with idiopathic OAB and daily urgency UI to placebo or different doses of botulinum toxin.⁵²³ The outcomes were compared after intradetrusor injections of 50, 100, 150, 200, or 300 U of botulinum toxin or placebo.⁵²³ Continence rates were greater with the active drug (29.8 to 57.1 percent) than with placebo (15.9 percent, $P < 0.5$) in a dose responsive fashion.⁵²³ One unpublished RCT³¹⁵ demonstrated a significant increase in continence after a single injection of 100U to 300U of botulinum toxin.

Improvement in UI

One RCT reported greater rates of significant improvement in UI (>75 percent decrease in daily UI episodes) with botulinum toxin than with placebo⁵²⁰ (Appendix Table F65). Recently published RCTs examined different doses of the drug and demonstrated minimal additional or clinically relevant improvement in symptoms with doses higher than 150 U.⁵²³ One RCT reported improvement in several domains in King's Health Questionnaire on quality of life after botulinum toxin compared to placebo⁵¹⁹ (Appendix Table F66). The differences were small but statistically significant for UI impact, severity measure, and sleep-energy disturbances.⁵¹⁹

A systematic review demonstrated a significant reduction in daily UI episodes by 3.88 episodes per day (95 percent CI, -6.15 to -1.62) after botulinum.⁵²² Botulinum toxin, however, increased the risk of elevated post-void residual (pooled RR 8.55, 95 percent CI, 3.2 to 22.71).⁵²²

Published RCTs found that the drug caused treatment-related adverse effects in 40 percent, and post-void residual (PVR) related catheterization in 20 percent of patients.⁵²³ The rates of urinary tract infection increased in a dose responsive manner from 37 percent with 100 U to 47.2 percent with 300 U.⁵²³ The rates of urinary retention also increased in a dose responsive manner from 19 percent with 100 U to 25 percent with 300 U.⁵²³ Treatment failure with unchanged or increased UI was less common with botulinum than with placebo (RR 0.29, 95 percent CI, 0.14 to 0.63).⁵²⁰

Clinical Effectiveness of Resiniferatoxin

Evidence on the benefits and harms of resiniferatoxin versus placebo in women with urgency UI was insufficient for definitive conclusion about benefits and harms with the drug.

A single RCT enrolled 58 women with idiopathic detrusor overactivity and urgency incontinence to examine clinical outcomes of resiniferatoxin versus placebo (Appendix Table F27).⁵²⁴ The study did not demonstrate benefits of resiniferatoxin versus placebo⁵²⁴ (Appendix Table F67). The rates of the expected adverse effects, including hypogastric pain, dysuria, and minor hematuria, did not differ between resiniferatoxin and placebo.⁵²⁴

Clinical Effectiveness of Nimodipine

Evidence was insufficient for the benefits or harms of nimodipine compared to placebo in older women with predominant urgency UI.

A single RCT enrolled 86 older adult women with urodynamic urgency UI and without clinically important stress UI to examine outcomes after 3 weeks of 30 mg nimodipine twice

daily or placebo⁵²⁵ (Appendix Table F27). Nimodipine reduced incontinent episodes but did not improve IIQ scores and American Urological Association symptom scores (Appendix Table F68). Treatment discontinuation did not differ between nimodipine and placebo.⁵²⁵

Table 6. Clinical outcomes with duloxetine treatments (pooled with random effects estimates from head-to-head RCTs)

Reference Number of studies	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number deeded to treat (95% CI)	Attributable events/1000 treated (95% CI)	Bayesian odds ratio median (2.5; 97.5%)	Evidence
Continence 2 studies ^{384,390}	736	0.92 (0.86 to 0.99)	-0.03 (-0.12 to 0.06)			0.67 (0.23 to 1.88)	Low
Improvement in PGI rating: very much or much better 4 studies ^{319,384,385}	1,138	1.68 (0.94 to 3.00)	0.08 (0.01 to 0.14)	13 (7 to 143)	75 (7 to 142)	1.99 (1.10 to 4.19)	High
Improvement in UI: >50% reduction in UI episodes 5 studies ^{319,364,384,386,387}	4,304	1.5 (1.3 to 1.7)	0.14 (0.08 to 0.21)	7 (5 to 13)	140 (80 to 210)	1.9 (1.4 to 2.9)	High
Deterioration in PGI-I rating scale: very much worse 4 studies ^{319,384,385,402}	1,268	0.74 (0.54 to 1.02)	0.00 (-0.02 to 0.02)			0.68 (0.20 to 2.82)	Moderate
Deterioration in PGI-I rating scale: much worse 3 studies ^{384,385,402}	1,159	1.19 (0.29 to 4.90)	0.00 (-0.01 to 0.01)			1.18 (0.27 to 5.44)	Moderate
No improvement in PGI-I rating scale: no change 3 studies ^{384,385,402}	1,159	0.78 (0.65 to 0.94)	-0.07 (-0.12 to -0.02)			0.71 (0.44 to 1.17)	Low
Deterioration in PGI-I rating scale: a little worse 3 studies ^{384,385,402}	1,160	0.58 (0.32 to 1.05)	-0.03 (-0.06 to; 0.01)			0.51 (0.23 to 1.11)	Low
Adverse Effects That Resulted in Discontinuation of the Treatment							
Anxiety 2 studies ^{384,397}	2,371	10.92 (1.41 to 84.60)	0.01 (0.00 to 0.02)		8 (0 to 16)		Low
Asthenia 4 studies ^{386,389,393,402}	1,166	3.71 (0.79 to 17.52)	0.01 (0.00 to 0.02)				Low
Constipation 2 studies ^{393,397}	2,114	1.29 (0.15 to 11.00)	0.00 (0.00 to 0.01)			1.42 (0.12 to 14.77)	Low
Dizziness 8 studies ^{384,386,389-393,397}	4,404	5.49 (2.56 to 11.74)	0.02 (0.01 to 0.02)	59 (43 to 91)	17 (11 to 23)	8.25 (3.59 to 24.02)	High
Fatigue 4 studies ^{389,391,397,402}	3,440	4.02 (0.91 to 17.71)	0.01 (0.00 to 0.02)	91 (45 to 1000)	11 (1 to 20)	5.04 (1.63 to 16.90)	High
Insomnia 7 studies ^{384,386,389,391-393,397}	4,126	5.70 (2.46 to 13.19)	0.02 (0.01 to 0.02)	67 (48 to 111)	15 (9 to 21)	8.53 (3.37 to 25.41)	High
Nausea 9 studies ^{384,386,389-393,397,402}	4,992	11.27 (5.69 to 22.30)	0.04 (0.03 to 0.05)	25 (20 to 32)	40 (31 to 50)	20.92 (9.26 to 60.26)	High

Table 6. Clinical outcomes with duloxetine treatments (pooled with random effects estimates from head-to-head RCTs) (continued)

Reference Number of studies	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number deeded to treat (95% CI)	Attributable events/1000 treated (95% CI)	Bayesian odds ratio median (2.5; 97.5%)	Evidence
Somnolence 6 studies ^{386,390,391,393,397,402}	3,784	6.68 (2.34 to 19.08)	0.01 (0.01 to 0.02)	91 (59 to 167)	11 (6 to 17)	15.73 (4.14 to 148.80)	High
Diarrhea 2 studies ^{397,402}	2,501	2.42 (0.47 to 12.54)	0.00 (0.00 to 0.01)			2.91 (0.45 to 29.21)	Low
Headache 3 studies ^{389,390,402}	1,122	4.31 (0.93 to 20.02)	0.01 (0.00 to 0.03)	71 (40 to 500)	14 (2 to 25)	11.67 (1.71 to 263.20)	Moderate

Table 7. Continence, improvement in UI, treatment failure, and adverse effects with pharmacological interventions compared to placebo (pooled with random effects estimates from head-to-head RCTs)

Active drug	Outcome	RCTs, Reference	Patients in analyses	Rate Active/control %	Risk Difference* (95% CI)	Attributable events per 1000 treated	Bayesian odds ratio median (2.5 to 97.5%)	Strength of evidence
Darifenacin	Clinically important improvement in incontinence	3 ^{479,481,482}	1,011	48.4/33	0.12 (0.06 to 0.17)	117 (57 to 177)	1.7 (1.04 to 2.9)	High
Darifenacin	Serious adverse effects	2 ^{482,483}	655	1.2/2.1	-0.01 (-0.02 to 0.01)		0.6 (0.1 to 2.6)	Low
Darifenacin	Discontinuation: Adverse effects	7 ^{306,307,479,481-483,489}	3,138	4.6/3.3	0.00 (-0.01 to 0.02)		1.2 (0.7 to 2.0)	High
Darifenacin	Discontinuation: Treatment failure	4 ^{306,307,482,483}	1,280	1.0/1.7	-0.01 (-0.01 to 0.01)		0.6 (0.2 to 1.7)	Moderate
Darifenacin	Dry mouth	5 ^{479,480,482,483,489}	2,382	22.0/5.6	0.16 (0.07 to 0.27)	158 (65 to 269)	4.1 (2.1 to 8.1)	High
Darifenacin	Dyspepsia	4 ^{480,482,483,489}	1,772	4.4/1.3	0.03 (0.01 to 0.06)	31 (7 to 62)	3.6 (1.7 to 7.9)	High
Darifenacin	Headache	3 ^{480,482,483}	1,155	4.1/1.1	0.03 (0.01 to 0.06)	34 (13 to 61)	4.2 (1.6 to 12.3)	Moderate
Darifenacin	Nausea	2 ^{480,483}	573	1.3/0.7	0.00 (-0.01 to 0.03)		1.4 (0.2 to 9.9)	Low
Darifenacin	Urinary tract infection	2 ^{482,483}	655	2.9/2.3	0.01 (-0.01 to 0.04)		1.2 (0.3 to 4.1)	Low
Darifenacin	Constipation	5 ^{479,480,482,483,489}	2,239	14.6/5.7	0.08 (0.02 to 0.15)	80 (24 to 148)	2.6 (1.4 to 4.4)	High
Fesoterodine	Continence	2 ^{309,313}	2,465	61.0/48.5	0.13 (0.06 to 0.20)	130 (58 to 202)	1.7 (0.9 to 3.3)	Low
Fesoterodine	Clinically important improvement in incontinence	2 ^{309,461,503}	1,896	42/32	0.10 (0.06 to 0.15)	100 (56 to 145)	1.5(0.8 to 2.9)	High
Fesoterodine	Treatment failure	2 ^{309,461,503,505}	1,896	4/8	-0.04 (-0.06 to -0.02)	-43 (-59 to -24)	0.4 (0.2 to 1.0)	High
Fesoterodine	Serious adverse effects	2 ^{309,505}	1,905	1.8/1.9	0.00 (-0.01 to 0.01)		0.9 (0.3 to 2.3)	Low
Fesoterodine	Discontinuation: adverse effects	4 ^{309,313,316,461,503,505}	4,433	6/3	0.03 (0.01 to 0.06)	31 (10 to 56)	2.0 (1.2 to 3.2)	High
Fesoterodine	Discontinuation: treatment failure	2 ^{309,461,503,505}	1,896	2/3	-0.01 (-0.03 to 0.02)		0.6 (0.2 to 1.7)	Moderate
Fesoterodine	Abdominal pain	309,316	1,747	3.7/2.7	0.02 (0.00 to 0.04)		1.9 (0.8 to 4.0)	Low
Fesoterodine	Abnormal vision	1 ³¹⁶	1,094	0.3/1.0	-0.01 (-0.01 to 0.00)		0.2 (0.0 to 1.4)	Insufficient
Fesoterodine	Back pain	2 ^{309,316}	2,116	2.1/3.0	-0.01 (-0.02 to 0.01)		0.8 (0.4 to 1.7)	Low

Table 7. Continence, improvement in UI, treatment failure, and adverse effects with pharmacological interventions compared to placebo (pooled with random effects estimates from head-to-head RCTs) (continued)

Active drug	Outcome	RCTs, Reference	Patients in analyses	Rate Active/control %	Risk Difference* (95% CI)	Attributable events per 1000 treated	Bayesian odds ratio median (2.5 to 97.5%)	Strength of evidence
Fesoterodine	Constipation	7 ^{309,313,316,460,461,503,505,506}	7,695	11/3	0.04 (0.00 to 0.10)	41 (1 to 97)	2.4 (1.4 to 3.9)	High
Fesoterodine	Cough	3 ^{309,316,505}	2,999	1.8/1.9	0.00 (-0.01 to 0.02)		1.1 (0.6 to 2.2)	Moderate
Fesoterodine	Diarrhea	2 ^{309,461,505}	1,896	2/3	0.00 (-0.03 to 0.03)		0.8 (0.3 to 2.1)	Low
Fesoterodine	Dizziness	2 ^{309,316}	3,138	1.2/0.9	0.00 (-0.01 to 0.01)		0.9 (0.4 to 2.0)	Low
Fesoterodine	Dry eye	4 ^{309,460,503,505,506}	4,145	2/1	0.03 (0.01 to 0.06)	28 (6 to 60)	3.4 (1.6 to 8)	High
Fesoterodine	Dry mouth	5 ^{309,313,316,460,461,503,505,506}	6,674	27/7	0.20 (0.16 to 0.24)	199 (161 to 239)	4.9 (3.8 to 6.3)	High
Fesoterodine	Fatigue	2 ^{309,505}	1,905	2.0/0.3	0.02 (0.01 to 0.04)	24 (11 to 41)	10.3 (2.2 to 88.5)	Low
Fesoterodine	Headache	5 ^{309,316,460,461,503,505,506}	5,230	7/6	0.00 (-0.01 to 0.02)		1.1 (0.8 to 1.4)	High
Fesoterodine	Influenza-like symptoms	1 ³¹⁶	1,094	5.7/8.0	-0.03 (-0.05 to 0.01)			Insufficient
Fesoterodine	Nasopharyngitis	4 ^{309,460,505,506}	4,145	2.5/3.3	-0.01 (-0.02 to 0.00)		0.8 (0.5 to 1.2)	Moderate
Fesoterodine	Nausea	5 ^{309,316,460,505,506}	5,239	2.0/3.1	-0.01 (-0.02 to 0.00)		0.6 (0.4 to 1.0)	High
Fesoterodine	Upper respiratory tract infection	2 ^{309,505}	1,905	2.0/3.5	-0.01 (-0.02 to 0.01)		0.6 (0.1 to 1.9)	Low
Fesoterodine	Urinary tract infection	2 ^{309,461,505}	1,896	2/2	0.01 (-0.01 to 0.05)		1.2 (0.4 to 3.7)	Low
Oxybutynin	Continence	4 ^{409,413,416,437,438}	992	27/16	0.11 (0.06 to 0.16)	114 (64 to 163)	2.1 (1.2 to 3.9)	High
Oxybutynin	Clinically important improvement in incontinence	9 ^{322,406,415,416,418,437-443}	1,244	53/32	0.17 (0.10 to 0.24)	167 (95 to 240)	2.5 (1.7 to 3.7)	Moderate
Oxybutynin	Treatment failure	5 ^{415,437,439,441,443}	874	12.2/22.9	-0.11 (-0.16 to -0.05)	-110 (-161 to -46)	0.4 (0.2 to 0.7)	Moderate
Oxybutynin	Serious adverse effects	3 ^{321,413,441}	1,393	3.7/2.0	0.02 (-0.02 to 0.15)		1.5 (0.3 to 6.4)	Moderate
Oxybutynin	Discontinuation: adverse effects	5 ^{322,413,415,441,442,446}	1,483	10/5	0.06 (0.01 to 0.13)	63 (12 to 127)	2.0 (1.1 to 3.8)	High
Oxybutynin	Blurred vision	5 ^{405,406,437,441,446}	663	10.4/9.1	0.10 (0.02 to 0.19)	98 (22 to 187)		Moderate
Oxybutynin	Constipation	7 ^{405,410,413,416,437,441,446}	1,743	7.3/5.5	0.03 (-0.01 to 0.09)		1.4 (0.8 to 2.6)	Moderate
Oxybutynin	Dizziness	5 ^{410,413,416,441,446}	1,541	2.3/1.7	0.01 (0.00 to 0.03)			Moderate

Table 7. Continence, improvement in UI, treatment failure, and adverse effects with pharmacological interventions compared to placebo (pooled with random effects estimates from head-to-head RCTs) (continued)

Active drug	Outcome	RCTs, Reference	Patients in analyses	Rate Active/control %	Risk Difference* (95% CI)	Attributable events per 1000 treated	Bayesian odds ratio median (2.5 to 97.5%)	Strength of evidence
Oxybutynin	Dry mouth	9 ^{322,405,406,410,413,416,437,441,442,446}	2,238	34/15	0.35 (0.16 to 0.54)	347 (158 to 536)	7.2 (3.2 to 16.5)	High
Oxybutynin	Dry skin	3 ^{405,406,441}	493	10.0/10.4	0.09 (-0.07 to 0.35)			Low
Oxybutynin	Dyspepsia	3 ^{322,408,441}	613	12.1/3.3	0.08 (0.03 to 0.16)	85 (27 to 158)	3.9 (1.2 to 12.2)	Moderate
Oxybutynin	Dysuria	2 ^{410,413}	1,046	0.8/0.2	0.01 (0.00 to 0.07)		5.8 (0.5 to 254.9)	Low
Oxybutynin	Headache	3 ^{408,413,441}	1,299	4.1/4.5	-0.01 (-0.03 to 0.01)		0.9 (0.4 to 2.2)	Moderate
Oxybutynin	Nausea	7 ^{322,405,408,410,413,416,439}	1,743	3.9/3.0	0.00 (-0.02 to 0.05)		1.0 (0.4 to 2.4)	High
Oxybutynin	Retention	3 ^{413,437,441}	1,287	3.2/0.5	0.04 (-0.01 to 0.16)		6.1 (0.2 to 57.0)	Moderate
Oxybutynin	Somnolence	3 ^{410,413,441}	1,412	0.9/0.8	0.00 (-0.01 to 0.02)			Low
Oxybutynin	Vision disorder	3 ^{410,415,439}	589	8.1/4.7	0.00 (-0.04 to 0.09)		1.1 (0.2 to 3.4)	Low
Oxybutynin	Vomiting	2 ^{408,439}	361	2.3/1.4	0.03 (-0.01 to 0.14)		2.0 (0.3 to 19.0)	Low
Solifenacin	Continence	5 ^{492,494,496,497,499}	6,304	39.2/28.1	0.11 (0.06 to 0.16)	107 (58 to 156)	1.7 (1.3 to 2.1)	High
Solifenacin	Clinically important improvement in incontinence	2 ^{492,495}	1,507	60.2/42.0	0.18 (0.10 to 0.26)	180 (97 to 263)	2.2 (1.1 to 4.3)	Low
Solifenacin	Treatment failure	4 ^{478,492,493,495}	2,918	27.7/30.1	-0.14 (-0.22 to -0.06)	-143 (-217 to -60)		Moderate
Solifenacin	Discontinuation: adverse effects	7 ^{478,493-497,499,502}	9,080	5/4	0.01 (0.00 to 0.03)	13 (1 to 26)	1.3 (1.0 to 1.7)	High
Solifenacin	Discontinuation: treatment failure	4 ^{478,493,495,496}	2,812	1.5/1.3	0.00 (-0.01 to 0.01)		1.0 (0.4 to 2.2)	Moderate
Solifenacin	Blurred vision	9 ^{477,478,492-497,499,502}	12,922	4/2	0.02 (0.01 to 0.03)	17 (10 to 26)	2 (1.4 to 2.7)	High
Solifenacin	Dry mouth	7 ^{477,492-495,497,499,502}	11,089	21/5	0.17 (0.12 to 0.23)	175 (122 to 232)	5.2 (3.7 to 7.2)	High
Solifenacin	Dyspepsia	3 ^{477,492,496}	1,663	3.4/0.4	0.04 (0.02 to 0.06)	37 (16 to 64)	11.4 (3.3 to 53.4)	Moderate
Solifenacin	Fatigue	2 ^{492,494,495}	1,507	2/1	0.01 (0.00 to 0.03)	12 (0 to 28)	2.6 (0.8 to 9.4)	Low
Solifenacin	Headache	4 ^{477,492,494-496}	2,481	3/4	-0.01 (-0.02 to 0.01)		0.8 (0.4 to 1.4)	Moderate
Solifenacin	Nausea	2 ^{492,496}	1,440	3.2/2.7	0.00 (-0.01 to 0.03)		1.1 (0.3 to 3.1)	Low
Solifenacin	Urinary retention	2 ^{477,496}	747	2.4/0.8	0.03 (-0.01 to 0.12)		3.6 (0.8 to 23.4)	Low

Table 7. Continence, improvement in UI, treatment failure, and adverse effects with pharmacological interventions compared to placebo (pooled with random effects estimates from head-to-head RCTs) (continued)

Active drug	Outcome	RCTs, Reference	Patients in analyses	Rate Active/control %	Risk Difference* (95% CI)	Attributable events per 1000 treated	Bayesian odds ratio median (2.5 to 97.5%)	Strength of evidence
Solifenacin	Constipation	8 ^{477,492-497,499,502}	11,765	11/3	0.07 (0.05 to 0.10)	73 (49 to 99)	3.1 (2.3 to 4.2)	High
Solifenacin	Dizziness	2 ⁴⁹⁴⁻⁴⁹⁶	1,411	3/2	0.01 (-0.01 to 0.03)		1.5 (0.6 to 3.8)	Low
Tolterodine	Continence	4 ^{309,312,313,344}	3,404	53.2/43.7	0.09 (0.04 to 0.13)	85 (40 to 129)	1.5 (1.0 to 2.1)	High
Tolterodine	Clinically important improvement in incontinence	7 ^{88,309,313,454,456,461,463,464}	6,119	45/37	0.10 (0.04 to 0.15)	96(42 to 149)	1.5(1.2 to 2.0)	High
Tolterodine	Treatment failure	6 ^{309,312,454,456,461,463,464}	4,260	9/16	-0.05 (-0.10 to 0.01)		0.6 (0.4 to 1.0)	High
Tolterodine	Serious adverse effects	5 ^{309,448,450-452}	3,550	1.8/3.1	-0.01 (-0.02 to 0.00)		0.6 (0.3 to 1.1)	Moderate
Tolterodine	Discontinuation: adverse effects	10 ^{309,313,321,322,450,452,453,457,458,460,461,463,478}	4,466	4/3	0.01 (-0.01 to 0.03)		1.1 (0.8 to 1.7)	High
Tolterodine	Discontinuation: treatment failure	5 ^{309,457,461,463,478}	4,049	0.7/1.6	-0.01 (-0.01 to 0.00)		0.4 (0.2 to 0.9)	High
Tolterodine	Autonomic nervous system disorders	3 ⁴⁴⁸⁻⁴⁵⁰	831	27.2/15.5	0.12 (0.05 to 0.20)	117 (46 to 195)	2.0 (1.1 to 3.5)	Moderate
Tolterodine	Blurred vision	2 ^{477,478}	608	1.3/3.0	-0.03 (-0.02 to 0.03)		0.4 (0.1 to 1.7)	Low
Tolterodine	Constipation	14 ^{309,312,313,321,449,451-453,455,457,458,460,461,463,477,478}	9,592	4/3	0.01 (0.00 to 0.02)	12 (3 to 22)	1.4 (1.1 to 1.9)	High
Tolterodine	Diarrhea	4 ^{309,451,452,455,457,461}	4,056	2/2	0.01 (0.00 to 0.02)		1.2 (0.7 to 2.2)	High
Tolterodine	Dizziness	6 ^{309,451,452,455,457,460,463}	5,257	2/2	0.00 (0.00 to 0.01)		1.0 (0.6 to 1.7)	High
Tolterodine	Dry mouth	14 ^{309,312,313,321,322,343,451,453,460,461,463,465,477,478}	7,637	18.4/6.7	0.14 (0.10 to 0.18)	139 (104 to 175)	3.4 (2.7 to 4.5)	High
Tolterodine	Dyspepsia	6 ^{309,322,343,451,452,455,457}	3,525	3/2	0.02 (0.00 to 0.05)	22 (1 to 53)	2.1 (1.1 to 4.4)	High
Tolterodine	Fatigue	4 ^{309,451,460,463}	3,234	1.9/0.7	0.02 (0.01 to 0.03)	17 (7 to 29)	3.1 (1.3 to 7.8)	High
Tolterodine	General body disorders	2 ^{449,450}	308	22.3/18.6	0.03 (-0.09 to 0.18)		1.1 (0.3 to 3.5)	Low

Table 7. Continence, improvement in UI, treatment failure, and adverse effects with pharmacological interventions compared to placebo (pooled with random effects estimates from head-to-head RCTs) (continued)

Active drug	Outcome	RCTs, Reference	Patients in analyses	Rate Active/control %	Risk Difference* (95% CI)	Attributable events per 1000 treated	Bayesian odds ratio median (2.5 to 97.5%)	Strength of evidence
Tolterodine	Headache	1 ^{309,312,343,449,451-453,455,457,458,460,461,463,477}	6,766	4/4	0.01 (0.00 to 0.03)		1.3 (1.0 to 1.8)	High
Tolterodine	Insomnia	2 ^{312,451,455}	1,428	1.7/1.3	0.02 (-0.01 to 0.10)		1.5 (0.5 to 5.8)	Moderate
Tolterodine	Nasopharyngitis	5 ^{88,309,312,460,463,468}	2,835	3/3	0.00 (-0.01 to 0.02)		1.1 (0.7 to 1.9)	High
Tolterodine	Nausea	7 ^{309,322,451,452,455,457,460}	5,642	1.6/2.0	0.00 (-0.01 to 0.01)		0.8 (0.5 to 1.3)	High
Tolterodine	Somnolence	2 ^{451,455,457}	1,869	1/1	0.00 (-0.01 to 0.02)		0.9 (0.1 to 3.7)	Low
Tolterodine	Urinary tract infection	5 ^{309,312,449,451,455,457,461}	4,465	2/3	0.00 (-0.01 to 0.01)		0.9 (0.6 to 1.5)	High
Tolterodine	Abdominal pain	5 ^{309,451-453,455,457}	4,637	3/2	0.01 (0.00 to 0.02)	9 (1 to 20)	1.6 (0.9 to 2.8)	High
Tolterodine	Abnormal vision	2 ^{321,451,455}	1,141	2/1	0.00 (-0.01 to 0.02)		1.4 (0.4 to 5.5)	Moderate
Trospium	Continence	4 ^{325,512-514}	2,677	28.3/16.6	0.11 (0.08 to 0.14)	114 (83 to 144)	2.0 (1.4 to 2.9)	High
Trospium	Clinically important improvement in incontinence	2 ^{509,513}	1,176	32.4/25.4	0.08 (-0.10 to 0.25)		1.4 (0.4 to 3.8)	Low
Trospium	Discontinuation: adverse effects	6 ^{329,330,510,512-514}	3,936	5.8/3.9	0.02 (0.00 to 0.03)	18 (4 to 33)	1.5 (1.0 to 2.2)	High
Trospium	Abdominal distention	2 ^{512,514}	989	1.0/0.3	0.01 (0.00 to 0.02)	8 (0 to 21)	3.4 (0.8 to 19.1)	Low
Trospium	Abdominal pain	3 ⁵¹²⁻⁵¹⁴	2,113	1.7/0.7	0.01 (0.00 to 0.02)	10 (1 to 23)	2.7 (1.0 to 8.1)	Moderate
Trospium	Central Nervous System Disorders	2 ^{325,509}	1,217	3.9/3.8	0.00 (-0.02 to 0.03)		1.0 (0.4 to 2.6)	
Trospium	Constipation	5 ^{325,510,512-514}	3,335	9.3/2.6	0.07 (0.05 to 0.09)	70 (47 to 95)	3.9 (2.5 to 6.3)	High
Trospium	Diarrhea	2 ^{510,513}	1,181	2.5/4.6	-0.02 (-0.04 to 0.00)		0.5 (0.2 to 1.4)	Low
Trospium	Dry eye	2 ^{512,514}	1,590	1.7/0.2	0.01 (0.00 to 0.03)	14 (4 to 29)	8.0 (1.7 to 59.3)	Low
Trospium	Dry mouth	6 ^{325,465,510,512-514}	3,490	15.1/4.5	0.11 (0.07 to 0.14)	106 (75 to 140)	3.9 (2.6 to 5.8)	High
Trospium	Dry skin	2 ^{512,514}	1,590	1.0/0.1	0.01 (0.00 to 0.02)	11 (2 to 24)	12.3 (1.6 to 420.5)	Low
Trospium	Dyspepsia	2 ^{512,514}	1,590	1.5/0.9	0.00 (-0.01 to 0.02)		1.8 (0.6 to 6.4)	Low
Trospium	Headache	4 ^{510,512-514}	2,771	3.3/3.5	-0.01 (-0.02 to 0.01)		0.9 (0.4 to 1.7)	High

Table 7. Continence, improvement in UI, treatment failure, and adverse effects with pharmacological interventions compared to placebo (pooled with random effects estimates from head-to-head RCTs) (continued)

Active drug	Outcome	RCTs, Reference	Patients in analyses	Rate Active/control %	Risk Difference* (95% CI)	Attributable events per 1000 treated	Bayesian odds ratio median (2.5 to 97.5%)	Strength of evidence
Trospium	Nausea	2 ^{512,514}	1,590	1.3/0.4	0.01 (0.00 to 0.02)		3.7 (0.8 to 20.0)	Low
Trospium	Urinary tract infection	3 ^{510,512,514}	2,248	2.6/1.3	0.01 (0.00 to 0.03)		2.0 (0.9 to 4.6)	Moderate

*Risk differences for adverse effects were calculated using arcsine transformation

Table 8. Rates of adverse effects after drugs vs. placebo (significant differences only, pooled with random effects estimates from head-to-head RCTs)

Drug	Adverse effect	Subjects in analyses	Rates,% of adverse effects with drug vs. (placebo)	Number needed to treat to harm one patient (95% CI)	Number of attributable effects per 1000 treated (95% CI)
Darifenacin	All adverse effects	1495	57.0 (43.2)	5 (4 to 8)	190 (118 to 260)
Fesoterodine	All adverse effects	4145	51.4 (37.8)	6 (5 to 9)	156 (112 to 200)
Propiverine	All adverse effects	985	32.9 (18.9)	6 (4 to 12)	163 (83 to 248)
Solifenacin	All adverse effects	1713	51.9 (36.3)	6 (4 to 12)	177 (85 to 267)
Tolterodine	All adverse effects	4162	44.7 (38.1)	12 (8 to 21)	83 (47 to 120)
Trospium	All adverse effects	2967	40.5 (28.7)	8 (6 to 11)	123 (88 to 159)
Fesoterodine	Bothersome adverse effects leading to treatment discontinuation	4433	6.2 (3.2)	33 (18 to 102)	31 (10 to 56)
Oxybutynin	Bothersome adverse effects leading to treatment discontinuation	1483	10.4 (4.8)	16 (8 to 86)	63 (12 to 127)
Propiverine	Bothersome adverse effects leading to treatment discontinuation	1401	4.7 (2.0)	29 (16 to 77)	34 (13 to 61)
Solifenacin	Bothersome adverse effects leading to treatment discontinuation	9080	5.4 (4.2)	78 (39 to 823)	13 (1 to 26)
Trospium	Bothersome adverse effects leading to treatment discontinuation	3936	5.8 (3.9)	56 (30 to 228)	18 (4 to 33)
Darifenacin	Constipation	2239	14.6 (5.7)	12 (7 to 41)	80 (24 to 148)
Fesoterodine	Constipation	6673	11.5 (2.8)	24 (10 to 995)	41 (1 to 97)
Propiverine	Constipation	1793	7.5 (2.4)	10 (6 to 26)	101 (39 to 180)
Solifenacin	Constipation	11765	10.7 (3.4)	14 (10 to 20)	73 (49 to 99)
Tolterodine	Constipation	9592	3.8 (2.8)	84 (46 to 329)	12 (3 to 22)
Trospium	Constipation	3335	9.3 (2.6)	14 (11 to 21)	70 (47 to 95)
Darifenacin	Dry mouth	2382	22.0 (5.6)	6 (4 to 15)	158 (65 to 269)
Fesoterodine	Dry mouth	6674	27.4 (7.0)	5 (4 to 6)	199 (161 to 239)
Oxybutynin	Dry mouth	2238	34.1 (14.6)	3 (2 to 6)	347 (158 to 536)
Propiverine	Dry mouth	1793	22.6 (6.2)	6 (5 to 9)	163 (110 to 221)
Solifenacin	Dry mouth	11089	21.4 (4.5)	6 (4 to 8)	175 (122 to 232)
Tolterodine	Dry mouth	7637	18.4 (6.7)	7 (6 to 10)	139 (104 to 175)
Trospium	Dry mouth	3490	15.1 (4.5)	9 (7 to 13)	106 (75 to 140)
Trospium	Dry skin	1590	1.0 (0.1)	94 (42 to 442)	11 (2 to 24)

Table 8. Rates of adverse effects after drugs vs. placebo (significant differences only, pooled with random effects estimates from head-to-head RCTs) (continued)

Drug	Adverse effect	Subjects in analyses	Rates,% of adverse effects with drug vs. (placebo)	Number needed to treat to harm one patient (95% CI)	Number of attributable effects per 1000 treated (95% CI)
Fesoterodine	Dry eye	4145	2.3 (0.7)	35 (17 to 160)	28 (6 to 60)
Trospium	Dry eye	1590	1.7 (0.2)	70 (34 to 258)	14 (4 to 29)
Darifenacin	Dyspepsia	1772	4.4 (1.3)	32 (16 to 139)	31 (7 to 62)
Oxybutynin	Dyspepsia	613	12.1 (3.3)	12 (6 to 36)	85 (27 to 158)
Solifenacin	Dyspepsia	1663	3.4 (0.4)	27 (16 to 61)	37 (16 to 64)
Tolterodine	Dyspepsia	3525	2.8 (1.6)	45 (19 to 991)	22 (1 to 53)
Fesoterodine	Fatigue	1905	2.0 (0.3)	42 (25 to 91)	24 (11 to 41)
Tolterodine	Fatigue	3234	1.9 (0.7)	60 (34 to 149)	17 (7 to 29)
Darifenacin	Headache	1155	4.1 (1.1)	30 (16 to 76)	34 (13 to 61)
Trospium	Abdominal pain	2113	1.7 (0.7)	97 (43 to 849)	10 (1 to 23)
Tolterodine	Autonomic nervous system disorders	831	27.2 (15.5)	9 (5 to 22)	117 (46 to 195)
Oxybutynin	Blurred vision	663	10.4 (9.1)	10 (5 to 46)	98 (22 to 187)
Propiverine	Blurred vision	1401	4.2 (1.5)	31 (13 to 674)	32 (1 to 77)
Solifenacin	Blurred vision	12922	3.5 (1.8)	57 (38 to 102)	17 (10 to 26)

Comparative Effectiveness of Pharmacological Treatments

Comparative Effectiveness of Topical Estrogen on Stress UI

Evidence was insufficient to determine whether an estrogen releasing intravaginal ring was more effective in resolving and improving UI than a pessary or to determine whether an intravaginal tablet was more effective than intravaginal estrogen cream (Appendix Table F69).

Two RCTs of 291 women compared different estrogen formulations (Appendix Table F27).^{526,527} The studies enrolled postmenopausal women with lower urinary tract symptoms including UI.^{526,527} The first study compared an intravaginal tablet with intravaginal conjugated estrogen cream administered for 8 weeks.⁵²⁶ The second study compared an estrogen releasing ring with an estrogen pessary administered for 24 weeks.⁵²⁷ Continence rates did not differ between the intravaginal tablet and the intravaginal cream⁵²⁶ (Appendix Table F70). Women treated with an estrogen releasing ring did not experience urgency UI more often than those treated with a pessary.⁵²⁷ The rates of resolved stress UI did not differ between estrogen rings and pessaries.⁵²⁷ Women were satisfied with the estrogen ring more often than with the estrogen pessary.⁵²⁷

An estradiol vaginal ring and oral oxybutynin demonstrated similar effects in decreasing the number of daily voids in postmenopausal women with overactive bladder.⁵²⁸ Quality of life score did not differ with two drugs.⁵²⁸ Women experienced constipation and dry mouth more often with oxybutynin than with an estrogen ring.⁵²⁸ Botherome adverse effects leading to treatment discontinuation did not differ between the drugs.⁵²⁸

Comparative Effectiveness of Darifenacin and Oxybutynin on Urgency UI

Evidence was insufficient from which to conclude comparative effectiveness between darifenacin and oxybutynin on continence or improved UI. A low level of evidence indicated lower rates of total adverse effects and dry mouth with darifenacin, with no differences in adverse effects leading to treatment discontinuation.

Two RCTs^{446,529} compared clinical outcomes of oxybutynin and darifenacin.

Continence

The studies did not examine continence outcomes of oxybutynin compared to darifenacin.

Improvement in UI

The studies found no differences in improvement of UI between the two drugs. Both drugs significantly reduced incontinence episodes compared to placebo, with no differences between drugs.⁴⁴⁶

Adverse Effects

Darifenacin was safer than oxybutynin. Total rates of adverse effects were lower with darifenacin than with oxybutynin⁵²⁹ (Appendix Table F71). Rates of dry mouth were lower with darifenacin than oxybutynin.⁴⁴⁶ Severe dry mouth was less common with 7.5 mg/day of darifenacin than with 7.5mg/day of oxybutynin, and lower with 15 mg/day of darifenacin than with 15 mg/day of oxybutynin⁵²⁹ (Appendix Table F72). Only one adverse effect, constipation, was more common with 30 mg of darifenacin than with 15 mg of oxybutynin⁵²⁹ (Appendix Table

F73). Discontinuations from the study due to treatment-related adverse effects were lower with darifenacin than with oxybutynin in one RCT⁴⁴⁶ (Appendix Table F74). Pooled analysis of two RCTs found no significant differences between the two drugs in adverse effects leading to treatment discontinuation (Table 9).

Comparative Effectiveness of Oxybutynin and Tolterodine on Urgency UI

Evidence was insufficient from which to draw conclusions about comparative effectiveness between oxybutynin and tolterodine on continence. A moderate level of evidence indicated no difference between the drugs for UI improvement. A high level of evidence indicated more frequent treatment discontinuation due to adverse effects with oxybutynin than with tolterodine. Women experienced dry mouth and several other adverse effects more often with oxybutynin than with tolterodine. Thus, the drugs offered equal benefits, but tolterodine resulted in fewer harms.

We identified 15 publications that compared clinical outcomes of oxybutynin and tolterodine,^{87,322,408,411,441,442,450,530-537} including secondary data analyses,^{87,535,536} OBJECT Study group,⁵³⁰ OPERA Study group (Overactive bladder: Performance of Extended Release Agents),⁵³³ Transdermal Oxybutynin Study Group,⁴¹¹ and Japanese and Korean Tolterodine Study Group⁴⁴¹ (Appendix Table F27).

Continence

Urinary continence was reported in the OPERA trial of 790 women.⁵³³ Ten mg/day of oxybutynin, compared to 4mg/day of tolterodine, resulted in greater rates of continence⁵³³ (Appendix Table F75). Drugs had to be given to 16 women to achieve continence in one (Table 10).

Improvement in UI

We found no difference between the two drugs^{322,441,531} (Figure 5). Treatment-related rates of improved bladder condition did not differ between the two drugs in a pooled analysis of individual patient data from four RCTs⁸⁷ (Appendix Table F76).

Adverse Effects

Tolterodine demonstrated better safety than oxybutynin in several individual RCTs and secondary data analyses (Appendix Table F71). Total adverse effects did not differ between the drugs according to the pooled aggregate data from the published studies.^{450,531,532} However, one pooled analysis of individual patient data from four RCTs demonstrated higher rates of moderate and severe adverse effects with 10 mg/day of oxybutynin compared to 4 mg/day of extended-release tolterodine⁵³⁶ (Appendix Table F77). Even though another pooled analysis of individual patient data from four RCTs found no differences in serious adverse effects between oxybutynin and tolterodine, dose reduction rates due to intolerance were more common with oxybutynin than with tolterodine.⁸⁷

Among individual adverse effects, dry mouth was more common with oxybutynin than with tolterodine^{441,442,450,530,531,533,534} (Figure 5). Severe dry mouth was also more common with 5 mg/day of oxybutynin than with 2mg/day or 1mg/day of tolterodine.⁸⁷ In addition to dry mouth, women experienced asthenia,⁵³⁶ autonomic nervous system disorder,⁸⁷ gastrointestinal

disorders,⁸⁷ dyspepsia,⁸⁷ nausea,⁵³⁶ pain,⁵³⁶ palpitations,⁸⁷ rhinitis,⁵³⁶ and urinary tract infections⁵³⁶ more often with oxybutynin than with tolterodine.

Women stopped taking oxybutynin more often than tolterodine because of adverse effects (Figure 5).^{411,441,442,450,530,531,533,534} During the studies, 13 percent of women stopped taking oxybutynin and six percent of women stopped taking tolterodine because of adverse effects^{87,322,442,450,530,531,533-536} (Table 9).

Comparative Effectiveness of Propiverine and Oxybutynin on Urgency UI

Evidence was insufficient from which to draw conclusions about comparative effectiveness and safety of propiverine and oxybutynin.

One RCT compared clinical outcomes of propiverine and oxybutynin.⁴³⁹

Improvement in UI and subject satisfaction did not differ between the two drugs (Appendix Table F76). Total adverse effects did not differ between the two drugs (Appendix Table F71). Fewer subjects experienced severe dry mouth with propiverine than with oxybutynin.⁴³⁹ No studies compared rates of treatment discontinuation due to adverse effects between the two drugs.

Comparative Effectiveness of Flavoxate and Oxybutynin on Urgency UI

Evidence was insufficient from which to draw conclusions about comparative effectiveness and safety of flavoxate and oxybutynin.

A single RCT of 100 subjects compared clinical outcomes of 1,200 mg/day of flavoxate hydrochloride and 15mg/day of oxybutynin.⁵³⁸ Neither urinary continence nor improvement in UI differed between the two drugs⁵³⁸ (Appendix Tables F75 and F76). Neither treatment failure with worsening of UI nor total number of adverse effects differed between the two drugs.⁵³⁸ Rates of dry mouth and dry eyes were significantly lower with flavoxate than with oxybutynin. Nausea was also significantly less common with flavoxate than with oxybutynin.⁵³⁸

Comparative Effectiveness of Tolterodine and Propiverine on Urgency UI

Evidence was insufficient from which to draw conclusions about comparative effectiveness and safety of propiverine and tolterodine.

We identified one RCT of 202 patients treated with 15 mg of propiverine twice daily or 2 mg of tolterodine twice daily.⁵³⁹ No studies compared continence and improvement in UI with the two drugs.⁵³⁹ Improvement in urodynamic criteria of detrusor overactivity did not differ between the two drugs.⁵³⁹ Both drugs improved quality of life scores without significant differences between them. The rates of total adverse effects did not differ between the two drugs (Appendix Table F71).

Comparative Effectiveness of Tolterodine and Fesoterodine on Urgency UI

A low level of evidence indicated greater continence rates with fesoterodine than with tolterodine. A high level of evidence indicated greater rates of improvement in UI with fesoterodine than with tolterodine. A moderate level of evidence indicated higher rates of adverse effects that led to treatment discontinuation with fesoterodine than with tolterodine.

Six publications of RCTs compared clinical outcomes of fesoterodine and tolterodine.^{88,309,313,460,461,468}

Continence

Urinary continence was more often achieved with fesoterodine than with tolterodine^{309,313} (Table 10).

Improvement in UI

Rates of improvement in UI were greater with fesoterodine.^{88,309,313,461} Pooled analysis of individual patient data from two RCTs that included 1,548 women analyzed self-rated substantial benefits from the treatments⁸⁸ and found no difference in the rates of this outcome between fesoterodine and tolterodine (Appendix Table F78).

Quality of life did not differ between fesoterodine (4 or 8 mg) and tolterodine extended release in pooled analysis of individual subject data from two RCTs.⁵⁴⁰

Adverse Effects

Rates of total adverse effects did not differ between 4 mg of tolterodine and 4 mg of fesoterodine, but were less with tolterodine than with 8 mg of fesoterodine.⁴⁶⁰ Rates of dry mouth were less with tolterodine than with 4 mg of fesoterodine. Pooled analysis of individual patient data from two RCTs found that dry mouth was less common in women treated with tolterodine than with 8 mg/day of fesoterodine, with no significant differences when compared to 4 mg of fesoterodine.⁸⁸ Urinary tract infection was also less common in women treated with tolterodine than with 8 mg/day of fesoterodine, with no significant differences compared to 4 mg of fesoterodine.⁸⁸

Adverse effects resulting in treatment discontinuation were more common with fesoterodine than with tolterodine^{309,313,460,461} (Table 9).

Comparative Effectiveness of Solifenacin and Tolterodine on Urgency UI

Comparative effectiveness evidence was insufficient for solifenacin and tolterodine. A moderate level of evidence indicated that adverse effects leading to treatment discontinuation did not differ between the two drugs.

Six publications of RCTs compared clinical outcomes of solifenacin and tolterodine,^{114,477,478,541-543} including the Solifenacin and Tolterodine as an Active comparator in a Randomized STAR study group that compared clinical outcomes of 5 or 10 mg of solifenacin and 4 mg of extended-release tolterodine.^{541,542} The studies examined different doses of the drugs on a variety of outcomes that hampered the synthesis of evidence.

Continence

Urinary continence was greater with solifenacin than with tolterodine⁵⁴¹ (Table 10).

Improvement in UI

Solifenacin resulted in greater rates of improvement than tolterodine⁵⁴¹ (Appendix Table F79). Both drugs improved quality of life without evidence of differences between them.

Adverse Effects

Total rates of adverse effects did not differ between solifenacin and tolterodine^{114,477} (Appendix Table F71). However, one published RCT demonstrated a significant increase in adverse effects with the highest dose of solifenacin (20mg once daily) compared to tolterodine. A lower dose of solifenacin resulted in the same rates of adverse effects as tolterodine in one published⁴⁷⁷ and one unpublished RCT.¹¹⁴ Dry mouth and constipation were more common in women treated with solifenacin than with tolterodine.⁵⁴² Blurred vision was less common with solifenacin than with tolterodine⁵⁴² (Appendix Table F80).

Treatment discontinuation rates due to adverse effects did not differ between the two drugs.^{114,478,542,543}

Comparative Effectiveness of Solifenacin and Darifenacin on Urgency UI

Evidence was insufficient from which to conclude comparative effectiveness and safety of solifenacin and darifenacin.

One unpublished RCT, the Solidair study, compared solifenacin and darifenacin.⁵⁴⁴

No studies compared continence and improvement in UI with solifenacin and darifenacin.

The Solidair study found that women taking solifenacin had to increase the dose of the drug more often than women taking darifenacin.⁵⁴⁴ The Solidair study found that the rates of treatment discontinuation due to adverse effects did not differ between solifenacin and darifenacin.

Comparative Effectiveness of Solifenacin and Oxybutynin on Urgency UI

Evidence was insufficient from which to conclude comparative effectiveness and safety of solifenacin oxybutynin.

A single RCT, the VECTOR trial, compared 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release three times daily.⁵⁴⁵ Both drugs improved results in the Patient Perception of Bladder Condition scale and Overactive Bladder Questionnaire, without evident differences between them.

Rates of adverse effects were lower with solifenacin than with oxybutynin.⁵⁴⁵ Dry mouth was less common with solifenacin than with oxybutynin.⁵⁴⁵ Rates of dry mouth leading to treatment discontinuation were lower with solifenacin than with oxybutynin.⁵⁴⁵ Rates of other adverse effects resulting in treatment discontinuation did not differ between the two drugs.⁵⁴⁵

Comparative Effectiveness of Solifenacin and Propiverine on Urgency UI

Evidence was insufficient from which to conclude comparative effectiveness and safety of solifenacin and propiverine.

A single RCT compared clinical outcomes of solifenacin and propiverine.⁵⁰²

This study reported a significant reduction in UI episodes with both drugs, without significant differences between them.⁵⁰²

The highest dose of solifenacin, 10 mg daily, caused greater rates of constipation and dry mouth than propiverine.⁵⁰²

The rates of dry mouth did not differ between 5mg/day of solifenacin and propiverine.⁵⁰²

Adverse effects leading to treatment discontinuation did not differ between the two drugs.

Comparative Effectiveness of Trospium and Oxybutynin on Urgency UI

Evidence was insufficient from which to conclude comparative effectiveness between trospium and oxybutynin. Individual studies found lower rates of dry mouth with trospium than with oxybutynin. A low level of evidence indicated no differences in treatment discontinuation due to adverse effects between the two drugs.

Two RCTs compared clinical outcomes of oxybutynin and trospium chloride.^{305,546}

Continence

Urinary continence was achieved more often with trospium than with oxybutynin⁵⁴⁶ (Appendix Table F75).

Improvement in UI

One RCT compared improvement in UI with oxybutynin and trospium and did not find significant differences³⁰⁵ (Appendix Table F76). Dose escalation of either trospium or oxybutynin reduced frequency of urge UI without statistically significant differences between the two drugs.⁵⁴⁷

Adverse Effects

Trospium was better tolerated with fewer adverse effects than oxybutynin⁵⁴⁶ (Appendix Table F71). Dry mouth was less common with trospium than with oxybutynin⁵⁴⁶ (Appendix Table F72). With dose escalation, worsening of dry mouth was lower in the trospium groups than in the oxybutynin groups.⁵⁴⁷ Treatment discontinuation due to adverse effects did not differ between the two drugs^{305,546} (Table 9).

Comparative Effectiveness of Trospium and Tolterodine on Urgency UI

Evidence was insufficient from which to conclude the comparative effectiveness and safety of trospium and tolterodine.

A single unpublished study compared clinical outcomes of trospium and tolterodine.⁴⁶⁵

The rates of total adverse effects and dry mouth were the same with trospium and tolterodine.⁴⁶⁵

Indirect Evidence of Comparative Effectiveness of Pharmacological Treatments on Urgency UI

Indirect evidence did not indicate substantial differences in resolving or improving UI with different drugs. Differences in discontinuation due to adverse effects, including dry mouth, were more evident than differences in benefits. However, head-to-head comparisons were rarely available in more than one study, and the studies used different definitions of treatment success and different tools to measure quality of life.

We compared relative benefits and harms of drugs compared to placebo. Such indirect evidence from all RCTs that examined clinical outcomes of active drugs versus placebo indicated that trospium was the most effective to resolve UI (Figure 6), but the differences across the drugs were not significant. Absolute rates of continence were the highest with solifenacin and fesoterodine (Figure 7). Indirect statistical comparisons were difficult because of substantial variability in continence rates with placebo. For instance, women became continent with placebo

in RCTs of fesoterodine (48 percent), oxybutynin (16 percent), solifenacin (28 percent), tolterodine (44 percent), and trospium (17 percent).

We analyzed which factors might contribute to such differences in continence with placebo. The studies that did not report whether they included cases of mixed incontinence had lower rates of continence with placebo (18 percent) than studies that excluded women with stress UI (30 percent). The studies that included women with severe daily UI reported higher rates of continence with placebo (28 percent) than the studies that omitted baseline daily frequency of UI (15 percent).

From quality criteria of the studies, masking of treatment would be the most obvious candidate to explain continence with placebo. All drug studies that examined continence, however, were double blinded. From other quality criteria, the studies that reported justification of the sample size had higher continence with placebo (28 percent) than the studies that did not justify sample size (17 percent). Considering substantial variability in continence rates with drugs and placebo, but comparable relative effectiveness of the drugs, comparative safety of the drugs may influence decisions on which drug offers a better balance between benefits and harms.

Compared to placebo, all drugs except darifenacin and tolterodine led to more treatment discontinuation due to adverse effects. The number needed to treated was the highest with solifenacin (NNT=78) and the lowest with oxybutynin (NNT=16). The absolute rates of adverse effects leading to treatment discontinuation were the highest with oxybutynin, and were comparable between other drugs (Figure 8). Dry mouth was the most common adverse effect (Figure 9). Rates of dry mouth were the highest with oxybutynin. Among other adverse effects, constipation and blurred vision were the most common (Figure 10).

Indirect comparisons indicated comparable effectiveness of the drugs on continence. Oxybutynin had higher rates of dry mouth and treatment discontinuation due to adverse effects than other drugs.

Several retrospective observational studies analyzed comparative effectiveness and safety of pharmacological treatments for UI. The evidence-based cost utility analysis reported that more than half of patients stop taking drugs for UI after 1 year of treatment (Figure 11).⁵⁴⁸ The lowest rates of treatment discontinuation were with 5 mg of solifenacin.⁵⁴⁸ The authors estimated quality adjusted life years using treatment response rates and discontinuation rates for all drugs and demonstrated the largest gain in quality adjusted life years per 1,000 treated with solifenacin (Figure 12). Trospium, which demonstrated the highest continence rates, was not included in this analysis (Appendix Figure F26).

Table 9. Discontinuation due to adverse effects with pharmacological treatments for urgency UI (pooled with random effects estimates from head-to-head RCTs)

Active drug	Control drug	RCTs, Reference	Patients In analyses	Rate in active group, %	Rate in control group, %	Absolute risk difference* (95% CI)	Attributable events per 1000 treated (95% CI)	Strength of evidence
Darifenacin 7.5 daily	Oxybutynin 7.5 daily	1 ⁵²⁹	16	0	12.5	-0.13 (-0.41 to .16)		Insufficient
Darifenacin 7.5-15mg daily	Oxybutynin 15 mg daily	2 ^{446,529}	62	3.2	12.9	-0.065 (-0.35 to 0.223)	Not significant	Low
Darifenacin control release 30 mg daily	Oxybutynin-IR 1 5mg daily	2 ^{446,529}	63	6.25	19.4	-0.13 (-0.19 to 0.04)	Not significant	Low
Solifenacin	Darifenacin	1 ⁵⁴⁴	77	20	21.6	-0.02(-0.20 to .17)		Insufficient
Fesoterodine	Tolterodine	4 ^{309,313,460,461}	4,440	5.4	3.5	0.02 (0.00 to 0.03)	17 (5 to 31)	Moderate
Oxybutynin	Tolterodine	6 ^{87,322,442,450,530,531,533-536}	2,323	13	6	0.07 (0.01 to 0.15)	72 (7 to 154)	High
Solifenacin	Tolterodine	3 ^{114,478,542,543}	2,755	4	3	0.01 (0.00 to 0.03)		Moderate
Trospium	Oxybutynin	2 ^{305,546}	2,015	5	7	0.00 (-0.03 to 0.05)		Low
Trospium 20mg twice daily	Oxybutynin 5mg twice daily	1 ⁵⁴⁶	357	3.7	6.7	-0.029(-0.086 to 0.027)		Insufficient
Solifenacin	Oxybutynin IR	1 ⁵⁴⁵	132	10.3	10.9	-0.006 (-0.112 to 0.099)		Insufficient

* Risk differences were calculated using arcsine transformation

Table 10. Continence with pharmacological treatments for urgency UI

Active drug	Control drug	RCTs, Reference	Patients in analyses	Rate in active group, %	Rate in control group, %	Relative risk (95% CI)	Absolute risk difference (95% CI)	Strength of evidence
Fesoterodine 4 to 8 mg once daily	Tolterodine 4 to 8 mg once daily	2 ^{309,313}	3,312	61.0	55.5	1.10 (1.04 to 1.16)	0.06 (0.02 to 0.09)	Low
Trospium 20 mg twice daily	Oxybutynin 5 mg twice daily	1 ⁵⁴⁶	357	22.5	12.2	1.84 (1.01 to 3.34)	0.1 (0.02 to 0.19)	Insufficient
Oxybutynin 10 mg daily	Tolterodine 4 mg daily	1 ⁵³³	790	23.0	16.8	1.37 (1.03 to 1.82)	0.06 (0.01 to 0.12)	Insufficient
Solifenacin 5-10 mg once daily	Tolterodine 4 mg once daily	1 ⁵⁴¹	1,177	59.0	49.0	1.20 (1.08 to 1.34)	0.1 (0.04 to 0.16)	Insufficient

Figure 5. Comparative effectiveness of oxybutynin vs. tolterodine (pooled results from individual RCTs)^{87,322,411,441,442,450,530-536}




Figure 6. Continence with drugs for overactive bladder when compared to placebo (pooled with random effects estimates from head-to-head RCTs)






Figure 7. Continence rates (%) with drugs vs. placebo (pooled results from RCTs)




Vertical axis = percentage of continent with treatments
Horizontal axis = treatments with drug or placebo

Figure 8. Discontinuation of treatments due to adverse effects (%) with drugs vs. placebo (pooled results from RCTs)




Vertical axis = percentage of those who discontinued treatments due to adverse effects
Horizontal axis = treatments with drug or placebo

Figure 9. Dry mouth rates (%) with drugs vs. placebo (pooled results from RCTs)




Vertical axis = percentage of subjects with dry mouth with treatment
Horizontal axis = treatments with drug or placebo

Figure 10. Rates (%) of the most common (>10%) adverse effects with drugs vs. placebo (pooled results from RCTs)



Horizontal axis = percentage of subjects with adverse effects

Figure 11. Treatment persistence during 1 year of followup of the drugs for UI⁵⁴⁸



The Role of Patient Characteristics on Patient Outcomes With Pharmacological Treatments

Age

The rates of clinical outcomes were similar in age subgroups. Clinical outcomes in age subgroups were reported in four studies involving duloxetine,³⁹⁸ solifenacin,⁴⁹⁷ tolterodine,³¹⁴ and oxybutynin.^{314,398,497,534} Active and control treatments, outcomes, and definitions of age subgroups varied across the studies. We describe clinical outcomes in age subgroups treated with the drugs from individual studies and pooled analyses of individual subject data.

In 1,913 women ages 22 to 83 years with predominant stress UI, duloxetine compared to placebo did not improve UI in older women (Figure 12).³⁹⁸

In contrast, younger women reported improvement in UI more often with duloxetine than with placebo.³⁹⁸ Duloxetine prevented worsening of UI in older women, but was not better than placebo in women younger than 50 years of age.³⁹⁸

Solifenacin increased continence rates more often than placebo in all age groups (Figure 13).⁴⁹⁷ The drug tended to benefit older women more than younger women. For instance, the relative increase in continence with 5 mg was 38 percent in younger and 69 percent in older individuals.⁴⁹⁷ We observed the same tendency with 10 mg of solifenacin, with a relative increase in continence of 49 percent in younger people and of 63 percent in older people.⁴⁹⁷ This tendency was not statistically significant.

Tolterodine extended release, when compared to placebo in 1,015 individuals with urgency UI, improved UI more than placebo in older but not younger subjects³¹⁴ (Figure 14).

Oxybutynin reduced the number of urgency and total UI episodes more often than tolterodine in women younger than 64 years with urgency or mixed UI in one RCT.⁵³⁴ The rates of adverse effects did not differ between age groups.

Several studies did not directly compare the outcomes among treatment groups but aimed to test treatment effects in older populations. Oxybutynin, trospium, and darifenacin improved UI in older women. Oxybutynin reduced UI frequency and produced subjective benefits compared to placebo in frail community-dwelling older people.⁴⁰⁶ Darifenacin was examined in older populations in two RCTs^{479,480} and one pooled analysis of three RCTs.⁴⁸⁷ Darifenacin resulted in improvement in UI when compared to placebo in the older women.⁴⁷⁹ The drug needed to be given to eight older patients to achieve more than a 50 percent reduction in UI episodes in one person. Cognitive function changes did not differ between darifenacin and placebo in short-term (2-week) treatment.⁴⁸⁰ Dry mouth, constipation, and dyspepsia were the most common adverse effects in the older subjects.

Evidence suggested that age did not modify the effects of the tested drugs on examined clinical outcomes. Trospium was effective improving UI and quality of life in older subjects with overactive bladder.⁵⁴⁹ A high level of evidence suggested that duloxetine was no better than a placebo in improving UI in older women. A high level of evidence suggested that solifenacin increased continence rates more often than placebo, regardless of age. Oxybutynin, trospium, and darifenacin improved UI in older women.

Race

Evidence was inconclusive about differences among racial groups in the effects of duloxetine for stress UI. Only one study, DESIRE (Duloxetine Efficacy and Safety for Incontinence in

Racial and Ethnic Populations) examined clinical outcomes in different race groups.³⁸⁸ Women with stress UI were treated with 80 mg of duloxetine per day. Weekly UI episodes were reduced compared to baseline in all race groups, by 65.7 percent in African Americans, by 73.0 percent in Hispanics, and by 75.0 percent in Caucasian women. Clinical outcomes rarely differed between racial subgroups (Figure 15).³⁸⁸ African American women reported improvement in UI more often than Caucasian women. Hispanic women experienced a reduction in UI by more than 50 percent less often than Caucasian women. Several adverse effects, including dizziness, headache, and somnolence, were less common among African American women and more common among Hispanic women than among Caucasian women. The biological plausibility of such differences is not clear.

Baseline Type of UI

Evidence was not sufficient for individualized prediction of benefits by the urodynamic type of UI.

The studies of antimuscarinic drugs enrolled subjects with overactive bladder and predominant urgency UI. The studies of duloxetine enrolled subjects with predominant stress UI. Few studies compared the outcomes in subgroups with the predominant type of UI. One RCT of tolterodine compared continence rates, reduction in UI episodes, and pad utilization in subjects with predominant urgency and pure urgency UI, and concluded the same treatment benefits in all subjects regardless of the type of UI.⁴⁶⁹ Two pooled analyses of individual patient data compared clinical outcomes between 5 or 10 mg of solifenacin and placebo.^{497,498}

Both doses of solifenacin increased continence rates compared to placebo. Solifenacin increased continence rates in subjects with pure urgency and mixed UI. The effect size did not differ between subgroups with different types of UI (Figure 16). The relative increase in continence rates was greater with 5 mg of solifenacin in patients with pure urgency UI than those with mixed UI. One pooled analysis demonstrated that 5 mg of solifenacin was not better than placebo in achieving continence in subjects with mixed UI.⁴⁹⁸ Individuals with mixed UI required longer treatment duration to achieve greater benefits from solifenacin. At the end of 40 weeks of treatment, 52 percent of the people with mixed UI reported regaining continence, and 34 percent reported resolution of symptomatic urgency on uncontrolled extension in one RCT.⁴⁹⁹

Clinical outcomes of tolterodine and solifenacin did not differ in individuals with baseline mixed or pure urgency UI. Individuals with mixed UI may require a larger dose and longer treatment than women with urgency UI to achieve clinical benefits from solifenacin.

Baseline Frequency of UI

The baseline frequency of UI demonstrated no significant or consistent association with clinical outcomes of any drug. Individuals with more frequent UI had slightly greater benefits with drugs than with placebo. Variability in definitions of baseline severity and clinical outcomes lowered the level of evidence.

Three secondary data analyses of drug trials examined clinical outcomes among subgroups with different baseline frequency of UI.^{467,497,508} The results indicated that baseline frequency of UI tended to modify the treatment effects of the drugs; however, statistical significance of such modifications was not consistent across the definitions of baseline severity, drugs, and treatment outcomes.

Several drugs resulted in greater benefits for patients with more frequent baseline UI. In a post hoc analysis of an RCT, tolterodine extended-release increased continence rates compared

to placebo in patients with symptoms of urinary frequency and pure urgency UI. Urinary continence rates varied by diary-recorded duration and frequency of UI at baseline (Figure 17).⁴⁶⁷ Individuals with more frequent baseline UI had a larger relative benefit with the drug than with placebo. Five or 10 mg of solifenacin per day increased the rates of continence regardless of baseline frequency of UI in a pooled analysis of 1,873 people with OAB.⁴⁹⁷ Those with more than three episodes of urgency UI per day at baseline experienced a slightly larger relative benefit than those with less frequent UI.⁴⁹⁷ Patients with more than two urgency UI episodes per day experienced a greater reduction in the number of urgency UI episodes with 8 mg of fesoterodine in a pooled analysis of two RCTs.⁵⁰⁸ In contrast, trospium was better than placebo at resolving UI only in subjects with fewer than five UI episodes/day.⁵⁵⁰ Trospium did not resolve UI in subgroups with more than five episodes of UI /day.⁵⁵⁰

Adverse effects leading to discontinuation were more common with 8 mg of fesoterodine in patients with two to four episodes of urgency UI per day (Figure 18).⁵⁰⁸

Prior Treatment Status

Solifenacin was effective regardless of the response to previous treatments, even though poor responders did not benefit from increasing the dose of the drug (high level of evidence). One study reported that darifenacin was effective in those for whom previous treatments failed. Tolterodine was no better than placebo in achieving clinical benefits among poor responders to the previous muscarinic antagonists in one RCT.

Many studies reported prior treatment status, but very few reported clinical outcomes in subgroups by the response to previous treatments. In a pooled analysis of individual patient data from four RCTs, solifenacin increased continence rates when compared to placebo, regardless of the response to previous treatments (Figure 19).⁴⁹⁷ Previous nonresponders experienced a greater relative benefit than those who responded to previous treatments.⁴⁹⁷ Patients who did not respond to previous treatments did not benefit from increasing the dose of solifenacin.⁴⁹⁷ Post hoc analysis of the OPERA trial demonstrated greater rates of continence with oxybutynin than with tolterodine in patients with prior treatments with antimuscarinic drugs, but no difference was demonstrated between the two drugs in treatment of naïve patients.⁵⁵¹ In one RCT, tolterodine was not better than placebo among poor responders to the previous muscarinic antagonists.⁴⁵³

In one nonrandomized study, darifenacin improved clinical outcomes in OAB patients who expressed dissatisfaction with prior extended-release (ER) oxybutynin or tolterodine therapy.⁴⁸⁵ Darifenacin improved the Patient's Perception of Bladder Condition regardless of previous treatments by 108 percent (OR 2.08, 95 percent CI, 1.48 to 2.92) in oxybutynin treated patients and by 77 percent (OR 1.77, 95 percent CI, 1.29 to 2.43) in tolterodine treated patients.⁴⁸⁵

Concomitant Treatments

Trospium reduced the number of urgency UI episodes irrespective of concomitant medications. Adverse effects were more common in those taking seven or more concomitant medications.⁵⁵²

Comorbidities

Duloxetine was no better than placebo in women with stress UI and comorbidities (one RCT).


One RCT examined clinical outcomes with duloxetine compared to placebo in women with comorbidities (Figure 20).³⁹⁸ Duloxetine was not better than placebo in women with depression,

diabetes, and chronic lung diseases, nor was it better than placebo in preventing worsening of UI in underweight women and women with depression, diabetes, and chronic lung diseases.³⁹⁸

Obesity

Baseline obesity did not modify the effect of tadalafil in pooled analysis of individual patient data from RCTs (Table 11).⁵⁵³ Tadalafil was more effective than placebo in achieving continence in obese and nonobese adults.⁵⁵³ The magnitude of the benefit was similarly low in subgroups with different baseline body mass index (BMI). Tadalafil resolved urgency UI in 140 per 1,000 treated adults with normal weight or obesity.

Figure 12. Clinical outcomes with duloxetine vs. placebo in age subgroups (pooled analysis of individual data on women from four RCTs)⁴²⁵



PGI-I = Patient Global Impression of Improvement

Figure 13. Urinary continence with solifenacin when compared to placebo (pooled analysis of individual patient data from four RCTs)⁴⁹⁷




Figure 14. Clinical outcomes with tolterodine vs. placebo in age subgroups (individual RCTs)³¹⁴




Figure 15. Clinical outcomes with duloxetine in racial subgroups of women with stress UI, DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations)³⁸⁸




Figure 16. Continence with solifenacin compared to placebo in patients with mixed or pure urgency UI (pooled analyses of individual patient data)^{497,498}




Figure 17. Complete continence with tolterodine, extended release of 4 mg/day vs. placebo in groups with different baseline frequency UI (episodes/week)⁴⁶⁷




Figure 19. Continence with solifenacin vs. placebo in subgroup by response to the previous treatment with antimuscarinic medications (pooled analysis of RCT)⁴⁹⁷




Figure 20. Patient global impression of improvement rating as “better” with duloxetine when compared to placebo in subgroups with different comorbidity status (duloxetine urinary incontinence study group)³⁹⁸




Table 11. Continence with 60 mg once daily of tiroprium vs. placebo in obese and nonobese adults with overactive bladder (pooled results from RCTs using the WHO criteria for obesity)⁵⁵³

Baseline body mass index	Drug events/ randomized	Placebo events/ randomized	Rate (%) in active/ control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events per 1,000 treated (95% CI)
BMI <30kg/m ²	214/578	133/578	37/23	1.6 (1.3 to 1.9)	0.14 (0.09 to 0.19)	7 (5 to 11)	140 (88 to 192)
BMI <35kg/m ²	202/578	133/578	35/23	1.5 (1.3 to 1.8)	0.12 (0.07 to 0.17)	8 (6 to 15)	119 (68 to 171)
BMI >30kg/m ²	191/578	127/578	33/22	1.5 (1.2 to 1.8)	0.11 (0.06 to 0.16)	9 (6 to 17)	111 (60 to 162)
BMI >35kg/m ²	202/578	121/578	35/21	1.7 (1.4 to 2.0)	0.14 (0.09 to 0.19)	7 (5 to 11)	140 (89 to 191)

Key Question 3. How effective is the nonpharmacological treatment of UI?

One hundred forty eight RCTs tested nonsurgical nonpharmacological treatments for UI (Appendix Table F81). A small proportion of RCTs reported sponsorship and conflict of interest (Appendix Table F82). Sample size was justified in 63 RCTs (43 percent) (Appendix Table F83). Quality of the studies, including intention to treat principle and adequacy of allocation concealment, did not demonstrate significant modification of the association between treatments and patient outcomes (Appendix Table F84). In addition, we reviewed five RCTs that examined eligible treatments for female UI, but did not report the rates of clinical outcomes that can be reproduced and synthesized (Appendix Table F85). We also reviewed the results from 45 nonrandomized studies that reported crude rates of outcomes with medical devices that have never been tested in RCTs (Appendix Table F26). Here, we review clinical effects of nonpharmacological treatments compared to regular care or no active treatment. The majority of the trials included women with mixed UI. We examined the effects of predominantly stress or urgency UI when reported by the authors (Appendix Table F86).

Efficacy of Nonpharmacological Treatments for Stress UI

Clinical Effects of Pelvic Floor Muscle Training (PFMT)

A high level of evidence indicated significant benefits from PFMT for women with UI. Compared to regular care, PFMT increased urinary continence rates and improvement in UI. Benefits were consistent across different regimens of training and definitions of improvement in UI.

Eleven studies⁵⁵⁴⁻⁵⁶⁴ examined PFMT compared to regular care or no active treatment.

Continence

Despite differences in exercise regimens, the majority of the studies reported significant increases in urinary continence rates with PFMT compared to no active treatment (Appendix Table F87).^{554,555,557,558,560-564} The studies that included women with pure stress UI reported greater benefits from PFMT (pooled RR 6.8, 95 percent CI, 3.2 to 14.9)^{554,558,560} than the studies with mixed UI (pooled RR 3.5 95 percent CI, 1.9 to 6.4).^{554,557,561}

Improvement in UI

The majority of the studies also demonstrated a significant benefit from PFMT on improvement of UI (Appendix Table F87).^{555-557,560,563,564} Women reported improvement in UI with PFMT more often than with regular care.^{555-557,560,563,564} PFMT improved UI in one of every two women treated. Improvement rates did not differ in the studies with pure stress, mixed, or unreported types of UI.

Quality of life improved after PFMT^{555,559} (Appendix Table F88). Women expressed improvement in psychological impact of UI and in activity restrictions,⁵⁵⁵ less overall interference of UI with life, fewer problems with painful intercourse and other interactions of UI with sexual life, and less dissatisfaction from spending the rest of their lives with their present symptoms.⁵⁵⁹ Several studies reported inconsistent improvement in scores of quality of life after PFMT when compared to no active treatment^{559,560,565-567} (Appendix Table F89).

Clinical Effects of Vaginal Cones and Pessaries

Evidence was insufficient to draw valid conclusions about the benefits of vaginal cones. Two RCTs compared clinical outcomes with vaginal cones and no active treatment^{558,563} (Appendix Table F81). One study treated women with clinical and urodynamic stress UI with vaginal cones of 20, 40, and 70g for 20 minutes per day.⁵⁵⁸ Another study examined nine cones of equal shape and volume, increasing in weight from 20 to 100g.⁵⁶³

Continence

Vaginal cones increased continence rates (pooled RR 2.88, 95 percent CI, 1.10 to 7.55) (Appendix Table F90), but the absolute rate difference was not statistically significant.

Improvement in UI

Use of vaginal cones improved UI⁵⁶³ (Appendix Table F90). Use of vaginal cones reduced the Leakage Index but did not change the Social Activity Index (Appendix Table F91).⁵⁶¹

Several noncontrolled studies reported clinical outcomes after pessary use.⁵⁶⁸⁻⁵⁷⁵

Continence rates varied from 36 percent among women with urgency UI to 47 percent among those with stress UI after using Pessary Uresta/EastMed Inc.⁵⁷⁴ More than half the women (53 percent) reported improvement.⁵⁷⁴ Among women who used the pessary ring with floor45 percent reported improved stress UI, and 21 percent reported improved urgency UI; however, 6 percent reported newly developed urgency UI.⁵⁷³ Discontinuation rates varied from 11 percent⁵⁷¹ after different pessaries to 34 percent⁵⁷⁴ after Pessary Uresta/EastMed Inc, and to 47 percent after Pessary Gelhorn.⁵⁷² Unsuccessful fitting was the most commonly reported reason for discontinuation.

Clinical Effects of PFMT With Biofeedback Using Vaginal Electromyography (EMG) Probe

A low level of evidence indicated increased urinary continence with PFMT with biofeedback when compared to usual care. Evidence was high that this treatment improved UI.

Four RCTs examined PFMT with biofeedback using a vaginal EMG probe.^{440,556,557,560}

The studies included women over 55 years of age with urodynamic UI^{440,556,557,560} (Appendix Table F81).

Continence

PFMT with biofeedback increased urinary continence in both RCTs that reported this outcome^{557,560} (Appendix Table F92). Overall, continence rates were significantly greater with active treatment than with usual care.^{557,560} Increase in continence was greater in the study of pure stress UI⁵⁶⁰ than of mixed UI.⁵⁵⁷ Pooled absolute risk difference was not significant, however.^{557,560}

Improvement in UI

PFMT with biofeedback improved UI.^{440,556,557,560} On average, three women needed to be treated to achieve UI improvement in one (Table 10). The study of weekly sessions of PFMT reported larger improvement in UI.^{556,557} One study reported impact from UI, finding a small significant improvement on the Social Activity Index⁵⁶⁰ (Appendix Table F93). One of four studies⁵⁶⁰ included women with pure stress UI and found no significant improvement in UI. Improvement was consistent in studies of mixed UI.

One study examined the effects of PFMT supervised weekly by skilled physical therapists in women with pure urodynamic stress UI⁵⁵⁸ (Appendix Table F94). The study reported a large and significant increase in continence (RR 13.24, 95 percent CI, 1.83 to 95.63).⁵⁵⁸ The treatment had to be provided to three women to achieve continence in one. The same study reported a small but significant improvement in the Leakage Index and in the Social Activity Index (Appendix Table F95).

One noncontrolled study examined the effects of pelvic fitness and education classes taught by a lay instructor to women with urgency UI.⁵⁷⁶ The training improved quality of life and sexual function measured with Urogenital Distress Inventory-Short Form (UDI-SF) scores. Achievement of self-selected goals was reported by 71 percent at 11 weeks and by 67 percent at 1 year of followup. Evidence was insufficient to draw valid conclusions that PFMT performed under the supervision of nonmedical instructors may improve continence or quality of life in women with UI.

Clinical Effects of Electrical Stimulation

A high level of evidence suggests increased continence rates and improvement in UI with electrical stimulation.

Nine studies examined intravaginal electrical stimulation.^{558,577-584} The studies included women with predominant urgency UI,^{581,583} clinical^{579,580} or urodynamic stress UI,^{558,577} or urodynamic mixed UI⁵⁷⁸ (Appendix Table F81). Few studies excluded women with detrusor overactivity.^{577,579} Electrical stimulation was described with different levels of detail and had variable stimulation parameters, depending on the UI type being treated, including the use of 4 Hz,⁵⁸³ 10 Hz,⁵⁸¹ 20 Hz,⁵⁷⁸ or 50 Hz^{558,579,580} frequency for 4 weeks,^{558,581} 7 to 8 weeks,^{578,583} 12 weeks,⁵⁷⁹ or 15 weeks.⁵⁷⁷

Continence

Electrical stimulation increased continence rates more often than sham stimulation (Appendix Table F96).^{558,563,577,579-581,584} The benefit was consistent across the studies, despite differences in women and treatment characteristics. One RCT reported significantly higher rates of continence with electrical stimulation.⁵⁸⁴ Increase in continence did not differ across the studies with mixed versus pure stress UI. Electrical stimulation needed to be administered in nine women to achieve continence in one (Table 12).

Improvement in UI

Electrical stimulation improved UI in pooled analysis of RCTs^{558,563,577-581,583} (Appendix Table F97). Benefit was consistent across the studies, despite differences in women and treatment characteristics, and mixed versus pure stress UI (heterogeneity was not significant). Electrical stimulation needed to be administered in six women to improve UI in one woman (Appendix Table F97).

Improvement in UI was also demonstrated in a large prospective cohort study of 3,198 women treated with home-managed vaginal/anal stimulators (20–50 Hz) for at least 3 months before evaluation of the effect⁵⁸⁵ (Appendix Table F26). Women experienced daily urine loss, substantial urine loss, and severe UI less often with treatment when compared to baseline.⁵⁸⁵

Electrical stimulation improved quality of life in the majority of RCTs that examined this outcome^{558,565,580,582} (Appendix Table F98). We could not conclude consistency in improvement across the studies because the studies used different tools to measure quality of life. Electrical stimulation did not reduce prevalence of detrusor overactivity or urgency UI in the few studies that reported this outcome^{578,583,586} (Appendix Table F99). One RCT found that discontinuation of the treatment did not differ between active and sham stimulation⁵⁸² (Appendix Table F100). A cohort study found that 12 percent of women stopped using electrical stimulation at home at 2 years of followup.⁵⁸⁵

Clinical Effects of Magnetic Stimulation

A moderate level of evidence indicated that magnetic stimulation improved UI but did not increase urinary continence more than sham stimulation. Evidence of improved quality of life was low.

Five RCTs examined magnetic stimulation.⁵⁸⁷⁻⁵⁹¹ The studies of magnetic stimulation included women with UI,⁵⁸⁸ stress UI,^{587,590} mixed,⁵⁹⁰ or predominant urgency UI⁵⁸⁹ (Appendix Table F81). Magnetic stimulation was described with different levels of detail using 10 Hz,^{588,591} 15Hz,^{587,590} or 18.5Hz⁵⁸⁹ for 1,⁵⁸⁷ 2,⁵⁹⁰ 6,⁵⁹¹ or 8 weeks.^{588,589} The studies compared active with sham stimulation using double blind,^{587,589,590} single blind,⁵⁸⁸ or open label⁵⁹¹ designs.

Continence

Magnetic stimulation increased continence rates in one RCT⁵⁸⁸ of three^{587,589,591} that examined this outcome (Appendix Table F101). Pooled analysis demonstrated no significant increase in continence after active versus sham stimulation.^{587,589,591}

Improvement in UI

Active magnetic stimulation, however, improved UI in two^{587,588} of three RCTs⁵⁸⁷⁻⁵⁸⁹ that examined this outcome (Appendix Table F101). A single RCT of pure stress UI demonstrated a greater increase in improvement rates.⁵⁸⁷ Pooled analysis demonstrated a 130 percent relative increase in improved UI⁵⁸⁷⁻⁵⁸⁹ (Appendix Table F102). Magnetic stimulation had to be administered in four women to achieve improvement in UI in one woman (Appendix Table F97).

Limited evidence from nonrandomized studies demonstrated that 28 percent of women reported continence with magnetic innervations (ExMI) therapy⁵⁹² (Appendix Table F26).

Magnetic stimulation improved quality of life in one⁵⁹¹ of two RCTs^{590,591} that examined this outcome (Appendix Table F103).

Clinical Effects of Medical Devices

Evidence was insufficient to draw valid conclusions about the benefits of using intravaginal and intraurethral devices. Uncontrolled studies demonstrated improvement in UI, but also high discontinuation rates due to adverse effects.

Clinical outcomes with a variety of medical devices were reported in nonrandomized, noncontrolled studies^{568-572,574,575,593-608} (Appendix Table F26). Continence rates were 82 percent after using the CapSure (Re/Stor) continence⁵⁹³ and 20 percent⁵⁹⁴ to 54 percent⁵⁹⁵ after using the Contiform intravaginal device. Rates of continence and improved UI were 58 percent⁵⁹⁸ to 69 percent^{596,597} after using the Conveen Continence Guard. Improvement in quality of life was reported by 50 percent⁶⁰⁰ to 59 percent⁶⁰¹ of women after using the FemAssist silicone cup. The continence rate was 93 percent at 48 months after using the FemSoft urethral insert.⁶⁰² Some studies reported discontinuation rates that varied from 27 percent⁶⁰¹ to 41 percent.⁶⁰² A few studies reported adverse effects in women after using the devices, including urinary tract infection in 31.3 percent, mild trauma in 6.7 percent, hematuria in 3.3 percent,⁶⁰² local discomfort in 62 percent,⁵⁹⁷ acute bacterial cystitis in 5 percent, a small degree of fracture of the curvature of the device in 22 percent,⁵⁹⁴ or residual volume >100 ml in 5.4 percent.⁵⁹⁵

Clinical Effects of Bulking Agents for Refractory Stress UI

A low level of evidence suggests that bulking agents did not demonstrate improvement in UI when compared to placebo. Evidence was insufficient to draw valid conclusions about improvement in quality of life. Uncontrolled studies reported high rates of improvement, but also adverse effects.

Clinical outcomes after bulking agents compared to placebo or sham treatments were reported in two RCTs of 241 women^{609,610} (Appendix Table F81). The studies enrolled women with urodynamic stress UI and without detrusor overactivity. Women were treated with periurethral injections of autologous fat.⁶¹⁰ Active treatments did not improve UI^{609,610} (Appendix Table F104). Periurethral injections of autologous fat did not improve the mean incontinence quality of life score⁶¹⁰ (Appendix Table F105).

Uncontrolled studies reported outcomes after injection of copolymer system⁶¹¹ or nonendoscopic injection of nonanimal stabilized hyaluronic acid/dextranomer (NASHA/Dx) gel.^{612,613} Improvement rate after NASHA/Dx was 76 percent,⁶¹³ improvement in quality of life was 67 percent,⁶¹² but 36 percent had adverse effects.⁶¹³

Efficacy of Nonpharmacological Treatments for Urgency UI

Clinical Effects of Bladder Training

A low level of evidence indicated an improvement in UI with bladder training compared to usual care. Evidence of benefits from bladder training for urinary incontinence was insufficient.

Two RCTs examined bladder training compared to no active treatment.^{614,615}

Continence

Urinary continence was reported in one RCT that found a borderline significant increase in continence rates with bladder training compared to usual care.⁶¹⁴ (Appendix Table F106)

Improvement in UI

Bladder training improved UI (Appendix Table F106).^{637,638} Both trials included older women with mixed UI. Bladder training needed to be provided to two women to achieve an improvement in UI in one woman^{637,638} (Appendix Table F97).

One study found clinically important improvement in quality of life measured with the Incontinence Impact Questionnaire⁶³⁹ (Appendix Table F107). The evidence from individual RCTs was insufficient to extrapolate results for all women with UI.

Clinical Effects of Percutaneous Tibial Nerve Stimulation

Percutaneous tibial nerve stimulation improved UI in adults with OAB.

Four RCTs examined clinical effects of percutaneous tibial nerve stimulation,⁶¹⁷⁻⁶²⁰ including the Study of Urgent PC versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms (SUmiT) trial⁶¹⁷ and the Overactive Bladder Innovative Therapy Trial (OrBIT)^{618,621} (Appendix Table F108). The studies treated adults with either active stimulation with a current level of 0.5 to 9 mA at 20 Hz, or with sham stimulation.

Continence

No RCTs compared continence after percutaneous tibial nerve stimulation versus sham stimulation in adults with UI. Participants in OrBIT Trial reported 16 to 20 percent cure rates with 12 months of active stimulation.⁶²¹ The study did not report cure rates with sham stimulation. Continence rates were 94 percent among women with predominant urgency UI and 91 percent in women with mixed UI in an uncontrolled trial.⁶²² Continence did not differ with more frequent stimulation (three versus one time/week).⁶²³

Improvement in UI

Percutaneous tibial nerve stimulation improved UI.^{617,618} Three women need to be treated with percutaneous tibial nerve stimulation to achieve improvement in one woman (Appendix Table F97). Improvement in UI was attributable to active treatment in 308 women per 1,000 treated (95 percent CI, 40 to 557). Participants in the OrBIT Trial experienced 76 to 80 percent improvement rates with 12 months of active stimulation.⁶²¹ Nonrandomized studies reported 63 to 64 percent success rate with active stimulation.^{624,625}

Adverse Effects

Patients experienced ankle bruising (1 of 110, 0.9 percent), discomfort at the needle site (2 of 110, 1.8 percent), bleeding at the needle site (3 of 110, 2.7 percent), and tingling in the leg (1 of 110, 0.9 percent) without statistical significance when compared to sham stimulation.⁶¹⁷ Treatment discontinuation did not differ with active versus sham stimulation. One patient did not complete the treatment because of aggravating pre-existing cardiac arrhythmia in an uncontrolled clinical trial of 39 subjects with voiding dysfunction.⁶²⁶

Efficacy of Nonpharmacological Treatments for Mixed UI

Clinical Effects of PFMT Combined With Bladder Training

A high level of evidence indicated significant benefits from PFMT combined with bladder training on urinary continence and improvement in UI. The evidence was low that this treatment reduced bother of UI and was insufficient that it improved quality of life.

Six publications of five RCTs examined PFMT combined with bladder training in adults with mixed UI.⁶²⁷⁻⁶³²

Continence

Urinary continence was significantly more common in women with PFMT combined with bladder training than with no active treatment (Appendix Table F109).^{627-629,631,632} One study reported very large significant increases in continence.⁶³² Excluding that study, sensitivity analysis demonstrated smaller but still highly significant increases in continence with PFMT combined with bladder training.^{627,629} PFMT combined with bladder training needed to be administered to six women to achieve continence in one (Table 12).

Improvement in UI

PFMT combined with bladder training resulted in a significant improvement in UI in all studies that examined this outcome (Appendix Table F97).^{627-629,631} PFMT combined with bladder training had to be administered in three women to improve UI in one woman.

PFMT combined with bladder training reduced severity of UI (Appendix Table F110).^{627,632,633} One study found that self-reported severe UI was reduced by 82 percent.⁶²⁷ Another study demonstrated that self-reported bothersome UI was reduced by 31 percent.⁶³³ Use of absorbent pads for UI was reduced by 29 percent in one study.⁶³³ One study found a significant reduction in stress and urgency UI, but not in mixed UI⁶³² (Appendix Table F100).

Quality of life was examined in one study that reported significant changes in IIQ score after treatment and at the 6 month-followup⁶³² (Appendix Table F111). Evidence was insufficient to determine improvement in quality of life with PFMT combined with bladder training (Table 13).

Clinical Effects of Continence Services That Were Implemented by Specialized Health Care Providers

A low level of evidence indicated no consistent benefits from continence services implemented by specialized health care providers on continence and improvement of UI when compared to usual care. Promising results on improved quality of care need further confirmation. Comparison across the studies was difficult because of the variety of interventions that constituted complex continence services.

Clinical outcomes were reported in four RCTs that compared continence services with usual care⁶³⁴⁻⁶³⁷ (Appendix Table F81). Continence services were described with different levels of detail and usually included advice on diet and fluids, bladder training, pelvic floor muscle education and awareness, lifestyle advice,⁶³⁴ use of an audiovisual program, calendar, counseling, voiding schedule recommendations, and assessing self-care methods.⁶³⁵ The services were implemented by continence nurse advisors^{636,637} and consulting urogynecologists.⁶³⁶ The studies included subjects with any UI.

Continence

Continence was reported in three studies (Appendix Table F112).⁶³⁴⁻⁶³⁶ The Continence Efficacy Intervention Program increased the rate of continence when compared to conventional care by 556 percent in women with pure stress UI.⁶³⁵ Among every 1,000 women treated with the program, 743 cases of continence would be attributable to the Continence Efficacy Intervention Program.⁶³⁵ The largest RCT of 2,248 women with mixed UI reported smaller benefits from continence service than with usual care, with 90 additional cases of continence

attributable to active treatment per 1,000 treated.⁶³⁴ Pooled analysis of three studies found a significant relative increase of 58 percent with continence services, but no significant differences in absolute rates of continence.⁶³⁴⁻⁶³⁶

Improvement in Incontinence

Improvement was inconsistent across the studies (Appendix Table F113).^{634,637} Pooled analysis of two studies^{634,637} found significant improvement in UI (33 percent) but no significant differences in absolute rates of improved incontinence. Continence services improved quality of life (Appendix Table F114).^{634,638} With services delivered by a continence nurse and a multidisciplinary team consisting of a general practitioner, urologist, and physiotherapist, women did not experience pain or discomfort at 1 year of followup (RR 3.88, 95 percent CI, 1.57 to 9.58), did not have a UI related problem with usual activities (RR 3.74, 95 percent CI, 1.66 to 8.44), and did not complain about anxiety/depression more often than with usual care.⁶³⁸ Two to four women needed to be treated with a multidisciplinary team to achieve improved quality of life in one woman.⁶³⁸ Another study that compared continence services to usual care found that continence services resulted in a 21 percent relative increase in the proportion of women satisfied with their level of current urinary symptoms for the rest of their lives (RR 1.21, 95 percent CI, 1.12 to 1.30).⁶³⁴ Such services needed to be provided to nine women to achieve improved quality of life in one woman.⁶³⁴ Several RCTs reported quality of life scores with continence services when compared to usual care (Appendix Table F115).^{635,636,638-640} The differences rarely achieved statistical significance. Significant differences were not consistent across domains of quality of life (Table 13). The magnitude of the differences was unlikely of any clinical importance.

Clinical Effects of Group Behavioral Modification Program (BMP)

Group BMP was a combination of PFMT and bladder-training education.⁶⁴¹ Evidence from one RCT was insufficient for valid conclusions about the effectiveness of behavioral modification programs in women with mixed UI.

A single study randomized 44 adult women with mixed UI to a behavioral modification program consisting of a group lecture by two trained urology nurses with individualized meetings and assessment of knowledge and modification of behavior.⁶⁴¹ The control group received no treatments for UI. The behavioral modification program significantly improved UI (ARD 0.38, 95 percent CI, 0.13 to 0.63).⁶⁴¹ The program improved UI in every third woman (NNT 3 95 percent CI, 2 to 8) when compared to no active treatment.⁶⁴¹ Improvement in UI was achieved in 379 per 1,000 treated women (95 percent CI, 126 to 632).

Clinical Effects of Weight Loss

A moderate level of evidence indicated improvement in UI after weight loss and exercise in obese women. The evidence was insufficient to conclude if there was an increase in continence or improved quality of life.

Three studies reported clinical outcomes after weight loss programs (Appendix Table F116).⁶⁴²⁻⁶⁴⁴ One RCT compared an intensive 6-month weight loss program to no active treatment.⁶⁴² The trial enrolled women with a BMI of 25 to 50 kg/m² with any daily UI. The program included self-administered diet, exercise, and behavior modification, and aimed to produce an average loss of 7 to 9 percent of initial body weight. The second study treated women with a BMI between 25 and 45 kg/m² and at least four incontinent episodes per week.⁶⁴³ A diet

study provided a 3-month standard low calorie liquid diet (800 kcals/day or less), increased physical activity to 60 minutes/day, and training by a nutritionist, exercise physical therapist, or behavioral therapist.⁶⁴³

Continence

Weight loss did not increase continence rates when compared to regular care (Appendix Table F116).⁶⁴²

Improvement in UI

Significant improvement in UI was demonstrated in both studies (Appendix Table F116).^{642,643} Weight loss had to be maintained in four women to achieve improvement in UI in one woman (Appendix Table F97). Bayesian analysis also found improvement in UI after weight loss in obese women with UI.

Quality of life after weight loss was examined in two RCTs (Appendix Table F117).^{642,644} Women reported that UI became somewhat or much less of a problem more often after 6 months of treatment. The PRIDE study (Program to Reduce Incontinence by Diet and Exercise) examined the effects of intensive weight loss on sexual function in overweight and obese women with BMI of 25 to 50 kg/m² and daily UI.⁶⁴⁴ The study found no significant increase in the odds of overall sexual satisfaction (OR 1.28, 95 percent CI, 0.83 to 1.99) or sexual desire (OR 1.12, 95 percent CI, 0.79 to 1.61).⁶⁴⁴

An uncontrolled study of a low calorie diet and exercise with a target loss of 5 to 10 percent of body weight reported significant improvement in quality of life when compared to baseline.⁶⁴⁵

Discontinuation rates were significantly lower with weight loss programs than with structured education^{642,644} (Appendix Table F118).

Clinical Outcomes of Soy-Enriched Diet

One study tested the effects of the soy-enriched diet on urogenital symptoms in perimenopausal and postmenopausal Thai women, and demonstrated no reduction in UI (Appendix Table F119).⁶⁴⁶

Clinical Effects of Acupuncture

Evidence was insufficient to conclude improvement in UI after acupuncture. Low evidence suggested possible improvement in quality of life after active acupuncture.

Clinical outcomes of active acupuncture versus acupuncture of inactive points were reported in two RCTs of 137 women^{647,648} (Appendix Table F81) and one uncontrolled study.⁶⁴⁹ The RCTs enrolled women with symptoms of overactive bladder with urgency incontinence⁶⁴⁷ or with stress UI.⁶⁴⁸ Active acupuncture did not resolve urgency UI⁶⁴⁷ (Appendix Table F120). An uncontrolled study reported an improvement rate of 80 percent in older women for whom previous treatments had failed.⁶⁴⁹ Improvement in quality of life was inconsistent across two RCTs^{647,648} (Appendix Table F121).

Comparative Effectiveness of Nonpharmacological Treatments

We concluded with high confidence that PFMT alone and in combination with bladder training or biofeedback, electrical stimulation, or weight loss with exercise was effective to achieve continence and improvement in UI. These treatments had comparable effects when

compared to each other. Evidence was not sufficient to conclude better effects from medical devices or bulking agents when compared to each other.

Clinical outcomes with one nonpharmacological treatment versus another were reported in 54 RCTs (Appendix Table F81). These trials rarely compared the same treatment effects, which decreased the level of evidence to low or insufficient.

Comparative Effectiveness of Nonpharmacological Treatments for Stress UI

(Appendix Tables F122-F146)

Comparative Effectiveness of Supervised PFMT and Self-Administered PFMT

A high level of evidence indicated no difference in UI outcomes between supervised PFMT combined with bladder training and self-administered PFMT.

Supervised PFMT combined with bladder training was not more effective than self-administered PFMT⁶⁵⁰⁻⁶⁵⁴ (Appendix Table F122). Continence rates were similar between the two interventions (Table 15).⁶⁵⁰⁻⁶⁵⁴ Improvement in UI was similar between supervised and self-administered PFMT (Appendix Table F123).⁶⁵⁰⁻⁶⁵⁴ Rates of treatment failure and treatment discontinuation did not differ between the two treatments (Appendix Table F122).⁶⁵⁰⁻⁶⁵³ One RCT reported better patient satisfaction with supervised versus self-administered PFMT in 44 women with urodynamic stress UI.⁶⁵²

Differences in quality of life were inconsistent across studies. One RCT did not demonstrate better quality of life with supervised versus self-administered PFMT in 88 women with mixed UI⁶⁵⁵ (Appendix Table F125). Supervised PFMT versus self-administered PFMT worsened two domains of King's Health Questionnaire (physical limitations and physical activity limitations), with no differences in other domains in 61 women with urodynamic stress UI⁶⁵¹ (Appendix Table F126).

Prevalence of UI did not differ between supervised and self-administered PFMT.^{650,655-657} Only one RCT of intensive PFMT under the supervision of a physical therapist for 6 months in 52 women with urodynamic stress UI demonstrated no sustained reduction in prevalence of severe UI (RR 0.18, 95 percent CI, 0.02 to 1.33) and urgency UI (RR 0.37, 95 percent CI, 0.12 to 1.18) at 15 years (Appendix Table F125).⁶⁵⁰

The studies of individual PFMT did not report better outcomes than group PFMT in individual RCTs of women with different types of UI (Appendix Table F127).^{658,659}

Comparative Effectiveness of PFMT With and Without Biofeedback Using Vaginal EMG Probe

A high level of evidence indicated no differences in clinical outcomes between PFMT with or without biofeedback using vaginal EMG probe.

The studies that compared PFMT with or without biofeedback using vaginal EMG probe found no consistent differences in continence (Table 15, Appendix Table F124). Nor did quality of life rates differ.^{660,661} Scores of Leakage Index,^{660,662} Social Activity Index,⁶⁶⁰ Incontinence Impact Questionnaire,⁶⁶³ or IIQ-7 scores⁶⁶⁴ did not differ between PFMT with and without biofeedback (Appendix Table F128). Prevalence and impact of UI did not differ between treatments, either^{660,663} (Appendix Table F129).

Comparative Effectiveness of PFMT and Electrical Stimulation

A moderate level of evidence suggested no differences in UI with PFMT and electrical stimulation. PFMT did not result in better outcomes than electrical stimulation^{563,665,666} (Appendix Table F130). Rates of improvement in UI and treatment failure also did not differ between the two treatments^{563,665,666} (Appendix Table F123).

Comparative Effectiveness of PFMT Combined With Electrical Stimulation Versus PFMT

Evidence was insufficient to draw conclusions about comparative effectiveness of PFMT combined with electrical stimulation versus PFMT alone. A combination of PFMT with electrical stimulation reduced the frequency of UI and improved quality of life more often than PFMT alone⁶⁶⁷ (Appendix Table F131).

Comparative Effectiveness of PFMT and Medical Devices

A moderate level of evidence indicated no difference in outcomes for UI treated with PFMT compared to vaginal cones. Evidence was insufficient to draw valid conclusions about comparative effectiveness of PFMT and vaginal rings and balls.

Relative benefits of PFMT compared to medical devices were inconsistent across the studies. The rates of continence or improvement in predominant stress UI did not differ between PFMT and vaginal cones^{561,563,668} (Appendix Table F132). PFMT combined with biofeedback did not result in greater continence rates than use of vaginal cones⁶⁶⁹ (Appendix Table F131). Rates of treatment discontinuation did not differ between the two treatments.⁶⁶⁹ PFMT with biofeedback resulted in the same quality of life as vaginal cones^{670,671} (Appendix Table F133).

PFMT using weighted vaginal balls 50 to 100 g resulted in increased continence rates and improvement in UI compared to regular PFMT in one study that examined this association⁶⁷² in 37 women with stress UI (Appendix Table F131).

PFMT resulted in greater improvement in UI and lower treatment discontinuation than vaginal rings⁶⁷³ (Appendix Table F131).

PFMT combined with the use of a vaginal ring resulted in greater improvement in UI and lower rates of treatment discontinuation than a ring alone⁶⁷³ (Appendix Table F131).

PFMT and the use of a vaginal ring did not differ from PFMT alone in causing improvement of UI or treatment discontinuation⁶⁷³ (Appendix Table F131).

Comparative Effectiveness of Circular Muscle Exercises and PFMT

Evidence was insufficient to draw valid conclusions about comparative effectiveness of muscle training regimens.

Continence and improvement in predominant stress UI were greater with circular muscle exercises (Paula method) than PFMT⁶⁷⁴ in women with UI (Appendix Table F134). Quality of life was reported in two RCTs that compared circular muscle exercises with PFMT, with no consistent differences^{674,675} (Appendix Table F135). With circular muscle exercises, women experienced less “leakage annoyance” but not less frequency of UI⁶⁷⁴ (Appendix Table F136). Back pain was more common with the Paula method than with regular PFMT.⁶⁷⁴

Quality of life did not differ significantly in studies that compared PFMT with other active treatments^{561,660,661,674,676} (Appendix Tables F137 and F138).

Comparative Effectiveness of Interventions To Increase Adherence to PFMT

Evidence was insufficient to draw valid conclusions about comparative effectiveness of interventions to increase adherence to PFMT.

Adding personal reminders to enhance adherence to PFMT did not improve outcomes in 129 women with UI⁶⁷⁷ (Appendix Table F139). Providing women with an audiocassette tape to enhance adherence to PFMT increased routine pelvic floor muscle exercise more often than usual verbal instructions for PFMT.⁶⁷⁸ Women performed pelvic floor exercises twice per day more often after listening to audiocassette tapes.⁶⁷⁸ Providing audiocassette tapes resulted in better adherence to PFMT in 698 women per 1,000 treated (Appendix Table F139).

Comparative Effectiveness of PFMT in Different Positions

Available evidence did not indicate differences in benefits between different regimens and combinations of PFMT treatments.

PFMT with EMG biofeedback in both supine and upright positions versus supine position resulted in the same outcomes in 44 women with stress UI.⁶⁷⁹

Comparative Effectiveness of Electrical Stimulation Methods

Evidence was insufficient to conclude comparative effectiveness of electrical stimulation and other nonpharmacological treatments for UI.

Comparative effectiveness of once versus three times per week posterior tibial nerve stimulation resulted in the same outcomes in 35 subjects with urgency UI who failed oxybutynin treatment.⁶²³

Frequency of UI episodes, pad test, quality of life, and treatment discontinuation rates did not differ between intravaginal electrical stimulation with or without biofeedback⁶⁸⁰ (Appendix Table F131).

Electrical stimulation compared to the use of vaginal cones resulted in the same rates of continence, improvement in UI, and discontinuation of treatments due to failure to improve UI⁵⁶³ (Appendix Table F131).

Physical therapy that included PFMT in combination with biofeedback compared to physical therapy alone increased rates of continence and improvement in UI in one study of 40 women with stress UI.⁶⁶¹

Comparative Effectiveness of Medical Devices

Evidence was insufficient to conclude comparative effectiveness of examined medical devices.

Clinical outcomes were examined in seven RCTs of vaginal cone therapy, Contrelle Continence Tampon, CCT, Conveen Continence disposable Intravaginal device Guard, CCG, Hodge pessary with support and Durasphere and Urethral device (NEAT), sterile urethral insert^{561,670,681-684} (Appendix Table F140). The studies did not demonstrate significant differences in outcomes. One RCT of 94 women with the predominant symptom of stress UI found that women reported “no bother from UI” more often after Contrelle Continence Tampon versus Conveen Continence Disposable Intravaginal Device Guard.⁶⁸¹ Quality of life did not differ after examined devices^{561,670,683} (Appendix Tables F141 and F142). One cross-over RCT of 20 women with light UI examined patient comfort, absorbency, and leakage performance after different pads, and found no significant differences⁶⁸⁵ (Appendix Table F143).

Comparative Effectiveness of Various Bulking Agents for Refractory Stress UI

Evidence was insufficient to conclude comparative effectiveness of examined bulking agents.

Seven RCTs examined clinical outcomes after different bulking agents in women with pure stress UI and did not find consistent differences⁶⁸⁶⁻⁶⁹² (Appendix Table F144). Continence was greater after Macroplastique versus Contigen[®] in 260 women⁶⁹³ and after autologous myoblasts and fibroblasts versus collagen in 63 women.⁶⁹⁰ Autologous myoblasts and fibroblasts versus collagen improved quality of life scores in 63 women with intrinsic sphincter insufficiency or stress UI⁶⁹⁰ (Appendix Table F145). Adverse effects were more common with Zuidex Implanter than with Contigen Endoscopic guidance in 344 women with stress UI⁶⁹² (Appendix Table F146). Continence rates were greater with duraspHERE than with contigen in one RCT in 52 women with stress UI.⁶⁸³

Comparative Effectiveness of Nonpharmacological Treatments for Urgency UI

Comparative Effectiveness of Bladder Training

Evidence indicated that continence did not differ between bladder training combined with PFMT and bladder training alone. Evidence was insufficient to draw conclusions based on other tested comparisons.

Bladder training by listening to an audiotape daily improved UI more often than bladder training without the audiotape⁶⁹⁴ (Appendix Tables F131 and F147).

Continence did not differ between bladder training and PFMT.⁶⁶⁰ Satisfaction with current UI and feelings of no impact from UI on quality of life did not differ between bladder training and PFMT.⁵⁶¹ Transcutaneous tibial nerve combined with bladder and PFMT increased rates of continence or clinically important reduction in daily UI episodes in older women with urgency UI compared to bladder and PFMT (Appendix Table F148). Bladder training combined with PFMT did not increase continence or improve UI more often than bladder training alone^{93,695} (Appendix Table F149). Bladder training did not increase continence more often than use of vaginal cones (Appendix Table F131).⁵⁶¹

Comparative Effectiveness of Nonpharmacological Treatments for Mixed UI

Comparative Effectiveness of Continence Services Implemented by Specialized Health Care Providers

Evidence was insufficient to draw valid conclusions about comparative effectiveness of continence services and other tested individual treatments (Table 14).

Outpatient continence services involving bladder retraining and physical therapy resulted in the same continence as treatment with an inpatient 5-day hospital stay in 74 women with any UI⁶⁹⁶ (Appendix Table F131).

The Continence Efficacy Intervention Program increased continence rates more often than PFMT in 48 women with stress or mixed UI.⁶³⁵ Quality of life scores, however, did not differ between the two treatments⁶³⁵ (Appendix Table F150). Face-to-face behavioral consultation by the nurse specialist giving digital assessment feedback on pelvic floor contraction resulted in the

same continence as video conferences with continence nurses in 32 older women with symptoms of urgency or stress incontinence⁶⁹⁷ (Appendix Table F131).

Comparative Effectiveness of Group Versus Individual Physical Therapy Sessions

Evidence was insufficient to draw conclusions about comparative effectiveness of group versus individual therapy for UI.

Women reported lower benefits from group versus individual physical therapy sessions for mixed UI at 5 months of followup (RR 0.79, 95 percent CI, 0.65 to 0.98) in one RCT.⁶⁹⁸ Symptom severity or quality of life outcomes did not differ between treatment groups.⁶⁹⁸

Comparative Effectiveness of Behavioral Weight Loss and Education

Evidence was insufficient to conclude comparative effectiveness between behavioral weight loss intervention and education. Women reported more frequent improvement in mixed UI (defined as more than 70 percent reduction in weekly UI episodes) at 12 months with a behavioral weight loss intervention than with education⁶⁹⁹ (Appendix Table F131). The differences remained significant only for urgency UI at 18 months posttreatment.⁶⁹⁹

Indirect Evidence of Comparative Effectiveness of Nonpharmacological Treatments

Indirect comparisons indicated similar effectiveness of nonpharmacological treatments on continence.

We evaluated the effectiveness of different nonpharmacological treatment compared to no active treatment. Such indirect evidence from all RCTs indicated that all active treatments increased continence rates without evident differences (Figure 21). Absolute rate differences were significant for electrical stimulation, PFMT, and PFMT combined with bladder training. Attributable cases of continence were 299 per 1,000 for PFMT compared to 162 cases for electrical stimulation, and 166 cases for PFMT combined with bladder training. Rates of continence were similar between different treatments: 38 percent of women became continent with PFMT, 23 percent became continent with electrical stimulation, and 21 percent became continent with PFMT combined with bladder training.

Statistical indirect comparisons were difficult because of substantial variability in continence rates with control treatment (Figure 21). We analyzed which factors potentially contribute to such differences in continence with the control treatment, and found no statistically significant associations.

Comparative Effectiveness of Nonpharmacological Treatments When Compared to Drugs or Combined Modalities

Evidence was insufficient to draw valid conclusions about comparative effectiveness and safety of nonpharmacological treatments compared to drugs or combined modalities (Table 16).

Comparative Effectiveness of Nonpharmacological Treatments When Compared to Drugs or Combined Modalities for Stress UI

Duloxetine

Evidence was insufficient to conclude comparative effectiveness or harms of duloxetine combined with PFMT compared to duloxetine alone.

One study, Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group, compared clinical outcomes of duloxetine with and without PFMT in 201 women with stress UI.³⁹³ Women were enrolled in 17 continence clinics in the Netherlands, the United Kingdom, and the United States, and randomized to one of four combinations of 80 mg duloxetine daily, placebo, PFMT, and imitation PFMT.³⁹³ Combined treatment with duloxetine and PFMT resulted in a greater reduction in UI episode frequency than PFMT alone.³⁹³ Response rates (defined as >50 percent decrease in incontinent episode frequency), clinically important improvement in I-QOL score, and perceived treatment success did not differ between treatment groups.³⁹³ Women who completed paper diaries at each visit experienced greater improvement in UI, quality of life, and perceived treatment success with PFMT than with duloxetine. Adverse effects and treatment discontinuation due to adverse effects were more often associated with duloxetine combined with PFMT than with PFMT or placebo.³⁹³

Comparative Effectiveness of Nonpharmacological Treatments When Compared to Drugs or Combined Modalities for Urgency UI

Oxybutynin

Oxybutynin Compared to Biofeedback-Assisted PFMT

Evidence was insufficient to conclude effectiveness and safety with behavioral biofeedback-assisted PFMT versus oxybutynin in older women.

Adjustable doses of oxybutynin and behavioral biofeedback-assisted PFMT resulted in the same rates of continence and improvement in UI in 197 older women with urgency or predominant urgency UI.^{418,437,438} Women perceived their bladder condition as “much better”⁴³⁷ and were completely satisfied with the treatment more often with biofeedback-assisted training.⁴³⁸ Adverse effects, including inability to void, constipation, and dry mouth, were less common with biofeedback-assisted PFMT than with oxybutynin.⁴³⁷

Oxybutynin Combined With PFMT and Urge Suppression Techniques Compared to Individualized Drug Therapy Alone

Evidence was insufficient to conclude comparative effectiveness of oxybutynin combined with PFMT and urge suppression techniques compared to individualized drug therapy alone. Adjustable doses of oxybutynin combined with behavioral therapy resulted in the same reduction in UI episodes, perceived improvement in UI, and treatment satisfaction as oxybutynin alone³²⁴ (Appendix Table F151).

Oxybutynin Compared to Electrical Stimulation

Available limited evidence was insufficient to draw valid conclusions about comparative effectiveness of electrical stimulation compared to oxybutynin or with combined treatments compared to electrical stimulation alone.

Electrical stimulation with a 10-Hz frequency resulted in greater effects on UI episodes and quality of life scores than oxybutynin 7.5 mg/day.⁴⁴³ The rates of resolved urgency and reduction in OAB symptoms did not differ between the electrical stimulation and drug therapy groups⁴⁴³ (Appendix Table F151).

Electrical stimulation with frequency 20 Hz and amplitude 0.5 to 10 mA combined with 5 mg of oral oxybutynin resulted in the same rates of urinary continence and UI improvement as electrical stimulation alone⁷⁰⁰ (Appendix Table F151).

Transdermal Oxybutynin Combined With Behavioral Intervention Compared to Transdermal Oxybutynin Alone

Evidence was insufficient to conclude significant benefits from combined therapy compared to the drug alone. The Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial compared 3.9 mg of transdermal oxybutynin plus the behavioral intervention of enhanced patient education with transdermal oxybutynin alone.⁴²⁸ Combined treatment resulted in lower negative impact from UI on sexual life (RR 0.77, 95 percent CI, 0.69 to 0.86).⁴²⁸

Tolterodine

Tolterodine Combined With PFMT, Bladder Control Techniques, Fluid Management Versus Tolterodine Alone

Evidence was insufficient to conclude comparative effectiveness and safety of tolterodine combined with PFMT, bladder control techniques, fluid management versus tolterodine alone. The Urinary Incontinence Treatment Network compared clinical outcomes in 307 women with predominant urgency UI treated with a combination of tolterodine plus supervised behavioral training versus tolterodine alone⁷⁰¹⁻⁷⁰³ (Appendix Table F152). Combined therapy resulted in greater rates of complete satisfaction with therapy at the end of the treatment and at 8 months followup.⁷⁰² The rates of perceived improvement with UI as “better” or “much better” were also higher with combined treatment at the end of the trial and at 8 months followup.⁷⁰²

Standard educational programs that included printed information and an explanation about OAB, medication use, and behavioral treatments combined with tolterodine were compared to tolterodine alone in one RCT of 84 adults with OAB (Kegel exercise, bladder stretching, fluid regulation with medication treatment alone).⁷⁰⁴ Self-reported perception of treatment success and the use of behavior modification therapies were greater with combined therapy than with tolterodine alone.⁷⁰⁴ More women used Kegel exercises and urge suppression techniques, regulated fluid intake, and limited caffeine intake with combined treatment than with drugs alone. Patient satisfaction was associated with changes in Urogenital Distress Inventory (UDI) score, but not with a reduction in UI daily episodes.⁷⁰⁵ After multivariable analysis, every 10-point increase in UDI score was associated with 11 percent higher odds of treatment satisfaction (OR 1.11, 95 percent CI, 1.04 to 1.19).⁷⁰⁵

Tolterodine Versus Percutaneous Tibial Nerve Stimulation

Evidence from one study was insufficient to conclude better effectiveness of percutaneous tibial nerve stimulation compared to tolterodine. The Overactive Bladder Innovative Therapy trial compared clinical outcomes with percutaneous tibial nerve stimulation and extended-release tolterodine in 100 adults with urinary frequency⁷⁰⁶ (Appendix Table F153). Patient assessment and investigator assessment of improvement or cure were greater with stimulation than with

tolterodine. Self-reported change in health-related quality of life score did not differ between stimulation and drug treatment.⁷⁰⁶ Subjects reported worsening of the symptoms less often with stimulation than with the drug.⁷⁰⁶

Tolterodine Versus Intravaginal Electrical Stimulation

Evidence from one RCT was insufficient to conclude better effectiveness of intravaginal electrical stimulation compared to tolterodine.⁷⁰⁷ Women with overactive bladder and predominant urgency UI experienced improvement in symptoms from baseline with electrical stimulation and with tolterodine, without significant differences between treatment groups.⁷⁰⁷ Dry mouth was less common with stimulation than with the drug (ARD -0.26, 95 percent CI, -0.41 to -0.11).⁷⁰⁷ Both treatments improved quality of life. Improvement in severity of urinary symptoms and in social and personal relationships were significantly greater with electrical stimulation than with tolterodine at 6 months followup.⁷⁰⁷

Tolterodine Combined With Simplified Bladder Training Versus Tolterodine Alone

The Tolterodine Scandinavian Study Group compared clinical outcomes with tolterodine combined with simplified bladder training versus tolterodine alone. This randomized trial enrolled adults with OAB, including 75 percent of women.⁷⁰⁸ The number of UI episodes and perceived improvement in symptoms did not differ between treatment groups.⁷⁰⁸ Symptom deterioration tended to be lower with combined treatment, but the difference did not reach statistical significance.⁷⁰⁸ The total number of adverse effects, including dry mouth, headache, and constipation, were similar between combined treatment and drug treatment alone.⁷⁰⁸

Solifenacin

Evidence was insufficient to conclude comparative effectiveness and safety of a combination of solifenacin with bladder training and the drug alone. The SOLifenacin Alone and with simplified bladder Re-training (SOLAR) RCT compared clinical outcomes of flexible-dose solifenacin 5/10 mg with and without bladder training in patients with overactive bladder⁷⁰⁹ (Appendix Table F154). Combined therapy was better in reducing micturition frequency.⁷⁰⁹ Quality of life scores did not differ between treatment groups.⁷⁰⁹ Adverse effects did not differ between treatments.⁷⁰⁹

Trospium

Evidence was insufficient to conclude comparative effectiveness and safety of trospium and electrical stimulation. Trospium was compared with intravaginal electrical stimulation in women with overactive bladder syndrome³²⁶ (Appendix Table F155). Improvement in UI did not differ between trospium and electrical stimulation.³²⁶ Both treatments improved VAS urgency severity and Beck Depression Inventory scores when compared to baseline levels. However, neither post-treatment VAS urgency severity nor Beck Depression Inventory scores differed between the drug and electrical stimulation. Dry mouth was more common with drug (ARD 0.29, 95 percent CI, 0.07 to 0.52).³²⁶

Darifenacin

Darifenacin Compared to Behavioral Modification Program

We found insufficient evidence to conclude differences in benefits and harms of darifenacin combined with behavioral modification compared to darifenacin alone. The ABLE trial

randomized adults with OAB to the flexible dose of darifenacin (7.5 to 15 mg/day) alone or combined with behavioral brochures on modification of diet and daily habits and training for pelvic floor muscle exercise.⁷¹⁰ The differences between the two groups for both the Overactive Bladder Questionnaire (OAB-q) and the Overactive Bladder Satisfaction with Treatment Questionnaire (OAB-SAT-q) at week 12 were not significant. However, the rate of adverse effects leading to discontinuation of treatment was higher in the combined treatment group (RR 3.24, 95 percent CI, 1.34 to 7.86).⁷¹⁰

Table 12. Continence with nonpharmacological treatments compared to no active treatment (pooled with random effects estimates from head-to-head RCTs)

Treatment	Studies Patients	Rate in active/ control	Relative risk (95% CI)	Absolute risk difference 95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Bayesian odds ratio median (2.5% to 97.5%)	Level of evidence
Continence Service	3 ⁶³⁴⁻⁶³⁶ 3,939	28.8/20.4	1.58 (1.07 to 2.34)	0.30 (-0.01 to 0.60)				Moderate
Bladder Training	1 ⁶¹⁴ 131	12.3/3	4.06 (0.90 to 18.41)	0.09 (0.00 to 0.18)	10 (5 to 353)	93 (3 to 18)		Insufficient
Pelvic Floor Muscle Training	10 ^{554,555,557,558,560-564} 959	37.5/12.3	3.77 (2.09 to 6.80)	0.30 (0.19 to 0.41)	3 (2 to 5)	299 (188 to 410)	8 (5 to 15)	High
Pelvic Floor Muscle Training + Bladder Training	5 ^{627-629,631,632} 1,369	21.2/12.2	3.79 (1.55 to 9.27)	0.17 (0.06 to 0.27)	6 (4 to 16)	166 (63 to 268)	5 (5 to 18)	High
Pelvic Floor Muscle Training with EMG Biofeedback	2 ^{557,560} 185	42.0/2.4	11.17 (2.21 to 56.44)	0.494 (-0.10 to 1.08)				Low
Electrical Stimulation	7 ^{558,563,577,579-581,584} 420	22.7/7.7	2.86 (1.57 to 5.23)	0.16 (0.06 to 0.26)	6 (4 to 16)	162 (64 to 259)	4 (2 to 9)	High
Magnetic Stimulation	3 ^{587,589,591} 171	30.7/17.8	1.22 (0.78 to 1.88)	0.09 (-0.01 to 0.18)				Moderate
Vaginal Cones	2 ^{558,563} 118	23/8	2.88 (1.10 to 7.55)	0.14 (-0.01 to 0.29)				Low
Weight Loss	1 ⁶⁴² 338		Urgency UI 1.78 (0.98 to 3.23)	0.08 (0.01 to 0.16)	12 (6 to 16)	83 (6 to 160)		Insufficient
			Stress: 1.78 (1.09 to 2.90)	0.12 (0.03 to 0.21)	8 (5 to 33)	118 (30 to 206)		Insufficient

Table13. Improvement in severity of incontinence and quality of life with nonpharmacological treatments compared to no active treat

Treatment	Studies Reference	Number of subjects	Significance of the effect	Evidence
Continence service	2 studies ^{634,638}	3,847	Significant improvement in both RCTs	Moderate
Continence service	5 studies that reported scores ^{635,636,638-640}	1,598	Inconsistent differences in scoring	Moderate
Bladder training	1 study ⁶¹⁶	131	Significant improvement in scoring	Single RCT
Pelvic floor muscle training	2 studies ^{555,559}	125	Significant improvement	Moderate
Pelvic floor muscle training	6 studies that reported scores ^{559,560,565-567}	199	Significant improvement in scoring	Moderate
Pelvic floor muscle training + bladder training	1 study ⁶³²	164	Significant improvement in scoring	Single RCT
Pelvic floor muscle training + biofeedback	1 study ⁵⁶⁰	30	Significant improvement in scoring	Single RCT
Supervised pelvic floor muscle training	1 study ⁵⁵⁸	61	Significant improvement in scoring	Single RCT
Acupuncture	2 studies ^{647,648}	137	Inconsistent differences in scoring	Low
Electrical stimulation	4 studies ^{558,565,580,582}	274	Significant improvement in scoring	Moderate
Magnetic stimulation	2 studies ^{590,591}	90	Improvement in scoring in one of two RCTs	Low
Vaginal cones	1 study ⁵⁵⁸	61	Significant improvement in scoring	Single RCT
Percutaneous Tibial Nerve Stimulation	3 studies ⁶¹⁷⁻⁶¹⁹	405	Significant improvement in UI	Moderate
Bulking agent	1 study ⁶¹⁰	68	Not significant changes in scoring	Single RCT
Weight loss	2 studies ^{642,644}	651	Inconsistent differences	Low

Table 14. Continence with nonpharmacological treatments

Active	Control	Individual RCTs Reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events 95% CI)
Continence service	Bladder training	1 study ⁶⁹⁶	74	Not significant			
Continence service	PFMT	1 study ⁶³⁵	33	7.44 (2.00 to 27.70)	0.76 (0.53 to 0.98)	1 (1 to 2)	757 (534 to 980)
Continence service	Tele continence service	1 study ⁶⁹⁷	58	Not significant			
PFMT+ reminder	PFMT+ bladder training	1 study ⁶⁷⁷	103	Not significant			
PFMT in the supine position	PFMT in both supine and upright positions	1 study ⁶⁷⁹	44	Not significant			
Group physical therapy	Biofeedback	1 study ⁶⁵⁸	40	Not significant			
Individual PFMT+BT	Group PFMT	1 study ⁶⁵⁹	530	1.58 (1.05 to 2.36)	0.08 (0.00 to 0.16)	12 (6 to 1003)	81 (1 to 161)
Circular muscle exercises (Paula method)	PFMT	1 study ⁶⁷⁴	245	1.50 (1.11 to 2.03)	0.17 (0.05 to 0.29)	6 (3 to 21)	171 (48 to 295)
PFMT	PFMT+ Balls	1 study ⁶⁷²	37	0.11 (0.01 to 1.83)	-0.22 (-0.43 to -0.02)	5 (2 to 52)	222 (19 to 425)
Physical therapy in combination with biofeedback	Physical therapy	1 study ⁶⁶¹	40	3.67 (1.20 to 11.19)	0.40 (0.13 to 0.67)	3 (1 to 8)	400 (132 to 668)
Weekly posterior tibial nerve simulation	Posterior tibial nerve simulation three times per week	1 study ⁶²³	35	Not significant			
Vaginal cone	behavioral intervention	1 study ⁵⁶¹	238	Not significant			
Conveen Continence Device Guard, CCG	Contrelle Continenace Tampon, CCT	1 study ⁶⁸¹	94	Not significant			
Hodge pessary with support	Super tampon	1 study ⁶⁸²	40	Not significant			

Table 14. Continence with nonpharmacological treatments (continued)

Active	Control	Individual RCTs Reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events 95% CI)
Durasphere	Contigen	1 study ⁶⁸³	52	3.33 (1.03 to 10.74)	0.27 (0.05 to 0.49)	4 (2 to 22)	269 (46 to 493)
Urethral device (NEAT)	Reliance insert sterile balloon	1 study ⁶⁸⁴	24	Not significant			
Calcium hydroxylapatite (CaHA)	Bovine Dermal Collagen	1 study ⁶⁸⁶	296	Not significant			
Peri or transurethral porcine dermal implant injection (Permacol)	Transurethral silicone injection (Macroplastique)	1 study ⁶⁸⁷		Not significant			
Periurethral route of injection of bulking agent-dextran copolymer	Transurethral route of injection of bulking agent-dextran copolymer	1 study ⁶⁸⁸		Not significant			
Macroplastique	Contigen®	1 study ⁶⁸⁹	247	1.49 (1.01 to 2.18) NS for self reported continence	0.12 (0.01 to 0.24)	8 (4 to 152)	121 (7 to 235)
Autologous myoblasts and fibroblasts	Collagen	1 study ⁶⁹⁰	63	9.50 (2.53 to 35.63)	0.81 (0.66 to 0.96)	1 (1 to 2)	810 (656 to 963)
Zuidex Implacer	Contigen Endoscopic guidance	1 study ⁶⁹²	344	Not significant			

Table 15. Continence rates compared between nonpharmacological treatments (pooled with random effects estimates from head-to-head RCTs)

Active treatment	Control treatment	Studies	Patients	Rate active/ control, %	Relative risk (95% CI)	Absolute risk difference (95% CI)	Level of evidence
Pelvic floor muscle training + bladder training	Bladder training	3 ^{93,695}	406	22/19	1.17 (0.60 to 2.28)	0.03 (-0.10 to 0.16)	High
Pelvic floor muscle training +biofeedback	Pelvic floor muscle training	6 ^{653,660,661,711-713}	542	30/25	1.27 (0.88 to 1.85)	0.08 (-0.03 to 0.19)	High
Supervised pelvic floor muscle training	Pelvic floor muscle training	4 ⁶⁵⁰⁻⁶⁵³	300	35/22	1.92 (0.87 to 4.23)	0.20 (-0.03 to 0.43)	High
Pelvic floor muscle training	Electrical stimulation	3 ^{563,665,666}	99	24/29	0.85 (0.45 to 1.61)	-0.04 (-0.20 to 0.11)	Moderate
Pelvic floor muscle training	Vaginal cone	3 ^{561,563,668}	320	22/27	0.78 (0.58 to 1.06)	-0.11 (-0.26 to 0.04)	Moderate

Figure 21. Continence with nonpharmacological treatments for UI when compared to no active treatment (pooled with random effects estimates from head-to-head RCTs)




Table 16. Continence with pharmacological treatments compared to nonpharmacological treatments or combined modalities

Outcome	Active	Control	Individual RCTs Reference	Patients	Relative risk (95% CI)	Absolute risk difference (95% CI)
Cured from urgency UI	Stoller afferent neurostimulation	Stoller afferent neurostimulation + oxybutynin	Karademir, 2005 ⁷⁰⁰	44	1.10 (0.25 to 4.84)	0.01 (-0.19 to 0.22)
Subject assessment OAB symptom cured	Percutaneous Tibial Nerve Stimulation	Tolterodine	Peters, 2009 ⁷⁰⁶	100	0.50 (0.05 to 5.34)	-0.02 (-0.09 to 0.05)
Investigator assessment OAB symptom cured	Percutaneous Tibial Nerve Stimulation	Tolterodine	Peters, 2009 ⁷⁰⁶	100	1.00 (0.15 to 6.82)	0.00 (-0.08 to 0.08)
Subject reported OAB symptom improvement or cure	Percutaneous Tibial Nerve Stimulation	Tolterodine	Peters, 2009 ⁷⁰⁶	100	1.48(1.11 to1.98)	0.26(0.083 to 0.437)
Investigator assessment OAB symptom improvement or cure	Percutaneous Tibial Nerve Stimulation	Tolterodine	Peters, 2009 ⁷⁰⁶	100	1.33(1.02 to1.74)	0.2(0.025 to 0.375)
Totally dry	Tolterodine + PFMT	Tolterodine	Burgio, 2008 ⁷⁰²	307	1.22 (0.77 to 1.95)	0.04 (-0.05 to 0.13)
Continence	PFMT biofeedback-assisted	Oxybutynin, 7.5 to 15	Goode, 2004 ⁴³⁸	132	1.37 (0.77 to 2.44)	0.08 (-0.07 to 0.23)
Continence	PFMT biofeedback-assisted	Oxybutynin, 7.5 to 15	Burgio, 1998 ⁴³⁷	132	1.31 (0.73 to 2.34)	0.07 (-0.08 to 0.22)

Discussion

Key Findings

A number of important findings emerged from this review.

Diagnosis

Clinical evaluation with validated tools for diagnosis of UI, its type, frequency, severity, and impact on quality of life informs nonsurgical treatment decisions.

Compared with diagnosis by patients' symptom reports, multichannel urodynamics did not better predict which patients would benefit from nonsurgical treatments.

Measuring Treatment Success

Women with daily stress UI perceived important clinical benefit from reductions of approximately 50 percent in UI frequency, and important incremental clinical value from reductions of 75 percent and 90 to 100 percent.

Women reported improved quality of life and clinical success only when they experienced a greater than 70 percent reduction in UI episode frequency assessed by a voiding diary.

More than 60 percent of women with persistent urgency, stress, or mixed UI reported complete treatment satisfaction when they experienced more than 70 percent reduction of UI episodes. Validated tools have been used to assess minimum important differences in UI in women.

Validated tools have been used to assess threshold values of clinical importance for evaluating treatment success.

Pharmacological Treatments

All anticholinergic medications were more effective than placebo in achieving continence and improving UI, but the degree of benefit was low for all drugs, with fewer than 200 cases of continence attributable to treatment per 1,000 patients treated (absolute risk difference with placebo <20 percent).

Treatment benefits, including continence, were achieved with antimuscarinic drugs, including trospium, solifenacin, fesoterodine, tolterodine, and oxybutynin.

Drugs for urgency UI demonstrated similar effectiveness. Treatment discontinuation due to adverse effects was most common with oxybutynin and least common with solifenacin.

Pharmacological treatments for stress UI, including off-label use of low-dose topical estrogen formulations, may improve stress UI in postmenopausal women.

Duloxetine has an unfavorable balance between improvement in stress UI and treatment discontinuation due to adverse effects.

Compliance rates for prescription drugs are low; discontinuation due to side effects is common. Dry mouth, constipation, and blurred vision were among the most frequent adverse effects.

There is insufficient evidence of the long-term safety of pharmacological treatments.

Women with urgency UI whose prior treatments failed may benefit from solifenacin; however, poor responders would not benefit from increasing the dose of the drug.

Oxybutynin, trospium, and darifenacin improved UI in older women.

Nonpharmacological Treatments

Nonpharmacological treatments result in significant clinical benefit with a low risk of adverse effects. The magnitude of benefit is large, with more than 100 percent relative difference in continence rates. Women with stress UI can achieve continence performing PFMT. Continence rates are similar between those who undergo PFMT with and without biofeedback.

UI Diagnosis

Diagnosis of different types of UI in ambulatory care settings includes clinical history and evaluation, voiding diary, and validated scales. Urodynamic diagnosis is more invasive and not applicable to ambulatory settings. Although it more sensitively distinguishes detrusor overactivity, it did not better predict treatment benefits for patients undergoing nonsurgical UI treatments. Baseline urodynamic diagnosis did, however, better predict harms from surgery for women with refractory stress UI by identifying women with detrusor overactivity, which is associated with greater risk of postsurgical urgency UI. Diagnosis of pure urodynamic stress UI or detrusor overactivity can influence treatment decisions for women undergoing surgical treatments for urogenital prolapse or pelvic floor trauma.^{345,714} An ongoing trial conducted by the Urinary Incontinence Treatment Network will shed light on the association between utility of urodynamic testing and better prediction of outcomes of stress UI surgery.⁷¹⁵

Previously published systematic reviews also demonstrated a weak association between self-reported UI symptoms and instrumental urodynamic findings.^{73,716} However, investigators still use urodynamic evaluation as a reference method. In contrast, guidelines recommend urodynamic evaluation as one component of the complex algorithm for women with pelvic floor dysfunction.¹⁰ Evaluations of women who report UI symptoms begin with physical examination and exclusion of several potential underlying conditions, including urinary tract infection, pelvic organ prolapse, poor bladder emptying, and post-void residual volume determination.⁶⁹ Examination methods for urinary tract infection and pelvic organ prolapse have been addressed by previous reviews, and are beyond our scope.^{69,717} Measurement of PVR urine volume can be used to diagnose UI associated with poor bladder emptying. Some experts consider urinary catheterization the gold standard for measuring PVR.⁷¹⁸ However, invasive urinary catheterization can be performed only in specialized care settings. Portable ultrasound is an accurate and feasible method for estimating PVR urine volume in ambulatory care settings.^{719,720} Ultrasound is preferable to catheterization when decreased bladder emptying is suspected.⁶⁹ Vaginal and transrectal ultrasound accurately diagnosed urodynamic stress UI.^{291,292} Other instrumental radiological and magnetic resonance imaging is useful for diagnosis of anatomical pelvic pathology including fibroids, ovarian and uterine tumors, foreign bodies, or diverticulum.¹⁰ Associations are unclear between the criteria for excessive bladder neck mobility identified via ultrasound or MRI and UI treatment outcomes.

Considering the multifactorial syndromic nature of UI, any one instrument, symptom, or test cannot accurately diagnosis UI type. Clinicians utilize several aspects of patient history, pelvic exam, and other assorted factors to determine UI type and severity.

Diagnosis of Baseline Frequency, Severity, and Bothersomeness of UI

Urodynamic evaluations diagnose the presence of UI but not baseline severity, frequency, or bothersomeness of the condition, all of which help inform the best treatment options. Ambulatory care physicians may choose between several validated tools for diagnosing

predominant stress or urgency UI and for judging treatment effectiveness. Treatment effectiveness for female UI should be assessed according to issues women value: 50 to 70 percent or greater reduction in UI episode frequency, meaningful changes in quality of life measures, and overall treatment satisfaction.⁷²¹ Women do not consider small reductions in UI frequency or in urinary loss as treatment success, even though such reductions are statistically significant.²⁹⁵ Clinically important differences have been determined for several questionnaires and scales.^{259,264,296-299} Many validated tools are available to monitor quality of life in women with different UI types. Several tools that define clinically important differences in scores can be used to assess treatment success in clinical settings.³⁰⁰⁻³⁰² All tools for assessing symptom bother have been validated. The Incontinence Severity Index,^{334,335} Patient Global Impression of Improvement and of Severity,³³¹ Urogenital Distress Inventory,^{222,336,337} and Patient Perception of Bladder Condition^{333,338,339} have identified minimum threshold levels for improvements of clinical importance in UI. Treatment success in clinical settings can be determined according to improvements that meet or exceed these threshold levels.

UI Treatment

Defining and Measuring Outcomes of Treatments for UI

Meaningful assessment of treatment outcomes depends on how those outcomes are defined. Market approval and coverage decisions have been made based on intermediate outcomes rather than on continence or on women's treatment satisfaction. Despite intensive discussions about the importance of patient centered outcomes, the majority of drug studies aimed to detect statistical differences in the frequency of UI episodes. The most common outcome examined by RCTs was a reduction in UI episode frequency.^{115,305-326} Previous reviews of drugs for overactive bladder also focused on a reduction in the frequency of UI episodes and the frequency of micturitions.^{112,722,723} The FDA reviews focused primarily on the same continuous reduction in UI episode frequency, and not on continence or self-reported treatment success and satisfaction.^{115,306,307,327-330} In contrast, our review emphasized the role of clinical outcomes, including continence, quality of life, and adverse effects of treatment.

Treatments for UI

PFMT, bladder training, and electrical stimulation more often result in continence than does no active treatment. Weight loss and exercise improve UI in obese women. Long-term adherence to and benefits of these treatments are not clear, nor are specific characteristics of women associated with better benefits and compliance. The best time to start pelvic muscle floor exercise and bladder training in relation to either menopause or the onset of UI is not clear. Adverse effects with nonpharmacological treatments were uncommon and the magnitude of effect was large.

All drugs for overactive bladder, when compared to placebo, demonstrated better rates of continence and improved UI. All drugs offered similar benefits, but treatment discontinuation due to adverse effects was most common with oxybutynin. Informed decisions, therefore, should consider the drugs' adverse effects. RCTs rarely reported long-term comparative drug safety. In contrast with RCTs, continuous prescription-event monitoring as a part of postmarketing surveillance has provided valuable information about unfavorable long-term safety of tolterodine, which posed significantly higher risk of hallucinations than 10 drugs of other therapeutic classes.⁷²⁴ Postmarketing surveillance may provide data on long-term safety of UI

drugs when combined with other medications for comorbidities. RCTs did not examine the role of concurrent treatments. For instance, limited information exists on the cognitive effects of drugs in older adults. Older adults had lower risk of depression with tolterodine ER than with oxybutynin IR group (HR, 0.865; 95 percent CI, 0.78 to 0.95).⁷²⁵ The relative risks of ventricular arrhythmias (adjusted RR 5.5, 95 percent CI, 1.3 to 22.3) or sudden death (adjusted RR 21.5, 95 percent CI, 5.2 to 88.3) were very high in elderly patients using UI medications in combination with antihistamine/cytochrome inhibitors.⁷²⁶

Only a few RCTs examined the comparative effectiveness of drugs and nonpharmacological treatments. Direct evidence was insufficient to draw valid conclusions about the benefits of combined modalities compared to monotherapy. Existing guidelines recommend PFMT combined with stress and bladder training as the first treatment choice for women with urgency UI but do not provide evidence-based recommendations about combined therapy.¹¹⁸ Other guidelines list many treatment options, including electrical intravaginal stimulation and percutaneous tibial nerve stimulation, but do not provide evidence-based recommendations about first therapy options or combined modalities. Existing guidelines may provide individualized treatment recommendations based on age or predominant type of UI, but they do not address baseline severity of UI or comorbidities.

Meanwhile, very few studies provided evidence for individualized treatment decisions. Evidence of aggregate treatment effects may not be applicable to individuals with specific characteristics.⁷²⁷ An average treatment effect in a clinically diverse population may not reflect the actual effect for a specific group.⁷²⁸ Yet, few existing studies examined the role of clinical predictors of treatment failure and success in patient subpopulations.⁷²⁹ Patient comorbidity and baseline severity of UI were associated with differences in treatment benefits. The direction and magnitude of the association varied. Benefits from solifenacin and fesoterodine were greater in those with more than two or three daily episodes of UI; tiroprium was not better than placebo in those with frequent baseline UI (>5 episodes/day). We are not certain which factors are associated with differences in harms.

Very limited evidence exists for long-term benefits and harms from drugs and nonpharmacological treatments for UI. The bulk of RCTs reported clinical outcomes at 12 to 24 weeks of treatment. A few nonrandomized studies and long-term followup RCTs reported rates of benefits and harms with active treatments, but did not include control comparisons. Such uncontrolled crude rates cannot provide valid information about long-term effects.

Very few studies addressed adherence to prescribed nonpharmacological and drug regimens. Observational economic evaluations⁷³⁰⁻⁷³² demonstrated greater absolute rates of treatment discontinuation due to adverse effects or treatment failure than have been demonstrated in RCTs. Long-term adherence to drug treatment for overactive bladder was as low as 13 percent.⁷²⁵ Among possible explanatory factors for poor adherence is that polypharmacy or previous use of the drugs for urinary tract infections was associated with adherence to drugs for overactive bladder in California Medicaid program beneficiaries.⁷³¹

Cost-effectiveness analyses^{730,733-736} were beyond the scope of our review. Our review provides valid information about treatment benefits according to patient-centered outcomes including continence, and about adverse effects that can be used for cost-effectiveness analyses.

The quality of most drug RCTs was good. The majority of drug studies were double blind with adequate randomization, clear reporting of planned intention to treat analysis, and adequate allocation concealment. Benefits and harms with drugs did not differ by individual quality criteria. We concluded low risk of bias in drug studies.

The quality of most nonpharmacological RCTs was good. Baseline data demonstrated adequacy of randomization in the majority of RCTs. Double or single blinding was reported in approximately half of RCTs. Quality of the studies, including intention to treat principle and adequacy of allocation concealment, did not demonstrate significant modification of the association between treatments and patient outcomes. We concluded moderate risk of bias in nonpharmacological studies.

Our review has limitations. We restricted our review to English language studies published in journals, presented at scientific meetings, reviewed by the FDA,⁷³⁷ or reported on the ClinicalTrials.gov Web site. Even after such an exhaustive review of evidence, we do not know how many studies we missed in our review. We did not review regulatory documents or grant databases from other countries. Evidence was insufficient for individualized treatment recommendations by age, race, comorbidity, and baseline UI. Evidence specific to women whose prior treatments had failed was also insufficient. However, previous research has demonstrated that women with stress UI whose conservative treatments failed may benefit from tension-free vaginal tape procedure.⁷³⁸ For women with urgency UI whose conservative treatments failed, percutaneous tibial nerve stimulation,⁷³⁹ sacral neuromodulation,⁷⁴⁰ and botulinum toxin injections⁷⁴¹ may be of benefit. We were unable to explain the substantial variability in outcome rates with placebo treatments. Future large, well-designed head-to-head randomized trials may conclude superior efficacy of combined treatment modalities with nonsurgical treatments.

Our findings can inform clinicians' evidence-based recommendations for UI diagnosis and management (Tables 17 and 18). Ambulatory care physicians may arrive at treatment decisions and monitor treatment effectiveness by diagnosing predominant stress or urgency UI and evaluating the frequency, severity, and quality of life at baseline and with treatment. Nonpharmacological treatments offer a better balance between benefits and adverse effects than do drugs. First treatment choice, therefore, might be based on known benefits and harms with nonpharmacological and drug treatments, along with patient preference. Evidence was insufficient to conclude better benefits from nonpharmacological treatments combined with drugs. Women's opinions about treatment success should be considered before combining nonpharmacological treatments with available drugs or increasing the doses of the drugs.

Future Research

Our report points to areas for future research (Table 19). First, future research should clarify which female characteristics are associated with greater benefits and lower harms of treatments and better treatment adherence. Second, treatment success should be assessed with outcomes centered on women, including long-term continence, clinically important reduction in UI episodes, and improvement in scales of severity and quality of life. More work is needed on how physiological measures correspond with symptoms. Third, all harms should be analyzed, regardless of investigator judgment about possible association with tested treatments. Fourth, better drugs are needed. Few of the currently used medications are sustained for even a year, and fewer still are very effective. Fifth, nonsurgical treatments for predominant stress UI are limited to PFMT, with very few ongoing studies of bulking agents and devices. One issue with PFMT is sustaining it. Programs should explore how to extend the period of adherence. Future research should explore new treatment options for women with stress UI and should also address the preventive potential of various nonpharmacological treatments, including PFMT, bladder training, and electrical stimulation, for premenopausal women. The results from all studies,

including 25 closed and 124 ongoing registered studies, should be made available for future reviews of the evidence.

Table 17. Conclusions about diagnosis of UI in women

Conclusions about diagnosis of UI	Level of evidence
Symptoms of stress UI, urgency, or urgency UI have minimal or small diagnostic value to identify women with urodynamic stress UI or detrusor overactivity.	High
Complex clinical algorithms demonstrated better diagnostic performance than symptoms. Individual studies suggested good diagnostic value for questionnaires on the epidemiology of prolapse and incontinence.	Moderate
Women in ambulatory care settings can be accurately diagnosed with UI after obtaining clinical history and evaluation, a voiding diary to assess predominant stress or urgency UI, cough stress test, and exclusion of urogenital prolapse and urinary tract infections.	High
Decisions to start treatments can be based on assessment of frequency, severity, and bothersomeness of UI with validated tools.	High
Urodynamic examination was not associated with better outcomes after nonsurgical treatments for UI.	Moderate
Monitoring treatment success can address differences in the voiding diary (>50-70 percent in frequency of UI episodes) and scales measuring quality of life that are important for women, and womens' impressions of global improvement and treatment satisfaction. A variety of the validated tools are available to monitor quality of life in women with UI and with different UI types. Several tools that can define clinically important differences in scores can be used to assess treatment success in clinical settings.	High

Table 18. Conclusions about management of UI in women

Conclusions	Level of evidence
Drug treatment for predominant stress UI	
Duloxetine was worse than placebo at resolving stress UI.	Low
Duloxetine improved stress UI in women.	High
Risk of adverse effects was significantly higher with duloxetine compared to placebo. Women stopped taking the drug because of nausea, somnolence, insomnia, dizziness, headache, fatigue, diarrhea, and constipation.	High
Drug treatment for predominant urgency UI	
Oxybutynin increased continence rates and improved UI compared to placebo.	High
Oxybutynin increased treatment discontinuation due to adverse effects compared to placebo. Dry mouth was the most common adverse effect.	High
Immediate-release oxybutynin resulted in greater rates of adverse effects and dry mouth when compared to controlled-release oral or transdermal oxybutynin.	Low
Higher vs. lower doses of oxybutynin resulted in greater improvement in UI, the same rates of dry mouth, but greater treatment withdrawal.	Low
Tolterodine increased continence rates and improved UI when compared to placebo.	High
Tolterodine improved quality of life in women with urgency UI.	Low
Adverse effects, including autonomic nervous system disorders, abdominal pain, dry mouth, dyspepsia, and fatigue, were significantly more common in women taking tolterodine compared to placebo.	High
Discontinuation of the treatment and stopping the treatment due to adverse effects did not differ with tolterodine compared to placebo.	High
Darifenacin, 7.5 and 15 mg, improved urgency UI and several domains of quality of life when compared to placebo.	High
Adverse effects were more common with darifenacin than placebo. Among examined adverse effects, darifenacin increased rates of constipation, dry mouth, dyspepsia, and headache.	Moderate
Larger dose, 30 mg of darifenacin/day, did not result in better benefits but caused greater rates of adverse effects.	High
Treatment discontinuation rates because of adverse effects were the same with darifenacin vs. placebo.	High
Solifenacin increased continence rates, with greater benefits with the larger dose of the drug in women with urgency and mixed UI.	High
Solifenacin increased risk of dry mouth, constipation, and blurred vision; 10 mg of solifenacin increased the risk of severe dry mouth and constipation.	High
Treatment discontinuation because of adverse effects was more common with solifenacin compared to placebo.	High
Fesoterodine increased continence rate when compared to placebo.	Low
Fesoterodine improved urgency UI compared to placebo, with a better response with 8 mg vs. 4 mg.	High
Fesoterodine improved quality of life in women with urgency UI.	Low
Fesoterodine treatment resulted in higher rates of adverse effects and discontinuation of the treatments because of adverse effects compared to placebo. Adverse effects were more common with 8 mg compared to 4 mg of fesoterodine.	High
Trospium increased continence rate when compared to placebo.	High
Women experienced dry mouth, dry eye, dry skin, and constipation more often with the drug than with placebo.	Moderate
Treatment discontinuation because of adverse effects was more common with trospium than with placebo.	High
Fesoterodine resulted in greater rates of continence when compared to tolterodine.	Low
Fesoterodine resulted in greater rates of improved UI when compared to tolterodine.	High
Fesoterodine resulted in greater treatment discontinuation due to adverse effects when compared to tolterodine.	Moderate
Oxybutynin resulted in greater treatment discontinuation due to adverse effects when compared to tolterodine.	High
Improvement in UI did not differ with oxybutynin when compared to tolterodine.	Moderate
Adherence to drug treatments is low; more than 50 percent of women stopped treatments within 1 year.	Moderate

Table 18. Conclusions about management of UI in women (continued)

Conclusions	Level of evidence
Role of women characteristics in association with treatment effects	
Age did not modify the effects of the tested drugs on examined clinical outcomes.	Moderate
Duloxetine was no better than a placebo in improving UI in older women.	High
Solifenacin increased continence rate when compared to placebo, irrespective of age.	High
Baseline frequency of UI did not dramatically modify the effects of the drugs on clinical outcomes. Subjects with more frequent UI had slightly greater benefits when compared to placebo.	Low
Solifenacin was effective irrespective of the response to previous treatments, even though poor responders did not benefit from increasing the dose of the drug.	High
Trospium was more effective than placebo in achieving continence in obese and nonobese adults.	High
Trospium reduced number of urgency UI episodes irrespective of taking concomitant drugs. Adverse effects were more common in those taking seven or more concomitant medications.	Moderate
Nonpharmacological treatments	
Stress UI	
Pelvic floor muscle training increased continence rate and improved UI when compared to no active treatment.	High
PFMT also improved several domains of quality of life in women with UI.	Low
PFMT with biofeedback increased continence rate when compared to usual care.	Low
PFMT with biofeedback improved UI when compared to usual care.	High
Electrical stimulation increased continence rate and improved UI when compared to sham stimulation.	High
Electrical stimulation improved quality of life when compared to sham stimulation.	Moderate
Magnetic stimulation improved UI but did not increase urinary continence rates when compared to sham stimulation.	Moderate
Magnetic stimulation improved quality of life.	Low
Uncontrolled studies of intravaginal and intraurethral devices demonstrated improvement in UI but also high discontinuation rates and evident harms.	Low
Continence did not differ with PFMT + biofeedback when compared to PFMT.	High
Continence did not differ with supervised PFMT when compared to PFMT.	High
Continence did not differ with PFMT when compared to electrical stimulation.	Moderate
Urgency UI	
Bladder training improved UI compared to usual care.	Low
PFMT combined with bladder training increased continence rate and improved UI.	High
PFMT combined with bladder training reduced severity of UI.	Low
Percutaneous tibial nerve stimulation improved predominant urgency UI.	Moderate
Continence did not differ with PFMT + bladder training when compared to bladder training.	High
Mixed UI	
Continence services that were implemented by specialized health care providers increased continence and improved UI when compared to usual care.	Low
Weight loss and exercise improved UI in obese women.	Moderate
Acupuncture improved quality of life when compared to sham acupuncture.	Low

Table 19. Future research recommendations

Key question	Results of literature review	Types of studies needed to answer question	Future research recommendation
What constitutes an adequate diagnostic evaluation for women in the ambulatory care setting on which to base treatment of urinary incontinence (UI)?	<p>Symptoms of stress UI, urgency, or urgency UI have minimal or small diagnostic value to identify women with pure urodynamic stress UI or detrusor overactivity.</p> <p>Urodynamic examination was not associated with better outcomes after nonsurgical treatments for UI.</p> <p>Monitoring treatment success can address differences in the voiding diary (>70 percent in the frequency of UI episodes) and scales measuring quality of life that are important for women, and women's impressions of global improvement and treatment satisfaction.</p>	Observational studies	<p>Examine the association between diagnostic algorithms that include voiding diary, validated questionnaires to determine frequency and severity of pure or predominant stress and urgency UI, and baseline quality of life with or without portable ultrasound with the effects of nonpharmacological treatments.</p> <p>Determine minimal clinically important reduction in frequency and severity of different types of UI in women subpopulations by age, baseline severity and frequency, and bothersomeness.</p> <p>Examine the association between diagnostic values with women's treatment preferences.</p> <p>Determine whether women in clinical settings receive adequate diagnostic evaluation to differentiate pelvic floor trauma, pelvic organ prolapsed, urinary tract infection, and UI associated with poor bladder emptying.</p> <p>Examine treatment effects in women who failed initial diagnostic evaluation (delayed diagnosis).</p>
How effective is the pharmacological treatment of UI in women?	<p>Women with predominant urgency UI may achieve continence taking antimuscarinic drugs including trospium, solifenacin, fesoterodine, tolterodine, or oxybutynin. Degree of the benefits was low for all drugs (absolute risk difference <20 percent).</p> <p>Drugs demonstrated similar effectiveness, but treatment discontinuation due to adverse effects was most common after oxybutynin and least common after solifenacin.</p> <p>Dry mouth, constipation, and blurred vision are among the most frequent adverse effects. Evidence of long-term safety of pharmacological treatments is insufficient.</p>	<p>Head-to-head trials</p> <p>Pooled analysis of individual patient data</p>	<p>Examine effectiveness of the drugs on long term continence and adverse effects in women with pure urgency vs. mixed UI.</p> <p>Examine comparative effectiveness of all available antimuscarinic drugs on continence, reduction by 70% in UI episodes, quality of life, adverse effects, and discontinuation due to adverse effects in female subgroups by age, race, baseline predominant type and severity of UI, comorbidities, and prior treatment status.</p>

Table 19. Future research recommendations (continued)

Key question	Results of literature review	Types of studies needed to answer question	Future research recommendation
How effective is the nonpharmacological treatment of UI in women?	<p>Nonpharmacological treatments result in significant clinical benefit with low risk of adverse effects.</p> <p>Women with predominant stress UI can achieve continence performing PFMT. Continence rates are similar between those who undergo PFMT with and without biofeedback.</p> <p>Women with predominant urgency UI can achieve continence performing PFMT with bladder training and/or electrical stimulation.</p> <p>Weight loss may improve UI in obese women.</p>	<p>Head-to-head trials</p> <p>Pooled analysis of individual patient data</p>	<p>Examine effectiveness of nonpharmacological treatments on long-term continence and treatment adherence in women with pure urgency or stress vs. mixed UI.</p> <p>Examine comparative effectiveness of nonpharmacological treatments on continence, reduction by 70% in UI episodes, quality of life, and treatment adherence in female subgroups by age, race, baseline predominant type and severity of UI, comorbidities, and prior treatment status.</p> <p>Examine continence in women with UI by the onset time of UI and the order of the prescribed nonpharmacological treatments.</p> <p>Examine which women subpopulations may benefit from combined (drugs + nondrug) treatments.</p> <p>Examine the effectiveness of different methods for delivering nonpharmacological treatments on short-term and long-term continence, reduction by 70% in UI episodes, quality of life, and treatment adherence in female subgroups by age, race, baseline predominant type and severity of UI, comorbidities, and prior treatment status.</p>

References

1. Abrams P. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008. 4th ed. [Paris]: Health Publications Ltd. 2009, Committee 1 Epidemiology of Urinary (UI) and Fecal (FI) Incontinence and Pelvic Organ Prolapse (POP).
2. Carls C. The prevalence of stress urinary incontinence in high school and college-age female athletes in the midwest: implications for education and prevention. *Urol Nurs*. 2007 Feb;27(1):21-4, 39. PMID 17390923.
3. Kinchen KS, Lee J, Fireman B, et al. The prevalence, burden, and treatment of urinary incontinence among women in a managed care plan. *J Womens Health (Larchmt)*. 2007 Apr;16(3):415-22. PMID 17439386.
4. Sampsel CM, Harlow SD, Skurnick J, et al. Urinary incontinence predictors and life impact in ethnically diverse perimenopausal women. *Obstet Gynecol*. 2002 Dec;100(6):1230-8. PMID 12468167.
5. Boyington JE, Howard DL, Carter-Edwards L, et al. Differences in resident characteristics and prevalence of urinary incontinence in nursing homes in the southeastern United States. *Nurs Res*. 2007;56:97-107. PMID 17356440.
6. Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. *Value Health*. 2006 Jul-Aug;9(4):272-4. PMID 16903997.
7. Anger JT, Saigal CS, Madison R, et al. Increasing costs of urinary incontinence among female Medicare beneficiaries. *J Urol*. 2006 Jul;176(1):247-51; discussion 51. PMID 16753411.
8. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. *Urology*. 2004 Mar;63(3):461-5. PMID 15028438.
9. Shamliyan T, Wyman J, Bliss DZ, et al. Prevention of urinary and fecal incontinence in adults. *Evid Rep Technol Assess (Full Rep)*. 2007 Dec(161):1-379. PMID 18457475.
10. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn*. 2010;29(1):4-20. PMID 19941278.
11. Samuelsson E, Victor A, Tibblin G. A population study of urinary incontinence and nocturia among women aged 20-59 years. Prevalence, well-being and wish for treatment. *Acta Obstet Gynecol Scand*. 1997 Jan;76(1):74-80. PMID 9033249.
12. Foldspang A, Mommsen S, Djurhuus JC. Prevalent urinary incontinence as a correlate of pregnancy, vaginal childbirth, and obstetric techniques. *Am J Public Health*. 1999 Feb;89(2):209-12. PMID 9949751.
13. Hannestad YS, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. *J Clin Epidemiol*. 2000 Nov;53(11):1150-7. PMID 11106889.
14. Peyrat L, Haillot O, Bruyere F, et al. Prevalence and risk factors of urinary incontinence in young and middle-aged women. *BJU Int*. 2002 Jan;89(1):61-6. PMID 11849162.
15. van der Vaart CH, de Leeuw JR, Roovers JP, et al. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. *BJU Int*. 2002 Oct;90(6):544-9. PMID 12230614.
16. Chen GD, Lin TL, Hu SW, et al. Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. *Neurourol Urodyn*. 2003;22(2):109-17. PMID 12579627.
17. Rortveit G, Daltveit AK, Hannestad YS, et al. Urinary incontinence after vaginal delivery or cesarean section. *N Engl J Med*. 2003 Mar 6;348(10):900-7. PMID 12621134.
18. Miller YD, Brown WJ, Russell A, et al. Urinary incontinence across the lifespan. *Neurourol Urodyn*. 2003;22(6):550-7. PMID 12951662.

19. Parazzini F, Chiaffarino F, Lavezzari M, et al. Risk factors for stress, urge or mixed urinary incontinence in Italy. *Bjog*. 2003 Oct;110(10):927-33. PMID 14550363.
20. Mawajdeh SM, Al-Qutob R, Schmidt A. Measuring reproductive morbidity: a community-based approach, Jordan. *Health Care Women Int*. 2003 Aug;24(7):635-49. PMID 14627210.
21. Andersson G, Johansson JE, Garpenholt O, et al. Urinary incontinence--prevalence, impact on daily living and desire for treatment: a population-based study. *Scand J Urol Nephrol*. 2004;38:125-30. PMID 15204395.
22. Nygaard I, Girts T, Fultz NH, et al. Is urinary incontinence a barrier to exercise in women? *Obstet Gynecol*. 2005 Aug;106(2):307-14. PMID 16055580.
23. Rohr G, Stovring H, Christensen K, et al. Characteristics of middle-aged and elderly women with urinary incontinence. *Scand J Prim Health Care*. 2005 Dec;23(4):203-8. PMID 16272067.
24. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol*. 2006 Dec;50(6):1306-14; discussion 14-5. PMID 17049716.
25. Burgio KL, Burgio LD, McCormick KA, et al. Assessing toileting skills and habits in an adult day care center. *J Gerontol Nurs*. 1991 Dec;17(12):32-5. PMID 1761819.
26. Mommsen S, Foldspang A. Body mass index and adult female urinary incontinence. *World J Urol*. 1994;12(6):319-22. PMID 7881469.
27. Bogren MA, Hvarfwen E, Fridlund B. Urinary incontinence among a 65-year old Swedish population: medical history and psychosocial consequences. *Vard Nord Utveckl Forsk*. 1997 Winter;17(4):14-7. PMID 9464154.
28. Kuh D, Cardozo L, Hardy R. Urinary incontinence in middle aged women: childhood enuresis and other lifetime risk factors in a British prospective cohort. *J Epidemiol Community Health*. 1999 Aug;53(8):453-8. PMID 10562862.
29. Moller LA, Lose G, Jorgensen T. The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. *Acta Obstet Gynecol Scand*. 2000 Apr;79(4):298-305. PMID 10746846.
30. Ueda T, Tamaki M, Kageyama S, et al. Urinary incontinence among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception. *Int J Urol*. 2000 Mar;7(3):95-103. PMID 10750888.
31. Temml C, Haidinger G, Schmidbauer J, et al. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. *Neurourol Urodyn*. 2000;19(3):259-71. PMID 10797583.
32. Swithinbank LV, Donovan JL, du Heaume JC, et al. Urinary symptoms and incontinence in women: relationships between occurrence, age, and perceived impact. *Br J Gen Pract*. 1999 Nov;49(448):897-900. PMID 10818656.
33. Alling Moller L, Lose G, Jorgensen T. Risk factors for lower urinary tract symptoms in women 40 to 60 years of age. *Obstet Gynecol*. 2000 Sep;96(3):446-51. PMID 10960640.
34. Muscatello DJ, Rissel C, Szonyi G. Urinary symptoms and incontinence in an urban community: prevalence and associated factors in older men and women. *Intern Med J*. 2001 Apr;31(3):151-60. PMID 11478344.
35. van der Vaart CH, van der Bom JG, de Leeuw JR, et al. The contribution of hysterectomy to the occurrence of urge and stress urinary incontinence symptoms. *BJOG*. 2002 Feb;109(2):149-54. PMID 11911100.
36. Sze EH, Jones WP, Ferguson JL, et al. Prevalence of urinary incontinence symptoms among black, white, and Hispanic women. *Obstet Gynecol*. 2002 Apr;99(4):572-5. PMID 12039113.
37. McGrother CW, Donaldson MM, Shaw C, et al. Storage symptoms of the bladder: prevalence, incidence and need for services in the UK. *BJU Int*. 2004 Apr;93(6):763-9. PMID 15049987.

38. Ozerdogan N, Beji NK, Yalcin O. Urinary incontinence: its prevalence, risk factors and effects on the quality of life of women living in a region of Turkey. *Gynecol Obstet Invest.* 2004;58(3):145-50. PMID 15237249.
39. Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. *Can J Urol.* 2004 Jun;11(3):2278-84. PMID 15287994.
40. Vandoninck V, Bemelmans BL, Mazzetta C, et al. The prevalence of urinary incontinence in community-dwelling married women: a matter of definition. *BJU Int.* 2004 Dec;94(9):1291-5. PMID 15610108.
41. Melville JL, Katon W, Delaney K, et al. Urinary incontinence in US women: a population-based study. *Arch Intern Med.* 2005 Mar 14;165(5):537-42. PMID 15767530.
42. Kocak I, Okyay P, Dundar M, et al. Female urinary incontinence in the west of Turkey: prevalence, risk factors and impact on quality of life. *Eur Urol.* 2005 Oct;48(4):634-41. PMID 15963633.
43. Tegerstedt G, Maehle-Schmidt M, Nyren O, et al. Prevalence of symptomatic pelvic organ prolapse in a Swedish population. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005 Nov-Dec;16(6):497-503. PMID 15986100.
44. Teleman P, Lidfeldt J, Nerbrand C, et al. Lower urinary tract symptoms in middle-aged women--prevalence and attitude towards mild urinary incontinence: a community-based population study. *Acta Obstet Gynecol Scand.* 2005 Nov;84(11):1108-12. PMID 16232181.
45. Fritel X, Ringa V, Varnoux N, et al. Mode of delivery and severe stress incontinence. a cross-sectional study among 2,625 perimenopausal women. *Bjog.* 2005 Dec;112(12):1646-51. PMID 16305569.
46. Goldberg RP, Abramov Y, Botros S, et al. Delivery mode is a major environmental determinant of stress urinary incontinence: results of the Evanston-Northwestern Twin Sisters Study. *Am J Obstet Gynecol.* 2005 Dec;193(6):2149-53. PMID 16325632.
47. Thom DH, van den Eeden SK, Ragins AI, et al. Differences in prevalence of urinary incontinence by race/ethnicity. *J Urol.* 2006 Jan;175(1):259-64. PMID 16406923.
48. Lukacz ES, Lawrence JM, Contreras R, et al. Parity, mode of delivery, and pelvic floor disorders. *Obstet Gynecol.* 2006 Jun;107(6):1253-60. PMID 16738149.
49. Waetjen LE, Liao S, Johnson WO, et al. Factors associated with prevalent and incident urinary incontinence in a cohort of midlife women: a longitudinal analysis of data: study of women's health across the nation. *Am J Epidemiol.* 2007 Feb 1;165(3):309-18. PMID 17132698.
50. Chen YC, Chen GD, Hu SW, et al. Is the occurrence of storage and voiding dysfunction affected by menopausal transition or associated with the normal aging process? *Menopause.* 2003 May-Jun;10(3):203-8. PMID 12792290.
51. Nygaard IE, Lemke JH. Urinary incontinence in rural older women: prevalence, incidence and remission. *J Am Geriatr Soc.* 1996 Sep;44(9):1049-54. PMID 8790229.
52. Thom DH, van den Eeden SK, Brown JS. Evaluation of parturition and other reproductive variables as risk factors for urinary incontinence in later life. *Obstet Gynecol.* 1997 Dec;90(6):983-9. PMID 9397116.
53. Koyama W, Koyanagi A, Mihara S, et al. Prevalence and conditions of urinary incontinence among the elderly. *Methods Inf Med.* 1998 Jun;37(2):151-5. PMID 9656656.
54. Damiaan J, Martin-Moreno JM, Lobo F, et al. Prevalence of urinary incontinence among Spanish older people living at home. *Eur Urol.* 1998;34:333-8. PMID 9748681.
55. Brown JS, Grady D, Ouslander JG, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. *Heart & Estrogen/Progestin Replacement Study (HERS) Research Group.* *Obstet Gynecol.* 1999 Jul;94(1):66-70. PMID 10389720.
56. Stenberg A, Heimer G, Holmberg L, et al. Prevalence of postmenopausal symptoms in two age groups of elderly women in relation to oestrogen replacement therapy. *Maturitas.* 1999 Dec 15;33(3):229-37. PMID 10656501.

57. Bortolotti A, Bernardini B, Colli E, et al. Prevalence and risk factors for urinary incontinence in Italy. *Eur Urol.* 2000 Jan;37(1):30-5. PMID 10671782.
58. Buchsbaum GM, Chin M, Glantz C, et al. Prevalence of urinary incontinence and associated risk factors in a cohort of nuns. *Obstet Gynecol.* 2002 Aug;100(2):226-9. PMID 12151141.
59. Nuotio M, Jylha M, Luukkaala T, et al. Urinary incontinence in a Finnish population aged 70 and over. Prevalence of types, associated factors and self-reported treatments. *Scand J Prim Health Care.* 2003 Sep;21(3):182-7. PMID 14531512.
60. Espino DV, Palmer RF, Miles TP, et al. Prevalence and severity of urinary incontinence in elderly Mexican-American women. *J Am Geriatr Soc.* 2003 Nov;51(11):1580-6. PMID 14687387.
61. Jackson RA, Vittinghoff E, Kanaya AM, et al. Urinary incontinence in elderly women: findings from the Health, Aging, and Body Composition Study. *Obstet Gynecol.* 2004 Aug;104(2):301-7. PMID 15292003.
62. Adelman PK. Prevalence and detection of urinary incontinence among older Medicaid recipients. *J Health Care Poor Underserved.* 2004;15:99-112. PMID 15359977.
63. Oskay UY, Beji NK, Yalcin O. A study on urogenital complaints of postmenopausal women aged 50 and over. *Acta Obstet Gynecol Scand.* 2005 Jan;84(1):72-8. PMID 15603571.
64. Jackson SL, Boyko EJ, Scholes D, et al. Predictors of urinary tract infection after menopause: a prospective study. *Am J Med.* 2004 Dec 15;117(12):903-11. PMID 15629728.
65. Bradley CS, Kennedy CM, Nygaard IE. Pelvic floor symptoms and lifestyle factors in older women. *J Womens Health (Larchmt).* 2005 Mar;14(2):128-36. PMID 15775730.
66. Jackson SL, Scholes D, Boyko EJ, et al. Urinary incontinence and diabetes in postmenopausal women. *Diabetes Care.* 2005 Jul;28(7):1730-8. PMID 15983327.
67. Tannenbaum C, Corcos J, Assalian P. The relationship between sexual activity and urinary incontinence in older women. *J Am Geriatr Soc.* 2006 Aug;54(8):1220-4. PMID 16913988.
68. Swanson JG, Kaczorowski J, Skelly J, et al. Urinary incontinence: common problem among women over 45. *Can Fam Physician.* 2005 Jan;51:84-5. PMID 16926957.
69. Abrams P. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008. 4th ed. [Paris]: Health Publications Ltd.; 2009.
70. Thom DH, Nygaard IE, Calhoun EA. Urologic diseases in America project: urinary incontinence in women-national trends in hospitalizations, office visits, treatment and economic impact. *J Urol.* 2005 Apr;173(4):1295-301. PMID 15758785.
71. Wyman JF. Management of urinary incontinence in adult ambulatory care populations. *Annu Rev Nurs Res.* 2000;18:171-94. PMID 10918936.
72. Holroyd-Leduc JM, Tannenbaum C, Thorpe KE, et al. What type of urinary incontinence does this woman have? *Jama.* 2008 Mar 26;299(12):1446-56. PMID 18364487.
73. Martin JL, Williams KS, Abrams KR, et al. Systematic review and evaluation of methods of assessing urinary incontinence. *Health Technol Assess.* 2006 Feb;10(6):1-132, iii-iv. PMID 16487456.
74. Goepel M, Hoffmann JA, Piro M, et al. Prevalence and physician awareness of symptoms of urinary bladder dysfunction. *Eur Urol.* 2002 Mar;41(3):234-9. PMID 12180221.
75. Davila GW, Ghoniem GM, Kapoor DS, et al. Pelvic floor dysfunction management practice patterns: a survey of members of the International Urogynecological Association. *Int Urogynecol J Pelvic Floor Dysfunct.* 2002;13(5):319-25. PMID 12355293.
76. Teunissen D, van den Bosch W, van Weel C, et al. Urinary incontinence in the elderly: attitudes and experiences of general practitioners. A focus group study. *Scand J Prim Health Care.* 2006 Mar;24(1):56-61. PMID 16464816.

77. Wagg A, Das Gupta R, Assassa P, et al. Secondary-care treatment patterns in the UK for women with urinary incontinence. *BJU Int.* 2005;96:839-42. PMID 16153213.
78. Abrams P. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008: Health Publications Ltd: 2009. Committee 12. Adult Conservative Management.
79. Fantl JA, Newman DK, Colling J, et al. Managing acute and chronic urinary incontinence. Clinical Practice Guideline. Quick Reference Guide for Clinicians, No. 2, 1996 Update Agency for Health Care Policy and Research, January 1996. AHCPR Publication No. 96-0686. Available at <http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hsarchive&part=A32554#A32573>. Washington, DC.
80. United States Agency for Health Care Policy and Research Urinary Incontinence Guideline Panel. Urinary incontinence in adults: clinical practice guideline. Rockville, MD: US Department of Health and Human Services 1992.
81. Thomas LH, Barrett J, Cross S, et al. Prevention and treatment of urinary incontinence after stroke in adults. *Cochrane Database Syst Rev.* 2005(3):CD004462. PMID 16034933.
82. Shaikh S, Ong EK, Glavind K, et al. Mechanical devices for urinary incontinence in women. *Cochrane Database Syst Rev.* 2006;3(CD001756)PMID 16855977.
83. Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. *Cochrane Database Syst Rev.* 2000(2):CD001308. PMID 10796768.
84. Pickard R, Reaper J, Wyness L, et al. Periurethral injection therapy for urinary incontinence in women. *Cochrane Database Syst Rev.* 2003(2):CD003881. PMID 12804494.
85. Ostaszkievicz J, Johnston L, Roe B. Timed voiding for the management of urinary incontinence in adults. *Cochrane Database Syst Rev.* 2004(1):CD002802. PMID 14973993.
86. Ostaszkievicz J, Johnston L, Roe B. Habit retraining for the management of urinary incontinence in adults. *Cochrane Database Syst Rev.* 2004(2):CD002801. PMID 15106179.
87. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. *Urology.* 1997 Dec;50(6A Suppl):90-6; discussion 7-9. PMID 9426760.
88. Sand PK, Morrow JD, Bavendam T, et al. Efficacy and tolerability of fesoterodine in women with overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009 Jul;20(7):827-35. PMID 19495545.
89. Moehrer B, Ellis G, Carey M, et al. Laparoscopic colposuspension for urinary incontinence in women. *Cochrane Database Syst Rev.* 2002(1):CD002239. PMID 11869634.
90. Maher C, Baessler K, Glazener CM, et al. Surgical management of pelvic organ prolapse in women. *Cochrane Database Syst Rev.* 2004(4):CD004014. PMID 15495076.
91. Lapitan MC, Cody DJ, Grant AM. Open retropubic colposuspension for urinary incontinence in women. *Cochrane Database Syst Rev.* 2005(3):CD002912. PMID 16034879.
92. Lappin MS, Lawrie FW, Richards TL, et al. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial. *Altern Ther Health Med.* 2003 Jul-Aug;9(4):38-48. PMID 12868251.
93. Wyman JF, Fantl JA, McClish DK, et al. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. *Am J Obstet Gynecol.* 1998 Oct;179(4):999-1007. PMID 9790388.
94. Herbison P, Plevnik S, Mantle J. Weighted vaginal cones for urinary incontinence. *Cochrane Database Syst Rev.* 2002(1):CD002114. PMID 11869623.
95. Herbison P, Plevnik S, Mantle J. Weighted vaginal cones for urinary incontinence. *Cochrane Database Syst Rev.* 2000(2):CD002114. PMID 10796862.

96. Hay-Smith EJ, Dumoulin C. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. *Cochrane Database Syst Rev.* 2006(1):CD005654. PMID 16437536.
97. Hay-Smith EJ, Bo Berghmans LC, Hendriks HJ, et al. Pelvic floor muscle training for urinary incontinence in women. *Cochrane Database Syst Rev.* 2001(1):CD001407. PMID 11279716.
98. Glazener CM, Lapitan MC. Urodynamic investigations for management of urinary incontinence in adults. *Cochrane Database Syst Rev.* 2002(3):CD003195. PMID 12137680.
99. Glazener CM, Cooper K. Bladder neck needle suspension for urinary incontinence in women. *Cochrane Database Syst Rev.* 2004(2):CD003636. PMID 15106209.
100. Glazener CM, Cooper K. Bladder neck needle suspension for urinary incontinence in women. *Cochrane Database Syst Rev.* 2002(2):CD003636. PMID 12076494.
101. Glazener CM, Cooper K. Anterior vaginal repair for urinary incontinence in women. *Cochrane Database Syst Rev.* 2001(1):CD001755. PMID 11279728.
102. Glazener CM, Cooper K. Anterior vaginal repair for urinary incontinence in women. *Cochrane Database Syst Rev.* 2000(3):CD001755. PMID 10908510.
103. Eustice S, Roe B, Paterson J. Prompted voiding for the management of urinary incontinence in adults. *Cochrane Database Syst Rev.* 2000(2):CD002113. PMID 10796861.
104. Dean NM, Ellis G, Wilson PD, et al. Laparoscopic colposuspension for urinary incontinence in women. *Cochrane Database Syst Rev.* 2006;3:CD002239. PMID 16855989.
105. Bezerra CA, Bruschini H, Cody DJ. Traditional suburethral sling operations for urinary incontinence in women. *Cochrane Database Syst Rev.* 2005(3):CD001754. PMID 16034866.
106. Bezerra CA, Bruschini H. Suburethral sling operations for urinary incontinence in women. *Cochrane Database Syst Rev.* 2001(3):CD001754. PMID 11686996.
107. Bezerra CA, Bruschini H. Suburethral sling operations for urinary incontinence in women. *Cochrane Database Syst Rev.* 2000(3):CD001754. PMID 10908509.
108. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, et al. Draft Guidance for Industry and FDA Staff - Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence. Rockville, MD 20852: Food and Drug Administration; 2008. Available: <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument/s/ucm070852.htm>. Accessed August 2009.
109. Coyne KS, Sexton CC, Kopp ZS, et al. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. *BJU Int.* 2011 Mar 3 PMID 21371240.
110. Tennstedt SL, Fitzgerald MP, Nager CW, et al. Quality of life in women with stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 May;18(5):543-9. PMID 17036169.
111. Coyne KS, Zhou Z, Thompson C, et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. *BJU Int.* 2003 Nov;92(7):731-5. PMID 14616456.
112. Hartmann KE, McPheeters ML, Biller DH, et al. Treatment of overactive bladder in women. *Evid Rep Technol Assess (Full Rep).* 2009 Aug(187):1-120, v. PMID 19947666.
113. Shamliyan TA, Kane RL, Wyman J, et al. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. *Ann Intern Med.* 2008 Mar 18;148(6):459-73. PMID 18268288.
114. Pharmaceutical Research and Manufacturers of America. Solifenacin in a flexible dose regimen with tolterodine as an active comparator in a double-blind, double-dummy, randomized overactive bladder symptom trial (STAR). Available at: http://www.clinicalstudyresults.org/documents/company-study_8350_0.pdf. Accessed June 25, 2010.

115. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for Ditropan XL (Oxybutinin Chloride) Tablets. 1998. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20897.cfm. Accessed June 25, 2010.
116. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. *Cochrane Database Syst Rev*. 2003(2):CD001405. PMID 12804406.
117. Moehrer B, Carey M, Wilson D. Laparoscopic colposuspension: a systematic review. *BJOG*. 2003 Mar;110(3):230-5. PMID 12628259.
118. National Collaborating Centre for Women's and Children's Health. Urinary incontinence: The management of urinary incontinence in women Commissioned by the National Institute for Health and Clinical Excellence,. October 2006. Available at: <http://www.nice.org.uk/nicemedia/pdf/CG40NICEguideline.pdf>.
119. Shih YC, Hartzema AG, Tolleson-Rinehart S. Labor costs associated with incontinence in long-term care facilities. *Urology*. 2003 Sep;62(3):442-6. PMID 12946743.
120. Engstrom G, Henningsohn L, Steineck G, et al. Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. *BJU Int*. 2005;95:810-5. PMID 15794788.
121. Brittain KR, Shaw C. The social consequences of living with and dealing with incontinence--a carers perspective. *Soc Sci Med*. 2007 Sep;65(6):1274-83. PMID 17509743.
122. Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. *Cochrane Database Syst Rev*. 2010(9):CD007063. PMID 20824855.
123. Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. *Climacteric*. 2005 Sep;8(3):214-20. PMID 16390753.
124. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. *BJU Int*. 2007 Nov;100(5):987-1006. PMID 17922784.
125. Andersson KE. Drug therapy for urinary incontinence. *Baillieres Best Pract Res Clin Obstet Gynaecol*. 2000 Apr;14(2):291-313. PMID 10897323.
126. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. *Urology*. 2000 May;55(5A Suppl):33-46; discussion 50. PMID 10767450.
127. Abramov Y, Sand PK. Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. *Expert Opin Pharmacother*. 2004 Nov;5(11):2351-9. PMID 15500382.
128. Appell RA. The newer antimuscarinic drugs: bladder control with less dry mouth. *Cleve Clin J Med*. 2002 Oct;69(10):761, 5-6, 8-9. PMID 12371799.
129. Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. *Drug Saf*. 2004;27(13):1043-57. PMID 15471509.
130. Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. *Eur Urol*. 2007 Apr;51(4):907-14; discussion 14. PMID 17157979.
131. Crandall C. Tolterodine: a clinical review. *J Womens Health Gend Based Med*. 2001 Oct;10(8):735-43. PMID 11703885.
132. Croom KF, Keating GM. Darifenacin: in the treatment of overactive bladder. *Drugs Aging*. 2004;21(13):885-92; discussion 93-4. PMID 15493952.
133. Davila GW. Transdermal oxybutynin: a new treatment for overactive bladder. *Expert Opin Pharmacother*. 2003 Dec;4(12):2315-24. PMID 14640930.
134. Robinson D, Cardozo L. Solifenacin in the management of the overactive bladder syndrome. *Int J Clin Pract*. 2005 Oct;59(10):1229-36. PMID 16178992.
135. Rovner ES. Trosipium chloride in the management of overactive bladder. *Drugs*. 2004;64(21):2433-46. PMID 15482001.
136. Simpson D, Wagstaff AJ. Solifenacin in overactive bladder syndrome. *Drugs Aging*. 2005;22(12):1061-9. PMID 16363887.

137. Zinner NR. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. *Expert Opin Pharmacother*. 2005 Jul;6(8):1409-20. PMID 16013990.
138. Subak LL, Brown JS, Kraus SR, et al. The "costs" of urinary incontinence for women. *Obstet Gynecol*. 2006 Apr;107(4):908-16. PMID 16582131.
139. Papanicolaou S, Pons ME, Hampel C, et al. Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study. *Maturitas*. 2005 Nov 30;52 Suppl 2:S35-47. PMID 16297577.
140. Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. *Pharmacotherapy*. 2005 Apr;25(4):511-9. PMID 15977912.
141. Abrams P, Cardozo L, Fall M, et al. for the Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. *Urology*. 2003;61:37-49. PMID 12559262.
142. Schorge JO, Schaffer JI, Halvorson LM, et al. Chapter 23. Urinary Incontinence. In: Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG, et al., eds. *Gynecology* Available at: www.accessmedicine.com/content.aspx?aID=3150435.
143. Tarnay CM, Bhatia Narender N. Chapter 45. Urinary Incontinence. In: DeCherney AH, Nathan L, eds. *Current Diagnosis & Treatment Obstetrics & Gynecology*. 10e: Available at: www.accessmedicine.com/content.aspx?aID=2390665.
144. Haylen BT, Freeman RM, Swift SE, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. *Neurourol Urodyn*. 2011 Jan;30(1):2-12. PMID 21181958.
145. AHCPR Urinary Incontinence in Adults Guideline Update Panel. Managing acute and chronic urinary incontinence. *Am Fam Physician*. 1996;54:1661-72. PMID 8857788.
146. Resnick NM. Urinary incontinence. In: Beers MH, Jones TV, Berkwits M, Kaplan JL, Rahman MI, Merck Research Laboratories, eds. *The Merck manual of geriatrics* [online]. Whitehouse Station, NJ: Merck & Co. Inc., 2010. Available at www.merck.com/mkgr/mmg/home.jsp.
147. Higgins J, Green S, Cochrane Collaboration. *Cochrane handbook for systematic reviews of interventions*. Chichester, West Sussex ; Hoboken NJ: John Wiley & Sons; 2008.
148. Norris S, Atkins D, Bruening W, et al. Selecting observational studies for comparing medical interventions. Agency for Healthcare Research and Quality. *Methods Guide for Comparative Effectiveness Reviews*. 2010.
149. Agency for Healthcare Research and Quality, (AHRQ). *Methods Guide for Comparative Effectiveness Reviews 2007*. <http://www.effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=60>. Accessed August 2009.
150. Chou R, Aronson N, Atkins D, et al. Assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. *J Clin Epidemiol*. 2008 Sep 25; PMID 18823754.
151. Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. *BMC Med Res Methodol*. 2006;6:9. PMID 16519814.
152. Bruns DE. The STARD initiative and the reporting of studies of diagnostic accuracy. *Clin Chem*. 2003 Jan;49(1):19-20. PMID 12507955.
153. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. *Ann Intern Med*. 2003 Jan 7;138(1):40-4. PMID 12513043.
154. Bossuyt PM, Reitsma JB. The STARD initiative. *Lancet*. 2003 Jan 4;361(9351):71. PMID 12517476.

155. Jones R. Reporting studies of diagnostic accuracy: the STARD initiative. *Fam Pract.* 2004 Feb;21(1):3. PMID 14760035.
156. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *Fam Pract.* 2004 Feb;21(1):4-10. PMID 14760036.
157. Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the Effective Health Care Program. *J Clin Epidemiol.* 2009 Jul 10; PMID 19595577.
158. Aschengrau A, Seage GR. *Essentials of Epidemiology in Public Health.* Sudbury, Mass: Jones and Bartlett; 2003.
159. Egger M, Smith GD. Bias in location and selection of studies. *BMJ.* 1998 Jan 3;316(7124):61-6. PMID 9451274.
160. Dickersin K, Min YI. NIH clinical trials and publication bias. *Online J Curr Clin Trials.* 1993 Apr 28;Doc No 50:[4967 words; 53 paragraphs]. PMID 8306005.
161. Higgins J, Green S. *The Cochrane Collaboration. The Cochrane handbook for systematic reviews of interventions.* Chichester, UK: John Wiley & Sons, Ltd. Cochrane Collaboration; 2005. Available at: <http://www.cochrane.org/resources/handbook/handbook.pdf2006>.
162. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. *J Clin Epidemiol.* 2000 Feb;53(2):207-16. PMID 10729693.
163. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. *BMJ.* 2004 Jul 17;329(7458):168-9. PMID 15258077.
164. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet.* 1986 Feb 8;1(8476):307-10. PMID 2868172.
165. Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. *BMJ.* 1994 Jul 16;309(6948):188. PMID 8044101.
166. *Methods Guide for Medical Test Reviews.* Rockville, MD: Agency for Healthcare Research and Quality; 2010.
167. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. *BMJ.* 1994 Jul 9;309(6947):102. PMID 8038641.
168. Wallace BC, Schmid CH, Lau J, et al. *Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data.* *BMC Med Res Methodol.* 2009;9:80. PMID 19961608.
169. Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. *BMC Med Res Methodol.* 2002 Jul 3;2:9. PMID 12097142.
170. Deeks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. *BMJ.* 2001 Jul 21;323(7305):157-62. PMID 11463691.
171. Whitehead A. *Meta-analysis of controlled clinical trials.* Chichester, New York: John Wiley & Sons; 2002.
172. DerSimonian R, Laird N. *Meta-analysis in clinical trials.* *Control Clin Trials.* 1986 Sep;7(3):177-88. PMID 3802833.
173. Fu R, Gartlehner G, Grant M, et al. *Conducting Quantitative Synthesis When Comparing Medical Interventions: AHRQ and the Effective Health Care Program. Methods Guide for Comparative Effectiveness Reviews.* Rockville, MD.: Agency for Healthcare Research and Quality, . 2010.
174. Egger M, Smith GD, Altman DG. *Systematic Reviews in Health Care.* London: NetLibrary, Inc. BMJ Books; 2001.
175. Ebrahim S. The use of numbers needed to treat derived from systematic reviews and meta-analysis. Caveats and pitfalls. *Eval Health Prof.* 2001 Jun;24(2):152-64. PMID 11523384.
176. Altman DG. Confidence intervals for the number needed to treat. *Bmj.* 1998 Nov 7;317(7168):1309-12. PMID 9804726.
177. Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program. *J Clin Epidemiol.* 2011 Apr 6; PMID 21477993.
178. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Stat Med.* 2007 Jan 15;26(1):53-77. PMID 16596572.

179. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med.* 2004 May 15;23(9):1351-75. PMID 15116347.
180. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. *Stat Med.* 2010 Dec 20;29(29):3046-67. PMID 20827667.
181. Rucker G, Schwarzer G, Carpenter J, et al. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. *Stat Med.* 2009 Feb 28;28(5):721-38. PMID 19072749.
182. Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. *Stat Med.* 2006 Feb 6;25(4):643-55. PMID 16463355.
183. Knapp G, Biggerstaff BJ, Hartung J. Assessing the amount of heterogeneity in random-effects meta-analysis. *Biom J.* 2006 Apr;48(2):271-85. PMID 16708778.
184. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ.* 2003 Sep 6;327(7414):557-60. PMID 12958120.
185. Herbison P, Hay-Smith J, Gillespie WJ. Adjustment of meta-analyses on the basis of quality scores should be abandoned. *J Clin Epidemiol.* 2006 Dec;59(12):1249-56. PMID 17098567.
186. Eastwood HD. Urodynamic studies in the management of urinary incontinence in the elderly. *Age Ageing.* 1979 Feb;8(1):41-8. PMID 443110.
187. Drutz HP, Mandel F. Urodynamic analysis of urinary incontinence symptoms in women. *Am J Obstet Gynecol.* 1979 Aug 1;134(7):789-92. PMID 463981.
188. Farrar DJ, Whiteside CG, Osborne JL, et al. A urodynamic analysis of micturition symptoms in the female. *Surg Gynecol Obstet.* 1975 Dec;141(6):875-81. PMID 1188564.
189. Niecestro RM, Wheeler JS, Jr., Nanminga J, et al. Use of stresscath for diagnosing stress incontinence. *Urology.* 1992 Mar;39(3):266-9. PMID 1546422.
190. Rosenzweig BA, Pushkin S, Blumenfeld D, et al. Prevalence of abnormal urodynamic test results in continent women with severe genitourinary prolapse. *Obstet Gynecol.* 1992 Apr;79(4):539-42. PMID 1553172.
191. De Muylder X, Claes H, Neven P, et al. Usefulness of urodynamic investigations in female incontinence. *Eur J Obstet Gynecol Reprod Biol.* 1992 May 13;44(3):205-8. PMID 1607060.
192. Versi E, Cardozo L, Anand D, et al. Symptoms analysis for the diagnosis of genuine stress incontinence. *Br J Obstet Gynaecol.* 1991 Aug;98(8):815-9. PMID 1911591.
193. Bergman A, Bader K. Reliability of the patient's history in the diagnosis of urinary incontinence. *Int J Gynaecol Obstet.* 1990 Jul;32(3):255-9. PMID 1972118.
194. Sand PK, Brubaker LT, Novak T. Simple standing incremental cystometry as a screening method for detrusor instability. *Obstet Gynecol.* 1991 Mar;77(3):453-7. PMID 1992416.
195. Lagro-Janssen AL, Debruyne FM, van Weel C. Value of the patient's case history in diagnosing urinary incontinence in general practice. *Br J Urol.* 1991 Jun;67(6):569-72. PMID 2070199.
196. Lagro-Janssen TL, Smits AJ, Van Weel C. Women with urinary incontinence: self-perceived worries and general practitioners' knowledge of problem. *Br J Gen Pract.* 1990 Aug;40(337):331-4. PMID 2121179.
197. Diokno AC, Normolle DP, Brown MB, et al. Urodynamic tests for female geriatric urinary incontinence. *Urology.* 1990 Nov;36(5):431-9. PMID 2238302.
198. Hastie KJ, Moisey CU. Are urodynamics necessary in female patients presenting with stress incontinence? *Br J Urol.* 1989 Feb;63(2):155-6. PMID 2702401.
199. Haylen BT, Sutherst JR, Frazer MI. Is the investigation of most stress incontinence really necessary? *Br J Urol.* 1989 Aug;64(2):147-9. PMID 2765780.
200. Sand PK, Hill RC, Ostergard DR. Incontinence history as a predictor of detrusor stability. *Obstet Gynecol.* 1988 Feb;71(2):257-60. PMID 3336562.

201. Wyman JF, Choi SC, Harkins SW, et al. The urinary diary in evaluation of incontinent women: a test-retest analysis. *Obstet Gynecol.* 1988 Jun;71(6 Pt 1):812-7. PMID 3368165.
202. Walters MD, Shields LE. The diagnostic value of history, physical examination, and the Q-tip cotton swab test in women with urinary incontinence. *Am J Obstet Gynecol.* 1988 Jul;159(1):145-9. PMID 3394734.
203. Valente S. The usefulness of urodynamics in urogynaecological disorders. *Clin Exp Obstet Gynecol.* 1988;15(3):102-7. PMID 3402082.
204. Byrne DJ, Stewart PA, Gray BK. The role of urodynamics in female urinary stress incontinence. *Br J Urol.* 1987 Mar;59(3):228-9. PMID 3567483.
205. Wyman JF, Harkins SW, Choi SC, et al. Psychosocial impact of urinary incontinence in women. *Obstet Gynecol.* 1987 Sep;70(3 Pt 1):378-81. PMID 3627585.
206. Thiede HA, Saini VD. Urogynecology: comments and caveats. *Am J Obstet Gynecol.* 1987 Sep;157(3):563-8. PMID 3631157.
207. Ouslander J, Staskin D, Raz S, et al. Clinical versus urodynamic diagnosis in an incontinent geriatric female population. *J Urol.* 1987 Jan;137(1):68-71. PMID 3795368.
208. Montz FJ, Stanton SL. Q-Tip test in female urinary incontinence. *Obstet Gynecol.* 1986 Feb;67(2):258-60. PMID 3945436.
209. Glezerman M, Glasner M, Rikover M, et al. Evaluation of reliability of history in women complaining of urinary stress incontinence. *Eur J Obstet Gynecol Reprod Biol.* 1986 Mar;21(3):159-64. PMID 3956835.
210. Versi E, Cardozo LD. Perineal pad weighing versus videographic analysis in genuine stress incontinence. *Br J Obstet Gynaecol.* 1986 Apr;93(4):364-6. PMID 3964613.
211. Bates CP, Loose H, Stanton SL. The objective study of incontinence after repair operations. *Surg Gynecol Obstet.* 1973 Jan;136(1):17-22. PMID 4682258.
212. Arnold EP, Webster JR, Loose H, et al. Urodynamics of female incontinence: factors influencing the results of surgery. *Am J Obstet Gynecol.* 1973 Nov 15;117(6):805-13. PMID 4795646.
213. Moolgaoker AS, Ardran GM, Smith JC, et al. The diagnosis and management of urinary incontinence in the female. *J Obstet Gynaecol Br Commonw.* 1972 Jun;79(6):481-97. PMID 5064185.
214. Sutherst JR, Brown MC. Comparison of single and multichannel cystometry in diagnosing bladder instability. *Br Med J (Clin Res Ed).* 1984 Jun 9;288(6432):1720-2. PMID 6428513.
215. Eastwood HD, Warrell R. Urinary incontinence in the elderly female: prediction in diagnosis and outcome of management. *Age Ageing.* 1984 Jul;13(4):230-4. PMID 6475652.
216. Awad SA, McGinnis RH. Factors that influence the incidence of detrusor instability in women. *J Urol.* 1983 Jul;130(1):114-5. PMID 6683325.
217. Hilton P, Stanton SL. Algorithmic method for assessing urinary incontinence in elderly women. *Br Med J (Clin Res Ed).* 1981 Mar 21;282(6268):940-2. PMID 6781660.
218. Bent AE, Richardson DA, Ostergard DR. Diagnosis of lower urinary tract disorders in postmenopausal patients. *Am J Obstet Gynecol.* 1983 Jan 15;145(2):218-22. PMID 6849357.
219. Cardozo LD, Stanton SL. Genuine stress incontinence and detrusor instability--a review of 200 patients. *Br J Obstet Gynaecol.* 1980 Mar;87(3):184-90. PMID 7387918.
220. Haeusler G, Hanzal E, Joura E, et al. Differential diagnosis of detrusor instability and stress-incontinence by patient history: the Gaudenz-Incontinence-Questionnaire revisited. *Acta Obstet Gynecol Scand.* 1995 Sep;74(8):635-7. PMID 7660771.
221. Swift SE, Ostergard DR. Evaluation of current urodynamic testing methods in the diagnosis of genuine stress incontinence. *Obstet Gynecol.* 1995 Jul;86(1):85-91. PMID 7784028.

222. Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. *Continence Program in Women (CPW) Research Group. Qual Life Res.* 1994 Oct;3(5):291-306. PMID 7841963.
223. Sandvik H, Hunskaar S, Vanvik A, et al. Diagnostic classification of female urinary incontinence: an epidemiological survey corrected for validity. *J Clin Epidemiol.* 1995 Mar;48(3):339-43. PMID 7897455.
224. Caputo RM, Benson JT. The Q-tip test and urethrovesical junction mobility. *Obstet Gynecol.* 1993 Dec;82(6):892-6. PMID 8233260.
225. Versi E, Orrego G, Hardy E, et al. Evaluation of the home pad test in the investigation of female urinary incontinence. *Br J Obstet Gynaecol.* 1996 Feb;103(2):162-7. PMID 8616134.
226. Theofrastous JP, Cundiff GW, Harris RL, et al. The effect of vesical volume on Valsalva leak-point pressures in women with genuine stress urinary incontinence. *Obstet Gynecol.* 1996 May;87(5 Pt 1):711-4. PMID 8677072.
227. Jackson S, Donovan J, Brookes S, et al. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. *Br J Urol.* 1996 Jun;77(6):805-12. PMID 8705212.
228. Cundiff GW, Harris RL, Coates KW, et al. Clinical predictors of urinary incontinence in women. *Am J Obstet Gynecol.* 1997 Aug;177(2):262-6; discussion 6-7. PMID 9290438.
229. Clarke B. The role of urodynamic assessment in the diagnosis of lower urinary tract disorders. *Int Urogynecol J Pelvic Floor Dysfunct.* 1997;8(4):196-9. PMID 9449295.
230. Videla FL, Wall LL. Stress incontinence diagnosed without multichannel urodynamic studies. *Obstet Gynecol.* 1998 Jun;91(6):965-8. PMID 9611005.
231. Yoon E, Swift S. A comparison of maximum cystometric bladder capacity with maximum environmental voided volumes. *Int Urogynecol J Pelvic Floor Dysfunct.* 1998;9(2):78-82. PMID 9694135.
232. Dinokno AC, Dimaculangan RR, Lim EU, et al. Office based criteria for predicting type II stress incontinence without further evaluation studies. *J Urol.* 1999 Apr;161(4):1263-7. PMID 10081882.
233. Miller JM, Ashton-Miller JA, Carchidi LT, et al. On the lack of correlation between self-report and urine loss measured with standing provocation test in older stress-incontinent women. *J Womens Health.* 1999 Mar;8(2):157-62. PMID 10100129.
234. Lemack GE, Zimmern PE. Predictability of urodynamic findings based on the Urogenital Distress Inventory-6 questionnaire. *Urology.* 1999 Sep;54(3):461-6. PMID 10475355.
235. Chiarelli P, Brown W, McElduff P. Leaking urine: prevalence and associated factors in Australian women. *Neurourol Urodyn.* 1999;18(6):567-77. PMID 10529705.
236. James M, Jackson S, Shepherd A, et al. Pure stress leakage symptomatology: is it safe to discount detrusor instability? *Br J Obstet Gynaecol.* 1999 Dec;106(12):1255-8. PMID 10609718.
237. Morkved S, Bo K. Prevalence of urinary incontinence during pregnancy and postpartum. *Int Urogynecol J Pelvic Floor Dysfunct.* 1999;10(6):394-8. PMID 10614977.
238. Ishiko O, Hirai K, Sumi T, et al. The urinary incontinence score in the diagnosis of female urinary incontinence. *Int J Gynaecol Obstet.* 2000 Feb;68(2):131-7. PMID 10717817.
239. Lemack GE, Zimmern PE. Identifying patients who require urodynamic testing before surgery for stress incontinence based on questionnaire information and surgical history. *Urology.* 2000 Apr;55(4):506-11. PMID 10736492.
240. Gunthorpe W, Brown W, Redman S. The development and evaluation of an incontinence screening questionnaire for female primary care. *Neurourol Urodyn.* 2000;19(5):595-607. PMID 11002302.
241. Moore KN, Jensen L. Testing of the Incontinence Impact Questionnaire (IIQ-7) with men after radical prostatectomy. *J Wound Ostomy Continence Nurs.* 2000 Nov;27(6):304-12. PMID 11096410.

242. Weidner AC, Myers ER, Visco AG, et al. Which women with stress incontinence require urodynamic evaluation? *Am J Obstet Gynecol.* 2001 Jan;184(2):20-7. PMID 11174474.
243. Harvey MA, Kristjansson B, Griffith D, et al. The Incontinence Impact Questionnaire and the Urogenital Distress Inventory: a revisit of their validity in women without a urodynamic diagnosis. *Am J Obstet Gynecol.* 2001 Jul;185(1):25-31. PMID 11483899.
244. FitzGerald MP, Brubaker L. Urinary incontinence symptom scores and urodynamic diagnoses. *Neurourol Urodyn.* 2002;21(1):30-5. PMID 11835421.
245. Stach-Lempinen B, Kujansuu E, Laippala P, et al. Visual analogue scale, urinary incontinence severity score and 15 D-- psychometric testing of three different health-related quality-of-life instruments for urinary incontinent women. *Scand J Urol Nephrol.* 2001 Dec;35(6):476-83. PMID 11848427.
246. Klingele CJ, Carley ME, Hill RF. Patient characteristics that are associated with urodynamically diagnosed detrusor instability and genuine stress incontinence. *Am J Obstet Gynecol.* 2002 May;186(5):866-8. PMID 12015497.
247. Digesu GA, Khullar V, Cardozo L, et al. Overactive bladder symptoms: do we need urodynamics? *Neurourol Urodyn.* 2003;22(2):105-8. PMID 12579626.
248. Amarenco G, Arnould B, Carita P, et al. European psychometric validation of the CONTILIFE: a Quality of Life questionnaire for urinary incontinence. *Eur Urol.* 2003 Apr;43(4):391-404. PMID 12667721.
249. Scarpero HM, Fiske J, Xue X, et al. American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life. *Urology.* 2003 Jun;61(6):1118-22. PMID 12809877.
250. Bump RC, Norton PA, Zinner NR, et al. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. *Obstet Gynecol.* 2003 Jul;102(1):76-83. PMID 12850610.
251. Warrell DW. Investigation and Treatment of Incontinence of Urine in Women Who Have Had a Prolapse Repair Operation. *Br J Urol.* 1965 Apr;37:233-9. PMID 14282088.
252. Kulseng-Hanssen S, Borstad E. The development of a questionnaire to measure the severity of symptoms and the quality of life before and after surgery for stress incontinence. *BJOG.* 2003 Nov;110(11):983-8. PMID 14592582.
253. Khan MS, Chaliha C, Leskova L, et al. The relationship between urinary symptom questionnaires and urodynamic diagnoses: an analysis of two methods of questionnaire administration. *BJOG.* 2004 May;111(5):468-74. PMID 15104612.
254. Yalcin I, Versi E, Benson JT, et al. Validation of a clinical algorithm to diagnose stress urinary incontinence for large studies. *J Urol.* 2004 Jun;171(6 Pt 1):2321-5. PMID 15126813.
255. Homma Y, Uemura S. Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder. *BJU Int.* 2004 May;93(7):1009-13. PMID 15142153.
256. Abdel-fattah M, Barrington JW, Youssef M. The standard 1-hour pad test: does it have any value in clinical practice? *Eur Urol.* 2004 Sep;46(3):377-80. PMID 15306111.
257. Lin LY, Yeh NH, Lin CY, et al. Comparisons of urodynamic characteristics between female patients with overactive bladder and overactive bladder plus stress urinary incontinence. *Urology.* 2004 Nov;64(5):945-9. PMID 15533483.
258. Matharu G, Donaldson MM, McGrother CW, et al. Relationship between urinary symptoms reported in a postal questionnaire and urodynamic diagnosis. *Neurourol Urodyn.* 2005;24(2):100-5. PMID 15605372.
259. Bradley CS, Rovner ES, Morgan MA, et al. A new questionnaire for urinary incontinence diagnosis in women: development and testing. *Am J Obstet Gynecol.* 2005 Jan;192(1):66-73. PMID 15672005.

260. Massolt ET, Groen J, Vierhout ME. Application of the Blaivas-Groutz bladder outlet obstruction nomogram in women with urinary incontinence. *Neurourol Urodyn*. 2005;24(3):237-42. PMID 15747342.
261. Oh SJ, Ku JH, Hong SK, et al. Factors influencing self-perceived disease severity in women with stress urinary incontinence combined with or without urge incontinence. *Neurourol Urodyn*. 2005;24(4):341-7. PMID 15791635.
262. Lukacz ES, Lawrence JM, Buckwalter JG, et al. Epidemiology of prolapse and incontinence questionnaire: validation of a new epidemiologic survey. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Jul-Aug;16(4):272-84. PMID 15856132.
263. Bent AE, Gousse AE, Hendrix SL, et al. Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence. *Obstet Gynecol*. 2005 Oct;106(4):767-73. PMID 16199634.
264. Coyne KS, Zyczynski T, Margolis MK, et al. Validation of an overactive bladder awareness tool for use in primary care settings. *Adv Ther*. 2005 Jul-Aug;22(4):381-94. PMID 16418145.
265. Shimabukuro T, Takahashi Y, Naito K. Lower urinary tract symptoms in 1,912 apparently healthy persons of both sexes. *Hinyokika Kyo*. 2006 Mar;52(3):189-95. PMID 16617872.
266. Brown JS, Bradley CS, Subak LL, et al. The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. *Ann Intern Med*. 2006 May 16;144(10):715-23. PMID 16702587.
267. Nager CW, Albo ME, Fitzgerald MP, et al. Reference urodynamic values for stress incontinent women. *Neurourol Urodyn*. 2007;26(3):333-40. PMID 17315221.
268. Borup K, Hvidman L, Nielsen JB, et al. Validity of a self-administered questionnaire, with reference to a clinical stress urinary incontinence test. *Scand J Urol Nephrol*. 2008;42(2):148-53. PMID 17853006.
269. Franco AV, Lee F, Fynes MM. Is there an alternative to pad tests? Correlation of subjective variables of severity of urinary loss to the 1-h pad test in women with stress urinary incontinence. *BJU Int*. 2008 Aug 5;102(5):586-90. PMID 18384632.
270. Lowenstein L, Kenton K, FitzGerald MP, et al. Clinically useful measures in women with mixed urinary incontinence. *Am J Obstet Gynecol*. 2008 Jun;198(6):664 e1-3; discussion e3-4. PMID 18538148.
271. Costantini E, Lazzeri M, Bini V, et al. Sensitivity and specificity of one-hour pad test as a predictive value for female urinary incontinence. *Urol Int*. 2008;81(2):153-9. PMID 18758212.
272. Stav K, Dwyer PL, Rosamilia A. Women overestimate daytime urinary frequency: the importance of the bladder diary. *J Urol*. 2009 May;181(5):2176-80. PMID 19296975.
273. Tyagi V, Hamoodi I, Yousef M, et al. How reliable is history taking in diagnosing type of urinary incontinence? *Neurourology and Urodynamics*. 2010;29:1134-5.
274. Shepherd AM, Powell PH, Ball AJ. The place of urodynamic studies in the investigation and treatment of female urinary tract symptoms. *J Obstet Gynaecol*. 1982;3:123-5.
275. Versi E, L. C, Anand D. The use of pad tests in the investigation of female urinary incontinence. *J Obstet Gynecol*. 1988;8:270-3.
276. Ramsay N, Ali HM, Heslington K. Can scoring the severity of symptoms help to predict the urodynamic diagnosis? . *Int Urogynecol J* 1995;6:267-70.
277. Ramsay IN, Hilton P, Rice N. The symptomatic characterization of patients with destrusor instability and those with genuine stress incontinence. *Int Urogynecol J*. 1993;4:23-6.
278. Phua SM, Shields LE. The role of urodynamics in evaluation of incontinent females. *Singapore Med J*. 1992;33:139-42.
279. Jarvis GJ, Hall S, Stamp S, et al. An assessment of urodynamic examination in incontinent women. *Br J Obstet Gynaecol*. 1980 Oct;87(10):893-6. PMID 7426486.

280. Diokno AC, Wells TJ, Brink CA. Urinary incontinence in elderly women: urodynamic evaluation. *J Am Geriatr Soc.* 1987 Oct;35(10):940-6. PMID 3655177.
281. Korda A, Krieger M, Hunter P, et al. The value of clinical symptoms in the diagnosis of urinary incontinence in the female. *Aust N Z J Obstet Gynaecol.* 1987 May;27(2):149-51. PMID 3675441.
282. Kujansuu E, Kauppila A. Scored urological history and urethrocytometry in the differential diagnosis of female urinary incontinence. *Ann Chir Gynaecol.* 1982;71(4):197-202. PMID 6889831.
283. Sunshine T, J. , Glowacki GA. Clinical correlation of urodynamic testing in patients with urinary incontinence. *Journal of Gynecologic Surgery* 1989;5:93-8.
284. Cantor TJ, Bates CP. A comparative study of symptoms and objective urodynamic findings in 214 incontinent women. *Br J Obstet Gynaecol.* 1980 Oct;87(10):889-92. PMID 7191720.
285. Fischer-Rasmussen W, Hansen RI, Stage P. Predictive values of diagnostic tests in the evaluation of female urinary stress incontinence. *Acta Obstet Gynecol Scand.* 1986;65(4):291-4. PMID 3739640.
286. Bergman A, McCarthy TA, Ballard CA, et al. Role of the Q-tip test in evaluating stress urinary incontinence. *J Reprod Med.* 1987 Apr;32(4):273-5. PMID 3585870.
287. Klovning A, Hunskaar S, Eriksen BC. Validity of a scored urological history in detecting detrusor instability in female urinary incontinence. *Acta Obstet Gynecol Scand.* 1996 Nov;75(10):941-5. PMID 9003097.
288. Contreras Ortiz O, Lombardo RJ, Pellicari A. Non-invasive diagnosis of bladder instability using the Bladder Instability Discriminant Index (BIDI). *Zentralbl Gynakol.* 1993;115(10):446-9. PMID 8273434.
289. Chen GD, Su TH, Lin LY. Applicability of perineal sonography in anatomical evaluation of bladder neck in women with and without genuine stress incontinence. *J Clin Ultrasound.* 1997 May;25(4):189-94. PMID 9142618.
290. Kiilholma PJ, Makinen JI, Pitkanen YA, et al. Perineal ultrasound: an alternative for radiography for evaluating stress urinary incontinence in females. *Ann Chir Gynaecol Suppl.* 1994;208:43-5. PMID 8092770.
291. Bergman A, Ballard CA, Platt LD. Ultrasonic evaluation of urethrovesical junction in women with stress urinary incontinence. *J Clin Ultrasound.* 1988 Jun;16(5):295-300. PMID 3152386.
292. Bergman A, McKenzie CJ, Richmond J, et al. Transrectal ultrasound versus cystography in the evaluation of anatomical stress urinary incontinence. *Br J Urol.* 1988 Sep;62(3):228-34. PMID 3056562.
293. Quinn MJ, Fansworth BA, Pollard WJ, et al. Vaginal ultrasound in the diagnosis of stress incontinence: a prospective comparison to urodynamic investigations. *Neurourol Urodyn* 1989;8:8:302-3.
294. Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. *J Clin Epidemiol.* 2003 Nov;56(11):1129-35. PMID 14615004.
295. Yalcin I, Peng G, Viktrup L, et al. Reductions in stress urinary incontinence episodes: what is clinically important for women? *Neurourol Urodyn.* 2010 Mar;29(3):344-7. PMID 19475576.
296. Shaw C, Matthews RJ, Perry SI, et al. Validity and reliability of an interviewer-administered questionnaire to measure the severity of lower urinary tract symptoms of storage abnormality: the Leicester Urinary Symptom Questionnaire. *BJU Int.* 2002 Aug;90(3):205-15. PMID 12133054.
297. Diokno AC, Brock BM, Brown MB, et al. Prevalence of urinary incontinence and other urological symptoms in the noninstitutionalized elderly. *J Urol.* 1986 Nov;136(5):1022-5. PMID 3490584.
298. Haab F, Richard F, Amarenco G, et al. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire. *Urology.* 2008 Apr;71(4):646-56. PMID 18313122.

299. Basra R, Artibani W, Cardozo L, et al. Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ). *Eur Urol*. 2007 Jul;52(1):230-7. PMID 17129667.
300. Blaivas JG, Panagopoulos G, Weiss JP, et al. Validation of the overactive bladder symptom score. *J Urol*. 2007 Aug;178(2):543-7; discussion 7. PMID 17570417.
301. Pleil AM, Coyne KS, Reese PR, et al. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW. *Value Health*. 2005 Nov-Dec;8 Suppl 1:S25-34. PMID 16336486.
302. Burgio KL, Goode PS, Richter HE, et al. Global ratings of patient satisfaction and perceptions of improvement with treatment for urinary incontinence: validation of three global patient ratings. *Neurourol Urodyn*. 2006;25(5):411-7. PMID 16652380.
303. Colman S, Chapple C, Nitti V, et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. *Urology*. 2008 Oct;72(4):803-7. PMID 18722655.
304. Abrams P, Cardozo L, Khoury S, et al. Incontinence. 4th International Consultation on Incontinence, Paris July 5-8, 2008. Paris, France: Health Publications Ltd; 2009:331-412.
305. Zellner M, Madersbacher H, Palmtag H, et al. Trosipium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. *Clin Ther*. 2009 Nov;31(11):2519-39. PMID 20109997.
306. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for Enablex (Clarifenacin) Extended Release Tablets. 2004. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex.cfm. Accessed June 25, 2010.
307. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Statistical Review for Enablex (Darifenacin Hydrobromide) Extended Release Tablets. 2004. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex.cfm. Accessed June 25, 2010.
308. Dmochowski RR, Rosenberg MT, Zinner NR, et al. Extended-release trospium chloride improves quality of life in overactive bladder. *Value Health*. 2010 Mar;13(2):251-7. PMID 19818062.
309. NCT00444925. Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB). Available at: www.clinicaltrials.gov/ct2/show/NCT00444925?term=NCT00444925&rank=1.
310. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. *World J Urol*. 2005 Sep;23(4):263-70. PMID 16151816.
311. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. *Eur Urol*. 2004 Apr;45(4):420-9; discussion 9. PMID 15041104.
312. Rogers R, Bachmann G, Jumadilova Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Nov;19(11):1551-7. PMID 18685795.
313. Kaplan SA, Schneider T, Foote J, et al. Superior efficacy of fesoterodine over tolterodine with rapid onset: A prospective, head-to-head, placebo-controlled trial. *Neurourology and Urodynamics*. 2010;29:905-7.
314. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. *J Am Geriatr Soc*. 2002 May;50(5):799-807. PMID 12028164.

315. NCT00168454. A Research Study for Patients With Overactive Bladder. 2008. <http://clinicaltrials.gov/ct2/show/NCT00168454>.
316. Chapple C. Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study. 2004 Congress of the International Continence Society; August 25-27, 2004; Paris, France. Abstract 142. 2004.
317. Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. *J Urol*. 2004 Feb;171(2 Pt 1):752-6. PMID 14713803.
318. NCT00178191. Randomized Trial for Botox Urinary Incontinence. <http://www.clinicaltrials.gov/ct2/show/NCT00178191?term=NCT00178191&rank=1>.
319. Cardozo L, Drutz HP, Baygani SK, et al. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. *Obstet Gynecol*. 2004 Sep;104(3):511-9. PMID 15339761.
320. Junemann KP, Hessdorfer E, Unamba-Oparah I, et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. *Urol Int*. 2006;77(4):334-9. PMID 17135784.
321. Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. *Br J Urol*. 1998 Jan;81(1):42-8. PMID 9467475.
322. Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. *Br J Urol*. 1998 Jun;81(6):801-10. PMID 9666761.
323. MacDiarmid SA, Anderson RU, Armstrong RB, et al. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. *J Urol*. 2005 Oct;174(4 Pt 1):1301-5; discussion 5. PMID 16145407.
324. Burgio KL, Goode PS, Richter HE, et al. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. *J Urol*. 2010 Aug;184(2):598-603. PMID 20639023.
325. Dmochowski RR, Sand PK, Zinner NR, et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. *Urology*. 2008 Mar;71(3):449-54. PMID 18342185.
326. Ozdedeli S, Karapolat H, Akkoc Y. Comparison of intravaginal electrical stimulation and trospium hydrochloride in women with overactive bladder syndrome: a randomized controlled study. *Clin Rehabil*. 2010 Apr;24(4):342-51. PMID 20212061.
327. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for Sanctura (Trospium Chloride) Tablets. 2004. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-595_Sanctura.cfm. Accessed June 25 2010.
328. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Statistical Review for Sanctura (Trospium Chloride) Tablets. 2004. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-595_Sanctura.cfm. Accessed June 25 2010.
329. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for Sanctura XR (Trospium Chloride) Extended Release Capsules. 2007. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022103s000TOC.cfm. Accessed June 25 2010.
330. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Statistical Review for Sanctura XR (Trospium Chloride) Extended Release Capsules. 2007. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022103s000TOC.cfm. Accessed June 25 2010.
331. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. *Am J Obstet Gynecol*. 2003 Jul;189(1):98-101. PMID 12861145.

332. Black N, Griffiths J, Pope C. Development of a symptom severity index and a symptom impact index for stress incontinence in women. *Neurourol Urodyn*. 1996;15(6):630-40. PMID 8916115.
333. Matza LS, Thompson CL, Krasnow J, et al. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). *Neurourol Urodyn*. 2005;24(3):215-25. PMID 15747340.
334. Sandvik H, Hunskaar S, Seim A, et al. Validation of a severity index in female urinary incontinence and its implementation in an epidemiological survey. *J Epidemiol Community Health*. 1993 Dec;47(6):497-9. PMID 8120507.
335. Sandvik H, Seim A, Vanvik A, et al. A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests. *Neurourol Urodyn*. 2000;19(2):137-45. PMID 10679830.
336. Uebersax JS, Wyman JF, Shumaker SA, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. *Neurourol Urodyn*. 1995;14(2):131-9. PMID 7780440.
337. Barber MD, Spino C, Janz NK, et al. The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. *Am J Obstet Gynecol*. 2009 May;200(5):580 e1-7. PMID 19375574.
338. Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. *Eur Urol*. 2006 Jun;49(6):1079-86. PMID 16460875.
339. Capo JP, Jr., Laramée C, Lucente V, et al. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESiCare Open-Label Trial. *Int J Clin Pract*. 2008 Jan;62(1):39-46. PMID 18036164.
340. Høltedahl K, Verelst M, Schiefloe A, et al. Usefulness of urodynamic examination in female urinary incontinence--lessons from a population-based, randomized, controlled study of conservative treatment. *Scand J Urol Nephrol*. 2000 Jun;34(3):169-74. PMID 10961470.
341. Majumdar A, Latthe P, Toozs-Hobson P. Urodynamics prior to treatment as an intervention: a pilot study. *Neurourol Urodyn*. 2010 Apr;29(4):522-6. PMID 19731310.
342. Nitti VW, Rovner ES, Bavendam T. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. *BJU Int*. 2010 May;105(9):1268-75. PMID 19889062.
343. Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. *BJU Int*. 2009 Apr;103(7):931-7. PMID 19281469.
344. Malone-Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. *BJU Int*. 2003 Sep;92(4):415-7. PMID 12930431.
345. Agur W, Housami F, Drake M, et al. Could the National Institute for Health and Clinical Excellence guidelines on urodynamics in urinary incontinence put some women at risk of a bad outcome from stress incontinence surgery? *BJU international*. 2009 Mar;103(5):635-9. PMID 19021606.
346. Impact of increased abdominal pressure during micturition on inguinal hernia development after radical prostatectomy: Analysis in pressure flow study. Joint Annual Meeting of the International Continence Society and International Urogynecological Association, 23-27 August, 2010, Toronto, Canada; 2010; Toronto, Canada.
347. Summitt RL, Jr., Stovall TG, Bent AE, et al. Urinary incontinence: correlation of history and brief office evaluation with multichannel urodynamic testing. *Am J Obstet Gynecol*. 1992 Jun;166(6 Pt 1):1835-40; discussion 40-4. PMID 1615993.

348. Griffiths DJ, McCracken PN, Harrison GM, et al. Characteristics of urinary incontinence in elderly patients studied by 24-hour monitoring and urodynamic testing. *Age Ageing*. 1992 May;21(3):195-201. PMID 1615782.
349. . Minimum important difference for validated instruments in women with urgency incontinence. *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. 29.
350. Brookes ST, Donovan JL, Wright M, et al. A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. *Am J Obstet Gynecol*. 2004 Jul;191(1):73-82. PMID 15295345.
351. Reid FM, Smith AR, Dunn G. Which questionnaire? A psychometric evaluation of three patient-based outcome measures used to assess surgery for stress urinary incontinence. *Neurourol Urodyn*. 2007;26(1):123-8. PMID 16998861.
352. Abdel-Fattah M, Ramsay I, Barrington JW. A simple visual analogue scale to assess the quality of life in women with urinary incontinence. *Eur J Obstet Gynecol Reprod Biol*. 2007 Jul;133(1):86-9. PMID 16797114.
353. Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. *Neurourol Urodyn*. 2004;23(4):322-30. PMID 15227649.
354. Klovning A, Avery K, Sandvik H, et al. Comparison of two questionnaires for assessing the severity of urinary incontinence: The ICIQ-UI SF versus the incontinence severity index. *Neurourol Urodyn*. 2009;28(5):411-5. PMID 19214996.
355. Stothers L. Reliability, validity, and gender differences in the quality of life index of the SEAPI-QMM incontinence classification system. *Neurourol Urodyn*. 2004;23(3):223-8. PMID 15098217.
356. Rai GS, Kiniors M, Wientjes H. Urinary incontinence handicap inventory. *Arch Gerontol Geriatr*. 1994 Jul-Aug;19(1):7-10. PMID 15374289.
357. Hagen S, Hanley J, Capewell A. Test-retest reliability, validity, and sensitivity to change of the urogenital distress inventory and the incontinence impact questionnaire. *Neurourol Urodyn*. 2002;21(6):534-9. PMID 12382243.
358. Bjelic-Radisic V, Dorfer M, Tamussino K, et al. The Incontinence Outcome Questionnaire: an instrument for assessing patient-reported outcomes after surgery for stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 Oct;18(10):1139-49. PMID 17308862.
359. Patrick DL, Martin ML, Bushnell DM, et al. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). *Urology*. 1999 Jan;53(1):71-6. PMID 9886591.
360. Bushnell DM, Martin ML, Summers KH, et al. Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL. *Qual Life Res*. 2005 Oct;14(8):1901-13. PMID 16155777.
361. Wagner TH, Patrick DL, Bavendam TG, et al. Quality of life of persons with urinary incontinence: development of a new measure. *Urology*. 1996 Jan;47(1):67-71; discussion -2. PMID 8560665.
362. Oh SJ, Ku JH. Comparison of three disease-specific quality-of-life questionnaires (Bristol Female Lower Urinary Tract Symptoms, Incontinence Quality of Life and King's Health Questionnaire) in women with stress urinary incontinence. *Scand J Urol Nephrol*. 2007;41(1):66-71. PMID 17366105.
363. Schurch B, Denys P, Kozma CM, et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. *Arch Phys Med Rehabil*. 2007 May;88(5):646-52. PMID 17466735.

364. Yalcin I, Patrick DL, Summers K, et al. Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence. *Urology*. 2006 Jun;67(6):1304-8. PMID 16750246.
365. Hollingworth W, Campbell JD, Kowalski J, et al. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. *Qual Life Res*. 2010 Apr;19(3):323-31. PMID 20094804.
366. Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. *Br J Obstet Gynaecol*. 1997 Dec;104(12):1374-9. PMID 9422015.
367. Reese PR, Pleil AM, Okano GJ, et al. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. *Qual Life Res*. 2003 Jun;12(4):427-42. PMID 12797715.
368. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. *BJU Int*. 2007 Apr;99(4):836-44. PMID 17187655.
369. Kelleher CJ, Pleil AM, Reese PR, et al. How much is enough and who says so? *BJOG*. 2004 Jun;111(6):605-12. PMID 15198790.
370. . Can the patient global impression of improvement questionnaire predict the results of long quality of life and sexual function questionnaires? *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. 29.
371. Shaw C, Matthews RJ, Perry SI, et al. Validity and reliability of a questionnaire to measure the impact of lower urinary tract symptoms on quality of life: the Leicester Impact Scale. *Neurorol Urodyn*. 2004;23(3):229-36. PMID 15098218.
372. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. *Qual Life Res*. 2002 Sep;11(6):563-74. PMID 12206577.
373. Coyne KS, Matza LS, Thompson CL, et al. Determining the importance of change in the overactive bladder questionnaire. *J Urol*. 2006 Aug;176(2):627-32; discussion 32. PMID 16813906.
374. Rogers RG, Kammerer-Doak D, Villarreal A, et al. A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse. *Am J Obstet Gynecol*. 2001 Mar;184(4):552-8. PMID 11262452.
375. Hendriks EJ, Bernards AT, Berghmans BC, et al. The psychometric properties of the PRAFAB-questionnaire: a brief assessment questionnaire to evaluate severity of urinary incontinence in women. *Neurorol Urodyn*. 2007;26(7):998-1007. PMID 17563109.
376. Hendriks EJ, Bernards AT, de Bie RA, et al. The minimal important change of the PRAFAB questionnaire in women with stress urinary incontinence: results from a prospective cohort study. *Neurorol Urodyn*. 2008;27(5):379-87. PMID 18288703.
377. Hendriks EJ, Bernards AT, Staal JB, et al. Factorial validity and internal consistency of the PRAFAB questionnaire in women with stress urinary incontinence. *BMC Urol*. 2008;8:1. PMID 18218110.
378. Lee PS, Reid DW, Saltmarche A, et al. Measuring the psychosocial impact of urinary incontinence: the York Incontinence Perceptions Scale (YIPS). *J Am Geriatr Soc*. 1995 Nov;43(11):1275-8. PMID 7594164.
379. Holtedahl K, Verelst M, Schiefloe A. A population based, randomized, controlled trial of conservative treatment for urinary incontinence in women. *Acta Obstet Gynecol Scand*. 1998 Jul;77(6):671-7. PMID 9688247.
380. Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. *Menopause*. 2004 Jan-Feb;11(1):49-56. PMID 14716182.
381. Waetjen LE, Brown JS, Vittinghoff E, et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. *Obstet Gynecol*. 2005 Nov;106(5 Pt 1):946-52. PMID 16260511.

382. Rufford J, Hextall A, Cardozo L, et al. A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Jun;14(2):78-83. PMID 12851747.
383. Schagen van Leeuwen JH, Lange RR, Jonasson AF, et al. Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. *Maturitas.* 2008 Jun 20;60(2):138-47. PMID 18547757.
384. Millard RJ, Moore K, Rencken R, et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. *BJU Int.* 2004 Feb;93(3):311-8. PMID 14764128.
385. Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. *BJU Int.* 2007 Aug;100(2):337-45. PMID 17511767.
386. Lin AT, Sun MJ, Tai HL, et al. Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial. *BMC Urol.* 2008;8:2. PMID 18221532.
387. Cardozo L, Lange R, Voss S, et al. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence. *Curr Med Res Opin.* 2010 Feb;26(2):253-61. PMID 19929591.
388. Weinstein DL, Cohen JS, Liu C, et al. Duloxetine in the treatment of women with stress urinary incontinence: results from DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations). *Curr Med Res Opin.* 2006 Nov;22(11):2121-9. PMID 17076972.
389. Castro-Diaz D, Palma PC, Bouchard C, et al. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Aug;18(8):919-29. PMID 17160693.
390. Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. *Am J Obstet Gynecol.* 2002 Jul;187(1):40-8. PMID 12114886.
391. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. *J Urol.* 2003 Oct;170(4 Pt 1):1259-63. PMID 14501737.
392. van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. *BJOG.* 2004 Mar;111(3):249-57. PMID 14961887.
393. Ghoniem GM, Van Leeuwen JS, Elser DM, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. *J Urol.* 2005 May;173(5):1647-53. PMID 15821528.
394. Duckett JR, Vella M, Kavalakuntla G, et al. Tolerability and efficacy of duloxetine in a nontrial situation. *BJOG: An International Journal of Obstetrics & Gynaecology.* 2007 May;114(5):543-7. PMID 17355360.
395. Vella M, Duckett J, Basu M. Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Jul;19(7):961-4. PMID 18231697.
396. Yalcin I, Bump RC. The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. *Am J Obstet Gynecol.* 2004 Jul;191(1):194-7. PMID 15295364.
397. Hurley DJ, Turner CL, Yalcin I, et al. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. *Eur J Obstet Gynecol Reprod Biol.* 2006 Mar 1;125(1):120-8. PMID 16188367.
398. Viktrup L, Yalcin I. Duloxetine treatment of stress urinary incontinence in women: effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus, and depression on efficacy. *Eur J Obstet Gynecol Reprod Biol.* 2007 Jul;133(1):105-13. PMID 16769171.

399. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. *Curr Med Res Opin.* 2007 Jan;23(1):175-84. PMID 17257478.
400. Bump RC, Voss S, Beardsworth A, et al. Long-term efficacy of duloxetine in women with stress urinary incontinence. *BJU Int.* 2008 Jul;102(2):214-8. PMID 18422764.
401. Kinchen KS, Obenchain R, Swindle R. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005 Sep-Oct;16(5):337-44. PMID 15662490.
402. Bent AE, Gousse AE, Hendrix SL, et al. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. *Neurourol Urodyn.* 2008;27(3):212-21. PMID 17580357.
403. Wernick JE, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. *Drug Saf.* 2007;30(5):437-55. PMID 17472422.
404. Brunton S, Wang F, Edwards SB, et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. *Drug Saf.* 2010 May 1;33(5):393-407. PMID 20397739.
405. Tapp AJ, Cardozo LD, Versi E, et al. The treatment of detrusor instability in postmenopausal women with oxybutynin chloride: a double blind placebo controlled study. *Br J Obstet Gynaecol.* 1990 Jun;97(6):521-6. PMID 2198921.
406. Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. *Age Ageing.* 1995/07/01 ed; 1995. p. 287-91.
407. Burgio KL, Locher JL, Roth DL, et al. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. *J Gerontol B Psychol Sci Soc Sci.* 2001 Jan;56(1):P46-51. PMID 11192337.
408. Chancellor MB, Appell RA, Sathyan G, et al. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. *Clin Ther.* 2001 May;23(5):753-60. PMID 11394733.
409. Lehtoranta K, Tainio H, Lukkari-Lax E, et al. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. *Scand J Urol Nephrol.* 2002 Feb;36(1):18-24. PMID 12002352.
410. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. *J Urol.* 2002 Aug;168(2):580-6. PMID 12131314.
411. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. *Urology.* 2003 Aug;62(2):237-42. PMID 12893326.
412. Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. *J Am Geriatr Soc.* 2008 May;56(5):862-70. PMID 18410326.
413. Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. *J Urol.* 2009 Apr;181(4):1764-72. PMID 19233423.
414. Wang AC, Chen MC, Kuo WY, et al. Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009 Jul;20(7):819-25. PMID 19495544.
415. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. *J Urol.* 1991 Apr;145(4):813-6; discussion 6-7. PMID 2005707.
416. Moore KH, Hay DM, Imrie AE, et al. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. *Br J Urol.* 1990 Nov;66(5):479-85. PMID 2249115.

417. Enzelsberger H, Helmer H, Kurz C. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. *Br J Obstet Gynaecol.* 1995 Nov;102(11):929-30. PMID 8534633.
418. Johnson TM, 2nd, Burgio KL, Redden DT, et al. Effects of behavioral and drug therapy on nocturia in older incontinent women. *J Am Geriatr Soc.* 2005 May;53(5):846-50. PMID 15877562.
419. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. *J Urol.* 1999 Jun;161(6):1809-12. PMID 10332441.
420. Gupta SK, Sathyan G, Lindemulder EA, et al. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. *Clin Pharmacol Ther.* 1999 Jun;65(6):672-84. PMID 10391673.
421. Tincello DG, Adams EJ, Sutherst JR, et al. Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. *BJU Int.* 2000 Mar;85(4):416-20. PMID 10691817.
422. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. *Obstet Gynecol.* 2000 May;95(5):718-21. PMID 10775736.
423. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. *J Urol.* 2001 Jul;166(1):140-5. PMID 11435842.
424. Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. *Clin Ther.* 2004 Jul;26(7):1026-36. PMID 15336467.
425. Preik M, Albrecht D, O'Connell M, et al. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. *BJU Int.* 2004 Oct;94(6):821-7. PMID 15476516.
426. Salvatore S, Khullar V, Cardozo L, et al. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. *Eur J Obstet Gynecol Reprod Biol.* 2005 Apr 1;119(2):237-41. PMID 15808387.
427. Corcos J, Casey R, Patrick A, et al. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. *BJU Int.* 2006 Mar;97(3):520-7. PMID 16469019.
428. Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. *Am J Obstet Gynecol.* 2006 Dec;195(6):1730-5. PMID 17132474.
429. Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. *Urology.* 1999 Sep;54(3):420-3. PMID 10475346.
430. Newman DK. The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin. Director. 2008 Winter;16(1):22-5. PMID 19343871.
431. Pizzi LT, Talati A, Gemmen E, et al. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. *Pharmacoeconomics.* 2009;27(4):329-39. PMID 19485428.
432. Hussain RM, Hartigan-Go K, Thomas SH, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. *Br J Clin Pharmacol.* 1996 Jan;41(1):73-5. PMID 8824696.

433. Nilsson CG, Lukkari E, Haarala M, et al. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. *Neurourol Urodyn*. 1997;16(6):533-42. PMID 9353802.
434. Bemelmans BL, Kiemeny LA, Debruyne FM. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. *Eur Urol*. 2000 Jun;37(6):709-13. PMID 10828672.
435. Radomski SB, Caley B, Reiz JL, et al. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence. *Curr Med Res Opin*. 2004;20(2):249-53. PMID 15006020.
436. Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. *Int Urol Nephrol*. 2002;34(1):43-9. PMID 12549638.
437. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. *JAMA*. 1998 Dec 16;280(23):1995-2000. PMID 9863850.
438. Goode PS. Behavioral and drug therapy for urinary incontinence. *Urology*. 2004 Mar;63(3 Suppl 1):58-64. PMID 15013654.
439. Madersbacher H, Halaska M, Voigt R, et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. *BJU Int*. 1999 Oct;84(6):646-51. PMID 10510109.
440. Goode PS, Burgio KL, Locher JL, et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. *J Am Geriatr Soc*. 2002 May;50(5):808-16. PMID 12028165.
441. Homma Y, Paick JS, Lee JG, et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. *BJU Int*. 2003 Nov;92(7):741-7. PMID 14616458.
442. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. *World J Urol*. 2004 Oct;22(4):251-6. PMID 15455256.
443. Wang AC, Chih SY, Chen MC. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. *Urology*. 2006 Nov;68(5):999-1004. PMID 17113893.
444. Homma Y, Koyama N. Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. *Neurourol Urodyn*. 2006;25(3):228-35. PMID 16532466.
445. Cartwright R, Srikrishna S, Cardozo L, et al. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. *BJU Int*. 2011 Jan;107(1):70-6. PMID 20626389.
446. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. *World J Urol*. 2005 Sep;23(4):248-52. PMID 16096831.
447. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. *J Clin Pharmacol*. 1999 Mar;39(3):289-96. PMID 10073329.
448. Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. *J Urol*. 1999 May;161(5):1551-5. PMID 10210394.
449. Jonas U, Hofner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. *World J Urol*. 1997;15(2):144-51. PMID 9144906.

450. Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct.* 1999;10(5):283-9. PMID 10543335.
451. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. *Urology.* 2001 Mar;57(3):414-21. PMID 11248608.
452. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. *J Am Geriatr Soc.* 2001 Jun;49(6):700-5. PMID 11454106.
453. Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. *Eur J Obstet Gynecol Reprod Biol.* 2001 Sep;98(1):97-102. PMID 11516807.
454. Kelleher CJ, Reese PR, Pleil AM, et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. *The American journal of managed care;* 2002. p. S608-15.
455. Swift S, Garely A, Dimpfl T, et al. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Feb;14(1):50-4; discussion 4-5. PMID 12601517.
456. Freeman R, Hill S, Millard R, et al. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. *Obstet Gynecol.* 2003 Sep;102(3):605-11. PMID 12962951.
457. Khullar V, Hill S, Laval KU, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. *Urology.* 2004 Aug;64(2):269-74; discussion 74-5. PMID 15302476.
458. DuBeau CE, Khullar V, Versi E. "Unblinding" in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. *Neurourol Urodyn.* 2005;24(1):13-20. PMID 15570576.
459. Dmochowski R, Kreder K, MacDiarmid S, et al. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. *BJU Int.* 2007 Jul;100(1):107-10. PMID 17552957.
460. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. *Eur Urol.* 2007 Oct;52(4):1204-12. PMID 17651893.
461. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. *BJU Int.* 2010 Jan;105(1):58-66. PMID 20132103.
462. Robinson D, Cardozo L, Terpstra G, et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. *BJU Int.* 2007 Oct;100(4):840-5. PMID 17822465.
463. Herschorn S, Heesakkers J, Castro-Diaz D, et al. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. *Curr Med Res Opin.* 2008 Dec;24(12):3513-21. PMID 19032133.
464. Rogers RG, Bachmann G, Scarpero H, et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. *Curr Med Res Opin.* 2009 Sep;25(9):2159-65. PMID 19601704.
465. Junemann KP, Al-Shukri S. Efficacy and tolerability of trospium cholride and tolterodine in 234 patients with urge syndrome: a double-blinded, placebo-controlled, multicentre clinical trial. *Neurourol Urodyn.* 2000;19:488-90.
466. Rogers RG, Omotosho T, Bachmann G, et al. Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009 Apr;20(4):381-5. PMID 19132285.

467. Wein AJ, Khullar V, Wang JT, et al. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. *BJU Int.* 2007 Feb;99(2):360-3. PMID 17155987.
468. Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. *BJU Int.* 2008 Nov;102(9):1128-32. PMID 18647298.
469. Kreder KJ, Jr., Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. *BJU Int.* 2003 Sep;92(4):418-21. PMID 12930432.
470. Coyne KS, Elinoff V, Gordon DA, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. *Int J Clin Pract.* 2008 Jun;62(6):925-31. PMID 18479285.
471. Elinoff V, Bavendam T, Glasser DB, et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. *Int J Clin Pract.* 2006 Jun;60(6):745-51. PMID 16805763.
472. Roberts R, Bavendam T, Glasser DB, et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. *Int J Clin Pract.* 2006 Jun;60(6):752-8. PMID 16805764.
473. Sussman DO, Kraus SR, Carlsson M, et al. Onset of efficacy of tolterodine extended release in patients with overactive bladder. *Curr Med Res Opin.* 2007 Apr;23(4):777-81. PMID 17407634.
474. Michel MC, Oelke M, Goepel M, et al. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. *Neurourol Urodyn.* 2007;26(2):190-5. PMID 17096320.
475. Michel MC, de la Rosette JJ, Piro M, et al. Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? *J Urol.* 2004 Aug;172(2):601-4. PMID 15247741.
476. Michel MC, Schneider T, Krage S, et al. Does gender or age affect the efficacy and safety of tolterodine? *J Urol.* 2002 Sep;168(3):1027-31. PMID 12187215.
477. Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. *BJU Int.* 2004 Jan;93(1):71-7. PMID 14678372.
478. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. *BJU Int.* 2004 Feb;93(3):303-10. PMID 14764127.
479. Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients \geq 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. *Curr Med Res Opin.* 2007 Oct;23(10):2347-58. PMID 17706004.
480. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. *J Urol.* 2005 Feb;173(2):493-8. PMID 15643227.
481. Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. *BJU Int.* 2005 Mar;95(4):580-6. PMID 15705084.
482. Hill S, Khullar V, Wyndaele JJ, et al. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 May;17(3):239-47. PMID 15999217.
483. Zinner N, Susset J, Gittelman M, et al. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. *Int J Clin Pract.* 2006 Jan;60(1):119-26. PMID 16409440.
484. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. *BJU Int.* 2006 Nov;98(5):1025-32. PMID 16879437.

485. Zinner N, Kobashi KC, Ebinger U, et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. *Int J Clin Pract.* 2008 Nov;62(11):1664-74. PMID 18811599.
486. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. *BJU Int.* 2005 May;95(7):993-1001. PMID 15839920.
487. Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. *Eur Urol.* 2005 Sep;48(3):471-7. PMID 15990219.
488. Abrams P, Kelleher C, Huels J, et al. Clinical relevance of health-related quality of life outcomes with darifenacin. *BJU Int.* 2008 Jul;102(2):208-13. PMID 18325056.
489. Chapple CR. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. *Expert Opin Investig Drugs.* 2004 Nov;13(11):1493-500. PMID 15500396.
490. Cardozo L, Lisek M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. *J Urol.* 2004 Nov;172(5 Pt 1):1919-24. PMID 15540755.
491. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. *Eur Urol.* 2005 Mar;47(3):376-84. PMID 15716204.
492. Vardy MD, Mitcheson HD, Samuels TA, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. *Int J Clin Pract.* 2009 Dec;63(12):1702-14. PMID 19930331.
493. Cardozo L, Hessdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. *BJU Int.* 2008 Nov;102(9):1120-7. PMID 18990175.
494. Karram MM, Toglia MR, Serels SR, et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. *Urology.* 2009 Jan;73(1):14-8. PMID 18995887.
495. Toglia MR, Serels SR, Laramee C, et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. *Postgrad Med.* 2009 Sep;121(5):151-8. PMID 19820284.
496. Chu F, Smith N, Uchida T. Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. *Current Therapeutic Research.* 2009 December;70(6):405-20. PMID 10.1016/j.curtheres.2009.11.001.
497. Cardozo L, Castro-Diaz D, Gittelman M, et al. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 Sep;17(5):512-9. PMID 16625311.
498. Kelleher C, Cardozo L, Kobashi K, et al. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 Jun;17(4):382-8. PMID 16283422.
499. Staskin DR, Te AE. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. *BJU Int.* 2006 Jun;97(6):1256-61. PMID 16686722.
500. Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESiCare Open-Label Trial (VOLT). *Clin Ther.* 2006 Nov;28(11):1935-46. PMID 17213014.

501. Garely AD, Lucente V, Vapnek J, et al. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. *Ann Pharmacother*. 2007 Mar;41(3):391-8. PMID 17341526.
502. Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. *BJU Int*. 2007 Sep;100(3):579-87. PMID 17669143.
503. Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. *Urology*. 2010 Jan;75(1):62-8. PMID 19931895.
504. Malhotra B, Wood N, Sachse R, et al. Thorough QT study of the effect of fesoterodine on cardiac repolarization. *Int J Clin Pharmacol Ther*. 2010 May;48(5):309-18. PMID 20420787.
505. NCT00536484. Fesoterodine Flexible Dose Study. <http://www.clinicaltrials.gov/ct2/show/NCT00536484?term=NCT00536484&rank=1>.
506. Nitti C VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. *J Urol*. 2007 Dec;178(6):2488-94. PMID 17937959.
507. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. *Urology*. 2008 May;71(5):839-43. PMID 18342923.
508. Cardozo L, Khullar V, Wang JT, et al. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? *BJU Int*. 2010 Feb 11; PMID 20151972.
509. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. *Curr Urol Rep*. 2004 Dec;5(6):423-6. PMID 15541209.
510. Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. *Urology*. 2006 Feb;67(2):275-80. PMID 16461077.
511. Rudy D, Cline K, Harris R, et al. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. *BJU Int*. 2006 Mar;97(3):540-6. PMID 16469022.
512. Sand PK, Dmochowski RR, Zinner NR, et al. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Aug 29; PMID 19727537.
513. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. *J Urol*. 2004 Jun;171(6 Pt 1):2311-5, quiz 435. PMID 15126811.
514. Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. *J Urol*. 2007 Sep;178(3 Pt 1):978-83; discussion 83-4. PMID 17632131.
515. Staskin DR, Rosenberg MT, Sand PK, et al. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. *Int J Clin Pract*. 2009 Dec;63(12):1715-23. PMID 19930332.
516. Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. *Eur Urol*. 2000 Jun;37(6):702-8. PMID 10828671.
517. Abrams P, Cardozo L, Chapple C, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. *Int J Urol*. 2006 Jun;13(6):692-8. PMID 16834644.
518. Lee KS, Lee HW, Choo MS, et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. *BJU Int*. 2010 Jun;105(11):1565-70. PMID 19912183.

519. Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. *J Urol*. 2005 Nov;174(5):1873-7; discussion 7. PMID 16217327.
520. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. *J Urol*. 2008 Jul;180(1):217-22. PMID 18499184.
521. Flynn MK, Amundsen CL, Perevich M, et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. *J Urol*. 2009 Jun;181(6):2608-15. PMID 19375091.
522. Anger JT, Weinberg A, Suttorp MJ, et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. *J Urol*. 2010 Jun;183(6):2258-64. PMID 20400142.
523. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. *J Urol*. 2010 Oct 16; PMID 20952013.
524. Rios LA, Panhoca R, Mattos D, Jr., et al. Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: A single dose, 4 weeks, double-blind, randomized, placebo controlled trial. *Neurourol Urodyn*. 2007;26(6):773-8. PMID 17638305.
525. Naglie G, Radomski SB, Brymer C, et al. A randomized, double-blind, placebo controlled crossover trial of nimodipine in older persons with detrusor instability and urge incontinence. *J Urol*. 2002 Feb;167(2 Pt 1):586-90. PMID 11792923.
526. Chompootaweep S, Nunthapisud P, Trivijitsilp P, et al. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. *Clin Pharmacol Ther*. 1998 Aug;64(2):204-10. PMID 9728901.
527. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. *BJOG*. 2000 Aug;107(8):1029-34. PMID 10955437.
528. Nelken RS, Ozel BZ, Leegant AR, et al. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. *Menopause*. 2011 Sep;18(9):962-6. PMID 21532512.
529. Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. *Eur Urol*. 2005 Jul;48(1):102-9. PMID 15936869
530. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. *Mayo Clin Proc*. 2001 Apr;76(4):358-63. PMID 11322350.
531. Lee JG, Hong JY, Choo MS, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. *Int J Urol*. 2002 May;9(5):247-52. PMID 12060436.
532. Leung HY, Yip SK, Cheon C, et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. *BJU Int*. 2002 Sep;90(4):375-80. PMID 12175392.
533. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. *Mayo Clin Proc*. 2003 Jun;78(6):687-95. PMID 12934777.
534. Sand PK, Miklos J, Ritter H, et al. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. *Int Urogynecol J Pelvic Floor Dysfunct*. 2004 Jul-Aug;15(4):243-8. PMID 15517668.

535. Armstrong RB, Lubner KM, Peters KM. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. *Int Urol Nephrol.* 2005;37(2):247-52. PMID 16142551.
536. Armstrong RB, Dmochowski RR, Sand PK, et al. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. *Int Urol Nephrol.* 2007;39(4):1069-77. PMID 17333521.
537. Chu FM, Dmochowski RR, Lama DJ, et al. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. *Am J Obstet Gynecol.* 2005 Jun;192(6):1849-54; discussion 54-5. PMID 15970828.
538. Milani R, Scalabrino S, Milia R, et al. Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. *Int Urogynecol J;* 1993. p. 3-8.
539. Junemann KP, Halaska M, Rittstein T, et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. *Eur Urol.* 2005 Sep;48(3):478-82. PMID 15967567.
540. Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. *BJU Int.* 2008 Jul;102(1):56-61. PMID 18564231.
541. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. *Eur Urol.* 2005 Sep;48(3):464-70. PMID 15990220.
542. Chapple CR, Fianu-Jonsson A, Indig M, et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. *Eur Urol.* 2007 Oct;52(4):1195-203. PMID 17574730.
543. Choo MS, Lee JZ, Lee JB, et al. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. *Int J Clin Pract.* 2008 Nov;62(11):1675-83. PMID 19143854.
544. But I, Pakiz M, Hlebic G, et al. Comparison of efficacy and tolerability of two selective M3 receptor antagonists Solifenacin and Darifenacin in women with overactive bladder- the Solidar study. *Neurourology and Urodynamics.* 2010;29:1217-9.
545. Herschorn S, Stothers L, Carlson K, et al. Tolerability of 5 mg Solifenacin Once Daily Versus 5 mg Oxybutynin Immediate Release 3 Times Daily: Results of the VECTOR Trial. *J Urol.* 2010 Mar 17PMID 20303119.
546. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. *World J Urol.* 2003 May;20(6):392-9. PMID 12811500.
547. Bodeker RH, Madersbacher H, Neumeister C, et al. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. *BMC Urol.* 2010;10:15. PMID 20840754.
548. Cardozo L, Thorpe A, Warner J, et al. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. *BJU Int.* 2010 Feb 3PMID 20132203.
549. Sand PK, Johnson Ii TM, Rovner ES, et al. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged \geq 75 years) with overactive bladder syndrome. *BJU Int.* 2011 Feb;107(4):612-20. PMID 20707790.
550. Staskin DR, Cardozo L. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. *Int J Clin Pract.* 2009 Jun;63(6):973-6. PMID 19459997.

551. Anderson RU, MacDiarmid S, Kell S, et al. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 Sep;17(5):502-11. PMID 16724169.
552. Sand PK, Rovner ES, Watanabe JH, et al. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. *Drugs Aging.* 2011 Feb 1;28(2):151-60. PMID 21275440.
553. Chancellor MB, Oefelein MG, Vasavada S. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. *Neurourol Urodyn.* 2010 Apr;29(4):551-4. PMID 19634167.
554. Kim H, Yoshida H, Suzuki T. Exercises treatment to reduce the urine leakage in elderly community-dwelling Japanese women with stress, urge, and mixed urinary incontinence. 39th Annual Meeting of the International Continence Society (ICS 2009), Moscone West, San Francisco, 29 Sep - 3 Oct 2009. 2009.
555. Lagro-Janssen TL, Debruyne FM, Smits AJ, et al. Controlled trial of pelvic floor exercises in the treatment of urinary stress incontinence in general practice. *Br J Gen Pract.* 1991 Nov;41(352):445-9. PMID 1807303.
556. Burns PA, Pranikoff K, Nochajski T, et al. Treatment of stress incontinence with pelvic floor exercises and biofeedback. *J Am Geriatr Soc.* 1990 Mar;38(3):341-4. PMID 2179379.
557. Burns PA, Pranikoff K, Nochajski TH, et al. A comparison of effectiveness of biofeedback and pelvic muscle exercise treatment of stress incontinence in older community-dwelling women. *J Gerontol.* 1993 Jul;48(4):M167-74. PMID 8315230.
558. Bo K, Talseth T, Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. *BMJ.* 1999 Feb 20;318(7182):487-93. PMID 10024253.
559. Bo K, Talseth T, Vinsnes A. Randomized controlled trial on the effect of pelvic floor muscle training on quality of life and sexual problems in genuine stress incontinent women. *Acta Obstet Gynecol Scand.* 2000 Jul;79(7):598-603. PMID 10929962.
560. Aksac B, Aki S, Karan A, et al. Biofeedback and pelvic floor exercises for the rehabilitation of urinary stress incontinence. *Gynecol Obstet Invest.* 2003;56(1):23-7. PMID 12867764.
561. Williams KS, Assassa RP, Gillies CL, et al. A randomized controlled trial of the effectiveness of pelvic floor therapies for urodynamic stress and mixed incontinence. *BJU Int.* 2006 Nov;98(5):1043-50. PMID 17034605.
562. Kim H, Suzuki T, Yoshida Y, et al. Effectiveness of multidimensional exercises for the treatment of stress urinary incontinence in elderly community-dwelling Japanese women: a randomized, controlled, crossover trial. *J Am Geriatr Soc.* 2007 Dec;55(12):1932-9. PMID 17944890.
563. Castro RA, Arruda RM, Zanetti MR, et al. Single-blind, randomized, controlled trial of pelvic floor muscle training, electrical stimulation, vaginal cones, and no active treatment in the management of stress urinary incontinence. *Clinics (Sao Paulo).* 2008 Aug;63(4):465-72. PMID 18719756.
564. Hung HC, Hsiao SM, Chih SY, et al. An alternative intervention for urinary incontinence: retraining diaphragmatic, deep abdominal and pelvic floor muscle coordinated function. *Man Ther.* 2010 Jun;15(3):273-9. PMID 20185357.
565. Sung MS, Choi YH, Back SH, et al. The effect of pelvic floor muscle exercises on genuine stress incontinence among Korean women--focusing on its effects on the quality of life. *Yonsei Med J.* 2000 Apr;41(2):237-51. PMID 10817026.

566. Tibaek S, Jensen R, Lindskov G, et al. Can quality of life be improved by pelvic floor muscle training in women with urinary incontinence after ischemic stroke? A randomised, controlled and blinded study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 Mar-Apr;15(2):117-23; discussion 23. PMID 15014939.
567. Tibaek S, Gard G, Jensen R. Is there a long-lasting effect of pelvic floor muscle training in women with urinary incontinence after ischemic stroke? A 6-month follow-up study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Mar;18(3):281-7. PMID 16673051.
568. Macaulay M, van den Heuvel E, Jowitt F, et al. A noninvasive continence management system: development and evaluation of a novel toileting device for women. *J Wound Ostomy Continence Nurs.* 2007 Nov-Dec;34(6):641-8. PMID 18030103.
569. Donnelly MJ, Powell-Morgan S, Olsen AL, et al. Vaginal pessaries for the management of stress and mixed urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 Sep-Oct;15(5):302-7. PMID 15300365.
570. Brincat C, Kenton K, Pat Fitzgerald M, et al. Sexual activity predicts continued pessary use. *Am J Obstet Gynecol.* 2004 Jul;191(1):198-200. PMID 15295365.
571. Maito JM, Quam ZA, Craig E, et al. Predictors of successful pessary fitting and continued use in a nurse-midwifery pessary clinic. *J Midwifery Womens Health.* 2006 Mar-Apr;51(2):78-84. PMID 16504903.
572. Sulak PJ, Kuehl TJ, Shull BL. Vaginal pessaries and their use in pelvic relaxation. *J Reprod Med.* 1993 Dec;38(12):919-23. PMID 8120847.
573. Clemons JL, Aguilar VC, Tillinghast TA, et al. Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. *Am J Obstet Gynecol.* 2004 Apr;190(4):1025-9. PMID 15118635.
574. Farrell SA, Baydock S, Amir B, et al. Effectiveness of a new self-positioning pessary for the management of urinary incontinence in women. *Am J Obstet Gynecol.* 2007 May;196(5):474 e1-8. PMID 17466709.
575. Nguyen JN, Jones CR. Pessary treatment of pelvic relaxation: factors affecting successful fitting and continued use. *J Wound Ostomy Continence Nurs.* 2005 Jul-Aug;32(4):255-61; quiz 62-3. PMID 16030465.
576. Brubaker L, Shott S, Tomezsko J, et al. Pelvic floor fitness using lay instructors. *Obstet Gynecol.* 2008 Jun;111(6):1298-304. PMID 18515512.
577. Sand PK, Richardson DA, Staskin DR, et al. Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: a multicenter, placebo-controlled trial. *Am J Obstet Gynecol.* 1995 Jul;173(1):72-9. PMID 7631730.
578. Brubaker L, Benson JT, Bent A, et al. Transvaginal electrical stimulation for female urinary incontinence. *Am J Obstet Gynecol.* 1997 Sep;177(3):536-40. PMID 9322620.
579. Luber KM, Wolde-Tsadik G. Efficacy of functional electrical stimulation in treating genuine stress incontinence: a randomized clinical trial. *Neurourol Urodyn.* 1997;16(6):543-51. PMID 9353803.
580. Yamanishi T, Yasuda K, Sakakibara R, et al. Pelvic floor electrical stimulation in the treatment of stress incontinence: an investigational study and a placebo controlled double-blind trial. *The Journal of urology;* 1997. p. 2127-31.
581. Yamanishi T, Yasuda K, Sakakibara R, et al. Randomized, double-blind study of electrical stimulation for urinary incontinence due to detrusor overactivity. *Urology.* 2000 Mar;55(3):353-7. PMID 10699609.
582. Jeyaseelan SM, Haslam EJ, Winstanley J, et al. An evaluation of a new pattern of electrical stimulation as a treatment for urinary stress incontinence: a randomized, double-blind, controlled trial. *Clin Rehabil.* 2000 Dec;14(6):631-40. PMID 11128739.
583. Amaro JL, Gameiro MO, Kawano PR, et al. Intravaginal electrical stimulation: a randomized, double-blind study on the treatment of mixed urinary incontinence. *Acta Obstet Gynecol Scand.* 2006;85(5):619-22. PMID 16752244.

584. Blowman C, Pickles c, Emery S, et al. Prospective double blind controlled trial of intensive physiotherapy with and without stimulation of the pelvic floor in treatment of genuine stress incontinence. *Physiotherapy*. 1991 October;77(10):661-4.
585. Indrekvam S, Sandvik H, Hunskaar S. A Norwegian national cohort of 3198 women treated with home-managed electrical stimulation for urinary incontinence--effectiveness and treatment results. *Scand J Urol Nephrol*. 2001 Feb;35(1):32-9. PMID 11291684.
586. Amaro JL, Gameiro MO, Padovani CR. Effect of intravaginal electrical stimulation on pelvic floor muscle strength. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Sep-Oct;16(5):355-8. PMID 15647885.
587. Fujishiro T, Enomoto H, Ugawa Y, et al. Magnetic stimulation of the sacral roots for the treatment of stress incontinence: an investigational study and placebo controlled trial. *J Urol*. 2000 Oct;164(4):1277-9. PMID 10992380.
588. But I. Conservative treatment of female urinary incontinence with functional magnetic stimulation. *Urology*. 2003 Mar;61(3):558-61. PMID 12639647.
589. But I, Faganelj M, Sostaric A. Functional magnetic stimulation for mixed urinary incontinence. *J Urol*. 2005 May;173(5):1644-6. PMID 15821527.
590. Manganotti P, Zaina F, Vedovi E, et al. Repetitive magnetic stimulation of the sacral roots for the treatment of stress incontinence: a brief report. *Eura Medicophys*. 2007 Sep;43(3):339-44. PMID 17259914.
591. Gilling PJ, Wilson LC, Westenberg AM, et al. A double-blind randomized controlled trial of electromagnetic stimulation of the pelvic floor vs sham therapy in the treatment of women with stress urinary incontinence. *BJU Int*. 2009 May;103(10):1386-90. PMID 19154474.
592. Galloway NT, El-Galley RE, Sand PK, et al. Update on extracorporeal magnetic innervation (EXMI) therapy for stress urinary incontinence. *Urology*. 2000 Dec 4;56(6 Suppl 1):82-6. PMID 11114568.
593. Bellin P, Smith J, Poll W, et al. Results of a multicenter trial of the CapSure (Re/Stor) Continence shield on women with stress urinary incontinence. *Urology*. 1998 May;51(5):697-706. PMID 9610582.
594. Morris AR, Moore KH. The Contiform incontinence device - efficacy and patient acceptability. *Int Urogynecol J Pelvic Floor Dysfunct*. 2003 Dec;14(6):412-7. PMID 14677003.
595. Allen WA, Leek H, Izurieta A, et al. Update: the "Contiform" intravaginal device in four sizes for the treatment of stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Jun;19(6):757-61. PMID 18183342.
596. Sander P, Thyssen H, Lose G, et al. Effect of a vaginal device on quality of life with urinary stress incontinence. *Obstet Gynecol*. 1999 Mar;93(3):407-11. PMID 10074989.
597. Hahn I, Milsom I. Treatment of female stress urinary incontinence with a new anatomically shaped vaginal device (Conveen Continence Guard). *Br J Urol*. 1996 May;77(5):711-5. PMID 8689116.
598. Nilsson CG. Effectiveness of the conveen continence guard (a disposable vaginal device) in the treatment of complicated female stress incontinence. *Acta Obstet Gynecol Scand*. 2000 Dec;79(12):1052-5. PMID 11130086.
599. Pieper B, Cleland V. An external urine-collection device for women: a clinical trial. *J ET Nurs*. 1993 Mar-Apr;20(2):51-5. PMID 8507726.
600. Versi E, Harvey MA. Efficacy of an external urethral device in women with genuine stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 1998;9(5):271-4. PMID 9849759.
601. Versi E, Griffiths DJ, Harvey MA. A new external urethral occlusive device for female urinary incontinence. *Obstet Gynecol*. 1998 Aug;92(2):286-91. PMID 9699768.
602. Sirls LT, Foote JE, Kaufman JM, et al. Long-term results of the FemSoft urethral insert for the management of female stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2002;13(2):88-95; discussion PMID 12054188.

603. Staskin D, Bavendam T, Miller J, et al. Effectiveness of a urinary control insert in the management of stress urinary incontinence: early results of a multicenter study. *Urology*. 1996 May;47(5):629-36. PMID 8650857.
604. Kocjancic E, Crivellaro S, Smith JJ, 3rd, et al. Adjustable continence therapy for treatment of recurrent female urinary incontinence. *J Endourol*. 2008 Jul;22(7):1403-7. PMID 18613782.
605. Brubaker L, Harris T, Gleason D, et al. The external urethral barrier for stress incontinence: a multicenter trial of safety and efficacy. *Miniguard Investigators Group. Obstet Gynecol*. 1999 Jun;93(6):932-7. PMID 10362157.
606. Moore KH, Simons A, Dowell C, et al. Efficacy and user acceptability of the urethral occlusive device in women with urinary incontinence. *J Urol*. 1999 Aug;162(2):464-8. PMID 10411058.
607. Sand PK, Staskin D, Miller J, et al. Effect of a urinary control insert on quality of life in incontinent women. *Int Urogynecol J Pelvic Floor Dysfunct*. 1999;10(2):100-5. PMID 10384971.
608. Aboseif SR, Franke EI, Nash SD, et al. The adjustable continence therapy system for recurrent female stress urinary incontinence: 1-year results of the North America Clinical Study Group. *J Urol*. 2009 May;181(5):2187-91. PMID 19296967.
609. Appell RA, Juma S, Wells WG, et al. Transurethral radiofrequency energy collagen micro-remodeling for the treatment of female stress urinary incontinence. *Neurourol Urodyn*. 2006;25(4):331-6. PMID 16673379.
610. Lee PE, Kung RC, Drutz HP. Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial. *J Urol*. 2001 Jan;165(1):153-8. PMID 11125386.
611. van Kerrebroeck P, ter Meulen F, Larsson G, et al. Treatment of stress urinary incontinence using a copolymer system: impact on quality of life. *BJU Int*. 2004 Nov;94(7):1040-3. PMID 15541124.
612. Chapple CR, Haab F, Cervigni M, et al. An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence. *Eur Urol*. 2005 Sep;48(3):488-94. PMID 15967568.
613. van Kerrebroeck P, ter Meulen F, Larsson G, et al. Efficacy and safety of a novel system (NASHA/Dx copolymer using the Implacer device) for treatment of stress urinary incontinence. *Urology*. 2004 Aug;64(2):276-81. PMID 15302478.
614. Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. *JAMA*. 1991 Feb 6;265(5):609-13. PMID 1987410.
615. Subak LL, Quesenberry CP, Posner SF, et al. The effect of behavioral therapy on urinary incontinence: a randomized controlled trial. *Obstet Gynecol*. 2002 Jul;100(1):72-8. PMID 12100806.
616. Wyman JF, Fantl JA, McClish DK, et al. Quality of life following bladder training in older women with urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 1997;8(4):223-9. PMID 9449301.
617. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUMiT trial. *J Urol*. 2010 Apr;183(4):1438-43. PMID 20171677.
618. Peters K, Carrico DJ, Perez-Marrero RA, et al. 12 week results from the Sumit trial: Percutaneous tibial nerve stimulation vs validated sham in those exposed to pharmacologic therapy. *Neurourology and Urodynamics*. 2010;29:988-9.
619. Finazzi-Agro E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *J Urol*. 2010 Nov;184(5):2001-6. PMID 20850833.
620. Schreiner L, dos Santos TG, Knorst MR, et al. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. *Int Urogynecol J Pelvic Floor Dysfunct*. 2010 Sep;21(9):1065-70. PMID 20458465.

621. MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. *J Urol*. 2010 Jan;183(1):234-40. PMID 19913821.
622. Surwit E, Campbell JD, Karaszewski K. Neuromodulation of the pudendal, hypogastric, and tibial nerves with pelvic floor muscle rehabilitation in the treatment of urinary urge incontinence. *Neuromodulation: Technology at the Neural Interface*. 2009 2009;12(3):175-9.
623. Finazzi Agro E, Campagna A, Sciobica F, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? *Minerva Urol Nefrol*. 2005 Jun;57(2):119-23. PMID 15951736.
624. Vandoninck V, van Balken MR, Finazzi Agro E, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. *Neurourol Urodyn*. 2003;22(3):227-32. PMID 12707873.
625. Vandoninck V, Van Balken MR, Finazzi Agro E, et al. Posterior tibial nerve stimulation in the treatment of urge incontinence. *Neurourol Urodyn*. 2003;22(1):17-23. PMID 12478596.
626. Vandoninck V, van Balken MR, Finazzi Agro E, et al. Posterior tibial nerve stimulation in the treatment of voiding dysfunction: urodynamic data. *Neurourol Urodyn*. 2004;23(3):246-51. PMID 15098221.
627. Lagro-Janssen AL, Debruyne FM, Smits AJ, et al. The effects of treatment of urinary incontinence in general practice. *Fam Pract*. 1992 Sep;9(3):284-9. PMID 1459383.
628. O'Brien J, Austin M, Sethi P, et al. Urinary incontinence: prevalence, need for treatment, and effectiveness of intervention by nurse. *BMJ*. 1991 Nov 23;303(6813):1308-12. PMID 1747675.
629. McFall SL, Yerkes AM, Cowan LD. Outcomes of a small group educational intervention for urinary incontinence: episodes of incontinence and other urinary symptoms. *J Aging Health*. 2000 May;12(2):250-67. PMID 11010699.
630. McFall SL, Yerkes AM, Cowan LD. Outcomes of a small group educational intervention for urinary incontinence: health-related quality of life. *J Aging Health*. 2000 Aug;12(3):301-17. PMID 11067699.
631. Diokno AC, Sampsel CM, Herzog AR, et al. Prevention of urinary incontinence by behavioral modification program: a randomized, controlled trial among older women in the community. *J Urol*. 2004 Mar;171(3):1165-71. PMID 14767293.
632. Kumari S, Jain V, Mandal AK, et al. Behavioral therapy for urinary incontinence in India. *Int J Gynaecol Obstet*. 2008 Nov;103(2):125-30. PMID 18755458.
633. McFall S, Yerkes AM, Bernard M, et al. Evaluation and treatment of urinary incontinence. Report of a physician survey. *Arch Fam Med*. 1997 Mar-Apr;6(2):114-9. PMID 9075444.
634. Williams KS, Assassa RP, Cooper NJ, et al. Clinical and cost-effectiveness of a new nurse-led continence service: a randomised controlled trial. *Br J Gen Pract*. 2005 Sep;55(518):696-703. PMID 16176737.
635. Kim JI. Continence efficacy intervention program for community residing women with stress urinary incontinence in Japan. *Public Health Nurs*. 2001 Jan-Feb;18(1):64-72. PMID 11251875.
636. Moore KH, O'Sullivan RJ, Simons A, et al. Randomised controlled trial of nurse continence advisor therapy compared with standard urogynaecology regimen for conservative incontinence treatment: efficacy, costs and two year follow up. *BJOG*. 2003 Jul;110(7):649-57. PMID 12842055.
637. O'Brien J. Evaluating primary care interventions for incontinence. *Nurs Stand*. 1996 Feb 28;10(23):40-3. PMID 8695463.
638. Du Moulin MF, Hamers JP, Paulus A, et al. Effects of introducing a specialized nurse in the care of community-dwelling women suffering from urinary incontinence: a randomized controlled trial. *J Wound Ostomy Continence Nurs*. 2007 Nov-Dec;34(6):631-40. PMID 18030102.

639. Chadha Y, Mollison J, Howie F, et al. Guidelines in gynaecology: evaluation in menorrhagia and in urinary incontinence. *BJOG*. 2000 Apr;107(4):535-43. PMID 10759275.
640. Borrie MJ, Bawden M, Speechley M, et al. Interventions led by nurse continence advisers in the management of urinary incontinence: a randomized controlled trial. *CMAJ*. 2002 May 14;166(10):1267-73. PMID 12041843.
641. Diokno AC, Ocampo MS, Jr., Ibrahim IA, et al. Group session teaching of behavioral modification program (BMP) for urinary incontinence: a randomized controlled trial among incontinent women. *Int Urol Nephrol*. 2010 Jun;42(2):375-81. PMID 19701691.
642. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. *N Engl J Med*. 2009 Jan 29;360(5):481-90. PMID 19179316.
643. Subak LL, Whitcomb E, Shen H, et al. Weight loss: a novel and effective treatment for urinary incontinence. *J Urol*. 2005 Jul;174(1):190-5. PMID 15947625.
644. Huang AJ, Stewart AL, Hernandez AL, et al. Sexual function among overweight and obese women with urinary incontinence in a randomized controlled trial of an intensive behavioral weight loss intervention. *J Urol*. 2009 May;181(5):2235-42. PMID 19296980.
645. Auwad W, Steggle P, Bombieri L, et al. Moderate weight loss in obese women with urinary incontinence: a prospective longitudinal study. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Sep;19(9):1251-9. PMID 18421406.
646. Manonai J, Songchitsomboon S, Chanda K, et al. The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial. *Maturitas*. 2006 May 20;54(2):135-40. PMID 16297576.
647. Emmons SL, Otto L. Acupuncture for overactive bladder: a randomized controlled trial. *Obstet Gynecol*. 2005 Jul;106(1):138-43. PMID 15994629.
648. Kim JH, Nam D, Park MK, et al. Randomized control trial of hand acupuncture for female stress urinary incontinence. *Acupunct Electrother Res*. 2008;33(3-4):179-92. PMID 19301628.
649. Bergstrom K, Carlsson CP, Lindholm C, et al. Improvement of urge- and mixed-type incontinence after acupuncture treatment among elderly women - a pilot study. *J Auton Nerv Syst*. 2000 Mar 15;79(2-3):173-80. PMID 10699649.
650. Bo K, Kvarstein B, Nygaard I. Lower urinary tract symptoms and pelvic floor muscle exercise adherence after 15 years. *Obstet Gynecol*. 2005 May;105(5 Pt 1):999-1005. PMID 15863536.
651. de Oliveira Camargo F, Rodrigues AM, Arruda RM, et al. Pelvic floor muscle training in female stress urinary incontinence: comparison between group training and individual treatment using PERFECT assessment scheme. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Aug 19; PMID 19690792.
652. Zanetti MR, Castro Rde A, Rotta AL, et al. Impact of supervised physiotherapeutic pelvic floor exercises for treating female stress urinary incontinence. *Sao Paulo Med J*. 2007 Sep 6;125(5):265-9. PMID 18094892.
653. Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. *JAMA*. 2002 Nov 13;288(18):2293-9. PMID 12425706.
654. Felicissimo MF, Carneiro MM, Saleme CS, et al. Intensive supervised versus unsupervised pelvic floor muscle training for the treatment of stress urinary incontinence: a randomized comparative trial. *Int Urogynecol J Pelvic Floor Dysfunct*. 2010 Jul;21(7):835-40. PMID 20179901.
655. Ng SC, Lin TL, Chang SJ, et al. Nursing intervention to enhance efficacy of home practice of pelvic floor muscle exercises in treating mixed urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 May;19(5):637-42. PMID 18004495.

656. Tsai YC, Liu CH. The effectiveness of pelvic floor exercises, digital vaginal palpation and interpersonal support on stress urinary incontinence: an experimental study. *Int J Nurs Stud.* 2009 Sep;46(9):1181-6. PMID 19361800.
657. Konstantinidou E, Apostolidis A, Kondelidis N, et al. Short-term efficacy of group pelvic floor training under intensive supervision versus unsupervised home training for female stress urinary incontinence: a randomized pilot study. *Neurourol Urodyn.* 2007;26(4):486-91. PMID 17245777.
658. Pages IH, Jahr S, Schaufele MK, et al. Comparative analysis of biofeedback and physical therapy for treatment of urinary stress incontinence in women. *Am J Phys Med Rehabil.* 2001 Jul;80(7):494-502. PMID 11421517.
659. Janssen CC, Lagro-Janssen AL, Felling AJ. The effects of physiotherapy for female urinary incontinence: individual compared with group treatment. *BJU Int.* 2001 Feb;87(3):201-6. PMID 11167642.
660. Morkved S, Bo K, Fjortoft T. Effect of adding biofeedback to pelvic floor muscle training to treat urodynamic stress incontinence. *Obstet Gynecol.* 2002 Oct;100(4):730-9. PMID 12383542.
661. Glavind K, Nohr SB, Walter S. Biofeedback and physiotherapy versus physiotherapy alone in the treatment of genuine stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 1996;7(6):339-43. PMID 9203484.
662. Aukee P, Immonen P, Penttinen J, et al. Increase in pelvic floor muscle activity after 12 weeks' training: a randomized prospective pilot study. *Urology.* 2002 Dec;60(6):1020-3; discussion 3-4. PMID 12475661.
663. McDowell D, Ashe RG, Marshall K, et al. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. *Neurourol Urodyn.* 2006;25(4):337-48. PMID 16637070.
664. Wong KS, Fung KY, Fung SM, et al. Biofeedback of pelvic floor muscles in the management of genuine stress incontinence in Chinese women. *Physiotherapy.* 2001. p. 644-8.
665. Hahn I, Sommar S, Fall M. A comparative study of pelvic floor training and electrical stimulation for the treatment of genuine female stress urinary incontinence. *Neurourology and Urodynamics.* 1991;10(6):545-54.
666. Smith JJ, 3rd. Intravaginal stimulation randomized trial. *J Urol.* 1996 Jan;155(1):127-30. PMID 7490809.
667. Oldham J, McBride K, Herbert J. Evaluation of a new electrostim technology for the treatment of urinary incontinence in women: a randomised controlled trial. *Neurourology and Urodynamics.* 2010;29:1067.
668. Gameiro MO, Moreira EH, Gameiro FO, et al. Vaginal weight cone versus assisted pelvic floor muscle training in the treatment of female urinary incontinence. A prospective, single-blind, randomized trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2010 Apr;21(4):395-9. PMID 20052573.
669. Harvey CA. A Randomised, Single-Blind Comparison of Pelvic Floor Muscle Exercises With Biofeedback Versus Weighted Vaginal Cones in the Management of Genuine Stress Incontinence : A Pilot Study. 2002.
670. Seo JT, Yoon H, Kim YH. A randomized prospective study comparing new vaginal cone and FES-Biofeedback. *Yonsei Med J.* 2004 Oct 31;45(5):879-84. PMID 15515199.
671. Cammu H, Van Nysten M. Pelvic floor exercises versus vaginal weight cones in genuine stress incontinence. *Eur J Obstet Gynecol Reprod Biol.* 1998 Mar;77(1):89-93. PMID 9550207.
672. Arvonen T, Fianu-Jonasson A, Tyni-Lenne R. Effectiveness of two conservative modes of physical therapy in women with urinary stress incontinence. *Neurourol Urodyn.* 2001;20(5):591-9. PMID 11574936.
673. Richter HE, Burgio KL, Brubaker L, et al. Continence pessary compared with behavioral therapy or combined therapy for stress incontinence: a randomized controlled trial. *Obstet Gynecol.* 2010 Mar;115(3):609-17. PMID 20177294.

674. Liebergall-Wischnitzer M, Hochner-Celnikier D, Lavy Y, et al. Randomized trial of circular muscle versus pelvic floor training for stress urinary incontinence in women. *J Womens Health (Larchmt)*. 2009 Mar;18(3):377-85. PMID 19281321.
675. Liebergall-Wischnitzer M, Hochner-Celnikier D, Lavy Y, et al. Paula method of circular muscle exercises for urinary stress incontinence--a clinical trial. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Sep-Oct;16(5):345-51. PMID 15660184.
676. Sherman RA, Davis GD, Wong MF. Behavioral treatment of exercise-induced urinary incontinence among female soldiers. *Mil Med*. 1997 Oct;162(10):690-4. PMID 9339085.
677. Alewijnse D, Metsemakers JF, Mesters IE, et al. Effectiveness of pelvic floor muscle exercise therapy supplemented with a health education program to promote long-term adherence among women with urinary incontinence. *Neurourol Urodyn*. 2003;22(4):284-95. PMID 12808702.
678. Gallo ML, Staskin DR. Cues to action: pelvic floor muscle exercise compliance in women with stress urinary incontinence. *Neurourol Urodyn*. 1997;16(3):167-77. PMID 9136139.
679. Borello-France DF, Zyczynski HM, Downey PA, et al. Effect of pelvic-floor muscle exercise position on continence and quality-of-life outcomes in women with stress urinary incontinence. *Phys Ther*. 2006 Jul;86(7):974-86. PMID 16813477.
680. Demirturk F, Akbayrak T, Karakaya IC, et al. Interferential current versus biofeedback results in urinary stress incontinence. *Swiss Medical Weekly*. 2008 May 31;138(21-22):317-21. PMID 18516753.
681. Thyssen H, Bidmead J, Lose G, et al. A new intravaginal device for stress incontinence in women. *BJU Int*. 2001 Dec;88(9):889-92. PMID 11851609.
682. Nygaard I. Prevention of exercise incontinence with mechanical devices. *J Reprod Med*. 1995 Feb;40(2):89-94. PMID 7738934.
683. Andersen RC. Long-term follow-up comparison of Durasphere and Contigen in the treatment of stress urinary incontinence. *Journal of Lower Genital Tract Disease*. 2002(4):239-43. PMID 17051030
684. Robinson H, Schulz J, Flood C, et al. A randomized controlled trial of the NEAT expandable tip continence device. *Int Urogynecol J Pelvic Floor Dysfunct*. 2003 Aug;14(3):199-203; discussion PMID 12955343.
685. Thornburn P, Fader M, Dean G, et al. Improving the performance of small incontinence pads: a study of "wet comfort". *J Wound Ostomy Continence Nurs*. 1997 Jul;24(4):219-25. PMID 9274279.
686. Mayer RD, Dmochowski RR, Appell RA, et al. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. *Urology*. 2007 May;69(5):876-80. PMID 17482925.
687. Bano F, Barrington JW, Dyer R. Comparison between porcine dermal implant (Permacol) and silicone injection (Macroplastique) for urodynamic stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Mar-Apr;16(2):147-50; discussion 50. PMID 15378234.
688. Schulz JA, Nager CW, Stanton SL, et al. Bulking agents for stress urinary incontinence: short-term results and complications in a randomized comparison of periurethral and transurethral injections. *Int Urogynecol J Pelvic Floor Dysfunct*. 2004 Jul-Aug;15(4):261-5. PMID 15517671.
689. Ghoniem G, Corcos J, Comiter C, et al. Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. *J Urol*. 2009 Jan;181(1):204-10. PMID 19013613.
690. Strasser H, Marksteiner R, Margreiter E, et al. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. *Lancet*. 2007 Jun 30;369(9580):2179-86. PMID 17604800.

691. Lightner D, Calvosa C, Andersen R, et al. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. *Urology*. 2001 Jul;58(1):12-5. PMID 11445471.
692. Lightner D, Rovner E, Corcos J, et al. Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. *Urology*. 2009 Oct;74(4):771-5. PMID 19660800.
693. Starr CH. The numbers lie. *Bus Health*. 2002 Spring;Spec No:4-7, 23. PMID 11974569.
694. Dowd T, Kolcaba K, Steiner R. Using cognitive strategies to enhance bladder control and comfort. *Holist Nurs Pract*. 2000 Jan;14(2):91-103. PMID 12119974.
695. Elser DM, Wyman JF, McClish DK, et al. The effect of bladder training, pelvic floor muscle training, or combination training on urodynamic parameters in women with urinary incontinence. *Continence Program for Women Research Group. Neurourol Urodyn*. 1999;18(5):427-36. PMID 10494113.
696. Ramsay IN, Ali HM, Hunter M, et al. A prospective, randomized controlled trial of inpatient versus outpatient continence programs in the treatment of urinary incontinence in the female. *Int Urogynecol J Pelvic Floor Dysfunct*. 1996;7(5):260-3. PMID 9127183.
697. Hui E, Lee PS, Woo J. Management of urinary incontinence in older women using videoconferencing versus conventional management: a randomized controlled trial. *J Telemed Telecare*. 2006;12(7):343-7. PMID 17059650.
698. Lamb SE, Pepper J, Lall R, et al. Group treatments for sensitive health care problems: a randomised controlled trial of group versus individual physiotherapy sessions for female urinary incontinence. *BMC Womens Health*. 2009;9:26. PMID 19751517.
699. Wing RR, West DS, Grady D, et al. Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months. *J Urol*. 2010 Sep;184(3):1005-10. PMID 20643425.
700. Karademir K, Baykal K, Sen B, et al. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. *Scand J Urol Nephrol*. 2005;39(3):230-3. PMID 16118096.
701. Fitzgerald MP, Lemack G, Wheeler T, et al. Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Nov;19(11):1545-50. PMID 18704249.
702. Burgio KL, Kraus SR, Menefee S, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. *Ann Intern Med*. 2008 Aug 5;149(3):161-9. PMID 18678843.
703. Zimmern P, Litman HJ, Mueller E, et al. Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. *BJU Int*. 2010 Jun;105(12):1680-5. PMID 19912207.
704. Herschorn S, Becker D, Miller E, et al. Impact of a health education intervention in overactive bladder patients. *Can J Urol*. 2004 Dec;11(6):2430-7. PMID 15636668.
705. Goode PS, Burgio KL, Kraus SR, et al. Correlates and predictors of patient satisfaction with drug therapy and combined drug therapy and behavioral training for urgency urinary incontinence in women. *Int Urogynecol J*. 2011 Mar;22(3):327-34. PMID 20945064.
706. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. *J Urol*. 2009 Sep;182(3):1055-61. PMID 19616802.
707. Franzen K, Johansson JE, Lauridsen I, et al. Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women--a randomized controlled trial. *Int Urogynecol J Pelvic Floor Dysfunct*. 2010 Dec;21(12):1517-24. PMID 20585755.

708. Mattiasson A, Blaakaer J, Hoyer K, et al. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. *BJU Int.* 2003 Jan;91(1):54-60. PMID 12614251.
709. Mattiasson A, Masala A, Morton R, et al. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study. *BJU Int.* 2009 Oct 10; PMID 19818077.
710. Chancellor MB, Kianifard F, Beamer E, et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. *Int J Clin Pract.* 2008 Apr;62(4):606-13. PMID 18324952.
711. Berghmans LC, Frederiks CM, de Bie RA, et al. Efficacy of biofeedback, when included with pelvic floor muscle exercise treatment, for genuine stress incontinence. *Neurourol Urodyn.* 1996;15(1):37-52. PMID 8696355.
712. Goode PS, Burgio KL, Locher JL, et al. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. *JAMA.* 2003 Jul 16;290(3):345-52. PMID 12865375.
713. Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. *Urology.* 2004 Jan;63(1):61-6. PMID 14751349.
714. Dmochowski RR, Blaivas JM, Gormley EA, et al. Update of AUA guideline on the surgical management of female stress urinary incontinence. *J Urol.* 2010 May;183(5):1906-14. PMID 20303102.
715. Nager CW, Kraus SR, Kenton K, et al. Urodynamics, the supine empty bladder stress test, and incontinence severity. *Neurourol Urodyn.* 2010 Sep;29(7):1306-11. PMID 20127832.
716. Martin JL, Williams KS, Sutton AJ, et al. Systematic review and meta-analysis of methods of diagnostic assessment for urinary incontinence. *Neurourol Urodyn.* 2006;25:674-83. PMID 17016795.
717. Abrams P. Identifying and evaluating urinary incontinence in a female population. *Eur Urol.* 1997;32 Suppl 2:1-2. PMID 9248805.
718. Ireton RC, Krieger JN, Cardenas DD, et al. Bladder volume determination using a dedicated, portable ultrasound scanner. *J Urol.* 1990 May;143(5):909-11. PMID 2184254.
719. Goode PS, Locher JL, Bryant RL, et al. Measurement of postvoid residual urine with portable transabdominal bladder ultrasound scanner and urethral catheterization. *Int Urogynecol J Pelvic Floor Dysfunct.* 2000;11(5):296-300. PMID 11052565.
720. Ouslander JG, Simmons S, Tuico E, et al. Use of a portable ultrasound device to measure post-void residual volume among incontinent nursing home residents. *J Am Geriatr Soc.* 1994 Nov;42(11):1189-92. PMID 7963206.
721. Ghoniem G, Stanford E, Kenton K, et al. Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice. *International Urogynecology Journal.* 2008 Jan;19(1):5-33. PMID 21118 PMID: 18026681.
722. Campbell JD, Gries KS, Watanabe JH, et al. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. *BMC Urol.* 2009;9:18. PMID 19930578.
723. McDonagh MS, Selover D, Santa J, et al. Drug class review on agents for overactive bladder: Final report Oregon Health & Science University. Dec 2005.
724. Layton D, Pearce GL, Shakir SA. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. *Drug Saf.* 2001;24(9):703-13. PMID 11522122.
725. Jumadilova Z, Varadharajan S, Girase P, et al. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin. *Am J Health Syst Pharm.* 2006 Dec 1;63(23):2357-64. PMID 17106009.

726. Wang PS, Levin R, Zhao SZ, et al. Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients. *J Am Geriatr Soc.* 2002 Jan;50(1):117-24. PMID 12028256.
727. Ioannidis JPA, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. *Am J Epidemiol.* 1998;148:1117-26.
728. Arends LR, Hoes AW, Lubsen J, et al. Baseline risk as predictor of treatment benefit: three clinical = meta-re-analyses. *Stat Med.* 2000;19:3497-518.
729. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. *BMJ.* 1994;309:1351-5.
730. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. *Pharmacotherapy.* 2006 Dec;26(12):1694-702. PMID 17125433.
731. Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. *Value Health.* 2005 Jul-Aug;8(4):495-505. PMID 16091027.
732. Prescribing antimuscarinics for overactive bladder; how many chances do we have to get it right? *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. 29.
733. Perfetto EM, Subedi P, Jumadilova Z. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. *Am J Manag Care.* 2005 Jul;11(4 Suppl):S150-7. PMID 16161388.
734. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. *Pharmacoeconomics.* 2004;22(16):1047-59. PMID 15524493.
735. O'Brien BJ, Goeree R, Bernard L, et al. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. *Clin Ther.* 2001 Dec;23(12):2038-49. PMID 11813937.
736. Varadharajan S, Jumadilova Z, Girase P, et al. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. *Am J Manag Care.* 2005 Jul;11(4 Suppl):S140-9. PMID 16161387.
737. Wieseler B, McGauran N, Kaiser T. Finding studies on reboxetine: a tale of hide and seek. *BMJ.* 2010;341:c4942. PMID 20940211.
738. Imamura M, Abrams P, Bain C, et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. *Health Technol Assess.* 2010 Aug;14(40):1-188, iii-iv. PMID 20738930.
739. National Institute for Health and Clinical Excellence. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome: guidance. Oct 27 2010. <http://www.nice.org.uk/nicemedia/live/12412/51304/51304.pdf>.
740. Goode PS, Burgio KL, Richter HE, et al. Incontinence in older women. *JAMA.* 2010 Jun 2;303(21):2172-81. PMID 20516418.
741. Thuroff JW, Abrams P, Andersson KE, et al. EAU Guidelines on Urinary Incontinence. *Eur Urol.* 2011 Mar;59(3):387-400. PMID 21130559.

Abbreviations

AHRQ	Agency for Healthcare Research and Quality
ARD	Absolute risk difference
BMI	Body Mass Index
CI	Confidence interval
ER	Extended release
FDA	Food and Drug Administration
ICI	International Consultation on Incontinence
ICS	International Continence Society
I-QOL	Incontinence Quality of Life
IUGA	International Urogynecological Association
MeSH	Medical Subject Headings
NNT	Number needed to treat
OAB	Overactive bladder
OPERA	Overactive bladder: Performance of Extended Release Agents
PFMT	Pelvic floor muscle training
PVR	Post-void residual
RCTs	Randomized controlled trials
RR	Relative risk
SRC	Scientific Resource Center
UDI	Urogenital Distress Inventory
UI	Urinary incontinence

Appendix A. Search Strings

April 14, 2009

Literature Strings	Result
Search ("Urinary Incontinence/radiotherapy"[Mesh] OR "Urinary Incontinence/rehabilitation"[Mesh] OR "Urinary Incontinence/surgery"[Mesh] OR "Urinary Incontinence/therapy"[Mesh]) Limits: Humans, Randomized Controlled Trial, English	612
Search ("Urinary Incontinence/radiotherapy"[Mesh] OR "Urinary Incontinence/rehabilitation"[Mesh] OR "Urinary Incontinence/surgery"[Mesh] OR "Urinary Incontinence/therapy"[Mesh]) Limits: Humans, Journal Article, English	9,182
Search "Epidemiologic Studies"[Mesh] AND #4 Limits: Humans, Journal Article, English	2,367
Search "Epidemiologic Studies"[Mesh] Limits: Humans, Journal Article, English	901,758
Search ("Urinary Incontinence/radiotherapy"[Mesh] OR "Urinary Incontinence/rehabilitation"[Mesh] OR "Urinary Incontinence/surgery"[Mesh] OR "Urinary Incontinence/therapy"[Mesh])	13,222

April 16, 2009

Database: Ovid MEDLINE(R) <1950 to April Week 1 2009> Search Strategy:

-
- 1 exp Urinary Incontinence/di [Diagnosis] (2,523)
 - 2 limit 1 to (english language and humans and (guideline or practice guideline)) (13)
 - 3 exp Clinical Protocols/ (91,702)
 - 4 1 and 3 (18)
 - 5 exp Decision Trees/ (6,776)
 - 6 1 and 5 (19)
 - 7 6 or 4 (34)
 - 8 limit 7 to (English language and humans) (25)
 - 9 2 or 8 (37)

Database: Ovid MEDLINE(R) <1950 to April Week 2 2009> Search Strategy:

-
- 1 exp urinary incontinence/dh, th, su, rt (9,205)
 - 2 exp urinary incontinence/dt (1,539)
 - 3 1 not 2 (8,998)
 - 4 (non pharmacologic or nonpharmacologic).mp. (2,448)
 - 5 1 and 4 (8)
 - 6 exp treatment outcome/ (383,394)
 - 7 exp epidemiologic studies/ (1,103,515)
 - 8 3 or 5 (9,001)
 - 9 6 and 7 and 8 (939)
 - 10 exp quality of life/ (73,696)
 - 11 7 and 8 and 10 (230)
 - 12 9 or 11 (1,032)
 - 13 limit 12 to (English language and humans) (908)
 - 14 limit 13 to journal article (893)

Database: Ovid MEDLINE(R) <1950 to April Week 2 2009> Search Strategy:

-
- 1 exp urinary incontinence/dt (1,539)
 - 2 exp treatment outcome/ (383,394)
 - 3 exp quality of life/ (73,696)
 - 4 3 or 2 (444,907)
 - 5 4 and 1 (365)
 - 6 exp epidemiologic studies/ (1,103,515)
 - 7 6 and 5 (96)
 - 8 limit 7 to (English language and humans) (85)
 - 9 limit 8 to journal article (84)

Database: Ovid MEDLINE(R) <1950 to April Week 2 2009> Search Strategy:

-
- 1 exp Urinary Incontinence/dh, nu, th, su, rt, dt, rh [Diet Therapy, Nursing, Therapy, Surgery, Radiotherapy, Drug Therapy, Rehabilitation] (12,453)
 - 2 exp Office Visits/ or exp Medical Office Buildings/ (4554)
 - 3 exp Hospitals/ (161857)
 - 4 exp Nursing Homes/ (26676)
 - 5 4 or 3 or 2 (191276)
 - 6 1 and 5 (314)
 - 7 exp epidemiologic studies/ (1103515)
 - 8 6 and 7 (52)
 - 9 limit 8 to (English language and humans) (48)

Database: Ovid MEDLINE(R) <1950 to April Week 2 2009> Search Strategy:

-
- 1 exp urinary incontinence/ (20,881)
 - 2 exp primary health care/ (55,252)
 - 3 1 and 2 (124)
 - 4 exp epidemiologic studies/ (1,103,515)
 - 5 4 and 3 (16)
 - 6 exp physician-patient relations/ (48,990)
 - 7 6 and 4 and 1 (12)
 - 8 7 or 5 (26)
 - 9 limit 8 to English language (23)
 - 10 limit 9 to journal article (22)

Database: Ovid MEDLINE(R) <1950 to April Week 2 2009> Search Strategy:

-
- 1 exp Urinary Incontinence/di [Diagnosis] (2,529)
 - 2 exp Diagnosis, Differential/ (316,330)
 - 3 1 and 2 (190)
 - 4 limit 3 to (English language and humans) (115)

Database: Ovid MEDLINE(R) <1950 to April Week 2 2009> Search Strategy:

-
- 1 exp Urinary Incontinence/th, su, dt, rh [Therapy, Surgery, Drug Therapy, Rehabilitation] (11,383)
 - 2 exp Treatment Outcome/ (383,394)
 - 3 1 and 2 (2,157)
 - 4 exp Evidence-Based Practice/ or exp Evidence-Based Medicine/ or evidence.mp. (756,148)
 - 5 4 and 3 (146)
 - 6 limit 3 to "therapy (optimized)" (399)
 - 7 6 or 5 (502)
 - 8 limit 7 to (English language and humans) (463)
 - 9 exp epidemiological studies/ (1,103,515)
 - 10 8 and 9 (180)
 - 11 limit 10 to journal article (177)

April 27, 2009

Literature Strings	Results
Search "Health Services Research"[Mesh] AND "Urinary incontinence" [Mesh] NOT review Limits: Humans, Journal Article, English	137

April 20, 2009

- #10 Select 12 document(s) 17:17:22 12 #9 Search "Evidence-Based Medicine"[Mesh] Urinary incontinence Limits:
Humans, English 17:03:46 124
- #17 Search "Caregivers"[Mesh] AND "Urinary Incontinence"[Mesh] NOT review Limits: Humans, Journal Article,
English 17:32:56 22

May 26, 2009

Search	Literature Strings	Result
Search #6 or #7 Limits: Humans, Randomized Controlled Trial, English		46
Search #6 or #7 Limits: Humans, English		758
Search #9 and #1 and #3 Limits: Humans, Randomized Controlled Trial, English		402
Search #9 and #1 and #3 Limits: Humans, English		5,442
Search clinic or office or hospital or nursing home or longterm care, Limits: Humans, English		1,645,316
Search "health services research"[MeSH Terms] and urine incontinence Limits: Humans, English		214
Search #4 or #5 Limits: Humans, English		588
Search "Physician's Practice Patterns"[MeSH Terms] and urine incontinence Limits: Humans, English		64
Search #1 and #2 and #3		539
Search treatment or outcome		3,837,858
Search primary care or specialized care or urologist or urogynecologist		118,680
Search urine incontinence		18,607
Search urine incontinence and professional practice Limits: Humans, English		228
Stem cell AND "urinary incontinence" Limits: Humans, Journal Article, English		42
Estrogen AND "urinary incontinence" Limits: Humans, Journal Article, English		368
Adrenergic Uptake Inhibitors AND "urinary incontinence" Limits: Humans, Journal Article, English		162
Imipramine hydrochloride AND "urinary incontinence" Limits: Humans, Journal Article, English		76
Tricyclic antidepressant AND "urinary incontinence" Limits: Humans, Journal Article, English		81
Botulinum toxin AND "urinary incontinence" Limits: Humans, Journal Article, English		109
Alpha-blockers AND "Urinary Incontinence" Limits: Humans, Journal Article, English		101
Solifenacin AND "Urinary Incontinence" Limits: Humans, Journal Article, English		48
Vesicare AND "Urinary Incontinence" Limits: Humans, Journal Article, English		4
Enablex AND "Urinary Incontinence" Limits: Humans, Journal Article, English		54
Sanctura AND "Urinary Incontinence" Limits: Humans, Journal Article, English		3
Ditropan AND "Urinary Incontinence" Limits: Humans, Journal Article, English		286
Detrol AND "Urinary Incontinence" Limits: Humans, Journal Article, English		198
"Urinary Incontinence" Limits: Humans, Randomized Controlled Trial, English		789
("Urinary Incontinence/radiotherapy"[Mesh] OR "Urinary Incontinence/rehabilitation"[Mesh] OR "Urinary Incontinence/surgery"[Mesh] OR "Urinary Incontinence/therapy"[Mesh]) Limits: Humans, Randomized Controlled Trial, English		621
("Urinary Incontinence/radiotherapy"[Mesh] OR "Urinary Incontinence/rehabilitation"[Mesh] OR "Urinary Incontinence/surgery"[Mesh] OR "Urinary Incontinence/therapy"[Mesh])		13,302
"Caregivers"[Mesh] AND "Urinary Incontinence" Limits: Humans, Journal Article, English		40
"Physician-Patient Relations" [Mesh] AND "Urinary incontinence"		48
"Delivery of Health Care"[Mesh] AND "Urinary incontinence" Limits: Humans, Journal Article, English		1,438
"Health services re"[MeSH] AND "Urinary incontinence" Limits: Humans, Journal Article, English		186
"Physician's Practice Patterns"[MeSH] AND "Urinary incontinence" Limits: Humans, Journal Article, English		57
"Quality of life" AND "Urinary incontinence" Limits: Humans, Journal Article, English		1,689
"Urinary Incontinence/diagnosis"[Mesh] Limits: Humans, Randomized Controlled Trial, English		83
"Urinary Incontinence/diagnosis"[Mesh] Limits: Humans, Journal Article, English		2,328
"Epidemiologic Studies"[Mesh] AND "Urinary Incontinence/diagnosis"[Mesh] Limits: Humans, Randomized Controlled Trial, Controlled Clinical Trial, Multicenter Study, Validation Studies, English		66
"Urinary Incontinence" AND urologist Limits: Humans, Journal Article, English		78
"Urinary Incontinence" AND urogynecologist Limits: Humans, Journal Article, English		7
"Urinary Incontinence" AND gynecologist Limits: Humans, Journal Article, English		29

June 26, 2009

Search (Urinary incontinence) AND systematic[sb] 581
Search diary AND "urinary incontinence" AND sensitivity Limits: Humans, English 20

July 20, 2009

Cochrane RCT database:
Urinary incontinence and Women 457
Urinary incontinence NOT surgery 138

Updated search August 20, 2009

Search ("Urinary Incontinence/diagnosis"[Mesh] OR "Urinary Incontinence/diet therapy"[Mesh] OR "Urinary Incontinence/drug therapy"[Mesh] OR "Urinary Incontinence/therapy"[Mesh]) Limits: published in the last 180 days, Humans, Journal Article, English, All Adult: 19+ years 86

October 13, 2009

Search "Duloxetine Urinary Incontinence Study Group"[Corporate Author] 4

Updated search November 10, 2009:

Search (("Urinary incontinence"[Text Word]) AND ("2009/04/01"[Publication Date] : "3000"[Publication Date])) AND (Urinary incontinence) Limits: Randomized Controlled Trial English 33

March 25, 2010

Search tolterodine Limits: Randomized Controlled Trial ("2009/04/01"[Publication Date] : "3000"[Publication Date])) AND (Urinary incontinence) Limits: Randomized Controlled Trial, English 134

Search fesoterodine 48

Search Solifenacin 194

March 30, 2011

"urinary incontinence" OR "overactive bladder" OR fesoterodine OR oxybutynin OR trospium OR solifenacin OR tolterodine Limits: Female, Randomized Controlled Trial, English, All Adult: 19+ years 865

Grey Literature search using key words "Urinary incontinence" on July 27, 2010:

Regulatory Information

FDA
Health Canada
Authorized Medicines for EU

Clinical Trial Registries

ClinicalTrials.gov - 120
Search for UI among all close studies: additional -100 records
Australian New Zealand Clinical Trials Registry (ANZCTR) - 1
Clinical Study Results - 4
WHO Clinical Trials - 18
Clinical Trials Registry - India (CTRI) - 1
Japanese Registry of clinical trials (JPRN) - 4
Netherlands Trial Register - 6

Abstracts and Conference Papers

Conference Papers Index - 318
Scopus - 243
International Continence Society and the International Urogynecological Association – 2010 meeting

Grants and Federally Funded Research

NIH RePORTER (a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other research institutions)- 487

September 2010

"Urinary incontinence" OR "overactive bladder" OR fesoterodine OR oxybutynin OR trospium OR solifenacin OR tolterodine Limits: Female, Randomized Controlled Trial, English, All Adult: 19+ years 794

"Urinary incontinence" Limits: Humans, Journal Article, English, All Adult: 19+ years, Publication Date from 2009/01/01 to 2010/12/31 903

Additional searches recommended by the peer reviewers

Contigen "urinary incontinence" Limits: Humans, Randomized Controlled Trial, Multicenter Study, English 10

Search "transcutaneous tibial nerve stimulation" AND "urinary incontinence" NOT review Limits: Humans, English 11

Search "tibial nerve stimulation" AND "urinary incontinence" NOT review Limits: Humans, English 16

Continuously updated search

November 2011- updated searches

"Urinary incontinence" OR "overactive bladder" OR fesoterodine OR oxybutynin OR trospium OR solifenacin OR tolterodine Limits: Humans, Randomized Controlled Trial, English, published in the last 3 years 267

December 2011

Search "urinary incontinence" OR "overactive bladder" OR fesoterodine OR oxybutynin OR trospium OR solifenacin OR tolterodine Limits: Female, Randomized Controlled Trial, English, All Adult: 19+ years 893

Database: Ovid MEDLINE(R) <1950 to December 2011> Search Strategy:

-
- 1 exp Urinary Incontinence/di [Diagnosis] (2,849)
 - 2 exp Diagnosis, Differential/ (347,297)
 - 3 1 and 2 (201)
 - 4 limit 3 to (English language and humans) (120)

Database: Ovid MEDLINE(R) <1950 to December 2011> Search Strategy:

-
- 1 exp urinary incontinence/dt (1,728)
 - 2 exp treatment outcome/ (517,761)
 - 3 exp quality of life/ (94,744)
 - 4 3 or 2 (595309)
 - 5 4 and 1 (447)
 - 6 exp epidemiologic studies/ (1359275)
 - 7 6 and 5 (116)
 - 8 limit 7 to (English language and humans) (103)

Table A1. Results of the request for Scientific Information Packets (SIP) by the Scientific Resource Center

Company	SIP Letter Sent	SIP Received
Abbott Laboratories	8/13/2010	[no SIP]
Accelerated Care Plus	8/13/2010	[no SIP]
ACP - Accelerated Care Plus Corporation	8/13/2010	[no SIP]
Actavis US	8/13/2010	[no SIP]
AL Voss Associates	8/13/2010	[no SIP]
Allergan, Inc.	8/13/2010	[no SIP]
Astellas Pharmaceuticals	8/13/2010	[no SIP]
AstraZeneca Pharmaceuticals, LP	8/13/2010	[no SIP]
Bioness, Inc.	8/13/2010	[no SIP]
BIOTEQUE AMERICA, INC.	8/13/2010	[no SIP]
Bristol-Myers Squibb	8/13/2010	[no SIP]
Duramed Subsidiary of Barr Pharmaceuticals	8/13/2010	[no SIP]
Eli Lilly & Co	8/13/2010	[no SIP]
Hollister Incorporated	8/13/2010	[no SIP]
Impax Laboratories, Inc.	8/13/2010	[no SIP]
Ivax Pharmaceuticals (Teva Pharmaceuticals)	8/13/2010	[no SIP]
Laborie Medical Technologies	8/13/2010	[no SIP]
Mentor Corp	8/13/2010	[no SIP]
Mikart	8/13/2010	[no SIP]
Mutual Pharma (URL Pharma Inc)	8/13/2010	[no SIP]
Mylan Pharmaceuticals	8/13/2010	[no SIP]
New River Pharmaceuticals	8/13/2010	[no SIP]
Nexstim Inc	8/13/2010	[no SIP]
Novartis Pharmaceuticals Corporation	8/13/2010	[no SIP]
Novavax Inc.	8/13/2010	[no SIP]
Nycomed US Inc	8/13/2010	[no SIP]
Odyssey Pharmaceuticals, Inc	8/13/2010	[no SIP]
Ortho-McNeil Janssen Scientific Affairs, LLC	8/13/2010	8/31/2010
Osmotica Pharmaceutical Corp	8/13/2010	[no SIP]
Pfizer Inc	8/13/2010	[no SIP]
Purepac Pharmaceuticals	8/13/2010	[no SIP]
Ranbaxy	8/13/2010	[no SIP]
Reliant Technologies, Inc.	8/13/2010	[no SIP]
Roche Laboratories	8/13/2010	[no SIP]
Rochester Medical Corporation	8/13/2010	9/10/2010
Roxane	8/13/2010	[no SIP]
Sandoz Inc	8/13/2010	[no SIP]
Sanofi Aventis US	8/13/2010	[8/27/2010 nothing to supply]
Schering-Plough Corporation	8/13/2010	[no SIP]
Silarx Pharmaceuticals, Inc.	8/13/2010	[no SIP]
Somaxon Pharmaceuticals	8/13/2010	[no SIP]
Taro Pharmaceuticals	8/13/2010	[no SIP]
Teva Pharmaceuticals USA	8/13/2010	[no SIP]
UCB, Inc	8/13/2010	[no SIP]
USL Pharmaceuticals	8/13/2010	[no SIP]
Vanguard Pharma	8/13/2010	[no SIP]
Warner Chilcott Company, Inc.	8/13/2010	[no SIP]
Wockhardt	8/13/2010	[no SIP]
Wyeth Pharmaceuticals Headquarters	8/13/2010	[no SIP]
PLIVA HRVATSKA DOO	8/13/2010	[no SIP]
Tyco Healthcare UK Commercial Ltd.	8/13/2010	[no SIP]

Appendix B. Excluded Studies

Reason for Exclusion: Not Eligible Target Population (1025 Studies)

1. Aaron R, Muliylil J, Abraham S. Medico-social dimensions of menopause: a cross-sectional study from rural south India. *Natl Med J India*. 2002 Jan-Feb;15(1):14-7. PMID: 11855585.
2. Abdul MA, Yusuf MD, Liadi S, et al. Congenital vaginal fistula from a single system ectopic ureter: A case report. *Niger J Med*. 2006 Oct-Dec;15(4):441-3. PMID: 17111735.
3. Abouassaly R, Lane BR, Lakin MM, et al. Ejaculatory urine incontinence after radical prostatectomy. *Urology*. 2006 Dec;68(6):1248-52. PMID: 17141827.
4. Abrams P, Donovan JL, de la Rosette JJ, et al. International Continence Society "Benign Prostatic Hyperplasia" Study: background, aims, and methodology. *Neurourol Urodyn*. 1997;16(2):79-91. PMID: 9042670.
5. Abrams P, Kaplan S, De Koning Gans HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. *J Urol*. 2006 Mar;175(3 Pt 1):999-1004; discussion PMID: 16469601.
6. Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. *Eur Urol*. 2005 Sep;48(3):483-7. PMID: 16005564.
7. Addington-Hall J, Lay M, Altmann D, et al. Symptom control, communication with health professionals, and hospital care of stroke patients in the last year of life as reported by surviving family, friends, and officials. *Stroke*. 1995 Dec;26(12):2242-8. PMID: 7491644.
8. Adler US, Kirshblum SC. A new assistive device for intermittent self-catheterization in men with tetraplegia. *J Spinal Cord Med*. 2003 Summer;26(2):155-8. PMID: 12828294.
9. Agarwal A, Dhiraaj S, Singhal V, et al. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. *Br J Anaesth*. 2006 Mar;96(3):377-80. PMID: 16415311.
10. Agnew G, Byrne P. The evaluation and treatment of female urinary incontinence--a comparison of clinical practice in the Republic of Ireland with the recommendations of the International Continence Society. *Ir Med J*. 2004 Sep;97(8):238-40. PMID: 15532970.
11. Agur WI, Steggles P, Waterfield M, et al. The long-term effectiveness of antenatal pelvic floor muscle training: eight-year follow up of a randomised controlled trial. *BJOG*. 2008 Jul;115(8):985-90. PMID: 18651881.
12. Ahmed S, Davies J. Managing the complications of prostate cryosurgery. *BJU Int*. 2005 Mar;95(4):480-1. PMID: 15705063.

13. Akakura K, Isaka S, Akimoto S, et al. Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. *Urology*. 1999 Aug;54(2):313-8. PMID: 10443731.
14. Akbal C, Genc Y, Burgu B, et al. Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population. *J Urol*. 2005 Mar;173(3):969-73. PMID: 15711352.
15. Al-Abany M, Helgason AR, Adolfsson J, et al. Reliability of assessment of urgency and other symptoms indicating anal sphincter, large bowel or urinary dysfunction. *Scand J Urol Nephrol*. 2006;40(5):397-408. PMID: 17060087.
16. Albani JM, Zippe CD. Urethral catheter removal 3 days after radical retropubic prostatectomy is feasible and desirable. *Prostate Cancer Prostatic Dis*. 2002;5(4):291-5. PMID: 12627214.
17. Albertsen PC. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. *J Urol*. 2005 Nov;174(5):1969-70. PMID: 16217368.
18. Alessi CA, Ouslander JG, Maldague S, et al. Incidence and costs of acute medical conditions in long-stay incontinent nursing home residents. *J Am Med Dir Assoc*. 2003 Mar-Apr;4(2 Suppl):S4-S18. PMID: 12807565.
19. Alessi CA, Schnelle JF, MacRae PG, et al. Does physical activity improve sleep in impaired nursing home residents? *J Am Geriatr Soc*. 1995 Oct;43(10):1098-102. PMID: 7560698.
20. Alessi CA, Yoon EJ, Schnelle JF, et al. A randomized trial of a combined physical activity and environmental intervention in nursing home residents: do sleep and agitation improve? *J Am Geriatr Soc*. 1999 Jul;47(7):784-91. PMID: 10404920.
21. Alfano CM, McGregor BA, Kuniyuki A, et al. Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. *Psychooncology*. 2006 Nov;15(11):985-1000. PMID: 16470891.
22. Al-Jadid MS, Al-Asmari AK, Al-Moutaery KR. Quality of life in males with spinal cord injury in Saudi Arabia. *Saudi Med J*. 2004 Dec;25(12):1979-85. PMID: 15711680.
23. Allahdin S, Oo N, Jones C. Intractable flatus incontinence treated by percutaneous tibial nerve stimulation. *Int J Colorectal Dis*. 2011 Jan 6; PMID: 21210132.
24. Allareddy V, Kennedy J, West MM, et al. Quality of life in long-term survivors of bladder cancer. *Cancer*. 2006 Jun 1;106(11):2355-62. PMID: 16649218.
25. Alloussi S, Alloussi SH, Eichel R, et al. Post-Prostatectomy Stress Urinary Incontinence: Long Term Follow Up after Injection Treatment with Non-Animal Stabilized Dextranomer/Hyaluronic Acid (NASHA/DX). 2008 Annual Meeting of the American Urological Association, Orlando, Florida (USA), 17-22 May 2008.
26. Almodhen F, Capolicchio JP, Jednak R, et al. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele. *J Urol*. 2007 Oct;178(4 Pt 1):1479-82. PMID: 17706702.

27. Al-Samarrai NR, Uman GC, Al-Samarrai T, et al. Introducing a new incontinence management system for nursing home residents. *J Am Med Dir Assoc.* 2007 May;8(4):253-61. PMID: 17498610.
28. Altinova S, Demirci DA, Ozdemir AT, et al. Incorporation of anterior rectus fascial sling into radical retropubic prostatectomy improves postoperative continence. *Urol Int.* 2009;83(1):19-21. PMID: 19641353.
29. Altomare DF, Rinaldi M, Petrolino M, et al. Permanent sacral nerve modulation for fecal incontinence and associated urinary disturbances. *Int J Colorectal Dis.* 2004 May;19(3):203-9. PMID: 13680281.
30. Altwein J, Ekman P, Barry M, et al. How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. *Urology.* 1997 Apr;49(4A Suppl):66-76. PMID: 9111616.
31. Al-Waili NS. Carbamazepine to treat primary nocturnal enuresis: double-blind study. *Eur J Med Res.* 2000 Jan 26;5(1):40-4. PMID: 10657288.
32. Amark P, Beck O. Effect of phenylpropanolamine on incontinence in children with neurogenic bladders. A double-blind crossover study. *Acta Paediatr.* 1992 Apr;81(4):345-50. PMID: 1606397.
33. Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. *Eur Urol.* 1998 Aug;34(2):148-53. PMID: 9693251.
34. Amark P, Eksborg S, Juneskans O, et al. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. *Br J Urol.* 1998 Dec;82(6):859-64. PMID: 9883225.
35. Anderson CS, Jamrozik KD, Broadhurst RJ, et al. Predicting survival for 1 year among different subtypes of stroke. Results from the Perth Community Stroke Study. *Stroke.* 1994 Oct;25(10):1935-44. PMID: 8091436.
36. Anderson KD, Borisoff JF, Johnson RD, et al. The impact of spinal cord injury on sexual function: concerns of the general population. *Spinal Cord.* 2007 May;45(5):328-37. PMID: 17033620.
37. Angioli R, Zullo MA, Plotti F, et al. Urologic function and urodynamic evaluation of urinary diversion (Rome pouch) over time in gynecologic cancers patients. *Gynecol Oncol.* 2007 Nov;107(2):200-4. PMID: 17692906.
38. Arai Y, Okubo K, Aoki Y, et al. Patient-reported quality of life after radical prostatectomy for prostate cancer. *Int J Urol.* 1999 Feb;6(2):78-86. PMID: 10226812.
39. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. *J Neurol Neurosurg Psychiatry.* 2000 Apr;68(4):429-33. PMID: 10727477.
40. Aslan E, Komurcu N, Beji NK, et al. Bladder training and Kegel exercises for women with urinary complaints living in a rest home. *Gerontology.* 2008;54(4):224-31. PMID: 21084.

41. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. *J Urol*. 2003 Jun;169(6):2253-6. PMID: 12771763.
42. Augustin H, Pummer K, Daghofer F, et al. Patient self-reporting questionnaire on urological morbidity and bother after radical retropubic prostatectomy. *Eur Urol*. 2002 Aug;42(2):112-17. PMID: 12160580.
43. Autret E, Jonville AP, Dutertre JP, et al. Plasma levels of oxybutynine chloride in children. *Eur J Clin Pharmacol*. 1994;46(1):83-5. PMID: 8005192.
44. Yokoyama O, Yusup A, Oyama N, et al. Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. *Neurourol Urodyn*. 2006;25(5):461-7. PMID: 16673377.
45. Azuma R, Murakami K, Iwamoto M, et al. Prevalence and risk factors of urinary incontinence and its influence on the quality of life of Japanese women. *Nurs Health Sci*. 2008 Jun;10(2):151-8. PMID: 18466389.
46. Babu R. Effectiveness of tolterodine in nonneurogenic voiding dysfunction. *Indian Pediatr*. 2006 Nov;43(11):980-3. PMID: 17151401.
47. Bachmann CJ, Heilenkotter K, Janhsen E, et al. Long-term effects of a urotherapy training program in children with functional urinary incontinence: a 2-year follow-up. *Scandinavian Journal of Urology & Nephrology*. 2008;42(4):337-43. PMID: 21039.
48. Bael A, Lax H, de Jong TP, et al. The relevance of urodynamic studies for Urge syndrome and dysfunctional voiding: a multicenter controlled trial in children. *J Urol*. 2008 Oct;180(4):1486-93; discussion 94-5. PMID: 18710726.
49. Bael A, Winkler P, Lax H, et al. Behavior profiles in children with functional urinary incontinence before and after incontinence treatment. *Pediatrics*. 2008 May;121(5):e1196-200. PMID: 18450862.
50. Bales GT, Gerber GS, Minor TX, et al. Effect of preoperative biofeedback/pelvic floor training on continence in men undergoing radical prostatectomy. *Urology*. 2000 Oct 1;56(4):627-30. PMID: 11018619.
51. Barker J, Jr., Wallner K, Merrick G. Gross hematuria after prostate brachytherapy. *Urology*. 2003 Feb;61(2):408-11. PMID: 12597957.
52. Barreto F, Dall'Oglio M, Srougi M. Recurrent vesicourethral stenosis after radical prostatectomy: how to treat it? *Int Braz J Urol*. 2005 Nov-Dec;31(6):552-4. PMID: 16386124.
53. Barroso U, Jr., Nova T, Dultra A, et al. Comparative analysis of the symptomatology of children with lower urinary tract dysfunction in relation to objective data. *Int Braz J Urol*. 2006 Jan-Feb;32(1):70-6. PMID: 16519833.
54. Bassili A, Zaki A, Zaher SR, et al. Quality of care of children with chronic diseases in Alexandria, Egypt: the models of asthma, type I diabetes, epilepsy, and rheumatic heart disease. *Egyptian-Italian Collaborative Group on Pediatric Chronic Diseases. Pediatrics*. 2000 Jul;106(1):E12. PMID: 10878181.

55. Bastian PJ, Albers P, Haferkamp A, et al. Modified ureterosigmoidostomy (Mainz Pouch II) in different age groups and with different techniques of ureteric implantation. *BJU Int.* 2004 Aug;94(3):345-9. PMID: 15291865.
56. Bates TS, Wright MP, Gillatt DA. Prevalence and impact of incontinence and impotence following total prostatectomy assessed anonymously by the ICS-male questionnaire. *Eur Urol.* 1998;33(2):165-9. PMID: 9519358.
57. Bates-Jensen BM, Alessi CA, Al-Samarrai NR, et al. The effects of an exercise and incontinence intervention on skin health outcomes in nursing home residents. *J Am Geriatr Soc.* 2003 Mar;51(3):348-55. PMID: 12588578.
58. Batista JE, Bauer SB, Shefner JM, et al. Urodynamic findings in children with spinal cord ischemia. *J Urol.* 1995 Sep;154(3):1183-7. PMID: 7637085.
59. Bau MO, Younes S, Aupy A, et al. The Malone antegrade colonic enema isolated or associated with urological incontinence procedures: evaluation from patient point of view. *J Urol.* 2001 Jun;165(6 Pt 2):2399-403. PMID: 11371986.
60. Becmeur F, Demarche M, Lacreuse I, et al. Cecostomy button for antegrade enemas: survey of 29 patients. *J Pediatr Surg.* 2008 Oct;43(10):1853-7. PMID: 18926220.
61. Beguin AM, Combes T, Lutzler P, et al. Health education improves older subjects' attitudes toward urinary incontinence and access to care: a randomized study in sheltered accommodation centers for the aged. *J Am Geriatr Soc.* 1997 Mar;45(3):391-2. PMID: 9063297.
62. Beitz JM. Advanced practice nursing: wound, ostomy, continence: a role for the new century. *Pa Nurse.* 2006 Mar;61(1):22. PMID: 16625771.
63. Beitz JM, Zuzelo PR. The lived experience of having a neobladder. *West J Nurs Res.* 2003 Apr;25(3):294-316; discussion 7-21. PMID: 12705113.
64. Bellina M, Mari M, Ambu A, et al. Seminal monolateral nerve-sparing radical prostatectomy in selected patients. *Urol Int.* 2005;75(2):175-80. PMID: 16123574.
65. Belloli G, Campobasso P, Mercurella A. Neuropathic urinary incontinence in pediatric patients: management with artificial sphincter. *J Pediatr Surg.* 1992 Nov;27(11):1461-4. PMID: 1479510.
66. Bender CM, Engberg SJ, Donovan HS, et al. Symptom clusters in adults with chronic health problems and cancer as a comorbidity. *Oncol Nurs Forum.* 2008 Jan;35(1):E1-E11. PMID: 18192145.
67. Bennett RG, Baran PJ, DeVone LV, et al. Low airloss hydrotherapy versus standard care for incontinent hospitalized patients. *J Am Geriatr Soc.* 1998 May;46(5):569-76. PMID: 9588369.
68. Bentas W, Wolfram M, Jones J, et al. Robotic technology and the translation of open radical prostatectomy to laparoscopy: the early Frankfurt experience with robotic radical prostatectomy and one year follow-up. *Eur Urol.* 2003 Aug;44(2):175-81. PMID: 12875935.

69. Berger M, Wagner TH, Baker LC. Internet use and stigmatized illness. *Soc Sci Med*. 2005 Oct;61(8):1821-7. PMID: 16029778.
70. Berlowitz DR, Brandeis GH, Morris JN, et al. Deriving a risk-adjustment model for pressure ulcer development using the Minimum Data Set. *J Am Geriatr Soc*. 2001 Jul;49(7):866-71. PMID: 11527476.
71. Berlowitz DR, Young GJ, Hickey EC, et al. Clinical practice guidelines in the nursing home. *Am J Med Qual*. 2001 Nov-Dec;16(6):189-95. PMID: 11816849.
72. Berry T, Tepera C, Staneck D, et al. Is there correlation of nerve-sparing status and return to baseline urinary function after robot-assisted laparoscopic radical prostatectomy? *J Endourol*. 2009 Mar;23(3):489-93. PMID: 19265472.
73. Bertaccini A, Vassallo F, Martino F, et al. Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH. *Eur Urol*. 2001;40 Suppl 1:13-8. PMID: 11598348.
74. Bestmann B, Loetters C, Diemer T, et al. Prostate-specific symptoms of prostate cancer in a German general population. *Prostate Cancer Prostatic Dis*. 2007;10(1):52-9. PMID: 17102801.
75. Bharucha AE, Ravi K, Zinsmeister AR. Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. *Am J Physiol Gastrointest Liver Physiol*. 2010 Jul;299(1):G215-9. PMID: 20395537.
76. Bhattacharya S, Mollison J, Pinion S, et al. A comparison of bladder and ovarian function two years following hysterectomy or endometrial ablation. *Br J Obstet Gynaecol*. 1996 Sep;103(9):898-903. PMID: 8813310.
77. Bhojani N, Perrotte P, Jeldres C, et al. The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screening. *J Sex Med*. 2008 Mar;5(3):668-76. PMID: 18221289.
78. Bianco FJ, Jr., Riedel ER, Begg CB, et al. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. *J Urol*. 2005 Jun;173(6):2099-103. PMID: 15879851.
79. Bishoff JT, Motley G, Optenberg SA, et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. *J Urol*. 1998 Aug;160(2):454-8. PMID: 9679897.
80. Bjornsdottir LT, Geirsson RT, Jonsson PV. Urinary incontinence and urinary tract infections in octogenarian women. *Acta Obstet Gynecol Scand*. 1998 Jan;77(1):105-9. PMID: 9492729.
81. Black NA, Griffiths JM, Pope C, et al. Sociodemographic and symptomatic characteristics of women undergoing stress incontinence surgery in the UK. *Br J Urol*. 1996 Dec;78(6):847-55. PMID: 9014707.
82. Bo K, Haakstad LA. Is pelvic floor muscle training effective when taught in a general fitness class in pregnancy? A randomised controlled trial. *Physiotherapy*. 2011 Sep;97(3):190-5. PMID: 21820536.

83. Boemers TM. Urinary incontinence and vesicourethral dysfunction in pediatric surgical conditions. *Semin Pediatr Surg.* 2002 May;11(2):91-9. PMID: 11973761.
84. Bolduc S, Upadhyay J, Payton J, et al. The use of tolterodine in children after oxybutynin failure. *BJU Int.* 2003 Mar;91(4):398-401. PMID: 12603422.
85. Boone TB, Roehrborn CG, Hurt G. Transurethral intravesical electrotherapy for neurogenic bladder dysfunction in children with myelodysplasia: a prospective, randomized clinical trial. *J Urol.* 1992 Aug;148(2 Pt 2):550-4. PMID: 1640520.
86. Borawski KM, Grafstein NH, Webster GD. Management of Large Volume Post Prostatectomy Urinary Incontinence using a Single Cuff Artificial Urinary Sphincter. 2007 Annual Meeting of the American Urological Association (AUA 2007), Anaheim, California (USA), 19-24 May 2007.
87. Borchers H, Kirschner-Hermanns R, Brehmer B, et al. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results. *BJU Int.* 2004 Oct;94(6):805-11. PMID: 15476513.
88. Bossema E, Stiggelbout A, Baas-Thijssen M, et al. Patients' preferences for low rectal cancer surgery. *Eur J Surg Oncol.* 2008 Jan;34(1):42-8. PMID: 17905562.
89. Botros SM, Abramov Y, Miller JJ, et al. Effect of parity on sexual function: an identical twin study. *Obstet Gynecol.* 2006 Apr;107(4):765-70. PMID: 16582110.
90. Boyd BG, McCallum SW, Lewis RW, et al. Assessment of patient concern and adequacy of informed consent regarding infertility resulting from prostate cancer treatment. *Urology.* 2006 Oct;68(4):840-4. PMID: 17070364.
91. Boyd SD, Lieskovsky G, Skinner DG. Kock pouch bladder replacement. *Urol Clin North Am.* 1991 Nov;18(4):641-8. PMID: 1949397.
92. Boyle DJ, Prosser K, Allison ME, et al. Percutaneous tibial nerve stimulation for the treatment of urge fecal incontinence. *Dis Colon Rectum.* 2010 Apr;53(4):432-7. PMID: 20305443.
93. Bradley EB, Bissonette EA, Theodorescu D. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer. *BJU Int.* 2004 Nov;94(7):1003-9. PMID: 15541117.
94. Bradway C, Strumpf N. Seeking care: women's narratives concerning long-term urinary incontinence. *Urol Nurs.* 2008 Apr;28(2):123-9. PMID: 18488588.
95. Brady L. Prompted voiding yields results. CNAs are key to the success of a pilot study that reduced urinary incontinence for residents of one Illinois facility. *Provider.* 2009 Mar;35(3):41-4. PMID: 19326800.
96. Braekken IH, Majida M, Engh ME, et al. Can pelvic floor muscle training reverse pelvic organ prolapse and reduce prolapse symptoms? An assessor-blinded, randomized, controlled trial. *Am J Obstet Gynecol.* 2010 Aug;203(2):170 e1-7. PMID: 20435294.
97. Braslis KG, Santa-Cruz C, Brickman AL, et al. Quality of life 12 months after radical prostatectomy. *Br J Urol.* 1995 Jan;75(1):48-53. PMID: 7850295.

98. Brazier AM. Assessment of urinary incontinence in nursing homes: level 2. *Nurse Pract Forum*. 1994 Sep;5(3):158-62. PMID: 7950495.
99. Brendler C, Schlegel P, Dowd J, et al. Surgical treatment for benign prostatic hyperplasia. *Cancer*. 1992 Jul 1;70(1 Suppl):371-3. PMID: 1376210.
100. Brett TD. Patients' attitudes to prostate cancer. *Aust Fam Physician*. 1998 Jul;27 Suppl 2:S84-8. PMID: 9679361.
101. Breza J, Hornak M, Bardos A, et al. Transformation of the Bricker to a continent urinary reservoir to eliminate severe complications of uretero-ileostomy performed in eight patients among 200 Bricker. *Ann Urol (Paris)*. 1995;29(4):227-31. PMID: 8554293.
102. Brooks V. Treat incontinence early. *Nurs Stand*. 2002 May 1-7;16(33):22. PMID: 12035302.
103. Brown JA, Elliott DS, Barrett DM. Postprostatectomy urinary incontinence: a comparison of the cost of conservative versus surgical management. *Urology*. 1998 May;51(5):715-20. PMID: 9610584.
104. Brown JS, Vittinghoff E, Kanaya AM, et al. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. *Obstet Gynecol*. 2001 Dec;98(6):1045-52. PMID: 11755552.
105. Bruner DW, Hanlon A, Mazzoni S, et al. Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2004 Jan 1;58(1):34-42. PMID: 14697418.
106. Buchanan RJ, Choi M, Wang S, et al. Analyses of nursing home residents in hospice care using the minimum data set. *Palliat Med*. 2002 Nov;16(6):465-80. PMID: 12465693.
107. Buchanan RJ, Wang S, Huang C, et al. Profiles of nursing home residents with multiple sclerosis using the minimum data set. *Mult Scler*. 2001 Jun;7(3):189-200. PMID: 11475444.
108. Buchanan RJ, Wang S, Huang C, et al. Analyses of nursing home residents with Parkinson's disease using the minimum data set. *Parkinsonism Relat Disord*. 2002 Jun;8(5):369-80. PMID: 15177067.
109. Bunyavejchevin S, Veerananarapanich S. Quality of life assessment in Thai postmenopausal women with an overactive bladder. *J Med Assoc Thai*. 2005 Aug;88(8):1023-7. PMID: 16404827.
110. Burgio KL, Goode PS, Urban DA, et al. Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy incontinence: a randomized, controlled trial. *J Urol*. 2006 Jan;175(1):196-201; discussion PMID: 16406909.
111. Burgio LD, Engel BT, Hawkins A, et al. A staff management system for maintaining improvements in continence with elderly nursing home residents. *J Appl Behav Anal*. 1990 Spring;23(1):111-8. PMID: 2335482.
112. Buron C, Le Vu B, Cosset JM, et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. *Int J Radiat Oncol Biol Phys*. 2007 Mar 1;67(3):812-22. PMID: 17293235.

113. Burt J, Caelli K, Moore K, et al. Radical prostatectomy: men's experiences and postoperative needs. *J Clin Nurs*. 2005 Aug;14(7):883-90. PMID: 16000103.
114. Butler L, Downe-Wamboldt B, Marsh S, et al. Behind the scenes: partners' perceptions of quality of life post radical prostatectomy. *Urol Nurs*. 2000 Aug;20(4):254-8. PMID: 11998088.
115. Butler L, Downe-Wamboldt B, Marsh S, et al. Quality of life post radical prostatectomy: a male perspective. *Urol Nurs*. 2001 Aug;21(4):283-8. PMID: 11998457.
116. Butler WM, Merrick GS, Dorsey AT, et al. Modern prostate brachytherapy. *Med Dosim*. 2000 Fall;25(3):149-53. PMID: 11025262.
117. Byers PH, Ryan PA, Regan MB, et al. Effects of incontinence care cleansing regimens on skin integrity. *Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society / WOCN*; 1995. p. 187-92.
118. Cain MP, Wu SD, Austin PF, et al. Alpha blocker therapy for children with dysfunctional voiding and urinary retention. *J Urol*. 2003 Oct;170(4 Pt 2):1514-5; discussion 6-7. PMID: 14501648.
119. Campbell EB, Knight M, Benson M, et al. Effect of an incontinence training program on nursing home staff's knowledge, attitudes, and behavior. *Gerontologist*. 1991 Dec;31(6):788-94. PMID: 1800252.
120. Capitanucci ML, Camanni D, Demelas F, et al. Long-term efficacy of percutaneous tibial nerve stimulation for different types of lower urinary tract dysfunction in children. *J Urol*. 2009 Oct;182(4 Suppl):2056-61. PMID: 19695611.
121. Caplan GA, Ward JA, Brennan NJ, et al. Hospital in the home: a randomised controlled trial. *Med J Aust*. 1999 Feb 15;170(4):156-60. PMID: 10078179.
122. Cardenas DD, Topolski TD, White CJ, et al. Sexual functioning in adolescents and young adults with spina bifida. *Arch Phys Med Rehabil*. 2008 Jan;89(1):31-5. PMID: 18164327.
123. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. *J Urol*. 2005 Apr;173(4):1214-8. PMID: 15758755.
124. Caress JB, Kothari MJ, Bauer SB, et al. Urinary dysfunction in Duchenne muscular dystrophy. *Muscle Nerve*. 1996 Jul;19(7):819-22. PMID: 8965833.
125. Carr MC. Conservative nonsurgical management of spina bifida. *Curr Urol Rep*. 2010 Mar;11(2):109-13. PMID: 20425098.
126. Casale AJ, Metcalfe PD, Kaefer MA, et al. Total continence reconstruction: a comparison to staged reconstruction of neuropathic bowel and bladder. *J Urol*. 2006 Oct;176(4 Pt 2):1712-5. PMID: 16945629.
127. Castro-Gago M, Novo I, Cimadevila A, et al. Management of neurogenic bladder dysfunction secondary to myelomeningocele. *Eur J Pediatr*. 1990 Nov;150(1):62-5. PMID: 2079080.

128. Chakrabarty A, Hsiao KC, Mulcahy JJ. De Novo Double Cuff Artificial Urinary Sphincter (DCAUS), for Post- Prostatectomy Urinary Incontinence: Long-Term Subjective Results. 2007 Annual Meeting of the American Urological Association (AUA 2007), Anaheim, California (USA), 19-24 May 2007.
129. Chancellor MB, Bennett C, Simoneau AR, et al. Sphincteric stent versus external sphincterotomy in spinal cord injured men: prospective randomized multicenter trial. *J Urol.* 1999 Jun;161(6):1893-8. PMID: 10332461.
130. Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. *Br J Urol.* 1997 Jul;80(1):100-4. PMID: 9240187.
131. Chang PL, Tsai LH, Huang ST, et al. The early effect of pelvic floor muscle exercise after transurethral prostatectomy. *J Urol.* 1998 Aug;160(2):402-5. PMID: 9679887.
132. Chapple CR, Nilvebrant L. Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. *Drugs R D.* 2002;3(2):75-81. PMID: 12001821.
133. Chatwin NA, Ribordy M, Givel JC. Clinical outcomes and quality of life after low anterior resection for rectal cancer. *Eur J Surg.* 2002;168(5):297-301. PMID: 12375612.
134. Chaussy C, Thuroff S. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. *J Endourol.* 2001 May;15(4):437-40; discussion 47-8. PMID: 11394458.
135. Chen GD, Lin TL, Hu SW, et al. Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. *Neurourol Urodyn.* 2003;22(2):109-17. PMID: 12579627.
136. Chen KK, Chang LS, Chen MT. Neobladder construction using completely detubularized sigmoid colon after radical cystoprostatectomy. *J Urol.* 1991 Aug;146(2):311-5. PMID: 1856923.
137. Chen TY, Ponsot Y, Carmel M, et al. Multi-centre study of intraurethral valve-pump catheter in women with a hypocontractile or acontractile bladder. *Eur Urol.* 2005 Oct;48(4):628-33. PMID: 15964124.
138. Cheng H, Gurland BJ, Maurer MS. Self-reported lack of energy (anergia) among elders in a multiethnic community. *J Gerontol A Biol Sci Med Sci.* 2008 Jul;63(7):707-14. PMID: 18693225.
139. Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. *J Auton Pharmacol.* 2001 Oct-Dec;21(5-6):243-8. PMID: 12123469.
140. Chiarelli P, Murphy B, Cockburn J. Acceptability of a urinary continence promotion programme to women in postpartum. *BJOG.* 2003 Feb;110(2):188-96. PMID: 12618164.
141. Chin-Peuckert L, Rennick JE, Jednak R, et al. Should warm infusion solution be used for urodynamic studies in children? A prospective randomized study. *The Journal of urology;* 2004. p. 1657-61; discussion 61.

142. Chopra B, Barrick SR, Meyers S, et al. Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. *J Physiol.* 2005 Feb 1;562(Pt 3):859-71. PMID: 15576455.
143. Christie D, Denham J, Steigler A, et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. *Radiother Oncol.* 2005 Nov;77(2):117-25. PMID: 16271786.
144. Chuang YC, Fraser MO, Yu Y, et al. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. *J Urol.* 2001 Mar;165(3):975-9. PMID: 11176525.
145. Chun FK, Walz J, Gallina A, et al. Stress Urinary Incontinence and Erectile Dysfunction in a Prostate Cancer Screening Cohort. 2007 Annual Meeting of the American Urological Association (AUA 2007), Anaheim, California (USA), 19-24 May 2007.
146. Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. *J Endourol.* 2003 Mar;17(2):103-7. PMID: 12689404.
147. Citterio A, Franceschini M, Spizzichino L, et al. Nontraumatic spinal cord injury: an Italian survey. *Arch Phys Med Rehabil.* 2004 Sep;85(9):1483-7. PMID: 15375821.
148. Clancy B, Malone-Lee J. Reducing the leakage of body-worn incontinence pads. *J Adv Nurs.* 1991 Feb;16(2):187-93. PMID: 2013661.
149. Clark JA, Bokhour BG, Inui TS, et al. Measuring patients' perceptions of the outcomes of treatment for early prostate cancer. *Med Care.* 2003 Aug;41(8):923-36. PMID: 12886172.
150. Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. *Med Care.* 2001 Oct;39(10):1118-30. PMID: 11567174.
151. Clayman C, Thompson V, Forth H. Development of a continence assessment pathway in acute care. *Nursing times.* 2005 May 3-9;101(18):46-8. PMID: 21126.
152. Coffey A, McCarthy G, McCormack B, et al. Incontinence: assessment, diagnosis, and management in two rehabilitation units for older people. *Worldviews Evid Based Nurs.* 2007;4(4):179-86. PMID: 18076461.
153. Cohen SJ, Robinson D, Dugan E, et al. Communication between older adults and their physicians about urinary incontinence. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences.* 1999 Jan;54(1):M34-7. PMID: 21160.
154. Cohn JH, El-Galley R. Radical prostatectomy in a community practice. *J Urol.* 2002 Jan;167(1):224-8. PMID: 11743311.
155. Colombo T, Augustin H, Breinl E, et al. The use of polydimethylsiloxane in the treatment of incontinence after radical prostatectomy. *Br J Urol.* 1997 Dec;80(6):923-6. PMID: 9439411.

156. Connor JP, Betrus G, Fleming P, et al. Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients. *J Urol*. 1994 Apr;151(4):1045-7. PMID: 8126787.
157. Cooper P, Gray D. Comparison of two skin care regimes for incontinence. *Br J Nurs*. 2001 Mar;10(6 Suppl):S6, S8, S10 passim. PMID: 12070396.
158. Cooperberg MR, Master VA, Carroll PR. Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. *J Urol*. 2003 Aug;170(2 Pt 1):512-5. PMID: 12853811.
159. Cramer EH, Jones P, Keenan NL, et al. Is naturopathy as effective as conventional therapy for treatment of menopausal symptoms? *J Altern Complement Med*. 2003 Aug;9(4):529-38. PMID: 14499029.
160. Creasey GH, Kilgore KL, Brown-Triolo DL, et al. Reduction of costs of disability using neuroprostheses. *Assist Technol*. 2000;12(1):67-75. PMID: 11067579.
161. Cucchi A, Quaglini S, Rovereto B. Relationships between micturition urgency and involuntary voiding dynamics in men with urinary incontinence from idiopathic detrusor overactivity. *J Urol*. 2007 Aug;178(2):563-7; discussion 7. PMID: 17570436.
162. Cullen B. Roles for the WOC nurse in a disaster. *J Wound Ostomy Continence Nurs*. 2008 May-Jun;35(3):282-6. PMID: 18496084.
163. Culligan PJ, Myers JA, Goldberg RP, et al. Elective cesarean section to prevent anal incontinence and brachial plexus injuries associated with macrosomia--a decision analysis. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Jan-Feb;16(1):19-28; discussion PMID: 15647962.
164. Cummings V, Holt R, van der Sloot C, et al. Costs and management of urinary incontinence in long-term care. *J Wound Ostomy Continence Nurs*. 1995 Jul;22(4):193-8. PMID: 7627295.
165. Cunningham RS. Clinical practice guideline use by oncology advanced practice nurses. *Applied Nursing Research*. 2006 Aug;19(3):126-33. PMID: 21152.
166. Cusick G, Birkett A, Clarke-O'Neill S, et al. A system for logging incontinence events using a simple disposable sensor. *Proc Inst Mech Eng [H]*. 2003;217(4):305-10. PMID: 12885201.
167. Dahlen HG, Homer CS, Cooke M, et al. Perineal outcomes and maternal comfort related to the application of perineal warm packs in the second stage of labor: a randomized controlled trial. *Birth*. 2007 Dec;34(4):282-90. PMID: 18021143.
168. Dalkin BL, Christopher BA, Shawler D. Health related quality of life outcomes after radical prostatectomy: attention to study design and the patient-based importance of single-surgeon studies. *Urol Oncol*. 2006 Jan-Feb;24(1):28-32. PMID: 16414489.
169. Dalkin BL, Wessells H, Cui H. A national survey of urinary and health related quality of life outcomes in men with an artificial urinary sphincter for post-radical prostatectomy incontinence. *J Urol*. 2003 Jan;169(1):237-9. PMID: 12478144.

170. Damen-Elias HA, Luijnenburg SE, Visser GH, et al. Mild pyelectasis diagnosed by prenatal ultrasound is not a predictor of urinary tract morbidity in childhood. *Prenat Diagn.* 2005 Dec;25(13):1239-47. PMID: 16353272.
171. Damon H, Schott AM, Barth X, et al. Clinical characteristics and quality of life in a cohort of 621 patients with faecal incontinence. *Int J Colorectal Dis.* 2008 Sep;23(9):845-51. PMID: 18506453.
172. Das AK, Carlson AM, Hull M. Improvement in depression and health-related quality of life after sacral nerve stimulation therapy for treatment of voiding dysfunction. *Urology.* 2004 Jul;64(1):62-8. PMID: 15245937.
173. Das P, Smith JJ, Tekkis PP, et al. Quality of life after indefinite diversion/pouch excision in ileal pouch failure patients. *Colorectal Dis.* 2007 Oct;9(8):718-24. PMID: 17764535.
174. Dave S, Grover VP, Agarwala S, et al. The role of imipramine therapy in bladder exstrophy after bladder neck reconstruction. *BJU Int.* 2002 Apr;89(6):557-60; discussion 60-1. PMID: 11942963.
175. Davila HH, Weber T, Burday D, et al. Total or partial prostate sparing cystectomy for invasive bladder cancer: long-term implications on erectile function. *BJU Int.* 2007 Nov;100(5):1026-9. PMID: 17868423.
176. Davison BJ, Goldenberg SL. Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer. *BJU Int.* 2003 Jan;91(1):14-7. PMID: 12614242.
177. Day PL. Findings of a three-year retrospective study to investigate prevalence and incidence of urinary incontinence and overactive bladder in a typical managed care setting. *Pharm Pract Manag Q.* 2000 Apr;20(1):1-11. PMID: 10947537.
178. de Aloysio D, Altieri P, Penacchioni P, et al. Premenopause-dependent changes. *Gynecol Obstet Invest.* 1996;42(2):120-7. PMID: 8878718.
179. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. *Int J Geriatr Psychiatry.* 2004 Feb;19(2):115-26. PMID: 14758577.
180. De E, Pisters LL, Pettaway CA, et al. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient reported continence outcomes at 32 months. *J Urol.* 2007 Jun;177(6):2200-4; discussion 4. PMID: 17509319.
181. De Gennaro M, Capitanucci ML, Mastracci P, et al. Percutaneous tibial nerve neuromodulation is well tolerated in children and effective for treating refractory vesical dysfunction. *J Urol.* 2004 May;171(5):1911-3. PMID: 15076308.
182. de Kort LM, Klijn AJ, Dik P, et al. Oxybutynin for diagnosis of infravesical obstruction in boys with urinary incontinence. *Urology.* 2003 Jul;62(1):127-30; discussion 30-1. PMID: 12837438.
183. de la Portilla F, Rada R, Vega J, et al. Evaluation of the use of posterior tibial nerve stimulation for the treatment of fecal incontinence: preliminary results of a prospective study. *Dis Colon Rectum.* 2009 Aug;52(8):1427-33. PMID: 19617756.

184. de Leval J, Waltregny D. The inside-out trans-obturator sling: a novel surgical technique for the treatment of male urinary incontinence. *Eur Urol.* 2008 Nov;54(5):1051-65. PMID: 18036729.
185. de Reijke TM, de Boer EC, Kurth KH, et al. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. *J Urol.* 1996 Feb;155(2):477-82. PMID: 8558640.
186. de Sèze M, Wiart L, Joseph PA, et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. *Neurourology and urodynamics.* 1998(5):513-23. PMID: 9776014.
187. Del Priore G, Taylor SY, Esdaile BA, et al. Urinary incontinence in gynecological oncology patients. *Int J Gynecol Cancer.* 2005 Sep-Oct;15(5):911-4. PMID: 16174244.
188. DeLancey JO, Sampsel CM, Punch MR. Kegel dyspareunia: levator ani myalgia caused by overexertion. *Obstet Gynecol.* 1993 Oct;82(4 Pt 2 Suppl):658-9. PMID: 8378003.
189. Deliveliotis C, Delis A, Papatsoris A, et al. Local steroid application during nerve-sparing radical retropubic prostatectomy. *BJU Int.* 2005 Sep;96(4):533-5. PMID: 16104905.
190. Deliveliotis C, Liakouras C, Delis A, et al. Prostate operations: long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population. *Urol Res.* 2004 Aug;32(4):283-9. PMID: 15057494.
191. Delo DM, Eberli D, Williams JK, et al. Angiogenic gene modification of skeletal muscle cells to compensate for ageing-induced decline in bioengineered functional muscle tissue. *BJU Int.* 2008 Sep;102(7):878-84. PMID: 18489526.
192. Demirkesen O, Onal B, Tunc B, et al. Assessment of the continence status and patients' satisfaction after retropubic radical prostatectomy: a questionnaire based study. *Int Urol Nephrol.* 2007;39(2):531-6. PMID: 17006734.
193. Denberg TD, Flanigan RC, Kim FJ, et al. Self-reported volume of radical prostatectomies among urologists in the USA. *BJU Int.* 2007 Feb;99(2):339-43. PMID: 17155974.
194. Derikx JP, De Backer A, van de Schoot L, et al. Long-term functional sequelae of sacrococcygeal teratoma: a national study in The Netherlands. *J Pediatr Surg.* 2007 Jun;42(6):1122-6. PMID: 17560233.
195. Dickersin K, Munro M, Langenberg P, et al. Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB): design and methods. *Control Clin Trials.* 2003 Oct;24(5):591-609. PMID: 14500057.
196. Dietz V, Huisman M, de Jong JM, et al. Functional outcome after sacrospinous hysteropexy for uterine descensus. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Jun;19(6):747-52. PMID: 18297228.
197. Dinc A, Kizilkaya Beji N, Yalcin O. Effect of pelvic floor muscle exercises in the treatment of urinary incontinence during pregnancy and the postpartum period. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009 Oct;20(10):1223-31. PMID: 19649552.
198. Dingwall L, McLafferty E. Do nurses promote urinary continence in hospitalized older people?: An exploratory study. *J Clin Nurs.* 2006 Oct;15(10):1276-86. PMID: 16968432.

199. Djaladat H, Mehra A, Saraji A, et al. Suprapubic prostatectomy with a novel catheter. *J Urol*. 2006 Jun;175(6):2083-6. PMID: 16697808.
200. Dobson P, David J. Developing integrated paediatric continence services. *Nurs Times*. 2006 Jan 10-16;102(2):42-3. PMID: 16429691.
201. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2001 May 8;56(9):1154-66. PMID: 11342679.
202. Dorey G, Glazener C, Buckley B, et al. Developing a pelvic floor muscle training regimen for use in a trial intervention. *Physiotherapy*. 2009 Sep;95(3):199-209. PMID: 19635340.
203. Dorey G, Speakman M, Feneley R, et al. Pelvic floor exercises for treating post-micturition dribble in men with erectile dysfunction: a randomized controlled trial. *Urologic Nursing*. 2004 512; Dec;24(6):490-7. PMID: 21127.
204. Dosa D, Bowers B, Gifford DR. Critical review of resident assessment protocols. *J Am Geriatr Soc*. 2006 Apr;54(4):659-66. PMID: 16686879.
205. Dowd T, Kolcaba K, Steiner R. Correlations among measures of bladder function and comfort. *J Nurs Meas*. 2002 Spring-Summer;10(1):27-38. PMID: 12048966.
206. Downs TM, Sadetsky N, Pasta DJ, et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE. *J Urol*. 2003 Nov;170(5):1822-7. PMID: 14532784.
207. Du C, Jin X, Bai F, et al. Holmium laser enucleation of the prostate: the safety, efficacy, and learning experience in China. *J Endourol*. 2008 May;22(5):1031-6. PMID: 18377236.
208. DuBeau CE, Ouslander JG, Palmer MH. Knowledge and attitudes of nursing home staff and surveyors about the revised federal guidance for incontinence care. *Gerontologist*. 2007 Aug;47(4):468-79. PMID: 17766668.
209. Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. *J Am Geriatr Soc*. 2006 Sep;54(9):1325-33. PMID: 16970638.
210. Dubow JS. Autonomic dysfunction in Parkinson's disease. *Dis Mon*. 2007 May;53(5):265-74. PMID: 17656188.
211. Due U, Ottesen M. The Danish anal sphincter rupture questionnaire: validity and reliability. *Acta Obstet Gynecol Scand*. 2009;88(1):36-42. PMID: 19023680.
212. Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. *J Am Geriatr Soc*. 2000 Apr;48(4):413-6. PMID: 10798468.
213. Dumoulin C, Bourbonnais D, Morin M, et al. Predictors of success for physiotherapy treatment in women with persistent postpartum stress urinary incontinence. *Arch Phys Med Rehabil*. 2010 Jul;91(7):1059-63. PMID: 20537314.

214. Edwards DF, Hahn M, Dromerick A. Post stroke urinary loss, incontinence and life satisfaction: when does post-stroke urinary loss become incontinence? *Neurourol Urodyn*. 2006;25(1):39-45. PMID: 16299814.
215. Edwards NI, Jones D. The prevalence of faecal incontinence in older people living at home. *Age Ageing*. 2001 Nov;30(6):503-7. PMID: 11742780.
216. Eekhof J, De Bock G, Schaapveld K, et al. Effects of screening for disorders among the elderly: an intervention study in general practice. *Fam Pract*. 2000 Aug;17(4):329-33. PMID: 10934182.
217. Ehlert FJ, Griffin MT, Abe DM, et al. The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. *J Pharmacol Exp Ther*. 2005 Apr;313(1):368-78. PMID: 15608083.
218. Eilber KS. Stress Urinary Incontinence Following Transurethral Resection of the Prostate in Patients who have Undergone Radiation Therapy for Prostate Cancer. 82nd Annual Meeting of the Western Section American Urological Association (MAUI 2006), Hyatt Regency, Maui, Hawaii (USA), 22-27 Oct 2006.
219. Eisenberg ML, Elliott SP, McAninch JW. Preservation of lower urinary tract function in posterior urethral stenosis: selection of appropriate patients for urethral stents. *J Urol*. 2007 Dec;178(6):2456-60; discussion 60-1. PMID: 17937962.
220. Ellsworth PI, Webb HW, Crump JM, et al. The Malone antegrade colonic enema enhances the quality of life in children undergoing urological incontinence procedures. *J Urol*. 1996 Apr;155(4):1416-8. PMID: 8632601.
221. Emberton M, Neal DE, Black N, et al. The effect of prostatectomy on symptom severity and quality of life. *Br J Urol*. 1996 Feb;77(2):233-47. PMID: 8800892.
222. Engstrom G, Henningsohn L, Walker-Engstrom ML, et al. Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. *Scand J Urol Nephrol*. 2006;40(6):485-94. PMID: 17130101.
223. Engstrom G, Walker-Engstrom ML, Henningsohn L, et al. Prevalence of distress and symptom severity from the lower urinary tract in men: a population-based study with the DAN-PSS questionnaire. *Fam Pract*. 2004 Dec;21(6):617-22. PMID: 15465878.
224. Ercolano E. Follow up of men post-prostatectomy: who is responsible? *Urol Nurs*. 2008 Oct;28(5):370-7; discussion 8-80. PMID: 18980103.
225. Ethans KD, Nance PW, Bard RJ, et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. *J Spinal Cord Med*. 2004;27(3):214-8. PMID: 15478523.
226. Ewings P, Spencer S, Marsh H, et al. Obstetric risk factors for urinary incontinence and preventative pelvic floor exercises: cohort study and nested randomized controlled trial. *J Obstet Gynaecol*. 2005 Aug;25(6):558-64. PMID: 16234140.
227. Fader M, Macaulay M, Pettersson L, et al. A multi-centre evaluation of absorbent products for men with light urinary incontinence. *Neurourol Urodyn*. 2006;25(7):689-95. PMID: 17009303.

228. Fader M, Pettersson L, Dean G, et al. Sheaths for urinary incontinence: a randomized crossover trial. *BJU Int.* 2001 Sep;88(4):367-72. PMID: 11564023.
229. Faria CA, Sartori MG, Baracat EC, et al. Effects of tamoxifen on Doppler velocimetry parameters of periurethral vessels in postmenopausal women. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005 Jan-Feb;16(1):56-9; discussion 9. PMID: 15338114.
230. Feigenberg SJ, Lee WR, Desilvio ML, et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. *Int J Radiat Oncol Biol Phys.* 2005 Jul 15;62(4):956-64. PMID: 15989995.
231. Fenner DE, Genberg B, Brahma P, et al. Fecal and urinary incontinence after vaginal delivery with anal sphincter disruption in an obstetrics unit in the United States. *Am J Obstet Gynecol.* 2003 Dec;189(6):1543-9; discussion 9-50. PMID: 14710059.
232. Ferrer M, Suarez JF, Guedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys.* 2008 Oct 1;72(2):421-32. PMID: 18325680.
233. Ficarra V, Novara G, Galfano A, et al. Twelve-month self-reported quality of life after retropubic radical prostatectomy: a prospective study with Rand 36-Item Health Survey (Short Form-36). *BJU Int.* 2006 Feb;97(2):274-8. PMID: 16430628.
234. Filocamo MT, Li Marzi V, Del Popolo G, et al. Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence. *Eur Urol.* 2005 Nov;48(5):734-8. PMID: 16002204.
235. Filocamo MT, Li Marzi V, Del Popolo G, et al. Pharmacologic treatment in postprostatectomy stress urinary incontinence. *European urology.* 2007 Jun;51(6):1559-64. PMID: 21143.
236. Fink HA, Taylor BC, Tacklind JW, et al. Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials. *Mayo Clin Proc.* 2008 Dec;83(12):1332-43. PMID: 19046552.
237. Finkelstein MM, Skelly J, Kaczorowski J, et al. Incontinence Quality of Life Instrument in a survey of primary care physicians. *J Fam Pract.* 2002 Nov;51(11):952. PMID: 12485550.
238. Finne-Soveri H, Sorbye LW, Jonsson PV, et al. Increased work-load associated with faecal incontinence among home care patients in 11 European countries. *Eur J Public Health.* 2008 Jun;18(3):323-8. PMID: 17766995.
239. Fitzgerald MP, Thom DH, Wassel-Fyr C, et al. Childhood urinary symptoms predict adult overactive bladder symptoms. *J Urol.* 2006 Mar;175(3 Pt 1):989-93. PMID: 16469599.
240. Fleshner N, Herschorn S. The artificial urinary sphincter for post-radical prostatectomy incontinence: impact on urinary symptoms and quality of life. *J Urol.* 1996 Apr;155(4):1260-4. PMID: 8632546.

241. Floratos DL, Sonke GS, Rapidou CA, et al. Biofeedback vs verbal feedback as learning tools for pelvic muscle exercises in the early management of urinary incontinence after radical prostatectomy. *BJU Int.* 2002 May;89(7):714-9. PMID: 11966630.
242. Fonda D, Woodward M, D'Astoli M, et al. Sustained improvement of subjective quality of life in older community-dwelling people after treatment of urinary incontinence. *Age Ageing.* 1995 Jul;24(4):283-6. PMID: 7484483.
243. Fontaine E, Ben Mouelli S, Thomas L, et al. Urinary continence after salvage radiation therapy following radical prostatectomy, assessed by a self-administered questionnaire: a prospective study. *BJU Int.* 2004 Sep;94(4):521-3. PMID: 15329104.
244. Forbes A, While A, Mathes L, et al. Health problems and health-related quality of life in people with multiple sclerosis. *Clin Rehabil.* 2006 Jan;20(1):67-78. PMID: 16502752.
245. Forster JA, Thomas WM. Patient preferences and side effects experienced with oral bowel preparations versus self-administered phosphate enema. *Ann R Coll Surg Engl.* 2003 May;85(3):185-6. PMID: 12831492.
246. Fowler FJ, Jr., Barry MJ, Lu-Yao G, et al. Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. *Urology.* 1995 Jun;45(6):1007-13; discussion 13-5. PMID: 7771002.
247. Fowler FJ, Jr., Barry MJ, Lu-Yao G, et al. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. *J Clin Oncol.* 1996 Aug;14(8):2258-65. PMID: 8708715.
248. Franco I, Landau-Dyer L, Isom-Batz G, et al. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children. *Journal of Urology.* 2007 discussion 1779-80; Oct;178(4 Pt 2):1775-9. PMID: 21141.
249. Frank SJ, Pisters LL, Davis J, et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. *J Urol.* 2007 Jun;177(6):2151-6; discussion 6. PMID: 17509305.
250. Franke JJ, Gilbert WB, Grier J, et al. Early post-prostatectomy pelvic floor biofeedback. *J Urol.* 2000 Jan;163(1):191-3. PMID: 10604344.
251. Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. *J Clin Psychiatry.* 2004 Dec;65(12):1660-5. PMID: 15641871.
252. Fransson P. Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer--15 years' follow-up. A comparison with age-matched controls. *Acta Oncol.* 2008;47(5):852-61. PMID: 17899451.
253. Fransson P, Damber JE, Tomic R, et al. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. *Cancer.* 2001 Dec 15;92(12):3111-9. PMID: 11753990.

254. Frantz RA, Xakellis GC, Jr., Harvey PC, et al. Implementing an incontinence management protocol in long-term care. Clinical outcomes and costs. *J Gerontol Nurs.* 2003 Aug;29(8):46-53. PMID: 13677160.
255. Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 Nov;17(6):636-41. PMID: 16552618.
256. Freundl M, Dugan J. Urinary incontinence in the elderly: knowledge and attitude of long-term care staff. *Geriatr Nurs.* 1992 Mar-Apr;13(2):70-5. PMID: 1321083.
257. Frimberger D, Gearhart JP, Mathews R. Female exstrophy: failure of initial reconstruction and its implications for continence. *J Urol.* 2003 Dec;170(6 Pt 1):2428-31. PMID: 14634445.
258. Frimberger D, Lakshmanan Y, Gearhart JP. Continent urinary diversions in the exstrophy complex: why do they fail? *J Urol.* 2003 Oct;170(4 Pt 1):1338-42. PMID: 14501765.
259. Fulmer BR, Bissonette EA, Petroni GR, et al. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. *Cancer.* 2001 Jun 1;91(11):2046-55. PMID: 11391584.
260. Furst CJ. Radiotherapy for cancer. Quality of life. *Acta Oncol.* 1996;35 Suppl 7:141-8. PMID: 9154107.
261. Furuta A, Jankowski RJ, Pruchnic R, et al. Physiological effects of human muscle-derived stem cell implantation on urethral smooth muscle function. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Sep;19(9):1229-34. PMID: 18421407.
262. Gallagher BL, Dwyer NT, Gaynor-Krupnick DM, et al. Objective and quality-of-life outcomes with bone-anchored male bulbourethral sling. *Urology.* 2007 Jun;69(6):1090-4. PMID: 17572193.
263. Gallo M, Staskin DR. Patient satisfaction with a reusable undergarment for urinary incontinence. *J Wound Ostomy Continence Nurs.* 1997 Jul;24(4):226-36. PMID: 9274280.
264. Gallo ML, Fallon PJ. Evaluation of a pelvic floor treatment plan for patients undergoing radical prostatectomy. *Urol Nurs.* 1996 Mar;16(1):9-13. PMID: 8826389.
265. Gallucci M, Puppo P, Perachino M, et al. Transurethral electrovaporization of the prostate vs. transurethral resection. Results of a multicentric, randomized clinical study on 150 patients. *Eur Urol.* 1998;33(4):359-64. PMID: 9612677.
266. Game X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. *Eur Urol.* 2008 Mar;53(3):613-8. PMID: 17804150.
267. Ganta SB, Chakravarti A, Somani B, et al. Removal of catheter at midnight versus early morning: the patients' perspective. *Urol Int.* 2005;75(1):26-9. PMID: 16037704.

268. Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. *J Natl Cancer Inst.* 2002 Jan 2;94(1):39-49. PMID: 11773281.
269. Ganz PA, Greendale GA, Kahn B, et al. Are older breast carcinoma survivors willing to take hormone replacement therapy? *Cancer.* 1999 Sep 1;86(5):814-20. PMID: 10463980.
270. Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. *J Natl Cancer Inst.* 2000 Jul 5;92(13):1054-64. PMID: 10880548.
271. Gardner BG, Zietman AL, Shipley WU, et al. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. *J Urol.* 2002 Jan;167(1):123-6. PMID: 11743288.
272. Gearhart SL, Pannu HK, Cundiff GW, et al. Perineal descent and levator ani hernia: a dynamic magnetic resonance imaging study. *Dis Colon Rectum.* 2004 Aug;47(8):1298-304. PMID: 15484342.
273. Geary ES, Dendinger TE, Freiha FS, et al. Nerve sparing radical prostatectomy: a different view. *J Urol.* 1995 Jul;154(1):145-9. PMID: 7776409.
274. Ghaly M, Wallner K, Merrick G, et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. *Int J Radiat Oncol Biol Phys.* 2003 Apr 1;55(5):1288-93. PMID: 12654439.
275. Ghoniem GM, Bryan W. Male perineal sling. *Tech Urol.* 2001 Sep;7(3):229-32. PMID: 11575520.
276. Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. *J Urol.* 2002 Apr;167(4):1710-4. PMID: 11912393.
277. Giberti C, Gallo F, Schenone M, et al. The bone-anchor sub-urethral sling for the treatment of iatrogenic male incontinence: subjective and objective assessment after 41 months of mean follow-up. *World J Urol.* 2008 Apr;26(2):173-8. PMID: 17982750.
278. Giberti C, Gallo F, Schenone M, et al. The bone anchor suburethral synthetic sling for iatrogenic male incontinence: critical evaluation at a mean 3-year followup. *J Urol.* 2009 May;181(5):2204-8. PMID: 19296976.
279. Gilbert R, Glen M. Implementing an NHS continence service for nursing home residents. *Prof Nurse.* 2004 Nov;20(3):35-7. PMID: 15552438.
280. Gilbert SM, Wood DP, Dunn RL, et al. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). *Cancer.* 2007 May 1;109(9):1756-62. PMID: 17366596.
281. Gilling P, Tu L, Nash S, et al. The Proact Adjustable Continence Therapy Device for the Treatment of Postprostatectomy Stress Urinary Incontinence. 26th World Congress of Endourology (WCE 26), Shanghai International Convention Center (SICC), Shanghai (China), 30 Nov-3 Dec 2008.

282. Gilling PJ, Bell DF, Wilson LC, et al. An adjustable continence therapy device for treating incontinence after prostatectomy: a minimum 2-year follow-up. *BJU Int.* 2008 Nov;102(10):1426-30; discussion 30-1. PMID: 18564132.
283. Gimbel H, Zobbe V, Andersen BJ, et al. Lower urinary tract symptoms after total and subtotal hysterectomy: results of a randomized controlled trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005 Jul-Aug;16(4):257-62. PMID: 16220584.
284. Gimbel H, Zobbe V, Andersen BM, et al. Randomised controlled trial of total compared with subtotal hysterectomy with one-year follow up results. *BJOG.* 2003 Dec;110(12):1088-98. PMID: 14664880.
285. Giramonti KM, Kogan BA, Halpern LF. The effects of anticholinergic drugs on attention span and short-term memory skills in children. *Neurourol Urodyn.* 2008;27(4):315-8. PMID: 17828786.
286. Gladh G, Eldh M, Mattsson S. Quality of life in neurologically healthy children with urinary incontinence. *Acta Paediatr.* 2006 Dec;95(12):1648-52. PMID: 17129976.
287. Glazener CM, Herbison GP, MacArthur C, et al. Randomised controlled trial of conservative management of postnatal urinary and faecal incontinence: six year follow up. *BMJ.* 2005 Feb 12;330(7487):337. PMID: 15615766.
288. Glazener CM, Herbison GP, Wilson PD, et al. Conservative management of persistent postnatal urinary and faecal incontinence: randomised controlled trial. *BMJ.* 2001 Sep 15;323(7313):593-6. PMID: 11557703.
289. Goeman L, Salomon L, La De Taille A, et al. Long-term functional and oncological results after retroperitoneal laparoscopic prostatectomy according to a prospective evaluation of 550 patients. *World J Urol.* 2006 Aug;24(3):281-8. PMID: 16508788.
290. Gold MF. Restoring dignity. *Provider.* 1992 Apr;18(4):16-8, 20, 2-4. PMID: 10117297.
291. Gomes CM, Broderick GA, Sanchez-Ortiz RF, et al. Artificial urinary sphincter for post-prostatectomy incontinence: impact of prior collagen injection on cost and clinical outcome. *J Urol.* 2000 Jan;163(1):87-90. PMID: 10604321.
292. Gomes CM, Hisano M, Machado LR, et al. Urological manifestations of chronic schistosomal myeloradiculopathy. *BJU Int.* 2005 Oct;96(6):853-6. PMID: 16153216.
293. Gomha MA, Boone TB. Artificial urinary sphincter for post-prostatectomy incontinence in men who had prior radiotherapy: a risk and outcome analysis. *J Urol.* 2002 Feb;167(2 Pt 1):591-6. PMID: 11792924.
294. Gonzalez-Argente FX, Jain A, Nogueras JJ, et al. Prevalence and severity of urinary incontinence and pelvic genital prolapse in females with anal incontinence or rectal prolapse. *Dis Colon Rectum.* 2001 Jul;44(7):920-6. PMID: 11496068.
295. Goode PS, Burgio KL, Redden DT, et al. Population based study of incidence and predictors of urinary incontinence in black and white older adults. *J Urol.* 2008 Apr;179(4):1449-53; discussion 53-4. PMID: 18295279.

296. Gopal M, Sammel MD, Arya LA, et al. Association of change in estradiol to lower urinary tract symptoms during the menopausal transition. *Obstet Gynecol*. 2008 Nov;112(5):1045-52. PMID: 18978104.
297. Gosney M. General care of the older cancer patient. *Clin Oncol (R Coll Radiol)*. 2009 Mar;21(2):86-91. PMID: 19059769.
298. Gotoh M, Mizutani K, Furukawa T, et al. Quality of micturition in male patients with orthotopic neobladder replacement. *World J Urol*. 2000 Dec;18(6):411-6. PMID: 11204260.
299. Gotoh M, Yoshikawa Y, Ohshima S. Pathophysiology and subjective symptoms in women with impaired bladder emptying. *Int J Urol*. 2006 Aug;13(8):1053-7. PMID: 16903929.
300. Govaert B, Pares D, Delgado-Aros S, et al. A prospective multicentre study to investigate percutaneous tibial nerve stimulation for the treatment of faecal incontinence. *Colorectal Dis*. 2010 Dec;12(12):1236-41. PMID: 19674028.
301. Gozzi C, Schwentner C, Rehder P. Principles of Anatomy for Male Transobturator Tape (TOT) Suspension for the Treatment of Post-Prostatectomy Urinary Incontinence. 2006 Annual Meeting of the American Urological Association (AUA 2006), Atlanta, Georgia (USA), 20-25 May 2006.
302. Gralnek D, Wessells H, Cui H, et al. Differences in sexual function and quality of life after nerve sparing and nonnerve sparing radical retropubic prostatectomy. *J Urol*. 2000 Apr;163(4):1166-9; discussion 9-70. PMID: 10737488.
303. Gray M. Context for WOC practice: bowel & bladder management. *J Wound Ostomy Continence Nurs*. 2007 Nov-Dec;34(6):592-4. PMID: 18030095.
304. Gray M. Context for WOC practice: diabetic foot care, ostomy complications and pouch wear time, continence pad use, and challenges in research. Editorial. *J Wound Ostomy Continence Nurs*. 2008 Sep-Oct;35(5):458-60. PMID: 18794695.
305. Green JP, Smoker I, Ho MT, et al. Urinary incontinence in subacute care--a retrospective analysis of clinical outcomes and costs. *Med J Aust*. 2003 Jun 2;178(11):550-3. PMID: 12765502.
306. Greenberger M, Steiner MS. The University of Tennessee experience with the Indigo 830e laser device for the minimally invasive treatment of benign prostatic hyperplasia: interim analysis. *World J Urol*. 1998;16(6):386-91. PMID: 9870285.
307. Greendale GA, Petersen L, Zibecchi L, et al. Factors related to sexual function in postmenopausal women with a history of breast cancer. *Menopause*. 2001 Summer;8(2):111-9. PMID: 11256871.
308. Greenfield SP, Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. *J Urol*. 1991 Aug;146(2 (Pt 2)):532-4. PMID: 1861294.
309. Grein U, Meyer WW. Local recurrent cancer after radical prostatectomy and incontinence. Is the artificial urinary sphincter a useful therapeutic option? *Urol Int*. 2001;66(1):9-12. PMID: 11150943.

310. Grieve T. Continence promotion among children with severe disabilities. *Nurs Times*. 1998 Oct 14-20;94(41):58-9. PMID: 9832873.
311. Grignaffini A, Bazzani F, Bertoli P, et al. Intravesicular prostaglandin E2 for the prophylaxis of urinary retention after colpohysterectomy. *J Int Med Res*. 1998 Mar-Apr;26(2):87-92. PMID: 9602987.
312. Grimby A, Rosenhall U. Health-related quality of life and dizziness in old age. *Gerontology*. 1995;41(5):286-98. PMID: 8537013.
313. Grimby A, Svanborg A. Morbidity and health-related quality of life among ambulant elderly citizens. *Aging (Milano)*. 1997 Oct;9(5):356-64. PMID: 9458996.
314. Grodstein F, Lifford K, Resnick NM, et al. Postmenopausal hormone therapy and risk of developing urinary incontinence. *Obstet Gynecol*. 2004 Feb;103(2):254-60. PMID: 14754692.
315. Groen J, van der Horst A, Blok B. Urodynamic Effects of Adjustable Continence Therapy for Men with Stress Urinary Incontinence after Radical Prostatectomy. 39th Annual Meeting of the International Continence Society (ICS 2009), Moscone West, San Francisco, 29 Sep - 3 Oct 2009.
316. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. *Eur Urol*. 2005 May;47(5):653-9. PMID: 15826758.
317. Guimaraes M, Oliveira R, Pinto R, et al. Intermediate-term results, up to 4 years, of a bone-anchored male perineal sling for treating male stress urinary incontinence after prostate surgery. *BJU Int*. 2009 Feb;103(4):500-4. PMID: 18782301.
318. Gundian JC, Barrett DM, Parulkar BG. Mayo Clinic experience with the AS800 artificial urinary sphincter for urinary incontinence after transurethral resection of prostate or open prostatectomy. *Urology*. 1993 Apr;41(4):318-21. PMID: 8470315.
319. Gunningberg L. Risk, prevalence and prevention of pressure ulcers in three Swedish healthcare settings. *J Wound Care*. 2004 Jul;13(7):286-90. PMID: 15977770.
320. Gupta NP, Doddamani D, Aron M, et al. Vapor resection: a good alternative to standard loop resection in the management of prostates >40 cc. *J Endourol*. 2002 Dec;16(10):767-71. PMID: 12542882.
321. Guys JM, Haddad M, Planche D, et al. Sacral neuromodulation for neurogenic bladder dysfunction in children. *J Urol*. 2004 Oct;172(4 Pt 2):1673-6. PMID: 15371787.
322. Haab F, Trockman BA, Zimmern PE, et al. Quality of life and continence assessment of the artificial urinary sphincter in men with minimum 3.5 years of followup. *J Urol*. 1997 Aug;158(2):435-9. PMID: 9224318.
323. Hafez AT, Elsherbiny MT, Ghoneim MA. Complete repair of bladder exstrophy: preliminary experience with neonates and children with failed initial closure. *J Urol*. 2001 Jun;165(6 Pt 2):2428-30. PMID: 11371991.

324. Hagen S, Glazener C, Cook J, et al. Further properties of the pelvic organ prolapse symptom score: Minimally important change and test-retest reliability. *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. 29.
325. Hagglof B, Andren O, Bergstrom E, et al. Self-esteem before and after treatment in children with nocturnal enuresis and urinary incontinence. *Scand J Urol Nephrol Suppl.* 1997;183:79-82. PMID: 9165615.
326. Hagglund D, Wadensten B. Fear of humiliation inhibits women's care-seeking behaviour for long-term urinary incontinence. *Scand J Caring Sci.* 2007 Sep;21(3):305-12. PMID: 17727542.
327. Hagglund D, Walker-Engstrom ML, Larsson G, et al. Reasons why women with long-term urinary incontinence do not seek professional help: a cross-sectional population-based cohort study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Nov;14(5):296-304; discussion PMID: 14618304.
328. Hagstroem S, Mahler B, Madsen B, et al. Transcutaneous electrical nerve stimulation for refractory daytime urinary urge incontinence. *J Urol.* 2009 Oct;182(4 Suppl):2072-8. PMID: 19695629.
329. Hagstroem S, Rittig N, Kamperis K, et al. Treatment outcome of day-time urinary incontinence in children. *Scand J Urol Nephrol.* 2008;42(6):528-33. PMID: 18609267.
330. Hahn RG, Fagerstrom T, Tammela TL, et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. *BJU Int.* 2007 Mar;99(3):587-94. PMID: 17407516.
331. Hall JD, Boyd JC, Lippert MC, et al. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. *Urology.* 2003 Feb;61(2):402-7. PMID: 12597956.
332. Haltbakk J, Hanestad BR, Hunskaar S. Relevance and variability of the severity of incontinence, and increased daytime and night-time voiding frequency, associated with quality of life in men with lower urinary tract symptoms. *BJU Int.* 2005 Jul;96(1):83-7. PMID: 15963126.
333. Haltbakk J, Hanestad BR, Hunskaar S. How important are men's lower urinary tract symptoms (LUTS) and their impact on the quality of life (QOL)? *Qual Life Res.* 2005 Sep;14(7):1733-41. PMID: 16119184.
334. Halverson AL, Hull TL, Paraiso MF, et al. Outcome of sphincteroplasty combined with surgery for urinary incontinence and pelvic organ prolapse. *Dis Colon Rectum.* 2001 Oct;44(10):1421-6. PMID: 11598469.
335. Hamilton AS, Stanford JL, Gilliland FD, et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. *J Clin Oncol.* 2001 May 1;19(9):2517-26. PMID: 11331331.
336. Hampel C, Wienhold D, Benken N, et al. Prevalence and natural history of female incontinence. *Eur Urol.* 1997;32 Suppl 2:3-12. PMID: 9248806.

337. Han E, Black LK, Lavelle JP. Incontinence related to management of benign prostatic hypertrophy. *Am J Geriatr Pharmacother*. 2007 Dec;5(4):324-34. PMID: 18179990.
338. Hannah ME, Hannah WJ, Hodnett ED, et al. Outcomes at 3 months after planned cesarean vs planned vaginal delivery for breech presentation at term: the international randomized Term Breech Trial. *JAMA*. 2002 Apr 10;287(14):1822-31. PMID: 11939868.
339. Hannah ME, Whyte H, Hannah WJ, et al. Maternal outcomes at 2 years after planned cesarean section versus planned vaginal birth for breech presentation at term: the international randomized Term Breech Trial. *Am J Obstet Gynecol*. 2004 Sep;191(3):917-27. PMID: 15467565.
340. Hannappel J, Krieger S. Subjective and clinical results after transurethral resection and suprapubic prostatectomy in benign prostatic hypertrophy. *Eur Urol*. 1991;20(4):272-6. PMID: 1726084.
341. Hara I, Kawabata G, Miyake H, et al. Comparison of quality of life following laparoscopic and open prostatectomy for prostate cancer. *J Urol*. 2003 Jun;169(6):2045-8. PMID: 12771715.
342. Harano M, Eto M, Nakamura M, et al. A pilot study of the assessment of the quality of life, functional results, and complications in patients with an ileal neobladder for invasive bladder cancer. *Int J Urol*. 2007 Feb;14(2):112-7. PMID: 17302566.
343. Harari D, Martin FC, BATTERY A, et al. The older persons' assessment and liaison team 'OPAL': evaluation of comprehensive geriatric assessment in acute medical inpatients. *Age Ageing*. 2007 Nov;36(6):670-5. PMID: 17656421.
344. Harke JM, Richgels K. Barriers to implementing a continence program in nursing homes. *Clin Nurs Res*. 1992 May;1(2):158-68. PMID: 1301859.
345. Harmanli OH, Dandolu V, Chatwani AJ, et al. Total colpocleisis for severe pelvic organ prolapse. *J Reprod Med*. 2003 Sep;48(9):703-6. PMID: 14562635.
346. Harrington C, Zimmerman D, Karon SL, et al. Nursing home staffing and its relationship to deficiencies. *J Gerontol B Psychol Sci Soc Sci*. 2000 Sep;55(5):S278-87. PMID: 10985299.
347. Hassink EA, Rieu PN, Severijnen RS, et al. Are adults content or continent after repair for high anal atresia? A long-term follow-up study in patients 18 years of age and older. *Ann Surg*. 1993 Aug;218(2):196-200. PMID: 8343000.
348. Hautmann RE, Sauter TW, Wenderoth UK. Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. *Urology*. 1994 Feb;43(2 Suppl):47-51. PMID: 8116133.
349. Hay-Smith J, Morkved S, Fairbrother KA, et al. Pelvic floor muscle training for prevention and treatment of urinary and faecal incontinence in antenatal and postnatal women. *Cochrane Database Syst Rev*. 2008(4):CD007471. PMID: 18843750.
350. Heathcote PS, Mactaggart PN, Boston RJ, et al. Health-related quality of life in Australian men remaining disease-free after radical prostatectomy. *Med J Aust*. 1998 May 18;168(10):483-6. PMID: 9631671.

351. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. *Life Sci.* 1999;64(6-7):419-28. PMID: 10069505.
352. Heit M, Blackwell L, Thomas S, et al. Prevalence and severity of urinary incontinence in kidney transplant recipients. *Obstet Gynecol.* 2004 Feb;103(2):352-8. PMID: 14754708.
353. Helgason AR, Adolfsson J, Dickman P, et al. Waning sexual function--the most important disease-specific distress for patients with prostate cancer. *Br J Cancer.* 1996 Jun;73(11):1417-21. PMID: 8645589.
354. Hellstrom A, Hanson E, Hansson S, et al. Micturition habits and incontinence at age 17--reinvestigation of a cohort studied at age 7. *Br J Urol.* 1995 Aug;76(2):231-4. PMID: 7663917.
355. Hernandez RD, Hurwitz RS, Foote JE, et al. Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. *J Urol.* 1994 Nov;152(5 Pt 1):1582-5. PMID: 7933209.
356. Herr HW. Quality of life of incontinent men after radical prostatectomy. *J Urol.* 1994 Mar;151(3):652-4. PMID: 8308974.
357. Herschorn S, Jones JS, Oelke M, et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. *Urology.* 2010 May;75(5):1149-55. PMID: 19914702.
358. Herschorn S, Liu M. Artificial Urinary Sphincter and In-Vance Male Sling in the Treatment of Post-Prostatectomy Incontinence: A Comparison Study. 21st Annual Congress of the European Association of Urology (EAU 2006), Palais des Congres, Paris (France), 5-8 Apr 2006.
359. Herwig R, Bruns F, Strasser H, et al. Late urologic effects after adjuvant irradiation in stage I endometrial carcinoma. *Urology.* 2004 Feb;63(2):354-8. PMID: 14972490.
360. Hetzer FH, Hahnloser D, Clavien PA, et al. Quality of life and morbidity after permanent sacral nerve stimulation for fecal incontinence. *Arch Surg.* 2007 Jan;142(1):8-13. PMID: 17224495.
361. Hicken BL, Putzke JD, Richards JS. Bladder management and quality of life after spinal cord injury. *Am J Phys Med Rehabil.* 2001 Dec;80(12):916-22. PMID: 11821674.
362. Higashi T, Hays RD, Brown JA, et al. Do proxies reflect patients' health concerns about urinary incontinence and gait problems? *Health Qual Life Outcomes.* 2005;3:75. PMID: 16305748.
363. Hilton EL, Henderson LJ. Lived female experience of chronic bladder cancer: a phenomenologic case study. *Urol Nurs.* 2003 Oct;23(5):349-54. PMID: 14621357.
364. Hjalmas K, Hellstrom AL, Mogren K, et al. The overactive bladder in children: a potential future indication for tolterodine. *BJU Int.* 2001 Apr;87(6):569-74. PMID: 11298060.
365. Ho YH, Muller R, Veitch C, et al. Faecal incontinence: an unrecognised epidemic in rural North Queensland? Results of a hospital-based outpatient study. *Aust J Rural Health.* 2005 Feb;13(1):28-34. PMID: 15720312.

366. Hoebeke P, De Caestecker K, Vande Walle J, et al. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. *J Urol*. 2006 Jul;176(1):328-30; discussion 30-1. PMID: 16753434.
367. Hoebeke P, De Kuyper P, Goeminne H, et al. Bladder neck closure for treating pediatric incontinence. *Eur Urol*. 2000 Oct;38(4):453-6. PMID: 11025385.
368. Hofner K, Burkart M, Jacob G, et al. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. *World J Urol*. 2007 Dec;25(6):627-33. PMID: 17906864.
369. Hohenfellner M, Nunes L, Schmidt RA, et al. Interstitial cystitis: increased sympathetic innervation and related neuropeptide synthesis. *J Urol*. 1992 Mar;147(3):587-91. PMID: 1538434.
370. Holland AJ, King PA, Chauvel PJ, et al. Intravesical therapy for the treatment of neurogenic bladder in children. *Aust N Z J Surg*. 1997 Oct;67(10):731-3. PMID: 9322726.
371. Hollenbeck BK, Lipp ER, Hayward RA, et al. Concurrent assessment of obstructive/irritative urinary symptoms and incontinence after radical prostatectomy. *Urology*. 2002 Mar;59(3):389-93. PMID: 11880076.
372. Homma Y, Kawabe K, Hayashi K. Urologic morbidity and its influence on global satisfaction with treatment outcome after radical prostatectomy for prostate cancer. *Int J Urol*. 1998 Nov;5(6):556-61. PMID: 9855124.
373. Horstmann M, Schaefer T, Aguilar Y, et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. *Neurourol Urodyn*. 2006;25(5):441-5. PMID: 16847942.
374. Hosseini SV, Sharifi K, Ahmadfard A, et al. Role of internal sphincterotomy in the treatment of hemorrhoids: a randomized clinical trial. *Arch Iran Med*. 2007 Oct;10(4):504-8. PMID: 17903056.
375. Hsieh CL, Sheu CF, Hsueh IP, et al. Trunk control as an early predictor of comprehensive activities of daily living function in stroke patients. *Stroke*. 2002 Nov;33(11):2626-30. PMID: 12411652.
376. Hu TW, Kaltreider DL, Igou JF, et al. Cost effectiveness of training incontinent elderly in nursing homes: a randomized clinical trial. *Health Serv Res*. 1990 Aug;25(3):455-77. PMID: 2116385.
377. Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. *BJU Int*. 2005 Sep;96 Suppl 1:43-5. PMID: 16086679.
378. Hubner WA, Schlarp OM. Treatment of incontinence after prostatectomy using a new minimally invasive device: adjustable continence therapy. *BJU Int*. 2005 Sep;96(4):587-94. PMID: 16104915.
379. Hubner WA, Schlarp OM. Adjustable continence therapy (ProACT): evolution of the surgical technique and comparison of the original 50 patients with the most recent 50 patients at a single centre. *Eur Urol*. 2007 Sep;52(3):680-6. PMID: 17097218.

380. Huebner W, Kocjancic E, Rocha FT, et al. International Long Term Evaluation of the Adjustable Continence Therapy (ProACT) for Male Post Prostatectomy Stress Urinary Incontinence. 2008 Annual Meeting of the American Urological Association, Orlando, Florida (USA), 17-22 May 2008.
381. Hughes KM. Measurement of Oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. *Xenobiotica*. 1992;22(7):859-69.
382. Hunter KF, Moore KN, Allen M. Lower urinary tract symptoms in older adults undergoing hip arthroplasty: a feasibility study. *J Wound Ostomy Continence Nurs*. 2008 May-Jun;35(3):334-40. PMID: 18496092.
383. Hunter S, Anderson J, Hanson D, et al. Clinical trial of a prevention and treatment protocol for skin breakdown in two nursing homes. *Journal of Wound, Ostomy, & Continence Nursing*; 2003. p. 250-8.
384. Hurley RM, Harris D, Shepherd RR. Incontinence in myelodysplasia: imipramine hydrochloride revisited. *Clin Pediatr (Phila)*. 2000 Aug;39(8):489-91. PMID: 10961822.
385. Hyams G, McCoull K, Smith PS, et al. Behavioural continence training in mental handicap: a 10-year follow-up study. *J Intellect Disabil Res*. 1992 Dec;36 (Pt 6):551-8. PMID: 1477492.
386. Imamoglu MA, Tuygun C, Bakirtas H, et al. The comparison of artificial urinary sphincter implantation and endourethral macropastique injection for the treatment of postprostatectomy incontinence. *Eur Urol*. 2005 Feb;47(2):209-13. PMID: 15661416.
387. Ip V. Evaluation of a patient education tool to reduce the incidence of incontinence post-prostate surgery. *Urol Nurs*. 2004 Oct;24(5):401-7. PMID: 15575109.
388. Irwin DE, Milsom I, Reilly K, et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. *J Sex Med*. 2008 Dec;5(12):2904-10. PMID: 19090944.
389. Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six Western countries. *BJU Int*. 2009 Jan;103(2):202-9. PMID: 19278532.
390. Ishikawa M. Clinical guidelines for idiopathic normal pressure hydrocephalus. *Neurol Med Chir (Tokyo)*. 2004 Apr;44(4):222-3. PMID: 15185767.
391. Iskandar BJ, Fulmer BB, Hadley MN, et al. Congenital tethered spinal cord syndrome in adults. *J Neurosurg*. 1998 Jun;88(6):958-61. PMID: 9609288.
392. Jack GS, Almeida FG, Zhang R, et al. Processed lipoaspirate cells for tissue engineering of the lower urinary tract: implications for the treatment of stress urinary incontinence and bladder reconstruction. *J Urol*. 2005 Nov;174(5):2041-5. PMID: 16217390.
393. Jackson RA, Vittinghoff E, Kanaya AM, et al. Urinary incontinence in elderly women: findings from the Health, Aging, and Body Composition Study. *Obstet Gynecol*. 2004 Aug;104(2):301-7. PMID: 15292003.

394. Jackson SL, Boyko EJ, Scholes D, et al. Predictors of urinary tract infection after menopause: a prospective study. *Am J Med.* 2004 Dec 15;117(12):903-11. PMID: 15629728.
395. Jackson SL, Scholes D, Boyko EJ, et al. Predictors of urinary incontinence in a prospective cohort of postmenopausal women. *Obstet Gynecol.* 2006 Oct;108(4):855-62. PMID: 17012446.
396. Jacobsen NE, Moore KN, Estey E, et al. Open versus laparoscopic radical prostatectomy: a prospective comparison of postoperative urinary incontinence rates. *J Urol.* 2007 Feb;177(2):615-9. PMID: 17222646.
397. Jain R, Radhapyari K, Jadon N. Adsorptive stripping voltammetric behavior and determination of anticholinergic agent oxybutynin chloride on a mercury electrode. *J Colloid Interface Sci.* 2007 Oct 15;314(2):572-7. PMID: 17618643.
398. Jani AB, Hellman S. Early prostate cancer: hedonic prices model of provider-patient interactions and decisions. *Int J Radiat Oncol Biol Phys.* 2008 Mar 15;70(4):1158-68. PMID: 17881151.
399. Jansen L, Forbes D. The psychometric testing of a urinary incontinence nursing assessment instrument. *J Wound Ostomy Continence Nurs.* 2006 Jan-Feb;33(1):69-76. PMID: 16444108.
400. Jarow JP. Puboprostatic ligament sparing radical retropubic prostatectomy. *Semin Urol Oncol.* 2000 Feb;18(1):28-32. PMID: 10719927.
401. Jawaheer G, Rangescroft L. The Pippi Salle procedure for neurogenic urinary incontinence in childhood: a three-year experience. *Eur J Pediatr Surg.* 1999 Dec;9 Suppl 1:9-11. PMID: 10661782.
402. Jeong SH, Kim JH, Ahn YM, et al. A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. *J Clin Psychopharmacol.* 2008 Dec;28(6):618-24. PMID: 19011429.
403. Jervis LL. The pollution of incontinence and the dirty work of caregiving in a U.S. nursing home. *Med Anthropol Q.* 2001 Mar;15(1):84-99. PMID: 11288620.
404. Johanson RB, Heycock E, Carter J, et al. Maternal and child health after assisted vaginal delivery: five-year follow up of a randomised controlled study comparing forceps and ventouse. *Br J Obstet Gynaecol.* 1999 Jun;106(6):544-9. PMID: 10426611.
405. Johansson C, Hellstrom L, Ekelund P, et al. Urinary incontinence: a minor risk factor for hip fractures in elderly women. *Maturitas.* 1996 Aug;25(1):21-8. PMID: 8887305.
406. John H. Bulbourethral composite suspension:: a new operative technique for post-prostatectomy incontinence. *J Urol.* 2004 May;171(5):1866-70; discussion 9-70. PMID: 15076295.
407. Johnson TM, Miller M, Tang T, et al. Oral ddAVP for nighttime urinary incontinence in characterized nursing home residents: a pilot study. *Journal of the American Medical Directors Association*; 2006. p. 6-11.

408. Johnson TM, 2nd, Ouslander JG. The newly revised F-Tag 315 and surveyor guidance for urinary incontinence in long-term care. *J Am Med Dir Assoc.* 2006 Nov;7(9):594-600. PMID: 17095426.
409. Johnson TM, Ouslander JG, Uman GC, et al. Urinary incontinence treatment preferences in long-term care. *J Am Geriatr Soc.* 2001 Jun;49(6):710-8. PMID: 11454108.
410. Joly F, Brune D, Couette JE, et al. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. *Ann Oncol.* 1998 Jul;9(7):751-7. PMID: 9739442.
411. Jonler M, Madsen FA, Rhodes PR, et al. A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. *Urology.* 1996 Sep;48(3):433-40. PMID: 8804498.
412. Jonler M, Messing EM, Rhodes PR, et al. Sequelae of radical prostatectomy. *Br J Urol.* 1994 Sep;74(3):352-8. PMID: 7953267.
413. Jonler M, Nielsen OS, Wolf H. Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment. *Urology.* 1998 Dec;52(6):1055-62; discussion 63. PMID: 9836554.
414. Jonler M, Ritter MA, Brinkmann R, et al. Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis. *Urology.* 1994 Dec;44(6):876-82. PMID: 7985316.
415. Joseph AC. Noninvasive therapies for treating post-prostatectomy urinary incontinence. *Urol Nurs.* 2006 Aug;26(4):271-5, 69; quiz 6. PMID: 16939044.
416. Joseph AC, Chang MK. Comparison of behavior therapy methods for urinary incontinence following prostate surgery: a pilot study. *Urol Nurs.* 2000 Jun;20(3):203-4. PMID: 11998139.
417. Jumadilova Z, Zyczynski T, Paul B, et al. Urinary incontinence in the nursing home: resident characteristics and prevalence of drug treatment. *American Journal of Managed Care.* 2005 Jul;11(4 Suppl):S112-20. PMID: 21094.
418. Kajbafzadeh AM, Elmi A, Payabvash S, et al. Transurethral autologous myoblast injection for treatment of urinary incontinence in children with classic bladder exstrophy. *J Urol.* 2008 Sep;180(3):1098-105. PMID: 18639289.
419. Kajbafzadeh AM, Moosavi S, Tajik P, et al. Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. *Urology.* 2006 Nov;68(5):1091-6; discussion 6-7. PMID: 17113899.
420. Kajiwarra M, Kato M, Mutaguchi K, et al. Overactive bladder in children should be strictly differentiated from monosymptomatic nocturnal enuresis. *Urologia internationalis.* 2008;80(1):57-61. PMID: 21514.
421. Kalpakjian CZ, Scelza WM, Forchheimer MB, et al. Preliminary reliability and validity of a Spinal Cord Injury Secondary Conditions Scale. *J Spinal Cord Med.* 2007;30(2):131-9. PMID: 17591225.

422. Kalsi V, Apostolidis A, Popat R, et al. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. *Eur Urol*. 2006 Mar;49(3):528-35. PMID: 16426735.
423. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. *Annals of Neurology*. 2007 Nov;62(5):452-7. PMID: 21137.
424. Kao TC, Cruess DF, Garner D, et al. Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. *J Urol*. 2000 Mar;163(3):858-64. PMID: 10687992.
425. Kaplan SA, Roehrborn CG, Chancellor M, et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. *BJU Int*. 2008 Nov;102(9):1133-9. PMID: 18510659.
426. Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. *Urology*. 2006 Aug;68(2):328-32. PMID: 16904446.
427. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. *JAMA*. 2006 Nov 15;296(19):2319-28. PMID: 17105794.
428. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. *J Urol*. 2005 Dec;174(6):2273-5 discussion 5-6. PMID: 16280803.
429. Kaplinsky R, Greenfield S, Wan J, et al. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. *J Urol*. 1996 Aug;156(2 Pt 2):753-6. PMID: 8683776.
430. Kapoor R, Dubey D, Kumar A, et al. Modified bulbar urethral sling procedure for the treatment of male sphincteric incontinence. *J Endourol*. 2001 Jun;15(5):545-9. PMID: 11465337.
431. Karakiewicz PI, Bhojani N, Neugut A, et al. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. *J Sex Med*. 2008 Apr;5(4):919-27. PMID: 18371045.
432. Katz G, Rodriguez R. Use of a modified American Urological Association Symptom Score for the evaluation of the quality of life of patients with prostate cancer. *Urology*. 2001 Jan;57(1):112-6. PMID: 11164154.
433. Katz G, Rodriguez R. Changes in continence and health-related quality of life after curative treatment and watchful waiting of prostate cancer. *Urology*. 2007 Jun;69(6):1157-60. PMID: 17572206.
434. Kaufman MW, Bajracharya S. Enterostomal therapy nursing in Nepal. *J Wound Ostomy Continence Nurs*. 2000 Sep;27(5):255-6. PMID: 10999962.

435. Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. *BJU Int.* 2005 Nov;96(7):1055-62. PMID: 16225528.
436. Kaya H, Sezik M, Ozbasar D, et al. Intrafascial versus extrafascial abdominal hysterectomy: effects on urinary urge incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 May-Jun;15(3):171-4. PMID: 15167995.
437. Kaye KW. Changing trends in urology practice: increasing outpatient surgery. *Aust N Z J Surg.* 1995 Jan;65(1):31-4. PMID: 7818420.
438. Kelly M, Tan BK, Thompson J, et al. Healthy adults can more easily elevate the pelvic floor in standing than in crouching: an experimental study. *Aust J Physiother.* 2007;53(3):187-91. PMID: 17725476.
439. Kenton K, Brincat C, Mutone M, et al. Repeat cesarean section and primary elective cesarean section: recently trained obstetrician-gynecologist practice patterns and opinions. *Am J Obstet Gynecol.* 2005 Jun;192(6):1872-5; discussion 5-6. PMID: 15970836.
440. Kerfoot BP, Turek PJ. What every graduating medical student should know about urology: the stakeholder viewpoint. *Urology.* 2008 Apr;71(4):549-53. PMID: 18387383.
441. Keshtgar AS, Rickwood AM. Urological consequences of incomplete cord lesions in patients with myelomeningocele. *Br J Urol.* 1998 Aug;82(2):258-60. PMID: 9722763.
442. Kessler TM, Burkhard FC, Studer UE. Nerve-sparing open radical retropubic prostatectomy. *Eur Urol.* 2007 Jan;51(1):90-7. PMID: 17074431.
443. Khastgir J, Hamid R, Arya M, et al. Surgical and patient reported outcomes of 'clam' augmentation ileocystoplasty in spinal cord injured patients. *Eur Urol.* 2003 Mar;43(3):263-9. PMID: 12600429.
444. Khorsandi M, Ginsberg PC, Harkaway RC. Reassessing the role of urodynamics after cerebrovascular accident. Males versus females. *Urol Int.* 1998;61(3):142-6. PMID: 9933833.
445. Kilic N, Balkan E, Akgoz S, et al. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. *Int J Urol.* 2006 Feb;13(2):105-8. PMID: 16563131.
446. Kim MR, Kim JH, Cho HH. Infracoccygeal sacropexy improves the quality of life of women with uterine prolapse. *Maturitas.* 2008 Feb 20;59(2):158-62. PMID: 18242893.
447. Kim Y, Yoshimura N, Masuda H, et al. Intravesical instillation of human urine after oral administration of tiroprium, tolterodine and oxybutynin in a rat model of detrusor overactivity. *BJU Int.* 2006 Feb;97(2):400-3. PMID: 16430654.
448. Kim YH, Kattan MW, Boone TB. Correlation of urodynamic results and urethral coaptation with success after transurethral collagen injection. *Urology.* 1997 Dec;50(6):941-8. PMID: 9426727.

449. Kincade JE, Boyington AR, Lekan-Rutledge D, et al. Bladder management in adult care homes. Review of a program in North Carolina. *J Gerontol Nurs.* 2003 Oct;29(10):30-6; quiz 54-5. PMID: 14558233.
450. Kinn AC, Larsson PO. Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. *Scand J Urol Nephrol.* 1990;24(2):109-12. PMID: 2192444.
451. Kjerulff KH, Langenberg PW, Greenaway L, et al. Urinary incontinence and hysterectomy in a large prospective cohort study in American women. *J Urol.* 2002 May;167(5):2088-92. PMID: 11956446.
452. Klay M, Marfyak K. Use of a continence nurse specialist in an extended care facility. *Urol Nurs.* 2005 Apr;25(2):101-2, 7-8. PMID: 15900978.
453. Kneist W, Junginger T. Long-term urinary dysfunction after mesorectal excision: a prospective study with intraoperative electrophysiological confirmation of nerve preservation. *Eur J Surg Oncol.* 2007 Nov;33(9):1068-74. PMID: 17524598.
454. Koch MO, Nayee AH, Sloan J, et al. Early catheter removal after radical retropubic prostatectomy: long-term followup. *J Urol.* 2003 Jun;169(6):2170-2. PMID: 12771741.
455. Koch T, Kelly S. Understanding what is important for women who live with multiple sclerosis. *Aust J Holist Nurs.* 1999 Apr;6(1):14-24. PMID: 11898197.
456. Koch T, Kelly S. Identifying strategies for managing urinary incontinence with women who have multiple sclerosis. *J Clin Nurs.* 1999 Sep;8(5):550-9. PMID: 10786527.
457. Koch T, Kralik D, Eastwood S, et al. Breaking the silence: women living with multiple sclerosis and urinary incontinence. *Int J Nurs Pract.* 2001 Feb;7(1):16-23. PMID: 11811342.
458. Kocjancic E, Crivellaro S, Ranzoni S, et al. Adjustable Continence Therapy for the treatment of male stress urinary incontinence: a single-centre study. *Scand J Urol Nephrol.* 2007;41(4):324-8. PMID: 17763225.
459. Kocjancic E, Hubner W, Trigo Rocha F, et al. International multi-centre evaluation of the adjustable continence therapy (proact(TM(TM))) for male post prostatectomy stress urinary incontinence. 38th Annual Meeting of the International Continence Society (ICS 2008), Cairo International Congress Center (CICC), Cairo (Egypt), 20-24 Oct 2008.
460. Kondo A, Yokoyama E, Koshiha K, et al. Bladder neck support prosthesis: a nonoperative treatment for stress or mixed urinary incontinence. *J Urol.* 1997 Mar;157(3):824-7. PMID: 9072577.
461. Korfage IJ, de Koning HJ, Habbema JD, et al. Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls? *BJU Int.* 2007 Apr;99(4):801-6. PMID: 17233804.
462. Koyama W, Koyanagi A, Mihara S, et al. Prevalence and conditions of urinary incontinence among the elderly. *Methods Inf Med.* 1998 Jun;37(2):151-5. PMID: 9656656.

463. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. *Med Care*. 2003 Jan;41(1):153-64. PMID: 12544552.
464. Kramer SA, Rathbun SR, Elkins D, et al. Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population. *J Urol*. 2005 Jun;173(6):2121-4; discussion 4. PMID: 15879863.
465. Kristiansson P, Samuelsson E, von Schoultz B, et al. Reproductive hormones and stress urinary incontinence in pregnancy. *Acta Obstet Gynecol Scand*. 2001 Dec;80(12):1125-30. PMID: 11846710.
466. Krogh K, Christensen P, Sabroe S, et al. Neurogenic bowel dysfunction score. *Spinal Cord*. 2006 Oct;44(10):625-31. PMID: 16344850.
467. Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. *J Urol*. 2003 Oct;170(4 Pt 1):1291-4. PMID: 14501744.
468. Kubler HR, Tseng TY, Sun L, et al. Impact of nerve sparing technique on patient self-assessed outcomes after radical perineal prostatectomy. *J Urol*. 2007 Aug;178(2):488-92; discussion 92. PMID: 17561133.
469. Kumar A, Litt ER, Ballert KN, et al. Artificial urinary sphincter versus male sling for post-prostatectomy incontinence--what do patients choose? *J Urol*. 2009 Mar;181(3):1231-5. PMID: 19152937.
470. Kumar V, Toussi H, Marr C, et al. The benefits of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer. *BJU Int*. 2004 Mar;93(4):507-9. PMID: 15008719.
471. Kunkel EJ, Myers RE, Lartey PL, et al. Communicating effectively with the patient and family about treatment options for prostate cancer. *Semin Urol Oncol*. 2000 Aug;18(3):233-40. PMID: 10975496.
472. Kuo HC. Clinical outcome and quality of life after enterocystoplasty for contracted bladders. *Urol Int*. 1997;58(3):160-5. PMID: 9188137.
473. Kuo HC. Quality of life after active urological management of chronic spinal cord injury in eastern Taiwan. *Eur Urol*. 1998;34(1):37-46. PMID: 9676412.
474. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. *Urology*. 2004 May;63(5):868-72. PMID: 15134967.
475. Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? *Urology*. 2006 Nov;68(5):993-7; discussion 7-8. PMID: 17113890.
476. Kuo HC. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection. *Urology*. 2008 Nov;72(5):1056-60. PMID: 18533231.

477. Kuznetsov DD, Kim HL, Patel RV, et al. Comparison of artificial urinary sphincter and collagen for the treatment of postprostatectomy incontinence. *Urology*. 2000 Oct 1;56(4):600-3. PMID: 11018614.
478. Lagergren M, Fratiglioni L, Hallberg IR, et al. A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC). *Aging Clin Exp Res*. 2004 Apr;16(2):158-68. PMID: 15195992.
479. Lai HH, Hsu EI, Teh BS, et al. 13 years of experience with artificial urinary sphincter implantation at Baylor College of Medicine. *Journal of Urology*. 2007 Mar;177(3):1021-5. PMID: 21090.
480. Lakeman M, Kruitwagen RF, Vos MC, et al. Electrosurgical bipolar vessel sealing versus conventional clamping and suturing for total abdominal hysterectomy: a randomized trial. *J Minim Invasive Gynecol*. 2008 Sep-Oct;15(5):547-53. PMID: 18619923.
481. Langley T. Training staff to provide a continence helpline. *Prof Nurse*. 1995 Nov;11(2):121-4. PMID: 7480053.
482. Larson B, Collins A, Landgren BM. Urogenital and vasomotor symptoms in relation to menopausal status and the use of hormone replacement therapy (HRT) in healthy women during transition to menopause. *Maturitas*. 1997 Dec 15;28(2):99-105. PMID: 9522318.
483. Lassmann J, Garibay Gonzalez F, Melchionni JB, et al. Sexual function in adult patients with spina bifida and its impact on quality of life. *J Urol*. 2007 Oct;178(4 Pt 2):1611-4. PMID: 17707040.
484. Lawhorne LW, Ouslander JG, Parmelee PA, et al. Urinary incontinence: a neglected geriatric syndrome in nursing facilities. *J Am Med Dir Assoc*. 2008 Jan;9(1):29-35. PMID: 18187110.
485. Lazzeri M, Calo G, Spinelli M, et al. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. *Urology*. 2003 May;61(5):946-50. PMID: 12736013.
486. Leach GE. Local anesthesia for urologic procedures. *Urology*. 1996 Aug;48(2):284-8. PMID: 8753742.
487. Leandri P, Rossignol G, Gautier JR, et al. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. *J Urol*. 1992 Mar;147(3 Pt 2):883-7. PMID: 1538489.
488. Learman LA, Summitt RL, Jr., Varner RE, et al. A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. *Obstet Gynecol*. 2003 Sep;102(3):453-62. PMID: 12962924.
489. Leuret T, Botto H, Benchetrit J, et al. Results of the French Multicentric Prospective Study for Treatment of Stress Urinary Incontinence with Proact Balloons after Prostate Surgery. 2006 Annual Meeting of the American Urological Association (AUA 2006), Atlanta, Georgia (USA), 20-25 May 2006.

490. Lebret T, Cour F, Benchetrit J, et al. Treatment of postprostatectomy stress urinary incontinence using a minimally invasive adjustable continence balloon device, ProACT: results of a preliminary, multicenter, pilot study. *Urology*. 2008 Feb;71(2):256-60. PMID: 18308096.
491. Lee CT, Sandler HM, Kim KM, et al. Conformational radiation therapy after radical prostatectomy: Effect of urinary incontinence. 82nd Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL (USA), 1-6 Dec 1996. (World Meeting Number 964 0124).
492. Lee E, Yoo KY, Kim Y, et al. Prevalence of lower urinary tract symptoms in Korean men in a community-based study. *Eur Urol*. 1998;33(1):17-21. PMID: 9471036.
493. Lee IS, Choi ES. Pelvic floor muscle exercise by biofeedback and electrical stimulation to reinforce the pelvic floor muscle after normal delivery. *Taehan Kanho Hakhoe Chi*; 2006. p. 1374-80.
494. Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. *BJU Int*. 2004 Oct;94(6):817-20. PMID: 15476515.
495. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. *J Urol*. 2005 Oct;174(4 Pt 1):1334-8. PMID: 16145414.
496. Lee YJ, Chiang YF, Tsai JC. Severe nonproductive cough and cough-induced stress urinary incontinence in diabetic postmenopausal women treated with ACE inhibitor. *Diabetes Care*. 2000 Mar;23(3):427-8. PMID: 10868884.
497. Leibovich BC, Barrett DM. Use of the artificial urinary sphincter in men and women. *World J Urol*. 1997;15(5):316-9. PMID: 9372584.
498. Leiby DM, Shanahan N. Clinical study: assessing the performance and skin environments of two reusable underpads. *Ostomy Wound Manage*. 1994 Oct;40(8):30-2, 4-7. PMID: 7546098.
499. Lekan-Rutledge D. Diffusion of innovation. A model for implementation of prompted voiding in long-term care settings. *J Gerontol Nurs*. 2000 Apr;26(4):25-33. PMID: 11272963.
500. Lekan-Rutledge D, Palmer MH, Belyea M. In their own words: nursing assistants' perceptions of barriers to implementation of prompted voiding in long-term care. *Gerontologist*. 1998 Jun;38(3):370-8. PMID: 9640857.
501. Lekka E, Lee LK. Successful treatment with intradetrusor Botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. *Eur Urol*. 2006 Oct;50(4):806-9; discussion 9-10. PMID: 16413661.
502. Lemelle JL, Guillemin F, Aubert D, et al. Quality of life and continence in patients with spina bifida. *Qual Life Res*. 2006 Nov;15(9):1481-92. PMID: 17033913.

503. Lepisto M, Eriksson E, Hietanen H, et al. Developing a pressure ulcer risk assessment scale for patients in long-term care. *Ostomy Wound Manage.* 2006 Feb;52(2):34-46. PMID: 16464993.
504. Lerner SE, Fleischmann J, Taub HC, et al. Combined laparoscopic pelvic lymph node dissection and modified belt radical perineal prostatectomy for localized prostatic adenocarcinoma. *Urology.* 1994 Apr;43(4):493-8. PMID: 8154070.
505. Letourneau R, Pang X, Sant GR, et al. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. *Br J Urol.* 1996 Jan;77(1):41-54. PMID: 8653316.
506. Levinson AW, Bagga HS, Pavlovich CP, et al. The impact of prostate size on urinary quality of life indexes following laparoscopic radical prostatectomy. *J Urol.* 2008 May;179(5):1818-22. PMID: 18353375.
507. Levitt MA, Pena A. Outcomes from the correction of anorectal malformations. *Curr Opin Pediatr.* 2005 Jun;17(3):394-401. PMID: 15891433.
508. Levy-Storms L, Schnelle JF, Simmons SF. What do family members notice following an intervention to improve mobility and incontinence care for nursing home residents? An analysis of open-ended comments. *Gerontologist.* 2007 Feb;47(1):14-20. PMID: 17327536.
509. Lewinshtein DJ, Perrotte P, Lebeau T, et al. Normal urinary and sexual function in men without evidence of prostate cancer from Montreal, Canada. *BJU Int.* 2006 Jun;97(6):1273-7. PMID: 16686725.
510. Lewis-Byers K, Thayer D. An evaluation of two incontinence skin care protocols in a long-term care setting. *Ostomy Wound Manage.* 2002 Dec;48(12):44-51. PMID: 12490752.
511. Liapis A, Bakas P, Georgantopoulou C, et al. The use of oestradiol therapy in postmenopausal women after TVT-O anti-incontinence surgery. *Maturitas.* 2010 May;66(1):101-6. PMID: 20236776.
512. Lilleby W, Fossa SD, Waehre HR, et al. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. *Int J Radiat Oncol Biol Phys.* 1999 Mar 1;43(4):735-43. PMID: 10098428.
513. Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. *Surg Gynecol Obstet.* 1990 Dec;171(6):493-6. PMID: 2244283.
514. Lim AJ, Brandon AH, Fiedler J, et al. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. *J Urol.* 1995 Oct;154(4):1420-5. PMID: 7658548.
515. Lim YM, Song J, Oh H. Translation and validation of the Korean version of MUDI and MUSIQ with urinary incontinent older men. *Yonsei Med J.* 2009 Feb 28;50(1):122-31. PMID: 19259358.
516. Lindehall B, Moller A, Hjalmas K, et al. Psychosocial factors in teenagers and young adults with myelomeningocele and clean intermittent catheterization. *Scandinavian Journal of Urology & Nephrology.* 2008;42(6):539-44. PMID: 21040.

517. Link RE, Su LM, Sullivan W, et al. Health related quality of life before and after laparoscopic radical prostatectomy. *J Urol*. 2005 Jan;173(1):175-9; discussion 9. PMID: 15592069.
518. Litman HJ, Bhasin S, O'Leary MP, et al. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. *BJU Int*. 2007 Aug;100(2):321-6. PMID: 17506868.
519. Little DJ, Kuban DA, Levy LB, et al. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. *Urology*. 2003 Oct;62(4):707-13. PMID: 14550448.
520. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. *J Urol*. 1999 Mar;161(3):743-57. PMID: 10022678.
521. Litwiller SE, Kim KB, Fone PD, et al. Post-prostatectomy incontinence and the artificial urinary sphincter: a long-term study of patient satisfaction and criteria for success. *J Urol*. 1996 Dec;156(6):1975-80. PMID: 8911369.
522. Loeb S, Roehl KA, Helfand BT, et al. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. *Urology*. 2008 Oct;72(4):887-91. PMID: 18329080.
523. Loeb S, Smith ND, Roehl KA, et al. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. *Urology*. 2007 Jun;69(6):1170-5. PMID: 17572209.
524. Logigian EL, Shefner JM, Goumnerova L, et al. The critical importance of stimulus intensity in intraoperative monitoring for partial dorsal rhizotomy. *Muscle Nerve*. 1996 Apr;19(4):415-22. PMID: 8622718.
525. Long CY, Liu CM, Wu TP, et al. A randomized comparison of vesicourethral function after laparoscopic hysterectomy with and without vaginal cuff suspension. *J Minim Invasive Gynecol*. 2005 Mar-Apr;12(2):137-43. PMID: 15904617.
526. Long R. Ingenuity encounters incontinence. *Contemp Longterm Care*. 2001 Jun;24(6):24-8. PMID: 11417097.
527. Longworth J, Davila Y, Sampsel C. La perdida de orina: Hispanic women's experience of urinary incontinence. *Hispanic Health Care International*. 2003;2(1):13-21(9).
528. Lopez Pereira P, Miguelez C, Caffarati J, et al. Trospium chloride for the treatment of detrusor instability in children. *J Urol*. 2003 Nov;170(5):1978-81. PMID: 14532838.
529. Lorenzo AJ, Chait PG, Wallis MC, et al. Minimally invasive approach for treatment of urinary and fecal incontinence in selected patients with spina bifida. *Urology*. 2007 Sep;70(3):568-71. PMID: 17905118.
530. Luber KM, Boero S, Choe JY. The demographics of pelvic floor disorders: current observations and future projections. *Am J Obstet Gynecol*. 2001 Jun;184(7):1496-501; discussion 501-3. PMID: 11408873.

531. Maas CP, ter Kuile MM, Laan E, et al. Objective assessment of sexual arousal in women with a history of hysterectomy. *BJOG : an international journal of obstetrics and gynaecology*; 2004. p. 456-62.
532. Macaulay M, Clarke-O'Neill S, Fader M, et al. A pilot study to evaluate reusable absorbent body-worn products for adults with moderate/heavy urinary incontinence. *J Wound Ostomy Continence Nurs.* 2004 Nov-Dec;31(6):357-66. PMID: 15867711.
533. Macaulay M, Pettersson L, Fader M, et al. A multicenter evaluation of absorbent products for children with incontinence and disabilities. *J Wound Ostomy Continence Nurs.* 2004 Jul-Aug;31(4):235-44. PMID: 15851868.
534. MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. *Mayo Clin Proc.* 2008 Sep;83(9):1002-10. PMID: 18775200.
535. MacDonagh RP, Forster DM, Thomas DG. Urinary continence in spinal injury patients following complete sacral posterior rhizotomy. *Br J Urol.* 1990 Dec;66(6):618-22. PMID: 2265335.
536. MacDonald CD, Butler L. Silent no more: elderly women's stories of living with urinary incontinence in long-term care. *J Gerontol Nurs.* 2007 Jan;33(1):14-20. PMID: 17305265.
537. Madalinska JB, Essink-Bot ML, de Koning HJ, et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. *J Clin Oncol.* 2001 Mar 15;19(6):1619-28. PMID: 11250990.
538. Madjar S, Evans D, Duncan RC, et al. Collaboration and practice patterns among urologists and gynecologists in the treatment of urinary incontinence and pelvic floor prolapse: a survey of the International Continence Society members. *Neurourol Urodyn.* 2001;20(1):3-11. PMID: 11135377.
539. Magera JS, Jr., Inman BA, Elliott DS. Outcome analysis of urethral wall stent insertion with artificial urinary sphincter placement for severe recurrent bladder neck contracture following radical prostatectomy. *J Urol.* 2009 Mar;181(3):1236-41. PMID: 19152938.
540. Mahawong P, Chaiyaprasithi B, Soontrapa S, et al. A role of intravesical capsaicin instillation in benign prostatic hyperplasia with overactive bladder symptoms: the first reported study in the literature. *J Med Assoc Thai.* 2007 Nov;90(11):2301-9. PMID: 18181311.
541. Maliski SL, Litwin MS. Unsolicited written comments: an untapped data source. *Oncol Nurs Forum.* 2007 Jan;34(1):142-7. PMID: 17562641.
542. Malone PS, Wheeler RA, Williams JE. Continence in patients with spina bifida: long term results. *Arch Dis Child.* 1994 Feb;70(2):107-10. PMID: 8129429.
543. Malone-Lee J, Shaffu B, Anand C, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. *The Journal of urology*; 2001. p. 1452-6.

544. Manassero F, Traversi C, Ales V, et al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: results of a prospective controlled randomized trial. *Neurourol Urodyn*. 2007;26(7):985-9. PMID: 17487874.
545. Mancini JG, Kizer WS, Jones LA, et al. Patient satisfaction after dual implantation of inflatable penile and artificial urinary sphincter prostheses. *Urology*. 2008 May;71(5):893-6. PMID: 18374398.
546. Mangnall J, Taylor P, Thomas S, et al. Continence problems in care homes: auditing assessment and treatment. *Nurs Older People*. 2006 Mar;18(2):20-2. PMID: 16538991.
547. Mansson A, Anderson H, Colleen S. Time lag to diagnosis of bladder cancer--influence of psychosocial parameters and level of health-care provision. *Scand J Urol Nephrol*. 1993;27(3):363-9. PMID: 8290917.
548. Mariappan P, Chong WL. Prevalence and correlations of lower urinary tract symptoms, erectile dysfunction and incontinence in men from a multiethnic Asian population: Results of a regional population-based survey and comparison with industrialized nations. *BJU Int*. 2006 Dec;98(6):1264-8. PMID: 17034498.
549. Mariotti G, Sciarra A, Gentilucci A, et al. Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment. *J Urol*. 2009 Apr;181(4):1788-93. PMID: 19233390.
550. Markland AD, Richter HE, Burgio KL, et al. Fecal incontinence in obese women with urinary incontinence: prevalence and role of dietary fiber intake. *Am J Obstet Gynecol*. 2009 May;200(5):566 e1-6. PMID: 19136088.
551. Marschall-Kehrel D, Feustel C, Persson de Geeter C, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. *Eur Urol*. 2009 Mar;55(3):729-36. PMID: 18502028.
552. Marshall DF, Boston VE. Altered bladder and bowel function following cutaneous electrical field stimulation in children with spina bifida--interim results of a randomized double-blind placebo-controlled trial. *Eur J Pediatr Surg*. 1997 Dec;7 Suppl 1:41-3. PMID: 9497117.
553. Martis G, Diana M, Ombres M, et al. Retropubic versus perineal radical prostatectomy in early prostate cancer: eight-year experience. *J Surg Oncol*. 2007 May 1;95(6):513-8. PMID: 17226809.
554. Maruyama S, Oki T, Otsuka A, et al. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. *J Urol*. 2006 Jan;175(1):365-9. PMID: 16406943.
555. Masood S, Djaladat H, Kouriefs C, et al. The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. *BJU Int*. 2004 Dec;94(9):1271-4. PMID: 15610103.

556. Massoud R, Federici G, Casciani S, et al. Extraction and determination of oxybutynin in human bladder samples by reversed-phase high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl.* 1999 Oct 29;734(1):163-7. PMID: 10574202.
557. Mather KF, Bakas T. Nursing assistants' perceptions of their ability to provide continence care. *Geriatr Nurs.* 2002 Mar-Apr;23(2):76-81. PMID: 11956519.
558. Mathewson-Chapman M. Pelvic muscle exercise/biofeedback for urinary incontinence after prostatectomy: an education program. *J Cancer Educ.* 1997 Winter;12(4):218-23. PMID: 9440013.
559. Matoka DJ, Averch TD. Predictability of irritative voiding symptoms following photoselective laser vaporization of the prostate. *Can J Urol.* 2007 Oct;14(5):3710-4. PMID: 17949529.
560. Matsubara A, Yasumoto H, Mutaguchi K, et al. Impact of radical perineal prostatectomy on urinary continence and quality of life: a longitudinal study of Japanese patients. *Int J Urol.* 2005 Nov;12(11):953-8. PMID: 16351650.
561. Matsukawa Y, Hattori R, Yoshikawa Y, et al. Declined Urethral Sphincter Function Related to Aging Contributes to Urinary Incontinence after Radical Prostatectomy. 2008 Annual Meeting of the American Urological Association, Orlando, Florida (USA), 17-22 May 2008.
562. Matsuoka N, Moriya Y, Akasu T, et al. Long-term outcome of urinary function after extended lymphadenectomy in patients with distal rectal cancer. *Eur J Surg Oncol.* 2001 Mar;27(2):165-9. PMID: 11289753.
563. Mavuduru RM, Mandal AK, Singh SK, et al. Comparison of HoLEP and TURP in terms of efficacy in the early postoperative period and perioperative morbidity. *Urol Int.* 2009;82(2):130-5. PMID: 19321996.
564. Mayo NE, Gloutney L, Levy AR. A randomized trial of identification bracelets to prevent falls among patients in a rehabilitation hospital. *Arch Phys Med Rehabil.* 1994 Dec;75(12):1302-8. PMID: 7993168.
565. Mazur DJ, Merz JF. Older patients' willingness to trade off urologic adverse outcomes for a better chance at five-year survival in the clinical setting of prostate cancer. *J Am Geriatr Soc.* 1995 Sep;43(9):979-84. PMID: 7657938.
566. McAndrew HF, Malone PS. Continent catheterizable conduits: which stoma, which conduit and which reservoir? *BJU Int.* 2002 Jan;89(1):86-9. PMID: 11849168.
567. McCallum TJ, Moore KN, Griffiths D. Urinary incontinence after radical prostatectomy: implications and urodynamics. *Urol Nurs.* 2001 Apr;21(2):113-9, 24. PMID: 11998279.
568. McCammon KA, Kolm P, Main B, et al. Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. *Urology.* 1999 Sep;54(3):509-16. PMID: 10475363.
569. McCarthy M, Addington-Hall J, Altmann D. The experience of dying with dementia: a retrospective study. *Int J Geriatr Psychiatry.* 1997 Mar;12(3):404-9. PMID: 9152728.

570. McClurg D, Ashe RG, Lowe-Strong AS. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis--a double blind, placebo controlled, randomised clinical trial. *Neurourol Urodyn*. 2008;27(3):231-7. PMID: 17705160.
571. McConnell ES, Lekan-Rutledge D, Nevidjon B, et al. Complexity theory: a long-term care specialty practice exemplar for the education of advanced practice nurses. *J Nurs Educ*. 2004 Feb;43(2):84-7. PMID: 14974517.
572. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med*. 2003 Dec 18;349(25):2387-98. PMID: 14681504.
573. McCormick KA. From clinical trial to health policy--research on urinary incontinence in the adult, Part II. *J Prof Nurs*. 1991 Jul-Aug;7(4):202. PMID: 1894834.
574. McDowell D, Ashe RG, Marshall K, et al. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. *Neurourol Urodyn*. 2006;25(4):337-48. PMID: 16637070.
575. McElveen TL, Waterman FM, Kim H, et al. Factors predicting for urinary incontinence after prostate brachytherapy. *Int J Radiat Oncol Biol Phys*. 2004 Aug 1;59(5):1395-404. PMID: 15275725.
576. McGhee M, O'Neill K, Major K, et al. Evaluation of a nurse-led continence service in the south-west of Glasgow, Scotland. *J Adv Nurs*. 1997 Oct;26(4):723-8. PMID: 9354984.
577. McGlynn B, Al-Saffar N, Begg H, et al. Management of urinary incontinence following radical prostatectomy. *Urol Nurs*. 2004 Dec;24(6):475-82, 515. PMID: 15658733.
578. McPherson CP, Swenson KK, Kjellberg J. Quality of life in patients with prostate cancer. *Semin Oncol Nurs*. 2001 May;17(2):138-46. PMID: 11383245.
579. Melville JL, Fan MY, Newton K, et al. Fecal incontinence in US women: a population-based study. *Am J Obstet Gynecol*. 2005 Dec;193(6):2071-6. PMID: 16325618.
580. Menarini M, Del Popolo G, Di Benedetto P, et al. Trosipium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? *Int J Clin Pharmacol Ther*. 2006 Dec;44(12):623-32. PMID: 17190372.
581. Menon M, Muhletaler F, Campos M, et al. Assessment of early continence after reconstruction of the periprostatic tissues in patients undergoing computer assisted (robotic) prostatectomy: results of a 2 group parallel randomized controlled trial. *J Urol*. 2008 Sep;180(3):1018-23. PMID: 18639300.
582. Merrick GS, Butler WM, Lief JH, et al. Temporal resolution of urinary morbidity following prostate brachytherapy. *Int J Radiat Oncol Biol Phys*. 2000 Apr 1;47(1):121-8. PMID: 10758313.
583. Merrick GS, Butler WM, Wallner K, et al. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. *Urology*. 2002 Jul;60(1):104-8. PMID: 12100933.

584. Merrick GS, Butler WM, Wallner KE, et al. Long-term urinary quality of life after permanent prostate brachytherapy. *Int J Radiat Oncol Biol Phys.* 2003 Jun 1;56(2):454-61. PMID: 12738320.
585. Messer KL, Herzog AR, Seng JS, et al. Evaluation of a mass mailing recruitment strategy to obtain a community sample of women for a clinical trial of an incontinence prevention intervention. *Int Urol Nephrol.* 2006;38(2):255-61. PMID: 16868693.
586. Meyer S, Hohlfeld P, Achtari C, et al. Pelvic floor education after vaginal delivery. *Obstetrics and gynecology;* 2001. p. 673-7.
587. Mezey M, Lavizzo-Mourey RJ, Brunswick J, et al. Consensus among geriatric experts on the components of a complete nursing-home admission assessment. *Nurse Pract.* 1992 Jun;17(6):50, 3-6, 61. PMID: 1608570.
588. Migliari R, Pistolesi D, Leone P, et al. Male bulbourethral sling after radical prostatectomy: intermediate outcomes at 2 to 4-year followup. *J Urol.* 2006 Nov;176(5):2114-8; discussion 8. PMID: 17070273.
589. Miles BJ, Khera M. Can preoperative behavioral training reduce postprostatectomy incontinence? *Nat Clin Pract Urol.* 2006 Jun;3(6):302-3. PMID: 16763638.
590. Miles-Thomas J, Gearhart JP, Gearhart SL. An initial evaluation of pelvic floor function and quality of life of bladder exstrophy patients after ureterosigmoidostomy. *J Gastrointest Surg.* 2006 Apr;10(4):473-7. PMID: 16627210.
591. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. *J Clin Oncol.* 2005 Apr 20;23(12):2772-80. PMID: 15837992.
592. Miller KC, Mack GW, Knight KL, et al. Reflex inhibition of electrically induced muscle cramps in hypohydrated humans. *Med Sci Sports Exerc.* 2010 May;42(5):953-61. PMID: 19997012.
593. Miller NL, Bissonette EA, Bahnson R, et al. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy. *Cancer.* 2003 Mar 1;97(5):1203-10. PMID: 12599226.
594. Milne JL, Spiers JA, Moore KN. Men's experiences following laparoscopic radical prostatectomy: a qualitative descriptive study. *Int J Nurs Stud.* 2008 May;45(5):765-74. PMID: 17482192.
595. Mitropoulos D, Papadoukakis S, Zervas A, et al. Efficacy of tolterodine in preventing urge incontinence immediately after prostatectomy. *Int Urol Nephrol.* 2006;38(2):263-8. PMID: 16868694.
596. Mitsui T, Tanaka H, Moriya K, et al. Outcomes of lower urinary and bowel function in meningomyelocele patients with augmentation enterocystoplasty. *Spinal Cord.* 2008 Jun;46(6):432-7. PMID: 18317489.
597. Mitterberger M, Marksteiner R, Margreiter E, et al. Myoblast and fibroblast therapy for post-prostatectomy urinary incontinence: 1-year followup of 63 patients. *J Urol.* 2008 Jan;179(1):226-31. PMID: 18001790.

598. Mo F, Choi BC, Li FC, et al. Using Health Utility Index (HUI) for measuring the impact on health-related quality of Life (HRQL) among individuals with chronic diseases. *ScientificWorldJournal*. 2004 Aug 27;4:746-57. PMID: 15349514.
599. Mogielnicki RP, Nelson WA, Dulac J. A study of the dying process in elderly hospitalized males. *J Cancer Educ*. 1990;5(2):135-45. PMID: 2206934.
600. Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. *Br J Urol*. 1980 Dec;52(6):472-5. PMID: 7006730.
601. Mok VC, Lam WW, Fan YH, et al. Effects of statins on the progression of cerebral white matter lesion: Post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. *J Neurol*. 2009 May;256(5):750-7. PMID: 19252811.
602. Molander U, Arvidsson L, Milsom I, et al. A longitudinal cohort study of elderly women with urinary tract infections. *Maturitas*. 2000 Feb 15;34(2):127-31. PMID: 10714907.
603. Molander U, Milsom I, Ekelund P, et al. An epidemiological study of urinary incontinence and related urogenital symptoms in elderly women. *Maturitas*. 1990 Apr;12(1):51-60. PMID: 2333037.
604. Moller LA, Lose G, Jorgensen T. The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. *Acta Obstet Gynecol Scand*. 2000 Apr;79(4):298-305. PMID: 10746846.
605. Montague DK, Angermeier KW, Paolone DR. Long-term continence and patient satisfaction after artificial sphincter implantation for urinary incontinence after prostatectomy. *J Urol*. 2001 Aug;166(2):547-9. PMID: 11458065.
606. Moore AA, Siu A, Partridge JM, et al. A randomized trial of office-based screening for common problems in older persons. *Am J Med*. 1997 Apr;102(4):371-8. PMID: 9217619.
607. Moore K, Allen M, Voaklander DC. Pad tests and self-reports of continence in men awaiting radical prostatectomy: establishing baseline norms for males. *Neurourol Urodyn*. 2004;23(7):623-6. PMID: 15382185.
608. Moore K, Griffiths D, Latimer G, et al. Twenty four-hour monitoring of incontinence and bladder function in a community hospital. *J ET Nurs*. 1993 Jul-Aug;20(4):163-8. PMID: 8343556.
609. Moore KN, Estey A. The early post-operative concerns of men after radical prostatectomy. *J Adv Nurs*. 1999 May;29(5):1121-9. PMID: 10320495.
610. Moore KN, Griffiths D, Hughton A. Urinary incontinence after radical prostatectomy: a randomized controlled trial comparing pelvic muscle exercises with or without electrical stimulation. *BJU Int*. 1999 Jan;83(1):57-65. PMID: 10233453.
611. Moore KN, Schieman S, Ackerman T, et al. Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. *Urology*. 2004 Jan;63(1):150-4. PMID: 14751370.

612. Moore KN, Truong V, Estey E, et al. Urinary incontinence after radical prostatectomy: can men at risk be identified preoperatively? *J Wound Ostomy Continence Nurs.* 2007 May-Jun;34(3):270-9; quiz 80-1. PMID: 17505246.
613. Moore KN, Valiquette L, Chetner MP, et al. Return to continence after radical retropubic prostatectomy: a randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. *Urology.* 2008 Dec;72(6):1280-6. PMID: 18384853.
614. Morgan C, Endozoa N, Paradiso C, et al. Enhanced toileting program decreases incontinence in long term care. *Jt Comm J Qual Patient Saf.* 2008 Apr;34(4):206-8. PMID: 18468358.
615. Morgan DJ, Blackburn M, Bax M. Adults with spina bifida and/or hydrocephalus. *Postgrad Med J.* 1995 Jan;71(831):17-21. PMID: 7708585.
616. Mori K. Management of idiopathic normal-pressure hydrocephalus: a multiinstitutional study conducted in Japan. *J Neurosurg.* 2001 Dec;95(6):970-3. PMID: 11765841.
617. Mørkved S, Bø K. Effect of postpartum pelvic floor muscle training in prevention and treatment of urinary incontinence: a one-year follow up. *BJOG : an international journal of obstetrics and gynaecology;* 2000. p. 1022-8.
618. Morkved S, Bo K, Schei B, et al. Pelvic floor muscle training during pregnancy to prevent urinary incontinence: a single-blind randomized controlled trial. *Obstet Gynecol.* 2003 Feb;101(2):313-9. PMID: 12576255.
619. Morkved S, Salvesen KA, Bo K, et al. Pelvic floor muscle strength and thickness in continent and incontinent nulliparous pregnant women. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 Nov-Dec;15(6):384-9; discussion 90. PMID: 15278255.
620. Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. *Value Health.* 2006 Jul-Aug;9(4):272-4. PMID: 16903997.
621. Moseley CB. The impact of federal regulations on urethral catheterization in Virginia nursing homes. *Am J Med Qual.* 1996 Winter;11(4):222-6. PMID: 8972940.
622. Mottet N, Boyer C, Chartier-Kastler E, et al. Artificial urinary sphincter AMS 800 for urinary incontinence after radical prostatectomy: the French experience. *Urol Int.* 1998;60 Suppl 2:25-9; discussion 35. PMID: 9607555.
623. Muncie HL, Jr., Warren JW. Reasons for replacement of long-term urethral catheters: implications for randomized trials. *J Urol.* 1990 Mar;143(3):507-9. PMID: 2406463.
624. Munding M, Wessells H, Thornberry B, et al. Use of tolterodine in children with dysfunctional voiding: an initial report. *J Urol.* 2001 Mar;165(3):926-8. PMID: 11176516.
625. Namiki S, Ishidoya S, Saito S, et al. Natural history of voiding function after radical retropubic prostatectomy. *Urology.* 2006 Jul;68(1):142-7. PMID: 16777193.
626. Namiki S, Kuwahara M, Ioritani N, et al. An evaluation of urinary function after radical prostatectomy in Japanese men: concordance with definitions of urinary continence. *BJU Int.* 2005 Mar;95(4):530-3. PMID: 15705074.

627. Namiki S, Saito S, Ishidoya S, et al. Adverse effect of radical prostatectomy on nocturia and voiding frequency symptoms. *Urology*. 2005 Jul;66(1):147-51. PMID: 15992905.
628. Namiki S, Saito S, Nakagawa H, et al. Impact of unilateral sural nerve graft on recovery of potency and continence following radical prostatectomy: 3-year longitudinal study. *J Urol*. 2007 Jul;178(1):212-6; discussion 6. PMID: 17499797.
629. Namiki S, Takegami M, Kakehi Y, et al. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer. *J Urol*. 2007 Aug;178(2):473-7; discussion 7. PMID: 17561164.
630. Narayanan S, Cerulli A, Kahler KH, et al. Is drug therapy for urinary incontinence used optimally in long-term care facilities? *Journal of the American Medical Directors Association*. 2007 Feb;8(2):98-104. PMID: 21091.
631. Natsume O, Kondo H, Cho M, et al. The impact of radical prostatectomy on patient well-being: a prospective urodynamic study focused on detrusor function. *Hinyokika Kyo*. 2004 Jan;50(1):1-6. PMID: 15032007.
632. Nazarko L. Managing bladder dysfunction using intermittent self-catheterization. *Br J Nurs*. 2009 Jan 22-Feb 11;18(2):110-5. PMID: 19270610.
633. Nemett DR, Fivush BA, Mathews R, et al. A randomized controlled trial of the effectiveness of osteopathy-based manual physical therapy in treating pediatric dysfunctional voiding. *J Pediatr Urol*. 2008 Apr;4(2):100-6. PMID: 18631903.
634. Newman DK. Urinary incontinence in long-term care facilities: current clinical practice. *Director*. 2004 Winter;12(1):30-3; quiz 4. PMID: 19178115.
635. Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. *BJU Int*. 2008 Apr;101(8):1036-42. PMID: 18279452.
636. Nijman RJ, Borgstein NG, Ellsworth P, et al. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. *J Urol*. 2005 Apr;173(4):1334-9. PMID: 15758796.
637. Nijman RJ, Borgstein NG, Ellsworth P, et al. Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. *European urology*. 2007 Nov;52(5):1511-6. PMID: 21140.
638. Nikoletti S, Young J, King M. Evaluation of an electronic monitoring device for urinary incontinence in elderly patients in an acute care setting. *J Wound Ostomy Continence Nurs*. 2004 May-Jun;31(3):138-49. PMID: 15867743.
639. Nitti VW, Adler H, Combs AJ. The role of urodynamics in the evaluation of voiding dysfunction in men after cerebrovascular accident. *J Urol*. 1996 Jan;155(1):263-6. PMID: 7490851.
640. Nitti VW, Dmochowski R, Appell RA, et al. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. *BJU Int*. 2006 Jun;97(6):1262-6. PMID: 16686723.

641. Noguchi M, Kakuma T, Suekane S, et al. A randomized clinical trial of suspension technique for improving early recovery of urinary continence after radical retropubic prostatectomy. *BJU Int.* 2008 Sep;102(8):958-63. PMID: 18485031.
642. Noguchi M, Kakuma T, Tomiyasu K, et al. Effect of an extract of *Ganoderma lucidum* in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study. *Asian J Androl.* 2008 Jul;10(4):651-8. PMID: 18097503.
643. Noonan VK, Kopec JA, Zhang H, et al. Impact of associated conditions resulting from spinal cord injury on health status and quality of life in people with traumatic central cord syndrome. *Arch Phys Med Rehabil.* 2008 Jun;89(6):1074-82. PMID: 18503802.
644. O'Connell B, Baker L, Munro I. The nature and impact of incontinence in men who have undergone prostate surgery and implications for nursing practice. *Contemp Nurse.* 2007 Feb;24(1):65-78. PMID: 17348784.
645. O'Connor I. Management of urinary continence problems in an acute general hospital. *Int J Nurs Pract.* 1996 Mar;2(1):47-9. PMID: 9305033.
646. O'Connor RC, Kuznetsov DD, Patel RV, et al. Artificial urinary sphincter placement in men after cystectomy with orthotopic ileal neobladder: continence, complications, and quality of life. *Urology.* 2002 Apr;59(4):542-5. PMID: 11927310.
647. O'Connor RC, Lyon MB, Guralnick ML, et al. Long-Term Follow-Up of Single Versus Double Cuff Artificial Urinary Sphincter Insertion for Post-Prostatectomy Stress Urinary Incontinence. 2006 Annual Meeting of the American Urological Association (AUA 2006), Atlanta, Georgia (USA), 20-25 May 2006.
648. O'Connor RC, Lyon MB, Guralnick ML, et al. Long-term follow-up of single versus double cuff artificial urinary sphincter insertion for the treatment of severe postprostatectomy stress urinary incontinence. *Urology.* 2008 Jan;71(1):90-3. PMID: 18242372.
649. O'Dell KK, Jacelon C, Morse AN. 'I'd rather just go on as I am'--pelvic floor care preferences of frail, elderly women in residential care. *Urol Nurs.* 2008 Feb;28(1):36-47. PMID: 18335696.
650. O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. *J Geriatr Psychiatry Neurol.* 1992 Jan-Mar;5(1):45-52. PMID: 1571074.
651. Oefelein MG. Prospective predictors of urinary continence after anatomical radical retropubic prostatectomy: a multivariate analysis. *World J Urol.* 2004 Oct;22(4):267-71. PMID: 14727136.
652. Ogushi T, Takahashi S. Effect of Chinese herbal medicine on overactive bladder. *Hinyokika Kyo.* 2007 Dec;53(12):857-62. PMID: 18203522.
653. Ostaszkiwicz J. A clinical nursing leadership model for enhancing continence care for older adults in a subacute inpatient care setting. *J Wound Ostomy Continence Nurs.* 2006 Nov-Dec;33(6):624-9. PMID: 17108772.
654. Ouslander JG. Quality improvement initiatives for urinary incontinence in nursing homes. *J Am Med Dir Assoc.* 2007 Mar;8(3 Suppl):S6-S11. PMID: 17336875.

655. Ouslander JG, Ai-Samarrai N, Schnelle JF. Prompted voiding for nighttime incontinence in nursing homes: is it effective? *Journal of the American Geriatrics Society*; 2001. p. 706-9.
656. Ouslander JG, Greendale GA, Uman G, et al. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. *J Am Geriatr Soc.* 2001 Jun;49(6):803-7. PMID: 11454122.
657. Ouslander JG, Griffiths P, McConnell E, et al. Functional Incidental Training: applicability and feasibility in the Veterans Affairs nursing home patient population. *J Am Med Dir Assoc.* 2005 Mar-Apr;6(2):121-7. PMID: 15871887.
658. Ouslander JG, Griffiths PC, McConnell E, et al. Functional incidental training: a randomized, controlled, crossover trial in Veterans Affairs nursing homes. *J Am Geriatr Soc.* 2005 Jul;53(7):1091-100. PMID: 16108924.
659. Ouslander JG, Schapira M, Schnelle JF. Urine specimen collection from incontinent female nursing home residents. *Journal of the American Geriatrics Society*; 1995. p. 279-81.
660. Ouslander JG, Schapira M, Schnelle JF, et al. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? *Ann Intern Med.* 1995 May 15;122(10):749-54. PMID: 7717597.
661. Ouslander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. *J Am Geriatr Soc.* 1995 Jun;43(6):610-7. PMID: 7775717.
662. Owan T, Kohra T, Miyara Y, et al. Urination assessment after the removal of bladder catheter using a novel urination chart. *Nurs Health Sci.* 2003 Sep;5(3):189-97. PMID: 12877720.
663. Pagliacci MC, Franceschini M, Di Clemente B, et al. A multicentre follow-up of clinical aspects of traumatic spinal cord injury. *Spinal Cord.* 2007 Jun;45(6):404-10. PMID: 17102809.
664. Palese A, Regattin L, Venuti F, et al. Incontinence pad use in patients admitted to medical wards: an Italian multicenter prospective cohort study. *J Wound Ostomy Continence Nurs.* 2007 Nov-Dec;34(6):649-54. PMID: 18030104.
665. Palmer MH. Nurses' knowledge and beliefs about continence interventions in long-term care. *J Adv Nurs.* 1995 Jun;21(6):1065-72. PMID: 7665769.
666. Palmer MH, Bennett RG, Marks J, et al. Urinary incontinence: a program that works. *J Long Term Care Adm.* 1994 Summer;22(2):19-25. PMID: 10137999.
667. Palmer MH, Newman DK. Bladder matters: urinary incontinence in nursing homes. *Am J Nurs.* 2004 Nov;104(11):57-9. PMID: 15616452.
668. Pang X, Boucher W, Triadafilopoulos G, et al. Mast cell and substance P-positive nerve involvement in a patient with both irritable bowel syndrome and interstitial cystitis. *Urology.* 1996 Mar;47(3):436-8. PMID: 8633418.

669. Pang X, Marchand J, Sant GR, et al. Increased number of substance P positive nerve fibres in interstitial cystitis. *Br J Urol*. 1995 Jun;75(6):744-50. PMID: 7542136.
670. Parekh AR, Feng MI, Kirages D, et al. The role of pelvic floor exercises on post-prostatectomy incontinence. *J Urol*. 2003 Jul;170(1):130-3. PMID: 12796664.
671. Park R, Martin S, Goldberg JD, et al. Anastomotic strictures following radical prostatectomy: insights into incidence, effectiveness of intervention, effect on continence, and factors predisposing to occurrence. *Urology*. 2001 Apr;57(4):742-6. PMID: 11306394.
672. Park SC, Jung SW, Lee JW, et al. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. *J Endourol*. 2009 Nov;23(11):1913-7. PMID: 19814699.
673. Parkinson L, Chiarelli P, Byrne J, et al. Continence promotion for older hospital patients following surgery for fractured neck of femur: pilot of a randomized controlled trial. *Clin Interv Aging*. 2007;2(4):705-14. PMID: 18225472.
674. Parsons CL, Rosenberg MT, Sassani P, et al. Quantifying symptoms in men with interstitial cystitis/prostatitis, and its correlation with potassium-sensitivity testing. *BJU international*; 2005. p. 86-90.
675. Parsons JK, Marschke P, Maples P, et al. Effect of methylprednisolone on return of sexual function after nerve-sparing radical retropubic prostatectomy. *Urology*. 2004 Nov;64(5):987-90. PMID: 15533491.
676. Paterson J, Pinnock CB, Marshall VR. Pelvic floor exercises as a treatment for post-micturition dribble. *Br J Urol*. 1997 Jun;79(6):892-7. PMID: 9202555.
677. Payne KA, Hendrix MR, Wade WJ. Caudal bupivacaine for postoperative analgesia in pediatric lower limb surgery. *J Pediatr Surg*. 1993 Feb;28(2):155-7. PMID: 8437068.
678. Pearman JW, Bailey M, Riley LP. Bladder instillations of trisdine compared with catheter introducer for reduction of bacteriuria during intermittent catheterisation of patients with acute spinal cord trauma. *Br J Urol*. 1991 May;67(5):483-90. PMID: 1903999.
679. Peeters ST, Lebesque JV, Heemsbergen WD, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2006 Mar 15;64(4):1151-61. PMID: 16414208.
680. Peirce B. Wound care and the WOC nurse: how did we get here? *J Wound Ostomy Continence Nurs*. 2007 Nov-Dec;34(6):602-4. PMID: 18030097.
681. Pemberton P, Brooks A, Eriksen CM, et al. A comparative study of two types of urinary sheath. *Nurs Times*. 2006 Feb 14-20;102(7):36-41. PMID: 16512048.
682. Pena A. Anorectal malformations. *Semin Pediatr Surg*. 1995 Feb;4(1):35-47. PMID: 7728507.
683. Penalver MA, Barreau G, Sevin BU, et al. Surgery for the treatment of locally recurrent disease. *J Natl Cancer Inst Monogr*. 1996(21):117-22. PMID: 9023840.

684. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. *J Urol*. 2005 May;173(5):1701-5. PMID: 15821561.
685. Perez LM, Webster GD. Successful outcome of artificial urinary sphincters in men with post-prostatectomy urinary incontinence despite adverse implantation features. *J Urol*. 1992 Oct;148(4):1166-70. PMID: 1404630.
686. Perez MA, Meyerowitz BE, Lieskovsky G, et al. Quality of life and sexuality following radical prostatectomy in patients with prostate cancer who use or do not use erectile aids. *Urology*. 1997 Nov;50(5):740-6. PMID: 9372885.
687. Perez MA, Skinner EC, Meyerowitz BE. Sexuality and intimacy following radical prostatectomy: patient and partner perspectives. *Health Psychol*. 2002 May;21(3):288-93. PMID: 12027035.
688. Perissinotto MCR, Da'Ancona CAL, Campos RM, et al. Physiotherapeutic for Treatment of Post Radical Prostatectomy Urinary Incontinence. 38th Annual Meeting of the International Continence Society (ICS 2008), Cairo International Congress Center (CICC), Cairo (Egypt), 20-24 Oct 2008.
689. Perrotte P, Litwin MS, McGuire EJ, et al. Quality of life after salvage cryotherapy: the impact of treatment parameters. *J Urol*. 1999 Aug;162(2):398-402. PMID: 10411046.
690. Peschers UM, Fanger G, Schaer GN, et al. Bladder neck mobility in continent nulliparous women. *BJOG : an international journal of obstetrics and gynaecology*; 2001. pp. 320-4.
691. Peters K, Carrico D, Burks F. Validation of a sham for percutaneous tibial nerve stimulation (PTNS). *Neurourol Urodyn*. 2009;28(1):58-61. PMID: 18671297.
692. Petersen T, Nielsen JB, Schroder HD. Intravesical capsaicin in patients with detrusor hyper-reflexia--a placebo-controlled cross-over study. *Scand J Urol Nephrol*. 1999 Apr;33(2):104-10. PMID: 10360450.
693. Petronijevic V, Lazovic M, Vlajkovic M, et al. Botulinum toxin type A in combination with standard urotherapy for children with dysfunctional voiding. *J Urol*. 2007 Dec;178(6):2599-602; discussion 602-3. PMID: 17945299.
694. Petry H, Berry DL, Spichiger E, et al. Responses and experiences after radical prostatectomy: perceptions of married couples in Switzerland. *Int J Nurs Stud*. 2004 Jul;41(5):507-13. PMID: 15120979.
695. Pfister C, Cappele O, Dunet F, et al. Assessment of the intrinsic urethral sphincter component function in postprostatectomy urinary incontinence. *Neurourol Urodyn*. 2002;21(3):194-7. PMID: 11948711.
696. Pfister SM, Dougherty MC. Behavioral management for bladder control: response in selected rural residential care homes. *J Community Health Nurs*. 1994;11(3):155-64. PMID: 7964934.
697. Phelan MW, Franks M, Somogyi GT, et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. *J Urol*. 2001 Apr;165(4):1107-10. PMID: 11257648.

698. Phelan S, Kanaya AM, Subak LL, et al. Prevalence and risk factors for urinary incontinence in overweight and obese diabetic women: action for health in diabetes (look ahead) study. *Diabetes Care*. 2009 Aug;32(8):1391-7. PMID: 19487639.
699. Phillips CD, Morris JN, Hawes C, et al. Association of the Resident Assessment Instrument (RAI) with changes in function, cognition, and psychosocial status. *J Am Geriatr Soc*. 1997 Aug;45(8):986-93. PMID: 9256853.
700. Pinar K, Moore KN, Smits E, et al. Leg bag comparison: reported skin health, comfort, and satisfaction. *J Wound Ostomy Continence Nurs*. 2009 May-Jun;36(3):319-26. PMID: 19448514.
701. Pinkawa M, Fishedick K, Asadpour B, et al. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer - a prospective analysis. *Radiother Oncol*. 2008 Jul;88(1):135-9. PMID: 18022263.
702. Pisarska M, Sajdak S. Lower urinary tract function after postoperative radiotherapy in the treatment of cervical cancer. *Eur J Gynaecol Oncol*. 2003;24(6):490-4. PMID: 14658587.
703. Pisters LL, Dinney CP, Pettaway CA, et al. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. *J Urol*. 1999 Feb;161(2):509-14. PMID: 9915437.
704. Pisters LL, von Eschenbach AC, Scott SM, et al. The efficacy and complications of salvage cryotherapy of the prostate. *J Urol*. 1997 Mar;157(3):921-5. PMID: 9072600.
705. Pohar SL, Jones CA, Warren S, et al. Health status and health care utilization of multiple sclerosis in Canada. *Can J Neurol Sci*. 2007 May;34(2):167-74. PMID: 17598593.
706. Pollack J, Holm T, Cedermark B, et al. Late adverse effects of short-course preoperative radiotherapy in rectal cancer. *Br J Surg*. 2006 Dec;93(12):1519-25. PMID: 17054311.
707. Ponholzer A, Brossner C, Struhal G, et al. Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. *World J Urol*. 2006 Aug;24(3):325-30. PMID: 16688458.
708. Porpiglia F, Fiori C, Grande S, et al. Selective versus standard ligation of the deep venous complex during laparoscopic radical prostatectomy: effects on continence, blood loss, and margin status. *Eur Urol*. 2009 Jun;55(6):1377-83. PMID: 19243886.
709. Porru D, Campus G, Caria A, et al. Impact of early pelvic floor rehabilitation after transurethral resection of the prostate. *Neurourol Urodyn*. 2001;20(1):53-9. PMID: 11135382.
710. Porru D, Tinelli C, Gerardini M, et al. Evaluation of urinary and general symptoms and correlation with other clinical parameters in interstitial cystitis patients. *Neurourol Urodyn*. 2005;24(1):69-73. PMID: 15573384.
711. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. *J Natl Cancer Inst*. 2004 Sep 15;96(18):1358-67. PMID: 15367568.

712. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. *J Natl Cancer Inst.* 2000 Oct 4;92(19):1582-92. PMID: 11018094.
713. Powel LL, Clark JA. The value of the marginalia as an adjunct to structured questionnaires: experiences of men after prostate cancer surgery. *Qual Life Res.* 2005 Apr;14(3):827-35. PMID: 16022075.
714. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. *Clin Rehabil.* 2003 Feb;17(1):42-7. PMID: 12617378.
715. Praud C, Sebe P, Bierinx AS, et al. Improvement of urethral sphincter deficiency in female rats following autologous skeletal muscle myoblasts grafting. *Cell Transplant.* 2007;16(7):741-9. PMID: 18019363.
716. Protogerou V, Moschou M, Antoniou N, et al. Modified S-pouch neobladder vs ileal conduit and a matched control population: a quality-of-life survey. *BJU Int.* 2004 Aug;94(3):350-4. PMID: 15291866.
717. Puri A, Bhatnagar V, Grover VP, et al. Urodynamics-based evidence for the beneficial effect of imipramine on valve bladders in children. *Eur J Pediatr Surg.* 2005 Oct;15(5):347-53. PMID: 16254848.
718. Radojicic ZI, Perovic SV, Milic NM. Is it reasonable to treat refractory voiding dysfunction in children with botulinum-A toxin? *J Urol.* 2006 Jul;176(1):332-6; discussion 6. PMID: 16753436.
719. Rajpurkar AD, Onur R, Singla A. Patient satisfaction and clinical efficacy of the new perineal bone-anchored male sling. *Eur Urol.* 2005 Feb;47(2):237-42; discussion 42. PMID: 15661420.
720. Rantz MJ. Examining MDS (Minimum Data Set) resident assessments for the impact on public policy. *J Long Term Care Adm.* 1995 Fall-Winter;23(3):18-21. PMID: 10156663.
721. Rao J, Koay SK, Lau WK, et al. Patient-reported urinary continence (third-party interview): results of post-radical retropubic prostatectomy in Singaporeans. *Asian J Surg.* 2005 Jul;28(3):207-10. PMID: 16024318.
722. Rapp DE, Reynolds WS, Lucioni A, et al. Advance Sling Placement in the Treatment of Post-Prostatectomy Urinary Incontinence. 2007 Annual Meeting of the American Urological Association (AUA 2007), Anaheim, California (USA), 19-24 May 2007.
723. Rapp K, Lamb SE, Buchele G, et al. Prevention of falls in nursing homes: subgroup analyses of a randomized fall prevention trial. *Journal of the American Geriatrics Society*; 2008. p. 1092-7.
724. Ratto C, Grillo E, Parello A, et al. Sacral neuromodulation in treatment of fecal incontinence following anterior resection and chemoradiation for rectal cancer. *Dis Colon Rectum.* 2005 May;48(5):1027-36. PMID: 15785890.
725. Reddy SM, Ruby J, Wallace M, et al. Patient self-assessment of complications and quality of life after conformal neutron and photon irradiation for localized prostate cancer. *Radiat Oncol Investig.* 1997;5(5):252-6. PMID: 9372548.

726. Reeve BB, Potosky AL, Willis GB. Should function and bother be measured and reported separately for prostate cancer quality-of-life domains? *Urology*. 2006 Sep;68(3):599-603. PMID: 16979720.
727. Rehder P, Gozzi C. Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy. *Eur Urol*. 2007 Sep;52(3):860-6. PMID: 17316969.
728. Rehder P, Lunacek A, Bartsch G, et al. Principles of Anatomy and Histology for Male Transobturator Tape (TOT) Suspension for the Treatment of Post-Prostatectomy Urinary Incontinence. 21st Annual Congress of the European Association of Urology (EAU 2006), Palais des Congres, Paris (France), 5-8 Apr 2006.
729. Rehman J, Ragab MM, Venkatesh R, et al. Laparoscopic radical prostatectomy: Washington University initial experience and prospective evaluation of quality of life. *J Endourol*. 2004 Apr;18(3):277-87. PMID: 15225395.
730. Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. *Arch Intern Med*. 2004 Apr 26;164(8):871-9. PMID: 15111373.
731. Reinberg Y, Crocker J, Wolpert J, et al. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. *J Urol*. 2003 Jan;169(1):317-9. PMID: 12478180.
732. Reis F, Netto NR, Jr., Reinato JA, et al. The impact of prostatectomy and brachytherapy in patients with localized prostate cancer. *Int Urol Nephrol*. 2004;36(2):187-90. PMID: 15368690.
733. Reitz A, Schmid DM, Curt A, et al. Afferent fibers of the pudendal nerve modulate sympathetic neurons controlling the bladder neck. *Neurourol Urodyn*. 2003;22(6):597-601. PMID: 12951671.
734. Remsburg RE, Palmer MH, Langford AM, et al. Staff compliance with and ratings of effectiveness of a prompted voiding program in a long-term care facility. *J Wound Ostomy Continence Nurs*. 1999 Sep;26(5):261-9. PMID: 10795210.
735. Resnick B, Keilman LJ, Calabrese B, et al. Nursing staff beliefs and expectations about continence care in nursing homes. *J Wound Ostomy Continence Nurs*. 2006 Nov-Dec;33(6):610-8. PMID: 17108770.
736. Reuben DB, Maly RC, Hirsch SH, et al. Physician implementation of and patient adherence to recommendations from comprehensive geriatric assessment. *Am J Med*. 1996 Apr;100(4):444-51. PMID: 8610732.
737. Reynolds WS, Patel R, Msezane L, et al. Current use of artificial urinary sphincters in the United States. *J Urol*. 2007 Aug;178(2):578-83. PMID: 17570407.
738. Ricketts RR, Woodard JR, Zwiren GT, et al. Modern treatment of cloacal exstrophy. *J Pediatr Surg*. 1991 Apr;26(4):444-8; discussion 8-50. PMID: 2056406.
739. Rintala R, Lahdenne P, Lindahl H, et al. Anorectal function in adults operated for a benign sacrococcygeal teratoma. *J Pediatr Surg*. 1993 Sep;28(9):1165-7. PMID: 8308684.

740. Rintala R, Mildh L, Lindahl H. Fecal continence and quality of life for adult patients with an operated high or intermediate anorectal malformation. *J Pediatr Surg.* 1994 Jun;29(6):777-80. PMID: 8078019.
741. Rizk DE, Shaheen H, Thomas L, et al. The prevalence and determinants of health care-seeking behavior for urinary incontinence in United Arab Emirates women. *Int Urogynecol J Pelvic Floor Dysfunct.* 1999;10(3):160-5. PMID: 10430008.
742. Roberts JM, Gonzalez CB, Sampsel C. Why do supportive birth attendants become directive of maternal bearing-down efforts in second-stage labor? *J Midwifery Womens Health.* 2007 Mar-Apr;52(2):134-41. PMID: 17336819.
743. Roberts RO, Jacobsen SJ, Rhodes T, et al. Urinary incontinence in a community-based cohort: prevalence and healthcare-seeking. *J Am Geriatr Soc.* 1998 Apr;46(4):467-72. PMID: 9560070.
744. Robinson JP. Managing urinary incontinence in the nursing home: residents' perspectives. *J Adv Nurs.* 2000 Jan;31(1):68-77. PMID: 10632795.
745. Robinson JP. Phases of the qualitative research interview with institutionalized elderly individuals. *J Gerontol Nurs.* 2000 Nov;26(11):17-23. PMID: 11883617.
746. Robinson JP, Avi-Itzhak T, McCorkle R. Psychometric properties of the Male Urogenital Distress Inventory (MUDI) and Male Urinary Symptom Impact Questionnaire (MUSIQ) in patients following radical prostatectomy. *Urol Nurs.* 2007 Dec;27(6):512-8. PMID: 18217534.
747. Robinson JW, Donnelly BJ, Coupland K, et al. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. *Urol Oncol.* 2006 Nov-Dec;24(6):472-86. PMID: 17138127.
748. Roehrborn CG, Abrams P, Rovner ES, et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. *BJU Int.* 2006 May;97(5):1003-6. PMID: 16643482.
749. Roehrborn CG, Kaplan SA, Kraus SR, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. *Urology.* 2008 Nov;72(5):1061-7; discussion 7. PMID: 18817961.
750. Rogers CG, Su LM, Link RE, et al. Age stratified functional outcomes after laparoscopic radical prostatectomy. *J Urol.* 2006 Dec;176(6 Pt 1):2448-52. PMID: 17085126.
751. Rogers J. Care pathways for paediatric continence. *Nurs Times.* 2006 Jun 27-Jul 3;102(26):51. PMID: 16845820.
752. Rogers MA, Mody L, Kaufman SR, et al. Use of urinary collection devices in skilled nursing facilities in five states. *Journal of the American Geriatrics Society.* 2008 May;56(5):854-61. PMID: 21087.
753. Rondorf-Klym LM, Colling J. Quality of life after radical prostatectomy. *Oncol Nurs Forum.* 2003 Mar-Apr;30(2):E24-32. PMID: 12692667.

754. Rose MA, Baigis-Smith J, Smith D, et al. Behavioral management of urinary incontinence in homebound older adults. *Home Healthc Nurse*. 1990 Sep-Oct;8(5):10-5. PMID: 2243023.
755. Rossignol G, Leandri P, Gautier JR, et al. Radical retropubic prostatectomy: complications and quality of life (429 cases, 1983-1989). *Eur Urol*. 1991;19(3):186-91. PMID: 1855524.
756. Rovner ES, Kreder K, Sussman DO, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. *J Urol*. 2008 Sep;180(3):1034-41. PMID: 18639297.
757. Rovner ES, Rackley R, Nitti VW, et al. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. *Urology*. 2008 Sep;72(3):488-93. PMID: 18639327.
758. Ruiz-Deya G, Davis R, Srivastav SK, et al. Outpatient radical prostatectomy: impact of standard perineal approach on patient outcome. *J Urol*. 2001 Aug;166(2):581-6. PMID: 11458072.
759. Sacco E, Prayer-Galetti T, Pinto F, et al. Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. *BJU Int*. 2006 Jun;97(6):1234-41. PMID: 16686718.
760. Sackett CK. Spina bifida. Part 3. Implications for bladder and bowel management. *Urol Nurs*. 1993 Dec;13(4):104-6. PMID: 8290995.
761. Sackley CM, Rodriguez NA, van den Berg M, et al. A phase II exploratory cluster randomized controlled trial of a group mobility training and staff education intervention to promote urinary continence in UK care homes. *Clin Rehabil*. 2008 Aug;22(8):714-21. PMID: 18678571.
762. Sahai A, Dowson C, Khan MS, et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. *Urology*. 2010 Mar;75(3):552-8. PMID: 20035984.
763. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. *J Urol*. 2007 Jun;177(6):2231-6. PMID: 17509328.
764. Saigal CS, Gornbein J, Reid K, et al. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer. *Qual Life Res*. 2002 Aug;11(5):405-14. PMID: 12113388.
765. Saint S, Lipsky BA, Baker PD, et al. Urinary catheters: what type do men and their nurses prefer? *J Am Geriatr Soc*. 1999 Dec;47(12):1453-7. PMID: 10591242.
766. Saito M, Kawatani M, Kinoshita Y, et al. Effectiveness of an anti-inflammatory drug, loxoprofen, for patients with nocturia. *Int J Urol*. 2005 Aug;12(8):779-82. PMID: 16174058.
767. Saito S, Namiki S, Numahata K, et al. Relevance of postcatheter removal incontinence to postoperative urinary function after radical prostatectomy. *Int J Urol*. 2006 Sep;13(9):1191-6. PMID: 16984551.

768. Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. *Auton Neurosci*. 2001 Sep 17;92(1-2):76-85. PMID: 11570707.
769. Sakuragi N, Todo Y, Kudo M, et al. A systematic nerve-sparing radical hysterectomy technique in invasive cervical cancer for preserving postsurgical bladder function. *Int J Gynecol Cancer*. 2005 Mar-Apr;15(2):389-97. PMID: 15823132.
770. Salomon L, Anastasiadis A, Saint F, et al. Introducing a new, simple scoring system to evaluate oncological and functional outcome after radical prostatectomy. *Scand J Urol Nephrol*. 2003;37(5):392-5. PMID: 14594687.
771. Salomon L, Saint F, Anastasiadis AG, et al. Combined reporting of cancer control and functional results of radical prostatectomy. *Eur Urol*. 2003 Dec;44(6):656-60. PMID: 14644116.
772. Saltvedt I, Mo ES, Fayers P, et al. Reduced mortality in treating acutely sick, frail older patients in a geriatric evaluation and management unit. A prospective randomized trial. *J Am Geriatr Soc*. 2002 May;50(5):792-8. PMID: 12028163.
773. Salvesen KA, Morkved S. Randomised controlled trial of pelvic floor muscle training during pregnancy. *BMJ*. 2004 Aug 14;329(7462):378-80. PMID: 15253920.
774. Sampsel CM, Messer KL, Seng JS, et al. Learning outcomes of a group behavioral modification program to prevent urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Nov-Dec;16(6):441-6. PMID: 16237512.
775. Sampsel CM, Miller JM, Luecha Y, et al. Provider support of spontaneous pushing during the second stage of labor. *J Obstet Gynecol Neonatal Nurs*. 2005 Nov-Dec;34(6):695-702. PMID: 16282227.
776. Samuelsson EC, Victor FT, Svardsudd KF. Five-year incidence and remission rates of female urinary incontinence in a Swedish population less than 65 years old. *Am J Obstet Gynecol*. 2000 Sep;183(3):568-74. PMID: 10992175.
777. Sanchez-Ortiz RF, Broderick GA, Chaikin DC, et al. Collagen injection therapy for post-radical retropubic prostatectomy incontinence: role of Valsalva leak point pressure. *J Urol*. 1997 Dec;158(6):2132-6. PMID: 9366329.
778. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. *N Engl J Med*. 2008 Mar 20;358(12):1250-61. PMID: 18354103.
779. Sanderson KM, Penson DF, Cai J, et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. *J Urol*. 2006 Nov;176(5):2025-31; discussion 31-2. PMID: 17070244.
780. Santaniello F, Giannantoni A, Cochetti G, et al. Body mass index and lower urinary tract symptoms in women. *Arch Ital Urol Androl*. 2007 Mar;79(1):17-9. PMID: 17484398.
781. Santarosa RP, Blaiwas JG. Periurethral injection of autologous fat for the treatment of sphincteric incontinence. *J Urol*. 1994 Mar;151(3):607-11. PMID: 8308969.

782. Santis WF, Hoffman MA, Dewolf WC. Early catheter removal in 100 consecutive patients undergoing radical retropubic prostatectomy. *BJU Int.* 2000 Jun;85(9):1067-8. PMID: 10848696.
783. Santoro G, Wieczorek P, Shobeiri SA, et al. Interobserver and interdisciplinary reliability of 3D endovaginal ultrasound assessment of pelvic floor anatomy. *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. 29.
784. Saxer S, de Bie RA, Dassen T, et al. Nurses' knowledge and practice about urinary incontinence in nursing home care. *Nurse education today.* 2008 Nov;28(8):926-34. PMID: 21083.
785. Schafer JW, Welzel G, Trojan L, et al. Long-term health-related quality-of-life outcomes after permanent prostate brachytherapy. *Onkologie.* 2008 Nov;31(11):599-603. PMID: 19145092.
786. Schaffer JI, Bloom SL, Casey BM, et al. A randomized trial of the effects of coached vs uncoached maternal pushing during the second stage of labor on postpartum pelvic floor structure and function. *Am J Obstet Gynecol.* 2005 May;192(5):1692-6. PMID: 15902179.
787. Schlarp O, Huebner WA. Single Centre Austrian Study Evaluating the Adjustable Continence Therapy (Proact) for Male Post Prostatectomy Stress Urinary Incontinence- Last 17 Months Follow Up. 21st Annual Congress of the European Association of Urology (EAU 2006), Palais des Congres, Paris (France), 5-8 Apr 2006.
788. Schlenker B, Gratzke C, Reich O, et al. Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. *Eur Urol.* 2006 Jun;49(6):1075-8. PMID: 16481094.
789. Schneider T, Sperling H, Rossi R, et al. Do early injections of bulking agents following radical prostatectomy improve early continence? *World J Urol.* 2005 Nov;23(5):338-42. PMID: 16261366.
790. Schnelle JF. Treatment of urinary incontinence in nursing home patients by prompted voiding. *Journal of the American Geriatrics Society.* 1990;38(3):356-60.
791. Schnelle JF, Alessi CA, Al-Samarrai NR, et al. The nursing home at night: effects of an intervention on noise, light, and sleep. *J Am Geriatr Soc.* 1999 Apr;47(4):430-8. PMID: 10203118.
792. Schnelle JF, Kapur K, Alessi C, et al. Does an exercise and incontinence intervention save healthcare costs in a nursing home population? *J Am Geriatr Soc.* 2003 Feb;51(2):161-8. PMID: 12558711.
793. Schnelle JF, Keeler E, Hays RD, et al. A cost and value analysis of two interventions with incontinent nursing home residents. *J Am Geriatr Soc.* 1995 Oct;43(10):1112-7. PMID: 7560701.
794. Schnelle JF, Leung FW. Urinary and Fecal Incontinence in Nursing Homes. *Gastroenterology.* 2004;126(1).

795. Schnelle JF, Leung FW, Rao SS, et al. A controlled trial of an intervention to improve urinary and fecal incontinence and constipation. *J Am Geriatr Soc.* 2010 Aug;58(8):1504-11. PMID: 20653804.
796. Schnelle JF, MacRae PG, Ouslander JG, et al. Functional Incidental Training, mobility performance, and incontinence care with nursing home residents. *J Am Geriatr Soc.* 1995 Dec;43(12):1356-62. PMID: 7490386.
797. Schnelle JF, Ouslander JG, Cruise PA. Policy without technology: a barrier to improving nursing home care. *Gerontologist.* 1997 Aug;37(4):527-32. PMID: 9279042.
798. Schnelle JF, Ouslander JG, Osterweil D, et al. Total quality management: administrative and clinical applications in nursing homes. *J Am Geriatr Soc.* 1993 Nov;41(11):1259-66. PMID: 8227902.
799. Schnelle JF, Ouslander JG, Simmons SF, et al. The nighttime environment, incontinence care, and sleep disruption in nursing homes. *J Am Geriatr Soc.* 1993 Sep;41(9):910-4. PMID: 8409176.
800. Schoeggl A, Reddy M, Matula C. Neurological outcome following laminectomy in spinal metastases. *Spinal Cord.* 2002 Jul;40(7):363-6. PMID: 12080464.
801. Schulte-Baukloh H, Knispel HH, Stolze T, et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. *Urology.* 2005 Oct;66(4):865-70; discussion 70. PMID: 16230156.
802. Schulte-Baukloh H, Murtz G, Henne T, et al. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis. *BJU Int.* 2006 Feb;97(2):355-8. PMID: 16430646.
803. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. *J Urol.* 2005 Jul;174(1):196-200. PMID: 15947626.
804. Schurch B, Denys P, Kozma CM, et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. *Eur Urol.* 2007 Sep;52(3):850-8. PMID: 17467889.
805. Schuster TG, Marcovich R, Sheffield J, et al. Radical cystectomy for bladder cancer after definitive prostate cancer treatment. *Urology.* 2003 Feb;61(2):342-7; discussion 7. PMID: 12597943.
806. Sears CL, Wright J, O'Brien J, et al. The racial distribution of female pelvic floor disorders in an equal access health care system. *J Urol.* 2009 Jan;181(1):187-92. PMID: 19013607.
807. Sebesta M, Cespedes RD, Luhman E, et al. Questionnaire-based outcomes of urinary incontinence and satisfaction rates after radical prostatectomy in a national study population. *Urology.* 2002 Dec;60(6):1055-8. PMID: 12475669.
808. Seki N, Mochida O, Kinukawa N, et al. Holmium laser enucleation for prostatic adenoma: analysis of learning curve over the course of 70 consecutive cases. *J Urol.* 2003 Nov;170(5):1847-50. PMID: 14532790.

809. Seki N, Tatsugami K, Naito S. Holmium laser enucleation of the prostate: comparison of outcomes according to prostate size in 97 Japanese patients. *J Endourol.* 2007 Feb;21(2):192-6. PMID: 17338621.
810. Selli C, De Antoni P, Moro U, et al. Role of bladder neck preservation in urinary continence following radical retropubic prostatectomy. *Scand J Urol Nephrol.* 2004;38(1):32-7. PMID: 15204424.
811. Senior J. Clean intermittent self-catheterisation and children. *Br J Community Nurs.* 2001 Aug;6(8):381-6. PMID: 11865205.
812. Seveso M, Ceresoli A, Zanetti G, et al. Bladder training in patients with urinary incontinence in prostatic post-adenomectomy and TURP. *IL BLADDER TRAINING NEL PAZIENTE INCONTINENTE POST ADENOMECTOMIA PROSTATICA E TURP.* 1993;7(SUPPL. 2):167-8.
813. Sgadari A, Topinkova E, Bjornson J, et al. Urinary incontinence in nursing home residents: a cross-national comparison. *Age Ageing.* 1997 Sep;26 Suppl 2:49-54. PMID: 9464555.
814. Shafik A. Straining puborectalis reflex: Description and significance of a “new” reflex. *Anatomical Record;* 1991. p. 281-4.
815. Shafik A, Shafik IA. Overactive bladder inhibition in response to pelvic floor muscle exercises. *World journal of urology;* 2003. p. 374-7.
816. Shah PN, Maly RC, Frank JC, et al. Managing geriatric syndromes: what geriatric assessment teams recommend, what primary care physicians implement, what patients adhere to. *J Am Geriatr Soc.* 1997 Apr;45(4):413-9. PMID: 9100708.
817. Shahin AY, Hameed DA. Does visceral peritoneal closure affect post-cesarean urinary symptoms? A randomized clinical trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2010 Jan;21(1):33-41. PMID: 19771385.
818. Shehu BB, Ameh EA, Ismail NJ. Spina bifida cystica: selective management in Zaria, Nigeria. *Ann Trop Paediatr.* 2000 Sep;20(3):239-42. PMID: 11064780.
819. Shelfo SW, Obek C, Soloway MS. Update on bladder neck preservation during radical retropubic prostatectomy: impact on pathologic outcome, anastomotic strictures, and continence. *Urology.* 1998 Jan;51(1):73-8. PMID: 9457292.
820. Sherman AM, Shumaker SA, Kancler C, et al. Baseline health-related quality of life in postmenopausal women with coronary heart disease: the Estrogen Replacement and Atherosclerosis (ERA) trial. *J Womens Health (Larchmt).* 2003 May;12(4):351-62. PMID: 12804342.
821. Sherman AM, Shumaker SA, Sharp P, et al. No effect of HRT on health-related quality of life in postmenopausal women with heart disease. *Minerva Ginecol.* 2003 Dec;55(6):511-7. PMID: 14676740.
822. Shih YC, Hartzema AG, Tolleson-Rinehart S. Labor costs associated with incontinence in long-term care facilities. *Urology.* 2003 Sep;62(3):442-6. PMID: 12946743.

823. Shimabukuro T, Naito K. Evaluation of lower urinary tract symptoms and how bothersome it was with or without urinary incontinence in apparently healthy persons of both sexes. *Hinyokika Kyo*. 2007 Mar;53(3):157-62. PMID: 17447483.
824. Shukla AR, Pow-Sang JM, Helal MA, et al. Urinary incontinence after continent urinary diversion using cecal wrap or plicated ileum: a patient questionnaire review. *Urology*. 2003 Feb;61(2):328-31. PMID: 12597940.
825. Siegmund W, Sillen U, Lackgren G, et al. Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder. *Clin Pharmacokinet*. 2010 May 1;49(5):335-42. PMID: 20384395.
826. Silva C, Silva J, Ribeiro MJ, et al. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. *Eur Urol*. 2005 Oct;48(4):650-5. PMID: 15961217.
827. Silver N, Sandage B, Sabounjian L, et al. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. *J Clin Pharmacol*. 2010 Feb;50(2):143-50. PMID: 19948948.
828. Simmons SF, Ouslander JG. Resident and family satisfaction with incontinence and mobility care: sensitivity to intervention effects? *Gerontologist*. 2005 Jun;45(3):318-26. PMID: 15933272.
829. Simmons SF, Schnelle JF. Strategies to measure nursing home residents' satisfaction and preferences related to incontinence and mobility care: implications for evaluating intervention effects. *Gerontologist*. 1999 Jun;39(3):345-55. PMID: 10396892.
830. Singh BK, Masey H, Morton R. Levels of continence in children with cerebral palsy. *Paediatr Nurs*. 2006 May;18(4):23-6. PMID: 16719038.
831. Sink KM, Thomas J, 3rd, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. *Journal of the American Geriatrics Society*. 2008 May;56(5):847-53. PMID: 21086.
832. Sitoh YY, Lau TC, Zochling J, et al. Determinants of health-related quality of life in institutionalised older persons in northern Sydney. *Intern Med J*. 2005 Feb;35(2):131-4. PMID: 15705146.
833. Skjeldestad FE, Hagen B. Long-term consequences of gynecological cancer treatment on urinary incontinence: a population-based cross-sectional study. *Acta Obstet Gynecol Scand*. 2008;87(4):469-75. PMID: 18382876.
834. Skjeldestad FE, Rannestad T. Urinary incontinence and quality of life in long-term gynecological cancer survivors: a population-based cross-sectional study. *Acta Obstet Gynecol Scand*. 2009;88(2):192-9. PMID: 19031296.
835. Skobejko-Wlodarska L. Treatment of neuropathic urinary and faecal incontinence. *Eur J Pediatr Surg*. 2002 Oct;12(5):318-21. PMID: 12469258.
836. Sladden MJ, Hughes AM, Hirst GH, et al. A community study of lower urinary tract symptoms in older men in Sydney, Australia. *Aust N Z J Surg*. 2000 May;70(5):322-8. PMID: 10830592.

837. Sloane PD, Davidson S, Knight N, et al. Severe disruptive vocalizers. *J Am Geriatr Soc*. 1999 Apr;47(4):439-45. PMID: 10203119.
838. Sloss EM, Solomon DH, Shekelle PG, et al. Selecting target conditions for quality of care improvement in vulnerable older adults. *J Am Geriatr Soc*. 2000 Apr;48(4):363-9. PMID: 10798460.
839. Smith DN, Appell RA, Rackley RR, et al. Collagen injection therapy for post-prostatectomy incontinence. *J Urol*. 1998 Aug;160(2):364-7. PMID: 9679878.
840. Smith DS, Krygiel J, Nease RF, Jr., et al. Patient preferences for outcomes associated with surgical management of prostate cancer. *J Urol*. 2002 May;167(5):2117-22. PMID: 11956454.
841. Smith EA, Woodard JR, Broecker BH, et al. Current urologic management of cloacal exstrophy: experience with 11 patients. *J Pediatr Surg*. 1997 Feb;32(2):256-61; discussion 61-2. PMID: 9044133.
842. Smith PG, Bradshaw S. Innervation of the proximal urethra of ovariectomized and estrogen-treated female rats. *Histol Histopathol*. 2004 Oct;19(4):1109-16. PMID: 15375753.
843. Soler D, Borzyskowski M. Lower urinary tract dysfunction in children with central nervous system tumours. *Arch Dis Child*. 1998 Oct;79(4):344-7. PMID: 9875046.
844. Soliman SA, Wadie BS, Ibrahim el HE, et al. Rotoresection versus transurethral resection of the prostate: short-term evaluation of a prospective randomized study. *J Urol*. 2007 Mar;177(3):1036-9. PMID: 17296407.
845. Sommer BR, O'Hara R, Askari N, et al. The effect of oxybutynin treatment on cognition in children with diurnal incontinence. *J Urol*. 2005 Jun;173(6):2125-7. PMID: 15879864.
846. Sommers BD, Beard CJ, D'Amico AV, et al. Predictors of patient preferences and treatment choices for localized prostate cancer. *Cancer*. 2008 Oct 15;113(8):2058-67. PMID: 18704993.
847. Sousa-Escandon A, Cabrera J, Mantovani F, et al. Adjustable suburethral sling (male remeex system) in the treatment of male stress urinary incontinence: a multicentric European study. *Eur Urol*. 2007 Nov;52(5):1473-9. PMID: 17560016.
848. Sousa-Escandon A, Rodriguez Gomez JI, Uribarri Gonzalez C, et al. Externally readjustable sling for treatment of male stress urinary incontinence: points of technique and preliminary results. *J Endourol*. 2004 Feb;18(1):113-8. PMID: 15006064.
849. Spaliviero M, Araki M, Culkin DJ, et al. Incidence, management, and prevention of perioperative complications of GreenLight HPS laser photoselective vaporization prostatectomy: experience in the first 70 patients. *J Endourol*. 2009 Mar;23(3):495-502. PMID: 19265468.
850. Spaliviero M, Araki M, Wong C. Short-term outcomes of Greenlight HPS laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH). *J Endourol*. 2008 Oct;22(10):2341-7. PMID: 18937595.

851. Spector WD. Correlates of pressure sores in nursing homes: evidence from the National Medical Expenditure Survey. *J Invest Dermatol.* 1994 Jun;102(6):42S-5S. PMID: 8006435.
852. Srinualnad S. Early experience of robotic assisted laparoscopic radical prostatectomy. *J Med Assoc Thai.* 2008 Mar;91(3):377-82. PMID: 18575292.
853. Srougi M, Nesrallah LJ, Kauffmann JR, et al. Urinary continence and pathological outcome after bladder neck preservation during radical retropubic prostatectomy: a randomized prospective trial. *J Urol.* 2001 Mar;165(3):815-8. PMID: 11176476.
854. Srougi M, Paranhos M, Leite KM, et al. The influence of bladder neck mucosal eversion and early urinary extravasation on patient outcome after radical retropubic prostatectomy: a prospective controlled trial. *BJU Int.* 2005 Apr;95(6):757-60. PMID: 15794777.
855. Stanton AL, Bernaards CA, Ganz PA. The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. *J Natl Cancer Inst.* 2005 Mar 16;97(6):448-56. PMID: 15770009.
856. Staskin DR, Rosenberg MT, Dahl NV, et al. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. *Int J Clin Pract.* 2008 Jan;62(1):27-38. PMID: 17983434.
857. Steginga SK, Occhipinti S, Gardiner RA, et al. Making decisions about treatment for localized prostate cancer. *BJU Int.* 2002 Feb;89(3):255-60. PMID: 11856106.
858. Stein A, Ratzkovitzki R, Lurie A. Perivesical fat closure during suprapubic prostatectomy: does it prevent urinary leakage? A prospective randomized study. *Tech Urol.* 1996 Summer;2(2):99-101. PMID: 9118417.
859. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. *N Engl J Med.* 2002 Sep 12;347(11):790-6. PMID: 12226149.
860. Stenberg A, Heimer G, Ulmsten U, et al. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. *Maturitas.* 1996 May;24(1-2):31-6. PMID: 8794431.
861. Stern JA, Clemens JQ, Tiplitsky SI, et al. Long-term results of the bulbourethral sling procedure. *J Urol.* 2005 May;173(5):1654-6. PMID: 15821529.
862. Stewart ST, Lenert L, Bhatnagar V, et al. Utilities for prostate cancer health states in men aged 60 and older. *Med Care.* 2005 Apr;43(4):347-55. PMID: 15778638.
863. Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. *Urology.* 2007 Feb;69(2):338-42. PMID: 17320674.
864. Stothers L, Thom D, Calhoun E. Urologic diseases in America project: urinary incontinence in males--demographics and economic burden. *J Urol.* 2005 Apr;173(4):1302-8. PMID: 15758786.
865. Strachan-Bennett S. Care homes failing to address continence. *Nurs Times.* 2005 Nov 8-14;101(45):6. PMID: 16312070.

866. Sueppel C, Kreder K, See W. Improved continence outcomes with preoperative pelvic floor muscle strengthening exercises. *Urol Nurs*. 2001 Jun;21(3):201-10. PMID: 11998651.
867. Sumino Y, Hirata Y, Sato F, et al. Growth mechanism of satellite cells in human urethral rhabdosphincter. *Neurourol Urodyn*. 2007;26(4):552-61. PMID: 17262837.
868. Sumiya T, Kawamura K, Tokuhira A, et al. A survey of wheelchair use by paraplegic individuals in Japan. Part 2: Prevalence of pressure sores. *Spinal Cord*. 1997 Sep;35(9):595-8. PMID: 9300965.
869. Sung VW, Glasgow MA, Wohlrab KJ, et al. Impact of age on preoperative and postoperative urinary incontinence quality of life. *Am J Obstet Gynecol*. 2007 Dec;197(6):680 e1-5. PMID: 18060981.
870. Sureshkumar P, Cumming RG, Craig JC. Validity and reliability of parental report of frequency, severity and risk factors of urinary tract infection and urinary incontinence in children. *J Urol*. 2006 Jun;175(6):2254-62. PMID: 16697849.
871. Suzuki T, Yasuda K, Yamanishi T, et al. Randomized, double-blind, sham-controlled evaluation of the effect of functional continuous magnetic stimulation in patients with urgency incontinence. *Neurourol Urodyn*. 2007;26(6):767-72. PMID: 17397061.
872. Swaddiwudhipong W, Koonchote S, Nguntra P, et al. Assessment of socio-economic, functional and medical problems among the elderly in one rural community of Thailand. *Southeast Asian J Trop Med Public Health*. 1991 Sep;22(3):299-306. PMID: 1818379.
873. Swartztrauber K, Graf E, Cheng E. The quality of care delivered to Parkinson's disease patients in the U.S. Pacific Northwest Veterans Health System. *BMC Neurol*. 2006;6:26. PMID: 16875503.
874. Symon Z, Daignault S, Symon R, et al. Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. *Urology*. 2006 Dec;68(6):1224-9. PMID: 17141840.
875. Szonyi G, Millard RJ. Controlled trial evaluation of a General Practitioner education package on incontinence: use of a mailed questionnaire. *Br J Urol*. 1994 Jun;73(6):615-20. PMID: 8032826.
876. Tadros Y, Ruiz-Deya G, Crawford BE, et al. In vivo proteomic analysis of cytokine expression in laser capture-microdissected urothelial cells of obstructed ureteropelvic junction procured by laparoscopic dismembered pyeloplasty. *J Endourol*. 2003 Jun;17(5):333-6. PMID: 12885361.
877. Tahseen S, Reid P. Effect of transobturator tape on overactive bladder symptoms and urge urinary incontinence in women with mixed urinary incontinence. *Obstet Gynecol*. 2009 Mar;113(3):617-23. PMID: 19300325.
878. Takahashi S, Tajima A, Matsushima H, et al. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. *Int J Urol*. 2006 Jan;13(1):15-20. PMID: 16448426.

879. Takayanagi R, Mizushima H, Ozeki T, et al. Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects. *Biol Pharm Bull.* 2007 Jul;30(7):1297-300. PMID: 17603170.
880. Talcott JA, Clark JA, Manola J, et al. Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand. *J Urol.* 2006 Oct;176(4 Pt 1):1558-63; discussion 63-4. PMID: 16952681.
881. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. *J Clin Oncol.* 2003 Nov 1;21(21):3979-86. PMID: 14581420.
882. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. *J Clin Oncol.* 1998 Jan;16(1):275-83. PMID: 9440753.
883. Tan AH, Gilling PJ, Kennett KM, et al. Long-term results of high-power holmium laser vaporization (ablation) of the prostate. *BJU Int.* 2003 Nov;92(7):707-9. PMID: 14616451.
884. Tannenbaum C, Labrecque D, Lepage C. Understanding barriers to continence care in institutions. *Canadian Journal on Aging.* 2005;24(2):151-9. PMID: 21095.
885. Taunton RL, Swagerty DL, Lasseter JA, et al. Continent or incontinent? That is the question. *J Gerontol Nurs.* 2005 Sep;31(9):36-44. PMID: 16190011.
886. Te AE, Malloy TR, Stein BS, et al. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. *BJU Int.* 2006 Jun;97(6):1229-33. PMID: 16686717.
887. Tefilli MV, Gheiler EL, Tiguert R, et al. Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer. *J Surg Oncol.* 1998 Nov;69(3):156-61. PMID: 9846502.
888. Tei TM, Stolzenburg T, Buntzen S, et al. Use of transpelvic rectus abdominis musculocutaneous flap for anal cancer salvage surgery. *Br J Surg.* 2003 May;90(5):575-80. PMID: 12734865.
889. Teichman JM, Harris JM, Currie DM, et al. Malone antegrade continence enema for adults with neurogenic bowel disease. *J Urol.* 1998 Oct;160(4):1278-81. PMID: 9751335.
890. Teplin V, Vittinghoff E, Lin F, et al. Oophorectomy in premenopausal women: health-related quality of life and sexual functioning. *Obstet Gynecol.* 2007 Feb;109(2 Pt 1):347-54. PMID: 17267835.
891. Tewari A, Jhaveri J, Rao S, et al. Total reconstruction of the vesico-urethral junction. *BJU Int.* 2008 Apr;101(7):871-7. PMID: 18321319.
892. Tewari A, Srivasatava A, Menon M. A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution. *BJU Int.* 2003 Aug;92(3):205-10. PMID: 12887468.

893. Tewari AK, Bigelow K, Rao S, et al. Anatomic restoration technique of continence mechanism and preservation of puboprostatic collar: a novel modification to achieve early urinary continence in men undergoing robotic prostatectomy. *Urology*. 2007 Apr;69(4):726-31. PMID: 17445659.
894. Theodorou C, Moutzouris G, Floratos D, et al. Incontinence after surgery for benign prostatic hypertrophy: the case for complex approach and treatment. *Eur Urol*. 1998;33(4):370-5. PMID: 9612679.
895. Thom DH, van den Eeden SK, Ragins AI, et al. Differences in prevalence of urinary incontinence by race/ethnicity. *J Urol*. 2006 Jan;175(1):259-64. PMID: 16406923.
896. Thompson IM, Jr., Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. *JAMA*. 2006 Nov 15;296(19):2329-35. PMID: 17105795.
897. Thompson RH, Slezak JM, Webster WS, et al. Radical prostatectomy for octogenarians: how old is too old? *Urology*. 2006 Nov;68(5):1042-5. PMID: 17095073.
898. Thomson AJ, Tincello DG. The influence of pad test loss on management of women with urodynamic stress incontinence. *BJOG*. 2003 Aug;110(8):771-3. PMID: 12892690.
899. Thongboonkerd V, McLeish KR, Arthur JM, et al. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. *Kidney Int*. 2002 Oct;62(4):1461-9. PMID: 12234320.
900. Tibaek S, Klarskov P, Lund Hansen B, et al. Pelvic floor muscle training before transurethral resection of the prostate: a randomized, controlled, blinded study. *Scand J Urol Nephrol*. 2007;41(4):329-34. PMID: 17763226.
901. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. *Drug Metab Dispos*. 2005 Dec;33(12):1859-66. PMID: 16183781.
902. Tong Y, Jia Q, Sun Y, et al. Acupuncture in the treatment of diabetic bladder dysfunction. *J Altern Complement Med*. 2009 Aug;15(8):905-9. PMID: 19678782.
903. Townsend JC, Sadler WA, Shanks GM. The effect of storage pH on the precipitation of proteins in deep frozen urine samples. *Ann Clin Biochem*. 1987 Jan;24 (Pt 1):111-2. PMID: 3827174.
904. Trieman N, Hughes J, Leff J. The TAPS Project 42: the last to leave hospital--a profile of residual long-stay populations and plans for their resettlement. Team for the Assessment of Psychiatric Services. *Acta Psychiatr Scand*. 1998 Nov;98(5):354-9. PMID: 9845172.
905. Trigo Rocha F, Gomes C, Figueiredo J, et al. Adjustable Transobturator Sling (Argus TRG) for the Treatment of Post Radical Prostatectomy Urinary Incontinence (Prpui). 39th Annual Meeting of the International Continence Society (ICS 2009), Moscone West, San Francisco, 29 Sep - 3 Oct 2009.
906. Trigo Rocha F, Gomes CM, Mitre AI, et al. A prospective study evaluating the efficacy of the artificial sphincter AMS 800 for the treatment of postradical prostatectomy urinary incontinence and the correlation between preoperative urodynamic and surgical outcomes. *Urology*. 2008 Jan;71(1):85-9. PMID: 18242371.

907. Trigo-Rocha F, Gomes CM, Pompeo AC, et al. Prospective study evaluating efficacy and safety of Adjustable Continence Therapy (ProACT) for post radical prostatectomy urinary incontinence. *Urology*. 2006 May;67(5):965-9. PMID: 16698356.
908. Turnbull GB. An ostomy can mean continence. *Ostomy Wound Manage*. 2004 Dec;50(12):24-6. PMID: 15632452.
909. Twiss CO, Fischer MC, Nitti VW. Comparison between reduction in 24-hour pad weight, International Consultation on Incontinence-Short Form (ICIQ-SF) score, International Prostate Symptom Score (IPSS), and Post-Operative Patient Global Impression of Improvement (PGI-I) score in patient evaluation after male perineal sling. *Neurourol Urodyn*. 2007;26(1):8-13. PMID: 17016797.
910. U.S. Food and Drug Administration CfDEaR. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESicare® (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR: VESicare® In Combination With Tamsulosin in OAB Residual Symptoms. http://www.clinicalstudyresults.org/drugdetails/?drug_name_id=836&sort=c.company_name&page=1&drug_id=4521. Accessed June 25 2010.
911. U.S. Food and Drug Administration CfDEaR. Statistical Review for Dysport (abobotulinumtoxinA) Injection. 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125274s000TOC.cfm. Accessed June 25 2010.
912. Uckert S, Stief CG, Odenthal KP, et al. Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder. *Arzneimittelforschung*. 2000 May;50(5):456-60. PMID: 10858873.
913. Ukoli FA, Lynch BS, Adams-Campbell LL. Radical prostatectomy and quality of life among African Americans. *Ethn Dis*. 2006 Autumn;16(4):988-93. PMID: 17061757.
914. Ullrich NF, Comiter CV. The male sling for stress urinary incontinence: 24-month followup with questionnaire based assessment. *J Urol*. 2004 Jul;172(1):207-9. PMID: 15201775.
915. Umlauf MG, Sherman SM. Symptoms of urinary incontinence among older community-dwelling men. *J Wound Ostomy Continence Nurs*. 1996 Nov;23(6):314-21. PMID: 9043282.
916. Upton N, Reed V. The meaning of incontinence in dementia care. *Int J Psychiatr Nurs Res*. 2005 Sep;11(1):1200-10. PMID: 16268229.
917. Vahtera T, Haaranen M, Viramo-Koskela AL, et al. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. *Clinical rehabilitation*; 1997. p. 211-9.
918. Vaidyanathan S, Soni BM, Brown E, et al. Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction. *Spinal Cord*. 1998 Jun;36(6):409-14. PMID: 9648197.

919. Vaidyanathan S, Soni BM, Sett P, et al. Flawed trial of micturition in cervical spinal cord injury patients: guidelines for trial of voiding in men with tetraplegia. *Spinal Cord*. 2003 Dec;41(12):667-72. PMID: 14639445.
920. Valencic M, Spanjol J, Maricic A, et al. Cystocoele and sensory urgency--our experience. *Coll Antropol*. 2008 Oct;32 Suppl 2:207-9. PMID: 19138026.
921. Valtonen K, Karlsson AK, Siosteen A, et al. Satisfaction with sexual life among persons with traumatic spinal cord injury and meningomyelocele. *Disabil Rehabil*. 2006 Aug 30;28(16):965-76. PMID: 16882636.
922. van Andel G, Bottomley A, Fossa SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. *Eur J Cancer*. 2008 Nov;44(16):2418-24. PMID: 18774706.
923. Van Andel G, Visser AP, Hulshof MC, et al. Health-related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. *BJU Int*. 2003 Aug;92(3):217-22. PMID: 12887470.
924. van Andel G, Visser AP, Zwinderman AH, et al. A prospective longitudinal study comparing the impact of external radiation therapy with radical prostatectomy on health related quality of life (HRQOL) in prostate cancer patients. *Prostate*. 2004 Mar 1;58(4):354-65. PMID: 14968436.
925. Van Arendonk KJ, Austin JC, Boyt MA, et al. Frequency of wetting is predictive of response to anticholinergic treatment in children with overactive bladder. *Urology*. 2006 May;67(5):1049-53; discussion 53-4. PMID: 16698366.
926. Van Arendonk KJ, Knudson MJ, Austin JC, et al. Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin. *Urology*. 2006 Oct;68(4):862-5. PMID: 17070368.
927. van Balken MR, Vandoninck V, Messelink BJ, et al. Percutaneous tibial nerve stimulation as neuromodulative treatment of chronic pelvic pain. *Eur Urol*. 2003 Feb;43(2):158-63; discussion 63. PMID: 12565774.
928. van Balken MR, Vergunst H, Bemelmans BL. Prognostic factors for successful percutaneous tibial nerve stimulation. *Eur Urol*. 2006 Feb;49(2):360-5. PMID: 16359781.
929. van Balken MR, Vergunst H, Bemelmans BL. Sexual functioning in patients with lower urinary tract dysfunction improves after percutaneous tibial nerve stimulation. *Int J Impot Res*. 2006 Sep-Oct;18(5):470-5; discussion 6. PMID: 16528293.
930. Van Brummen HJ, Bruinse HW, Van de Pol G, et al. What is the effect of overactive bladder symptoms on woman's quality of life during and after first pregnancy? *BJU Int*. 2006 Feb;97(2):296-300. PMID: 16430633.
931. van Brummen HJ, Bruinse HW, van de Pol G, et al. Bothersome lower urinary tract symptoms 1 year after first delivery: prevalence and the effect of childbirth. *BJU Int*. 2006 Jul;98(1):89-95. PMID: 16831150.
932. van Brummen HJ, Bruinse HW, van de Pol G, et al. The effect of vaginal and cesarean delivery on lower urinary tract symptoms: what makes the difference? *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 Feb;18(2):133-9. PMID: 16628375.

933. Van Cangh PJ, Richard F, Lorge F, et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. *J Urol*. 1998 Jan;159(1):164-6. PMID: 9400462.
934. van den Esschert JW, van Geloven AA, Vermulst N, et al. Laparoscopic ventral rectopexy for obstructed defecation syndrome. *Surg Endosc*. 2008 Dec;22(12):2728-32. PMID: 18320283.
935. van der Vaart CH, de Leeuw JR, Roovers JP, et al. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. *BJU Int*. 2002 Oct;90(6):544-9. PMID: 12230614.
936. van Dijk MM, Mochtar CA, Wijkstra H, et al. The bell-shaped nitinol prostatic stent in the treatment of lower urinary tract symptoms: experience in 108 patients. *Eur Urol*. 2006 Feb;49(2):353-9. PMID: 16426738.
937. van Eijken M, Wensing M, de Konink M, et al. Health education on self-management and seeking health care in older adults: a randomised trial. *Patient Educ Couns*. 2004 Oct;55(1):48-54. PMID: 15476989.
938. van Houten P, Achterberg W, Ribbe M. Urinary incontinence in disabled elderly women: a randomized clinical trial on the effect of training mobility and toileting skills to achieve independent toileting. *Gerontology*. 2007;53(4):205-10. PMID: 17347567.
939. Van Kampen M, De Weerd W, Van Poppel H, et al. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. *Lancet*. 2000 Jan 8;355(9198):98-102. PMID: 10675166.
940. van Leijssen SA, Kluivers KB, Mol BW, et al. Protocol for the value of urodynamics prior to stress incontinence surgery (VUSIS) study: a multicenter randomized controlled trial to assess the cost effectiveness of urodynamics in women with symptoms of stress urinary incontinence in whom surgical treatment is considered. *BMC Womens Health*. 2009;9:22. PMID: 19622153.
941. Van Poppel H, Collette L, Kirkali Z, et al. Quality control of radical prostatectomy: a feasibility study. *Eur J Cancer*. 2001 May;37(7):884-91. PMID: 11313177.
942. Varma MG, Brown JS, Creasman JM, et al. Fecal incontinence in females older than aged 40 years: who is at risk? *Dis Colon Rectum*. 2006 Jun;49(6):841-51. PMID: 16741640.
943. Vasconcelos M, Lima E, Caiafa L, et al. Voiding dysfunction in children. Pelvic-floor exercises or biofeedback therapy: a randomized study. *Pediatr Nephrol*. 2006 Dec;21(12):1858-64. PMID: 16967285.
944. Verhoef M, Barf HA, Post MW, et al. Functional independence among young adults with spina bifida, in relation to hydrocephalus and level of lesion. *Dev Med Child Neurol*. 2006 Feb;48(2):114-9. PMID: 16417666.
945. Verhoef M, Lurvink M, Barf HA, et al. High prevalence of incontinence among young adults with spina bifida: description, prediction and problem perception. *Spinal Cord*. 2005 Jun;43(6):331-40. PMID: 15685262.

946. Vickerman J. Selecting urinals for male patients. *Nurs Times*. 2006 May 9-15;102(19):47-8. PMID: 16711290.
947. Vironen JH, Kairaluoma M, Aalto AM, et al. Impact of functional results on quality of life after rectal cancer surgery. *Dis Colon Rectum*. 2006 May;49(5):568-78. PMID: 16583289.
948. Volk RJ, Cantor SB, Cass AR, et al. Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. *J Gen Intern Med*. 2004 Apr;19(4):339-48. PMID: 15061743.
949. Volkan T, Ihsan TA, Yilmaz O, et al. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate. *Eur Urol*. 2005 Oct;48(4):608-13. PMID: 16135396.
950. von Gontard A, Lettgen B, Olbing H, et al. Behavioural problems in children with urge incontinence and voiding postponement: a comparison of a paediatric and child psychiatric sample. *Br J Urol*. 1998 May;81 Suppl 3:100-6. PMID: 9634031.
951. Wadie BS, Edwan A, Nabeeh AM. Autologous fascial sling vs polypropylene tape at short-term followup: a prospective randomized study. *J Urol*. 2005 Sep;174(3):990-3. PMID: 16094020.
952. Walsh IK, Williams SG, Mahendra V, et al. Artificial urinary sphincter implantation in the irradiated patient: safety, efficacy and satisfaction. *BJU Int*. 2002 Mar;89(4):364-8. PMID: 11872025.
953. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. *J Urol*. 2000 Jun;163(6):1802-7. PMID: 10799186.
954. Walsh PC, Marschke P, Ricker D, et al. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. *Urology*. 2000 Jan;55(1):58-61. PMID: 10654895.
955. Walsh PC, Marschke PL. Intussusception of the reconstructed bladder neck leads to earlier continence after radical prostatectomy. *Urology*. 2002 Jun;59(6):934-8. PMID: 12031385.
956. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. *J Urol*. 1994 Nov;152(5 Pt 2):1831-6. PMID: 7523730.
957. Waltregny D, Leruth J, de Leval J. The inside-Out Transobturator Sling for the Surgical Treatment of Post-Radical Prostatectomy Urinary Incontinence: Interim Results of a Prospective, Observational Study after a 1-Year Minimum Follow-Up. 39th Annual Meeting of the International Continence Society (ICS 2009), Moscone West, San Francisco, 29 Sep - 3 Oct 2009.
958. Wang J, Kane RL, Eberly LE, et al. The effects of resident and nursing home characteristics on activities of daily living. *J Gerontol A Biol Sci Med Sci*. 2009 Apr;64(4):473-80. PMID: 19201787.

959. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. *J Pharmacol Exp Ther.* 1995 May;273(2):959-66. PMID: 7752101.
960. Warming L, Christoffersen C, Riis BJ, et al. Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. *Maturitas.* 2003 Mar 28;44(3):189-99. PMID: 12648882.
961. Warnke A, Meyer G, Bender R, et al. Predictors of adherence to the use of hip protectors in nursing home residents. *J Am Geriatr Soc.* 2004 Mar;52(3):340-5. PMID: 14962146.
962. Wasserberg N, Haney M, Petrone P, et al. Fecal incontinence among morbid obese women seeking for weight loss surgery: an underappreciated association with adverse impact on quality of life. *Int J Colorectal Dis.* 2008 May;23(5):493-7. PMID: 18228028.
963. Wasserberg N, Kaiser AM, Nunoo-Mensah JW, et al. Preservation of bowel and urinary continence in the management of locally recurrent rectal cancer. *J Surg Oncol.* 2005 Oct 1;92(1):76-81. PMID: 16180216.
964. Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. *N Engl J Med.* 1995 Jan 12;332(2):75-9. PMID: 7527493.
965. Watanabe T, Vaccaro AR, Kumon H, et al. High incidence of occult neurogenic bladder dysfunction in neurologically intact patients with thoracolumbar spinal injuries. *J Urol.* 1998 Mar;159(3):965-8. PMID: 9474194.
966. Watson NM. Advancing quality of urinary incontinence evaluation and treatment in nursing homes through translational research. *Worldviews Evid Based Nurs.* 2004;1 Suppl 1:S21-5. PMID: 17129331.
967. Watson NM, Brink CA, Zimmer JG, et al. Use of the Agency for Health Care Policy and Research Urinary Incontinence Guideline in nursing homes. *J Am Geriatr Soc.* 2003 Dec;51(12):1779-86. PMID: 14687358.
968. Weatherall M, Slow T, Wiltshire K. Risk factors for entry into residential care after a support-needs assessment. *N Z Med J.* 2004 Sep 24;117(1202):U1075. PMID: 15477909.
969. Weaver A, Jacques E. Encouraging adolescents to seek continence help. *Nurs Times.* 2008 Nov 18-24;104(46):46-8. PMID: 19054972.
970. Webber EM, Crofts PG, Pomeroy C, et al. Augmentation ileocystoplasty in children with myelodysplasia. *Can J Surg.* 1990 Apr;33(2):135-8. PMID: 2268813.
971. Weber AM, Walters MD, Schover LR, et al. Functional outcomes and satisfaction after abdominal hysterectomy. *Am J Obstet Gynecol.* 1999 Sep;181(3):530-5. PMID: 10486459.
972. Weber BA, Roberts BL, Chumblor NR, et al. Urinary, sexual, and bowel dysfunction and bother after radical prostatectomy. *Urol Nurs.* 2007 Dec;27(6):527-33. PMID: 18217536.
973. Weber BA, Roberts BL, McDougall GJ, Jr. Exploring the efficacy of support groups for men with prostate cancer. *Geriatr Nurs.* 2000 Sep-Oct;21(5):250-3. PMID: 11035307.

974. Weber BA, Roberts BL, Resnick M, et al. The effect of dyadic intervention on self-efficacy, social support, and depression for men with prostate cancer. *Psychooncology*. 2004 Jan;13(1):47-60. PMID: 14745745.
975. Weese DL, Roskamp DA, Leach GE, et al. Intravesical oxybutynin chloride: experience with 42 patients. *Urology*. 1993 Jun;41(6):527-30. PMID: 8516987.
976. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. *J Clin Oncol*. 2002 Jan 15;20(2):557-66. PMID: 11786586.
977. Wei JT, Montie JE. Comparison of patients' and physicians' rating of urinary incontinence following radical prostatectomy. *Semin Urol Oncol*. 2000 Feb;18(1):76-80. PMID: 10719937.
978. Weiss JP, Blaivas JG, Jones M, et al. Age related pathogenesis of nocturia in patients with overactive bladder. *J Urol*. 2007 Aug;178(2):548-51; discussion 51. PMID: 17570424.
979. Wells M. Managing urinary incontinence with BioDerm external continence device. *Br J Nurs*. 2008 May 8-21;17(9):s24-9. PMID: 18567167.
980. Wells M, Wagg A. Integrated continence services and the female Bangladeshi population. *Br J Nurs*. 2007 May 10-23;16(9):516-9. PMID: 17551440.
981. Whiteside JL, Ensrud-Bowlin KM, Wang G, et al. Lead placement and associated nerve distribution of an implantable periurethral electrostimulator. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Mar;20(3):325-9. PMID: 19052686.
982. Wiener JS, Scales MT, Hampton J, et al. Long-term efficacy of simple behavioral therapy for daytime wetting in children. *J Urol*. 2000 Sep;164(3 Pt 1):786-90. PMID: 10953156.
983. Wiersma R. Overview of bladder exstrophy: a third world perspective. *J Pediatr Surg*. 2008 Aug;43(8):1520-3. PMID: 18675645.
984. Wijma J, Potters AE, de Wolf BT, et al. Anatomical and functional changes in the lower urinary tract following spontaneous vaginal delivery. *BJOG*. 2003 Jul;110(7):658-63. PMID: 12842056.
985. Wijma J, Weis Potters AE, de Wolf BT, et al. Anatomical and functional changes in the lower urinary tract during pregnancy. *BJOG*. 2001 Jul;108(7):726-32. PMID: 11467699.
986. Wilcox DT. The management of urinary incontinence in the exstrophy complex, posterior urethral valves, and infrasphincteric ureters. *Semin Pediatr Surg*. 2002 May;11(2):128-33. PMID: 11973765.
987. Wille S, Sobottka A, Heidenreich A, et al. Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: results of a prospective randomized trial. *J Urol*. 2003 Aug;170(2 Pt 1):490-3. PMID: 12853806.
988. Willener R, Hantikainen V. Individual quality of life following radical prostatectomy in men with prostate cancer. *Urol Nurs*. 2005 Apr;25(2):88-90, 5-100. PMID: 15900977.
989. Williams C, Lorton L. Attends Slip with S-form: a new design of an all-in-one product. *Br J Nurs*. 2006 Apr 27-May 10;15(8):440-3. PMID: 16723950.

990. Williams ER, Malone PS. The social implications of lower urinary tract reconstruction performed during childhood. *Br J Urol.* 1995 Aug;76(2):226-30. PMID: 7663916.
991. Williams MA, Noe HN, Smith RA. The importance of urinary tract infection in the evaluation of the incontinent child. *J Urol.* 1994 Jan;151(1):188-90. PMID: 8254811.
992. Wilson LC, Gilling PJ, Williams A, et al. A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. *Eur Urol.* 2006 Sep;50(3):569-73. PMID: 16704894.
993. Wilson PD, Herbison GP. A randomized controlled trial of pelvic floor muscle exercises to treat postnatal urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 1998;9(5):257-64. PMID: 9849757.
994. Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. *Int Urogynecol J Pelvic Floor Dysfunct.* 1998;9(2):100-2. PMID: 9694139.
995. Withagen MI, Milani AL. Which factors influenced the result of a tension free vaginal tape operation in a single teaching hospital? *Acta Obstetrica et Gynecologica Scandinavica.* 2007;86(9):1136-9. PMID: 21088.
996. Woldringh C, van den Wijngaart M, Albers-Heitner P, et al. Pelvic floor muscle training is not effective in women with UI in pregnancy: a randomised controlled trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Apr;18(4):383-90. PMID: 16937072.
997. Wollin J, Bennie M, Leech C, et al. Multiple sclerosis and continence issues: an exploratory study. *Br J Nurs.* 2005 Apr 28-May 11;14(8):439-40, 42, 44-6. PMID: 15924024.
998. Wright JL, Nathens AB, Rivara FP, et al. Specific fracture configurations predict sexual and excretory dysfunction in men and women 1 year after pelvic fracture. *J Urol.* 2006 Oct;176(4 Pt 1):1540-5; discussion 5. PMID: 16952678.
999. Yamamoto M, Hibi H, Miyake K. A comparison of transurethral resection of the prostate and medical treatment for the patient with moderate symptoms of benign prostatic hyperplasia. *Nagoya J Med Sci.* 1996 Mar;59(1-2):11-6. PMID: 8725483.
1000. Yamashita M, Amagai M. Family caregiving in dementia in Japan. *Appl Nurs Res.* 2008 Nov;21(4):227-31. PMID: 18995165.
1001. Yang SS, Wang CC, Chen YT. Effectiveness of alpha1-adrenergic blockers in boys with low urinary flow rate and urinary incontinence. *J Formos Med Assoc.* 2003 Aug;102(8):551-5. PMID: 14569320.
1002. Yip SK, Chung TK. Treatment-seeking behavior in Hong Kong Chinese women with urinary symptoms. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Feb;14(1):27-30; discussion PMID: 12601513.
1003. Yokoyama O, Yusup A, Miwa Y, et al. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. *J Urol.* 2005 Nov;174(5):2032-6. PMID: 16217388.

1004. Yokoyama T, Inoue M, Fujita O, et al. Preliminary results of the effect of extracorporeal magnetic stimulation on urinary incontinence after radical prostatectomy: a pilot study. *Urol Int.* 2005;74(3):224-8. PMID: 15812208.
1005. Yokoyama T, Nishiguchi J, Watanabe T, et al. Comparative study of effects of extracorporeal magnetic innervation versus electrical stimulation for urinary incontinence after radical prostatectomy. *Urology.* 2004 Feb;63(2):264-7. PMID: 14972468.
1006. Yong C. Effect of food on the pharmacokinetics of Oxybutynin in normal subjects. *Pharm Res.* 1991;8(Suppl.):S-320.
1007. Yono M, Yoshida M, Takahashi W, et al. Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle. *BJU Int.* 2000 Oct;86(6):719-25. PMID: 11069384.
1008. Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. *Urology.* 2002 Mar;59(3):428-32. PMID: 11880086.
1009. Young MD, Weizer AZ, Silverstein AD, et al. Urinary continence and quality of life in the first year after radical perineal prostatectomy. *J Urol.* 2003 Dec;170(6 Pt 1):2374-8. PMID: 14634420.
1010. Youssef AHA, Fathalla M, Taema K, et al. Perineal Dermal Dartos Pedicled Flap (PDDP) a Novel Surgical Technique for Treatment of Post Prostatectomy Urinary Incontinence, Short Term Results. 2007 Annual Meeting of the American Urological Association (AUA 2007), Anaheim, California (USA), 19-24 May 2007.
1011. Yu LC, Johnson K, Kaltreider DL, et al. Urinary incontinence: nursing home staff reaction toward residents. *J Gerontol Nurs.* 1991 Nov;17(11):34-41. PMID: 1940115.
1012. Yu LC, Rohner TJ, Kaltreider DL, et al. Profile of urinary incontinent elderly in long-term care institutions. *J Am Geriatr Soc.* 1990 Apr;38(4):433-9. PMID: 2109766.
1013. Yucel S, Akkaya E, Guntekin E, et al. Can alpha-blocker therapy be an alternative to biofeedback for dysfunctional voiding and urinary retention? A prospective study. *J Urol.* 2005 Oct;174(4 Pt 2):1612-5; discussion 5. PMID: 16148665.
1014. Yucel S, Akkaya E, Guntekin E, et al. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? *Urology.* 2005 Feb;65(2):369-73. PMID: 15708055.
1015. Zaccardi JE, Wilson L, Mokrzycki ML. The effect of pelvic floor re-education on comfort in women having surgery for stress urinary incontinence. *Urol Nurs.* 2010 Mar-Apr;30(2):137-46, 48. PMID: 20469573.
1016. Zafar SN, Ganatra HA, Tehseen S, et al. Health and needs assessment of geriatric patients: results of a survey at a teaching hospital in Karachi. *J Pak Med Assoc.* 2006 Oct;56(10):470-4. PMID: 17144398.
1017. Zahariou A, Papaioannou P, Kalogirou G. Is HCl duloxetine effective in the management of urinary stress incontinence after radical prostatectomy? *Urol Int.* 2006;77(1):9-12. PMID: 16825808.

1018. Zambroski CH, Moser DK, Roser LP, et al. Patients with heart failure who die in hospice. *Am Heart J.* 2005 Mar;149(3):558-64. PMID: 15864247.
1019. Zehrer CL, Lutz JB, Hedblom EC, et al. A comparison of cost and efficacy of three incontinence skin barrier products. *Ostomy Wound Manage.* 2004 Dec;50(12):51-8. PMID: 15632456.
1020. Zehrer CL, Newman DK, Grove GL, et al. Assessment of diaper-clogging potential of petrolatum moisture barriers. *Ostomy Wound Manage.* 2005 Dec;51(12):54-8. PMID: 16439811.
1021. Zhang AY, Strauss GJ, Siminoff LA. Intervention of urinary incontinence and quality of life outcome in prostate cancer patients. *J Psychosoc Oncol.* 2006;24(2):17-30. PMID: 17046804.
1022. Zhang AY, Strauss GJ, Siminoff LA. Effects of combined pelvic floor muscle exercise and a support group on urinary incontinence and quality of life of postprostatectomy patients. *Oncol Nurs Forum.* 2007 Jan;34(1):47-53. PMID: 17562632.
1023. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. *J Urol.* 2003 Nov;170(5):1772-6. PMID: 14532773.
1024. Zulkowski K, Kindsfater D. Examination of care-planning needs for elderly newly admitted to an acute care setting. *Ostomy Wound Manage.* 2000 Jan;46(1):32-8. PMID: 10732634.
1025. Zwergel U, Wullich B, Lindenmeir U, et al. Long-term results following transurethral resection of the prostate. *Eur Urol.* 1998;33(5):476-80. PMID: 9643667

Reason for Exclusion: Not Eligible Exposure (869 Studies)

1. Effects of terodiline on urinary incontinence among older non-institutionalized women. Terodiline in the Elderly American Multicenter Study Group. *J Am Geriatr Soc.* 1993 Sep;41(9):915-22. PMID: 8409177.
2. Abdel-Fattah M, Barrington JW, Arunkalaivanan AS. Pelvicol pubovaginal sling versus tension-free vaginal tape for treatment of urodynamic stress incontinence: a prospective randomized three-year follow-up study. *Eur Urol.* 2004 Nov;46(5):629-35. PMID: 15474274.
3. Abdel-Fattah M, Ramsay I. Transobturator tension free vaginal tapes: are they the way forward in the surgical treatment of urodynamic stress incontinence? *Int J Surg.* 2007 Feb;5(1):3-10. PMID: 17386907.
4. Abdel-Hady el S, Constantine G. Outcome of the use of tension-free vaginal tape in women with mixed urinary incontinence, previous failed surgery, or low valsalva pressure. *J Obstet Gynaecol Res.* 2005 Feb;31(1):38-42. PMID: 15669990.
5. Aboseif S, Tamaddon K, Chalfin S, et al. Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. *Urology.* 2002 Jul;60(1):52-6. PMID: 12100921.

6. Abouassaly R, Steinberg JR, Lemieux M, et al. Complications of tension-free vaginal tape surgery: a multi-institutional review. *BJU Int.* 2004 Jul;94(1):110-3. PMID: 15217442.
7. ACTRN12605000755639. Efficacy of non-invasive magnetic stimulation of the pelvic floor in the control of urinary incontinence.
8. Adamiak A, Milart P, Skorupski P, et al. The efficacy and safety of the tension-free vaginal tape procedure do not depend on the method of analgesia. *Eur Urol.* 2002 Jul;42(1):29-33. PMID: 12121726.
9. Addison R. Intermittent self-catheterisation. *Nurs Times.* 2001 May 17-23;97(20):67-9. PMID: 11962054.
10. Adekanmi OA, Freeman RM, Bombieri L. How colposuspensions are performed in the UK: a survey of gynecologists' practice. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Aug;14(3):151-9; discussion 9. PMID: 12955335.
11. Alam SM, Hoq MM, Hoque M, et al. Initial experience with 10 cases of Indiana pouch continent urinary diversion. *Bangladesh Med Res Counc Bull.* 2008 Apr;34(1):21-5. PMID: 18783073.
12. Albo M, Wruck L, Baker J, et al. The relationships among measures of incontinence severity in women undergoing surgery for stress urinary incontinence. *J Urol.* 2007 May;177(5):1810-4. PMID: 17437826.
13. Albo ME, Richter HE, Brubaker L, et al. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. *N Engl J Med.* 2007 May 24;356(21):2143-55. PMID: 17517855.
14. Alcalay M, Thompson PK, Boone TB. Ball urethroplasty combined with Marshall-Marchetti-Krantz urethropexy versus suburethral sling in patients with intrinsic sphincter deficiency and urethral hypermobility. *Am J Obstet Gynecol.* 2000 Dec;183(6):1348-53; discussion 53-4. PMID: 11120495.
15. Allahdin S, McKinley C, Mahmood TA, et al. Tension-free vaginal tape: 162 cases in a district general hospital. *J Obstet Gynaecol.* 2004 Aug;24(5):539-41. PMID: 15369936.
16. Allahdin S, McKinley CA, Mahmood TA. Tension free vaginal tape: a procedure for all ages. *Acta Obstet Gynecol Scand.* 2004 Oct;83(10):937-40. PMID: 15453889.
17. Al-Singary W, Shergill IS, Allen SE, et al. Trans-obturator tape for incontinence: a 3-year follow-up. *Urol Int.* 2007;78(3):198-201. PMID: 17406126.
18. Altman D, Vayrynen T, Engh ME, et al. Short-term outcome after transvaginal mesh repair of pelvic organ prolapse. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Jun;19(6):787-93. PMID: 18074068.
19. Amat ITL, Martinez Franco E, Laila Vicens JM. Contasure-Needleless compared with transobturator-TVT for the treatment of stress urinary incontinence. *Int Urogynecol J.* 2011 Jul;22(7):827-33. PMID: 21365331.

20. Amrute KV, Eisenberg ER, Rastinehad AR, et al. Analysis of outcomes of single polypropylene mesh in total pelvic floor reconstruction. *Neurourol Urodyn*. 2007;26(1):53-8. PMID: 17080416.
21. Amundsen CL, Guralnick ML, Webster GD. Variations in strategy for the treatment of urethral obstruction after a pubovaginal sling procedure. *J Urol*. 2000 Aug;164(2):434-7. PMID: 10893603.
22. Amundsen CL, Visco AG, Ruiz H, et al. Outcome in 104 pubovaginal slings using freeze-dried allograft fascia lata from a single tissue bank. *Urology*. 2000 Dec 4;56(6 Suppl 1):2-8. PMID: 11114556.
23. Andonian S, Chen T, St-Denis B, et al. Randomized clinical trial comparing suprapubic arch sling (SPARC) and tension-free vaginal tape (TVT): one-year results. *Eur Urol*. 2005 Apr;47(4):537-41. PMID: 15774255.
24. Andonian S, St-Denis B, Lemieux MC, et al. Prospective clinical trial comparing Obtape and DUPS to TVT: one-year safety and efficacy results. *Eur Urol*. 2007 Jul;52(1):245-51. PMID: 17234331.
25. Ankardal M, Ekerydh A, Crafoord K, et al. A randomised trial comparing open Burch colposuspension using sutures with laparoscopic colposuspension using mesh and staples in women with stress urinary incontinence. *BJOG*. 2004 Sep;111(9):974-81. PMID: 15327613.
26. Ankardal M, Heiwall B, Lausten-Thomsen N, et al. Short- and long-term results of the tension-free vaginal tape procedure in the treatment of female urinary incontinence. *Acta Obstetricia et Gynecologica Scandinavica*. 2006;85(8):986-92. PMID: 21093.
27. Antovska SV, Dimitrov DG. Vaginosacral colpopexy (VSC)--a new modification of the Mc Call operation using vaginosacral ligaments as autologous sliding grafts in posthysterectomy vault prolapse. *Bratisl Lek Listy*. 2006;107(3):62-72. PMID: 16796126.
28. Appell RA. Surgery or collagen for the treatment of female stress urinary incontinence: results of a multicenter, randomized trial supports either as first line of treatment. *Curr Urol Rep*. 2001 Oct;2(5):343. PMID: 12084239.
29. Araco F, Gravante G, Sorge R, et al. TVT-O vs TVT: a randomized trial in patients with different degrees of urinary stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Jul;19(7):917-26. PMID: 18217177.
30. Arunkalaivanan AS, Barrington JW. Randomized trial of porcine dermal sling (Pelvicol implant) vs. tension-free vaginal tape (TVT) in the surgical treatment of stress incontinence: a questionnaire-based study. *Int Urogynecol J Pelvic Floor Dysfunct*. 2003 Feb;14(1):17-23; discussion 1-2. PMID: 12601511.
31. Athanassopoulos A, Barbaliias G. Burch colposuspension versus stamey endoscopic bladder neck suspension: a urodynamic appraisal. *Urol Int*. 1996;56(1):23-7. PMID: 8903550.

32. Awad SA, Al-Zahrani HM, Gajewski JB, et al. Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. *Br J Urol.* 1998 Apr;81(4):569-73. PMID: 9598629.
33. Ayhan A, Esin S, Guven S, et al. The Manchester operation for uterine prolapse. *Int J Gynaecol Obstet.* 2006 Mar;92(3):228-33. PMID: 16427641.
34. Baatenburg de Jong H, Admiraal H. Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. *J Wound Care.* 2004 Oct;13(9):398-400. PMID: 15517755.
35. Baessler K, Stanton SL. Does Burch colposuspension cure coital incontinence? *Am J Obstet Gynecol.* 2004 Apr;190(4):1030-3. PMID: 15118636.
36. Bafghi A, Valerio L, Benizri EI, et al. Comparison between monofilament and multifilament polypropylene tapes in urinary incontinence. *Eur J Obstet Gynecol Reprod Biol.* 2005 Oct 1;122(2):232-6. PMID: 16219524.
37. Bai SW, Roh JL, Kim JY, et al. Outcomes and surgical therapeutic index of Burch colposuspension in stress urinary incontinence. *J Reprod Med.* 2003 Feb;48(2):102-6. PMID: 12621793.
38. Bai SW, Sohn WH, Chung DJ, et al. Comparison of the efficacy of Burch colposuspension, pubovaginal sling, and tension-free vaginal tape for stress urinary incontinence. *Int J Gynaecol Obstet.* 2005 Dec;91(3):246-51. PMID: 16242695.
39. Bakas P, Liapis A, Giner M, et al. Quality of life in relation to TVT procedure for the treatment of stress urinary incontinence. *Acta Obstet Gynecol Scand.* 2006;85(6):748-52. PMID: 16752270.
40. Balakrishnan S, Lim YN, Barry C, et al. Sling distress: a subanalysis of the IVS tapes from the SUSPEND trial. *Aust N Z J Obstet Gynaecol.* 2007 Dec;47(6):496-8. PMID: 17991116.
41. Barbalias G, Liatsikos E, Barbalias D. Use of slings made of indigenous and allogenic material (Goretex) in type III urinary incontinence and comparison between them. *Eur Urol.* 1997;31(4):394-400. PMID: 9187896.
42. Barber MD, Kleeman S, Karram MM, et al. Risk factors associated with failure 1 year after retropubic or transobturator midurethral slings. *American Journal of Obstetrics & Gynecology.* 2008 Dec;199(6):666.e1-.e7. PMID: 21527.
43. Barber MD, Kleeman S, Karram MM, et al. Transobturator tape compared with tension-free vaginal tape for the treatment of stress urinary incontinence: a randomized controlled trial. *Obstet Gynecol.* 2008 Mar;111(3):611-21. PMID: 18310363.
44. Barber MD, Visco AG, Wyman JF, et al. Sexual function in women with urinary incontinence and pelvic organ prolapse. *Obstet Gynecol.* 2002 Feb;99(2):281-9. PMID: 11814510.
45. Barrington JW, Dyer R, Bano F. Bladder augmentation using Pelvicol implant for intractable overactive bladder syndrome. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 Jan;17(1):50-3. PMID: 16001132.

46. Barry C, Lim YN, Muller R, et al. A multi-centre, randomised clinical control trial comparing the retropubic (RP) approach versus the transobturator approach (TO) for tension-free, suburethral sling treatment of urodynamic stress incontinence: the TORP study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Feb;19(2):171-8. PMID: 17634853.
47. Basok EK, Yildirim A, Atsu N, et al. Cadaveric fascia lata versus intravaginal slingplasty for the pubovaginal sling: surgical outcome, overall success and patient satisfaction rates. *Urol Int.* 2008;80(1):46-51. PMID: 18204233.
48. Basu M, Duckett J. A randomised trial of a retropubic tension-free vaginal tape versus a mini-sling for stress incontinence. *BJOG.* 2010 May;117(6):730-5. PMID: 20175874.
49. Benderev TV. Anchor fixation and other modifications of endoscopic bladder neck suspension. *Urology.* 1992 Nov;40(5):409-18. PMID: 1441037.
50. Bent AE, Foote J, Siegel S, et al. Collagen implant for treating stress urinary incontinence in women with urethral hypermobility. *J Urol.* 2001 Oct;166(4):1354-7. PMID: 11547073.
51. Bent AE, Tutrone RT, McLennan MT, et al. Treatment of intrinsic sphincter deficiency using autologous ear chondrocytes as a bulking agent. *Neurourol Urodyn.* 2001;20(2):157-65. PMID: 11170190.
52. Bergert FW, Conrad D, Ehrenthal K, et al. Pharmacotherapy guidelines for the aged by family doctors for the use of family doctors: part C--Special pharmacology. *Int J Clin Pharmacol Ther.* 2009 Mar;47(3):141-52. PMID: 19281722.
53. Berglund AL, Eisemann M, Lalos A, et al. Predictive factors of the outcome of primary surgical treatment of stress incontinence in women. *Scand J Urol Nephrol.* 1997 Feb;31(1):49-55. PMID: 9060084.
54. Berglund AL, Lalos O. The pre- and postsurgical nursing of women with stress incontinence. *J Adv Nurs.* 1996 Mar;23(3):502-11. PMID: 8655825.
55. Bergman A, Elia G. Three surgical procedures for genuine stress incontinence: five-year follow-up of a prospective randomized study. *Am J Obstet Gynecol.* 1995 Jul;173(1):66-71. PMID: 7631729.
56. Bergman A, McCarthy TA, Ballard CA, et al. Role of the Q-tip test in evaluating stress urinary incontinence. *J Reprod Med.* 1987 Apr;32(4):273-5. PMID: 3585870.
57. Berman CJ, Kreder KJ. Comparative cost analysis of collagen injection and fascia lata sling cystourethropexy for the treatment of type III incontinence in women [see comments]. *J Urol.* 1997 Jan;157(1):122-4. PMID: 8976231.
58. Berthier A, Sentilhes L, Taibi S, et al. Sexual function in women following the transvaginal tension-free tape procedure for incontinence. *Int J Gynaecol Obstet.* 2008 Aug;102(2):105-9. PMID: 18420207.
59. Bezerra CA, Bruschini H. Suburethral sling operations for urinary incontinence in women. *Cochrane Database Syst Rev.* 2000(3):CD001754. PMID: 10908509.
60. Bezerra CA, Bruschini H. Suburethral sling operations for urinary incontinence in women. *Cochrane Database Syst Rev.* 2001(3):CD001754. PMID: 11686996.

61. Bezerra CA, Bruschini H, Cody DJ. Traditional suburethral sling operations for urinary incontinence in women. *Cochrane Database Syst Rev.* 2005(3):CD001754. PMID: 16034866.
62. Bidmead J, Cardozo L, McLellan A, et al. A comparison of the objective and subjective outcomes of colposuspension for stress incontinence in women. *BJOG.* 2001 Apr;108(4):408-13. PMID: 11305549.
63. Bjelic-Radisic V, Dorfer M, Greimel E, et al. Quality of life and continence 1 year after the tension-free vaginal tape operation. *Am J Obstet Gynecol.* 2006 Dec;195(6):1784-8. PMID: 17132481.
64. Black N, Griffiths J, Pope C, et al. Impact of surgery for stress incontinence on morbidity: cohort study. *BMJ.* 1997 Dec 6;315(7121):1493-8. PMID: 9420489.
65. Black NA, Bowling A, Griffiths JM, et al. Impact of surgery for stress incontinence on the social lives of women. *Br J Obstet Gynaecol.* 1998 Jun;105(6):605-12. PMID: 9647150.
66. Boccasanta P, Venturi M, Salamina G, et al. New trends in the surgical treatment of outlet obstruction: clinical and functional results of two novel transanal stapled techniques from a randomised controlled trial. *International journal of colorectal disease;* 2004. p. 359-69.
67. Bodell DM, Leach GE. Needle suspension procedures for female incontinence. *Urol Clin North Am.* 2002 Aug;29(3):575-84. PMID: 12476521.
68. Bombier L, Freeman RM, Perkins EP, et al. Why do women have voiding dysfunction and de novo detrusor instability after colposuspension? *BJOG.* 2002 Apr;109(4):402-12. PMID: 12013161.
69. Bordman R, Telner D, Jackson B, et al. Step-by-step approach to managing pelvic organ prolapse: information for physicians. *Can Fam Physician.* 2007 Mar;53(3):485-7. PMID: 17872686.
70. Borstad E, Abdelnoor M, Staff AC, et al. Surgical strategies for women with pelvic organ prolapse and urinary stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2010 Feb;21(2):179-86. PMID: 19940978.
71. Bosman G, Vierhout ME, Huikeshoven FJ. A modified Raz bladder neck suspension operation. Results of a one to three years follow-up investigation. *Acta Obstet Gynecol Scand.* 1993 Jan;72(1):47-9. PMID: 8382433.
72. Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States, 1979-1997. *Am J Obstet Gynecol.* 2003 Jan;188(1):108-15. PMID: 12548203.
73. Bradley CS, Kenton KS, Richter HE, et al. Obesity and outcomes after sacrocolpopexy. *Am J Obstet Gynecol.* 2008 Dec;199(6):690 e1-8. PMID: 18845288.
74. Branch LG, Walker LA, Wetle TT, et al. Urinary incontinence knowledge among community-dwelling people 65 years of age and older. *J Am Geriatr Soc.* 1994 Dec;42(12):1257-62. PMID: 7983288.

75. Brink CA, Wells TJ, Sampsel CM, et al. A digital test for pelvic muscle strength in women with urinary incontinence. *Nurs Res.* 1994 Nov-Dec;43(6):352-6. PMID: 7971299.
76. Brown JS, Grady D, Ouslander JG, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. *Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol.* 1999 Jul;94(1):66-70. PMID: 10389720.
77. Brown SL, Govier FE. Cadaveric versus autologous fascia lata for the pubovaginal sling: surgical outcome and patient satisfaction. *J Urol.* 2000 Nov;164(5):1633-7. PMID: 11025722.
78. Browning A. Prevention of residual urinary incontinence following successful repair of obstetric vesico-vaginal fistula using a fibro-muscular sling. *BJOG.* 2004 Apr;111(4):357-61. PMID: 15008773.
79. Browning A, Menber B. Women with obstetric fistula in Ethiopia: a 6-month follow up after surgical treatment. *BJOG.* 2008 Nov;115(12):1564-9. PMID: 19035992.
80. Brubaker L, Chiang S, Zyczynski H, et al. The impact of stress incontinence surgery on female sexual function. *Am J Obstet Gynecol.* 2009 May;200(5):562 e1-7. PMID: 19286143.
81. Brubaker L, Cundiff G, Fine P, et al. A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods. *Control Clin Trials.* 2003 Oct;24(5):629-42. PMID: 14500059.
82. Brubaker L, Cundiff GW, Fine P, et al. Abdominal sacrocolpopexy with Burch colposuspension to reduce urinary stress incontinence. *N Engl J Med.* 2006 Apr 13;354(15):1557-66. PMID: 16611949.
83. Buchsbaum GM, McConville J, Korn R, et al. Outcome of transvaginal radiofrequency for treatment of women with stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Mar;18(3):263-5. PMID: 16788852.
84. Bukkapatnam R, Shah S, Raz S, et al. Anterior vaginal wall surgery in elderly patients: outcomes and assessment. *Urology.* 2005 Jun;65(6):1104-8. PMID: 15953501.
85. Bull E, Chilton CP, Gould CA, et al. Single-blind, randomised, parallel group study of the Bard Biocath catheter and a silicone elastomer coated catheter. *Br J Urol.* 1991 Oct;68(4):394-9. PMID: 1933160.
86. Bump RC, Hurt WG, Theofrastous JP, et al. Randomized prospective comparison of needle colposuspension versus endopelvic fascia plication for potential stress incontinence prophylaxis in women undergoing vaginal reconstruction for stage III or IV pelvic organ prolapse. The Continence Program for Women Research Group. *Am J Obstet Gynecol.* 1996 Aug;175(2):326-33; discussion 33-5. PMID: 8765249.
87. Burgio KL, Locher JL, Zyczynski H, et al. Urinary incontinence during pregnancy in a racially mixed sample: characteristics and predisposing factors. *Int Urogynecol J Pelvic Floor Dysfunct.* 1996;7(2):69-73. PMID: 8798089.

88. Burgio KL, Nygaard IE, Richter HE, et al. Bladder symptoms 1 year after abdominal sacrocolpopexy with and without Burch colposuspension in women without preoperative stress incontinence symptoms. *Am J Obstet Gynecol*. 2007 Dec;197(6):647 e1-6. PMID: 18060965.
89. Burns PA, Nochajski TH, Pranikoff K. Factors discriminating between genuine stress and mixed incontinence. *J Am Acad Nurse Pract*. 1992 Jan-Mar;4(1):15-21. PMID: 1605988.
90. But I, Faganelj M. Complications and short-term results of two different transobturator techniques for surgical treatment of women with urinary incontinence: a randomized study. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Jun;19(6):857-61. PMID: 18188489.
91. Byck DB, Varner RE, Clough C. Urinary complaints after modified Burch urethropexy: an analysis. *Am J Obstet Gynecol*. 1994 Dec;171(6):1460-2; discussion 2-4. PMID: 7802054.
92. Campeau L, Tu LM, Lemieux MC, et al. A multicenter, prospective, randomized clinical trial comparing tension-free vaginal tape surgery and no treatment for the management of stress urinary incontinence in elderly women. *Neurourol Urodyn*. 2007;26(7):990-4. PMID: 17638307.
93. Carey JM, Leach GE. Transvaginal surgery in the octogenarian using cadaveric fascia for pelvic prolapse and stress incontinence: minimal one-year results compared to younger patients. *Urology*. 2004 Apr;63(4):665-70. PMID: 15072875.
94. Carey MP, Goh JT, Rosamilia A, et al. Laparoscopic versus open Burch colposuspension: a randomised controlled trial. *BJOG*. 2006 Sep;113(9):999-1006. PMID: 16956331.
95. Carlisle D. Silent suffering. *Nurs Times*. 1998 Apr 15-21;94(15):63-4, 7. PMID: 9615666.
96. Carr LK, Steele D, Steele S, et al. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Jun;19(6):881-3. PMID: 18204978.
97. Carta G, Cerrone L, Iovenitti P. Tension-free vaginal tape procedure for treatment of USI: subjective and objective efficacy evaluation. *Clin Exp Obstet Gynecol*. 2002;29(4):247-50. PMID: 12635739.
98. Cayir G, Beji NK, Yalcin O. Effectiveness of nursing care after surgery for stress urinary incontinence. *Urol Nurs*. 2007 Feb;27(1):25-33. PMID: 17390924.
99. Cespedes RD, Cross CA, McGuire EJ. Pubovaginal fascial slings. *Tech Urol*. 1997 Winter;3(4):195-201. PMID: 9531102.
100. Chai TC, Albo ME, Richter HE, et al. Complications in women undergoing Burch colposuspension versus autologous rectus fascial sling for stress urinary incontinence. *J Urol*. 2009 May;181(5):2192-7. PMID: 19296969.
101. Chang CH, Gonzalez CM, Lau DT, et al. Urinary incontinence and self-reported health among the U.S. Medicare managed care beneficiaries. *J Aging Health*. 2008 Jun;20(4):405-19. PMID: 18372429.

102. Chapple CR, Patroneva A, Raines SR. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). *Eur Urol*. 2006 May;49(5):879-86. PMID: 16517051.
103. Cheater FM, Baker R, Gillies C, et al. The nature and impact of urinary incontinence experienced by patients receiving community nursing services: a cross-sectional cohort study. *Int J Nurs Stud*. 2008 Mar;45(3):339-51. PMID: 17178120.
104. Chen B, Wen Y, Wang H, et al. Differences in estrogen modulation of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-1 expression in cultured fibroblasts from continent and incontinent women. *Am J Obstet Gynecol*. 2003 Jul;189(1):59-65. PMID: 12861139.
105. Chen B, Wen Y, Yu X, et al. Elastin metabolism in pelvic tissues: is it modulated by reproductive hormones? *Am J Obstet Gynecol*. 2005 May;192(5):1605-13. PMID: 15902165.
106. Chen B, Wen Y, Zhang Z, et al. Menstrual phase-dependent gene expression differences in periurethral vaginal tissue from women with stress incontinence. *Am J Obstet Gynecol*. 2003 Jul;189(1):89-97. PMID: 12861144.
107. Chen CC, Rooney CM, Paraiso MF, et al. Leak point pressure does not correlate with incontinence severity or bother in women undergoing surgery for urodynamic stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Sep;19(9):1193-8. PMID: 18414765.
108. Chene G, Amblard J, Tardieu AS, et al. Long-term results of tension-free vaginal tape (TVT) for the treatment of female urinary stress incontinence. *Eur J Obstet Gynecol Reprod Biol*. 2007 Sep;134(1):87-94. PMID: 16891051.
109. Cheon WC, Mak JH, Liu JY. Prospective randomised controlled trial comparing laparoscopic and open colposuspension. *Hong Kong Med J*. 2003 Feb;9(1):10-4. PMID: 12547950.
110. Chien GW, Tawadroas M, Kaptein JS, et al. Surgical treatment for stress urinary incontinence with urethral hypermobility: what is the best approach? *World J Urol*. 2002 Sep;20(4):234-9. PMID: 12215853.
111. Cho CY, Alessi CA, Cho M, et al. The association between chronic illness and functional change among participants in a comprehensive geriatric assessment program. *J Am Geriatr Soc*. 1998 Jun;46(6):677-82. PMID: 9625181.
112. Choe JM. Preventing urethral obstruction using the 6-point fixation and weight-adjusted spacing nomogram during sling surgery. *Int Urogynecol J Pelvic Floor Dysfunct*. 2001;12(2):122-8. PMID: 11374510.
113. Choe JM. Suprapubic sling adjustment: minimally invasive method of curing recurrent stress incontinence after sling surgery. *J Urol*. 2002 Nov;168(5):2059-62. PMID: 12394708.
114. Choe JM. Pubovaginal sling surgery without using abdominal leak point pressure: an outcomes analysis. *Adv Exp Med Biol*. 2003;539(Pt A):467-80. PMID: 15088923.

115. Choe JM. The use of synthetic materials in pubovaginal sling. *Adv Exp Med Biol.* 2003;539(Pt A):481-92. PMID: 15088924.
116. Choe JM. Surgical implantation of the synthetic sling (the 6-point fixation technique and weight-adjusted spacing nomogram): technique and results. *Adv Exp Med Biol.* 2003;539(Pt A):493-507. PMID: 15088925.
117. Choe JM, Ogan K, Battino BS. Antimicrobial mesh versus vaginal wall sling: a comparative outcomes analysis. *J Urol.* 2000 Jun;163(6):1829-34. PMID: 10799192.
118. Choe JM, Ogan K, Bennett S. Antibacterial mesh sling: a prospective outcome analysis. *Urology.* 2000 Apr;55(4):515-20. PMID: 10736494.
119. Cholhan HJ, Lotze PM. Voiding function after a modified no-tension pubovaginal sling. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 Jul-Aug;15(4):249-56. PMID: 15517669.
120. Christensen H, Laybourn C, Eickhoff JH, et al. Long-term results of the Stamey Bladder-neck suspension procedure and of the Burch colposuspension. *Scand J Urol Nephrol.* 1997 Aug;31(4):349-53. PMID: 9290164.
121. Cindolo L, Salzano L, Rota G, et al. Tension-free transobturator approach for female stress urinary incontinence. *Minerva Urol Nefrol.* 2004 Mar;56(1):89-98. PMID: 15195034.
122. Clark AL, Gregory T, Smith VJ, et al. Epidemiologic evaluation of reoperation for surgically treated pelvic organ prolapse and urinary incontinence. *Am J Obstet Gynecol.* 2003 Nov;189(5):1261-7. PMID: 14634551.
123. Clemens JQ, Markossian TW, Meenan RT, et al. Overlap of voiding symptoms, storage symptoms and pain in men and women. *J Urol.* 2007 Oct;178(4 Pt 1):1354-8; discussion 8. PMID: 17706719.
124. Clyne OJ, O'Sullivan O, Flood HD. Pubovaginal sling for urodynamic stress incontinence: effect on patient quality of life. *Ir Med J.* 2005 Mar;98(3):75-7. PMID: 15869063.
125. Cochran A. Don't ask, don't tell: the incontinence conspiracy. *Manag Care Q.* 2000 Winter;8(1):44-52. PMID: 11009733.
126. Collste L. Phenylpropanolamine in treatment of female stress urinary incontinence. *Urology.* 1987 October 1987;30(4) PMID: 3310369.
127. Colombo M, Maggioni A, Scalabrino S, et al. Surgery for genitourinary prolapse and stress incontinence: a randomized trial of posterior pubourethral ligament plication and Pereyra suspension. *Am J Obstet Gynecol.* 1997 Feb;176(2):337-43. PMID: 9065178.
128. Colombo M, Maggioni A, Zanetta G, et al. Prevention of postoperative urinary stress incontinence after surgery for genitourinary prolapse. *Obstet Gynecol.* 1996 Feb;87(2):266-71. PMID: 8559537.
129. Colombo M, Milani R, Vitobello D, et al. A randomized comparison of Burch colposuspension and abdominal paravaginal defect repair for female stress urinary incontinence. *Am J Obstet Gynecol.* 1996 Jul;175(1):78-84. PMID: 8694079.

130. Colombo M, Scalabrino S, Maggioni A, et al. Burch colposuspension versus modified Marshall-Marchetti-Krantz urethropexy for primary genuine stress urinary incontinence: a prospective, randomized clinical trial. *Am J Obstet Gynecol.* 1994 Dec;171(6):1573-9. PMID: 7802070.
131. Colombo M, Vitobello D, Proietti F, et al. Randomised comparison of Burch colposuspension versus anterior colporrhaphy in women with stress urinary incontinence and anterior vaginal wall prolapse. *BJOG.* 2000 Apr;107(4):544-51. PMID: 10759276.
132. Comiter CV, Colegrove PM. High rate of vaginal extrusion of silicone-coated polyester sling. *Urology.* 2004 Jun;63(6):1066-70. PMID: 15183951.
133. Conrad S, Pieper A, De la Maza SF, et al. Long-term results of the Stamey bladder neck suspension procedure: a patient questionnaire based outcome analysis. *J Urol.* 1997 May;157(5):1672-7. PMID: 9112503.
134. Constantinou CE. Pharmacologic treatment of detrusor incontinence with thiphenamil HCl. *Urol Int.* 1992;48(1):42-7. PMID: 1598734.
135. Coombes GM, Millard RJ. Urinary urge incontinence: randomised crossover trials of penthienate versus placebo and propantheline. *Med J Aust.* 1996 Nov 4;165(9):473-6. PMID: 8937366.
136. Cortesse A, Jacquetin B, Grise P, et al. Prospective multicenter clinical trial of Uretex Sup for surgical treatment of stress urinary incontinence. *Int J Urol.* 2007 Jul;14(7):611-5. PMID: 17645604.
137. Costantini E, Lazzeri M, Bini V, et al. Burch colposuspension does not provide any additional benefit to pelvic organ prolapse repair in patients with urinary incontinence: a randomized surgical trial. *J Urol.* 2008 Sep;180(3):1007-12. PMID: 18639302.
138. Costantini E, Lazzeri M, Giannantoni A, et al. Preoperative Valsalva leak point pressure may not predict outcome of mid-urethral slings. Analysis from a randomized controlled trial of retropubic versus transobturator mid-urethral slings. *Int Braz J Urol.* 2008 Jan-Feb;34(1):73-81; discussion -3. PMID: 18341724.
139. Costantini E, Mearini L, Biscotto S, et al. Impact of different sized catheters on pressure-flow studies in women with lower urinary tract symptoms. *Neurourol Urodyn.* 2005;24(2):106-10. PMID: 15616966.
140. Costantini E, Mearini L, Mearini E, et al. Assessing outcome after a modified vaginal wall sling for stress incontinence with intrinsic sphincter deficiency. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005 Mar-Apr;16(2):138-46; discussion 46. PMID: 15789147.
141. Costantini E, Zucchi A, Giannantoni A, et al. Must colposuspension be associated with sacropexy to prevent postoperative urinary incontinence? *Eur Urol.* 2007 Mar;51(3):788-94. PMID: 17011699.
142. Couillard DR, Deckard-Janatpour KA, Stone AR. The vaginal wall sling: a compressive suspension procedure for recurrent incontinence in elderly patients. *Urology.* 1994 Feb;43(2):203-8. PMID: 8116116.

143. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. *BJU Int.* 2008 Jun;101(11):1388-95. PMID: 18454794.
144. Coyne KS, Zhou Z, Thompson C, et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. *BJU Int.* 2003 Nov;92(7):731-5. PMID: 14616456.
145. Craig JB, Noblett KL, Conner CA, et al. Reconstructive pelvic surgery and plastic surgery: safety and efficacy of combined surgery. *Am J Obstet Gynecol.* 2008 Dec;199(6):701 e1-5. PMID: 18845294.
146. Crivellaro S, Smith JJ, Kocjancic E, et al. Transvaginal sling using acellular human dermal allograft: safety and efficacy in 253 patients. *J Urol.* 2004 Oct;172(4 Pt 1):1374-8. PMID: 15371848.
147. CTRI/2009/091/000820. A comparative, single blind, parallel group, non-crossover, multi-centric trial of Imidafenacin Tablets 0.1 mg, with Uritos Tablets, in-patients suffering from Overactive Bladder.
148. Culligan PJ, Goldberg RP, Blackhurst DW, et al. Comparison of microtransducer and fiberoptic catheters for urodynamic studies. *Obstet Gynecol.* 2001 Aug;98(2):253-7. PMID: 11506841.
149. Culligan PJ, Goldberg RP, Sand PK. A randomized controlled trial comparing a modified Burch procedure and a suburethral sling: long-term follow-up. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Oct;14(4):229-33; discussion 33. PMID: 14530832.
150. Cundiff GW, Varner E, Visco AG, et al. Risk factors for mesh/suture erosion following sacral colpopexy. *Am J Obstet Gynecol.* 2008 Dec;199(6):688 e1-5. PMID: 18976976.
151. Curtis MR, Gormley EA, Latini JM, et al. Prospective development of a cost-efficient program for the pubovaginal sling. *Urology.* 1997 Jan;49(1):41-5. PMID: 9000183.
152. Dainer M, Hall CD, Choe J, et al. Pregnancy following incontinence surgery. *Int Urogynecol J Pelvic Floor Dysfunct.* 1998;9(6):385-90. PMID: 9891960.
153. Dainer MJ, Zorn BH. Burch-Cooper's ligament sling procedure: an augmented incontinence operation. *Tech Urol.* 2000 Sep;6(3):175-7. PMID: 10963481.
154. Daneshgari F, Moore C, Frinjari H, et al. Patient related risk factors for recurrent stress urinary incontinence surgery in women treated at a tertiary care center. *J Urol.* 2006 Oct;176(4 Pt 1):1493-9. PMID: 16952667.
155. Daneshgari F, Sorensen C. Practice pattern of urologists in the Rocky Mountains region with regard to use of urodynamic studies. *Urology.* 2003 May;61(5):942-5. PMID: 12736012.
156. Darai E, Coutant C, Rouzier R, et al. Genital prolapse repair using porcine skin implant and bilateral sacrospinous fixation: midterm functional outcome and quality-of-life assessment. *Urology.* 2009 Feb;73(2):245-50. PMID: 19038431.

157. Darai E, Frobert JL, Grisard-Anaf M, et al. Functional results after the suburethral sling procedure for urinary stress incontinence: a prospective randomized multicentre study comparing the retropubic and transobturator routes. *Eur Urol*. 2007 Mar;51(3):795-801; discussion -2. PMID: 17010507.
158. Das S. Comparative outcome analysis of laparoscopic colposuspension, abdominal colposuspension and vaginal needle suspension for female urinary incontinence. *J Urol*. 1998 Aug;160(2):368-71. PMID: 9679879.
159. David-Montefiore E, Frobert JL, Grisard-Anaf M, et al. Peri-operative complications and pain after the suburethral sling procedure for urinary stress incontinence: a French prospective randomised multicentre study comparing the retropubic and transobturator routes. *Eur Urol*. 2006 Jan;49(1):133-8. PMID: 16310932.
160. Davila GW, Ghoniem GM, Kapoor DS, et al. Pelvic floor dysfunction management practice patterns: a survey of members of the International Urogynecological Association. *Int Urogynecol J Pelvic Floor Dysfunct*. 2002;13(5):319-25. PMID: 12355293.
161. Davila GW, Neal D, Horbach N, et al. A bladder-neck support prosthesis for women with stress and mixed incontinence. *Obstet Gynecol*. 1999 Jun;93(6):938-42. PMID: 10362158.
162. Davila GW, Stanford E, Korn A. Prospective trial of gasless laparoscopic Burch colposuspension using conventional surgical instruments. *J Am Assoc Gynecol Laparosc*. 2004 May;11(2):197-203. PMID: 15200775.
163. Davis TL, Lukacz ES, Luber KM, et al. Determinants of patient satisfaction after the tension-free vaginal tape procedure. *Am J Obstet Gynecol*. 2004 Jul;191(1):176-81. PMID: 15295361.
164. de Seze M, Gallien P, Denys P, et al. Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study. *Neurourol Urodyn*. 2006;25(7):752-7. PMID: 16986136.
165. de Tayrac R, Deffieux X, Resten A, et al. A transvaginal ultrasound study comparing transobturator tape and tension-free vaginal tape after surgical treatment of female stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2006 Sep;17(5):466-71. PMID: 16311712.
166. Debodinance P, Delporte P, Engrand JB, et al. Tension-free vaginal tape (TVT) in the treatment of urinary stress incontinence: 3 years experience involving 256 operations. *Eur J Obstet Gynecol Reprod Biol*. 2002 Oct 10;105(1):49-58. PMID: 12270565.
167. Debodinance P, Querleu D. Comparison of the Bologna and Ingelman-Sundberg procedures for stress incontinence associated with genital prolapse: prospective randomized study. *Eur J Obstet Gynecol Reprod Biol*. 1993 Nov;52(1):35-40. PMID: 8119472.
168. Deffieux X, Donnadiu AC, Porcher R, et al. Long-term results of tension-free vaginal tape for female urinary incontinence: follow up over 6 years. *Int J Urol*. 2007 Jun;14(6):521-6. PMID: 17593097.

169. Demirci F, Ozdemir I, Somunkiran A, et al. Abdominal sacrohysteropexy in young women with uterovaginal prolapse: results of 20 cases. *J Reprod Med.* 2006 Jul;51(7):539-43. PMID: 16913544.
170. Denman MA, Gregory WT, Boyles SH, et al. Reoperation 10 years after surgically managed pelvic organ prolapse and urinary incontinence. *Am J Obstet Gynecol.* 2008 May;198(5):555 e1-5. PMID: 18355779.
171. deTayrac R, Deffieux X, Droupy S, et al. A prospective randomized trial comparing tension-free vaginal tape and transobturator suburethral tape for surgical treatment of stress urinary incontinence. *Am J Obstet Gynecol.* 2004 Mar;190(3):602-8. PMID: 15041987.
172. Deval B, Ferchaux J, Berry R, et al. Objective and subjective cure rates after trans-obturator tape (OBTAPE) treatment of female urinary incontinence. *Eur Urol.* 2006 Feb;49(2):373-7. PMID: 16413657.
173. Deval B, Jeffry L, Al Najjar F, et al. Determinants of patient dissatisfaction after a tension-free vaginal tape procedure for urinary incontinence. *J Urol.* 2002 May;167(5):2093-7. PMID: 11956447.
174. Diamond DA, Quimby GF, Rink RC, et al. Use of the silastic sheath in bladder neck reconstruction. *TheScientificWorldJournal*; 2004. p. 103-7.
175. Dietz HP, Barry C, Lim YN, et al. Two-dimensional and three-dimensional ultrasound imaging of suburethral slings. *Ultrasound Obstet Gynecol.* 2005 Aug;26(2):175-9. PMID: 15988786.
176. Dietz HP, Foote AJ, Mak HL, et al. TVT and Sparc suburethral slings: a case-control series. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 Mar-Apr;15(2):129-31; discussion 31. PMID: 15014941.
177. Dietz V, de Jong J, Huisman M, et al. The effectiveness of the sacrospinous hysteropexy for the primary treatment of uterovaginal prolapse. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Nov;18(11):1271-6. PMID: 17384894.
178. Digesu G, Hewett S, Hendricken C, et al. Does the onset or bother of mixed urinary incontinence help in the urodynamic diagnosis? *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. 29.
179. Diokno AC, Burgio K, Fultz H, et al. Prevalence and outcomes of continence surgery in community dwelling women. *J Urol.* 2003 Aug;170(2 Pt 1):507-11. PMID: 12853810.
180. Diokno AC, Sand PK, Macdiarmid S, et al. Perceptions and behaviours of women with bladder control problems. *Fam Pract.* 2006 Oct;23(5):568-77. PMID: 16731545.
181. Dmochowski RR. Management of postoperative overactive bladder complications. *Geriatrics.* 2002 May;57 Suppl 1:18-23. PMID: 12040599.
182. Dmochowski RR, Avon M, Ross J, et al. Transvaginal radio frequency treatment of the endopelvic fascia: a prospective evaluation for the treatment of genuine stress urinary incontinence. *J Urol.* 2003 Mar;169(3):1028-32. PMID: 12576838.

183. Dmochowski RR, Zimmern PE, Ganabathi K, et al. Role of the four-corner bladder neck suspension to correct stress incontinence with a mild to moderate cystocele. *Urology*. 1997 Jan;49(1):35-40. PMID: 9000182.
184. Dolan LM, Dixon WE, Hilton P. Urinary symptoms and quality of life in women following urogenital fistula repair: a long-term follow-up study. *BJOG*. 2008 Nov;115(12):1570-4. PMID: 19035993.
185. Dolan LM, Walsh D, Hamilton S, et al. A study of quality of life in primigravidae with urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2004 May-Jun;15(3):160-4. PMID: 15167993.
186. Domingo S, Alama P, Ruiz N, et al. Transobturator tape procedure outcome: a clinical and quality of life analysis of a 1-year follow-up. *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 Aug;18(8):895-900. PMID: 17136483.
187. Duckett JR, Tamilselvi A. Effect of tension-free vaginal tape in women with a urodynamic diagnosis of idiopathic detrusor overactivity and stress incontinence. *BJOG*. 2006 Jan;113(1):30-3. PMID: 16398768.
188. Dugan E, Cohen SJ, Robinson D, et al. The quality of life of older adults with urinary incontinence: determining generic and condition-specific predictors. *Qual Life Res*. 1998 May;7(4):337-44. PMID: 9610217.
189. Dumville JC, Manca A, Kitchener HC, et al. Cost-effectiveness analysis of open colposuspension versus laparoscopic colposuspension in the treatment of urodynamic stress incontinence. *BJOG*. 2006 Sep;113(9):1014-22. PMID: 16956333.
190. Eckford SB, Kohler-Ockmore J, Feneley RC. Long-term follow-up of transvaginal urethral closure and suprapubic cystostomy for urinary incontinence in women with multiple sclerosis. *Br J Urol*. 1994 Sep;74(3):319-21. PMID: 7953263.
191. Edlund C, Hellstrom M, Pecker R, et al. First Scandinavian experience of electrical sacral nerve stimulation in the treatment of the overactive bladder. *Scand J Urol Nephrol*. 2000 Dec;34(6):366-76. PMID: 11195901.
192. Edwall L, Carlstrom K, Jonasson AF. Endocrine status and markers of collagen synthesis and degradation in serum and urogenital tissue from women with and without stress urinary incontinence. *Neurourol Urodyn*. 2007;26(3):410-5. PMID: 17266139.
193. Ek M, Tegerstedt G, Falconer C, et al. Urodynamic assessment of anterior vaginal wall surgery: a randomized comparison between colporrhaphy and transvaginal mesh. *Neurourol Urodyn*. 2010 Apr;29(4):527-31. PMID: 19731311.
194. el Hemaly AK, Mousa LA. Stress urinary incontinence, a new concept. *Eur J Obstet Gynecol Reprod Biol*. 1996 Sep;68(1-2):129-35. PMID: 8886695.
195. El-Barky E, El-Shazly A, El-Wahab OA, et al. Tension free vaginal tape versus Burch colposuspension for treatment of female stress urinary incontinence. *Int Urol Nephrol*. 2005;37(2):277-81. PMID: 16142556.
196. Elia G, Bergman A. Genuine stress urinary incontinence with low urethral pressure. Five-year follow-up after the Ball-Burch procedure. *J Reprod Med*. 1995 Jul;40(7):503-6. PMID: 7473438.

197. Elkabir JJ, Mee AD. Long-term evaluation of the Gittes procedure for urinary stress incontinence. *J Urol*. 1998 Apr;159(4):1203-5. PMID: 9507834.
198. Elmer C, Altman D, Engh ME, et al. Trocar-guided transvaginal mesh repair of pelvic organ prolapse. *Obstet Gynecol*. 2009 Jan;113(1):117-26. PMID: 19104367.
199. el-Sayed RF, Morsy MM, el-Mashed SM, et al. Anatomy of the urethral supporting ligaments defined by dissection, histology, and MRI of female cadavers and MRI of healthy nulliparous women. *AJR Am J Roentgenol*. 2007 Nov;189(5):1145-57. PMID: 17954653.
200. Elzevier HW, Putter H, Delaere KP, et al. Female sexual function after surgery for stress urinary incontinence: transobturator suburethral tape vs. tension-free vaginal tape obturator. *J Sex Med*. 2008 Feb;5(2):400-6. PMID: 18042216.
201. Elzevier HW, Venema PL, Lycklama a Nijeholt AA. Sexual function after tension-free vaginal tape (TVT) for stress incontinence: results of a mailed questionnaire. *Int Urogynecol J Pelvic Floor Dysfunct*. 2004 Sep-Oct;15(5):313-8. PMID: 15278249.
202. Enzelsberger H, Helmer H, Schatten C. Comparison of Burch and lyodura sling procedures for repair of unsuccessful incontinence surgery. *Obstet Gynecol*. 1996 Aug;88(2):251-6. PMID: 8692511.
203. Enzelsberger H, Schatten C, Kurz C. Comparison of emepronium bromide and intravesically administered lidocain gel in the management of females with urge incontinence. *Geburtshilfe Frauenheilkd.*; 1991. p. 54-7.
204. Erdinc A, Gurates B, Celik H, et al. The efficacy of venlafaxine in the treatment of women with stress urinary incontinence. *Arch Gynecol Obstet*. 2009 Mar;279(3):343-8. PMID: 18629526.
205. Etheridge F, Tannenbaum C, Couturier Y. A systemwide formula for continence care: overcoming barriers, clarifying solutions, and defining team members' roles. *J Am Med Dir Assoc*. 2008 Mar;9(3):178-89. PMID: 18294601.
206. Fader M, Moore KN, Cottenden AM, et al. Coated catheters for intermittent catheterization: smooth or sticky? *BJU Int*. 2001 Sep;88(4):373-7. PMID: 11564024.
207. Falconer C, Ekman-Ordeberg G, Blomgren B, et al. Paraurethral connective tissue in stress-incontinent women after menopause. *Acta Obstet Gynecol Scand*. 1998 Jan;77(1):95-100. PMID: 9492727.
208. Farrell SA, Baskett TF, Baydock S. The use of intraoperative cystoscopy by general gynaecologists in Canada. *J Obstet Gynaecol Can*. 2009 Jan;31(1):48-53. PMID: 19208283.
209. Fatthy H, El Hao M, Samaha I, et al. Modified Burch colposuspension: laparoscopy versus laparotomy. *J Am Assoc Gynecol Laparosc*. 2001 Feb;8(1):99-106. PMID: 11172123.
210. Filbeck T, Ullrich T, Pichlmeier U, et al. Correlation of persistent stress urinary incontinence with quality of life after suspension procedures: is continence the only decisive postoperative criterion of success? *Urology*. 1999 Aug;54(2):247-51. PMID: 10443719.

211. Fiori M, Gunelli R, Mercuriali M, et al. Tension-free vaginal tape and female stress incontinence: further evidence of effectiveness. *Urol Int.* 2004;72(4):325-8. PMID: 15153731.
212. Fischer A, Fink T, Zachmann S, et al. Comparison of retropubic and outside-in transoburator sling systems for the cure of female genuine stress urinary incontinence. *Eur Urol.* 2005 Nov;48(5):799-804. PMID: 16140455.
213. FitzGerald MP, Elliott C, Brubaker L. New vs old: descriptors can affect patients' surgical preferences. *Am J Obstet Gynecol.* 2008 Nov;199(5):476 e1-3. PMID: 18468572.
214. FitzGerald MP, Kenton K, Shott S, et al. Responsiveness of quality of life measurements to change after reconstructive pelvic surgery. *Am J Obstet Gynecol.* 2001 Jul;185(1):20-4. PMID: 11483898.
215. FitzGerald MP, Mollenhauer J, Brubaker L. The fate of rectus fascia suburethral slings. *Am J Obstet Gynecol.* 2000 Oct;183(4):964-6. PMID: 11035347.
216. Foglia G, Mistrangelo E, Lijoi D, et al. Transfascial vaginal tape (TFT): a simple, safe and cost-effective procedure for stress urinary incontinence. A preliminary study. *Arch Gynecol Obstet.* 2007 Jul;276(1):59-63. PMID: 17219162.
217. Fontaine E, Hajri M, Rhein F, et al. Reappraisal of endoscopic sphincterotomy for post-traumatic neurogenic bladder: a prospective study. *J Urol.* 1996 Jan;155(1):277-80. PMID: 7490855.
218. Foote AJ, Maughan V, Carne C. Laparoscopic colposuspension versus vaginal suburethral slingplasty: a randomised prospective trial. *Aust N Z J Obstet Gynaecol.* 2006 Dec;46(6):517-20. PMID: 17116057.
219. Foote AJ, Moore KH. The cost of urogynaecological treatments: which are more cost-effective? *Aust N Z J Obstet Gynaecol.* 2007 Jun;47(3):240-6. PMID: 17550494.
220. Fox PD, Coleman E. Managing common geriatric conditions. *Healthplan.* 2002 Mar-Apr;43(2):47-53. PMID: 11961924.
221. Franco N, Shobeiri SA, Echols KT. Medium-term follow-up of transvaginal suburethral slings: variance in outcome success using two different evaluation methods. *Urology.* 2002 Oct;60(4):607-10; discussion 10-1. PMID: 12385917.
222. Frederick RW, Leach GE. Cadaveric prolapse repair with sling: intermediate outcomes with 6 months to 5 years of followup. *J Urol.* 2005 Apr;173(4):1229-33. PMID: 15758758.
223. Friedman SM, Steinwachs DM, Rathouz PJ, et al. Characteristics predicting nursing home admission in the program of all-inclusive care for elderly people. *Gerontologist.* 2005 Apr;45(2):157-66. PMID: 15799980.
224. Fritel X, Schaal JP, Fauconnier A, et al. Pelvic floor disorders 4 years after first delivery: a comparative study of restrictive versus systematic episiotomy. *BJOG.* 2008 Jan;115(2):247-52. PMID: 17970794.

225. Fultz NH, Rahrig Jenkins K, Ostbye T, et al. The impact of own and spouse's urinary incontinence on depressive symptoms. *Soc Sci Med*. 2005 Jun;60(11):2537-48. PMID: 15814179.
226. Gateau T, Faramarzi-Roques R, Le Normand L, et al. Clinical and urodynamic repercussions after TVT procedure and how to diminish patient complaints. *Eur Urol*. 2003 Sep;44(3):372-6; discussion 6. PMID: 12932939.
227. Gebhart JB, Dixon DA, Trabuco EC, et al. Three-year outcomes of Uretex Urethral Support System for treatment of stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Aug;19(8):1075-9. PMID: 18305884.
228. German KA, Kynaston H, Weight S, et al. A prospective randomized trial comparing a modified needle suspension procedure with the vagina/obturator shelf procedure for genuine stress incontinence. *Br J Urol*. 1994 Aug;74(2):188-90. PMID: 7921936.
229. Ghali WA, Freund KM, Boss RD, et al. Menopausal hormone therapy: physician awareness of patient attitudes. *Am J Med*. 1997 Jul;103(1):3-10. PMID: 9236479.
230. Ghoniem GM. The recalcitrant overactive bladder patient. *Geriatrics*. 2002 May;57 Suppl 1:23-9. PMID: 12040600.
231. Giberti C, Gallo F, Cortese P, et al. Transobturator tape for treatment of female stress urinary incontinence: objective and subjective results after a mean follow-up of two years. *Urology*. 2007 Apr;69(4):703-7. PMID: 17445655.
232. Giberti C, Rovida S. Transvaginal bone-anchored synthetic sling for the treatment of stress urinary incontinence: an outcomes analysis. *Urology*. 2000 Dec 20;56(6):956-61. PMID: 11113740.
233. Giberti C, Siracusano S, Gallo F, et al. Transvaginal bone-anchored sling procedure: 4 years of follow-up on more than 200 consecutive patients. *Urology*. 2008 Aug;72(2):313-7; discussion 7. PMID: 18554693.
234. Gilja I. Transvaginal needle suspension operation: the way we do it. Clinical and urodynamic study: long-term results. *Eur Urol*. 2000 Mar;37(3):325-30. PMID: 10720860.
235. Gilja I, Puskar D, Mazuran B, et al. Comparative analysis of bladder neck suspension using Raz, Burch and transvaginal Burch procedures. A 3-year randomized prospective study. *Eur Urol*. 1998;33(3):298-302. PMID: 9555556.
236. Giri SK, Drumm J, Saunders JA, et al. Day-case sling surgery for stress urinary incontinence: feasibility and safety. *BJU Int*. 2005 Apr;95(6):827-32. PMID: 15794792.
237. Glavind K. Conservative treatment of stress incontinence with Geisha balls. *Int Urogynecol J Pelvic Floor Dysfunct*. 2001;12(4):223-4; discussion 4-5. PMID: 11569648.
238. Glavind K, Kempf L. Colpectomy or Le Fort colpocleisis--a good option in selected elderly patients. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Jan-Feb;16(1):48-51; discussion PMID: 15322743.

239. Glazener CM, Cooper K. Anterior vaginal repair for urinary incontinence in women. *Cochrane Database Syst Rev.* 2000(3):CD001755. PMID: 10908510.
240. Glazener CM, Cooper K. Anterior vaginal repair for urinary incontinence in women. *Cochrane Database Syst Rev.* 2001(1):CD001755. PMID: 11279728.
241. Glazener CM, Cooper K. Bladder neck needle suspension for urinary incontinence in women. *Cochrane Database Syst Rev.* 2002(2):CD003636. PMID: 12076494.
242. Glazener CM, Cooper K. Bladder neck needle suspension for urinary incontinence in women. *Cochrane Database Syst Rev.* 2004(2):CD003636. PMID: 15106209.
243. Gnessin E, Livne PM, Baniel J, et al. Continence and quality of life assessment after artificial urinary sphincter implantation. *Isr Med Assoc J.* 2004 Oct;6(10):592-4. PMID: 15473584.
244. Goel MC, Roberts JG. Dynamic rectus abdominis tendon colposuspension for female stress urinary incontinence: a new procedure and its follow-up. *Urol Int.* 2003;71(1):45-50. PMID: 12845260.
245. Gordon D, Groutz A, Ascher-Landsberg J, et al. Double-blind, placebo-controlled study of magnesium hydroxide for treatment of sensory urgency and detrusor instability: preliminary results. *Br J Obstet Gynaecol.* 1998 Jun;105(6):667-9. PMID: 9647159.
246. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. *Obstet Gynecol.* 2001 Jan;97(1):116-20. PMID: 11152919.
247. Granese R, Adile B. Tension-free cystocele repair: an analysis after a follow-up of 24 months. *Minerva Ginecol.* 2007 Aug;59(4):369-76. PMID: 17923828.
248. Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. *J Urol.* 2006 Dec;176(6 Pt 1):2535-40; discussion 40. PMID: 17085151.
249. Guerette NL, Peterson TV, Aguirre OA, et al. Anterior repair with or without collagen matrix reinforcement: a randomized controlled trial. *Obstet Gynecol.* 2009 Jul;114(1):59-65. PMID: 19546759.
250. Guerrero K, Emery S, Owen L, et al. Intravesical oxybutynin: practicalities of clinical use. *J Obstet Gynaecol.* 2006 Feb;26(2):141-3. PMID: 16483973.
251. Guerrero K, Watkins A, Emery S, et al. A randomised controlled trial comparing two autologous fascial sling techniques for the treatment of stress urinary incontinence in women: short, medium and long-term follow-up. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Nov;18(11):1263-70. PMID: 17347792.
252. Haab F, Trockman BA, Zimmern PE, et al. Results of pubovaginal sling for the treatment of intrinsic sphincteric deficiency determined by questionnaire analysis. *J Urol.* 1997 Nov;158(5):1738-41. PMID: 9334590.
253. Haab F, Zimmern PE, Leach GE. Urinary stress incontinence due to intrinsic sphincteric deficiency: experience with fat and collagen periurethral injections. *The Journal of urology*; 1997. p. 1283-6.

254. Hadley HR, Pineda EB. The urethral sling and stress urinary incontinence. *West J Med.* 1998 Sep;169(3):167-8. PMID: 9771157.
255. Haferkamp A, Staehler G, Gerner HJ, et al. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. *Spinal Cord.* 2000 Apr;38(4):250-4. PMID: 10822396.
256. Hagglund D, Walker-Engstrom ML, Larsson G, et al. Changes in urinary incontinence and quality of life after four years. A population-based study of women aged 22-50 years. *Scand J Prim Health Care.* 2004 Jun;22(2):112-7. PMID: 15255492.
257. Hajebrahimi S, Corcos J, Lemieux MC. International consultation on incontinence questionnaire short form: comparison of physician versus patient completion and immediate and delayed self-administration. *Urology.* 2004 Jun;63(6):1076-8. PMID: 15183953.
258. Harmanli OH, Okafor O, Ayaz R, et al. Lidocaine jelly and plain aqueous gel for urethral straight catheterization and the Q-tip test: a randomized controlled trial. *Obstet Gynecol.* 2009 Sep;114(3):547-50. PMID: 19701033.
259. Hassouna ME, Ghoniem GM. Long-term outcome and quality of life after modified pubovaginal sling for intrinsic sphincteric deficiency. *Urology.* 1999 Feb;53(2):287-91. PMID: 9933041.
260. Hawkins E, Taylor D, Hughes-Nurse J. Long term follow up of the cruciate fascial sling for women with genuine stress incontinence. *BJOG.* 2002 Mar;109(3):327-38. PMID: 11950189.
261. Heit M, Blackwell L, Kelly S. Measuring barriers to incontinence care seeking. *Neurourol Urodyn.* 2008;27(3):174-8. PMID: 17621356.
262. Heliovaara-Peippo S, Halmesmaki K, Hurskainen R, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial. *BJOG.* 2010 Apr;117(5):602-9. PMID: 20156209.
263. Helstrom L, Nilsson B. Impact of vaginal surgery on sexuality and quality of life in women with urinary incontinence or genital descensus. *Acta Obstet Gynecol Scand.* 2005 Jan;84(1):79-84. PMID: 15603572.
264. Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. *JAMA.* 2005 Feb 23;293(8):935-48. PMID: 15728164.
265. Higgs P, Goh J, Krause H, et al. Abdominal sacral colpopexy: an independent prospective long-term follow-up study. *Aust N Z J Obstet Gynaecol.* 2005 Oct;45(5):430-4. PMID: 16171482.
266. Hiltunen R, Nieminen K, Takala T, et al. Low-weight polypropylene mesh for anterior vaginal wall prolapse: a randomized controlled trial. *Obstet Gynecol.* 2007 Aug;110(2 Pt 2):455-62. PMID: 17666627.
267. Hirata H, Matsuyama H, Yamakawa G, et al. Does surgical repair of pelvic prolapse improve patients' quality of life? *Eur Urol.* 2004 Feb;45(2):213-8. PMID: 14734009.

268. Hol M, van Bolhuis C, Vierhout ME. Vaginal ultrasound studies of bladder neck mobility. *Br J Obstet Gynaecol*. 1995 Jan;102(1):47-53. PMID: 7833310.
269. Holmgren C, Hellberg D, Lanner L, et al. Quality of life after tension-free vaginal tape surgery for female stress incontinence. *Scand J Urol Nephrol*. 2006;40(2):131-7. PMID: 16608811.
270. Holmgren C, Nilsson S, Lanner L, et al. Long-term results with tension-free vaginal tape on mixed and stress urinary incontinence. *Obstet Gynecol*. 2005 Jul;106(1):38-43. PMID: 15994615.
271. Holmgren C, Nilsson S, Lanner L, et al. Frequency of de novo urgency in 463 women who had undergone the tension-free vaginal tape (TVT) procedure for genuine stress urinary incontinence--a long-term follow-up. *Eur J Obstet Gynecol Reprod Biol*. 2007 May;132(1):121-5. PMID: 16815624.
272. Hooper P, Tincello DG, Richmond DH. The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study. *Br J Urol*. 1997 Sep;80(3):414-6. PMID: 9313659.
273. Horrocks S, Somerset M, Stoddart H, et al. What prevents older people from seeking treatment for urinary incontinence? A qualitative exploration of barriers to the use of community continence services. *Fam Pract*. 2004 Dec;21(6):689-96. PMID: 15528285.
274. Huang YH, Lin AT, Chen KK, et al. High failure rate using allograft fascia lata in pubovaginal sling surgery for female stress urinary incontinence. *Urology*. 2001 Dec;58(6):943-6. PMID: 11744464.
275. Hullfish KL, Bovbjerg VE, Gibson J, et al. Patient-centered goals for pelvic floor dysfunction surgery: what is success, and is it achieved? *Am J Obstet Gynecol*. 2002 Jul;187(1):88-92. PMID: 12114893.
276. Hullfish KL, Bovbjerg VE, Steers WD. Colpocleisis for pelvic organ prolapse: patient goals, quality of life, and satisfaction. *Obstet Gynecol*. 2007 Aug;110(2 Pt 1):341-5. PMID: 17666609.
277. Hung MJ, Liu FS, Shen PS, et al. Analysis of two sling procedures using polypropylene mesh for treatment of stress urinary incontinence. *Int J Gynaecol Obstet*. 2004 Feb;84(2):133-41. PMID: 14871515.
278. Iglesias X, Espuna M, Puig M, et al. Pubic bone anchoring devices for the surgical treatment of urinary stress incontinence in patients with severe genital prolapse. *Int Urogynecol J Pelvic Floor Dysfunct*. 2002;13(5):314-8. PMID: 12355292.
279. Ignjatovic I, Vuckovic M, Srzentic Z. Transobturator tension-free composite sling for urethral support in patients with stress urinary incontinence: favorable experience after 1 year follow up. *Int J Urol*. 2006 Jun;13(6):728-32. PMID: 16834651.
280. Ijland MM, Fischer DC, Kieback DG, et al. Midline intravaginal slingplasty for treatment of urinary stress incontinence: results of an independent audit up to 2 years after surgery. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Nov-Dec;16(6):447-54. PMID: 15742119.

281. Innerkofler PC, Guenther V, Rehder P, et al. Improvement of quality of life, anxiety and depression after surgery in patients with stress urinary incontinence: results of a longitudinal short-term follow-up. *Health Qual Life Outcomes*. 2008;6:72. PMID: 18823552.
282. Ishiko O, Ushiroyama T, Saji F, et al. beta(2)-adrenergic agonists and pelvic floor exercises for female stress incontinence. *Int J Gynaecol Obstet*. 2000 Oct;71(1):39-44. PMID: 11044540.
283. Iskander MN, Kapoor DS, Mohammed A. Subjective outcomes of the TVT procedure. *Int J Gynaecol Obstet*. 2003 Oct;83(1):69-70. PMID: 14511876.
284. Ismail SI. Radiofrequency remodelling of the endopelvic fascia is not an effective procedure for urodynamic stress incontinence in women. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Sep;19(9):1205-9. PMID: 18504516.
285. ISRCTN01717074. The treatment of urinary incontinence in stroke patients.
286. ISRCTN15411586. The measurement of urinary incontinence via survey questionnaires.
287. ISRCTN15553880. Effects of introducing a specialised nurse in the care of community-dwelling women suffering from urinary incontinence.
288. ISRCTN16772662. Group treatment: an acceptable and effective method of physiotherapy provision for female urinary incontinence?
289. ISRCTN23418270. A randomised controlled trial of educational group sessions and conventional individual management in the physiotherapeutic treatment of female urinary incontinence (FUI).
290. ISRCTN27633617. A pilot study to evaluate the effectiveness of dynamic lumbo-pelvic stability training as a treatment strategy for women with stress incontinence: a randomised controlled trial.
291. ISRCTN29863839. A prospective, randomised, controlled trial to evaluate the efficacy and safety of endoscopic choroid plexus coagulation with third ventriculostomy in the treatment of idiopathic Normal Pressure Hydrocephalus.
292. ISRCTN31004502. A randomised, double blind, placebo controlled, crossover trial of the adjuvant properties of imipramine for the overactive bladder.
293. ISRCTN34759911. Colposuspension or tension free vaginal tape with anterior repair for urinary incontinence and prolapse: a pilot study.
294. ISRCTN37726767. A prospective randomised controlled trial of pelvic floor exercises plus biofeedback versus pelvic floor exercises alone in treating stress urinary incontinence.
295. ISRCTN39853232. A phase II, multi-centre, double-blind, placebo-controlled, 2-way cross-over study to evaluate efficacy, plasma concentrations and safety of 0.25 mL of 20 % w/w PSD503 for topical application in female volunteer patients with stress urinary incontinence.
296. ISRCTN44339585. Laparoscopic Treatment for Female Urinary Incontinence.

297. ISRCTN59388318. Re-education of the pelvic floor in women with urinary stress incontinence.
298. ISRCTN62722772. The effects of involving a nurse practitioner in primary care for adult patients with urinary incontinence.
299. ISRCTN66713401. Pilot study for the comparison of drug treatment with conservative treatment for people with overactive bladders.
300. ISRCTN71247587. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised trial.
301. ISRCTN97337606. A study to compare bladder function of healthy Asian and Caucasian women.
302. ISRCTN97355181. A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with symptoms of overactive bladder.
303. Itano N, Berman CJ, Rodriguez LV, et al. Polypropylene sling for the treatment of stress urinary incontinence: intermediate term results. *Journal of Urology*. 2003;169S:270.
304. Jakimiuk AJ, Maciejewski T, Fritz A, et al. Surgical treatment of stress urinary incontinence using the tension-free vaginal tape-obturator system (TVT-O) technique. *Eur J Obstet Gynecol Reprod Biol*. 2007 Nov;135(1):127-31. PMID: 17466437.
305. Jakobsen H, Kromann-Andersen B, Nielsen KK, et al. Pad weighing tests with 50% or 75% bladder filling. Does it matter? *Acta Obstet Gynecol Scand*. 1993 Jul;72(5):377-81. PMID: 8392270.
306. Jarvis SK, Hallam TK, Lujic S, et al. Peri-operative physiotherapy improves outcomes for women undergoing incontinence and or prolapse surgery: results of a randomised controlled trial. *Aust N Z J Obstet Gynaecol*. 2005 Aug;45(4):300-3. PMID: 16029296.
307. Jelovsek JE, Barber MD, Karram MM, et al. Randomised trial of laparoscopic Burch colposuspension versus tension-free vaginal tape: long-term follow up. *BJOG*. 2008 Jan;115(2):219-25; discussion 25. PMID: 18081602.
308. Jeter KF, Wagner DB. Incontinence in the American home. A survey of 36,500 people. *J Am Geriatr Soc*. 1990 Mar;38(3):379-83. PMID: 2313016.
309. Jha S, Moran P, Greenham H, et al. Sexual function following surgery for urodynamic stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 Aug;18(8):845-50. PMID: 17115231.
310. John H, Blick N. Mid-term outcome after bulbourethral composite suspension for postprostatectomy incontinence. *Urology*. 2008 Jun;71(6):1191-5. PMID: 18538695.
311. Johnson TM, 2nd, Kincade JE, Bernard SL, et al. The association of urinary incontinence with poor self-rated health. *J Am Geriatr Soc*. 1998 Jun;46(6):693-9. PMID: 9625183.
312. Jolic V, Gilja I. Vaginal vs. transabdominal ultrasonography in the evaluation of female urinary tract anatomy, stress urinary incontinence and pelvic organs static disturbances. *Zentralbl Gynakol*. 1997;119(10):483-91. PMID: 9361397.

313. Jones JS, Vasavada SP, Rackley RR. Prospective randomized controlled trial of modified hypermobility test for urinary incontinence. *Journal of Pelvic Medicine and Surgery*; 2007. p. 13-7.
314. Jongen VH, Brouwer WK. Comparison of the modified Pereyra procedure using permanent suture material and Burch urethropexy. *Eur J Obstet Gynecol Reprod Biol*. 1999 May;84(1):7-11. PMID: 10413219.
315. JPRN-JapicCTI-050025. CS-801 phase 3 comparative study.
316. JPRN-JapicCTI-050026. CS-801 phase 3 long-term study.
317. JPRN-JapicCTI-070432. Long-term study of imidafenacin in patients with overactive bladder.
318. JPRN-JapicCTI-090874. A Phase 2 Study of TRK-130 in Patients With Overactive Bladder.
319. Juang CM, Yu KJ, Chou P, et al. Efficacy analysis of trans-obturator tension-free vaginal tape (TVT-O) plus modified Ingelman-Sundberg procedure versus TVT-O alone in the treatment of mixed urinary incontinence: a randomized study. *Eur Urol*. 2007 Jun;51(6):1671-8; discussion 9. PMID: 17254697.
320. Juma S, Brito CG. Transobturator tape (TOT): Two years follow-up. *Neurourol Urodyn*. 2007;26(1):37-41. PMID: 17083100.
321. Jung HC, Kim HT, Song PH, et al. Experience of REMEEX system for the treatment of female urinary incontinence, intrinsic sphincteric deficiency and neurogenic bladder. 38th Annual Meeting of the International Continence Society (ICS 2008), Cairo International Congress Center (CICC), Cairo (Egypt), 20-24 Oct 2008.
322. Kalble T, Roth S. Serosa lined and tapered ileum as primary and secondary continence mechanism for various catheterizable pouches. *J Urol*. 2008 Nov;180(5):2053-7. PMID: 18804246.
323. Kammerer-Doak DN, Dorin MH, Rogers RG, et al. A randomized trial of burch retropubic urethropexy and anterior colporrhaphy for stress urinary incontinence. *Obstet Gynecol*. 1999 Jan;93(1):75-8. PMID: 9916960.
324. Kammerer-Doak DN, Rogers RG, Bellar B. Vaginal erosion of cadaveric fascia lata following abdominal sacrocolpopexy and suburethral sling urethropexy. *Int Urogynecol J Pelvic Floor Dysfunct*. 2002;13(2):106-9; discussion 9. PMID: 12054177.
325. Kane L, Chung T, Lawrie H, et al. The pubofascial anchor sling procedure for recurrent genuine urinary stress incontinence. *BJU Int*. 1999 Jun;83(9):1010-4. PMID: 10368246.
326. Kaplan HJ, Mamo GJ. Pubovaginal sling technique utilizing a unique bone anchor instrumentation system. *Can J Urol*. 2000 Oct;7(5):1116-21. PMID: 11114875.
327. Karantanis E, Fynes MM, Stanton SL. The tension-free vaginal tape in older women. *BJOG*. 2004 Aug;111(8):837-41. PMID: 15270933.
328. Keepnews D, Capitman JA, Rosati RJ. Measuring patient-level clinical outcomes of home health care. *J Nurs Scholarsh*. 2004;36(1):79-85. PMID: 15098423.

329. Kelleher CJ, Cardozo LD, Khullar V, et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. *Br J Obstet Gynaecol*. 1997 Sep;104(9):988-93. PMID: 9307522.
330. Kenton K, Sadowski D, Shott S, et al. A comparison of women with primary and recurrent pelvic prolapse. *Am J Obstet Gynecol*. 1999 Jun;180(6 Pt 1):1415-8. PMID: 10368479.
331. Kilonzo M, Vale L, Stearns SC, et al. Cost effectiveness of tension-free vaginal tape for the surgical management of female stress incontinence. *Int J Technol Assess Health Care*. 2004 Fall;20(4):455-63. PMID: 15609795.
332. Kim JC, Chung BS, Choi JB, et al. A safety and quality of life analysis of intravaginal slingplasty in female stress incontinence: a prospective, open label, multicenter, and observational study. *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 Nov;18(11):1331-5. PMID: 17333435.
333. Kim JC, Park EY, Seo SI, et al. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. *J Urol*. 2006 May;175(5):1773-6; discussion 6. PMID: 16600756.
334. Kim JH, Rivas DA, Shenot PJ, et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. *The journal of spinal cord medicine*. 2003(4):358-63. PMID: CN-00468838.
335. Kim SP, Sarmast Z, Daignault S, et al. Long-term durability and functional outcomes among patients with artificial urinary sphincters: a 10-year retrospective review from the University of Michigan. *J Urol*. 2008 May;179(5):1912-6. PMID: 18353376.
336. Kinn AC. Tension-free vaginal tape evaluated using patient self-reports and urodynamic testing--a two-year follow-up. *Scand J Urol Nephrol*. 2001 Dec;35(6):484-90. PMID: 11848428.
337. Kitamura H, Miyao N, Yanase M, et al. Quality of life in patients having an ileal conduit, continent reservoir or orthotopic neobladder after cystectomy for bladder carcinoma. *Int J Urol*. 1999 Aug;6(8):393-9. PMID: 10466451.
338. Kitchener HC, Dunn G, Lawton V, et al. Laparoscopic versus open colposuspension--results of a prospective randomised controlled trial. *BJOG : an international journal of obstetrics and gynaecology*; 2006. p. 1007-13.
339. Kjolhede P. Long-term efficacy of Burch colposuspension: a 14-year follow-up study. *Acta Obstet Gynecol Scand*. 2005 Aug;84(8):767-72. PMID: 16026403.
340. Kjolhede P, Wahlstrom J, Wingren G. Pelvic floor dysfunction after Burch colposuspension--a comprehensive study. Part I. *Acta Obstet Gynecol Scand*. 2005 Sep;84(9):894-901. PMID: 16097983.
341. Klein MC, Gauthier RJ, Jorgensen SH, et al. Does episiotomy prevent perineal trauma and pelvic floor relaxation? *Online J Curr Clin Trials*. 1992 Jul 1;Doc No 10:[6019 words; 65 paragraphs]. PMID: 1343606.

342. Kluivers KB, Mol BW, Bremer GL, et al. Pelvic organ function in randomized patients undergoing laparoscopic or abdominal hysterectomy. *J Minim Invasive Gynecol.* 2007 Jul-Aug;14(4):442-8. PMID: 17630161.
343. Ko Y, Lin SJ, Salmon JW, et al. The impact of urinary incontinence on quality of life of the elderly. *Am J Manag Care.* 2005 Jul;11(4 Suppl):S103-11. PMID: 16161383.
344. Kobak W, Lu J, Hardart A, et al. Expression of lysyl oxidase and transforming growth factor beta2 in women with severe pelvic organ prolapse. *J Reprod Med.* 2005 Nov;50(11):827-31. PMID: 16419630.
345. Kochakarn W. Tension-free vaginal tape procedure for the treatment of stress urinary incontinence: the first experience in Thailand. *J Med Assoc Thai.* 2002 Jan;85(1):87-91. PMID: 12075727.
346. Kocjancic E, Crivellaro S, Oyama IA, et al. Transobturator tape in the management of female stress incontinence: clinical outcomes at medium term follow-up. *Urol Int.* 2008;80(3):275-8. PMID: 18480630.
347. Kondo A, Isobe Y, Kimura K, et al. Efficacy, safety and hospital costs of tension-free vaginal tape and pubovaginal sling in the surgical treatment of stress incontinence. *J Obstet Gynaecol Res.* 2006 Dec;32(6):539-44. PMID: 17100814.
348. Koonings PP, Bergman A, Ballard CA. Prostaglandins for enhancing detrusor function after surgery for stress incontinence in women. *J Reprod Med.* 1990 Jan;35(1):1-5. PMID: 2299605.
349. Korman HJ, Sirls LT, Kirkemo AK. Success rate of modified Pereyra bladder neck suspension determined by outcomes analysis. *J Urol.* 1994 Nov;152(5 Pt 1):1453-7. PMID: 7933182.
350. Krofta L, Feyereisl J, Otcenasek M, et al. TVT and TVT-O for surgical treatment of primary stress urinary incontinence: prospective randomized trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2010 Feb;21(2):141-8. PMID: 19907913.
351. Kuczyk MA, Klein S, Grunewald V, et al. A questionnaire-based outcome analysis of the Stamey bladder neck suspension procedure for the treatment of urinary stress incontinence: the Hannover experience. *Br J Urol.* 1998 Aug;82(2):174-80. PMID: 9722750.
352. Kuhn A, Stadlmayr W, Lengsfeld D, et al. Where should bulking agents for female urodynamic stress incontinence be injected? *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Jun;19(6):817-21. PMID: 18157642.
353. Kulseng-Hanssen S, Husby H, Schiotz HA. The tension free vaginal tape operation for women with mixed incontinence: Do preoperative variables predict the outcome? *Neurourol Urodyn.* 2007;26(1):115-21; discussion 22. PMID: 16894616.
354. Kumar H, Cauchi J, MacKinnon AE. Periurethral Goretex sling in lower urinary reconstruction. *Eur J Pediatr Surg.* 1999 Dec;9 Suppl 1:33-4. PMID: 10661790.
355. Kung RC, Lie K, Lee P, et al. The cost-effectiveness of laparoscopic versus abdominal Burch procedures in women with urinary stress incontinence. *J Am Assoc Gynecol Laparosc.* 1996 Aug;3(4):537-44. PMID: 9050685.

356. Kuo HC. Comparison of video urodynamic results after the pubovaginal sling procedure using rectus fascia and polypropylene mesh for stress urinary incontinence. *J Urol*. 2001 Jan;165(1):163-8. PMID: 11125388.
357. Kuo HC. Long-term results of surgical treatment for female stress urinary incontinence. *Urol Int*. 2001;66(1):13-7. PMID: 11150944.
358. Kuo HC. Anatomical and functional results of pubovaginal sling procedure using polypropylene mesh for the treatment of stress urinary incontinence. *J Urol*. 2001 Jul;166(1):152-7. PMID: 11435845.
359. Kuo HC. The surgical results of the pubovaginal sling procedure using polypropylene mesh for stress urinary incontinence. *BJU Int*. 2001 Dec;88(9):884-8. PMID: 11851608.
360. Kuo HC, Liu HT, Yang WC. Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. *J Urol*. 2006 Aug;176(2):641-5. PMID: 16813911.
361. Kursh ED. Factors influencing the outcome of a no incision endoscopic urethropexy. *Surg Gynecol Obstet*. 1992 Sep;175(3):254-8. PMID: 1514161.
362. Kuschel S, Schuessler B. Results on function and safety of the Safyre-t, a hybrid transobturator vaginal sling for the treatment of stress urinary incontinence. *Neurourol Urodyn*. 2008;27(5):403-6. PMID: 17985372.
363. Kwon E, Schulz JA, Flood CG. Success of pubovaginal sling in patients with stress urinary incontinence and efficacy of vaginal sling release in patients with post-sling voiding dysfunction. *J Obstet Gynaecol Can*. 2006 Jun;28(6):519-25. PMID: 16857120.
364. Labrie J, van der Graaf Y, Buskens E, et al. Protocol for Physiotherapy Or TVT Randomised Efficacy Trial (PORTRET): a multicentre randomised controlled trial to assess the cost-effectiveness of the tension free vaginal tape versus pelvic floor muscle training in women with symptomatic moderate to severe stress urinary incontinence. *BMC Womens Health*. 2009;9:24. PMID: 19723313.
365. Ladwig D, Miljkovic-Petkovic L, Hewson AD. Simplified colposuspension: a 15-year follow-up. *Aust N Z J Obstet Gynaecol*. 2004 Feb;44(1):39-45. PMID: 15089867.
366. Lal R, Bhatnagar V, Agarwala S, et al. Urodynamic evaluation in boys treated for posterior urethral valves. *Pediatr Surg Int*. 1999 Jul;15(5-6):358-62. PMID: 10415286.
367. Lal R, Bhatnagar V, Mitra DK. Urinary continence following posterior urethral valves treatment. *Indian J Pediatr*. 1999 Jan-Feb;66(1):49-54. PMID: 10798036.
368. Lalos O, Berglund AL, Bjerle P. Urodynamics in women with stress incontinence before and after surgery. *Eur J Obstet Gynecol Reprod Biol*. 1993 Mar;48(3):197-205. PMID: 8335138.
369. Lalos O, Berglund AL, Lalos A. Impact of urinary and climacteric symptoms on social and sexual life after surgical treatment of stress urinary incontinence in women: a long-term outcome. *J Adv Nurs*. 2001 Feb;33(3):316-27. PMID: 11251718.
370. Land R, Parry E, Rane A, et al. Personal preferences of obstetricians towards childbirth. *Aust N Z J Obstet Gynaecol*. 2001 Aug;41(3):249-52. PMID: 11592537.

371. Langer R, Golan A, Arad D, et al. Effects of induced menopause on Burch colposuspension for urinary stress incontinence. *J Reprod Med.* 1992 Dec;37(12):956-8. PMID: 1287204.
372. Lapitan MC, Cody DJ, Grant AM. Open retropubic colposuspension for urinary incontinence in women. *Cochrane Database Syst Rev.* 2005(3):CD002912. PMID: 16034879.
373. Latini JM, Brown JA, Kreder KJ. Abdominal sacral colpopexy using autologous fascia lata. *J Urol.* 2004 Mar;171(3):1176-9. PMID: 14767295.
374. Latini JM, Lux MM, Kreder KJ. Efficacy and morbidity of autologous fascia lata sling cystourethropexy. *J Urol.* 2004 Mar;171(3):1180-4. PMID: 14767296.
375. Laurikainen E, Valpas A, Kivelä A, et al. Retropubic compared with transobturator tape placement in treatment of urinary incontinence: a randomized controlled trial. *Obstetrics and gynecology*; 2007. p. 4-11.
376. Lee CL, Yen CF, Wang CJ, et al. Extraperitoneal approach to laparoscopic Burch colposuspension. *J Am Assoc Gynecol Laparosc.* 2001 Aug;8(3):374-7. PMID: 11509776.
377. Lee CL, Yen CF, Wang CJ, et al. Trocar-assisted sling suspension for stress urinary incontinence. *J Am Assoc Gynecol Laparosc.* 2002 Nov;9(4):500-2. PMID: 12386363.
378. Lee JH, Kim KH, Lee HW, et al. Distal urethral polypropylene sling surgical management for urodynamic stress incontinence in Korean women. *Urol Int.* 2009;82(2):191-5. PMID: 19322009.
379. Lee KS, Choo MS, Doo CK, et al. The long term (5-years) objective TVT success rate does not depend on predictive factors at multivariate analysis: a multicentre retrospective study. *Eur Urol.* 2008 Jan;53(1):176-82. PMID: 17825478.
380. Lee KS, Choo MS, Lee YS, et al. Prospective comparison of the 'inside-out' and 'outside-in' transobturator-tape procedures for the treatment of female stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Apr;19(4):577-82. PMID: 17940717.
381. Lee KS, Han DH, Choi YS, et al. A prospective trial comparing tension-free vaginal tape and transobturator vaginal tape inside-out for the surgical treatment of female stress urinary incontinence: 1-year followup. *J Urol.* 2007 Jan;177(1):214-8. PMID: 17162048.
382. Lehtonen T. The Effect of Phenylpropanolamine on female stress urinary incontinence. *Annales chirurgiae et gynaecologiae.* 1986;75:236-41. PMID: 3535621.
383. Lemack GE, Krauss S, Litman H, et al. Normal preoperative urodynamic testing does not predict voiding dysfunction after Burch colposuspension versus pubovaginal sling. *J Urol.* 2008 Nov;180(5):2076-80. PMID: 18804239.
384. Lemack GE, Xu Y, Brubaker L, et al. Clinical and demographic factors associated with valsalva leak point pressure among women undergoing burch bladder neck suspension or autologous rectus fascial sling procedures. *Neurourol Urodyn.* 2007;26(3):392-6. PMID: 17304525.

385. Lemack GE, Zimmern PE. Sexual function after vaginal surgery for stress incontinence: results of a mailed questionnaire. *Urology*. 2000 Aug 1;56(2):223-7. PMID: 10925082.
386. Lepor H, Theune C. Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. *J Urol*. 1995 Jul;154(1):116-8. PMID: 7776406.
387. Liapis A, Bakas P, Christopoulos P, et al. Tension-free vaginal tape for elderly women with stress urinary incontinence. *Int J Gynaecol Obstet*. 2006 Jan;92(1):48-51. PMID: 16253254.
388. Liapis A, Bakas P, Creatsas G. Burch colposuspension and tension-free vaginal tape in the management of stress urinary incontinence in women. *Eur Urol*. 2002 Apr;41(4):469-73. PMID: 12074820.
389. Liapis A, Bakas P, Creatsas G. Assessment of TVT efficacy in the management of patients with genuine stress incontinence with the use of epidural vs intravenous anesthesia. *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 Oct;18(10):1197-200. PMID: 17268766.
390. Liapis A, Bakas P, Creatsas G. Monarc vs TVT-O for the treatment of primary stress incontinence: a randomized study. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Feb;19(2):185-90. PMID: 17668144.
391. Liapis A, Bakas P, Giner M, et al. Tension-free vaginal tape versus tension-free vaginal tape obturator in women with stress urinary incontinence. *Gynecol Obstet Invest*. 2006;62(3):160-4. PMID: 16707901.
392. Liapis A, Pyrgiotis E, Kontoravdis A, et al. Genuine stress incontinence: prospective randomized comparison of two operative methods. *Eur J Obstet Gynecol Reprod Biol*. 1996 Jan;64(1):69-72. PMID: 8801153.
393. Lim J, Cornish A, Carey MP. Clinical and quality-of-life outcomes in women treated by the TVT-O procedure. *BJOG*. 2006 Nov;113(11):1315-20. PMID: 17059393.
394. Lim MY, Perera M, Ramsay I, et al. Surgical management of stress urinary incontinence in Scotland and Wales: a questionnaire study. *Int J Surg*. 2007 Jun;5(3):162-6. PMID: 17509497.
395. Lim YN, Muller R, Corstiaans A, et al. Suburethral slingplasty evaluation study in North Queensland, Australia: the SUSPEND trial. *Aust N Z J Obstet Gynaecol*. 2005 Feb;45(1):52-9. PMID: 15730366.
396. Lionis C, Vlachonikolis L, Bathianaki M, et al. Urinary incontinence, the hidden health problem of Cretan women: report from a primary care survey in Greece. *Women Health*. 2000;31(4):59-66. PMID: 11310811.
397. Litwiller SE, Nelson RS, Fone PD, et al. Vaginal wall sling: long-term outcome analysis of factors contributing to patients satisfaction and surgical success. *J Urol*. 1997 Apr;157(4):1279-82. PMID: 9120920.
398. Lockhart JL, Pow-Sang JM, Persky L, et al. Results, complications and surgical indications of the Florida pouch. *Surg Gynecol Obstet*. 1991 Oct;173(4):289-96. PMID: 1925899.

399. Logan K, Proctor S. Developing an interdisciplinary integrated continence service. *Nurs Times*. 2003 May 27-Jun 2;99(21):34-7. PMID: 12800526.
400. Long CY, Hsu CS, Liu CM, et al. Clinical and ultrasonographic comparison of tension-free vaginal tape and transobturator tape procedure for the treatment of stress urinary incontinence. *J Minim Invasive Gynecol*. 2008 Jul-Aug;15(4):425-30. PMID: 18588852.
401. Lord HE, Taylor JD, Finn JC, et al. A randomized controlled equivalence trial of short-term complications and efficacy of tension-free vaginal tape and suprapubic urethral support sling for treating stress incontinence. *BJU Int*. 2006 Aug;98(2):367-76. PMID: 16879679.
402. Lose G. Laparoscopic Burch colposuspension. *Acta Obstet Gynecol Scand Suppl*. 1998;168:29-33. PMID: 9744787.
403. Lose G, Jorgensen L, Thunedborg P. Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study. *J Urol*. 1989 Oct;142(4):1024-6. PMID: 2795725.
404. Lose G, Mouritsen L, Nielsen JB. A new bulking agent (polyacrylamide hydrogel) for treating stress urinary incontinence in women. *BJU Int*. 2006 Jul;98(1):100-4. PMID: 16831152.
405. Ludviksson K. The value of clinical examination of the female incontinent patient. *Acta Obstet Gynecol Scand Suppl*. 1997;166:19-23. PMID: 9253373.
406. Lukacz ES, Luber KM, Nager CW. The effects of the tension-free vaginal tape on voiding function: a prospective evaluation. *Int Urogynecol J Pelvic Floor Dysfunct*. 2004 Jan-Feb;15(1):32-8; discussion 8. PMID: 14752596.
407. Lukban JC. Suburethral sling using the transobturator approach: a quality-of-life analysis. *Am J Obstet Gynecol*. 2005 Dec;193(6):2138-43. PMID: 16325630.
408. Maaita M, Bhaumik J, Davies AE. Sexual function after using tension-free vaginal tape for the surgical treatment of genuine stress incontinence. *BJU Int*. 2002 Oct;90(6):540-3. PMID: 12230613.
409. Macura KJ, Genadry RR, Bluemke DA. Role of MR Imaging in Diagnosis of Urethra Hypermobility and Intrinsic Sphincter Deficiency in Women with Stress Urinary Incontinence. 14th Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine (ISMRM 2006), Washington State Convention & Trade Center, Seattle, Washington (USA), 6-12 May 2006.
410. Madersbacher H, Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. *Paraplegia*. 1991 Feb;29(2):84-90. PMID: 2023781.
411. Madersbacher S, Pycha A, Schatzl G, et al. The aging lower urinary tract: a comparative urodynamic study of men and women. *Urology*. 1998 Feb;51(2):206-12. PMID: 9495699.
412. Madjar S, Covington-Nichols C, Secrest CL. New periurethral bulking agent for stress urinary incontinence: modified technique and early results. *J Urol*. 2003 Dec;170(6 Pt 1):2327-9. PMID: 14634407.

413. Madjar S, Wald M, Halachmi S, et al. Minimally invasive pervaginam procedures for the treatment of female stress incontinence using a new pubic bone anchoring system. *Artif Organs*. 1998 Oct;22(10):879-85. PMID: 9790087.
414. Magera JS, Jr., Elliott DS. Tandem transcorporal artificial urinary sphincter cuff salvage technique: surgical description and results. *J Urol*. 2007 Mar;177(3):1015-9; discussion 9-20. PMID: 17296400.
415. Mahajan ST, Elkadry EA, Kenton KS, et al. Patient-centered surgical outcomes: the impact of goal achievement and urge incontinence on patient satisfaction one year after surgery. *American Journal of Obstetrics & Gynecology*. 2006 Mar;194(3):722-8. PMID: 21153.
416. Maher C, Baessler K, Glazener CM, et al. Surgical management of pelvic organ prolapse in women. *Cochrane Database Syst Rev*. 2004(4):CD004014. PMID: 15495076.
417. Maher C, Dwyer P, Carey M, et al. The Burch colposuspension for recurrent urinary stress incontinence following retropubic continence surgery. *Br J Obstet Gynaecol*. 1999 Jul;106(7):719-24. PMID: 10428530.
418. Maher CF, O'Reilly BA, Dwyer PL, et al. Pubovaginal sling versus transurethral Macroplastique for stress urinary incontinence and intrinsic sphincter deficiency: a prospective randomised controlled trial. *BJOG*. 2005 Jun;112(6):797-801. PMID: 15924540.
419. Major H, Culligan P, Heit M. Urethral sphincter morphology in women with detrusor instability. *Obstetrics and gynecology*; 2002. p. 63-8.
420. Mallett VT, Brubaker L, Stoddard AM, et al. The expectations of patients who undergo surgery for stress incontinence. *Am J Obstet Gynecol*. 2008 Mar;198(3):308 e1-6. PMID: 18313452.
421. Mallipeddi PK, Steele AC, Kohli N, et al. Anatomic and functional outcome of vaginal paravaginal repair in the correction of anterior vaginal wall prolapse. *Int Urogynecol J Pelvic Floor Dysfunct*. 2001;12(2):83-8. PMID: 11374518.
422. Manca A, Sculpher MJ, Ward K, et al. A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. *BJOG*. 2003 Mar;110(3):255-62. PMID: 12628263.
423. Manhes H. Laparoscopic Retzvio-plasty. A new surgical approach to stress incontinence. *Int Surg*. 1996 Oct-Dec;81(4):371-3. PMID: 9127797.
424. Manikandan R, Kujawa M, Pearson E, et al. Results of the tension-free vaginal tape procedure for stress incontinence: patient's perspective. *Int J Urol*. 2004 Apr;11(4):206-12. PMID: 15028098.
425. Mansi MK. Continent urinary undiversion to modified ureterosigmoidostomy in bladder extrophy patients. *World J Surg*. 1999 Feb;23(2):207-13. PMID: 9880434.
426. Marinkovic SP, Stanton SL. Triple compartment prolapse: sacrocolpopexy with anterior and posterior mesh extensions. *BJOG*. 2003 Mar;110(3):323-6. PMID: 12628277.

427. Markland AD, Kraus SR, Richter HE, et al. Prevalence and risk factors of fecal incontinence in women undergoing stress incontinence surgery. *Am J Obstet Gynecol*. 2007 Dec;197(6):662 e1-7. PMID: 18060972.
428. Martinez AM, Ramos NM, Requena JF, et al. Analysis of retropubic colpourethrosuspension results by suburethral sling with REMEEX prosthesis. *Eur J Obstet Gynecol Reprod Biol*. 2003 Feb 10;106(2):179-83. PMID: 12551789.
429. Mason RC, Roach M. Modified pubovaginal sling for treatment of intrinsic sphincteric deficiency. *J Urol*. 1996 Dec;156(6):1991-4. PMID: 8965334.
430. Masson DB, Govier FE. Modified Pereyra bladder neck suspension in patients with intrinsic sphincter deficiency and bladder neck hypermobility: patient satisfaction with a mean follow-up of 4 years. *Urology*. 2000 Feb;55(2):217-21; discussion 21-2. PMID: 10688082.
431. Mathews RI, Gan M, Gearhart JP. Urogynaecological and obstetric issues in women with the exstrophy-epispadias complex. *BJU Int*. 2003 Jun;91(9):845-9. PMID: 12780845.
432. Matsuyama H, Hirata H, Tomimatsu T, et al. Follow up of surgical repair of female pelvic floor disorders by a mailed questionnaire. *Int J Urol*. 2006 Apr;13(4):389-94. PMID: 16734856.
433. Mazouni C, Karsenty G, Bretelle F, et al. Urinary complications and sexual function after the tension-free vaginal tape procedure. *Acta Obstet Gynecol Scand*. 2004 Oct;83(10):955-61. PMID: 15453893.
434. McBride AW, Ellerkmann RM, Bent AE, et al. Comparison of long-term outcomes of autologous fascia lata slings with Suspend Tutoplast fascia lata allograft slings for stress incontinence. *Am J Obstet Gynecol*. 2005 May;192(5):1677-81. PMID: 15902176.
435. McDowell BJ, Silverman M, Martin D, et al. Identification and intervention for urinary incontinence by community physicians and geriatric assessment teams. *J Am Geriatr Soc*. 1994 May;42(5):501-5. PMID: 8176144.
436. McLennan MT, Theofrastous JP, Melick CF. Randomized trial of cefazolin prophylaxis for open burch retropubic urethropexy. *Journal of Pelvic Medicine & Surgery*; 2004. p. 239-44.
437. McMurdo ME, Davey PG, Elder MA, et al. A cost-effectiveness study of the management of intractable urinary incontinence by urinary catheterisation or incontinence pads. *J Epidemiol Community Health*. 1992 Jun;46(3):222-6. PMID: 1645076.
438. Meier U, Kiefer M, Sprung C. Evaluation of the Miethke dual- switch valve in patients with normal pressure hydrocephalus. *Surg Neurol*. 2004 Feb;61(2):119-27; discussion 27-8. PMID: 14751612.
439. Mellier G, Benayed B, Bretones S, et al. Suburethral tape via the obturator route: is the TOT a simplification of the TVT? *Int Urogynecol J Pelvic Floor Dysfunct*. 2004 Jul-Aug;15(4):227-32. PMID: 15517665.

440. Mellier G, Mistrangelo E, Gery L, et al. Tension-free obturator tape (Monarc Subfascial Hammock) in patients with or without associated procedures. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Feb;18(2):165-72. PMID: 16773232.
441. Meltomaa SS, Haarala MA, Taalikka MO, et al. Outcome of Burch retropubic urethropexy and the effect of concomitant abdominal hysterectomy: a prospective long-term follow-up study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2001;12(1):3-8. PMID: 11294528.
442. Meschia M, Bertozzi R, Pifarotti P, et al. Peri-operative morbidity and early results of a randomised trial comparing TVT and TVT-O. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Nov;18(11):1257-61. PMID: 17345002.
443. Meschia M, Bruschi F, Amicarelli F, et al. The sacrospinous vaginal vault suspension: Critical analysis of outcomes. *Int Urogynecol J Pelvic Floor Dysfunct.* 1999;10(3):155-9. PMID: 10430007.
444. Meschia M, Pifarotti P, Bernasconi F, et al. Tension-free vaginal tape (TVT) and intravaginal slingplasty (IVS) for stress urinary incontinence: a multicenter randomized trial. *Am J Obstet Gynecol.* 2006 Nov;195(5):1338-42. PMID: 16769016.
445. Meschia M, Pifarotti P, Spennacchio M, et al. A randomized comparison of tension-free vaginal tape and endopelvic fascia plication in women with genital prolapse and occult stress urinary incontinence. *Am J Obstet Gynecol.* 2004 Mar;190(3):609-13. PMID: 15041988.
446. Mikkelsen AL, Felding C, Clausen HV. Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. *Gynecol Obstet Invest.* 1995;40(2):125-8. PMID: 8575690.
447. Miller YD, Brown WJ, Smith N, et al. Managing urinary incontinence across the lifespan. *Int J Behav Med.* 2003;10(2):143-61. PMID: 12763707.
448. Mills R, Persad R, Handley Ashken M. Long-term follow-up results with the Stamey operation for stress incontinence of urine. *Br J Urol.* 1996 Jan;77(1):86-8. PMID: 8653322.
449. Mizunaga M, Miyata M, Kaneko S, et al. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. *Paraplegia.* 1994 Jan;32(1):25-9. PMID: 8015832.
450. Moghimi K, Valbo A. Genital prolapse: a follow-up study assessing subjective and objective results five years or more after surgical intervention. *Eur J Obstet Gynecol Reprod Biol.* 2005 Jun 1;120(2):198-201. PMID: 15925052.
451. Molander U. Urinary incontinence and related urogenital symptoms in elderly women. *Acta Obstet Gynecol Scand Suppl.* 1993;158:1-22. PMID: 8396841.
452. Monga AK, Robinson D, Stanton SL. Periurethral collagen injections for genuine stress incontinence: a 2-year follow-up. *Br J Urol.* 1995 Aug;76(2):156-60. PMID: 7663903.
453. Moore KH, Foote A, Burton G, et al. An open study of the bladder neck support prosthesis in genuine stress incontinence. *Br J Obstet Gynaecol.* 1999 Jan;106(1):42-9. PMID: 10426258.

454. Moore KH, Foote A, Siva S, et al. The use of the bladder neck support prosthesis in combined genuine stress incontinence and detrusor instability. *Aust N Z J Obstet Gynaecol.* 1997 Nov;37(4):440-5. PMID: 9429710.
455. Morell JD, Morales A. Assessment of long-term patient satisfaction after vesical neck suspension for stress urinary incontinence. *Can J Urol.* 2001 Aug;8(4):1323-5. PMID: 11564275.
456. Morgan DM, Dunn RL, Fenner DE, et al. Comparative analysis of urinary incontinence severity after autologous fascia pubovaginal sling, pubovaginal sling and tension-free vaginal tape. *J Urol.* 2007 Feb;177(2):604-8; discussion 8-9. PMID: 17222642.
457. Morgan DM, Dunn RL, Stoffel JT, et al. Are persistent or recurrent symptoms of urinary incontinence after surgery associated with adverse effects on sexual activity or function? *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Apr;19(4):509-15. PMID: 17938843.
458. Morgan TO, Jr., Westney OL, McGuire EJ. Pubovaginal sling: 4-YEAR outcome analysis and quality of life assessment. *J Urol.* 2000 Jun;163(6):1845-8. PMID: 10799196.
459. Morin M, Dumoulin C, Bourbonnais D, et al. Pelvic floor maximal strength using vaginal digital assessment compared to dynamometric measurements. *Neurourology and urodynamics*; 2004. p. 336-41.
460. Mortensen N, Humphreys MS. The anal continence plug: a disposable device for patients with anorectal incontinence. *Lancet.* 1991(8762):295-7. PMID: CN-00076813.
461. Mostafa A, Hassafa Z, Abdel-Fattah M. Can the patient global impression of improvement questionnaire predict the results of long quality of life and sexual function questionnaires? *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. 29.
462. Mourtzinis A, Maher MG, Raz S, et al. Spiral sling salvage anti-incontinence surgery for women with refractory stress urinary incontinence: surgical outcome and satisfaction determined by patient-driven questionnaires. *Urology.* 2008 Nov;72(5):1044-8; discussion 8-50. PMID: 18804264.
463. Mukherjee K, Constantine G. Urinary stress incontinence in obese women: tension-free vaginal tape is the answer. *BJU Int.* 2001 Dec;88(9):881-3. PMID: 11851607.
464. Munir N, Bunce C, Gelister J, et al. Outcome following TVT sling procedure: a comparison of outcome recorded by surgeons to that reported by their patients at a London district general hospital. *Eur Urol.* 2005 May;47(5):635-40; discussion 40. PMID: 15826755.
465. Murphy DJ, Macleod M, Bahl R, et al. A randomised controlled trial of routine versus restrictive use of episiotomy at operative vaginal delivery: a multicentre pilot study. *BJOG.* 2008 Dec;115(13):1695-702; discussion 702-3. PMID: 19035944.
466. Murphy M, Culligan PJ, Arce CM, et al. Is the cough-stress test necessary when placing the tension-free vaginal tape? *Obstet Gynecol.* 2005 Feb;105(2):319-24. PMID: 15684159.

467. Murphy M, van Raalte H, Mercurio E, et al. Incontinence-related quality of life and sexual function following the tension-free vaginal tape versus the “inside-out” tension-free vaginal tape obturator. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Apr;19(4):481-7. PMID: 17940718.
468. Muskat Y, Bukovsky I, Schneider D, et al. The use of scopolamine in the treatment of detrusor instability. *J Urol.* 1996 Dec;156(6):1989-90. PMID: 8911372.
469. Musselman DM, Ford AP, Gennevois DJ, et al. A randomized crossover study to evaluate Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist in women with stress urinary incontinence. *BJU Int.* 2004 Jan;93(1):78-83. PMID: 14678373.
470. Myers DL, Peipert JF, Rosenblatt PL, et al. Patient satisfaction with laparoscopic Burch retropubic urethropexy. *J Reprod Med.* 2000 Nov;45(11):939-43. PMID: 11127109.
471. Nager CW, FitzGerald M, Kraus SR, et al. Urodynamic measures do not predict stress continence outcomes after surgery for stress urinary incontinence in selected women. *J Urol.* 2008 Apr;179(4):1470-4. PMID: 18295276.
472. Naidu A, Lim YN, Barry C, et al. Transobturator tape for stress incontinence: the North Queensland experience. *Aust N Z J Obstet Gynaecol.* 2005 Oct;45(5):446-9. PMID: 16171486.
473. Nauth MA, Funfgeld C. Correction of cystocele and stress incontinence with anterior transobturator mesh. *Eur J Obstet Gynecol Reprod Biol.* 2008 Feb;136(2):249-53. PMID: 17669580.
474. Nazemi TM, Rapp DE, Govier FE, et al. Cadaveric fascial sling with bone anchors: minimum of 24 months of follow-up. *Urology.* 2008 May;71(5):834-8. PMID: 18372032.
475. Nazemi TM, Yamada B, Govier FE, et al. Minimum 24-month followup of the sling for the treatment of stress urinary incontinence. *J Urol.* 2008 Feb;179(2):596-9. PMID: 18082220.
476. NCT00012740. A Casefinding and Referral System for Older Veterans Within Primary Care. 2001.
477. NCT00064662. Randomized Clinical Trial of Burch vs Sling Procedures for Women With Stress Urinary Incontinence. 2006.
478. NCT00075114. Prevent Inability To Control Urination. 2006.
479. NCT00090584. Behavior Enhances Drug Reduction of Incontinence (BE-DRI). 2006.
480. NCT00091988. Program to Reduce Incontinence by Diet and Exercise (PRIDE). 2007.
481. NCT00124904. Biofeedback for Fecal Incontinence. 2006.
482. NCT00127257. Biofeedback for Dyssynergic Constipation. 2006.
483. NCT00127270. Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder. 2006.
484. NCT00137397. A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder. 2006.

485. NCT00138749. An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence. 2006.
486. NCT00139724. Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet. 2006.
487. NCT00141128. Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.
488. NCT00143377. Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB. 2005.
489. NCT00143481. Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women.
490. NCT00147654. Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction.
491. NCT00170755. A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder. 2005.
492. NCT00171145. A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. 2004.
493. NCT00174798. MILADY: A Randomized, Placebo-Controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
494. NCT00178191. Randomized Trial for Botox Urinary Incontinence. 2008.
495. NCT00178334. Screening for Urinary Incontinence by Primary Care Providers. 2006.
496. NCT00190567. Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence. 2006.
497. NCT00190606. Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence. 2006.
498. NCT00190619. Efficacy and Safety of Duloxetine. 2006.
499. NCT00190632. To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence. 2006.
500. NCT00190645. To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence. 2006.
501. NCT00190814. Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge. 2006.
502. NCT00190827. Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine). 2006.
503. NCT00190853. Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence. 2006.
504. NCT00190905. Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions. 2005.

505. NCT00190996. Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence. 2006.
506. NCT00191087. Duloxetine in the Treatment of Stress Urinary Incontinence. 2006.
507. NCT00191204. Open Label Phase III Duloxetine Study for Stress Urinary Incontinence. 2006.
508. NCT00196404. Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder. 2006.
509. NCT00196521. A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence (Urinary Leakage). 2007.
510. NCT00197314. Effectiveness of Circular Muscle Exercise (Paula Method) Versus Kegel Exercise for Urinary Stress Incontinence. 2006.
511. NCT00212264. Conservative Treatment of Postprostatectomy Incontinence. 2009.
512. NCT00213317. Effect of Lumbo-sacral Magnetic Stimulation on Colonic Motility. 2008.
513. NCT00223106. Treatment for Stress and Mixed Urinary Incontinence and Vaginal Vault Prolapse.
514. NCT00223821. Enhancing Conservative Treatment for Urge Incontinence. 2009.
515. NCT00224146. Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder.
516. NCT00230360. Diagnosis of Functional Defecation Disorders in Childhood. 2006.
517. NCT00230789. Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
518. NCT00231790. A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder.
519. NCT00234754. Trans-Obturator Tape vs. Trans-Vaginal Tape for Stress Urinary Incontinence in Women. 2009.
520. NCT00238680. Programmable Timer in the Bladder Rehabilitation Treatment of OAB. 2007.
521. NCT00239824. Pelvic Floor Muscle Training to Treat Urinary Incontinence After Radical Prostatectomy. 2008.
522. NCT00244296. To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms. 2007.
523. NCT00255372. To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.
524. NCT00269724. A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence. 1997.
525. NCT00269750. A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. 1997.

526. NCT00270998. ATLAS: Ambulatory Treatments for Leakage Associated With Stress. 2008.
527. NCT00271037. Colpocleisis for Advanced Pelvic Organ Prolapse. 2007.
528. NCT00282490. Surface Nerve Stimulation Treatment for OAB in Children. 2008.
529. NCT00282932. Detrol LA In Men With Overactive Bladder.
530. NCT00286520. Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury. 2005.
531. NCT00290563. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Study of MK0594 in Patients With Overactive Bladder.
532. NCT00293839. Efficacy and Tolerability of DITROPAN® XL (Oxybutynin Chloride) Versus DETROL® LA (Tolterodine Tartrate) in Treatment of Overactive Bladder. 2002.
533. NCT00304499. Efficacy and Safety of OROS Oxybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence. 1996.
534. NCT00307775. Vaginal Estrogen for the Treatment of Faecal Incontinence in Women. 2007.
535. NCT00308009. Comparison of the Result of TVT Performed at the Time of Prolapse Surgery or 3 Months After. 2007.
536. NCT00333112. A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. 2007.
537. NCT00337090. A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON). 2007.
538. NCT00337558. A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR). 2007.
539. NCT00350636. A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo. 2007.
540. NCT00368706. A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients. 2008.
541. NCT00376298. Urology Database to Evaluate Clinical Information and Improve Patient Care. 2029.
542. NCT00392210. Assessment of Two Postoperative Techniques Used to Predict Voiding Efficiency After Gynecologic Surgery. 2009.
543. NCT00448175. Overactive Bladder Innovative Therapy Trial (OrBIT). 2008.
544. NCT00463554. TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence. 2007.
545. NCT00475358. Efficacy and Safety Stress Urinary Incontinence Study. 2005.
546. NCT00475397. Duloxetine Stress Urinary Incontinence Efficacy and Safety Study. 2004.

547. NCT00475696. Urge Incontinence Bladder Overactivity Study. 2005.
548. NCT00475839. Study Comparing Tension-Free Vaginal Tape With the Monarc Procedure for Stress Urinary Incontinence. 2007.
549. NCT00506116. Promoting Effective Recovery From Labor Urinary Incontinence (PERL). 2006.
550. NCT00506766. Promoting Self Care to Prevent Urinary Incontinence (UI): A Four-Year Follow-up. 2006.
551. NCT00525291. Triple Target Treatment (3T) Which Combines Stimulation With Amplitude Modulated Middle Frequency (AM-MF), Electromyography (EMG)-Triggered Stimulation and EMG-Biofeedback Compared With EMG-Biofeedback in Anal Incontinence. 2008.
552. NCT00535301. Anatomic and Visceral Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair: a Randomized Controlled Trial. 2008.
553. NCT00564226. SSR240600C Treatment in Women With Overactive Bladder. 2009.
554. NCT00565838. Quality-of-Life Outcomes After Autologous Fascial Sling and TVT: a Prospective Randomized Trial. 2007.
555. NCT00576004. Pelvic Organ Prolapse Repair With or Without Concomitant Burch Colposuspension in Patients With Urinary Incontinence. 2006.
556. NCT00603343. Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence. 2006.
557. NCT00604838. Pivotal Study of the AI-Sense Study Protocol. 2006.
558. NCT00658944. Predictive Objective Parameters for Outcome of the Treatment of Stress Urinary Incontinence. 2008.
559. NCT00662207. Two Devices for Reflex Voiding Following Spinal Cord Injury. 2009.
560. NCT00662909. Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Patients With Symptoms of Overactive Bladder. 2009.
561. NCT00688298. Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence. 2008.
562. NCT00689104. Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder. 2009.
563. NCT00691093. Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy. 2009.
564. NCT00699049. A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder. 2010.
565. NCT00740428. Pelvic Floor Exercises During Gestation in the Prevention of Urinary Incontinence and Pelvic Floor Muscle Dysfunction. 2009.
566. NCT00742833. A Phase II Study of KUC-7483 in Patients With Overactive Bladder.

567. NCT00747370. Dynamic MRI of the Behaviour of Female Pelvic Floor. 2008.
568. NCT00749632. A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence. 2008.
569. NCT00765622. Assessment of Pelvic Floor Function in Elderly. 2007.
570. NCT00782990. A 3 Year Follow-up Prospective Open Randomized Trial of TVT Versus Colposuspension for Primary Stress Incontinence. 2007.
571. NCT00795925. Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder. 2005.
572. NCT00801203. A Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence. 2009.
573. NCT00843908. Tension Free Vaginal Tape (TVT) Versus the Miniarc Sling. 2009.
574. NCT00850590. Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights.
575. NCT00850733. 516-BOTOX Urinary Incontinence Detrusor. 2009.
576. NCT00857467. Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.
577. NCT00880880. Improving Women's Health by Using an Electronic Pelvic Floor Questionnaire.
578. NCT00893607. Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum. 2007.
579. NCT00904618. Safety and Efficacy Study on the Implantation of the Tension-Free Vaginal Tape (TVT-Secur) Under Local Anesthesia. 2009.
580. NCT00906607. Prevalence of Urinary Incontinence in Different Age Categories. 2008.
581. NCT00906854. Urinary Incontinence and Practice of Physical Exercises. 2008.
582. NCT00911235. The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects. 2009.
583. NCT00912964. A Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder. 2010.
584. NCT00927849. Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy. 2008.
585. NCT00939432. Taboo Perception of Incontinence, Depression and Cancer. 2007.
586. NCT00942370. Electromyographic (EMG) and Mechanomyographic (MMG) Comparison. 2009.
587. NCT00965926. A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers. 2009.

588. NCT00972998. Study to Examine the Effect of Coated Phenylephrine Suppositories on Anal Pressure in Healthy Subjects. 2009.
589. NCT01042275. Patient-reported Outcome After Sling Insertion Using the Incontinence Outcome Questionnaire (IOQ). 2010.
590. NCT01042821. Treatment of Anal Fistulas Advancement Flap. 2008.
591. NCT01056666. Conveen Optima Urisheaths With Collecting Bags Versus Absorbents on Men Suffering of Moderate to Severe Urinary Incontinence. 2009.
592. NCT01057550. Randomised Controlled Trial Comparing Tension-Free Vaginal Tape (TVT), Pelvicol & Autologous Slings for Stress Urinary Incontinence(SUI). 2006.
593. NCT01091727. Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity. 2009.
594. NCT01108367. Transient Urinary Incontinence After Holmium Laser Enucleation of the Prostate (HoLEP).
595. Ngninkeu BN, van Heugen G, di Gregorio M, et al. Laparoscopic artificial urinary sphincter in women for type III incontinence: preliminary results. *Eur Urol*. 2005 Jun;47(6):793-7; discussion 7. PMID: 15925075.
596. Nguyen JK, Glowacki CA, Bhatia NN. Survey of voiding dysfunction and urinary retention after anti-incontinence procedures. *Obstet Gynecol*. 2001 Dec;98(6):1011-7. PMID: 11755546.
597. Nguyen JN. Tape mobilization for urinary retention after tension-free vaginal tape procedures. *Urology*. 2005 Sep;66(3):523-6. PMID: 16140070.
598. Nigam AK, Otite U, Badenoch DF. Endoscopic bladder neck suspension revisited: long-term results of Stamey and Gittes procedures. *Eur Urol*. 2000 Dec;38(6):677-80. PMID: 11111183.
599. Nilsson CG, Falconer C, Rezapour M. Seven-year follow-up of the tension-free vaginal tape procedure for treatment of urinary incontinence. *Obstet Gynecol*. 2004 Dec;104(6):1259-62. PMID: 15572486.
600. Nilsson CG, Palva K, Rezapour M, et al. Eleven years prospective follow-up of the tension-free vaginal tape procedure for treatment of stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Aug;19(8):1043-7. PMID: 18535753.
601. Nordstrom G, Nyman CR, Theorell T. Psychosocial adjustment and general state of health in patients with ileal conduit urinary diversion. *Scand J Urol Nephrol*. 1992;26(2):139-47. PMID: 1626203.
602. Norton C. Providing appropriate services for continence: an overview. *Nurs Stand*. 1996 Jun 26;10(40):41-5. PMID: 8718019.
603. Norton P, Karram M, Wall LL, et al. Randomized double-blind trial of terodiline in the treatment of urge incontinence in women. *Obstet Gynecol*. 1994 Sep;84(3):386-91. PMID: 8058236.

604. Novi JM, Mulvihill BH. Surgical intervention for stress urinary incontinence: comparison of midurethral sling procedures. *Journal of the American Osteopathic Association*. 2008 Nov;108(11):634-8. PMID: 21044.
605. NTR602. Primary prevention of bed-wetting: the effectiveness of simple interventions by the parents.
606. NTR778. Performance of the miniaturized I system for treatment of overactive bladder.
607. NTR829. Effects of introducing a specialized nurse in the care of community-dwelling women suffering from urinary incontinence.
608. NTR1131. Optimal Stimulation Rates in Sacral Neuromodulation Therapy.
609. NTR1141. A multi-centre randomised comparison of the effectiveness and safety of TVT-O and TVT-S.
610. Nygaard I, Handa VL, Brubaker L, et al. Changes in physical activity after abdominal sacrocolpopexy for advanced pelvic organ prolapse. *Am J Obstet Gynecol*. 2008 May;198(5):570 e1-5. PMID: 18455536.
611. O'Flynn KJ, Thomas DG. Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. *Br J Urol*. 1993 Nov;72(5 Pt 1):566-70. PMID: 10071538.
612. Olsen AL, Benson JT, McClellan E. Urethral sphincter needle electromyography in women: comparison of periurethral and transvaginal approaches. *Neurourol Urodyn*. 1998;17(5):531-5. PMID: 9776016.
613. Olsson I, Kroon U. A three-year postoperative evaluation of tension-free vaginal tape. *Gynecol Obstet Invest*. 1999;48(4):267-9. PMID: 10592431.
614. Omotosho TB, Hardart A, Rogers RG, et al. Validation of Spanish versions of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ): a multicenter validation randomized study. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Jun;20(6):623-39. PMID: 19214363.
615. Onur R, Singla A, Kobashi KC. Comparison of solvent-dehydrated allograft dermis and autograft rectus fascia for pubovaginal sling: questionnaire-based analysis. *Int Urol Nephrol*. 2008;40(1):45-9. PMID: 17610038.
616. Ordorica R, Rodriguez AR, Coste-Delvecchio F, et al. Disabling complications with slings for managing female stress urinary incontinence. *BJU Int*. 2008 Aug;102(3):333-6. PMID: 18384633.
617. Orovan WL, Davis IR. Kock to urethra: continent functional bladder replacement. *Can J Surg*. 1990 Apr;33(2):91-4. PMID: 2268818.
618. Osman T. Stress incontinence surgery for patients presenting with mixed incontinence and a normal cystometrogram. *BJU Int*. 2003 Dec;92(9):964-8. PMID: 14632856.
619. Ostergard DR. Lessons from the past: directions for the future. Do new marketed surgical procedures and grafts produce ethical, personal liability, and legal concerns for physicians? *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 Jun;18(6):591-8. PMID: 17364134.

620. O'Sullivan DC, Chilton CP, Munson KW. Should Stamey colposuspension be our primary surgery for stress incontinence? *Br J Urol.* 1995 Apr;75(4):457-60. PMID: 7788256.
621. Owens DC, Winters JC. Pubovaginal sling using Duraderm graft: intermediate follow-up and patient satisfaction. *Neurourol Urodyn.* 2004;23(2):115-8. PMID: 14983421.
622. Pace G, Vicentini C. Female sexual function evaluation of the tension-free vaginal tape (TVT) and transobturator suburethral tape (TOT) incontinence surgery: results of a prospective study. *J Sex Med.* 2008 Feb;5(2):387-93. PMID: 18237371.
623. Pakbaz M, Mogren I, Lofgren M. Outcomes of vaginal hysterectomy for uterovaginal prolapse: a population-based, retrospective, cross-sectional study of patient perceptions of results including sexual activity, urinary symptoms, and provided care. *BMC Womens Health.* 2009;9:9. PMID: 19379514.
624. Palomba S, Russo T, Iuzzolino D, et al. Comparison between two laparoscopic retropublic urethropexy. *Minerva Chir.* 2002 Jun;57(3):323-9. PMID: 12029227.
625. Pang MW, Chan LW, Yip SK. One-year urodynamic outcome and quality of life in patients with concomitant tension-free vaginal tape during pelvic floor reconstruction surgery for genitourinary prolapse and urodynamic stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Oct;14(4):256-60; discussion 9-60. PMID: 14530838.
626. Paraiso MF, Barber MD, Muir TW, et al. Rectocele repair: a randomized trial of three surgical techniques including graft augmentation. *Am J Obstet Gynecol.* 2006 Dec;195(6):1762-71. PMID: 17132479.
627. Park S, Hong B, Lee KS, et al. Risk factors of voiding dysfunction and patient satisfaction after tension-free vaginal tape procedure. *J Korean Med Sci.* 2005 Dec;20(6):1006-10. PMID: 16361813.
628. Patki P, Woodhouse JB, Patil K, et al. An effective day case treatment combination for refractory neuropathic mixed incontinence. *Int Braz J Urol.* 2008 Jan-Feb;34(1):63-71; discussion -2. PMID: 18341723.
629. Perk H, Soyupek S, Serel TA, et al. Tension-free vaginal tape for surgical treatment of stress urinary incontinence: two years follow-up. *Int J Urol.* 2003 Mar;10(3):132-5. PMID: 12622708.
630. Persson J, Iosif C, Wolner-Hanssen P. Risk factors for rejection of synthetic suburethral slings for stress urinary incontinence: a case-control study. *Obstet Gynecol.* 2002 Apr;99(4):629-34. PMID: 12039125.
631. Persson J, Telemann P, Eten-Bergquist C, et al. Cost-analyses based on a prospective, randomized study comparing laparoscopic colposuspension with a tension-free vaginal tape procedure. *Acta Obstet Gynecol Scand.* 2002 Nov;81(11):1066-73. PMID: 12421176.
632. Persson J, Wolner-Hanssen P. Laparoscopic Burch colposuspension for stress urinary incontinence: a randomized comparison of one or two sutures on each side of the urethra. *Obstet Gynecol.* 2000 Jan;95(1):151-5. PMID: 10636519.

633. Petros PE. New ambulatory surgical methods using an anatomical classification of urinary dysfunction improve stress, urge and abnormal emptying. *Int Urogynecol J Pelvic Floor Dysfunct.* 1997;8(5):270-7. PMID: 9557990.
634. Petros PE, Richardson PA. Midurethral Tissue Fixation System sling -- a 'micromethod' for cure of stress incontinence -- preliminary report. *Aust N Z J Obstet Gynaecol.* 2005 Oct;45(5):372-5. PMID: 16171470.
635. Petrou SP, Jones J, Parra RO. Martius flap harvest site: patient self-perception. *J Urol.* 2002 May;167(5):2098-9. PMID: 11956448.
636. Pham K, Guralnick ML, O'Connor RC. Unilateral versus bilateral stage I neuromodulator lead placement for the treatment of refractory voiding dysfunction. *Neurourology & Urodynamics.* 2008;27(8):779-81. PMID: 21042; 18551562.
637. Pham T, Kenton K, Mueller E, et al. New pelvic symptoms are common after reconstructive pelvic surgery. *Am J Obstet Gynecol.* 2009 Jan;200(1):88 e1-5. PMID: 18845285.
638. Philip J, Willmott S, Irwin P. Interstitial cystitis versus detrusor overactivity: a comparative, randomized, controlled study of cystometry using saline and 0.3 M potassium chloride. *J Urol.* 2006 Feb;175(2):566-70; discussion 70-1. PMID: 16406997.
639. Pianezza ML, Joffe R, Chugh T, et al. Long-term patient satisfaction following cadaveric pubovaginal sling incontinence surgery using the UDI and IIQ-7 questionnaires. *Neurourol Urodyn.* 2007;26(2):185-9. PMID: 16998860.
640. Pinto AC, Baracat F, Montellato ND, et al. The short-term effect of surgical treatment for stress urinary incontinence using sub urethral support techniques on sexual function. *Int Braz J Urol.* 2007 Nov-Dec;33(6):822-8. PMID: 18199351.
641. Porena M, Costantini E, Frea B, et al. Tension-free vaginal tape versus transobturator tape as surgery for stress urinary incontinence: results of a multicentre randomised trial. *Eur Urol.* 2007 Nov;52(5):1481-90. PMID: 17482343.
642. Pozowski J, Sobanski A, Dudkiewicz D, et al. Quality of life in women with urinary stress incontinence and evaluation of tension-free vaginal tape treatment. *Gynecol Obstet Invest.* 2007;64(1):55-60. PMID: 17287606.
643. Prashar S, Simons A, Bryant C, et al. Attitudes to vaginal/urethral touching and device placement in women with urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2000;11(1):4-8. PMID: 10738927.
644. Pregazzi R, Sartore A, Bortoli P, et al. Perineal ultrasound evaluation of urethral angle and bladder neck mobility in women with stress urinary incontinence. *BJOG.* 2002 Jul;109(7):821-7. PMID: 12135220.
645. Primus G. One year follow-up on the SPARC sling system for the treatment of female urodynamic stress incontinence. *Int J Urol.* 2006 Nov;13(11):1410-4. PMID: 17083393.
646. Quadri G, Magatti F, Belloni C, et al. Marshall-Marchetti-Krantz urethropexy and Burch colposuspension for stress urinary incontinence in women with low pressure and hypermobility of the urethra: early results of a prospective randomized clinical trial. *Am J Obstet Gynecol.* 1999 Jul;181(1):12-8. PMID: 10411835.

647. Quek ML, Ginsberg DA. Long-term urodynamics followup of bladder augmentation for neurogenic bladder. *J Urol*. 2003 Jan;169(1):195-8. PMID: 12478134.
648. Qureshi A, Nicolaou J, Lynch CB, et al. Outcome of tension-free vaginal tape (TVT) procedure in women with stress urinary incontinence--patients' perspective. *J Obstet Gynaecol*. 2003 May;23(3):297-300. PMID: 12850866.
649. Rackley R, Weiss JP, Rovner ES, et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. *Urology*. 2006 Apr;67(4):731-6; discussion 6. PMID: 16618562.
650. Radley SC, Chapple CR, Bryan NP, et al. Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study. *Neurourol Urodyn*. 2001;20(1):43-52. PMID: 11135381.
651. Ragins AI, Shan J, Thom DH, et al. Effects of urinary incontinence, comorbidity and race on quality of life outcomes in women. *J Urol*. 2008 Feb;179(2):651-5; discussion 5. PMID: 18082212.
652. Rapp DE, Kobashi KC. Outcomes following sling surgery: importance of definition of success. *J Urol*. 2008 Sep;180(3):998-1002. PMID: 18639263.
653. Rapp DE, Nazemi TM, Kobashi KC, et al. Transvaginal bone-anchored sling for the treatment of female stress urinary incontinence: effect of Valsalva leak point pressure and prior pelvic surgery on outcomes. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Sep;19(9):1211-5. PMID: 18465078.
654. Raz S, Nitti VW, Bregg KJ. Transvaginal repair of enterocele. *J Urol*. 1993 Apr;149(4):724-30. PMID: 8455231.
655. Rechberger T, Futyma K, Jankiewicz K, et al. Body mass index does not influence the outcome of anti-incontinence surgery among women whereas menopausal status and ageing do: a randomised trial. *Int Urogynecol J Pelvic Floor Dysfunct*. 2010 Jul;21(7):801-6. PMID: 20179903.
656. Rechberger T, Futyma K, Miotla P, et al. Changing trends in the surgical treatment of female stress urinary incontinence--twenty two years observation. *Ginekol Pol*. 2008 Jan;79(1):36-41. PMID: 18510048.
657. Rechberger T, Rzezniczuk K, Skorupski P, et al. A randomized comparison between monofilament and multifilament tapes for stress incontinence surgery. *Int Urogynecol J Pelvic Floor Dysfunct*. 2003 Dec;14(6):432-6. PMID: 14677007.
658. Reichelt O, Weirich T, Wunderlich H, et al. Pubovaginal cutaneous fascial sling procedure for stress urinary incontinence: 10 years' experience. *Urol Int*. 2004;72(4):318-23; discussion 23-4. PMID: 15153730.
659. Rezapour M, Falconer C, Ulmsten U. Tension-Free vaginal tape (TVT) in stress incontinent women with intrinsic sphincter deficiency (ISD)--a long-term follow-up. *Int Urogynecol J Pelvic Floor Dysfunct*. 2001;12 Suppl 2:S12-4. PMID: 11450973.
660. Rezapour M, Ulmsten U. Tension-Free vaginal tape (TVT) in women with mixed urinary incontinence--a long-term follow-up. *Int Urogynecol J Pelvic Floor Dysfunct*. 2001;12 Suppl 2:S15-8. PMID: 11450974.

661. Rezapour M, Ulmsten U. Tension-Free vaginal tape (TVT) in women with recurrent stress urinary incontinence--a long-term follow up. *Int Urogynecol J Pelvic Floor Dysfunct.* 2001;12 Suppl 2:S9-11. PMID: 11450980.
662. Richter HE, Albo ME, Zyczynski HM, et al. Retropubic versus transobturator midurethral slings for stress incontinence. *N Engl J Med.* 2010 Jun 3;362(22):2066-76. PMID: 20479459.
663. Richter HE, Burgio KL, Brubaker L, et al. Factors associated with incontinence frequency in a surgical cohort of stress incontinent women. *Am J Obstet Gynecol.* 2005 Dec;193(6):2088-93. PMID: 16325621.
664. Richter HE, Burgio KL, Holley RL, et al. Cadaveric fascia lata sling for stress urinary incontinence: a prospective quality-of-life analysis. *Am J Obstet Gynecol.* 2003 Dec;189(6):1590-5; discussion 5-6. PMID: 14710075.
665. Richter HE, Creasman JM, Myers DL, et al. Urodynamic characterization of obese women with urinary incontinence undergoing a weight loss program: the Program to Reduce Incontinence by Diet and Exercise (PRIDE) trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Dec;19(12):1653-8. PMID: 18679560.
666. Richter HE, Diokno A, Kenton K, et al. Predictors of treatment failure 24 months after surgery for stress urinary incontinence. *J Urol.* 2008 Mar;179(3):1024-30. PMID: 18206917.
667. Richter HE, Goode PS, Brubaker L, et al. Two-year outcomes after surgery for stress urinary incontinence in older compared with younger women. *Obstetrics & Gynecology.* 2008 Sep;112(3):621-9. PMID: 21531.
668. Richter HE, Norman AM, Burgio KL, et al. Tension-free vaginal tape: a prospective subjective and objective outcome analysis. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005 Mar-Apr;16(2):109-13. PMID: 15789144.
669. Richter HE, Nygaard I, Burgio KL, et al. Lower urinary tract symptoms, quality of life and pelvic organ prolapse: irritative bladder and obstructive voiding symptoms in women planning to undergo abdominal sacrocolpopexy for advanced pelvic organ prolapse. *J Urol.* 2007 Sep;178(3 Pt 1):965-9; discussion 9. PMID: 17632167.
670. Richter HE, Varner RE, Sanders E, et al. Effects of pubovaginal sling procedure on patients with urethral hypermobility and intrinsic sphincteric deficiency: would they do it again? *Am J Obstet Gynecol.* 2001 Jan;184(2):14-9. PMID: 11174473.
671. Rinne K, Laurikainen E, Kivela A, et al. A randomized trial comparing TVT with TVT-O: 12-month results. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Aug;19(8):1049-54. PMID: 18373046.
672. Ripetti V, Caputo D, Ausania F, et al. Sacral nerve neuromodulation improves physical, psychological and social quality of life in patients with fecal incontinence. *Tech Coloproctol.* 2002 Dec;6(3):147-52. PMID: 12525907.
673. Rivera R, Gousse A. Does postmenopausal hormone therapy cause urinary incontinence? *Nat Clin Pract Urol.* 2006 Jun;3(6):304-5. PMID: 16763639.

674. Robinson D, Cardozo L, Akeson M, et al. Antidiuresis: a new concept in managing female daytime urinary incontinence. *BJU Int.* 2004 May;93(7):996-1000. PMID: 15142150.
675. Rodriguez LV, Berman J, Raz S. Polypropylene sling for treatment of stress urinary incontinence: an alternative to tension-free vaginal tape. *Tech Urol.* 2001 Jun;7(2):87-9. PMID: 11383999.
676. Rodriguez LV, Blander DS, Dorey F, et al. Discrepancy in patient and physician perception of patient's quality of life related to urinary symptoms. *Urology.* 2003 Jul;62(1):49-53. PMID: 12837421.
677. Rodriguez LV, Bukkapatnam R, Shah SM, et al. Transvaginal paravaginal repair of high-grade cystocele central and lateral defects with concomitant suburethral sling: report of early results, outcomes, and patient satisfaction with a new technique. *Urology.* 2005 Nov;66(5 Suppl):57-65. PMID: 16194709.
678. Rodriguez LV, de Almeida F, Dorey F, et al. Does Valsalva leak point pressure predict outcome after the distal urethral polypropylene sling? Role of urodynamics in the sling era. *J Urol.* 2004 Jul;172(1):210-4. PMID: 15201776.
679. Rodriguez LV, Raz S. Prospective analysis of patients treated with a distal urethral polypropylene sling for symptoms of stress urinary incontinence: surgical outcome and satisfaction determined by patient driven questionnaires. *J Urol.* 2003 Sep;170(3):857-63; discussion 63. PMID: 12913716.
680. Rogers RG, Kammerer-Doak D, Olsen A, et al. A randomized, double-blind, placebo-controlled comparison of the effect of nitrofurantoin monohydrate macrocrystals on the development of urinary tract infections after surgery for pelvic organ prolapse and/or stress urinary incontinence with suprapubic catheterization. *Am J Obstet Gynecol.* 2004 Jul;191(1):182-7. PMID: 15295362.
681. Rogers RG, Leeman LM, Migliaccio L, et al. Does the severity of spontaneous genital tract trauma affect postpartum pelvic floor function? *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Mar;19(3):429-35. PMID: 17896065.
682. Romancik M, Lutter I, Goncalves F, et al. Valsalva leak point pressure predicts outcome after transobturator suburethral tape implantation--fact or fiction? *Bratisl Lek Listy.* 2006;107(11-12):426-9. PMID: 17425159.
683. Romero Maroto J, Ortiz Gorraiz M, Prieto Chaparro L, et al. Transvaginal adjustable tape: an adjustable mesh for surgical treatment of female stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Aug;19(8):1109-16. PMID: 18360735.
684. Roovers JP, van der Vaart CH, van der Bom JG, et al. A randomised controlled trial comparing abdominal and vaginal prolapse surgery: effects on urogenital function. *BJOG.* 2004 Jan;111(1):50-6. PMID: 14687052.
685. Ross J. Two techniques of laparoscopic Burch repair for stress incontinence: a prospective, randomized study. *J Am Assoc Gynecol Laparosc.* 1996 May;3(3):351-7. PMID: 9050655.

686. Ross JW, Galen DI, Abbott K, et al. A prospective multisite study of radiofrequency bipolar energy for treatment of genuine stress incontinence. *J Am Assoc Gynecol Laparosc.* 2002 Nov;9(4):493-9. PMID: 12386362.
687. Ross S, Robert M, Swaby C, et al. Transobturator tape compared with tension-free vaginal tape for stress incontinence: a randomized controlled trial. *Obstet Gynecol.* 2009 Dec;114(6):1287-94. PMID: 19935032.
688. Roumeguere T, Quackels T, Bollens R, et al. Trans-obturator vaginal tape (TOT) for female stress incontinence: one year follow-up in 120 patients. *Eur Urol.* 2005 Nov;48(5):805-9. PMID: 16182440.
689. Roy S. Continence. Services for a new century. *Nurs Times.* 1999 Oct 20-26;95(42):65-7. PMID: 10788893.
690. Rutman M, Itano N, Deng D, et al. Long-term durability of the distal urethral polypropylene sling procedure for stress urinary incontinence: minimum 5-year followup of surgical outcome and satisfaction determined by patient reported questionnaires. *J Urol.* 2006 Feb;175(2):610-3. PMID: 16407006.
691. Rutman MP, Deng DY, Shah SM, et al. Spiral sling salvage anti-incontinence surgery in female patients with a nonfunctional urethra: technique and initial results. *J Urol.* 2006 May;175(5):1794-8; discussion 8-9. PMID: 16600764.
692. Saadoun K, Ringa V, Fritel X, et al. Negative impact of urinary incontinence on quality of life, a cross-sectional study among women aged 49-61 years enrolled in the GAZEL cohort. *Neurourol Urodyn.* 2006;25(7):696-702. PMID: 16917934.
693. Saban R, Saban MR, Nguyen NB, et al. Neurokinin-1 (NK-1) receptor is required in antigen-induced cystitis. *Am J Pathol.* 2000 Mar;156(3):775-80. PMID: 10702392.
694. Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study. *Br J Clin Pharmacol.* 2006 Apr;61(4):456-63. PMID: 16542207.
695. Sahai A, Kalsi V, Khan MS, et al. Techniques for the intradetrusor administration of botulinum toxin. *BJU Int.* 2006 Apr;97(4):675-8. PMID: 16536751.
696. Saint S, Kaufman SR, Rogers MA, et al. Condom versus indwelling urinary catheters: a randomized trial. *J Am Geriatr Soc.* 2006 Jul;54(7):1055-61. PMID: 16866675.
697. Saito M, Watanabe T, Tabuchi F, et al. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. *Int J Urol.* 2004 Aug;11(8):592-6. PMID: 15285747.
698. Salin A, Conquy S, Elie C, et al. Identification of risk factors for voiding dysfunction following TVT placement. *Eur Urol.* 2007 Mar;51(3):782-7; discussion 7. PMID: 17098355.
699. Salle JL, McLorie GA, Bagli DJ, et al. Modifications of and extended indications for the Pippi Salle procedure. *World J Urol.* 1998;16(4):279-84. PMID: 9775428.

700. Sand PK, Winkler H, Blackhurst DW, et al. A prospective randomized study comparing modified Burch retropubic urethropexy and suburethral sling for treatment of genuine stress incontinence with low-pressure urethra. *Am J Obstet Gynecol.* 2000 Jan;182(1 Pt 1):30-4. PMID: 10649153.
701. Sange C, Thomas L, Lyons C, et al. Urinary incontinence in Muslim women. *Nurs Times.* 2008 Jun 24-30;104(25):49-52. PMID: 18672845.
702. Sartore A, De Seta F, Maso G, et al. The effects of mediolateral episiotomy on pelvic floor function after vaginal delivery. *Obstetrics and gynecology.* 2004(4):669-73. PMID: CN-00470613.
703. Sartori MG, Baracat EC, Girao MJ, et al. Menopausal genuine stress urinary incontinence treated with conjugated estrogens plus progestogens. *Int J Gynaecol Obstet.* 1995 May;49(2):165-9. PMID: 7649322.
704. Schettini M, Diana M, Gallucci M. Treatment of urinary incontinence with AMS 800 artificial urinary sphincter. *Int Surg.* 1998 Jul-Sep;83(3):257-61. PMID: 9870787.
705. Schierlitz L, Dwyer PL, Rosamilia A, et al. Effectiveness of tension-free vaginal tape compared with transobturator tape in women with stress urinary incontinence and intrinsic sphincter deficiency: a randomized controlled trial. *Obstet Gynecol.* 2008 Dec;112(6):1253-61. PMID: 19037033.
706. Schiøtz HA. Comparison of 1 and 3 days' transurethral Foley catheterization after retropubic incontinence surgery. *International urogynecology journal and pelvic floor dysfunction;* 1996. p. 98-101.
707. Schmidt AP, Sanches PR, Silva DP, Jr., et al. A new pelvic muscle trainer for the treatment of urinary incontinence. *Int J Gynaecol Obstet.* 2009 Jun;105(3):218-22. PMID: 19232601.
708. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. *Sacral Nerve Stimulation Study Group. J Urol.* 1999 Aug;162(2):352-7. PMID: 10411037.
709. Schraffordt Koops SE, Bisseling TM, Heintz AP, et al. Prospective analysis of complications of tension-free vaginal tape from The Netherlands Tension-free Vaginal Tape study. *American Journal of Obstetrics & Gynecology.* 2005 Jul;193(1):45-52. PMID: 21097.
710. Schraffordt Koops SE, Bisseling TM, Heintz AP, et al. Quality of life before and after TVT, a prospective multicentre cohort study, results from the Netherlands TVT database. *BJOG.* 2006 Jan;113(1):26-9. PMID: 16398767.
711. Schraffordt Koops SE, Bisseling TM, Heintz AP, et al. The effectiveness of tension-free vaginal tape (TVT) and quality of life measured in women with previous urogynecologic surgery: analysis from The Netherlands TVT database. *Am J Obstet Gynecol.* 2006 Aug;195(2):439-44. PMID: 16635472.

712. Schraffordt Koops SE, Bisseling TM, van Brummen HJ, et al. Result of the tension-free vaginal tape in patients with concomitant prolapse surgery: a 2-year follow-up study. An analysis from the Netherlands TVT database. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Apr;18(4):437-42. PMID: 16909194.
713. Schulte-Baukloh H, Thalau F, Sturzebecher B, et al. Pubovaginal bone anchor fixation with polyethylene versus fascia lata slings in the treatment of female stress incontinence: sling material and processing are predominant factors in success. *Can J Urol.* 2005 Apr;12(2):2581-7. PMID: 15877939.
714. Schweitzer KJ, Vierhout ME, Milani AL. Surgery for pelvic organ prolapse in women of 80 years of age and older. *Acta Obstet Gynecol Scand.* 2005 Mar;84(3):286-9. PMID: 15715538.
715. Segal J, Steele A, Vassallo B, et al. Various surgical approaches to treat voiding dysfunction following anti-incontinence surgery. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 Jun;17(4):372-7. PMID: 16429244.
716. Serels S, Stein M. Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. *Neurourol Urodyn.* 1998;17(1):31-6. PMID: 9453690.
717. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and suprathreshold doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. *J Clin Pharmacol.* 2005 Sep;45(9):1038-47. PMID: 16100298.
718. Sevestre S, Ciofu C, Deval B, et al. Results of the tension-free vaginal tape technique in the elderly. *Eur Urol.* 2003 Jul;44(1):128-31. PMID: 12814688.
719. Sharifiaghdas F, Mortazavi N. Tension-free vaginal tape and autologous rectus fascia pubovaginal sling for the treatment of urinary stress incontinence: a medium-term follow-up. *Med Princ Pract.* 2008;17(3):209-14. PMID: 18408389.
720. Shaw C, Das Gupta R, Williams KS, et al. A survey of help-seeking and treatment provision in women with stress urinary incontinence. *BJU Int.* 2006 Apr;97(4):752-7. PMID: 16536767.
721. Sherman FT. Functional assessment. Easy-to-use screening tools speed initial office work-up. *Geriatrics.* 2001 Aug;56(8):36-40; quiz 3. PMID: 11505859.
722. Shinopulos NM, Dann JA, Smith JJ, 3rd. Patient selection and education for use of the CapSure (Re/Stor) continence shield. *Urol Nurs.* 1999 Jun;19(2):135-40. PMID: 10633764.
723. Showalter PR, Zimmern PE, Roehrborn CG, et al. Standing cystourethrogram: an outcome measure after anti-incontinence procedures and cystocele repair in women. *Urology.* 2001 Jul;58(1):33-7. PMID: 11445475.
724. Shukla A, Johnson D, Bibby J. Impact of patient position on filling phase of urodynamics in women. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 May;17(3):231-3. PMID: 16001131.

725. Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. *Urology*. 2000 Dec 4;56(6 Suppl 1):87-91. PMID: 11114569.
726. Siltberg H, Larsson G, Hallen B, et al. Validation of cough-induced leak point pressure measurement in the evaluation of pharmacological treatment of stress incontinence. *Neurourology & Urodynamics*; 1999. p. 591-602.
727. Silva C, Silva J, Castro H, et al. Bladder sensory desensitization decreases urinary urgency. *BMC Urol*. 2007;7:9. PMID: 17561998.
728. Silva WA, Pauls RN, Segal JL, et al. Uterosacral ligament vault suspension: five-year outcomes. *Obstet Gynecol*. 2006 Aug;108(2):255-63. PMID: 16880293.
729. Silva-Filho AL, Candido EB, Noronha A, et al. Comparative study of autologous pubovaginal sling and synthetic transobturator (TOT) SAFYRE sling in the treatment of stress urinary incontinence. *Arch Gynecol Obstet*. 2006 Feb;273(5):288-92. PMID: 16189692.
730. Simeonova Z, Milsom I, Kullendorff AM, et al. The prevalence of urinary incontinence and its influence on the quality of life in women from an urban Swedish population. *Acta Obstet Gynecol Scand*. 1999 Jul;78(6):546-51. PMID: 10376867.
731. Sinha D, Blackwell A, Moran PA. Outcome measures after TVT for mixed urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Jul;19(7):927-31. PMID: 18250947.
732. Sivanesan K, Fattah MA, Ramsay I. Transobturator tape as a day surgery procedure: a case control study. *Int J Surg*. 2007 Jun;5(3):152-4. PMID: 17509495.
733. Sivaslioglu AA, Caliskan E, Dolen I, et al. A randomized comparison of transobturator tape and Burch colposuspension in the treatment of female stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 Sep;18(9):1015-9. PMID: 17180553.
734. Sivaslioglu AA, Demir B, Dolen Y, et al. Residents performance in transobturator tape procedures for stress urinary incontinence. *Eur J Obstet Gynecol Reprod Biol*. 2007 Oct;134(2):259-61. PMID: 17258381.
735. Sivaslioglu AA, Unlubilgin E, Dolen I. The multifilament polypropylene tape erosion trouble: tape structure vs surgical technique. Which one is the cause? *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Mar;19(3):417-20. PMID: 17876489.
736. Sivaslioglu AA, Unlubilgin E, Dolen I. A randomized comparison of polypropylene mesh surgery with site-specific surgery in the treatment of cystocele. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Apr;19(4):467-71. PMID: 17901910.
737. Slors FJ, van Zuijlen PP, van Dijk GJ. Sexual and bladder dysfunction after total mesorectal excision for benign diseases. *Scand J Gastroenterol Suppl*. 2000(232):48-51. PMID: 11232492.
738. Soderberg MW, Johansson B, Masironi B, et al. Pelvic floor sex steroid hormone receptors, distribution and expression in pre- and postmenopausal stress urinary incontinent women. *Acta Obstet Gynecol Scand*. 2007;86(11):1377-84. PMID: 17963065.

739. Sotomayor M, Bernal GF. Transurethral delivery of radiofrequency energy for tissue micro-remodeling in the treatment of stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Dec;14(6):373-9. PMID: 14676996.
740. Sotomayor M, Bernal GF. Twelve-month results of nonsurgical radiofrequency energy micro-remodeling for stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005 May-Jun;16(3):192-6; discussion 6. PMID: 15378235.
741. Soulie M, Cuvillier X, Benaissa A, et al. The tension-free transvaginal tape procedure in the treatment of female urinary stress incontinence: a French prospective multicentre study. *Eur Urol.* 2001 Jun;39(6):709-14; discussion 15. PMID: 11464062.
742. Stach-Lempinen B, Hakala AL, Laippala P, et al. Severe depression determines quality of life in urinary incontinent women. *Neurourol Urodyn.* 2003;22(6):563-8. PMID: 12951664.
743. Starr CH. The numbers lie. *Bus Health.* 2002 Spring;Spec No:4-7, 23. PMID: 11974569.
744. Steele AC, Walsh P, Bentley M, et al. A randomized, double-blind placebo-controlled trial of the effects of the 5-hydroxytryptamine(4) agonist cisapride on the female urinary bladder. *Am J Obstet Gynecol.* 2001 Jul;185(1):62-4. PMID: 11483905.
745. Stein M, Weinberg JJ. Polytetrafluoroethylene vs. polypropylene suture for endoscopic bladder neck suspension. *Urology.* 1991 Aug;38(2):119-22. PMID: 1877125.
746. Stikkelbroeck NM, Beerendonk CC, Willemsen WN, et al. The long term outcome of feminizing genital surgery for congenital adrenal hyperplasia: anatomical, functional and cosmetic outcomes, psychosexual development, and satisfaction in adult female patients. *J Pediatr Adolesc Gynecol.* 2003 Oct;16(5):289-96. PMID: 14597017.
747. Stones RW, Padmadas SS, Guo S, et al. Dyspareunia, urinary sensory symptoms, and incontinence among young Chinese women. *Arch Sex Behav.* 2006 Oct;35(5):561-7. PMID: 17031583.
748. Strasser H, Marksteiner R, Margreiter E, et al. Transurethral ultrasonography-guided injection of adult autologous stem cells versus transurethral endoscopic injection of collagen in treatment of urinary incontinence. *World J Urol.* 2007 Aug;25(4):385-92. PMID: 17701044.
749. Su KC, Mutone MF, Terry CL, et al. Abdominovaginal sacral colpoperineopexy: patient perceptions, anatomical outcomes, and graft erosions. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 May;18(5):503-11. PMID: 16988778.
750. Su TH, Wang KG, Hsu CY, et al. Prospective comparison of laparoscopic and traditional colposuspensions in the treatment of genuine stress incontinence. *Acta Obstet Gynecol Scand.* 1997 Jul;76(6):576-82. PMID: 9246967.
751. Subak LL, Brubaker L, Chai TC, et al. High costs of urinary incontinence among women electing surgery to treat stress incontinence. *Obstet Gynecol.* 2008 Apr;111(4):899-907. PMID: 18378749.
752. Subak LL, Waetjen LE, van den Eeden S, et al. Cost of pelvic organ prolapse surgery in the United States. *Obstet Gynecol.* 2001 Oct;98(4):646-51. PMID: 11576582.

753. Sullivan LD, Chow VD, Ko DS, et al. An evaluation of quality of life in patients with continent urinary diversions after cystectomy. *Br J Urol*. 1998 May;81(5):699-704. PMID: 9634044.
754. Sun MJ, Chang NE, Chen GD, et al. Comparison of suprapubic versus transobturator surgical treatments of female stress urinary incontinence. *Taiwan J Obstet Gynecol*. 2008 Jun;47(2):175-9. PMID: 18603502.
755. Sun MJ, Chang SY, Lin KC, et al. Is an indwelling catheter necessary for bladder drainage after modified Burch colposuspension? *Int Urogynecol J Pelvic Floor Dysfunct*. 2004 May-Jun;15(3):203-7. PMID: 15168002.
756. Sun MJ, Ng SC, Tsui KP, et al. Are there any predictors for failed Burch colposuspension? *Taiwan J Obstet Gynecol*. 2006 Mar;45(1):33-8. PMID: 17272205.
757. Swift SE. The reliability of performing a screening cystometrogram using a fetal monitoring device for the detection of detrusor instability. *Obstet Gynecol*. 1997 May;89(5 Pt 1):708-12. PMID: 9166306.
758. Tahseen S, Reid PC, Charan P. Short-term complications of the trans-obturator foramen procedure for urinary stress incontinence. *J Obstet Gynaecol*. 2007 Jul;27(5):500-2. PMID: 17701800.
759. Tamanini JT, Dambros M, D'Ancona CA, et al. Concurrent validity, internal consistency and responsiveness of the Portuguese version of the King's Health Questionnaire (KHQ) in women after stress urinary incontinence surgery. *Int Braz J Urol*. 2004 Nov-Dec;30(6):479-86. PMID: 15663805.
760. Tamanini JT, D'Ancona CA, Netto NR, Jr. Treatment of intrinsic sphincter deficiency using the Macroplastique Implantation System: two-year follow-up. *J Endourol*. 2004 Nov;18(9):906-11. PMID: 15659931.
761. Tamanini JT, D'Ancona CA, Netto NR. Macroplastique implantation system for female stress urinary incontinence: long-term follow-up. *J Endourol*. 2006 Dec;20(12):1082-6. PMID: 17206907.
762. Tamanini JT, D'Ancona CA, Tadini V, et al. Macroplastique implantation system for the treatment of female stress urinary incontinence. *J Urol*. 2003 Jun;169(6):2229-33. PMID: 12771756.
763. Tannenbaum C, Brouillette J, Corcos J. Rating improvements in urinary incontinence: do patients and their physicians agree? *Age Ageing*. 2008 Jul;37(4):379-83. PMID: 18586834.
764. Tannenbaum C, Mayo N. Women's health priorities and perceptions of care: a survey to identify opportunities for improving preventative health care delivery for older women. *Age Ageing*. 2003 Nov;32(6):626-35. PMID: 14600004.
765. Tcherniakovsky M, Fernandes CE, Bezerra CA, et al. Comparative results of two techniques to treat stress urinary incontinence: synthetic transobturator and aponeurotic slings. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Aug;20(8):961-6. PMID: 19582386.
766. Teichman JM. Laparoscopic Burch colposuspension. *Tech Urol*. 1995 Spring;1(1):19-24. PMID: 9118362.

767. Tennstedt S. Design of the Stress Incontinence Surgical Treatment Efficacy Trial (SISTER). *Urology*. 2005 Dec;66(6):1213-7. PMID: 16360445.
768. Tennstedt SL, Fitzgerald MP, Nager CW, et al. Quality of life in women with stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 May;18(5):543-9. PMID: 17036169.
769. Tennstedt SL, Litman HJ, Zimmern P, et al. Quality of life after surgery for stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Dec;19(12):1631-8. PMID: 18682875.
770. Thakar R, Stanton S, Prodigalidad L, et al. Secondary colposuspension: results of a prospective study from a tertiary referral centre. *BJOG*. 2002 Oct;109(10):1115-20. PMID: 12387463.
771. Theodorou C, Floratos D, Katsifotis C, et al. Transvaginal incisionless bladder neck suspension. A simplified technique for female genuine stress incontinence. *Int Urol Nephrol*. 1998;30(3):273-8. PMID: 9696332.
772. Thornton MJ, Lam A, King DW. Bowel, bladder and sexual function in women undergoing laparoscopic posterior compartment repair in the presence of apical or anterior compartment dysfunction. *Aust N Z J Obstet Gynaecol*. 2005 Jun;45(3):195-200. PMID: 15904443.
773. Tibaek S, Gard G, Klarskov P, et al. Prevalence of lower urinary tract symptoms (LUTS) in stroke patients: a cross-sectional, clinical survey. *Neurourol Urodyn*. 2008;27(8):763-71. PMID: 18551565.
774. Tomlinson AJ, Thornton JG. A randomised controlled trial of antibiotic prophylaxis for vesico-vaginal fistula repair. *Br J Obstet Gynaecol*. 1998 Apr;105(4):397-9. PMID: 9609264.
775. Tomoe H, Kondo A, Takei M, et al. Quality of life assessments in women operated on by tension-free vaginal tape (TVT). *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Mar-Apr;16(2):114-8; discussion 08. PMID: 15448883.
776. Townsend MK, Curhan GC, Resnick NM, et al. Postmenopausal hormone therapy and incident urinary incontinence in middle-aged women. *Am J Obstet Gynecol*. 2009 Jan;200(1):86 e1-5. PMID: 19019333.
777. Trabuco EC, Klingele CJ, Weaver AL, et al. Medium-term comparison of continence rates after rectus fascia or midurethral sling placement. *American Journal of Obstetrics & Gynecology*. 2009 Mar;200(3):300.e1-.e6. PMID: 21034.
778. Tseng LH, Wang AC, Lin YH, et al. Randomized comparison of the suprapubic arc sling procedure vs tension-free vaginal taping for stress incontinent women. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 May-Jun;16(3):230-5. PMID: 15875240.
779. Tsui KP, Ng SC, Yeh GP, et al. Outcomes of autologous fascial slingplasty procedure for treating female urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Jul;19(7):949-54. PMID: 18231696.

780. Turner CE, Young JM, Solomon MJ, et al. Vaginal delivery compared with elective caesarean section: the views of pregnant women and clinicians. *BJOG*. 2008 Nov;115(12):1494-502. PMID: 18752584.
781. U.S. Food and Drug Administration CfDEaR. Medical Review for ANAFRANIL (Brand Name Drug). 1999.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019906_S022_ANAFRANIL_A_P.pdf. Accessed June 25 2010.
782. U.S. Food and Drug Administration CfDEaR. Medical Review for PAMELOR (Brand Name Drug). 2001.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/018013_s053_PAMELOR%20CAPSULES.pdf. Accessed June 25 2010.
783. U.S. Food and Drug Administration CfDEaR. Statistical Review for Premarin (Conjugated Estrogens) Tablets. 2003.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-417_Premarin.cfm. Accessed June 25 2010.
784. Uchil D, Thakar R, Sultan AH, et al. Continence pads: have we got it right? *Int Urogynecol J Pelvic Floor Dysfunct*. 2006 May;17(3):234-8. PMID: 15999216.
785. Ulmsten U, Henriksson L, Johnson P, et al. An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 1996;7(2):81-5; discussion 5-6. PMID: 8798092.
786. Ushiroyama T, Ikeda A, Ueki M. Clinical efficacy of clenbuterol and propiverine in menopausal women with urinary incontinence: improvement in quality of life. *J Med*. 2000;31(5-6):311-9. PMID: 11508324.
787. Ustun Y, Engin-Ustun Y, Gungor M, et al. Tension-free vaginal tape compared with laparoscopic Burch urethropexy. *J Am Assoc Gynecol Laparosc*. 2003 Aug;10(3):386-9. PMID: 14567818.
788. Ustün Y, Engin-Ustün Y, Güngör M, et al. Randomized comparison of Burch urethropexy procedures concomitant with gynecologic operations. *Gynecologic and obstetric investigation*; 2005. p. 19-23.
789. Valpas A, Kivela A, Penttinen J, et al. Tension-free vaginal tape and laparoscopic mesh colposuspension in the treatment of stress urinary incontinence: immediate outcome and complications--a randomized clinical trial. *Acta Obstet Gynecol Scand*. 2003 Jul;82(7):665-71. PMID: 12790850.
790. Valpas A, Kivela A, Penttinen J, et al. Tension-free vaginal tape and laparoscopic mesh colposuspension for stress urinary incontinence. *Obstet Gynecol*. 2004 Jul;104(1):42-9. PMID: 15228999.
791. Valpas A, Rissanen P, Kujansuu E, et al. A cost-effectiveness analysis of tension-free vaginal tape versus laparoscopic mesh colposuspension for primary female stress incontinence. *Acta Obstet Gynecol Scand*. 2006;85(12):1485-90. PMID: 17260226.

792. van der Vaart CH, Lamers BH, Heintz AP. Feasibility and patient satisfaction with pelvic organ prolapse and urinary incontinence day surgery. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 May;18(5):531-6. PMID: 16932871.
793. van Raalte HM, Lucente VR, Molden SM, et al. One-year anatomic and quality-of-life outcomes after the Prolift procedure for treatment of posthysterectomy prolapse. *Am J Obstet Gynecol.* 2008 Dec;199(6):694 e1-6. PMID: 18986641.
794. van Waalwijk van Doorn ES, Zwiers W. Ambulant monitoring to assess the efficacy of oxybutynin chloride in patients with mixed incontinence. *Eur Urol.* 1990;18(1):49-51. PMID: 2401307.
795. Vardy MD, Brodman M, Olivera CK, et al. Anterior intravaginal slingplasty tunneller device for stress incontinence and posterior intravaginal slingplasty for apical vault prolapse: a 2-year prospective multicenter study. *Am J Obstet Gynecol.* 2007 Jul;197(1):104 e1-8. PMID: 17618778.
796. Vassallo BJ, Kleeman SD, Segal JL, et al. Tension-free vaginal tape: a quality-of-life assessment. *Obstet Gynecol.* 2002 Sep;100(3):518-24. PMID: 12220772.
797. Vernarec E. The high costs of hidden conditions. *Bus Health.* 1998 Jan;16(1):19-23. PMID: 10176562.
798. Vervest HA, Bisseling TM, Heintz AP, et al. The prevalence of voiding difficulty after TVT, its impact on quality of life, and related risk factors. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Feb;18(2):173-82. PMID: 16633883.
799. Vianello A, Costantini E, Del Zingaro M, et al. Mini-invasive techniques for the treatment of female stress urinary incontinence. *Minerva Ginecol.* 2007 Dec;59(6):557-69. PMID: 18043568.
800. Viereck V, Bader W, Krauss T, et al. Intra-operative introital ultrasound in Burch colposuspension reduces post-operative complications. *BJOG.* 2005 Jun;112(6):791-6. PMID: 15924539.
801. Viereck V, Pauer HU, Bader W, et al. Introital ultrasound of the lower genital tract before and after colposuspension: a 4-year objective follow-up. *Ultrasound Obstet Gynecol.* 2004 Mar;23(3):277-83. PMID: 15027018.
802. Visco AG, Brubaker L, Nygaard I, et al. The role of preoperative urodynamic testing in stress-continent women undergoing sacrocolpopexy: the Colpopexy and Urinary Reduction Efforts (CARE) randomized surgical trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 May;19(5):607-14. PMID: 18185903.
803. Viseshsindh W, Kochakarn W, Waikakul W, et al. A randomized controlled trial of pubovaginal sling versus vaginal wall sling for stress urinary incontinence. *J Med Assoc Thai.* 2003 Apr;86(4):308-15. PMID: 12757074.
804. von Pechmann WS, Mutone M, Fyffe J, et al. Total colpopcleisis with high levator plication for the treatment of advanced pelvic organ prolapse. *Am J Obstet Gynecol.* 2003 Jul;189(1):121-6. PMID: 12861149.

805. Walker GT, Texter JH, Jr. Success and patient satisfaction following the Stamey procedure for stress urinary incontinence. *J Urol.* 1992 Jun;147(6):1521-3. PMID: 1593680.
806. Wall LL, Copas P, Galloway NT. Use of a pedicled rectus abdominis muscle flap sling in the treatment of complicated stress urinary incontinence. *Am J Obstet Gynecol.* 1996 Dec;175(6):1460-4; discussion 4-6. PMID: 8987925.
807. Wallwiener D, Grischke EM, Rimbach S, et al. Endoscopic retropubic colposuspension: "Retziusscopy" versus laparoscopy--a reasonable enlargement of the operative spectrum in the management of recurrent stress incontinence? *Endosc Surg Allied Technol.* 1995 Apr-Jun;3(2-3):115-8. PMID: 7552124.
808. Walsh IK, Nambirajan T, Donellan SM, et al. Cadaveric fascia lata pubovaginal slings: early results on safety, efficacy and patient satisfaction. *BJU Int.* 2002 Sep;90(4):415-9. PMID: 12175399.
809. Walsh K, Generao SE, White MJ, et al. The influence of age on quality of life outcome in women following a tension-free vaginal tape procedure. *J Urol.* 2004 Mar;171(3):1185-8. PMID: 14767297.
810. Walter AJ, Morse AN, Hammer RA, et al. Laparoscopic versus open Burch retropubic urethropexy: comparison of morbidity and costs when performed with concurrent vaginal prolapse repairs. *Am J Obstet Gynecol.* 2002 Apr;186(4):723-8. PMID: 11967498.
811. Waltregny D, Gaspar Y, Reul O, et al. TVT-O for the treatment of female stress urinary incontinence: results of a prospective study after a 3-year minimum follow-up. *Eur Urol.* 2008 Feb;53(2):401-8. PMID: 17728052.
812. Waltregny D, Reul O, Mathantu B, et al. Inside out transobturator vaginal tape for the treatment of female stress urinary incontinence: interim results of a prospective study after a 1-year minimum followup. *J Urol.* 2006 Jun;175(6):2191-5. PMID: 16697838.
813. Wang AC, Chen MC. Randomized comparison of local versus epidural anesthesia for tension-free vaginal tape operation. *J Urol.* 2001 Apr;165(4):1177-80. PMID: 11257665.
814. Wang AC, Chen MC. Comparison of tension-free vaginal taping versus modified Burch colposuspension on urethral obstruction: a randomized controlled trial. *Neurourol Urodyn.* 2003;22(3):185-90. PMID: 12707868.
815. Wang AC, Chen MC. The correlation between preoperative voiding mechanism and surgical outcome of the tension-free vaginal tape procedure, with reference to quality of life. *BJU Int.* 2003 Apr;91(6):502-6. PMID: 12656903.
816. Wang AC, Lin YH, Tseng LH, et al. Prospective randomized comparison of transobturator suburethral sling (Monarc) vs suprapubic arc (Sparc) sling procedures for female urodynamic stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 Sep;17(5):439-43. PMID: 16328116.
817. Wang F, Song Y, Huang H. Prospective randomized trial of TVT and TOT as primary treatment for female stress urinary incontinence with or without pelvic organ prolapse in Southeast China. *Arch Gynecol Obstet.* 2010 Feb;281(2):279-86. PMID: 19404656.

818. Wang W, Zhu L, Lang J. Transobturator tape procedure versus tension-free vaginal tape for treatment of stress urinary incontinence. *International Journal of Gynaecology & Obstetrics*. 2009 Feb;104(2):113-6. PMID: 21037.
819. Ward K, Hilton P, United K, et al. Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence. *BMJ (Clinical research ed.)*; 2002. p. 67.
820. Ward KL, Hilton P. A prospective multicenter randomized trial of tension-free vaginal tape and colposuspension for primary urodynamic stress incontinence: two-year follow-up. *Am J Obstet Gynecol*. 2004 Feb;190(2):324-31. PMID: 14981369.
821. Ward KL, Hilton P. Tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence: 5-year follow up. *BJOG*. 2008 Jan;115(2):226-33. PMID: 17970791.
822. Watson AJ, Currie I, Jarvis GJ. A prospective placebo controlled double blind randomised study to investigate the use of indoramin to prevent post-operative voiding disorders after surgical treatment for genuine stress incontinence. *Br J Obstet Gynaecol*. 1999 Mar;106(3):270-2. PMID: 10426648.
823. Weber AM, Walters MD, Schover LR, et al. Sexual function in women with uterovaginal prolapse and urinary incontinence. *Obstet Gynecol*. 1995 Apr;85(4):483-7. PMID: 7898820.
824. Wein AJ. Oral and intravaginal estrogens alone and in combination with alpha-adrenergic stimulation in genuine stress incontinence. *J Urol*. 1991 Dec;146(6):1670-1. PMID: 1942363.
825. Wein AJ. Antidiuresis: a new concept in managing female daytime urinary incontinence. *J Urol*. 2005 Jun;173(6):2054-5. PMID: 15879824.
826. Wein AJ. Transvaginal surgery in the octogenarian using cadaveric fascia for pelvic prolapse and stress incontinence: minimal one-year results compared to younger patients. *J Urol*. 2005 Sep;174(3):1009. PMID: 16094028.
827. Wein AJ. The effects of the tension-free vaginal tape on voiding function: a prospective evaluation. *J Urol*. 2005 Sep;174(3):1010. PMID: 16094030.
828. Wein AJ. Tension-free vaginal tape: do patients who fail to follow-up have the same results as those who do? *J Urol*. 2005 Sep;174(3):1009-10. PMID: 16094027.
829. Wen Y, Polan ML, Chen B. Do extracellular matrix protein expressions change with cyclic reproductive hormones in pelvic connective tissue from women with stress urinary incontinence? *Hum Reprod*. 2006 May;21(5):1266-73. PMID: 16452154.
830. Wen Y, Zhao YY, Polan ML, et al. Effect of relaxin on TGF-beta1 expression in cultured vaginal fibroblasts from women with stress urinary incontinence. *Reprod Sci*. 2008 Apr;15(3):312-20. PMID: 18421026.
831. Wennberg AL, Edlund C, Fall M, et al. Stamey's abdominovaginal needle colposuspension for the correction of female genuine stress urinary incontinence--long-term results. *Scand J Urol Nephrol*. 2003;37(5):419-23. PMID: 14594692.

832. Wielink G, Essink-Bot ML, van Kerrebroeck PE, et al. Sacral rhizotomies and electrical bladder stimulation in spinal cord injury. 2. Cost-effectiveness and quality of life analysis. Dutch Study Group on Sacral Anterior Root Stimulation. *Eur Urol*. 1997;31(4):441-6. PMID: 9187905.
833. Wilson CM, Williams BJ, Bilello S, et al. Bovine dermis: a novel biologic substitute for autologous tissue in sling surgery. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Dec;19(12):1671-6. PMID: 18690401.
834. Winton AL, Eastwood J, Powell MC, et al. An evaluation of conscious sedation using propofol and remifentanyl for tension-free vaginal tape insertion. *Anaesthesia*. 2008 Sep;63(9):932-7. PMID: 21532.
835. Wiseman PA, Malone-Lee J, Rai GS. Terodiline with bladder retraining for treating detrusor instability in elderly people. *BMJ*. 1991 Apr 27;302(6783):994-6. PMID: 2039897.
836. Wong T, Lau BY, Mak HL, et al. Changing prevalence and knowledge of urinary incontinence among Hong Kong Chinese women. *Int Urogynecol J Pelvic Floor Dysfunct*. 2006 Nov;17(6):593-7. PMID: 16525759.
837. Woodman PJ, Misko CA, Fischer JR. The use of short-form quality of life questionnaires to measure the impact of imipramine on women with urge incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2001;12(5):312-5; discussion 5-6. PMID: 11715997.
838. Wren PA, Janz NK, Brubaker L, et al. Reliability of health-related quality-of-life measures 1 year after surgical procedures for pelvic floor disorders. *Am J Obstet Gynecol*. 2005 Mar;192(3):780-8. PMID: 15746672.
839. Wren PA, Janz NK, FitzGerald MP, et al. Optimism in women undergoing abdominal sacrocolpopexy for pelvic organ prolapse. *J Am Coll Surg*. 2008 Aug;207(2):240-5. PMID: 18656053.
840. Wu JM, Visco AG, Weidner AC, et al. Is Burch colposuspension ever cost-effective compared with tension-free vaginal tape for stress incontinence? *Am J Obstet Gynecol*. 2007 Jul;197(1):62 e1-5. PMID: 17618760.
841. Wu MP, Huang KH, Long CY, et al. The distribution of different surgical types for female stress urinary incontinence among patients' age, surgeons' specialties and hospital accreditations in Taiwan: a descriptive 10-year nationwide study. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Dec;19(12):1639-46. PMID: 18696003.
842. Wyman JF. The psychiatric and emotional impact of female pelvic floor dysfunction. *Curr Opin Obstet Gynecol*. 1994 Aug;6(4):336-9. PMID: 7742497.
843. Yalcin I, Viktrup L. Comparison of physician and patient assessments of incontinence severity and improvement. *Int Urogynecol J Pelvic Floor Dysfunct*. 2007 Nov;18(11):1291-5. PMID: 17333436.
844. Yalcin OT, Hassa H, Ozalp S, et al. Results of the anti-incontinence operations and Kegel exercises in patients with type II anatomic stress incontinence. *Acta Obstet Gynecol Scand*. 1998 Mar;77(3):341-6. PMID: 9539284.

845. Yang SC, Park DS, Lee JM, et al. Laparoscopic extraperitoneal bladder neck suspension (LEBNS) for stress urinary incontinence. *J Korean Med Sci.* 1995 Dec;10(6):426-30. PMID: 8924227.
846. Yang SH, Yang JM, Wang KH, et al. Biologic correlates of sexual function in women with stress urinary incontinence. *J Sex Med.* 2008 Dec;5(12):2871-9. PMID: 18778309.
847. Yip SK, Chan A, Pang S, et al. The impact of urodynamic stress incontinence and detrusor overactivity on marital relationship and sexual function. *Am J Obstet Gynecol.* 2003 May;188(5):1244-8. PMID: 12748492.
848. Yokoyama E. Contigen Bard Collagen implant: the Japanese experience. *Int J Urol.* 1995 Apr;2 Suppl 1:11-5; discussion 6-8. PMID: 7614409.
849. Yokoyama T, Nozaki K, Fujita O, et al. Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity. *J Urol.* 2004 Aug;172(2):596-600. PMID: 15247740.
850. Yoo ES, Kim HT, Choi JD, et al. Comparison of the Two different Approaches for the Treatment of Stress Urinary Incontinence. 2007 Annual Meeting of the American Urological Association (AUA 2007), Anaheim, California (USA), 19-24 May 2007.
851. Young AE, Fine PM, McCrery R, et al. Spanish language translation of pelvic floor disorders instruments. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Oct;18(10):1171-8. PMID: 17576498.
852. Young SB, Howard AE, Baker SP. Mersilene mesh sling: short- and long-term clinical and urodynamic outcomes. *Am J Obstet Gynecol.* 2001 Jul;185(1):32-40. PMID: 11483900.
853. Zat'ura F, Vsetica J, Abadias M, et al. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. *Eur Urol.* 2010 Jan;57(1):145-52. PMID: 19446951.
854. Zhu L, Lang J, Hai N, et al. Comparing vaginal tape and transobturator tape for the treatment of mild and moderate stress incontinence. *Int J Gynaecol Obstet.* 2007 Oct;99(1):14-7. PMID: 17707822.
855. Zorzos I, Paterson PJ. Quality of life after a Marshall-Marchetti-Krantz procedure for stress urinary incontinence. *J Urol.* 1996 Jan;155(1):259-62. PMID: 7490849.
856. Zullo F, Morelli M, Russo T, et al. Two techniques of laparoscopic retropubic urethropexy. *J Am Assoc Gynecol Laparosc.* 2002 May;9(2):178-81. PMID: 11960044.
857. Zullo F, Palomba S, Piccione F, et al. Laparoscopic Burch colposuspension: a randomized controlled trial comparing two transperitoneal surgical techniques. *Obstet Gynecol.* 2001 Nov;98(5 Pt 1):783-8. PMID: 11704169.
858. Zullo F, Palomba S, Russo T, et al. Laparoscopic colposuspension using sutures or prolene meshes: a 3-year follow-up. *Eur J Obstet Gynecol Reprod Biol.* 2004 Dec 1;117(2):201-3. PMID: 15541858.

859. Zullo MA, Plotti F, Calcagno M, et al. One-year follow-up of tension-free vaginal tape (TVT) and trans-obturator suburethral tape from inside to outside (TVT-O) for surgical treatment of female stress urinary incontinence: a prospective randomised trial. *Eur Urol*. 2007 May;51(5):1376-82; discussion 83-4. PMID: 17110021.
860. U.S. Food and Drug Administration CfDEaR. Medical Review for Synthetic Conjugated Estrogens, A vaginal cream, 0.625 mg/g. 2008. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021788_synthetic_conjugated_estrogens_toc.cfm. Accessed June 25 2010.
861. U.S. Food and Drug Administration CfDEaR. Medical Review for Ditropan Tablets/Syrup. 2003. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/017577_s032&s033_DITROPAN%20TABS.pdf. Accessed June 25 2010.
862. U.S. Food and Drug Administration CfDEaR. Medical Review for Ditropan Tablets/Syrup B. 2003. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/018211_s014&s016_DITROPAN%20TABLETS.pdf. Accessed June 25 2010.
863. U.S. Food and Drug Administration CfDEaR. Statistical Review for Botulinum Toxin Type A. 2002. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088547.pdf>. Accessed June 25 2010.
864. U.S. Food and Drug Administration CfDEaR. Product Monograph for BOTOX COSMETIC. 2001. <http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=67653>. Accessed June 25 2010.
865. U.S. Food and Drug Administration CfDEaR. Statistical Review for Botulinum Toxin Type B Product Approval Information. 2000. <internal-pdf://ucm094414-0321775616/ucm094414.pdf>. Accessed June 25 2010.
866. Canada H. Product Monograph for XEOMIN. 2009. <http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=80952>. Accessed June 25 2010.
867. Canada H. Product Monograph for DITROPAN XL -(10MG). 2001. <http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=67904>. Accessed June 25 2010.
868. Canada H. Product Monograph for PREMARIN VAGINAL CREAM. 1994. <http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=15704>. Accessed June 25 2010.
869. Canada H. Product Monograph for BOTOX. 1992. <http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=13476>. Accessed June 25 2010.

Reason for Exclusion—Not Eligible Outcomes (136 Studies)

1. Dompeyre P, Fritel X, Bader G, et al. Bladder sensitivity testing using a visual analogue scale: comparative cystometric study on women. *Neurourol Urodyn*. 2007;26(3):350-5. PMID: 17245770.

2. Zhu L, Lang J, Wang H, et al. The prevalence of and potential risk factors for female urinary incontinence in Beijing, China. *Menopause*. 2008 May-Jun;15(3):566-9. PMID: 18467955.
3. Zhao YD, Qu Y, Rahardja D. Power approximation for the van Elteren test based on location-scale family of distributions. *J Biopharm Stat*. 2006;16(6):803-15. PMID: 17146980.
4. Zhao YD. Sample size estimation for the van Elteren test--a stratified Wilcoxon-Mann-Whitney test. *Stat Med*. 2006 Aug 15;25(15):2675-87. PMID: 16372389.
5. Yu HJ, Wong WY, Chen J, et al. Quality of life impact and treatment seeking of Chinese women with urinary incontinence. *Qual Life Res*. 2003 May;12(3):327-33. PMID: 12769145.
6. Yaycioglu O, Guvel S, Gul U, et al. Does the Urodynamic Evaluation Change the Treatment Decision for Uncomplicated Female Urinary Incontinence? 21st Annual Congress of the European Association of Urology (EAU 2006), Palais des Congres, Paris (France), 5-8 Apr 2006.
7. Xie Z, Shi H, Zhou C, et al. Alterations of estrogen receptor-alpha and -beta in the anterior vaginal wall of women with urinary incontinence. *Eur J Obstet Gynecol Reprod Biol*. 2007 Oct;134(2):254-8. PMID: 17287066.
8. Wong L. Incontinence has different meanings for different people. *Aust J Adv Nurs*. 1995 Spring;13(1):6-15. PMID: 7546464.
9. Wolters M, Methfessel HD, Goepel C, et al. Computer-assisted virtual urethral pressure profile in the assessment of female genuine stress incontinence. *Obstetrics and gynecology*; 2002. p. 69-74.
10. Winters JC, Chiverton A, Scarpero HM, et al. Collagen injection therapy in elderly women: long-term results and patient satisfaction. *Urology*. 2000 Jun;55(6):856-61. PMID: 10840091.
11. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. *Obstet Gynecol*. 2001 Sep;98(3):398-406. PMID: 11530119.
12. Williams KS, Assassa RP, Smith NK, et al. Educational preparation: specialist practice in continence care. *Br J Nurs*. 1999 Oct 14-27;8(18):1198-207, 202, 204 passim. PMID: 10897707.
13. Wenger NS, Roth CP, Shekelle PG, et al. A practice-based intervention to improve primary care for falls, urinary incontinence, and dementia. *J Am Geriatr Soc*. 2009 Mar;57(3):547-55. PMID: 19175441.
14. Wagg A, Das Gupta R, Assassa P, et al. Secondary-care treatment patterns in the UK for women with urinary incontinence. *BJU Int*. 2005;96:839-42. PMID: 16153213.
15. Van Oyen H, Van Oyen P. Urinary incontinence in Belgium; prevalence, correlates and psychosocial consequences. *Acta Clin Belg*. 2002 Jul-Aug;57(4):207-18. PMID: 12462797.

16. van der Weide M, Smits J. Adoption of innovations by specialised nurses: personal, work and organisational characteristics. *Health Policy*. 2004 Apr;68(1):81-92. PMID: 15033555.
17. van der Vaart CH, van der Bom JG, de Leeuw JR, et al. The contribution of hysterectomy to the occurrence of urge and stress urinary incontinence symptoms. *BJOG*. 2002 Feb;109(2):149-54. PMID: 11911100.
18. van der Linden MC, Gerretsen G, Brandhorst MS, et al. The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms. *Eur J Obstet Gynecol Reprod Biol*. 1993 Sep;51(1):29-33. PMID: 8282140.
19. Tincello DG, Williams KS, Joshi M, et al. Urinary diaries: a comparison of data collected for three days versus seven days. *Obstet Gynecol*. 2007 Feb;109(2 Pt 1):277-80. PMID: 17267824.
20. Thom DH, Nygaard IE, Calhoun EA. Urologic diseases in America project: urinary incontinence in women-national trends in hospitalizations, office visits, treatment and economic impact. *J Urol*. 2005 Apr;173(4):1295-301. PMID: 15758785.
21. Tannenbaum C, Brouillette J, Korner-Bitensky N, et al. Creation and testing of the Geriatric Self-Efficacy Index for Urinary Incontinence. *J Am Geriatr Soc*. 2008 Mar;56(3):542-7. PMID: 18179504.
22. Swanson JG, Skelly J, Hutchison B, et al. Urinary incontinence in Canada. National survey of family physicians' knowledge, attitudes, and practices. *Can Fam Physician*. 2002 Jan;48:86-92. PMID: 11852616.
23. Subak LL, Brown JS, Kraus SR, et al. The "costs" of urinary incontinence for women. *Obstet Gynecol*. 2006 Apr;107(4):908-16. PMID: 16582131.
24. Straus SE, Holroyd-Leduc J, Orr MS. Validation of electronic urinary incontinence questionnaires. *Can J Urol*. 2010 Jun;17(3):5195-9. PMID: 20566013.
25. Slack M, Culligan P, Tracey M, et al. Relationship of urethral retro-resistance pressure to urodynamic measurements and incontinence severity. *Neurourol Urodyn*. 2004;23(2):109-14. PMID: 14983420.
26. Skinner MH, Kuan HY, Skerjanec A, et al. Effect of age on the pharmacokinetics of duloxetine in women. *Br J Clin Pharmacol*. 2004 Jan;57(1):54-61. PMID: 14678340.
27. Sivaslioglu A, Dolen I, Yigitbasi S, et al. Vaginal Cones Stepfree in the Treatment of Mixt Stres Urinary Incontinence. 31st Annual Meeting of the International Urogynecological Association, Athens Hilton Hotel, Athens (Greece), 6-9 Sep 2006.
28. Siracusano S, Bertolotto M, Silvestre G, et al. The feasibility of urethral color ultrasound imaging in the diagnosis of female intrinsic sphincter deficiency: preliminary results. *Spinal Cord*. 2002 Apr;40(4):192-5. PMID: 11965558.
29. Schweitzer K, Daan N, vd Vaart H. The association between frequency as a subjective symptom and objective findings on bladder diaries and urodynamic investigation. *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. 29.

30. Sampsellem CM, Wyman JF, Thomas KK, et al. Continence for women: a test of AWHONN's evidence-based protocol in clinical practice. Association of Women's Health Obstetric and Neonatal Nurses. *J Obstet Gynecol Neonatal Nurs*. 2000 Jan-Feb;29(1):18-26. PMID: 10660273.
31. Sampsellem CM, Harlow SD, Skurnick J, et al. Urinary incontinence predictors and life impact in ethnically diverse perimenopausal women. *Obstet Gynecol*. 2002 Dec;100(6):1230-8. PMID: 12468167.
32. Sampsellem CM. Teaching women to use a voiding diary. *Am J Nurs*. 2003 Nov;103(11):62-4. PMID: 14625427.
33. Sachse R, Cawello W, Haag-Molkenteller C, et al. Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine [abstract]. *Arch Pharmacol*. 2003;367(Suppl 1):446.
34. Sachse R. Pharmacodynamics and pharmacokinetics of ascending multiple oral doses of the novel bladder-selective antimuscarinic fesoterodine [abstract #111]. *Eur Urol Suppl*. 2003;43(Suppl 2):30.
35. Romero Reyes R, Gorbea Chavez V, Rodriguez Colorado S, et al. Reduce-Intensive Pelvic Floor Exercise Program Efficacy for the Treatment of Urinary Incontinence. Randomized Controlled Trial. 34th Annual Meeting of the International Urogynecological Association, Villa Erba, Como, 16-20 Jun 2009.
36. Romero AA, Hardart A, Kobak W, et al. Validation of a Spanish version of the Pelvic Organ Prolapse Incontinence Sexual Questionnaire. *Obstet Gynecol*. 2003 Nov;102(5 Pt 1):1000-5. PMID: 14672477.
37. Rogers RG, Coates KW, Kammerer-Doak D, et al. A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). *Int Urogynecol J Pelvic Floor Dysfunct*. 2003 Aug;14(3):164-8; discussion 8. PMID: 12955337.
38. Robinson D, Anders K, Cardozo L, et al. Can ultrasound replace ambulatory urodynamics when investigating women with irritative urinary symptoms? *BJOG*. 2002 Feb;109(2):145-8. PMID: 11888096.
39. Reuben DB, Roth C, Kamberg C, et al. Restructuring primary care practices to manage geriatric syndromes: the ACOVE-2 intervention. *J Am Geriatr Soc*. 2003 Dec;51(12):1787-93. PMID: 14687359.
40. Rasmussen A, Mouritsen L, Dalgaard A, et al. Twenty-four hour pad weighing test: reproducibility and dependency of activity level and fluid intake. *Neurourol Urodyn*. 1994;13(3):261-5. PMID: 7920683.
41. Radziszewski P, Borkowski A, Torz C, et al. Distribution of collagen type VII in connective tissues of postmenopausal stress-incontinent women. *Gynecol Endocrinol*. 2005 Mar;20(3):121-6. PMID: 16019349.
42. Radley SC, Rosario DJ, Chapple CR, et al. Conventional and ambulatory urodynamic findings in women with symptoms suggestive of bladder overactivity. *J Urol*. 2001 Dec;166(6):2253-8. PMID: 11696746.

43. Quinn P, Goka J, Richardson H. Assessment of an electronic daily diary in patients with overactive bladder. *BJU Int.* 2003 May;91(7):647-52. PMID: 12699477.
44. Prutz C, Snedecor S, Botteman M, et al. Fesoterodine for the treatment of overactive bladder - a cost-effectiveness case study of Sweden. *International Society for Pharmacoeconomics & Outcomes Research Annual International Congress*; May 3-7, 2008; 2008; Toronto, Ontario, Canada.
45. Piault E, Evans CJ, Espindle D, et al. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. *Neurourol Urodyn.* 2008;27(3):179-90. PMID: 17565727.
46. Papanicolaou S, Pons ME, Hampel C, et al. Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study. *Maturitas.* 2005 Nov 30;52 Suppl 2:S35-47. PMID: 16297577.
47. Ouslander J. Pharmacokinetics and clinical effects of Oxybutynin in geriatric patients. *J. Urol.* 1988;140:47-50.
48. Odagaki M, Uomori Y, Hosaka H. Current distributions inside 3D abdomen models as obtained by electrical and magnetic stimulations for the treatment of urinary incontinence. 2007.
49. Notelovitz M. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. *Maturitas.* 1995 Dec;22 Suppl:S31-3. PMID: 8775774.
50. Nitz NM, Jumadilova Z, Darkow T, et al. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. *Am J Manag Care.* 2005 Jul;11(4 Suppl):S130-9. PMID: 16161386.
51. Ninan GK, Jutley RS, Eremin O. Urinary cytokines as markers of reflux nephropathy. *J Urol.* 1999 Nov;162(5):1739-42. PMID: 10524926.
52. Muller N. What Americans understand and how they are affected by bladder control problems: highlights of recent nationwide consumer research. *Urol Nurs.* 2005 Apr;25(2):109-15. PMID: 15900979.
53. Moskowitz MO, Byrne DS, Callahan HJ, et al. Decreased expression of a glycoprotein component of bladder surface mucin (GP1) in interstitial cystitis. *J Urol.* 1994 Feb;151(2):343-5. PMID: 8283520.
54. Morrill M, Lukacz ES, Lawrence JM, et al. Seeking healthcare for pelvic floor disorders: a population-based study. *Am J Obstet Gynecol.* 2007 Jul;197(1):86 e1-6. PMID: 17618770.
55. Minardi D, Piloni V, Amadi A, et al. Correlation between urodynamics and perineal ultrasound in female patients with urinary incontinence. *Neurourol Urodyn.* 2007;26(2):176-82; discussion 83-4. PMID: 17016799.
56. Milne J. The impact of information on health behaviors of older adults with urinary incontinence. *Clin Nurs Res.* 2000 May;9(2):161-76. PMID: 12162240.

57. Mehnert U, Reitz A, Youssef SA, et al. Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects--a placebo controlled double blind investigation using 4 and 8 mg tolterodine extended release. *Neurourol Urodyn*. 2010 Mar;29(3):464-9. PMID: 19637377.
58. Medina CA, Takacs P. Shortening the process of determining postvoid residual. *Int J Gynaecol Obstet*. 2005 Dec;91(3):266-7. PMID: 16226756.
59. Meade-D'Alisera P, Merriweather T, Wentland M. Impact of commercial marketing on patient demand. *Urol Nurs*. 2001 Dec;21(6):406-7, 10. PMID: 11998507.
60. McVeigh C. Perimenopause: more than hot flushes and night sweats for some Australian women. *J Obstet Gynecol Neonatal Nurs*. 2005 Jan-Feb;34(1):21-7. PMID: 15673642.
61. McClish DK, Wyman JF, Sale PG, et al. Use and costs of incontinence pads in female study volunteers. Continence Program for Women Research Group. *J Wound Ostomy Continence Nurs*. 1999 Jul;26(4):207-8, 10-3. PMID: 10476176.
62. Mardon RE, Halim S, Pawlson LG, et al. Management of urinary incontinence in Medicare managed care beneficiaries: results from the 2004 Medicare Health Outcomes Survey. *Arch Intern Med*. 2006 May 22;166(10):1128-33. PMID: 16717176.
63. Marchand JE, Sant GR, Kream RM. Increased expression of substance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis. *Br J Urol*. 1998 Feb;81(2):224-8. PMID: 9488063.
64. Malhotra BK, Crownover PH, LaBadie R, et al. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. *Eur J Clin Pharmacol*. 2010 Feb;66(2):171-6. PMID: 19915829.
65. Malhotra B, Sachse R, Wood N. Evaluation of drug-drug interactions with fesoterodine. *Eur J Clin Pharmacol*. 2009 Jun;65(6):551-60. PMID: 19347334.
66. Malhotra B, Guan Z, Wood N, et al. Pharmacokinetic profile of fesoterodine. *Int J Clin Pharmacol Ther*. 2008 Nov;46(11):556-63. PMID: 19000553.
67. Malhotra B, Gandelman K, Sachse R, et al. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. *J Clin Pharmacol*. 2009 Apr;49(4):477-82. PMID: 19246724.
68. Lubeck DP, Prebil LA, Peeples P, et al. A health related quality of life measure for use in patients with urge urinary incontinence: a validation study. *Qual Life Res*. 1999 Jun;8(4):337-44. PMID: 10472166.
69. Lowe EM, Anand P, Terenghi G, et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. *Br J Urol*. 1997 Apr;79(4):572-7. PMID: 9126085.
70. Locher JL, Burgio KL, Goode PS, et al. Effects of age and causal attribution to aging on health-related behaviors associated with urinary incontinence in older women. *Gerontologist*. 2002 Aug;42(4):515-21. PMID: 12145379.
71. Litwin MS, Saigal CS, Yano EM, et al. Urologic diseases in America Project: analytical methods and principal findings. *J Urol*. 2005 Mar;173(3):933-7. PMID: 15711342.

72. Litman HJ, Steers WD, Wei JT, et al. Relationship of lifestyle and clinical factors to lower urinary tract symptoms: results from Boston Area Community Health survey. *Urology*. 2007 Nov;70(5):916-21. PMID: 17919693.
73. Li Y, Cai X, Glance LG, et al. Gender differences in healthcare-seeking behavior for urinary incontinence and the impact of socioeconomic status: a study of the Medicare managed care population. *Med Care*. 2007 Nov;45(11):1116-22. PMID: 18049354.
74. Krauwinkel WJ, Smulders RA, Mulder H, et al. Effect of age on the pharmacokinetics of solifenacin in men and women. *Int J Clin Pharmacol Ther*. 2005 May;43(5):227-38. PMID: 15906588.
75. Kraus SR, Markland A, Chai TC, et al. Race and ethnicity do not contribute to differences in preoperative urinary incontinence severity or symptom bother in women who undergo stress incontinence surgery. *Am J Obstet Gynecol*. 2007 Jul;197(1):92 e1-6. PMID: 17618773.
76. Kobelt G, Fianu-Jonasson A. Treatment of stress urinary incontinence with non-animal stabilised hyaluronic acid/dextranomer (NASHA/Dx) gel : An analysis of utility and cost. *Clin Drug Investig*. 2006;26(10):583-91. PMID: 17163292.
77. Kobata SA, Girao MJ, Baracat EC, et al. Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Dopplervelocimetry analysis. *Maturitas*. 2008 Nov 20;61(3):243-7. PMID: 18845407.
78. Kinchen KS, Long S, Orsini L, et al. A retrospective claims analysis of the direct costs of stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2003 Dec;14(6):403-11. PMID: 14677002.
79. Kinchen KS, Long S, Chang S, et al. The direct cost of stress urinary incontinence among women in a Medicaid population. *Am J Obstet Gynecol*. 2005 Dec;193(6):1936-44. PMID: 16325594.
80. Khullar V, Abbot D, Cardoza LD, et al. Perineal ultrasound measurement of the urethral sphincter in women with urinary incontinence: An aid to diagnosis? Twenty-Fifth Annual Meeting of the British Medical Ultrasound Society, Eastbourne (UK), 7-9 Dec 1993. (World Meeting Number 934 5039).
81. Kerbusch T, Wahlby U, Milligan PA, et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. *Br J Clin Pharmacol*. 2003 Dec;56(6):639-52. PMID: 14616424.
82. Karantanis E, Fynes M, Moore KH, et al. Comparison of the ICIQ-SF and 24-hour pad test with other measures for evaluating the severity of urodynamic stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2004 Mar-Apr;15(2):111-6; discussion 6. PMID: 15014938.
83. Kapoor DS, Sultan AH, Thakar R, et al. Management of complex pelvic floor disorders in a multidisciplinary pelvic floor clinic. *Colorectal Dis*. 2008 Feb;10(2):118-23. PMID: 18199292.

84. Kang Y. Knowledge and attitudes about urinary incontinence among community-dwelling Korean American women. *J Wound Ostomy Continence Nurs.* 2009 Mar-Apr;36(2):194-9. PMID: 19287269.
85. Jones D, Perese EF. Promoting self-management of urinary incontinence in a geropsychiatric day treatment program. *J Psychosoc Nurs Ment Health Serv.* 2003 May;41(5):38-43. PMID: 12743965.
86. Johnson TM, 2nd, Kincade JE, Bernard SL, et al. Self-care practices used by older men and women to manage urinary incontinence: results from the national follow-up survey on self-care and aging. *J Am Geriatr Soc.* 2000 Aug;48(8):894-902. PMID: 10968292.
87. Jarmy-Di Bella ZI, Girao MJ, Di Bella V, et al. Hormonal influence on periurethral vessels in postmenopausal incontinent women using Doppler velocimetry analysis. *Maturitas.* 2007 Mar 20;56(3):297-302. PMID: 17092664.
88. Isherwood PJ, Rane A. Comparative assessment of pelvic floor strength using a perineometer and digital examination. *BJOG.* 2000 Aug;107(8):1007-11. PMID: 10955433.
89. Huang AJ, Subak LL, Wing R, et al. An intensive behavioral weight loss intervention and hot flushes in women. *Arch Intern Med.* 2010 Jul 12;170(13):1161-7. PMID: 20625026.
90. Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. *Urology.* 2006 Aug;68(2):318-23. PMID: 16904444.
91. Haywood KL, Garratt AM, Lall R, et al. EuroQol EQ-5D and condition-specific measures of health outcome in women with urinary incontinence: reliability, validity and responsiveness. *Qual Life Res.* 2008 Apr;17(3):475-83. PMID: 18274881.
92. Handa VL, Barber MD, Young SB, et al. Paper versus web-based administration of the Pelvic Floor Distress Inventory 20 and Pelvic Floor Impact Questionnaire 7. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Oct;19(10):1331-5. PMID: 18488134.
93. Grocela JA, Kanji A, Ternullo J. Prediction of Medicare drug formulary drugs for treatment of overactive bladder. *J Urol.* 2006 Jul;176(1):252-5; discussion 5-6. PMID: 16753413.
94. Goldstein SR, Neven P, Zhou L, et al. Raloxifene effect on frequency of surgery for pelvic floor relaxation. *Obstet Gynecol.* 2001 Jul;98(1):91-6. PMID: 11430963.
95. Geller EJ, Barbee ER, Wu JM, et al. Validation of telephone administration of 2 condition-specific quality-of-life questionnaires. *Am J Obstet Gynecol.* 2007 Dec;197(6):632 e1-4. PMID: 18060958.
96. Fu X, Rezapour M, Wu X, et al. Expression of estrogen receptor-alpha and -beta in anterior vaginal walls of genuine stress incontinent women. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Oct;14(4):276-81; discussion 81. PMID: 14530841.
97. Fader M, Clarke-O'Neill S, Cook D, et al. Management of night-time urinary incontinence in residential settings for older people: an investigation into the effects of different pad changing regimes on skin health. *J Clin Nurs.* 2003 May;12(3):374-86. PMID: 12709112.

98. Espuna-Pons M, Rebollo P, Puig-Clota M, et al. Eliciting Women's Preferences for Treatment of Stress Urinary Incontinence with the Method of Paired Comparison. 31st Annual Meeting of the International Urogynecological Association, Athens Hilton Hotel, Athens (Greece), 6-9 Sep 2006.
99. Engstrom G, Henningsohn L, Steineck G, et al. Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. *BJU Int.* 2005;95:810-5. PMID: 15794788.
100. Engberg S, Sereika S, Weber E, et al. Prevalence and recognition of depressive symptoms among homebound older adults with urinary incontinence. *J Geriatr Psychiatry Neurol.* 2001 Fall;14(3):130-9. PMID: 11563436.
101. Ellerkmann RM, McBride AW, Dunn JS, et al. A comparison of anticipatory and postprocedure pain perception in patients who undergo urodynamic procedures. *Am J Obstet Gynecol.* 2004 Apr;190(4):1034-8. PMID: 15118637.
102. Dumoulin C, Seaborne DE, Quirion-DeGirardi C, et al. Pelvic-floor rehabilitation, Part 1: Comparison of two surface electrode placements during stimulation of the pelvic-floor musculature in women who are continent using bipolar interferential currents. *Phys Ther.* 1995 Dec;75(12):1067-74. PMID: 7501709.
103. Duggan PM, Wilson PD, Norton P, et al. Utilization of preoperative urodynamic investigations by gynecologists who frequently operate for female urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Oct;14(4):282-7; discussion 6-7. PMID: 14530842.
104. Doroshenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of tiroprium chloride. *Clin Pharmacokinet.* 2005;44(7):701-20. PMID: 15966754.
105. Diokno A, Yuhico M, Jr. Preference, compliance and initial outcome of therapeutic options chosen by female patients with urinary incontinence. *J Urol.* 1995 Nov;154(5):1727-30; discussion 31. PMID: 7563333.
106. Dietz HP, Jarvis SK, Vancaillie TG. The assessment of levator muscle strength: a validation of three ultrasound techniques. *Int Urogynecol J Pelvic Floor Dysfunct.* 2002;13(3):156-9; discussion 9. PMID: 12140708.
107. Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. *Pharmacotherapy.* 2005 Apr;25(4):511-9. PMID: 15977912.
108. Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). *Qual Life Res.* 2005 Apr;14(3):849-55. PMID: 16022077.
109. Coyne KS, Matza LS, Thompson C, et al. The responsiveness of the OAB-q among OAB patient subgroups. *Neurourol Urodyn.* 2007;26(2):196-203. PMID: 17016794.
110. Clarke-O'Neill S, Pettersson L, Fader M. An evaluation of disposable pads for women with light incontinence. *Nurs Times.* 2003 May 13-19;99(19):69-72. PMID: 12768980.
111. Chen Y, DeSautel M, Anderson A, et al. Collagen synthesis is not altered in women with stress urinary incontinence. *Neurourol Urodyn.* 2004;23(4):367-73. PMID: 15227656.

112. Cawello W, Auer S, Hammes W, et al. Multiple does pharmacokinetics of fesoterodine in human subjects [abstract]. *Naunyn Schmiedebergs Arch Pharmacol.* 2002;365(Suppl 1):428.
113. Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. *BJU Int.* 2005 Mar;95(4):591-6. PMID: 15705086.
114. Cam C, Sakalli M, Ay P, et al. Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population. *Neurourol Urodyn.* 2007;26(1):129-33. PMID: 17083117.
115. Bulmer PJ, James M, Ellis-Jones J, et al. A randomized trial comparing the effectiveness and preference of a touch-screen computer system with a leaflet for providing women with information on urinary symptoms suggestive of detrusor instability. *BJU Int.* 2001 Oct;88(6):532-5. PMID: 11678745.
116. Buckley BS, Lapitan MC. Prevalence of urinary and faecal incontinence and nocturnal enuresis and attitudes to treatment and help-seeking amongst a community-based representative sample of adults in the United Kingdom. *Int J Clin Pract.* 2009 Apr;63(4):568-73. PMID: 19175680.
117. Brady CM, Apostolidis AN, Harper M, et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. *BJU Int.* 2004 Apr;93(6):770-6. PMID: 15049988.
118. Bradley CS, Arya LA, Rovner ES, et al. Questionnaire for female urinary incontinence diagnosis (QUID): Diagnostic accuracy compared to clinical assessment. 23rd Annual Meeting of the American Urogynecologic Society, San Francisco, CA (USA), 17-19 Oct 2002. (World Meeting Number 000 6467).
119. Borello-France DF, Handa VL, Brown MB, et al. Pelvic-floor muscle function in women with pelvic organ prolapse. *Phys Ther.* 2007 Apr;87(4):399-407. PMID: 17341510.
120. Bo K, Maanum M. Does vaginal electrical stimulation cause pelvic floor muscle contraction? A pilot study. *Scand J Urol Nephrol Suppl.* 1996;179:39-45. PMID: 8908663.
121. Blanes L, Pinto Rde C, Santos VL. Urinary incontinence knowledge and attitudes in Sao Paulo. *Ostomy Wound Manage.* 2001 Dec;47(12):43-51. PMID: 11889727.
122. Bhandari H, Li K, Tincello D. Maximum bladder volume as surrogate screening test for detrusor overactivity. *Neurourology and Urodynamics*; 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. 29.
123. Basu M, Duckett JR. Barriers to seeking treatment for women with persistent or recurrent symptoms in urogynaecology. *BJOG.* 2009 Apr;116(5):726-30. PMID: 19220235.
124. Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). *Am J Obstet Gynecol.* 2005 Jul;193(1):103-13. PMID: 16021067.

125. Barber MD, Kuchibhatla MN, Pieper CF, et al. Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders. *Am J Obstet Gynecol.* 2001 Dec;185(6):1388-95. PMID: 11744914.
126. Avedisian L, Kowalsky DS, Albro RC, et al. Abdominal strengthening using the AbVice machine as measured by surface electromyographic activation levels. *J Strength Cond Res.* 2005 Aug;19(3):709-12. PMID: 16095429.
127. Armstrong SM, Miller JM, Benson K, et al. Revisiting reliability of quantified perineal ultrasound: Bland and Altman analysis of a new protocol for the rectangular coordinate method. *Neurourol Urodyn.* 2006;25(7):731-8. PMID: 16897749.
128. Araki I, Zakoji H, Komuro M, et al. Lower urinary tract symptoms in men and women without underlying disease causing micturition disorder: a cross-sectional study assessing the natural history of bladder function. *J Urol.* 2003 Nov;170(5):1901-4. PMID: 14532803.
129. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. *J Urol.* 2005 Sep;174(3):977-82; discussion 82-3. PMID: 16094018.
130. Antonakos CL, Miller JM, Sampsel CM. Indices for studying urinary incontinence and levator ani function in primiparous women. *J Clin Nurs.* 2003 Jul;12(4):554-61. PMID: 12790869.
131. Anger JT, Saigal CS, Madison R, et al. Increasing costs of urinary incontinence among female Medicare beneficiaries. *J Urol.* 2006 Jul;176(1):247-51; discussion 51. PMID: 16753411.
132. Aboseif SR, Kim DH, Rieder JM, et al. Sacral neuromodulation: cost considerations and clinical benefits. *Urology.* 2007 Dec;70(6):1069-73; discussion 73-4. PMID: 18158016.
133. Abdel-Mageed AB, Bajwa A, Shenassa BB, et al. NF-kappaB-dependent gene expression of proinflammatory cytokines in T24 cells: possible role in interstitial cystitis. *Urol Res.* 2003 Oct;31(5):300-5. PMID: 14574533.
134. Zhu L, Lang J, Feng R, et al. Estrogen receptor in pelvic floor tissues in patients with stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 Sep-Oct;15(5):340-3. PMID: 15580421.
135. Reuben DB, Frank JC, Hirsch SH, et al. A randomized clinical trial of outpatient comprehensive geriatric assessment coupled with an intervention to increase adherence to recommendations. *J Am Geriatr Soc.* 1999 Mar;47(3):269-76. PMID: 10078887.
136. Finazzi-Agro E, Rocchi C, Pachatz C, et al. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. *Neurourol Urodyn.* 2009;28(4):320-4. PMID: 19090588.

Appendix C. Analysis of Results From Ongoing Studies

Appendix Table C1. Distribution of studies of nonsurgical treatments for UI closed in www.clinicaltrials.gov on May 20, 2010

Categories	Type	Frequency	Percent
Gender	Both	95	57.23
	Female	71	42.77
Age Groups	Adult	15	9.04
	Adult Senior	147	88.55
	Child Adult Senior	4	2.41
Diagnosis	Incontinence	3	1.81
	Overactive Bladder	96	57.83
	Stress Urinary Incontinence	13	7.83
	Urge Incontinence	4	2.41
	Urinary Incontinence	50	30.12
Funding Sources	Industry	122	73.49
	NIH	5	3.01
	NIH/Other	1	0.6
	Other	23	13.86
	Other/Industry	10	6.02
	Other/NIH	1	0.6
	Other/U.S. Fed	1	0.6
	Other Unknown/U.S. Fed	1	0.6
Study Types	Interventional	145	87.35
	Observational	21	12.65
Phases of Clinical Trials	Phase I	9	6.57
	Phase II	32	23.36
	Phase III	59	43.07
	Phase II/Phase III	3	2.19
	Phase IV	32	23.36
	Phase I/Phase II	2	1.46
Interventions	Behavioral	8	5.3
	Biological	4	2.65
	Device	10	6.62
	Dietary supplement	1	0.66
	Drug	121	80.13
	Genetic	1	0.66
	Other	4	2.65
	Procedure	2	1.32
Recruitment	Active, not recruiting	26	15.66
	Completed	120	72.29
	Enrolling by invitation	5	3.01
	Terminated	12	7.23
	Withdrawn	3	1.81
Study Results	Has Results	7	4.22
	No Results Available	159	95.78
Publication	No	138	83.13
	Yes	28	16.87

Note: The numbers may not round to the same sum of 166 studies because of missing information.

Appendix Table C2. Posting of results of UI studies by study category in www.clinicaltrial.gov

Categories	Type	Has results	No results available	Total	% with results
Gender	Both	7	88	95	7.4
	Female	0	71	71	0.0
Age	Adult	0	15	15	0.0
	Adult/Senior	7	140	147	4.8
	Child/Adult/Senior	0	4	4	0.0
Diagnosis	Incontinence	0	3	3	0.0
	Overactive Bladder	6	90	96	6.3
	Stress Urinary Incontinence	0	13	13	0.0
	Urge Incontinence	0	4	4	0.0
	Urinary Incontinence	1	49	50	2.0
Sponsorship	Industry	6	116	122	4.9
	NIH	0	5	5	0.0
	NIH/Other	0	1	1	0.0
	Other	0	23	23	0.0
	Other/Industry	0	10	10	0.0
	Other/NIH	1	0	1	100.0
	Other/U.S. Fed	0	1	1	0.0
	Other/Unknown/U.S. Fed	0	1	1	0.0
Study Type	U.S. Fed	0	2	2	0.0
	Interventional	7	138	145	4.8
Phase of Clinical Trials	Observational	0	21	21	0.0
	Phase I	0	9	9	0.0
Intervention	Phase I/Phase II	0	2	2	0.0
	Phase II	1	31	32	3.1
	Phase II/Phase III	0	3	3	0.0
	Phase III	4	55	59	6.8
	Phase IV	1	31	32	3.1
	Behavioral	0	8	8	0.0
Recruitment	Biological	1	3	4	25.0
	Device	0	10	10	0.0
	Dietary Supplement	0	1	1	0.0
	Drug	5	116	121	4.1
	Genetic	0	1	1	0.0
	Other	1	3	4	25.0
	Procedure	0	2	2	0.0
	Active, not recruiting	0	26	26	0.0
Publication	Completed	7	113	120	5.8
	Enrolling by invitation	0	5	5	0.0
	Terminated	0	12	12	0.0
	Withdrawn	0	3	3	0.0
Publication	No	4	134	138	2.9
	Yes	3	25	28	10.7

Appendix Table C3. Reporting of results by sponsors of closed studies of UI (sorted by total number of funded studies, shown if more than one study was funded)

Sponsors	Has results	No results available	Total	% with results
Total	7	159	166	4
Pfizer	3	26	29	10
Astellas Pharma, Inc.	0	14	14	0
Eli Lilly and Company/Boehringer Ingelheim Pharmaceuticals	0	12	12	0
GlaxoSmithKline	0	6	6	0
Allergan	1	3	4	25
Alza Corporation, DE, USA	0	4	4	0
Eli Lilly and Company	0	4	4	0
Duramed Research	0	3	3	0
Merck	0	3	3	0
Novartis/Procter and Gamble	0	3	3	0
Ono Pharma	0	3	3	0
Uroplasty, Inc	0	3	3	0
Astellas Pharma Inc./Astellas Pharma Europe BV	0	2	2	0
Astellas Pharma Inc./Astellas Pharma Korea, Inc.	0	2	2	0
Bayer	0	2	2	0
Cleveland Clinic Florida/Astellas Pharma US, Inc.	0	2	2	0
Department of Veterans Affairs	0	2	2	0
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	0	2	2	0
Kissei Pharmaceutical Co., Ltd.	0	2	2	0
Medtronic Neuro	0	2	2	0
Novartis	0	2	2	0
Sanofi-Aventis	0	2	2	0
University of Michigan	0	2	2	0
William Beaumont Hospitals	0	2	2	0
Watson Pharmaceuticals	1	1	2	50

Appendix Table C4. Publication of results in peer reviewed journals by categories of studies of UI

Category	Type	Not Published in peer reviewed journals	Published in peer review journals	Total	% published
Gender	Both	80	15	95	16
	Female	58	13	71	18
Age	Adult	14	1	15	7
	Adult/Senior	121	26	147	18
	Child/Adult/Senior	3	1	4	25
Diagnosis	Incontinence	3	0	3	0
	Overactive Bladder	80	16	96	17
	Stress Urinary Incontinence	12	1	13	8
	Urge Incontinence	4	0	4	0
	Urinary Incontinence	39	11	50	22
Sponsorship	Industry	105	17	122	14
	NIH	1	4	5	80
	NIH/Other	1	0	1	0
	Other	18	5	23	22
	Other/Industry	9	1	10	10
	Other/NIH	1	0	1	0
	Other/U.S. Fed	1	0	1	0
	Other/Unknown/U.S. Fed	1	0	1	0
Study Type	Interventional	119	26	145	18
	Observational	19	2	21	10
Phase of Clinical Trials	Phase I	9	0	9	0
	Phase I Phase II	2	0	2	0
	Phase II	30	2	32	6
	Phase III Phase III	1	2	3	67
	Phase III	45	14	59	24
	Phase IV	25	7	32	22
Intervention	Behavioral	4	4	8	50
	Biological	4	0	4	0
	Device	10	0	10	0
	Dietary Supplement	1	0	1	0
	Drug	99	22	121	18
	Genetic	1	0	1	0
	Other	4	0	4	0
	Procedure	2	0	2	0
Recruitment	Active, not recruiting	24	2	26	8
	Completed	95	25	120	21
	Enrolling by invitation	5	0	5	0
	Terminated	12	0	12	0
	Withdrawn	2	1	3	33

Appendix Table C5. Publication of results in peer reviewed journals by sponsors of studies of UI (sorted by total number of sponsored studies; shown if more than one study was sponsored)

Sponsors	Not published in	Published in	Total	% published
	peer review journals	peer review journals		
	No	Yes		
Total	138	28	166	17
Pfizer	25	4	29	14
Astellas Pharma, Inc.	10	4	14	29
Eli Lilly and Company/Boehringer Ingelheim Pharmaceuticals	11	1	12	8
GlaxoSmithKline	6	0	6	0
Allergan	4	0	4	0
Alza Corporation, DE, USA	3	1	4	25
Eli Lilly and Company	3	1	4	25
Duramed Research	3	0	3	0
Merck	3	0	3	0
Novartis/Procter and Gamble	2	1	3	33
Ono Pharma	3	0	3	0
Uroplasty, Inc.	3	0	3	0
Astellas Pharma Inc./Astellas Pharma Europe BV	2	0	2	0
Astellas Pharma Inc./Astellas Pharma Korea, Inc.	1	1	2	50
Bayer	2	0	2	0
Cleveland Clinic Florida/Astellas Pharma US, Inc.	1	1	2	50
Department of Veterans Affairs	1	1	2	50
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	0	2	2	100
Kissei Pharmaceutical Co., Ltd.	2	0	2	0
MedtronicNeuro	2	0	2	0
Novartis	1	1	2	50
Sanofi-Aventis	2	0	2	0
University of Michigan	0	2	2	100
Watson Pharmaceuticals	0	2	2	100
William Beaumont Hospitals	2	0	2	0

Appendix D. Analytical Framework

Table D1 Algorithm to define eligibility of studies

Research Question.

What constitutes an adequate diagnostic evaluation in the primary care setting on which to base treatment of UI?

Verification/Selection of Study Eligibility

Criteria 1 - Confirm eligibility of the target population

Eligible descriptors:

Adult women in the community	Yes	No	Combined
------------------------------	-----	----	----------

Elderly women in the community	Yes	No	Combined
--------------------------------	-----	----	----------

If NO – exclude

Criteria 2 - Confirm eligibility of the outcomes

Eligible descriptors:

Diagnosis of urinary incontinence	Yes	No	Combined
-----------------------------------	-----	----	----------

Incidence of urinary incontinence	Yes	No	Combined
-----------------------------------	-----	----	----------

If NO – exclude

Criteria 3 - Confirm eligibility of diagnostic strategies

Questionnaire

Scale

Diary

Interview

Pad test

Multichannel urodynamics

If NO – exclude

Criteria 4 – Confirm eligibility of the outcomes assessment:

Eligible descriptors:

True positive	Yes	No
---------------	-----	----

True negative	Yes	No
---------------	-----	----

False positive	Yes	No
----------------	-----	----

False negative	Yes	No
----------------	-----	----

Sensitivity	Yes	No
-------------	-----	----

Specificity	Yes	No
-------------	-----	----

Positive predictive likelihood of the test	Yes	No
--	-----	----

Validity of the scale	Yes	No
-----------------------	-----	----

Validity of the questionnaire	Yes	No
-------------------------------	-----	----

Reliability of the scale	Yes	No
--------------------------	-----	----

Reliability of the questionnaire	Yes	No
----------------------------------	-----	----

If NO for all descriptors – exclude

Criteria 5. Confirm eligible level of evidence

Eligible descriptors:

Randomized controlled clinical trials	Yes	No
---------------------------------------	-----	----

Multicenter controlled clinical trials	Yes	No
--	-----	----

Large (>100 subjects) observational studies	Yes	No
---	-----	----

Case-control studies with >10 cases	Yes	No
-------------------------------------	-----	----

If NO for all descriptors – exclude

2-3. How effective is the pharmacologic treatment of UI? How effective is the nonpharmacologic treatment of UI?

Verification/Selection of Study Eligibility

Criteria 1 - Confirm eligibility of the target population

Eligible descriptors:

Adult women with urinary incontinence in the community	Yes	No	Combined
Elderly women with urinary incontinence in the community	Yes	No	Combined
If NO – exclude			

Criteria 2 – Confirm eligibility of the outcomes

Eligible descriptors:

Prevalence of urinary incontinence/types	Yes	No	Combined
Progression of urinary incontinence/types	Yes	No	Combined
Improvement in urinary incontinence/types	Yes	No	Combined
Continence	Yes	No	Combined
Changes in severity or frequency of urinary incontinence/types	Yes	No	Combined
Quality of life related to urinary incontinence/types	Yes	No	Combined
Adverse events	Yes	No	Combined
If NO – exclude			

Criteria 3 – Confirm eligibility of interventions

Eligible drugs and nonpharmacologic treatments

If NO – exclude

Criteria 4 – Confirm eligible level of evidence

Eligible descriptors for clinical outcomes:

Randomized controlled clinical trials	Yes	No	
Multicenter controlled clinical trials	Yes	No	
Large (>100 subjects) observational studies	Yes	No	

If No for all descriptors – exclude

If adverse events reported – include

Table D2 Definitions of population, interventions, comparators, outcomes, and settings (PICOS) framework

Population(s):

For KQ1. Adult and elderly women with symptoms of UI.

For KQ2 and KQ3. Adult and elderly women with diagnosed UI.

Interventions:

For KQ1 about diagnostic methods, the method that was defined as the gold standard

Gold standard

Multichannel urodynamics

Bladder diary

For KQ2 and KQ3 about treatments for urinary incontinence:

Variable	Definition
Health education	Education that increases the awareness and favorably influences the attitudes and knowledge relating to the early detection and prevention of urinary incontinence
Behavioral therapy	The application of behavioral changes to detect and manage incontinence, including: education about urinary structure and function; development of individualized diaries of daily dietary, physical activities, urinary habits; pelvic floor muscle exercises; voiding schedules: prompted, timed, habit retraining, patterned urge response toileting
Biofeedback	Process by which a person uses biofeedback information to gain voluntary control over the function of pelvic floor muscles and urination process
Pelvic floor muscle training for urinary incontinence	A systematic program of pelvic floor muscle exercises (Kegel exercises) designed to improve the strength and coordination of the pelvic floor muscles in order to improve urinary sphincter function and to control urgency
Vaginal cones	Insertion of vaginal cone (weighted device) into the vagina and contraction of the pelvic floor muscles in an effort to hold the device in place
Electrical stimulation	Application of electric current in treatment without the generation of perceptible heat Using low-voltage electric current to stimulate the correct group of muscles by using an anal or vaginal probe for delivery
Urethral plugs and patches	Insertion of plastic shapes into the urethra to stop the flow of urine or placed externally at the urinary meatus to prevent urine leakage; used for female stress urinary incontinence
Pessaries	A plastic or silicone device that is inserted into the vagina to provide support to the uterus, vagina, bladder, or rectum when there is pelvic organ prolapse; special pessaries with knobs are available to treat urinary incontinence
Magnetic stimulation	Stimulation with a brief magnetic field on the pelvic floor muscles and sacral roots without insertion of an anal or vaginal probe
Urethral bulking: Transurethral or periurethral injection techniques for women	Artificially inflating the submucosal tissues of the bladder neck; FDA-approved urethral bulking agents include collagen (Contigen [®]), autologous fat, and carbon bead particles (Durasphere [®]).
Topical estrogen therapy	Topical vaginal administration of estrogen
Pharmacological interventions	Ditropan [®] (oxybutynin chloride) Sanctura [®] (trospium chloride) Enablex [®] (darifenacin) Vesicare [®] (solifenacin succinate) Fesoterodine Tolterodine
Other tested pharmaceuticals	Propiverine Botulinum toxin injections Tricyclic antidepressants Imipramine hydrochloride

Devices that have been examined in women with urinary incontinence available at <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070852.htm>

Classification (21 CFR)	Class	Product Code	Description
Gastroenterology-Urology Devices			
876.5270 Implanted electrical urinary continence device	III	EZT	Pacemaker, bladder
III	EZW	Stimulator, electrical, implantable, for incontinence	
876.5280 Implanted mechanical/hydraulic urinary continence device	III	EZY	Device, incontinence, mechanical/hydraulic
	III	LNM	Agent, bulking, injectable for gastro-urology use
	III	OCK	Transurethral occlusion insert, urinary incontinence-control, female
Classification (21 CFR)	Class	Product Code	Description
Gastroenterology-Urology Devices			
876.5310 Nonimplanted, peripheral electrical continence device	II	NAM	Stimulator, peripheral nerve, nonimplanted, for pelvic floor dysfunction
876.5320 Nonimplanted electrical continence device	II	KPI	Stimulator, electrical, nonimplanted, for incontinence
876.5920 Protective garment for incontinence	I 510(k) Exempt	EYQ	Garment, protective, for incontinence
N/A	Unclassified	MNG	External urethral occluder, urinary incontinence-control, female
Obstetrical and Gynecological Devices			
884.1425 Perineometer	II	HIR	Perineometer
884.3575 Vaginal pessary	II	HHW	Pessary, vaginal

Comparator

For KQ1 about diagnostic methods, the index methods that were tested:

Questionnaires
Checklists and scales
Self-reported UI during a clinical examination
Provocation stress test
Frequency volume chart
Pad tests
Paper towel test
Ultrasound

For KQ2 and KQ3 about treatments:

Efficacy	Placebo, no active treatment, or regular care
Comparative effectiveness	Active pharmacological treatment, education, behavioral therapy, biofeedback, bladder retraining (Kegel exercises), electrical stimulation, pads, and urethral plugs and pessaries in women

Outcomes

Outcomes for KQ1 about diagnostic methods:

True positive for any, stress, and urgency incontinence
True negative for any, stress, and urgency incontinence
False positive for any, stress, and urgency incontinence
False negative for any, stress, and urgency incontinence
Sensitivity for any, stress, and urgency incontinence
Specificity for any, stress, and urgency incontinence
Positive predictive likelihood ratio for any, stress, and urgency incontinence
Primary outcomes after treatments (clinical outcomes):
Continence

Quality of life: measured by using a validated generic or condition-specific measure of quality of life developed to address issues related specifically to UI

Secondary outcomes	Definition
Remission of incontinence	Diminution of symptoms and signs of incontinence
Contained incontinence	Urine contained with pads or appliances
Dependent continence	Dry with toileting assistance, behavioral treatment, and/or medications
Independent continence	Dry, not dependent on ongoing treatment
Symptoms of incontinence ^{1,2}	The subjective indicator of incontinence or change in its severity, as perceived by the patient, caregiver, or partner, and may lead her to seek help from health-care professionals
Signs of incontinence	Observed by the physician, including simple means, to verify symptoms and quantify them
Urodynamic observations	Observations made during urodynamic studies that have a number of possible underlying causes and do not represent a definitive diagnosis of a disease
<hr/> Measures of the frequency, severity, and impact of urinary incontinence²	
Micturition time chart	Records of times of micturitions (day and night) for at least 24 hours
Frequency volume chart (FVC)	Records of volumes voided and the time of each micturition (day and night) for at least 24 hours
Bladder diary	Records of times of micturitions, voided volumes, incontinence episodes, pad usage, and other information, such as fluid intake, the degree of urgency, and the degree of incontinence
Daytime frequency	The number of voids recorded during waking hours, including the last void before sleep and the first void after waking and rising in the morning
24-hour frequency	The total number of daytime voids and episodes of nocturia during a specified 24-hour period
24-hour production	All urine produced during 24 hours
Maximum voided volume	The largest volume of urine voided during a single micturition, as determined either from the frequency/volume chart or the bladder diary

Pad testing	The amount of urine lost during incontinence episodes (comparison of a short provocative test to a 24-hour pad test)
Improvement in incontinence	Reduction frequency and severity of incontinence episodes Reduction in restrictions of daily activities due to incontinence
Progression of incontinence	Increase in frequency and severity of incontinence episodes Increase in restrictions of daily activities because of incontinence Continence not achieved No reduction in the frequency and severity of incontinent episodes

Harms

Adverse events resulting from drugs
Adverse events resulting from nonpharmacological treatments

Settings

Primary care clinic
Specialized clinic (nurse practitioners)
Cointerventions as reported in the studies

Definition of Terms

The first step is to define what is meant by the term “incontinence,” which has many different implications for different groups of patients. Treating incontinence as a universal construct may impede understanding of the condition and its treatment. For example, incontinence in younger women occurs most likely because of pelvic floor failure, whereas in frail older persons it is often the result of problems with mobility or intellectual performance.

Definitions of urinary incontinence:

Variable	Definition
Symptoms of urinary incontinence ²	Any involuntary leakage of urine
Signs of urinary incontinence	Urine leakage seen during physical examination; this leakage may be urethral or extraurethral
Extra-urethral incontinence	Urine leakage occurring through channels other than the urethra
Uncategorized incontinence	Involuntary urine leakage that cannot be classified into any of the categories listed above on the basis of signs and symptoms
Transient urinary incontinence ^{3,4}	Potentially reversible incontinence resulting from conditions that may resolve if the underlying cause is managed: delirium/confusional state; urinary tract infection (symptomatic); atrophic urethritis/vaginitis; use of pharmaceuticals; psychological conditions, especially depression; excessive urine output related to another medical condition (e.g., congestive heart failure, hyperglycemia); restricted mobility; stool impaction
Established urinary incontinence ^{3,4}	Urinary incontinence that is attributed to bladder or urethral dysfunction, such as: detrusor overactivity; detrusor underactivity; urethral obstruction; urethral incompetence
Stress urinary incontinence	Involuntary urine leakage on physical exertion or effort or with sneezing or coughing
Urgency UI5	Involuntary leakage accompanied by or immediately preceded by urgency
Overflow incontinence ⁶	Urinary incontinence associated with: bladder overdistention; a contractile detrusor; hypotonic or underactive detrusor, occurring secondarily to drugs, fecal impaction, diabetes, lower spinal cord injury, or disruption of the motor innervation of the detrusor muscle
Mixed urinary incontinence ^{1,2}	Involuntary leakage associated with urgency and also with exertion, effort, sneezing, or coughing
Situational urinary incontinence	Incontinence during sexual intercourse or when giggling
Continuous urinary leakage	Continuous urinary leakage
Acute incontinence ⁷	Sudden onset of symptoms related to an illness, treatment, or medication
Chronic incontinence	Persistent urinary incontinence, including disorders of storage (stress and urgency) and of emptying (overflow) and functional and mixed incontinence

Variable	Definition
Severity of incontinence	Measured as incontinent episodes/unit time; pad changes/unit time; pad weight/unit time; number of micturitions/unit time; urine loss on a pad test Also indicated by urodynamically diagnosed detrusor overactivity; urodynamic stress incontinence
Sandvik's severity index ⁸	Multiplied reported frequency (4 levels) by the amount of leakage (2 levels).
Slight incontinence	Leakage of drops a few times a month (~6 g/24 hours, 95% confidence interval 2–9)
Moderate incontinence	Daily leakage or drops (~17 g/24 hours, 95% confidence interval 13–22)
Severe incontinence	Leakage of large amount of urine at least once a week (~56 g/24 hours, 95% confidence interval 44–67)

We prioritized clinical outcomes and measure of quality of life following the FDA guideline for UI9

Endpoint	Potential Advantages	Potential Disadvantages
1-Hour Pad Weight Test (Amount of urine leakage experienced by the subject in 1 hour during a standardized series of activities or exercises in the investigator's office) ²	<ul style="list-style-type: none"> * Objective * Standardized * Assesses severity of urine leakage 	<ul style="list-style-type: none"> * Outcomes other than dryness may not be meaningful to patients * Not correlated with patients' daily activities * Poor to moderate sensitivity * Subject to variability
24-Hour Pad Weight Test (Amount of urine leakage experienced by the subject at home during a 24-hour period; all pads used during the test period are weighed before and after use) Number of Incontinence Episodes/Day (Obtained using a voiding diary)	<ul style="list-style-type: none"> * Objective * Correlated with patients' daily activities * High sensitivity * Assesses severity of urine leakage * Objective * Meaningful to patients * Correlated with patients' daily activities 	<ul style="list-style-type: none"> * Outcomes other than dryness may not be meaningful to patients * Less standardized * Subject to variability * Requires patient compliance * May not directly correlate with the severity of urine leakage * Less standardized * Subject to variability * Requires patient compliance
Number of Pads Used/Day (Obtained using a voiding diary)	<ul style="list-style-type: none"> * Objective * Meaningful to patients * Correlated with patients' daily activities 	<ul style="list-style-type: none"> * May not directly correlate with the severity of urine leakage * Less standardized * Subject to variability * Requires patient compliance
Quality of Life (Assessed using a validated questionnaire)	<ul style="list-style-type: none"> * Meaningful to patients * Standardized * Patient's daily activities taken into account 	<ul style="list-style-type: none"> * Significant placebo effect * Subjective * Subject to variability * Not correlated with the severity of urine leakage
Urodynamics Measure (Measurement such as leak point pressure, cystometric outcome, etc.)	<ul style="list-style-type: none"> * Objective * Standardized * Less subject to variability 	<ul style="list-style-type: none"> * Not Meaningful to patients * Not correlated with patients' daily activities

Table D3. Refinement of the questions following PICOS framework

Question	Population	Intervention (Independent Variable)	Comparator	Outcomes (dependent variables)	Settings
<p>What constitutes an adequate diagnostic evaluation on which to base treatment of UI?</p> <p>Are there validated tools to distinguish stress from urge incontinence in primary care?</p> <p>Do validated tools to distinguish stress from urge incontinence in primary care make a clinical difference in response to treatment?</p>	<p>Adult and elderly women with symptoms of UI</p>	<p>Questionnaires</p> <p>Checklists and scales</p> <p>Self reported UI during clinical exam</p> <p>Provocation stress test</p> <p>Frequency volume chart</p> <p>Pad tests</p> <p>Paper towel test</p> <p>Ultrasound</p>	<p>Gold standard: multichannel urodynamics; Diary</p>	<p>Diagnostic value of the tests, validity of questionnaires for any, stress, urgency, mixed UI</p> <p>Patient outcomes</p>	<p>Primary Care</p> <p>Specialized on UI clinic (nurse practitioners)</p>
<p>How effective is pharmacologic treatment of UI?</p> <p>Do medication interventions with their adverse drug reactions make QoL sense vs. pads?</p> <p>Do medications have evidence of clinical benefit in the treatment of patients with incontinence?</p> <p>Are there clinical predictors of response to the (above) interventions?</p>	<p>Adult and elderly women with diagnosed UI</p> <p>Patient adherence and overcoming of barriers</p> <p>Clinical predictors of the effects :</p> <p>Patient age, comorbidities, baseline disease/condition for UI</p>	<p>Detrol (tolterodine tartrate), Ditropan (oxybutynin chloride), Sanctura (trospium chloride), Enablex (darifenacin), and Vesicare (solifenacin succinate).</p> <p>- Other tested therapy: botulinum toxin injections, tricyclic antidepressant imipramine hydrochloride</p>	<p>Placebo</p> <p>Comparative effectiveness with:</p> <p>Active pharmacological treatment</p> <p>Education</p> <p>Behavioral therapy</p> <p>Biofeedback</p> <p>Bladder retraining ("Kegel exercises")</p> <p>Electrical stimulation</p> <p>Pads</p> <p>Urethral "plugs" and pessaries in females</p>	<p>Continence</p> <p>Quality of life</p> <p>Improvement in frequency and severity of incontinence</p> <p>Adverse effects</p> <p>Differences in outcomes among subgroups of patients with different categories of the predictor (interaction models)</p> <p>Level of outcomes in subgroups of patients with different levels of predictors (subgroup analyses)</p>	<p>Primary Care</p> <p>Specialized on UI clinic (nurse practitioners)</p>

Table D3. Refinement of the questions following PICOS framework (continued)

Question	Population	Intervention (Independent Variable)	Comparator	Outcomes (dependent variables)	Settings
<p>How effective is non-pharmacologic treatment of UI? Do any of the following have evidence of clinical benefit in the treatment of patients with incontinence: Kegel exercises Minimally invasive techniques (e.g. collagen injection, etc.) Pessary</p> <p>Are there clinical predictors of response to the (above) interventions?</p>	<p>Adult and elderly women with diagnosed UI</p> <p>Patient adherence and overcoming of barriers</p> <p>Clinical predictors of the effects :</p> <p>Patient age, comorbidities, baseline disease/condition for UI</p>	<p>Education</p> <p>Behavioral therapy</p> <p>Biofeedback</p> <p>Bladder retraining (“Kegel exercises”)</p> <p>External electrical stimulation (tibial nerve stimulation</p> <p>Urethral “plugs” and pessaries in females</p> <p>Collagen injection devices</p>	<p>No active treatment</p> <p>Comparative effectiveness with: Pharmacological treatment</p> <p>Other nonpharmacological treatments</p>	<p>Continence</p> <p>Quality of life</p> <p>Improvement in frequency and severity of incontinence</p> <p>Adverse effects</p> <p>Differences in outcomes among subgroups of the patients with different categories of the predictor (interaction models)</p> <p>Level of outcomes in subgroups of patients with different levels of predictors (subgroup analyses)</p>	<p>Primary Care</p> <p>Specialized on UI clinic (nurse practitioners)</p>

Table D4. Pharmacological treatments for UI9

Drug Name	Active Ingredients	Dose	Dosage Form/Route
Labeled for UI			
DETROL	TOLTERODINE TARTRATE	1MG	TABLET; ORAL
DETROL	TOLTERODINE TARTRATE	2MG	TABLET; ORAL
DETROL LA	TOLTERODINE TARTRATE	2MG	CAPSULE, EXTENDED RELEASE; ORAL
DETROL LA	TOLTERODINE TARTRATE	4MG	CAPSULE, EXTENDED RELEASE; ORAL
OXYTROL	OXYBUTYNIN	3.9MG/24HR	FILM, EXTENDED RELEASE; TRANSDERMAL
GELNIQUE	OXYBUTYNIN CHLORIDE	10%(100MG/ PACKET)	GEL; TRANSDERMAL
DITROPAN XL	OXYBUTYNIN CHLORIDE	5MG	TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL	OXYBUTYNIN CHLORIDE	10MG	TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL	OXYBUTYNIN CHLORIDE	15MG	TABLET, EXTENDED RELEASE; ORAL
DITROPAN	OXYBUTYNIN CHLORIDE	5MG	TABLET; ORAL
SANCTURA	TROSPIUM CHLORIDE	20MG	TABLET; ORAL
SANCTURA XR	TROSPIUM CHLORIDE	60MG	CAPSULE, EXTENDED RELEASE; ORAL
ENABLEX	DARIFENACIN HYDROBROMIDE	EQ 7.5MG BASE	TABLET, EXTENDED RELEASE; ORAL
ENABLEX	DARIFENACIN HYDROBROMIDE	EQ 15MG BASE	TABLET, EXTENDED RELEASE; ORAL
VESICARE	SOLIFENACIN SUCCINATE	5MG	TABLET; ORAL
VESICARE	SOLIFENACIN SUCCINATE	10MG	TABLET; ORAL
TOVIAZ	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE; ORAL
TOVIAZ	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE; ORAL
Off label use			
BOTOX	Botulinum Toxin Type A	100U/VIAL	VIAL; SINGLE-USE
CYMBALTA	DULOXETINE HYDROCHLORIDE	EQ 20MG BASE	CAPSULE, DELAYED REL PELLETS; ORAL
CYMBALTA	DULOXETINE HYDROCHLORIDE	EQ 30MG BASE	CAPSULE, DELAYED REL PELLETS; ORAL
CYMBALTA	DULOXETINE HYDROCHLORIDE	EQ 60MG BASE	CAPSULE, DELAYED REL PELLETS; ORAL
IMIPRAMINE HYDROCHLORIDE	IMIPRAMINE HYDROCHLORIDE	50MG	TABLET; ORAL
PREMARIN	ESTROGENS, CONJUGATED	0.625MG/GM	CREAM; TOPICAL, VAGINAL
SYNTHETIC CONJUGATED ESTROGENS A	ESTROGENS, CONJUGATED SYNTHETIC A	0.625MG/GM	CREAM; VAGINAL

Pharmacological classification of the drugs for UI that was used by the 14th International Consultation on Incontinence¹⁸ served as a guide to synthesize comparative effectiveness and harms from available treatments. Drug therapy for stress urinary incontinence¹⁸

SEROTONIN-NORADRENALINE UPTAKE INHIBITORS

Duloxetine

Imipramine

ESTROGENS

Estrogen topical

Drugs used in the treatment of OAB/ DO1:

Antimuscarinic drugs

Tolterodine

Trospium

Solifenacin

Darifenacin

Fesoterodine

Propantheline

Drugs with mixed actions

Oxybutynin

Propiverine; Flavoxate

Table D5 Data Synthesis

For question 1 we calculated diagnostic values of different tests to diagnose incontinence:

Sensitivity= $TP/(TP+FN)$

Specificity= $TN/(FP+TN)$

Prevalence= $(TP+FN)/(TP+FN+FP+TN)$

Predictive value positive= $TP/(TP+FP)$

Positive predictive likelihood ratio:

probability of an individual with the condition having a positive test

LR+ = probability of an individual without the condition having a positive test

LR+ = sensitivity

$1 - \text{specificity}$

Clinical interpretations of likelihood ratios¹⁰

LR	Interpretation
> 10	Large and often conclusive increase in the likelihood of disease
5 - 10	Moderate increase in the likelihood of disease
2 - 5	Small increase in the likelihood of disease
1 - 2	Minimal increase in the likelihood of disease
1	No change in the likelihood of disease
0.5 - 1.0	Minimal decrease in the likelihood of disease
0.2 - 0.5	Small decrease in the likelihood of disease
0.1 - 0.2	Moderate decrease in the likelihood of disease
< 0.1	Large and often conclusive decrease in the likelihood of disease

Algorithms of meta-analysis11

Pooled estimate as a weighted average:

$$\theta_{IV} = \frac{\sum_i w_i \theta_i}{\sum_i w_i}$$

Weights are inverse of variance (standard error):

$$w_i = \frac{1}{SE(\theta_i)^2}$$

Standard error of pooled estimate:

$$SE(\theta_{IV}) = \frac{1}{\sqrt{\sum_i w_i}}$$

Heterogeneity (between-study variability) measured by:

$$Q = \sum_i w_i (\theta_i - \theta_{IV})^2$$

Assumptions for random effects model: true effect sizes θ_i have a normal distribution with mean μ and variance τ^2 ; τ^2 is the between-study variance

Between study variance:

$$\tau^2 = \frac{Q - (k - 1)}{\sum_i w_i - \left(\frac{\sum_i w_i^2}{\sum_i w_i} \right)}$$

Where:

w_i are the weights from the fixed effect inverse-variance method

Q is the heterogeneity test statistic from before (either from inverse-variance method or Mantel-Haenszel method)

k is the number of studies, and

τ^2 is set to zero if $Q < k - 1$

Random effect pooled estimate is weighted average:

$$\theta_{DL} = \frac{\sum_i w'_i \theta_i}{\sum_i w'_i}$$

Weights used for the pooled estimate are similar to the inverse-variance, but now incorporate a component for between-study variation:

$$w'_i = \frac{1}{SE(\theta_i)^2 + \tau^2}$$

Standard error of pooled estimate

$$SE(\theta_{DL}) = \frac{1}{\sqrt{\sum_i w'_i}}$$

Meta regression with random effects was obtained using aggregate level data.

Additive component of variance tau2 was estimated:

$$y[i] = a + B*x[i] + u[i] + e[i],$$

where u[i] is a normal error (standard deviations that may vary across units), e[i] is a normal error with variance tau2 to be estimated, assumed equal across units.

t-distribution was used calculating p-values and confidence intervals^{12,13}

Attributable risk was calculated as the outcome events rate in patients exposed to different clinical interventions¹⁴⁻¹⁶

Attributable risk of the outcome = rate of events in patients in the control group x (relative risk - 1)

Number needed to treat to prevent one event of incontinence was calculated as reciprocal to absolute risk differences in rates of outcomes events in the active and control groups:^{15,17}
1/(control group event rate - treatment group event rate).

The number of avoided or excess events (respectively) per 1000 population is the difference between the two event rates multiplied by 1000:

(control group event rate - treatment group event rate)*1000

References

1. Abrams P. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008. 4th ed. [Paris]: Health Publications Ltd. 2009, Committee 1 Epidemiology of Urinary (UI) and Fecal (FI) Incontinence and Pelvic Organ Prolapse (POP).
2. Abrams P, Cardozo L, Fall M, et al. for the Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. *Urology* 2003; 61:37-49.
3. Schorge JO, Schaffer JI, Halvorson LM, et al. Chapter 23. Urinary Incontinence. In: Schorge JO, Schaffer JI, Halvorson LM, et al., eds. *Gynecology* www.accessmedicine.com/content.aspx?aID=3150435.
4. Tarnay CM, Bhatia Narender N. Chapter 45. Urinary Incontinence. In: DeCherney AH, Nathan L, eds. *Current Diagnosis & Treatment Obstetrics & Gynecology*. 10e: www.accessmedicine.com/content.aspx?aID=2390665.

5. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn* 2010; 29(1):4-20.
6. AHCPR Urinary Incontinence in Adults Guideline Update Panel. Managing acute and chronic urinary incontinence. *Am Fam Physician* 1996; 54:1661-72.
7. Resnick NM. Urinary incontinence. In: Beers MH, Jones TV, Berkwits M, et al., eds. *The Merck manual of geriatrics* [online]. Whitehouse Station, NJ: Merck & Co. Inc., 2010. Available at www.merck.com/mkgtr/mmg/home.jsp.
8. Sandvik H, Hunskaar S, Seim A, et al. Validation of a severity index in female urinary incontinence and its implementation in an epidemiological survey. *J Epidemiol Community Health* 1993 Dec; 47(6):497-9.
9. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, et al. Draft Guidance for Industry and FDA Staff - Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence. Food and Drug Administration, 5630 Fishers Lane, Room 1061. Available at: www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070852.htm. Accessed August, 2009, 2009.
10. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. *BMJ* 1994 Jul 9; 309(6947):102.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986 Sep; 7(3):177-88.
12. Knapp G, Biggerstaff BJ, Hartung J. Assessing the amount of heterogeneity in random-effects meta-analysis. *Biom J* 2006 Apr; 48(2):271-85.
13. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. *Stat Med* 2003 Sep 15; 22(17):2693-710.
14. Kahn HA, Sempos CT. *Statistical Methods in Epidemiology (Monographs in Epidemiology and Biostatistics)*. USA: Oxford University Press; 1989.
15. Egger M, Smith GD, Altman DG. *Systematic Reviews in Health Care*. London: NetLibrary, Inc. BMJ Books; 2001.
16. Dawson B, Trapp RG. *Basic & Clinical Biostatistics (LANGE Basic Science)*. 3rd ed. New York: Lange Medical Books-McGraw-Hill; 2004.
17. Ebrahim S. The use of numbers needed to treat derived from systematic reviews and meta-analysis. Caveats and pitfalls. *Eval Health Prof* 2001 Jun; 24(2):152-64.
18. Abrams P. *Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008*. 4th ed. [Paris]: Health Publications Ltd.; 2009.

Appendix E. Abstraction Forms

Data Abstraction Form for Question 1

What constitutes an adequate diagnostic evaluation in the primary care setting on which to base treatment of UI?

(Complete for each study)

Number of the study in the database (PubMed ID, Cochrane accession number, ISBN)_____

First author_____

Year of the publication_____

Purpose/aim of study_____

Sponsorship_____

Conflict of interest_____

Design of the study (check one)

prospective cohort

retrospective cohort

cross-sectional

descriptive study

case-control

case-series

randomized controlled clinical trial

not randomized clinical interventions

other (specify)

Population variables (target population)

Data source for population variables (define)

Recruitment_____

Consent _____

Settings:

Community (general population)_____

Primary clinic_____

Specialized clinic_____

Location:

Country _____

Urban

Rural

Subjects:

Race

Define

African Continental Ancestry Group, % _____

Asian Continental Ancestry Group, % _____

European Continental Ancestry Group, % _____

Ethnicity:

Define

African Americans, % _____

Arabs, % _____

Asian Americans, % _____

Hispanic Americans, % _____

Age:

Mean age, years _____ Standard deviation _____

Age intervals: _____

Health status

Primary Health Condition, Diagnosis

Sample size:

Sampling strategy:

Random

Self-selected

Inclusion criteria: _____

Incontinence (dependent variable)

Definition of incontinence

Urinary _____

Combined _____

“Gold standard” to detect urinary incontinence used in the article _____

Multichannel urodynamics cut points of continence

- Maximal urethral pressure (MUP) _____
- Functional urethral length (FUL) _____
- Maximal cystometric capacity (MCC) _____
- Abdominal leak point pressure (ALPP) _____

Index diagnostic tests for urinary incontinence:

Define _____

Cut points of continence _____

Clinical history

Nature

Duration

Symptoms and their severity

Symptom bothersomeness or impact

Functional and mental status

Medical, surgical and gynecological history

Exacerbating factors: diet, fluid, and medications

Diagnostic tests for urinary incontinence:

- Provocation stress test_____
- Frequency volume chart_____
- Post-void residual volume (PVR)_____
- Distal Urethral Electrical Conductance test_____
- Pad tests_____
- Paper towel test_____
- Ultrasound_____
- Q-Tip test_____

Questionnaire _____

Scales_____

Define_____

For each test provide comparison with “gold standard”:

True positives_____

False positives_____

False negatives_____

True negatives

Sensitivity, %

Specificity, %

Reliability:

Cronbach alpha

Kappa statistics

Correlation coefficients

Inter-observer variability_____

Level of evidence of the individual study (check one)

Interventions:

- I Well-designed randomized controlled trial
- II-1A Well-designed controlled trial with pseudo-randomization
- I-1B Well-designed controlled trial without randomization

Observational studies

- I-2A Well-designed cohort (prospective) study with concurrent controls
- I-2B Well-designed cohort (prospective) study with historical controls
- II-2C Well-designed cohort (retrospective) study with concurrent controls
- II-3 Well-designed case-controlled (retrospective) study
- III Large differences from comparisons between times and/or places
- IY Opinion of respected authorities based in clinical experience

Data Abstraction Form for Questions 2 and 3

How effective is the pharmacological treatment of UI?

How effective is the nonpharmacological treatment of UI?

(Complete for each study)

Number of the study in the database (PubMed ID, Cochrane accession number, ISBN) _____

First author _____

Year of the publication _____

Purpose/aim of study _____

Sponsorship _____

Conflict of interest _____

Design of the study (check one)

prospective cohort

retrospective cohort

cross-sectional

descriptive study

case-control

case-series

randomized controlled clinical trial

not randomized clinical interventions

other (specify)

Length of intervention _____

Length of followup _____

Population variables (target population)

Recruitment of the subjects

Settings

Community (general population) _____

Primary care _____

Specialized clinic _____

Subjects

Race

African Continental Ancestry Group, % _____

Asian Continental Ancestry Group, % _____

European Continental Ancestry Group, % _____

Ethnicity

African Americans, % _____

Arabs, % _____

Asian Americans, % _____

Hispanic Americans, % _____

Age

Health status _____

Sample size:

Inclusion criteria _____

Exclusion criteria _____
Loss of followup _____

Incontinence (dependent variable)

1. Provide the definition of urinary incontinence used in the article.
2. Provide the data source to measure incontinence.
3. Mark how the outcome was reported.

/*Complete with values reported in article with page number in articles where data was extracted for quality control*/

/*Add as many lines for categories as necessary*/

/*Median is calculated when ranges only reported assuming normal distribution*/

/*Increment is analyzed when regression coefficients only reported*/

/*Provide means and standard deviation (95% CI) when reported*/

Methods to assess urinary incontinence:

Self report _____

Medical diagnosis _____

Medical procedure _____

Urinary Incontinence, Incidence

Define

Symptoms _____

Signs _____

Acuity _____

Severity _____

Length _____

Bothersomeness _____

Urinary Incontinence, Progression

Define

Symptoms _____

Signs _____

Acuity _____

Severity _____

Frequency _____

Urinary Continence

Define

Dependent Continence _____

Independent Continence _____

Clinical Interventions (independent variables)

Provide the definition of each variable used in the article.

For drug and devices: Manufacturing company with the address, trade name

Health Education

Define _____

Behavioral Therapy

Define _____

Education _____

Development of individualized diaries of daily dietary, physical activities, urinary habits

Development of individualized voiding schedules

Voiding schedules: prompted, timed, habit retraining

Patterned urge response toileting

Dose of intervention:

Length of therapy _____

Intensity of therapy, section number _____

Biofeedback

Define _____

Dose of intervention:

Length of therapy _____

Intensity of therapy _____

Monitoring device _____

Pelvic Floor Muscle Training

Define _____

Dose of intervention:

Length of training _____ Intensity of training _____

Weight Loss

Define _____

Dose of intervention:

Length of therapy _____

Intensity of therapy _____

Diet Therapy

Define _____

Dose of intervention:

Length of therapy _____

Intensity (dose) of therapy _____

Vaginal Cones

Define _____

Electrical Stimulation

Define _____

Dose of intervention:

Length of therapy _____

Intensity of therapy _____

Inserts Urethral Patch or Urethral Insert

Define _____

Vaginal Pessary

Define _____

Detrol (tolterodine tartrate)

Define _____

Dose of intervention:

Length of therapy _____

Dose _____

Ditropan

Define _____

Dose of intervention:

Length of therapy _____

Dose _____

Sanctura (trospium chloride)

Define _____

Dose of intervention:

Length of therapy _____

Dose _____

Enablex (darifenacin)

Define _____

Dose of intervention:

Length of therapy _____

Dose _____

Vesicare (solifenacin succinate)

Define _____

Dose of intervention:

Length of therapy _____

Dose _____

Botulinum Toxin Injections

Define _____

Dose of intervention:

Length of therapy _____

Intensity (dose) of therapy _____

Oral Estrogen Therapy

Define _____

Dose of intervention:

Length of therapy _____
 Intensity (dose) of therapy _____

Topical Estrogen Therapy
 Define _____
 Dose of intervention:
 Length of therapy _____
 Intensity (dose) of therapy _____

Magnetic Stimulation
 Define _____
 Dose of intervention:
 Length of therapy _____
 Intensity (dose) of therapy _____

Urethral Bulking Procedures
 Define _____
 Dose of intervention:
 Length of therapy _____
 Intensity (dose) of therapy _____

Intervention	Control	Outcomes Definition	Number in Active	Number in Control	Outcome Level in Active Group	Outcome Level in Control Group	Events in Active Group	Events in Control Group	Relative Risk, (95% CI)	Absolute Risk Difference, (95% CI)
		Urinary incontinence								

Quality of the studies:
 For clinical trials
 Random allocation
 Yes
 No
 Intention to treat:
 Yes
 No
 not stated but all subjected included in analysis

Masking of treatment status:
 Double blind
 Single blind
 Open label

Randomization regime _____
 Adequate: computer-generated random numbers or random numbers tables
 Inadequate: alternation, case record numbers, birth dates, or days of the week

Adequacy of randomization _____

Baseline data not reported _____
Baseline data confirmed the adequacy of randomization _____

Allocation concealment _____

Not reported _____

Adequate _____

Not adequate _____

Adequate approaches to concealment of allocation:

Centralized or pharmacy-controlled randomization

Serially-numbered identical containers

On-site computer based system with a randomization sequence that is not readable until allocation

Inferior approaches to concealment of allocation:

Use of alternation

Case record numbers

Birth dates or days of the week

Open random numbers lists

Serially numbered envelopes (even sealed opaque envelopes can be subject to manipulation)

For observational studies

Strategies to reduce bias _____

Relevant characteristics of providers _____

Justification for sample size _____

Level of evidence of the individual study (check one)

Interventions:

I Well-designed randomized controlled trial

II-1A Well-designed controlled trial with pseudo-randomization

I-1B Well-designed controlled trial without randomization

Observational studies

I-2A Well-designed cohort (prospective) study with concurrent controls

I-2B Well-designed cohort (prospective) study with historical controls

II-2C Well-designed cohort (retrospective) study with concurrent controls

II-3 Well-designed case-controlled (retrospective) study

III Large differences from comparisons between times and/or places

IY Opinion of respected authorities based in clinical experience

Appendix F. Evidence Tables and Evidence Figures

Appendix Table F1. Grading the level of evidence for clinical outcomes that were examined in RCTs (direct evidence)

Treatment	Outcome	Assumed risk of bias	Consistency	Statistical heterogeneity relative/absolute scale	Precision	Dose response	Magnitude of the effect	Evidence
Duloxetine vs. placebo	Continence	Low	No	NS/Yes	No	NS	Low	Low
Duloxetine vs. placebo	Improved UI	Low	Yes	NS/Yes	Yes	NS	Low	High
Duloxetine vs. placebo	Discontinuation due to adverse effects	Low	Yes	NS/Yes	Yes	Yes	Moderate	High
Darifenacin vs. placebo	Improved UI	Low	Yes	NS/NS	Yes	NS	Low	High
Darifenacin vs. placebo	Discontinuation due to adverse effects	Low	Yes	NS/NS	NA	Yes	Low	High
Darifenacin vs. placebo	Discontinuation due to failure	Low	Yes	NS/NS	NA	NS	Low	Moderate
Fesoterodine vs. placebo	Continence	Low	Yes	Yes/NS	No		Low	Low
Fesoterodine vs. placebo	Improved UI	Low	Yes	NS/NS	Yes	Yes	Low	High
Fesoterodine vs. placebo	Adverse effects	Low	Yes	Yes/NS	Yes	Yes	Low	High
Fesoterodine vs. placebo	Discontinuation due to adverse effects	Low	Yes	NS/Yes	Yes	Yes	Moderate	High
Fesoterodine vs. placebo	Discontinuation due to failure	Low	No	NS/Yes	NA		Low	Moderate
Oxybutynin vs. placebo	Continence	Low	Yes	NS/NS	Yes		Low	High
Oxybutynin vs. placebo	Improved UI	Low	No	Yes/Yes	No	Yes	Low	Moderate
Oxybutynin vs. placebo	Discontinuation due to adverse effects	Low	Yes	NS/NS	Yes	Yes	Low	High
Propiverine vs. placebo	Continence	Medium	Yes	NS/NS	No		Low	Low
Propiverine vs. placebo	Improved UI	Medium	Yes	NS/NS	Yes		Low	Moderate
Propiverine vs. placebo	Discontinuation due to adverse effects	Medium	Yes	NS/NS	Yes		Moderate	Low
Solifenacin vs. placebo	Continence	Low	Yes	NS/Yes	Yes	Yes	Low	High
Solifenacin vs. placebo	Improved UI	Low	Yes	Yes/NS	No		Low	Low

Appendix Table F1. Grading the level of evidence for clinical outcomes that were examined in RCTs (direct evidence) (continued)

Treatment	Outcome	Assumed risk of bias	Consistency	Statistical heterogeneity relative/absolute scale	Precision	Dose response	Magnitude of the effect	Evidence
Solifenacin vs. placebo	Adverse effects	Low	Yes	Yes/Yes	Yes	Yes	Low	High
Solifenacin vs. placebo	Discontinuation due to adverse effects	Low	Yes	NS/NS	Yes	Yes	Low	High
Solifenacin vs. placebo	Discontinuation due to failure	Low	No	NS/NS	NA		Low	Moderate
Tolterodine vs. placebo	Continence	Low	Yes	NS/NS	Yes		Low	High
Tolterodine vs. placebo	Improved UI	Low	Yes	Yes/Yes	Yes		Low	High
Tolterodine vs. placebo	Adverse effects	Low	Yes	NS/NS	Yes		Low	High
Tolterodine vs. placebo	Discontinuation due to adverse effects	Low	No	NS/NS	NA		Low	High
Tolterodine vs. placebo	Discontinuation due to failure	Low	No	NS/NS	NA		Low	High
Trospium vs. placebo	Continence	Low	Yes	NS/NS	Yes		Low	High
Trospium vs. placebo	Improved UI	Low	Yes	NS/Yes	NA		Low	Low
Trospium vs. placebo	Adverse effects	Low	Yes	Yes/NS	Yes		Low	Moderate
Trospium vs. placebo	Discontinuation due to adverse effects	Low	Yes	NS/NS	Yes			High
Fesoterodine vs. tolterodine	Continence	Medium	Yes	NS/NS	Yes		Low	Low
Fesoterodine vs. tolterodine	Improved UI	Low	Yes	NS/NS	No		Low	High
Fesoterodine vs. tolterodine	Discontinuation due to adverse effects	Low	Yes	NS/NS	No		Low	Moderate
Oxybutynin vs. tolterodine	Improved UI	Low	No	NS/NS	NA		Low	Moderate
Oxybutynin vs. tolterodine	Discontinuation due to adverse effects	Low	Yes	Yes/Yes	Yes		Low	High
Solifenacin vs. tolterodine	Discontinuation due to adverse effects	Low	No	NS/NS	NA		Low	Moderate
Trospium vs. oxybutynin	Discontinuation due to adverse effects	Low	No	NS/NS	NA		Low	Low
Bladder training vs. no active treatment	Improved UI	Medium	Yes	NS/NS	Yes		High	Low
Continence service vs. no active treatment	Continence	Medium	Yes	NS/Yes	NA		Moderate	Moderate
Continence service vs. no active treatment	Improved UI	Medium	Yes	Yes/Yes	NA		Moderate	Low

Appendix Table F1. Grading the level of evidence for clinical outcomes that were examined in RCTs (direct evidence) (continued)

Treatment	Outcome	Assumed risk of bias	Consistency	Statistical heterogeneity relative/absolute scale	Precision	Dose response	Magnitude of the effect	Evidence
Electrical stimulation vs. no active treatment	Continence	Low	Yes	NS/NS	Yes		Moderate	High
Electrical stimulation vs. no active treatment	Improved UI	Low	Yes	NS/NS	Yes		Moderate	High
Magnetic stimulation vs. no active treatment	Improved UI	Medium	Yes	NS/NS	Yes		High	Moderate
Magnetic stimulation vs. no active treatment	Continence	Medium	No	NS/NS	NA		Low	Moderate
Percutaneous electrical stimulation vs. no active treatment	Improved UI	Medium	Yes	NS/NS	Yes		Low	Moderate
PFMT vs. no active treatment	Continence	Medium	Yes	Yes/Yes	Yes		High	High
PFMT vs. no active treatment	Improved UI	Medium	Yes	Yes/Yes	Yes		High	High
PFMT + bladder training vs. no active treatment	Improved UI	Medium	Yes	Yes/Yes	Yes		High	High
PFMT with biofeedback vs. no active treatment	Continence	Medium	No	NS/Yes	NA		High	Low
PFMT with biofeedback vs. no active treatment	Improved UI	Medium	Yes	Yes/Yes	NA		High	High
PFMT with bladder training vs. no active treatment	Continence	Medium	Yes	Yes/Yes	Yes		Moderate	High
Weight Loss vs. no active treatment	Improved UI	Medium	Yes	NS/NS	Yes		High	Moderate
PFMT + bladder training vs. bladder training	Continence	Medium	Yes	NS/NS	NA		Low	High
PFMT + bladder training vs. no active treatment	Improved UI	Medium	Yes	Yes/Yes	Yes		High	High
PFMT vs. electrical stimulation	Continence	Medium	Yes	NS/NS	NA		Low	Moderate
PFMT vs. electrical stimulation	Improved UI	Medium	Yes	NS/NS	NA		Low	Moderate
PFMT vs. vaginal cone	Continence	Medium	No	NS/NS	NA		Low	Moderate
PFMT vs. vaginal cone	Improved UI	Medium	No	NS/NS	NA		Low	Moderate
PFMT with biofeedback vs. PFMT	Continence	Medium	Yes	NS/NS	NA		Low	High

Appendix Table F1. Grading the level of evidence for clinical outcomes that were examined in RCTs (direct evidence) (continued)

Treatment	Outcome	Assumed risk of bias	Consistency	Statistical heterogeneity relative/absolute scale	Precision	Dose response	Magnitude of the effect	Evidence
Supervised PFMT vs. self PFMT	Continence	Medium	No	Yes/Yes	NA		Moderate	High
Supervised PFMT vs. self-PFMT	Improved UI	Medium	No	Yes/Yes	NA		Low	Moderate

Abbreviations: PFMT = Pelvic floor muscle training; NS = Not significant; NA = Not applicable

Appendix Table F2. Review of grey literature

Title references	Type of review	Title	ID	Manufacturer	Trade name	Common name	Classification number
510(k) Summary for Pelvex hometrainer U.S. Food and Drug Administration, 2001 ¹	FDA 510 (K) review	510(k) Summary for pelvex hometrainer	K002043	Purdue Technology Park, West Lafayette, IN	pelvex	Perineometer	884.1425
510(k) summary for Vitala(tm) continence Control Device U.S. Food and Drug Administration, 2008 ²	FDA 510 (K) review	510(k) summary for Vitala(tm) continence Control Device	K083785	ConvaTec Inc. Skillman, Nj	Vitala Continence Control Device	Not reported	EZQ -C.F.R. Section 876.5900
510(k) Summary for uresta pessary U.S. Food and Drug Administration, 2008 ³	FDA 510 (K) review	510(k) Summary for uresta pessary	K081385	EastMed Inc., Halifax, Nova Scotia	Uresta Pessary	Vaginal Pessary	21CFR 884.3575
510(k) Summary for PelvicFlexer U.S. Food and Drug Administration, 2001 ⁴	FDA 510 (K) review	510(k) Summary for PelvicFlexer	K011688	PelvicFlex Inc., Sarasota, FL	PelvicFlexer Exercise Device	Pelvic Muscle Exerciser	884.1425
510(k) Summary for Hollister Contimed Pressure Biofeedback device U.S. Food and Drug Administration, 1996 ⁵	FDA 510 (K) review	510(k) Summary for Hollister Contimed Pressure Biofeedback device	K960311	Hollister Incorporated, Libertyville, IL	Hollister Contimed Pressure Biofeedback device	Not reported	Not reported
510(k) Summary of pathway vaginal emg/stimulation perineometer sensor U.S. Food and Drug Administration, 2000 ⁶	FDA 510 (K) review	510(k) Summary of pathway vaginal emg/stimulation perineometer sensor	K993976	The Prometheus Group, Dover, NH	Pathway Vaginal EMG/Stimulation Perineometer; Pathway Anal EMG/Stimulation Perineometer	Perineometer Sensor	876.5320; 884.1425
501(k) summary for UroMed Alternative Bladder Control Continence Device U.S. Food and Drug Administration, 1997 ⁷	FDA 510 (K) review	501(k) summary for UroMed Alternative Bladder Control Continence Device	K971992	UroMed Corporation, Needham, MA	UroMed Alternative Bladder Control Continence Device	Penile Clamp/Urological Clamp	21 CFR 876.5160

Appendix Table F2. Review of grey literature (continued)

Title references	Type of review	Title	ID	Manufacturer	Trade name	Common name	Classification number
510(k) Summary for InCare Pelvic Floor Therapy System with Desktop Computer U.S. Food and Drug Administration, 1997 ⁸	FDA 510 (K) review	510(k) Summary for InCare Pelvic Floor Therapy System with Desktop Computer	K974048	Hollister Incorporated, Libertyville, IL	InCare Pelvic Floor Therapy System with Desktop Computer	Not reported	876.5320; 884.1425
510(k) summary review for perineometer and vaginal probe U.S. Food and Drug Administration, 1997 ⁹	FDA 510 (K) review	510(k) summary review for perineometer and vaginal probe	K970145	BioSearch Medical Products, Inc., Somerville, NJ	Perineometer and Vaginal Probe	Not reported	884.1425
510(k) summary for vaginal stimulation/emg probe - tampon U.S. Food and Drug Administration, 1997 ¹⁰	FDA 510 (K) review	510(k) summary for vaginal stimulation/emg probe - tampon	K971541	Hollister Incorporated, Libertyville, IL	Vaginal Stimulation/EMG Probe -Tampon		876.5320; 884.1425
510(k) Summary for innoSense pelvic floor stimulation and electromyography system U.S. Food and Drug Administration, 1997 ¹¹	FDA 510 (K) review	510(k) Summary for innoSense pelvic floor stimulation and electromyography system	K971527	Empi Inc., St.Paul, Minnesota	Innosense Pelvic Floor Stimulation and Electromyography System	Pelvic Floor Stimulation and BioFeedback Device	876.5320; 884.1425
510(k) summary for vaginal stimulation/emg probe - small U.S. Food and Drug Administration, 1997 ¹²	FDA 510 (K) review	510(k) summary for vaginal stimulation/emg probe - small	K970602	Hollister Incorporated, Libertyville, IL	Vaginal Stimulation/EMG Probe -Small	Not reported	Not reported
510(k) summary for periform perineometric probe and pelvic floor contraction indicator U.S. Food and Drug Administration, 1998 ¹³	FDA 510 (K) review	510(k) summary for periform perineometric probe and pelvic floor contraction indicator	K981277	NEEN Healthcare, England, UK	Periform	Perineometer Probe	884.1425
510(k) summary review for peritron perineometer U.S. Food and Drug Administration, 1998 ¹⁴	FDA 510 (K) review	510(k) summary review for peritron perineometer	K983052	Cardio Design Pty Ltd	Peritron, Model 9300A with Anal Sensor; Model 9300V with Vaginal Sensor	Not reported	884.1425

Appendix Table F2. Review of grey literature (continued)

Title references	Type of review	Title	ID	Manufacturer	Trade name	Common name	Classification number
510(k) summary for reflex treatment system U.S. Food and Drug Administration, 1999 ¹⁵	FDA 510 (K) review	510(k) summary for reflex treatment system	K994079	DesChutes Medical Products, Inc., Bend, OR	The Reflex Treatment System	Pelvic Muscle Exerciser	884.1425
510(k) Summary for Mentor EvaCare Vaginal Pessaries U.S. Food and Drug Administration, 1999 ¹⁶	FDA 510 (K) review	510(k) Summary for Mentor EvaCare Vaginal Pessaries	K993308	Mentor Corporation, Santa Barbara, CA	Mentor EvaCare Vaginal Pessaries	Vaginal Pessary	884.3575
510(k) Summary for PelvX Incontinence Dish U.S. Food and Drug Administration, 1999 ¹⁶	FDA 510 (K) review	510(k) Summary for PelvX Incontinence Dish	K990593	DesChutes Medical Products, Inc., Bend, OR	PelvX Incontinence Dish	Vaginal Pessary	884.3575
Summary for pelvic muscle therapy U.S. Food and Drug Administration, 2000 ¹⁷	FDA 510 (K) review	510(k) Summary for pelvic muscle therapy	K002830	Colonial Medical Supply, Las Vegas, Nv	Pelvic Muscle Therapy	Pelvic Muscle Exerciser	884.1425
510(k) summary accuset sensor U.S. Food and Drug Administration, 2000 ¹⁸	FDA 510 (K) review	510(k) summary accuset sensor	K001386	PelviCare Inc., Laguna Niguel, CA	Accuset Sensor	Not reported	876.1620; 884.1425
510(k) summary for femiscan clinic system and personal system U.S. Food and Drug Administration, 2000 ¹⁹	FDA 510 (K) review	510(k) summary for femiscan clinic system and personal system	K993411	Mahoney Enterprises, East Longmeadow, MA	FemiScan Clinic System and the FemiScan Personal System	Biofeedback Monitoring device with vaginal EMG probe	876.5320; 884.1425
Summary Review for InCare Pelvic Floor Therapy System U.S. Food and Drug Administration, 2001 ²⁰	FDA 510 (K) review	510(k) Summary Review for InCare Pelvic Floor Therapy System	K013612	Hollister Incorporated, Libertyville, IL	InCare Pelvic Floor Therapy System	Not reported	876.5320; 884.1425
510(k) Summary for InCare Pressure Biofeedback Vaginal and Anal Pressure Probes U.S. Food and Drug Administration, 2001 ²¹	FDA 510 (K) review	510(k) Summary for InCare Pressure Biofeedback Vaginal and Anal Pressure Probes	K013653	Hollister Incorporated, Libertyville, IL	InCare Pressure Biofeedback Vaginal Pressure Probe; InCare Pressure Biofeedback Anal Pressure Probe	Not reported	884.1425

Appendix Table F2. Review of grey literature (continued)

Title references	Type of review	Title	ID	Manufacturer	Trade name	Common name	Classification number
510(k) Summary for MTI ST#1 Silicone Pessary U.S. Food and Drug Administration, 2002 ²²	FDA 510 (K) review	510(k) Summary for MTI ST#1 Silicone Pessary	K020512	Medical Technology & Innovations, Inc., Lee's Summit, MO	MTI ST#1 Silicone Pessary	Vaginal Pessary	884.3575
510(k) Summary for Portex Ring Pessary U.S. Food and Drug Administration, 2002 ²³	FDA 510 (K) review	510(k) Summary for Portex Ring Pessary	K012277	SIMS Registration Manager, Kent, CT	Portex Ring Pessary	Not reported	884.3575
510(k) Summary for marina Medical Silicone Pessary U.S. Food and Drug Administration, 2003 ²⁴	FDA 510 (K) review	510(k) Summary for marina Medical Silicone Pessary	K031463	Marina Medical Instruments, Inc., Alpharetta, GA	Marina Medical silicone Pessary	Not reported	884.3575
510(k) Summary for Kolpexin Sphere U.S. Food and Drug Administration, 2004 ²⁵	FDA 510 (K) review	510(k) Summary for Kolpexin Sphere	K032644	ADAMED Ltd., Poland	KOLPEXIN Sphere	Training Aid for Pelvic Floor Muscle or Kegel Exercise and Pessary for Vaginal Prolapse	884.3575
510(k) Summary for Intra-vaginal stress incontinence device U.S. Food and Drug Administration, 2006 ²⁶	FDA 510 (K) review	510(k) Summary for Intra-vaginal stress incontinence device	K060526	ConTIPI Ltd., Israel, c/o ProMedic, Incorporated, Mccordville, IN	Vaginal Pessary	Intra-vaginal stress incontinence device	884.3575
510(k) Summary for pathway vaginal/rectal perineometer probe U.S. Food and Drug Administration, ²⁷	FDA 510 (K) review	510(k) Summary for pathway vaginal/rectal perineometer probe	K974036	The Prometheus Group, Portsmouth, NH	Pathway Vaginal/Rectal Perineometer Probe	Perineometer Probe	884.1425
510(k) summary for anal stimulation/emg probe - w/Stop U.S. Food and Drug Administration, 1999 ²⁸	FDA 510 (K) review	510(k) summary for anal stimulation/emg probe - w/Stop	K990456	Hollister Incorporated, Libertyville, IL	Anal Stimulation/EMG Probe-w/Stop	Not reported	876.5320; 884.1425
510(k) Summary for uesta Pessary U.S. Food and Drug Administration, 2008 ³	FDA 510 (K) review	510(k) Summary for uesta pessary	K083769	EastMed Inc., Halifax, Nova Scotia B3J 1S5	Uresta Pessary	Vaginal Pessary	884.3575

Appendix Table F2. Review of grey literature (continued)

Title references	Type of review	Title	ID	Manufacturer	Trade name	Common name	Classification number
510(k) Summary for InCare Pelvic Floor Therapy System with Desktop Computer U.S. Food and Drug Administration, 1996 ⁸	FDA 510 (K) review	510(k) Summary for InCare Pelvic Floor Therapy System with Desktop Computer	K961872	Hollister Incorporated, Libertyville, IL	InCare Pelvic Floor Therapy System with Desktop Computer	Not reported	Not reported
510(k) Summary for liberty plus system pfs-300 U.S. Food and Drug Administration, 1997 ²⁹	FDA 510 (K) review	510(k) Summary for liberty plus system pfs-300	K970077	Utah Medical Products Inc.	Liberty Plus System, PFS-300	Electrical Pelvic Floor Stimulation System with Biofeedback	876.5320; 884.1425
Medical Review for Gelnique (oxybutynin chloride) 10% gel U.S. Food and Drug Administration, 2009 ³⁰ Staskin, 2009 ³¹	Medical review	Medical Review for Gelnique (oxybutynin chloride) 10% gel	22-204	Watson's laboratories	Gelnique	Oxybutynin chloride	Not reported
Medical Review for PAMELOR (Brand Name Drug) U.S. Food and Drug Administration, 2001 ³² No information about trials	Medical review	Medical Review for PAMELOR (Brand Name Drug)	18-012/S-024 & 18-013/S-053	Tyco Healthcare	Pamelor	Nortriptyline	Not reported
Medical Review for Sanctura (Trospium Chloride) Tablets U.S. Food and Drug Administration, 2004 ³³ Rudy, 2006 ³⁴ Zinner, 2004 ³⁵	Medical review	Medical Review for Sanctura (Trospium Chloride) Tablets	21-595	Indevus Pharmaceuticals	Sanctura	Trospium chloride	Not reported
Medical Review for VesiCare (Solifenacin Succinate) Tablets U.S. Food and Drug Administration, 2004 ³⁶ Staskin, 2006 ³⁷	Medical review	Medical Review for VesiCare (Solifenacin Succinate) Tablets	21-518	Yamanouchi Pharma America, Inc	Vesicare	Solifenacin Succinate	Not reported

Appendix Table F2. Review of grey literature (continued)

Title references	Type of review	Title	ID	Manufacturer	Trade name	Common name	Classification number
Medical Review for Sanctura XR (Trospium Chloride) Extended Release Capsules U.S. Food and Drug Administration, 2007 ³⁸ Not published	Medical review	Medical Review for Sanctura XR (Trospium Chloride) Extended Release Capsules	NDA 22-103	Indevus Pharmaceuticals	Sanctura	Trospium chloride	Not reported
Medical Review for Ditropan XL(Oxybutynin Chloride) Tablets U.S. Food and Drug Administration, 1998 ³⁹ Versi, 2000 ⁴⁰	Medical review	Medical Review for Ditropan XL (Oxybutynin Chloride) Tablets	NDA-20-897	Alza Corporation	DitropanXL	oxybutynin	Not reported
Medical Review for Enablex (Clarifenacin) Extended Release Tablets U.S. Food and Drug Administration, 2004 ⁴¹ Hill, 2006 ⁴² Steers, 2005 ⁴³	Medical review	Medical Review for Enablex (Clarifenacin) Extended Release Tablets	NDA-21-513	Novartis	Enablex	Darifenacin	Not reported
Statistical Review for Sanctura (Trospium Chloride) Tablets U.S. Food and Drug Administration, 2007 ⁴⁴ Staskin, 2007 ⁴⁵ Dmochowski, 2008 ⁴⁵	Statistical review	Statistical Review for Sanctura (Trospium Chloride) Tablets	22-103	Indevus Pharmaceuticals	Sanctura XR	Trospium chloride-extended release	Not reported
Product Monograph for ENABLEX Health Canada, 2006 ⁴⁶ Abrams, 2008 ⁴⁷	Statistical review	Product Monograph for ENABLEX	Not reported	Novartis	Enablex	Darifenacin-extended release	Not reported
Product Monograph for SANCTURA XR U.S. Food and Drug Administration, 2010 ⁴⁸ Staskin, 2009 ⁴⁹	Statistical review	Product Monograph for SANCTURA XR	Not reported	Indevus Pharmaceuticals	Sanctura XR	Trospium chloride-extended release	Not reported

Appendix Table F2. Review of grey literature (continued)

Title references	Type of review	Title	ID	Manufacturer	Trade name	Common name	Classification number
Product Monograph for VESICARE Health Canada, 2006 ⁵⁰ Cardozo, 2004 ⁵¹ Chapple, 2004 ⁵²	Statistical review	Product Monograph for VESICARE	Not reported	Astellas Pharma Canada, Inc.	Vesicare	Solifenacin Succinate	Not reported
NCT00168454 Posted results NCT00168454, 2008 ⁵³	Completed unpublished study from Clinicaltrials.gov	A Research Study for Patients With Overactive Bladder	191622-077	Allergan	Botulinum toxin Type A	Botulinum toxin	Not reported
NCT00178191 Posted results NCT00178191, ⁵⁴	Completed unpublished study from Clinicaltrials.gov	Randomized Trial for Botox Urinary Incontinence	10466	University of Rochester National Institutes of Health (NIH)	Bladder diary; Questionnaires; Urodynamics	Bladder diary; Questionnaires; Urodynamics	Not reported
NCT00269750 A Study Comparing the Efficacy and Safety of OROS [®] Oxybutynin to That of Ditropan [®] (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence NCT00269750, 2005 ⁵⁵	Completed unpublished study from Clinicaltrials.gov	A Study Comparing the Efficacy and Safety of OROS [®] Oxybutynin to That of Ditropan [®] (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence	CR005968	Alza Corporation	OROS	Oxybutynin chloride	Not reported
NCT00444925 Posted results NCT00444925, ⁵⁶	Completed unpublished study from Clinicaltrials.gov	Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)	A0221008	Pfizer	Fesoterodine fumarate	Fesoterodine	Not reported
NCT00536484 Posted results NCT00536484, ⁵⁷	Completed unpublished study from Clinicaltrials.gov	Fesoterodine Flexible Dose Study	A0221014	Pfizer	Fesoterodine	Fesoterodine	Not reported

Appendix Table F2. Review of grey literature (continued)

Title references	Type of review	Title	ID	Manufacturer	Trade name	Common name	Classification number
905-EC-001 Solifenacin in a flexible dose regimen with tolterodine as an active comparator in a double-blind, double-dummy, randomized overactive bladder symptom trial (STAR) Chapple, 2005 ^{58,59}	Synopsis posted in the website http://www.clinicalstudyresults.org	Solifenacin in a flexible dose regimen with tolterodine as an active comparator in a double-blind, double-dummy, randomized overactive bladder symptom trial (STAR)	905-EC-001	Astellas Pharma Europe B.V.	Solifenacin Succinate	Solifenacin	Not reported
Solifenacin in the treatment of urgency symptoms of overactive bladder in a rising dose, randomized, placebo-controlled, double-blind trial (SUNRISE) Cardozo, 2008 ^{59,60}	Synopsis posted in the website http://www.clinicalstudyresults.org	Solifenacin in the treatment of urgency symptoms of overactive bladder in a rising dose, randomized, placebo-controlled, double-blind trial (SUNRISE)	905-EC-002	Astellas Pharma Europe B.V.	Solifenacin Succinate	Solifenacin	Not reported
Solifenacin succinate in a flexible dose regimen with simplified bladder training versus solifenacin succinate in a flexible dose regimen alone in a prospective, randomized, parallel group, overactive bladder symptom study Mattiasson, 2009 ^{61,62}	Synopsis posted in the website http://www.clinicalstudyresults.org	Solifenacin succinate in a flexible dose regimen with simplified bladder training versus solifenacin succinate in a flexible dose regimen alone in a prospective, randomized, parallel group, overactive bladder symptom study	905-EC-003	Astellas Pharma Europe B.V.	Vesicare	Solifenacin Succinate	Not reported

Appendix Table F3. Quality Assessment of Diagnostic Accuracy Studies (QUADAS)^{66,67}

Criteria* reference	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Digesu, 2003 ⁶³	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Khan, 2004 ⁶⁴	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	yes	not relevant	yes	yes
Versi, 1996 ⁶⁵	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	no
Sandvik, 1995 ⁶⁶	no	unclear	yes	unclear	yes	yes	no	yes	unclear	yes	yes	not relevant	yes	no
Clarke, 1997 ⁶⁷	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Jarvis, 1980 ⁶⁸	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Hilton, 1981 ⁶⁹	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Dundiff, 1997 ⁷⁰	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Brown, 2006 ⁷¹	yes	yes	yes	unclear	yes	no	no	yes	unclear	yes	yes	not relevant	yes	yes
Costantini, 2008 ⁷²	no	yes	no	unclear	yes	yes	yes	yes	unclear	yes	unclear	not relevant	yes	yes
Ishiko, 2000 ⁷³	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Shepherd, 1982 ⁷⁴	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	yes	not relevant	yes	yes
Versi, 1988 ⁷⁵	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Bradley, 2005 ⁷⁶	no	yes	yes	unclear	yes	yes	no	yes	no	yes	unclear	not relevant	yes	yes
FitzGerald, 2002 ⁷⁷	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Sand, 1988 ⁷⁸	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Cantor, 1980 ⁷⁹	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Valente, 1988 ⁸⁰	no	no	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Hastie, 1989 ⁸¹	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Bent, 1983 ⁸²	no	unclear	yes	unclear	yes	yes	no	yes	no	yes	unclear	not relevant	no	yes
De Muylder, 1992 ⁸³	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Farrar, 1975 ⁸⁴	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Lagro-Janssen, 1991 ⁸⁵	yes	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Ouslander, 1987 ⁸⁶	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Bergman, 1990 ⁸⁷	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Haylen, 1989 ⁸⁸	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Versi, 1986 ⁸⁹	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Bates, 1973 ⁹⁰	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Arnold, 1973 ⁹¹	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Moolgaoker, 1972 ⁹²	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Warrell, 1965 ⁹³	unclear	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Klinge, 2002 ⁹⁴	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Niecestro, 1992 ⁹⁵	no	yes	no	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Diakno, 1990 ⁹⁶	yes	unclear	no	unclear	yes	yes	no	yes	no	yes	unclear	not relevant	yes	yes
Tyagi, 2010 ⁹⁷	no	yes	yes	unclear	unclear	yes	yes	yes	yes	yes	unclear	not relevant	yes	no
Thiede, 1987 ⁹⁸	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes

Appendix Table F3. Quality Assessment of Diagnostic Accuracy Studies (QUADAS)^{66,67} (continued)

Criteria* reference	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Awad, 1983 ⁹⁹	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Glezerman, 1986 ¹⁰⁰	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Walters, 1988 ¹⁰¹	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Versi, 1991 ¹⁰²	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Bump, 2003 ¹⁰³	unclear	yes	yes	unclear	unclear	yes	yes	yes	yes	yes	yes	not relevant	yes	unclear
Yalcin, 2004 ¹⁰⁴	unclear	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	not relevant	yes	unclear
Videla, 1998 ¹⁰⁵	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Dinokno, 1999 ¹⁰⁶	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	yes	not relevant	yes	yes
Lemack, 1999 ¹⁰⁷	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Ramsay, 1995 ¹⁰⁸	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	yes	not relevant	yes	yes
Ramsay, 1993 ¹⁰⁹	unclear	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Montz, 1986 ¹¹⁰	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	yes	not relevant	yes	yes
Haeusler, 1995 ¹¹¹	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Nager, 2007 ¹¹²	unclear	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Matharu, 2005 ¹¹³	no	unclear	yes	no	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Coyne, 2005 ¹¹⁴	yes	yes	no	unclear	yes	yes	no	yes	no	yes	unclear	not relevant	yes	yes
Lukacz, 2005 ¹¹⁵	no	unclear	no	unclear	yes	yes	no	yes	yes	yes	yes	not relevant	unclear	yes
Diokno, 1990 ⁹⁶	yes	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Fischer-Rasmussen, 1986 ¹¹⁶	no	unclear	yes	unclear	yes	yes	unclear	yes	unclear	yes	unclear	not relevant	yes	yes
Summitt, 1992 ¹¹⁷	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Griffiths, 1992 ¹¹⁸	no	yes	yes	yes	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Chen, 1997 ¹¹⁹	no	no	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Kiilholma, 1994 ¹²⁰	unclear	no	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Contreras Ortiz, 1993 ¹²¹	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Bergman, 1988 ¹²²	no	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	not relevant	yes	yes
Bergman, 1988 ¹²³	no	yes	yes	yes	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Bergman, 1987 ¹²⁴	no	yes	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Klovning, 1996 ¹²⁵	no	no	yes	unclear	yes	yes	yes	yes	yes	yes	yes	not relevant	yes	yes
Sunshine, 1989 ¹²⁶	unclear	no	yes	no	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Kujansuu, 1982 ¹²⁷	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Diokno, 1987 ¹²⁸	no	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Korda, 1987 ¹²⁹	unclear	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	unclear	not relevant	yes	yes
Quinn, 1989 ¹³⁰	no	unclear	yes	unclear	yes	yes	unclear	yes	unclear	yes	yes	not relevant	no	yes

*QUADAS Criteria	Used Codes
(1) Was the spectrum of patient's representative of the patients who will receive the test in practice?	Yes if community or primary care; no if others; unclear if not specified
(2) Were the selection criteria clearly described?	Yes if inclusion and exclusion criteria exist; unclear if missing one of them; no if missing both
(3) Is the reference standard likely to correctly classify the target intervention?	Yes if UD or clinical diagnosis; no if others
(4) Is the time period between reference standard and index test short enough to be reasonably sure the target condition did not change between the two tests?	Yes if no more than 2 weeks, no if more than 2 weeks, unclear if unknown
(5) Did the whole sample or a random selection of the sample receive verification using a reference standard of diagnosis?	Yes if random selection or no sampling; no if non-random selection; unclear is unknown
(6) Did the patients receive the same reference standard regardless of the index test?	Yes if all received gold standard method
(7) Was the reference standard independent of the index test (i.e., the index test did not form part of the reference standard)?	Yes if UD as gold standard; no if clinical diagnosis
(8) Was the execution of the index test described in sufficient detail to permit replication of the test?	All yes (inclusion criteria of the studies)
(9) Was the execution of the reference standard described in sufficient detail to permit its replication?	Y if UD or ICS; unclear if clinical diagnosis without clear definitions
(10) Were the index test results interpreted without knowledge of the results of the reference standard?	All yes
(11) Were the reference standard results interpreted without knowledge of the index test?	Yes if blinding, no if not blinding; unclear if not mentioned
(12) Were the same clinical data available when test results were interpreted as would be available when the test is used in practice?	Not relevant-omitted from quality assessment as Whiting's suggestions ⁶⁶
(13) Were uninterpretable/intermediate test results reported?	No if the results did not have mixed UI
(14) Were withdrawals for the study explained?	No if there are withdraw cases

Appendix Table F4. Eligible studies of diagnostic methods

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Abdel-fattah, 2004 ¹³¹ Country: UK Funding: not reported Sample: 160	Settings: District general hospital % of women: 100 Age: 58; Range: 42-73	Inclusion: Women undergoing surgical treatment for urodynamic stress incontinence Exclusion: Not reported
Amarenco, 2003 ¹³² Country: Europe Funding: not reported Sample: 505	Settings: A multicenter clinical study % of women: 100 Age: 51; Range: 18-75	Inclusion: Women enrolled in a European multicenter clinical study, ages 18-75, good health, mild to moderate genuine stress incontinence GSI with at least 3 leakages per week and 24 hour pad test 8-100g Exclusion: Not reported Only Cronbach's alpha coefficients in the English language group were abstracted
Amundsen, 1999 ¹³³ Country: U.S. Funding: not reported Sample: 115	Settings: urogynecologic clinic % of women: 100 Age: 53; Range: 21-79	Inclusion: Consecutive women with various complaints of urinary symptoms completed a 27-item questionnaire Exclusion: Not reported
Arnold, 1973 ⁹¹ Country: UK Funding: not reported Sample: 217	Settings: urodynamic unit % of women: 100 Age : Not available; Range: Not reported	Inclusion: Women with incontinence Exclusion: Women with neurologic disease, pelvic disease, a history of major pelvic operations, and the urethral syndromes
Awad, 1983 ⁹⁹ Country: Canada Funding: other Sample:108	Settings: urodynamic unit % of women:100 Age: Not available; Range: Not available	Inclusion: Women referred to authors' department for symptomatic UI Exclusion: Not available
Bates, 1973 ⁹⁰ Country: UK Funding: not reported Sample: 75	Settings: referral clinic % of women: 100 Age: 56; Range: 33-72	Inclusion: Patients referred for investigation of recurrent or persistent incontinence after one or more operations for presumed stress UI Exclusion: Neurologic disorders
Bent, 2005 ¹³⁴ Country: U.S. Funding: not reported Sample: 723	Settings: The principal investigators included urologists, gynecologists, and primary care physicians % of women: 100 Age: 53.6; Range: 19-85	Inclusion: Women older than 18 years, an average of at least 4 incontinence episodes per week, could not have received treatment for incontinence by a continence expert within the past 5 years, prior surgery, including correction of incontinence; was allowed if the procedure was completed 6 months before a subject entered the study; participants who performed pelvic floor muscle training could not initiate or change their regimen within 3 months before study entry or during the study, and written informed consent Exclusion: Not reported
Bent, 1983 ⁸² Country: U.S. Funding: not reported Sample: 100	Settings: urodynamic unit % of women: 100 Age: Over age 60; Range: Not reported	Inclusion: Consecutive patients over age 60 referred to authors' institute and a negative urine culture Exclusion: Not reported
Bergman, 1990 ⁹⁷ Country: U.S. Funding: not reported Sample: 154	Settings: referral clinic % of women: 100 Age: 54; Range: 17-78	Inclusion: 122 women referred for evaluation of urinary complaints and 32 no complaints as control Exclusion: Mixed urinary incontinence
Borup, 2008 ¹³⁵ Country: Denmark Funding: government Sample: 96	Settings: community-dwelling % of women: 100 Age: Not reported; Range: 20-59	Inclusion: Women with symptomatic UI invited in a stress UI test Exclusion: Not reported

Appendix Table F4. Eligible studies of diagnostic methods (continued)

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Bradley, 2005 ⁷⁶ Country: U.S. Funding: other Sample: 117	Settings: tertiary referral % of women: 100 Age: 56; Range: 22-87	Inclusion: Consecutive women having symptoms of UI and agreeing to participate Exclusion: A history of current pregnancy or within 6 months after delivery, extraurethral UI, urethral diverticulum, and active UTI
Brown, 2006 ⁷¹ Country: U.S. Funding: industry Sample: 301	Settings: community-dwelling % of women: 100 Age: 56.4; Range: 40-94	Inclusion: Ambulatory, were 40 years of age or older, reported 3 or more episodes of incontinence per week for at least 3 months, did not have urinary tract infection, and were bothered enough by their incontinence to seek treatment Exclusion: Women with incontinence who had complex problems that were more appropriate for specialist referral, including 4 or more urinary tract infections in the preceding year; pregnancy within 6 months; previous anti-incontinence or urethral surgery or procedures; previous major pelvic or abdominal surgery; pelvic radiation within 6 months; or known diseases of the genitourinary tract, such as lower urinary tract or rectal fistula, congenital abnormality leading to incontinence, interstitial cystitis, severe symptomatic pelvic prolapse, current or past urogenital cancer, spinal cord lesions, multiple sclerosis, stroke with clinically significant residual disability, Parkinson disease, or other major central nervous system abnormality affecting the lower urinary tract, or women who had been treated for incontinence in the previous 3 months
Bump, 2003 ⁸⁸ Country: U.S. Funding: industry Sample: 553	Settings: Randomized clinical trial in research laboratories % of women: 100 Age: 49.6; Range: 18-65	Inclusion: Female outpatients aged 18 to 65 years who had a clinical diagnosis of stress UI for at least 3 months in duration Exclusion: If they had prolapse stage II or greater; had a postvoid residual volume of 50 mL or more; were using any pharmacologic agent or device for urinary incontinence; had adopted or changed behavioral management for urinary incontinence
Byrne, 1987 ¹³⁶ Country: UK Funding: not reported Sample: 69	Settings: hospital % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women with the complaint of stress UI unassociated with other symptoms Exclusion: Not reported
Cantor, 1980 ⁷⁹ Country: UK Funding: not reported Sample: 214	Settings: urodynamic unit % of women: 100 Age: 47; Range: 16-84	Inclusion: Women complaining of urine incontinence Exclusion: Under age 16
Caputo, 1993 ¹³⁷ Country: U.S. Funding: not reported Sample: 114	Settings: urodynamic unit % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women with UI or genital prolapse Exclusion: Genital prolapse that protruded beyond the introitus while straining in the upright position
Cardozo, 1980 ¹³⁸ Country: UK Funding: not reported Sample: 100	Settings: urogynecologic clinic % of women: 100 Age: 50; Range: Not reported	Inclusion: All patients with stress incontinence complaints with GSI or DI confirmed Exclusion: Not reported

Appendix Table F4. Eligible studies of diagnostic methods (continued)

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Chiarelli, 1999 ¹³⁹ Country: Australia Funding: government +industry Sample: 41,724	Settings: Community % of women:100 Age: Not reported; Range: 18-75	Inclusion: The women were selected randomly from the national health insurance (Medicare) database Exclusion: Not reported Only "lower quality of life among women who report leaking urine, compared with those who do not" was abstracted.
Clarke, 1997 ⁶⁷ Country: Australia Funding: not reported Sample: 1,000	Settings: urogynecologic clinic % of women:100 Age: Not reported; Range: Not reported	Inclusion: Consecutive women with lower urinary tract symptomatology referred for UD Exclusion: Those records did not conform to the standard diagnoses (18 cases)
Costantini, 2008 ⁷² Country: Italy Funding: not reported Sample: 158	Settings: tertiary referral % of women:100 Age: 69; Range: 20-90	Inclusion: Consecutive women with or without UI referred for pelvic organ prolapse repair or anti-UI surgery Exclusion: Patients with a specific condition known to adversely affect the way the test works and that would inflate diagnosis accuracy
Cundiff, 1997 ⁷⁰ Country: U.S. Funding: not reported Sample: 535	Settings: Medical college of Virginia or Duke university medical center % of women: 100 Age: 55.7; Range: 21-95	Inclusion: Consecutive women with urinary incontinence. Exclusion: Without incontinence or advanced pelvic organ prolapse (stage III or IV)
De Muylder, 1992 ⁸³ Country: Belgium Funding: not reported Sample: 408	Settings: Urodynamic unit % of women: 100 Age: 48.2; Range: 18-78	Inclusion: Women with UI Exclusion: Not reported
Digesu, 2003 ⁸³ Country: UK Funding: not reported Sample: 4,500	Settings: tertiary referral % of women: 100 Age: 55.4; Range: 22-73	Inclusion: Women with lower urinary tract symptoms referred to a tertiary urodynamic clinic Exclusion: Women with neurological disorders
Diokno, 1990 ⁹⁶ Country: U.S. Funding: not reported Sample: 167	Settings: community-dwelling % of women: 100 Age: Not reported; Range: 60-86	Inclusion: Noninstitutionalized elderly participated in a household survey and 60 years and older accepted to free urodynamic testing Exclusion: Not reported
Dinokno, 1999 ¹⁰⁶ Country: U.S. Funding: not reported Sample: 101	Settings: Continence clinic % of women: 100 Age: No response; Range: No response	Inclusion: Women with incontinence seen at the Continence Clinic and underwent office based basic evaluation Exclusion: Incomplete documentation of office based or urodynamic data
Drutz, 1979 ¹⁴⁰ Country: Canada Funding: not reported Sample: 188	Settings: urodynamic unit % of women: 100 Age: 50.2; Range: 20-84	Inclusion: Women with complaints of UI and/or other lower urinary tract symptoms Exclusion: Not reported
Eastwood, 1984 ¹⁴¹ Country: UK Funding: not reported Sample: 65	Settings: referral clinic % of women: 100 Age: 82; Range: 68-94	Inclusion: Consecutively women referred for UD Exclusion: Not reported
Eastwood, 1979 ¹⁴² Country: No response Funding: not reported Sample: 30	Settings: urodynamic unit % of women:0 Age: 84; Range: 64-96	Inclusion: Elder patients referred to a geriatric service with the main presenting clinical features of UI Exclusion: Not reported

Appendix Table F4. Eligible studies of diagnostic methods (continued)

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Farrar, 1975 ⁸⁴ Country: UK Funding: not reported Sample: 251	Settings: urodynamic unit % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women with mainly complaints of UI, normal bladder capacity, normal pressure and flow rates, and be able to void to completion Exclusion: Women with overt or possible neurologic disorders, fistula, and ectopic ureter as well as those who have had extensive surgical procedures of the pelvis
FitzGerald, 2002 ⁷⁷ Country: U.S. Funding: not reported Sample: 293	Settings: tertiary referral % of women: 100 Age: 57; Range: 15-87	Inclusion: Women referred to a tertiary urogynecology practice who completed all the questionnaires and underwent UD Exclusion: Not reported
Glezerman, 1986 ¹⁰⁰ Country: Israel Funding: not reported Sample: 130	Settings: medical center % of women: 100 Age: 47.8; Range: 22-74	Inclusion: Women referred to authors' department for stress incontinence Exclusion: Not available
Gunthorpe, 2000 ¹⁴³ Country: Australia Funding: government Sample: 89	Settings: Primary care % of women: 100 Age: 42.4; Range: 19-79	Inclusion: Patients were invited to participate in the study with 89 consented to complete the ISQ and 48h pad test Exclusion: younger than 18 years or too ill to participate
Haeusler, 1995 ¹¹¹ Country: Austria Funding: not reported Sample: 1938	Settings: referral clinic % of women: 100 Age: 52.4; Range: 26-78	Inclusion: Consecutively patients referred for UD Exclusion: Pathologic types of incontinence due to calculi, fistula, upper motor neuron lesion, or carcinoma
Harvey, 2001 ¹⁴⁴ Country: United Kingdom Funding: not reported Sample: 154	Settings: A prospective before/after clinical trial % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Ambulatory women with symptoms of UI Exclusion: Women who were pregnant or had recently given birth, those with urinary tract infections, those presently undergoing treatment for UI, and patients with other debilitating medical conditions
Hastie, 1989 ⁸¹ Country: No response Funding: not reported Sample: 89	Settings: urodynamic unit % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women whose only reason for referral was symptom of stress incontinence Exclusion: Patients with urgency incontinence and mixed incontinence
Haylen, 1989 ⁸⁸ Country: Australia Funding: not reported Sample: 494	Settings: referral clinic % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women with complain of stress incontinence Exclusion: Previous surgery for urine incontinence
Hilton, 1981 ⁶⁹ Country: UK Funding: other Sample: 100	Settings: Urodynamic unit % of women: 100 Age: 74.6; Range: 65-93	Inclusion: Women referred to the urodynamic unit for urine incontinence Exclusion: Not reported
Homma, 2004 ¹⁴⁵ Country: Japan Funding: not reported Sample: 293	Settings: A randomized controlled trial % of women: 67 Age: 65.6; Range: Not reported	Inclusion: Details were presented in an abstract Exclusion: Details were presented in an abstract Only women's results were abstracted
Ishiko, 2000 ⁷³ Country: Japan Funding: not reported Sample: 198	Settings: tertiary referral % of women: 100 Age: 59.1; Range: 27-73	Inclusion: Women with UI Exclusion: Not reported

Appendix Table F4. Eligible studies of diagnostic methods (continued)

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Jackson, 1996 ¹⁴⁶ Country: UK Funding: not reported Sample: 105	Settings: Urodynamic unit % of women: 100 Age: 51; Range: 24-80	Inclusion: Consecutive women attending the department for a urodynamic assessment Exclusion: Not reported
James, 1999 ¹⁴⁷ Country: UK Funding: not reported Sample: 555	Settings: urodynamic unit % of women: 100 Age: 50; Range: 18-88	Inclusion: All women undergoing urodynamic studies Exclusion: Women with bladder filling symptoms (frequency, urgency, urgency incontinence or bladder pain) or an abnormal urinary diary (daytime frequency ≥ 8 , nighttime frequency ≥ 2 , or a fluid intake of $\geq 4L/24$ hours)
Jarvis, 1980 ⁶⁸ Country: UK Funding: not reported Sample: 100	Settings: urogynecologic clinic % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Consecutive women with urinary incontinence. Exclusion: Not reported
Khan, 2004 ⁶⁴ Country: UK Funding: not reported Sample: 114	Settings: tertiary referral % of women: 100 Age: 55.5 or 52.9; Range: 24-86	Inclusion: Women with lower urinary tract symptoms referred to a tertiary urogynecology clinic Exclusion: Abnormal urinalysis
Kinchen, 2007 ¹⁴⁸ Country: U.S. Funding: industry Sample: 3344	Settings: community-dwelling % of women: 100 Age: Not reported; Range: 21-75	Inclusion: All members aged 21-75 within 1 week of seeking care for any reason from a primary care physician Exclusion: Not reported
Klinge, 2002 ⁹⁴ Country: U.S. Funding: not reported Sample: 239	Settings: urogynecologic clinic % of women: 100 Age: 54.1(s), 54.7(m), 52.3(DO); Range: Not reported	Inclusion: Consecutive women referred to a urogynecologist for UI Exclusion: No symptoms or missing data
Kulseng-Hanssen, 2003 ¹⁴⁹ Country: Norway Funding: not reported Sample: 628	Settings: Tertiary referral urogynecology units % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Pre-operative forms from 20 departments Exclusion: Not reported
Lagro-Janssen, 1991 ⁸⁵ Country: The Netherlands Funding: not reported Sample: 103	Settings: general practice % of women: 100 Age: Not reported; Range: 20-65	Inclusion: Women with UI in general practitioner setting Exclusion: A previous operation for UI, underlying neurological etiology, DM, a temporary cause of UI, or UTI
Lagro-Janssen, 1990 ¹⁵⁰ Country: The Netherlands Funding: not reported Sample: 1442	Settings: community-dwelling % of women: 100 Age: Not reported; Range: 50-65	Inclusion: Women were randomly selected in the eastern part of the Netherlands, Exclusion: Not reported
Lemack, 1999 ¹⁰⁷ Country: U.S. Funding: not reported Sample: 128	Settings: tertiary referral % of women: 100 Age: 61 Range: 27-86	Inclusion: Women for an initial evaluation of LUTS or incontinence who had completed a UDI-6 questionnaire and UD study. Exclusion: Women with known neurologic diagnoses
Lemack, 2000 ¹⁵¹ Country: U.S. Funding: not reported Sample: 174	Settings: medical center % of women: 100 Age: No response; Range: No response	Inclusion: All women completed UDI-6 and underwent UD Exclusion: Known neurological conditions
Lin, 2004 ¹⁵² Country: Taiwan Funding: not reported Sample: 120	Settings: tertiary referral % of women: 100 Age: 51; Range: 43-64	Inclusion: Women complaining of lower urinary tract symptoms Exclusion: Women without symptoms suggestive of OAB

Appendix Table F4. Eligible studies of diagnostic methods (continued)

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Lowenstein, 2008 ¹⁵³ Country: U.S. Funding: industry Sample: 47	Settings: tertiary referral % of women: 100 Age: 62; Range: 34-86	Inclusion: Women with MUI Exclusion: Not reported
Lukacz, 2005 ¹¹⁵ Country: U.S. Funding: not reported Sample: 120	Settings: In either the general gynecology or the pelvic floor disorders clinic % of women: 100 Age: 52.6; Range: 25-84	Inclusion: Women awaiting appointments in either the general gynecology or the pelvis floor disorders clinic Exclusion: Inability to read or to participate in the informed consent process
Massolt, 2005 ¹⁵⁴ Country: The Netherlands Funding: not reported Sample: 109	Settings: urogynecologic clinic % of women: 100 Age: Not reported; Range: Not reported	Inclusion: All women visiting the authors' urogynecologic practice with complaints of UI Exclusion: Not reported
Matharu, 2005 ¹¹³ Country: UK Funding: government Sample: 1003	Settings: community % of women: 100 Age: 56.3; Range: 40-88	Inclusion: Women aged 40 years or over living in the community in Leicestershire and Rutland, who responded to a questionnaire and home interview, with symptoms of UI, enrolled in CNP arm, completed urodynamics. Exclusion: Not reported
Miller, 1999 ¹⁵⁵ Country: U.S. Funding: government Sample: 51	Settings: community-dwelling % of women: 100 Age: 69; Range: 59-84	Inclusion: Female, >60 years, ambulatory, mental intact (Mini-Mental State score >23, community dwelling, and history of leakage with coughing Exclusion: Prior urethral or bladder surgery, UTI, prolapse below the level of the hymenal ring
Montz, 1986 ¹¹⁰ Country: UK Funding: not reported Sample: 100	Settings: urodynamic unit % of women: 100 Age: 49.7; Range: Not reported	Inclusion: Consecutive women with complaints of UI Exclusion: Not reported
Moolgaoker, 1972 ⁹² Country: UK Funding: not reported Sample: 95	Settings: referral clinic % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women with UI and no neurological abnormalities Exclusion: Neurological lesions or fistulae
Morkved, 1999 ¹⁵⁶ Country: Norway Funding: not reported Sample: 144	Settings: local hospital % of women: 100 Age: 28; Range: 19-40	Inclusion: All women delivering at the local hospital and gave their written consent Exclusion: Those who did not understand or speak Norwegian
Nager, 2007 ¹¹² Country: U.S. Funding: government Sample: 655	Settings: A multicenter surgical trial % of women: 100 Age: 52; Range: 28-81	Predominant SUI with MESA3 stress score >MESA urge score; positive stress test (observed leakage from the external urethral meatus coincident with a cough or Valsalva maneuver) with a bladder volume ≤300 ml; urethral hypermobility as evidenced by Q- tip angle; maximum cystometric capacity (MCC) ≥200 ml; and non-obstructed voiding in the absence of Stage II–IV prolapse5 defined as: (a) postvoid residual <150 ml; (b) maximum flow rate (Qmax) ≥12 ml/sec; and (c) detrusor pressure (pdet) at Qmax <50 cm H2O Exclusion: Not reported
Niecestro, 1992 ⁹⁵ Country: U.S. Funding: not reported Sample: 66	Settings: urodynamic unit % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women >18 years referred to the urodynamic center for voiding symptoms Exclusion: Presence of UTI and judged unfit for participation by the investigator

Appendix Table F4. Eligible studies of diagnostic methods (continued)

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Oh, 2005 ¹⁵⁷ Country: Korea Funding: not reported Sample: 109	Settings: tertiary referral % of women: 100 Age: 54.9; Range: 31-77	Inclusion: Age 18 years or older, good visual acuity, and the ability to communicate, understand, and comply with the study requirements Exclusion: A confused state or depression, an inability to read the questionnaire, urinary tract infection, malignancy, pregnancy, or failure to provide consent, or incomplete workup and incomplete information
Ouslander, 1978 ⁸⁶ Country: U.S. Funding: not reported Sample: 135	Settings: referral clinic % of women: 100 Age: Not reported; Range: 65-95	Inclusion: Consecutive women referred to the clinics Exclusion: Not reported
Phua, 1992 ¹⁵⁸ Country: Singapore Funding: not reported Sample: 84	Settings: hospital % of women: 100 Age: Not available; Range: Not available	Inclusion: Women complained of UI and/or other urinary symptoms and were suspected of suffering from stress incontinence or detrusor instability Exclusion: Known or suspected neurological disease, urinary fistula or ectopic ureters
Ramsay, 1993 ¹⁰⁹ Country: UK Funding: not reported Sample: 200	Settings: No response % of women: 100 Age: 51.6; Range: Not reported	Inclusion: Patients with either pure DI or pure GSI Exclusion: Incontinence during intercourse
Ramsay, 1995 ¹⁰⁸ Country: UK Funding: not reported Sample: 207	Settings: urogynecology clinic % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Consecutive women attending urogynecology clinics Exclusion: Not reported
Rosenzweig, 1992 ¹⁵⁹ Country: U.S. Funding: not reported Sample: 22	Settings: gynecology clinic of medical center % of women: 100 Age: 60.3; Range: 34-77	Inclusion: Women with severe genitourinary prolapse (prolapse of pelvic structure through the vaginal introitus) and with no symptoms of UI except for an occasional episode (less than 1 per week) Exclusion: Not reported
Sand, 1991 ¹⁶⁰ Country: U.S. Funding: not reported Sample: 100	Settings: urodynamic unit % of women: 100 Age: 51.6; Range: 20-84	Inclusion: Consecutive neurologically normal women with complaint of UI who agreed to undergo two cystometrograms on two different days Exclusion: Not reported
Sand, 1988 ⁷⁸ Country: U.S. Funding: not reported Sample: 218	Settings: urodynamic unit % of women: 100 Age: 51.8; Range: 18-80	Inclusion: Patient referred for UD for lower urinary tract complaints Exclusion: Without thorough, detailed histories and preliminary evaluations
Sandvik, 1995 ⁸⁶ Country: Norway Funding: not reported Sample: 250	Settings: Outpatient clinic of University hospital % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Consecutive patients referred for urine incontinence Exclusion: Not reported
Scarpero, 2003 ¹⁶¹ Country: U.S. Funding: not reported Sample: 1,232	Settings: urology practice % of women: 100 Age: 54.6; Range: 18-93	Inclusion: Women presenting to a female urology practice, and all those who completed the American Urological Association Symptom Index, Symptom Problem Index, and Quality of life questions Exclusion: Younger than 18 years, with neurogenic diseases, and missing information
Shepherd, 1982 ⁷⁴ Country: UK Funding: other Sample: 1,800	Settings: urodynamic unit % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women referred to the urodynamic unit Exclusion: Not reported

Appendix Table F4. Eligible studies of diagnostic methods (continued)

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Shimabukuro, 2006 ¹⁶² Country: Japan Funding: not reported Sample: 1,052	Settings: community-dwelling % of women: 100 Age: 46.8; Range: 18-83	Inclusion: Apparently health participants for medical checkup Exclusion: Not reported
Shumaker, 1994 ¹⁶³ Country: U.S. Funding: not reported Sample: 162	Settings: community-dwelling % of women: 100 Age: 61.3; Range: ≥45	Inclusion: >45 years, mentally competent, capable of independent toileting, at least 1 episode of UI per week, and fulfilling urodynamic criteria of GSI and/or DI Exclusion: Metabolic decompensation, marked cyclical variation in UI, lower UTI, urinary obstruction, diverticulum, fistula, persistent indwelling catheter, and reversible cause of UI
Stach-Lempinen, 2001 ¹⁶⁴ Country: Finland Funding: not reported Sample: 82	Settings: University hospital % of women: 100 Age: 52; Range: 25-80	Inclusion: Women referred to authors' department for symptomatic UI Exclusion: Diabetic neuropathy, recently diagnosed cancer or other serious chronic conditions that may have caused neurogenic bladder disease and patients with incontinence surgery within the past 5 years
Stav, 2009 ¹⁶⁵ Country: Australia Funding: not reported Sample: 601	Settings: medical center % of women: 100 Age: 59.2; Range: 30-91	Inclusion: The medical records of 1,136 consecutive women who had urodynamic stress UI and underwent a suburethral sling operation at authors' institute Exclusion: Not reported
Sutherst, 1984 ¹⁶⁶ Country: UK Funding: not reported Sample: 100	Settings: Incontinent clinic % of women: 100 Age: 47 Range: 22-78	Inclusion: Women enrolled in a single blind crossover trial Exclusion: Not reported
Swift, 1995 ¹⁶⁷ Country: U.S. Funding: not reported Sample: 108	Settings: referral clinic % of women: 100 Age: 57.9; Range: Not reported	Inclusion: Consecutive women with lower urinary tract complaints referred for UD Exclusion: Not reported
Swithinbank, 1999 ¹⁶⁸ Country: UK Funding: not reported Sample: 2,075	Settings: community-dwelling % of women: 100 Age: 52; Range: 19-97	Inclusion: All women aged 19 years and over, registered with one group general practice Exclusion: Not reported
Thiede, 1987 ⁹⁸ Country: U.S. Funding: other Sample: 200	Settings: urogynecologic clinic % of women: 100 Age: Not available; Range: Not available	Inclusion: Women referred to authors' department for symptomatic UI Exclusion: Not available
Theofrastous, 1996 ¹⁶⁹ Country: U.S. Funding: not reported Sample: 120	Settings: referral clinic % of women: 100 Age: 57; Range: 22-81	Inclusion: Consecutive women who were referred to the urodynamic lab for evaluation of their UI Exclusion: Not reported
Tyagi, 2010 ⁹⁷ Country: UK Funding: not reported Sample: 159	Settings: urodynamic unit % of women: 100 Age: Not available; Range: Not available	Inclusion: Patients referred for urodynamic investigations Exclusion: Recurrent SUI after failed surgery for SUI or prior to POP surgery
Valente, 1998 ⁸⁰ Country: Italy Funding: not reported Sample: 102	Settings: urodynamic unit % of women: 100 Age: Not reported; Range: Not reported	Inclusion: consecutive women with clinical diagnosis of UI Exclusion: Not reported


Appendix Table F4. Eligible studies of diagnostic methods (continued)

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Versi, 1996 ⁶⁵ Country: UK Funding: not reported Sample: 161	Settings: urogynecologic clinic % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Patients presenting to a urogynecologic clinic at a teaching hospital Exclusion: 44 detrusor instability, sensory urgency, voiding difficulties or a combination of these diagnosis
Versi, 1991 ¹⁰² Country: UK Funding: other Sample: 252	Settings: referral urodynamic center % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Consecutive patients studied with a urodynamic diagnosis Exclusion: Not reported
Versi, 1988 ⁷⁵ Country: UK Funding: other Sample: 311	Settings: urodynamic unit % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women presenting to the urodynamic unit for investigation of their urinary complaints Exclusion: Not reported
Versi, 1986 ⁸⁹ Country: UK Funding: other Sample: 99	Settings: urodynamic unit % of women: 100 Age: Not reported; Range: Not reported	Inclusion: 99 postmenopausal women with urodynamic proven GSI and 90 women without UI as control group Exclusion: Not reported
Videla, 1998 ¹⁰⁵ Country: U.S. Funding: not reported Sample: 74	Settings: urogynecologic clinic % of women: 100 Age: 54; Range: 30-86	Inclusion: Women with a variety of lower urinary tract complaints and 1) a predominant complaint of stress incontinence, 2) positive cough stress-test results, 3) postvoid residual urine volume no more than 50 mL, 4) a functional bladder capacity of at least 400 mL as determined by a completed 24-hour frequency-volume chart, and 5) a full multichannel urodynamic evaluation Exclusion: The absence of any of five criteria
Walters, 1988 ¹⁰¹ Country: U.S. Funding: not reported Sample: 106	Settings: urodynamic unit % of women: 100 Age: 46.3; Range: Not available	Inclusion: Consecutive women complaining of urine incontinence who were referred to the authors' department Exclusion: Postmenopausal women who became asymptomatic after estrogen therapy
Warrell, 1965 ⁹³ Country: UK Funding: not reported Sample: 81	Settings: Not reported % of women: 100 Age: Not reported; Range: Not reported	Inclusion: Women with UI despite prolapse repair have been investigated Exclusion: Not reported
Weidner, 2001 ¹⁷⁰ Country: U.S. Funding: not reported Sample: 950	Settings: urogynecologic clinic % of women: 100 Age: 55.4 Range: Not reported	Inclusion: Consecutive patients referred for multichannel UD testing Exclusion: Women with stage III or IV pelvic organ prolapse, no reports of urinary incontinence, and undergoing repeated examinations
Wyman, 1988 ¹⁷¹ Country: U.S. Funding: government Sample: 50	Settings: Community dwelling % of women: 100 Age: 65.1; Range: 55-86	Inclusion: 55 years or older, ambulatory, mentally intact (Mini-Mental State score >23), independent residence in the community, and at least one episode of incontinence reported per week Exclusion: Permanent catheterization, persistent UTI, reversible cause of incontinence, metabolic decompensation, or outlet obstruction

Appendix Table F4. Eligible studies of diagnostic methods (continued)

Reference Country Funding and sample size	Settings, % of women, age	Inclusion and exclusion criteria
Wyman, 1987 ¹⁷² Country: U.S. Funding: government Sample: 69	Settings: Community-dwelling % of women: 100 Age: 67.8; Range: No response	Inclusion: Women had to be 55 years or older, reside independently in the community, mentally intact, ambulatory, and at least one episode of incontinence per week Exclusion: Permanent catheterization, intractable UTI, reversible cause of incontinence, metabolic decompensation, bladder atony or obstruction, and no evidence of urodynamic abnormality
Yalcin, 2004 ¹⁰⁴ Country: Europe and North America Funding: not reported Sample: 1,455	Settings: 3 randomized trials % of women: 100 Age: 51.3; Range: 28-81.7	Inclusion: Female outpatients aged 18 to 65 (phase 2 study) years who had a clinical diagnosis of SUI for at least 3 months in duration enrolled in 1 phase 2 study and 2 phase 3 studies Exclusion: Stage II or greater anterior segment prolapse, a post-void residual volume of 50 ml or greater, were on any pharmacological agent or device for UI, or had adopted or changed behavioral management for UI within the last 3 months, or those with previous continence surgery were excluded from the phase 2 study but not from the phase 3 studies.
Yoon, 1998 ¹⁷³ Country: U.S. Funding: not reported Sample: 174	Settings: Not reported % of women: 100 Age: 52; Range: 22-89	Inclusion: Women presented with primary complaints of UI and successfully completed a 24 hour voiding diary Exclusion: Not reported

Appendix Figure F1. Distribution of sample sizes of studies of diagnostic values of tests for UI



Notes:


Horizontal axis = categories of the sample size of the studies

Vertical axis = number of studies


Appendix Table F5. Diagnostic value of symptoms of stress incontinence compared to multichannel urodynamics (“gold standard”) for stress UI

Reference	True positive	False negative	True negative	False positive	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Bergman, 1990 ⁸⁷	66	7	6	18	0.90	0.25	1.21	0.38
Clarke, 1997 ⁸⁷	439	30	184	331	0.94	0.36	1.46	0.18
Cundiff, 1997 ⁷⁰	416	17	42	60	0.96	0.41	1.63	0.09
De Muylder, 1992 ⁸³	228	14	108	58	0.94	0.65	2.70	0.09
Diokno, 1990 ⁹⁶	65	30	52	14	0.68	0.79	3.23	0.40
Diokno, 1987 ¹²⁸	145	9	6	40	0.94	0.13	1.08	0.45
Farrar, 1975 ⁸⁴	93	0	41	117	1.00	0.26	1.35	0.00
FitzGerald, 2002 ⁷⁷	187	22	33	51	0.90	0.39	1.47	0.27
Glezerman, 1986 ¹⁰⁰	101	5	3	19	0.95	0.14	1.10	0.35
Hilton, 1981 ⁶⁹	23	17	32	23	0.58	0.58	1.38	0.73
Ishiko, 2000 ⁷³	152	14	28	4	0.92	0.88	7.33	0.10
Jarvis, 1980 ⁶⁸	47	1	26	26	0.98	0.50	1.96	0.04
Khan, 2004 ⁶⁴	21	3	14	44	0.88	0.24	1.15	0.52
Klinge, 2002 ⁹⁴	139	18	33	49	0.89	0.40	1.48	0.29
Korda, 1987 ¹²⁹	362	11	39	128	0.97	0.23	1.27	0.12
Kujansuu, 1982 ¹²⁷	46	11	43	20	0.81	0.68	2.55	0.28
Lagro-Janssen, 1991 ⁸⁵	76	3	15	9	0.96	0.63	2.57	0.06
Moolgaoker, 1972 ⁹²	41	0	7	47	1.00	0.13	1.15	0.00
Niecostro, 1992 ⁹⁵	13	3	32	17	0.81	0.65	2.34	0.29
Ouslander, 1987 ⁸⁶	82	5	17	31	0.94	0.35	1.46	0.16
Sand, 1988 ⁷⁸	152	0	43	23	1.00	0.65	2.87	0.00
Sunshine, 1989 ¹²⁶	73	0	15	14	1.00	0.52	2.07	0.00
Thiede, 1987 ⁹⁸	144	24	10	18	0.86	0.36	1.33	0.40
Tyagi, 2010 ⁹⁷	85	4	7	63	0.96	0.10	1.06	0.45
Valente, 1988 ⁸⁰	79	2	16	5	0.98	0.76	4.10	0.03
Walters, 1988 ¹⁰¹	70	4	9	23	0.95	0.28	1.32	0.19
Warrell, 1965 ⁹³	44	3	5	29	0.94	0.15	1.10	0.44

Appendix Figure F2. Sensitivity of symptoms of stress incontinence compared to multichannel urodynamics (“gold standard”) for any stress UI^{69,72-75,78,82,83,85,88-92,97-103,105,106,131-134}



Appendix Figure F3. Specificity of symptoms of stress incontinence compared to multichannel urodynamics (“gold standard”) for any stress UI^{69,72-75,78,82,83,85,88-92,97-103,105,106,131-134}




Appendix Table F6. Pooled diagnostic value of symptoms of stress incontinence compared to multichannel urodynamics (“gold standard”) for any stress UI^{69,72-75,78,82,83,85,88-92,97-103,105,106,131-134}

	Estimate	Lower 95% CI	Upper 95% CI	Tau-sq	I2	Q statistics	Degree of freedom	P-value
Specificity	0.413	0.338	0.492	0.605	0.906	266.152	26.000	0.000
Sensitivity	0.927	0.897	0.949	0.698	0.855	171.848	26.000	0.000
Positive Predictive Value	0.743	0.683	0.795	0.548	0.943	438.683	26.000	0.000
Negative Predictive Value	0.743	0.669	0.805	0.571	0.786	116.605	26.000	0.000
Accuracy	0.745	0.699	0.786	0.321	0.926	338.902	26.000	0.000
Diagnostic Odds Ratio	9.226	6.190	13.753	0.714	0.765	106.452	26.000	0.000
Positive Likelihood Ratio	1.542	1.398	1.700	0.048	0.880	207.663	26.000	0.000
Negative Likelihood Ratio	0.196	0.142	0.270	0.457	0.796	122.714	26.000	0.000


Appendix Table F7. Diagnostic value of urgency UI symptoms compared to multichannel urodynamics (“gold standard”) for detrusor overactivity

Reference	True positive	False negative	True negative	False positive	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Awad, 1983 ⁹⁹	81	3	6	18	0.96	0.25	1.29	0.14
Cantor, 1980 ⁹	107	11	43	53	0.91	0.45	1.64	0.21
Clarke, 1997 ⁶⁷	429	181	157	217	0.70	0.42	1.21	0.71
Cundiff, 1997 ⁷⁰	160	24	156	195	0.87	0.44	1.56	0.29
De Muylder, 1992 ⁸³	147	89	81	91	0.62	0.47	1.18	0.80
Diokno, 1987 ¹²⁸	2	12	180	6	0.14	0.97	4.47	0.89
Farrar, 1975 ⁸⁴	152	6	55	38	0.96	0.59	2.35	0.06
FitzGerald, 2002 ⁷⁷	92	6	56	139	0.94	0.29	1.32	0.21
Glezerman, 1986 ¹⁰⁰	9	6	42	71	0.60	0.37	0.96	1.08
Hilton, 1981 ⁶⁹	30	9	20	36	0.77	0.36	1.20	0.65
Ishiko, 2000 ⁷³	56	14	107	21	0.80	0.84	4.88	0.24
Jarvis, 1980 ⁶⁸	39	4	20	37	0.91	0.35	1.40	0.26
Klinge, 2002 ⁹⁴	138	18	43	40	0.89	0.52	1.84	0.22
Korda, 1987 ¹²⁹	97	109	210	121	0.47	0.63	1.29	0.83
Lagor-Janssen, 199 ¹⁸⁵	31	6	51	15	0.84	0.77	3.69	0.21
Moolgaoker, 1972 ⁹²	28	11	36	20	0.72	0.64	2.01	0.44
Ouslander, 1987 ⁸⁶	55	7	15	58	0.89	0.21	1.12	0.55
Sand, 1988 ⁷⁸	53	15	58	92	0.78	0.39	1.27	0.57
Thiede, 1987 ⁹⁸	56	8	51	81	0.88	0.39	1.43	0.32
Tyagi, 2010 ⁹⁷	26	5	77	51	0.84	0.60	2.11	0.27
Valente, 1988 ⁸⁰	25	9	66	2	0.74	0.97	25.34	0.27
Walters, 1988 ¹⁰¹	36	7	19	44	0.84	0.30	1.20	0.54
Warrell, 1965 ⁹³	48	5	8	20	0.91	0.29	1.27	0.33

Appendix Figure F4. Sensitivity of urgency UI symptoms compared to multichannel urodynamics (“gold standard”) for any detrusor overactivity^{72-75,78,82-85,88-91,97-99,102-106,133,134}




Appendix Figure F5. Specificity of urgency UI symptoms compared to multichannel urodynamics (“gold standard”) for any detrusor overactivity^{72-75,78,82-85,88-91,97-99,102-106,133,134}




Appendix Table F8. Diagnostic value of urgency UI symptoms compared to multichannel urodynamics (“gold standard”) for pure detrusor overactivity

Reference	True positive	False negative	True negative	False positive	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Arnold, 1973 ⁹¹	98	15	59	45	0.87	0.57	2.00	0.23
Bates, 1973 ⁹⁰	16	17	25	17	0.49	0.60	1.20	0.87
Clarke, 1997 ⁶⁷	271	116	222	375	0.70	0.37	1.11	0.81
Cundiff, 1997 ⁷⁰	95	7	173	260	0.93	0.40	1.55	0.17
De Muylder, 1992 ⁸³	96	36	134	142	0.73	0.49	1.41	0.56
FitzGerald, 2002 ⁷⁷	35	2	60	196	0.95	0.23	1.23	0.23
Glezerman, 1986 ¹⁰⁰	6	1	47	74	0.86	0.39	1.40	0.37
Hilton, 1981 ⁶⁹	23	6	23	43	0.79	0.35	1.22	0.59
Jarvis, 1980 ⁶⁸	31	4	21	44	0.89	0.32	1.31	0.35
Lagor, Janssen, 1991 ⁸⁵	16	2	55	30	0.89	0.65	2.52	0.17
Moolgaoker, 1972 ⁹²	18	4	43	30	0.82	0.59	1.99	0.31
Ouslander, 1987 ⁸⁶	34	3	19	79	0.92	0.19	1.14	0.42
Sand, 1998 ⁷⁸	23	7	56	132	0.77	0.30	1.09	0.78
Thiede, 1987 ⁹⁸	25	3	57	111	0.89	0.34	1.35	0.32
Tyagi, 2010 ⁹⁷	16	1	79	63	0.94	0.56	2.12	0.11
Valente, 1988 ⁸⁰	18	3	72	9	0.86	0.89	7.72	0.16
Warrell, 1965 ⁹³	31	3	10	37	0.91	0.21	1.16	0.41

Appendix Figure F6. Sensitivity of urgency UI symptoms compared to multichannel urodynamics (“gold standard”) for pure detrusor overactivity^{72-75,82,83,85,88,90,91,95-98,102,103,105}



Appendix Figure F7. Specificity of urgency UI symptoms compared to multichannel urodynamics (“gold standard”) for pure detrusor overactivity^{72-75,82,83,85,88,90,91,95-98,102,103,105}




Appendix Table F9. Pooled diagnostic value of urgency UI symptoms compared to multichannel urodynamics (“gold standard”) for pure detrusor overactivity^{72-75,82,83,85,88,90,91,95-98,102,103,105}

	Estimate	Lower 95% CI	Upper 95% CI	Tau2	I2	Q-statistic	Degree of freedom	P-value
Specificity	0.43	0.36	0.50	0.30	0.92	184.82	16.00	0.00
Sensitivity	0.84	0.78	0.89	0.41	0.77	66.16	16.00	0.00
Positive predictive value	0.33	0.26	0.41	0.44	0.93	209.80	16.00	0.00
Negative predictive value	0.89	0.83	0.93	0.86	0.88	123.86	16.00	0.00
Accuracy	0.53	0.48	0.59	0.21	0.92	183.24	16.00	0.00
Diagnostic odds ratio	4.17	2.59	6.70	0.66	0.80	75.47	16.00	0.00
Positive likelihood ratio	1.48	1.31	1.66	0.05	0.87	117.02	16.00	0.00
Negative likelihood ratio	0.40	0.29	0.54	0.24	0.74	58.69	16.00	0.00


Appendix Table F10. Diagnostic value of urgency symptoms with or without UI compared to multichannel urodynamics (“gold standard”) for detrusor overactivity

Reference	True positive	False negative	True negative	False positive	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Cantor, 1980 ⁷⁹	113	5	24	72	0.96	0.25	1.28	0.17
Clarke, 1997 ⁶⁷	524	86	104	270	0.86	0.28	1.19	0.51
Digesu, 2003 ⁸³	457	1184	2473	386	0.28	0.87	2.06	0.83
Glezerman, 1986 ¹⁰⁰	13	2	31	82	0.87	0.27	1.19	0.49
Hilton, 198 ¹⁶⁹	34	5	16	40	0.87	0.29	1.22	0.45
Jarvis, 1980 ⁶⁸	39	3	22	36	0.93	0.38	1.50	0.19
Moolgaoker, 1972 ⁹²	28	11	30	26	0.72	0.54	1.55	0.53
Thiede, 1987 ⁹⁸	51	13	46	86	0.80	0.35	1.22	0.58
Walters, 1988 ¹⁰¹	39	4	18	45	0.91	0.29	1.27	0.33

Appendix Figure F8. Sensitivity of urgency symptoms with or without UI compared to multichannel urodynamics (“gold standard”) for any detrusor overactivity^{68,72-74,84,97,103,105,106}



Appendix Figure F9. Specificity of urgency symptoms with or without UI compared to multichannel urodynamics (“gold standard”) for any detrusor overactivity^{68,72-74,84,97,105 103,106}




Appendix Table F11. Pooled diagnostic value of urgency symptoms with or without UI compared to multichannel urodynamics (“gold standard”) for any detrusor overactivity^{68,72-74,84,97,105 103,106}

	Estimate	Lower 95% CI	Upper 95% CI	Tau2	I2	Q-statistic	Degree of freedom	P-value
Specificity	0.39	0.17	0.67	2.91	0.99	898.68	8.00	0.00
Sensitivity	0.84	0.59	0.95	3.54	0.99	640.98	8.00	0.00
Positive predictive value	0.48	0.39	0.57	0.25	0.94	109.04	8.00	0.00
Negative predictive value	0.75	0.67	0.81	0.18	0.798	34.63	8.00	0.00
Accuracy	0.57	0.51	0.62	0.09	0.90	72.29	8.00	0.00
Diagnostic odds ratio	2.60	2.19	3.09	0.01	0.20	8.75	8.00	0.36
Positive likelihood ratio	1.36	1.18	1.58	0.04	0.89	64.89	8.00	0.00
Negative likelihood ratio	0.47	0.33	0.67	0.17	0.83	41.66	8.00	0.00


Appendix Table F12. Diagnostic value of urgency symptoms with or without UI compared to multichannel urodynamics (“gold standard”) for pure detrusor overactivity

Reference	True positive	False negative	True negative	False positive	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Clarke, 1997 ⁶⁷	337	50	140	457	0.87	0.24	1.14	0.55
Glezerman, 1986 ¹⁰⁰	6	1	32	89	0.86	0.26	1.16	0.54
Hilton, 1981 ⁶⁹	24	5	16	50	0.83	0.24	1.09	0.71
Jarvis, 1980 ⁶⁸	32	3	22	43	0.91	0.34	1.38	0.25
Moolgaoker, 1972 ⁹²	17	5	36	37	0.77	0.49	1.52	0.46
Thiede, 1987 ⁹⁸	24	4	55	113	0.86	0.33	1.27	0.44

Appendix Figure F10. Sensitivity of urgency symptoms with or without UI compared to multichannel urodynamics (“gold standard”) for pure detrusor overactivity^{72-74,97,103,105}



Appendix Figure F11. Specificity of urgency symptoms with or without UI compared to multichannel urodynamics (“gold standard”) for pure detrusor overactivity^{72-74,97,103,105}




Appendix Table F13. Pooled diagnostic value of urgency symptoms with or without UI compared to multichannel urodynamics (“gold standard”) for pure detrusor overactivity^{72-74,97,103,105}

	Estimate	Lower 95% CI	Upper 95% CI	Tau2	I2	Q-statistic	Degree of freedom	P-value
Specificity	0.31	0.24	0.39	0.14	0.84	25.01	5.00	0.00
Sensitivity	0.86	0.83	0.89	0.00	-0.46	2.74	5.00	0.74
Positive predictive value	0.27	0.17	0.40	0.45	0.93	58.88	5.00	0.00
Negative predictive value	0.86	0.76	0.93	0.47	0.77	17.05	5.00	0.00
Accuracy	0.45	0.38	0.52	0.09	0.84	24.71	5.00	0.00
Diagnostic odds ratio	2.26	1.68	3.04	0.00	-0.26	3.18	5.00	0.67
Positive likelihood ratio	1.21	1.11	1.32	0.00	0.46	7.35	5.00	0.20
Negative likelihood ratio	0.52	0.41	0.67	0.00	-0.69	2.37	5.00	0.80


Appendix Table F14. Diagnostic value of mixed symptoms compared to multichannel urodynamics (“gold standard”) for mixed UI

Reference	True positive	False negative	True negative	False positive	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Cundiff, 1997 ⁷⁰	56	26	213	240	0.68	0.47	1.29	0.67
De Muylder, 1992 ⁸³	45	59	233	71	0.43	0.77	1.85	0.74
FitzGerald, 2002 ⁷⁷	52	9	84	148	0.85	0.36	1.34	0.41
Haylen, 1989 ⁸⁸	57	3	74	360	0.95	0.17	1.15	0.29
KlingeLe, 2002 ⁹⁴	53	21	91	74	0.72	0.55	1.60	0.51
Lagro-Janssen, 1991 ⁸⁵	13	6	66	18	0.68	0.79	3.20	0.40
Ouslander, 1987 ⁸⁶	18	7	37	73	0.72	0.34	1.08	0.83
Sand, 1988 ⁷⁸	30	8	78	102	0.79	0.43	1.39	0.49
Tyagi, 2010 ⁹⁷	10	4	83	62	0.71	0.57	1.67	0.50
Valente, 1988 ⁸⁰	5	8	85	4	0.39	0.96	8.56	0.64
Warrell, 1965 ⁹³	17	2	19	43	0.90	0.31	1.29	0.34

Appendix Figure F12. Sensitivity of mixed symptoms compared to multichannel urodynamics (“gold standard”) for mixed UI^{75,82,83,85,88,90,91,93,98,99,102}



Appendix Figure F13. Specificity of mixed symptoms compared to multichannel urodynamics (“gold standard”) for mixed UI^{75,82,83,85,88,90,91,93,98,99,102}




Appendix Table F15. Pooled diagnostic value of mixed symptoms compared to multichannel urodynamics (“gold standard”) for mixed UI^{75,82,83,85,88,90,91,93,98,99,102}

	Estimate	Lower 95% CI	Upper 95% CI	Tau2	I2	Q-statistic	Degree of freedom	P-value
Specificity	0.53	0.40	0.66	0.80	0.97	327.20	10.00	0.00
Sensitivity	0.73	0.61	0.82	0.63	0.85	58.61	10.00	0.00
Positive predictive value	0.26	0.20	0.34	0.30	0.88	76.99	10.00	0.00
Negative predictive value	0.89	0.85	0.92	0.21	0.72	31.88	10.00	0.00
Accuracy	0.56	0.46	0.66	0.43	0.96	241.00	10.00	0.00
Diagnostic odds ratio	2.90	2.18	3.86	0.05	0.32	13.29	10.00	0.21
Positive likelihood ratio	1.45	1.27	1.67	0.04	0.80	45.18	10.00	0.00
Negative likelihood ratio	0.61	0.52	0.71	0.01	0.25	11.97	10.00	0.29


Appendix Table F16. Diagnostic value of pad test compared to multichannel uroynamics (“gold standard”) for stress UI

Reference	True positives [false negatives]	False positives [true negatives]	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
1 hour pad test vs. UD						
Versi, 1988 ⁷⁵	20 [19]	144 [128]	0.51	0.47	0.97	1.01
Costantini, 2008 ⁷²	53 [8]	34 [63]	0.87	0.65	2.48	0.2
Pad test vs. UD						
Versi, 1988 ⁷⁵	132 [35]	32 [112]	0.79	0.78	3.56	0.27
Versi, 1996 ⁶⁵	57 [5]	12 [31]	0.92	0.72	3.29	0.11
Costantini, 2008 ⁷²	73 [15]	14 [56]	0.83	0.80	4.15	0.21

Appendix Figure F14. Sensitivity of pad test compared to multichannel urodynamics (“gold standard”) for any stress UI^{70,77,80}




Appendix Figure F15. Specificity of pad test compared to multichannel urodynamics (“gold standard”) for any stress UI^{70,77,80}




Appendix Table 17. Pooled Diagnostic value of pad test compared to multichannel urodynamics (“gold standard”) for any stress UI^{70,77,80}

	Estimate	95% CI	Tau-sq	I2	Q-statistic	Degree of freedom	P-value
Specificity	0.773	0.718; 0.821	0.000	-0.032	0.969	2.000	0.616
Sensitivity	0.838	0.755; 0.897	0.123	0.796	4.908	2.000	0.086
Positive predictive value	0.818	0.772; 0.857	0.000	-1.088	0.479	2.000	0.787
Negative predictive value	0.781	0.726; 0.828	0.000	0.396	1.655	2.000	0.437
Accuracy	0.802	0.767; 0.833	0.000	0.397	1.660	2.000	0.436
Diagnostic odds ratio	16.343	10.761; 24.821	0.000	0.450	1.819	2.000	0.403
Positive likelihood ratio	3.624	2.875; 4.568	0.000	-1.138	0.468	2.000	0.791
Negative likelihood ratio	0.216	0.146; 0.319	0.057	0.736	3.782	2.000	0.151

Appendix Figure F16. Sensitivity of pad test compared to multichannel urodynamics (“gold standard”) for any detrusor overactivity^{77,80}



Appendix Figure F17. Specificity of pad test compared to multichannel urodynamics (“gold standard”) for any detrusor overactivity^{77,80}




Appendix Table F18. Pooled diagnostic value of pad test compared to multichannel urodynamics (“gold standard”) for any detrusor overactivity^{77,80}

	Estimate	95% CI	Tau-sq	Q statistics	Degree of freedom	P-value
Specificity	0.557	0.380; 0.721	0.240	8.987	1.000	0.003
Sensitivity	0.723	0.301; 0.941	1.569	13.728	1.000	0.000
Positive predictive value	0.318	0.042; 0.833	2.871	55.565	1.000	0.000
Negative predictive value	0.876	0.825; 0.914	0.000	0.121	1.000	0.728
Accuracy	0.611	0.345; 0.824	0.596	27.306	1.000	0.000
Diagnostic odds ratio	3.342	0.268; 41.640	3.160	21.616	1.000	0.000
Positive likelihood ratio	1.555	0.619; 3.904	0.417	17.943	1.000	0.000
Negative likelihood ratio	0.469	0.095; 2.325	1.263	18.387	1.000	0.000


Appendix Table F19. Diagnostic value of symptoms compared to clinical diagnosis (“gold standard”) for different types of urinary incontinence

Type of UI	Reference	True positives [false negatives]	False positives [true negatives]	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Urgency UI	Bent, 1983 ⁸²	15 [3]	32 [31]	0.83	0.49	1.64	0.34
Urgency UI	Bradley, 2005 ⁷⁶	77 [21]	4 [15]	0.79	0.79	3.76	0.27
Urgency UI	Brown, 2006 ⁷¹	121 [40]	32 [108]	0.75	0.77	3.29	0.32
Urgency UI	Sandvik, 1995 ⁶⁶	89 [8]	50 [89]	0.92	0.64	2.55	0.13
Urgency	Bent, 1983 ⁸²	16 [2]	37 [26]	0.89	0.41	1.51	0.27
Stress UI	Bent, 1983 ⁸²	20 [1]	22 [38]	0.95	0.63	2.60	0.08
Stress UI	Bradley, 2005 ⁷⁶	75 [13]	8 [21]	0.85	0.71	2.93	0.21
Stress UI	Brown, 2006 ⁷¹	149 [25]	51 [76]	0.86	0.60	2.13	0.24
Stress UI	Sandvik, 1995 ⁶⁶	179 [4]	26 [27]	0.98	0.51	1.99	0.04
Stress UI	Fischer-Rasmussen ¹¹⁶	68[62]	12[70]	0.52	0.85	3.6	0.6
Mixed UI	Bradley, 2005 ⁷⁶	50 [22]	78 [13]	0.70	0.86	5.00	0.35
Mixed UI	Brown, 2006 ⁷¹	15 [27]	47 [212]	0.36	0.82	1.97	0.79
Mixed UI	Sandvik, 1995 ⁶⁶	47 [9]	61 [119]	0.84	0.66	2.48	0.24

Appendix Figure F18. Sensitivity of urgency UI symptoms compared to clinical diagnosis (“gold standard”) for any detrusor overactivity (Bradley et al uses a composite diagnostic score)^{71,76,81,87}




Appendix Figure F19. Specificity of urgency UI symptoms compared to clinical diagnosis (“gold standard”) for any detrusor overactivity (Bradley et al uses a composite diagnostic scores)^{71,76,81,87}




Appendix Table F20. Pooled diagnostic value of urgency UI symptoms compared to clinical diagnosis (“gold standard”) for any detrusor overactivity^{71,76,81,87}

	Estimate	95% CI	Tau-sq	I2	Q statistic	Degree of freedom	P-value
Specificity	0.671	0.531; 0.785	0.271	0.880	16.715	3.000	0.001
Sensitivity	0.823	0.727; 0.890	0.209	0.804	10.221	3.000	0.017
Positive predictive value	0.724	0.479; 0.882	1.040	0.961	51.159	3.000	0.000
Negative predictive value	0.786	0.543; 0.919	1.168	0.943	34.992	3.000	0.000
Accuracy	0.727	0.646; 0.796	0.114	0.858	14.083	3.000	0.003
Diagnostic odds ratio	11.684	7.321; 18.648	0.044	0.452	3.651	3.000	0.302
Positive likelihood ratio	2.516	1.808; 3.502	0.073	0.807	10.374	3.000	0.016
Negative likelihood ratio	0.257	0.176; 0.375	0.071	0.675	6.156	3.000	0.104

Appendix Figure F20. Sensitivity of stress UI symptoms compared to clinical diagnosis (“gold standard”) for any stress UI^{71,76,81,87,121}




Appendix Figure F21. Specificity of stress UI symptoms compared to clinical diagnosis (“gold standard”) for any stress UI^{71,76,81,87,121}




Appendix Table F21. Pooled diagnostic value of stress UI symptoms compared to clinical diagnosis (“gold standard”) for any stress UI^{71,76,81,87,121}

	Estimate	Lower (95% CI)	Upper (95% CI)	Tau-sq	I2	Q-statistic	Degree of freedom	P-value
Specificity	0.67	0.54	0.78	0.30	0.85	20.10	4	0
Sensitivity	0.88	0.68	0.96	1.64	0.96	79.62	4	0
Positive predictive value	0.80	0.66	0.89	0.56	0.92	39.59	4	0
Negative predictive value	0.75	0.58	0.87	0.58	0.89	27.54	4	0
Accuracy	0.77	0.68	0.84	0.23	0.91	32.37	4	0
Diagnostic odds ratio	13.65	6.91	26.97	0.34	0.72	10.69	4	0.03
Positive likelihood ratio	2.35	1.97	2.81	0.01	0.44	5.39	4	0.25
Negative likelihood ratio	0.19	0.09	0.41	0.61	0.93	44.83	4	0

Appendix Figure F22. Sensitivity of mixed symptoms compared to clinical diagnosis (“gold standard”) for mixed UI^{71,76,81}



Appendix Figure F23. Specificity of mixed symptoms compared to clinical diagnosis (“gold standard”) for mixed UI^{71,76,81}




Appendix Table F22. Diagnostic value of mixed symptoms compared to clinical diagnosis (“gold standard”) for mixed UI^{71,76,81}

	Estimate	95% CI	Tau-sq	I2	Q-statistic	Degree of freedom	P-value
Specificity	0.538	0.206; 0.839	1.707	0.989	94.201	2.000	0.000
Sensitivity	0.651	0.362; 0.859	1.003	0.956	22.724	2.000	0.000
Positive predictive value	0.363	0.269; 0.469	0.101	0.841	6.293	2.000	0.043
Negative predictive value	0.799	0.428; 0.955	2.092	0.980	50.001	2.000	0.000
Accuracy	0.625	0.400; 0.807	0.635	0.984	62.148	2.000	0.000
Diagnostic odds ratio	2.131	0.347; 13.073	2.423	0.971	35.002	2.000	0.000
Positive likelihood ratio	1.567	0.684; 3.587	0.509	0.983	59.879	2.000	0.000
Negative likelihood ratio	0.743	0.284; 1.947	0.657	0.959	24.565	2.000	0.000


Appendix Table F23. Diagnostic value of urgency UI symptoms compared to clinical diagnosis for detrusor overactivity

Reference	True positives [false negatives]	False positives [true negatives]	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Brown, 2006 ⁷¹	96 [23]	57 [125]	0.81	0.69	0.63	0.84
Sandvik, 1995 ⁶⁶	23 [18]	116 [79]	0.56	0.41	0.17	0.81

Appendix Figure F24. Sensitivity of urgency UI symptoms compared to clinical diagnosis for pure detrusor overactivity^{71,76}



Appendix Figure F25. Specificity of urgency UI symptoms compared to clinical diagnosis for pure detrusor overactivity^{71,76}



Appendix Table F24. Pooled diagnostic value of urgency UI symptoms compared to clinical diagnosis for detrusor overactivity^{71,76}

	Estimate	95% CI	Tau-sq	Q- statistic	Degree of freedom	P-value
Specificity	0.550	0.279; 0.793	0.660	29.206	1.000	0.000
Sensitivity	0.702	0.425; 0.882	0.624	9.163	1.000	0.002
Positive predictive value	0.368	0.067; 0.825	2.248	57.170	1.000	0.000
Negative predictive value	0.832	0.780; 0.874	0.000	0.382	1.000	0.537
Accuracy	0.592	0.291; 0.837	0.814	48.453	1.000	0.000
Diagnostic odds ratio	2.847	0.284; 28.566	2.669	27.721	1.000	0.000
Positive likelihood ratio	1.565	0.585; 4.190	0.487	27.556	1.000	0.000
Negative likelihood ratio	0.552	0.147; 2.069	0.871	23.833	1.000	0.000

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Discontinued	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	4/25	6/28	0.75 (0.24; 2.35)	-0.05 (-0.26; 0.15)		
Discontinued	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	4/25	4/22	0.88 (0.25; 3.11)	-0.02 (-0.24; 0.19)		
Discontinued	Patients with DO and urgency	4mg	Placebo		4/25	7/24	0.55 (0.18; 1.64)	-0.13 (-0.36; 0.10)		
Discontinued	Patients with DO and urgency	8mg	Placebo		6/28	7/24	0.73 (0.29; 1.89)	-0.08 (-0.31; 0.16)		
Discontinued	Patients with DO and urgency	12mg	Placebo		22/22	7/24	3.26 (1.79; 5.95)	0.71 (0.52; 0.90)	1	708
Discontinued	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	6/28	4/22	1.18 (0.38; 3.67)	0.03 (-0.19; 0.25)		
Discontinued	Patients with no DO	4mg	Fesoterodine-extended release	8mg	1/18	3/19	0.35 (0.04; 3.08)	-0.10 (-0.30; 0.09)		
Discontinued	Patients with no DO	4mg	Fesoterodine-extended release	12mg	1/18	1/16	0.89 (0.06; 13.08)	-0.01 (-0.17; 0.15)		
Discontinued	Patients with no DO	4mg	Placebo		1/18	1/19	1.06 (0.07; 15.64)	0.00 (-0.14; 0.15)		
Discontinued	Patients with no DO	8mg	Placebo		3/19	1/19	3.00 (0.34; 26.33)	0.11 (-0.09; 0.30)		
Discontinued	Patients with no DO	12mg	Placebo		1/16	1/19	1.19 (0.08; 17.51)	0.01 (-0.15; 0.17)		
Discontinued	Patients with no DO	8mg	Fesoterodine-extended release	12mg	3/19	1/16	2.53 (0.29; 21.98)	0.10 (-0.11; 0.30)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴ (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Any adverse effects	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	22/25	25/28	0.99 (0.81; 1.20)	-0.01 (-0.18; 0.16)		
Any adverse effects	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	22/25	20/22	0.97 (0.80; 1.18)	-0.03 (-0.20; 0.15)		
Any adverse effects	Patients with DO and urgency	4mg	Placebo		22/25	16/24	1.32 (0.96; 1.81)	0.21 (-0.01; 0.44)		
Any adverse effects	Patients with DO and urgency	8mg	Placebo		25/28	16/24	1.34 (0.98; 1.83)	0.23 (0.01; 0.45)	4	226
Any adverse effects	Patients with DO and urgency	12mg	Placebo		20/22	16/24	1.36 (1.00; 1.86)	0.24 (0.02; 0.47)	4	242
Any adverse effects	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	25/28	20/22	0.98 (0.82; 1.18)	-0.02 (-0.18; 0.15)		
Any adverse effects	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	11/25	17/28	0.72 (0.43; 1.24)	-0.17 (-0.43; 0.10)		
Any adverse effects	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	11/25	14/22	0.69 (0.40; 1.19)	-0.20 (-0.48; 0.08)		
Any adverse effects	Patients with DO and urgency	4mg	Placebo		11/25	3/24	3.52 (1.12; 11.09)	0.32 (0.08; 0.55)	3	315
Dry mouth	Patients with DO and urgency	8mg	Placebo		17/28	3/24	4.86 (1.62; 14.59)	0.48 (0.26; 0.71)	2	482
Dry mouth	Patients with DO and urgency	12mg	Placebo		14/22	3/24	5.09 (1.69; 15.36)	0.51 (0.27; 0.75)	2	511
Dry mouth	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	17/28	14/22	0.95 (0.62; 1.47)	-0.03 (-0.30; 0.24)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴ (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Headache	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	5/25	7/28	0.80 (0.29; 2.20)	-0.05 (-0.27; 0.17)		
Headache	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	5/25	4/22	1.10 (0.34; 3.59)	0.02 (-0.21; 0.24)		
Headache	Patients with DO and urgency	4mg	Placebo		5/25	5/24	0.96 (0.32; 2.90)	-0.01 (-0.23; 0.22)		
Headache	Patients with DO and urgency	8mg	Placebo		7/28	5/24	1.20 (0.44; 3.29)	0.04 (-0.19; 0.27)		
Headache	Patients with DO and urgency	12mg	Placebo		4/22	5/24	0.87 (0.27; 2.84)	-0.03 (-0.26; 0.20)		
Headache	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	7/28	4/22	1.38 (0.46; 4.11)	0.07 (-0.16; 0.30)		
Influenza-like symptoms	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	6/25	3/28	2.24 (0.62; 8.03)	0.13 (-0.07; 0.34)		
Influenza-like symptoms	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	6/25	3/22	1.76 (0.50; 6.22)	0.10 (-0.12; 0.32)		
Influenza-like symptoms	Patients with DO and urgency	4mg	Placebo		6/25	2/24	2.88 (0.64; 12.90)	0.16 (-0.04; 0.36)		
Influenza-like symptoms	Patients with DO and urgency	8mg	Placebo		3/28	2/24	1.29 (0.23; 7.07)	0.02 (-0.14; 0.18)		
Influenza-like symptoms	Patients with DO and urgency	12mg	Placebo		3/22	2/24	1.64 (0.30; 8.90)	0.05 (-0.13; 0.23)		
Influenza-like symptoms	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	3/28	3/22	0.79 (0.18; 3.52)	-0.03 (-0.21; 0.15)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴ (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Dizziness	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	0/25	1/28	0.37 (0.02; 8.73)	-0.04 (-0.13; 0.06)		
Dizziness	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	0/25	2/22	0.18 (0.01; 3.50)	-0.09 (-0.23; 0.05)		
Dizziness	Patients with DO and urgency	4mg	Placebo		0/25	2/24	0.19 (0.01; 3.81)	-0.08 (-0.21; 0.05)		
Dizziness	Patients with DO and urgency	8mg	Placebo		1/28	2/24	0.43 (0.04; 4.44)	-0.05 (-0.18; 0.08)		
Dizziness	Patients with DO and urgency	12mg	Placebo		2/22	2/24	1.09 (0.17; 7.10)	0.01 (-0.16; 0.17)		
Dizziness	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	1/28	2/22	0.39 (0.04; 4.06)	-0.06 (-0.19; 0.08)		
Nausea	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	2/25	3/28	0.75 (0.14; 4.11)	-0.03 (-0.18; 0.13)		
Nausea	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	2/25	3/22	0.59 (0.11; 3.20)	-0.06 (-0.23; 0.12)		
Nausea	Patients with DO and urgency	4mg	Placebo		2/25	3/24	0.64 (0.12; 3.50)	-0.05 (-0.21; 0.12)		
Nausea	Patients with DO and urgency	8mg	Placebo		3/28	3/24	0.86 (0.19; 3.86)	-0.02 (-0.19; 0.16)		
Nausea	Patients with DO and urgency	12mg	Placebo		3/22	3/24	1.09 (0.25; 4.85)	0.01 (-0.18; 0.21)		
Nausea	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	3/28	3/22	0.79 (0.18; 3.52)	-0.03 (-0.21; 0.15)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴ (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Constipation	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	1/25	5/28	0.22 (0.03; 1.79)	-0.14 (-0.30; 0.02)		
Constipation	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	1/25	4/22	0.22 (0.03; 1.82)	-0.14 (-0.32; 0.04)		
Constipation	Patients with DO and urgency	4mg	Placebo		1/25	0/24	2.88 (0.12; 67.53)	0.04 (-0.07; 0.15)		
Constipation	Patients with DO and urgency	8mg	Placebo		5/28	0/24	9.48 (0.55; 163.15)	0.18 (0.03; 0.33)	6	179
Constipation	Patients with DO and urgency	12mg	Placebo		4/22	0/24	9.78 (0.56; 171.91)	0.18 (0.01; 0.35)	5	182
Constipation	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	5/28	4/22	0.98 (0.30; 3.23)	0.00 (-0.22; 0.21)		
Abdominal pain	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	2/25	2/28	1.12 (0.17; 7.37)	0.01 (-0.13; 0.15)		
Abdominal pain	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	2/25	3/22	0.59 (0.11; 3.20)	-0.06 (-0.23; 0.12)		
Abdominal pain	Patients with DO and urgency	4mg	Placebo		2/25	0/24	4.81 (0.24; 95.25)	0.08 (-0.05; 0.21)		
Abdominal pain	Patients with DO and urgency	8mg	Placebo		2/28	0/24	4.31 (0.22; 85.62)	0.07 (-0.04; 0.19)		
Abdominal pain	Patients with DO and urgency	12mg	Placebo		3/22	0/24	7.61 (0.42; 139.47)	0.14 (-0.02; 0.29)		
Abdominal pain	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	2/28	3/22	0.52 (0.10; 2.87)	-0.06 (-0.24; 0.11)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴ (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Diarrhea	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	4/25	0/28	10.04 (0.57; 177.65)	0.16 (0.01; 0.31)	6	160
Diarrhea	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	4/25	1/22	3.52 (0.42; 29.18)	0.11 (-0.05; 0.28)		
Diarrhea	Patients with DO and urgency	4mg	Placebo		4/25	0/24	8.65 (0.49; 152.58)	0.16 (0.00; 0.32)	6	160
Diarrhea	Patients with DO and urgency	8mg	Placebo		0/28	0/24	0.00 (0.00; 0.00)	0.00 (-0.07; 0.07)		
Diarrhea	Patients with DO and urgency	12mg	Placebo		1/22	0/24	3.26 (0.14; 76.10)	0.05 (-0.07; 0.16)		
Diarrhea	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	0/28	1/22	0.26 (0.01; 6.19)	-0.05 (-0.16; 0.07)		
Any adverse events	Patients with no DO	4mg	Fesoterodine-extended release	8mg	14/18	14/19	1.06 (0.73; 1.52)	0.04 (-0.23; 0.32)		
Any adverse events	Patients with no DO	4mg	Fesoterodine-extended release	12mg	14/18	13/16	0.96 (0.68; 1.35)	-0.03 (-0.31; 0.24)		
Any adverse events	Patients with no DO	4mg	Placebo		14/18	17/19	0.87 (0.65; 1.16)	-0.12 (-0.35; 0.12)		
Any adverse events	Patients with no DO	8mg	Placebo		14/19	17/19	0.82 (0.60; 1.12)	-0.16 (-0.40; 0.08)		
Any adverse events	Patients with no DO	12mg	Placebo		13/16	17/19	0.91 (0.69; 1.20)	-0.08 (-0.32; 0.15)		
Any adverse events	Patients with no DO	8mg	Fesoterodine-extended release	12mg	14/19	13/16	0.91 (0.63; 1.30)	-0.08 (-0.35; 0.20)		
Dry mouth	Patients with no DO	4mg	Fesoterodine-extended release	8mg	8/18	8/19	1.06 (0.50; 2.21)	0.02 (-0.30; 0.34)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴ (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Dry mouth	Patients with no DO	4mg	Fesoterodine-extended release	12mg	8/18	10/16	0.71 (0.37; 1.35)	-0.18 (-0.51; 0.15)		
Dry mouth	Patients with no DO	4mg	Placebo		8/18	4/19	2.11 (0.77; 5.81)	0.23 (-0.06; 0.53)		
Dry mouth	Patients with no DO	8mg	Placebo		8/19	4/19	2.00 (0.72; 5.53)	0.21 (-0.08; 0.50)		
Dry mouth	Patients with no DO	12mg	Placebo		10/16	4/19	2.97 (1.15; 7.68)	0.41 (0.11; 0.71)	2	414
Dry mouth	Patients with no DO	8mg	Fesoterodine-extended release	12mg	8/19	10/16	0.67 (0.35; 1.29)	-0.20 (-0.53; 0.12)		
Headache	Patients with no DO	4mg	Fesoterodine-extended release	8mg	3/18	0/19	7.37 (0.41; 133.37)	0.17 (-0.02; 0.35)		
Headache	Patients with no DO	4mg	Fesoterodine-extended release	12mg	3/18	3/16	0.89 (0.21; 3.80)	-0.02 (-0.28; 0.24)		
Headache	Patients with no DO	4mg	Placebo		3/18	3/19	1.06 (0.24; 4.57)	0.01 (-0.23; 0.25)		
Headache	Patients with no DO	8mg	Placebo		0/19	3/19	0.14 (0.01; 2.59)	-0.16 (-0.34; 0.02)		
Headache	Patients with no DO	12mg	Placebo		3/16	3/19	1.19 (0.28; 5.09)	0.03 (-0.22; 0.28)		
Headache	Patients with no DO	8mg	Fesoterodine-extended release	12mg	0/19	3/16	0.12 (0.01; 2.19)	-0.19 (-0.39; 0.02)		
Influenza-like symptoms	Patients with no DO	4mg	Fesoterodine-extended release	8mg	2/18	2/19	1.06 (0.17; 6.72)	0.01 (-0.19; 0.21)		
Influenza-like symptoms	Patients with no DO	4mg	Fesoterodine-extended release	12mg	2/18	1/16	1.78 (0.18; 17.80)	0.05 (-0.14; 0.24)		
Influenza-like symptoms	Patients with no DO	4mg	Placebo		2/18	3/19	0.70 (0.13; 3.73)	-0.05 (-0.27; 0.17)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴ (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Influenza-like symptoms	Patients with no DO	8mg	Placebo		2/19	3/19	0.67 (0.13; 3.55)	-0.05 (-0.27; 0.16)		
Influenza-like symptoms	Patients with no DO	12mg	Placebo		1/16	3/19	0.40 (0.05; 3.44)	-0.10 (-0.30; 0.11)		
Influenza-like symptoms	Patients with no DO	8mg	Fesoterodine-extended release	12mg	2/19	1/16	1.68 (0.17; 16.91)	0.04 (-0.14; 0.22)		
Dizziness	Patients with no DO	4mg	Fesoterodine-extended release	8mg	2/18	0/19	5.26 (0.27; 102.66)	0.11 (-0.06; 0.28)		
Dizziness	Patients with no DO	4mg	Fesoterodine-extended release	12mg	2/18	3/16	0.59 (0.11; 3.11)	-0.08 (-0.32; 0.16)		
Dizziness	Patients with no DO	4mg	Placebo		2/18	2/19	1.06 (0.17; 6.72)	0.01 (-0.19; 0.21)		
Dizziness	Patients with no DO	8mg	Placebo		0/19	2/19	0.20 (0.01; 3.91)	-0.11 (-0.27; 0.06)		
Dizziness	Patients with no DO	12mg	Placebo		3/16	2/19	1.78 (0.34; 9.38)	0.08 (-0.15; 0.32)		
Dizziness	Patients with no DO	8mg	Fesoterodine-extended release	12mg	0/19	3/16	0.12 (0.01; 2.19)	-0.19 (-0.39; 0.02)		
Nausea	Patients with no DO	4mg	Fesoterodine-extended release	8mg	4/18	3/19	1.41 (0.36; 5.43)	0.06 (-0.19; 0.32)		
Nausea	Patients with no DO	4mg	Fesoterodine-extended release	12mg	4/18	4/16	0.89 (0.26; 2.98)	-0.03 (-0.31; 0.26)		
Nausea	Patients with no DO	4mg	Placebo		4/18	5/19	0.84 (0.27; 2.66)	-0.04 (-0.32; 0.23)		
Nausea	Patients with no DO	8mg	Placebo		3/19	5/19	0.60 (0.17; 2.16)	-0.11 (-0.36; 0.15)		
Nausea	Patients with no DO	12mg	Placebo		4/16	5/19	0.95 (0.31; 2.95)	-0.01 (-0.30; 0.28)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴ (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Nausea	Patients with no DO	8mg	Fesoterodine-extended release	12mg	3/19	4/16	0.63 (0.17; 2.41)	-0.09 (-0.36; 0.18)		
Constipation	Patients with no DO	4mg	Fesoterodine-extended release	8mg	1/18	2/19	0.53 (0.05; 5.33)	-0.05 (-0.22; 0.12)		
Constipation	Patients with no DO	4mg	Fesoterodine-extended release	12mg	1/18	3/16	0.30 (0.03; 2.57)	-0.13 (-0.35; 0.09)		
Constipation	Patients with no DO	4mg	Placebo		1/18	2/19	0.53 (0.05; 5.33)	-0.05 (-0.22; 0.12)		
Constipation	Patients with no DO	8mg	Placebo		2/19	2/19	1.00 (0.16; 6.38)	0.00 (-0.20; 0.20)		
Constipation	Patients with no DO	12mg	Placebo		3/16	2/19	1.78 (0.34; 9.38)	0.08 (-0.15; 0.32)		
Constipation	Patients with no DO	8mg	Fesoterodine-extended release	12mg	2/19	3/16	0.56 (0.11; 2.96)	-0.08 (-0.32; 0.15)		
Abdominal pain	Patients with no DO	4mg	Fesoterodine-extended release	8mg	0/18	2/19	0.21 (0.01; 4.11)	-0.11 (-0.27; 0.06)		
Abdominal pain	Patients with no DO	4mg	Fesoterodine-extended release	12mg	0/18	3/16	0.13 (0.01; 2.30)	-0.19 (-0.39; 0.02)		
Abdominal pain	Patients with no DO	4mg	Placebo		0/18	2/19	0.21 (0.01; 4.11)	-0.11 (-0.27; 0.06)		
Abdominal pain	Patients with no DO	8mg	Placebo		2/19	2/19	1.00 (0.16; 6.38)	0.00 (-0.20; 0.20)		
Abdominal pain	Patients with no DO	12mg	Placebo		3/16	2/19	1.78 (0.34; 9.38)	0.08 (-0.15; 0.32)		
Abdominal pain	Patients with no DO	8mg	Fesoterodine-extended release	12mg	2/19	3/16	0.56 (0.11; 2.96)	-0.08 (-0.32; 0.15)		
Diarrhea	Patients with no DO	4mg	Fesoterodine-extended release	8mg	1/18	1/19	1.06 (0.07; 15.64)	0.00 (-0.14; 0.15)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)¹⁷⁴ (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Diarrhea	Patients with no DO	4mg	Fesoterodine-extended release	12mg	1/18	2/16	0.44 (0.04; 4.45)	-0.07 (-0.26; 0.12)		
Diarrhea	Patients with no DO	4mg	Placebo		1/18	2/19	0.53 (0.05; 5.33)	-0.05 (-0.22; 0.12)		
Diarrhea	Patients with no DO	8mg	Placebo		1/19	2/19	0.50 (0.05; 5.06)	-0.05 (-0.22; 0.12)		
Diarrhea	Patients with no DO	12mg	Placebo		2/16	2/19	1.19 (0.19; 7.50)	0.02 (-0.19; 0.23)		
Diarrhea	Patients with no DO	8mg	Fesoterodine-extended release	12mg	1/19	2/16	0.42 (0.04; 4.23)	-0.07 (-0.26; 0.12)		

Abbreviation: DO=detrusor overactivity

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Weight loss	Auwad, 2008 ¹⁷⁵	Effects of moderate weight loss in obese women with urodynamic stress UI	64	100	100	Weight reduction program low calorie diet + exercise with a target loss of 5-10%	2 years	Obese women with urodynamic stress UI, 52.5 years old	Weight loss was associated with a significant reduction in pad test loss and significant improvement in quality of life.
Weight loss	Wing, 2010 ¹⁷⁶	To examine the relationship between magnitude of weight loss and changes in urinary incontinence frequency.	338	100	100	Patients were randomly assigned to a 6 month weight loss program followed immediately by a 12-month weight maintenance program or to a structured education program. These groups were combined to examine the effects of the magnitude of weight loss on changes in urinary incontinence	18 months	Program to Reduce Incontinence by Diet and Exercise (PRIDE) trial: Women aged 30 years or older, having a body mass index (BMI) of 25–50, and reporting at least 10 urinary incontinent episodes (including both stress and urgency incontinent episodes) on a 7-day voiding diary at baseline.	The adjusted odds of at least 70% reduction in number of incontinent episodes per week in those who had more than 10% weight loss: At 6 months: Total UI: OR=3.8 (95% CI=1.5-9.6); Stress UI: OR=1.6 (95% CI=0.6-3.9); and Urge UI: OR=4.5 (95% CI=1.4-14.1). At 18 months: Total UI: OR=3.3 (95% CI=1.7-6.4); Stress UI: OR=2.3 (95% CI=1.0-5.1); and Urge UI: OR=4.0 (95% CI=2.1-7.9)

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Pelvic floor muscle training	Hines, 2007 ¹⁷⁷	To assess factors predictive of high adherence to a behavioral intervention to prevent UI	359, but data used for the treatment arm only (n=164)	100	100	Pelvic floor muscle training and bladder training	1 year	359 community-dwelling, post-menopausal women, aged 55 to 80 years old	Women incorporated PFMT into their lives using either a routine or ad hoc approach (Routine approach = Doing PME at set times of the day or linking with a daily routine that occurs at a set time; ad hoc approach = Doing PME when they think of it or by linking with a sporadic cue or situation). Those using a routine approach at 3 months were 12 times more likely to adhere (odds ratio=12.4, CI=4.0-38.8,p<0.001) at a high level at 3 months and significantly more likely to maintain that level 12 months post-intervention (OR=2.7,CI=1.2-6.0,p<0.014). High adherence to PFMT was operationally defined as an adherence score of 5 to 7 (reporting adherence of >=1 1 set of PFMT each day).

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Pelvic floor muscle training	Sugaya, 2003 ¹⁷⁸	Effects of the device to promote adherence to pelvic floor muscle exercise in women with stress UI	46	100	100	Device with a chime to sound three times a day when exercise sessions were scheduled and set a rhythm for the muscle contractions vs. pelvic floor muscle exercise alone	8 weeks	Women with stress UI	Quality of life category was delighted, pleased, or mostly satisfied in 15% patients from the control group and 48% from the device groups
Pelvic floor muscle training	Brubaker, 2008 ¹⁷⁹	Effectiveness of nonmedical pelvic floor muscle training class on UI	102	100	99	Pelvic fitness and education class taught by a lay instructor	11 weeks, 1 year of followup	Adult women with urgency or urgency UI 57.9 year, 11% after surgery for UI or prolapse	The training improved quality of life and sexual function improvements in after vs. before UDI-SF scores. Achievement of self selected goal-71% at 11 weeks, 67% at 1 year
Pelvic floor muscle training	Wang, 2000 ¹⁸⁰	Efficacy of bladder-sphincter-biofeedback in women with detrusor instability who failed to respond to oxybutynin treatment	31	100	100	Bladder sphincter biofeedback vs. pelvic floor muscle training	5 months	Women with urgency syndrome 44,.3 years who failed previous oxybutynin treatment	Continence 12.5% in biofeedback and 13.33% in exercise group. Improvement 87.5% in biofeedback and 86.67% in exercise group. 140 significant differences were found.
Pelvic floor muscle training	Wang, 2000 ¹⁸⁰	Efficacy of bladder-sphincter-biofeedback as a secondary treatment for those women with detrusor instability who failed to respond to oxybutynin chloride	31	100	100	Bladder-sphincter-biofeedback training group or control pelvic floor exercise group	Not reported	Women with detrusor instability who failed to respond to oxybutynin chloride	The cure rate or improvement rate of subjective changes (urgency, and frequency and episodes of urgency incontinence) did not significantly differ between treatments.

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Medical device	Bellin, 1998 ¹⁸¹	Efficacy of CapSure (Re/Stor) continence shield for stress UI in females	100	100	100	CapSure (Re/Stor) continence shield : no control	12 weeks	Women 40-69 years old (mean 54) with pure stress moderate UI and no urgency or urge UI	Continence - 82%, negative pad stress test - 91%; no UI episodes in diary - 48%, Bothersome vaginal or urethral irritation - 12%, positive urine culture - 1.56
Medical device	Crivellaro, 2010 ¹⁸²	To examine effects of the Adjustable Continence Therapy on female UI	60	100	100	Adjustable Continence Therapy implantation that involves two silicone balloons sited on either side of the proximal urethra under the bladder neck, each attached to a titanium port buried in the labia allowing post operative titration of the balloons.	Once	Adult women with stress urinary incontinence resulting from intrinsic sphincteric deficiency	82% were significantly improved, 8% were moderately improved and 10% remained unchanged. Post-operative complications necessitating device removal included migration seen in 8% of patients and urethral erosion in 3.5% of patients
Medical device	Morris, 2003 ¹⁸³	Efficacy of contiform incontinence device in women with stress UI and no prolapse	59	100	100	Contiform incontinence device no control	3 weeks	Women, 42-53 years old, with urodynamic mild to severe stress UI and no prolapse	Continence - 20%, withdrawal - 31%, acute bacterial cystitis - 5%, small degree of fracture of the curvature of device - 22%
Medical device	Allen, 2008 ¹⁸⁴	Efficacy of contiform intravaginal device for stress UI	73	100		Contiform intravaginal device, no control	4 weeks	Women 41-54 years old with predominant stress UI and no prolapse	Continence - 54%, withdrawal, 29%, residual volume >100 ml - 5.4%

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Medical device	Sander, 2008 ¹⁸⁵	The effect of a vaginal device (Continence Guard) on urine leakage and quality of life in women with stress UI	55	100	100	Continence Guard	12 weeks	Women with stress incontinence	Completion -74.5%; subjective cure 20% and improvement in 49%. Score of the Incontinence Impact Questionnaire showed highly significant improvement
Medical device	Hahn, 1996 ¹⁸⁵	Effectiveness of vaginal device for the treatment of female stress UI	90			Conveen Continence Guard	4 weeks	90 women with stress incontinence (mean age 47.5 years, range 31-65).	Continence - 46% Improvement - 29% ; objective improvement - 75%; Failure- 25% 72% of the women considered the product to function satisfactorily and 60% expressed a wish to continue with the treatment; local discomfort - 62%
Medical device	Nilsson, 2000 ¹⁸⁶	Efficacy of the conveen continence guard (a disposable vaginal device) in the treatment of complicated female stress incontinence	28			Decreases from baseline in RR, QRS and QT intervals for patients receiving duloxetine Conveen continence guard (a disposable vaginal device)	3 weeks	Women, with a urodynamically proven stress UI	Completion rate 68%; continence or improved incontinence 58%; objective improvement 55%
Medical device	Pieper, 1993 ¹⁸⁷	The efficacy of external urine-collection device for women with UI	7			External urine-collection device	5 days	Black women with UI, 21-35 years old	1 woman had vulvar irritation and redness; all were satisfied with the device

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Medical device	Versi, 1998 ¹⁸⁸	Efficacy of external urethral device in women with genuine stress urinary incontinence	14			FemAssist- non-invasive supple silicone domed cap that fits over the external urethral meatus	3-4 weeks	Women with symptoms of urinary incontinence and a videourodynamic diagnosis of genuine stress incontinence; mean age was 55 years	>50% improvement on their IIQ - 50% ; improvement in UDI - 21.4% UDI.
Medical device	Versi, 1998 ¹⁸⁹	Efficacy of external urethral device in women with genuine stress UI	131			FemAssist- non-invasive supple silicone domed cap that fits over the external urethral meatus	4 weeks	Ambulatory women with symptoms of UI	Withdrawal -27%; >50% improvement on the Incontinence Impact Questionnaire 59%; in the Urogenital Distress Inventory- 33%
Medical device	Sirls, 2002 ¹⁹⁰	Efficacy of FemSoft urethral insert for female stress urinary incontinence	150			FemSoft urethral insert no control	48-96 weeks	Women with mean age of 53.5 years, stable stress urinary incontinence, mixed UI with predominant stress UI	Continence -93% at 48 months, withdrawal rate - 41%. Adverse effects: urinary tract infection - 31.3%, mild trauma - 6.7%, hematuria - 3.3%. Significant improvement in quality of life.
Medical device	Macaulay, 2007 ¹⁹¹	The effects of Non-Invasive Continence Management System (NICMS) on women with UI	80			Non-Invasive Continence Management System (NICMS)	15 months	Women over 18 years of age with UI	Overall satisfaction 34%; among wheel chair users 21%

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Medical device	Donnelly, 2004 ¹⁹²	Predictors of successful fit and continuous use of pessaries	239			Pessaries	2 weeks, 48 weeks	Women with stress or mixed UI, 57.4 years old	Successful fit- 89.1%, Discontinuation-45%; Reason for discontinuation %: Persistent UI-58%; Discomfort using pessary-33%; Frequent pessary expulsion-18%; Women with pulmonary disease and those who used diuretics were more likely to use pessaries.
Medical device	Brincat, 2004 ¹⁹³	Predictors of discontinuation of pessaries use	136			Pessaries: dishes with and without floor, rings with and without floor, pessary rings with floor	96 weeks	Women with UI	Reason for pessary discontinuation and % sexually active women and women with prolapse used pessaries during study period more often
Medical device	Maito, 2006 ¹⁹⁴	Predictors of continuous use of pessaries	120			Pessary	24 weeks	Women with UI and/or pelvic floor organ prolapse, 61 years of age	Successful fit - 86% Discontinuation - 11% Predictors of unsuccessful fit - history of prolapse, procedure or hysterectomy. Predictors of discontinuation- severe posterior prolapse; Improved stress UI- 94%
Medical device	Sulak, 1993 ¹⁹⁵	Effectiveness of pessaries in women with pelvic relaxation.	107			Pessary Gelhorn	3 years	Women with symptomatic pelvic relaxation, 65.5 years	Discontinuation 46%

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Medical device	Clemons, 2004 ¹⁹⁶	Patient satisfaction and UI after pessary use	100			Pessary ring with floor, Gellhorn (Millex)		Women with systematic pelvic organ prolapse. Stage II or greater; 71 years old	Successful fit-73% Improved stress UI- 45% Improved urge UI - 21%. De novo urge UI - 6% Dissatisfaction 18% was associated with stress UI (OR 17.1; 95% CI, 1.9, 206)
Medical device	Farrell, 2007 ¹⁹⁷	Effectiveness of a new self-positioning women's pessary	32			Pessary Uresta/ EastMed Inc	48 weeks	Women with 41- 50 years old	Satisfaction with pessary - 66% Discontinuation - 34% Continence -47% (among stress UI), 36% (among urge UI) Improved UI- 53% No significant predictions for successful fitting were found
Medical device	Nguyen, 2005 ¹⁹⁸	Predictors of successful pessary fitting and continence pessary use	130			Pessary: Millex products, PeIX/Des Chutes medical products	4 years	Women with pelvic relaxation 66-69 years old	Successful fit- 74% Reasons for unsuccessful fit % Prolapse repair 29% Cystocele repair 21% Stress UI 69% Discontinuation among successfully fitted 50 %
Medical device	Staskin, 1996 ¹⁹⁹	Efficacy of urethral insert for female stress or mixed UI	135			Reliance urinary control insert no control	12 weeks	Women with mean age of 52.6 years of age with pure stress or mixed UI	Continence - 80%, improvement with >80& decrease in urine loss - 95%, adverse events - 13%, bacteriuria - 8%, withdrawal, - 37%

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Medical device	Kocjancic, 2008 ²⁰⁰	Effectiveness of adjustable device for the treatment of recurrent stress UI	49			The Adjustable Continence Therapy (ACT®)	1 year	Women with stress UI who previously failed anti-incontinence surgery	Continence -53%; improvement in UI - 16%; failure- 12%; migrations -12% and urethral or portal erosions -4%
Medical device	Brubaker, 1999 ²⁰¹	The efficacy and safety of an external urethral barrier for mild/moderate stress UI in adult women.	411			Urethral barrier device	12 weeks	Women with mild to moderate stress UI or mixed UI	Withdrawal – 16% comfortable use - 90% Positive urine culture - 4.1% Trace of blood in urine - 21% Bacterial vaginosis - 16%
Medical device	Moore, 1999 ²⁰²	The efficacy and user acceptability of the urethral occlusive device (FemAssist*) for incontinence	97			Urethral occlusive device (FemAssist*)	1 month	Women with UI 65 years of age with UI, 37% with severe UI	Discontinuation rate 41%; Continence 47%; >50% reduction in UI- 33% . Response did not differ by baseline severity of UI or type of UI (stress, urge or mixed incontinence)
Medical device	Sand, 1999 ²⁰³	Efficacy of reliance urinary control insert in women with stress UI	63			Uromed Corp, Needham, MA - reliance urinary control insert-no control	48 weeks	Women with mean age of 55 years old, predominant stress UI	Continence - 79%, urinary tract infection - 29%, gross hematuria - 22%, improved physical functioning and quality of life
Medical device	Aboseif, 2009 ²⁰⁴	Efficacy of adjustable continence device in women with recurrent stress UI	162			Uromedica, Plymouth, Minnesota - adjustable continence device. No control	48 weeks	Women 67.4 years old with recurrent stress UI after 6 months of prior conservative or surgical therapy	Continence - 52%, improvement >50% reduction on stress pad test - 80%, complications - 24.4%, most common adverse effect port erosion - 7.5%

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Stimulation	Indrekvam, 2001 ²⁰⁵	Effectiveness of home managed electrical stimulation in women with stress or mixed UI	3,198			Home managed 2 main types of vaginal/anal electro stimulators, Vitacon Norway AS and Conmax Sports Enterprises	2 years	Women with urge stress, or mixed UI	Discontinuation of treatment - 12% Continence, doctor assessment - 7%, continence patient self report - 4%. Compliers, doctor assessment - 14%, patient self report - 8%. Continence or much better, doctor assessment - 43%, patient self report - 31%. OR of treatment effect assessed by women : Increasing frequency of leakage - 0.82 (0.69;0.96), increasing amount of leakage - 0.77 (0.62;0.95), increasing discomfort with treatment - 0.77 (0.7;0.84)
Stimulation	Galloway, 2000 ²⁰⁶	Effects of extracorporeal magnetic innervation for stress 111 in women	111			Extracorporeal magnetic innervation (ExMI) therapy using Neocontrol chair, 20 minutes, 2 times/ week; 5-50h2	6 weeks, 6 month of followup	Women with stress UI, 55 years old	Countenance - 28% No pad or <1 pad per day- 53% Reduced pad use- 70% In women with recurrent after therapy stress UI or hysterectomy countenance rate was 18% and + improvement - 40%

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Stimulation	Bergstrom, 2000 ²⁰⁷	Efficacy of manual acupuncture could influence urge- or mixed-type incontinence among elderly women who failed previous treatments	15			Manual acupuncture	12 times, 3 months of followup	Elderly women with stress or mixed UI who failed previous treatments	Improvement rate 80%
Stimulation	Nuhoglu, 2006 ²⁰⁸	Efficacy of Stoller afferent nerve stimulation (SANS) in women with overactive bladder who failed anticholinergic treatment	35			Stoller afferent nerve stimulation (SANS)	10 weeks	With overactive bladder who failed therapy with oxybutynin	54% (n=19) women were continent at the end of the treatment but only 23% at followup
Stimulation	van Kerrebroeck, 2004 ²⁰⁹	Efficacy of copolymer system on female UI	42			Nonanimal stabilized hyaluronic acid/dextranomer copolymer injected transurethrally into the urethra via the Implacer TM device	1 year	Women not previously treated by invasive therapy and with urodynamically verified SUI	Satisfaction rate at 3 months -71%, at 9 months- 60%; failure 43%
Stimulation	van Kerrebroeck, 2004 ²¹⁰	Effects of the novel system (NASHA/Dx copolymer insertion using the Implacer) on female UI	42			Nonanimal stabilized hyaluronic acid/dextranomer (NASHA/Dx) copolymer for transurethral injection	12 months	Therapy-naive female patients with stress UI	Improvement - 76%; improvement by at least one category on the 6-point patient perception scale - 69%; Treatment-related AEs-36%.

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Stimulation	Chapple, 2005 ²¹¹	Efficacy of non-endoscopic injection of nonanimal stabilized hyaluronic acid/dexranomer (NASHA/Dx) gel and Implacer device on female stress UI	142			Zuidex TM system for injection of bulking agent NASHA/Dx gel and Implacer TM device	8 weeks, 12 months	Women with stress UI for >12 months 55.7 years old, who failed prior nonsurgical treatments and were not treated with invasive methods.	Reduction in provocation test leakage 750% vs. baseline - 77% at 1 year Continuance- 62% at 1 year Improvement of quality of life - 67% Adverse effects: Urinary retention - 29/142 Urinary tract infection - 17/142 Micturition urgency - 17/142 Injection sit reaction- 11/142 Vaginal discomfort- 10/142 Injection in injection site- 3 serious/142

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Evidence-based self-management tool	Tannenbaum, 2010 ²¹²	To develop and evaluate an evidence -based self-management urinary incontinence risk factor modification tool designed specifically for older women.	103	100	100	Self-management tool developed using evidence from a systematic review on risk factor modification for incontinence and input from focus groups of health care experts and incontinent women. Six risk factors were incorporated into a self-management tool with associated strategies for change and self-monitoring: 1) weak pelvic floor muscles, high caffeine intake (>400mg/day), high body mass index, vision and hearing impairment, smoking and constipation	3 months without intervention and 3 months with intervention	English and French speaking incontinent women 50 years of age and older who reported experiencing urinary incontinence at least twice a week for a period lasting at least 3 months during the prior 2 years were recruited via community-advertising. MMSE scores >24/30	Self-Efficacy Index (max score 150): Coefficient (mean change)=8.7 with 95% highest posterior density interval (CI)=3.6-13.7. UDI-6 (max score 100): Coefficient (mean change)=-7.3 with 95% highest posterior density interval (CI) =-12.3- -2.1. IIQ-7 (max score 100):Coefficient (mean change) =-0.5 with 95% highest posterior density interval (CI) =-5.4-4.9
Adjustable continence therapy	Crivellaro, 2010 ¹⁸²	The Adjustable Continence Therapy is a minimally invasive treatment for females with Stress Urinary incontinence resulting from Intrinsic Sphincteric Deficiency (ISD). This study represents the term results of the first series of patients	60	100	100	Adjustable Continence Therapy implantation that involves two silicone balloons sited on either side of the proximal urethra under the bladder neck, each attached to a titanium port buried in the labia allowing post operative titration of the balloons	Once	Women with stress UI	82% were significantly improved, 8% were moderately improved and 10% remained unchanged. Post-operative complications necessitating device removal included migration seen in 8% of patients and urethral erosion in 3.5% of patients

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Percutaneous tibial nerve stimulation	Vandoninck, 2003 ²¹³	To determine the safety and efficacy of percutaneous peripheral afferent nerve stimulation for treatment of refractive overactive bladder and/or pelvic floor dysfunction.	53	90.20	Not reported	Percutaneous Tibial Nerve Stimulation: 12 sessions	12 weeks	Patients older than 18 years with documented urgency, frequency, and/or pelvic floor dysfunction resulting in a mean frequency of at least 10 voids/day and/or 3 voids/night. In all these patients, all traditional therapy had failed.	Dependent on baseline conditions, treatment with the percutaneous device in the acute treatment phase (12 weeks) resulted in at least a 25% reduction or improvement in daytime frequency for 55.2% of patients having 10 or greater voids per day ($p < 0.05$), an average 25% reduction or improvement in mean daytime voiding frequency ($p < 0.05$), an average 22% reduction or improvement in mean 24-hour voiding frequency ($p < 0.05$) and an average 70% reduction, that is "mean daytime frequency defined as the mean number of voids greater than 10 per patient per day" ($p < 0.05$). Overall, treatment with the device resulted in an average 21% reduction or improvement in mean nighttime voiding frequency ($p < 0.05$). Overall, patients had a 35% reduction or improvement in daytime and nighttime urgency incontinence or leak episodes during the 12-week treatment ($p < 0.05$). 71% patients were

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Percutaneous tibial nerve stimulation	Vandoninck, 2003 ²¹⁴	To evaluate urodynamic changes after percutaneous tibial nerve stimulation (PTNS) for the treatment of complaints related to overactive bladder syndrome and to search for urodynamic-based predictive factors	90	74.44	75	Percutaneous Tibial Nerve Stimulation: 12 sessions	Not reported	Patients with overactive bladder syndrome (defined as urgency, frequency, and/or urgency incontinence) were enrolled. For urgency and urgency incontinence, International Continence Society definitions were used. Urinary frequency was defined as eight voids or more per 24 hours.	The objective success rate was 56% (leakages/24 hours). Subjective success rate was 64%. Subjects without detrusor instabilities at baseline were 1.7 times more prone to respond to PTNS (odds ratio, 1.75; 95% confidence interval [CI], 0.67-4.6). The more the bladder overactivity was pronounced, the less these patients were found to respond to PTNS, the area under the receiver operating curve was 0.644 (95% CI, 0.48-0.804).

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Percutaneous tibial nerve stimulation	Govier, 2001 ²¹⁵	To evaluate the effect of posterior tibial nerve stimulation for the treatment of urgency incontinence	35	71.43	100	Percutaneous Tibial Nerve Stimulation: 12 sessions	Not reported	Patients with symptoms of urgency incontinence	A total of 24 patients (69%) showed a reduction in incontinence episodes (primary outcome measure) of more than 50%; of these 24 patients, 16 had no leakage episodes. 22 patients (63%) reported a subjective success. Severity of incontinence and number of pads used, decreased more than 50% in 19 (54%) and 20 patients (57%), respectively.

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Percutaneous tibial nerve stimulation	Woolridge, 2009 ²¹⁶	To evaluate the application of percutaneous tibial nerve stimulation, a minimally invasive neuromodulation therapy	53	98.11	79.25	Percutaneous Tibial Nerve Stimulation: 12 sessions of 30 minutes duration each	12 weeks	Patients with chronic OAB symptoms referred to a community-based, nurse practitioner-led continence practice; older than 18 years with documented urgency, frequency, and/or pelvic floor dysfunction resulting in a mean frequency of at least 10 voids/day and/or 3 voids/night.	Patients experienced a statistically significant average decrease in daytime voids of 27.9% from baseline (p <0.0001). Patients experienced an average 63.5% decrease in nighttime voids from baseline (p <0.0001). Thirty-seven of the 42 patients reporting incontinence at baseline (88%) improved with 59.5% (25 of 42) patients cured (such as reporting no incontinence episodes during the period of review for the study).

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Percutaneous tibial nerve stimulation	Vandoninck, 2004 ²¹⁷	To determine urodynamic changes and predictive factors in patients with voiding dysfunction who underwent 12 percutaneous tibial nerve stimulations	39	69.23	Not reported	Percutaneous Tibial Nerve Stimulation: 12 sessions of 30 minutes duration each	12 weeks	Patients with idiopathic non-obstructive voiding dysfunction; symptoms existed for a minimum of 6 months	In 13 out of 23 patients, more than 50% decrement in 24 hour total catheterized volume was obtained. Another eight subjects noticed a reduction of their 24 hour residual volume with more than 25%. Side effects: diarrhea, headaches, calf cramps, and low back pain were reported; one patient did not complete the treatment because of aggravating pre-existing heart rhythm problems. However, these adverse effects were considered not to be related to PTNS.

Appendix Table F26. Clinical outcomes after nonpharmacological treatments in nonrandomized studies (continued)

Intervention	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
PFMT and electrical stimulation	Surwit, 2009 ²¹⁸	The hypothesis of the study is that adding percutaneous tibial nerve neuromodulation with pelvic floor muscle rehabilitation is safe, and more successful than either therapy alone for the treatment of urgency incontinence	256	100	100	Eight traditional PFMR (Pelvic Floor Muscle Rehabilitation) twice a week with biofeedback, PFMT exercises, and electrical stimulation at 100 Hz, and then an additional 8 weekly electrical stimulations at 10 Hz, utilizing the Hollister Evadri bladder control system equipment.	8 weeks	Patients with both urgency incontinence and mixed (urgency and stress incontinence) were eligible for this prospective clinical trial	935 achieved a totally dry status and an OAB-V8 score of less than 8, three months after the completion of their treatment (The criteria for successful treatment was an absence of incontinent episodes (dry) and an OAB-V8 score less than 8, indicating no OAB). The remaining 7% patients had a median improvement in UI episodes of 84%. No patient improved less than 70%, and all felt that the treatment had significantly improved their quality of life. The urge continence patients had a 94% dry rate at three months, while the mixed incontinence patients had a 91% dry rate. There were no adverse side events.

Appendix Table F27. Pharmacological treatments for female UI

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Abrams, 1998 ²¹⁹ RCT Multinational N: 293	Men and women aged ≥18 years having urodynamically confirmed bladder overactivity, an increased frequency of micturition (≥8 micturitions/24h) and urgency incontinence (≥1 incontinent episode/24h) and /or urgency during a 2-week washout/run-in period	Clinically significant stress incontinence; detrusor hyper-reflexia; hepatic, renal or hematological disorders; symptomatic or recurrent urinary tract infection; bladder outlet obstruction; those receiving bladder training, electro stimulation therapy; those with an indwelling catheter or who were on intermittent catheterization; pregnant or nursing women; or women of childbearing age who were not using reliable contraception	tolterodine	oxybutynin	Pharmacia and Upjohn AB, Uppsala, Sweden	Not reported
Abrams, 2006 ²²⁰ RCT UK N: 77	Men and women (aged >18 years) with a clinical diagnosis of idiopathic OAB with detrusor overactivity and two or more of the following OAB symptoms during the 2-week run-in period were enrolled: urinary frequency (7 or more micturitions/day), urgency incontinence (one or more episodes necessitating a change of clothing or pad), or urinary urgency (7 or more episodes preceding micturition/week)	Clinically significant hepatic, renal, or cardiac abnormalities; stress incontinence; evidence of untreated narrow angle glaucoma; urinary and gastric retention; bladder outlet obstruction >40 (Abrams-Griffiths number); indwelling catheter; recent urogenital surgery; and use of investigational drugs in the 30 days preceding the study	Propiverine 20 mg once daily or propiverine 15 mg three times daily or oxybutynin 5 mg three times daily	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Abrams, 2008 ⁴⁷ Pooled N: 1,059	Pooled analysis of three RCTs: Women and men, age >18 years with reported symptoms of OAB for >6 months, 5–50 episodes of UI per week during the treatment-free or placebo run-in periods, together with an increased frequency of micturition (a mean of at least 8 voids per day) and urgency (a mean of at least one episode per day)	The presence of clinically significant stress UI (i.e., >1 episode of stress UI per week), BOO and/or a postvoid residual urine volume of >200 mL (as measured by pelvic ultrasound); contraindications to antimuscarinic therapy (e.g., uncontrolled narrow-angle glaucoma, urinary retention, gastric retention).	Darifenacin 7.5 mg and 15 mg once daily	Placebo	ACUMED [®] provided editorial and project management services for this manuscript. Funding for this was provided by Novartis Pharma AG.	Paul Abrams is a consultant to Novartis Pharma AG and Jasper Huels, Erhard Quebe- Fehling, Mohamed A. Omar and Michael Steel are all employees of Novartis Pharma AG.
Altan-Yaycioglu, 2005 ²²¹ RCT Turkey N: 52	Women with urodynamic diagnosis of overactive bladder	History of ocular disease or surgery; dry eyes, ocular surface disorders, glaucoma, or issues that could affect visual acuity or accommodation (such as cataract, macular degeneration, or history of ocular surgery)	2 mg tolterodine bid	5 mg oxybutynin tid	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Appell, 1997 ²²² Pooled N: 1,120	Pooled analysis of 4 RCTS: men and women with detrusor overactivity (phasic detrusor contraction with an amplitude ≥ 10 cm H ₂ O); and urinary frequency (an average of 28 micturitions/24 hours) and urgency incontinence (an average of ≥ 1 incontinence episode/24 hours) or urinary frequency.	Clinically significant stress incontinence; hepatic or renal disease; recurrent urinary tract infections (UTIs); interstitial cystitis; uninvestigated hematuria or hematuria secondary to malignant disease; indwelling catheter or intermittent catheterization; treatment with any investigational drug in the 2 months prior to entry; previous treatment with tolterodine; electro stimulation therapy or bladder training within 14 days prior to entry or initiation during the study; treatment with any anti-cholinergic drug or any drug for urinary incontinence within 14 days prior to the baseline visit or initiation during the study; unstable dosage of any treatment with anticholinergic side effects of initiation of such treatment during the study; previously demonstrated serious side effects on oxybutynin; an average total voided volume $>3,000$ ml/24 hours; and clinically significant voiding difficulty with risk of urinary retention.	Tolterodine 2 mg twice daily; tolterodine 1 mg twice daily; oxybutynin (5 mg three times daily)	Placebo	Not reported	Not reported
Appell, 2001 ²²³ The OBJECT (Overactive Bladder: Judging Effective Control and Treatment) U.S. N: 378	Participants with overactive bladder who had between 7 and 50 episodes of urgency incontinence per week and 10 or more voids per 24 hours were included. Those with mixed stress and urgency incontinence were eligible if the majority of the leakage accidents were related to urgency	Urinary tract infection, interstitial cystitis, urinary tract obstruction, urethral diverticulum, bladder tumor, bladder stone were excluded, as were those who had delivered a baby or undergone pelvic, vaginal, or bladder surgery less than 6 months before study enrollment; participants with a post-void residual urine volume of more than 150ml at the time of screening; those at considerable risk of developing complete urinary	10 mg/d of extended-release oxybutynin	2 mg twice daily of tolterodine	ALZA Corporation, Mountain View, California	Dr Appell is an adviser, investigator, and speaker for ALZA Corporation and a speaker and investigator for Pharmacia Corporation. Dr Sand is an adviser, investigator, and speaker for ALZA Corporation and an

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
	incontinence.	retention if placed on an anti-muscarinic agent; those with clinically important medical problems or other organ abnormalities or pathologies for whom administration of extended-release oxybutynin or tolterodine would present undue risk (medically uncontrolled cardiovascular, pulmonary, gastrointestinal, renal, endocrine, neurological, autoimmune, hematological, urological, or psychiatric disorders; severely reduced hepatic function or renal impairment); subjects with hematuria, or a positive urine culture; those with narrow-angle glaucoma; obstructive uropathy; myasthenia gravis; pelvic organ prolapse to the hymenal ring; gastrointestinal conditions such as partial or complete obstruction, preexisting severe gastrointestinal narrowing (pathologic or iatrogenic), decreased gastrointestinal motility (paralytic ileus, intestinal atony, chronic and severe constipation), or risk of gastric retention; those who had taken an investigational drug within the previous month; those with known allergies or hypersensitivities to oxybutynin chloride, tolterodine tartrate, or components of the respective drugs; current alcohol or other drug abuse; women who were pregnant or breastfeeding; those who were not capable of following the study schedule or directions; and those who were not able to swallow the medication without chewing, crushing, biting, dividing, or				investigator for Pharmacia Corporation

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
		dissolving the capsule.				
Armstrong, 2005 ²²⁴ RCT N: 790	Post hoc analysis of the OPERA study: Women 18 years and older, with urinary urgency incontinence (21–60 episodes/week), urinary urgency, and frequency (on average at least 10 voids per day); may have a history of prior treatment with an antimuscarinic drug for overactive bladder	Treatable genitourinary conditions that could cause incontinence, 2 postvoid residual urine volumes greater than 150 ml at the time of screening, significant risk of developing complete urinary retention, clinically significant medical condition that could put the patient at undue risk from anti-cholinergic effects, hematuria, uncontrolled narrow-angle glaucoma, obstructive uropathy, reduced gastrointestinal motility, or known hypersensitivity to the study medications.	Extended release oxybutynin 10 mg once daily	Extended release tolterodine 4 mg once daily	Not reported	Not reported
Armstrong, 2007 ²²⁵ Pooled U.S.N: 1,168	OBJECT and OPERA trials: men and women 18 years of age and older with a diagnosis of overactive bladder with 7–50 episodes of urge UI/week in the OBJECT study and 21–60 episodes/week in the OPERA study	Reported previously ^{223, 226, 227}	Extended-release oxybutynin 10 mg qd	Extended-release tolterodine 4 mg qd; Immediate-release tolterodine 2 mg bid	This report was supported by Ortho Women's Health and Urology Division of Ortho Pharmaceutica I, Inc.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Barkin, 2004 ^{22b} UROMAX Study Group. Canada N: 125	Men and women with UI (≥7 episode/week) and frequency (≥8 micturitions/day)	Postvoid residual volume >100 mL; unstable dosage of any drug with anticholinergic or diuretic/antidiuretic side effects; allergy or previous life-threatening side effects with anticholinergic/antispasmodic medications; primary diagnosis of stress UI; conditions contraindicating anticholinergic therapy; daily fluid intake >3L; hepatic/renal disease; diagnosed painful bladder syndrome; uninvestigated voiding difficulty with risk of urinary retention, uninvestigated hematuria, hematuria secondary to malignant disease; urinary tract infection (UTI) or history of recurrent UTI (>3 UTIs/year); indwelling catheter or bladder training within 14 days of screening; drug/alcohol abuse; untreated psychiatric conditions affecting completion of voiding diaries; chronic untreated constipation; bladder outlet obstruction; pregnancy or breastfeeding; failure to use reliable contraception in women of childbearing potential.	CR oxybutynin 15 mg every morning	IR oxybutynin 5 mg t.i.d.	Purdue Pharma	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Bent, 2008 ²²⁹ RCT U.S. N: 588	Women, 19-85 years old with ≥ 4 incontinence episodes/week (at least one SUI and at least one UUI episode) for a minimum of three consecutive months prior to study entry	Treatment of UI by a specialist (a urologist, urogynecologist, gynecologist whose practice emphasized incontinence, continence nurse or advisor, or physiotherapist) within the past 5 years; an active urinary tract infection; the use of medication for UI within 3 months; any previous use of duloxetine; surgery within 6 months; pelvic organ prolapse greater than ICS Stage II; any non-pharmacological intervention (e.g., electrical stimulation, bladder training, continence devices) within 3 months; pelvic floor muscle training that had not been stable for 3 months or would not remain stable during the trial; and a major neurological lesion affecting lower urinary tract function.	Duloxetine 40 mg twice daily	Placebo	Eli Lilly and Company; Boehringer Ingelheim GmbH	Not reported
Birns, 2000 ²³⁰ The Oxybutynin CR Clinical Trial UK N: 130	Outpatients of either sex, aged 18-76 years, with voiding problems which were currently stabilized on and tolerant to treatment with the referent drug, were recruited.	Patients with any medical condition for which anticholinergic medication is contraindicated or with a history of myasthenia gravis, glaucoma or functional or organic gastrointestinal obstructive disorders; patients with symptomatic UTIs, clinically significant BOO or symptoms of only nocturnal enuresis; female patients who were pregnant, lactating, or of child-bearing age and using adequate contraceptive measures.	oxybutynin - controlled release	oxybutynin	Funded by Leiras Oy and Pharmacia & UpJohn	NR

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Blom, 1995 ²³¹ RCT The Netherlands N: 19	19 ambulant elderly women (52 years and older) with confirmed urgency incontinence	History of breast and endometrial cancer, thromboembolic disorders, severe hypertension, cardiac failure, diabetes mellitus, peptic ulceration	1. Estradiol transdermal therapeutic system (0.05mg estradiol/day). 2. Estradiol transdermal therapeutic system (0.05mg estradiol/day) combined with naproxen 250mg tablets twice daily.	Placebo	CIBA, Isando, South Africa supplied Estraderm TTS and PHARMATEZ Pharmaceutica ls. Lyndhurst, Johannesburg, South Africa supplied naproxen tablets	Not reported
Bodeker, 2010 ²³² Post-hoc N: 1,658	Men and women 18 years of age or older with urinary frequency (8 or more micturitions every 24 hours) plus urgency incontinence (5 or more episodes per week)	Subjects with a total daily urine volume of 2.8L or more, a mean micturition volume of more than 250mL, and/or a clinically significant bladder outlet obstruction (i.e., post void residual urine volume of more than 100mL); those with indwelling catheter or intermittent self-catheterization; urinary tract infection at the screening visit; interstitial cystitis and/or hematuria; contraindications to anticholinergic therapy (e.g., untreated narrow-angle glaucoma, mechanical gastrointestinal stenosis, myasthenia gravis syndrome), tachycardiac arrhythmia, severe psychiatric illnesses, hypersensitivity to trospium or oxybutynin or one of the vehicle ingredients; participation in a bladder training or electro stimulation program, or in another study within the past 30 days.	Trospium chloride	Oxybutynin chloride	Dr. R .Pfleger GmbH (Bamberg, Germany) sponsored the parent study and the post hoc analysis	Rolf-Hasso Bodekar is paid consultant to Dr. R. Pfleger GmbH. Claudia Neumeister is Project Manager Clinical Research of Dr.R.Pfleger GmbH. Helmut Madersbacher and Michael Zellner declare that they have no competing interests to disclose

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Brubaker, 2008 ²³³ Pelvic Floor Disorders Network. U.S. N: 43	Women at least 21 years with refractory urgency incontinence, detrusor overactivity incontinence and 6 or greater urgency incontinence episodes in 3 days	Not reported	BoNT-A (200 U)	Placebo	Grants from the National Institute of Child Health and Human Development	Not reported
Brunton, 2010 ²³⁴ RCT N: 17,822	52 multicenter studies with data from 17,822 patients. All patients were at least 18 years of age	Not reported	Duloxetine	Placebo	Sponsored/ supported by Eli Lilly and Company and Boehringer Ingelheim, GmbH	Fujun Wnag, S.Beth Edwards, Antonio Crucitti, Melissa Ossana, Daniel Walker and Michael Robinson own stock in and are employees of Eli Lilly and Company. Stephen Brunton has acted as consultant for Eli Lilly and Company, Novo Nordisk and Amylin Pharmaceuticals, Inc.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Bump, 2003 ¹⁰³ Duloxetine Urinary Incontinence Study Group. U.S. N: 553	The Duloxetine Urinary Incontinence Study Group: Women aged 18–65 years with urinary incontinence of at least 3 months' duration. The case definition included a predominant symptom of stress urinary incontinence with a weekly incontinent episode frequency of at least four; the lack of predominant symptoms of enuresis or urge urinary incontinence; diurnal and nocturnal frequencies less than eight and less than three, respectively, on screening history; negative funnel infusion cystometry with a first sensation greater than 100ml and a bladder capacity of at least 400ml; and a positive fixed volume cough stress test and stress pad test (greater than 2g).	Prolapse stage II or greater; had a postvoid residual volume of 50 mL or more; were using any pharmacologic agent or device for urinary incontinence; had adopted or changed behavioral management for urinary incontinence within 3 months; or had a history of prior continence surgery.	Duloxetine 20 mg per day (20 mg once daily), duloxetine 40 mg per day (20 mg twice daily), duloxetine 80 mg per day (40 mg twice daily)	Placebo	This work was sponsored by Eli Lilly and Company. Dr. Bump and Dr. Yalcin are full-time employees of Eli Lilly and Company and hold stock and stock options in the company.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Bump, 2008 ²³⁵ Pooled European countries N: 3,939	Women were >18 years with a clinical diagnosis of predominant SUI (an incontinence episode frequency, IEF of >7/week) identified with an identical, validated clinical algorithm that required a retrograde-filling bladder capacity of 400 mL and a positive cough-stress test and stress pad test. For study 4, the major diagnostic criteria were age >18 years and predominant SUI symptoms with an IEF >4/week and urine leakage most often associated with activity. Cohort B included 2,515 patients from not published RCT with predominant SUI that was defined as twice as many SUI episodes as urge UI episodes on the S/UIQ.	Not reported	Duloxetine 40-mg twice daily	Placebo	The studies and these analyses were sponsored by Eli Lilly and Company and by Boehringer Ingelheim GmbH.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Burgio, 2001 ²³⁶ RCT N: 197	Older, community-dwelling women at least 55 years of age, ambulatory, with predominant urgency incontinence (the number of urge accidents had to exceed the number of stress and other accidents) at least twice per week and persisting for at least 3 months.	Continual leakage, postvoid residual urine volume greater than 200 ml, uterine prolapse past the introitus, narrow-angle glaucoma, unstable angina, decompensated congestive heart failure, history of malignant arrhythmias, or impaired mental status (MMSE score below 20).	Four clinic visits at 2-week intervals; biofeedback-assisted behavioral treatment implemented by nurse specialist, or drug treatment with oxybutynin chloride 2.5 mg of oxybutynin chloride three times a day	Placebo; self-monitoring (bladder diary), and therapist contact	Supported by Grants AG 08010	Not reported
Burgio, 2000 ²³⁷ RCT analysis U.S. N: 197	Older, community dwelling women with urgency incontinence at least twice per week (the number of urge accidents had to exceed the number of stress accidents) and persisting for at least 3 months; urodynamic evidence of bladder dysfunction (detrusor instability during filling or provocation or maximal cystometric capacity of 350ml or less).	Continual leakage, postvoid residual urine volume >200ml, uterine prolapse past the introitus, narrow-angle glaucoma, unstable angina, decompensated congestive heart failure, history of malignancy arrhythmias, or impaired mental status (MMSE score <20).	Oxybutynin chloride individually titrated from 2.5 mg to 15 mg daily	2.5 to 5mg t.i.d./ Placebo	Supported by Grants AG 08010	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Burgio, 1998 ²³⁸ RCT U.S. N: 197	Adults with at least 2 urge accidents per week on the 2-week baseline bladder diary, and urgency incontinence had to be the predominant pattern (the number of urge accidents had to exceed the number of stress accidents). Also, there had to be urodynamic evidence of bladder dysfunction (detrusor instability filling or provocation or maximal cystometric capacity of ≤ 350 ml).	Continual leakage, postvoid residual urine volume >200 mL, uterine prolapse past the introitus, narrow-angle glaucoma, unstable angina, decompensated congestive heart failure, history of malignant arrhythmias, or impaired mental status (MMSE score <20).	Oxybutynin chloride, possible range of doses, 2.5 mg daily to 5.0 mg 3 times daily	Behavioral Training: biofeedback-assisted PFMT/ placebo	Grants AG08010	Not reported
Burgio, 2008 ²³⁹ Fitzgerald, 2008 ²⁴⁰ Zimmern, 2010 ²⁴¹ Urinary Incontinence Treatment Network. U.S. N: 307	The BE-DRI (Behavior Enhances Drug Reduction of Incontinence) trial: at least 7 episodes of incontinence in the diary, persistent incontinence for at least 3 months, no current use of antimuscarinic or other medications that could affect UI, and no evidence that incontinence was secondary to neurologic or other systemic diseases	Age <21 years; pregnancy, plan to become pregnant in the next 8 months, or declining medically acceptable birth control; <6 months postpartum delivery or other termination after 20 weeks of gestation; inability to contract pelvic floor muscles during evaluation; participated in a formal behavioral therapy program of >2 months in the past 2 years; reported continual leakage or always being damp; hypersensitive to study drug (extended-release tolterodine); systemic disease known to affect bladder function (e.g., Parkinson's disease, multiple sclerosis, spina bifida, or spinal cord injury or trauma); currently using catheter to empty bladder; postvoid residual volume >150 ml; treatment for pelvic organ prolapsed with pessary <3 months; incontinence, vaginal,	Tolterodine tartrate (extended-release capsules), 4 mg/day + behavioral intervention: teaching pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions, and prevent both stress and urge	Tolterodine tartrate (extended-release capsules), 4 mg/day	Grant support by the National Institute of Diabetes and Digestive and Kidney diseases. Additional support, including provision of study drugs and funding, was contributed by Pfizer	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
		bladder, or prolapse surgery in the past 6 months; urethral diverticulum, current or repaired; previous augmentation cystoplasty or artificial sphincter; neuromodulation for pelvic indications; currently using anticholinergic agents, cholinergic agonists, tricyclic antidepressants, or duloxetine-must have discontinued use for ≥ 4 weeks; currently using diuretics with dosage change in past 3 months; uncontrolled medical problem (e.g., poorly controlled diabetes or decompensated congestive heart failure); history of bladder or pelvic cancer or pelvic radiation therapy; glaucoma, with or without ophthalmologist clearance; gastric retention (by medical history); non-ambulatory (may use assisted device); and participation in another intervention trial that might influence the results of the trial.				

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Burgio, 2010 ²⁴² RCT N: 64	Community dwelling women with urgency predominant incontinence. Incontinence for 3 or more months, no formal behavioral therapy, an average of 2 or more urgency incontinence episodes per week on bladder diary, number of urgency incontinence episodes exceeding other types and cystometric evidence of bladder dysfunction (detrusor overactivity or reduced bladder capacity)	Not reported	Pelvic Floor Muscle training +Urge suppression techniques +Oxybutynin	Oxybutynin	Supported by a grant from the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service, and the Female Veterans Project, Birmingham/Atlanta Geriatric Research Education and Clinical Center, Birmingham VA Medical Center	Kathryn Burgio has financial interest and/or other relationship with Pfizer and Astellas; Patricia Goode has financial interest and/or other relationship with Pfizer; Holly Richter has financial interest and/or other relationship with Xanodyne, Pfizer and Astellas; Theodore Johnson has financial interest and/or other relationship with Aventis, Yamanouchi, Ortho McNeil, Boehringer Ingelheim, Johnson & Johnson and Pfizer
But, 2010 ²⁴³ SOLDAIR N: 77	Women with OAB symptoms	Not reported	solifenacin	darifenacin	Funded by a research grant from Astellas, Europe	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Cardozo, 2010 ²⁴⁴ RCT followed by open-label Multinational N: 2,758	Women aged ≥18 years with SUI, defined by either urodynamic evaluation within 12 months before study entry without intervening continence surgery or significant change in symptoms, or by episodes of SUI confirmed by question 1 of the validated Stress/Urgency incontinence Questionnaire(S/UIQ). In addition, eligible patients had at least twice as many SUI episodes as urgency incontinence episodes as defined by question 2 of the S/UIQ and an average of ≥7 incontinence episodes	Pregnancy; alcohol abuse; active or chronically recurring urinary tract infection; presence of ureteric, bladder, urethral or rectal fistula; uncorrected congenital abnormality leading to incomplete emptying or advanced pelvic organ prolapse (stage III or IV by ICS POP-Q criteria); active or chronic hepatitis A, B or C; previous urinary incontinence surgery; or any other condition that, in the opinion of the investigator, precludes evaluation of response to duloxetine hydrochloride. Patients were not allowed to be on a medication regimen that included diuretics where dose and/or frequency were unstable, nor did they allow taking other medications that were demonstrated to be effective for SUI. Subjects who regularly performed pelvic floor muscle exercises could not change their exercise regimen during the course of the study and subjects who did not perform pelvic floor exercises were not permitted to start during the study.	duloxetine	Placebo	Sponsored by Eli Lilly and Company and by Boehringer Ingelheim GmbH	L.C. has disclosed being in receipt of funding for research, lecturing, and/or advice/consultancies from Astellas, Pfizer, UCB Pharma, Plethora, cook, Organon, Biocell, and Sanofi-Aventis. R.L. is a member of European and German advisory boards and speaker in Lilly-sponsored congresses or training sessions. S.V., A.B., M.M., L.V. and Y.D.Z. are employed by Eli Lilly and Company and potentially own stock and/or hold stock options in the company
Cardozo, 2006 ²⁴⁴ Pooled N: 3,298	Men and women at least 18 years of age with a mean of >8 micturitions/day; >1 incontinence episode/day; >1 urgency episode/day	Reported previously ⁵²	Solifenacin 5 mg; solifenacin 10mg	Placebo	Grant from Yamanouchi Pharmaceutica I Co., Ltd., Tokyo, Japan.	Not reported
Cardozo, 2004 ²⁴⁵ RCT Australia, Canada, the	Women aged 18–75 years with severe stress urinary incontinence defined with both urodynamic and severity criteria. Pure	Not reported	Duloxetine (40 mg twice daily for 4 weeks, escalating to 60 mg twice daily	Placebo	This work was sponsored by Eli Lilly and Company and Boehringer	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Netherlands, and the K N: 109	urodynamic stress incontinence was defined as a predominant complaint of stress urinary incontinence and the finding of urodynamic stress incontinence without detrusor overactivity and with normal compliance on an urodynamic study within 6 months of enrollment. All urodynamic diagnoses conformed to the standards of the International Incontinence Society. Severity criteria included both 1) that the subject have at least 14 incontinence episodes per week and 2) that she had scheduled her continence surgery after having discussed all other reasonable options for stress urinary incontinence with her physician. Intrinsic sphincteric deficiency was defined as urodynamic stress incontinence with a maximum straining urethral axis less than 20o, maximum urethral closure pressure less than 20cm H2O, or Valsalva leak-point pressure less than 60 cm H2O.		for another 4 weeks)		Ingelheim.	

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Cardozo, 2004 ⁵¹ RCT N: 911	Men and women 18 years old or older with symptoms of OAB (including urinary frequency with urgency and/or urgency incontinence) for 3 months or more with an average micturition frequency of >8 times/day, with >3 episodes of urgency and/or >3 episodes of UI during the 3-day micturition period.	Reported previously ⁵²	Solifenacin 5 mg, solifenacin 10 mg	Placebo	Not reported	Not reported
Cartwright, 2011 ²⁴⁶ RCT UK N: 96	Adult women attending as new or followup patients between October 2006 and December 2007, with at least a 3-month history of OAB symptoms, with or without urgency urinary incontinence, were invited to participate. This included patients with mixed urinary incontinence symptoms, unless previous urodynamics had demonstrated isolated urodynamic stress incontinence.	History of hypersensitivity to oxybutynin or a previous transdermal skin patch; pregnancy or breastfeeding, voiding difficulties (flow rate <15 mL/s, or post void residual >50mLs), current UTI, or one of a number of medical complaints contraindicating anticholinergic treatment as detailed in the Summary of Product Characteristics for the licensed drug Kentera, including narrow-angle glaucoma and myasthenia gravis. Participants could be naive to anticholinergic treatment, previous anticholinergic users or current anticholinergic users, provided that they discontinued other anticholinergic agents at study entry. Participants taking any contraindicated medication listed in the Summary of Product Characteristics, or any other medication for incontinence, including duloxetine, were also excluded.	Oxybutynin	Placebo	Unrestricted educational grant from UCB Pharma	Rufus Cartwright is a study investigator funded by UCB Pharma and has a financial relationship with a competitor of the mentioned product; Sushma Srikishna and Dudley Robinson were both funded by UCB Pharma and have a financial relationship with a competitor of the mentioned product; Linda Cardozo is a paid consultant for, and was funded by, UCB Pharma, and has a financial relationship with a competitor of the mentioned product.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Castro, 2008 ²⁴⁷ RCT Brazil N: 118	Women with proven urodynamic stress urinary incontinence and no detrusor overactivity; positive cough stress test; and >3g leakage measured by a pad test with a standardized bladder volume (200ml). All subjects had symptoms of SUI with an average of at least 3 stress incontinence episodes a week	Patients with chronic degenerative diseases that would affect muscular and nerve tissues, advanced genital prolapses, pregnancy, active or recurrent urinary tract infections, vulvovaginitis, continence surgery within one year, patients with cardiac pacemakers, patients with intrinsic sphincteric deficiencies identified by the Valsalva leak point pressure≤60cm H2O measurement in the sitting position with a volume of 250ml in the bladder and/or by the measurement of a urethral closure pressure≤20cm H2O in the sitting position at maximum cystometric capacity.	Pelvic Floor Muscle Training/ electrical stimulation/ vaginal cone	No treatment	Not reported	Not reported
Castro-Diaz, 2007 ²⁴⁸ Duloxetine Dose Escalation Study Group. 8 countries N: 516	Duloxetine Dose Escalation Study Group: women ≥18 years old with symptoms of predominant SUI using the validated Stress/Urgency incontinence Questionnaire (S/UIQ), with ≥7 SUI episodes per week and at least twice as many SUI episodes as urge UI episodes, urodynamic diagnosis of incontinence within the 6 months of study entry or an average daytime voiding interval >2 hours, a nocturnal voiding frequency ≤2 per day and a positive cough stress test.	Continence surgery within 6 months or pharmacological treatment for symptoms of overactive bladder within 14 days of visit 1, pelvic organ prolapse beyond the hymen and previous participation in a duloxetine clinical trial.	Duloxetine 40 mg BID for 8 weeks, duloxetine 40 mg daily for 2 weeks escalating to 40 mg BID for 6 weeks, duloxetine 20 mg BID for 2 weeks escalating to 40 mg BID for 6 weeks	Placebo	This study was sponsored and funded by Eli Lilly and Company and by Boehringer Ingelheim GmbH	Commercial or other associations that might pose a conflict of interest: Drs. Voss, Yalcin and Bump are full-time employees of Lilly Research Laboratories and Eli Lilly and Company.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chancellor, 2001 ²⁴⁹ RCT U.S. N: 36	Subjects were healthy men and women who were within 15% of ideal weight for height and had no clinically relevant abnormalities, as determined by medical history, physical examination, blood chemistry, complete blood count, urinalysis, and electrocardiography.	Clinically significant medical problems, glaucoma, obstructive uropathy, partial or complete obstruction or narrowing of the gastrointestinal tract, paralytic ileus, intestinal atony, colitis, or myasthenia gravis; male subject with hemoglobin levels <13 g/dL and female subjects with hemoglobin levels <11.5 g/dL; subjects using prescription medications (except for estrogen replacement or birth control) within 14 days before start of the study; known allergies to the study drugs; who had smoked tobacco within the past 3 months, or who drank ≥ 2 ounces of alcoholic beverages per day or >40 ounces of caffeine-containing beverages per day.	ER-oxybutynin 10mg, tolterodine 2mg, IR-oxybutynin 5mg	Placebo	This study was sponsored by ALZA Corporation, Mountain View, California.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chancellor, 2008 ²⁵⁰ The ABLE trial U.S. N: 395	Male and female patients >18 years old with symptoms of OAB for at least 6 months; >8 micturitions on average per day, >2 episodes of UUI on average per day and/or >2 episodes of urgency on average per day	Use of any drug that could affect bladder function within 2 weeks prior and during the study, participation in any formal bladder-training program within 30 days of screening, predominant stress urinary incontinence and any bladder or neurological condition that could affect urinary bladder function or in which use of anti-cholinergic drugs was contraindicated.	Darifenacin with voluntary up-titration from 7.5 mg once daily (qd) to 15 mg qd and Behavioral Modification Program: brochures on modification of diet and daily habits; training in a primary physician's office about pelvic muscle exercises and urgency control techniques including timed voiding, dietary modifications and Kegel-type exercises.	Darifenacin with voluntary up-titration from 7.5 mg once daily (qd) to 15 mg qd	Funding for this study was provided by Novartis Pharmaceuticals Corp., who was involved in study design, data collection and analysis.	Michael Chancellor has no potential conflicts of interest within International Journal of Clinical Practice guidelines for financial disclosure.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chancellor, 2010 ²⁵¹ Post-hoc U.S. N: 1,156	Male or female patients aged ≥ 18 years with OAB for ≥ 6 months; required to have urinary frequency (an average of ≥ 10 toilet voids per day); symptoms of urgency (at least 1 "severe" urgency severity rating associated with a toilet void per 3 days, as measured by the Indevus Urgency Severity Scale [IUSS]); and an average of ≥ 1 urge urinary incontinence (UUI) episode per day, as recorded in a baseline 3-day patient urinary diary	Total void volume of >3000 mL per day, stress incontinence, insensate continence; history of neurogenic bladder; significant renal disease; urinary tract infections; and bladder obstructions	Trospium chloride XR	Placebo	Not reported	Dr. Oefelein-Director: Allergan; Dr. Chancellor-Consultant, Speaker honorarium, trial participant: Allergan
Chapple, 2005 ²⁵² RCT U.S. N: 65	Men and women aged 18–75 years with cystometric evidence of detrusor overactivity within the previous 6 months, either idiopathic or neurogenic (secondary to a neurological lesion present for >12 months), with >2 associated symptoms (average of >7 micturitions/day, >7 episodes of urgency/week, >1 urgency incontinence episode/week necessitating change of clothing or pads).	Previous bladder surgery for detrusor overactivity; bladder stones; treatment with diuretics, antimuscarinic, tricyclic antidepressants or digoxin within the previous 2 weeks; stress and mixed incontinence, unless detrusor overactivity was the principal urodynamic observation and the patient was experiencing normal recommended limits, contraindications to anticholinergics (e.g. untreated or narrow angle glaucoma, bladder outlet obstruction).	Darifenacin immediate release (IR) 2.5 mg three times a day ; darifenacin controlled release (CR) 15 mg once daily (q.d.); darifenacin CR 30 mg q.d.	Oxybutynin 2.5 mg t.i.d.; oxybutynin 5 mg t.i.d.; oxybutynin 5 mg t.i.d.	Pfizer Inc	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chapple, 2007 ²⁵³ RCT Belgium, Bulgaria, Czech Republic, Estonia, France, Germany, Hungary, Italy, the Netherlands, Poland, Romania, Russia, Spain, Sweden, Ukraine, the United Kingdom, South Africa, Australia, and New Zealand N: 1,135	Men and women with OAB symptoms with urinary urgency for >6 months and >3 UUI episodes per 24 hours (symptoms were recorded in a 3-day diary).	Pregnancy ;non adequate contraception throughout the trial; lower urinary tract pathology that could, in the investigator's opinion, be responsible for urgency or incontinence (e.g., genuine stress incontinence, bladder stones, interstitial cystitis urothelial tumors), pelvic prolapse of grade III or higher, clinically relevant bladder outlet obstruction, polyuria (>3 l per 24 hours), symptomatic or recurrent urinary tract infections, or postvoid residual (PVR) urine volume >100 ml; currently receiving treatment, were treated within 2 weeks of screening visit with antimuscarinic agents, were treated within the past 4 weeks with electro stimulation for bladder training, or had an active urinary tract infection or an underlying neurological disease responsible for their OAB; cardiac arrhythmia and/or unstable angina or a QT interval >500 ms.	Tolterodine ER 4 mg, fesoterodine 4 mg, fesoterodine 8 mg	Placebo	Schwarz BioSciences GmbH and Pfizer Inc	Professor Chapple is a consultant/ investigator/speaker for Astellas (Yamanouchi), Pfizer Inc, Novartis, and Schwarz BioSciences GmbH, and has acted as a consultant for UCB. Professor Van Kerrebroeck is an investigator and lecturer for Astellas

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chapple, 2008 ²⁵⁴ RCT analysis N: 1,135	Men and women aged ≥18 years with OAB syndrome for ≥ 6 months; urinary frequency (≥8 voids/24 hours), and urinary urgency (≥6 episodes during the 3-day diary period) or UUI (≥3 episodes during the 3-day diary period, and at least moderate bladder problems on a six-point Likert scale.	The presence of lower urinary tract pathology that could, in the investigator's opinion, be responsible for urgency or UI (e.g. significant stress UI, urolithiasis, interstitial cystitis, urothelial tumors); pelvic organ prolapse grade >III; clinically relevant BOO; a postvoid residual urine volume of >100 mL; polyuria (>3 L/24 hours); symptomatic or recurrent UTIs; current treatment with antimuscarinic agents; a neurogenic cause for OAB; clinically relevant arrhythmia, unstable angina, or a QT interval of >500 ms; and current treatment, or treatment within the past 4 weeks, with electro stimulation or bladder training.	Fesoterodine 8 mg, tolterodine ER 4 mg	Placebo	Schwarz BioSciences GmbH and Pfizer Inc.	Philip E. Van Kerrebroeck and Christopher R. Chapple are study investigators funded by the sponsor, and Joseph T. Wang and Marina Brodsky are Employees of the sponsor.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chapple, 2007 ²⁵⁵ RCT U.S., Poland, South Africa, Hungary, Sweden, UK and Germany N: 400	Men and women >65 years of age with OAB for at least 6 month with >1 urge UI/day and >10 micturitions/day	Dependent toileting, dependent diary completion, taking drugs that can affect bladder function or external urethral sphincter, total daily volume >3000ml, mean volume/micturition >300ml, clinically significant stress UI or bladder outlet obstruction (postvoid residual volume >100ml); marked cystocele, stage 3 or 4 pelvic prolapse; participation in bladder training program or electrical stimulation therapy within 3 months of screening; intermittent urinary tract infection, clinically significant congenital or acquired disorder of the urinary tract, chronic pain syndrome or other clinically significant medical conditions including cognitive impairment, uncontrolled severe hypertension, uncontrolled severe heart failure, recent myocardial infarction, or uncontrolled thyroid disease.	Darifenacin (7.5 mg once daily for 2 weeks, then optional titration to 15 mg daily)	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chapple, 2005 ²⁵⁶ Pooled N: 1,059	Men and women aged ≥18 years with symptoms of OAB for ≥6 months, and capable of independent toileting, with 5–50 episodes of incontinence per week during the run-in period, and a high voiding frequency (a mean of ≥8 voids/24 hours) and urgency (a mean of ≥1 episode/24 hours); women of childbearing potential required to use an adequate method of contraception throughout the study; those taking hormone-replacement therapy had to have received such therapy for ≥2 months before entering the study; those receiving long-term therapy with diuretics, antihypertensive medications, benzodiazepines or antihistamines had to be taking a stable dose before study recruitment, with no plans to change treatment during the study; and patients on bladder training program were not to modify or discontinue their training during the course of the study.	Initiation of a bladder training; pregnancy and lactation; clinically significant stress incontinence (i.e.>1 episode of stress incontinence per week), BOO and/or a postvoid residual urine volume of > 200 mL (as measured by pelvic ultrasonography); clinically important medical problems that would interfere with the patient's participation in the study; patients with interstitial cystitis, severe constipation (two or fewer bowel movements per week), hematuria or intermittent UTI; cystocele or other clinically significant pelvic prolapsed; patients with an indwelling catheter and those who practiced intermittent self-catheterization; urogenital surgery in the previous 6 months; patients with contraindications to antimuscarinic therapy (e.g., uncontrolled narrow-angle glaucoma, urinary retention, gastric retention); history of alcohol/drug abuse; and known hypersensitivity to study medication.	Darifenacin 7.5 mg or 15 mg/day	Placebo	The studies were funded by Pfizer Inc.	All authors are investigators in the study and/or have acted as consultants to Pfizer or Novartis.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chapple, 2007 ²⁵⁸ U.S. Food and Drug Admin ²⁵⁷ STAR study group N: 1,177	The STAR study :men and women aged at least 18 years who had OAB symptoms (including urinary frequency, urgency or urgency incontinence) for 3 months or more; with an average of >8 micturitions/day; >1 incontinence episode/day, or an average of >1 urgency episode/day.	Stress incontinence or mixed incontinence where stress was predominant (mixed incontinence was allowed otherwise) and patients with a neurological cause of abnormal detrusor activity.	Solifenacin 5 mg	Tolterodine ER 4 mg	Grant from Yamanouchi Pharmaceutica I Co, Ltd (now Astellas Pharma Inc). Tokyo, Japan.	Professor Chapple is a consultant, investigator, and speaker for Astellas Pharma Inc (Yamanouchi), Pfizer, Novartis, and Schwarz, and has acted as a consultant to UCB.
Chapple, 2006 ²⁵⁹ RCT Multinational N: 3,032	Outpatient men and women, at least 18 years of age, with symptoms of OAB. During a baseline 3-day micturition diary period, patients were required to report a mean of ≥8 micturitions per 24 h ,and either a mean of ≥1 incontinence episode per 24 h or a mean of ≥1 urgency episode per 24 h.	Patients with at least one on-treatment efficacy assessment	Solifenacin 5mg or 10mg	placebo	Funded by an educational grant from Astellas.	Christopher Chapple is an investigator/consultant for Pfizer, Astellas, Schwarz Pharma, Novartis and UCB Pharma. Linda Cardozo receives money for consultancy and/or advisory work, or research or lecturing from Astellas, Lilly/Boehringer Ingelheim, UCB Pharma, Pfizer, Gynecare, Plethora and Cook. William D.Steers is an investigator/consultant for Sanofi, Pfizer, Lilly and Astellas. Fred E.Govier has nothing to disclose

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chapple, 2004 ²⁶⁰ RCT Multinational N: 225	Men and women aged 18-80 years were eligible to enter the study if they had idiopathic detrusor overactivity (defined in this study as phasic contractions of ≥ 10 cmH ₂ O, assessed by filling cystometry) within 6 months of study initiation; a mean of ≥ 8 voids/24h for 3 days and ≥ 3 episodes of incontinence or urgency during the 3-day urinary diary period before randomization	Neurogenic detrusor overactivity, significant outlet obstruction, urinary retention, urodynamic stress incontinence, bladder stones, UTI, interstitial cystitis, previous or current malignant disease of the pelvic organs, previous pelvic radiation, and diabetic neuropathy; those taking concomitant anticholinergic medications, or had known or suspected hypersensitivity to anticholinergic medications or lactose; pregnant or lactating women and those not taking approved contraception methods	Solifenacin	Tolterodine and placebo	Not reported	Not reported
Chapple, 2004 ²⁶¹ RCT Multinational N: 728	Not reported	Not reported	Fesoterodine	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chapple, 2004 ⁵² RCT Not reported N: 1,081	Men and women aged ≥ 18 years with symptomatic OAB (including urgency, urgency incontinence, or frequency) for ≥ 3 months. After run-in period patients had to have had an average frequency of ≥ 8 voids/24 hours and have experienced at least 3 episodes of urgency and/or three episodes of incontinence during the 3-day voiding diary period.	Significant BOO, a postvoid residual volume of >200 mL, incontinence for which stress was determined to be the predominant factor, presence of a neurological cause for detrusor muscle overactivity, evidence of UTI or bladder stones, previous pelvic irradiation, or previous or current malignant disease of the pelvic organs, any medical condition contraindicating the use of antimuscarinic medication (including narrow-angle glaucoma and urinary or gastric retention), nonpharmacological treatment for OAB including electro stimulation therapy or start of a bladder training program during the 2 weeks before or during the study, diabetic neuropathy, use of drugs intended to treat incontinence, use of any drugs with cholinergic or anticholinergic side-effects, and participation in a clinical trial within 30 days before the study entry; pregnant or nursing women, women of child-bearing potential intending to become pregnant during the study or who were not going to use reliable contraceptive methods.	Solifenacin 5mg and 10mg	Tolterodine 2mg twice daily or placebo	Yamanouchi Pharma Co., Ltd, Tokyo, Japan	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chompootawee p, 1998 ²⁶² RCT Thailand N: 40	40 postmenopausal women with urogenital symptoms related to estrogen deficiency.	Thromboembolic disorders, severe liver diseases, estrogen-dependent tumors, high blood pressure (diastolic >100mm/Hg), those who had received oral estrogen in the 3 months before the study.	Combined contraceptive intravaginal 1 pill/week at bedtime with 250mg levonorgestrel +30mg ethinyl estradiol.	Intravaginal conjugated estrogen cream (1g=0.625mg conjugated equine estrogens) at bedtime, 3/week in week 1, 2/week in week 2, and then 1/week for 6 weeks	Grant from the Rhatchada-Pisakessompoj Fund, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Choo, 2008 ²⁶³ RCT Korea N: 357	Men and women aged ≥18 years with symptoms of OAB for ≥3months; average frequency of ≥8 voids per 24h and experienced at least three episodes of urgency or three episodes of urgency incontinence during the 3-day voiding diary period.	Clinically significant bladder outlet obstruction, a PVR volume of >200ml, incontinence for which stress was determined to be the predominant factor, presence of a neurological cause for detrusor muscle overactivity, evidence of urinary tract infection or bladder stones, previous pelvic irradiation, or previous or current malignant disease in the pelvic organs, any medical condition contraindicating the use of antimuscarinic medication(including narrow angle glaucoma and urinary or gastric retention), non-pharmacological treatment for OAB including electro stimulation therapy or start of a bladder training program during the 2 weeks before or during the study, diabetic neuropathy, use of drugs intended to treat incontinence, use of any drugs with cholinergic or anticholinergic side effects and participation in a clinical trial within 30 days before study entry; women of child-bearing potential who were pregnant or nursing, intending to become pregnant during the study, or who were not using reliable contraceptive methods.	solifenacin 5mg/10mg	tolterodine 4mg	Research grant from Astellas Pharma Inc., Tokyo, Japan	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Chu, 2009 ²⁶⁴ RCT U.S. N: 672	Men and women aged ≥18 years with a diagnosis of OAB made by an investigator based on symptoms (urinary frequency, urgency, or urgency incontinence); had to record a mean of ≥8 micturitions per 24 hours plus a mean of ≥1 incontinence episode per 24hours and/or a mean of ≥1 urgency episode per 24 hours	Stress urinary incontinence or mixed urinary incontinence in which stress was predominant (mixed incontinence was otherwise allowed), a neurologic cause of detrusor overactivity, urinary retention, grade III/IV prolapse with cystocele, and recurrent or active urinary tract infection; patients with abnormal findings on 12-lead ECG or abnormal laboratory findings. Women of childbearing potential were required to have a negative serum pregnancy test at screening and to use a medically acceptable form of contraception during study participation	Solifenacin	Placebo	Funded and sponsored by Astellas Pharma Inc., Tokyo, Japan	No

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Corcos, 2006 ²⁶⁵ Uromax Study Group Canada N: 237	Men and women (aged ≥18 years) with UUI	A screening postvoid residual urine volume of >100 mL; allergy/serious side-effects with anticholinergic medications; primary diagnosis of stress UI; conditions contraindicating anticholinergic therapy; hepatic/renal disease; interstitial cystitis, hematuria secondary to malignancy; recurrent UTI (more than three/year); indwelling catheter/bladder training within 14 days of screening; drug/alcohol abuse; untreated psychiatric conditions affecting participation; pregnant/nursing women; and women of childbearing potential not using reliable contraception. A urine sample was collected and analyzed at the first study visit. Confirmed UTI at study entry was treated, and initiation of the washout/baseline period followed confirmation of absence of bacteria. Use of pharmacotherapy for UUI was terminated at or before the baseline evaluation (if applicable).	Daily dose of 5, 10, and 15 mg controlled-release oxybutynin	Daily dose of 5, 10 and 15 mg controlled-release oxybutynin	Purdue Pharma	J. Corcos, A. Patrick, C. Andreou and R. Casey are study investigators funded by sponsor; P. Miceli is a paid consultant/writer; and A. Darke, J. Reiz and Z. Harsanyi are sponsor employees.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Corcos, 2011 ²⁶⁶ Fesoterodine Assessment and Comparison Versus Tolterodine (FACT) Study Group N: 1,022	Men and women aged ≥ 18 years with symptoms of OAB (self-assessed) for ≥ 3 months before screening and a mean of ≥ 1 UUI episode per 24 hours and ≥ 8 micturitions per 24 hours reported in 3-day bladder diaries completed at baseline.	Not reported	Fesoterodine	placebo	Funded by Pfizer Inc.	Jacques Corcos is a consultant and investigator for Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc, Johnson & Johnson, Inc, and Paladin Labs inc. Javier C. Angulo has no disclosures. Alan D. Garely is a consultant and speaker for Covidien and a speaker for Astellas and Pfizer Inc. Marin Carlsson, Jason Gong, and Zhonghong Guan are employees of Pfizer Inc. and hold stock in the company. The peer reviewers on this manuscript have disclosed that they have no relevant financial relationships.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Davila, 2001 ²⁶⁷ Transdermal Oxybutynin Study Group. N: 76	Men or women 18 years or older with a history of urge or mixed urinary incontinence with a predominance of urge symptoms, previously diagnosed with motor urge urinary incontinence and had symptomatic improvement during a minimum of 6 weeks of oral oxybutynin; a minimum of 3 incontinent episodes daily, and a greater than 30% increase after 2 week washout from current treatment.	Allergy to oxybutynin, intolerability of transdermal system, current pregnancy or lactation, overflow incontinence secondary to underactive or non-contractile detrusor or outlet obstruction, impaired bladder compliance, including tonic increase in pressure greater than 15 cm. water during filling cystometry, or current medical conditions or pharmacological therapies that could contribute to or cause urinary incontinence; medical conditions that could be worsened by oxybutynin.	Transdermal system with 1.3 mg. oxybutynin daily + oral placebo	Oral capsules with 2.5 mg. oxybutynin + transdermal placebo	Watson Laboratories, Inc.	Not reported
Dessole, 2004 ²⁶⁸ RCT Italy N: 88	88 postmenopausal women with incontinence confirmed by the direct visualization of loss of urine from the urethra during the standard stress test and by urodynamic investigation.	Estrogen treatment, anatomical lesions of the urogenital tract, detrusor over activity and abnormal maximal cystometric capacity; presence of severe systemic disorders, thromboembolic diseases, biliary lithiasis, previous breast or uterine cancer, abnormal uterine bleeding, and body mass index of 25 kg/m ² or higher.	Intravaginal estriol ovules: 1 ovule/day (1mg) for 2 weeks and then 2 ovules/week for 6 months.	Placebo: vaginal suppositories	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
<p>Diokno, 2003²²⁷ Chu, 2005²⁶⁹ Anderson, 2006²⁷⁰ OPERA (Overactive bladder: Performance of Extended Release Agents) OPERA (Overactive bladder: Performance of Extended Release Agents) trial U.S. N: 790</p>	<p>OPERA (Overactive bladder: Performance of Extended Release Agents): Women with OAB, aged 18 years and older, who documented 21 to 60 UUI episodes per week and an average of 10 or more voids per 24 hours; predominant urge UI; with or without history of prior treatment with an anticholinergic drug for OAB.</p>	<p>Treatable genitourinary conditions that could cause incontinence, 2 postvoid residual urine volumes shown by ultrasonography to exceed 150 mL; pronounced risk of developing complete urinary retention, clinically important medical problems that would put a participant at undue risk of anticholinergic effects, hematuria, uncontrolled narrow-angle glaucoma, obstructive uropathy, reduced gastrointestinal motility, and known hypersensitivity to the study medications.</p>	<p>Extended-release formulations of oxybutynin at 10 mg/d</p>	<p>Tolterodine at 4 mg/d</p>	<p>ALZA Corporation, Mountain View, California, and Ortho-McNeil Pharmaceuticals I, Raritan, NJ</p>	<p>Dr. Diokno is a medical consultant for Ortho-McNeil Pharmaceutical. Dr. Appell is on the Medical Advisory Board of Ortho-McNeil Pharmaceutical, Watson Pharmaceuticals, Inc, and Indevus Pharmaceuticals, Inc. Dr. Sand is an investigator/advisor for Pharmacia Corporation. Dr. Dmochowski is a consultant for Ortho-McNeil Pharmaceutical. Dr. Kell is a full-time employee of ALZA Corporation, a subsidiary of Johnson & Johnson; she owns Johnson & Johnson stock and has Johnson & Johnson stock options.</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Dmochowski, 2002 ²⁷¹ Transdermal Oxybutynin Study Group. U.S. N: 520	Male and female patients at least 18 years old with a history of overactive bladder, with or without neurological disease, 10 or more urge urinary incontinent episodes/week, with pure urgency or a predominant urgency UI, 56 or more voids and an average recorded voided volume of 350 ml. or less.	Incontinence related to chronic illness, anatomical weakness/abnormalities or concomitant medications, lower urinary tract surgery in the previous 6 months; a diagnosis of interstitial cystitis, urethral syndrome, painful bladder syndrome and overflow urinary incontinence; alcohol/drug abuse within the previous year; known hypersensitivity to oxybutynin, similar compounds or transdermal medications; active skin disorder; narrow-angle glaucoma or shallow anterior chamber evident on physical examination; and excessive consumption of caffeine, defined as greater than 5 cups of caffeine-containing beverages daily.	1.3, 2.6, or 3.9 mg Oxybutynin twice weekly to the abdomen	Placebo twice weekly to the abdomen	Not reported	All authors have financial interest and/or other relationships with Watson Pharmaceuticals; Roger R. Dmochowski has financial interest and/or other relationship with Lilly, Surx, Alza, Pharmacia, Bioform, and Genyx; Norman Zinner has financial interest and/or other relationship with Bayer, Lilly, Abbott, Praecis, Pharmacia, Interneuron, Alza, Amgen, AstraZeneca, and Roche; Marc Gittelman has financial interest and/or other relationship with Alza, Interneuron, Yamanouchi, Merck, Pfizer, Seprecor, Otsulta, Glaxo, Pharmacia, Praecis, Synthelabo, and Vivus; Sydney Lyttle has financial interest and/or other relationship with PPD Development.
Dmochowski, 2008 ²⁷²	Men and women aged 18 years or older with OAB of	Total voided volumes greater than 3000 mL/day or a mean volume	Trospium chloride 60 mg	Placebo	Esprit Pharma and Indevus	Dr. Dmochowski has acted as a consultant

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
RCT U.S. N: 564	6 months' or longer duration with symptoms of urinary frequency (a mean of 10 or more toilet voids per day), urgency (1 or more episodes of severe urgency associated with a toilet void), and UUI (a mean of 1 or more UUI episodes per day).	voided/void greater than 250 mL; predominantly stress, insensate, or overflow incontinence; history of neurogenic bladder, indwelling or intermittent catheterization, significant renal disease (defined as serum creatinine greater than 1.5 mg/dL), uninvestigated hematuria or urinary tract infection during screening, or a history of more than 3 urinary tract infections in the previous 12 months; other bladder pathologies, including clinically significant retention (defined as postvoid residual urine volume greater than 100 mL), cancer, and interstitial cystitis.	once daily		Pharmaceuticals Inc.	for Esprit Pharma, Indevus Pharmaceuticals Inc, Allergan, Novartis, Pfizer, and Watson; Dr Sand has acted as a consultant for Esprit Pharma, Indevus Pharmaceuticals Inc, Ortho, Allergan, Watson, GSK, Astellas, and Schwarz Pharma. In addition, Dr Sand has also been an investigator in clinical trials for Esprit Pharma, Indevus Pharmaceuticals Inc, Ortho, Allergan, Watson, and Astellas, and has participated in meetings for Esprit Pharma, Indevus Pharmaceuticals Inc, Ortho, Allergan, Watson, GSK, and Astellas; Dr Zinner has acted as a consultant for Esprit Pharma, Indevus Pharmaceuticals Inc, Novartis, Watson, Eli Lilly, GSK, Allergan, Astellas, and Medtronic. In addition, Dr Zinner has also been an investigator on clinical trials for

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
						Esprit Pharma, Indevus Pharmaceuticals Inc, Novartis, Watson, GSK, Allergan, and Astellas, and has participated in meetings for Esprit Pharma, Indevus Pharmaceuticals Inc., Eli Lilly, and Astellas; Dr. Staskin has acted as a consultant for Esprit Pharma, Indevus Pharmaceuticals Inc, Ortho-McNeil, Novartis, Watson, Pfizer, and Astellas.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Dmochowski, 2005 ²⁷³ Pooled U.S. N: 241	Pooled analysis of RCTs: men and women with urge or mixed urinary incontinence with a predominance of urge symptoms with >10 urgency incontinence episodes/week and 56 or more micturitions (>8 micturitions per day). For study 2 patients had to have a beneficial response to previous anticholinergic OAB treatment, at least 4 incontinence episodes, 24 or more voids, and a mean void volume of 350 mL or less over 3 days.	Postvoid residual volume >250 mL; abnormal physical, laboratory, or ECG examination; lower urinary tract surgery within preceding 6 months; an active dermatologic disorder; known narrow-angle glaucoma; shallow anterior chamber, evident on physical examination (study 1 only); hypersensitivity to oxybutynin or other anticholinergic medications; hypersensitivity to transdermal drug delivery systems; history of overflow incontinence caused by underactive or acontractile detrusor or outlet obstruction; failure to complete urinary diary during washout period; recent (within 1 year) alcohol and/or drug abuse; inability to maintain nonpharmacological urinary; incontinence management program during study; consumption of 5 or more cups of caffeinated beverages per day; use of medications that affect detrusor activity; use of medications that interfere with oxybutynin or tolterodine (study 2 only).	3 dosages of oxybutynin-TDS 1.3 mg/d, 2.6 mg/d, or 3.9 mg/d for 12-week (double-blind)+ 12-week (open-label)+ 28-week (open-label extension)	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Dmochowski, 2003 ²⁷⁴ Transdermal Oxybutynin Study Group. U.S. N: 361	Men and women at least 18 years of age taking current pharmacologic treatment for OAB with beneficial response to the pre-study treatment; four or more urge urinary incontinent episodes, with pure urge or a predominance of urge episodes, 24 or more voids, and an average recorded urinary void volume of 350 mL or less.	History of lower urinary tract surgery in the previous 6 months and a diagnosis of interstitial cystitis, urethral syndrome, painful bladder syndrome, and overflow urinary incontinence.	Transdermal oxybutynin 3.9 mg/day or oral tolterodine 4 mg/day	Placebo	Watson Pharma	R.R. Dmochowski, P.K. Sand, N.R. Zinner, M.C. Gittelman, and G.W. Davila are study investigators funded by, and members of the medical advisory board, the sponsor. S.W. Sanders is an employee of the sponsor.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
<p>Dmochowski, 2003²⁷⁵ Duloxetine Urinary Incontinence Study Group Canada and the U.S. N: 683</p>	<p>Non-pregnant women 18 years and older with a clinical diagnosis of bothersome SUI at least 3 months in duration, with predominant symptom of SUI with 7 or greater stress incontinent episodes weekly; daytime voiding frequency less than 8 times daily, nocturnal frequency less than 3 times daily and no predominant urgency incontinence symptoms. After filling a positive cough stress test and stress pad test were required. This clinical algorithm has been demonstrated to predict urodynamic stress incontinence with 92% accuracy.</p>	<p>Inability to tolerate retrograde bladder filling to 400 ml or who had a first sensation of bladder filling at less than 100 ml; treatment with other antidepressants.</p>	<p>80 mg duloxetine daily</p>	<p>Placebo</p>	<p>Supported by Eli Lilly and Co.</p>	<p>Roger Dmochowski has financial interest and/or other relationship with Lilly Pharmaceuticals, Watson Pharmaceuticals, Ortho McNeil and Indevus Pharmaceuticals; John Miklos, Ilker Yalcin and Richard Bump have financial interest and/or other relationship with Eli Lilly; Peggy Norton has Financial interest and/or other relationship with Eli Lilly, Pharmacia and Pfizer; Norman Zinner has Financial interest and/or other relationship with Lilly, Watson, Kyowa and Schwarz Pharmaceuticals.</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Dmochowski, 2007 ²⁷⁶ RCT U.S. N: 1,015	Post hoc analysis of RCT: men and women aged ≥18 years and reported symptoms of urinary frequency (≥ 8 voids/24 hours) and UUI (≥5 episodes/week) for ≥6 months.	Significant hepatic or renal disease, current or recurring UTI, stress UI, clinically relevant BOO, indwelling catheter or intermittent self-catheterization, and any condition for which antimuscarinic treatment was contraindicated; taking any anticholinergic drug or treatment for OAB and those who showed a mean of 200 mL/void or total daily of 3000 mL.	Tolterodine-ER (4 mg once daily)	Placebo	Pfizer Inc	Dr. Dmochowski is an advisor to Pfizer. Dr Kreder is a speaker for Astellas, Lilly, Merck, Novartis, and Pfizer; serves as a paid consultant to Astellas, Lilly, and Pfizer; receives research support from Lilly, Merck, and Pfizer; and holds stock options from Merck. Dr MacDiarmid is a speaker for Pfizer, Ortho-McNeil, Esprit, Astellas, Watson, and Novartis; he is a paid consultant to Pfizer, Ortho-McNeil, Esprit, Astellas, and Watson. Martin Carlsson and Zhonghong Guan are employees of Pfizer Inc.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
<p>Dmochowski, 2010²⁷⁷ RCT Multinational N: 313</p>	<p>Men and women 18 to 85 years old with symptoms of idiopathic OAB with UUI for 6 or more months who were not adequately treated with anticholinergic therapy (defined as inadequate response or intolerable side effects) were included in the study following informed consent. At baseline patients were required to have 8 or more UUI episodes a week, with no more than 1 incontinence-free day, and an average of 8 or more micturitions daily.</p>	<p>Patients using clean intermittent catheterization, history or evidence of pelvic or urological abnormalities, or diseases affecting bladder function, treatment for 2 or more UTIs within 6 months, or 24-hour total urine volume void greater than 3,000ml or postvoid residual urine volume greater than 200ml at screening</p>	<p>Onabotulinumtoxin A</p>	<p>Placebo</p>	<p>Supported by Allergen, Inc.</p>	<p>Roger Dmochowski has financial interest and/or other relationship with Allergen, Pfizer, Astellas, and Contura; Christopher Chapple has financial interest and/or other relationship with Pfizer, Allergen, Astellas, Novartis, Ono, and Recordati; Victor Nitti has financial interest and/or other relationship with Allergen, Astellas, Coloplast, Ethicon, Medtronic, Pfizer, Serenity, Uroplasty and Watson; Michael Chancellor, Catherine Thompson, Grace Daniell, Jihao Zhou and Cornelia Haag-Molkenteller have financial interest and/or other relationship with Allergen; and Karel Everaert has financial interest and/or other relationship with Allergen and Medtronic</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Dorschner, 2000 ²⁷⁸ RCT N: 107	Men and women older than 60 years of age with urgency, urgency incontinence, or mixed urge-stress incontinence, >1 episode of UI/day and micturition volume <300ml/micturition	Acute urinary tract infections, mechanical or functional bladder-emptying disorders, residual urine >20% of voided volume by ultrasound, micturition volume >300ml in uroflow, renal insufficiency, concomitant medications interfering with the drug studied (neurotropic/ musculotropic spasmolytics, centrally acting muscle relaxants, psychopharmacological agents or drugs for the treatment of Parkinson's disease, anti-arrhythmic), serious life threatening cardiovascular diseases (myocardial infarction within the previous 3 months, unstable coronary heart disease, implanted cardiac pace-maker, decompensated myocardial insufficiency, tachycardia or bradycardia at rest, second-or third-degree atrio-ventricular block, complete bundle branch interventricular heart block, chronic atrial fibrillation and ventricular extrasystoles Lown IVb in the pre-study ECG monitoring.	Propiverine (15 mg t.i.d.)	Placebo	Grant provided by Apogepha	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Drutz, 1999 ²⁷⁹ RCT U.S. and Canada N: 277	Age ≥18 years; all female patients were to be postmenopausal, surgically sterile, or using an adequate contraceptive method before and during the study; evidence of detrusor overactivity on subtracted cystometry (phasic detrusor contraction with an amplitude ≥10cm H ₂ O), along with urinary frequency (≥8 micturitions on average per 24 hours) and either urgency incontinence (≥1 incontinence episode on average per 24 hours), as confirmed by micturition diaries during the run-in period, and/or urinary urgency.	Clinically significant stress incontinence as determined by the investigator during a cough stress test maneuver; hepatic or renal disease; any disease which the investigator thought made the patient unsuitable for inclusion; recurrent urinary tract infections; interstitial cystitis; uninvestigated hematuria or hematuria secondary to malignant disease; indwelling catheter or intermittent catheterization; treatment with any investigational drug in the 2 months prior to entry; previous treatment with tolterodine; electro-stimulation therapy or bladder training within 14 days prior to entry or initiation during the study; treatment with any anticholinergic drug, or any drug for urinary urgency incontinence within 14 days prior to the baseline visit or initiation during the study; unstable dosage of any treatment with anticholinergic adverse effects or initiation of such treatment during the study; previously demonstrated serious adverse effects on oxybutynin average total voided volume/24 hours of >3000 ml; or clinically significant voiding difficulty with risk of urinary retention (such as residual volume >200 ml or urine flow rate <10ml/s).	Tolterodine 2mg b.i.d. or oxybutynin 5mg t.i.d.	Placebo	The study was funded by Pharmacia & Upjohn AB, Uppsala, Sweden	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
DuBeau, 2005 ²⁸⁰ RCT analysis Europe (Denmark, Finland, Ireland, Norway, Sweden, and United Kingdom) N: 854	Women aged >18 years with urge-predominant mixed incontinence (>5 episodes of urge UI per week), urinary frequency (mean > voids per 24 hours), and urgency (strong and sudden need to urinate), together with stress incontinence symptoms.	Any contraindication to antimuscarinic therapy (narrow angle glaucoma, urinary retention, gastric retention, allergy, or hypersensitivity); treatment within 2 weeks of randomization with any anticholinergic drug, or any drug for UI (excluding stable doses of estrogen and alpha-adrenergic agonists); interstitial cystitis, uninvestigated hematuria, bladder outlet obstruction, indwelling or intermittent catheterization; urinary tract infection during the run-in period or greater than three times in the last year; hepatic or renal dysfunction; use of inhibitors of cytochrome P450 3A4 isoenzymes; 24-hour urine volume >3L; significant renal or hepatic dysfunction; pregnancy, lactation, or childbearing potential without use of adequate contraception; and behavioral therapy for UI within 4 weeks of initial study visit.	Tolterodine 4 mg once daily	Placebo	Pfizer	Not reported
Duckett, 2007 ²⁸¹ RCT U.S. N: 222	Women with a diagnosis of urodynamic stress incontinence, with mixed USI and detrusor overactivity if they were predominantly complaining of moderate/severe stress incontinence	Women not assessed with cystometry and women who declined drug therapy were excluded from further analysis.	Duloxetine 40 mg twice a day	None	Not reported	Not reported
Enzelsberger, 1995 ²⁸² RCT Austria N: 52	52 women complaining of frequency (more than five times per 12 hours), nocturia (more than twice per night) and urgency.	Women with urodynamically assessed genuine stress incontinence and with neurologic disorders.	Oxybutynin	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Flynn, 2009 ²⁸³ RCT N: 22	Overactive bladder refractory to anticholinergic medications (at least 1 anticholinergic medication and behavioral modifications must have failed), multiple daily incontinence episodes and a 24-hour pad weight of 100 gm or greater; subjects with coexisting severe OAB and mild stress incontinence were allowed to enter the study; demonstrate willingness and ability to perform self-catheterization, and have negative urine culture.	Low leak point pressures, increased post-void residual volume or neurological etiologies; gross fecal incontinence or an absent detrusor contraction on pressure flow.	Cystoscopic administration of botulinum-A toxin 200 U and 300 U	Placebo	Supported by National Institutes of Health National Institute on Aging Grant #R21 AG25490-01.	Cindy L. Amundsen has financial interest and/or other relationship with Pfizer; George D. Webster has financial interest and/or other relationship with Lifetech and AMS.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Foote, 2005 ²⁸⁴ Pooled N: 317	Men and women with symptoms of OAB for at least 6 months and capable of visiting a toilet unaided with 5–50 episodes of incontinence per week, along with elevated micturition frequency (mean 8 voids/24 hours) and urgency (mean 1 episode/24 hours).	Clinically significant stress incontinence (i.e. 1 episode of stress incontinence per week); bladder outlet obstruction and/or post-void residual urine volume >200 ml; concomitant medical problems that would interfere with the patient's participation in the study; severe constipation (2 bowel movements per week); hematuria, intermittent urinary tract infection, cystocele or other clinically significant pelvic prolapse; use of an indwelling catheter or intermittent self-catheterization; urogenital surgery in the previous 6 months; contra-indications to antimuscarinic therapy (e.g., uncontrolled narrow-angle glaucoma, urinary retention or gastric retention); and a history of alcohol/drug abuse or known hypersensitivity to study medications; treatment with potent cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole), opioids (or other drugs that could cause significant constipation), non-study antimuscarinic agents or other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants); concomitant treatment with CYP2D6 inhibitors such as cimetidine, fluoxetine and paroxetine; initiation of bladder-training program was not permitted during the study.	Darifenacin 7.5 mg or 15 mg once daily	Placebo	The studies were funded by Pfizer Inc. Preparation of the manuscript was supported by an educational grant from Novartis Pharma AG.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Franzen, 2010 ²⁸⁵ RCT Sweden N:72	Women ≥18 years of age with urgency/urgency incontinence presenting to the gynecology/urology outpatient clinics; had symptoms for at least 3 months, had increased frequency of micturition (at least 8 micturitions per 24 hours), had a mean volume of urine voided per micturition of not more than 200ml, and had a total urine volume per 24 hours of less than 3,000ml during a 48-hour bladder diary.	Persistent urinary tract infection, post-void volume greater than 150ml, history of neurological disease or dementia, pregnancy, contraindications to anticholinergic therapy, and cardiac pacemaker; if they had used tolterodine or any other anticholinergic drugs in order to treat urgency/urgency incontinence during the last 2 months or had received electrical stimulation treatment within the last 3 years.	Electrical stimulation	Tolterodine	Not reported	None
Freeman, 2003 ²⁸⁶ RCT analysis Europe, North America, Australia, and New Zealand N: 1015	Tolterodine Study Group (secondary analysis): men and women at least 18 years old with urinary frequency (eight or more micturitions per 24 hours) and urgency incontinence (five or more episodes per week) irrespective of whether they had received prior antimuscarinic therapy and the outcome of that treatment.	Stress incontinence, total daily urine volume greater than 3 L, any contraindications to antimuscarinic treatment, significant hepatic or renal disease, symptomatic or recurrent urinary tract infections, interstitial cystitis, hematuria or bladder outlet obstruction, electro-stimulation or bladder training, indwelling catheter, or intermittent self-catheterization; pregnancy or nursing; any treatment for overactive bladder, including use of anticholinergic drugs or drugs that inhibit cytochrome P450 3A4 isoenzymes, within 14 days preceding randomization.	Tolterodine extended release 4 mg	Placebo	Pharmacia Corporation, Peapack, New Jersey	Investigator fees were paid by Pharmacia into the research funds of the authors and used to employ research staff, fund research, and purchase equipment. None of the authors own stock in Pharmacia or hold stock options.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Gahimer, 2007 ²⁸⁷ Duloxetine exposures integrated safety database U.S.A. N: 23,983	Reported previously for 64 pooled studies	Not reported	Duloxetine 20-120 mg/day	None	Eli Lilly	Not reported
Ghei, 2005 ²⁸⁸ RCT N: 20	Men and women 18 to 80 years old with urodynamic detrusor overactivity unresponsive to oral antimuscarinic agents willing to use intermittent self-catheterization.	Known bladder malignancies, previous bladder surgery, active urinary tract infections, known major drug allergies, major urethral access problems and children; anticholinergics during the study period were not permitted.	Botulinum toxin B (5,000 IU diluted up to 20 ml) intravesically	Placebo	Not reported	The trial was independent of industry sponsorship and involvement.
Ghoniem, 2005 ²⁸⁹ Duloxetine/ Pelvic Floor Muscle Training Clinical Trial Group. The Netherlands, UK and U.S. N: 201	Women 18 to 75 years old with SUI; urodynamic stress incontinence and no detrusor overactivity on studies within 6 months before entry (36 subjects) or a positive cough stress test and normal micturition frequency (less than 8 voids daily) at entry (165 subjects). All subjects had predominant symptoms of SUI with an average of at least 2 stress incontinent episodes daily.	Advanced pelvic organ prolapse, active or recurrent urinary tract infections, and continence surgery within 1 year, current device or pharmaceutical incontinence treatment, prior hip fracture or replacement and any prior formal PFMT with a continence nurse or physical therapist.	40 mg duloxetine twice daily plus imitation PFMT (duloxetine only), duloxetine plus PFMT (combined treatment), placebo plus PFMT (PFMT only). PFMT groups received 30 minutes of instruction and feedback initially and 15 minutes of re-instruction	Placebo plus imitation PFMT (no active treatment)	Supported by Eli Lilly and Company and Boehringer Ingelheim.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Goode, 2002 ²⁹⁰ RCT U.S. N: 105	Patients had to average at least two urge accidents per week documented in the 2-week bladder diary, and urgency incontinence had to be the predominant pattern (the number of urge accidents had to exceed the number of stress and other accidents). Also, there had to be urodynamic evidence of bladder dysfunction (DI during filling or provocation or bladder capacity of 350 mL or less).	Continual leakage, postvoid residual urine volume greater than 200 mL, uterine prolapse past the introitus, narrow-angle glaucoma, unstable angina pectoralis, decompensated congestive heart failure, history of malignant arrhythmias, or impaired mental status (Mini-Mental State Examination score <20).	Behavioral treatment	Oxybutynin treatment 2.5mg three times a day, placebo	Grants AG 08010 and K00431 from the National Institute on Aging to Dr. Burgio	Not reported
Goode, 2004 ²⁹¹ RCT analysis U.S. N: 197	Subjects were community-dwelling women aged ≥55 years who were recruited to a university based continence clinic through professional referrals and advertising. They had urgency incontinence or mixed incontinence with urge as the predominant pattern. All patients were ambulatory and not demented. They had urodynamic evidence of bladder dysfunction, either detrusor overactivity or a maximal cystometric capacity ≥350 mL.	Not reported	Behavioral therapy	Oxybutynin 2.5mg/day to 5mg t.i.d. or Placebo	NIH Grant	Patricia S. Goode has been a paid consultant to Alza, Eli Lilly, Pharmcia, and Yamanouchi

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Gupta, 1999 ²⁹² RCT Scotland N: 13	Subjects must have been at least 40 years of age, within 20% of the Metropolitan Life Insurance Table ideal weight for height value, normotensive with no clinically significant postural hypotension, and using a birth control method if premenopausal.	Volunteers were excluded for known sensitivity to any anti cholinergic drug; recent (or planned) medication usage other than estrogen replacement therapy or birth control pills; recent alcohol, caffeine, or investigational drug use; history of drug abuse; a positive urine drug screen; or recent smoking.	Three 5 mg OROS [®] oxybutynin chloride tablets at 0700 every day for 4 days	IR oxybutynin 5 mg t.i.d. 4 days	Not reported	Not reported
Gupta, 1999 ²⁹³ Pooled N: 187	Women and men with urge urinary incontinence or mixed urinary incontinence with clinically significant urge components who were known to be responsive to anticholinergic treatment of urinary incontinence but who might have discontinued such treatment because of side effects. Patients were allowed to enroll if they had at least six urge urinary incontinence episodes per week (based on off-medication run-in patient urinary diary results) and could distinguish between urge and non-urge episodes.	Not reported	Oxybutynin XL (Ditropan XL) 5 to 30mg once daily	Oxybutynin - immediate release 5mg once/twice/thrice or four times a day	Not reported	Not reported
Gousse, 2010 ²⁹⁴ RCT U.S. N:60	Patients with refractory idiopathic overactive bladder symptoms	Not reported	Botulinum toxin Type A	Botulinum toxin Type A	Funded by Allergan Inc., USA	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Haab, 2006 ²⁹⁵ RCT analysis N: 719	Successful completion of previous 12-week darifenacin studies without major protocol violation; few concomitant medications, a maximum darifenacin dose of 7.5 mg for patients taking potent inhibitors of cytochrome P450 3A4 and patients with moderate hepatic impairment (Child Pugh B); adequate contraception ; ability to complete patient diaries independently; capable of independent toileting.	Reported previously ^{43,296}	Patients received darifenacin CR 7.5 mg irrespective of previous study treatment, for the first 2 weeks of the extension followed by self-selected individualized dosing: patients were permitted to increase their dose to 15 mg or decreased from 15 to 7.5 mg.	None, all patients received darifenacin	Funded by Pfizer, Inc. and Novartis Pharma AG. Preparation of this manuscript was supported by an educational grant from Novartis Pharma AG and editorial and project management services were provided by ACUMED [®] .	F. Haab is a consultant for Novartis and Astellas and is a study investigator funded by sponsor; J. Corcos, P. Siami and P. Dwyer are study investigators funded by sponsor; J. Corcos is also a member of the board of sponsor; M. Steel, F. Kawakami and K. Lheritier are employees of sponsor; W. Steers is a paid consultant to sponsor and is a study investigator funded by sponsor.
Haab, 2005 ²⁹⁷ RCT analysis N: 1,633	Solifenacin Study Group: Patients completing treatment in the two previous RCTs <14 days prior to extension-study; with symptoms of OAB (including urinary frequency, urgency, or urgency incontinence) for >3 months, with >8 micturitions /day, either >1 urgency episode or >1 incontinence episode/day.	Clinically significant outflow obstruction, postvoid residual urine >200 ml, persistent or recurrent urinary tract infection, bladder stones, chronic interstitial cystitis, previous pelvic irradiation or previous or current malignant disease of the pelvic organs, and any medical condition contraindicating the use of anticholinergic medication (including narrow-angle glaucoma and urinary or gastric retention); pregnancy or nursing, or intention to become pregnant during the study, or unreliable method of contraception.	Solifenacin 5 mg daily for 4 weeks, after which a flexible dosing regimen based on patient satisfaction (5 mg or 10 mg)	No control	Grant from Yamanouchi Pharmaceutica I Co., Ltd., Tokyo, Japan.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Haab, 2004 ²⁹⁶ RCT N: 561	Men and women 19–88 years old, 85% females with symptoms of OAB for at least 6 months with urgency incontinence (5-50 episodes per week); frequency of micturition (a mean of >8 voids per 24 hours); and urgency (a strong desire to void at least once per day). Those who did not benefit from other antimuscarinic agents or participated in previous double-blind studies of darifenacin were eligible for inclusion in the intervening period was >4 months.	Contraindications to the use of antimuscarinic drugs (e.g. uncontrolled narrow-angle glaucoma, urinary or gastric retention), clinically significant stress incontinence (more than one episode per week), clinically significant bladder outlet obstruction and/or a post-void residual volume >200 ml, genitourinary conditions that could cause urinary symptoms, recent urogenital surgery, or hepatic disease; bladder training program while in the study; known hypersensitivity to the study medication.	Darifenacin controlled-release tablets 3.75 mg; 7.5 mg or 15 mg/day	Placebo	The study was funded by Pfizer Inc. Preparation of the manuscript was supported by an educational grant from Novartis PharmaAG. Editorial and project management services were provided by Thomson ACUMED	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Halaska, 2003 ²⁹⁸ RCT Austria, Bulgaria, Czechoslovakia, Germany, Russia and Spain N: 358	Men and women >18 years of age with urge syndrome (undue frequency of micturition, nocturia, overwhelming urge, wetting), urgency incontinence, urgency incontinence as one component of mixed incontinence, or urgency incontinence due to a neurological condition (detrusor hyperreflexia) as confirmed using urodynamic measurements.	Absolute tachycardia; closed-angle glaucoma; myasthenia gravis; severe arteriosclerosis of the cerebral vessels; stress incontinence; undue frequency of micturition due to heart failure, renal failure or diuretic therapy; bladder outlet obstruction; acute urinary tract infection at the beginning of the trial; hiatus hernia in combination with reflux esophagitis; stenoses in the gastrointestinal tract; megacolon; colonic ulceration; allergy or intolerance towards atropine, OXY, TCI or other constituents of the trial medication; concurrent medication with anticholinergics, tricyclic or tetracyclic antidepressants, alpha-blockers or beta-sympathomimetics within the last 7 days before starting the trial; urological or gynecological operations within the last 3 months before starting the trial; serious illnesses or conditions which would preclude participation in any clinical trial (malignant neoplasms, alcoholism, drug misuse); pregnancy or lactation; participation in any other study.	Trospium chloride (20 mg twice daily) or	Oxybutynin (5 mg twice daily).	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Herschorn, 2004 ²⁹⁹ RCT N: 138	Male and female adults older than 50 years of age with OAB symptoms (urinary urgency, frequency >8 micturition/day, nocturia >2/night) with or without urge UI who would benefit from tolterodine administration (according to physician's opinion).	Stress UI only, abnormal cognitive function, non English speakers; interstitial cystitis, acute urinary tract infections, taking investigational drug.	Tolterodine combined with an education intervention: printed information and an explanation about OAB, medication use, and behavioral treatments (kegel exercise, bladder stretching, fluid regulation). Previously trained nurse or physician provided education.	Tolterodine alone	Pharmacia Corporation and Pfizer	Not reported
Herschorn, 2010 ³⁰⁰ VECTOR Canada N:132	18 years old or older with OAB symptoms (more than 1 urgency episode per 24 hours and 8 micturitions or greater per 24 hours)	Significant stress incontinence, active urinary tract infection or another significant lower urinary tract pathology, clinically significant outflow obstruction, urinary retention and the use of concomitant tricyclic antidepressants, α -blockers, 5 α -reductase inhibitors or anti-Parkinson's disease agents	solifenacin 5mg	Oxybutynin IR 5mg thrice daily	Not reported	Sender Herschorn has financial interest and/or other relationship with Astellas, Pfizer, Allergan, American Medical Systems, Johnson & Johnson and Coloplast; Lynn Stothers has financial interest and/or other relationship with Astellas Canada, Merck, UroDynamix, Allergan, UBC; Kevin Carlson has financial interest and/or other relationship with Astellas Canada,

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
						Pfizer Canada, GlaxoSmithKline, American Medical Systems, BR Capital Inc. and Health Education United Partnership Inc.; Blair Egerdie has financial interest and/or other relationship with Astellas Canada, Amgen, Bayer, Protox Therapeutics and Pfizer; Jerzy Gajewski has financial interest and/or other relationship with Astellas Canada, Allergan, Pfizer, Sanofi-Aventis, Johnson & Johnson and Medtronic; Peter Pomerville has financial interest and/or other relationship with Astellas Canada, Aeterna Zentaris, American Medical Systems, Amgen, AstraZeneca, Dendreon, Eli Lilly, Ferring, Pfizer, Protox Therapeutics, Spectrum Uromedica, Bioniche Inc., Sanofi-Aventis, GlaxoSmithKline, Schering Plough,

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
						<p>Amgen, and Abbott; Jane Schulz has financial interest and/or other relationship with Astellas, Gynecare, Pfizer and Triton; Sidney Radomski has financial interest and/or other relationship with Astellas Canada, Pfizer, Bayer and Lilly; Harold Drutz has financial interest and/or other relationship with Astellas, Lilly, Pfizer, Caldion, Gynecare, Troton and Watson; Jack Barkin has financial interest and/or other relationship with Astellas, GlaxoSmithKline, Merck, AstraZeneca and Pfizer; Fran Paradiso-Hardy has financial interest and/or other relationship with Astellas Pharma Canada</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Herschorn, 2008 ³⁰¹ RCT Multinational N: 617	≥18 years of age; mean of ≥8 micturitions per 24 hours and ≥3 episodes of urgency or urgency urinary incontinence (UUI) in a 3-day bladder diary before randomization; experienced OAB symptoms for ≥3 months and at least moderate problems associated with their most bothersome OAB symptom, as reported on the OAB Bother Rating Scale	Patients who received any drug used to treat UUI or OAB within 14 days before the study treatment period	Tolterodine-ER	Placebo	Funded by Pfizer Inc	Sender Herschorn has served as an advisory board member for Pfizer Inc. and as a study investigator sponsored by Pfizer Inc., Astellas Pharma Inc., Johnson & Johnson, Sanofi Aventis, and Allergan Inc. John Heesakkers has no conflict of interest to declare. David Castro-Diaz has served as a study investigator sponsored by Pfizer Inc. Joseph Wang, Marina Brodsky and Zhonghong Guan are employed by Pfizer Inc.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Hill, 2006 ⁴² Darifenacin Study Group. N: 439	Male and female patients, aged >18 years, with urgency incontinence (>10 episodes over 14 days), high micturition frequency (mean of >8 voids per day), and urinary urgency (a strong desire to void on average at least once per day) for at least 6 months, regardless of previous antimuscarinic treatment.	Clinically significant stress incontinence, bladder outlet obstruction or a postvoid residual urinary volume >200 ml; local pathology that could cause urinary symptoms (e.g., interstitial cystitis, bladder stones), severe constipation (≤ 2 bowel movements per week), history of intermittent urinary tract infections; those who had undergone urogenital surgery within the previous 6 months, or cystoscopy in the previous 30 days; patients with indwelling catheter or using intermittent self-catheterization; presence of clinically significant systemic disease; patients who intended to start a bladder-training program during the study, or had contraindications to antimuscarinic therapy; pregnant and lactating women; no concomitant treatment with drugs (including drugs with significant anticholinergic effects), opioids, hormone replacement therapy (unless taken for >2 months), and drugs known to be significant inhibitors of cytochrome P450 2D6 or 3A4 isoenzymes (cimetidine, fluoxetine, ketoconazole, nitraconazole, etc.).	Oral Darifenacin (Novartis Pharma AG, Basel, Switzerland) once-daily 7.5, 15, 30 mg	Placebo	The study was funded by Pfizer Inc.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Ho, 2010 ³⁰² RCT Taiwan N: 75	Male or female patients aged ≥ 18 years; informed consent willing and able to complete the micturition diary correctly; OAB symptoms, including urinary frequency, urgency, or urgency incontinence, had persisted for ≥ 3 months; and having frequency, defined as ≥ 8 micturitions per 24 hours	Pregnant and lactating women or those who intended to become pregnant during the study; clinically significant bladder outflow obstruction (such as women with bladder outlet obstruction); significant post-void residual volume (>200 mL); genuine stress incontinence; evidence of symptomatic urinary tract infection, chronic inflammation, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs; patients with any medical condition that contraindicated the use of antimuscarinic medication; uncontrolled narrow angle glaucoma, urinary or gastric retention, or any other medical condition that, in opinion if the investigator, contraindicated the use of antimuscarinic	Solifenacin	Tolterodine	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Holtedahl, 2000 ³⁰³ RCT analysis Norway N: 87	Women 50-74 years of age reporting two or more leakage episodes per month.	Reported previously ³⁰⁴	Estriol and pelvic floor exercise for all patients, plus bladder training and maximal electrical stimulation in patients with urge, vaginal long-term electrical stimulation in patients with stress, and all elements in patients with mixed incontinence.	Estriol and pelvic floor exercise (for all patients, plus bladder training and maximal electrical stimulation in patients with urge, vaginal long-term electrical stimulation in patients with stress, and all elements in patients with mixed incontinence	The Norwegian Medical Association Fund no. 1, Odd Berg Medical Research Fund, Finnmark County Research Fund, Medicon A/S, Organon A/S, Coloplast A/S, SABA Mo"lnlycke A/S, and LIC Hygiene A/S.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Holtedahl, 1998 ³⁰⁴ RCT Norway N: 90	Women, 50-74 years of age with regular incontinence (>2 leakage episodes per month) diagnosed during gynecological examinations, with positive pad test, or self reported in 48 hour chart.	Cardiac pacemaker, dementia, medical conditions that would prevent following the protocol.	Local estrogen in vagitories or jelly plus physiotherapy and electro-stimulation	Usual care	Financial and material (pads, estriol) support from The Norwegian Medical Association Fund no. 1, Odd Berg Medical Research Fund, Finnmark County Research Fund, Medicon A/S, Organon A/S, Coloplast A/S, SABA Mo ^o Inlycke A/S, LIC Hygiene A/S.	Not reported
Homma, 2006 ³⁰⁵ RCT analysis Japan N: 637	Adult patients with OAB syndrome and having experienced urgency incontinence one or more times a day on average with urinations eight or more times a day during the preceding week.	22 patients were excluded from full-analysis-set for the following reasons: (1) non-OAB patients (n =8), (2) not treated (n = 2), (3) no efficacy data after randomization (n =11), (4) duplicated enrollment (n =1).	Three sizes of oxybutynin transdermal patch (26, 39, and 52 cm ²) were used	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Homma, 2004 ³⁰⁶ RCT Japan and Korea N: 293	Men and women aged ≥ 20 years were eligible for inclusion if they had symptoms of OAB for ≥ 6 months and urinary urgency, urinary frequency (≥ 8 micturitions/24 hours), urgency incontinence (≥ 5 episodes/week) as assessed by micturition diaries during the wash-out/run-in period. Patients were recruited solely on the basis of their OAB symptoms, irrespective of whether they had received prior antimuscarinic treatment and irrespective of their response to such therapy.	Demonstrable stress incontinence, total daily urine volume $> 3L$, average volume voided/ micturition > 200 ml, significant hepatic or renal disease, any contraindication for anticholinergic treatment (e.g., uncontrolled narrow-angled glaucoma, urinary retention, or gastric retention), symptomatic or recurrent urinary tract infection, interstitial cystitis, hematuria or bladder outlet obstruction, an indwelling catheter or intermittent self-catheterization, electro-stimulation or bladder training within 14 days before randomization or expected to commence during the study period.	Tolterodine ER 4 mg once daily	Oxybutynin 3 mg three times daily, placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Homma, 2003 ³⁰⁷ Japanese and Korean Tolterodine Study Group Korea and Japan N: 608	Men and women aged >20 years with symptoms of urinary urgency, urinary frequency (> 8 voids/24 hours), urgency incontinence (>5 episodes/ week) and symptoms of OAB for >6 months were eligible for inclusion. Patients were recruited based solely on their symptoms of OAB, irrespective of whether they had received previous antimuscarinic treatment and irrespective of their response to such therapy.	Demonstrable stress incontinence; total daily urine volume of >3 L; average volume voided/ void of >200 mL; significant hepatic or renal disease; any contraindication to anticholinergic treatment, e.g. uncontrolled narrow-angled glaucoma, urinary retention or gastric retention; symptomatic or recurrent UTI; interstitial cystitis; hematuria or BOO; an indwelling catheter or intermittent self-catheterization; and electro-stimulation or bladder training within 14 days before randomization or expected to commence during the study period; pregnant or nursing women and women of childbearing potential not using reliable contraception.	Tolterodine 4mg capsules once daily	Oxybutynin 3mg tablets three times daily, placebo	This study was supported by a grant from Pharmacia Corporation.	Not reported
Hurley, 2006 ³⁰⁸ Viktrup, 2007 ³⁰⁹ Pooled Africa, Australia, Europe, North America, and South America N: 2,188	1,913 women with SUI who participated in four controlled clinical trials of duloxetine vs. placebo. All had predominant SUI were enrolled using a clinical algorithm validated to be 90.2% predictive for urodynamic SUI.	Subjects who received lower doses of duloxetine (20 or 40 day, n = 275) in the phase 2 trial. Active substance abuse disorder within the 5 years prior to study entry; regular consumption of 21 or more alcoholic drinks per week; use of monoamine oxidase inhibitors or antidepressants within 14 days prior to study entry; a current diagnosis of a voiding abnormality or significant diseases of the genito-urinary tract; a history of urogenital cancer; symptomatic arrhythmia despite antiarrhythmic medication; uncontrolled angina, or a significant abnormality on electrocardiogram (ECG) at screening; any active cardiac ischemic condition, including myocardial infarction within 6 months	Duloxetine (80 mg per day). All subjects were given the option to continue taking duloxetine in open-label extensions of these studies. Those randomized to duloxetine 80 mg per day in the phase 2 studies were dose escalated over the first 2 weeks from 20 mg twice daily	Placebo	This work was sponsored by Eli Lilly and Company and Boehringer Ingelheim.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
		<p>prior to study entry; uncontrolled or poorly controlled hypertension; an active seizure disorder; unstable diabetes mellitus; a spinal cord lesion, multiple sclerosis, or neurological abnormality that affected the lower urinary tract; a history of severe allergies requiring emergency medical treatment or multiple adverse drug reactions; and . active or chronic hepatitis A, B, or C.</p>	<p>for the first week to 30 mg twice daily for the second week before taking 40 mg twice daily. At the end of the active-treatment phase, subjects had their duloxetine dose tapered over 2 weeks (30 mg twice daily for the first week and 20 mg twice daily for the second week) before duloxetine was discontinued.</p>			
Ishiko, 2001 ³¹⁰ RCT Japan N: 73	73 women with postmenopausal stress incontinence.	Urge or mixed incontinence	Combination of estriol (1 mg/day) and pelvic floor muscle exercise	Pelvic floor muscle exercise	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Jackson, 1999 ³¹¹ RCT UK N: 67	Postmenopausal women with symptoms of urinary incontinence. If genuine stress incontinence was diagnosed, and the woman was more than 12 months post-menopausal and had not taken hormone replacement therapy in the previous 12 months, she was fully informed about her options for treatment as well as being offered recruitment to the clinical trial.	History of cancer of the endometrium, liver, or breast; endometrial thickness >4mm	Estradiol valerate 2mg/day	Placebo	Industry + grant	Not reported
Jacquetin, 2001 ³¹² RCT Belgium and France N: 251	Male and female patients aged ≥18 years were eligible for inclusion in the study if they had urodynamically proven overactive bladder, and symptoms of urgency and/or urgency incontinence (≥1 incontinence episode/24 hours) with increased frequency of micturition (≥8 micturitions/24 hours) irrespective of prior treatment or treatment failure.	Significant stress incontinence; hepatic or renal disease; symptomatic or recurrent urinary tract infection; interstitial cystitis; hematuria; clinically significant voiding difficulty; patients receiving bladder training, electro-stimulation therapy or having an indwelling catheter or on intermittent catheterization; pregnant or nursing women, or women of childbearing age who were not using reliable contraception.	Tolterodine 1 or 2mg twice daily	Placebo	Pharmacia Corporation	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Johnson, 2005 ³¹³ RCT analysis U.S. N: 131	Participants had to report at least two accidents per week and to demonstrate the ability to complete an interpretable bladder diary that confirmed this frequency of urine loss. Urgency incontinence had to be the predominant pattern (urge accidents exceeded the number of stress and other accidents), with urodynamic evidence of bladder dysfunction. Two-channel supine water cystometry was performed to demonstrate detrusor instability (defined as urodynamic observation of involuntary detrusor contractions during the filling phase) or sensory urgency (defined as bladder capacity of less than 350 mL) for inclusion in the study.	Participants with continual leakage, elevated postvoid residual urine volume (4200 mL), narrow angle glaucoma, uterine prolapse past the vaginal introitus, unstable angina pectoris, decompensated congestive heart failure, or impaired mental status (MMSE score <20).	Behavioral training, drug treatment (oxybutynin IR titrated from 2.5 mg per day to 5.0 mg three times a day)	Placebo	Supported by grant from the National Institute on Aging. Dr. Johnson received additional support from the Emory University Center for Health in Aging. The John A. Hartford Foundation Southeast Center of Excellence in Geriatric Medicine and the Birmingham/Alabama VA GRECC provided infrastructural support that enabled this inter-institutional collaboration.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Jonas, 1997 ³¹⁴ The International Study Group N: 242	Men or women >18 years and presenting with detrusor overactivity, defined as the existence of any phasic detrusor contraction with an amplitude of >10 cm H2O or the existence of one strong detrusor contraction that caused the end of the infusion, with frequency (> 8 micturitions/24 hours) in combination with urgency incontinence (>1 incontinence episode/24 hours), urinary urgency, or both.	Significant stress incontinence hepatic disease, defined as twice the upper limit of the reference range for liver function tests, renal disease, defined as twice the upper limit of the reference range for creatinine, any condition contraindicating anticholinergic therapy, recurrent urinary tract infections, interstitial cystitis, uninvestigated hematuria, or clinically significant voiding difficulty with risk of urinary retention; any anticholinergic treatment; using an indwelling catheter, history of electro-stimulation therapy or bladder training (last 14 days prior to the inclusion visit).Concomitant treatment with anticholinergic drugs or treatment with any agent for urinary urgency incontinence (with the exception of any estrogen treatment started at more than 2 months prior to entry) was not permitted in the 14 days prior to entry or during the study.	Tolterodine 1 or 2 mg b.i.d	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Junemann, 2006 ³¹⁵ RCT Multinational N: 988	Patients with overactive bladder who met all of the following inclusion criteria were allowed to participate in the study: female and male patients ≥ 18 years, voluntarily signed informed consent, at least 2 incontinence episodes within 3 days, and at least 10 micturitions within 24h	Stress incontinence; intermittent catheterization; neurogenic detrusor under- and overactivity; postvoid residual urine ≥ 100 ml; acute urinary tract infections; electro stimulation therapy, bladder training if performed within 4 weeks before run-in period of this study; anomalies of the lower genitourinary tract (e.g. ectopic ureters, fistulas, urethral stenosis); pre-existing medical contraindications for anticholinergics (e.g. obstruction of the bowel, toxic megacolon, severe colitis ulcerosa, bladder or intestinal atony, significant degree of bladder outflow obstruction where urinary retention could be anticipated, pollakiuria of cardiac or renal genesis, tachyarrhythmia, narrow-angle glaucoma, myasthenia gravis); cardiac insufficiency(New York Heart Association stage III/IV); multiple sclerosis; evidence of severe renal, hepatic or metabolic disorders; history of drug or alcohol abuse; concomitant medications known to have a potential to interfere with the study medication; pregnant or breastfeeding women, or women of childbearing potential without using any reliable contraceptive method	Propiverine hydrochloride IR	Propiverine hydrochloride ER and placebo	Funded by Apogepha Arzneimittel GmbH	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Junemann, 2000 ³¹⁶ RCT N: 234	Patients with urge - syndrome (motor urge, sensory urge and combined motor urge and stress incontinence). Patients medical history and a urodynamic measurement (minimum one unstable detrusor contraction of 10 cm H2O or first desire to void at a bladder filling of <150ml) verified the diagnosis of urge-syndrome	Not reported	Trospium hydrochloride	Tolterodine and placebo	Not reported	Not reported
Junemann, 2005 ³¹⁷ RCT Bosnia, Czech Republic, Germany, Poland, Slovenia, United Kingdom N: 201	Men and women aged >18 years with overactive bladder, defined as at least one unstable detrusor contraction at a minimum of 10 cm H2O combined with an increased frequency of micturition (>8 micturitions/24 hours); sensoric urgency incontinence, defined as at least one incontinence episode/24 hours combined with increased frequency of micturition (>8 micturitions/24 hours).	Maximum cystometric bladder capacity 300 ml; post void residual >50 ml; acute urinary tract infection (>106 bacteria/ml urine); electro-stimulation therapy, bladder training if performed <4 weeks before run-in period of this study; intermittent catheterization; anomalies of the lower genitourinary tract (e.g. ectopic ureters, fistulas, urethral stenosis, etc.); operations of the lower urinary tract within the last 4 weeks; pre-existing medical contraindication for anticholinergics.	15 mg propiverine twice daily	2mg tolterodine twice daily	APOGEPHA Arzneimittel GmbH.	Not reported
Kaplan, 2010 ³¹⁸ RCT Multinational N: 2417	Subjects with OAB symptoms for >=months and recorded micturitions and >=1 urgency urinary incontinence episode per 24h in 3-day baseline diaries	Not reported	Fesoterodine	Tolterodine/ Placebo	Sponsored by Pfizer Inc.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Karademir, 2005 ³¹⁹ RCT Turkey N: 43	Patients with a >6-month history of overactive bladder symptoms and who had detrusor overactivity findings on urodynamic studies (UDS).	Urinary tract obstruction, urinary retention, a neurologic or metabolic disorder; any kind of intervention for urinary incontinence.	Stoller afferent neuro-stimulation (SANS) with low-dose anticholinergic (oxybutynin hydrochloride)	Stoller afferent neuro-stimulation (SANS)	Not reported	Not reported
Karram, 2009 ³²⁰ Toglia, 2009 ³²¹ VENUS U.S. N: 739	Patients aged ≥ 18 years with OAB (at least 1 urgency episode with or without incontinence and ≥ 8 micturitions per 24 hours) for ≥ 3 months	Presence of stress or stress-predominant mixed urinary incontinence, chronic inflammation or cystitis, and clinically significant bladder outlet obstruction	Solifenacin	Placebo	Research grant from Astellas Pharma US, Inc. and Glaxo-SmithKline	Marc Toglia discloses conflict of interest with Astellas Pharma US, Inc. and Ethicon Women's Health. Scott R. Serels discloses conflicts of interest with Astellas Pharma US, Inc., GlaxoSmithKline, and Takeda. Mickey Karram discloses conflict of interest with Allergan, Astellas Pharma US, Inc., Cooper, and Ehticon. Indrani Nandy discloses conflict of interest with GlaxoSmithKline. Masakazu Andoh discloses no conflict of interest. Raafat Seifeldin discloses conflict of interest with Astellas Pharma US, Inc. Sergio Forero-Schwanaeuser discloses conflict of interest with GlaxoSmithKline

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Kelleher, 2006 ³²² RCT U.S. N: 3,032	Pooled analysis of 4 RCTs: men and women at least 18 years of age with either MUI or UUI based on their history and the results of a cough test; a mean of ≥ 8 micturitions per 24 hours in addition to a mean of ≥ 1 incontinence episode per 24 hours or a mean of ≥ 1 urgency episode per 24 hours during the baseline 3-day micturition diary period.	Predominant stress UI.	5 mg solifenacin once daily, 10 mg solifenacin once daily	Placebo	Not reported	Not reported
Kelleher, 2002 ³²³ RCT U.S. N: 1,015	Male and female patients aged 18 years or older with urinary frequency (average of ≥ 8 micturitions/24 hours over a 7-day period), urgency incontinence (≥ 5 episodes/week), and symptoms of OAB for at least 6 months.	Other types of bladder dysfunction, with diseases that may have affected urinary output.	Tolterodine extended-release (ER) 4 mg once/day, or tolterodine immediate-release (IR) 2 mg twice daily	Placebo	Pharmacia Corporation	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Kelleher, 2008 ³²⁴ Pooled analysis U.S. N: 1,971	Men and women aged ≥18 years with OAB syndrome for ≥6 months; patients had to report at least moderate problems related to their bladder condition on a six-point Likert scale	Presence of lower urinary tract pathology that could, in the investigator's opinion, be responsible for urgency or UI (e.g. significant stress UI, interstitial cystitis, urothelial tumors); pelvic organ prolapse grade ≥III; clinically relevant BOO; a post void residual urine volume of >100mL; polyuria (>3L/24h); symptomatic or recurrent UTI; current treatment with antimuscarinic agents; a neurogenic cause of OAB; clinically relevant arrhythmia, unstable angina, or a QTcB interval of >500ms; and current treatment, or treatment within the past 4 weeks, with electro stimulation or bladder training	Fesoterodine	Tolterodine/ Placebo	Funded by Schwarz BioSciences GmbH and Pfizer Inc	Con J.Kelleher is an Advisor to Astellas and Novartis and a Lecturer for Pfizer. Andrea Tubaro is a paid Consultant and study investigator funded by the sponsor. Joseph is an employee of the sponsor
Khullar, 2004 ³²⁵ RCT UK N: 854	Women 18 years or older with urge-predominant mixed incontinence, including urgency incontinence (five or more episodes per week), urinary frequency (eight or more micturitions on average in 24 hours), and urgency in combination with stress incontinence irrespective of the use of previous antimuscarinic treatment.	Pure stress urinary incontinence; predominant stress urinary incontinence; a total daily urine volume greater than 3 L; suspected or documented hepatic or renal dysfunction; symptomatic urinary tract infection; interstitial cystitis, uninvestigated hematuria, or clinically significant bladder obstruction; any contraindication to antimuscarinic treatment; and any nonsurgical treatment for incontinence within 4 weeks of the first study visit; treatment within 2 weeks before randomization with any drug for incontinence (except estrogen therapy started more than 2 months before the first visit); agonist or potent inhibitors of cytochrome P450 3A4 isoenzymes; pregnancy, lactation, or inadequate contraception.	Tolterodine tartrate extended-release (ER) 4 mg	Placebo	Pfizer Inc	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Khullar, 2008 ³²⁶ Pooled U.S. N: 1,674	Pooled analysis of two RCTs: men and women 18 years of age or older with OAB syndrome for 6 or more months; urinary frequency (8 or more micturitions per 24 hours) and urinary urgency (6 or more episodes during the 3-day diary period) or UUI (3 or more episodes during the 3-day diary period).	Presence of lower urinary tract pathology that could, in the investigator's opinion, be responsible for urgency or incontinence (for example, significant stress incontinence, urolithiasis, interstitial cystitis, urothelial tumors); pelvic organ prolapse grade III or higher; clinically relevant bladder outlet obstruction; postvoid residual urine volume greater than 100mL; polyuria (more than 3L/24 hours); symptomatic or recurrent urinary tract infections; current treatment with antimuscarinic agents; a neurogenic cause of OAB symptoms; clinically relevant arrhythmia, unstable angina, or a QTcB interval greater than 500 ms; current treatment, or treatment within the past 4 weeks, with electro-stimulation or bladder training during the past 4 weeks.	Fesoterodine 4 mg, or fesoterodine 8 mg	Placebo	Schwarz BioSciences GmbH and Pfizer Inc	Dr. Vik Khullar has been a consultant and investigator in clinical trials by Pfizer Inc. Drs. Eric Rovner and Roger Dmochowski have served as consultants and investigators on clinical trials sponsored by Pfizer Inc. Dr. Victor Nitti has been a consultant and lecturer sponsored by Pfizer Inc. Joseph Wang and Dr. Zhonghong Guan are employed by Pfizer Inc.
Kinchen, 2005 ³²⁷ RCT Not reported N: 451	Ambulatory women with symptoms of SUI 18 years of age or older, >1 episode per week of urinary incontinence due to activities such as coughing, sneezing, lifting, and exercising. Women had to have experienced stress symptoms for >3 months but may have predominant symptoms of urgency incontinence	Pregnancy, breastfeeding, having an active urinary tract infection, participation in a previous trial of duloxetine, or having conditions such as arrhythmias, poorly controlled or uncontrolled hypertension, liver disease, seizure disorders, or an unstable cardiac condition.	Duloxetine (40 mg b.i.d.) but dose adjustment was allowed	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Kreder, 2003 ³²⁸ RCT analysis N: 994	Age >18 years with OAB, diagnosed by a physician assessment based on self-reported symptoms with urinary frequency (>8 voids/24 hours) and either urgency or UI (>1 incontinence episode/24 hours).	Predominating stress UI; contraindications to antimuscarinic therapy; significant hepatic or renal disease; symptomatic UTI or history of recurrent UTI; hematuria or interstitial cystitis; significant voiding difficulty with risk of urinary retention; and bladder training, electro stimulation therapy, or having an indwelling catheter or an intermittent catheterization, women with reproductive potential; pregnancy or nursing; concomitant treatment for OAB (other than estrogen-replacement therapy started at least 2 months before study commencement) and use of anticholinergic agents.	Tolterodine 1 mg twice daily for 4 weeks, after which the dose could be increased to 2 mg twice daily (and subsequently reduced to 1 mg if necessary), based on the patient's response	None. Outcomes were compared among patients with urge UI vs. mixed UI	Pharmacia Corporation.	Not reported
Lackner, 2008 ³²⁹ RCT U.S. N: 50	Nursing home resident for at least 3 months; aged ≥65; not residing in a subacute, transitional care, or rehabilitation unit of the nursing home; not enrolled in hospice; bladder incontinence (Minimum Data Set 2.0 score of 1–4); no indwelling catheter; able to swallow medication intact and obtained permission from potential participants or their designated proxies for chart review by the NP; Mini-Mental State Examination score of 5–23; Global Deterioration Scale score of 3–6; ≥1	Terminal illness; bed-bound; non-communicative; delirium (Confusion Assessment Method feature 1 (acute onset) and 2 (inattention) plus feature 3 (disorganized thinking) or 4 (altered level of consciousness)); Lewy body dementia; history of ≥3 urinary tract infections in previous year or current infection; postvoid residual urine volume ≥150 mL (bladder ultrasound); urethral diverticulum; bladder tumor or stone; severe pelvic organ prolapse or vaginitis; genitourinary surgery within past 6 months; hepatic disease; severe cardiovascular disease; myasthenia gravis; spinal cord injury; bowel movement <every 3 days; history of gastrointestinal obstruction or decreased motility; current drug therapy for urinary incontinence;	Extended release oxybutynin 5mg once daily	Placebo	Funded by a research grant from Ortho-McNeil Pharmaceutical, Raritan, New Jersey. ALZA Corporation, Mountain View, California, supplied oxybutynin extended-release (Ditropan XL) 5-mg tablets and matching placebo tablets.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
	<p>symptom or sign of urge urinary incontinence (≥ 4 micturitions or wet checks or requests to toilet within an 8-hour period of prompted voiding schedule on 2 consecutive days (8:00 a.m. to 4:00 p.m.); nocturia or nocturnal enuresis > 2 times per night; staff observation that incontinence occurs on way to toilet or resident reports urgency; or medical record documentation of detrusor overactivity or urgency); Medication adherence rate $\geq 80\%$ during the week before screening.</p>	<p>current use of acetylcholinesterase inhibitor or bisphosphonate; investigational drug, systemic or ophthalmic cholinomimetic drug, or gastrointestinal antispasmodic within 2 weeks before trial.</p>				
<p>Landis, 2004³³⁰ RCT North America, Europe and Australia/New Zealand. N: 1529</p>	<p>Men and women 18 years old or older with urinary frequency (8 micturitions or greater per 24 hours), urgency incontinence (5 episodes or greater a week) and symptoms of overactive bladder for 6 months; severe incontinence defined as 21 episodes or greater per week at baseline irrespective of prior antimuscarinic treatment and response to such treatment.</p>	<p>Reported previously³³¹</p>	<p>4 mg tolterodine ER once daily</p>	<p>Placebo</p>	<p>Pharmacia Corporation, Peapack, New Jersey</p>	<p>J. Richard Landis has financial interest and/or other relationship with Alza Pharmaceuticals, Pharmacia and Bristol-Myers Squibb; Eboo Versi has financial interest and/or other relationship with Pharmacia.</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Lee, 2002 ³³² RCT South Korea N: 228	Male and female subjects aged ≥ 18 years with symptoms of overactive bladder for ≥ 6 months were eligible for enrolment in the study. Symptoms, as measured by micturition diaries, were defined as urinary urgency and frequency (≥ 8 micturitions on average per 24 hours), with or without urgency incontinence. Patients were enrolled exclusively on the basis of symptoms (i.e. urodynamics was not performed), irrespective of whether they had received prior antimuscarinic therapy.	Significant stress incontinence; women of childbearing age who were not using reliable contraception; pregnant or nursing women; treatment with any drug with known anticholinergic side-effects in the 2 weeks prior to the study; significant renal or hepatic disease; any contraindication to antimuscarinic therapy (e.g. narrow-angle glaucoma, urinary or gastric retention, known hypersensitivity to tolterodine or oxybutynin); symptomatic acute or recurrent urinary tract infection; interstitial cystitis or hematuria; bladder outlet obstruction; and patients receiving bladder training, electro-stimulation therapy or having an indwelling catheter or on intermittent catheterization.	Tolterodine 2mg bid	Oxybutynin 5mg bid	Grant from Pharmacia	Not reported
Lee, 2010 ³³³ Propiverine study on overactive bladder including urgency data Korea N: 264	Men and women aged ≥ 18 years who had self-reported symptoms of OAB for ≥ 3 months; average urinary frequency of ≥ 10 voids/24h and urgency of two or more episodes/24h defined as 'moderate to severe' in the Indevus Urgency Severity Scale during the 3-day voiding diary period before randomization	Clinically significant stress urinary incontinence (more than one episode per week); genitourinary conditions that could cause OAB symptoms, such as UTI; and contraindications to the use of antimuscarinic drugs	Propiverine hydrochloride 60 mg/d	Placebo	Sponsored by Jeil Pharmaceutical Co. Ltd., Seoul, Korea	NR

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Lehtoranta, 2002 ³³⁴ RCT Finland N: 9	Female or male patients aged 18–75 years were recruited to the study. They had to have a history of urgency or urgency incontinence and cystometrically proven detrusor hyperreflexia or instability according to the ICS criteria (International Continence Society).	Stress incontinence and pure nocturnal enuresis	Oxybutynin 5mg/30ml three times daily	Placebo 30ml of sterile saline	Not reported	Not reported
Leung, 2002 ³³⁵ RCT Hong Kong N: 106	Age ≥18 years; a diagnosis of overactive bladder confirmed by urodynamic test (phasic detrusor contraction with an amplitude ≥15cm H ₂ O) in accordance with ICS criteria; urinary frequency (an average of ≥8 voids/24 hours), urgency or urgency incontinence (an average of ≥1 incontinence episode/24 hours); and willing to give written informed consent.	A diagnosis of genuine stress incontinence; clinically significant voiding difficulty (maximum flow rate <10 mL/s with a residual volume of >200 mL); recurrent or acute UTIs; require intermittent catheterization or an indwelling catheter; uninvestigated hematuria or bladder cancer; currently on treatment for an overactive bladder or on anticholinergic medications; presence of psychiatric disease or cognitive impairment, as shown by their history or an abnormal Mini Mental State Examination; clinically significant cardiac, hepatic, renal or hematological disorders, as shown by their history; the presence of contraindications for antimuscarinic agents; pregnant or lactating women and women of childbearing age who were not using reliable contraception.	Tolterodine 2mg twice daily	Oxybutynin 5mg twice daily	Financial Assistance from Pharmacia Limited	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Lin, 2008 ³³⁶ RCT Taiwan N: 121	Non-pregnant women 20 years of age and older with predominant symptoms of SUI during the last 3 months with an average of ≥ 1 incontinent episode/day, positive cough stress test after filling the bladder, daytime voiding frequency ≤ 8 voids daily, nocturnal frequency ≤ 2 voids daily and no predominant urgency incontinence symptoms.	Inability to tolerate retrograde bladder filling to 400 mL or who had a first sensation of bladder filling at ≤ 100 mL. Concomitant medications including urinary continence promoting drugs, antidepressants, drugs for obesity (including over the counter appetite suppressants and diet pills), and illicit drugs.	80 mg duloxetine (40 mg twice daily)	Placebo	This study was supported by Eli Lilly and Company and Boehringer Ingelheim.	Not reported
Lipton, 2005 ³³⁷ RCT N: 129	Male and female volunteers 65 years or older with a score of 10 or less on the Short Orientation Memory and Concentration Test, 12 which is a short version of the Blessed Information-Memory Concentration (no clinical dementia).	A diagnosis of clinical dementia, depression or any other medical, psychological or social condition that would impair participation in the study, clinically significant or unstable hematological, renal, hepatic or cardiac disease, or the use of cimetidine, psychotropic drugs, anticholinergic drugs, antihistamines or other drugs known to affect cognitive function; severe drug allergy or contraindications to antimuscarinic therapy (e.g., narrow angle glaucoma, significant urinary outflow obstruction or obstructive bowel disease); treatment with another investigational drug within the previous 3 months.	Darifenacin controlled release (3.75, 7.5 or 15 mg once daily), darifenacin immediate-release (5 mg 3 times daily)	Placebo	Supported by Pfizer, Inc. and an educational grant from Novartis Pharma AG.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Lose, 2000 ³³⁸ RCT Denmark N: 254	251 women reporting at least one bothersome lower urinary tract symptom after spontaneous or surgical post menopause	Known or suspected estrogen-dependent neoplasia or mammary, ovarian (endometroid) or corpus uteri malignancies, vaginal bleeding, clinically significant liver diseases, acute or intermittent porphyria, uterovaginal prolapse II-III, sex hormone treatment within the last 6 months, vaginal irritation other than atrophy derived or signs of vaginal ulceration; participation in clinical trials within last 3 months prior to inclusion	Estradiol-releasing ring, 7.5mg estradiol.	Estriol pessaries 0.5 mg every second day	Not reported	Not reported
MacDiarmid, 2005 ³³⁹ Pooled U.S. N: 420	Men and women with UUI or mixed incontinence with a predominating urge component; with at least 6 (studies 1 and 3) or 7 (study 2) UUI episodes weekly when unmedicated; with known response to oxybutynin in study 1 or to anticholinergic medications in study 2.	Reported previously ^{40,340-342}	ER oxybutynin was initiated at 5 mg daily and adjusted in 5 mg increments at intervals of approximately 1 week until continence was achieved	None	Grant from ortho-McNeil Pharmaceutical, Inc.	Not reported
Madersbacher, 1999 ³⁴³ RCT U.S. N: 366	History of urgency or urgency incontinence, a maximum cystometric bladder capacity of ≤300 ml, age ≥18years and body weight ≥45kg	Detrusor hyperreflexia, postoperative (bladder) incontinence, intravesical obstruction, a postvoid residual urine of >15% of the maximal cystometric bladder capacity, acute UTIs, angina pectoris, glaucoma, megacolon, clinically relevant cardiac, renal or hepatic dysfunctions, tachy/dysrhythmias, frequency or nocturia due to heart or renal insufficiency, or overt cerebral sclerosis.	Propiverine 15mg three times a day	Oxybutynin 5mg twice a day, placebo three times a day	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Malhotra, 2010 ³⁴⁴ RCT U.S. N: 261	Healthy subjects aged 45-65 years with a body mass index between 19 and 32kg/m ² (inclusive); had no clinically relevant abnormal findings on the physical examination, ECG, blood pressure, pulse rate, medical history, or clinical laboratory results at the eligibility assessment visit and were characterized as extensive metabolizers for CYP2D6	Medical history of any serious disease of the internal organs or of the central nervous system; a history or presence of urinary retention, obstructive disturbance of bladder emptying, micturition disturbance, nocturia, or pollakiuria, for example, prostatic hyperplasia, or urethral stricture; a history of ischemic heart disease or a positive diagnostic cardiac stress test within 12 weeks before the start of the trial; a supine systolic blood pressure of <100mg or >160mmHg or a supine diastolic blood pressure of >95mmHg; a supine pulse rate of <50bpm or >100bpm; and any clinically relevant changes in ECG such as second-or third-degree AV block, or prolongation of the QRS interval to >110ms, the PR interval to >240ms, or QTc(Bazett's correction, machine read) to >480ms	Fesoterodine 4mg/28mg	Placebo	Funded by Schwarz BioSciences GmbH and Pfizer Inc.	Bimal Malhotra and Kuan Gandelman are employees of Pfizer Inc., New York, NY, U.S.A. Nolan Wood was an employee of Pfizer Inc., Sandwich, Kent, UK at the time the study was conducted. Richard Sachse is an employee of Schwarz BioSciences, Monheim, Germany
Malone-Lee, 2009 ³⁴⁵ RCT UK N: 307	Male and female subjects aged ≥18 years with urinary frequency (defined as an average of ≥8 voids/24 hours, measured over a 7-day period) and urgency (with or without UUI), symptoms of OAB for ≥6 months before randomization, with no significant stress UI and adequate contraception.	Mean volume voided of >300 mL/void or a mean total volume of urine >3000 mL/24 hours; significant hepatic or renal disease, symptomatic UTI, diagnosed interstitial cystitis, un-investigated hematuria, or clinically significant BOO; anticholinergic drugs or other treatments for OAB in the 14 days before randomization; known hypersensitivity to tolterodine-ER or any of its recipients; oral cytochrome P450 3A4 inhibitors (e.g. macrolide antibiotics), and electro-stimulation or bladder retraining in the 3 months before randomization.	Tolterodine-ER (4 mg capsule od)	Placebo	Pharmacia (now Pfizer Ltd)	James Malone-Lee has received travel expenses for attending professional conferences from Pharmacia & Upjohn and Pfizer Inc, and has served as a consultant and received research funds from Pfizer Inc.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Malone-Lee, 2001 ³⁴⁶ RCT United Kingdom, France, and the Republic of Ireland N: 177	Older men and women (age ≥ 65 years) with symptoms of urinary urgency, increased frequency of micturition (≥ 8 micturitions/24 hours), and/or urgency incontinence (≥ 1 episode/24 hours).	Significant stress incontinence, urinary outflow obstruction, urinary retention (as determined by palpation after voiding), symptomatic urinary infection, interstitial cystitis, unexplained hematuria, use of urinary catheterization or electro-stimulation, hepatic and renal disease with biochemical markers twice the upper limit of the normal reference range, concomitant antimuscarinic medication, previous treatment with tolterodine, and exposure to any other investigational drug in the preceding 2 months.	Tolterodine 1 mg or 2 mg twice daily	Placebo	Pharmacia & Upjohn AB	Not reported
Mattiason, 2009 ⁶¹ SOLAR62 Multinational N: 643	Men or women aged ≥ 18 years with OAB symptoms were eligible if they gave written informed consent, were capable of completing a simplified bladder training regimen correctly, and were willing and able to complete a voiding diary correctly	Patients should not have received non-drug treatment for OAB, including electro stimulation therapy and pelvic floor exercises, in the 4 weeks before starting the study, or during the study except for those randomized to receive bladder training instructions. Patients were also excluded if they had received cognitive bladder training in the previous 6 months, or if they intended to commence bladder training other than the study regimen during the study.	Simplified Bladder training + Solifenacin	Solifenacin 5mg or 10mg	Research Grant from Astellas Pharma Europe Ltd.	Anders Mattiason: Astellas, Ferring; Pfizer; Alberto Masala: Astellas, Angelini Group; Richard Morton and John Bolodeoku: employees of Astellas

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Mattiasson, 2003 ³⁴⁷ Tolterodine Scandinavian Study Group Sweden, Norway and Denmark N: 501	Men and women aged ≥18 years with symptoms of urinary frequency (≥8 micturitions/24h on average) and urgency (a strong and sudden desire to urinate), with or with no urgency incontinence. Women of child-bearing potential were required to be using a reliable birth control method to enter the study	Any contraindication to antimuscarinic therapy; use of electro stimulation therapy or behavioral therapy within the previous 3 months; patients with an indwelling catheter or on intermittent catheterization; pregnancy and lactation; and use of anticholinergic agents or concomitant treatment for an overactive bladder (other than estrogen replacement therapy started at least 2 months before study commencement)	Tolterodine + Simplified Bladder training	Tolterodine	Supported by Pharmacia Corporation	Not reported
Milani, 1993 ³⁴⁸ RCT Milan N: 50	Women over 18 years of age with motor or sensory urgency	Severe illness, overt neurological diseases, acute or chronic urinary tract infections or obstructive diseases, pregnancy, taking concomitant medication which could affect urinary symptoms, continence or bladder function.	Flavoxate was 1 200 mg (400 mg t.i.d.)	Oxybutynin 15 mg (5 mg t.i.d.)	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Millard, 1999 ³⁴⁹ RCT Sweden N: 316	Male and female patients 18 years old or older with cystometrically proved detrusor overactivity (idiopathic instability or detrusor hyperreflexia, or uninhibited phasic detrusor contractions with an amplitude of 10 cm. water or greater) and average urinary frequency of 8 or more voids per 24 hours; urgency incontinence (an average of 1 or more incontinence episodes per 24 hours on the frequency volume chart) and/or urinary urgency.	Inadequate contraception; demonstrable stress incontinence (fluid escaping from the external urethral orifice during coughing when the bladder was stable), clinically significant voiding difficulty (maximum flow rate less than 10 ml. per second with post-void residual volume greater than 200 ml.), proved recurrent urinary tract infection, interstitial cystitis, uninvestigated hematuria or any bladder cancer; catheterization, indwelling catheterization, hepatic or renal disease, or narrow angle glaucoma, electro-stimulation therapy or bladder training, any primarily anticholinergic drug initiated 14 days before or at any time during the study, an unstable dose of any treatment with anticholinergic side effects; average total voided volume of greater than 3,000 ml/24 hours, or treatment with any investigational drug during or 2 months before the study.	1 or 2 mg. tolterodine twice daily	Placebo	Pharmacia and Upjohn AB	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Millard, 2004 ³⁵⁰ Duloxetine UI Study Group N: 458	Women aged ≥18 years with a clinical diagnosis of troublesome SUI of at least 3 months' duration with the predominant symptom of SUI with ≥7 incontinent episodes per week. An 'episode' was defined as an easily noticed leakage of urine that wet a pad or clothing and occurred with a physical stress such as coughing, sneezing or exercising. Patients also needed to report a diurnal frequency of <9 per day, nocturnal frequency of and the absence of predominant symptoms of urgency incontinence. In addition, objective testing was used to confirm normal bladder capacity and the sign of SUI. With the patient supine the bladder was filled with saline at 100 mL/min with no pressure measurements; positive cough-stress test (visualization of urine leakage concurrent with a cough) and a positive stress pad test (leakage of >2.0 g) (clinical algorithm has a sensitivity of 92% for urodynamic stress incontinence).	Inability to tolerate filling to 400 mL were excluded, as were those who experienced a first sensation of bladder filling at <100 mL, or who had no sensation at any time during the filling	Duloxetine 40 mg twice daily	Placebo	Sponsored by Eli Lilly and Company and Boehringer Ingelheim.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Moore, 1990 ³⁵¹ RCT N: 53	Patients with involuntary detrusor contractions >30cm H2O during the filling phase of cystometry	Those with neurological and other urological disorders; patients with coexistent genuine stress incontinence, low compliance bladder, bacterial or interstitial cystitis, age greater than 75 years or previous treatment with oxybutynin	Oxybutynin hydrochloride	Placebo	Tillots Laboratories provided oxybutynin and placebo tablets	NR
Naglie, 2002 ³⁵² RCT U.S. N: 86	Men and women 65 years or older with a history, physical exam and urodynamic findings consistent with urgency incontinence, and at least 4 documented episodes of urinary incontinence on a 5-day voiding record.	An indwelling or condom catheter, or intermittent catheterization; a clinical history of stress urinary incontinence; a history of >2 urinary tract infections per year; insulin dependent diabetes; spinal cord pathology; symptomatic orthostatic hypotension, congestive heart failure or ventricular arrhythmia; taking any calcium channel blocker; cognitive impairment; evidence of bladder cancer; cystoscopic or urodynamic evidence of outlet obstruction; post-void residual urine volume >100 cc or more than trivial urinary leakage occurring with coughing/straining in the sitting or standing position; unable to complete a 5-day voiding record during the run-in period.	30 mg. nimodipine twice daily	Placebo	Research grant from the Physicians' Services Incorporated	Not reported
NCT00269750 ⁵⁵ RCT U.S. N: 105	Men and women, age 40 to 75, with urge or mixed UI provided that stress UI was not the predominant manifestation of mixed UI. Patients who were currently taking immediate-release oxybutynin (Ditropan), hyoscyamine, or propantheline, or who had taken Ditropan® in the past for urge or mixed UI.	Not reported	Oxybutynin chloride ER	Oxybutynin chloride IR	ALZA Corporation	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
	<p>Patients who had taken and discontinued Ditropan[®] for urge or mixed UI should not have discontinued due to failure of efficacy; patients who had at least six urge UI episodes per week recorded on the Run-in Diary after washout of anticholinergic medications. Patients who were able to differentiate incontinent episodes associated with urgency from incontinent episodes not associated with urgency when recording incontinent episodes in the diary. The Run-in Diary after washout of all anticholinergic medications must have demonstrated that the number of urgency incontinent episodes per week was greater than the number of incontinent episodes not associated with urgency per week.</p>					

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
NCT00168454 ⁵³ RCT U.S. N: 313	Must be between 18-85 years old; must have been diagnosed by his/her doctor with overactive bladder at least 6 months ago; must weigh at least 50 kg (110 lbs); must be willing and able to record information regarding bladder function into a diary (provided); and must be willing and able to complete the entire course of the study	Cannot currently be cathetered as a way to control incontinence and must not have used botulinum toxin type A or any other botulinum toxin previously for any condition	Botulinum toxin Type A	Placebo	Sponsored by Allergan, Inc.	Principal Investigators are not employed by the organization sponsoring the study.
NCT00444925 ⁵⁶ RCT Multinational N: 1,712	Adult overactive bladder (OAB) patients who present with OAB symptoms, including urinary frequency ≥ 8 per day and urgency urinary incontinence ≥ 1 per day	Patients with conditions that would contraindicate for fesoterodine use, e.g., hypersensitivity to the active substance (fesoterodine) or to peanut or soya, urinary retention, and gastric retention; patients with significant hepatic and renal disease or other significant unstable diseases; and OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.	Fesoterodine	Tolterodine/ Placebo	Sponsored by Pfizer Inc.	Principal Investigators are not employed by the organization sponsoring the study.
NCT00536484 ⁵⁷ RCT U.S. N: 883	Adults 18 years and older; overactive bladder symptoms for greater than or equal to 3 months; mean urinary frequency of greater than or equal to 8 micturitions per 24 hours in bladder diary; and mean number of urgency episodes greater than or equal to 3 per 24 hours in bladder diary.	Known etiology of OAB (e.g., neurogenic, local urinary tract pathology); previous history of acute urinary retention requiring catheterization or severe voiding difficulties in the judgment of the investigator, prior to baseline; and unable to follow the study procedures, including completion of self-administered bladder diary and patient reported outcome questionnaires.	Fesoterodine	Placebo	Sponsored by Pfizer Inc.	Principal Investigators are not employed by the organization sponsoring the study.
NCT00178191 ⁵⁴ RCT	Adults 21 years and older; must have completed a	Children (< 21 years old), pregnant women and prisoners; history of	Botulinum toxin Type A	Placebo	Sponsored by University of	Principal Investigators are not employed by

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
U.S. N: 28	routine evaluation of incontinence (urodynamics, bladder diaries, and pad weights) through the urogynecology clinic within 3 months of the screening visit; symptoms of urgency incontinence associated with leakage on bladder diary; 24-hour pad weight >100 cc's (volume requiring multiple daily diaper changes); absence of a bladder infection or other condition that could explain urinary leakage; absence of stress incontinence or a cough leak point pressure >100 cm H2O on cystometry (this correlates with mild stress incontinence); failed anticholinergic therapy; willingness and ability to perform intermittent clean catheterization (due to the risk of prolonged urinary retention from Botox); the ability and willingness to return for surveillance evaluations; a negative urine pregnancy test if at risk for pregnancy; and competent to give signed consent and complete all of the study measures.	carcinoma of the bladder; absence of a measurable detrusor contraction on a pressure flow micturition study; a foreign body in the bladder or other correctable etiology for the UI; prior documented resistance to Botox; gross fecal incontinence (due to confounding effects on pad weights and counts); known allergy to lidocaine or related compounds (used for local analgesia); known allergy to or inability to take both Bactrim DS or Ciprofloxacin (used for urinary tract infection prophylaxis); current use of an aminoglycoside or preparing for general anesthesia within 1 week (risk of synergetic effects); and known neurologic conditions such as Parkinson's disease, myasthenia gravis, multiple sclerosis, autonomic dysfunction, Lambert-Eaton syndrome, Amyotrophic Lateral Sclerosis or other neurologic disorder that may impact urinary function or the effect of Botox.			Rochester, New York, U.S.A.	the organization sponsoring the study.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Nitti, 2007 ³⁵³ RCT U.S. N: 836	Men and women 18 years or older with OAB syndrome for 6 months or greater, including urinary frequency (8 micturitions or greater per 24 hours) and urinary urgency (6 episodes or greater during the 3-day diary period) or UUI (3 episodes or greater during the 3-day diary period). The amended inclusion criterion required 3 or greater UUI episodes in 3-day diary; at least moderate bladder problems on a Likert scale that was almost identical to the patient perception of bladder condition.	Positive pregnancy test and non adequate contraception throughout the trial; lower urinary tract pathology that could in the opinion of the investigator be responsible for urgency or incontinence, such as significant stress incontinence, urolithiasis, interstitial cystitis or urothelial tumors; pelvic organ prolapse grade III or greater; clinically relevant bladder outlet obstruction; PVR volume greater than 100 ml; polyuria (greater than 3 l/24 hours); symptomatic or recurrent urinary tract infections; current treatment with antimuscarinic agents; a neurogenic cause of OAB; clinically relevant arrhythmia, unstable angina or a corrected QT interval (Bazett's formula) of greater than 500 milliseconds; or current treatment or treatment within the last 4 weeks with electro-stimulation or bladder training.	4 mg fesoterodine or 8 mg fesoterodine once daily	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Norton, 2002 ³⁵⁴ Sahai, 2006 ³⁵⁵ Duloxetine Urinary Incontinence Study Group. U.S. N: 553	Women aged 18 to 65 years with a predominant symptom of stress urinary incontinence for at least 3 months with ≥ 4 incontinent episodes per week (easily noticeable leakage of urine that wets a pad or clothing and occurs with a physical stress such as coughing, sneezing, or exercising); urinary diurnal frequency ≤ 7 per day, nocturnal frequency ≤ 2 per day; both a positive cough stress test, visualization of urine leakage concurrent with a cough) and leakage of >2.0 g.	Predominant symptoms of enuresis or urgency incontinence, and no previous continence or prolapse surgical procedure, inability to tolerate the filling, who had a first sensation of bladder filling at <100 mL, or who had no sensation at any time during the filling.	Duloxetine at one of three doses (20 mg/d, n = 138 women; 40 mg/d, n = 137 women; or 80 mg/d, n = 140 women)	Placebo	Supported by Eli Lilly and Company.	Not reported
Ozdedeli, 2010 ³⁵⁶ RCT Turkey N: 35	35 female patients who presented to the University Departments of Urology and Physical Medicine and Rehabilitation for urgency incontinence and had overactive bladder or mixed incontinence with predominantly overactive bladder symptoms	History of pelvic surgery, a neurological deficit or peripheral neuropathy that may cause neurogenic bladder, presence of a medical condition that may preclude anticholinergic drug use, pregnancy or suspicion of pregnancy, cardiac pacemaker, genitourinary infection or hemorrhage, deterioration in cognitive or intellectual functions, anatomical abnormality that hinders the use of vaginal probe, and post-voiding residual volume >100 mL	Trospium hydrochloride	Electrical stimulation	Not reported	Not reported
Peters, 2009 ³⁵⁷ MacDiarmid, 2010 ³⁵⁸ The Overactive Bladder Innovative	The Overactive Bladder Innovative Therapy trial : ambulatory men and women with OAB symptoms, with or without a history of previous	OAB pharmacotherapy within the previous month, primary complaint of stress urinary incontinence, demonstrated sensitivity to tolterodine or its ingredients, pacemakers or implantable	Weekly percutaneous 30-minute tibial nerve stimulation	4 mg daily extended-release tolterodine with a subsequent	Supported by Uroplasty Inc.	Kenneth Peters has financial interest and/or relationship with Medtronic Inc., Advanced Bionics, Boston Scientific,

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Therapy U.S. N: 100	anticholinergic drug use, with at least 8 voids per 24 hours	defibrillators, excessive bleeding, urinary or gastric retention, nerve damage or neuropathy, uncontrolled narrow angle glaucoma, positive urinalysis for infection or pregnancy, or current pregnancy or planning to become pregnant during the trial		decrease to 2 mg daily if intolerability was experienced		Allergan, Pfizer, Celegene and Trillium Therapeutics; Scott MacDiarmid has financial interest and/or other relationship with Watson, Pfizer, Astellas, Allergan, Novartis and Uroplasty; Leslie S. Wooldridge has financial and /or relationship with Astellas, Uroplasty and Watson; Eric Rovner has financial and/or relationship with Novartis, Astellas, Allergan, Contura, Solace, Tengion and Pfizer; Steven Siegel has financial and/or relationship with Medtronic, American Medical Systems, Uroplasty, Uromedica, North Central Section of the American Urological Association, and Society for Urodynamics and Female Urology; SU.S.A. B. Tate has financial and/or relationship with C.R. Bard; Peter

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
						Rosenblatt has financial and/or relationship with Pfizer; Brian A. Feagins has financial and/or relationship with Medtronic, American Medical Systems, Novartis, Astellas, Uroplasty and Boston Scientific.
Pontari, 2010 ³⁵⁹ RCT U.S. N: 20	Female gender, age 18 years or older, with symptoms of urinary frequency of at least 8 voids per day for at least 6 months	Stress incontinence, total daily volume greater than 3 L, significant hepatic or renal disease, symptomatic or recurrent urinary tract infections, concomitant sacral neurostimulation therapy, claustrophobia with magnetic resonance imaging, bladder outlet obstruction, self-catheterization, post-void residual volume greater than 100 ml, women who pregnant or nursing, or women of child bearing potential not using reliable contraceptive methods, or any neurological condition which may contribute to bladder dysfunction such as multiple sclerosis.	Tolterodine	Placebo	Supported by an educational grant from Pfizer	Michel Pontari has financial interest and/or relationship with Pfizer, Sanofi and Endo Pharmaceuticals

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Rentzhog, 1998 ³⁶⁰ RCT Multinational N: 81	Men and women aged 18-75 years; presence of symptoms of urinary urgency, increased frequency of micturition (at least 8 micturitions per 24 hours) and/or urgency incontinence (at least one episode of incontinence per 24 hours) during a 1-week pre-study run-in period. All eligible patients should have had urodynamically confirmed detrusor instability (defined as a phasic increase in detrusor pressure in the presence of typical symptoms) and a maximum urinary flow rate (Q max) of ≥ 15 mL/s (patients with a lower Qmax were eligible for inclusion provided there was no evidence of clinically significant bladder outlet obstruction), either sterile urine or clinically insignificant bacteriuria, and normal routine laboratory tests	Stress incontinence or detrusor hyperreflexia; clinically significant cardiac, hepatic, renal or hematological disorders; patients with contraindications to antimuscarinic agents; and pregnant or lactating women and women of childbearing age who were not using reliable contraception.	Tolterodine	Placebo	Pharmacia and Upjohn AB, Uppsala, Sweden	NR
Richter, 2010 ³⁶¹ ATLAS N: 446	Women at least 18 years old with symptoms of stress only or stress-predominant mixed-incontinence symptoms.	Not reported	Behavioral therapy	Pessary or pessary+ behavioral therapy	Grants from the Eunice Kennedy Shriver National Institute of Child Health	Dr. Burgio is a consultant for Pfizer (New York) and on the advisory board for Astellas (Deerfield, IL). Dr. Brubaker is a Research Consultant

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
					and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases, and National Institutes of Health Office of Research on Women's Health	for Pfizer (New York, NY) and a Research Investigator for Allergan (Irvine, CA). Dr. Zyczynski has performed contract research for Johnson and Johnson (New Brunswick, NJ). Dr. Lukacz is a consultant for Pfizer (New York, NY), Medtronic (Minneapolis, MN) and Watson Pharmaceuticals (Corona, CA). She has served on the speaker's bureau for Novartis (Basel, Switzerland) and Proctor and Gamble (Cincinnati, Ohio). She has been a consultant and proctor for Intuitive Surgical Corporation (Sunnyvale, CA), and she has been an editor First Consult. Dr. Schaffer is on the Speaker's bureau and National Advisory Board of Astellas/ GlaxoSmithKline (Deerfield, IL; Philadelphia, PA) and on the Specialty Surgeons Advisory Board of Cadence

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
						Pharmaceuticals (San Diego, CA)
Rios, 2007 ³⁶² RCT U.S. N: 58	Women clinically diagnosed with urgency incontinence and proven urodynamic DO for at least 6 months prior to the study	The use of anticholinergics or tricyclic antidepressants in the last 2 months, neurologic conditions, urinary tract infection, pelvic prolapses (greater than grade 2), history of pelvic radiation or bladder tumor, poor bladder wall compliance, and detrusor underactivity.	Single intravesical dose of 100 ml of resiniferatoxin 50 nM	Single intravesical dose of 100 ml placebo	Departments of Urology of the Federal University of Sao Paulo, Paulista School of Medicine and Hospital do Servidor Publico Estadual de Sao Paulo.	Not reported
Robinson, 2007 ³⁶³ The Tamsulosin Study Group Multinational N: 364	Women aged 18-75 years with symptoms of OAB (urinary urgency and frequency, with or without urgency incontinence) for ≥ 3 months; patients must have recorded a mean of at least eight voids/24h in the previous 3 days and one or more of the following during the 3-day period)at least 3 episodes of urinary urgency incontinence; or at least three episodes of urgency	Stress incontinence or mixed incontinence where stress symptoms were predominant and women with neurogenic DOA	Tolterodine	Placebo	Funded by Astellas	Gerben Terpstra and John Bolodeoku are both employees of the sponsor
Rogers, 2009 ³⁶⁴ Rogers, 2008 ³⁶⁵ RCT U.S. N: 413	Heterosexual women ≥ 18 years with OAB symptoms for ≥ 3 months; mean of ≥ 8 micturitions per 24 hours, including ≥ 0.6 UUI episodes and ≥ 3 OAB micturitions (i.e. micturitions associated with at least a moderate	One subject in the tolterodine group with an extreme increase in the number of UUI episodes per 24 hours from baseline to week 12 was identified as an influential outlier and was excluded from all efficacy analyses	Tolterodine-ER	Placebo	Funded by Pfizer Inc.	Zhanna Jumadilova, Franklin Sun, Jon Morrow and Zhonghong Guan have disclosed that they are employed by Pfizer Inc. Rebecca Rogers has disclosed that she received

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
	<p>degree of urgency), in a 5-day bladder diary at baseline; subjects also reported being in a stable, sexually active relationship (self-defined) for ≥6 months and having at least some moderate problems related to their bladder condition on the Patient Perception of Bladder Condition scale.</p>					<p>speaker honoraria and research funding support from Pfizer Inc., and has served a consultant for Pfizer Inc. She has also disclosed that she serves on the advisory board for American Medical Systems. Gloria Bachmann has disclosed that she has served as a consultant and received research funding support from Astellas Pharma Inc., Wyeth, and other pharmaceutical companies. Harriett Scaper has disclosed that she has received speaker honoraria from Pfizer Inc., Astellas Pharma, Inc., and Watson Inc. All peer reviewers receive honoraria from CMRO for their review work. Peer reviewer 1 has disclosed that he/she is on the speakers' bureau of Watson Pharmaceuticals. Reviewer 2 has no relevant financial relationships</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Rogers, 2009 ³⁶⁶ RCT U.S. N: 202	Sexually active women (≥18 years) reported OAB symptoms for ≥3 months, mean of ≥8 micturitions per 24 hour, including ≥0.6 UUI episodes and ≥3 OAB micturitions (i.e., micturitions associated with at least a moderate degree of urgency), in 5-day bladder diaries at baseline; reported being in a stable sexually active relationship (self-defined) with a male partner for ≥6 months; and indicated at least “some moderate problems” related to their bladder condition on the Patient Perception of Bladder Condition questionnaire.	Reported previously ³⁶⁵ Women who did not complete active treatment in the original study, women who were randomized to placebo were excluded from the analysis.	Tolterodine extended release 4 mg/day	Placebo for 12 weeks, none for 24 weeks	Pfizer Inc	Gloria Bachmann: Grant/Research Support: Astellas, Wyeth, Bayer, Duramed, Pfizer, Boehringer-Ingelheim, Roche, Merck, QuatRx, Bionovo, Glaxo Smith Kline, Femme Pharma, Hormos, Covance, Novartis, Johnson & Johnson, Boston Scientific, Novonordisk

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Rogers, 2008 ³⁶⁶ RCT U.S. N: 413	Women (aged ≥ 18 years) with a mean of greater than or equal to eight micturitions, ≥ 0.6 UUI episodes, and greater than or equal to three OAB micturitions (i.e., micturitions associated with moderate or severe urgency or UUI) per 24 hours with at least “some moderate problems” on the Patient Perception of Bladder Condition Questionnaire; with OAB symptoms for ≥ 3 months and to have been in a stable, sexually active relationship (self-defined) with a male partner for ≥ 6 months.	Stage ≥ 3 pelvic organ prolapse, history of lower urinary tract surgery, lifelong sexual dysfunction unrelated to lifelong UUI, or predominant stress UI.	Tolterodine ER (4 mg)	Placebo	Pfizer Inc	Not reported
Rudy, 2006 ³⁶⁷ RCT U.S. N: 658	Female and male patients aged 18 years or older with OAB symptoms for at least 6 months; a minimal urinary frequency average of >10 toilet voids/day, symptoms of urgency (i.e., at least one “mild,” “moderate,” or “severe” urgency severity rating under the “degree of urgency,” associated with “toilet void” events); >7 urge urinary incontinence episodes/week	Predominately stress, insensate, or overflow UI; neurogenic bladder disorders, significant renal disease, uninvestigated hematuria, and urinary tract infection at washout or more than twice during the prior year; significant bladder outlet obstruction defined as a postvoid residual volume >100 mL and in the clinical judgment of the investigator; using any anticholinergic drug or other drug therapy for OAB within 21 days before randomization, history of bladder surgery	Tropium chloride 20 mg twice daily	Placebo	Indevus Pharmaceuticals	D. Rudy, K. Cline, R. Harris, K. Goldberg, and R. Dmochowski are study investigators funded by the sponsor

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Rudy, 2006 ³⁴ RCT analysis U.S. N: 658	Men and women ≥ 18 years old with OAB symptoms for ≥ 6 months, a minimum urinary frequency of 70 toilet voids per 7 days (i.e. mean ≥ 10 voids/day), and symptoms of urgency; with at least seven UUI episodes/week	Predominately stress, insensate, or overflow; neurogenic bladder disorders, significant renal disease, uninvestigated hematuria, >2 UTIs during the previous year; significant BOO, concurrent anticholinergic drug use or other drug therapy for OAB within 21 days before randomization, bladder surgery within 6 months, cancer, interstitial cystitis, diuretic use, estrogen therapy, and non-pharmacological bladder therapy that were not part of a stable, long-term program.	Trospium chloride 20 mg twice daily	Placebo	Indevus Pharmaceuticals	Not reported
Rufford, 2003 ³⁶⁸ RCT England N: 40	Postmenopausal women (>1 year at menopause) with the 'urge syndrome'; with estradiol <150 pmol/l in women after hysterectomy with no contraindication for estrogen therapy.	Medication treatment of urge syndrome, diuretics, HRT, history of diabetes, endometrial thickness >4 mm urinary tract infection, pelvic masses and urogenital prolapse.	25mg 17 beta-estradiol implant subcutaneous tissue.	Placebo	Educational grant from Organon	Not reported
Salvatore, 2005 ³⁶⁹ RCT UK N: 96	Over a period of 1 year women with urinary symptoms referred to the Urogynecology Department of the King's College Hospital in London were recruited into this study. Women with urinary symptoms and having a videourodynamic diagnosis of detrusor overactivity or low bladder compliance and who signed an informed consent.	Not reported	Oxybutynin 2.5 mg twice a day to a maximum dose of 5 mg three times a day over a period of 6 weeks,	Oxybutynin 5 mg to increase oxybutynin to a maximum dose of 5 mg three times a day over a period of 6 weeks.	Not reported	Not reported
Sand, 2009 ³⁷⁰	Men and women ≥ 18	Lower urinary tract pathology that	Fesoterodine 4	Placebo	Schwarz Bio-	Peter Sand is an

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Pooled U.S. N: 1,971	years of age who reported OAB symptoms for ≥6 months and demonstrated urinary frequency (≥8 micturitions per 24 hours) and either urinary urgency (≥6 total episodes) or UUI (≥3 total episodes) in 3-day bladder diaries at least moderate bladder problems on a six-point Likert scale: “My bladder causes me no problems (0), very minor problems (1), minor problems (2), moderate problems (3), severe problems (4), or very severe problems (5).”	could (in the investigator’s opinion) be responsible for urgency or incontinence, significant pelvic prolapse (grade III or higher), clinically relevant bladder outlet obstruction, polyuria (>3 L/24 hours), symptomatic or recurrent urinary tract infections, postvoid residual volume >100 mL, and recent treatment with an antimuscarinic agent.	or 8 mg, or tolterodine extended release (ER) 4 mg		Sciences GmbH and Pfizer Inc.	advisor for Astellas, Allergan, American Medical Systems, Boston Scientific, Coloplast, Glaxo-SmithKline, Ortho McNeil, Pfizer Inc, and Watson Pharma; an investigator for Allergan, Boston Scientific, Ortho McNeil, Pfizer Inc, and Watson Pharma and a speaker for Allergan, Astellas, GlaxoSmithKline, Ortho McNeil, and Watson Pharma. Jon Morrow and Tamara Bavendam are employees of Pfizer Inc. Dana Creanga is a consultant for Pfizer Inc. Victor Nitti is an investigator for Schwarz Pharma, a consultant and lecturer for Pfizer Inc and Novartis, a consultant and investigator for Allergan, a consultant for Astellas, an advisor for Watson Pharma, Serenity Pharmaceuticals, and Coloplast Corp, and a lecturer for American Medical Systems.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Sand, 2004 ²²⁶ RCT U.S. N: 276	Participants with overactive bladder who had ≥ 7 and ≤ 50 urgency incontinence episodes/week and ≥ 10 voids/24 hours were included.	Those with mixed stress and urgency incontinence were eligible if the majority of the leakage accidents were related to urgency incontinence. Participants with other causes of incontinence (e.g. urinary tract infection, interstitial cystitis, urinary tract obstruction, urethral diverticulum, bladder tumor, bladder stone) were excluded, as were those who had delivered a baby or undergone pelvic, vaginal or bladder surgery fewer than 6 months before study enrollment. Participants with a postvoid residual urine volume of >150 ml at the time of screening were also excluded. In addition, those with clinically significant medical problems, or other organ abnormalities or pathologies for whom the administration of extended-release oxybutynin chloride or tolterodine tartrate would present an undue risk (medically uncontrolled cardiovascular, pulmonary, gastrointestinal, renal, endocrine, neurological, autoimmune, hematological, urological or psychiatric disorders, significantly reduced hepatic function or renal impairment) were excluded. Participants with hematuria or a positive urine culture, those with uncontrolled narrow-angle glaucoma, obstructive uropathy, myasthenia gravis, pelvic organ prolapse to the hymeneal ring, gastrointestinal conditions such as partial or complete obstruction, pre-existing severe	ER Oxybutynin Chloride	Tolterodine Tartrate	ALZA Corporation, Mountain View, California	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
		<p>gastrointestinal narrowing (pathologic or iatrogenic), decreased gastrointestinal motility (paralytic ileus, intestinal atony, chronic and severe constipation), or those at risk of gastric retention, were excluded. Subjects were recruited regardless of whether or not they had received prior treatment and regardless of their response to prior anticholinergic therapy. Any medications used for the treatment of overactive bladder, or medications with anticholinergic activity used to treat other conditions, had to be discontinued at screening. Participants who had taken an investigational drug within the last month or had known allergies or hypersensitivities to oxybutynin chloride, tolterodine tartrate, or components of the respective tablets were excluded. Participants with current drug or alcohol abuse, female participants who were pregnant or breastfeeding, and participants who were not capable of following the study schedule or directions were excluded. Those who were not able to swallow the medication without chewing, crushing, biting, dividing or dissolving the capsule were also excluded.</p>				
<p>Sand, 2009³⁷¹ Dmochowski, 2010³⁷² Pooled N: 989</p>	<p>Subgroup analysis of women aged ≥18 years with OAB of ≥6 months' duration with urinary urgency (≥1 severe urgency severity rating on the validated Indevus</p>	<p>Predominantly stress, insensate, or overflow incontinence (as determined by investigators), demonstrable renal or urinary disorders including neurogenic bladder disorders, significant renal disease, uninvestigated hematuria, current or</p>	<p>Trospium ER (60-mg capsules)</p>	<p>Placebo</p>	<p>Allergan, Inc. and Endo Pharmaceuticals (formerly Indevus Pharma-</p>	<p>Peter K. Sand, MD, serves as an advisor and speaker for Allergan, Inc., Astellas Pharma US, Inc., Pfizer, Ortho-McNeil, Colplast, and</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
	urgency severity scale); urinary frequency (average ≥ 10 voids/day, occurring at any time of the 24-hour period); and pure urge or mixed urinary incontinence with predominant UUI, with an average of ≥ 1 UUI episode/day	a history of ≥ 3 episodes of urinary tract infection in the preceding year, bladder outlet obstruction, interstitial cystitis, or bladder cancer; subjects requiring long-term diuretic or estrogen therapy			ceuticals Inc.).	Watson Pharmaceuticals. Dr. Sand has received grants from Allergan, Inc., Astellas Pharma US, Inc., Boston Scientific, Pfizer, Ortho-McNeil, Watson Pharmaceuticals, and Antares Pharma. Roger R. Dmochowski, MD, has financial relationships with Allergan, Inc., Pfizer, Watson Pharmaceuticals, Novartis, and Astellas Pharma US, Inc. David R. Staskin, MD, serves as a consultant and lecturer for Allergan, Inc., Pfizer, Watson Pharmaceuticals, and Astellas Pharma US, Inc. Norman R. Zinner, MD, serves as a consultant, speaker, and/or for a clinical trial for Allergan, Inc., Actelion, Watson Pharmaceuticals, Pfizer, Novartis, Ferring Pharmaceuticals, and GlaxoSmithKline. Rodney A. Appell, MD

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
						(deceased), was on the advisory board for Pfizer, Boston Scientific, and Astellas Pharma US, Inc. Dr. Appell held stock in American Medical Systems. Dr. Appell served as an investigator for Allergan, Inc., Astellas Pharma US, Inc., Watson Pharmaceuticals, American Medical Systems, Boston Scientific, Solace Technology, Bulkamid, and Novasys Medical.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Sand, 2006 ³⁷³ Sand, 2007 ³⁷⁴ The Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial U.S. N: 2,592	At least 18 years of age; have 1 or more symptoms of OAB (urge urinary incontinence, urgency, and/or frequency); be willing to discontinue any over-the-counter and/or prescription treatment for OAB for the duration of the study; be capable of completing Quality of Life Questionnaires without assistance; be willing and able to comply with the protocol; and for females of childbearing potential, have a negative urine pregnancy test and have used a medically acceptable contraceptive method.	Urinary retention or uncontrolled narrow-angle glaucoma or risk for these conditions; demonstrated hypersensitivity to oxybutynin or other components of the product; had 1 or more treatable conditions that might cause urinary incontinence or urgency (i.e., urinary tract infection, prostatitis, bladder tumor, bladder stone); had received an investigational product within 30 days prior to participation in this study; had been previously treated with transdermal oxybutynin; resided in long-term care facilities or nursing homes; or were judged by the investigator to be unsuitable for enrollment into the study	Transdermal oxybutynin 3.9 mg plus behavioral intervention of enhanced patient education	Transdermal oxybutynin alone	Supported by Watson Laboratories (Morriston, NJ)	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Sand, 2011 ^{3/5} RCT U.S. N: 1,165	Male and female subjects experiencing OAB for ≥6 months who met the following criteria (based on a 3-day bladder diary) were enrolled: urinary frequency of ≥30 toilet voids in 3 days (i.e. mean ≥10 toilet voids per day); ≥1 'severe' urgency severity rating in 3 days (according to the Indevus Urgency Severity Scale); and pure urge urinary incontinence (UUI) or mixed urinary incontinence with predominant UUI, with ≥3 UUI episodes in 3 days (i.e. mean ≥1 UUI/day).	Not reported	Trospium	Placebo	Supported by Allergan, Inc., and Endo Pharmaceuticals (formerly Indevus Pharmaceuticals, Inc.), Watson, Pfizer, Astellas and GSK.	Michael G. Oefelein is an employee of the sponsor; Pamela I. Ellsworth is a consultant speaker for Pfizer, a speaker for Novartis and is on the speaker bureau for Allergan; Eric S. Rovner is a paid consultant to Allergan and is a study investigator funded by Allergan; David R. Staskin is a speaker for Allergan, Astellas, Pfizer and Watson, and is a paid consultant to Allergan, Astellas and Pfizer; Peter K. Sand is a an advisor, investigator and speaker for Allergan, Watson, Pfizer, Astellas and GSK.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
<p>Scarpero, 2011³⁷⁶ RCT Multinational N: 890</p>	<p>Men and women who successfully completed double-blind treatment without meeting discontinuation criteria and did not experience any AE that, in the investigator's opinion, would jeopardize the subject's well-being upon continuation of treatment were eligible to participate in the open-label extension study.</p>	<p>Residual volume >200 mL, absolute corrected QT interval value >500ms or individual increase of >60 ms relative to the double-blind study baseline, those who had experienced any ongoing serious adverse effects during double-blind treatment that were treatment-related or of unknown origin, or had experienced an undercurrent illness that required termination of treatment.</p>	<p>Fesoterodine</p>	<p>None; extension of open-label study</p>	<p>Funded by Schwarz BioSciences GmbH and Pfizer Inc</p>	<p>Harriette Scarpero has been a consultant for AMS, Pfizer, and Watson and a speaker for Astellas and Watson. Con J. Kelleher has received educational funding for research from Pfizer and Astellas and is an advisor for Pfizer and Astellas. Peter K. Sand has been an advisor and speaker for Allergan, Astellas, GlaxoSmithKline, Ortho, Pfizer, and Watson and has received research grants from Allergan, Contura, Biofrom, Boston Scientific, Ortho, Pfizer, and Watson. Sandra Berriman, Tamara Bavendam, and Martin Carlsson are employees of Pfizer Inc. The peer reviewers on this manuscript have disclosed that they have no relevant financial relationships.</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Schagen van Leeuwen, 2008 ³⁷⁷ RCT Germany, France, the Netherlands, Spain, Sweden, Switzerland and South-Africa N: 265	Community-dwelling women of ≥65 years with symptoms of SUI or S-MUI for ≥3 consecutive months and ≥7 incontinence episodes per week as determined by the stress/urgency incontinence questionnaire S/UIQ; predominant stress UI with ≥50% of incontinence episodes had to be due to stress UI; post-void residual ≤100mL.	Language or significant cognitive barriers (modified mini-mental state exam score <80; >>4 urinary tract infections in the preceding year or a positive urine culture at visit 1, any nonpharmacological intervention (surgery, bulking agents, initiation of pelvic floor muscle training) for incontinence or prolapse within 3 months before study entry or throughout the study, increased suicidal risk (score ≥2 on question 9 of the Beck depression inventory), history of syncopal episodes, or hepatic dysfunction, defined as serum glutamate–pyruvate–transaminase (alanine aminotransferase) or glutamate–oxaloacetate–transaminase (aspartate aminotransferase) ≥3 times upper limit of normal (ULN) or bilirubin ≥1.5 times ULN.	Duloxetine 20 mg twice daily	Placebo	Funding was provided by Eli Lilly and Company, and Boehringer Ingelheim, GmbH	Not reported
Staskin, 2006 ³⁷ Pooled N: 3,298	Pooled analysis of 4 RCTs of men and women over 18 years with OAB (mean of ≥8 voids/24 hours, plus ≥1 incontinence episode or ≥1 urgency episode/24 hours) during the baseline 3- day voiding diary period.	Women with a history of stress-predominant UI, positive cough-provocation test; no baseline assessment or no episodes of the individual diary symptom during the baseline diary screening period.	Solifenacin 5mg; Solifenacin 10mg;	Placebo	Yamanouchi Pharma Inc.	D. Staskin is a consultant for Pfizer, Ortho- McNeil, Indevus, Watson, Astellas and Novartis; A. Te is an investigator for Sanofi- Aventis, Pfizer and NIH, and is a consultant for Sanofi-Aventis, Glaxo and Astellas. Source of funding: Astellas.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Staskin, 2007 ⁴⁵ Trospium Study Group. U.S. N: 601	Not reported	Not reported	Trospium chloride 60 mg/day	Placebo	Esprit Pharma and Indevus Pharmaceuticals	Not reported
Staskin, 2004 ^{37B} RCT U.S. N: 658	Not reported	Not reported	Trospium chloride 20-mg twice daily	Placebo	Not reported	Not reported
Staskin, 2009 ³¹ RCT U.S. N: 789	Men and women with OAB who were 18 years or older; urge or mixed UI with a predominance of urge UI episodes as well as a mean of 8 or more urinary voids per day and 4 or more urge UI episodes per day on a baseline 3-day bladder diary regardless of whether symptoms were of neurological origin. The bladder diary was to be independently completed by the patient. Patients needed to have a mean voided volume of 350 ml or less during a 2-day urine collection period and a postvoid residual volume of 250 ml or less on ultra-sonography or catheterization.	Potential participants were excluded from study based on criteria designed to rule out incontinence related to chronic illness, anatomical abnormality and concomitant medication.	OTG (oxybutynin chloride)	Placebo	Laboratory assessments were performed at Mayo Laboratory for Clinical Trials, Rochester, Minnesota	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Staskin, 2009 ³⁷⁹ Post-hoc U.S. N: 1,165	Adult men and women with OAB of ≥6 months' duration with urgency and an average of ≥1UUI episode/day and ≥10 toilet voids/day, as assessed using 3 -day bladder diaries	Not reported	Trospium chloride	Placebo	Supported by Allergen, Inc. and Indevus Pharmaceutica ls Inc.	Dr. Staskin has been an advisor and speaker for Allergen, Astellas Pharma, Pfizer and Watson. Professor Cardozo has received funding as a speaker, consultant or researcher from Astellas, Biocell, Pfizer, Recordati, Rottapharm and Allergan within the last year
Staskin, 2009 ⁴⁹ P pooled analysis U.S. N: 1,165	Adults with OAB of ≥6 months' duration with urinary urgency (≥1 severe urgency severity rating/3 days on the validated Indevus Urgency Severity Scale), frequency (mean ≥10 voids/day), and UUI (mean of ≥1 UUI episode/day), as assessed using the 3-day bladder diaries. Subjects undergoing current pharmacological therapy for OAB eligible after a 7-day washout period prior to 3-day bladder diary data collection.	A mean total volume voided of >3000 mL/day; a mean voided volume of >250 ml/void; predominantly stress, insensate, or overflow incontinence; interstitial cystitis; bladder cancer; and a history of neurogenic bladder; clinically significant renal disease (defined as screening serum creatinine values >1.5mg/dL), urinary tract infection or clinically significant urinary retention (defined as postvoid residual urine volume >100mL); subjects who and been treated with or received trospium chloride in previous trials.	Trospium XR 60 mg once daily	Placebo	Supported by Allergan, Inc. and Endo Pharmaceuticals Inc. (formerly Indevus Pharmaceutics, Inc.) Editorial support funded by Allergan, Inc.	David R. Staskin is a consultant and speaker for Allergan, Astellas, Pfizer, and Watson. Matt T. Resenberg receives grant/research support from Ortho-McNeil and Sanofi-Synthelabo and serves as a consultant for Ortho-McNeil, Sanofi-Sythelabo, Pfizer, GlaxoSmithKline, Endo Pharmaceuticals (formerly Indevus Pharmaceutics), Lilly, and Novartis. He is also on the Speakers' Bureau for Ortho-McNeil, Endo Pharmaceuticals,

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
						<p>GlaxoSmithKline, Pfizer, Lilly and AstraZeneca. Peter K.Sand is an advisor and speaker for Allergan, Astellas, Pfizer, Ortho, Colplast, and Watson. He has received grants from Allergan, Astellas, Boston Scientific, Pfizer, Ortho-McNeil, Watson, and Antares. Norman R. Zinner is a consultant, clinical trial investigator , and/or speaker for Allergan, Watson, Pfizer, Novartis, Ferring, GlaxoSmithKline and Astellas. Roger R. Dmochowski is a consultant for Allergan, Astellas, Novartis, Pfizer, and Watson.</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Steers, 2005 ⁴³ RCT Canada, U.S. N: 395	Patients aged >18 years with symptoms of OAB for at least 6 months, capable of independent toileting. Irrespective of response to previous treatments patients had to have urgency incontinence (>5 episodes per week), voiding frequency (>8 voids per day), and urgency (a strong desire to void at least once per day). Adequate method of contraception throughout the study for young women.	Contraindications to anticholinergic therapy (e.g., uncontrolled narrow-angle glaucoma, urinary retention or gastric retention); clinically significant stress incontinence, BOO and/or a postvoid residual urinary volume (PVR) of >200 mL ; pregnancy and lactation; genitourinary conditions that could cause urinary symptoms; fecal impaction or severe constipation (two or fewer bowel movements per week); urogenital surgery within the previous 6 months; bladder biopsy in the previous 30 days; indwelling catheter and intermittent self-catheterization; clinically significant disease; bladder-training program during the study; concomitant treatment with anticholinergic or antispasmodic drugs (including drugs with significant anticholinergic effects, e.g., imipramine), opioids and other drugs known to cause significant constipation, hormone replacement therapy (unless taken for >2 months), and drugs known to be potent cytochrome P450 3A4 inhibitors (e.g., ketoconazole).	Darifenacin controlled-release tablets 7.5 mg	Placebo	This study was funded by Pfizer Inc.	Jacques Corcos is a member of the board of Sponsor; Georg Kralidis is an employee of Sponsor; Jenelle Foote is a study investigator funded by Sponsor.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Steers, 2007 ³⁸⁰ Duloxetine OAB Study Group. Australia, Canada, U.S. N: 306	Duloxetine OAB Study Group: women aged ≥18 years and to be identified as having predominant symptoms of OAB for ≥3 consecutive months before study entry; no SUI, including a negative cough stress. The case definition for OAB: bothersome urinary urgency or urge UI+ abnormal voiding frequency (≥2 hours mean daytime voiding interval) documented by ≥2 days of recording of a screening urinary diary + urodynamic testing detected DOA or sensory urgency(urgent desire to void during the testing session in the absence of a DOA, with a maximum cystometric capacity of <400 mL, both with no SUI, including a negative cough stress test at MCC after the urethral catheter was removed.	A postvoid residual urine volume of >100 mL; a mean 24-hour total voided volume of < 3 L, documented on a 2-day frequency-volume chart ; a positive urine culture (>100 000 colony-forming units/mL) or four or more UTIs during the year before enrolment; the regular use of medications for OAB symptoms within a month of enrolment; any previous use of duloxetine; continence surgery within 6 months or any major surgery within 3 months of enrolment; pelvic organ prolapse greater than ICS Stage II; any nonpharmacological intervention (e.g., electrical stimulation, bladder training, continence devices) within 3 months of enrolment; and pelvic floor muscle training 3 months before the study.	Duloxetine (40-mg twice daily). After 4 weeks, the dose of duloxetine was increased to 60-mg twice daily	Placebo	Eli Lilly and Company and by Boehringer Ingelheim GmbH.	William D. Steers and Sender Herschorn are paid consultants and study investigators funded by the sponsor. Karl J. Kreder, Kate Moore and Kris Strohbehn are study investigators funded by the sponsor. Ilker Yalcin and Richard C. Bump are employees of Eli Lilly and company. Sponsored by Eli Lilly and Company and by Boehringer Ingelheim GmbH.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Swift, 2003 ³⁸¹ Tolterodine Study Group North America, Australia and New Zealand N: 1,235	Age 18 years or more with urinary frequency (≥ 8 micturitions/24 hours) and urgency incontinence (≥ 5 incontinence episodes/week), having had these symptoms of overactive bladder for 6 months or more whether or not they were treatment naïve, and irrespective of response to prior antimuscarinic therapy.	Demonstrable stress incontinence, total daily urine volume >3 L, any contraindications to antimuscarinic treatment, significant hepatic or renal disease (with biochemical markers twice the upper limit of the normal reference range), symptomatic or recurrent urinary tract infections (diagnosed by urinalysis), interstitial cystitis (diagnosed by clinical suspicion), hematuria or bladder outlet obstruction, current electro-stimulation or bladder training therapy, an indwelling catheter or intermittent self-catheterization; pregnant or nursing women; women of child-bearing potential not using reliable contraceptive methods; other treatments for overactive bladder, such as anticholinergic drugs, or drugs that inhibit cytochrome P450 3A4 isoenzymes were not permitted; treatment with an investigational drug in the 2 months prior to study entry was prohibited.	Tolterodine ER 4 mg capsules once daily, tolterodine IR tablets 2 mg twice daily	Placebo	This study was sponsored by a grant from Pharmacia Corporation.	Not reported
Szonyi, 1995 ³⁸² RCT N: 60	Outpatients of either sex aged over 70 with symptoms of urinary frequency, urgency and urgency incontinence were recruited. Patients had to be mobile, able to attend an outpatient department, able to keep a diary chart and willing to give consent.	Urinary infections at the time of recruitment, patients with severe hepatic or renal disease, glaucoma, or uncontrolled diabetes. Patients on concomitant anticholinergic therapy with imipramine were excluded.	Oxybutynin 2.5 mg twice daily	Placebo	Funded by Smith and Nephew Pharmaceuticals Ltd.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Takei, 2005 ³⁸³ Japanese Tolterodine Study Group. Japan N: 293	Eligible Japanese patients completing 12 weeks' treatment in a randomized, double-blind trial 20 continued with 12 months' open-label treatment with tolterodine ER 4 mg once daily, irrespective of (and without unblinding) the treatment received during the double blind study (tolterodine ER 4 mg capsules once daily [Detrol capsule, Detrusitol, Pharmacia Corporation, Peapack, NJ], oxybutynin 3 mg tablets three times daily [Pollakis, Aventis Pharma Ltd, Tokyo, Japan] or placebo). The 12-week randomized study enrolled men and women aged ≥20 years with OAB symptoms including urinary urgency, urinary frequency (≥8 micturitions/24 h) and urgency incontinence (≥5 episodes/week) for ≥6 months. Patients were recruited based solely on OAB symptoms, irrespective of prior antimuscarinic treatment or their response to such therapy.	Demonstrable stress incontinence, total daily urine volume >3 L, average volume voided/micturition >200 mL, significant hepatic or renal disease, any contraindication for anticholinergic treatment, symptomatic or recurrent urinary tract infection, interstitial cystitis, hematuria or bladder outlet obstruction, indwelling catheter or intermittent self-catheterization, electro-stimulation or bladder training within 14 days before randomization or expected to commence during the study. Patients who were poorly compliant (missed >25% of prescribed medication), had an ongoing serious adverse event and pregnant or nursing women and women of childbearing potential not using reliable contraception were also excluded.	Tolterodine ER	Oxybutynin, Placebo	Pfizer Japan Inc	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Tapp, 1990 ³⁸⁴ RCT N: 37	Postmenopausal women	Not reported	Oxybutynin 5mg four times daily	Placebo	Support from Tillots Laboratories	Not reported
Tincello, 2000 ³⁸⁵ RCT UK N: 67	Urodynamically confirmed diagnosis of idiopathic detrusor instability.	All patients were screened for UTI using commercially available reagent test-strips before cystometry, and those with positive results were deferred until appropriate treatment had been given. Patients with a residual volume of ≥ 100 mL and those with a maximum flow rate of < 15 mL/s were excluded.	Oxybutynin with salivary stimulant pastilles	Oxybutynin only	Drugs were supplied by Lorex Synthelabo and Thames Laboratories, Consolidated Chemicals, Wrexham, UK	Not reported
Thuroff, 1991 ³⁸⁶ Study: RCT N: 169	15 years old and older complaining of symptoms of frequency, urgency and/or incontinence, in whom cystometry findings were related to detrusor hyperactivity, whether idiopathic (unstable detrusor) or neurogenic (detrusor hyperreflexia) in origin.	Pregnancy, congestive heart failure, severe renal/liver disease, myasthenia gravis, unable to swallow/uncooperative patient, hiatal hernia/reflux esophagitis, gastrointestinal tract obstruction, urinary tract obstruction, residual urine greater than 50ml, untreated urinary tract infection and hyperreflexia without urge.	Oxybutynin chloride	Placebo	Pharmacia Leo Therapeutics, Helsingborg, Sweden provided the pharmaceutical preparations used in this study	NR

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Toglia, 2010 ³⁸⁷ Karram, 2009 ³²⁰ Post-hoc VENUS U.S. N: 739	Patients aged ≥18 years with OAB symptoms for ≥3 months	Reported previously ³²⁰	Solifenacin	Placebo	Supported by Astellas Pharma US, Inc. and Glaxo-SmithKline	Dr. Toglia is a consultant and speaker for Astellas; Dr. Ostergard is a consultant and speaker for Astellas, GlaxoSmithKline, Novartis, Pfizer and Watson. Dr. Fakhoury is an employee of Astellas. Mr. Andoh and Dr. Hussain were employees of Astellas at the time the study was conducted and have no other conflicts of interest to disclose

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
U.S. Food and Drug Admin ³⁸⁸ Cardozo, 2008 ⁶⁰ SUNRISE Multinational N: 865	Male or female aged ≥18 years, from whom written consent had been obtained, and who were willing and able to complete a voiding diary correctly; symptoms of OAB (including urinary frequency, urgency or urgency incontinence) for ≥3 months and three or more episodes of urgency with or without incontinence in the last 3 days	Not reported	Solifenacin	Placebo	Research grant from Astellas Pharma Europe Ltd.	Linda Cardozo: Astellas, Lilly, UCB Pharma, Pfizer, Gynecare, Plethora, Cook, Organon; Elke Heßdörfer: Astellas, Pfizer, Bayer-Schering, Sanofi Aventis, Apogepha, Merckle Recordati, Lilly; Rodolfo Milani: Astellas, BARD, Recordati; Pedro Arano: Astellas; Luc Dewilde: Astellas,; Mark Slack: Astellas, Pfizer, Lilly, Johnson & Johnson, Boston Scientific; Ted Drogendijk, Mark Wright and John Bolodeoku: employees of Astellas
U.S. Food and Drug Administration, 2004 ³⁸⁹ RCT U.S. N: 509	Male or female, 18 years and older, with symptoms of overactive bladder for at least 6 months prior to enrollment	Not reported	Trospium chloride	Placebo	Indevus Pharmaceuticals, Inc.	Not reported
U.S. Food and Drug Administration, 2004 ³³ RCT U.S. N: 509	Male or female, 18 years and older, with symptoms of overactive bladder for at least 6 months prior to enrollment	Not reported	Trospium chloride	Placebo	Indevus Pharmaceuticals, Inc.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
U.S. Food and Drug Administration, 2004 ⁴¹ RCT Multinational N: 680	Male and female subjects, aged 18 years and older with symptoms of overactive bladder for at least 6 months. Subjects must exhibit all of the following symptoms of overactive bladder during the run-in period: 1) incontinence 2) frequency of micturition -at least 8 times per 24 hours, on average, over the run-in period 3) urgency -at least once per 24 hours, on average, over the run-in period	Not reported	Darifenacin	Placebo	Not reported	Not reported
U.S. Food and Drug Administration, 2004 ³⁹⁰ RCT Multinational N: 562	Male and female subjects, aged 18 years and older with symptoms of overactive bladder for at least 6 months. Subjects must exhibit all of the following symptoms of overactive bladder during the run-in period: 1) incontinence 2) frequency of micturition -at least 8 times per 24 hours, on average, over the run-in period 3) urgency -at least once per 24 hours, on average, over the run-in period	Not reported	Darifenacin	Placebo	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
U.S. Food and Drug Administration, 2007 ³⁸ RCT U.S. N: 601	Patients currently undergoing OAB therapy at the time of enrollment were required to undergo 7-day wash-out period, followed by 3-day baseline urinary diary collection, prior to randomization. Patients not under OAB therapy could begin treatment after 3-days of baseline diary collection	Not reported	Trospium chloride ER	Placebo	Indevus Pharmaceuticals, Inc.	Not reported
U.S. Food and Drug Administration, 2007 ⁴⁴ RCT U.S. N: 564	Patients currently undergoing OAB therapy at the time of enrollment were required to undergo 7-day wash-out period, followed by 3-day baseline urinary diary collection, prior to randomization. Patients not under OAB therapy could begin treatment after 3-days of baseline diary collection	Not reported	Trospium chloride ER	Placebo	Indevus Pharmaceuticals, Inc.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
<p>U.S. Food and Drug Administration, 1998³⁹ Anderson, 1999^{340,341} Study: RCT OROS Oxybutynin Study Group U.S. N: 134</p>	<p>Female patients aged 40 years and older with urge urinary incontinence. Non-pregnant women determined to be in good health; patients with mixed urinary incontinence, provided that symptoms and/or signs of stress incontinence are not the predominant manifestation of UI and UUI episodes associated with urgency can be differentiated from urgency incontinence episodes not associated with urgency; normotensive, with or without hypertensive medication; no postural hypotension; patients who successfully completed the screening urinary diary for 7 days</p>	<p>Patients with known genitourinary conditions that may cause incontinence; those receiving any drugs that are considered effective in the treatment of incontinence less than the equivalent of 5 times the half-life of the drug and patients who have been treated with anticholinergic agents for urge UI and were found to be refractory to these agents</p>	<p>Oxybutynin as OROS-O5mg to 30mg/day based on achieved continence</p>	<p>Oxybutynin IR 5mg to 20mg/day based on achieved continence</p>	<p>ALZA Corporation Mountain View, California</p>	<p>M. Preik is an employee of Jansen-Cilag GmbH, Germany. A Albercht and M O'Connell are employees of ALZA Corp., U.S.A. R. Anderson is a stakeholder of Johson and Johson stock, is a member of the national advisory board for Ditropan XL, and also acts on behalf of the Speaker's Bureau of Ortho-McNeil.</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Van Kerrebroeck, 2004 ³⁹³ Duloxetine Urinary Incontinence Study Group. Belgium, Canada, Denmark, France, Germany, the Netherlands, Sweden and the United Kingdom N: 494	Women aged 24–83 years with predominant symptoms of stress urinary incontinence (according to clinical algorithm that was 100% predictive of urodynamic stress urinary incontinence), with >7 weekly incontinence episode, without predominant symptoms of urgency incontinence, normal diurnal and nocturnal frequencies, a bladder capacity >400 mL and both a positive cough stress test and positive stress pad test.	Inability to tolerate the filling to 400 mL or who experienced a first sensation of bladder filling <100 mL.	Duloxetine 40 mg BD	Placebo	Funded by Eli Lilly and Boehringer Ingelheim.	Dr Yalcin and Dr Bump are both full-time employees of Eli Lilly and hold stock and stock options in the company.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
<p>Van Kerrebroeck, 2001³⁹⁴ Tolterodine Study Group. 167 centers in Australasia, Europe, and North America N: 1,529</p>	<p>Men and women with urinary frequency (eight or more micturitions every 24 hours) and urgency incontinence (five or more episodes per week) irrespective of whether they had received prior treatment and irrespective of their response to prior antimuscarinic therapy.</p>	<p>Demonstrable stress incontinence, total daily urine volume greater than 3 L, any contraindications to antimuscarinic treatment, significant hepatic or renal disease (biochemical markers twice the upper limit of the normal reference range), symptomatic or recurrent urinary tract infections, interstitial cystitis, hematuria or bladder outlet obstruction, current electrostimulation or bladder training therapy, and indwelling catheter or intermittent self-catheterization, pregnancy, breastfeeding, unreliable contraceptive methods; other treatments for an overactive bladder such as anticholinergic drugs or drugs that inhibit cytochrome P450 3A4 isoenzymes; treatment with an investigational drug in the 2 months before study entry.</p>	<p>Tolterodine ER 4 mg once daily</p>	<p>Placebo</p>	<p>Not reported</p>	<p>Not reported</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
<p>Van Kerrebroeck, 2010³⁹¹ RCT 17 countries in Europe, South Africa, Australia, and New Zealand N: 417</p>	<p>Men and women were eligible to enroll in the open-label extension if they had completed the 12-week double-blind study without meeting discontinuation criteria and had not experienced an adverse event during double-blind treatment that, in the opinion of the investigator, would jeopardize their well-being upon continuation of treatment.</p>	<p>Any illness that required termination of treatment, a residual urine volume >200ml, an absolute corrected QT interval (QTc)>500 ms or an individual increase of >60 ms relative to baseline measurement in the double-blind study, or any ongoing serious AE during the double-blind study that was considered to be related to study medication or was of unknown origin.</p>	<p>Fesoterodine</p>	<p>None</p>	<p>Funded by Schwarz BioSciences GmbH and Pfizer Inc</p>	<p>Dr Van Kerrebroeck has been an investigator and lecturer for Astellas, Eli-Lilly, Ferring, Novartis and Pfizer Inc. John Heesakkers has been an investigator and lecturer for Astellas and Pfizer Inc. Sandra Berriman, Lalitha Padmanabhan Aiyer, Martin Carlsson and Zhongghong Guan are employees of Pfizer Inc. and hold stock in the company.</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Vardy, 2009 ³⁹² VIBRANT U.S. N: 768	Eligible patients (aged ≥18 years) were required to have OAB symptoms for ≥3 months (≥8 micturitions and ≥1 urgency episode, with or without incontinence, per 24 hours) and a PPBC score ≥3.	Significant stress or stress-predominant mixed incontinence, recurrent urinary tract infection (UTI; ≥3 episodes within the past 3 months) or evidence of UTI at baseline, evidence of chronic urologic inflammation/interstitial cystitis or urinary/gastric retention.	Solifenacin	Placebo	Research grant from Astellas Pharma U.S. Inc. and Glaxo-SmithKline	Dr. Vardy is a consultant for Astellas Pharma US, Inc. and a speaker for Wyeth and BARD Urologic. Dr. Mitcheson is a study investigator for Pfizer, Novartis, Eli Lilly, Watson, and Antares; he is a speaker for GlaxoSmithKline. Dr. Forero-Schwanaeuser is an employee of GlaxoSmithKline, and Drs. Marshall and He are employees of Astellas Pharma US Inc. Editorial support, including writing assistance, was provided by Linda A. Golstein, PhD, a medical writer at Envision Scientific Solutions and was funded by Astellas Pharma Global Development Inc. and GlaxoSmithKline
Vella, 2008 ³⁹³ CT UK N: 228	Women with a diagnosis of urodynamic stress incontinence (USI) or mixed USI and detrusor overactivity.	Concurrent prolapse or contraindications to drug therapy	Duloxetine: 20 to 40 mg bid	None	Not reported	Jonathan Duckett has received funding to attend conferences from the makers of duloxetine.

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Versi, 2000 ⁴⁰ Gleason, 1999 ³⁴² U.S. Food and Drug Administration, 1998 ³⁹ The Ditropan XL Study Group U.S. N: 226	Patients were included only if they had previously responded to treatment with anticholinergic medications or to a trial of oxybutynin before enrollment.	Patients with clinically significant medical problems, a postvoid residual urine volume over 100 mL, or other conditions in which oxybutynin is contraindicated were excluded.	Controlled-release oxybutynin tablets containing 5 mg oxybutynin or a placebo were placed in identical hard gelatin capsules and packaged in cards that provided total doses of 5, 10, 15, and 20 mg.	Immediate-release oxybutynin tablets containing 5 mg oxybutynin or a placebo were placed in identical hard gelatin capsules and packaged in cards that provided total doses of 5, 10, 15, and 20 mg.	Grant from ALZA Corporation	Not reported
Von Holst, 2000 ³⁹⁴ RCT Germany N: 186	Hysterectomized women age 40-65 years, with postmenopausal complaints, normal gynecological history and examination, serum estradiol <30pg/ml and follicle stimulating hormone >30IU/ml.	Use of sex hormones taken orally within the last 28 days; locally-applied sex hormones within the last 21 days or injectable sex hormones within the last 6 months.	7-day-Estradiol patch (1.5mg estradiol/week or 50mg estradiol/24 hours). All patients received active drug therapy (7-days). Estradiol patch) for a further 3 months (three cycles).	Placebo once-weekly	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Waetjen, 2005 ³⁹⁵ RCT U.S. N: 417	Postmenopausal women age 60-80 years, with a uterus and at least 5 years after menopause, with normal bone mineral density for age (z score not below -2.0 at the lumbar spine).	Use of estrogen or progestin within 3 months of randomization or having unexplained uterine bleeding, endometrial hyperplasia or an endometrium 5mm or more in double-wall thickness, abnormal mammogram, breast cancer, a history of metabolic disease, cancer, coronary disease, cerebrovascular disease, uncontrolled hypertension, uncontrolled thyroid disease, liver disease, fasting triglycerides more than 300 mg/dL, or fasting glucose more than 180 mg/dL.	14mg of transdermal E2 per day.	Placebo	Grant from Berlex laboratories inc, Montville, NJ; Grant IND No. 98188 from the U.S. Food and Drug administration	Dr. Pinkerton is on the Berlex speaker's bureau
Wagg, 2006 ⁴⁰⁰ Pooled analysis Not reported N: 1,045	Mean of ≥ 8 micturitions/24 hours and at least 1 of the following: 1) a mean of ≥ 1 incontinence episode/24 hours; or 2) a mean of ≥ 1 urgency episode/24 hours	Patients with existing urinary tract dysfunction including postvoid residual volume of >150 or >200 mL (depending on the trial), stress incontinence or mixed urinary incontinence with stress urinary incontinence predominating, neurologic dysfunction or injury affecting detrusor function or other lower urinary tract function, absolute urinary retention, grade III/IV prolapse with cystocele, recurrent or active urinary tract infection, bladder stones, current or previous bladder neoplasm, or history of interstitial cystitis; to discontinue any drug for treatment of urinary incontinence; use of anticholinergic or antimuscarinic agents only allowed only if receiving a stable dose; electro-stimulation, biofeedback, or bladder-training therapy not allowed during the study and not permitted during the 2 to 4 weeks immediately before the trials.	Solifenacin 5 or 10 mg	Placebo	Yamanouchi Pharma Co., Ltd, Tokyo, Japan	Dr. Wagg has received consultancy, lecture, and writing fees relating to OAB from Yamanouchi. Dr. Sieber is a member of the speaker's bureau for Yamanouchi and was also a principal investigator. Professor Wyndaele has no financial involvement with Yamanouchi

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Wang, 2006 ³⁹⁶ RCT Taiwan N: 74	Age: 16 to 80 years; OAB for more than 6 months. No patients had taken anticholinergics or tricyclic antidepressants and none had been treated with pelvic floor muscle training, bladder training, or pelvic prolapse repair.	Pregnancy, neurologic disorders, diabetes mellitus, demand cardiac pacemaker or intrauterine device use, genital prolapse greater than Stage II of the International Continence Society grading system, a postvoid residual urine volume greater than 100 mL, overt urinary stress incontinence, a history of anti-incontinence surgery, and urinary tract infection.	Electrical stimulation (ES)	Oxybutynin, placebo	Grant from National Science Council, Taiwan.	Not reported
Wang, 2009 ³⁹⁷ RCT Taiwan N: 73	Women with OAB for more than 6 months, and the symptom of urgency three times or more per day.	Treatment with anticholinergics or tricyclic antidepressants; treatment with pelvic floor or bladder training and pelvic prolapse repair, participation in prior trials; pregnancy, neurologic disorders, diabetes mellitus, demand cardiac pacemaker or intrauterine device use, genital prolapse greater than the International Continence Society (ICS) grading system stage II, overt urinary stress incontinence, a history of anti-incontinence surgery, urinary tract infection and patients receiving any OAB treatment during the 14-day washout/run-in period preceding randomization.	Vaginal electric stimulation (20 minutes per session, twice a week) or oxybutynin (2.5 mg) three times per day	Placebo three times per day	Grant from the National Science Council, Taiwan (NSC95-2314-B-182-062).	Not reported
Mazur, 1995 ³⁹⁸ RCT N: 185	Men and women with urge urinary incontinence or urgency	Neurogenic bladder dysfunctions, urinary tract infections, gastrointestinal obstructions, cardiovascular diseases, potential pregnancy.	Propiverine hydrochloride 60 mg/d	Propiverine hydrochloride 15, or 45 mg/d	Not reported	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Wein, 2007 ³⁹⁹ RCT analysis Australia, Europe and North America N: 1,005	Men and women aged ≥18 years with symptoms of urinary frequency (≥8 voids/24 hours) and urgency UI (≥5 episodes/week) for ≥6 months.	Stress UI, as determined by the investigator and confirmed by a cough provocation test; significant hepatic or renal disease, current or recurring UTI, clinically relevant BOO (defined by investigator's judgment based on a patient's history), indwelling catheter or intermittent self-catheterization, and any condition for which antimuscarinic treatment was contraindicated; anticholinergic drug or treatment for OAB during the 14-day washout/run-in period preceding randomization, and those with a mean micturition volume of 200 mL or total daily volume of 3 L on bladder diaries.	Tolterodine-ER (4 mg)	Placebo	Not reported	Alan J. Wein is a consultant to Astellas, Novartis, Pfizer and Indevus; Vik Khullar is a speaker and investigator for Pfizer on tolterodine; Joseph T. Wang and Zhonghong Guan are employees of Pfizer Inc.
Weinstein, 2006 ⁴⁰⁰ DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations). U.S. N: 3,983	DESIRE Study Group: women >18 years old with stress urinary incontinence (>1 episode/week) or stress predominant mixed incontinence (frequency of stress at least twice higher than urge)	Prior treatment with monoamine oxidase inhibitors and duloxetine; depression; diabetic peripheral neuropathic pain	Duloxetine 40 mg twice daily	Not controlled trial	Funded by Eli Lilly and Boehringer Ingelheim.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Yalcin, 2006 ⁴⁰¹ Pooled U.S. N: 1,133	Women with SUI who were enrolled in two double-blind, controlled, randomized studies of duloxetine versus placebo having predominant SUI that was diagnosed using a clinical algorithm demonstrated to be 90.2% predictive of urodynamic stress.	Reported previously in individual studies	Duloxetine 80mg/day	Placebo	This study was sponsored by Eli Lilly and Company and Boehringer Ingelheim.	Not reported
Yalcin, 2004 ⁴⁰² the Duloxetine UI Study Group one phase 2 study in the US, and 3 phase 3 studies in 16 countries in Africa, Australia, Europe, and North and South America N: 1,913	Women with SUI of at least 3 months' duration predominant symptom of SUI with a weekly IEF >4 in phase 2 and IEF >7 in the 3 phase 3 studies, where an episode was defined as an easily noticeable leakage of urine that wet a pad or clothing, and that occurred with a physical stress such as coughing, sneezing, or exercising; the lack of predominant symptoms of enuresis or urge urinary incontinence, daytime frequency mL per minute, without pressure measurements; a positive cough stress test (visualization of urine leakage concurrent with a cough) and a positive stress pad test (leakage of >2.0 g).	Inability to tolerate filling to 400 mL; a first sensation of bladder filling <100 mL, or who had no sensation at any time during the filling; previous continence surgery.	All phase 3 studies included only duloxetine 40 mg bid as an active treatment. The phase 2 study included 3 duloxetine treatment groups (20 mg qd, 20 mg bid, and 40 mg bid); however, data from subjects taking duloxetine doses <40 mg bid were not included in the analyses to avoid any potential confounding effects of lower efficacy (duloxetine 40 mg bid has	Placebo	This work was sponsored by Eli Lilly and Company	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
			been demonstrated to be the optimum dose). Subgroup analysis was performed within each treatment group based on baseline incontinence severity.			
Yamaguchi, 2007 ⁴⁰³ RCT Japan N: 1,593	Men and women aged ≥ 20 years and with symptoms of OAB reported for ≥ 6 months were eligible for screening and study enrolment. To be eligible for randomization after the 2-week placebo run-in period, patients had to report a mean number of voids/24 hr of ≥ 8 , ≥ 3 episodes of urgency and/or ≥ 3 episodes of urgency incontinence during a 3-day voiding - diary period.	Significant BOO, an assessment based on measuring the postvoid residual urine volume; patients with a PVR of ≥ 100 mL; presence of BOO symptoms assessed by investigators (who were all urologists); urinary retention, demonstrable stress incontinence, bladder stones, UTI, interstitial cystitis, previous or current malignant disease of the pelvic organs; those taking concomitant anticholinergic medications; known hypersensitivity to anticholinergic medications or lactose.	solifenacin 5mg or 10mg	Propiverine or placebo	Funded and sponsored by Astellas Pharma Inc. (formerly Yamanouchi Pharmaceutical Co. Ltd), Tokyo, Japan	Osamu Yamaguchi and Eji Marui are consultants to Astellas Pharma
Zellner, 2009 ⁴⁰⁴ RCT Germany N: 1,659	Male or female outpatients aged ≥ 18 years with urinary frequency ≥ 8 micturitions per day) and urgency incontinence (≥ 5 episodes per week), as verified in the micturition diary.	Patients were excluded if they did not complete the micturition diary correctly for 7 consecutive days to confirm that they met the inclusion criteria and to establish baseline symptoms and urgency severity before the entrance visit. Based on this diary, patients with a total daily urine volume ≥ 2.8 L (determined by	Oxybutynin Hydrochloride	Trospium Chloride	Dr. R. Pflieger GmbH (Bamberg, Germany) sponsored this study. Petra Schwantes, PhD, Biomedical	Petra Schwantes, PhD, Biomedical Services, assisted with the writing of this article; she received compensation from the sponsor. The authors have indicated that they

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
		<p>total daily urine for 2 days, divided by 2), a mean micturition volume of >250 mL, and/or a clinically significant bladder outlet obstruction (i.e., postvoid residual urine volume of >100 mL, determined via sonography) were also excluded as were those with an indwelling catheter or intermittent self-catheterization. Those with other significant medical problems or urogenital conditions, including urinary tract infection at the screening visit (or before or at the entrance visit), interstitial cystitis and/or hematuria (as determined via urinalysis), contraindications to anticholinergic therapy (e.g., untreated narrow-angle glaucoma, mechanical gastrointestinal stenosis, myasthenia gravis syndrome), tachycardiac arrhythmia, severe psychiatric illnesses, or hypersensitivity to trospium chloride or oxybutynin or 1 of the vehicle ingredients, were also excluded. Patients who had participated in a bladder-training program, or in another study within 30 days before screening, were also prohibited, as were those undergoing electro stimulation programs. Further reasons for exclusion were alcohol and/or drug abuse, pregnancy, breastfeeding, and insufficient contraception among women of childbearing age.</p>			<p>Services, assisted with the writing of this article; she received compensation from the sponsor.</p>	<p>have no other conflicts of interest regarding the content of this article.</p>

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Zinner, 2005 ⁴⁰⁵ RCT U.S. N: 76	Males and non-pregnant (nor breastfeeding) females aged 18–85 years with urgency incontinence (>4 significant incontinent episodes per week, where significant was defined as leakage that would normally require a change of clothing or absorbent pad) and urinary frequency (≥8 voids per day, on average).	Neurogenic bladder or stress incontinence, contraindications to antimuscarinic therapy, previous bladder surgery, bladder stones (as demonstrated by pelvic x-ray or ultrasound), acute or chronic urinary tract infection, significant urinary outflow obstruction, and clinically significant concomitant disease; Patients intending to start or modify either an existing bladder training program or existing treatment with thyroid or estrogen hormone replacement therapy; those who had received treatment with drugs that affect bladder function/urine production in the previous 2 weeks.	Darifenacin controlled-release tablets 15 mg and 30 mg once/daily	Oxybutynin 5 mg three times daily, Placebo	Industry +Grant	Disclosure

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Zinner, 2008 ⁴⁰⁶ CT N: 500	Men and women (>18 years of age) with OAB symptoms [an average of > 8 micturitions/ 24 hours]; >1 urgency episode/24 hours, with or without urgency urinary incontinence; >2 scores on the Patient Perception of Bladder Condition (PPBC) questionnaire; naive to darifenacin, dissatisfaction with previous oxybutynin ER or tolterodine ER administration after at least 1 week of taking these medications.	Mean daily urinary volume >3000 ml or a mean volume micturition of >300 ml (in micturition diary); clinically predominant and bothersome stress urinary incontinence, urinary retention, clinically significant bladder outlet obstruction, an indwelling catheter or intermittent self-catheterization; significant medical problems or urogenital conditions, including neurogenic bladder, cystocele or distal pelvic organ prolapse, frequent urinary tract infections (>3 over the preceding year) or urogenital surgery in the previous year or unexplained hematuria at screening; bladder-training program or any electro-stimulation therapy within 2 weeks prior to screening; pregnancy or inadequate contraception. Concomitant treatment with anticholinergics, antispasmodics, serotonin-noradrenalin-reuptake-inhibitors; cholinergic agonists, cholinesterase inhibitors (e.g. bethanecol, donepezil and rivastigmine), potent inhibitors of cytochrome CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone), potent P-glycoprotein inhibitors (e.g. cyclosporine and verapamil), drugs with significant anticholinergic side effects (e.g. tricyclic antidepressants, selective-serotonin-reuptake-inhibitors and first generation antihistamines) or any other investigational drug.	Darifenacin 7.5 mg once daily (qd) for the first 2 weeks with voluntary up-titration to darifenacin 15 mg if the patient required additional efficacy, and treatment was well tolerated	Placebo	Funding for this study and for the editorial and project management services of ACUMED in the preparation of this manuscript were provided by Novartis Pharma AG.	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Zinner, 2006 ⁴⁰⁷ RCT N: 445	Men and women aged >18 years with a history of OAB for >6 months and on average >1 urgency incontinence episodes/day; >8 micturitions/day; >4 urgency episodes/day and mean warning time of <15 minutes during 12 consecutive hours.	Stress urinary incontinence; marked cystocele or pelvic prolapse; those taking the following drugs in the 2 weeks prior to the screening visit: anticholinergic/antispasmodic drugs, or those with anticholinergic effects, cholinergic agonists, potent cytochrome P450 3A4 inhibitors, opioids and drugs that cause significant constipation; those who have contraindications to anticholinergic drugs, clinically significant bladder outlet obstruction, have the intention to start a bladder training program and an indwelling catheter or intermittent self-catheterization.	Darifenacin 15 mg controlled release qd	Placebo	This study was funded by Novartis Pharma AG	Not reported
Zinner, 2004 ³⁵ Trospium Study Group. U.S. N: 523	Male and female 18 years or older with OAB symptoms for at least 6 months; with urinary urgency, a minimum voiding frequency of 70 voids per week with at least 7 urgency incontinence episodes per week.	Predominantly stress UI, insensate or overflow in nature; with neurogenic bladder disorders, significant renal disease, uninvestigated hematuria and urinary tract infection at washout or more than twice during the prior year; significant bladder outlet obstruction (post-void residual volume >100 ml); concurrent use of any anticholinergic drug or other drug therapy for overactive bladder within 21 days before randomization, history of bladder surgery within 6 months before randomization, bladder cancer or interstitial cystitis; diuretic use, estrogen therapy and nonmedical bladder therapy that was not part of a stable, long-term program	20 mg trospium twice daily	Placebo	Indevus Corporation	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Zinner, 2002 ⁴⁰⁸ RCT Europe, U.S., Canada, Australia, and New Zealand N: 1,015	Men and women aged 18 and older with urinary frequency (>8 micturitions/24 hours), urgency incontinence (>5 episodes per week), symptoms of overactive bladder for 6 months or more, and ability and willingness to complete micturition charts.	Stress incontinence; total daily urine greater than 3 L; significant hepatic or renal disease; symptomatic or recurrent urinary tract infections; interstitial cystitis, hematuria, or clinically relevant bladder obstruction; bladder training or electro-stimulation within 14 days before randomization; and indwelling catheter or intermittent self-catheterization, pregnancy and breastfeeding; unreliable contraceptive methods; treatments for overactive bladder (excluding estrogen treatment started more than 2 months before randomization), anticholinergic drugs, or potent inhibitors of cytochrome P450 3A4 isoenzymes.	Tolterodine ER 4 mg once daily	Placebo	Pharmacia Corporation	Not reported
Zinner, 2005 ⁴⁰⁹ Pooled U.S. N: 1,157	Symptoms of urgency, an average of 10 or greater toilet voids daily and an average of 1 or greater UUI episode daily.	Reported previously ^{34, 35}	20 mg trospium chloride twice daily	Placebo	Indevus, Lilly, Pfizer, Watson, Bayer and Glaxo Smith Kline	Not reported

Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Zinner, 2011 ⁴¹⁰ RCT Not reported N: 944	Male and female subjects aged ≥ 18 years with symptoms of OAB for ≥ 6 months who met the following criteria (based on a 3-day patient diary): urinary frequency ≥ 30 toilet voids/3 days (i.e. average ≥ 10 toilet voids/day); ≥ 1 "severe" urgency severity rating/3 days (as measured by the Indevus Urgency Severity Scale [IUSS]); and ≥ 3 UUI episodes/3 days (i.e., average ≥ 1 UUI episodes/day).	Subjects with a total voided volume >3000 ml/day or a mean volume voided/void >250 ml ; subjects with predominantly stress, insensate, or overflow incontinence; history of neurogenic bladder, indwelling or intermittent catheterization, significant renal disease (serum creatinine >1.5 mg /dL), uninvestigated hematuria or urinary tract infection during screening, or a history of ≥ 3 urinary tract infections in the previous 12 months; clinically significant urinary retention (defined as post-void residual urine volume >100 mL), cancer, interstitial cystitis.	Trospium for 48 weeks	Trospium for 36 weeks	Sponsored by Allergan Inc. and Endo Pharmaceuticals (formerly Indevus Pharmaceuticals, Inc.). Neil Reynolds, Monica Grandison, and Sushma Soni of in Science communications provided editorial support funded by Allergan, Inc.	None

Abbreviation: NR = Not reported

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Abrams, 2006 ²²⁰	1032 Study Group.	Double-blind	Yes	Unclear	Adequate	No
Abrams, 1998 ²¹⁹	RCT	Double-blind	Yes	NR	Adequate	Yes
Abrams, 2008 ⁴⁷	Pooled	Double-blind	Yes	Previously reported ²⁵⁶	Adequate	No
Altan-Yaycioglu, 2005 ²²¹	RCT	Single blind	Not stated	Unclear	Adequate	No
Anderson, 1999 ³⁹¹ U.S. Food and Drug Administration, 1998 ⁴¹	OROS Oxybutynin Study Group	Double-blind	No	Not reported	Adequate	No
Appell, 1997 ²²²	Pooled	Double-blind	Yes	Unclear	Adequate	No
Appell, 2001 ²²³	OBJECT (Overactive Bladder: Judging Effective Control and Treatment)	Double-blind	Yes	Unclear	Adequate	No
Armstrong, 2005 ²²⁴	RCT	Double-blind	No	Previously reported ²²⁷	Previously reported ²²⁷	Previously reported ²²⁷
Armstrong, 2007 ²²⁵	Pooled	Double-blind	Yes	Previously reported ^{223,226,227}	Adequate	Previously reported ^{223,226,227}
Rios, 2007 ³⁶⁴	RCT	Double-blind	Yes	Unclear	No	Yes
Barkin, 2004 ²²⁸	UROMAX Study Group.	Double-blind	Yes	Unclear	Adequate	No
Bent, 2008 ²²⁹	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Birns, 2000 ²³⁰	The Oxybutynin CR Clinical Trial Study	Double-blind	Yes	Adequate	Adequate	Yes
Blom, 1995 ²³¹	RCT	Single blind	No	NR	NR	No
Bodeker, 2010 ²³²	Post-hoc	Double-blind	Reported previously ⁴¹⁷	Reported previously ⁴¹⁷	Adequate	Previously reported ⁴¹⁷
Brubaker, 2008 ²³³	Pelvic Floor Disorders Network.	Double-blind	Not stated	Unclear	Adequate	Yes
Brunton, 2010 ²³⁴	RCT	Double-Blind	NR	NR	Adequate	NR
Bump, 2003 ¹⁰³	Duloxetine Urinary Incontinence Study Group.	Double-blind	No	Previously reported ³⁵⁴	Adequate	Yes
Bump, 2008 ²³⁵	Pooled	Combination	Not stated	Previously reported ^{275,350,411}	Previously reported ^{275,350,411}	No
Burgio, 2001 ²³⁶	RCT	Double-blind	No	Unclear	Not reported	No

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Burgio, 2000 ²³⁷	RCT analysis	Double-blind	NR	NR	Not reported	No
Burgio, 1998 ²³⁸	RCT	Double-blind	Yes	Unclear	No	No
Burgio, 2008 ²³⁹	Urinary Incontinence Treatment Network	Open label	Yes	Unclear	Not reported	Yes
Burgio, 2010 ²⁴²	RCT	Open-label	Yes	NR	Not-adequate	Yes
But, 2010 ²⁴³	SOLIDAIR	Open-Label	Yes	NR	Not-adequate	NR
Cardozo, 2006 ⁴¹²	Pooled	Double-blind	No	Previously reported ⁵²	Adequate	Previously reported ⁵²
Cardozo, 2004 ²⁴⁵	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Cardozo, 2004 ⁵¹	RCT	Double-blind	No	Previously reported ⁵²	Adequate	Yes
Cardozo, 2010 ²⁴⁴	RCT followed by open-label	Double-blind	Yes	Adequate	Adequate	Yes
Cardozo, 2008 ⁶⁰	SUNRISE	Double-blind	Yes	NR	Adequate	Yes
Cartwright, 2011 ²⁴⁶	RCT	Not reported	Yes	Adequate	Adequate	Yes
Castro, 2008 ²⁴⁷	RCT	Single blind	No	NR	Not Adequate	Yes
Castro-Diaz, 2007 ²⁴⁸	Duloxetine Dose Escalation Study Group	Double-blind	Yes	Unclear	Adequate	Yes
Chancellor, 2001 ²⁴⁹	RCT	Double-blind	No	NR	Adequate	No
Chancellor, 2008 ²⁵⁰	The ABLE trial	Open label	Yes	Adequate	Adequate	Yes
Chancellor, 2010 ²⁵¹	Post-hoc	Double-blind	NR	Unclear	NR	NR
Chapple, 2005 ²⁵²	RCT	Double-blind	No	Adequate	Adequate	Yes
Chapple, 2007 ²⁵³	RCT	Double-blind	No	Adequate	Adequate	No
Chapple, 2008 ²⁵⁴	RCT analysis	Double-blind	No	Adequate	Previously reported ²⁵³	No
Chapple, 2007 ²⁵⁵	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Chapple, 2005 ²⁵⁶	Pooled	Double-blind	Yes	Previously reported	Previously reported	No
Chapple, 2004 ²⁶⁰	RCT	Double-blind	Yes	NR	Adequate	Yes
Chapple, 2004 ²⁶¹	RCT	Double-blind	No	NR	NR	NR
Chapple, 2007 ²⁵⁵	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Chapple, 2007 ²⁵⁸	STAR study group	Double-blind	Yes	Adequate	Adequate	Previously reported ⁵⁸
Chapple, 2005 ⁵⁸	STAR study group	Double-blind	Yes	Adequate	Adequate	Yes
Chapple, 2006 ²⁵⁹	RCT	Single-blind	No	NR	Not adequate	Yes
Chapple, 2004 ⁵²	RCT	Double-blind	NR	NR	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Chompootawee, 1998 ²⁶²	RCT	NR	NR	Unclear	Adequate	No
Choo, 2008 ²⁶³	RCT	Double-blind	No	NR	Adequate	No
Chu, 2009 ²⁶⁴	RCT	Double-blind	No	Adequate	Adequate	Yes
Corcos, 2006 ²⁶⁵	Uromax Study Group	Double-blind	Yes	NR	Adequate	Yes
Corcos, 2011 ²⁶⁶	Fesoterodine Assessment and Comparison Versus Tolterodine (FACT) Study Group	Double-blind	No	Unclear	Adequate	NR
Davilla, 2001 ²⁶⁷	Transdermal Oxybutynin Study Group	Double-blind	Not stated	Unclear	Adequate	Yes
Dessole, 2004 ²⁶⁸	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Diokno, 2003 ²²⁷ Anderson, 2006 ²⁷⁰ Chu, 2005 ²⁶⁹	OPERA (Overactive bladder: Performance of Extended Release Agents) trial	Double-blind	Yes	Unclear	Adequate	No
Dmochowski, 2002 ²⁷¹	Transdermal Oxybutynin Study Group	Double-blind	No	Unclear	Adequate	Yes
Dmochowski, 2008 ²⁷²	RCT	Double-blind	Not stated	Unclear	Adequate	No
Dmochowski, 2005 ²⁷³	Transdermal Oxybutynin Study Group.	Double-blind	Yes	Previously reported ^{271,274}	Previously reported ^{271,274}	Previously reported ^{271,274}
Dmochowski, 2003 ²⁷⁴	Transdermal Oxybutynin Study Group	Double-blind	Yes	Unclear	Adequate	Yes
Dmochowski, 2003 ²⁷⁵	Duloxetine Urinary Incontinence Study Group	Double-blind	Yes	Adequate	Adequate	Yes
Dmochowski, 2007 ²⁷⁶	RCT	Double-blind	Yes	Previously reported	Previously reported	Previously reported
Dmochowski, 2010 ³⁷²	RCT	Double-blind	Yes	Reported previously ^{272,404}	Adequate	Yes
Dmochowski, 2010 ²⁷⁷	RCT	Double-blind	Yes	Unclear	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Dorschner, 2000 ²⁷⁸	RCT	Double-blind	No	Unclear	Adequate	No
Drutz, 1999 ²⁷⁹	RCT	Double-blind	No	NR	Adequate	Yes
DuBeau, 2005 ²⁸⁰	RCT analysis	Double-blind	No	Adequate	Adequate	Yes
Duckett, 2007 ²⁸¹	Observational study	Open label	No	Not relevant	Not relevant	No
Enzelsberger, 1995 ²⁸²	RCT	Open label	NR	Adequate	Adequate	No
Fitzgerald, 2008 ²⁴⁰	Urinary Incontinence Treatment Network.	Open label	Yes	Unclear	Not reported	Yes
Flynn, 2009 ²⁸³	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Foote, 2005 ²⁸⁴	Pooled	Double-blind	Yes	Unclear	Adequate	No
Franzen, 2010 ²⁸⁵	RCT	Open label	Yes	Adequate	Adequate	Yes
Freeman, 2003 ²⁸⁶	RCT analysis	Double-blind	No	Adequate	No	Previously reported ³³¹
Gahimer, 2007 ²⁸⁷	The duloxetine exposures integrated safety database	Open label	Yes	Previously reported ^{275,350,354,411}	Not relevant	No
Ghei, 2005 ²⁸⁸	RCT	Double-blind	Yes	Adequate	Not reported	Yes
Ghoniem, 2005 ²⁸⁹	Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group	Double-blind	Yes	Adequate	Adequate	Yes
Gleason, 1999 ³⁴²	Ditropan XL Study Group, non RCT	Open label	No	Not relevant	Not relevant	No
Goode, 2002 ²⁹⁰	RCT	Double-blind	No	NR	Adequate	No
Goode, 2004 ²⁹¹	RCT analysis	Double-blind	No	NR	Not reported	No
Gupta, 1999 ²⁹²	RCT	Open label	No	NR	Not reported	No
Gupta, 1999 ²⁹³	Pooled	Double-blind	Not reported	NR	Not reported	No
Gousse, 2010 ²⁹⁴	RCT	NR	NR	NR	Adequate	NR
Haab, 2006 ²⁹⁵	RCT analysis	Open label	Yes	RCT analysis	RCT analysis	No
Haab, 2005 ²⁹⁷	RCT analysis	Open label	Yes	Previously reported ⁵²	Previously reported ⁵²	Previously reported ⁵²
Haab, 2004 ²⁹⁶	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Halaska, 2003 ²⁹⁸	RCT	Double-blind	Yes	Unclear	Adequate	No
Herschorn, 2004 ²⁹⁹	RCT	Open label	Yes	Adequate	No	No
Herschorn, 2010 ³⁰⁰	VECTOR	Double-blind	Yes	NR	Adequate	Yes
Herschorn, 2008 ³⁰¹	RCT	Double-blind	Yes	NR	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Hill, 2006 ⁴²	Darifenacin Study Group	Double-blind	Yes	Unclear	Adequate	Yes
Ho, 2010 ³⁰²	RCT	Open label	Yes	Unclear	Adequate	NR
Holtedahl, 2000 ³⁰³	RCT analysis	NR	Yes	Not adequate	Adequate	Reported previously ³⁰⁴
Holtedahl, 1998 ³⁰⁴	RCT	Not reported	No	Unclear	Adequate	Yes
Homma, 2006 ³⁰⁵	RCT analysis	Double-blind	No	NR	Adequate	No
Homma, 2004 ³⁰⁶	RCT	Double-blind	Yes	NR	No	No
Homma, 2003 ³⁰⁷	Japanese and Korean Tolterodine Study Group	Double-blind	Yes	NR	Adequate	Yes
Hurley, 2006 ³⁰⁸ Viktrup, 2007 ³⁰⁹	Duloxetine Urinary Incontinence Study Group	Double-blind	No	Previously reported ^{275,350,354,411}	Not reported	Pooled analysis
Ishiko, 2001 ³¹⁰	RCT	Open label	No	Unclear	Adequate	No
Jackson, 1999 ³¹¹	RCT	Double-blind	NR	Not reported	Adequate	Yes
Jacquetin, 2001 ³¹²	RCT	Double-blind	Yes	Unclear	No	Yes
Johnson, 2005 ³¹³	RCT analysis	Double-blind	NR	Adequate	Adequate	Yes
Jonas, 1997 ³¹⁴	International Study Group	Double-blind	Not stated	Unclear	Adequate	No
Junemann, 2000 ³¹⁶	RCT	Double-blind	No	NR	NR	NR
Junemann, 2005 ³¹⁷	RCT	Double-blind	Yes	Unclear	Not reported	No
Junemann, 2006 ³¹⁵	RCT	Double-blind	No	NR	NR	NR
Kaplan, 2010 ³¹⁸	RCT	Double-blind	NR	NR	NR	Yes
Karademir, 2005 ³¹⁹	RCT	Open label	No	NR	Adequate	No
Karram, 2009 ³²⁰	VENUS	Double-blind	No	NR	Adequate	Yes
Kelleher, 2006 ³²²	RCT	Double-blind	No	Previously reported ⁵²	Previously reported ⁵²	No
Kelleher, 2002 ³²³	RCT	Double-blind	Yes	Unclear	Adequate	No
Kelleher, 2008 ³²⁴	Pooled analysis	Double-blind	NR	Unclear	Adequate	NR
van Kerrebroeck, 2004 ⁴¹¹	Duloxetine Urinary Incontinence Study Group.	Double-blind	Yes	Adequate	No	Yes
Van Kerrebroeck, 2001 ³³¹	Tolterodine Study Group.	Double-blind	Yes	Unclear	Adequate	No

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Khullar, 2004 ³²⁵	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Khullar, 2008 ³²⁶	Pooled	Double-blind	Yes	Previously reported ^{253,353}	Previously reported ^{253,353}	Previously reported ^{253,353}
Kinchen, 2005 ³²⁷	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Kreder, 2003 ³²⁸	RCT analysis	Single blind	No	Unclear	Adequate	No
Lackner, 2008 ³²⁹	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Landis, 2004 ³³⁰	RCT	Double-blind	No	Previously reported ⁴⁰⁸	No	Previously reported ⁴⁰⁸
Lee, 2002 ³³²	RCT	Double-blind	Yes	Not reported	Adequate	No
Lee, 2010 ³³³	Propiverine study on overactive bladder including urgency data	Double-blind	No	Not adequate	Adequate	Yes
Lehtoranta, 2002 ³³⁴	RCT	Double-blind	Yes	NR	NR	No
Leung, 2002 ³³⁵	RCT	Open label	Yes	NR	Adequate	Yes
Lin, 2008 ³³⁶	RCT	Double-blind	Yes	Adequate	No	Yes
Lipton, 2005 ³³⁷	RCT	Double-blind	No	Unclear	NR	Yes
Lose, 2000 ³³⁸	RCT	Open label	Yes	Unclear	Adequate	Yes
MacDiarmid, 2005 ³³⁹	Pooled	2 Double-blind and one open label	Yes	Previously reported ^{40,340-342}	Previously reported ^{40,340-342}	Previously reported ^{40,340-342}
Madersbacher, 1999 ³⁴³	RCT	Double-blind	Yes	NR	Adequate	No
Malhotra, 2010 ³⁴⁴	RCT	Double-blind	Yes	NR	Not adequate	Yes
Malone-Lee, 2009 ³⁴⁵	RCT	Double-blind	No	Unclear	Adequate	Yes
Malone-Lee, 2009 ³⁴⁶	RCT	Double-blind	Yes	Adequate	No	No
Mattiasson, 2009 ⁶¹	SOLAR	Single blind	Yes	NR	Adequate	Yes
Mattiasson, 2003 ³⁴⁷	RCT Tolterodine Scandinavian Study Group	Single blind	Yes	Adequate	Adequate	Yes
Milani, 1993 ³⁴⁸	RCT	Double-blind	No	Unclear	NR	No
Millard, 1999 ³⁴⁹	RCT	Double-blind	Yes	Unclear	No	Yes
Millard, 2004 ³⁵⁰	Duloxetine UI Study Group	Double-blind	Yes	Adequate	No	Yes
Moore, 1990 ³⁵¹	RCT	Double-blind	No	Adequate	Adequate	NR
Naglie, 2002 ³⁵²	RCT	Double-blind	Yes	Unclear	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
NCT00269750, 2005 ⁵⁵	RCT	Double-blind	NR	NR	NR	NR
NCT00168454, 2008 ⁵³	RCT	Double-blind	NR	NR	NR	NR
NCT00444925 ⁵⁶	RCT	Double-blind	NR	NR	NR	NR
NCT00536484 ⁵⁷	RCT	Double-blind	NR	NR	NR	NR
NCT00178191 ⁵⁴	RCT	Double-blind	NR	NR	NR	NR
Nitti C, 2007 ³⁵³	RCT	Double-blind	No	Adequate	Adequate	No
Norton, 2002 ³⁵⁴ Sahai, 2006 ³⁵⁵	Duloxetine Urinary Incontinence Study Group.	Double-blind	Yes	Adequate	Adequate	Yes
Ozdedeli, 2010 ³⁵⁶	RCT	Open-label	No	Not adequate	Adequate	NR
Peters, 2009 ³⁵⁷	Overactive Bladder Innovative Therapy	Open label	No	Unclear	Adequate	Yes
Pontari, 2010 ³⁵⁹	RCT	Double-blind	Yes	NR	Not adequate	No
Preik, 2004 ³⁴⁰	RCT	Double-blind	No	Not reported	Adequate	No
Rentzhog, 1998 ³⁶⁰	RCT	Double-blind	No	NR	Adequate	Yes
Richter, 2010 ³⁶¹	ATLAS	Open label	Yes	Not adequate	Adequate	Yes
Robinson, 2007 ³⁶³	The Tamsulosin Study Group	Double-blind	No	Adequate	Adequate	Yes
Rogers, 2009 ³⁶⁴	RCT	Double-blind	No	NR	Adequate	NR
Rogers, 2009 ³⁶⁶	RCT	Open label	No	Previously reported ^{364,365}	Previously reported ^{364,365}	Previously reported ^{364,365}
Rogers, 2008 ³⁶⁵	RCT	Double-blind	No	Unclear	Adequate	Yes
Rudy, 2006 ³⁶⁷	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Rudy, 2006 ³⁴	RCT analysis	Double-blind	Yes	Unclear	Adequate	Yes
Rufford, 2003 ³⁶⁸	RCT	Double-blind	No	Adequate	Adequate	Yes
Salvatore, 2005 ³⁶⁹	RCT	Open label	No	NR	NR	Yes
Sand, 2009 ³⁷⁰	Pooled	Double-blind	No	Previously reported ^{253, 254,353}	Adequate	No
Sand, 2004 ²²⁶	RCT	Double-blind	Yes	NR	Adequate	No
Sand, 2009 ³⁷¹	Pooled	Double-blind	Yes	Unclear	Adequate	Previously reported ^{45,272}
Sand, 2006 ³⁷³ Sand, 2007 ³⁷⁴	Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial	Open label	Yes	Not adequate	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Sand, 2011 ³⁷⁵	RCT	Double-blind	Yes	Adequate	Not adequate (for the subgroup analysis)	NR
Scarpero, 2011 ³⁷⁶	Post-hoc, pooled subset analysis	Open-label	No	Unclear	Adequate	NR
Schagen van Leeuwen, 2008 ³⁷⁷	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Staskin, 2006 ³⁷	Pooled	Double-blind	No	Previously reported ^{396,412}	Not reported	Previously reported ⁴¹²
Staskin, 2007 ⁴⁵	Trospium Study Group	Double-blind	Yes	Adequate	Adequate	Yes
Staskin, 2004 ³⁷⁸	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Staskin, 2009 ³¹	RCT	Double-blind	Yes	Not reported	Adequate	Yes
Staskin, 2009 ³⁷⁹	Post-hoc	Double-blind	Yes	Reported previously ^{272,404}	Adequate	NR
Staskin, 2009 ⁴⁹	RCT	Double-blind	Yes	NR	Adequate	Yes
Staskin, 2009 ⁴⁹	Pooled analysis of individual patient data	Not reported	Yes	Not reported	Adequate	Not reported
Steers, 2005 ⁴³	RCT	Double-blind	No	Unclear	Adequate	Yes
Steers, 2007 ³⁸⁰	Duloxetine OAB Study Group	Double-blind	Yes	Unclear	Adequate	Yes
Swift, 2003 ³⁸¹	Tolterodine Study Group	Double-blind	Yes	Unclear	Adequate	No
Szonyi, 1995 ³⁸²	RCT	Double-blind	No	NR	Adequate	Yes
Takei, 2005 ³⁸³	Japanese Tolterodine Study Group.	Combination	Yes	NR	Adequate	No
Tapp, 1990 ³⁸⁴	RCT	Double-blind	No	Adequate	Adequate	Yes
Tincello, 2000 ³⁸⁵	RCT	Open label	Not reported	Adequate	Not adequate	Yes
Thuroff, 1991 ³⁸⁶	RCT	Double-blind	No	Adequate	Adequate	NR
Toglia, 2009 ³²¹	VENUS	Double-blind	No	NR	Adequate	Yes
Toglia, 2010 ³⁸⁷	Post-hoc VENUS	Double-blind	NR	Unclear	Not adequate	Previously reported ^{320,321}
U.S. Food and Drug Administration, 2004 ³⁸⁹	RCT	Double-blind	NR	NR	NR	NR
U.S. Food and Drug Administration, 2004 ³³	RCT	Double-blind	NR	NR	NR	NR

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
U.S. Food and Drug Administration, 2004 ⁴¹	RCT	Double-blind	Yes	NR	NR	NR
Pharmaceutical Research and Manufacturers of America ⁵⁹	SUNRISE	Double-blind	Yes	NR	Adequate	Yes
U.S. Food and Drug Administration, 2004 ³⁹⁰	RCT	Double-blind	Yes	NR	NR	NR
U.S. Food and Drug Administration, 1998 ³⁹	RCT	Double-blind	NR	NR	NR	Yes
Pharmaceutical Research and Manufacturers of America ⁶²	SOLAR	Single blind	Yes	NR	Adequate	Yes
U.S. Food and Drug Administration, 2007 ³⁸	RCT	12 weeks double-blind followed by 9 months open-label	Yes	NR	Adequate	Yes
U.S. Food and Drug Administration, 2007 ⁴⁴	RCT	12 weeks double-blind followed by 9 months open-label	Yes	NR	Adequate	Yes
U.S. Food and Drug Administration ²⁵⁷	STAR	Double-blind	NR	NR	Adequate	NR
Van Kerrebroeck, 2010 ³⁹¹	Subgroup analysis of pooled data	Open-label	Yes	Reported previously ²⁵³	NA	NR
Vardy, 2009 ³⁹²	VIBRANT	Double-blind	No	Not reported	Adequate	Yes
Vella, 2008 ³⁹³	Not RCT	Open label	No	Not relevant	Not relevant	No
Versi, 2000 ⁴⁰	Ditropan XL Study Group	Double-blind	Not reported	Adequate	No	No
von Holst ³⁹⁴	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Waetjen, 2005 ³⁹⁵	RCT	Double-blind	Yes	Adequate	Adequate	Yes

Appendix Table F28. Quality of the studies that examined pharmacological treatments for UI (continued)

Reference	Study	Masking of the treatment status	Intention to treat	Allocation concealment	Adequacy of randomization	Sample size justification
Wagg, 2006 ³⁹⁶	pooled analysis	4 double-blind studies and one open-label	NR	NR	NR	NR
Wang, 2006 ⁴¹³	RCT	Single blind	No	Not adequate	Adequate	Yes
Wang, 2009 ³⁹⁷	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Mazur, 1995 ³⁹⁸	RCT	Open label	No	Unclear	Not reported	No
Wein, 2007 ³⁹⁹	RCT analysis	Double-blind	Yes	Previously reported ^{323,408}	Adequate	No
Weinstein, 2006 ⁴⁰⁰	DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations).	Open label	Yes	Unclear	Not adequate	No
Yalcin, 2006 ⁴⁰¹	Pooled	Double-blind	Yes	Previously reported ^{275,354}	Previously reported ^{275,354}	Previously reported ^{275,354}
Yalcin, 2004 ⁴⁰²	Duloxetine UI Study Group	Double-blind	Yes	Previously reported ^{275,350,354,411}	Adequate	Pooled analysis
Yamaguchi, 2007 ⁴⁰³	RCT	Double-blind	No	NR	Adequate	Yes
Zellner, 2009 ⁴⁰⁴	RCT	Double-blind	Yes	Not adequate	Adequate	Yes
Zinner, 2005 ⁴⁰⁵	RCT	Double-blind	No	Unclear	Adequate	Yes
Zinner, 2008 ⁴⁰⁶	RCT	Open label	No	Unclear	NR	Yes
Zinner, 2006 ⁴⁰⁷	RCT	Double-blind	Yes	Unclear	Adequate	Yes
Zinner, 2004 ³⁵	Trospium Study Group	Double-blind	Yes	Unclear	Adequate	No
Zinner, 2002 ⁴⁰⁸	RCT	Double-blind	Yes	Adequate	Adequate	Yes
Zinner, 2005 ⁴⁰⁹	Pooled	Double-blind	Yes	Previously reported ^{34,35,367}	Adequate	No
Zinner, 2011 ⁴¹⁰	Open-label of RCT	Open-label	No	Reported previously ^{45,272}	Adequate	NR

Abbreviation: NR = Not reported

Table F29. Effects from local estrogen therapy compared to no active treatment

Treatments	Reference Studies	Subjects	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)	Evidence
Continence							
Estrogen in tablets or jelly	1 ³⁰⁴	80	20.68 (1.23;346.46)	0.22 (0.08; 0.36)	5 (3; 12)	222 (83; 361)	Insufficient
Estradiol implant	1 ³⁶⁸	40	Not Significant				Insufficient
Improvement							
Estrogen in tablets or jelly	1 ³⁰⁴	80	4.28 (1.54; 11.87)	0.30 (0.12; 0.48)	3 (2; 9)	298 (117; 478)	Insufficient
Intravaginal estriol ovules	1 ²⁶⁸	88	4.29 (2.11; 8.71)	0.52 (0.35; 0.70)	2 (1; 3)	523 (348; 698)	Insufficient
Transdermal E2	1 ³⁹⁵	417	Stress 0.53 (0.36; 0.79) – Not significant in urgency UI	-0.13 (-0.21; -0.05)	-8 (-19 ;-5)	-128 (-205; -52)	Insufficient

Appendix Table F30. Continence after topical estrogen treatment compared to no active treatment (individual RCTs)

Reference N	Active	Definition of continence	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Holtedahl, 1998 ³⁰⁴ 80	Local estrogen in tablets or jelly plus physiotherapy and electro stimulation	Number of cured: no reported leakage and no wet episodes	36/44	8/22	0/0	20.68 (1.23; 346.46)	0.22 (0.08; 0.36)	5 (3; 12)	222 (83; 361)
Rufford, 2003 ³⁶⁸ 40	25 mg 17 beta-estradiol implant	Urgency, % of cured	20/20	3/15	2/10	1.50 (0.28; 8.04)	0.05 (-0.15; 0.25)		
Rufford, 2003 ³⁶⁸ 40	25 mg 17 beta-estradiol implant	Stress incontinence, % cured	20/20	4/20	3/15	1.33 (0.34; 5.21)	0.05 (-0.18; 0.28)		
Rufford, 2003 ³⁶⁸ 40	25 mg 17 beta-estradiol implant	Dysuria, % of cured	20/20	4/20	3/15	1.33 (0.34; 5.21)	0.05 (-0.18; 0.28)		
Rufford, 2003 ³⁶⁸ 40	25 mg 17 beta-estradiol implant	Urgency incontinence, % of cured	20/20	7/35	6/30	1.17 (0.48; 2.86)	0.05 (-0.24; 0.34)		

Appendix Table F31. Improvement in incontinence after topical estrogen treatment compared to no active treatment (individual RCTs)

Reference N	Active	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Holtedahl, 1998 ³⁰⁴ 80	Local estrogen in tablets or jelly	Number of improved: reduction in frequency amount, or wet episodes	36/44	14/39	4/9	4.28 (1.54; 11.87)	0.30 (0.12; 0.48)	3 (2; 9)	298 (117; 478)
Dessole, 2004 ²⁶⁸ 88	Intravaginal estriol ovules: 1 ovule (1 mg) once daily for 2 weeks and then 2 ovules once weekly for 6 months	Rate of cured and improved	44/44	30/68	7/16	4.29 (2.11; 8.71)	0.52 (0.35; 0.70)	2 (1; 3)	523 (348; 698)
Waetjen, 2005 ³⁹⁵ 417	14 mg of transdermal E2 per day for 4 months	Improved incontinence: the number of incontinence episodes per week decreased by 2 or more, 4 months	208/209	52/25	74/35	0.71 (0.52; 0.95)	-0.10 (-0.19; -0.02)		
Waetjen, 2005 ³⁹⁵ 417	14 mg of transdermal E2 per day for 4 months	Improved incontinence: the number of incontinence episodes per week decreased by 2 or more, 2 years	208/209	57/27	80/38	0.72 (0.54; 0.95)	-0.11 (-0.20; -0.02)	-9 (-52; -5)	-109 (-198; -19)

Appendix Table F31. Improvement in incontinence after topical estrogen treatment compared to no active treatment (individual RCTs) (continued)

Reference N	Active	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Waetjen, 2005 ³⁹⁵ 417	14 mg of transdermal E2 per day for 4 months	Improved stress incontinence: the number of incontinence episodes per week decreased by 2 or more, 4 months	208/209	30/14	57/27	0.53 (0.36; 0.79)	-0.13 (-0.21; -0.05)	-8 (-19; -5)	-128 (-205 ; -52)
Waetjen, 2005 ³⁹⁵ 417	14 mg of transdermal E2 per day for 4 months	Improved stress incontinence: the number of incontinence episodes per week decreased by 2 or more, 2 years	208/209	37/18	61/29	0.61 (0.43; 0.87)	-0.11 (-0.19; -0.03)	-9 (-30; -5)	-114 (-195; -33)
Waetjen, 2005 ³⁹⁵ 417	14 mg of transdermal E2 per day for 4 months	Improved urgency incontinence: the number of incontinence episodes per week decreased by 2 or more, 4 months	208/209	25/12	26/13	0.97 (0.58; 1.62)	0.00 (-0.07; 0.06)		
Waetjen, 2005 ³⁹⁵ 417	14 mg of transdermal E2 per day for 4 months	Improved urgency incontinence: the number of incontinence episodes per week decreased by 2 or more, 2 years	208/209	27/13	35/17	0.78 (0.49; 1.23)	-0.04 (-0.11; 0.03)		

Appendix Table F32. Clinical outcomes after topical estrogen therapy compared to no treatment (individual RCTs)

Reference, Sample/ men	Active	Definition of outcome	Randomized active/ control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 4 months	Worsened urgency incontinence: the number of incontinence episodes per week increased by 2 or more.	208/209	5/2	21/10	0.24 (0.09; 0.62)	-0.08 (-0.12; -0.03)	-13 (-33; -8)	-76 (-122; -31)
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 2 years	Worsened urgency incontinence: the number of incontinence episodes per week increased by 2 or more.	208/209	27/13	38/18	0.71 (0.45; 1.12)	-0.05 (-0.12; 0.02)		
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 2 years	Worsened incontinence	208/209	35/17	35/17	1.00 (0.66; 1.54)	0.00 (-0.07; 0.07)		
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 2 years	Worsened stress incontinence	208/209	20/10	19/9	1.06 (0.58; 1.92)	0.01 (-0.05; 0.06)		
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 4 months	Unchanged stress incontinence	208/209	136/66	124/59	1.10 (0.95; 1.28)	0.06 (-0.03; 0.15)		
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 4 months	Unchanged urgency incontinence	208/209	178/86	162/77	1.10 (1.01; 1.21)	0.08 (0.01; 0.15)	12 (6; 152)	81 (7; 155)
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 4 months	Unchanged incontinence	208/209	106/51	95/46	1.12 (0.92; 1.37)	0.06 (-0.04; 0.15)		

Appendix Table F32. Clinical outcomes after topical estrogen therapy compared to no treatment (individual RCTs) (continued)

Reference, Sample/ men	Active	Definition of outcome	Randomized active/ control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 2 years	Unchanged urgency incontinence	208/209	154/74	136/65	1.14 (1.00; 1.29)	0.09 (0.00; 0.18)	11 (6; 568)	90 (2; 178)
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 2 years	Unchanged stress incontinence	208/209	151/73	129/62	1.18 (1.03; 1.35)	0.11 (0.02; 0.20)	9 (5; 52)	109 (19; 198)
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 2 years	Unchanged incontinence	208/209	116/56	94/45	1.24 (1.02; 1.50)	0.11 (0.01; 0.20)	9 (5; 80)	108 (13; 203)
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 4 months	Worsened incontinence	208/209	50/24	40/19	1.26 (0.87; 1.82)	0.05 (-0.03; 0.13)		
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 4 months	Worsened stress incontinence	208/209	42/20	28/14	1.51 (0.97; 2.34)	0.07 (0.00; 0.14)		
Waetjen, 2005 ³⁹⁵ 417/0	14 mg of transdermal E2 per day for 2 years	New developed incontinence at 2 years	208/209	81/39	77/37	1.06 (0.83; 1.35)	0.02 (-0.07; 0.11)		
Dessole, 2004 ²⁶⁸ 88/0	Intravaginal estriol ovules: 1 ovule (1 mg) once daily for 2 weeks and then 2 ovules once weekly for 6 months.	Subjective complaints of stress urinary incontinence.	44/44	14/32	37/84	0.38 (0.24; 0.59)	-0.52 (-0.70; -0.35)	-2 (-3; -1)	-523 (-698; -348)

Appendix Table F32. Clinical outcomes after topical estrogen therapy compared to no treatment (individual RCTs) (continued)

Reference, Sample/ men	Active	Definition of outcome	Randomized active/ control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Holtedahl, 1998 ³⁰⁴ 80/0	Local estrogen in tablets or jelly	Worse incontinence: self reported worsening of severity or impact	36/44	4/11	13/30	0.38 (0.13; 1.05)	-0.18 (-0.35; -0.01)	-5 (-67; -3)	-184 (-354; -15)
Holtedahl, 1998 ³⁰⁴ 80/0	Local estrogen in tablets or jelly	Unchanged incontinence: no changes in frequency, amount, or wet episodes	36/44	10/28	27/61	0.45 (0.25; 0.81)	-0.34 (-0.54; -0.13)	-3 (-8; -2)	-336 (-541; -131)

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Adherence to the drugs	Yeaw, 2009 ⁴¹⁴	To assess variations in adherence and persistence for antimuscarinic medications (overactive bladder)	7,722	78.20	NR	Retrospective analysis	1 year	PharMetrics Patient-Centric Database, a nationally representative database of more than 64 million individual members enrolled in 100 U.S. health plans. Patients were included in the analysis if they initiated a retail or mail-order prescription drug of interest between January 1 and December 31, 2005.	At 6 months post-index, with the application of a 60-day refill grace period, persistence rate (A patient was considered persistent until an excessive gap in days supplied occurred; refill gaps of 30, 60, and 90 days were used to calculate persistence for all cohorts) for OAB medications was 28% and at 1-year it was 18%. Mean (SD) patient adherence calculated as a continuation measure of PDC over a 12-month followup period was 35% (32%) for OAB medications.
Drug fesoterodine	Michel, 2008 ⁴¹⁵	To review the preclinical and clinical data on fesoterodine	NR	NR	NR	2, 4, 8, or 12mg/day of fesoterodine	NA	20 phase I, three phase II and two phase III studies	4 and 8mg once daily doses were consistently superior to placebo in improving the symptoms of overactive bladder syndrome, with 8mg/day having significantly greater effects than 4mg/day

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Drug fesoterodine	Cole, 2004 ⁴¹⁶	NR	728	NR	NR	4, 8 and 12mg fesoterodine once daily	12 weeks	Phase II clinical trial in 728 patients with OAB at sites in Europe, Israel and South Africa	Dropout rates due to adverse events were 4% in the placebo group, 6%, 2% and 12% in the 4mg, 8mg and 12mg groups, respectively. Dry mouth was reported in 9%, 25%, 26% and 34% of patients in placebo and fesoterodine 4-, 8-, and 12-mg groups, respectively
Drug fesoterodine	Kelleher, 2008 ⁴¹⁷	To present an overview of the components and construction of an economic model using the costs and outcomes associated with fesoterodine	NR	NR	NR	Fesoterodine 4mg daily and fesoterodine 8mg daily	12 weeks	NR	The QALY (Quality-adjusted life year) gained were 0.0111 for tolterodine 4mg/d, 0.0115 for solifenacin, 0.0124 for fesoterodine 4mg/d and 0.0143 for fesoterodine 8mg/d. Fesoterodine may result in fewer overall costs and greater QALYs gained than treatment with tolterodine and solifenacin for the management of patients with OAB and incontinence

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Drug tolterodine	Kelleher, 2002 ⁴¹⁸	To evaluate the long-term effects of tolterodine on the health-related quality of life (HRQoL) of patients diagnosed with overactive bladder with incontinence	1,077	82.00	NR	Tolterodine 4mg once daily	12 weeks of RCT followed by 12 months of open - label	Participants of 12 weeks RCT continued a one-year open-label, uncontrolled, nonrandomized study at 138 research centers and clinics. They were eligible if they had an average of 8 or more micturitions per 24 hours over a 7-day period and at least 5 urgency incontinence episodes per week	Mean changes in the KHQ scores from rollover (start of open-label study) and month 12: in PT (placebo-treated group: incontinence impact=-12.7 (1.8) and in TT (tolterodine-treated) group=-5.9 (1.2); role limitations in PT=-11.6 (1.8) and in TT=-4.1 (1.2); physical limitations in PT=-10.1 (1.7) and in TT=-2.9 (1.2) severity (coping) measures in PT=-5.1 (1.3) and in TT= -2.1 (0.9) and symptom severity in PT=-6.6 (0.9) and in TT=-0.8 (0.6)

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Drug tolterodine	Siami, 2002 ⁴¹⁹	To assess the speed of onset of therapeutic benefit with tolterodine extended-release 4mg	1,138	73.46	NR	Tolterodine extended-release 4mg once daily	12 weeks	The Speed of Onset of Therapeutic Assessment Trial (STAT). Men and women aged ≥18 years with a diagnosis of OAB, with symptoms of urinary frequency (≥8 micturitions/24 hours) and urgency with or without urgency incontinence. Patients were categorized into drug-naïve and previously treated (that is those receiving pharmacologic treatment other than tolterodine for OAB)	72% of the maximum effect on urgency incontinence was observed in both groups; and 84.7% of drug-naïve patients and 83.6% of previously treated patients perceived a benefit from benefit. Dry mouth was reported in 15.5% of drug naïve patients and 15.5% of previously treated patients also. In drug -naive group:10.8% had mild dry mouth, 3.1% had moderate and 1.6% had severe and in previously treated patients 11.85 had mild dry mouth, 3% had moderate and 0.7% had severe dry mouth

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Drug tolterodine	Kreder, 2002 ⁴²⁰	To examine the long-term safety, tolerability and efficacy of tolterodine extended-release in patients who had completed 12 weeks of treatment in a randomized, double-blind study comparing tolterodine ER4mg once daily, tolterodine immediate-release 2mg twice daily and placebo	1,077	82	NR	Tolterodine extended-release 4mg once daily	12 month open-label after 12 weeks RCT	Men and women aged ≥18 years with urinary frequency (≥8 micturitions/24 hours; urgency incontinence (≥5 incontinence episodes per week) and urgency; and symptoms of overactive bladder for ≥6 months	A total of 75% of patients had an improvement in their bladder condition and 51% had an improvement in their urgency. 139 (12.9%) reported dry mouth, 35 (3.3%) had constipation, 24 (2.2%) had dyspepsia, 43 (4%) had upper respiratory tract infection, 28 (2.6%) had bronchitis, 44 (4.1%) had UTI, 23 (2.1%) had cystitis, 26 (2.4%) had headache
Duloxetine	Wernick, 2007 ⁴²¹	The cardiovascular safety profile of the SNRI duloxetine through evaluation of cardiovascular-related parameters and adverse events	8,504	83.5	NR	Duloxetine 40-80mg vs. placebo	Varied	Adults with major depressive disorder (15 studies), diabetic peripheral neuropathic pain (3 studies), fibromyalgia (2 studies), generalized anxiety disorder (3 studies) and lower urinary tract disorders (19 studies, all related to incontinence).	Duloxetine resulted in decrease from baseline in RR, QRS and QT intervals but not clinically significant

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Duloxetine	Michel, 2009 ⁴²²	To evaluate the safety and tolerability of duloxetine in the treatment of female stress incontinence in women greater than 18 years of age	5,879	100	100	20mg duloxetine daily	Not reported	Female patients with stress incontinence and greater than 18 years of age	Adverse events occurred at a rate of 9.1% in the duloxetine group and 5.7% in the control group
Estrogen combined with tolterodine	Serati, 2009 ⁴²³	To compare the efficacy of antimuscarinic alone versus antimuscarinic combination with local estrogens for OAB; to verify whether risk factors for lower antimuscarinic efficacy can be overcome by the concomitant use of local estrogens	236	100	NR	Subjects in group 1 were prescribed only tolterodine ER 4mg once daily to be taken at night for at least 12 weeks; subjects in group 2 were prescribed both tolterodine ER 4mg and concomitant estrogen cream application once daily to be taken at night for at least 12 weeks	12 weeks	Postmenopausal (women were considered postmenopausal if they were >40 years old and reported absence of menses for at least 12 months) women with symptomatic urodynamically proven detrusor overactivity	The efficacy of the therapy was 80.6% in the tolterodine group and 82% in the tolterodine and estrogen group. 62.8% were cured, 17.8% showed improvement, and 19.4% were nonresponders in the tolterodine alone; and 62% were cured, 20% showed improvement, and 18% were nonresponders in the tolterodine and estrogen group
Anti-muscarinic drugs and bladder training vs. bladder training alone	Ghei, 2006 ⁴²⁴	Cooperative effectiveness of antimuscarinic drugs and bladder training vs. bladder training alone in adults with urge UI	708	93.8	100	Oxybutynin, tolterodine, or imipramine combined with antimuscarinic drugs and bladder	16 weeks	Adults with mean 54 years and overactive bladder and no significant stress UI	Antimuscarinic drugs were more effective reducing UI

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Solifenacin VOLT (VESIcare Open-Label Trial)	Garely, 2006 ⁴²⁵	VOLT study: perceptions of improvements in symptom bother and health-related quality of life with solifenacin succinate 5- and 10-mg treatments in patients with OAB	2,225	82.2	100	Solifenacin succinate 5- and 10-mg	12 weeks	VOLT (VESIcare Open-Label Trial): adult (aged >18 years) men and women (82.2%) with OAB (urgency, urge UI, frequency, and/or nocturia for ≥3 months)	Some improvement- 73%; improvement in UI- 60%; Treatment-emergent adverse events -59%; 10% discontinued treatment due to adverse events
Solifenacin VOLT (VESIcare Open-Label Trial)	Garely, 2006 ⁴²⁵	VOLT study: OAB patients' perceptions of improvements in symptom bother and quality of life after solifenacin under conditions reflecting day- to-day practice.	582	92.1	100	Flexibly dosed, once-daily solifenacin	12 weeks	VOLT (VESIcare Open-Label Trial): Adults who had OAB symptoms and urge UI for 3 months or longer	80% of patients achieved improvement in their PPBC score. (61.3%) experienced an adverse event during treatment. Adverse Event: Dry mouth 104 (17.9)
Solifenacin VOLT (VESIcare Open-Label Trial)	Capo, 2008 ⁴²⁶	To report patient satisfaction with treatment, as measured by symptom bother and HRQoL, in a subgroup of Hispanics participating in an open-label study of solifenacin succinate	94	74	63	Solifenacin 5m/d with a dosing option of 5 or 10mg/d at weeks 4 and 8	12 weeks	This is a subset analyses of Hispanic patients enrolled in the VOLT study. Ambulatory men and women 18 years of age and older with symptoms of OAB for at least 3 months and able to use the toilet without difficulty	Over 72% of patients experienced PPBC score improvement. Hispanics receiving solifenacin for OAB reported improvement from baseline in symptom bother and HRQoL

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Solifenacin VOLT (VESIcare Open-Label Trial)	Sand, 2009 ⁴²⁷	To determine the efficacy of solifenacin to improve subjects' MBS (Most Bothersome Symptom) based on PRO (Patient-Reported-Outcome) measures	2,225	74.56	26.16	Solifenacin 5m/d with a dosing option of 5 or 10mg/d at weeks 4 and 8	12 weeks	VOLT is a study in adults with OAB symptoms for >=3 months	The UUI group showed the largest VAS(Visual Analogue Scale), OAB-q, and PPBC improvements. 90.7% of patients whose MBS was UUI showed improved VAS score; 94% of patients whose MBS was UUI showed improved VAS:UUI score; 88.8% of patients whose MBS was UUI showed improved VAS: daytime urinary frequency, and 86.6% of patients whose MBS was UUI showed improvement in VAS: Nocturia score

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Solifenacin VOLT (VESIcare Open-Label Trial)	Mallett, 2007 ⁴²⁸	To present patient-reported outcomes, as measured by symptom bother and HRQoL, in black patients participating in an open-label study of solifenacin succinate	2,479	81.73	26.83	Solifenacin 5mg or 10mg once daily according to an individualized flexible-dosing regimen	12 weeks	VOLT study: Men and women aged 18 years or older with symptoms of OAB for 3 months or longer; ambulatory who were able to use the toilet without difficulty and who had not received solifenacin	86.5% of black patients with urinary urgency found it bothersome after solifenacin treatment than at baseline; 87.9% found urgency incontinence less bothersome. 46.4% of black subjects experienced an adverse event ; of these 30.1% had at least one treatment-related adverse event; 13% had dry mouth, 6.9% had constipation, 2.5% had blurred vision, 2.5% had nausea, and 2.2% had rash. A total of 7.6% black subjects discontinued treatment due to an adverse event.

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Solifenacin VERSUS study	Chancellor, 2008 ⁴²⁹	To assess the efficacy, tolerability, and effects on HRQL of solifenacin in patients with residual urgency after ≥4 weeks of treatment with tolterodine extended release 4mg	441	88.2	69.39	Solifenacin 5m/d with dose adjustment at weeks 4 and 8	12 weeks	VERSUS study: patients ages >18 years who had symptoms of OAB for ≥3 months, had been treated with tolterodine ER 4mg for ≥4 weeks and wished to switch therapy because of a lack of sufficient subjective improvement in urgency.	A mean decrease of 3.4 urgency episodes/24 hours (95% CI, -3.8 to -3.0; p<0.001); a mean improvement of 1.2 points (95% CI, -1.3 to -1.1; p<0.001) in PPBC score; changes in all OAB-q scales and domains (symptom bother, coping, concern, sleep, social interaction, and total HRQL) were also statistically significant(p<0.0001). Treatment emergent AEs such as dry mouth (77[17.5%]), constipation (51[11.6%]), and blurred vision (10[2.3%]).

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Solifenacin VERSUS study	Swift, 2009 ⁴³⁰	To evaluate the effects of solifenacin in OAB patients with high symptom bother, this post hoc analysis focuses on the VERSUS 'severe cohort', as defined by patients with scores ≥ 5 on the PPBC scale at baseline (on tolterodine ER mg/d) who remained severe at post-washout (when the patients were receiving no drug)	440, but 116 were from the severe cohort	88.8	NR	Solifenacin 5m/d with dose adjustment at weeks 4 and 8	12 weeks	VERSUS study: Men and women ages >18 years with symptoms of OAB for ≥ 3 months who were ambulatory and able to use the toilet without difficulty and who had received tolterodine ER 4mg/d for ≥ 4 weeks but wished to switch therapy because of lack of sufficient subjective improvement in urgency	In the severe OAB cohort, the mean number of urgency episodes/24 hours decreased by 3.95(95% CI: -4.81, -3.08; $p < 0.0001$)
Solifenacin VERSUS study	Zinner, 2009 ⁴³⁰	To assess changes in health-related quality of life, medical care resource utilization, work, and activity impairment, and health utility among elderly patients with OAB who continued to have urgency symptoms with tolterodine and were willing to try solifenacin	441	88	NR	Solifenacin 5mg/d with dosing adjustments allowed at week 4 (to 10mg/d) and at week 8 (back to 5mg/d for patients whose dose was increased to 10mg/d at week 4)	12 weeks	Patients who have been treated with tolterodine 4mg/d for ≥ 4 weeks immediately preceding study entry without sufficient improvement in urgency episodes	Subgroup analysis included 108 patients 65 to 74 years of age and 86 patients ≥ 75 years of age. Patients in both groups experienced significant improvement in HRQoL ($p < 0.001$), as well as significant reduction in non protocol-related office visits ($p < 0.001$) and activity management ($p < 0.025$). A significant reduction in the use of pads/diapers was reported for patients 65 to 74 years of age

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
									<p>($p < 0.018$), and patients in this age group who were working reported significantly less impairment related to OAB while working during solifenacin treatment than during tolterodine treatment ($p < 0.042$). No significant differences in HUI2/3 scores were observed in either of the elderly groups. Solifenacin was found to improve symptom bother, HRQoL, work productivity, activity participation, and reduced medical care resource utilization in the elderly subjects with OAB who continued to have urgency symptoms with tolterodine and were willing to try solifenacin</p>

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Solifenacin VERSUS study	Zinner, 2008 ⁴³¹	To evaluate the health outcomes, in terms of medical resource use, work and activity impairment, and health utility, of these patients	441	88.2	NR	Solifenacin 5m/day with dose adjustment at weeks 4 and 8	12 weeks	Men and women aged ≥ 18 years with symptoms of OAB for ≥ 3 months who were ambulatory and bale to use the toilet without difficulty and who had been treated with tolterodine ER 4mg/d for at least 4 weeks immediately preceding study entry, but failed to achieve satisfactory improvement in urgency episodes	3.9% discontinued treatment due to adverse events. Patients who were working reported a reduction in percent of work time missed (0.2% vs. 2.1%; $p=0.0017$), a reduction in percent of impairment while working (11.3% vs. 22.9%; $p<0.0001$), and a reduction in percent of overall work impairment (11.9% vs. 24.0%; $p<0.0001$), while a larger group of patients reported a reduction in percent of activity impairment (18.4% vs. 31.6%; $p<0.0001$)

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Treatments for overactive bladder	Sexton, 2009 ⁴³²	To assess the impact of OAB on work productivity among employed men and women under the age 65 in the U.S.	5,696	52.92%	7.86%	Drugs for OAB	NA	Cross-sectional survey of working (full-or part-time) men and women aged 40 to 65 years. This study is part of a study conducted in the US, UK and Sweden. This study focused only on US participants.	Work limitations questionnaire total score, mean (SD): women and continent group=10.8 (15.6); and women and incontinent group=12.6 (16.7); women and no/minimal symptoms=1.0 (5.3) The regression coefficient in women=0.960; UUI and urinary-specific work impairment scores in women=0.941; SUI and urinary-specific impairment scores in women=1.312 and nocturnal enuresis and urinary-specific impairment scores in women=1.025

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Treatments for overactive bladder	Irwin, 2006 ⁴³³	To determine the impact of overactive bladder symptoms on issues related to employment, social interactions, and emotional well-being in a population aged 40-64 years	1,272	50.80	NR	Treatments for OAB	NA	Cross-sectional survey of 11,521 individuals aged 40-64 years and 1,272 of them had OAB	Of those with OAB, approx. 32% reported that having these symptoms made them feel depressed and 28% reported feeling very stressed. 36.4% of OAB with incontinence patients reported emotional stress as compared to 19.6% of patients with OAB and no incontinence. 39.8% of OAB with incontinence patients reported depression as compared to 23.3% patients with OAB and no incontinence. Overall, 76% of individuals reporting OAB symptoms stated that this condition interfered with or made it more difficult to perform daily activities
Treatments for overactive bladder	Wu, 2005 ⁴³⁴	To assess the indirect work loss costs to employers as the result of employees with overactive bladder	21,087	NR	NR	Drugs for OAB	NA	There were two samples: Sample1 was used to analyze OAB employees' work loss patterns and costs and sample2 was used to assess OAB employees' time to disability and related risk factors. Individual	Employees with OAB had 2.2 excess days of work loss absenteeism to medically related absenteeism and 3.4 excess days attributable to disability compared with control subjects (p<0.01 for both comparisons).Multivariate regression analysis revealed that employees with AOB had 4.4 more days of

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
								enrollees in both samples were active employees, 18 to 64 years, with at least one diagnostic code to identify OAB	work loss per year than control subjects(p<0.05).The average annual indirect work loss cost of an employee with OAB was \$1220 from an employer's prospective, which was 1.7 times the indirect work loss cost of a control employee (i.e., \$715) (p<0.01). Multivariate regression analysis showed that OAB imposes an indirect work loss cost burden of \$391 per OAB employee per year from an employers' perspective (p<0.05). Kaplan -Meier analysis showed that employees with OAB had significantly shorter times to disability than did their non-OAB controls
Treatments for overactive bladder	Pelletier, 2009 ⁴³⁵	To evaluate adherence with overactive bladder pharmacotherapy and compare costs between patients receiving pharmacotherapy versus nonpharmacological management	86,734	78	NR	OAB therapy	1 year	Anonymous, patient-level data were obtained from the PharMetrics Patient-Centric Database (Watertown, MA) which contains adjudicated medical and pharmaceutical claims for more	14.4% of the aggregate OAB therapy cohort (43, 576) reached a PDC (proportion of days covered) of 80% or higher, with an average PDC of 32.4%. Following pharmacotherapy initiation, OAB therapy subjects had significantly higher mean (median) total

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
								<p>than 90 US managed health care plans across the U.S. Patients were 18 years or older and had at least 1 OAB diagnostic code or at least 1 prescription for an antimuscarinic OAB medication during a 24-month index window from January 1, 2005 through December 31, 2006. Subjects were required to have continuous health plan enrollment for a minimum of 6 months before and 12 months after the index date; during periods of continuous enrollment, all medical (inpatient and outpatient) and pharmacy (retail and mail order) claims are captured.</p>	<p>costs compared with nonpharmacological managed subjects (\$9917 [\$4598] vs. \$9657 [\$4299]; p<0.001). Nonpharmacologically managed subjects averaged \$277 for OAB-related outpatient services compared with \$176 for OAB therapy subjects (p<0.001), with 69% more OAB-related physician office visits and more than double the number of OAB-related laboratory tests among nonpharmacologically managed subjects contributing to this difference</p>

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Treatments for overactive bladder	Schabert, 2009 ⁴³⁶	To describe the challenges to improving management of overactive bladder outcomes and summarize research findings on critical success factors for supporting OAB treatment	5,392	NR	NR	OAB therapy	NA	OAB Persistence Survey: respondents who had been prescribed one antimuscarinic or more for OAB over the prior 12 months	24.5% reported discontinuing one antimuscarinic prescription medication or more during the prior 12 months. Among these patients discontinuing medications, 45.4% reported unmet treatment expectations as the reason for discontinuation

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Treatments for overactive bladder	Bolge, 2006 ⁴³⁷	To examine the impact of overactive bladder on health care resource utilization, daily activities, work productivity, and health complications	441	76.40	76.40	Drugs for OAB	NA	US National Health and Wellness Survey, 18, and internet population-based survey conducted annually by Consumer Health Sciences. It was administered to a representative sample of registered adult panelists aged 18 years or older in the U.S. There were 2602 respondents who reported a history of OAB diagnosed by a physician and out of these 441 respondents were administered the survey for the study.	Of the 196 patients receiving prescription medication, 147 (75%) reported satisfaction with therapy. Of the 31 patients receiving behavioral therapy, 21 (67.7%) were satisfied with treatment. 63 of (48.8%) the 129 respondents taking Kegel exercises were satisfied with this treatment. Impairment in productivity was primarily attributed to lack of concentration (40%), followed by inability to complete tasks (5.4%). OAB reduced their daily activities but 27.6%. Successful treatment of OAB was associated with a significantly lower incidence of complications than unsuccessful treatment(p <0.05)

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Treatments for overactive bladder	Dmochowski, 2007 ⁴³⁸	To examine the effects of OAB on participants; treatment-seeking behaviors, patient satisfaction with oral OAB therapies, and desirable characteristics of new treatments	1,228	100	43	Cross-sectional survey	NA	Women with symptoms of OAB , aged 40-65 years	87% of current users of OAB medications took their medication daily, with 70% taking it once daily. Only 32% were completely satisfied with their medications. Among respondents with OAB symptoms, 61% felt that less frequent dosing was 'very important' or 'extremely important. Among lapsed users of OAB medications, as compared with current users, significantly higher percentages indicated that it was extremely or very important to not feel nausea (79% vs. 59%), not have dry eyes (68% vs. 54%), not experience constipation as often(71% vs. 59%) and not have to take a high dose of medication (75% vs. 64%)

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Treatments for overactive bladder	Zhou, 2001 ⁴³⁹	To identify components of costs attributable to OAB, using medical claims data on insured patients with OAB between 18 and 64 years of age; to examine the demographic and health risk characteristics of patients with a primary or secondary diagnosis of OAB; and to suggest cost-effective treatment strategies for OAB	148,697	NR	NR	Presence of OAB	NA	Two cohorts were identified on the basis of whether individuals had received formal OAB treatment based on the ICD-9 codes for bladder disorders in the claims data. The OAB cohort consisted of 2,385 persons with an outpatient claim, primary or secondary ICD-0 code specified for OAB; or persons with an inpatient claim, primary ICD-9 code specified for OAB. The non-OAB cohort included 146,312 patients whose claims over the entire period showed none of the specified ICD-9 codes for OAB	The probability of hospital admission during the year was 20.65 among OAB patients compared with 7% among non-OAB patients. After adjustment for patient risk characteristics, total annual claims for a patient with OAB were 45% higher (p=0.0001), than for a patient without OAB. Annual inpatient claims were 23% higher but not significantly different from claims for a non-OAB patient. Much of the significance in cost for the OAB patients was due to age, sex, and the presence of non-OAB medical conditions.
Treatments for overactive bladder	Brubaker, 2010 ⁴⁴⁰	To identify predictors of self-reported discontinuation of overactive bladder medication using a	5,392	76	NR	OAB therapy	1 year	OAB Medication Use Survey. Participants were representatives of the U.S. population	Among 2,838 respondents at phase3, 1,194 had recently discontinued and 1,644 were persistent with

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
		three-phase survey						identified from the Taylor Nelson Sofres (formerly National Family Opinion) household panel	medications at phase2. Among phase3 respondents who were persistent at phase2, 1,040 continued to be persistent at phase3, 280 had discontinued between phases 2 and 3, and 261 had switched medication between phases 2 and 2; 63 had missing prescription at phase 3. Predictors of discontinuing at phase3 included smoking (OR:1.80; 95%CI=1.15-2.83, p=0.010), not knowing whether treating bladder problems requires multiple daily doses of medications (1.71, 1.10-2.67 ;p=0.018), believing (2.11, 1.34-3.33, p=0.001) or not knowing (1.76, 1.23-2.52, p=0.002) whether adverse effects of OAB medications are often severe, and being bothered 'quite a bit or more' by a sudden urge to urinate (1.54, 1.05-2.26; p=0.028). Respondents taking 2 or more medications were less likely to discontinue (OR: 0.45-0.58, p<0.05)

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Treatments for overactive bladder	Benner, 2010 ⁴⁴¹	To evaluate patient-reported reasons for discontinuing antimuscarinic prescription medications for OAB	5,392	77.60	26.80	OAB therapy	1 year	Representative sample of households in the U.S. (260,000) that agreed to participate in surveys from the Taylor Nelson Sofres (formerly National Family Opinion)	Among the 5,392 phase2 respondents, 1,322 (24.5%) reported discontinuing one or more antimuscarinic prescription AOB medication during the previous 12 months. Most respondents (89%) reported discontinuing OAB medication primarily due to unmet treatment expectations (46.2%) and/or tolerability (21.1%); many respondents in this class switched to a new antimuscarinic agent. A smaller group (11%) indicated a general aversion to taking medication.
Tolterodine	Coyne, 2008 ⁴⁴²	The IMPACT trial: Relationship between treatment-related improvements in overactive bladder symptoms as recorded in bladder diaries and patient reported symptom bother, bladder-related problems and health-related quality of life (HRQL).	863	82		Tolterodine ER (4 mg once daily)	12 weeks	>18 years of age (82% women) and have frequency (>8 micturitions per 24 hours) and either urgency (strong, sudden desire to urinate) or urgency urinary incontinence (UUI) (>2 episodes per day as recorded in 3-day bladder diaries)	Tolterodine ER-related improvements in OAB symptoms (assessed by diary variables) and patients' perceptions of changes in symptom bother, bladder-related problems and HRQoL (assessed by PPBC and OAB- were significantly correlated).

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Tolterodine	Elinoff, 2006 ⁴⁴³	The IMPACT trial: the efficacy of tolterodine extended release (ER) for patients' most bothersome overactive bladder (OAB) symptom in a primary care setting	863	82	24	Tolterodine ER (4 mg q.d.)	12 weeks	>18 years of age (82% women) and have frequency (>8 micturitions per 24 hours) and either urgency (strong, sudden desire to urinate) or urgency urinary incontinence (UUI) (>2 episodes per day as recorded in 3-day bladder diaries)	Discontinuation due to adverse events-7%; improvement in bladder condition (1 point) - 78.8% and 74.6% of the UUI group; all-cause AE- 51%; treatment-related adverse events - 23%
Tolterodine	Michel, 2007 ⁴⁴⁴	The association between symptoms of UI, bother, and patient satisfaction with treatment using tolterodine in overactive bladder	3,824	75.8	69	Tolterodine ER (4 mg q.d.)	9 months	Adults with OAB	Patient bother was the strongest individual predictor of patient treatment satisfaction in overactive bladder. Changes in episodes of the four symptoms of OAB were not associated with patient satisfaction
Tolterodine	Michel, 2004 ⁴⁴⁵	The impact of concomitant stress incontinence (SI) on the therapeutic effects of tolterodine in patients with OAB with and without concomitant SI.	2,250	76.9	NR	2 mg tolterodine twice daily	12 weeks	Adults with OAB	Patients with concomitant III degree SI (but not I or II degree) have significantly less improvement

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Tolterodine	Michel, 2002 ⁴⁴⁶	The association between patient age and gender and the therapeutic response to tolterodine in adults with OAB	2,251	76.9	95.5	2 mg tolterodine twice daily	12 weeks	Adults with OAB	Age (OR/yr. 0.978 (0.968–0.987)) and baseline Incontinence (OR 0.744 (0.716–0.774)) was negatively associated with treatment success. Increasing of tolterodine dose was associated with worse response (OR 0.866 (0.784–0.956)) and less tolerance (OR 1.114 (1.028–1.206))
Tolterodine	Roberts, 2006 ⁴⁴⁷	The IMPACT trial: the effect of tolterodine extended release (ER) on patient- and clinician-reported outcomes in a primary care setting	863	82	89.5	Tolterodine ER (4 mg once daily)	12 weeks	Adults with overactive bladder (OAB) symptoms for ≥3 months and were at least moderately bothered by their most bothersome symptom	improvement in their overall bladder condition - 79%; Major improvement (improvement of two or more points) - 50.4% and 49.7% of the UUI group
Tolterodine	Sussman, 2007 ⁴⁴⁸	Timing of the efficacy of tolterodine extended release (ER) in patients with overactive bladder	698	NR	NR	Tolterodine ER (4 mg qd)	12 weeks	Adults (aged ≥18 years) with urinary frequency ≥8 micturitions/24 hours) and urgency (strong and sudden desire to urinate) with or without urgency urinary incontinence (UUI).	Patients with OAB experienced significant reductions in OAB symptoms as early as Day 5 of treatment with tolterodine ER

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Tolterodine vs. Oxybutynin	Lawrence, 2000 ⁴⁴⁹	Adherence to treatment with immediate-release (IR) oxybutynin and Tolterodine`	1,531	67.5	NR	Tolterodine, IR Oxybutynin	6 months	All patients age 18 years and over who began therapy with either Tolterodine or IR Oxybutynin during April or May 1998	The proportion of patients continuing therapy for 6 months was statistically superior for Tolterodine (32%) Compared with IR Oxybutynin 22% Oxybutynin was switched to another therapy more commonly than Tolterodine (19% and 14%, respectively) Patients discontinuing all therapy within 6 months Men: Tolterodine 33%; Oxybutynin 39 % Women: Tolterodine 67%; Oxybutynin 61% Only 35 (32%) of IR Oxybutynin recipients were fully adherent compared with 87 (53%) of Tolterodine recipients.

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Tolterodine vs. Oxybutynin	Shaya, 2005 ⁴⁵⁰	Predictions of persistence with tolterodine or oxybutynin in patients with over active bladder	3,054, 1,637, included in analysis	75	NR	Tolterodine ER, Oxybutynin ER, Oxybutynin IR 4 weeks		Adults, 75% women, 45% African-American 26% younger than 18, with prescriptions of Tolterodine or Oxybutynin for over active bladder.	Hazard ratio of non persistence adjusted for age, sex, race Oxybutynin IR vs. Tolterodine ER 30 days 1.09 (0.88; 1.35) >30 days 1.13 (0.84; 1.51) Oxybutynin ER vs. Tolterodine ER <30 days 0.96 (0.6; 1.53) > 30 days 1.47 (1.01; 2.14) Age <18 vs. 18-39 1.56 (1.33; 1.82) > 40 vs. 18-39 0.85 (0.74, 0.97) African Americans vs. Whites 1.22 (1.09; 1.36)
Oxybutynin	Hussain, 1996 ⁴⁵¹	Effect of oxybutynin on the QTc interval in elderly patients with UI	21	42.9	100	Oxybutynin	4 weeks	Elderly	No QTc interval prolongation or ventricular arrhythmias
Oxybutynin	Nilsson, 1997 ⁴⁵²	The efficacy and tolerability of controlled release vs. 5-mg conventional oxybutynin twice daily	17	100	100	10-mg Controlled Release Oxybutynin vs. a 5-mg Oxybutynin Tablet	9 weeks	Women with urge UI	No difference in efficacy or safety of two formulations
Oxybutynin	Bemelmans, 2000 ⁴⁵³	The efficacy of a low-dose oxybutynin (2.5 mg three times daily) in men and women with symptomatic urge incontinence	416	83.6	NR	Oxybutynin (2.5 mg three times daily)	6 weeks	Men and women in primary care practice with symptomatic urgency incontinence	Complete symptomatic cure -95%; side effects attributable to the use of oxybutynin - 30%; 10% had to stop the medication because of the severity of these side effects.

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Oxybutynin	Radomski, 2004 ⁴⁵⁴	The efficacy of controlled-release (CR) oxybutynin tablet taken once-daily in patients with urinary urge incontinence	12	66.7	NR	Oxybutynin (2.5-5 mg bid)	8 weeks	Men and women with urodynamically-confirmed detrusor instability, micturition frequency (≥ 8 voids/day) and/or urinary incontinence (≥ 2 incontinence periods/day)	CR oxybutynin (15 mg OD) was at least as effective as the patients' previous dose of IR oxybutynin (mean dose: 6.7 +/- 2.5 mg/day).
Oxybutynin	Wang, 2002 ⁴⁵⁵	Risk of ventricular arrhythmia or sudden death after treatment with oxybutynin or other urinary antispasmodics	14,368,	70.5	NR	Oxybutynin or flavoxate	Not specified	Adults who filled prescriptions for Oxybutynin or Flavoxate via Medicaid program.	Relative risk of ventricular arrhythmias adjusted for age gender time - varying exposure urinary antispasmodic use 1,23 (0.87-1.75) Concurrent antihistamine/ cytochrome inhibitor use 5.47(1.34- 22.26) Relative risk of sudden death adjusted for age gender, and full of exposure urinary antispasmodic use 0.7 (0.28-1.74) Concurrent antihistamine/ cytochrome inhibitor use 21.5 (5.23-88.32)

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Oxybutynin	Diokno, 2002 ⁴⁵⁶	Long-term safety of oxybutynin in adults with over active bladder	1,067	84.7	100	Oxybutynin ER	12 weeks-1 year	Adults with urge or mixed UI, mean age 64 years	Discontinuations during 3 month - 25.5%, 1 year-53.8% Discontinuations due to adverse events 15.6% Dry mouth- 5.6% Lack of efficacy -4.9% Central nervous system at 91-180 days Headache-0.6% Dizziness- 0.4% Blurred vision-0.4% Somnolence 0.2% (181 day) Confusion 0.1%
Oxybutynin MATRIX study	Pizzi, 2009 ⁴⁵⁷	To evaluate the impact of oxybutynin transdermal system (OXY-TDS) and subsequent treatment on productivity among working participants	2,878 and 1,112 were employed (that formed the study population)	92.2	53.51	OXY-TDS 3.9mg/day, twice weekly patch applications	6 months	MATRIX study: Community - based; 2978 adults aged ≥18 years with symptoms of OAB	Participants experienced significant improvements in mean scores for all four WPQ (Work Productivity Questionnaire) scales (p<=0.0002) and the mean WPQ Index decreased from 8.2 to 5.5 (p<0.0001). The WPLS (Work Productivity Loss Score) decreased from 7.7% to 5.2% (p<0.0001)

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Oxybutynin MATRIX study	Newman, 2008 ⁴⁵⁸	To evaluate the effectiveness of transdermal oxybutynin (OXY-TDS) in improving HRQoL in a community-based adult population	2,878	87.2	NR	OXY-TDS 3.9mg/day, twice weekly patch applications	6 months	MATRIX study: community-based; men and women aged ≥18 years having at least one symptom of OAB, such as urge UI, urgency, and/or frequency	Among all participants, 16.5% discontinued OXY-TDS due to adverse events. Overall, this study found that OXY-TDS administered resulted in improvement in HRQoL, with the medication having its greatest effect on the impact of incontinence, severity of symptoms, and role limitations
Darifenacin	Zinner, 2008 ⁴⁰⁶	To investigate patient-reported outcomes and clinical parameters during darifenacin treatment in OAB patients who expressed dissatisfaction with prior extended-release oxybutynin or tolterodine therapy	497	84.1	82.9	7.5mg darifenacin once daily with the possibility of up-titrating to 15mg after 2 weeks, for up to 12 weeks	12 weeks	Men and women (≥18 years of age) with OAB symptoms [an average of ≥8 micturitions/24 hours and ≥1 urgency episode/24 hours, with or without urgency urinary incontinence episodes] for at least 6 months prior to randomization, and with a baseline score of ≥2 on the Patient Perception of Bladder Condition questionnaire at screening. Patients were	Darifenacin treatment resulted in statistically significant improvements in PPBC scores, micturition frequency, urgency, and UUI episodes from baseline at 12 weeks. More than 85% of patients expressed satisfaction with darifenacin. The odds (and 95% CI) for improvement in PPBC amongst previous recipients of oxybutynin ER or tolterodine ER were 2.08 (1.48, 2.92) and 1.77(1.29, 2.43). The odds for reporting satisfaction (and 95%CI) were 4.35 (2.90, 6.53) amongst previous oxybutynin ER recipients and 5.23 (3.50, 7.80) for

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
								required to be naive to darifenacin treatment, to have received at least 1 week of treatment with oxybutynin ER or tolterodine ER within the year prior to this trial and to report that they were dissatisfied with the most recent of these treatments	tolterodine ER recipients, representing an odd ratio (95% CI) of 0.83 (0.50, 1.40). 14.2 % discontinued in group who had prior treatment with oxybutynin and 10.4 % in group who had prior treatment with tolterodine. 58.4% had AEs, 20.1% dry mouth, 14.1% constipation, 6.6% urinary tract infection, 3.6% headache, 3.2% nausea, 2.6% dyspepsia, 2.2% dry eye, and 2% upper respiratory tract infection. 40.1% of total patients reported ≥90% improvement in number of UUI episodes/week, 39.1% of patients in group that had prior treatment with oxybutynin reported ≥90% improvement, and 40.4% in group that had prior treatment with tolterodine reported ≥90% improvement.

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Fesoterodine	Wyndaele, 2009 ⁴⁵⁹	To evaluate the efficacy and tolerability of flexible -dose fesoterodine in subjects with overactive bladder who were dissatisfied with previous tolterodine treatment	516	77	50	Fesoterodine 4mg once daily for 4 weeks; thereafter, daily dosage maintained at 4mg or increased to 8mg	12 weeks	Men and women aged ≥18 years with self-reported OAB symptoms for ≥3 months with a mean micturition frequency of ≥8 micturitions per 24 hours and mean number of urgency episodes ≥3 per 24 hours in a 5-day bladder diary; they had to rate their bladder condition as causing at least 'some moderate problems' on the PPBC questionnaire at baseline; they were required to have been treated with tolterodine or tolterodine ER for OAB within 2 years of screening	Approximately 80% of subjects who responded to the TSQ (Treatment Satisfaction Question) at week 12 reported satisfaction with treatment; 38% reported being very satisfied. 8.5% of patients reported no problems on the PPBC scale; 38.9% patients reported 'Usually able to finish what I am doing' on the UPS (Urgency Perception Scale) scale. Significant improvements from baseline (p<0.0001) exceeding the minimally important difference (10 points) were observed in OAB-q Symptom Bother and Health-Related Quality of Life scales and all four HRQoL domains.

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Botulinum-A toxin	Werner, 2005 ⁴⁶⁰	To investigate the efficacy and safety of botulinum -A toxin treatment for non-neurologic detrusor overactivity incontinence	26	100	100	100 units of botulinum -A toxin(BTX-A) injected into the detrusor at 30 sites	One day	Women with urgency incontinence and urodynamically demonstrable detrusor overactivity incontinence who failed to respond to various antimuscarinic	53.8% women were dry after 4 weeks, 65% after 12 weeks, and 60% after 36 weeks. 2 women failed to respond. 15.4% showed subjective improvement in effect on life and 11.5% showed subjective improvement in urgency incontinence after 36 weeks. Within the 51 followup visits, 30.8% patients had 9 urinary tract infections
Role of urodynamics in evaluation of outcomes	Malone-Lee, 2009 ⁴⁷³	The place of urodynamics in the evaluation of patients with symptoms of the overactive bladder by comparing the response to antimuscarinic therapy in those with and with no urodynamically verified symptoms	356	100	NR	Oxybutynin 2.5 mg twice daily and bladder retraining	6-8 weeks	Women ≥18 years with symptoms of overactive bladder and urgency, with or without urgency incontinence	<p>Patients respond equally to antimuscarinic therapy independent of urodynamic results. Detrusor instability-no detrusor</p> <p>Change from baseline 0 (2-6) / 0 (2-6)</p> <p>Dry mouth 84% / 70%</p> <p>Constipation 32% / 22%</p> <p>Heartburn 27% / 23%</p> <p>Dry skin 18% / 5%</p> <p>Headache 10% / 3.5%</p> <p>Dry eyes / 5% / 1%</p> <p>4 were excluded 76% had detrusor instability on cystometry</p>

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Adherence to anti-muscarinic medication	Balkrishnan, 2006 ⁴⁶¹	Relationship between adherence to antimuscarinic medication and health care services utilization.	275	76	100	Antimuscarinic medications; medications possessions score was calculated as the days of antimuscarinic prescriptions supply dispensed divided by the number of days between these prescription refills.	6 months or more	Enrollees in Medicare magnet care plan in the southern US, 16-24% men; 73-74 years old who dispensed antimuscarinic drugs every 6 months	Charlson index comorbidity, patient perception of quality of life, and total number of prescribed medications during the year before enrollment in Medicare where predictors of poor adherence to antimuscarinic drugs.
Adherence to anti-muscarinic medication	Yu, 2005 ⁴⁶²	Predictors of adherence to medications for over active bladder syndrome	2,496	80	NR	Tolterodine, Oxybutynin, Oxybutynin ER	6-12 months	20% random sample of California Medicaid program 20-25% men, 63-64 years old who dispersed any OAB/UI medication	Discontinuation-16% Hazard ratios of drug persistence White race – insignificant Tolterodine vs. Oxybutynin 0.7(0.67; 0.81) Previous antipsychotics use 0.85; 0.83; 0.88) Hazard ratios of drug adherence; Tolterodine vs. Oxybutynin 1.75 (1.10; 2.78) Oxybutynin ER vs. Oxybutynin 2.25 (1.36; 3.75)
Cost effectiveness	Perfetto, 2005 ⁴⁶³	1-year total healthcare costs for patients with overactive bladder	14,514	NR	NR	Tolterodine tartrate extended release capsules (tolterodine ER) versus extended release oxybutynin chloride (oxybutynin ER).	1-year	Pharmetrics Patien-Centric database	Tolterodine ER had lower monthly drug and medical management costs

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Cost effectiveness	Hughes, 2004 ⁴⁶⁴	Cost-Effectiveness Analysis of Extended-Release Formulations of Oxybutynin and Tolterodine for the Management of Urge Incontinence	1,504	82.2	NR	Oxy-IR 5mg tablets Oxy-XL 10mg tablets Tol-IR 2mg tablets Tol-ER 4mg tablets	12 weeks	Patients with urge urinary incontinence as fined by the International Contience Society; total number of weekly incontinent episodes recorded as endpoint; fixed dose or dose titration (not forced dose escalation); and patients and investigator blinded to treatment allocation	The incremental cost per incontinent-free week for Oxy-IR (versus no treatment) ranged from £2.58 to £16.59. Oxy-XL and Tol-ER were more effective than Oxy-IR but at additional costs per incontinent-free week. Tol-IR did not appear to be a cost-effective option as it was less effective and more costly than the extended-release formulations
Cost effectiveness	O'Brien, 2001 ⁴⁶⁵	Cost-effectiveness of Tolterodine for Patients with urge incontinence who discontinue initial therapy with Oxybutynin	312	NR	NR	Tolterodine in patients who discontinued Oxybutynin	12 weeks	Patients were required to have urodynamically confirmed bladder overactivity, with increased frequency of micturition(>8 micturitions/24h) and UI(>1 incontinent episode/24h) and/or urgency during a 2-week washout/run-in period.	The incremental cost per QALY was Can \$9982 and appeared to be robust

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Cost effectiveness	Varadharajan, 2005 ⁴⁶⁶	Post treatment medical costs for patients with overactive bladder	25,306	75.6	NR	Oxybutynin chloride immediate release (oxybutynin IR), oxybutynin chloride extended release (oxybutynin ER), or tolterodine extended-release tartrate capsules (tolterodine ER).	12 months	Pharmetrics Patien-Centric database	Costs for patients taking oxybutynin IR were 48% higher than costs for patients taking tolterodine ER (P=.026), and costs for patients taking oxybutynin ER were 191% higher than costs for patients taking tolterodine ER (P <.0001).
Cost effectiveness	Ko, 2006 ⁴⁶⁷	The cost-effectiveness of various antimuscarinic agents for the treatment of overactive bladder	NRI	NR	NR	Darifenacin, solifenacin, trospium, immediate release oxybutynin, extended-release oxybutynin, transdermal oxybutynin, immediate-release tolterodine, and extended-release tolterodine	3 months	NR	Expected costs for each patient with OAB ranged from \$3373 when treated with solifenacin to \$3769 when treated with immediate-release oxybutynin. The average cost/patient with continued and successful treatment was lowest for solifenacin (\$6863). Solifenacin dominated all other antimuscarinic agents because they were associated with high costs and low effectiveness.

Appendix Table F33. Clinical outcomes after pharmacological treatments in nonrandomized studies (continued)

Treatment	Reference	Aim	Number	% Women	% with UI	Treatment	Duration	Population	Results
Cost effectiveness	Yu, 2005 ⁴⁶²	Cost effectiveness of antimuscarinic medications	2,496	80	NR	Tolterodine Oxybutynin extended-release Oxybutynin Other OAB drugs	6 months-12 months	20% random sample of the administrative files provided by the California Medicaid program (Medi-Cal) from January 1999 to April 2002 with chronic OAB/UI	Expected costs for each patient with OAB ranged from \$3373 when treated with solifenacin to \$3769 when treated with immediate-release oxybutynin. The average cost/patient with continued and successful treatment was lowest for solifenacin (\$6863). Solifenacin

Abbreviation: NR=Not reported

Appendix Table F34. Continence after duloxetine vs. placebo, random effects model

Reference	Active events/randomized	Control events/randomized	Relative risk (95% CI)	Weight	Absolute risk difference (95% CI)	Weight
Norton, 2002 ⁴⁶⁸	123/140	132/138	0.92 (0.86; 0.99)	98.96	-0.08 (-0.14; -0.01)	46.58
Millard, 2004 ³⁵⁰	16/227	14/231	1.16 (0.58; 2.33)	1.04	0.01 (-0.04; 0.06)	53.42
Pooled estimate			0.92 (0.86; 1.0)	100	-0.03 (-0.12; 0.06)	100
I squared			0.00%		79.30%	
p value for heterogeneity			0.507		0.028	

Appendix Table F35. Continence after different doses of duloxetine

Reference sample size	Outcome as reported	Daily dose mg/day	Events in active group/randomized to active	Events in control group/randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)
Norton, 2002 ³⁵⁴ 275	SPT ≤2G	20mg/day vs. 40mg/d	110/138	111/137	0.98 (0.88; 1.11)	-0.01 (-0.11; 0.08)
Norton, 2002 ³⁵⁴ 275	Negative CST	20mg/day vs. 40mg/d	112/138	112/137	0.99 (0.89; 1.11)	-0.01 (-0.10; 0.09)
Norton, 2002 ³⁵⁴ 275	Zero incontinent episodes of diary	20mg/day vs. 40mg/d	128/138	123/137	1.03 (0.96; 1.11)	0.03 (-0.04; 0.10)
Norton, 2002 ³⁵⁴ 278	SPT ≤2G	20mg/day vs. 80mg/d	110/138	113/140	0.99 (0.88; 1.11)	-0.01 (-0.10; 0.08)
Norton, 2002 ³⁵⁴ 278	Negative CST	20mg/day vs. 80mg/d	112/138	114/140	1.00 (0.89; 1.12)	0.00 (-0.09; 0.09)
Norton, 2002 ³⁵⁴ 278	Zero incontinent episodes of diary	20mg/day vs. 80mg/d	128/138	123/140	1.06 (0.98; 1.14)	0.05 (-0.02; 0.12)
Norton, 2002 ³⁵⁴ 277	SPT ≤2G	40mg/day vs. 80mg/d	111/137	113/140	1.00 (0.90; 1.13)	0.00 (-0.09; 0.10)
Norton, 2002 ³⁵⁴ 277	Negative CST	40mg/day vs. 80mg/d	112/137	114/140	1.00 (0.90; 1.12)	0.00 (-0.09; 0.09)
Norton, 2002 ³⁵⁴ 277	Zero incontinent episodes of diary	40mg/day vs. 80mg/d	123/137	123/140	1.02 (0.94; 1.11)	0.02 (-0.05; 0.09)

Abbreviations: SPT = Stress pad test, CST = Cough stress test

Appendix Table F36. Improvement in UI after duloxetine vs. placebo (random effects model)

Outcome	Reference	Active events/randomized	Control events/randomized	Relative risk (95% CI)	Weight	Absolute risk difference (95% CI)	Weight
Improvement in PGI rating	Schagen van Leeuwen, 2008 ³⁷⁷	18/131	14/134	1.32 (0.68; 2.53)	29.16	0.03 (-0.05; 0.11)	25.46
Improvement in PGI rating	Millard, 2004 ³⁵⁰	167/227	148/231	1.15 (1.01; 1.3)	45.4	0.10 (0.01; 0.18)	24.16
Improvement in PGI rating	Steers, 2007 ³⁸⁰	5/153	1/153	5 (0.59; 42.30)	6.39	0.03 (-0.01; 0.06)	35.95
Improvement in PGI rating	Cardozo, 2004 ²⁴⁵	17/55	4/54	4.17 (1.50; 11.60)	19.05	0.24 (0.09; 0.38)	14.43
Improvement in PGI rating: very much better, much better	Pooled estimate			1.68 (0.94; 3.00)	100	0.08 (0.01; 0.14)	100
I squared	I squared			62.10%		69.40%	
p value for heterogeneity	p value for heterogeneity			0.048		0.02	
Improvement in UI	Lin, 2008 ³³⁶	42/60	28/61	1.53 (1.11; 2.10)	12.7	0.24 (0.07; 0.41)	10.63
Improvement in UI	Yalcin, 2006 ⁴⁰¹	198/433	152/425	1.28 (1.09; 1.51)	48.26	0.10 (-0.03; 0.17)	34.27
Improvement in UI	Cardozo, 2004 ²⁴⁵	4/55	1/54	3.93 (0.45; 34.02)	0.28	0.05 (-0.02; 0.13)	29.68
Improvement in UI	Millard, 2004 ³⁵⁰	135/227	100/231	1.37 (1.15; 1.65)	38.76	0.16 (0.07; 0.25)	25.42
Improvement in UI	Cardozo, 2010 ²⁴⁴	697/1378	431/1380	1.62 (1.47; 1.78)	37.29	0.19 (0.16; 0.23)	27.76
Improvement in UI: 50% or more reduction in urinary episode frequency	Pooled estimate			1.46 (1.28; 1.66)	100	0.14 (0.08; 0.21)	100
p value for heterogeneity	I squared			0.10		0.01	
I squared				49.20%		72.60%	

Appendix Table F37. Perceived treatment success after different doses of duloxetine

Reference Sample size	Outcome	Subgroup	Daily dose	Events in active/ randomized	Events in control/ randomized	Relative Risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 Treated
Norton, 2002 ³⁵⁴ 275	PGI-I score Percent in “very much” or “much better” categories	Baseline IEF ≥14	20 vs. 40mg/day	29/138	56/138	0.51 (0.35; 0.75)	-0.20 (-0.31; -0.09)	-5 (-11; -3)	-199 (-305; -92)
Norton, 2002 ³⁵⁴ 275	Increase in avoidance/limiting domain of I-QOL score from baseline		20 vs. 40mg/day	4/138	14/138	0.28 (0.10; 0.84)	-0.07 (-0.13; -0.02)	-14 (-65; -8)	-73 (-131; -15)
Norton, 2002 ³⁵⁴ 275	Increase in psychosocial domain of I-QOL score from baseline		20 vs. 40mg/day	4/138	10/138	0.40 (0.13; 1.24)	-0.04 (-0.10; 0.01)		
Norton, 2002 ³⁵⁴ 275	Increase in social embarrassment domain of I-QOL score from baseline		20 vs. 40mg/day	5/138	16/138	0.31 (0.12; 0.82)	-0.08 (-0.14; -0.02)	-12 (-54; -7)	-81 (-143; -18)
Norton, 2002 ³⁵⁴ 278	PGI-I score Percent in “very much” or “much better” categories		20 vs. 80mg/day	29/138	70/138	0.42 (0.29; 0.60)	-0.29 (-0.40; -0.18)	-3 (-5; -3)	-290 (-397; -183)
Norton, 2002 ³⁵⁴ 278	Increase in avoidance/limiting domain of I-QOL score from baseline		20 vs. 80mg/day	4/138	20/138	0.20 (0.07; 0.58)	-0.11 (-0.18; -0.05)	-9 (-20; -6)	-114 (-178; -50)
Norton, 2002 ³⁵⁴ 278	Increase in psychosocial domain of I-QOL score from baseline		20 vs. 80mg/day	4/138	16/138	0.25 (0.09; 0.74)	-0.09 (-0.14; -0.03)	-12 (-39; -7)	-85 (-145; -26)
Norton, 2002 ³⁵⁴ 278	Increase in social embarrassment domain of I-QOL score from baseline		20 vs. 80mg/day	5/138	21/138	0.24 (0.09; 0.62)	-0.11 (-0.18; -0.05)	-9 (-21; -6)	-114 (-181; -47)
Norton, 2002 ³⁵⁴ 277	PGI-I score Percent in “very much” or “much better” categories		40 vs. 80mg/day	56/137	70/137	0.82 (0.63; 1.06)	-0.09 (-0.21; 0.03)		
Norton, 2002 ³⁵⁴ 277	Increase in avoidance/limiting domain of I-QOL score from baseline		40 vs. 80mg/day	14/137	20/137	0.72 (0.38; 1.36)	-0.04 (-0.12; 0.04)		

Appendix Table F37. Perceived treatment success after different doses of duloxetine (continued)

Reference Sample size	Outcome	Subgroup	Daily dose	Events in active/ randomized	Events in control/ randomized	Relative Risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 Treated
Norton, 2002 ³⁵⁴ 277	Increase in psychosocial domain of I-QOL score from baseline		40 vs. 80mg/day	10/137	16/137	0.64 (0.30; 1.36)	-0.04 (-0.11; 0.03)		
Norton, 2002 ³⁵⁴ 277	Increase in social embarrassment domain of I-QOL score from baseline		40 vs. 80mg/day	16/137	21/137	0.78 (0.42; 1.43)	-0.03 (-0.11; 0.05)		
Duckett, 2007 ²⁸¹ 222	PGI-I score: very much better	in stress vs. mixed UI	60 vs. 40mg twice daily	10/123	8/123	1.01 (0.41; 2.45)	0.00 (-0.07; 0.07)		
Duckett, 2007 ²⁸¹ 222	PGI-I score: much better	in stress vs. mixed UI	60 vs. 40mg twice daily	22/123	11/123	1.61 (0.82; 3.16)	0.07 (-0.02; 0.16)		
Duckett, 2007 ²⁸¹ 222	PGI-I score: a little better	in stress vs. mixed UI	60 vs. 40mg twice daily	15/123	14/123	0.86 (0.44; 1.70)	-0.02 (-0.11; 0.07)		
Duckett, 2007 ²⁸¹ 222	PGI-I score: no change	in stress vs. mixed UI	60 vs. 40mg twice daily	21/123	10/123	1.69 (0.84; 3.42)	0.07 (-0.02; 0.16)		
Duckett, 2007 ²⁸¹ 222	PGI-I score: a little worse	in stress vs. mixed UI	60 vs. 40mg twice daily	1/123	3/123	0.27 (0.03; 2.54)	-0.02 (-0.06; 0.02)		
Duckett, 2007 ²⁸¹ 222	PGI-I score: much worse	in stress vs. mixed UI	60 vs. 40mg twice daily	1/123	3/123	0.27 (0.03; 2.54)	-0.02 (-0.06; 0.02)		
Duckett, 2007 ²⁸¹ 222	PGI-I score: very much worse	in stress vs. mixed UI	60 vs. 40mg twice daily	0/123	1/123	0.27 (0.01; 6.53)	-0.01 (-0.04; 0.02)		
Duckett, 2007 ²⁸¹ 222	PGI-I score: total	in stress vs. mixed UI	60 vs. 40mg twice daily	70/123	50/123	1.13 (0.88; 1.44)	0.06 (-0.07; 0.20)		
Bump, 2003 ¹⁰³ 277	Mixed urinary incontinence		40 vs. 0mg/day	85/137	88/137	0.99 (0.82; 1.18)	-0.01 (-0.12; 0.11)		
Bump, 2003 ¹⁰³ 277	Stress urinary incontinence		40 vs. 80mg twice daily	79/137	91/137	0.89 (0.74; 1.07)	-0.07 (-0.19; 0.04)		

Evidence Table F38. Treatment failure after duloxetine vs. placebo (random effects model)

Change in PGI-I rating scale	Reference	Active events/randomized	Control events/randomized	Relative risk (95% CI)	Weight	Absolute risk difference (95% CI)	Weight
Deterioration very much worse	Schagen van Leeuwen, 2008 ³⁷⁷	0/131	1/134	0.34 (0.01; 8.29)	0.99	-0.01 (-0.03; 0.01)	30.27
Deterioration very much worse	Bent, 2008 ²²⁹	4/300	0/288	8.64 (0.47; 159.78)	1.19	0.01 (-0.00; 0.03)	35.81
Deterioration very much worse	Steers, 2007 ³⁸⁰	1/153	1/153	1 (0.06; 15.84)	1.32	0 (-0.02; 0.02)	32.56
Deterioration very much worse	Cardozo, 2004 ²⁴⁵	31/55	42/54	0.73 (0.55; 0.95)	96.5	-0.21 (-0.39; -0.04)	1.36
Deterioration very much worse	Pooled estimate			0.74 (0.54; 1.02)	100	0 (-0.02; 0.02)	100
Deterioration very much worse	I squared			0.70%		67.30%	
Deterioration very much worse	p value for heterogeneity			0.39		0.03	
Deterioration much worse	Schagen van Leeuwen, 2008 ³⁷⁷	1/131	1/134	1.02 (0.07; 16.18)	26.1	0 (-0.02; 0.02)	22.7
Deterioration much worse	Bent, 2008 ²²⁹	3/300	1/288	2.88 (0.30; 27.53)	39.06	0.01 (-0.01; 0.02)	57.04
Deterioration much worse	Steers, 2007 ³⁸⁰	1/153	2/153	0.5 (0.05; 5.46)	34.84	-0.01; -0.03; 0.02)	20.26
Deterioration much worse	Pooled estimate			1.19 (0.29; 4.90)	100	0.00 (-0.01; 0.01)	100
Deterioration much worse	I squared			0.00%		0.00%	
Deterioration much worse	p value for heterogeneity			0.575		0.591	
No change	Schagen van Leeuwen, 2008 ³⁷⁷	26/131	35/134	0.76 (0.49; 1.19)	17.76	-0.06 (-0.16; 0.04)	25.63
No change	Bent, 2008 ²²⁹	74/300	94/288	0.76 (0.58; 0.98)	53.17	-0.08 (-0.15; -0.01)	49.21
No change	Steers, 2007 ³⁸⁰	41/153	49/153	0.84 (0.59; 1.19)	29.07	-0.05 (-0.15; 0.05)	25.16
No change	Pooled estimate			0.78 (0.65; 0.94)	100	-0.07 (-0.12; -0.02)	100

Evidence Table F38. Treatment failure after duloxetine vs. placebo (random effects model) (continued)

Change in PGI-I rating scale	Reference	Active events/randomized	Control events/randomized	Relative risk (95% CI)	Weight	Absolute risk difference (95% CI)	Weight
No change	I squared			0.00%		0.00%	
No change	p value for heterogeneity			0.89		0.90	
Deterioration a little worse	Schagen van Leeuwen, 2008 ³⁷⁷	4/131	14/134	0.29 (0.10; 0.87)	28.82	-0.07 (-0.13; -0.01)	22.62
Deterioration a little worse	Bent, 2008 ²²⁹	8/300	10/288	0.77 (0.31; 1.91)	39.65	-0.01 (-0.04; 0.02)	47.04
Deterioration a little worse	Steers, 2007 ³⁸⁰	6/153	8/153	0.75 (0.27; 2.11)	31.53	-0.01 (-0.06; 0.03)	30.34
Deterioration a little worse	Pooled estimate			0.58 (0.32; 1.05)	100	-0.03 (-0.06; 0.01)	100
Deterioration a little worse	I squared			5.80%		48.80%	
Deterioration a little worse	p value for heterogeneity			0.35		0.14	

Evidence Table F39. Quality of life after duloxetine vs. placebo

Reference Sample size	Dose	Outcome measure, MID	Randomized to active/control	Mean +/-standard deviation active	Mean +/- standard deviation control	Mean difference (95% CI)
Yalcin, 2006 ⁴⁰¹ 858	80mg daily	Increase in total I-QOL score from baseline; 2 to 5	433/425	10.5+/-14.0	6.4+/-12.6	4.1 (2.3; 5.90)
Yalcin, 2006 ⁴⁰¹ 858	80mg daily	Increase in avoidance/limiting domain of I-QOL score from baseline	433/425	10.8+/-10.8	7.2+/-13.9	3.6 (1.9; 5.30)
Yalcin, 2006 ⁴⁰¹ 858	80mg daily	Increase in psychosocial domain of I-QOL score from baseline	433/425	9.4+/-14.8	4.9+/-12.9	4.5 (2.6; 6.40)
Yalcin, 2006 ⁴⁰¹ 858	80mg daily	Increase in social embarrassment domain of I-QOL score from baseline	433/425	12.1+/-18.4	8.1+/-17.6	4.0 (1.6; 6.40)
Dmochowski, 2003 ²⁷⁵ 683	40mg twice daily	Increase in I-QOL score from baseline	344/339	11.1+/-14.8	6.8+/-13.8	4.3 (2.2; 6.40)
Dmochowski, 2003 ²⁷⁵ 683	40mg twice daily	Increase in I-QOL score from baseline for the avoidance/limiting behavior domain	344/339	11.1+/-15.8	7.1+/-14.8	4.0 (1.7; 6.30)
Dmochowski, 2003 ²⁷⁵ 683	40mg twice daily	Increase in I-QOL score from baseline for psychosocial domain	344/339	10.2+/-15.5	5.7+/-14.6	4.5 (2.2; 6.80)
Dmochowski, 2003 ²⁷⁵ 683	40mg twice daily	Increase in I-QOL score from baseline for social embarrassment domain	344/339	12.4+/-19.8	8.4+/-18.6	4.0 (1.1; 6.90)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	I-QOL Total score (0 worse to 100)	227/231	69.2+/-23.8	64.7+/-24.9	4.5 (0.0; 9.00)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	I-QOL Total score (0 worse to 100)	227/231	69.0+/-24.4	64.9+/-24.9	4.1 (-0.4; 8.60)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	avoidance/limiting behavior- I-QOL subscale	227/231	69.7+/-23.7	65.5+/-24.7	4.2 (-0.2; 8.60)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	psychosocial- I-QOL subscale	227/231	75.5+/-24.8	71.4+/-26.2	4.1 (-0.6; 8.80)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	social embarrassment- I-QOL subscale	227/231	57.1+/-27.8	51.5+/-29.7	5.6 (0.3; 10.90)
Steers, 2007 ³⁸⁰ 306	40-60mg twice daily	I-QOL	153/153	65.0+/-23.8	62.0+/-25.3	3.0 (-2.5; 8.50)

Evidence Table F39. Quality of life after duloxetine vs. placebo (continued)

Reference Sample size	Dose	Outcome measure, MID	Randomized to active/control	Mean +/-standard deviation active	Mean +/-standard deviation control	Mean difference (95% CI)
Cardozo, 2004 ²⁴⁵ 109	40mg twice daily for 4 weeks, 60 mg twice daily for 4 weeks	Avoidance and Limiting Behavior, I-QOL Subscales	55/54	10.1+/-20.8	2.0+/-11.1	8.1 (1.9; 14.30)
Cardozo, 2004 ²⁴⁵ 109	40mg twice daily for 4 weeks, 60 mg twice daily for 4 weeks	Psychosocial Impacts, I-QOL Subscales	55/54	10.6+/-18.7	2.1+/-9.6	8.5 (2.9; 14.10)
Cardozo, 2004 ²⁴⁵ 109	40mg twice daily for 4 weeks, 60 mg twice daily for 4 weeks	Social Embarrassment, I-QOL Subscales	55/54	11.5+/-22.6	3.6+/-12.6	7.9 (1.0; 14.80)
Cardozo, 2004 ²⁴⁵ 109	40mg twice daily for 4 weeks, 60 mg twice daily for 4 weeks	I-QOL total score	55/54	10.6+/-19.1	2.4+/-9.4	8.2 (2.6; 13.80)
Lin, 2008 ³³⁶ 121	40mg twice daily	Mean change in I-QOL from baseline	60/61	13.6+/-0.0	13.3+/-0.0	0.3 (-4.8; 6.80)
Lin, 2008 ³³⁶ 121	40mg twice daily	change from baseline in I-QOL avoidance and limiting behavior	60/61	12.7+/-0.0	12.8+/-0.0	-0.1 (-5.3; 6.50)
Lin, 2008 ³³⁶ 121	40mg twice daily	change from baseline in I-QOL psychological impact subscale score	60/61	12.9+/-0.0	12.0+/-0.0	0.9 (-3.7; 7.90)
Lin, 2008 ³³⁶ 121	40mg twice daily	change from baseline in I-QOL social embarrassment subscale score	60/61	16.4+/-0.0	16.5+/-0.0	-0.1 (-7.4; 6.80)
Viktrup, 2007 ³⁰⁹ 1913	40mg twice daily	I-QOL mean % change, for patient's age <50	958/955	9.1+/-13.5	0.0+/-0.0	5.1 (-22.3; 32.50)
Viktrup, 2007 ³⁰⁹ 1913	40mg twice daily	I-QOL mean % change, for patient's age ≥51	958/955	9.3+/-15.4	0.0+/-0.0	6.4 (-20.8; 33.60)

Appendix Table F40. Adverse effects after duloxetine vs. placebo (random effects model)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Abnormal elevation in bilirubin	Millard, 2004 ³⁵⁰	1/227	9/231	0.11 (0.01; 0.89)	33.43	-0.04 (-0.06; -0.01)	40.86
Total bilirubin above ULN	Hurley, 2006 ³⁰⁸	4/958	8/955	0.50 (0.15; 1.65)	66.57	-0.00 (-0.01; 0.00)	59.14
	Pooled	5/1185	17/1186	0.30 (0.08 1.20)	100	-0.02 (-0.05; 0.01)	100
	P value/I squared			0.22 33.00%		0.03 78.90%	
Abnormal elevation in alanine aminotransferase	Millard, 2004 ³⁵⁰	4/227	2/231	2.04 (0.38; 11.00)	3.38	0.01 (-0.01; 0.03)	56.46
ALT above ULN	Hurley, 2006 ³⁰⁸	84/958	62/955	1.35 (0.99; 1.85)	96.62	0.02 (-0.00; 0.05)	43.54
	Pooled	88/1185	64/1186	1.37 (1.00; 1.87)	100	0.02 (-0.00; 0.03)	100
	P value/I squared			0.64 0.00%		0.39 0.00%	
Abnormal elevation in aspartate aminotransferase	Millard, 2004 ³⁵⁰	3/227	6/231	0.51 (0.13; 2.01)	28.62	-0.01 (-0.04; 0.01)	46.87
AST above ULN	Hurley, 2006 ³⁰⁸	60/958	42/955	1.42 (0.97; 2.09)	71.38	0.02 (-0.00; 0.04)	53.13
	Pooled	63/1185	48/1186	1.06 (0.43; 2.64)	100	0.00 (-0.03; 0.04)	100
	P value/I squared			0.16 50.00%		0.06 72.40%	
Anorexia	Millard, 2004 ³⁵⁰	15/227	0/231	31.54 (1.90; 524.06)	17.1	0.07 (0.03; 0.10)	19.84
Anorexia	Hurley, 2006 ³⁰⁸	37/958	2/955	18.44 (4.46; 76.3)	66.97	0.04 (0.02; 0.05)	59.74
Anorexia	Schagen van Leeuwen, 2008 ³⁷⁷	4/131	0/134	9.21 (0.5; 169.28)	15.93	0.03 (-0.00; 0.06)	20.42
	Pooled	56/1316	2/1320	18.10 (5.66; 57.85)	100	0.04 (0.02; 0.06)	100
	P value/I squared			0.84 0.00%		0.23 32.50%	
Anorgasmia	Hurley, 2006 ³⁰⁸	13/958	0/955	26.92 (1.60; 452.12)	51.14	0.01 (0.01; 0.02)	81.44
Anorgasmia	Steers, 2007 ³⁸⁰	5/153	0/153	11 (0.61; 197.22)	48.86	0.03 (0.00; 0.06)	18.56
	Pooled	18/1111	0/1108	17.38 (2.31; 130.72)	100	0.02 (0.00; 0.03)	100
	P value/I squared			0.66 0.00%		0.24 28.90%	
Anxiety	Hurley, 2006 ³⁰⁸	18/958	7/955	2.56 (1.08; 6.11)	70.6	0.01 (0.00; 0.02)	61.05
Anxiety	Kinchen, 2005 ³²⁷	9/224	2/227	4.56 (1.00; 20.87)	23.01	0.03 (0.00; 0.06)	20.6
Anxiety	Steers, 2007 ³⁸⁰	5/153	0/153	11 (0.61; 197.22)	6.39	0.03 (0.00; 0.06)	18.35
	Pooled	32/1335	9/1335	3.21 (1.55; 6.66)	100	0.02 (0.01; 0.03)	100
	P value/I squared			0.56 0.00%		0.22 33.50%	

Appendix Table F40. Adverse effects after duloxetine vs. placebo (random effects model) (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Appetite decreased	Hurley, 2006 ³⁰⁸	22/958	2/955	10.97 (2.59; 46.50)	34.81	0.02 (0.01; 0.03)	64.18
Appetite decreased	Kinchen, 2005 ³²⁷	10/224	2/227	5.07 (1.12; 22.87)	32	0.04 (0.01; 0.07)	7.18
Appetite decreased	Lin, 2008 ³³⁶	4/60	1/61	4.07 (0.47; 35.34)	15.54	0.05 (-0.02; 0.12)	1.26
Appetite decreased	Bent, 2008 ²²⁹	6/300	0/288	12.48 (0.71; 220.56)	8.81	0.02 (0.00; 0.04)	21.58
Appetite decreased	Steers, 2007 ³⁸⁰	6/153	0/153	13 (0.74 (23; 77)	8.84	0.04 (0.01; 0.07)	5.8
	Pooled	48/1695	5/1684	7.54 (3.21; 17.68)	100	0.02 (0.02; 0.03)	100
	P value/I squared			0.90 0.00%		0.64 0.00%	
Asthenia	Ghoniem, 2005 ²⁸⁹	6/104	0/97	12.13 (0.69; 212.55)	7.05	0.06 (0.10; 0.11)	4.14
Asthenia	Hurley, 2006 ³⁰⁸	7/958	0/955	14.95 (0.86; 261.45)	7.05	0.01 (0.00; 0.01)	50.11
Asthenia	Lin, 2008 ³³⁶	3/60	1/61	3.05 (0.33; 28.51)	11.56	0.03 (-0.03; 0.10)	2.44
Asthenia	Cardozo, 2010 ²⁴⁴	27/1378	6/1380	4.51 (1.87; 10.88)	74.34	0.02 (0.01; 0.02)	43.31
	Pooled	43/2500	7/2493	5.03 (2.35; 10.75)	100	0.01 (0.00; 0.02)	100
	P value/I squared			0.76 0.00%		0.08 55.10%	
Constipation	Ghoniem, 2005 ²⁸⁹	15/104	3/97	4.66 (1.39; 15.61)	2.95	0.11 (0.04; 0.19)	2.98
Constipation	Millard, 2004 ³⁵⁰	29/227	4/231	7.38 (2.64; 20.65)	4.07	0.11 (0.06; 0.16)	6.62
Constipation	Hurley, 2006 ³⁰⁸	105/958	22/955	4.76 (3.03; 7.47)	21.2	0.09 (0.07; 0.11)	15.57
Constipation	Kinchen, 2005 ³²⁷	20/224	5/227	4.05 (1.55; 10.61)	4.65	0.07 (0.03; 0.11)	7.7
Constipation	van Kerrebroeck, 2004 ⁴¹¹	35/247	10/247	3.5 (1.77; 6.91)	9.31	0.10 (0.05; 0.15)	5.96
Constipation	Norton, 2002 ³⁵⁴	6/140	1/138	5.91 (0.72; 48.49)	0.97	0.04 (-0.00; 0.07)	9.29
Constipation	Castro-Diaz, 2007 ²⁴⁸	16/136	6/120	2.35 (0.95; 5.82)	5.25	0.07 (0.00; 0.13)	3.72
Constipation	Lin, 2008 ³³⁶	10/60	0/61	21.34 (1.28; 356.28)	0.54	0.17 (0.07; 0.26)	1.9
Constipation	Schagen van Leeuwen, 2008 ³⁷⁷	14/131	1/134	14.32 (1.91; 107.35)	1.06	0.10 (0.05; 0.15)	5.15
Constipation	Dmochowski, 2003 ²⁷⁵	33/344	7/339	4.65 (2.08; 10.36)	6.7	0.08 (0.04; 0.11)	9.9
Constipation	Bent, 2008 ²²⁹	25/300	12/288	2 (1.02; 3.91)	9.62	0.04 (0.00; 0.08)	8.54
Constipation	Steers, 2007 ³⁸⁰	21/153	5/153	4.2 (1.63; 10.85)	4.78	0.11 (0.04; 0.17)	4.29
Constipation	Cardozo, 2010 ²⁴⁴	125/1378	31/1380	4.04 (2.75; 5.94)	28.89	0.07 (0.05; 0.09)	18.38
	Pooled	454/4402	107/4370	4.01 (3.26; 4.93)	100	0.08 (0.06; 0.09)	100
	P value/I squared			0.55 0.00%		0.10 35.10%	
Diarrhea	Hurley, 2006 ³⁰⁸	49/958	26/955	1.88 (1.18; 3.00)	48.74	0.02 (0.01; 0.04)	27.08
Diarrhea	Kinchen, 2005 ³²⁷	19/224	8/227	2.41 (1.08; 5.38)	16.4	0.05 (0.01; 0.09)	12.38
Diarrhea	Norton, 2002 ³⁵⁴	4/140	3/138	1.31 (0.30; 5.76)	4.86	0.01 (-0.03; 0.04)	15.23
Diarrhea	Castro-Diaz, 2007 ²⁴⁸	1/136	4/120	0.22 (0.03; 1.95)	2.24	-0.03 (-0.06; 0.01)	16

Appendix Table F40. Adverse effects after duloxetine vs. placebo (random effects model) (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Diarrhea	Dmochowski, 2003 ²⁷⁵	21/344	9/339	2.30 (1.07; 4.95)	18.1	0.03 (0.00; 0.07)	18.46
Diarrhea	Steers, 2007 ³⁸⁰	10/153	5/153	2 (0.70; 5.72)	9.65	0.03 (-0.02; 0.08)	10.84
	Pooled	104/1955	55/1932	1.91 (1.38; 2.65)	100	0.02 (0; 0.04)	100
	P value/I squared			0.47 0.00%		0.07 50.70%	
Dizziness	Ghoniem, 2005 ²⁸⁹	19/104	5/97	3.54 (1.38; 9.12)	5.03	0.13 (0.05; 0.22)	3.2
Dizziness	Millard, 2004 ³⁵⁰	25/227	6/231	4.24 (1.77; 10.14)	5.92	0.08 (0.04; 0.13)	7.79
Dizziness	Cardozo, 2004 ²⁴⁵	9/55	2/54	4.42 (1; 19.52)	2.04	0.13 (0.02; 0.24)	2.12
Dizziness	Hurley, 2006 ³⁰⁸	91/958	25/955	3.63 (2.35; 5.60)	23.95	0.07 (0.05; 0.09)	13.78
Dizziness	Kinchen, 2005 ³²⁷	30/224	8/227	3.8 (1.78; 8.11)	7.84	0.10 (0.05; 0.15)	6.9
Dizziness	van Kerrebroeck, 2004 ⁴¹¹	30/247	8/247	3.75 (1.75; 8.02)	7.8	0.09 (0.04; 0.14)	7.65
Dizziness	Norton, 2002 ³⁵⁴	7/140	2/138	3.45 (0.73; 16.32)	1.86	0.04 (-0.01; 0.08)	8.66
Dizziness	Castro-Diaz, 2007 ²⁴⁸	14/136	1/120	12.35 (1.65; 92.55)	1.11	0.10 (0.04; 0.15)	6.43
Dizziness	Lin, 2008 ³³⁶	8/60	6/61	1.36 (0.50; 3.67)	4.53	0.04 (-0.08; 0.15)	2
Dizziness	Schagen van Leeuwen, 2008 ³⁷⁷	12/131	6/134	2.05 (0.79; 5.29)	4.99	0.05 (-0.01; 0.11)	5.48
Dizziness	Dmochowski, 2003 ²⁷⁵	26/344	8/339	3.20 (1.47; 6.97)	7.43	0.05 (0.02; 0.08)	10.77
Dizziness	Bent, 2008 ²²⁹	29/300	7/288	3.98 (1.77; 8.94)	6.87	0.07 (0.03; 0.11)	9.41
Dizziness	Cardozo, 2010 ²⁴⁴	68/1378	23/1380	2.96 (1.86; 4.72)	20.64	0.03 (0.02; 0.05)	15.8
	Pooled	368/4304	107/4271	3.33 (2.69; 4.11)	100	0.07 (0.045; 0.08)	100
	P value/I squared			0.86 0.00%		0.01 56.20%	
Dry mouth	Ghoniem, 2005 ²⁸⁹	19/104	3/97	5.91 (1.81; 19.34)	6.36	0.15 (0.07; 0.23)	5.12
Dry mouth	Millard, 2004 ³⁵⁰	28/227	4/231	7.12 (2.54; 19.98)	7.39	0.11 (0.06; 0.15)	7.97
Dry mouth	Cardozo, 2004 ²⁴⁵	12/55	0/54	24.55 (1.49; 404.63)	1.75	0.22 (0.11; 0.33)	3.53
Dry mouth	Kinchen, 2005 ³²⁷	26/224	5/227	5.27 (2.06; 13.48)	8.09	0.09 (0.05; 0.14)	7.95
Dry mouth	van Kerrebroeck, 2004 ⁴¹¹	48/247	6/247	8 (3.49; 18.35)	9	0.17 (0.12; 0.22)	7.35
Dry mouth	Norton, 2002 ³⁵⁴	7/140	1/138	6.9 (0.86; 55.35)	2.89	0.04 (0.00; 0.08)	8.6
Dry mouth	Castro-Diaz, 2007 ²⁴⁸	22/136	5/120	3.88 (1.52; 9.93)	8.09	0.12 (0.05; 0.19)	5.85
Dry mouth	Lin, 2008 ³³⁶	10/60	2/61	5.08 (1.16; 22.24)	4.83	0.13 (0.03; 0.24)	3.87
Dry mouth	Schagen van Leeuwen, 2008 ³⁷⁷	26/131	2/134	13.30 (3.22; 54.90)	5.09	0.18 (0.11; 0.26)	5.86
Dry mouth	Dmochowski, 2003 ²⁷⁵	42/344	3/339	13.80 (4.32; 44.08)	6.51	0.11 (0.08; 0.15)	8.84
Dry mouth	Bent, 2008 ²²⁹	36/300	8/288	4.32 (2.04; 9.14)	9.72	0.09 (0.05; 0.13)	8.37

Appendix Table F40. Adverse effects after duloxetine vs. placebo (random effects model) (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Dry mouth	Steers, 2007 ³⁸⁰	25/153	2/153	12.5 (3.01; 51.86)	5.07	0.15 (0.09; 0.21)	6.65
Dry mouth	Cardozo, 2010 ²⁴⁴	117/1378	47/1380	2.49 (1.79; 3.47)	13.56	0.05 (0.03; 0.07)	10.19
Dry mouth	Hurley, 2006 ³⁰⁸	128/958	14/955	9.11 (5.29; 15.71)	11.65	0.12 (0.10; 0.14)	9.86
	Pooled	546/4457	102/4424	6.26 (4.22; 9.28)	100	0.12 (0.09; 0.14)	100
	P value/I squared			0.00 58.20%		0 78.60%	
Fatigue	Millard, 2004 ³⁵⁰	23/227	8/231	2.93 (1.34; 6.40)	6.04	0.07 (0.02; 0.11)	8.93
Fatigue	Cardozo, 2004 ²⁴⁵	10/55	6/54	1.64 (0.64; 4.19)	4.2	0.07 (-0.06; 0.20)	2.52
Fatigue	Hurley, 2006 ³⁰⁸	122/958	36/955	3.38 (2.36; 4.85)	28.49	0.09 (0.07; 0.11)	11.92
Fatigue	Kinchen, 2005 ³²⁷	45/224	12/227	3.8 (2.07; 6.99)	9.98	0.15 (0.09; 0.21)	7.14
Fatigue	van Kerrebroeck, 2004 ⁴¹¹	34/247	11/247	3.09 (1.60; 5.96)	8.6	0.09 (0.04; 0.14)	8.36
Fatigue	Norton, 2002 ³⁵⁴	10/140	3/138	3.29 (0.92; 11.68)	2.3	0.05 (0.00; 0.10)	8.49
Fatigue	Lin, 2008 ³³⁶	5/60	0/61	11.18 (0.63; 197.86)	0.45	0.08 (0.01; 0.16)	5.6
Fatigue	Schagen van Leeuwen, 2008 ³⁷⁷	19/131	7/134	2.78 (1.21; 6.38)	5.35	0.09 (0.02; 0.160)	5.98
Fatigue	Dmochowski, 2003 ²⁷⁵	51/344	13/339	3.87 (2.14; 6.98)	10.64	0.11 (0.07; 0.15)	9.35
Fatigue	Bent, 2008 ²²⁹	20/300	8/288	2.4 (1.07; 5.36)	5.74	0.04 (0.01; 0.07)	10.59
Fatigue	Steers, 2007 ³⁸⁰	16/153	3/153	5.33 (1.59; 17.93)	2.52	0.09 (0.03; 0.14)	7.96
Fatigue	Cardozo, 2010 ²⁴⁴	65/1378	21/1380	3.1 (1.91; 5.04)	15.68	0.03 (0.02; 0.05)	13.16
	Pooled	420/4217	128/4207	3.22 (2.66; 3.90)	100	0.08 (0.05; 0.10)	100
	P value/I squared			0.94 0.00%		0 73.70%	
Headache	Millard, 2004 ³⁵⁰	33/227	20/231	1.68 (0.99; 2.84)	9.44	0.06 (0; 0.12)	4.8
Headache	Cardozo, 2004 ²⁴⁵	15/55	5/54	2.95 (1.15; 7.54)	2.94	0.18 (0.04; 0.32)	0.87
Headache	Hurley, 2006 ³⁰⁸	93/958	63/955	1.47 (1.08; 2)	27.54	0.03 (0.01; 0.06)	21.9
Headache	Kinchen, 2005 ³²⁷	28/224	14/227	2.03 (1.10; 3.75)	6.87	0.06 (0.01; 0.12)	5.69
Headache	van Kerrebroeck, 2004 ⁴¹¹	24/247	19/247	1.26 (0.71; 2.25)	7.84	0.02 (-0.03; 0.07)	6.51
Headache	Norton, 2002 ³⁵⁴	8/140	9/138	0.88 (0.35; 2.21)	3.05	-0.01 (-0.06; 0.05)	5.15
Headache	Castro-Diaz, 2007 ²⁴⁸	11/136	11/120	0.88 (0.40; 1.96)	4.07	-0.01 (-0.08; 0.06)	3.5
Headache	Dmochowski, 2003 ²⁷⁵	25/344	12/339	2.05 (1.05; 4.02)	5.75	0.04 (0.00; 0.07)	13.02
Headache	Steers, 2007 ³⁸⁰	13/153	8/153	1.63 (0.69; 3.81)	3.58	0.03 (-0.02; 0.09)	5.11
Headache	Cardozo, 2010 ²⁴⁴	109/1378	64/1380	1.71 (1.26; 2.30)	28.93	0.03 (0.02; 0.05)	33.46
	Pooled	359/3862	225/3844	1.58 (1.35; 1.86)	100	0.03 (0.02; 0.05)	100
	P value/I squared			0.57 0.00%		0.34 10.90%	

Appendix Table F40. Adverse effects after duloxetine vs. placebo (random effects model) (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Hyperhidrosis	Lin, 2008 ³³⁶	5/60	0/61	11.18 (0.63; 197.86)	0.94	0.08 (0.01; 0.16)	3.1
Hyperhidrosis	Schagen van Leeuwen, 2008 ³⁷⁷	7/131	0/134	15.34 (0.89; 265.91)	0.95	0.05 (0.01; 0.09)	8.15
Hyperhidrosis	Cardozo, 2010 ²⁴⁴	45/1378	13/1380	3.47 (1.88; 6.40)	20.58	0.02 (0.01; 0.03)	22.23
Hyperhidrosis	Brunton, 2010 ²³⁴	189/10326	34/7496	4.04 (2.80; 5.81)	58.33	0.01 (0.01; 0.02)	25.17
Hyperhidrosis	Millard, 2004 ³⁵⁰	13/227	2/231	6.62 (1.51; 28.98)	3.54	0.05 (0.02; 0.08)	10.84
Hyperhidrosis	Kinchen, 2005 ³²⁷	15/224	1/227	15.20 (2.03; 114.11)	1.9	0.06 (0.03; 0.10)	10.34
Hyperhidrosis	Hurley, 2006 ³⁰⁸	43/958	8/955	5.36 (2.53; 11.34)	13.76	0.04 (0.02; 0.05)	20.17
	Pooled	317/13304	58/10484	4.34 (3.29; 5.73)	100	0.04 (0.02; 0.05)	100
	P value/I squared			0.69 0.00%		0 79.40%	
Insomnia	Ghoniem, 2005 ²⁸⁹	12/104	1/97	11.19 (1.48;84.47)	2.85	0.11 (0.04; 0.17)	7.07
Insomnia	Millard, 2004 ³⁵⁰	31/227	6/231	5.26 (2.24;12.36)	9.09	0.11 (0.06; 0.16)	8.3
Insomnia	Cardozo, 2004 ²⁴⁵	7/55	3/54	2.29 (0.63; 8.40)	5.6	0.07 (-0.04; 0.18)	4.37
Insomnia	Hurley, 2006 ³⁰⁸	121/958	18/955	6.70 (4.12; 10.91)	13.41	0.11 (0.09; 0.13)	10.24
Insomnia	Kinchen, 2005 ³²⁷	33/224	13/227	2.57 (1.39; 4.76)	11.81	0.09 (0.04; 0.15)	7.8
Insomnia	van Kerrebroeck, 2004 ⁴¹¹	31/247	3/247	10.33 (3.20; 33.36)	6.41	0.11 (0.07; 0.16)	8.76
Insomnia	Norton, 2002 ³⁵⁴	7/140	1/138	6.9 (0.86; 55.35)	2.71	0.04 (0.00; 0.08)	9.13
Insomnia	Castro-Diaz, 2007 ²⁴⁸	14/136	6/120	2.06 (0.82;5.19)	8.41	0.05 (-0.01; 0.12)	7.1
Insomnia	Dmochowski, 2003 ²⁷⁵	49/344	8/339	6.04 (2.90; 12.55)	10.42	0.12 (0.08; 0.16)	9.01
Insomnia	Bent, 2008 ²²⁹	7/300	7/288	0.96 (0.34; 2.70)	7.44	-0.00 (-0.03; 0.02)	10.13
Insomnia	Steers, 2007 ³⁸⁰	20/153	5/153	4 (1.54; 10.38)	8.14	0.10 (0.04; 0.16)	7.4
Insomnia	Cardozo, 2010 ²⁴⁴	63/1378	24/1380	2.63 (1.65; 4.18)	13.7	0.03 (0.02; 0.04)	10.69
	Pooled	395/4266	95/4229	3.76 (2.59; 5.47)	100	0.08 (0.05; 0.11)	100
	P value/I squared			0.01 55.20%		0 86.90%	
Nausea	Ghoniem, 2005 ²⁸⁹	40/104	5/97	7.46 (3.07; 18.13)	6.09	0.33 (0.23; 0.44)	5.49
Nausea	Millard, 2004 ³⁵⁰	57/227	9/231	6.45 (3.27; 12.71)	7.72	0.21 (0.15; 0.27)	7.51
Nausea	Cardozo, 2004 ²⁴⁵	25/55	7/54	3.51 (1.66; 7.42)	7.13	0.33 (0.17; 0.48)	3.48
Nausea	Hurley, 2006 ³⁰⁸	222/958	35/955	6.32 (4.48; 8.93)	10.74	0.20 (0.17; 0.22)	8.92
Nausea	Kinchen, 2005 ³²⁷	70/224	13/227	5.46 (3.11; 9.58)	8.76	0.26 (0.19; 0.32)	7.21
Nausea	van Kerrebroeck, 2004 ⁴¹¹	69/247	16/247	4.31 (2.58; 7.21)	9.21	0.22 (0.15; 0.28)	7.41
Nausea	Norton, 2002 ³⁵⁴	13/140	2/138	6.41 (1.47; 27.87)	3.22	0.08 (0.03; 0.13)	7.98
Nausea	Castro-Diaz, 2007 ²⁴⁸	40/136	7/120	5.04 (2.35; 10.83)	7.01	0.24 (0.15; 0.32)	6.23
Nausea	Lin, 2008 ³³⁶	9/60	0/61	19.31 (1.15; 324.56)	1.08	0.15 (0.06; 0.24)	5.93

Appendix Table F40. Adverse effects after duloxetine vs. placebo (random effects model) (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Nausea	Schagen van Leeuwen, 2008 ³⁷⁷	10/131	4/134	2.56 (0.82; 7.95)	4.6	0.05 (-0.01; 0.10)	7.9
Nausea	Dmochowski, 2003 ²⁷⁵	78/344	7/339	10.98 (5.14; 23.45)	7.06	0.21 (0.16; 0.25)	8.23
Nausea	Bent, 2008 ²²⁹	54/300	13/288	3.99 (2.23; 7.15)	8.57	0.13 (0.09; 0.19)	8.09
Nausea	Steers, 2007 ³⁸⁰	47/153	7/153	6.71 (3.13; 14.38)	7.03	0.26 (0.18; 0.34)	6.58
Nausea	Cardozo, 2010 ²⁴⁴	279/1378	113/1380	2.47 (2.01; 3.04)	11.78	0.12 (0.10; 0.15)	9.04
	Pooled	1013/4457	238/4424	5.02 (3.70; 6.82)	100	0.19 (0.15; 0.22)	100
	P value/I squared			0 70.40%		0 84.30%	
Sleep disorder	Schagen van Leeuwen, 2008 ³⁷⁷	4/131	1/134	4.09 (0.46; 36.12)	6.18	0.02 (-0.01; 0.06)	8.58
Somnolence	Ghoniem, 2005 ²⁸⁹	11/104	1/97	10.26 (1.35; 77.99)	6.84	0.10 (0.03; 0.16)	5.43
Somnolence	Millard, 2004 ³⁵⁰	19/227	0/231	39.68 (2.41; 653.35)	4.17	0.08 (0.05; 0.12)	8.13
Somnolence	Cardozo, 2004 ²⁴⁵	7/55	1/54	6.87 (0.88; 54.00)	6.69	0.11 (0.01; 0.20)	3.25
Somnolence	Hurley, 2006 ³⁰⁸	65/958	1/955	64.80 (9.01; 466.01)	7.12	0.07 (0.05; 0.08)	10.33
Somnolence	Kinchen, 2005 ³²⁷	23/224	4/227	5.83 (2.05; 16.58)	14.22	0.09 (0.04; 0.13)	7.38
Somnolence	van Kerrebroeck, 2004 ⁴¹¹	10/247	0/247	21 (1.24; 356.41)	4.1	0.04 (0.02; 0.07)	9.4
Somnolence	Castro-Diaz, 2007 ²⁴⁸	15/136	2/120	6.62 (1.55; 28.35)	10.42	0.09 (0.04; 0.15)	5.89
Somnolence	Lin, 2008 ³³⁶	9/60	0/61	19.31 (1.15; 324.56)	4.12	0.15 (0.06; 0.24)	3.32
Somnolence	Dmochowski, 2003 ²⁷⁵	30/344	1/339	29.56 (4.06; 215.57)	7.05	0.08 (0.05; 0.12)	8.87
Somnolence	Bent, 2008 ²²⁹	8/300	1/288	7.68 (0.97; 61.02)	6.64	0.02 (0.00; 0.04)	10.03
Somnolence	Steers, 2007 ³⁸⁰	6/153	0/153	13 (0.74; 228.77)	4.01	0.04 (0.01; 0.07)	8.57
Somnolence	Cardozo, 2010 ²⁴⁴	28/1378	12/1380	2.34 (1.19; 4.58)	18.45	0.01 (0.00; 0.02)	10.81
	Pooled	235/4317	24/4286	8.61 (4.58; 16.20)	100	0.06 (0.04; 0.08)	100
	P value/I squared			0.08 38.40%		0 85.20%	
Treatment associated adverse effects	Dmochowski, 2003 ²⁷⁵	255/344	170/339	1.48 (1.31; 1.68)	13.35	0.24 (0.17; 0.31)	13.9
Treatment associated adverse effects	Millard, 2004 ³⁵⁰	173/227	137/231	1.29 (1.13; 1.46)	12.63	0.169 0.085 0.253	11.46
Treatment associated adverse effects	van Kerrebroeck, 2004 ⁴¹¹	200/247	158/247	1.27 (1.13; 1.42)	14.93	0.17 (0.09; 0.25)	12.61
Treatment associated adverse effects	Cardozo, 2004 ²⁴⁵	51/55	39/54	1.28 (1.07; 1.54)	7.98	0.21 (0.07; 0.34)	5.77

Appendix Table F40. Adverse effects after duloxetine vs. placebo (random effects model) (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Treatment associated adverse effects	Kinchen, 2005 ³²⁷	198/224	159/227	1.26 (1.15; 1.39)	17.06	0.18 (0.11; 0.26)	13.44
Treatment associated adverse effects	Steers, 2007 ³⁸⁰	121/153	85/153	1.42 (1.21; 1.68)	9.27	0.24 (0.13; 0.34)	9.01
Treatment associated adverse effects	Lin, 2008 ³³⁶	48/60	27/61	1.81 (1.33; 2.46)	3.29	0.36 (0.20; 0.52)	4.49
Treatment associated adverse effects	Schagen van Leeuwen, 2008 ³⁷⁷	58/131	49/134	1.21 (0.90; 1.63)	3.59	0.08 (-0.04; 0.20)	7.32
Treatment associated adverse effects	Cardozo, 2010 ²⁴⁴	666/1378	460/1380	1.45 (1.32; 1.59)	17.88	0.15 (0.11; 0.19)	21.99
	Pooled	1769/2819	1283/2826	1.36 (1.28; 1.44)	100	0.19 (0.15; 0.22)	100
	P value/I squared			0.12 37.70%		0.07 44.60%	
Vomiting	Millard, 2004 ³⁵⁰	14/227	4/231	3.56 (1.19; 10.66)	7.65	0.04 (0.01; 0.08)	6.05
Vomiting	Cardozo, 2004 ²⁴⁵	7/55	1/54	6.87 (0.88; 54.00)	2.16	0.11 (0.01; 0.20)	0.85
Vomiting	Hurley, 2006 ³⁰⁸	46/958	15/955	3.06 (1.72; 5.44)	27.71	0.03 (0.02; 0.05)	29.24
Vomiting	Kinchen, 2005 ³²⁷	19/224	8/227	2.41 (1.08; 5.38)	14.17	0.05 (0.01; 0.09)	4.02
Vomiting	van Kerrebroeck, 2004 ⁴¹¹	16/247	5/247	3.2 (1.19; 8.60)	9.4	0.05 (0.01; 0.08)	6.1
Vomiting	Steers, 2007 ³⁸⁰	5/153	3/153	1.67 (0.41; 6.85)	4.6	0.01 (-0.02; 0.05)	5.98
Vomiting	Cardozo, 2010 ²⁴⁴	54/1378	19/1380	2.85 (1.70; 4.78)	34.31	0.03 (0.01; 0.04)	47.75
		161/3242	55/3247	2.9 (2.14; 3.93)	100	0.03 (0.02; 0.04)	100
				0.95 0.00%		0.40 2.90%	
Adverse effects	Bent, 2008 ²²⁹	5/300	5/288	0.96 (0.28; 3.28)	61.32	-0.00 (-0.02; 0.02)	57.85
	Steers, 2007 ³⁸⁰	6/153	1/153	6 (0.73; 49.25)	38.68	0.03 (-0.00; 0.07)	42.15
	Pooled	11/453	6/441	1.95 (0.34; 11.22)	100	0.01 (-0.02; 0.05)	100
	P value/I squared			0.14 53.90%		0.10 63.90%	

Appendix Table F41. Adverse effects after duloxetine treatments compared to placebo (pooled results from RCTs)

Outcome	Studies	Patients	Rate active/control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Bayesian odds ratio median (2.5; 97.5%)	Evidence
Total bilirubin above ULN	2 ^{308,350}	2,371	0.4/1.4	0.30 (0.08; 1.20)	-0.02 (-0.05; 0.01)			0.26 (0.06; 0.90)	Low
ALT above ULN/ Abnormal elevation in alanine aminotransferase	2 ^{308,350}	2,371	7.4/5.4	1.37 (1.00; 1.87)	0.02 (0.00; 0.03)			1.38 (0.55; 3.34)	Low
AST above ULN/ Abnormal elevation in aspartate aminotransferase	2 ^{308,350}	2,371	5.3/4.0	1.06 (0.43; 2.64)	0.00 (-0.03; 0.04)			1.06 (0.28; 2.76)	Low
Anorexia	3 ^{308,350,377}	2,636	4.3/0.2	18.10 (5.66; 57.85)	0.04 (0.02; 0.06)	24 (17; 42)	41 (24; 58)	36.13 (9.10; 233.30)	Moderate
Anorgasmia	2 ^{308,380}	2,219	1.6/0.0	17.38 (2.31; 130.72)	0.02 (0.00; 0.03)	59 (31; 333)	17 (3; 32)		Low
Anxiety	3 ^{308,327,380}	2,670	2.4/0.7	3.21 (1.55; 6.66)	0.02 (0.01; 0.03)	53 (29; 200)	19 (5; 34)	4.11 (1.65; 11.50)	High
Appetite decreased	5 ^{229,308,327,336,380}	3,379	2.8/0.3	7.54 (3.21; 17.68)	0.02 (0.02; 0.03)	43 (32; 67)	23 (15; 31)	11.44 (4.43; 35.72)	High
Asthenia	4 ^{244,289,308,336}	4,993	1.7/0.3	5.03 (2.35; 10.75)	0.01 (0.00; 0.02)	77 (42; 333)	13 (3; 24)	7.47 (2.90; 23.90)	Moderate
Constipation	13 ^{229,244,248,275,289,308,327,336,350,354,377,380,411}	8,772	10.3/2.4	4.01 (3.26; 4.93)	0.08 (0.06; 0.09)	13 (11; 16)	78 (64; 91)	4.67 (3.55; 6.17)	High
Diarrhea	6 ^{248,275,308,327,354,380}	3,887	5.3/2.9	1.91 (1.38; 2.65)	0.02 (0.00; 0.04)			1.80 (1.01; 2.95)	Moderate
Dizziness	13 ^{229,244,245,248,275,289,308,327,336,350,354,377,411}	8,575	8.6/2.5	3.33 (2.69; 4.11)	0.07 (0.05; 0.08)	15 (12; 20)	67 (49; 84)	3.80 (2.89; 5.06)	High
Dry mouth	14 ^{229,244,245,248,275,289,308,327,336,350,354,377,380,411}	8,881	12.2/2.3	6.26 (4.22; 9.28)	0.12 (0.09; 0.14)	9 (7; 11)	115 (89; 141)	6.94 (5.07; 9.76)	High
Fatigue	12 ^{229,244,245,275,308,327,336,350,354,377,380,411}	8,424	10.0/3.0	3.22 (2.66; 3.90)	0.08 (0.05; 0.1)	13 (10; 19)	77 (53; 100)	3.60 (2.75; 4.73)	High

Appendix Table F41. Adverse effects after duloxetine treatments compared to placebo (pooled results from RCTs) (continued)

Outcome	Studies	Patients	Rate active/control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Bayesian odds ratio median (2.5; 97.5%)	Evidence
Headache	10 ^{244,245,248,275,308,327,350,354,380,411}	7,706	9.3/5.9	1.58 (1.35; 1.86)	0.03 (0.02; 0.05)	30 (22; 50)	33 (20; 46)	1.67 (1.28; 2.21)	High
Hyperhidrosis	7 ^{244,289,308,327,336,350,377}	23,788	2.4/0.6	4.34 (3.29; 5.73)	0.04 (0.02; 0.05)	29 (20; 48)	35 (21; 49)	6.02 (3.85; 10.53)	High
Insomnia	12 ^{229,244,245,248,275,289,308,327,350,354,380,411}	8,495	9.3/2.3	3.76 (2.59; 5.47)	0.08 (0.05; 0.11)	13 (10; 21)	76 (47; 105)	4.35 (3.01; 6.26)	High
Nausea	14 ^{229,244,245,248,275,289,308,327,336,350,354,377,380,411}	8,881	22.7/5.4	5.02 (3.70; 6.82)	0.19 (0.15; 0.22)	5 (4; 7)	187 (149; 224)	6.25 (4.66; 8.50)	High
Somnolence	13 ^{229,244,245,248,275,289,308,327,336,350,377,380,411}	8,603	5.4/0.6	8.61 (4.58; 16.20)	0.06 (0.04; 0.08)	17 (13; 26)	59 (39; 80)	11.84 (6.99; 21.58)	High
Treatment associated adverse effects	9 ^{244,245,275,327,336,350,377,380,411}	5,646	62.7/45.4	1.36 (1.28; 1.44)	0.19 (0.15; 0.22)	5 (4; 7)	187 (150; 224)	2.53 (1.95; 3.44)	High
Vomiting	7 ^{244,245,308,327,350,380,411}	6,489	5.0/1.7	2.90 (2.14; 3.93)	0.03 (0.02; 0.04)	32 (26; 45)	31 (22; 39)	3.21 (2.16; 4.95)	High
Adverse effects	2 ^{229,380}	894	2.4/1.4	1.95 (0.34; 11.22)	0.01 (-0.02; 0.05)			1.94 (0.54; 8.21)	Low

Appendix Table F42. Outcomes after different doses of duloxetine

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Any TEAE mild	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg BID for 6 weeks	49/136	51/133	0.94 (0.69; 1.28)	-0.02 (-0.14; 0.09)		
Any TEAE mild	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	49/136	65/127	0.70 (0.53; 0.93)	-0.15 (-0.27; -0.03)	-7 (-30; -4)	-152 (-270; -33)
At least one adverse event	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	62/138	68/137	0.91 (0.70; 1.16)	-0.05 (-0.16; 0.07)		
At least one adverse event	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	62/138	73/140	0.86 (0.68; 1.10)	-0.07 (-0.19; 0.05)		
At least one adverse event	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	68/137	73/140	0.95 (0.76; 1.20)	-0.03 (-0.14; 0.09)		
Constipation	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	4/138	4/137	0.99 (0.25; 3.89)	0.00 (-0.04; 0.04)		
Constipation	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	4/138	6/140	0.68 (0.20; 2.34)	-0.01 (-0.06; 0.03)		
Constipation	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	4/137	6/140	0.68 (0.20; 2.36)	-0.01 (-0.06; 0.03)		
Constipation	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg BID for 6 weeks	16/136	18/133	0.87 (0.46; 1.63)	-0.02 (-0.10; 0.06)		
Constipation	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	16/136	6/127	2.49 (1.01; 6.17)	0.07 (0.00; 0.14)	14 (7; 205)	70 (5; 136)

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Constipation	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	6/127	18/133	0.35 (0.14; 0.85)	-0.09 (-0.16; -0.02)	-11 (-52; -6)	-88 (-157; -19)
Constipation	Gahimer, 2007 ²⁸⁷ 15,178	20-60mg/day vs. 20-120mg once/twice a day	48/826	1149/14352	0.73 (0.55; 0.96)	-0.02 (-0.04; -0.01)	-46 (-186; -26)	-21 (-39; -5)
Diarrhea	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	5/138	4/137	1.24 (0.34; 4.52)	0.01 (-0.03; 0.05)		
Diarrhea	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	5/138	4/140	1.27 (0.35; 4.62)	0.01 (-0.03; 0.05)		
Diarrhea	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	4/137	4/140	1.02 (0.26; 4.00)	0.00 (-0.04; 0.04)		
Diarrhea	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	1/136	0/133	2.93 (0.12; 71.39)	0.01 (-0.01; 0.03)		
Diarrhea	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	1/136	4/127	0.23 (0.03; 2.06)	-0.02 (-0.06; 0.01)		
Diarrhea	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	4/127	0/133	9.42 (0.51; 173.25)	0.03 (0.00; 0.07)		
Diarrhea	Gahimer, 2007 ²⁸⁷ 15178	20-60mg/day vs. 20-120mg once/twice a day	11/826	502/14352	0.38 (0.21; 0.69)	-0.02 (-0.03; -0.01)	-46 (-75; -33)	-22 (-30; -13)
Dizziness	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	2/138	6/137	0.33 (0.07; 1.61)	-0.03 (-0.07; 0.01)		
Dizziness	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	2/138	7/140	0.29 (0.06; 1.37)	-0.04 (-0.08; 0.01)		
Dizziness	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	6/137	7/140	0.88 (0.30; 2.54)	-0.01 (-0.06; 0.04)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Dizziness	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	14/136	4/133	3.42 (1.16; 10.13)	0.07 (0.01; 0.13)	14 (8; 71)	73 (14; 132)
Dizziness	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg BID for 6 weeks	14/136	10/127	1.31 (0.60; 2.84)	0.02 (-0.05; 0.09)		
Dizziness	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	10/127	4/133	2.62 (0.84; 8.14)	0.05 (-0.01; 0.10)		
Dizziness	Gahimer, 2007 ²⁸⁷ 15,178	20-60mg/day vs. 20-120mg once/twice a day	31/826	852/14,352	0.63 (0.44; 0.90)	-0.02 (-0.04; -0.01)	-46 (-120; -28)	-22 (-35; -8)
Dry mouth	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	4/138	5/137	0.79 (0.22; 2.89)	-0.01 (-0.05; 0.03)		
Dry mouth	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	4/138	7/140	0.58 (0.17; 1.94)	-0.02 (-0.07; 0.02)		
Dry mouth	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	5/137	7/140	0.73 (0.24; 2.24)	-0.01 (-0.06; 0.03)		
Dry mouth	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	22/136	19/133	1.13 (0.64; 1.99)	0.02 (-0.07; 0.10)		
Dry mouth	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	22/136	15/127	1.37 (0.74; 2.52)	0.04 (-0.04; 0.13)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Dry mouth	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	15/127	19/133	0.83 (0.44; 1.56)	-0.02 (-0.11; 0.06)		
Dry mouth	Gahimer, 2007 ²⁸⁷ 15,178	20-60mg/day vs. 20-120mg once/twice a day	63/826	1559/14,352	0.70 (0.55; 0.89)	-0.03 (-0.05; -0.01)	-31 (-74; -20)	-32 (-51; -14)
Fatigue	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	1/138	8/137	0.12 (0.02; 0.98)	-0.05 (-0.09; -0.01)	-20 (-106; -11)	-51 (-93; -9)
Fatigue	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	1/138	10/140	0.10 (0.01; 0.78)	-0.06 (-0.11; -0.02)	-16 (-52; -9)	-64 (-109; -19)
Fatigue	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	8/137	10/140	0.82 (0.33; 2.01)	-0.01 (-0.07; 0.04)		
Fatigue	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	12/136	8/133	1.47 (0.62; 3.47)	0.03 (-0.03; 0.09)		
Fatigue	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg BID for 6 weeks	12/136	6/127	1.87 (0.72; 4.83)	0.04 (-0.02; 0.10)		
Fatigue	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg BID for 2 weeks escalating to 40mg b.i.d. for 6 weeks	6/127	8/133	0.79 (0.28; 2.20)	-0.01 (-0.07; 0.04)		
Fatigue	Gahimer, 2007 ²⁸⁷ 15,178	20-60mg/day vs. 20-120mg once/twice a day	41/826	1102/14,352	0.65 (0.48; 0.88)	-0.03 (-0.04; -0.01)	-37 (-85; -24)	-27 (-43; -12)
Headache	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	7/138	10/137	0.69 (0.27; 1.77)	-0.02 (-0.08; 0.03)		
Headache	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	7/138	8/140	0.89 (0.33; 2.38)	-0.01 (-0.06; 0.05)		
Headache	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	10/137	8/140	1.28 (0.52; 3.14)	0.02 (-0.04; 0.07)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Headache	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	11/136	9/133	1.20 (0.51; 2.79)	0.01 (-0.05; 0.08)		
Headache	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	11/136	11/127	0.93 (0.42; 2.08)	-0.01 (-0.07; 0.06)		
Headache	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	11/127	9/133	1.28 (0.55; 2.98)	0.02 (-0.05; 0.08)		
Headache	Gahimer, 2007 ²⁸⁷ 15,178	20-60mg/day vs. 20-120mg once/twice a day	68/826	1029/14352	1.15 (0.91; 1.45)	0.01 (-0.01; 0.03)		
Hyperhidrosis	Gahimer, 2007 ²⁸⁷ 15,178	20-60mg/day vs. 20-120mg once/twice a day	54/826	549/14352	1.71 (1.30; 2.24)	0.03 (0.01; 0.04)	37 (23; 100)	27 (10; 44)
Insomnia	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	2/138	7/137	0.28 (0.06; 1.34)	-0.04 (-0.08; 0.01)		
Insomnia	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	2/138	7/140	0.29 (0.06; 1.37)	-0.04 (-0.08; 0.01)		
Insomnia	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	7/137	7/140	1.02 (0.37; 2.84)	0.00 (-0.05; 0.05)		
Insomnia	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	14/136	8/133	1.71 (0.74; 3.94)	0.04 (-0.02; 0.11)		
Insomnia	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg BID for 6 weeks	14/136	6/127	2.18 (0.86; 5.50)	0.06 (-0.01; 0.12)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Insomnia	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	6/127	8/133	0.79 (0.28; 2.20)	-0.01 (-0.07; 0.04)		
Insomnia	Gahimer, 2007 ²⁸⁷ 15,178	20-60mg/day vs. 20-120mg once/twice a day	59/826	1179/14352	0.87 (0.68; 1.12)	-0.01 (-0.03; 0.01)		
Nasopharyngitis	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	8/138	4/137	1.99 (0.61; 6.44)	0.03 (-0.02; 0.08)		
Nasopharyngitis	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	8/138	6/140	1.35 (0.48; 3.80)	0.02 (-0.04; 0.07)		
Nasopharyngitis	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	4/137	6/140	0.68 (0.20; 2.36)	-0.01 (-0.06; 0.03)		
Nausea	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	9/138	9/137	0.99 (0.41; 2.43)	0.00 (-0.06; 0.06)		
Nausea	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	9/138	13/140	0.70 (0.31; 1.59)	-0.03 (-0.09; 0.04)		
Nausea	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	9/137	13/140	0.71 (0.31; 1.60)	-0.03 (-0.09; 0.04)		
Nausea	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	40/136	22/133	1.78 (1.12; 2.82)	0.13 (0.03; 0.23)	8 (4; 34)	129 (30; 228)
Nausea	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	40/136	32/127	1.17 (0.78; 1.74)	0.04 (-0.07; 0.15)		
Nausea	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	32/127	22/133	1.52 (0.94; 2.47)	0.09 (-0.01; 0.18)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Nausea	Gahimer, 2007 ²⁸⁷ 15,178	20-60mg/day vs. 20-120mg once/twice a day	19/826	2204/14352	0.15 (0.10; 0.23)	-0.13 (-0.14; -0.12)	-8 (-8; -7)	-131 (-142; -119)
Nausea mild	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	56/136	78/133	0.70 (0.55; 0.90)	-0.17 (-0.29; -0.06)	-6 (-18; -3)	-175 (-292; -57)
Nausea mild	Castro-Diaz, 2007 ²⁴⁸ 264	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	56/136	64/127	0.82 (0.63; 1.07)	-0.09 (-0.21; 0.03)		
Nausea moderate	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	48/127	43/133	1.17 (0.84; 1.63)	0.05 (-0.06; 0.17)		
Nausea severe	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	14/136	12/133	1.14 (0.55; 2.37)	0.01 (-0.06; 0.08)		
Nausea severe	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	14/136	15/127	0.87 (0.44; 1.73)	-0.02 (-0.09; 0.06)		
Nausea severe	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	15/127	12/133	1.31 (0.64; 2.69)	0.03 (-0.05; 0.10)		
Sinusitis	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	4/138	4/137	0.99 (0.25; 3.89)	0.00 (-0.04; 0.04)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Sinusitis	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	4/138	4/140	1.01 (0.26; 3.98)	0.00 (-0.04; 0.04)		
Sinusitis	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	4/137	4/140	1.02 (0.26; 4.00)	0.00 (-0.04; 0.04)		
Somnolence	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	15/136	11/133	1.33 (0.64; 2.80)	0.03 (-0.04; 0.10)		
Somnolence	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	15/136	6/127	2.33 (0.93; 5.83)	0.06 (0.00; 0.13)		
Somnolence	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	6/127	11/133	0.57 (0.22; 1.50)	-0.04 (-0.10; 0.02)		
Somnolence	Gahimer, 2007 ²⁸⁷ 15,178	20-60mg/day vs. 20-120mg once/twice a day	60/826	990/14352	1.05 (0.82; 1.35)	0.00 (-0.01; 0.02)		
TEAE moderate	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	65/136	64/133	0.99 (0.77; 1.27)	0.00 (-0.12; 0.12)		
TEAE moderate	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	42/127	64/133	0.69 (0.51; 0.93)	-0.15 (-0.27; -0.03)	-7 (-31; -4)	-151 (-268; -33)
TEAE severe	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	20/136	19/133	1.03 (0.58; 1.84)	0.00 (-0.08; 0.09)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
TEAE severe	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	20/136	20/127	0.93 (0.53; 1.65)	-0.01 (-0.10; 0.08)		
TEAE severe	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. D for 2 weeks escalating to 40mg b.i.d. for 6 weeks	20/127	19/133	1.10 (0.62; 1.97)	0.01 (-0.07; 0.10)		
Upper respiratory tract infection	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	2/138	2/137	0.99 (0.14; 6.95)	0.00 (-0.03; 0.03)		
Upper respiratory tract infection	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	2/138	1/140	2.03 (0.19; 22.12)	0.01 (-0.02; 0.03)		
Upper respiratory tract infection	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	2/137	1/140	2.04 (0.19; 22.28)	0.01 (-0.02; 0.03)		
Adverse effects leading to discontinuation	Duckett, 2007 ²⁸¹ 215	60mg/day vs. 40mg twice daily	21/67	74/148	0.63 (0.42; 0.93)	-0.19 (-0.32; -0.05)	-5 (-20; -3)	-187 (-324; -49)
Discontinuation due to any adverse event	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	22/136	10/133	2.15 (1.06; 4.37)	0.09 (0.01; 0.16)	12 (6; 98)	87 (10; 163)
Discontinuation due to any adverse event	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	22/136	15/127	1.37 (0.74; 2.52)	0.04 (-0.04; 0.13)		
Discontinuation due to any adverse event	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	15/127	10/133	1.57 (0.73; 3.37)	0.04 (-0.03; 0.11)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Discontinuation due to asthenia	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	2/136	1/133	1.96 (0.18; 21.31)	0.01 (-0.02; 0.03)		
Discontinuation due to asthenia	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	2/136	0/127	4.67 (0.23; 96.38)	0.01 (-0.01; 0.04)		
Discontinuation due to asthenia	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	0/127	1/133	0.35 (0.01; 8.49)	-0.01 (-0.03; 0.01)		
Discontinuation	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	13/138	17/137	0.76 (0.38; 1.50)	-0.03 (-0.10; 0.04)		
Discontinuation	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	13/138	21/140	0.63 (0.33; 1.20)	-0.06 (-0.13; 0.02)		
Discontinuation	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	17/137	21/140	0.83 (0.46; 1.50)	-0.03 (-0.11; 0.05)		
Discontinuation due to dizziness	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	0/138	2/137	0.20 (0.01; 4.10)	-0.01 (-0.04; 0.01)		
Discontinuation due to dizziness	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	0/138	1/140	0.34 (0.01; 8.23)	-0.01 (-0.03; 0.01)		
Discontinuation due to dizziness	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	2/137	1/140	2.04 (0.19; 22.28)	0.01 (-0.02; 0.03)		
Discontinuation due to dizziness	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	2/136	0/133	4.89 (0.24; 100.92)	0.01 (-0.01; 0.04)		
Discontinuation due to dizziness	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	2/136	2/127	0.93 (0.13; 6.53)	0.00 (-0.03; 0.03)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Discontinuation due to dizziness	Castro-Diaz, 2007 ²⁴⁸	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	2/127	0/133	5.23 (0.25; 107.98)	0.02 (-0.01; 0.04)		
Discontinuation due to fatigue	Castro-Diaz, 2007 ²⁴⁸	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	0/136	0/133	0.00 (0.00; 0.00)	0.00 (-0.01; 0.01)		
Discontinuation due to fatigue	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. D for 6 weeks	0/136	1/127	0.31 (0.01; 7.58)	-0.01 (-0.03; 0.01)		
Discontinuation due to fatigue	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	1/127	0/133	3.14 (0.13; 76.39)	0.01 (-0.01; 0.03)		
Discontinuation due to headache	Castro-Diaz, 2007 ²⁴⁸ 275	20mg/day vs. 40mg/d	1/138	1/137	0.99 (0.06; 15.71)	0.00 (-0.02; 0.02)		
Discontinuation due to headache	Castro-Diaz, 2007 ²⁴⁸ 278	20mg/day vs. 80mg/d	1/138	2/140	0.51 (0.05; 5.53)	-0.01 (-0.03; 0.02)		
Discontinuation due to headache	Castro-Diaz, 2007 ²⁴⁸ 277	40mg/day vs. 80mg/d	1/137	2/140	0.51 (0.05; 5.57)	-0.01 (-0.03; 0.02)		
Discontinuation due to headache	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	3/136	0/133	6.85 (0.36; 131.29)	0.02 (-0.01; 0.05)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Discontinuation due to headache	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	3/136	1/127	2.80 (0.30; 26.59)	0.01 (-0.01; 0.04)		
Discontinuation due to headache	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. D for 6 weeks	1/127	0/133	3.14 (0.13; 76.39)	0.01 (-0.01; 0.03)		
Discontinuation due to insomnia	Castro-Diaz, 2007 ²⁴⁸ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. for 6 weeks	2/136	1/133	1.96 (0.18; 21.31)	0.01 (-0.02; 0.03)		
Discontinuation due to insomnia	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	2/136	1/127	1.87 (0.17; 20.35)	0.01 (-0.02; 0.03)		
Discontinuation due to insomnia	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. D for 6 weeks	1/127	1/133	1.05 (0.07; 16.56)	0.00 (-0.02; 0.02)		
Discontinuation due to menorrhagia	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	2/138	0/137	4.96 (0.24; 102.46)	0.01 (-0.01; 0.04)		
Discontinuation due to menorrhagia	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	2/138	0/140	5.07 (0.25; 104.69)	0.01 (-0.01; 0.04)		
Discontinuation due to menorhagia	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	0/137	0/140		0.00 (-0.01; 0.01)		
Discontinuation due to nausea	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	2/138	5/137	0.40 (0.08; 2.01)	-0.02 (-0.06; 0.02)		

Appendix Table F42. Outcomes after different doses of duloxetine (continued)

Outcome	Reference sample size	Daily dose mg/day	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Discontinuation due to nausea	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	2/138	6/140	0.34 (0.07; 1.65)	-0.03 (-0.07; 0.01)		
Discontinuation due to nausea	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	5/137	6/140	0.85 (0.27; 2.73)	-0.01 (-0.05; 0.04)		
Discontinuation due to nausea	Norton, 2002 ³⁵⁴ 269	80mg/day vs. 20mg b.i.d. for 2 weeks escalating to 40mg b.i.d. D for 6 weeks	4/136	3/133	1.30 (0.30; 5.72)	0.01 (-0.03; 0.04)		
Discontinuation due to nausea	Castro-Diaz, 2007 ²⁴⁸ 263	80mg/day vs. 40mg QD for 2 weeks escalating to 40mg b.i.d. for 6 weeks	4/136	2/127	1.87 (0.35; 10.02)	0.01 (-0.02; 0.05)		
Discontinuation due to nausea	Castro-Diaz, 2007 ²⁴⁸ 260	100mg/day vs. 20mg b.i.d. D for 2 weeks escalating to 40mg b.i.d. for 6 weeks	2/127	3/133	0.70 (0.12; 4.11)	-0.01 (-0.04; 0.03)		
Discontinuation due to somnolence	Norton, 2002 ³⁵⁴ 275	20mg/day vs. 40mg/d	1/138	0/137	2.98 (0.12; 72.48)	0.01 (-0.01; 0.03)		
Discontinuation due to somnolence	Norton, 2002 ³⁵⁴ 278	20mg/day vs. 80mg/d	1/138	2/140	0.51 (0.05; 5.53)	-0.01 (-0.03; 0.02)		
Discontinuation due to somnolence	Norton, 2002 ³⁵⁴ 277	40mg/day vs. 80mg/d	0/137	2/140	0.20 (0.01; 4.22)	-0.01 (-0.04; 0.01)		
Discontinuation due to lack of efficacy leading to discontinuation	Duckett, 2007 ²⁸¹ 215	60mg/day vs. 40mg twice daily	14/67	37/148	0.84 (0.49; 1.44)	-0.04 (-0.16; 0.08)		

Appendix Table F43. Adverse effects that result in discontinuation of treatment after duloxetine vs. placebo (random effects models)

Reference	Active events/ randomized	Control events/ randomized	Relative risk	Lower (95% CI)	Upper (95% CI)	Weight	Absolute risk difference	Lower (95% CI)	Upper (95% CI)	Weight
Anxiety										
	6/958	0/955	9.158	0.496	169.125	49.29	0.018	-0.001	0.037	16.45
	4/227	0/231	12.959	0.731	229.72	50.71	0.006	0.001	0.012	83.55
Pooled estimate			10.921	1.41	84.603	100	0.008	0	0.016	100
I squared			0.00%				21.20%			
p value for heterogeneity			0.868				0.26			
Asthenia										
	1/60	0/61	2.8	0.115	67.922	23.69	0.01	-0.017	0.036	12.41
	2/136	0/120	4.416	0.214	91.081	26.3	0.015	-0.01	0.04	14
	2/300	0/288	3.049	0.127	73.398	23.81	0.017	-0.028	0.061	4.42
	1/104	0/97	4.801	0.231	99.566	26.2	0.007	-0.005	0.018	69.18
Pooled estimate			3.71	0.786	17.516	100	0.009	-0.001	0.018	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.994				0.926			
Constipation										
Hurley, 2006308	1/955	1/955	0.311	0.013	7.547	37.16	-0.01	-0.038	0.017	2.14
Constipation-discontinuation due to adverse event										
Ghoniem, 2005289	1/97	1/97	2.991	0.312	28.699	62.84	0.002	-0.002	0.006	97.86
Pooled estimate			1.29	0.151	11.001	100	0.002	-0.002	0.006	100
I squared			22.30%				0.00%			
p value for heterogeneity			0.257				0.385			
Dizziness										
Ghoniem, 2005289	2/104	0/97	4.667	0.227	95.996	6.33	0.019	-0.013	0.052	3.74
Millard, 2004350	5/227	0/231	11.193	0.623	201.255	6.93	0.022	0.001	0.043	9.08
Hurley, 2006308	20/958	2/955	9.969	2.337	42.531	27.48	0.019	0.009	0.028	43.41
van Kerrebroeck, 2004411	9/247	1/247	9	1.149	70.504	13.65	0.032	0.008	0.057	6.45
Norton, 2002354	1/140	0/138	2.957	0.122	71.977	5.68	0.007	-0.012	0.027	10.17
Castro-Diaz, 2007248	2/136	0/120	4.416	0.214	91.081	6.32	0.015	-0.01	0.04	6.2
Lin, 2008336	4/60	2/61	2.033	0.387	10.689	21	0.034	-0.043	0.111	0.66
Dmochowski, 2003275	5/344	1/339	4.927	0.579	41.954	12.61	0.012	-0.002	0.025	20.3
Pooled estimate			5.487	2.564	11.739	100	0.017	0.011	0.023	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.914				0.821			
Fatigue										

Appendix Table F43. Adverse effects that result in discontinuation of treatment after duloxetine vs. placebo (random effects models) (continued)

Reference	Active events/ randomized	Control events/ randomized	Relative risk	Lower (95% CI)	Upper (95% CI)	Weight	Absolute risk difference	Lower (95% CI)	Upper (95% CI)	Weight
Hurley, 2006 ³⁰⁸	13/958	2/955	6.48	1.466	28.636	37.22	0.011	0.004	0.019	41.12
Castro-Diaz, 2007 ²⁴⁸	0/136	2/120	0.177	0.009	3.643	17.1	-0.017	-0.044	0.011	11.54
Bent, 2008 ²²⁹	4/300	0/288	8.869	1.13	69.624	27.67	0.023	0.005	0.041	20.97
Dmochowski, 2003 ²⁷⁵	9/344	1/339	8.641	0.467	159.784	18.01	0.013	-0.001	0.028	26.37
Pooled estimate			4.021	0.913	17.71	100	0.011	0.001	0.022	100
I squared			42.60%				48.30%			
p value for heterogeneity			0.156				0.121			
Insomnia										
Hurley, 2006 ³⁰⁸	16/958	2/955	10.267	0.575	183.248	8.47	0.048	0.003	0.093	1.91
van Kerrebroeck, 2004 ⁴¹¹	5/247	1/247	7.123	0.37	137.119	8.05	0.013	-0.004	0.03	13.25
Castro-Diaz, 2007 ²⁴⁸	2/136	1/120	7.975	1.839	34.589	32.69	0.015	0.006	0.023	51.81
Lin, 2008 ³³⁶	1/60	0/61	5	0.588	42.488	15.37	0.016	-0.003	0.035	10.37
Dmochowski, 2003 ²⁷⁵	7/344	1/339	1.765	0.162	19.218	12.34	0.006	-0.02	0.032	5.71
Ghoniem, 2005 ²⁸⁹	5/104	0/97	3.049	0.127	73.398	6.96	0.017	-0.028	0.061	1.92
Millard, 2004 ³⁵⁰	3/227	0/231	6.898	0.853	55.767	16.11	0.017	0.001	0.033	15.03
Pooled estimate			5.7	2.463	13.189	100	0.015	0.009	0.021	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.959				0.85			
Nausea										
Ghoniem, 2005 ²⁸⁹	7/104	0/97	14	0.81	241.894	5.74	0.067	0.016	0.119	3.31
Millard, 2004 ³⁵⁰	7/227	0/231	15.263	0.877	265.685	5.71	0.031	0.007	0.055	12.96
Hurley, 2006 ³⁰⁸	48/958	3/955	15.95	4.985	51.03	34.44	0.047	0.033	0.061	27.18
van Kerrebroeck, 2004 ⁴¹¹	13/247	2/247	6.5	1.482	28.503	21.32	0.045	0.015	0.075	8.83
Norton, 2002 ³⁵⁴	6/140	1/138	5.914	0.721	48.486	10.52	0.036	-0.001	0.072	6.26
Castro-Diaz, 2007 ²⁴⁸	4/136	0/120	7.949	0.432	146.134	5.5	0.029	-0.003	0.061	7.91
Lin, 2008 ³³⁶	2/60	0/61	5.082	0.249	103.691	5.12	0.033	-0.021	0.088	2.94
Dmochowski, 2003 ²⁷⁵	22/344	0/339	44.348	2.701	728.141	5.95	0.064	0.038	0.09	11.02
Bent, 2008 ²²⁹	7/300	0/288	14.402	0.826	251.018	5.7	0.023	0.005	0.042	19.61
Pooled estimate			11.267	5.693	22.295	100	0.04	0.031	0.05	100
I squared			0.00%				16.40%			
p value for heterogeneity			0.958				0.297			
Somnolence										
Norton, 2002 ³⁵⁴	2/140	0/138	4.667	0.227	95.996	12.04	0.019	-0.013	0.052	2.74
Bent, 2008 ²²⁹	3/300	0/288	9.969	1.279	77.721	26.09	0.009	0.003	0.016	63.07
Lin, 2008 ³³⁶	2/60	0/61	4.929	0.239	101.744	12.01	0.014	-0.01	0.038	5.02

Reference	Active events/ randomized	Control events/ randomized	Relative risk	Lower (95% CI)	Upper (95% CI)	Weight	Absolute risk difference	Lower (95% CI)	Upper (95% CI)	Weight
Dmochowski, 2003 ²⁷⁵	7/344	1/339	5.082	0.249	103.691	12.1	0.033	-0.021	0.088	0.97
Hurley, 2006 ³⁰⁸	10/958	1/955	6.898	0.853	55.767	25.19	0.017	0.001	0.033	11.24
Ghoniem, 2005 ²⁸⁹	2/104	0/97	6.721	0.349	129.543	12.57	0.01	-0.003	0.023	16.96
Pooled estimate			6.684	2.341	19.081	100	0.011	0.006	0.017	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.998				0.874			
Any adverse event										
Millard, 2004 ³⁵⁰	39/227	4/231	9.922	3.604	27.312	9.98	0.154	0.103	0.206	11.06
Cardozo, 2004 ²⁴⁵	18/55	3/54	5.891	1.841	18.851	9.37	0.272	0.133	0.41	7.66
Castro-Diaz, 2007 ²⁴⁸	22/136	7/120	5	0.241	103.616	3.8	0.008	-0.006	0.022	11.87
Bent, 2008 ²²⁹	47/300	9/288	2.957	1.299	6.731	10.72	0.099	0.03	0.169	10.45
Norton, 2002 ³⁵⁴	21/140	7/138	2.773	1.228	6.261	10.75	0.103	0.029	0.178	10.26
Lin, 2008 ³³⁶	16/60	4/61	4.067	1.443	11.46	9.88	0.201	0.073	0.329	8.07
Schagen van Leeuwen, 2008 ³⁷⁷	15/131	7/134	2.192	0.924	5.202	10.56	0.062	-0.004	0.129	10.57
Dmochowski, 2003 ²⁷⁵	83/344	14/339	5.842	3.384	10.086	11.66	0.2	0.15	0.25	11.12
Duckett, 2007 ²⁸¹	21/67	74/148	0.627	0.425	0.925	12.08	-0.187	-0.324	-0.049	7.7
van Kerrebroeck, 2004 ⁴¹¹	2/247	0/247	5.013	2.503	10.041	11.19	0.125	0.08	0.171	11.24
Pooled estimate			3.434	1.691	6.974	100	0.105	0.041	0.169	100
I squared			87.40%				92.80%			
p value for heterogeneity			0.00%				0.00%			
Diarrhea										
Bent, 2008 ²²⁹	3/300	1/288	1.994	0.181	21.951	46.97	0.001	-0.003	0.005	93.23
Hurley, 2006 ³⁰⁸	2/958	1/955	2.88	0.301	27.527	53.03	0.007	-0.007	0.02	6.77
Pooled estimate			2.423	0.468	12.541	100	0.001	-0.002	0.005	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.827				0.43			
Headache										
Norton, 2002 ³⁵⁴	3/136	1/120	4.929	0.239	101.744	25.72	0.014	-0.01	0.038	22.85
Castro-Diaz, 2007 ²⁴⁸	4/300	0/288	2.647	0.279	25.11	46.58	0.014	-0.016	0.043	15
Bent, 2008 ²²⁹	3/136	1/120	8.641	0.467	159.784	27.7	0.013	-0.001	0.028	62.15
Pooled estimate			4.311	0.928	20.016	100	0.014	0.002	0.025	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.816				0.998			

Appendix Table F44. Exploring clinical diversity in discontinuation rates due to adverse effects after duloxetine compared to placebo

Reference	Country	Weeks of treatment	Age	Prior treatment	Concurrent medication	% Women	Inclusion of women with surgical risk factors for UI	Inclusion of those who failed prior treatments	Inclusion of minorities	Presence of mixed UI	Daily UI
Millard, 2004 ³⁵⁰	Poland, South Africa, Australia, Brazil, Argentina and Finland	12	53.7-52.6	Previous continence surgery including injections, 18.5% in active and 17.3% in control group	No response	100	No response	No response	Yes	No response	Yes
Cardozo, 2004 ²⁴⁵	Australia, Canada, the Netherlands, and the United Kingdom	8	54.5-52.4	Prior continence surgery in 16.4% duloxetine and 14.8% placebo women	Hormone replacement therapy in 47.3% duloxetine and 40.7% placebo group	100	No response	No response	Yes	No response	Yes
Castro-Diaz, 2007 ²⁴⁸	64 study centers in 8 countries	8	52.7-53.3	No response	No response	100	No response	No response	No response	No response	Yes
Bent, 2008 ²²⁹	U.S.	8	53.2-54.2	Antimuscarinic agents (either tolterodine or oxybutynin) were used by 7.8% of subjects	Antidepressant medications, including other SNRIs and selective serotonin reuptake inhibitors: 19.4% in placebo and 23.0% in active group	100	No	No	Yes	Yes	Yes
Norton, 2002 ³⁵⁴	U.S.	12	49.3-53.2	No response	No response	100	No	No response	Yes	No response	Yes
Lin, 2008 ³³⁶	Taiwan	8	53-56	Previous surgery had 3 women in duloxetine and 5 in placebo group	Were not permitted	100	No response	No response	No response	No response	Yes

Appendix Table F44. Exploring clinical diversity in discontinuation rates due to adverse effects after duloxetine compared to placebo (continued)

Reference	Country	Weeks of treatment	Age	Prior treatment	Concurrent medication	% Women	Inclusion of women with surgical risk factors for UI	Inclusion of those who failed prior treatments	Inclusion of minorities	Presence of mixed UI	Daily UI
Schagen van Leeuwen, 2008 ³⁷⁷	Germany, France, The Netherlands, Spain, Sweden, Switzerland and South-Africa	12	70.63-71.1	Previous incontinence surgery 15.3% in placebo and 11.9% in duloxetine	Approximately 80% of patients reported concomitant drug therapies before and after randomization. Behavioral therapy 0.8% in placebo and 0.7% in duloxetine; Current PFMT 9.9% in placebo and 9.7% in duloxetine group	100	No	No response	Yes	Yes	Yes
Dmochowski, 2003 ²⁷⁵	Canada and the U.S.	12	52.3-53.3	% prior continence surgery, including injection 12.2% in duloxetine and 13.1% in placebo group % PFMT 16.9% in duloxetine and 18.0% in placebo group	No response	100	No response	No response	Yes	No response	Yes
van Kerrebroeck, 2004 ⁴¹¹	Belgium, Canada, Denmark, France, Germany, The Netherlands, Sweden and the United Kingdom	12	52-54	Prior continence surgery in 7.7% in duloxetine and in 7.7% placebo group	No response	100	No response	No response	Yes	No response	Yes

Appendix Table F45. Exploring heterogeneity in discontinuation rates due to adverse effects after duloxetine compared to placebo (results from meta-regression)

Variable	Coefficient	Standard error	T statistic	P>t	Lower 95% CI	Upper 95% CI
Daily dose	0.01	0.004	1.83	0.11	-0.01	0.02
Constant	-0.49	0.34	-1.47	0.19	-1.69	0.69
Conflict of interest	0.03	0.06	0.52	0.62	-0.17	0.23
Constant	0.08	0.10	0.78	0.46	-0.27	0.42
Adequacy of randomization	0.06	0.06	1.00	0.36	-0.16	0.28
Allocation concealment	0.08	0.07	1.20	0.28	-0.17	0.33
Constant	-0.12	0.18	-0.64	0.55	-0.80	0.57
Presence of mixed UI	-0.04	0.14	-0.26	0.81	-0.70	0.63
Inclusion of minorities	0.00	0.09	0.00	1.00	-0.43	0.43
Presence of those who failed prior treatments	0.06	0.14	0.45	0.68	-0.59	0.71
Presence of women with surgical risk factors for UI	-0.05	0.11	-0.42	0.70	-0.57	0.48
Constant	0.15	0.08	1.90	0.13	-0.21	0.50

Appendix Table F46. Exploring methodological diversity in discontinuation rates due to adverse effects after duloxetine compared to placebo

Reference	Masking	Intention to treat	Allocation concealment	Adequacy of randomization	Justification for sample size	Presence of conflict of interest
Millard, 2004 ³⁵⁰	Double blind	Yes	Adequate	No	Yes	No response
Cardozo, 2004 ²⁴⁵	Double blind	Yes	Adequate	Adequate	Yes	Yes
Castro-Diaz, 2007 ²⁴⁸	Double blind	Yes	Unclear	Adequate	Yes	Yes
Bent, 2008 ²²⁹	Double blind	Yes	Adequate	Adequate	Yes	Yes
Norton, 2002 ³⁵⁴	Double blind	Yes	Adequate	Adequate	Yes	No response
Lin, 2008 ³³⁶	Double blind	Yes	Adequate	No	Yes	Yes
Schagen van Leeuwen, 2008 ³⁷⁷	Double blind	Yes	Unclear	Adequate	Yes	No response
Dmochowski, 2003 ²⁷⁵	Double blind	Yes	Adequate	Adequate	Yes	Yes
van Kerrebroeck, 2004 ⁴¹¹	Double blind	Yes	Adequate	No	Yes	Yes

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs)
Relative risk and absolute risk differences pooled with random effects models, weighs using inverse variance method**

Active Drug	Outcome	Reference Dose	Events/ randomized with drug	Events/ randomized with placebo	Relative risk (95% CI)	Weight, inverse variance	Absolute risk difference (95% CI)	Weight, Inverse variance
Darifenacin	Clinically Important Improvement in UI	Steers, 2005 ⁴³ 11.25	160/268	60/127	1.3 (1.0;1.6)	56.93	0.125 (0.02;0.23)	32.51
Darifenacin	Clinically Important Improvement in UI	Hill, 2006 ⁴² 7.5	28/108	15/109	1.9 (1.1;3.3)	7.67	0.122 (0.02;0.23)	32.43
Darifenacin	Clinically Important Improvement in UI	Chapple, 2007 ²⁵⁵ 7.5	122/266	47/133	1.3 (1.0;1.7)	35.39	0.105 (0.00;0.21)	35.06
Darifenacin	Clinically Important Improvement in UI	Pooled RR (IV)			1.3 (1.1;1.5)	100	0.117 (0.06;0.18)	100.0
Darifenacin	Clinically Important Improvement in UI	P value/I squared			0.422	0	0.961	0
Fesoterodine	Continence	Kaplan, 2010 ³¹⁸ 6	609/963	258/480	1.18 (1.07; 1.30)	54.44	0.095 (0.04; 0.15)	52.89
Fesoterodine	Continence	NCT00444925 ⁵⁶ 6	396/685	138/337	1.41 (1.22; 1.63)	45.56	0.169 (0.10; 0.23)	47.11
Fesoterodine	Continence	Pooled RR (IV)			1.28 (1.07; 1.53)	100	0.130 (0.06; 0.20)	100
Fesoterodine	Continence	P value/I squared			0.038	0.767	0.085	0.663
Fesoterodine	Clinically Important Improvement in UI	Dmochowski, 2010 ⁴⁶⁹ 6	182/438	137/445	1.35 (1.13; 1.61)	48.54	0.108 (0.05; 0.17)	49.96
Fesoterodine	Clinically Important Improvement in UI	Herschorn, 2010 ⁴⁷⁰ 6	293/679	113/334	1.28 (1.07; 1.52)	51.46	0.093 (0.03; 0.16)	50.04
Fesoterodine	Clinically Important Improvement in UI	Pooled RR (IV)			1.3 (1.2;1.5)	100	0.10 (0.06;0.15)	100
Fesoterodine	Clinically Important Improvement in UI	P value/I squared			0.655	0	0.75	0
Oxybutynin		Moore, 1990 ³⁵¹ 3	5/28	0/25	9.86 (0.57; 169.86)	0.76	0.179 (0.03; 0.33)	10.58
Oxybutynin	Continence	Staskin, 2009 ³¹ 10	108/389	69/400	1.61 (1.23; 2.10)	86.2	0.105 (0.05; 0.16)	73.07
Oxybutynin	Continence	Lehtoranta, 2002 ³³⁴ 15	4/9	2/9	2.00 (0.48; 8.31)	3.05	0.222 (-0.20; 0.65)	1.37
Oxybutynin	Continence	Burgio, 1998 ²³⁸ 11.5	15/67	8/65	1.82 (0.83; 4.00)	9.98	0.101 (-0.03; 0.23)	14.99
Oxybutynin	Continence	Pooled RR (IV)			1.7 (1.3;2.1)	100	0.11 (0.06;0.16)	100
Oxybutynin	Continence	P value/I squared			0.643	0	0.783	0
Oxybutynin	Clinically Important Improvement in UI	Moore, 1990 ³⁵¹ 3	10/28	1/25	8.93 (1.23; 64.90)	1.1	0.317 (0.12; 0.51)	8.41

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk and absolute risk differences pooled with random effects models, weighs using inverse variance method

Active Drug	Outcome	Reference Dose	Events/ randomized with drug	Events/ randomized with placebo	Relative risk (95% CI)	Weight, inverse variance	Absolute risk difference (95% CI)	Weight, Inverse variance
Oxybutynin	Clinically Important Improvement in UI	Johnson, 2005 ³¹³ 4	4/46	1/38	3.30 (0.39; 28.33)	0.94	0.061 (-0.04; 0.16)	15.35
Oxybutynin	Clinically Important Improvement in UI	Szonyi, 1995 ³⁸² 5	22/28	16/29	1.42 (0.97; 2.08)	15.18	0.234 (0.00; 0.47)	6.49
Oxybutynin	Clinically Important Improvement in UI	Wang, 2006 ⁴¹³ 7.5	2/23	0/21	4.58 (0.23; 90.30)	0.5	0.087 (-0.05; 0.22)	11.98
Oxybutynin	Clinically Important Improvement in UI	Homma, 2003 ³⁰⁷ 9	129/244	31/122	2.10 (1.51; 2.91)	17.44	0.277 (0.18; 0.38)	15.09
Oxybutynin	Clinically Important Improvement in UI	Madersbacher, 1999 ³⁴³ 10	116/145	43/72	1.34 (1.09; 1.65)	23.22	0.203 (0.07; 0.33)	12.48
Oxybutynin	Clinically Important Improvement in UI	Burgio, 1998 ²³⁸ 11.5	37/67	20/65	1.80 (1.18; 2.74)	13.6	0.245 (0.08; 0.41)	10.14
Oxybutynin	Clinically Important Improvement in UI	Thuroff, 1991 ³⁸⁶ 15	26/63	15/52	1.43 (0.85; 2.40)	17.32	0.124 (-0.05; 0.30)	10.51
Oxybutynin	Clinically Important Improvement in UI	Abrams, 1998 ²¹⁹ 15	58/118	27/57	1.04 (0.75; 1.44)	10.7	0.018 (-0.14; 0.18)	9.55
Oxybutynin	Clinically Important Improvement in UI	Pooled RR (IV)			1.5 (1.2;1.9)	100	0.17 (0.10;0.24)	100
Oxybutynin	Clinically Important Improvement in UI	P value/I squared			0.064	0.459	0.02	0.559
Solifenacin	Clinically Important Improvement in UI	Toglia, 2009 ³²¹ 7.5	260/372	206/367	1.25 (1.11; 1.39)	52.27	0.138 (0.07; 0.21)	49.62
Solifenacin	Clinically Important Improvement in UI	Vardy, 2009 ³⁹² 5 to 10	196/386	109/382	1.78 (1.48; 2.15)	47.73	0.222 (0.16; 0.29)	50.38
Solifenacin	Clinically Important Improvement in UI	Pooled RR (IV)			1.48 (1.04; 2.09)	100	0.180 (0.10; 0.26)	100
Solifenacin	Clinically Important Improvement in UI	P value/I squared			0.001	0.903	0.085	0.664
Solifenacin	Continence	Cardozo, 2006 ⁴¹² 5	160/314	266/781	1.50 (1.29; 1.73)	23.09	0.169 (0.10; 0.23)	14.08
Solifenacin	Continence	Staskin, 2006 ³⁷ 5	49/159	122/430	1.53 (1.36; 1.72)	34.95	0.180 (0.13; 0.23)	15.75
Solifenacin	Continence	Karram, 2009 ³²⁰ 7.5	133/372	93/367	1.09 (0.82; 1.43)	6.4	0.024 (-0.06; 0.11)	12.11
Solifenacin	Continence	Cardozo, 2006 ⁴¹² 10	405/778	266/781	1.44 (1.19; 1.73)	14.08	0.123 (0.06; 0.19)	14.32

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk and absolute risk differences pooled with random effects models, weighs using inverse variance method

Active Drug	Outcome	Reference Dose	Events/ randomized with drug	Events/ randomized with placebo	Relative risk (95% CI)	Weight, inverse variance	Absolute risk difference (95% CI)	Weight, Inverse variance
Solifenacin	Continence	Staskin, 2006 ³⁷ 10	184/452	122/430	1.41 (1.13; 1.76)	9.96	0.104 (0.04; 0.17)	13.92
Solifenacin	Continence	Chu, 2009 ²⁶⁴ 10	119/340	80/332	1.32 (0.88; 1.99)	2.95	0.030 (-0.01; 0.07)	16.16
Solifenacin	Continence	Vardy, 2009 ³⁹² 5 to 10	48/386	36/382	1.45 (1.14; 1.85)	8.56	0.109 (0.04; 0.18)	13.66
Solifenacin	Continence	Pooled RR (IV)			1.45 (1.35; 1.56)	100	0.107 (0.06; 0.16)	100
Solifenacin	Continence	P value/I squared			0.496	0	0	0.786
Tolterodine	Continence	Rogers, 2008 ³⁶⁵ 4	115/202	89/211	1.35 (1.11; 1.65)	22.57	0.148 (0.05; 0.24)	17.05
Tolterodine	Continence	Malone-Lee, 2009 ³⁴⁵ 4	41/165	26/142	1.36 (0.88; 2.10)	6.99	0.065 (-0.03; 0.16)	18.14
Tolterodine	Continence	Kaplan, 2010 ³¹⁸ 4	566/974	258/480	1.08 (0.98; 1.19)	39.93	0.044 (-0.01; 0.10)	35.49
Tolterodine	Continence	NCT00444925 ⁵⁶ 6	358/690	138/337	1.27 (1.09; 1.47)	30.52	0.109 (0.05; 0.17)	29.32
Tolterodine	Continence	Pooled RR (IV)			1.21 (1.07; 1.37)	100	0.085 (0.04; 0.13)	100
Tolterodine	Continence	P value/I squared			0.11	0.502	0.209	0.34
Tolterodine	Clinically Important Improvement in UI	Kelleher, 20020 ³²³ 4	294/507	218/508	1.35 (1.19; 1.53)	18.63	0.151 (0.09; 0.21)	14.81
Tolterodine	Clinically Important Improvement in UI	Herschorn, 2008 ^{301,471} 4	156/410	64/207	1.23 (0.97; 1.56)	11.93	0.071 (-0.01; 0.15)	13.12
Tolterodine	Clinically Important Improvement in UI	Sand, 2009 ³⁷⁰ 4	140/227	167/430	1.59 (1.36; 1.86)	16.59	0.228 (0.15; 0.31)	13.15
Tolterodine	Clinically Important Improvement in UI	Rogers, 2009 ³⁶⁴ 4	79/202	58/211	1.42 (1.08; 1.88)	10.09	0.116 (0.03; 0.21)	12.01
Tolterodine	Clinically Important Improvement in UI	Herschorn, 2010 ⁴⁷⁰ 4	256/684	113/334	1.11 (0.93; 1.32)	15.24	0.036 (-0.03; 0.10)	14.67
Tolterodine	Clinically Important Improvement in UI	Kaplan, 2010318 4	654/974	287/480	1.12 (1.03; 1.22)	20.99	0.074 (0.02; 0.13)	15.55
Tolterodine	Clinically Important Improvement in UI	NCT00444925 ⁵⁶ 6	79/690	32/337	1.21 (0.82; 1.78)	6.52	0.020 (-0.02; 0.06)	16.7
Tolterodine	Clinically Important Improvement in UI	Pooled RR (IV)			1.3 (1.1;1.4)	100	0.10 (0.04;0.15)	100
Tolterodine	Clinically Important Improvement in UI	P value/I squared			0.004	0.685	0	0.804

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk and absolute risk differences pooled with random effects models, weighs using inverse variance method

Active Drug	Outcome	Reference Dose	Events/ randomized with drug	Events/ randomized with placebo	Relative risk (95% CI)	Weight, inverse variance	Absolute risk difference (95% CI)	Weight, Inverse variance
Trospium	Continence	Zinner, 2004 ³⁵ 40	55/262	29/261	1.89 (1.25; 2.86)	12.28	0.099 (0.04; 0.16)	23.9
Trospium	Continence	Staskin, 2007 ⁴⁵ 60	61/298	34/303	1.82 (1.24; 2.69)	14.12	0.092 (0.04; 0.15)	27.62
Trospium	Continence	Dmochowski, 2008 ²⁷² 60	95/280	58/284	1.66 (1.25; 2.20)	26.74	0.135 (0.06; 0.21)	17.61
Trospium	Continence	Sand, 2009 ³⁷¹ 60	163/484	103/505	1.65 (1.34; 2.04)	46.86	0.133 (0.08; 0.19)	30.87
Trospium	Continence	Pooled RR (IV)			1.71 (1.47; 1.97)	100	0.114 (0.08; 0.14)	100
Trospium	Continence	P value/I squared			0.925	0	0.675	0
Trospium	Clinically Important Improvement in UI	Staskin, 2004 ³⁷⁸ 20	5/327	8/326	0.62 (0.21; 1.89)	21.8	-0.009 (-0.03; 0.01)	52.53
Trospium	Clinically Important Improvement in UI	Zinner, 2004 ³⁵ 40	186/262	141/261	1.31 (1.15; 1.51)	78.2	0.170 (0.09; 0.25)	47.47
Trospium	Clinically Important Improvement in UI	Pooled RR (IV)			1.12 (0.61; 2.04)	100	0.076 (-0.10; 0.25)	100
Trospium	Clinically Important Improvement in UI	P value/I squared			0.19	0.419	0	0.942

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 7.5mg	Adverse effects	Hill, 2006 ⁴²	62/108	54/109	0.19 (0.06 to 0.33)	17.46	0.19 (0.06 to 0.30)	17.46
Darifenacin 7.5mg	Adverse effects	Chapple, 2007 ²⁵⁵	99/266	24/133	0.08 (-0.05 to 0.21)	17.51	0.06 (-0.04 to 0.19)	17.51
Darifenacin 15mg	Adverse effects	Hill, 2006 ⁴²	73/107	54/109	0.33 (0.20 to 0.46)	17.82	0.31 (0.19 to 0.40)	17.82
Darifenacin 15mg	Adverse effects	Zinner, 2006 ⁴⁰⁷	136/214	110/225	0.15 (0.06 to 0.24)	24.68	0.15 (0.05 to 0.23)	24.68

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 30mg	Adverse effects	Hill, 2006 ⁴²	92/115	54/109	0.22 (0.11 to 0.32)	22.54	0.21 (0.11 to 0.30)	22.54
Darifenacin	Adverse effects	Pooled	462/810	296/685	0.19 (0.12 to 0.27)	100	0.19 (0.12 to 0.26)	100
Darifenacin	Adverse effects	Heterogeneity			p value 0.097	49.10%	I-squared	49.10%
Darifenacin 15mg	Nausea	Lipton, 2005 ³³⁷	1/65	1/69	0.00 (-0.17 to 0.17)	23.38	0.00 (-0.01 to 0.07)	23.38
Darifenacin 15mg	Nausea	Zinner, 2006 ⁴⁰⁷	3/214	2/225	0.03 (-0.07 to 0.12)	76.62	0.01 (-0.01 to 0.03)	76.62
Darifenacin	Nausea	Pooled	4/279	3/294	0.02 (-0.06 to 0.11)	100	0.00 (-0.01 to 0.03)	100
Darifenacin	Nausea	Heterogeneity			p value 0.799	0.00%	I-squared	0.00%
Darifenacin 15mg	Serious adverse effects	Hill, 2006 ⁴²	2/107	2/109	0.00 (-0.13 to 0.14)	32.99	0.00 (-0.02 to 0.05)	32.99
Darifenacin 15mg	Serious adverse effects	Zinner, 2006 ⁴⁰⁷	2/214	5/225	-0.05 (-0.15 to 0.04)	67.01	-0.01 (-0.02 to 0.01)	67.01
Darifenacin	Serious adverse effects	Pooled	4/321	7/334	-0.04 (-0.11 to 0.04)	100	-0.01 (-0.02 to 0.01)	100
Darifenacin	Serious adverse effects	Heterogeneity			p value 0.515	0.00%	I-squared	0.00%
Darifenacin 15mg	Urinary tract infection	Hill, 2006 ⁴²	3/107	2/109	0.03 (-0.10 to 0.17)	32.99	0.01 (-0.02 to 0.07)	32.99
Darifenacin 15mg	Urinary tract infection	Zinner, 2006 ⁴⁰⁷	6/214	6/225	0.01 (-0.08 to 0.11)	67.01	0.00 (-0.02 to 0.04)	67.01
Darifenacin	Urinary tract infection	Pooled	9/321	8/334	0.02 (-0.06 to 0.10)	100	0.01 (-0.01 to 0.04)	100
Darifenacin	Urinary tract infection	Heterogeneity			p value 0.808	0.00%	I-squared	0.00%
Darifenacin 7.5mg	Constipation	Hill, 2006 ⁴²	17/108	5/109	-0.07 (-0.22 to 0.09)	11.16	-0.02 (-0.05 to 0.04)	11.16
Darifenacin 7.5mg	Constipation	Chapple, 2007 ^{25b}	41/266	11/133	0.13 (0.03 to 0.23)	13.83	0.08 (0.02 to 0.16)	13.83
Darifenacin 15mg	Constipation	Chapple, 2004 ⁴⁷²	2/53	11/164	0.06 (-0.11 to 0.23)	10.48	0.03 (-0.04 to 0.16)	10.48
Darifenacin 15mg	Constipation	Lipton, 2005 ³³⁷	8/65	6/69	0.19 (0.06 to 0.33)	12.22	0.14 (0.04 to 0.25)	12.22

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 15mg	Constipation	Hill, 2006 ⁴²	27/107	5/109	0.31 (0.18 to 0.44)	12.21	0.21 (0.10 to 0.33)	12.21
Darifenacin 15mg	Constipation	Zinner, 2006 ⁴⁰⁷	9/214	8/225	0.34 (0.21 to 0.47)	12.32	0.22 (0.12 to 0.34)	12.32
Darifenacin 30mg	Constipation	Chapple, 2004 ⁴⁷²	33/229	11/164	0.02 (-0.07 to 0.12)	14.14	0.01 (-0.03 to 0.07)	14.14
Darifenacin 30mg	Constipation	Hill, 2006 ⁴²	32/115	5/109	0.11 (0.01 to 0.22)	13.64	0.06 (0.00 to 0.13)	13.64
Darifenacin	Constipation	Pooled	169/1157	62/1082	0.14 (0.05 to 0.23)	100	0.08 (0.02 to 0.15)	100
Darifenacin	Constipation	Heterogeneity			p value 0	76.60%	I-squared	76.60%
Darifenacin 15mg	Treatment discontinuation	Chapple, 2004 ⁴⁷²	4/53	12/164	0.00 (-0.15 to 0.16)	26.75	0.00 (-0.06 to 0.10)	26.75
Darifenacin 15mg	Treatment discontinuation	Zinner, 2006 ⁴⁰⁷	29/214	37/225	-0.04 (-0.13 to 0.05)	73.25	-0.03 (-0.09 to 0.04)	73.25
Darifenacin	Treatment discontinuation	Pooled	33/267	49/389	-0.03 (-0.11 to 0.05)	100	-0.02 (-0.06 to 0.04)	100
Darifenacin	Treatment discontinuation	Heterogeneity			p value 0.626	0.00%	I-squared	0.00%
Darifenacin 7.5mg	Treatment discontinuation due to adverse effects	Steers, 2005 ⁴³	12/108	4/41	-0.11 (-0.27 to 0.04)	6.71	-0.06 (-0.09 to 0.03)	6.71
Darifenacin 7.5mg	Treatment discontinuation due to adverse effects	Hill, 2006 ⁴²	2/108	3/109	0.00 (-0.10 to 0.10)	11.72	0.00 (-0.02 to 0.04)	11.72
Darifenacin 7.5mg	Treatment discontinuation due to adverse effects	Chapple, 2007 ²⁵⁵	12/266	9/133	0.02 (-0.16 to 0.20)	5.34	0.01 (-0.06 to 0.13)	5.34
Darifenacin 7.5mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration ^{41,390}	3/229	3/164	-0.12 (-0.29 to 0.05)	5.75	-0.02 (0.01 to 0.02)	5.75

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 15mg	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁴⁷²	0/53	2/164	-0.03 (-0.16 to 0.10)	8.31	-0.01 (-0.01 to 0.03)	8.31
Darifenacin 15mg	Treatment discontinuation due to adverse effects	Steers, 2005 ⁴³	6/160	4/41	0.18 (0.05 to 0.31)	8.48	0.13 (0.03 to 0.24)	8.48
Darifenacin 15mg	Treatment discontinuation due to adverse effects	Zinner, 2006 ⁴⁰⁷	17/214	10/225	0.07 (-0.02 to 0.17)	12.59	0.03 (-0.01 to 0.09)	12.59
Darifenacin 15mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration ^{41,390}	8/112	4/115	-0.05 (-0.15 to 0.06)	11.24	-0.02 (-0.03 to 0.02)	11.24
Darifenacin 15mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration ^{41,390}	3/115	3/164	0.08 (-0.05 to 0.21)	8.56	0.03 (-0.01 to 0.10)	8.56
Darifenacin 30mg	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁴⁷²	3/229	2/164	-0.02 (-0.12 to 0.08)	11.72	0.00 (-0.01 to 0.02)	11.72
Darifenacin 30mg	Treatment discontinuation due to adverse effects	Hill, 2006 ⁴²	13/115	3/109	0.03 (-0.09 to 0.15)	9.58	0.01 (-0.02 to 0.07)	9.58
Darifenacin	Treatment discontinuation due to adverse effects	Pooled	79/1709	47/1429	0.01 (-0.04 to 0.06)	100	0.00 (-0.01 to 0.02)	100
Darifenacin	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.105	36.80%	I-squared	36.80%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 15mg	Treatment discontinuation due to failure	Hill, 2006 ⁴²	2/107	2/109	0.00 (-0.13 to 0.14)	17.55	0.00 (-0.02 to 0.05)	17.55
Darifenacin 15mg	Treatment discontinuation due to failure	Zinner, 2006 ⁴⁰⁷	2/214	5/225	-0.05 (-0.15 to 0.04)	35.66	-0.01 (-0.02 to 0.01)	35.66
Darifenacin 15mg	Treatment discontinuation due to failure	U.S. Food and Drug Administration ^{41,390}	1/112	2/115	-0.04 (-0.17 to 0.09)	18.45	-0.01 (-0.02 to 0.03)	18.45
Darifenacin 15mg	Treatment discontinuation due to failure	U.S. Food and Drug Administration ^{41,390}	2/269	1/129	0.00 (-0.11 to 0.10)	28.34	0.00 (-0.01 to 0.03)	28.34
Darifenacin	Treatment discontinuation due to failure	Pooled	7/702	10/578	-0.03 (-0.08 to 0.03)	100	-0.01 (-0.01 to 0.01)	100
Darifenacin	Treatment discontinuation due to failure	Heterogeneity			p value 0.871	0.00%	I-squared	0.00%
Darifenacin 7.5mg	Dry mouth	Lipton, 2005 ³³⁷	5/74	2/69	0.08 (-0.08 to 0.23)	10.64	0.03 (-0.02 to 0.12)	10.64
Darifenacin 7.5mg	Dry mouth	Hill, 2006 ⁴²	25/108	6/109	0.15 (0.05 to 0.25)	11.74	0.09 (0.03 to 0.17)	11.74
Darifenacin 7.5mg	Dry mouth	Chapple, 2007 ²⁵⁵	59/266	5/133	0.09 (-0.07 to 0.26)	10.43	0.04 (-0.02 to 0.15)	10.43
Darifenacin 15mg	Dry mouth	Chapple, 2004 ⁴⁷²	7/53	14/164	0.14 (-0.03 to 0.31)	10.31	0.09 (-0.02 to 0.24)	10.31
Darifenacin 15mg	Dry mouth	Lipton, 2005 ³³⁷	6/65	2/69	0.27 (0.13 to 0.40)	11.11	0.15 (0.06 to 0.26)	11.11
Darifenacin 15mg	Dry mouth	Hill, 2006 ⁴²	43/107	6/109	0.45 (0.32 to 0.58)	11.1	0.35 (0.22 to 0.48)	11.1
Darifenacin 15mg	Dry mouth	Zinner, 2006 ⁴⁰⁷	15/214	10/225	0.64 (0.51 to 0.77)	11.15	0.52 (0.39 to 0.65)	11.15
Darifenacin 30mg	Dry mouth	Chapple, 2004 ⁴⁷²	43/229	14/164	0.06 (-0.03 to 0.16)	11.85	0.04 (-0.02 to 0.11)	11.85
Darifenacin 30mg	Dry mouth	Hill, 2006 ⁴²	68/115	6/109	0.30 (0.19 to 0.40)	11.67	0.20 (0.12 to 0.30)	11.67

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin	Dry mouth	Pooled	271/1231	65/1151	0.24 (0.12 to 0.37)	100	0.16 (0.07 to 0.27)	100
Darifenacin	Dry mouth	Heterogeneity			p value 0	88.90%	I-squared	88.90%
Darifenacin 7.5mg	Dyspepsia	Lipton, 2005 ³³⁷	1/74	1/69	-0.02 (-0.13 to 0.08)	17.98	-0.01 (-0.01 to 0.02)	17.98
Darifenacin 7.5mg	Dyspepsia	Hill, 2006 ⁴²	4/108	1/109	0.00 (-0.17 to 0.16)	10.8	0.00 (0.00 to 0.05)	10.8
Darifenacin 15mg	Dyspepsia	Lipton, 2005 ³³⁷	4/71	1/69	0.12 (-0.05 to 0.29)	10.66	0.04 (-0.01 to 0.14)	10.66
Darifenacin 15mg	Dyspepsia	Hill, 2006 ⁴²	9/107	1/109	0.10 (-0.04 to 0.23)	13.81	0.03 (-0.01 to 0.09)	13.81
Darifenacin 15mg	Dyspepsia	Zinner, 2006 ⁴⁰⁷	9/214	2/225	0.20 (0.07 to 0.33)	13.77	0.08 (0.02 to 0.17)	13.77
Darifenacin 30mg	Dyspepsia	Chapple, 2004 ⁴⁷²	4/229	4/164	0.20 (0.07 to 0.33)	14.04	0.10 (0.03 to 0.20)	14.04
Darifenacin 30mg	Dyspepsia	Hill, 2006 ⁴²	10/115	1/109	0.10 (0.00 to 0.19)	18.95	0.03 (0.00 to 0.07)	18.95
Darifenacin	Dyspepsia	Pooled	41/918	11/854	0.10 (0.03 to 0.16)	100	0.03 (0.01 to 0.06)	100
Darifenacin	Dyspepsia	Heterogeneity			p value 0.066	49.30%	I-squared	49.30%
Darifenacin 7.5mg	Headache	Lipton, 2005 ³³⁷	1/74	0/69	0.12 (-0.05 to 0.28)	12.37	0.01 (0.00 to 0.08)	12.37
Darifenacin 7.5mg	Headache	Hill, 2006 ⁴²	7/108	2/109	0.17 (0.00 to 0.33)	12.12	0.07 (0.00 to 0.19)	12.12
Darifenacin 15mg	Headache	Lipton, 2005 ³³⁷	2/71	0/69	0.12 (-0.01 to 0.26)	18.8	0.01 (0.00 to 0.06)	18.8
Darifenacin 15mg	Headache	Hill, 2006 ⁴²	7/107	2/109	0.12 (-0.01 to 0.26)	18.71	0.05 (0.00 to 0.13)	18.71
Darifenacin 15mg	Headache	Zinner, 2006 ⁴⁰⁷	7/214	2/225	0.07 (-0.02 to 0.17)	38	0.02 (0.00 to 0.06)	38
Darifenacin	Headache	Pooled	24/574	6/581	0.11 (0.05 to 0.17)	100	0.03 (0.01 to 0.06)	100
Darifenacin	Headache	Heterogeneity			p value 0.886	0.00%	I-squared	0.00%
Fesoterodine 4mg	Dry mouth	Chapple, 2004 ²⁶¹	47/186	16/183	0.22 (0.12 to 0.32)	8.41	0.16 (0.08 to 0.25)	8.41

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 4mg	Dry mouth	Chapple, 2007 ²⁵³	59/272	20/285	0.23 (0.13 to 0.33)	8.27	0.16 (0.08 to 0.25)	8.27
Fesoterodine 4mg	Dry mouth	Nitti, 2007 ³⁵³	45/283	19/274	0.32 (0.22 to 0.42)	8.41	0.24 (0.15 to 0.33)	8.41
Fesoterodine 6mg	Dry mouth	Dmochowski, 2010 ⁴⁶⁹	113/438	34/445	0.22 (0.13 to 0.30)	9.91	0.15 (0.08 to 0.22)	9.91
Fesoterodine 6mg	Dry mouth	Herschorn, 2010 ⁴⁷⁰	189/679	20/334	0.35 (0.27 to 0.43)	10.01	0.26 (0.18 to 0.34)	10.01
Fesoterodine 6mg	Dry mouth	Kaplan, 2010 ³¹⁸	270/963	24/480	0.14 (0.06 to 0.23)	9.91	0.08 (0.03 to 0.14)	9.91
Fesoterodine 8mg	Dry mouth	Chapple, 2004 ²⁶¹	45/173	16/183	0.37 (0.29 to 0.46)	9.89	0.30 (0.22 to 0.38)	9.89
Fesoterodine 8mg	Dry mouth	Chapple, 2007 ²⁵³	97/288	20/285	0.25 (0.19 to 0.32)	11.39	0.18 (0.12 to 0.24)	11.39
Fesoterodine 8mg	Dry mouth	Nitti, 2007 ³⁵³	99/279	19/274	0.31 (0.24 to 0.37)	11.43	0.23 (0.17 to 0.29)	11.43
Fesoterodine 12mg	Dry mouth	Chapple, 2004 ²⁶¹	63/186	16/183	0.33 (0.28 to 0.39)	12.37	0.26 (0.21 to 0.32)	12.37
Fesoterodine	Dry mouth	Pooled	1026/3747	205/2926	0.28 (0.23 to 0.32)	100	0.20 (0.16 to 0.24)	100
Fesoterodine	Dry mouth	Heterogeneity			p value 0.001	67.50%	I-squared	67.50%
Fesoterodine 6mg	Abdominal pain	NCT00444925 ⁵⁶	10/685	4/337	0.09 (-0.02 to 0.19)	22.91	0.03 (0.00 to 0.07)	22.91
Fesoterodine 8mg	Abdominal pain	Chapple, 2004 ²⁶¹	14/173	7/183	0.09 (-0.02 to 0.19)	23.71	0.04 (-0.01 to 0.10)	23.71
Fesoterodine 12mg	Abdominal pain	Chapple, 2004 ²⁶¹	15/186	7/183	0.01 (-0.05 to 0.08)	53.38	0.00 (-0.02 to 0.04)	53.38
Fesoterodine	Abdominal pain	Pooled	39/1044	19/703	0.05 (-0.01 to 0.10)	100	0.02 (0.00 to 0.04)	100
Fesoterodine	Abdominal pain	Heterogeneity			p value 0.338	7.80%	I-squared	7.80%
Fesoterodine 6mg	Treatment discontinuation due to failure	Dmochowski, 2010 ⁴⁶⁹	5/438	16/445	-0.08 (-0.15 to - 0.02)	49.92	-0.02 (-0.03 to - 0.01)	49.92
Fesoterodine 6mg	Treatment discontinuation due to failure	Herschorn, 2010 ⁴⁷⁰	13/679	5/334	0.02 (-0.05 to 0.08)	50.08	0.00 (-0.01 to 0.03)	50.08

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine	Treatment discontinuation due to failure	Pooled	18/1117	21/779	-0.03 (-0.13 to 0.06)	100	-0.01 (-0.03 to 0.02)	100
Fesoterodine	Treatment discontinuation due to failure	Heterogeneity			p value 0.035	77.50%	I-squared	77.50%
Fesoterodine 4mg	Dizziness	Chapple, 2004 ²⁶¹	7/186	5/183	0.03 (-0.08 to 0.13)	18.47	0.01 (-0.02 to 0.06)	18.47
Fesoterodine 6mg	Dizziness	NCT00444925 ⁵⁶	8/685	3/337	-0.07 (-0.18 to 0.03)	17.81	-0.01 (0.00 to 0.01)	17.81
Fesoterodine 8mg	Dizziness	Chapple, 2004 ²⁶¹	2/173	5/183	-0.03 (-0.13 to 0.07)	18.47	-0.01 (-0.03 to 0.03)	18.47
Fesoterodine 12mg	Dizziness	Chapple, 2004 ²⁶¹	4/186	5/183	0.01 (-0.05 to 0.08)	45.24	0.00 (-0.01 to 0.03)	45.24
Fesoterodine	Dizziness	Pooled	21/1230	19/886	-0.01 (-0.05 to 0.04)	100	0.00 (-0.01 to 0.01)	100
Fesoterodine	Dizziness	Heterogeneity			p value 0.449	0.00%	I-squared	0.00%
Fesoterodine 4mg	Dry eye	Chapple, 2007 ²⁵³	6/272	0/285	0.15 (0.07 to 0.23)	16.19	0.02 (0.00 to 0.05)	16.19
Fesoterodine 4mg	Dry eye	Nitti, 200 ³⁵³	2/283	0/274	0.21 (0.12 to 0.29)	16.28	0.04 (0.02 to 0.08)	16.28
Fesoterodine 6mg	Dry eye	Dmochowski, 2010 ⁴⁶⁹	13/438	8/445	0.08 (0.00 to 0.17)	16.19	0.03 (0.00 to 0.07)	16.19
Fesoterodine 6mg	Dry eye	NCT00444925 ⁵⁶	9/685	6/337	0.18 (0.10 to 0.26)	16.16	0.08 (0.03 to 0.13)	16.16
Fesoterodine 8mg	Dry eye	Chapple, 2007 ²⁵³	12/288	0/285	0.04 (-0.03 to 0.11)	17.56	0.00 (0.00 to 0.01)	17.56
Fesoterodine 8mg	Dry eye	Nitti, 2007 ³⁵³	9/279	0/274	-0.02 (-0.08 to 0.05)	17.62	0.00 (0.01 to 0.00)	17.62
Fesoterodine	Dry eye	Pooled	51/2245	14/1900	0.10 (0.03 to 0.18)	100	0.03 (0.01 to 0.06)	100
Fesoterodine	Dry eye	Heterogeneity			p value 0	81.60%	I-squared	81.60%
Fesoterodine 6mg	Treatment failure	Dmochowski, 2010 ⁴⁶⁹	14/438	29/445	-0.08 (-0.14 to -0.01)	49.65	-0.03 (-0.05 to -0.01)	49.65
Fesoterodine 6mg	Treatment failure	Herschorn, 2010 ⁴⁷⁰	32/679	34/334	-0.11 (-0.17 to -0.04)	50.35	-0.06 (-0.08 to -0.02)	50.35

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine	Treatment failure	Pooled	46/1117	63/779	-0.09 (-0.14 to -0.05)	100	-0.04 (-0.06 to -0.02)	100
Fesoterodine	Treatment failure	Heterogeneity			p value 0.511	0.00%	I-squared	0.00%
Fesoterodine 6mg	Fatigue	NCT00444925 ⁵⁶	12/685	0/337	0.13 (0.07 to 0.20)	50.58	0.02 (0.00 to 0.04)	50.58
Fesoterodine 6mg	Fatigue	NCT00536484 ⁵⁷	11/438	2/445	0.09 (0.03 to 0.16)	49.42	0.02 (0.00 to 0.05)	49.42
Fesoterodine	Fatigue	Pooled	23/1123	2/782	0.11 (0.07 to 0.16)	100	0.02 (0.01 to 0.04)	100
Fesoterodine	Fatigue	Heterogeneity			p value 0.39	0.00%	I-squared	0.00%
Fesoterodine 4mg	Headache	Chapple, 2004 ²⁶¹	32/186	29/183	0.01 (-0.09 to 0.12)	7.7	0.01 (-0.06 to 0.09)	7.7
Fesoterodine 4mg	Headache	Chapple, 2007 ²⁵³	12/272	14/285	0.00 (-0.10 to 0.10)	7.45	0.00 (-0.03 to 0.05)	7.45
Fesoterodine 4mg	Headache	Nitti, 2007 ³⁵³	12/283	9/274	-0.01 (-0.12 to 0.09)	7.7	0.00 (-0.03 to 0.04)	7.7
Fesoterodine 6mg	Headache	Dmochowski, 2010 ⁴⁶⁹	19/438	15/445	-0.01 (-0.10 to 0.07)	11.07	0.00 (-0.03 to 0.03)	11.07
Fesoterodine 6mg	Headache	Herschorn, 2010 ⁴⁷⁰	38/679	8/334	-0.07 (-0.15 to 0.02)	11.35	-0.02 (-0.02 to 0.00)	11.35
Fesoterodine 8mg	Headache	Chapple, 2004 ²⁶¹	28/173	29/183	0.03 (-0.06 to 0.11)	11.08	0.02 (-0.04 to 0.09)	11.08
Fesoterodine 8mg	Headache	Chapple, 2007 ²⁵³	7/288	14/285	-0.01 (-0.10 to 0.07)	11.01	-0.01 (-0.03 to 0.04)	11.01
Fesoterodine 8mg	Headache	Nitti, 2007 ³⁵³	8/279	9/274	0.03 (-0.04 to 0.09)	16.22	0.01 (-0.01 to 0.04)	16.22
Fesoterodine 12mg	Headache	Chapple, 2004 ²⁶¹	28/186	29/183	0.08 (0.02 to 0.15)	16.41	0.07 (0.01 to 0.12)	16.41
Fesoterodine	Headache	Pooled	183/2784	157/2446	0.01 (-0.02 to 0.04)	100	0.00 (-0.01 to 0.02)	100
Fesoterodine	Headache	Heterogeneity			p value 0.316	14.10%	I-squared	14.10%
Fesoterodine 4mg	Nasopharyngitis	Chapple, 2007 ²⁵³	8/272	7/285	0.02 (-0.07 to 0.10)	13.83	0.00 (-0.02 to 0.04)	13.83
Fesoterodine 4mg	Nasopharyngitis	Nitti, 2007 ³⁵³	10/283	7/274	-0.03 (-0.11 to 0.06)	14.23	-0.01 (-0.02 to 0.02)	14.23

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 6mg	Nasopharyngitis	NCT00444925 ⁵⁶	13/685	10/337	0.03 (-0.05 to 0.11)	13.83	0.01 (-0.02 to 0.05)	13.83
Fesoterodine 6mg	Nasopharyngitis	NCT00536484 ⁵⁷	19/438	25/445	-0.08 (-0.16 to 0.01)	13.73	-0.03 (-0.05 to 0.00)	13.73
Fesoterodine 8mg	Nasopharyngitis	Chapple, 2007 ²⁵³	5/288	7/285	-0.04 (-0.10 to 0.03)	22.44	-0.01 (-0.02 to 0.01)	22.44
Fesoterodine 8mg	Nasopharyngitis	Nitti, 2007 ³⁵³	2/279	7/274	-0.03 (-0.10 to 0.04)	21.93	-0.01 (-0.02 to 0.01)	21.93
Fesoterodine	Nasopharyngitis	Pooled	57/2245	63/1900	-0.02 (-0.05 to 0.01)	100	-0.01 (-0.02 to 0.00)	100
Fesoterodine	Nasopharyngitis	Heterogeneity			p value 0.551	0.00%	I-squared	0.00%
Fesoterodine 4mg	Abnormal vision	Chapple, 2004 ²⁶¹	0/186	2/183	-0.10 (-0.20 to 0.00)	33.66	-0.01 (0.00 to 0.00)	33.66
Fesoterodine 8mg	Abnormal vision	Chapple, 2004 ²⁶¹	0/173	2/183	-0.10 (-0.20 to 0.00)	32.67	-0.01 (0.00 to 0.00)	32.67
Fesoterodine 12mg	Abnormal vision	Chapple, 2004 ²⁶¹	2/186	2/183	0.00 (-0.10 to 0.10)	33.66	0.00 (-0.01 to 0.03)	33.66
Fesoterodine	Abnormal vision	Pooled	2/545	5/549	-0.07 (-0.13 to 0.00)	100	-0.01 (-0.01 to 0.00)	100
Fesoterodine	Abnormal vision	Heterogeneity			p value 0.293	18.50%	I-squared	18.50%
Fesoterodine 4mg	Nausea	Chapple, 2004 ²⁶¹	9/186	13/183	-0.04 (-0.14 to 0.06)	8.53	-0.02 (-0.05 to 0.03)	8.53
Fesoterodine 4mg	Nausea	Chapple, 2007 ²⁵³	1/272	1/285	-0.13 (-0.23 to - 0.02)	8.31	0.00 (0.03 to 0.00)	8.31
Fesoterodine 4mg	Nausea	Nitti, 2007 ³⁵³	3/283	6/274	-0.02 (-0.12 to 0.08)	8.53	-0.01 (-0.02 to 0.03)	8.53
Fesoterodine 6mg	Nausea	NCT00444925 ⁵⁶	12/685	6/337	0.00 (-0.08 to 0.08)	11.25	0.00 (-0.02 to 0.03)	11.25
Fesoterodine 6mg	Nausea	NCT00536484 ⁵⁷	6/438	18/445	0.06 (-0.02 to 0.14)	11.46	0.03 (-0.01 to 0.07)	11.46
Fesoterodine 8mg	Nausea	Chapple, 2004 ²⁶¹	3/173	13/183	-0.05 (-0.13 to 0.04)	11.25	-0.02 (-0.05 to 0.02)	11.25
Fesoterodine 8mg	Nausea	Chapple, 2007 ²⁵³	4/288	1/285	0.01 (-0.07 to 0.09)	11.2	0.00 (0.00 to 0.02)	11.2
Fesoterodine 8mg	Nausea	Nitti, 2007 ³⁵³	7/279	6/274	0.00 (-0.07 to 0.06)	14.82	0.00 (-0.02 to 0.02)	14.82

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 12mg	Nausea	Chapple, 2004 ²⁶¹	11/186	13/183	-0.09 (-0.15 to - 0.02)	14.64	-0.04 (-0.06 to - 0.01)	14.64
Fesoterodine	Nausea	Pooled	57/2790	76/2449	-0.03 (-0.06 to 0.01)	100	-0.01 (-0.02 to 0.00)	100
Fesoterodine	Nausea	Heterogeneity			p value 0.119	37.50%	I-squared	37.50%
Fesoterodine 6mg	Serious adverse effects	NCT00444925 ⁵⁶	15/685	8/337	-0.01 (-0.07 to 0.06)	50.58	0.00 (-0.02 to 0.02)	50.58
Fesoterodine 6mg	Serious adverse effects	NCT00536484 ⁵⁷	5/438	7/445	-0.02 (-0.09 to 0.05)	49.42	0.00 (-0.01 to 0.01)	49.42
Fesoterodine	Serious adverse effects	Pooled	20/1123	15/782	-0.01 (-0.06 to 0.03)	100	0.00 (-0.01 to 0.01)	100
Fesoterodine	Serious adverse effects	Heterogeneity			p value 0.791	0.00%	I-squared	0.00%
Fesoterodine 6mg	Upper respiratory tract infection	NCT00444925 ⁵⁶	2/685	4/337	-0.06 (-0.12 to 0.01)	50.58	-0.01 (-0.01 to 0.00)	50.58
Fesoterodine 6mg	Upper respiratory tract infection	NCT00536484 ⁵⁷	21/438	23/445	-0.01 (-0.08 to 0.06)	49.42	0.00 (-0.03 to 0.03)	49.42
Fesoterodine	Upper respiratory tract infection	Pooled	23/1123	27/782	-0.03 (-0.08 to 0.01)	100	-0.01 (-0.02 to 0.01)	100
Fesoterodine	Upper respiratory tract infection	Heterogeneity			p value 0.326	0.00%	I-squared	0.00%
Fesoterodine 6mg	Urinary tract infection	Herschorn, 2010 ⁴⁷⁰	15/679	2/334	0.07 (0.01 to 0.14)	50.08	0.02 (0.00 to 0.04)	50.08
Fesoterodine 6mg	Urinary tract infection	NCT00536484 ⁵⁷	8/438	12/445	-0.03 (-0.10 to 0.04)	49.92	-0.01 (-0.02 to 0.01)	49.92
Fesoterodine	Urinary tract infection	Pooled	23/1117	14/779	0.02 (-0.08 to 0.12)	100	0.01 (-0.01 to 0.05)	100
Fesoterodine	Urinary tract infection	Heterogeneity			p value 0.034	77.80%	I-squared	77.80%
Fesoterodine 4mg	Influenza-like symptoms	Chapple, 2004 ²⁶¹	17/186	15/183	0.02 (-0.08 to 0.12)	33.64	0.01 (-0.04 to 0.08)	33.64

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 8mg	Influenza-like symptoms	Chapple, 2004 ²⁶¹	7/173	15/183	-0.09 (-0.19 to 0.02)	32.71	-0.04 (-0.07 to 0.01)	32.71
Fesoterodine 12mg	Influenza-like symptoms	Chapple, 2004 ²⁶¹	7/186	15/183	-0.09 (-0.19 to 0.02)	33.64	-0.04 (-0.07 to 0.01)	33.64
Fesoterodine	Influenza-like symptoms	Pooled	31/545	44/549	-0.05 (-0.12 to 0.02)	100	-0.03 (-0.05 to 0.01)	100
Fesoterodine	Influenza-like symptoms	Heterogeneity			p value 0.271	23.40%	I-squared	23.40%
Fesoterodine 4mg	Adverse effects	Chapple, 2007 ²⁵³	135/272	107/285	0.12 (0.04 to 0.21)	15.34	0.12 (0.04 to 0.20)	15.34
Fesoterodine 4mg	Adverse effects	Nitti, 2007 ³⁵³	171/283	149/274	0.21 (0.12 to 0.29)	15.58	0.20 (0.12 to 0.26)	15.58
Fesoterodine 6mg	Adverse effects	NCT00444925 ⁵⁶	290/685	76/337	0.06 (-0.02 to 0.14)	15.34	0.05 (-0.02 to 0.13)	15.34
Fesoterodine 6mg	Adverse effects	NCT00536484 ⁵⁷	199/438	130/445	0.15 (0.07 to 0.24)	15.28	0.15 (0.07 to 0.23)	15.28
Fesoterodine 8mg	Adverse effects	Chapple, 2007 ²⁵³	167/288	107/285	0.21 (0.15 to 0.28)	19.32	0.21 (0.15 to 0.28)	19.32
Fesoterodine 8mg	Adverse effects	Nitti, 2007 ³⁵³	193/279	149/274	0.17 (0.10 to 0.24)	19.14	0.16 (0.10 to 0.22)	19.14
Fesoterodine	Adverse effects	Pooled	1155/2245	718/1900	0.16 (0.11 to 0.20)	100	0.16 (0.11 to 0.20)	100
Fesoterodine		Heterogeneity			p value 0.071	50.70%	I-squared	50.70%
Fesoterodine 4mg	Back pain	Chapple, 2004 ²⁶¹	6/186	5/183	0.00 (-0.10 to 0.10)	18.47	0.00 (-0.02 to 0.04)	18.47
Fesoterodine 6mg	Back pain	NCT00444925 ⁵⁶	10/685	10/337	0.03 (-0.08 to 0.13)	17.81	0.01 (-0.02 to 0.06)	17.81
Fesoterodine 8mg	Back pain	Chapple, 2004 ²⁶¹	7/173	5/183	-0.03 (-0.13 to 0.07)	18.47	-0.01 (-0.03 to 0.03)	18.47
Fesoterodine 12mg	Back pain	Chapple, 2004 ²⁶¹	4/186	5/183	-0.05 (-0.12 to 0.01)	45.24	-0.02 (-0.03 to 0.00)	45.24
Fesoterodine	Back pain	Pooled	26/1230	26/886	-0.03 (-0.07 to 0.02)	100	-0.01 (-0.02 to 0.01)	100
Fesoterodine	Back pain	Heterogeneity			p value 0.598	0.00%	I-squared	0.00%
Fesoterodine 4mg	Constipation	Chapple, 2004 ²⁶¹	4/186	5/183	-0.03 (-0.13 to 0.07)	9.64	-0.01 (-0.03 to 0.03)	9.64

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 4mg	Constipation	Chapple, 2007 ²⁵³	9/272	4/285	0.00 (-0.10 to 0.10)	9.6	0.00 (-0.01 to 0.03)	9.6
Fesoterodine 4mg	Constipation	Nitti, 2007 ³⁵³	14/283	7/274	0.07 (-0.03 to 0.18)	9.64	0.03 (-0.01 to 0.08)	9.64
Fesoterodine 6mg	Constipation	Dmochowski, 2010 ⁴⁶⁹	48/438	25/445	0.06 (-0.02 to 0.15)	10.01	0.03 (-0.01 to 0.09)	10.01
Fesoterodine 6mg	Constipation	Herschorn, 2010 ⁴⁷⁰	37/679	10/334	0.10 (0.01 to 0.18)	10.03	0.04 (0.00 to 0.09)	10.03
Fesoterodine 6mg	Constipation	Kaplan, 2010 ³¹⁸	270/963	10/480	0.06 (-0.02 to 0.15)	10.01	0.02 (0.00 to 0.06)	10.01
Fesoterodine 8mg	Constipation	Chapple, 2004 ²⁶¹	5/173	5/183	0.12 (0.03 to 0.20)	10.01	0.05 (0.01 to 0.10)	10.01
Fesoterodine 8mg	Constipation	Chapple, 2007 ²⁵³	13/288	4/285	0.10 (0.03 to 0.16)	10.3	0.03 (0.01 to 0.06)	10.3
Fesoterodine 8mg	Constipation	Nitti, 2007 ³⁵³	21/279	7/274	0.06 (-0.01 to 0.13)	10.31	0.02 (0.00 to 0.05)	10.31
Fesoterodine 12mg	Constipation	Chapple, 2004 ²⁶¹	11/186	5/183	0.42 (0.36 to 0.47)	10.46	0.28 (0.23 to 0.33)	10.46
Fesoterodine	Constipation	Pooled	431/3747	83/2926	0.10 (0.00 to 0.19)	100	0.04 (0.00 to 0.10)	100
Fesoterodine	Constipation	Heterogeneity			p value 0	93.20%	I-squared	93.20%
Fesoterodine 4mg	Cough	Chapple, 2004 ²⁶¹	6/186	7/183	-0.03 (-0.13 to 0.08)	17.42	-0.01 (-0.03 to 0.03)	17.42
Fesoterodine 6mg	Cough	NCT00444925 ⁵⁶	8/685	1/337	-0.10 (-0.21 to 0.00)	17.12	0.00 (0.02 to 0.00)	17.12
Fesoterodine 6mg	Cough	NCT00536484 ⁵⁷	9/438	2/445	-0.03 (-0.13 to 0.08)	17.42	0.00 (0.00 to 0.02)	17.42
Fesoterodine 8mg	Cough	Chapple, 2004 ²⁶¹	2/173	7/183	0.05 (-0.01 to 0.12)	24.09	0.02 (0.00 to 0.06)	24.09
Fesoterodine 12mg	Cough	Chapple, 2004 ²⁶¹	6/186	7/183	0.08 (0.01 to 0.14)	23.94	0.04 (0.00 to 0.07)	23.94
Fesoterodine	Cough	Pooled	30/1668	25/1331	0.00 (-0.06 to 0.07)	100	0.00 (-0.01 to 0.02)	100
Fesoterodine	Cough	Heterogeneity			p value 0.03	62.80%	I-squared	62.80%
Fesoterodine 6mg	Diarrhea	Herschorn, 2010 ⁴⁷⁰	14/679	4/334	0.04 (-0.03 to 0.10)	50.08	0.01 (-0.01 to 0.03)	50.08

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 6mg	Diarrhea	NCT00536484 ⁵⁷	9/438	19/445	-0.06 (-0.13 to 0.00)	49.92	-0.02 (-0.04 to 0.00)	49.92
Fesoterodine	Diarrhea	Pooled	23/1117	23/779	-0.01 (-0.11 to 0.08)	100	0.00 (-0.03 to 0.03)	100
Fesoterodine	Diarrhea	Heterogeneity			p value 0.035	77.50%	I-squared	77.50%
Fesoterodine 4mg	Treatment discontinuation	Chapple, 2007 ²⁵³	41/272	33/285	0.05 (-0.03 to 0.14)	13.86	0.04 (-0.02 to 0.10)	13.86
Fesoterodine 4mg	Treatment discontinuation	Nitti, 2007 ³⁵³	58/283	41/274	0.01 (-0.07 to 0.10)	14.26	0.01 (-0.05 to 0.07)	14.26
Fesoterodine 6mg	Treatment discontinuation	Dmochowski, 2010 ⁴⁶⁹	56/438	60/445	0.07 (-0.01 to 0.16)	13.86	0.05 (-0.01 to 0.12)	13.86
Fesoterodine 6mg	Treatment discontinuation	Herschorn, 2010 ⁴⁷⁰	81/679	30/334	0.07 (-0.02 to 0.15)	13.76	0.04 (-0.01 to 0.10)	13.76
Fesoterodine 8mg	Treatment discontinuation	Chapple, 2007 ²⁵³	36/288	33/285	-0.01 (-0.08 to 0.06)	21.98	-0.01 (-0.04 to 0.04)	21.98
Fesoterodine 8mg	Treatment discontinuation	Nitti, 2007 ³⁵³	56/279	41/274	0.05 (-0.02 to 0.11)	22.29	0.04 (-0.01 to 0.09)	22.29
Fesoterodine	Treatment discontinuation	Pooled	328/2239	238/1897	0.04 (0.01 to 0.07)	100	0.03 (0.00 to 0.05)	100
Fesoterodine	Treatment discontinuation	Heterogeneity			p value 0.59	0.00%	I-squared	0.00%
Fesoterodine 4mg	Treatment discontinuation due to adverse effects	Chapple, 2004 ²⁶¹	11/186	7/183	0.05 (-0.06 to 0.15)	12.89	0.02 (-0.02 to 0.08)	12.89
Fesoterodine 6mg	Treatment discontinuation due to adverse effects	Dmochowski, 2010 ⁴⁶⁹	34/438	21/445	-0.06 (-0.16 to 0.04)	12.61	-0.02 (-0.04 to 0.02)	12.61
Fesoterodine 6mg	Treatment discontinuation due to adverse effects	Herschorn, 2010 ⁴⁷⁰	44/679	6/334	0.15 (0.05 to 0.25)	12.89	0.06 (0.02 to 0.13)	12.89

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 6mg	Treatment discontinuation due to adverse effects	Kaplan, 2010 ³¹⁸	48/963	10/480	0.06 (0.00 to 0.13)	19.64	0.02 (0.00 to 0.05)	19.64
Fesoterodine 8mg	Treatment discontinuation due to adverse effects	Chapple, 2004 ²⁶¹	3/173	7/183	0.12 (0.06 to 0.19)	19.74	0.06 (0.03 to 0.10)	19.74
Fesoterodine 12mg	Treatment discontinuation due to adverse effects	Chapple, 2004 ²⁶¹	22/186	7/183	0.08 (0.03 to 0.14)	22.23	0.04 (0.01 to 0.07)	22.23
Fesoterodine	Treatment discontinuation due to adverse effects	Pooled	163/2625	59/1808	0.07 (0.03 to 0.12)	100	0.03 (0.01 to 0.06)	100
Fesoterodine	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.048	55.30%	I-squared	55.30%
Oxybutynin 3.9mg	Adverse effects	Dmochowski, 2003 ²⁷⁴	7/121	13/117	0.31 (0.17 to 0.45)	32.45	0.25 (0.12 to 0.39)	32.45
Oxybutynin 9mg	Adverse effects	Homma, 200 ³⁰⁷	30/244	4/122	-0.10 (-0.22 to 0.03)	33.28	-0.03 (-0.03 to 0.01)	33.28
Oxybutynin 10mg	Adverse effects	Madersbacher, 1999 ³⁴³	104/145	30/72	0.18 (0.07 to 0.28)	34.28	0.18 (0.07 to 0.28)	34.28
Oxybutynin	Adverse effects	Pooled	141/510	47/311	0.13 (-0.10 to 0.35)	100	0.10 (-0.06 to 0.31)	100
Oxybutynin	Adverse effects	Heterogeneity			p value 0	89.50%	I-squared	89.50%
Oxybutynin 5mg	Dyspepsia	Chancellor, 2001 ²⁴⁹	1/36	0/36	0.27 (0.11 to 0.43)	31.24	0.07 (0.01 to 0.17)	31.24
Oxybutynin 9mg	Dyspepsia	Homma, 2003 ³⁰⁷	20/244	4/122	0.17 (-0.06 to 0.40)	16.81	0.08 (-0.02 to 0.27)	16.81
Oxybutynin 15mg	Dyspepsia	Abrams, 1998 ²¹⁹	27/118	3/57	0.11 (0.00 to 0.22)	51.95	0.06 (0.00 to 0.14)	51.95

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin	Dyspepsia	Pooled	48/398	7/215	0.17 (0.07 to 0.27)	100	0.08 (0.03 to 0.16)	100
Oxybutynin	Dyspepsia	Heterogeneity			p value 0.267	24.30%	I-squared	24.30%
Oxybutynin 3.9mg	Dysuria	Dmochowski, 2002 ²⁷¹	3/125	0/132	0.16 (0.03 to 0.28)	44.52	0.02 (0.00 to 0.08)	44.52
Oxybutynin 10mg	Dysuria	Staskin, 2009 ³¹	1/389	1/400	0.00 (-0.07 to 0.07)	55.48	0.00 (0.00 to 0.01)	55.48
Oxybutynin	Dysuria	Pooled	4/514	1/532	0.07 (-0.08 to 0.22)	100	0.01 (0.00 to 0.07)	100
Oxybutynin	Dysuria	Heterogeneity			p value 0.031	78.50%	I-squared	78.50%
Oxybutynin 7.5mg	Treatment failure	Wang, 2006 ⁴¹³	14/23	19/21	-0.26 (-0.44 to -0.07)	17.01	-0.20 (-0.37 to -0.05)	17.01
Oxybutynin 9mg	Treatment failure	Homma, 2003 ³⁰⁷	12/244	10/122	-0.09 (-0.27 to 0.08)	18.87	-0.04 (-0.08 to 0.05)	18.87
Oxybutynin 10mg	Treatment failure	Madersbacher, 1999 ³⁴³	28/145	23/72	-0.15 (-0.29 to -0.01)	24.13	-0.13 (-0.23 to -0.01)	24.13
Oxybutynin 11.5mg	Treatment failure	Burgio, 1998 ²³⁸	1/67	3/65	-0.06 (-0.17 to 0.05)	32.1	-0.02 (-0.04 to 0.02)	32.1
Oxybutynin 15mg	Treatment failure	Thuroff, 1991 ³⁸⁶	11/63	21/52	-0.36 (-0.66 to -0.07)	7.9	-0.30 (-0.41 to -0.06)	7.9
Oxybutynin	Treatment failure	Pooled	66/542	76/332	-0.15 (-0.24 to -0.06)	100	-0.11 (-0.16 to -0.05)	100
Oxybutynin	Treatment failure	Heterogeneity			p value 0.201	33.10%	I-squared	33.10%
Oxybutynin 5mg	Headache	Chancellor, 2001 ²⁴⁹	6/36	4/36	0.08 (-0.15 to 0.31)	5.72	0.06 (-0.08 to 0.26)	5.72
Oxybutynin 9mg	Headache	Homma, 2003 ³⁰⁷	11/244	8/122	0.08 (-0.15 to 0.31)	5.72	0.05 (-0.05 to 0.23)	5.72
Oxybutynin 10mg	Headache	Chancellor, 2001 ²⁴⁹	6/36	4/36	-0.05 (-0.15 to 0.06)	25.86	-0.03 (-0.08 to 0.04)	25.86
Oxybutynin 10mg	Headache	Staskin, 2009 ³¹	6/389	11/400	-0.04 (-0.11 to 0.03)	62.7	-0.01 (-0.02 to 0.01)	62.7
Oxybutynin	Headache	Pooled	29/705	27/594	-0.03 (-0.08 to 0.03)	100	-0.01 (-0.03 to 0.01)	100
Oxybutynin	Headache	Heterogeneity			p value 0.583	0.00%	I-squared	0.00%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin 3mg	Nausea	Moore, 1990 ³⁵¹	4/48	1/43	0.45 (0.22 to 0.69)	9.31	0.30 (0.11 to 0.53)	9.31
Oxybutynin 3.9mg	Nausea	Dmochowski, 2002 ²⁷¹	2/125	7/132	0.14 (-0.07 to 0.35)	10.64	0.08 (-0.03 to 0.25)	10.64
Oxybutynin 5mg	Nausea	Chancellor, 2001 ²⁴⁹	1/36	1/36	-0.08 (-0.24 to 0.07)	13.21	-0.02 (-0.02 to 0.03)	13.21
Oxybutynin 10mg	Nausea	Madersbacher, 1999 ³⁴³	14/145	6/72	0.03 (-0.11 to 0.17)	14.2	0.02 (-0.05 to 0.12)	14.2
Oxybutynin 10mg	Nausea	Chancellor, 2001 ²⁴⁹	0/36	1/36	0.00 (-0.23 to 0.23)	9.47	0.00 (-0.02 to 0.12)	9.47
Oxybutynin 10mg	Nausea	Staskin, 2009 ³¹	1/389	2/400	-0.17 (-0.40 to 0.06)	9.47	0.00 (0.10 to 0.01)	9.47
Oxybutynin 15mg	Nausea	Abrams, 1998 ²¹⁹	7/118	6/57	-0.11 (-0.23 to 0.02)	15.35	-0.06 (-0.09 to 0.01)	15.35
Oxybutynin 20mg	Nausea	Tapp, 1990 ³⁸⁴	7/37	0/33	-0.02 (-0.09 to 0.05)	18.34	0.00 (0.01 to 0.00)	18.34
Oxybutynin	Nausea	Pooled	36/934	24/809	0.01 (-0.08 to 0.11)	100	0.00 (-0.02 to 0.05)	100
Oxybutynin	Nausea	Heterogeneity			p value 0.002	68.40%	I-squared	68.40%
Oxybutynin 9mg	Retention	Homma, 2003 ³⁰⁷	8/244	0/122	0.30 (0.13 to 0.47)	30.03	0.09 (0.02 to 0.21)	30.03
Oxybutynin 10mg	Retention	Staskin, 2009 ³¹	0/389	1/400	0.18 (0.07 to 0.29)	34.03	0.05 (0.01 to 0.11)	34.03
Oxybutynin 11.5mg	Retention	Burgio, 1998 ²³⁸	14/67	2/65	-0.05 (-0.12 to 0.02)	35.94	-0.02 (-0.03 to 0.01)	35.94
Oxybutynin	Retention	Pooled	22/700	3/587	0.14 (-0.08 to 0.35)	100	0.04 (-0.01 to 0.16)	100
Oxybutynin	Retention	Heterogeneity			p value 0	90.90%	I-squared	90.90%
Oxybutynin 3.9mg	Serious adverse effects	Dmochowski, 2003 ²⁷⁴	1/121	3/117	-0.07 (-0.20 to 0.06)	32.04	-0.02 (-0.02 to 0.02)	32.04
Oxybutynin 9mg	Serious adverse effects	Homma, 2003 ³⁰⁷	20/244	0/122	0.29 (0.18 to 0.40)	33.08	0.08 (0.03 to 0.15)	33.08
Oxybutynin 10mg	Serious adverse effects	Staskin, 2009 ³¹	7/389	10/400	-0.02 (-0.09 to 0.05)	34.89	-0.01 (-0.02 to 0.02)	34.89
Oxybutynin	Serious adverse effects	Pooled	28/754	13/639	0.07 (-0.15 to 0.28)	100	0.02 (-0.02 to 0.15)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin	Serious adverse effects	Heterogeneity			p value 0	92.50%	I-squared	92.50%
Oxybutynin 3.9mg	Somnolence	Dmochowski, 2002 ²⁷¹	2/125	1/132	0.04 (-0.08 to 0.16)	22.13	0.01 (-0.01 to 0.05)	22.13
Oxybutynin 9mg	Somnolence	Homma, 2003 ³⁰⁷	4/244	4/122	-0.05 (-0.16 to 0.06)	26.88	-0.02 (-0.03 to 0.02)	26.88
Oxybutynin 10mg	Somnolence	Staskin, 2009 ³¹	1/389	0/400	0.05 (-0.02 to 0.12)	51	0.00 (0.00 to 0.01)	51
Oxybutynin	Somnolence	Pooled	7/758	5/654	0.02 (-0.04 to 0.08)	100	0.00 (-0.01 to 0.02)	100
Oxybutynin	Somnolence	Heterogeneity			p value 0.274	22.80%	I-squared	22.80%
Oxybutynin 3.9mg	Vision disorder	Dmochowski, 2002 ²⁷¹	0/125	2/132	0.13 (-0.06 to 0.31)	28.4	0.05 (-0.01 to 0.16)	28.4
Oxybutynin 10mg	Vision disorder	Madersbacher, 1999 ³⁴³	26/145	10/72	0.06 (-0.09 to 0.20)	34.38	0.04 (-0.05 to 0.16)	34.38
Oxybutynin 15mg	Vision disorder	Thuroff, 1991 ³⁸⁶	1/63	0/52	-0.12 (-0.25 to 0.00)	37.22	0.02 (0.06 to 0.00)	37.22
Oxybutynin	Vision disorder	Pooled	27/333	12/256	0.01 (-0.14 to 0.16)	100	0.00 (-0.04 to 0.09)	100
Oxybutynin	Vision disorder	Heterogeneity			p value 0.045	67.90%	I-squared	67.90%
Oxybutynin 5mg	Blurred vision	Szonyi, 1995 ³⁸²	14/28	17/29	0.31 (0.07 to 0.54)	15.51	0.27 (0.07 to 0.39)	15.51
Oxybutynin 9mg	Blurred vision	Homma, 2003 ³⁰⁷	8/244	0/122	-0.09 (-0.35 to 0.17)	13.28	0.01 (0.12 to 0.03)	13.28
Oxybutynin 11.5mg	Blurred vision	Burgio, 1998 ²³⁸	10/67	6/65	0.09 (-0.08 to 0.26)	23.98	0.06 (-0.04 to 0.20)	23.98
Oxybutynin 15mg	Blurred vision	Zinner, 2005 ⁴⁰⁵	1/19	0/19	0.18 (0.07 to 0.29)	37.71	0.03 (0.01 to 0.08)	37.71
Oxybutynin 20mg	Blurred vision	Tapp, 1990 ³⁸⁴	8/37	1/33	0.18 (-0.14 to 0.50)	9.53	0.09 (-0.03 to 0.36)	9.53
Oxybutynin	Blurred vision	Pooled	41/395	24/268	0.14 (0.04 to 0.25)	100	0.10 (0.02 to 0.19)	100
Oxybutynin	Blurred vision	Heterogeneity			p value 0.202	32.90%	I-squared	32.90%
Oxybutynin 5mg	Vomiting	Chancellor, 2001 ²⁴⁹	2/36	0/36	-0.05 (-0.19 to 0.09)	40.89	0.00 (0.04 to 0.01)	40.89

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin 10mg	Vomiting	Madersbacher, 1999 ³⁴³	2/145	2/72	0.24 (0.01 to 0.47)	29.56	0.13 (0.00 to 0.33)	29.56
Oxybutynin 10mg	Vomiting	Chancellor, 2001 ²⁴⁹	1/36	0/36	0.17 (-0.06 to 0.40)	29.56	0.03 (0.00 to 0.15)	29.56
Oxybutynin	Vomiting	Pooled	5/217	2/144	0.10 (-0.09 to 0.29)	100	0.03 (-0.01 to 0.14)	100
Oxybutynin	Vomiting	Heterogeneity			p value 0.067	63.10%	I-squared	63.10%
Oxybutynin 3mg	Constipation	Moore, 1990 ³⁵¹	6/48	0/43	0.19 (-0.04 to 0.43)	9.47	0.04 (0.00 to 0.17)	9.47
Oxybutynin 3.9mg	Constipation	Dmochowski, 2002 ²⁷¹	1/125	4/132	0.36 (0.16 to 0.57)	11.12	0.23 (0.08 to 0.43)	11.12
Oxybutynin 9mg	Constipation	Homma, 2003 ³⁰⁷	15/244	6/122	0.01 (-0.16 to 0.19)	13.57	0.01 (-0.04 to 0.11)	13.57
Oxybutynin 10mg	Constipation	Staskin, 2009 ³¹	5/389	4/400	-0.09 (-0.21 to 0.04)	17.78	-0.01 (0.00 to 0.01)	17.78
Oxybutynin 11.5mg	Constipation	Burgio, 1998 ²³⁸	26/67	24/65	0.03 (-0.08 to 0.14)	19.09	0.03 (-0.08 to 0.13)	19.09
Oxybutynin 15mg	Constipation	Zinner, 2005 ⁴⁰⁵	2/19	1/19	0.11 (-0.21 to 0.43)	6.16	0.05 (-0.03 to 0.29)	6.16
Oxybutynin 20mg	Constipation	Tapp, 1990 ³⁸⁴	13/37	6/33	0.01 (-0.06 to 0.08)	22.81	0.01 (-0.04 to 0.07)	22.81
Oxybutynin	Constipation	Pooled	67/929	45/814	0.06 (-0.03 to 0.15)	100	0.03 (-0.01 to 0.09)	100
Oxybutynin	Constipation	Heterogeneity			p value 0.015	61.90%	I-squared	61.90%
Oxybutynin 5mg	Treatment discontinuation	Szonyi, 1995 ³⁸²	8/28	5/29	0.14 (-0.12 to 0.40)	4.72	0.11 (-0.08 to 0.37)	4.72
Oxybutynin 10mg	Treatment discontinuation	Madersbacher, 1999 ³⁴³	16/145	7/72	0.02 (-0.16 to 0.19)	10.92	0.01 (-0.07 to 0.14)	10.92
Oxybutynin 10mg	Treatment discontinuation	Staskin, 2009 ³¹	43/389	45/400	0.02 (-0.12 to 0.16)	15.93	0.01 (-0.06 to 0.12)	15.93
Oxybutynin 11.5mg	Treatment discontinuation	Burgio, 1998 ²³⁸	10/67	9/65	0.12 (-0.20 to 0.44)	3.15	0.09 (-0.11 to 0.40)	3.15
Oxybutynin 15mg	Treatment discontinuation	Zinner, 2005 ⁴⁰⁵	6/19	4/19	0.00 (-0.07 to 0.07)	65.29	0.00 (-0.06 to 0.06)	65.29
Oxybutynin	Treatment discontinuation	Pooled	83/648	70/585	0.01 (-0.04 to 0.07)	100	0.01 (-0.03 to 0.05)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin	Treatment discontinuation	Heterogeneity			p value 0.824	0.00%	I-squared	0.00%
Oxybutynin 9mg	Treatment discontinuation due to adverse effects	Homma, 2003 ³⁰⁷	42/244	11/122	0.18 (0.00 to 0.36)	15.58	0.13 (0.00 to 0.29)	15.58
Oxybutynin 10mg	Treatment discontinuation due to adverse effects	Staskin, 2009 ³¹	19/389	13/400	0.07 (-0.09 to 0.22)	18.53	0.03 (-0.02 to 0.12)	18.53
Oxybutynin 15mg	Treatment discontinuation due to adverse effects	Thuroff, 1991 ³⁸⁶	2/63	0/52	0.12 (0.01 to 0.23)	25.97	0.01 (0.00 to 0.05)	25.97
Oxybutynin 15mg	Treatment discontinuation due to adverse effects	Abrams, 1998 ²¹⁹	20/118	7/57	0.48 (0.16 to 0.80)	6.98	0.43 (0.12 to 0.71)	6.98
Oxybutynin 15mg	Treatment discontinuation due to adverse effects	Zinner, 2005 ⁴⁰⁵	4/19	0/19	0.04 (-0.03 to 0.11)	32.93	0.00 (0.00 to 0.01)	32.93
Oxybutynin	Treatment discontinuation due to adverse	Pooled	87/833	31/650	0.12 (0.03 to 0.21)	100	0.06 (0.01 to 0.13)	100
Oxybutynin	Treatment discontinuation due to adverse	Heterogeneity			p value 0.066	54.60%	I-squared	54.60%
Oxybutynin 3mg	Dizziness	Moore, 1990 ³⁵¹	2/48	3/43	-0.06 (-0.27 to 0.14)	6.05	-0.03 (-0.07 to 0.09)	6.05
Oxybutynin 3.9mg	Dizziness	Dmochowski, 2002 ²⁷¹	5/125	5/132	0.01 (-0.12 to 0.13)	17.12	0.00 (-0.03 to 0.06)	17.12
Oxybutynin 9mg	Dizziness	Homma, 2003 ³⁰⁷	6/244	2/122	0.03 (-0.08 to 0.14)	21.69	0.01 (-0.01 to 0.05)	21.69
Oxybutynin 10mg	Dizziness	Staskin, 2009 ³¹	6/389	2/400	0.13 (-0.19 to 0.45)	2.53	0.03 (0.01 to 0.24)	2.53

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin	Dizziness	Zinner, 2005 ⁴⁰⁵	0/19	0/19	0.05 (-0.02 to 0.12)	52.6	0.00 (0.00 to 0.02)	52.6
Oxybutynin	Dizziness	Pooled	19/806	12/697	0.04 (-0.02 to 0.09)	100	0.01 (0.00 to 0.03)	100
Oxybutynin	Dizziness	Heterogeneity			p value 0.795	0.00%	I-squared	0.00%
Oxybutynin 3mg	Dry mouth	Moore, 1990 ³⁵¹	42/48	14/43	0.50 (0.27 to 0.74)	10.52	0.48 (0.27 to 0.62)	10.52
Oxybutynin 2.6mg	Dry mouth	Dmochowski, 2002 ²⁷¹	27/388	11/132	0.61 (0.40 to 0.81)	10.91	0.53 (0.32 to 0.71)	10.91
Oxybutynin 5mg	Dry mouth	Szonyi, 1995 ³⁸²	26/28	25/29	0.12 (-0.14 to 0.38)	10.16	0.07 (-0.11 to 0.14)	10.16
Oxybutynin 9mg	Dry mouth	Homma, 2003 ³⁰⁷	131/244	12/122	0.72 (0.56 to 0.88)	11.49	0.64 (0.49 to 0.77)	11.49
Oxybutynin 10mg	Dry mouth	Staskin, 2009 ³¹	27/389	11/400	0.56 (0.39 to 0.73)	11.34	0.41 (0.25 to 0.58)	11.34
Oxybutynin 11.5mg	Dry mouth	Burgio, 1998 ²³⁸	65/67	36/65	-0.02 (-0.12 to 0.07)	12.05	-0.02 (-0.12 to 0.07)	12.05
Oxybutynin 15mg	Dry mouth	Abrams, 1998 ²¹⁹	102/118	12/57	0.50 (0.40 to 0.61)	11.97	0.48 (0.38 to 0.57)	11.97
Oxybutynin 15mg	Dry mouth	Zinner, 2005 ⁴⁰⁵	7/19	1/19	0.42 (0.10 to 0.74)	9.31	0.31 (-0.05 to 0.62)	9.31
Oxybutynin 20mg	Dry mouth	Tapp, 1990 ³⁸⁴	29/37	10/33	0.10 (0.03 to 0.17)	12.24	0.10 (0.03 to 0.16)	12.24
Oxybutynin	Dry mouth	Pooled	456/1338	132/900	0.39 (0.19 to 0.58)	100	0.35 (0.16 to 0.54)	100
Oxybutynin	Dry mouth	Heterogeneity			p value 0	94.00%	I-squared	94.00%
Oxybutynin 5mg	Dry skin	Szonyi, 1995 ³⁸²	14/28	17/29	0.46 (0.23 to 0.69)	31.64	0.36 (0.20 to 0.41)	31.64
Oxybutynin 9mg	Dry skin	Homma, 2003 ³⁰⁷	4/244	1/122	-0.09 (-0.35 to 0.17)	30.17	-0.01 (0.06 to 0.06)	30.17
Oxybutynin 20mg	Dry skin	Tapp, 1990 ³⁸⁴	13/37	1/33	0.04 (-0.07 to 0.15)	38.19	0.01 (-0.02 to 0.07)	38.19
Oxybutynin	Dry skin	Pooled	31/309	19/184	0.13 (-0.15 to 0.42)	100	0.09 (-0.07 to 0.35)	100
Oxybutynin	Dry skin	Heterogeneity			p value 0.002	83.70%	I-squared	83.70%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 2.5mg	Adverse effects	Chapple, 2004 ²⁶⁰	6/41	6/38	-0.02 (-0.24 to 0.21)	11.43	-0.01 (-0.13 to 0.17)	11.43
Solifenacin 5mg	Adverse effects	Chapple, 2004 ²⁶⁰	12/37	6/38	0.20 (-0.03 to 0.42)	11.05	0.17 (-0.02 to 0.39)	11.05
Solifenacin 7.5mg	Adverse effects	Karram, 2009 ³²⁰	160/372	88/367	0.22 (-0.01 to 0.45)	10.84	0.20 (-0.01 to 0.43)	10.84
Solifenacin 10mg	Adverse effects	Chapple, 2004 ²⁶⁰	12/35	6/38	0.45 (0.22 to 0.67)	11.05	0.41 (0.19 to 0.62)	11.05
Solifenacin 10mg	Adverse effects	Chu, 2009 ²⁶⁴	236/340	197/332	0.20 (0.13 to 0.28)	28.06	0.19 (0.12 to 0.24)	28.06
Solifenacin 20mg	Adverse effects	Chapple, 2004 ²⁶⁰	21/37	6/38	0.11 (0.03 to 0.18)	27.58	0.08 (0.02 to 0.15)	27.58
Solifenacin	Adverse effects	Pooled	447/862	309/851	0.18 (0.09 to 0.27)	100	0.18 (0.09 to 0.27)	100
Solifenacin	Adverse effects	Heterogeneity			p value 0.032	59.00%	I-squared	59.00%
Solifenacin 5mg	Dry mouth	Chapple, 2004 ²⁶⁰	5/37	0/38	0.38 (0.15 to 0.60)	4.74	0.13 (0.02 to 0.32)	4.74
Solifenacin 5mg	Dry mouth	Cardozo, 2006 ⁴¹²	35/314	35/781	0.39 (0.16 to 0.62)	4.66	0.28 (0.09 to 0.50)	4.66
Solifenacin 5mg	Dry mouth	Staskin, 2006 ³⁷	63/578	51/1216	0.66 (0.44 to 0.89)	4.74	0.54 (0.32 to 0.75)	4.74
Solifenacin 5mg	Dry mouth	Yamaguchi, 2007 ⁴⁰³	67/400	23/406	0.12 (0.06 to 0.19)	9.48	0.07 (0.03 to 0.12)	9.48
Solifenacin 7.5mg	Dry mouth	Cardozo, 2008 ⁶⁰	80/641	6/224	0.36 (0.31 to 0.41)	9.87	0.22 (0.18 to 0.26)	9.87
Solifenacin 7.5mg	Dry mouth	Karram, 2009 ³²⁰	94/372	33/367	0.13 (0.08 to 0.18)	9.87	0.09 (0.05 to 0.13)	9.87
Solifenacin 7.5mg	Dry mouth	Vardy, 2009 ³⁹²	51/386	9/382	0.35 (0.31 to 0.39)	10.07	0.21 (0.17 to 0.24)	10.07
Solifenacin 10mg	Dry mouth	Chapple, 2004 ²⁶⁰	5/35	0/38	0.18 (0.11 to 0.25)	9.39	0.03 (0.01 to 0.06)	9.39
Solifenacin 10mg	Dry mouth	Cardozo, 2006 ⁴¹²	226/778	35/781	0.38 (0.31 to 0.45)	9.37	0.27 (0.21 to 0.33)	9.37
Solifenacin 10mg	Dry mouth	Staskin, 2006 ³⁷	340/1233	51/1216	0.20 (0.12 to 0.27)	9.19	0.11 (0.06 to 0.17)	9.19

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 10mg	Dry mouth	Yamaguchi, 2007 ⁴⁰³	130/385	23/406	0.22 (0.15 to 0.29)	9.3	0.14 (0.09 to 0.20)	9.3
Solifenacin 20mg	Dry mouth	Chapple, 2004 ²⁶⁰	14/37	0/38	0.22 (0.15 to 0.29)	9.34	0.05 (0.02 to 0.08)	9.34
Solifenacin	Dry mouth	Pooled	1110/5196	266/5893	0.27 (0.21 to 0.34)	100	0.17 (0.12 to 0.23)	100
Solifenacin	Dry mouth	Heterogeneity			p value 0	90.10%	I-squared	90.10%
Solifenacin 5mg	Dyspepsia	Chapple, 2004 ²⁶⁰	1/37	0/38	0.17 (-0.06 to 0.39)	6.55	0.03 (0.00 to 0.15)	6.55
Solifenacin 7.5mg	Dyspepsia	Vardy, 2009 ³⁹²	5/386	0/382	0.17 (-0.06 to 0.40)	6.38	0.03 (0.00 to 0.15)	6.38
Solifenacin 10mg	Dyspepsia	Chapple, 2004 ²⁶⁰	1/35	0/38	0.38 (0.15 to 0.60)	6.55	0.13 (0.02 to 0.32)	6.55
Solifenacin 10mg	Dyspepsia	Chu, 2009 ²⁶⁴	16/340	3/332	0.11 (0.04 to 0.19)	41.88	0.03 (0.01 to 0.07)	41.88
Solifenacin 20mg	Dyspepsia	Chapple, 2004 ²⁶⁰	5/37	0/38	0.12 (0.05 to 0.20)	38.65	0.02 (0.00 to 0.04)	38.65
Solifenacin	Dyspepsia	Pooled	28/835	3/828	0.14 (0.08 to 0.20)	100	0.04 (0.02 to 0.06)	100
Solifenacin	Dyspepsia	Heterogeneity			p value 0.292	19.20%	I-squared	19.20%
Solifenacin 5mg	Treatment failure	Chapple, 2004 ⁵²	2/279	2/267	0.00 (-0.09 to 0.08)	24.12	0.00 (-0.01 to 0.02)	24.12
Solifenacin 7.5mg	Treatment failure	Cardozo, 2008 ⁶⁰	298/641	147/224	-0.20 (-0.27 to - 0.12)	24.97	-0.19 (-0.27 to - 0.12)	24.97
Solifenacin 7.5mg	Treatment failure	Toglia, 2009 ³²¹	112/372	191/367	-0.23 (-0.30 to - 0.15)	25.38	-0.22 (-0.28 to - 0.15)	25.38
Solifenacin 7.5mg	Treatment failure	Vardy, 2009 ³⁹²	53/386	115/382	-0.20 (-0.27 to - 0.13)	25.53	-0.16 (-0.21 to - 0.11)	25.53
Solifenacin	Treatment failure	Pooled	465/1678	455/1240	-0.16 (-0.25 to - 0.06)	100	-0.14 (-0.22 to - 0.06)	100
Solifenacin	Treatment failure	Heterogeneity			p value 0	84.10%	I-squared	84.10%
Solifenacin 7.5mg	Fatigue	Karram, 2009 ³²⁰	10/372	4/367	0.06 (-0.01 to 0.13)	49.04	0.02 (0.00 to 0.04)	49.04
Solifenacin 7.5mg	Fatigue	Vardy, 2009 ³⁹²	5/386	2/382	0.04 (-0.03 to 0.11)	50.96	0.01 (0.00 to 0.03)	50.96

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin	Fatigue	Pooled	15/758	6/749	0.05 (0.00 to 0.10)	100	0.01 (0.00 to 0.03)	100
Solifenacin	Fatigue	Heterogeneity			p value 0.722	0.00%	I-squared	0.00%
Solifenacin 2.5mg	Headache	Chapple, 2004 ²⁶⁰	0/41	1/38	-0.16 (-0.38 to 0.06)	3.18	-0.03 (0.02 to 0.02)	3.18
Solifenacin 5mg	Headache	Chapple, 2004 ²⁶⁰	2/37	1/38	0.07 (-0.16 to 0.30)	3.02	0.03 (-0.03 to 0.17)	3.02
Solifenacin 7.5mg	Headache	Karram, 2009 ³²⁰	17/372	19/367	0.08 (-0.15 to 0.31)	2.94	0.04 (-0.05 to 0.21)	2.94
Solifenacin 7.5mg	Headache	Vardy, 2009 ³⁹²	3/386	5/382	0.07 (-0.16 to 0.30)	3.02	0.02 (-0.01 to 0.15)	3.02
Solifenacin 10mg	Headache	Chapple, 2004 ²⁶⁰	2/35	1/38	-0.01 (-0.09 to 0.06)	29.79	0.00 (-0.02 to 0.02)	29.79
Solifenacin 10mg	Headache	Chu, 2009 ²⁶⁴	16/340	24/332	-0.03 (-0.10 to 0.04)	30.96	-0.01 (-0.04 to 0.02)	30.96
Solifenacin 20mg	Headache	Chapple, 2004 ²⁶⁰	2/37	1/38	-0.05 (-0.13 to 0.02)	27.09	-0.01 (-0.03 to 0.01)	27.09
Solifenacin	Headache	Pooled	42/1248	52/1233	-0.03 (-0.07 to 0.01)	100	-0.01 (-0.02 to 0.01)	100
Solifenacin	Headache	Heterogeneity			p value 0.633	0.00%	I-squared	0.00%
Solifenacin 7.5mg	Nausea	Vardy, 2009 ³⁹²	4/386	6/382	-0.02 (-0.09 to 0.05)	52.34	-0.01 (-0.01 to 0.01)	52.34
Solifenacin 10mg	Nausea	Chu, 2009 ²⁶⁴	19/340	13/332	0.04 (-0.04 to 0.12)	47.66	0.02 (-0.01 to 0.06)	47.66
Solifenacin	Nausea	Pooled	23/726	19/714	0.01 (-0.06 to 0.07)	100	0.00 (-0.01 to 0.03)	100
Solifenacin	Nausea	Heterogeneity			p value 0.232	30.00%	I-squared	30.00%
Solifenacin 10mg	Urinary retention	Chu, 2009 ²⁶⁴	7/340	3/332	0.24 (0.01 to 0.46)	32.85	0.10 (0.00 to 0.27)	32.85
Solifenacin 20mg	Urinary retention	Chapple, 2004 ²⁶⁰	2/37	0/38	0.05 (-0.03 to 0.12)	67.15	0.00 (0.00 to 0.02)	67.15
Solifenacin	Urinary retention	Pooled	9/377	3/370	0.11 (-0.06 to 0.28)	100	0.03 (-0.01 to 0.12)	100
Solifenacin	Urinary retention	Heterogeneity			p value 0.127	57.10%	I-squared	57.10%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 2.5mg	Blurred vision	Chapple, 2004 ²⁶⁰	1/41	2/38	-0.08 (-0.30 to 0.15)	0.94	-0.03 (-0.05 to 0.08)	0.94
Solifenacin 5mg	Blurred vision	Chapple, 2004 ²⁶⁰	1/37	2/38	-0.07 (-0.29 to 0.16)	0.9	-0.03 (-0.05 to 0.09)	0.9
Solifenacin 5mg	Blurred vision	Chapple, 2004 ⁵²	10/279	7/267	0.16 (-0.07 to 0.39)	0.87	0.07 (-0.02 to 0.25)	0.87
Solifenacin 5mg	Blurred vision	Cardozo, 2006 ⁴¹²	13/314	14/781	0.15 (-0.08 to 0.37)	0.9	0.06 (-0.02 to 0.22)	0.9
Solifenacin 5mg	Blurred vision	Staskin, 2006 ³⁷	22/578	22/1216	0.03 (-0.06 to 0.11)	5.4	0.01 (-0.01 to 0.04)	5.4
Solifenacin 5mg	Blurred vision	Yamaguchi, 2007 ⁴⁰³	7/400	8/406	0.08 (-0.01 to 0.16)	5.33	0.03 (0.00 to 0.07)	5.33
Solifenacin 7.5mg	Blurred vision	Cardozo, 2008 ⁸⁰	4/641	2/224	0.07 (0.00 to 0.13)	7.86	0.02 (0.00 to 0.04)	7.86
Solifenacin 7.5mg	Blurred vision	Karram, 2009 ³²⁰	14/372	4/367	0.08 (0.03 to 0.13)	11.25	0.02 (0.01 to 0.04)	11.25
Solifenacin 7.5mg	Blurred vision	Vardy, 2009 ³⁹²	4/386	5/382	0.06 (0.01 to 0.11)	11.29	0.02 (0.00 to 0.04)	11.29
Solifenacin 10mg	Blurred vision	Chapple, 2004 ²⁶⁰	5/35	2/38	0.09 (0.05 to 0.13)	14.28	0.04 (0.02 to 0.07)	14.28
Solifenacin 10mg	Blurred vision	Chapple, 2004 ⁵²	15/269	7/267	-0.01 (-0.08 to 0.06)	7.28	0.00 (-0.02 to 0.02)	7.28
Solifenacin 10mg	Blurred vision	Cardozo, 2006 ⁴¹²	36/778	14/781	0.06 (-0.01 to 0.13)	7.18	0.02 (0.00 to 0.05)	7.18
Solifenacin 10mg	Blurred vision	Staskin, 2006 ³⁷	59/1233	22/1216	-0.02 (-0.09 to 0.06)	6.3	0.00 (-0.02 to 0.02)	6.3
Solifenacin 10mg	Blurred vision	Yamaguchi, 2007 ⁴⁰³	16/385	8/406	0.09 (0.02 to 0.16)	6.83	0.03 (0.01 to 0.07)	6.83
Solifenacin 10mg	Blurred vision	Chu, 2009 ²⁶⁴	3/340	0/332	-0.01 (-0.08 to 0.06)	7.03	0.00 (0.01 to 0.00)	7.03
Solifenacin 20mg	Blurred vision	Chapple, 2004 ²⁶⁰	5/37	2/38	0.09 (0.02 to 0.17)	6.36	0.05 (0.01 to 0.10)	6.36
Solifenacin	Blurred vision	Pooled	215/6125	121/6797	0.06 (0.03 to 0.08)	100	0.02 (0.01 to 0.03)	100
Solifenacin	Blurred vision	Heterogeneity			p value 0.17	25.20%	I-squared	25.20%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 2.5mg	Constipation	Chapple, 2004 ²⁶⁰	1/41	0/38	0.16 (-0.06 to 0.38)	2.66	0.02 (0.00 to 0.14)	2.66
Solifenacin 5mg	Constipation	Cardozo, 2006 ⁴¹²	20/314	28/781	0.24 (0.01 to 0.47)	2.5	0.14 (0.00 to 0.34)	2.5
Solifenacin 5mg	Constipation	Staskin, 2006 ³⁷	31/578	35/1216	0.41 (0.19 to 0.64)	2.56	0.28 (0.09 to 0.50)	2.56
Solifenacin 5mg	Constipation	Yamaguchi, 2007 ⁴⁰³	42/400	16/406	0.07 (0.00 to 0.13)	9.13	0.03 (0.00 to 0.07)	9.13
Solifenacin 7.5mg	Constipation	Cardozo, 2008 ⁶⁰	35/641	5/224	0.19 (0.14 to 0.24)	10.14	0.09 (0.06 to 0.12)	10.14
Solifenacin 7.5mg	Constipation	Karram, 2009 ³²⁰	55/372	34/367	0.06 (0.01 to 0.11)	10.15	0.04 (0.01 to 0.08)	10.15
Solifenacin 7.5mg	Constipation	Vardy, 2009 ³⁹²	31/386	7/382	0.20 (0.16 to 0.24)	10.72	0.09 (0.07 to 0.12)	10.72
Solifenacin 10mg	Constipation	Chapple, 2004 ²⁶⁰	2/35	0/38	0.13 (0.06 to 0.20)	8.9	0.02 (0.00 to 0.04)	8.9
Solifenacin 10mg	Constipation	Cardozo, 2006 ⁴¹²	109/778	28/781	0.25 (0.18 to 0.32)	8.85	0.14 (0.09 to 0.20)	8.85
Solifenacin 10mg	Constipation	Staskin, 2006 ³⁷	165/1233	35/1216	0.09 (0.01 to 0.16)	8.44	0.04 (0.00 to 0.08)	8.44
Solifenacin 10mg	Constipation	Yamaguchi, 2007 ⁴⁰³	72/385	16/406	0.09 (0.01 to 0.16)	8.7	0.04 (0.01 to 0.08)	8.7
Solifenacin 10mg	Constipation	Chu, 2009 ²⁶⁴	26/340	7/332	0.15 (0.08 to 0.22)	8.79	0.06 (0.03 to 0.11)	8.79
Solifenacin 20mg	Constipation	Chapple, 2004 ²⁶⁰	6/37	0/38	0.13 (0.06 to 0.21)	8.47	0.02 (0.00 to 0.04)	8.47
Solifenacin	Constipation	Pooled	595/5540	212/6225	0.15 (0.11 to 0.19)	100	0.07 (0.05 to 0.10)	100
Solifenacin	Constipation	Heterogeneity			p value 0	74.80%	I-squared	74.80%
Solifenacin 7.5mg	Death	Cardozo, 2008 ⁶⁰	1/641	0/224	0.00 (-0.08 to 0.08)	31.26	0.00 (0.01 to 0.01)	31.26
Solifenacin 10mg	Death	Chapple, 2004 ⁵²	1/269	0/267	0.06 (-0.02 to 0.15)	30.7	0.00 (0.00 to 0.02)	30.7
Solifenacin 5mg	Death	Chapple, 2004 ⁵²	0/279	0/267	0.04 (-0.04 to 0.12)	38.03	0.00 (0.00 to 0.01)	38.03

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin	Death	Pooled	2/1189	0/758	0.03 (-0.01 to 0.08)	100	0.00 (0.00 to 0.01)	100
Solifenacin	Death	Heterogeneity			p value 0.594	0.00%	I-squared	0.00%
Solifenacin 5mg	Treatment discontinuation	Chapple, 2004 ²⁶⁰	3/37	6/38	-0.12 (-0.35 to 0.11)	1.6	-0.08 (-0.15 to 0.08)	1.6
Solifenacin 5mg	Treatment discontinuation	Chapple, 2004 ⁵²	28/279	32/267	0.06 (-0.18 to 0.29)	1.56	0.04 (-0.09 to 0.24)	1.56
Solifenacin 5mg	Treatment discontinuation	Yamaguchi, 2007 ⁴⁰³	34/400	34/406	-0.03 (-0.12 to 0.05)	11.25	-0.02 (-0.05 to 0.03)	11.25
Solifenacin 7.5mg	Treatment discontinuation	Cardozo, 2008 ⁶⁰	49/641	24/224	-0.08 (-0.16 to 0.01)	11.05	-0.04 (-0.08 to 0.00)	11.05
Solifenacin 7.5mg	Treatment discontinuation	Toglia, 2009 ³²¹	9/372	18/367	0.00 (-0.07 to 0.07)	16.28	0.00 (-0.02 to 0.04)	16.28
Solifenacin 10mg	Treatment discontinuation	Chapple, 2004 ²⁶⁰	7/35	6/38	0.00 (-0.07 to 0.07)	15.99	0.00 (-0.05 to 0.05)	15.99
Solifenacin 10mg	Treatment discontinuation	Chapple, 2004 ⁵²	20/269	32/267	-0.05 (-0.13 to 0.02)	13.56	-0.03 (-0.07 to 0.02)	13.56
Solifenacin 10mg	Treatment discontinuation	Yamaguchi, 2007 ⁴⁰³	32/385	34/406	-0.07 (-0.14 to 0.01)	15	-0.03 (-0.06 to 0.00)	15
Solifenacin 10mg	Treatment discontinuation	Chu, 2009 ²⁶⁴	70/340	58/332	0.04 (-0.04 to 0.12)	13.71	0.03 (-0.03 to 0.10)	13.71
Solifenacin	Treatment discontinuation	Pooled	252/2758	244/2345	-0.03 (-0.05 to 0.00)	100	-0.01 (-0.03 to 0.00)	100
Solifenacin	Treatment discontinuation	Heterogeneity			p value 0.401	4.10%	I-squared	4.10%
Solifenacin 5mg	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁵²	9/279	10/267	-0.01 (-0.10 to 0.07)	7.4	-0.01 (-0.03 to 0.03)	7.4
Solifenacin 5mg	Treatment discontinuation due to adverse effects	Cardozo, 2006 ⁴¹²	14/314	40/781	-0.03 (-0.12 to 0.05)	7.31	-0.01 (-0.04 to 0.03)	7.31

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 5mg	Treatment discontinuation due to adverse effects	Staskin, 2006 ³⁷	4/159	19/430	-0.02 (-0.08 to 0.05)	10.16	-0.01 (-0.03 to 0.02)	10.16
Solifenacin 5mg	Treatment discontinuation due to adverse effects	Yamaguchi, 2007 ⁴⁰³	20/400	11/406	0.03 (-0.02 to 0.08)	13.5	0.01 (-0.01 to 0.03)	13.5
Solifenacin 7.5mg	Treatment discontinuation due to adverse effects	Cardozo, 2008 ⁶⁰	15/641	4/224	-0.04 (-0.13 to 0.05)	6.59	-0.01 (-0.02 to 0.01)	6.59
Solifenacin 7.5mg	Treatment discontinuation due to adverse effects	Karram, 2009 ³²⁰	24/372	17/367	0.05 (-0.01 to 0.12)	10.07	0.02 (-0.01 to 0.06)	10.07
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁵²	7/269	10/267	0.06 (-0.01 to 0.13)	9.54	0.03 (0.00 to 0.06)	9.54
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Cardozo, 2006 ⁴¹²	51/778	40/781	0.10 (0.03 to 0.17)	9.43	0.05 (0.01 to 0.10)	9.43
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Staskin, 2006 ³⁷	31/452	19/430	0.02 (-0.06 to 0.10)	8.44	0.01 (-0.02 to 0.05)	8.44
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Yamaguchi, 2007 ⁴⁰³	26/385	11/406	0.04 (-0.03 to 0.11)	9.04	0.02 (-0.01 to 0.05)	9.04
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Chu, 2009 ²⁶⁴	37/340	18/332	0.10 (0.03 to 0.18)	8.51	0.05 (0.01 to 0.11)	8.51

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin	Treatment discontinuation due to adverse effects	Pooled	237/4389	198/4691	0.03 (0.00 to 0.06)	100	0.01 (0.00 to 0.03)	100
Solifenacin	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.095	38.10%	I-squared	38.10%
Solifenacin 7.5mg	Treatment discontinuation due to failure	Cardozo, 2008 ⁶⁰	11/641	6/224	-0.03 (-0.11 to 0.06)	20.53	-0.01 (-0.02 to 0.02)	20.53
Solifenacin 7.5mg	Treatment discontinuation due to failure	Toglia, 2009 ³²¹	8/372	5/367	-0.03 (-0.11 to 0.04)	25.43	-0.01 (-0.01 to 0.01)	25.43
Solifenacin 10mg	Treatment discontinuation due to failure	Chapple, 2004 ⁵²	1/269	2/267	0.03 (-0.04 to 0.10)	28.3	0.01 (-0.01 to 0.03)	28.3
Solifenacin 10mg	Treatment discontinuation due to failure	Chu, 2009 ²⁶⁴	4/340	3/332	0.01 (-0.06 to 0.09)	25.74	0.00 (-0.01 to 0.02)	25.74
Solifenacin	Treatment discontinuation due to failure	Pooled	24/1622	16/1190	0.00 (-0.04 to 0.04)	100	0.00 (-0.01 to 0.01)	100
Solifenacin	Treatment discontinuation due to failure	Heterogeneity			p value 0.601	0.00%	I-squared	0.00%
Solifenacin 7.5mg	Dizziness	Karram, 2009 ³²⁰	12/372	7/367	0.04 (-0.03 to 0.11)	52.38	0.01 (-0.01 to 0.04)	52.38
Solifenacin 10mg	Dizziness	Chu, 2009 ²⁶⁴	10/340	8/332	0.02 (-0.06 to 0.09)	47.62	0.01 (-0.01 to 0.04)	47.62
Solifenacin	Dizziness	Pooled	22/712	15/699	0.03 (-0.02 to 0.08)	100	0.01 (-0.01 to 0.03)	100
Solifenacin	Dizziness	Heterogeneity			p value 0.638	0.00%	I-squared	0.00%
Tolterodine 2mg	Abdominal pain	Jackquetin, 2001 ³¹²	6/97	2/51	0.07 (0.01 to 0.13)	24.53	0.03 (0.00 to 0.07)	24.53

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Abdominal pain	Van Kerrebroeck, 2001 ³³¹	19/507	8/508	0.03 (-0.03 to 0.10)	24.69	0.01 (-0.01 to 0.03)	24.69
Tolterodine 4mg	Abdominal pain	Van Kerrebroeck, 2001 ³³¹	13/514	8/508	0.03 (-0.13 to 0.19)	3.64	0.01 (-0.02 to 0.08)	3.64
Tolterodine 4mg	Abdominal pain	Malone-Lee, 2001 ³⁴⁶	6/73	5/74	0.05 (-0.12 to 0.22)	3.31	0.03 (-0.05 to 0.15)	3.31
Tolterodine 4mg	Abdominal pain	Jackquetin, 2001 ³¹²	4/103	2/51	0.00 (-0.17 to 0.17)	3.38	0.00 (-0.04 to 0.09)	3.38
Tolterodine 4mg	Abdominal pain	Khullar, 2004 ³²⁵	12/569	2/285	0.06 (-0.01 to 0.13)	18.49	0.01 (0.00 to 0.04)	18.49
Tolterodine 4mg	Abdominal pain	NCT00444925 ⁵⁶	4/690	4/337	-0.03 (-0.10 to 0.03)	21.95	-0.01 (-0.01 to 0.01)	21.95
Tolterodine	Abdominal pain	Pooled	64/2553	31/1814	0.03 (0.00 to 0.06)	100	0.01 (0.00 to 0.02)	100
Tolterodine	Abdominal pain	Heterogeneity			p value 0.413	1.60%	I-squared	1.60%
Tolterodine 2mg	Treatment discontinuation due to adverse effects	Jackquetin, 2001 ³¹²	3/97	1/51	-0.33 (-0.62 to - 0.03)	2.18	0.01 (0.20 to - 0.01)	2.18
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Abrams, 1998 ²¹⁹	10/118	7/57	-0.06 (-0.22 to 0.10)	6.16	-0.04 (-0.10 to 0.07)	6.16
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Drutz, 1999 ²⁷⁹	7/109	4/56	-0.01 (-0.18 to 0.15)	5.99	-0.01 (-0.06 to 0.09)	5.99
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Malone-Lee, 2001 ³⁴⁶	7/73	1/74	0.18 (0.02 to 0.34)	5.96	0.08 (0.01 to 0.20)	5.96
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Jackquetin, 2001 ³¹²	2/103	1/51	0.04 (-0.13 to 0.21)	5.56	0.01 (-0.02 to 0.10)	5.56

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁵²	5/266	10/267	0.00 (-0.17 to 0.17)	5.65	0.00 (-0.04 to 0.09)	5.65
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Khullar, 2004 ³²⁵	26/569	16/285	-0.06 (-0.14 to 0.03)	12.68	-0.02 (-0.05 to 0.01)	12.68
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Chapple, 2007 ²⁵³	9/290	6/285	-0.02 (-0.09 to 0.05)	14.53	-0.01 (-0.02 to 0.02)	14.53
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Herschorn, 2008 ³⁰¹	12/410	2/207	0.03 (-0.05 to 0.11)	13.09	0.01 (-0.01 to 0.03)	13.09
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Herschorn, 2010 ⁴⁷⁰	28/684	6/334	0.07 (-0.01 to 0.16)	12.85	0.02 (0.00 to 0.06)	12.85
Tolterodine 7.5mg	Treatment discontinuation due to adverse effects	Rentzhog, 1998 ³⁶⁰	2/67	3/13	0.07 (0.00 to 0.14)	15.35	0.06 (0.00 to 0.12)	15.35
Tolterodine	Treatment discontinuation due to adverse effects	Pooled	111/2786	57/1680	0.01 (-0.03 to 0.06)	100	0.01 (-0.01 to 0.03)	100
Tolterodine	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.044	46.60%	I-squared	46.60%
Tolterodine 4mg	Treatment discontinuation due to failure	Khullar, 2004 ³²⁵	3/569	2/285	0.02 (-0.07 to 0.11)	16.45	0.00 (-0.01 to 0.03)	16.45

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Treatment discontinuation due to failure	Herschorn, 2008 ³⁰¹	3/410	9/207	-0.01 (-0.08 to 0.06)	20.76	-0.01 (-0.03 to 0.03)	20.76
Tolterodine 4mg	Treatment discontinuation due to failure	Herschorn, 2010 ⁴⁷⁰	5/684	5/334	-0.12 (-0.21 to - 0.04)	16.81	-0.01 (-0.01 to - 0.01)	16.81
Tolterodine 4mg	Treatment discontinuation due to failure	NCT00444925 ⁵⁶	5/690	5/337	-0.04 (-0.10 to 0.03)	22.93	-0.01 (-0.01 to 0.01)	22.93
Tolterodine 10mg	Treatment discontinuation due to failure	Chapple, 2004 ⁵²	3/266	2/267	-0.04 (-0.10 to 0.03)	23.05	-0.01 (-0.01 to 0.01)	23.05
Tolterodine	Treatment discontinuation due to failure	Pooled	19/2619	23/1430	-0.04 (-0.08 to 0.00)	100	-0.01 (-0.01 to 0.00)	100
Tolterodine	Treatment discontinuation due to failure	Heterogeneity			p value 0.174	37.10%	I-squared	37.10%
Tolterodine 4mg	Dizziness	Van Kerrebroeck, 2001 ³³¹	11/507	5/508	0.05 (-0.01 to 0.11)	19.93	0.01 (0.00 to 0.03)	19.93
Tolterodine 4mg	Dizziness	Van Kerrebroeck, 2001 ³³¹	9/514	5/508	0.03 (-0.03 to 0.10)	20.05	0.01 (0.00 to 0.03)	20.05
Tolterodine 4mg	Dizziness	Malone-Lee, 2001 ³⁴⁶	4/73	7/74	-0.08 (-0.24 to 0.09)	3.23	-0.04 (-0.09 to 0.06)	3.23
Tolterodine 4mg	Dizziness	Khullar, 2004 ³²⁵	6/569	3/285	0.00 (-0.07 to 0.07)	15.39	0.00 (-0.01 to 0.02)	15.39
Tolterodine 4mg	Dizziness	Chapple, 2007 ²⁵³	4/290	7/285	-0.04 (-0.12 to 0.04)	11.93	-0.01 (-0.02 to 0.01)	11.93
Tolterodine 4mg	Dizziness	Herschorn, 200 ⁸³⁰¹	5/410	5/207	-0.05 (-0.13 to 0.04)	11.45	-0.01 (-0.02 to 0.01)	11.45
Tolterodine 4mg	Dizziness	NCT00444925 ⁵⁶	10/690	3/337	0.03 (-0.04 to 0.09)	18.02	0.01 (-0.01 to 0.03)	18.02
Tolterodine	Dizziness	Pooled	49/3053	35/2204	0.01 (-0.02 to 0.04)	100	0.00 (0.00 to 0.01)	100
Tolterodine	Dizziness	Heterogeneity			p value 0.362	8.70%	I-squared	8.70%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 1mg	Dry mouth	Rentzhog, 1998 ³⁶⁰	2/21	2/13	-0.09 (-0.44 to 0.26)	1.46	-0.06 (-0.15 to 0.22)	1.46
Tolterodine 2mg	Dry mouth	Rentzhog, 1998 ³⁶⁰	2/16	2/13	-0.04 (-0.41 to 0.32)	1.32	-0.03 (-0.15 to 0.29)	1.32
Tolterodine 4mg	Dry mouth	Rentzhog, 1998 ³⁶⁰	5/14	2/13	0.24 (-0.14 to 0.62)	1.25	0.20 (-0.09 to 0.57)	1.25
Tolterodine 4mg	Dry mouth	Abrams, 1998 ²¹⁹	59/118	12/57	0.45 (0.08 to 0.81)	1.32	0.42 (0.07 to 0.71)	1.32
Tolterodine 4mg	Dry mouth	Van Kerrebroeck, 2001 ³³¹	118/507	39/508	0.31 (0.15 to 0.47)	4.76	0.23 (0.10 to 0.39)	4.76
Tolterodine 4mg	Dry mouth	Jackquetin, 2001 ³¹²	35/103	3/51	0.22 (0.16 to 0.28)	9.61	0.14 (0.10 to 0.20)	9.61
Tolterodine 4mg	Dry mouth	Chapple, 2004 ²⁶⁰	9/37	0/38	0.38 (0.21 to 0.55)	4.42	0.14 (0.04 to 0.27)	4.42
Tolterodine 4mg	Dry mouth	Chapple, 2007 ²⁵³	49/290	20/285	0.52 (0.29 to 0.74)	2.93	0.43 (0.21 to 0.65)	2.93
Tolterodine 4mg	Dry mouth	Rogers, 2008 ³⁶⁵	26/202	19/211	0.22 (0.14 to 0.31)	8.25	0.16 (0.09 to 0.24)	8.25
Tolterodine 4mg	Dry mouth	Herschorn, 2008 ³⁰¹	89/410	21/207	0.16 (0.07 to 0.24)	8.43	0.11 (0.05 to 0.18)	8.43
Tolterodine 4mg	Dry mouth	Malone-Lee, 2009 ³⁴⁵	20/165	0/142	0.06 (-0.03 to 0.16)	7.59	0.00 (0.00 to 0.03)	7.59
Tolterodine 4mg	Dry mouth	Herschorn, 2010 ⁴⁷⁰	112/684	20/334	0.16 (0.08 to 0.24)	8.33	0.10 (0.04 to 0.16)	8.33
Tolterodine 4mg	Dry mouth	Junemann, 2000 ³¹⁶	21/76	5/79	0.35 (0.24 to 0.47)	6.75	0.26 (0.16 to 0.37)	6.75
Tolterodine 4mg	Dry mouth	Kaplan, 2010 ³¹⁸	127/974	24/480	0.17 (0.10 to 0.24)	9.39	0.10 (0.05 to 0.15)	9.39
Tolterodine 4mg	Dry mouth	NCT00444925 ⁵⁶	112/690	20/337	0.30 (0.14 to 0.46)	4.78	0.21 (0.08 to 0.36)	4.78
Tolterodine 8mg	Dry mouth	Rentzhog, 1998 ³⁶⁰	9/16	2/13	0.14 (0.09 to 0.20)	10	0.12 (0.07 to 0.17)	10
Tolterodine 10mg	Dry mouth	Chapple, 2004 ⁵²	49/266	13/267	0.17 (0.10 to 0.23)	9.4	0.10 (0.05 to 0.15)	9.4
Tolterodine	Dry mouth	Pooled	844/4589	204/3048	0.21 (0.16 to 0.25)	100	0.14 (0.10 to 0.18)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine	Dry mouth	Heterogeneity			p value 0	63.60%	I-squared	63.60%
Tolterodine 4mg	Dyspepsia	Abrams, 1998 ²¹⁹	11/118	3/57	0.08 (-0.08 to 0.24)	10.84	0.04 (-0.03 to 0.15)	10.84
Tolterodine 4mg	Dyspepsia	Van Kerrebroeck, 2001 ³³¹	15/507	7/508	0.06 (-0.01 to 0.12)	21.66	0.02 (0.00 to 0.04)	21.66
Tolterodine 4mg	Dyspepsia	Malone-Lee, 2001 ³⁴⁶	6/73	9/74	-0.07 (-0.23 to 0.10)	10.55	-0.04 (-0.11 to 0.07)	10.55
Tolterodine 4mg	Dyspepsia	Khullar, 2004 ³²⁵	7/569	2/285	0.03 (-0.04 to 0.10)	20.43	0.01 (-0.01 to 0.03)	20.43
Tolterodine 4mg	Dyspepsia	Malone-Lee, 2009 ³⁴⁵	12/165	0/142	0.27 (0.16 to 0.38)	15.31	0.07 (0.02 to 0.14)	15.31
Tolterodine 4mg	Dyspepsia	NCT00444925 ⁵⁶	8/690	1/337	0.05 (-0.01 to 0.12)	21.2	0.01 (0.00 to 0.03)	21.2
Tolterodine	Dyspepsia	Pooled	59/2122	22/1403	0.07 (0.00 to 0.14)	100	0.02 (0.00 to 0.05)	100
Tolterodine	Dyspepsia	Heterogeneity			p value 0.006	69.50%	I-squared	69.50%
Tolterodine 4mg	Treatment failure	Freeman, 2003 ²⁸⁶	88/398	168/374	-0.25 (-0.32 to - 0.17)	17.28	-0.23 (-0.28 to - 0.17)	17.28
Tolterodine 4mg	Treatment failure	Rogers, 2008 ³⁶⁵	0/202	1/211	-0.07 (-0.17 to 0.03)	15.54	0.00 (0.00 to 0.00)	15.54
Tolterodine 4mg	Treatment failure	Herschorn, 2008 ³⁰¹	16/410	19/207	-0.10 (-0.19 to - 0.02)	16.43	-0.05 (-0.08 to - 0.01)	16.43
Tolterodine 4mg	Treatment failure	Rogers, 2009 ³⁶⁴	16/202	12/211	0.04 (-0.05 to 0.14)	15.54	0.02 (-0.02 to 0.08)	15.54
Tolterodine 4mg	Treatment failure	Herschorn, 2010 ⁴⁷⁰	64/684	34/334	-0.02 (-0.08 to 0.05)	17.6	-0.01 (-0.04 to 0.03)	17.6
Tolterodine 4mg	Treatment failure	NCT00444925 ⁵⁶	59/690	36/337	-0.04 (-0.10 to 0.03)	17.62	-0.02 (-0.05 to 0.02)	17.62
Tolterodine	Treatment failure	Pooled	244/2586	270/1674	-0.07 (-0.15 to 0.01)	100	-0.05 (-0.10 to 0.01)	100
Tolterodine	Treatment failure	Heterogeneity			p value 0	84.90%	I-squared	84.90%
Tolterodine 4mg	Fatigue	Van Kerrebroeck, 2001 ³³¹	11/507	4/508	0.06 (0.00 to 0.12)	32.85	0.01 (0.00 to 0.04)	32.85
Tolterodine 4mg	Fatigue	Chapple, 2007 ²⁵³	10/290	1/285	0.13 (0.05 to 0.21)	19.2	0.03 (0.01 to 0.07)	19.2

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Fatigue	Herschorn, 2008 ³⁰¹	11/410	4/207	0.03 (-0.06 to 0.11)	18.41	0.01 (-0.01 to 0.04)	18.41
Tolterodine 4mg	Fatigue	NCT00444925 ⁵⁶	4/690	0/337	0.08 (0.01 to 0.14)	29.54	0.01 (0.00 to 0.02)	29.54
Tolterodine	Fatigue	Pooled	36/1897	9/1337	0.07 (0.03 to 0.11)	100	0.02 (0.01 to 0.03)	100
Tolterodine	Fatigue	Heterogeneity			p value 0.366	5.30%	I-squared	5.30%
Tolterodine 1mg	Abnormal vision	Rentzhog, 1998 ³⁶⁰	0/21	1/13	-0.28 (-0.63 to 0.07)	2.82	-0.08 (0.04 to 0.04)	2.82
Tolterodine 2mg	Abnormal vision	Rentzhog, 1998 ³⁶⁰	3/16	1/13	0.17 (-0.20 to 0.53)	2.52	0.11 (-0.07 to 0.45)	2.52
Tolterodine 4mg	Abnormal vision	Rentzhog, 1998 ³⁶⁰	1/14	1/13	-0.01 (-0.39 to 0.37)	2.37	-0.01 (-0.07 to 0.29)	2.37
Tolterodine 4mg	Abnormal vision	Van Kerrebroeck, 2001 ³³¹	4/514	2/508	-0.03 (-0.39 to 0.34)	2.52	0.00 (0.10 to 0.15)	2.52
Tolterodine 8mg	Abnormal vision	Rentzhog, 1998 ³⁶⁰	1/16	1/13	0.03 (-0.04 to 0.09)	89.77	0.01 (-0.02 to 0.05)	89.77
Tolterodine	Abnormal vision	Pooled	9/581	6/560	0.02 (-0.04 to 0.08)	100	0.00 (-0.01 to 0.02)	100
Tolterodine	Abnormal vision	Heterogeneity			p value 0.456	0.00%	I-squared	0.00%
Tolterodine 2mg	General body disorders	Jonas, 1997 ³¹⁴	6/99	4/44	-0.06 (-0.24 to 0.12)	47.67	-0.03 (-0.09 to 0.08)	47.67
Tolterodine 4mg	General body disorders	Drutz, 1999 ²⁷⁹	40/109	15/56	0.12 (-0.04 to 0.28)	52.33	0.11 (-0.04 to 0.27)	52.33
Tolterodine	General body disorders	Pooled	46/208	19/100	0.04 (-0.14 to 0.21)	100	0.03 (-0.09 to 0.18)	100
Tolterodine	General body disorders	Heterogeneity			p value 0.149	51.90%	I-squared	51.90%
Tolterodine 2mg	Headache	Jonas, 1997 ³¹⁴	3/99	1/44	0.02 (-0.15 to 0.20)	3.73	0.01 (-0.02 to 0.10)	3.73
Tolterodine 2mg	Headache	Malone-Lee, 2001 ³⁴⁶	5/61	2/74	0.02 (-0.15 to 0.20)	3.73	0.01 (-0.03 to 0.10)	3.73
Tolterodine 2mg	Headache	Jackquetin, 2001 ³¹²	3/97	2/51	0.04 (-0.02 to 0.10)	10.66	0.02 (-0.01 to 0.05)	10.66
Tolterodine 4mg	Headache	Jonas, 1997 ³¹⁴	3/99	1/44	-0.02 (-0.08 to 0.04)	10.68	-0.01 (-0.02 to 0.01)	10.68

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Headache	Van Kerrebroeck, 2001 ³³¹	32/507	23/508	0.13 (-0.04 to 0.30)	3.99	0.07 (-0.02 to 0.19)	3.99
Tolterodine 4mg	Headache	Van Kerrebroeck, 2001 ³³¹	19/514	23/508	0.15 (-0.01 to 0.31)	4.27	0.08 (0.00 to 0.21)	4.27
Tolterodine 4mg	Headache	Malone-Lee, 2001 ³⁴⁶	7/73	2/74	-0.02 (-0.19 to 0.15)	3.99	-0.01 (-0.03 to 0.07)	3.99
Tolterodine 4mg	Headache	Jackquetin, 2001 ³¹²	3/103	2/51	-0.03 (-0.20 to 0.14)	4.05	-0.01 (-0.04 to 0.07)	4.05
Tolterodine 4mg	Headache	Chapple, 2004 ²⁶⁰	0/37	1/38	-0.16 (-0.39 to 0.06)	2.55	-0.03 (0.02 to 0.02)	2.55
Tolterodine 4mg	Headache	Khullar, 2004 ³²⁵	22/569	8/285	0.03 (-0.04 to 0.10)	9.83	0.01 (-0.01 to 0.04)	9.83
Tolterodine 4mg	Headache	Chapple, 2007 ²⁵³	14/290	14/285	0.00 (-0.08 to 0.08)	8.93	0.00 (-0.03 to 0.04)	8.93
Tolterodine 4mg	Headache	Rogers, 2008 ³⁶⁵	7/202	6/211	0.02 (-0.08 to 0.11)	7.78	0.01 (-0.02 to 0.05)	7.78
Tolterodine 4mg	Headache	Herschorn, 2008 ³⁰¹	21/410	9/207	0.02 (-0.07 to 0.10)	8.78	0.01 (-0.02 to 0.05)	8.78
Tolterodine 4mg	Headache	Malone-Lee, 2009 ³⁴⁵	13/165	0/142	0.29 (0.18 to 0.40)	6.71	0.08 (0.03 to 0.15)	6.71
Tolterodine 4mg	Headache	Herschorn, 2010 ⁴⁷⁰	23/684	8/334	0.03 (-0.04 to 0.10)	10.32	0.01 (-0.01 to 0.04)	10.32
Tolterodine	Headache	Pooled	175/3910	102/2856	0.04 (0.00 to 0.08)	100	0.01 (0.00 to 0.03)	100
Tolterodine	Headache	Heterogeneity			p value 0.006	54.20%	I-squared	54.20%
Tolterodine 4mg	Insomnia	Van Kerrebroeck, 2001 ³³¹	7/507	9/508	-0.02 (-0.08 to 0.05)	52.38	0.00 (-0.01 to 0.01)	52.38
Tolterodine 4mg	Insomnia	Rogers, 2008 ³⁶⁵	5/202	0/211	0.16 (0.06 to 0.25)	47.62	0.02 (0.00 to 0.06)	47.62
Tolterodine	Insomnia	Pooled	12/709	9/719	0.07 (-0.10 to 0.24)	100	0.02 (-0.01 to 0.10)	100
Tolterodine	Insomnia	Heterogeneity			p value 0.003	88.70%	I-squared	88.70%
Tolterodine 4mg	Nasopharyngitis	Chapple, 2007 ²⁵³	10/290	7/285	0.03 (-0.05 to 0.11)	21.25	0.01 (-0.01 to 0.05)	21.25
Tolterodine 4mg	Nasopharyngitis	Chapple, 2008 ²⁵⁴	10/290	7/283	0.03 (-0.05 to 0.11)	21.18	0.01 (-0.01 to 0.05)	21.18

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Nasopharyngitis	Rogers, 2008 ³⁶⁵	9/202	10/211	-0.01 (-0.10 to 0.09)	15.26	0.00 (-0.03 to 0.05)	15.26
Tolterodine 4mg	Nasopharyngitis	Herschorn, 2008 ³⁰¹	9/410	5/207	-0.01 (-0.09 to 0.08)	20.34	0.00 (-0.02 to 0.03)	20.34
Tolterodine 4mg	Nasopharyngitis	Sand, 2009 ³⁷⁰	8/227	12/430	0.02 (-0.06 to 0.10)	21.97	0.01 (-0.02 to 0.04)	21.97
Tolterodine	Nasopharyngitis	Pooled	46/1419	41/1416	0.01 (-0.02 to 0.05)	100	0.00 (-0.01 to 0.02)	100
Tolterodine	Nasopharyngitis	Heterogeneity			p value 0.949	0.00%	I-squared	0.00%
Tolterodine 4mg	Nausea	Abrams, 1998 ²¹⁹	4/118	6/57	-0.15 (-0.30 to 0.01)	5.01	-0.07 (-0.10 to 0.01)	5.01
Tolterodine 4mg	Nausea	Van Kerrebroeck, 2001 ³³¹	7/507	10/508	-0.02 (-0.09 to 0.04)	20.04	-0.01 (-0.02 to 0.01)	20.04
Tolterodine 4mg	Nausea	Van Kerrebroeck, 2001 ³³¹	10/514	10/508	0.00 (-0.06 to 0.06)	20.12	0.00 (-0.01 to 0.02)	20.12
Tolterodine 4mg	Nausea	Malone-Lee, 2001 ³⁴⁶	3/73	2/74	0.04 (-0.12 to 0.20)	4.81	0.01 (-0.03 to 0.10)	4.81
Tolterodine 4mg	Nausea	Khullar, 2004 ³²⁵	7/569	5/285	-0.02 (-0.09 to 0.05)	16.98	-0.01 (-0.02 to 0.02)	16.98
Tolterodine 4mg	Nausea	Chapple, 2007 ²⁵³	6/290	1/285	0.09 (0.00 to 0.17)	14.21	0.02 (0.00 to 0.05)	14.21
Tolterodine 4mg	Nausea	NCT00444925 ⁵⁶	7/690	6/337	-0.03 (-0.10 to 0.03)	18.83	-0.01 (-0.02 to 0.01)	18.83
Tolterodine	Nausea	Pooled	44/2761	40/2054	-0.01 (-0.05 to 0.03)	100	0.00 (-0.01 to 0.01)	100
Tolterodine	Nausea	Heterogeneity			p value 0.163	34.70%	I-squared	34.70%
Tolterodine 2mg	Serious adverse effects	Millard, 1999 ³⁴⁹	5/129	1/64	0.07 (-0.08 to 0.22)	5.25	0.02 (-0.01 to 0.10)	5.25
Tolterodine 2mg	Serious adverse effects	Van Kerrebroeck, 2001 ³³¹	12/507	18/508	-0.09 (-0.26 to 0.07)	4.54	-0.03 (-0.03 to 0.03)	4.54
Tolterodine 2mg	Serious adverse effects	Malone-Lee, 2001 ³⁴⁶	2/61	1/74	-0.04 (-0.10 to 0.03)	29.72	-0.01 (-0.01 to 0.01)	29.72
Tolterodine 4mg	Serious adverse effects	Drutz, 1999 ²⁷⁹	1/109	2/56	-0.07 (-0.13 to - 0.01)	29.72	-0.02 (-0.03 to 0.00)	29.72
Tolterodine 4mg	Serious adverse effects	Van Kerrebroeck, 2001 ³³¹	7/507	18/508	0.07 (-0.10 to 0.24)	4.11	0.03 (-0.03 to 0.13)	4.11

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Serious adverse effects	NCT00444925 ⁵⁶	9/690	8/337	-0.04 (-0.11 to 0.03)	26.67	-0.01 (-0.02 to 0.01)	26.67
Tolterodine	Serious adverse effects	Pooled	36/2003	48/1547	-0.04 (-0.08 to - 0.01)	100	-0.01 (-0.02 to 0.00)	100
Tolterodine	Serious adverse effects	Heterogeneity			p value 0.399	2.80%	I-squared	2.80%
Tolterodine 4mg	Somnolence	Van Kerrebroeck, 2001 ³³¹	14/507	9/508	0.03 (-0.03 to 0.10)	52.92	0.01 (-0.01 to 0.03)	52.92
Tolterodine 4mg	Somnolence	Khullar, 2004 ³²⁵	1/569	2/285	-0.04 (-0.11 to 0.03)	47.08	-0.01 (-0.01 to 0.01)	47.08
Tolterodine	Somnolence	Pooled	15/1076	11/793	0.00 (-0.08 to 0.07)	100	0.00 (-0.01 to 0.02)	100
Tolterodine	Somnolence	Heterogeneity			p value 0.116	59.50%	I-squared	59.50%
Tolterodine 4mg	Urinary tract infection	Jonas, 1997 ³¹⁴	2/99	2/44	-0.07 (-0.25 to 0.11)	4.74	-0.03 (-0.04 to 0.05)	4.74
Tolterodine 4mg	Urinary tract infection	Van Kerrebroeck, 2001 ³³¹	16/507	20/508	-0.02 (-0.08 to 0.04)	21.72	-0.01 (-0.03 to 0.02)	21.72
Tolterodine 4mg	Urinary tract infection	Van Kerrebroeck, 2001 ³³¹	13/514	20/508	-0.04 (-0.10 to 0.02)	21.8	-0.01 (-0.03 to 0.01)	21.8
Tolterodine 4mg	Urinary tract infection	Khullar, 2004 ³²⁵	2/569	2/285	-0.03 (-0.10 to 0.05)	18.65	0.00 (-0.01 to 0.01)	18.65
Tolterodine 4mg	Urinary tract infection	Rogers, 2008 ³⁶⁵	12/202	5/211	0.09 (-0.01 to 0.19)	12.67	0.04 (0.00 to 0.09)	12.67
Tolterodine 4mg	Urinary tract infection	Herschorn, 2010 ⁴⁷⁰	10/684	2/334	0.05 (-0.02 to 0.11)	20.42	0.01 (0.00 to 0.03)	20.42
Tolterodine	Urinary tract infection	Pooled	55/2575	51/1890	0.00 (-0.04 to 0.04)	100	0.00 (-0.01 to 0.01)	100
Tolterodine	Urinary tract infection	Heterogeneity			p value 0.133	40.90%	I-squared	40.90%
Tolterodine 1mg	Adverse effects	Rentzhog, 1998 ³⁶⁰	8/21	6/13	-0.08 (-0.25 to 0.10)	3.86	-0.08 (-0.24 to 0.10)	3.86
Tolterodine 2mg	Adverse effects	Jonas, 1997 ³¹⁴	31/99	17/44	-0.06 (-0.44 to 0.32)	0.91	-0.06 (-0.33 to 0.31)	0.91
Tolterodine 2mg	Adverse effects	Rentzhog, 1998 ³⁶⁰	6/16	6/13	-0.08 (-0.43 to 0.26)	1.07	-0.08 (-0.36 to 0.26)	1.07

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Adverse effects	Rentzhog, 1998 ³⁶⁰	10/14	10/13	-0.09 (-0.45 to 0.28)	0.96	-0.08 (-0.44 to 0.18)	0.96
Tolterodine 4mg	Adverse effects	Abrams, 1998 ²¹⁹	105/118	46/57	0.30 (-0.07 to 0.67)	0.96	0.17 (-0.05 to 0.15)	0.96
Tolterodine 4mg	Adverse effects	Drutz, 1999 ²⁷⁹	85/109	42/56	0.12 (-0.04 to 0.28)	4.78	0.09 (-0.04 to 0.19)	4.78
Tolterodine 4mg	Adverse effects	Jackquetin, 2001 ³¹²	55/103	16/51	0.04 (-0.13 to 0.20)	4.62	0.03 (-0.11 to 0.19)	4.62
Tolterodine 4mg	Adverse effects	Chapple, 2004 ²⁶⁰	12/37	6/38	0.23 (0.06 to 0.39)	4.29	0.19 (0.04 to 0.36)	4.29
Tolterodine 4mg	Adverse effects	Khullar, 2004 ³²⁵	221/569	96/285	0.20 (-0.03 to 0.42)	2.44	0.19 (-0.03 to 0.41)	2.44
Tolterodine 4mg	Adverse effects	Chapple, 2007 ²⁵³	144/290	107/285	0.05 (-0.02 to 0.13)	17.46	0.05 (-0.02 to 0.12)	17.46
Tolterodine 4mg	Adverse effects	Rogers, 2008 ³⁶⁵	114/202	111/211	0.12 (0.04 to 0.20)	14.36	0.12 (0.04 to 0.20)	14.36
Tolterodine 4mg	Adverse effects	Malone-Lee, 2009 ³⁴⁵	88/165	67/142	0.04 (-0.06 to 0.14)	11.15	0.04 (-0.06 to 0.13)	11.15
Tolterodine 4mg	Adverse effects	Junemann, 2000 ³¹⁶	25/76	12/79	0.06 (-0.05 to 0.17)	8.72	0.05 (-0.03 to 0.14)	8.72
Tolterodine 4mg	Adverse effects	NCT00444925 ⁵⁶	213/690	76/337	0.21 (0.05 to 0.37)	4.81	0.19 (0.05 to 0.35)	4.81
Tolterodine 8mg	Adverse effects	Rentzhog, 1998 ³⁶⁰	12/16	6/13	0.09 (0.03 to 0.16)	19.59	0.09 (0.03 to 0.16)	19.59
Tolterodine	Adverse effects	Pooled	1129/2525	624/1637	0.08 (0.05 to 0.12)	100	0.08 (0.05 to 0.12)	100
Tolterodine	Adverse effects	Heterogeneity			p value 0.306	13.20%	I-squared	13.20%
Tolterodine 2mg	Autonomic nervous system	Jonas, 1997 ³¹⁴	11/99	4/44	0.11 (-0.07 to 0.29)	17.49	0.07 (-0.04 to 0.22)	17.49
Tolterodine 2mg	Autonomic nervous system	Millard, 1999 ³⁴⁹	37/129	11/64	0.03 (-0.14 to 0.21)	17.49	0.03 (-0.09 to 0.18)	17.49
Tolterodine 4mg	Autonomic nervous system	Jonas, 1997 ³¹⁴	16/99	4/44	0.14 (-0.01 to 0.29)	22.51	0.10 (0.00 to 0.23)	22.51
Tolterodine 4mg	Autonomic nervous system	Millard, 1999 ³⁴⁹	53/123	11/64	0.29 (0.14 to 0.44)	22.26	0.26 (0.12 to 0.41)	22.26

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Autonomic nervous system	Drutz, 1999 ²⁷⁹	35/109	12/56	0.11 (-0.05 to 0.27)	20.26	0.10 (-0.04 to 0.26)	20.26
Tolterodine	Autonomic nervous system	Pooled	152/559	42/272	0.14 (0.06 to 0.23)	100	0.12 (0.05 to 0.20)	100
Tolterodine	Autonomic nervous system	Heterogeneity			p value 0.25	25.70%	I-squared	25.70%
Tolterodine 4mg	Back pain	Herschorn, 2008 ³⁰¹	8/410	2/207	0.04 (-0.04 to 0.13)	47.25	0.01 (-0.01 to 0.04)	47.25
Tolterodine 4mg	Back pain	NCT00444925 ⁵⁶	7/690	10/337	-0.07 (-0.14 to - 0.01)	52.75	-0.02 (-0.03 to 0.00)	52.75
Tolterodine	Back pain	Pooled	15/1100	12/544	-0.02 (-0.13 to 0.09)	100	0.00 (-0.02 to 0.04)	100
Tolterodine	Back pain	Heterogeneity			p value 0.035	77.50%	I-squared	77.50%
Tolterodine 4mg	Blurred vision	Chapple, 2004 ²⁶⁰	0/37	2/38	-0.23 (-0.46 to - 0.01)	34.42	-0.05 (0.00 to 0.00)	34.42
Tolterodine 10mg	Blurred vision	Chapple, 2004 ⁵²	4/266	7/267	-0.04 (-0.13 to 0.05)	65.58	-0.01 (-0.02 to 0.02)	65.58
Tolterodine	Blurred vision	Pooled	4/303	9/305	-0.11 (-0.28 to 0.07)	100	-0.03 (-0.02 to 0.03)	100
Tolterodine	Blurred vision	Heterogeneity			p value 0.12	58.60%	I-squared	58.60%
Tolterodine 1mg	Constipation	Rentzhog, 1998 ³⁶⁰	1/21	0/13	-0.07 (-0.25 to 0.11)	1.73	0.01 (0.06 to 0.01)	1.73
Tolterodine 2mg	Constipation	Jonas, 1997 ³¹⁴	2/99	2/44	-0.04 (-0.22 to 0.14)	1.73	-0.02 (-0.05 to 0.07)	1.73
Tolterodine 2mg	Constipation	Rentzhog, 1998 ³⁶⁰	3/16	0/13	0.22 (-0.13 to 0.57)	0.47	0.05 (0.02 to 0.29)	0.47
Tolterodine 2mg	Constipation	Malone-Lee, 2001 ³⁴⁶	5/61	2/74	0.45 (0.08 to 0.81)	0.42	0.30 (0.03 to 0.66)	0.42
Tolterodine 2mg	Constipation	Jackquetin, 2001 ³¹²	4/97	2/51	0.27 (-0.11 to 0.65)	0.4	0.17 (-0.03 to 0.52)	0.4
Tolterodine 4mg	Constipation	Jonas, 1997 ³¹⁴	3/99	2/44	0.36 (-0.01 to 0.73)	0.42	0.25 (0.00 to 0.61)	0.42
Tolterodine 4mg	Constipation	Rentzhog, 1998 ³⁶⁰	1/14	0/13	0.04 (-0.03 to 0.10)	10.44	0.00 (0.00 to 0.01)	10.44
Tolterodine 4mg	Constipation	Van Kerrebroeck, 2001 ³³¹	30/507	22/508	0.05 (-0.01 to 0.12)	10.49	0.02 (0.00 to 0.06)	10.49

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Constipation	Van Kerrebroeck, 2001 ³³¹	35/514	22/508	0.13 (-0.04 to 0.30)	1.89	0.06 (-0.02 to 0.19)	1.89
Tolterodine 4mg	Constipation	Malone-Lee, 2001 ³⁴⁶	0/73	2/74	-0.17 (-0.33 to 0.00)	2.07	-0.03 (0.00 to 0.00)	2.07
Tolterodine 4mg	Constipation	Jackquetin, 2001 ³¹²	2/103	2/51	0.01 (-0.16 to 0.18)	1.89	0.00 (-0.04 to 0.09)	1.89
Tolterodine 4mg	Constipation	Chapple, 2004 ²⁶⁰	1/37	0/38	-0.06 (-0.23 to 0.11)	1.93	0.00 (0.05 to 0.01)	1.93
Tolterodine 4mg	Constipation	Khullar, 2004 ³²⁵	9/569	2/285	0.17 (-0.06 to 0.39)	1.09	0.05 (-0.01 to 0.20)	1.09
Tolterodine 4mg	Constipation	Chapple, 2007 ²⁵³	8/290	4/285	0.03 (-0.06 to 0.11)	6.44	0.01 (-0.01 to 0.04)	6.44
Tolterodine 4mg	Constipation	Rogers, 2008 ³⁶⁵	7/202	8/211	0.04 (-0.03 to 0.11)	8.48	0.02 (-0.01 to 0.05)	8.48
Tolterodine 4mg	Constipation	Herschorn, 2008 ³⁰¹	11/410	3/207	0.05 (-0.03 to 0.13)	6.84	0.01 (-0.01 to 0.05)	6.84
Tolterodine 4mg	Constipation	Herschorn, 2010 ⁴⁷⁰	28/684	10/334	-0.01 (-0.11 to 0.09)	5.22	0.00 (-0.03 to 0.04)	5.22
Tolterodine 4mg	Constipation	Kaplan, 2010 ³¹⁸	29/974	10/480	0.04 (-0.04 to 0.13)	6.61	0.01 (-0.01 to 0.05)	6.61
Tolterodine 4mg	Constipation	NCT00444925 ⁵⁶	28/690	10/337	0.03 (-0.04 to 0.10)	9.58	0.01 (-0.01 to 0.04)	9.58
Tolterodine 8mg	Constipation	Rentzhog, 1998 ³⁶⁰	2/16	0/13	0.03 (-0.02 to 0.09)	12.21	0.00 (0.00 to 0.01)	12.21
Tolterodine 10mg	Constipation	Chapple, 2004 ⁵²	7/266	5/267	0.03 (-0.04 to 0.10)	9.64	0.01 (-0.01 to 0.03)	9.64
Tolterodine	Constipation	Pooled	216/5742	108/3850	0.03 (0.01 to 0.06)	100	0.01 (0.00 to 0.02)	100
Tolterodine	Constipation	Heterogeneity			p value 0.258	15.50%	I-squared	15.50%
Tolterodine 4mg	Diarrhea	Van Kerrebroeck, 2001 ³³¹	10/507	11/508	-0.01 (-0.07 to 0.06)	26.42	0.00 (-0.02 to 0.02)	26.42
Tolterodine 4mg	Diarrhea	Van Kerrebroeck, 2001 ³³¹	16/514	11/508	0.03 (-0.03 to 0.09)	26.61	0.01 (-0.01 to 0.03)	26.61
Tolterodine 4mg	Diarrhea	Malone-Lee, 2001 ³⁴⁶	4/73	5/74	-0.03 (-0.19 to 0.14)	3.83	-0.01 (-0.06 to 0.08)	3.83

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Diarrhea	Khullar, 2004 ³²⁵	10/569	3/285	0.03 (-0.04 to 0.10)	19.77	0.01 (-0.01 to 0.03)	19.77
Tolterodine 4mg	Diarrhea	Herschorn, 2010 ⁴⁷⁰	15/684	4/334	0.04 (-0.03 to 0.11)	23.37	0.01 (0.00 to 0.03)	23.37
Tolterodine	Diarrhea	Pooled	55/2347	34/1709	0.02 (-0.01 to 0.05)	100	0.01 (0.00 to 0.02)	100
Tolterodine	Diarrhea	Heterogeneity			p value 0.818	0.00%	I-squared	0.00%
Tolterodine 4mg	Treatment discontinuation	Drutz, 1999 ²⁷⁹	14/109	8/56	-0.02 (-0.18 to 0.14)	3.84	-0.01 (-0.10 to 0.11)	3.84
Tolterodine 4mg	Treatment discontinuation	Van Kerrebroeck, 2001 ³³¹	1/507	8/508	-0.08 (-0.14 to - 0.02)	18.26	-0.01 (-0.02 to 0.00)	18.26
Tolterodine 4mg	Treatment discontinuation	Chapple, 2004 ²⁶⁰	5/37	6/38	-0.03 (-0.26 to 0.19)	2.02	-0.02 (-0.14 to 0.16)	2.02
Tolterodine 4mg	Treatment discontinuation	DuBeau, 2005 ²⁸⁰	29/569	18/285	-0.02 (-0.10 to 0.07)	11.57	-0.01 (-0.04 to 0.04)	11.57
Tolterodine 4mg	Treatment discontinuation	Chapple, 2007 ²⁵³	37/290	33/285	-0.03 (-0.10 to 0.05)	15.03	-0.02 (-0.05 to 0.03)	15.03
Tolterodine 4mg	Treatment discontinuation	Robinson, 2007 ³⁶³	8/61	2/61	0.02 (-0.06 to 0.10)	12.26	0.01 (-0.02 to 0.04)	12.26
Tolterodine 4mg	Treatment discontinuation	Herschorn, 2010 ⁴⁷⁰	56/684	30/334	0.19 (0.01 to 0.37)	3.21	0.13 (0.01 to 0.30)	3.21
Tolterodine 4mg	Treatment discontinuation	NCT00444925 ⁵⁶	6/690	3/337	-0.01 (-0.08 to 0.05)	16.85	0.00 (-0.01 to 0.01)	16.85
Tolterodine 10mg	Treatment discontinuation	Chapple, 2004 ⁵²	29/266	32/267	0.00 (-0.07 to 0.06)	16.95	0.00 (-0.04 to 0.04)	16.95
Tolterodine	Treatment discontinuation	Pooled	185/3213	140/2171	-0.02 (-0.05 to 0.02)	100	-0.01 (-0.02 to 0.01)	100
Tolterodine	Treatment discontinuation	Heterogeneity			p value 0.241	22.80%	I-squared	22.80%
Trospium 60mg	Abdominal distention	Staskin, 2007 ⁴⁵	3/298	1/303	0.04 (-0.04 to 0.12)	37.81	0.01 (0.00 to 0.03)	37.81
Trospium 60mg	Abdominal distention	Sand, 2009 ³⁷¹	6/484	2/505	0.05 (-0.01 to 0.11)	62.19	0.01 (0.00 to 0.03)	62.19
Trospium	Abdominal distention	Pooled	9/782	3/808	0.05 (0.00 to 0.10)	100	0.01 (0.00 to 0.02)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Trospium	Abdominal distention	Heterogeneity			p value 0.914	0.00%	I-squared	0.00%
Trospium 60mg	Dry eye	Staskin, 2007 ⁴⁵	4/298	1/303	0.06 (-0.02 to 0.14)	37.81	0.01 (0.00 to 0.03)	37.81
Trospium 60mg	Dry eye	Sand, 2009 ³⁷¹	9/484	1/505	0.09 (0.03 to 0.16)	62.19	0.02 (0.00 to 0.04)	62.19
Trospium	Dry eye	Pooled	13/782	2/808	0.08 (0.03 to 0.13)	100	0.01 (0.00 to 0.03)	100
Trospium	Dry eye	Heterogeneity			p value 0.515	0.00%	I-squared	0.00%
Trospium 40mg	Dry mouth	Zinner, 2004 ³⁵	57/262	17/261	0.23 (0.14 to 0.31)	16.5	0.15 (0.09 to 0.23)	16.5
Trospium 40mg	Dry mouth	Rudy, 2006 ³⁶⁷	65/329	17/329	0.23 (0.16 to 0.31)	18.75	0.15 (0.09 to 0.21)	18.75
Trospium 40mg	Dry mouth	Junemann, 2000 ³¹⁶	22/76	5/79	0.13 (0.05 to 0.21)	17.85	0.08 (0.02 to 0.13)	17.85
Trospium 60mg	Dry mouth	Staskin, 2007 ⁴⁵	26/298	9/303	0.15 (0.07 to 0.23)	17.23	0.07 (0.03 to 0.13)	17.23
Trospium 60mg	Dry mouth	Dmochowski, 2008 ²⁷²	36/280	13/284	0.15 (0.09 to 0.21)	22.76	0.08 (0.04 to 0.13)	22.76
Trospium 60mg	Dry mouth	Sand, 2009 ³⁷¹	55/484	19/505	0.31 (0.16 to 0.47)	6.91	0.20 (0.08 to 0.34)	6.91
Trospium	Dry mouth	Pooled	261/1729	80/1761	0.19 (0.14 to 0.23)	100	0.11 (0.07 to 0.14)	100
Trospium	Dry mouth	Heterogeneity			p value 0.116	43.30%	I-squared	43.30%
Trospium 60mg	Dry skin	Staskin, 2007 ⁴⁵	3/298	0/303	0.10 (0.02 to 0.18)	37.81	0.01 (0.00 to 0.03)	37.81
Trospium 60mg	Dry skin	Sand, 2009 ³⁷¹	5/484	1/505	0.06 (-0.01 to 0.12)	62.19	0.01 (0.00 to 0.02)	62.19
Trospium	Dry skin	Pooled	8/782	1/808	0.07 (0.02 to 0.12)	100	0.01 (0.00 to 0.02)	100
Trospium	Dry skin	Heterogeneity			p value 0.404	0.00%	I-squared	0.00%
					0.00 (0.00 to 0.00)		0.00 (0.00 to 0.00)	
Trospium 60mg	Dyspepsia	Staskin, 2007 ⁴⁵	6/298	3/303	0.04 (-0.04 to 0.12)	37.81	0.01 (-0.01 to 0.04)	37.81

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tropium 60mg	Dyspepsia	Sand, 2009 ³⁷¹	6/484	4/505	0.02 (-0.04 to 0.09)	62.19	0.00 (-0.01 to 0.02)	62.19
Tropium	Dyspepsia	Pooled	12/782	7/808	0.03 (-0.02 to 0.08)	100	0.00 (0.00 to 0.00)	100
Tropium	Dyspepsia	Heterogeneity			p value 0.695	0.00%	I-squared	0.00%
Tropium 40mg	Headache	Zinner, 2004 ³⁵	17/262	12/261	0.04 (-0.04 to 0.13)	21.17	0.02 (-0.02 to 0.07)	21.17
Tropium 40mg	Headache	Rudy, 2006 ³⁶⁷	18/329	15/329	0.02 (-0.06 to 0.10)	24.58	0.01 (-0.02 to 0.05)	24.58
Tropium 60mg	Headache	Staskin, 2007 ⁴⁵	3/298	8/303	-0.06 (-0.14 to 0.02)	23.2	-0.02 (-0.03 to 0.01)	23.2
Tropium 60mg	Headache	Sand, 2009 ³⁷¹	7/484	14/505	-0.05 (-0.11 to 0.02)	31.05	-0.01 (-0.02 to 0.01)	31.05
Tropium	Headache	Pooled	45/1373	49/1398	-0.02 (-0.06 to 0.03)	100	-0.01 (-0.02 to 0.01)	100
Tropium	Headache	Heterogeneity			p value 0.182	38.30%	I-squared	38.30%
Tropium 60mg	Nausea	Staskin, 2007 ⁴⁵	3/298	2/303	0.02 (-0.06 to 0.10)	39.91	0.00 (-0.01 to 0.03)	39.91
Tropium 60mg	Nausea	Sand, 2009 ³⁷¹	7/484	1/505	0.08 (0.01 to 0.14)	60.09	0.01 (0.00 to 0.03)	60.09
Tropium	Nausea	Pooled	10/782	3/808	0.05 (0.00 to 0.11)	100	0.01 (0.00 to 0.02)	100
Tropium	Nausea	Heterogeneity			p value 0.272	17.30%	I-squared	17.30%
Tropium 40mg	Urinary tract infection	Rudy, 2006 ³⁶⁷	16/329	8/329	0.07 (-0.01 to 0.14)	29.28	0.02 (0.00 to 0.06)	29.28
Tropium 60mg	Urinary tract infection	Staskin, 2007 ⁴⁵	6/298	3/303	0.04 (-0.04 to 0.12)	26.74	0.01 (-0.01 to 0.04)	26.74
Tropium 60mg	Urinary tract infection	Sand, 2009 ³⁷¹	7/484	4/505	0.03 (-0.03 to 0.09)	43.98	0.01 (0.00 to 0.03)	43.98
Tropium	Urinary tract infection	Pooled	29/1111	15/1137	0.05 (0.00 to 0.09)	100	0.01 (0.00 to 0.03)	100
Tropium	Urinary tract infection	Heterogeneity			p value 0.791	0.00%	I-squared	0.00%
Tropium 40mg	Abdominal pain	Zinner, 2004 ³⁵	8/262	3/261	0.07 (-0.02 to 0.15)	24.76	0.02 (0.00 to 0.06)	24.76

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Trospium 60mg	Abdominal pain	Staskin, 2007 ⁴⁵	3/298	2/303	0.02 (-0.06 to 0.10)	28.45	0.00 (-0.01 to 0.03)	28.45
Trospium 60mg	Abdominal pain	Sand, 2009 ³⁷¹	7/484	2/505	0.06 (-0.01 to 0.12)	46.8	0.01 (0.00 to 0.03)	46.8
Trospium	Abdominal pain	Pooled	18/1044	7/1069	0.05 (0.01 to 0.09)	100	0.01 (0.00 to 0.02)	100
Trospium	Abdominal pain	Heterogeneity			p value 0.67	0.00%	I-squared	0.00%
Trospium 40mg	Adverse effects	Rudy, 2006 ³⁶⁷	196/329	153/329	0.13 (0.06 to 0.21)	22.18	0.13 (0.05 to 0.20)	22.18
Trospium 40mg	Adverse effects	Junemann, 2000 ³¹⁶	26/76	12/79	0.11 (0.03 to 0.19)	20.26	0.09 (0.02 to 0.16)	20.26
Trospium 60mg	Adverse effects	Staskin, 2007 ⁴⁵	80/298	53/303	0.09 (0.01 to 0.18)	19.01	0.07 (0.01 to 0.15)	19.01
Trospium 60mg	Adverse effects	Dmochowski, 2008 ²⁷²	154/280	130/284	0.15 (0.08 to 0.21)	33.32	0.15 (0.08 to 0.20)	33.32
Trospium 60mg	Adverse effects	Sand, 2009 ³⁷¹	138/484	83/505	0.22 (0.07 to 0.38)	5.22	0.19 (0.05 to 0.35)	5.22
Trospium	Adverse effects	Pooled	594/1467	431/1500	0.13 (0.09 to 0.17)	100	0.12 (0.09 to 0.16)	100
Trospium	Adverse effects	Heterogeneity			p value 0.627	0.00%	I-squared	0.00%
Trospium 20mg	Central nervous system disorders	Staskin, 2004 ³⁷⁸	19/327	17/326	0.01 (-0.06 to 0.09)	53.66	0.01 (-0.02 to 0.05)	53.66
Trospium 60mg	Central nervous system disorders	Dmochowski, 2008 ²⁷²	5/280	6/284	-0.01 (-0.09 to 0.07)	46.34	0.00 (-0.02 to 0.03)	46.34
Trospium	Central nervous system disorders	Pooled	24/607	23/610	0.00 (-0.06 to 0.06)	100	0.00 (-0.02 to 0.03)	100
Trospium	Central nervous system disorders	Heterogeneity			p value 0.664	0.00%	I-squared	0.00%
Trospium 40mg	Constipation	Zinner, 2004 ³⁵	25/262	10/261	0.12 (0.03 to 0.20)	16.99	0.06 (0.01 to 0.11)	16.99
Trospium 40mg	Constipation	Rudy, 2006 ³⁶⁷	36/329	19/329	0.09 (0.02 to 0.17)	20.06	0.05 (0.01 to 0.10)	20.06

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Trospium 60mg	Constipation	Staskin, 2007 ⁴⁵	28/298	4/303	0.20 (0.12 to 0.28)	18.81	0.08 (0.04 to 0.13)	18.81
Trospium 60mg	Constipation	Dmochowski, 2008 ²⁷²	21/280	5/284	0.14 (0.06 to 0.23)	17.96	0.06 (0.02 to 0.11)	17.96
Trospium 60mg	Constipation	Sand, 2009 ³⁷¹	43/484	6/505	0.19 (0.13 to 0.26)	26.18	0.08 (0.04 to 0.12)	26.18
Trospium	Constipation	Pooled	153/1653	44/1682	0.15 (0.11 to 0.19)	100	0.07 (0.05 to 0.09)	100
Trospium	Constipation	Heterogeneity			p value 0.221	30.10%	I-squared	30.10%
Trospium 40mg	Diarrhea	Zinner, 2004 ³⁵	8/262	14/261	-0.06 (-0.14 to 0.03)	44.28	-0.02 (-0.05 to 0.01)	44.28
Trospium 40mg	Diarrhea	Rudy, 2006 ³⁶⁷	7/329	13/329	-0.05 (-0.13 to 0.02)	55.72	-0.02 (-0.03 to 0.01)	55.72
Trospium	Diarrhea	Pooled	15/591	27/590	-0.06 (-0.11 to 0.00)	100	-0.02 (-0.04 to 0.00)	100
Trospium	Diarrhea	Heterogeneity			p value 0.941	0.00%	I-squared	0.00%
Trospium 60mg	Treatment discontinuation	U.S. Food and Drug Administration ^{38,44}	37/280	36/284	0.01 (-0.08 to 0.09)	48.41	0.01 (-0.05 to 0.07)	48.41
Trospium 60mg	Treatment discontinuation	U.S. Food and Drug Administration ^{38,44}	35/298	30/303	0.03 (-0.05 to 0.11)	51.59	0.02 (-0.03 to 0.07)	51.59
Trospium	Treatment discontinuation	Pooled	72/578	66/587	0.02 (-0.04 to 0.08)	100	0.01 (-0.02 to 0.05)	100
Trospium	Treatment discontinuation	Heterogeneity			p value 0.711	0.00%	I-squared	0.00%
Trospium 40mg	Treatment discontinuation due to adverse effects	Zinner, 2004 ³⁵	23/262	15/261	0.06 (-0.03 to 0.15)	13.29	0.03 (-0.01 to 0.09)	13.29
Trospium 40mg	Treatment discontinuation due to adverse effects	Rudy, 2006 ³⁶⁷	24/329	15/329	0.06 (-0.02 to 0.13)	16.72	0.03 (-0.01 to 0.07)	16.72
Trospium 60mg	Treatment discontinuation due to adverse effects	Staskin, 2007 ⁴⁵	12/298	11/303	0.01 (-0.07 to 0.09)	15.27	0.00 (-0.02 to 0.04)	15.27

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were pooled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Trospium 60mg	Treatment discontinuation due to adverse effects	Sand, 2009 ^{37,1}	24/484	18/505	0.04 (-0.03 to 0.10)	25.12	0.01 (-0.01 to 0.04)	25.12
Trospium 60mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration ^{38,44}	18/280	8/284	0.09 (0.01 to 0.17)	14.33	0.04 (0.00 to 0.08)	14.33
Trospium 60mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration ^{38,44}	12/298	11/303	0.01 (-0.07 to 0.09)	15.27	0.00 (-0.02 to 0.04)	15.27
Trospium	Treatment discontinuation due to adverse effects	Pooled	113/1951	78/1985	0.04 (0.01 to 0.07)	100	0.02 (0.00 to 0.03)	100
Trospium	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.736	0.00%	I-squared	0.00%

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach**

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Solifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁵²	9/279	10/267	0.9 (0.3; 2.1)	6.07	-0.01 (-0.04; 0.03)	8.74
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2006 ⁴¹²	14/314	40/781	0.7 (0.2; 2.2)	3.93	-0.05 (0.03; 6.82)	6.82
Solifenacin	Treatment discontinuation due to adverse effects	Staskin, 1981 ³⁷	4/159	19/430	0.9 (0.5; 1.6)	11.5	-0.03 (0.02; 9.93)	9.93
Solifenacin	Treatment discontinuation due to adverse effects	Yamaguchi, 2007 ⁴⁰³	20/400	11/406	1.3 (0.8; 2.0)	19.46	-0.01 (0.04; 11.79)	11.79
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2008 ⁶⁰	15/641	4/224	0.6 (0.2; 1.7)	4.42	-0.05 (0.01; 8.62)	8.62
Solifenacin	Treatment discontinuation due to adverse effects	Karram, 2009 ³²⁰	24/372	17/367	1.6 (0.9; 2.9)	12.59	-0.01 (0.06; 8.90)	8.9
Solifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁵²	7/269	10/267	1.9 (0.9; 4.0)	8.57	0.00 (0.05; 10.34)	10.34
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2006 ⁴¹²	51/778	40/781	2.8 (1.1; 7.4)	5.46	0.01 (0.08; 7.94)	7.94
Solifenacin	Treatment discontinuation due to adverse effects	Staskin, 1981 ³⁷	31/452	19/430	1.3 (0.4; 4.0)	4.28	-0.02 (0.03; 12.95)	12.95

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach (continued)**

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Solifenacin	Treatment discontinuation due to adverse effects	Yamaguchi, 2007 ⁴⁰³	26/385	11/406	1.4 (0.8; 2.7)	11.07	-0.02 (0.05; 8.04)	8.04
Solifenacin	Treatment discontinuation due to adverse effects	Chu, 2009 ²⁶⁴	37/340	18/332	2.1 (1.2; 3.8)	12.66	0.01 (0.10; 5.94)	5.94
Solifenacin	Treatment discontinuation due to adverse effects	Pooled (IV) odds ratio and ARD with divided placebo size and rates	237/4389	198/4691	1.4 (1.1; 1.7)	100	0.00 (0.02; 100.00)	100
Tolterodine	Treatment discontinuation due to adverse effects	Jacquetin, 2001 ³¹²	3/97	1/51	0.1 (0.0; 0.7)	5.55	-0.43 (0.03; 0.38)	0.38
Tolterodine	Treatment discontinuation due to adverse effects	Abrams, 1998 ²¹⁹	10/118	7/57	0.7 (0.2; 1.8)	12.68	-0.14 (0.06; 2.00)	2
Tolterodine	Treatment discontinuation due to adverse effects	Drutz, 1999 ²⁷⁹	7/109	4/56	0.9 (0.3; 3.2)	9.87	-0.09 (0.07; 2.85)	2.85
Tolterodine	Treatment discontinuation due to adverse effects	Malone-Lee, 2001 ³⁴⁶	7/73	1/74	7.7 (0.9; 64.6)	4.68	0.01 (0.16; 3.54)	3.54
Tolterodine	Treatment discontinuation due to adverse effects	Jacquetin, 2001 ³¹²	2/103	1/51	1.6 (0.2; 15.7)	4.13	-0.04 (0.06; 6.42)	6.42
Tolterodine	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁵²	5/266	10/267	1.0 (0.1; 11.2)	3.74	-0.05 (0.05; 7.53)	7.53

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach (continued)**

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Tolterodine	Treatment discontinuation due to adverse effects	Khullar, 2004 ³²⁵	26/569	16/285	0.5 (0.1; 1.7)	10.02	-0.06 (0.02; 10.89)	10.89
Tolterodine	Treatment discontinuation due to adverse effects	Chapple, 2007 ²⁵³	9/290	6/285	0.8 (0.4; 1.5)	18.49	-0.04 (0.02; 12.95)	12.95
Tolterodine	Treatment discontinuation due to adverse effects	Herschorn, 2008 ³⁰¹	12/410	2/207	1.5 (0.5; 4.2)	12.37	-0.02 (0.04; 16.35)	16.35
Tolterodine	Treatment discontinuation due to adverse effects	Herschorn, 2010 ⁴⁷⁰	28/684	6/334	3.1 (0.7; 13.9)	7.9	0.00 (0.04; 20.02)	20.02
Tolterodine	Treatment discontinuation due to adverse effects	Rentzhog, 1998 ³⁶⁰	2/67	3/13	2.3 (0.7; 7.8)	10.58	0.00 (0.05; 17.08)	17.08
Tolterodine	Treatment discontinuation due to adverse effects	Pooled (IV) odds ratio and ARD with divided placebo size and rates	111/2786	57/1680	1.0 (0.6; 1.7)	100	-0.01 (0.02; 100.00)	100
Propiverine	Treatment discontinuation due to adverse effects	Yamaguchi, 2007 ⁴⁰³	26/402	11/406	5.8 (0.7; 45.4)	16.22	0.00 (0.04; 75.15)	75.15
Propiverine	Treatment discontinuation due to adverse effects	Junemann, 2006 ³¹⁵	11/391	1/202	2.3 (0.9; 5.7)	83.78	0.00 (0.07; 24.85)	24.85
Propiverine	Treatment discontinuation due to adverse effects	Pooled (IV) odds ratio and ARD with divided placebo size and rates	37/793	12/608	2.7 (1.2; 6.2)	100	0.01 (0.04; 100.00)	100

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach (continued)**

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004 ²⁶¹	11/186	7/183	1.6 (0.6; 4.2)	14.64	-0.02 (0.07; 13.04)	13.04
Fesoterodine	Treatment discontinuation due to adverse effects	Dmochowski, 2010 ⁴⁶⁹	34/438	21/445	0.4 (0.1; 1.7)	8.74	-0.06 (0.01; 16.63)	16.63
Fesoterodine	Treatment discontinuation due to adverse effects	Herschorn, 2010 ⁴⁷⁰	44/679	6/334	3.4 (1.4; 8.1)	16.74	0.03 (0.13; 10.17)	10.17
Fesoterodine	Treatment discontinuation due to adverse effects	Kaplan, 2010 ³¹⁸	48/963	10/480	1.7 (1.0; 3.0)	26.8	0.00 (0.06; 17.48)	17.48
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004 ²⁶¹	3/173	7/183	3.8 (1.2; 12.3)	11.01	0.02 (0.07; 19.39)	19.39
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004 ²⁶¹	22/186	7/183	2.5 (1.2; 4.9)	22.07	0.01 (0.05; 23.29)	23.29
Fesoterodine	Treatment discontinuation due to adverse effects	Pooled (IV) odds ratio and ARD with divided placebo size and rates	163/2625	59/1808	2.0 (1.3; 3.1)	100	0.01 (0.05; 100.00)	100
Fesoterodine	Continence	Kaplan, 2010 ³¹⁸	609/963	258/480	1.5 (1.1; 2.0)	55.67	0.02 (0.17; 54.82)	54.82
Fesoterodine	Continence	NCT004444925 ⁵⁶	396/685	138/337	2.0 (1.4; 2.8)	44.33	0.08 (0.25; 45.18)	45.18
Fesoterodine	Continence	Pooled (IV) odds ratio and ARD with divided placebo size and rates	1005/1648	396/817	1.7 (1.3; 2.2)	100	0.06 (0.20; 100.00)	100
Tolterodine	Continence	Rogers, 2008 ³⁶⁵	115/202	89/211	1.8 (1.2; 2.7)	21.76	0.05 (0.24; 19.86)	19.86

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach (continued)**

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Tolterodine	Continence	Malone-Lee, 2009 ³⁴⁵	41/165	26/142	1.5 (0.8; 2.6)	11.2	-0.03 (0.16; 21.33)	21.33
Tolterodine	Continence	Kaplan, 2010 ³¹⁸	566/974	258/480	1.2 (0.9; 1.6)	39.12	-0.03 (0.11; 33.50)	33.5
Tolterodine	Continence	NCT00444925 ⁵⁶	358/690	138/337	1.6 (1.1; 2.2)	27.91	0.03 (0.19; 25.32)	25.32
Tolterodine	Continence	Pooled (IV) odds ratio and ARD with divided placebo size and rates	1080/2031	511/1170	1.4 (1.2; 1.7)	100	0.04 (0.13; 100.00)	100
Fesoterodine	Improvement in UI	Dmochowski, 2010 ⁴⁶⁹	182/438	137/445	1.6 (1.2; 2.1)	62.29	0.05 (0.17; 62.30)	62.3
Fesoterodine	Improvement in UI	Herschorn, 2010 ⁴⁷⁰	293/679	113/334	1.5 (1.0; 2.1)	37.71	0.01 (0.18; 37.70)	37.7
Fesoterodine	Improvement in UI	Pooled (IV) odds ratio and ARD with divided placebo size and rates	474/1117	250/779	1.6 (1.3; 1.9)	100	0.05 (0.15; 100.00)	100
Tolterodine	Improvement in UI	Kelleher, 2002 ³²³	294/507	218/508	1.8 (1.4; 2.4)	17.43	0.09 (0.21; 15.05)	15.05
Tolterodine	Improvement in UI	Herschorn, 2008 ³⁰¹	156/410	64/207	1.4 (1.0; 2.0)	13.51	-0.01 (0.15; 13.37)	13.37
Tolterodine	Improvement in UI	Sand, 2009 ³⁷⁰	140/227	167/430	2.5 (1.8; 3.5)	14.38	0.15 (0.31; 13.41)	13.41
Tolterodine	Improvement in UI	Rogers, 2009 ³⁶⁴	79/202	58/211	1.7 (1.1; 2.6)	11.69	0.03 (0.21; 12.28)	12.28
Tolterodine	Improvement in UI	Herschorn, 2010 ⁴⁷⁰	256/684	113/334	1.4 (1.1; 1.7)	18.31	0.02 (0.13; 15.78)	15.78
Tolterodine	Improvement in UI	Kaplan, 2010 ³¹⁸	654/974	287/480	1.2 (0.8; 1.9)	11.15	-0.02 (0.06; 16.90)	16.9
Tolterodine	Improvement in UI	NCT00444925 ⁵⁶	79/690	32/337	1.2 (0.8; 1.7)	13.54	-0.05 (0.12; 13.21)	13.21
Tolterodine	Improvement in UI	Pooled (IV) odds ratio and ARD with divided placebo size and rates	1658/3694	939/2507	1.6 (1.3; 1.9)	100	0.04 (0.15; 100.00)	100

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Darifenacin	Treatment discontinuation due to adverse effects	Steers, 200543	12/108	4/41	1.1 (0.4; 3.3)	10.85	0.02 (-0.02; 0.06)	5.3
Darifenacin	Treatment discontinuation due to adverse effects	Hill, 200642	2/108	3/109	0.7 (0.1; 3.9)	5.59	0.00 (-0.03; 0.02)	17.3
Darifenacin	Treatment discontinuation due to adverse effects	Chapple, 2007255	12/266	9/133	0.7 (0.3; 1.5)	22.45	0.01 (-0.02; 0.04)	11.4
Darifenacin	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration41, 390	3/229	3/164	0.7 (0.1; 3.5)	6.54	-0.01 (-0.04; 0.02)	13.4
Darifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004472	0/53	2/164	0.6 (0.0; 12.5)	2.31	0.00 (-0.02; 0.02)	19.5
Darifenacin	Treatment discontinuation due to adverse effects	Steers, 200543	6/160	4/41	0.4 (0.1; 1.3)	11.91	0.01 (-0.04; 0.06)	1.7
Darifenacin	Treatment discontinuation due to adverse effects	Zinner, 2006407	17/214	10/225	1.8 (0.8; 3.8)	18.24	-0.01 (-0.06; 0.04)	2.2
Darifenacin	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration41, 390	8/112	4/115	2.1 (0.6; 6.6)	7.38	0.00 (-0.04; 0.03)	9.7
Darifenacin	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration41, 390	3/115	3/164	1.4 (0.3; 6.9)	4.63	0.04 (0.00; 0.08)	4.3

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Darifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁴⁷²	3/229	2/164	1.1 (0.2; 6.4)	4.36	0.02 (-0.01; 0.06)	8.1
Darifenacin	Treatment discontinuation due to adverse effects	Hill, 2006 ⁴²	13/115	3/109	4.1 (1.2; 14.0)	5.76	-0.01 (-0.05; 0.03)	7
Darifenacin	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	79/1709	47/1429	1.2 (0.9; 1.8)	100	0.01 (-0.01; 0.03)	100
Darifenacin	Improvement in UI	Hill, 2006 ⁴²	28/108	15/109	1.9 (1.1; 3.3)	9.39	0.12 (0.10; 0.14)	32.5
Darifenacin	Improvement in UI	Chapple, 2007 ²⁵⁵	122/266	47/133	1.3 (1.0; 1.7)	39.41	0.12 (0.10; 0.14)	32.4
Darifenacin	Improvement in UI	Steers, 2005 ⁴³	160/268	60/127	1.3 (1.0; 1.6)	51.2	0.12 (0.10; 0.14)	35.1
Darifenacin	Improvement in UI	Pooled RR (MH) and ARD (ML)	310/642	122/369	1.3 (1.1; 1.6)	100	0.12 (0.06; 0.18)	100
Fesoterodine	Continence	Kaplan, 2010 ³¹⁸	609/963	258/480	1.2 (1.1; 1.3)	65.05	0.11 (0.06; 0.15)	52.9
Fesoterodine	Continence	NCT00444925 ⁵⁶	396/685	138/337	1.4 (1.2; 1.6)	34.95	0.15 (0.10; 0.20)	47.1
Fesoterodine	Continence	Pooled RR (MH) and ARD (ML)	1005/1648	396/817	1.3 (1.2; 1.4)	100	0.13 (0.07; 0.19)	100
Fesoterodine	Improvement in UI	Dmochowski, 2010 ⁴⁶⁹	182/438	137/445	1.4 (1.1; 1.6)	47.29	0.10 (0.08; 0.12)	50
Fesoterodine	Improvement in UI	Herschorn, 2010 ⁴⁷⁰	293/679	113/334	1.3 (1.1; 1.5)	52.71	0.10 (0.08; 0.12)	50
Fesoterodine	Improvement in UI	Pooled RR (MH) and ARD (ML)	474/1117	250/779	1.3 (1.2; 1.5)	100	0.10 (0.05; 0.15)	100
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004 ²⁶¹	11/186	7/183	1.5 (0.6; 3.9)	11.18	0.03 (-0.01; 0.06)	12.8

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Fesoterodine	Treatment discontinuation due to adverse effects	Dmochowski, 2010 ⁴⁶⁹	34/438	21/445	1.6 (1.0; 2.8)	33	-0.01 (-0.03; 0.02)	16.3
Fesoterodine	Treatment discontinuation due to adverse effects	Herschorn, 2010 ⁴⁷⁰	44/679	6/334	3.6 (1.6; 8.4)	12.74	0.05 (0.02; 0.09)	10
Fesoterodine	Treatment discontinuation due to adverse effects	Kaplan, ³¹⁸	48/963	10/480	2.4 (1.2; 4.7)	21.14	0.03 (0.00; 0.06)	17.2
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004 ²⁶¹	3/173	7/183	0.5 (0.1; 1.7)	10.77	0.04 (0.02; 0.07)	20.9
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004 ²⁶¹	22/186	7/183	3.1 (1.4; 7.1)	11.18	0.03 (0.01; 0.05)	22.9
Fesoterodine	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	163/2625	59/1808	2.1 (1.5; 2.8)	100	0.03 (0.01; 0.05)	100
Oxybutynin	Improvement in UI	Moore, 1990 ³⁵¹	10/28	1/25	8.9 (1.2; 64.9)	0.56	0.15 (0.02; 0.27)	9.5
Oxybutynin	Improvement in UI	Johnson, 2005 ³¹³	4/46	1/38	3.3 (0.4; 28.3)	0.58	0.24 (0.11; 0.37)	8.4
Oxybutynin	Improvement in UI	Szonyi, 1995 ³⁸²	22/28	16/29	1.4 (1.0; 2.1)	8.26	0.09 (-0.03; 0.20)	10.5
Oxybutynin	Improvement in UI	Wang, 2006 ⁴¹³	2/23	0/21	4.6 (0.2; 90.3)	0.27	0.19 (0.05; 0.33)	6.5
Oxybutynin	Improvement in UI	Homma, 20034 ³⁰⁷	129/244	31/122	2.1 (1.5; 2.9)	21.67	0.21 (0.09; 0.33)	10.1
Oxybutynin	Improvement in UI	Madersbacher, 1999 ³⁴³	116/145	43/72	1.3 (1.1; 1.6)	30.21	0.19 (0.09; 0.30)	12.5

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Oxybutynin	Improvement in UI	Burgio, 1998 ²³⁸	37/67	20/65	1.8 (1.2; 2.7)	10.67	0.25 (0.16; 0.34)	15.1
Oxybutynin	Improvement in UI	Thuroff, 1991 ³⁸⁶	26/63	15/52	1.4 (0.9; 2.4)	8.64	0.09 (0.00; 0.17)	15.4
Oxybutynin	Improvement in UI	Abrams, 1998 ²¹⁹	58/118	27/57	1.0 (0.7; 1.4)	19.14	0.12 (0.01; 0.23)	12
Oxybutynin	Improvement in UI	Pooled RR (MH) and ARD (ML)	405/762	153/481	1.6 (1.4; 1.8)	100	0.17 (0.10; 0.24)	100
Oxybutynin	Treatment discontinuation due to adverse effects	Homma, 2003 ³⁰⁷	42/244	11/122	1.9 (1.0; 3.6)	38.62	0.04 (-0.01; 0.09)	25.5
Oxybutynin	Treatment discontinuation due to adverse effects	Staskin, 2009 ³¹	19/389	13/400	1.5 (0.8; 3.0)	33.76	0.06 (-0.02; 0.13)	9.6
Oxybutynin	Treatment discontinuation due to adverse effects	Thuroff, 1991 ³⁸⁶	2/63	0/52	4.1 (0.2; 84.4)	1.44	0.08 (0.02; 0.14)	18.8
Oxybutynin	Treatment discontinuation due to adverse effects	Abrams, 1998 ²¹⁹	20/118	7/57	1.4 (0.6; 3.1)	24.86	0.10 (0.00; 0.19)	3.4
Oxybutynin	Treatment discontinuation due to adverse effects	Zinner, 2005 ⁴⁰⁵	4/19	0/19	9.0 (0.5; 156.4)	1.32	0.02 (-0.01; 0.05)	42.8
Oxybutynin	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	87/833	31/650	1.8 (1.2; 2.6)	100	0.06 (0.01; 0.11)	100
Oxybutynin	Continence	Moore, 1990 ³⁵¹	5/28	0/25	9.9 (0.6; 169.9)	0.67	0.15 (0.07; 0.23)	10.6
Oxybutynin	Continence	Staskin, 2009 ³¹	108/389	69/400	1.6 (1.2; 2.1)	86.47	0.14 (0.05; 0.24)	1.4

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Oxybutynin	Continence	Goode, 2004 ²⁹¹	15/67	8/65	1.8 (0.8; 4.0)	10.32	0.13 (0.05; 0.20)	15
Oxybutynin	Continence	Lehtoranta, 2002 ³³⁴	4/9	2/9	2.0 (0.5; 8.3)	2.54	0.12 (0.07; 0.16)	73.1
Oxybutynin	Continence	Pooled RR (MH) and ARD (ML)	132/493	79/499	1.7 (1.3; 2.2)	100	0.13 (0.06; 0.21)	100
Propiverine	Improvement in UI	Lee, 2010 ³³³	55/176	12/88	2.3 (1.3; 4.1)	10.6	0.19 (0.15; 0.23)	52.2
Propiverine	Improvement in UI	Junemann, 2006 ³¹⁵	264/391	94/202	1.5 (1.2; 1.7)	82.11	0.18 (0.14; 0.22)	36.6
Propiverine	Improvement in UI	Dorschner, 2000 ²⁷⁸	19/49	11/49	1.7 (0.9; 3.2)	7.29	0.18 (0.14; 0.23)	11.2
Propiverine	Improvement in UI	Pooled RR (MH) and ARD (ML)	338/616	117/339	1.6 (1.3; 1.8)	100	0.19 (0.12; 0.25)	100
Propiverine	Treatment discontinuation due to adverse effects	Yamaguchi, 2007 ⁴⁰³	26/402	11/406	2.4 (1.2; 4.8)	89.25	0.03 (0.02; 0.04)	69.5
Propiverine	Treatment discontinuation due to adverse effects	Junemann, 2006 ³¹⁵	11/391	1/202	5.7 (0.7; 43.7)	10.75	0.03 (0.02; 0.05)	30.5
Propiverine	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	37/793	12/608	2.7 (1.4; 5.3)	100	0.03 (0.01; 0.05)	100
Propiverine	Continence	Junemann, 2006 ³¹⁵	211/391	77/202	1.4 (1.2; 1.7)	87.13	0.17 (0.14; 0.20)	84
Propiverine	Continence	Dorschner, 2000 ²⁷⁸	24/49	15/49	1.6 (1.0; 2.7)	12.87	0.17 (0.14; 0.20)	16
Propiverine	Continence	Pooled RR (MH) and ARD (ML)	235/440	92/251	1.4 (1.2; 1.7)	100	0.17 (0.09; 0.25)	100
Solifenacin	Improvement in UI	Toglia, 2009 ³²¹	260/372	206/367	1.2 (1.1; 1.4)	65.43	0.15 (0.10; 0.21)	49.6
Solifenacin	Improvement in UI	Vardy, 2009 ³⁹²	196/386	109/382	1.8 (1.5; 2.1)	34.57	0.21 (0.15; 0.26)	50.4

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Solifenacin	Improvement in UI	Pooled RR (MH) and ARD (ML)	456/758	314/749	1.4 (1.3; 1.6)	100	0.18 (0.11; 0.25)	100
Solifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁵²	9/279	10/267	0.9 (0.4; 2.1)	5.82	0.00 (-0.02; 0.03)	8.5
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2006 ⁴¹²	14/314	40/781	0.9 (0.5; 1.6)	13.05	0.00 (-0.03; 0.02)	8.8
Solifenacin	Treatment discontinuation due to adverse effects	Staskin, 2006 ³⁷	4/159	19/430	0.6 (0.2; 1.6)	5.84	0.02 (0.00; 0.04)	10
Solifenacin	Treatment discontinuation due to adverse effects	Yamaguchi, 2007 ⁴⁰³	20/400	11/406	1.8 (0.9; 3.8)	6.21	0.03 (0.01; 0.05)	8.9
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2008 ⁶⁰	15/641	4/224	1.3 (0.4; 3.9)	3.37	0.01 (-0.01; 0.03)	12.3
Solifenacin	Treatment discontinuation due to adverse effects	Karram, 2009 ³²⁰	24/372	17/367	1.4 (0.8; 2.5)	9.74	0.02 (-0.01; 0.04)	7.8
Solifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁵²	7/269	10/267	0.7 (0.3; 1.8)	5.71	0.03 (0.00; 0.06)	5.8
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2006 ⁴¹²	51/778	40/781	1.3 (0.9; 1.9)	22.72	0.00 (-0.02; 0.02)	9.6

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Solifenacin	Treatment discontinuation due to adverse effects	Staskin, 2006 ³⁷	31/452	19/430	1.6 (0.9; 2.7)	11.08	0.01 (-0.01; 0.03)	11.3
Solifenacin	Treatment discontinuation due to adverse effects	Yamaguchi, 2007 ⁴⁰³	26/385	11/406	2.5 (1.2; 5.0)	6.09	-0.01 (-0.03; 0.02)	8.4
Solifenacin	Treatment discontinuation due to adverse effects	Chu, 2009 ²⁶⁴	37/340	18/332	2.0 (1.2; 3.5)	10.36	0.02 (0.00; 0.04)	8.6
Solifenacin	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	237/4389	198/4691	1.4 (1.1; 1.6)	100	0.01 (0.00; 0.03)	100
Solifenacin	Continence	Cardozo, 2006 ⁴¹²	160/314	266/781	1.5 (1.3; 1.7)	18.61	0.11 (0.05; 0.16)	13.9
Solifenacin	Continence	Staskin, 1981 ³⁷	49/159	122/430	1.1 (0.8; 1.4)	8.04	0.04 (0.00; 0.08)	16.2
Solifenacin	Continence	Karram, 2009 ³²⁰	133/372	93/367	1.4 (1.1; 1.8)	11.42	0.11 (0.05; 0.17)	13.7
Solifenacin	Continence	Vardy, 2009 ³⁹²	48/386	36/382	1.3 (0.9; 2.0)	4.41	0.15 (0.10; 0.21)	14.1
Solifenacin	Continence	Cardozo, 2006 ⁴¹²	405/778	266/781	1.5 (1.4; 1.7)	32.39	0.17 (0.12; 0.21)	15.7
Solifenacin	Continence	Staskin, 2006 ³⁷	184/452	122/430	1.4 (1.2; 1.7)	15.25	0.06 (-0.01; 0.12)	12.1
Solifenacin	Continence	Chu, 2009 ²⁶⁴	119/340	80/332	1.5 (1.1; 1.8)	9.88	0.12 (0.07; 0.17)	14.3
Solifenacin	Continence	Pooled RR (MH) and ARD (ML)	1098/2801	984/3503	1.4 (1.3; 1.5)	100	0.11 (0.06; 0.15)	100
Tolterodine	Treatment discontinuation due to adverse effects	Jacquetin, 2001 ³¹²	3/97	1/51	1.6 (0.2; 14.8)	1.83	0.00 (-0.05; 0.04)	0.4

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Tolterodine	Treatment discontinuation due to adverse effects	Abrams, 1998 ²¹⁹	10/118	7/57	0.7 (0.3; 1.7)	13.21	0.00 (-0.05; 0.04)	2.1
Tolterodine	Treatment discontinuation due to adverse effects	Drutz, 1999 ²⁷⁹	7/109	4/56	0.9 (0.3; 2.9)	7.39	-0.01 (-0.04; 0.01)	14
Tolterodine	Treatment discontinuation due to adverse effects	Malone-Lee, 2001 ³⁴⁶	7/73	1/74	7.1 (0.9; 56.2)	1.39	0.02 (0.00; 0.04)	17.9
Tolterodine	Treatment discontinuation due to adverse effects	Jacquetin, 2001 ³¹²	2/103	1/51	1.0 (0.1; 10.7)	1.87	0.02 (0.00; 0.04)	18.2
Tolterodine	Treatment discontinuation due to adverse effects	Chapple, 2004 ⁵²	5/266	10/267	0.5 (0.2; 1.4)	13.97	0.00 (-0.04; 0.04)	2.9
Tolterodine	Treatment discontinuation due to adverse effects	Khullar, 2004 ³²⁵	26/569	16/285	0.8 (0.4; 1.5)	29.83	0.03 (-0.01; 0.07)	3.6
Tolterodine	Treatment discontinuation due to adverse effects	Chapple, 2007 ²⁵³	9/290	6/285	1.5 (0.5; 4.1)	8.47	0.01 (-0.03; 0.04)	6.4
Tolterodine	Treatment discontinuation due to adverse effects	Herschorn, 2008 ³⁰¹	12/410	2/207	3.0 (0.7; 13.4)	3.72	0.00 (-0.03; 0.04)	7.4
Tolterodine	Treatment discontinuation due to adverse effects	Herschorn, 2010 ⁴⁷⁰	28/684	6/334	2.3 (1.0; 5.5)	11.28	-0.01 (-0.03; 0.02)	12.2

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Tolterodine	Treatment discontinuation due to adverse effects	Rentzhog, 1998 ³⁶⁰	2/67	3/13	0.1 (0.0; 0.7)	7.03	0.01 (-0.01; 0.03)	15
Tolterodine	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	111/2786	57/1680	1.1 (0.8; 1.5)	100	0.01 (-0.01; 0.02)	100
Tolterodine	Continence	Rogers, 2008 ³⁶⁵	115/202	89/211	1.4 (1.1; 1.6)	13.47	0.06 (0.02; 0.10)	35.5
Tolterodine	Continence	Malone-Lee, 2009 ³⁴⁵	41/165	26/142	1.4 (0.9; 2.1)	4.33	0.10 (0.05; 0.15)	29.3
Tolterodine	Continence	Kaplan, 2010 ³¹⁸	566/974	258/480	1.1 (1.0; 1.2)	53.5	0.11 (0.05; 0.17)	17.1
Tolterodine	Continence	NCT00444925 ⁵⁶	358/690	138/337	1.3 (1.1; 1.5)	28.7	0.08 (0.02; 0.14)	18.1
Tolterodine	Continence	Pooled RR (MH) and ARD (ML)	1080/2031	511/1170	1.2 (1.1; 1.3)	100	0.09 (0.04; 0.14)	100
Tolterodine	Improvement in UI	Kelleher, 2002 ³²³	294/507	218/508	1.4 (1.2; 1.5)	20.66	0.08 (0.01; 0.15)	13.1
Tolterodine	Improvement in UI	Herschorn, 2008 ³⁰¹	156/410	64/207	1.2 (1.0; 1.6)	8.07	0.11 (0.04; 0.18)	12
Tolterodine	Improvement in UI	Sand, 2009 ³⁷⁰	140/227	167/430	1.6 (1.4; 1.9)	10.95	0.05 (-0.01; 0.10)	14.7
Tolterodine	Improvement in UI	Rogers, 2009 ³⁶⁴	79/202	58/211	1.4 (1.1; 1.9)	5.38	0.08 (0.03; 0.13)	15.5
Tolterodine	Improvement in UI	Herschorn, 2010 ⁴⁷⁰	256/684	113/334	1.1 (0.9; 1.3)	14.4	0.03 (-0.01; 0.06)	16.7
Tolterodine	Improvement in UI	Kaplan, 2010 ³¹⁸	654/974	287/480	1.1 (1.0; 1.2)	36.47	0.14 (0.09; 0.20)	14.8
Tolterodine	Improvement in UI	NCT00444925 ⁵⁶	79/690	32/337	1.2 (0.8; 1.8)	4.08	0.19 (0.13; 0.26)	13.1
Tolterodine	Improvement in UI	Pooled RR (MH) and ARD (ML)	1658/3694	939/2507	1.2 (1.2; 1.3)	100	0.10 (0.05; 0.15)	100
Tropium	Continence	Zinner, 2004 ³⁵	55/262	29/261	1.9 (1.2; 2.9)	13.14	0.11 (0.08; 0.14)	23.9

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Tropium	Continenence	Staskin, 2007 ⁴⁵	61/298	34/303	1.8 (1.2; 2.7)	15.24	0.11 (0.08; 0.14)	27.6
Tropium	Continenence	Dmochowski, 2008 ²⁷²	95/280	58/284	1.7 (1.3; 2.2)	26.04	0.12 (0.09; 0.15)	17.6
Tropium	Continenence	Sand, 2009 ³⁷¹	163/484	103/505	1.7 (1.3; 2.0)	45.58	0.12 (0.09; 0.15)	30.9
Tropium	Continenence	Pooled RR (MH) and ARD (ML)	374/1324	224/1353	1.7 (1.5; 2.0)	100	0.11 (0.08; 0.15)	100
Tropium	Improvement in UI	Staskin, 2004 ³⁷⁸	5/327	8/326	0.6 (0.2; 1.9)	5.37	0.15 (0.08; 0.23)	47.5
Tropium	Improvement in UI	Zinner, 2004 ³⁵	186/262	141/261	1.3 (1.1; 1.5)	94.63	-0.01 (-0.03; 0.01)	52.5
Tropium	Improvement in UI	Pooled RR (MH) and ARD (ML)	191/589	149/587	1.3 (1.1; 1.5)	100	0.07 (-0.05; 0.20)	100
Tropium	Treatment discontinuation due to adverse effects	Zinner, 2004 ³⁵	23/262	15/261	1.5 (0.8; 2.9)	19.42	0.02 (0.01; 0.04)	14.4
Tropium	Treatment discontinuation due to adverse effects	Rudy, 2006 ³⁶⁷	24/329	15/329	1.6 (0.9; 3.0)	19.38	0.01 (-0.01; 0.03)	18.3
Tropium	Treatment discontinuation due to adverse effects	Staskin, 2007 ⁴⁵	12/298	11/303	1.1 (0.5; 2.5)	14.09	0.02 (0.00; 0.04)	8.7
Tropium	Treatment discontinuation due to adverse effects	Sand, 2009 ³⁷¹	24/484	18/505	1.4 (0.8; 2.5)	22.76	0.02 (0.00; 0.04)	13.3
Tropium	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration ^{38,44}	18/280	8/284	2.3 (1.0; 5.2)	10.26	0.01 (-0.01; 0.03)	18.3

**Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)**

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Tropium	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration ^{38,44}	12/298	11/303	1.1 (0.5; 2.5)	14.09	0.02 (0.00; 0.03)	27.1
Tropium	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	113/1951	78/1985	1.5 (1.1; 1.9)	100	0.02 (0.00; 0.03)	100

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Darifenacin	Constipation	Country	Restricted maximum likelihood	-0.01	0.04	0.71
Study	Darifenacin	Constipation	Intention to treat	Restricted maximum likelihood	0.04	0.06	0.5
Treatment	Darifenacin	Constipation	Daily dose	Restricted maximum likelihood	0	0	0.43
Treatment	Darifenacin	Constipation	Weeks of treatment	Restricted maximum likelihood	0.01	0.01	0.63
Women	Darifenacin	Constipation	% of women	Restricted maximum likelihood	0	0	0.47
Women	Darifenacin	Constipation	Daily UI	Restricted maximum likelihood	0.08	0.11	0.5
Women	Darifenacin	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.08	0.11	0.5
Women	Darifenacin	Constipation	Inclusion of mixed UI	Restricted maximum likelihood	-0.13	0.06	0.08
Women	Darifenacin	Constipation	Inclusion of prior failures	Restricted maximum likelihood	0.04	0.04	0.41
Women	Darifenacin	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.11	0.06	0.15
Women	Darifenacin	Constipation	Rate in placebo group	Restricted maximum likelihood	-1.62	1.86	0.42
Study	Darifenacin	Dry mouth	Adequate randomization	Restricted maximum likelihood	0.1	0.07	0.23
Study	Darifenacin	Dry mouth	Country	Restricted maximum likelihood	0	0.07	0.96
Study	Darifenacin	Dry mouth	Intention to treat	Restricted maximum likelihood	0.1	0.07	0.23
Treatment	Darifenacin	Dry mouth	Daily dose	Restricted maximum likelihood	0.01	0.01	0.24
Treatment	Darifenacin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	0.01	0.01	0.3
Women	Darifenacin	Dry mouth	% of women	Restricted maximum likelihood	0.01	0.01	0.24
Women	Darifenacin	Dry mouth	Daily UI	Restricted maximum likelihood	0.2	0.15	0.23

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Darifenacin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.2	0.15	0.23
Women	Darifenacin	Dry mouth	Inclusion of mixed UI*	Restricted maximum likelihood	-0.26	0.1	0.04
Women	Darifenacin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.09	0.07	0.26
Women	Darifenacin	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.13	0.16	0.47
Women	Darifenacin	Dry mouth	Rate in placebo group	Restricted maximum likelihood	0.59	3.01	0.85
Study	Darifenacin	Dyspepsia	Adequate randomization	Restricted maximum likelihood	0.02	0.01	0.23
Study	Darifenacin	Dyspepsia	Intention to treat	Restricted maximum likelihood	0.02	0.01	0.23
Treatment	Darifenacin	Dyspepsia	Daily dose	Restricted maximum likelihood	0	0	0.87
Treatment	Darifenacin	Dyspepsia	Weeks of treatment	Restricted maximum likelihood	0	0	0.54
Women	Darifenacin	Dyspepsia	% of women	Restricted maximum likelihood	0	0	0.25
Women	Darifenacin	Dyspepsia	Daily UI	Restricted maximum likelihood	0.03	0.02	0.23
Women	Darifenacin	Dyspepsia	Inclusion of minorities	Restricted maximum likelihood	-0.03	0.02	0.23
Women	Darifenacin	Dyspepsia	Inclusion of mixed UI	Restricted maximum likelihood	-0.03	0.02	0.22
Women	Darifenacin	Dyspepsia	Inclusion of prior failures	Restricted maximum likelihood	0.02	0.01	0.23
Women	Darifenacin	Dyspepsia	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.01	0.03	0.84
Women	Darifenacin	Dyspepsia	Rate in placebo group*	Restricted maximum likelihood	-3.54	1.3	0.04
Study	Darifenacin	Improvement in UI	Country	Restricted maximum likelihood	0	0.01	0.98
Study	Darifenacin	Improvement in UI	Intention to treat	Restricted maximum likelihood	-0.01	0.03	0.83

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Darifenacin	Improvement in UI	Daily dose	Restricted maximum likelihood	0	0.01	0.82
Women	Darifenacin	Improvement in UI	% of women	Restricted maximum likelihood	0	0.01	0.83
Women	Darifenacin	Improvement in UI	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.02	0.07	0.83
Study	Fesoterodine	Constipation	Adequate randomization	Restricted maximum likelihood	-0.01	0.02	0.51
Study	Fesoterodine	Constipation	Allocation concealment	Restricted maximum likelihood	-0.01	0.02	0.52
Study	Fesoterodine	Constipation	Conflict of interest	Restricted maximum likelihood	-0.02	0.04	0.61
Study	Fesoterodine	Constipation	Country	Restricted maximum likelihood	0.01	0.02	0.73
Study	Fesoterodine	Constipation	Intention to treat	Restricted maximum likelihood	0.06	0.04	0.14
Study	Fesoterodine	Constipation	Justification of sample size	Restricted maximum likelihood	0.04	0.02	0.16
Treatment	Fesoterodine	Constipation	Daily dose	Restricted maximum likelihood	0	0.01	1
Women	Fesoterodine	Constipation	% of women*	Restricted maximum likelihood	-0.01	0	0.04
Women	Fesoterodine	Constipation	Inclusion of mixed UI	Restricted maximum likelihood	0.05	0.05	0.3
Women	Fesoterodine	Constipation	Inclusion of prior failures	Restricted maximum likelihood	-0.03	0.04	0.48
Women	Fesoterodine	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.02	0.04	0.64
Women	Fesoterodine	Constipation	Rate in placebo group	Restricted maximum likelihood	-0.49	1.62	0.77
Study	Fesoterodine	Discontinuation due to failure	Adequate randomization	Restricted maximum likelihood	0.01	0.01	0.33
Study	Fesoterodine	Discontinuation due to failure	Allocation concealment	Restricted maximum likelihood	0	0.01	1
Study	Fesoterodine	Discontinuation due to failure	Conflict of interest	Restricted maximum likelihood	0	0.02	1

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Fesoterodine	Discontinuation due to failure	Country	Restricted maximum likelihood	0	0.01	0.78
Study	Fesoterodine	Discontinuation due to failure	Justification of sample size	Restricted maximum likelihood	0	0.02	1
Women	Fesoterodine	Discontinuation due to failure	% of women	Restricted maximum likelihood	-0.01	0	0.2
Women	Fesoterodine	Discontinuation due to failure	Inclusion of minorities	Restricted maximum likelihood	0	0.02	1
Women	Fesoterodine	Discontinuation due to failure	Inclusion of prior failures	Restricted maximum likelihood	0.02	0.02	0.44
Women	Fesoterodine	Discontinuation due to failure	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.02	0.02	0.41
Women	Fesoterodine	Discontinuation due to failure	Rate in placebo group	Restricted maximum likelihood	-1.36	0.44	0.09
Study	Fesoterodine	Dry eye	Adequate randomization	Restricted maximum likelihood	0.01	0	0.22
Study	Fesoterodine	Dry eye	Allocation concealment	Restricted maximum likelihood	0.01	0.01	0.18
Study	Fesoterodine	Dry eye	Conflict of interest	Restricted maximum likelihood	0.01	0.01	0.27
Study	Fesoterodine	Dry eye	Country	Restricted maximum likelihood	0	0.01	0.83
Study	Fesoterodine	Dry eye	Intention to treat	Restricted maximum likelihood	-0.02	0.01	0.17
Study	Fesoterodine	Dry eye	Justification of sample size	Restricted maximum likelihood	-0.01	0.01	0.29
Treatment	Fesoterodine	Dry eye	Daily dose	Restricted maximum likelihood	0.01	0	0.22
Women	Fesoterodine	Dry eye	% of women	Restricted maximum likelihood	0	0	0.35
Women	Fesoterodine	Dry eye	Inclusion of minorities	Restricted maximum likelihood	0.02	0.01	0.18
Women	Fesoterodine	Dry eye	Inclusion of prior failures	Restricted maximum likelihood	0.02	0.01	0.17
Women	Fesoterodine	Dry eye	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.02	0.01	0.18

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Fesoterodine	Dry eye	Rate in placebo group	Restricted maximum likelihood	-0.96	0.6	0.17
Study	Fesoterodine	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.005	0.020	0.822
Study	Fesoterodine	Dry mouth	Adequate randomization	Restricted maximum likelihood	0.001	0.018	0.95
Study	Fesoterodine	Dry mouth	Conflict of interest	Restricted maximum likelihood	0.005	0.041	0.915
Study	Fesoterodine	Dry mouth	Intention to treat	Restricted maximum likelihood	0.016	0.043	0.718
Study	Fesoterodine	Dry mouth	Justification of sample size	Restricted maximum likelihood	0.009	0.024	0.742
Treatment	Fesoterodine	Dry mouth	Daily dose*	Restricted maximum likelihood	0.019	0.007	0.023
Women	Fesoterodine	Dry mouth	Country	Restricted maximum likelihood	-0.001	0.022	0.97
Women	Fesoterodine	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.001	0.041	0.98
Women	Fesoterodine	Dry mouth	% of women	Restricted maximum likelihood	-0.000	0.003	0.902
Women	Fesoterodine	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.010	0.042	0.822
Women	Fesoterodine	Dry mouth	Rate in placebo group	Restricted maximum likelihood	-0.789	1.574	0.63
Women	Fesoterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.017	0.0401	0.675
Study	Fesoterodine	Headache	Allocation concealment	Restricted maximum likelihood	0.001	0.012	0.944
Study	Fesoterodine	Headache	Adequate randomization	Restricted maximum likelihood	-0.002	0.007	0.806
Study	Fesoterodine	Headache	Conflict of interest	Restricted maximum likelihood	0.003	0.016	0.856
Study	Fesoterodine	Headache	Intention to treat	Restricted maximum likelihood	0.027	0.012	0.054
Study	Fesoterodine	Headache	Justification of sample size	Restricted maximum likelihood	0.014	0.006	0.053

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Fesoterodine	Headache	Daily dose	Restricted maximum likelihood	-0.004	0.004	0.37
Women	Fesoterodine	Headache	Country*	Restricted maximum likelihood	-0.015	0.005	0.029
Women	Fesoterodine	Headache	Inclusion of prior failures	Restricted maximum likelihood	-0.004	0.017	0.837
Women	Fesoterodine	Headache	% of women	Restricted maximum likelihood	-0.001	0.001	0.203
Women	Fesoterodine	Headache	Inclusion of minorities	Restricted maximum likelihood	0.002	0.025	0.944
Women	Fesoterodine	Headache	Rate in placebo group	Restricted maximum likelihood	-0.104	0.192	0.605
Women	Fesoterodine	Headache	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.027	0.013	0.069
Study	Oxybutynin	Improvement in UI	Allocation concealment	Restricted maximum likelihood	-0.004	0.036	0.906
Study	Oxybutynin	Improvement in UI	Adequate randomization	Restricted maximum likelihood	-0.029	0.041	0.507
Study	Oxybutynin	Improvement in UI	Intention to treat	Restricted maximum likelihood	0.011	0.041	0.794
Study	Oxybutynin	Improvement in UI	Justification of sample size	Restricted maximum likelihood	-0.048	0.044	0.306
Treatment	Oxybutynin	Improvement in UI	Daily dose	Restricted maximum likelihood	-0.006	0.010	0.55
Treatment	Oxybutynin	Improvement in UI	Weeks of treatment	Restricted maximum likelihood	-0.009	0.011	0.466
Women	Oxybutynin	Improvement in UI	Country	Restricted maximum likelihood	-0.058	0.028	0.076
Women	Oxybutynin	Improvement in UI	Daily UI	Restricted maximum likelihood	-0.074	0.076	0.363
Women	Oxybutynin	Improvement in UI	Inclusion of prior failures	Restricted maximum likelihood	0.031	0.057	0.597
Women	Oxybutynin	Improvement in UI	% of women	Restricted maximum likelihood	-0.001	0.003	0.74
Women	Oxybutynin	Improvement in UI	Rate in placebo group	Restricted maximum likelihood	0.068	0.178	0.715

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Oxybutynin	Improvement in UI	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.034	0.058	0.57
Study	Oxybutynin	Adverse effects	Country	Restricted maximum likelihood	0.01	0.15	0.94
Study	Oxybutynin	Adverse effects	Justification of sample size	Restricted maximum likelihood	-0.14	0.07	0.29
Treatment	Oxybutynin	Adverse effects	Daily dose	Restricted maximum likelihood	0.05	0.02	0.32
Treatment	Oxybutynin	Adverse effects	Weeks of treatment	Restricted maximum likelihood	-0.04	0.02	0.29
Women	Oxybutynin	Adverse effects	% of women	Restricted maximum likelihood	0	0.01	0.91
Women	Oxybutynin	Adverse effects	Daily UI	Restricted maximum likelihood	-0.28	0.14	0.29
Women	Oxybutynin	Adverse effects	Inclusion of minorities	Restricted maximum likelihood	-0.24	0.18	0.41
Women	Oxybutynin	Adverse effects	Inclusion of mixed UI	Restricted maximum likelihood	-0.12	0.09	0.41
Women	Oxybutynin	Adverse effects	Rate in placebo group	Restricted maximum likelihood	0.7	0.52	0.41
Study	Oxybutynin	Dry mouth	Adequate randomization	Restricted maximum likelihood	-0.06	0.06	0.38
Study	Oxybutynin	Dry mouth	Allocation concealment	Restricted maximum likelihood	0.1	0.1	0.33
Study	Oxybutynin	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.27	0.19	0.19
Study	Oxybutynin	Dry mouth	Country	Restricted maximum likelihood	-0.03	0.07	0.67
Study	Oxybutynin	Dry mouth	Intention to treat	Restricted maximum likelihood	0.07	0.08	0.37
Study	Oxybutynin	Dry mouth	Justification of sample size	Restricted maximum likelihood	-0.12	0.09	0.24
Treatment	Oxybutynin	Dry mouth	Daily dose	Restricted maximum likelihood	0.02	0.01	0.21
Treatment	Oxybutynin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.01	0.02	0.67

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Oxybutynin	Dry mouth	% of women	Restricted maximum likelihood	-0.01	0.01	0.39
Women	Oxybutynin	Dry mouth	Daily UI	Restricted maximum likelihood	-0.11	0.16	0.52
Women	Oxybutynin	Dry mouth	Inclusion of minorities*	Restricted maximum likelihood	-0.43	0.12	0.01
Women	Oxybutynin	Dry mouth	Inclusion of mixed UI	Restricted maximum likelihood	-0.14	0.08	0.09
Women	Oxybutynin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.09	0.13	0.48
Women	Oxybutynin	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.24	0.19	0.24
Women	Oxybutynin	Dry mouth	Rate in placebo group	Restricted maximum likelihood	-0.08	0.32	0.81
Study	Oxybutynin	Failure	Adequate randomization	Restricted maximum likelihood	-0.04	0.04	0.41
Study	Oxybutynin	Failure	Allocation concealment	Restricted maximum likelihood	-0.03	0.06	0.7
Study	Oxybutynin	Failure	Country	Restricted maximum likelihood	0.02	0.06	0.76
Study	Oxybutynin	Failure	Intention to treat	Restricted maximum likelihood	0.1	0.04	0.06
Study	Oxybutynin	Failure	Justification of sample size	Restricted maximum likelihood	-0.02	0.06	0.72
Study	Oxybutynin	Failure	Masking of treatment status	Restricted maximum likelihood	0.22	0.15	0.24
Treatment	Oxybutynin	Failure	Daily dose	Restricted maximum likelihood	-0.01	0.02	0.81
Treatment	Oxybutynin	Failure	Weeks of treatment	Restricted maximum likelihood	0.01	0.02	0.63
Women	Oxybutynin	Failure	% of women	Restricted maximum likelihood	0	0	0.47
Women	Oxybutynin	Failure	Daily UI	Restricted maximum likelihood	0.13	0.07	0.19
Women	Oxybutynin	Failure	Inclusion of mixed UI	Restricted maximum likelihood	0.03	0.06	0.68

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Oxybutynin	Failure	Inclusion of prior failures	Restricted maximum likelihood	0.08	0.07	0.33
Women	Oxybutynin	Failure	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.11	0.07	0.22
Women	Oxybutynin	Failure	Rate in placebo group	Restricted maximum likelihood	-0.37	0.12	0.05
Study	Solifenacin	Adverse effects	Allocation concealment	Restricted maximum likelihood	-0.04	0.07	0.59
Study	Solifenacin	Adverse effects	Conflict of interest	Restricted maximum likelihood	0.04	0.09	0.64
Study	Solifenacin	Adverse effects	Country	Restricted maximum likelihood	0.03	0.12	0.8
Study	Solifenacin	Adverse effects	Intention to treat analysis	Restricted maximum likelihood	0.02	0.06	0.8
Treatment	Solifenacin	Adverse effects	Daily dose	Restricted maximum likelihood	0.02	0.01	0.08
Treatment	Solifenacin	Adverse effects	Weeks of treatment	Restricted maximum likelihood	0	0.01	0.8
Women	Solifenacin	Adverse effects	% of women	Restricted maximum likelihood	0	0.01	0.82
Women	Solifenacin	Adverse effects	Daily UI	Restricted maximum likelihood	-0.03	0.14	0.83
Women	Solifenacin	Adverse effects	Inclusion of mixed UI	Restricted maximum likelihood	-0.02	0.07	0.83
Women	Solifenacin	Adverse effects	Inclusion of prior failures	Restricted maximum likelihood	-0.08	0.14	0.59
Women	Solifenacin	Adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.08	0.14	0.59
Women	Solifenacin	Adverse effects	Rate in placebo group	Restricted maximum likelihood	-0.18	0.33	0.61
Study	Solifenacin	Blurred vision	Adequacy of randomization	Restricted maximum likelihood	-0.01	0	0.16
Study	Solifenacin	Blurred vision	Allocation concealment	Restricted maximum likelihood	0.01	0	0.2
Study	Solifenacin	Blurred vision	Conflict of interest	Restricted maximum likelihood	0	0.01	0.76

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Solifenacin	Blurred vision	Country	Restricted maximum likelihood	0	0	0.24
Study	Solifenacin	Blurred vision	Intention to treat analysis	Restricted maximum likelihood	-0.01	0.01	0.2
Study	Solifenacin	Blurred vision	Justification for sample size*	Restricted maximum likelihood	-0.02	0.01	0
Treatment	Solifenacin	Blurred vision	Daily dose	Restricted maximum likelihood	0	0	0.11
Treatment	Solifenacin	Blurred vision	Weeks of treatment	Restricted maximum likelihood	0	0	0.38
Women	Solifenacin	Blurred vision	% of women	Restricted maximum likelihood	0	0	0.27
Women	Solifenacin	Blurred vision	Daily UI	Restricted maximum likelihood	0.01	0.01	0.61
Women	Solifenacin	Blurred vision	Inclusion of minorities	Restricted maximum likelihood	-0.01	0.01	0.51
Women	Solifenacin	Blurred vision	Inclusion of mixed UI	Restricted maximum likelihood	0	0.01	0.49
Women	Solifenacin	Blurred vision	Inclusion of prior failures	Restricted maximum likelihood	0.01	0.01	0.44
Women	Solifenacin	Blurred vision	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.01	0.01	0.64
Women	Solifenacin	Blurred vision	Rate in placebo group	Restricted maximum likelihood	0.33	0.44	0.47
Study	Solifenacin	Constipation	Adequacy of randomization	Restricted maximum likelihood	0	0.02	0.94
Study	Solifenacin	Constipation	Allocation concealment	Restricted maximum likelihood	0	0.02	0.84
Study	Solifenacin	Constipation	Conflict of interest	Restricted maximum likelihood	0.01	0.02	0.73
Study	Solifenacin	Constipation	Country	Restricted maximum likelihood	-0.01	0.01	0.34
Study	Solifenacin	Constipation	Intention to treat analysis	Restricted maximum likelihood	-0.01	0.01	0.46
Study	Solifenacin	Constipation	Justification for sample size	Restricted maximum likelihood	0	0.02	0.95

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Solifenacin	Constipation	Daily dose*	Restricted maximum likelihood	0.01	0	0
Treatment	Solifenacin	Constipation	Weeks of treatment	Restricted maximum likelihood	0	0	0.78
Women	Solifenacin	Constipation	% of women	Restricted maximum likelihood	0	0	0.95
Women	Solifenacin	Constipation	Daily UI	Restricted maximum likelihood	0.01	0.03	0.78
Women	Solifenacin	Constipation	Inclusion of mixed UI	Restricted maximum likelihood	0.01	0.02	0.47
Women	Solifenacin	Constipation	Inclusion of prior failures	Restricted maximum likelihood	-0.01	0.03	0.85
Women	Solifenacin	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.01	0.04	0.77
Women	Solifenacin	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.02	0.02	0.35
Women	Solifenacin	Constipation	Rate in placebo group	Restricted maximum likelihood	0.12	0.56	0.83
Study	Solifenacin	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.01	0.03	0.84
Study	Solifenacin	Dry mouth	Allocation concealment	Restricted maximum likelihood	0	0.04	0.92
Study	Solifenacin	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.01	0.05	0.88
Study	Solifenacin	Dry mouth	Country	Restricted maximum likelihood	0	0.02	0.86
Study	Solifenacin	Dry mouth	Intention to treat analysis	Restricted maximum likelihood	0.01	0.03	0.87
Study	Solifenacin	Dry mouth	Justification for sample size	Restricted maximum likelihood	0.01	0.06	0.82
Treatment	Solifenacin	Dry mouth	Daily dose*	Restricted maximum likelihood	0.03	0	0
Treatment	Solifenacin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.01	0.01	0.35
Women	Solifenacin	Dry mouth	% of women	Restricted maximum likelihood	0	0	0.56

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Solifenacin	Dry mouth	Daily UI	Restricted maximum likelihood	0.03	0.07	0.65
Women	Solifenacin	Dry mouth	Inclusion of mixed UI	Restricted maximum likelihood	0.03	0.04	0.54
Women	Solifenacin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.01	0.07	0.93
Women	Solifenacin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	0.01	0.06	0.87
Women	Solifenacin	Dry mouth	Rate in placebo group	Restricted maximum likelihood	-0.12	1.11	0.92
Study	Solifenacin	Treatment discontinuation due to adverse effects	Adequacy of randomization	Restricted maximum likelihood	0	0.01	0.58
Study	Solifenacin	Treatment discontinuation due to adverse effects	Allocation concealment	Restricted maximum likelihood	0.01	0.01	0.56
Study	Solifenacin	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	0	0.01	0.92
Study	Solifenacin	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	0	0.01	0.57
Study	Solifenacin	Treatment discontinuation due to adverse effects	Intention to treat analysis	Restricted maximum likelihood	-0.01	0.01	0.3
Study	Solifenacin	Treatment discontinuation due to adverse effects	Justification for sample size	Restricted maximum likelihood	0.01	0.01	0.4
Treatment	Solifenacin	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	0	0	0.11
Treatment	Solifenacin	Treatment discontinuation due to adverse effects	Weeks of treatment	Restricted maximum likelihood	0	0.01	0.76
Women	Solifenacin	Treatment discontinuation due to adverse effects	% of women	Restricted maximum likelihood	0	0	0.16

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Solifenacin	Treatment discontinuation due to adverse effects	Daily UI	Restricted maximum likelihood	-0.01	0.02	0.77
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	0	0.01	0.78
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of mixed UI	Restricted maximum likelihood	0	0.01	0.92
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	-0.01	0.01	0.51
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.05	0.02	0.1
Women	Solifenacin	Treatment discontinuation due to adverse effects	Rate in placebo group	Restricted maximum likelihood	-0.03	0.58	0.96
Study	Tolterodine	Dry mouth	Adequate randomization	Restricted maximum likelihood	-0.01	0.02	0.46
Study	Tolterodine	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.02	0.03	0.5
Study	Tolterodine	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.06	0.04	0.14
Study	Tolterodine	Dry mouth	Country	Restricted maximum likelihood	0	0.02	0.9
Study	Tolterodine	Dry mouth	Intention to treat	Restricted maximum likelihood	0.04	0.02	0.07
Study	Tolterodine	Dry mouth	Justification of sample size	Restricted maximum likelihood	0	0.03	0.97
Treatment	Tolterodine	Dry mouth	Daily dose	Restricted maximum likelihood	0.01	0.01	0.52
Treatment	Tolterodine	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.01	0.01	0.06
Women	Tolterodine	Dry mouth	% of women	Restricted maximum likelihood	0	0	0.14
Women	Tolterodine	Dry mouth	Daily UI	Restricted maximum likelihood	-0.05	0.05	0.31

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.04	0.04	0.36
Women	Tolterodine	Dry mouth	Inclusion of mixed UI	Restricted maximum likelihood	0	0.03	0.87
Women	Tolterodine	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.01	0.03	0.65
Women	Tolterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.07	0.05	0.21
Women	Tolterodine	Dry mouth	Rate in placebo group	Restricted maximum likelihood	0.16	0.45	0.73
Study	Tolterodine	Failure	Adequate randomization	Restricted maximum likelihood	0.05	0.02	0.07
Study	Tolterodine	Failure	Allocation concealment	Restricted maximum likelihood	-0.04	0.03	0.22
Study	Tolterodine	Failure	Conflict of interest	Restricted maximum likelihood	-0.06	0.04	0.21
Study	Tolterodine	Failure	Country	Restricted maximum likelihood	-0.03	0.03	0.34
Study	Tolterodine	Failure	Intention to treat	Restricted maximum likelihood	0.01	0.04	0.87
Study	Tolterodine	Failure	Justification of sample size	Restricted maximum likelihood	0.03	0.05	0.58
Treatment	Tolterodine	Failure	Daily dose	Restricted maximum likelihood	0.02	0.05	0.75
Women	Tolterodine	Failure	% of women	Restricted maximum likelihood	0	0	0.46
Women	Tolterodine	Failure	Daily UI	Restricted maximum likelihood	-0.04	0.07	0.61
Women	Tolterodine	Failure	Inclusion of minorities	Restricted maximum likelihood	-0.01	0.07	0.9
Women	Tolterodine	Failure	Inclusion of mixed UI	Restricted maximum likelihood	0.08	0.06	0.26
Women	Tolterodine	Failure	Inclusion of prior failures	Restricted maximum likelihood	-0.08	0.06	0.22
Women	Tolterodine	Failure	Rate in placebo group*	Restricted maximum likelihood	-0.51	0.09	0

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Tolterodine	Improvement in UI	Adequate randomization	Restricted maximum likelihood	0	0.02	0.92
Study	Tolterodine	Improvement in UI	Allocation concealment	Restricted maximum likelihood	0.02	0.03	0.53
Study	Tolterodine	Improvement in UI	Conflict of interest	Restricted maximum likelihood	0.05	0.04	0.24
Study	Tolterodine	Improvement in UI	Country	Restricted maximum likelihood	0.01	0.03	0.81
Study	Tolterodine	Improvement in UI	Intention to treat	Restricted maximum likelihood	-0.04	0.03	0.28
Study	Tolterodine	Improvement in UI	Justification of sample size	Restricted maximum likelihood	-0.06	0.03	0.07
Treatment	Tolterodine	Improvement in UI	Daily dose	Restricted maximum likelihood	-0.05	0.03	0.18
Women	Tolterodine	Improvement in UI	% of women	Restricted maximum likelihood	0	0	0.15
Women	Tolterodine	Improvement in UI	Daily UI	Restricted maximum likelihood	-0.09	0.05	0.1
Women	Tolterodine	Improvement in UI	Inclusion of minorities	Restricted maximum likelihood	0.05	0.05	0.41
Women	Tolterodine	Improvement in UI	Inclusion of mixed UI*	Restricted maximum likelihood	-0.13	0.04	0.02
Women	Tolterodine	Improvement in UI	Inclusion of prior failures	Restricted maximum likelihood	-0.02	0.04	0.7
Women	Tolterodine	Improvement in UI	Rate in placebo group	Restricted maximum likelihood	0.1	0.2	0.62
Study	Tolterodine	Treatment discontinuation due to adverse effects	Adequate randomization	Restricted maximum likelihood	-0.006	0.00713	0.461
Study	Tolterodine	Treatment discontinuation due to adverse effects	Allocation concealment	Restricted maximum likelihood	0.008	0.008	0.365
Study	Tolterodine	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	0.025	0.012	0.063
Study	Tolterodine	Treatment discontinuation due to adverse effects	Intention to treat	Restricted maximum likelihood	0.004	0.011	0.718

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Tolterodine	Treatment discontinuation due to adverse effects	Justification of sample size	Restricted maximum likelihood	-0.011	0.01	0.326
Treatment	Tolterodine	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	-0.012	0.015	0.432
Women	Tolterodine	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	0.0034	0.006	0.58
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	-0.003	0.021	0.872
Women	Tolterodine	Treatment discontinuation due to adverse effects	% of women	Restricted maximum likelihood	0.0000132	0.001	0.99
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	-0.004	0.021	0.854
Women	Tolterodine	Treatment discontinuation due to adverse effects	Rate in placebo group	Restricted maximum likelihood	-0.78	0.26	0.014
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.009	0.022	0.691
Women	Tolterodine	Treatment discontinuation due to adverse effects	Weeks of treatment	Restricted maximum likelihood	-0.0002	0.003	0.946
Study	Tolterodine	Headache	Adequate randomization	Restricted maximum likelihood	-0.003	0.007	0.659
Study	Tolterodine	Headache	Allocation concealment	Restricted maximum likelihood	0.0018	0.006	0.784
Study	Tolterodine	Headache	Conflict of interest	Restricted maximum likelihood	0.0083	0.012	0.498
Study	Tolterodine	Headache	Intention to treat	Restricted maximum likelihood	-0.0069	0.007	0.351
Study	Tolterodine	Headache	Justification of sample size	Restricted maximum likelihood	0.0021	0.006	0.729

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Tolterodine	Headache	Daily dose	Restricted maximum likelihood	-0.0012	0.011	0.914
Women	Tolterodine	Headache	Country	Restricted maximum likelihood	-0.0037	0.0047	0.445
Women	Tolterodine	Headache	Daily UI	Restricted maximum likelihood	0.01	0.014	0.492
Women	Tolterodine	Headache	Inclusion of prior failures	Restricted maximum likelihood	-0.017	0.01	0.079
Women	Tolterodine	Headache	% of women	Restricted maximum likelihood	-0.0003	0.001	0.606
Women	Tolterodine	Headache	Inclusion of minorities	Restricted maximum likelihood	-0.01	0.01	0.37
Women	Tolterodine	Headache	Rate in placebo group	Restricted maximum likelihood	-1.03	0.4	0.021
Women	Tolterodine	Headache	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.013	0.02	0.583
Women	Tolterodine	Headache	Weeks of treatment	Restricted maximum likelihood	0.0002	0.002	0.913
Study	Tolterodine	Constipation	Adequate randomization	Restricted maximum likelihood	0.003	0.003	0.402
Study	Tolterodine	Constipation	Allocation concealment	Restricted maximum likelihood	-0.001	0.003	0.841
Study	Tolterodine	Constipation	Conflict of interest	Restricted maximum likelihood	0.001	0.01	0.92
Study	Tolterodine	Constipation	Intention to treat	Restricted maximum likelihood	0.0001	0.01	0.98
Study	Tolterodine	Constipation	Justification of sample size	Restricted maximum likelihood	-0.001	0.004	0.745
Treatment	Tolterodine	Constipation	Daily dose	Restricted maximum likelihood	-0.0003	0.002	0.882
Women	Tolterodine	Constipation	Country	Restricted maximum likelihood	0.002	0.003	0.501
Women	Tolterodine	Constipation	Daily UI	Restricted maximum likelihood	-0.012	0.011	0.285
Women	Tolterodine	Constipation	Inclusion of prior failures	Restricted maximum likelihood	0.002	0.01	0.884

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Constipation	% of women	Restricted maximum likelihood	0.0001	0.0004	0.855
Women	Tolterodine	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.0004	0.01	0.956
Women	Tolterodine	Constipation	Rate in placebo group	Restricted maximum likelihood	-0.12	0.27	0.697
Women	Tolterodine	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.004	0.012	0.751
Women	Tolterodine	Constipation	Weeks of treatment	Restricted maximum likelihood	0.001	0.001	0.429
Study	Trospium	Dry mouth	Adequate randomization	Restricted maximum likelihood	-0.06	0.04	0.15
Study	Trospium	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.03	0.03	0.29
Study	Trospium	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.03	0.05	0.62
Study	Trospium	Dry mouth	Country	Restricted maximum likelihood	-0.01	0.03	0.77
Study	Trospium	Dry mouth	Intention to treat	Restricted maximum likelihood	-0.04	0.04	0.36
Study	Trospium	Dry mouth	Justification of sample size	Restricted maximum likelihood	-0.01	0.03	0.8
Treatment	Trospium	Dry mouth	Daily dose*	Restricted maximum likelihood	0	0	0.02
Treatment	Trospium	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.01	0.01	0.15
Women	Trospium	Dry mouth	% of women	Restricted maximum likelihood	0	0	0.12
Women	Trospium	Dry mouth	Daily UI	Restricted maximum likelihood	-0.13	0.07	0.15
Women	Trospium	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.13	0.07	0.15
Women	Trospium	Dry mouth	Inclusion of mixed UI	Restricted maximum likelihood	0.04	0.02	0.14
Women	Trospium	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.03	0.06	0.66

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Trospium	Dry mouth	Rate in placebo group*	Restricted maximum likelihood	3.28	0.85	0.02
Diversity factor	Drug	Outcome	Contributing variable	Estimate of between study variance	Coefficient (log RR)	Standard error	P values
Study	Darifenacin	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.40	0.30	0.236
Study	Darifenacin	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.40	0.30	0.236
Treatment	Darifenacin	Dry mouth	Daily dose	Restricted maximum likelihood	0.00	0.03	0.884
Treatment	Darifenacin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	0.05	0.07	0.537
Women	Darifenacin	Dry mouth	% women	Restricted maximum likelihood	0.02	0.02	0.294
Women	Darifenacin	Dry mouth	Control rate	Restricted maximum likelihood	-18.41	9.46	0.093
Women	Darifenacin	Dry mouth	Country	Restricted maximum likelihood	0.01	0.17	0.944
Women	Darifenacin	Dry mouth	Daily UI	Restricted maximum likelihood	0.80	0.60	0.236
Women	Darifenacin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.80	0.60	0.236
Women	Darifenacin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.17	0.20	0.438
Women	Darifenacin	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.15	0.33	0.663
Study	Darifenacin	Treatment discontinuation due to adverse effects	Adequacy of randomization	Restricted maximum likelihood	-0.11	0.29	0.726
Study	Darifenacin	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	-0.69	0.57	0.269
Study	Darifenacin	Treatment discontinuation due to adverse effects	Intention to treat analyses	Restricted maximum likelihood	0.34	0.29	0.269
Study	Darifenacin	Treatment discontinuation due to adverse effects	Justification of sample size	Restricted maximum likelihood	-0.21	0.59	0.726

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Darifenacin	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	0.06	0.03	0.064
Women	Darifenacin	Treatment discontinuation due to adverse effects	% women	Restricted maximum likelihood	0.10	0.06	0.151
Women	Darifenacin	Treatment discontinuation due to adverse effects	Control rate	Restricted maximum likelihood	-11.02	6.85	0.142
Women	Darifenacin	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	-0.27	0.14	0.096
Women	Darifenacin	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	0.21	0.59	0.726
Women	Darifenacin	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	0.25	0.33	0.462
Women	Darifenacin	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.57	0.48	0.278
Study	Fesoterodine	Constipation	Adequacy of randomization	Restricted maximum likelihood	0.00	0.23	0.993
Study	Fesoterodine	Constipation	Allocation concealment	Restricted maximum likelihood	-0.09	0.27	0.743
Study	Fesoterodine	Constipation	Conflict of interest	Restricted maximum likelihood	-0.16	0.54	0.77
Study	Fesoterodine	Constipation	Intention to treat analyses	Restricted maximum likelihood	0.62	0.53	0.273
Study	Fesoterodine	Constipation	Justification of sample size	Restricted maximum likelihood	0.17	0.31	0.601
Treatment	Fesoterodine	Constipation	Daily dose	Restricted maximum likelihood	0.02	0.12	0.853
Women	Fesoterodine	Constipation	% women	Restricted maximum likelihood	-0.06	0.03	0.125
Women	Fesoterodine	Constipation	Control rate	Restricted maximum likelihood	-21.40	21.02	0.338

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Fesoterodine	Constipation	Country	Restricted maximum likelihood	0.15	0.28	0.613
Women	Fesoterodine	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.19	0.55	0.743
Women	Fesoterodine	Constipation	Inclusion of prior failures	Restricted maximum likelihood	-0.05	0.54	0.925
Women	Fesoterodine	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.03	0.54	0.955
Study	Fesoterodine	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.03	0.08	0.748
Study	Fesoterodine	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.01	0.10	0.941
Study	Fesoterodine	Dry mouth	Conflict of interest	Restricted maximum likelihood	0.05	0.20	0.825
Study	Fesoterodine	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.22	0.19	0.276
Study	Fesoterodine	Dry mouth	Justification of sample size	Restricted maximum likelihood	0.08	0.11	0.472
Treatment	Fesoterodine	Dry mouth	Daily dose	Restricted maximum likelihood	0.05	0.04	0.247
Women	Fesoterodine	Dry mouth	% women	Restricted maximum likelihood	-0.01	0.01	0.422
Women	Fesoterodine	Dry mouth	Control rate	Restricted maximum likelihood	-13.35	6.11	0.061
Women	Fesoterodine	Dry mouth	Country	Restricted maximum likelihood	-0.04	0.10	0.711
Women	Fesoterodine	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.02	0.20	0.941
Women	Fesoterodine	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.05	0.20	0.82
Women	Fesoterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.10	0.19	0.61
Study	Fesoterodine	Headache	Adequacy of randomization	Restricted maximum likelihood	0.00	0.11	0.975
Study	Fesoterodine	Headache	Allocation concealment	Restricted maximum likelihood	0.05	0.11	0.656

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Fesoterodine	Headache	Conflict of interest	Restricted maximum likelihood	0.11	0.25	0.657
Study	Fesoterodine	Headache	Intention to treat analyses	Restricted maximum likelihood	0.55	0.28	0.092
Study	Fesoterodine	Headache	Justification of sample size	Restricted maximum likelihood	0.32	0.17	0.094
Treatment	Fesoterodine	Headache	Daily dose	Restricted maximum likelihood	-0.03	0.04	0.447
Women	Fesoterodine	Headache	% women	Restricted maximum likelihood	-0.04	0.02	0.145
Women	Fesoterodine	Headache	Control rate	Restricted maximum likelihood	-1.26	1.81	0.511
Women	Fesoterodine	Headache	Country	Restricted maximum likelihood	-0.28	0.13	0.059
Women	Fesoterodine	Headache	Inclusion of minorities	Restricted maximum likelihood	0.11	0.23	0.656
Women	Fesoterodine	Headache	Inclusion of prior failures	Restricted maximum likelihood	0.03	0.25	0.895
Women	Fesoterodine	Headache	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.15	0.24	0.535
Study	Fesoterodine	Nausea	Adequacy of randomization	Restricted maximum likelihood	0.27	0.23	0.285
Study	Fesoterodine	Nausea	Allocation concealment	Restricted maximum likelihood	0.27	0.23	0.285
Study	Fesoterodine	Nausea	Conflict of interest	Restricted maximum likelihood	1.32	0.91	0.188
Study	Fesoterodine	Nausea	Intention to treat analyses	Restricted maximum likelihood	-0.26	0.47	0.608
Study	Fesoterodine	Nausea	Justification of sample size	Restricted maximum likelihood	-0.54	0.47	0.285
Treatment	Fesoterodine	Nausea	Daily dose	Restricted maximum likelihood	0.04	0.08	0.61
Women	Fesoterodine	Nausea	% women	Restricted maximum likelihood	0.02	0.06	0.733
Women	Fesoterodine	Nausea	Control rate	Restricted maximum likelihood	-10.13	8.69	0.282

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Fesoterodine	Nausea	Country	Restricted maximum likelihood	0.31	0.44	0.51
Women	Fesoterodine	Nausea	Inclusion of minorities	Restricted maximum likelihood	0.54	0.47	0.285
Women	Fesoterodine	Nausea	Inclusion of prior failures	Restricted maximum likelihood	0.54	0.47	0.285
Women	Fesoterodine	Nausea	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.54	0.47	0.285
Study	Oxybutynin	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.11	0.23	0.65
Study	Oxybutynin	Dry mouth	Allocation concealment	Restricted maximum likelihood	0.09	0.27	0.755
Study	Oxybutynin	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.59	0.63	0.385
Study	Oxybutynin	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.29	0.20	0.198
Study	Oxybutynin	Dry mouth	Justification of sample size	Restricted maximum likelihood	0.11	0.33	0.744
Treatment	Oxybutynin	Dry mouth	Daily dose	Restricted maximum likelihood	0.05	0.04	0.198
Treatment	Oxybutynin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	0.02	0.06	0.708
Women	Oxybutynin	Dry mouth	% women	Restricted maximum likelihood	-0.03	0.02	0.145
Women	Oxybutynin	Dry mouth	Control rate	Restricted maximum likelihood	-1.16	0.72	0.151
Women	Oxybutynin	Dry mouth	Country	Restricted maximum likelihood	0.01	0.20	0.958
Women	Oxybutynin	Dry mouth	Daily UI	Restricted maximum likelihood	0.31	0.46	0.526
Women	Oxybutynin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.59	0.53	0.309
Women	Oxybutynin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.15	0.44	0.744
Women	Oxybutynin	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.16	0.53	0.768

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Oxybutynin	Improvement in UI	Adequacy of randomization	Restricted maximum likelihood	-0.06	0.11	0.593
Study	Oxybutynin	Improvement in UI	Allocation concealment	Restricted maximum likelihood	0.08	0.17	0.648
Study	Oxybutynin	Improvement in UI	Intention to treat analyses	Restricted maximum likelihood	-0.04	0.14	0.795
Study	Oxybutynin	Improvement in UI	Justification of sample size	Restricted maximum likelihood	0.00	0.13	0.988
Treatment	Oxybutynin	Improvement in UI	Daily dose	Restricted maximum likelihood	-0.04	0.03	0.21
Treatment	Oxybutynin	Improvement in UI	Weeks of treatment	Restricted maximum likelihood	0.00	0.04	0.903
Women	Oxybutynin	Improvement in UI	% women	Restricted maximum likelihood	0.00	0.01	0.833
Women	Oxybutynin	Improvement in UI	Control rate	Restricted maximum likelihood	-1.33	0.59	0.058
Women	Oxybutynin	Improvement in UI	Country	Restricted maximum likelihood	-0.14	0.07	0.074
Women	Oxybutynin	Improvement in UI	Daily UI	Restricted maximum likelihood	0.10	0.24	0.688
Women	Oxybutynin	Improvement in UI	Inclusion of prior failures	Restricted maximum likelihood	0.11	0.24	0.653
Women	Oxybutynin	Improvement in UI	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.18	0.24	0.471
Study	Solifenacin	Blurred vision	Adequacy of randomization	Restricted maximum likelihood	-0.12	0.12	0.323
Study	Solifenacin	Blurred vision	Allocation concealment	Restricted maximum likelihood	0.45	0.21	0.048
Study	Solifenacin	Blurred vision	Conflict of interest	Restricted maximum likelihood	0.04	0.23	0.853
Study	Solifenacin	Blurred vision	Intention to treat analyses	Restricted maximum likelihood	-0.26	0.19	0.198
Study	Solifenacin	Blurred vision	Justification of sample size	Restricted maximum likelihood	-0.41	0.24	0.105
Treatment	Solifenacin	Blurred vision	Daily dose	Restricted maximum likelihood	0.06	0.04	0.143

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Solifenacin	Blurred vision	Weeks of treatment	Restricted maximum likelihood	0.01	0.06	0.818
Women	Solifenacin	Blurred vision	% women	Restricted maximum likelihood	0.00	0.02	0.96
Women	Solifenacin	Blurred vision	Control rate	Restricted maximum likelihood	-9.74	12.93	0.464
Women	Solifenacin	Blurred vision	Country	Restricted maximum likelihood	-0.06	0.13	0.631
Women	Solifenacin	Blurred vision	Daily UI	Restricted maximum likelihood	0.10	0.45	0.823
Women	Solifenacin	Blurred vision	Inclusion of minorities	Restricted maximum likelihood	-0.15	0.27	0.576
Women	Solifenacin	Blurred vision	Inclusion of prior failures	Restricted maximum likelihood	0.12	0.24	0.637
Women	Solifenacin	Blurred vision	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-1.20	1.51	0.44
Study	Solifenacin	Constipation	Adequacy of randomization	Restricted maximum likelihood	-0.01	0.18	0.948
Study	Solifenacin	Constipation	Allocation concealment	Restricted maximum likelihood	-0.03	0.21	0.904
Study	Solifenacin	Constipation	Conflict of interest	Restricted maximum likelihood	-0.15	0.24	0.551
Study	Solifenacin	Constipation	Intention to treat analyses	Restricted maximum likelihood	0.05	0.26	0.855
Study	Solifenacin	Constipation	Justification of sample size	Restricted maximum likelihood	0.06	0.31	0.854
Treatment	Solifenacin	Constipation	Daily dose	Restricted maximum likelihood	0.14	0.05	0.012
Treatment	Solifenacin	Constipation	Weeks of treatment	Restricted maximum likelihood	-0.08	0.09	0.419
Women	Solifenacin	Constipation	% women	Restricted maximum likelihood	-0.01	0.02	0.615
Women	Solifenacin	Constipation	Control rate	Restricted maximum likelihood	-11.07	5.86	0.086
Women	Solifenacin	Constipation	Country	Restricted maximum likelihood	-0.09	0.14	0.511

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Solifenacin	Constipation	Daily UI	Restricted maximum likelihood	0.31	0.36	0.41
Women	Solifenacin	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.28	0.32	0.393
Women	Solifenacin	Constipation	Inclusion of prior failures	Restricted maximum likelihood	-0.02	0.34	0.949
Women	Solifenacin	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.21	0.59	0.721
Study	Solifenacin	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.02	0.18	0.926
Study	Solifenacin	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.09	0.25	0.708
Study	Solifenacin	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.24	0.33	0.478
Study	Solifenacin	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.26	0.25	0.334
Study	Solifenacin	Dry mouth	Justification of sample size	Restricted maximum likelihood	0.07	0.32	0.836
Treatment	Solifenacin	Dry mouth	Daily dose	Restricted maximum likelihood	0.17	0.03	0
Treatment	Solifenacin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.10	0.09	0.284
Women	Solifenacin	Dry mouth	% women	Restricted maximum likelihood	-0.02	0.02	0.367
Women	Solifenacin	Dry mouth	Control rate	Restricted maximum likelihood	-11.86	7.42	0.141
Women	Solifenacin	Dry mouth	Country	Restricted maximum likelihood	0.04	0.15	0.79
Women	Solifenacin	Dry mouth	Daily UI	Restricted maximum likelihood	0.18	0.38	0.657
Women	Solifenacin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.01	0.37	0.969
Women	Solifenacin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.06	0.37	0.881
Study	Solifenacin	Treatment discontinuation	Allocation concealment	Restricted maximum likelihood	0.19	0.09	0.09

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Solifenacin	Treatment discontinuation	Conflict of interest	Restricted maximum likelihood	-0.15	0.11	0.241
Study	Solifenacin	Treatment discontinuation	Intention to treat analyses	Restricted maximum likelihood	-0.18	0.11	0.148
Treatment	Solifenacin	Treatment discontinuation	Daily dose	Restricted maximum likelihood	0.02	0.05	0.653
Treatment	Solifenacin	Treatment discontinuation	Weeks of treatment	Restricted maximum likelihood	-0.02	0.04	0.627
Women	Solifenacin	Treatment discontinuation	% women	Restricted maximum likelihood	0.00	0.01	0.736
Women	Solifenacin	Treatment discontinuation	Control rate	Restricted maximum likelihood	3.61	2.31	0.162
Women	Solifenacin	Treatment discontinuation	Country	Restricted maximum likelihood	-0.01	0.09	0.905
Women	Solifenacin	Treatment discontinuation	Daily UI	Restricted maximum likelihood	0.62	0.43	0.193
Women	Solifenacin	Treatment discontinuation	Inclusion of minorities	Restricted maximum likelihood	-0.20	0.24	0.444
Women	Solifenacin	Treatment discontinuation	Inclusion of prior failures	Restricted maximum likelihood	0.08	0.22	0.71
Women	Solifenacin	Treatment discontinuation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.37	0.19	0.09
Study	Solifenacin	Treatment discontinuation due to adverse effects	Adequacy of randomization	Restricted maximum likelihood	0.08	0.18	0.676
Study	Solifenacin	Treatment discontinuation due to adverse effects	Allocation concealment	Restricted maximum likelihood	0.06	0.19	0.776
Study	Solifenacin	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	0.03	0.19	0.862
Study	Solifenacin	Treatment discontinuation due to adverse effects	Intention to treat analyses	Restricted maximum likelihood	-0.27	0.26	0.328
Study	Solifenacin	Treatment discontinuation due to adverse effects	Justification of sample size	Restricted maximum likelihood	0.29	0.23	0.233

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Solifenacin	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	0.08	0.05	0.134
Treatment	Solifenacin	Treatment discontinuation due to adverse effects	Weeks of treatment	Restricted maximum likelihood	-0.01	0.16	0.973
Women	Solifenacin	Treatment discontinuation due to adverse effects	% women	Restricted maximum likelihood	0.04	0.02	0.048
Women	Solifenacin	Treatment discontinuation due to adverse effects	Control rate	Restricted maximum likelihood	-7.58	12.27	0.552
Women	Solifenacin	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	0.11	0.13	0.397
Women	Solifenacin	Treatment discontinuation due to adverse effects	Daily UI	Restricted maximum likelihood	-0.05	0.42	0.912
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	-0.04	0.27	0.894
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	-0.26	0.24	0.315
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.45	0.34	0.214
Study	Tolterodine	Adverse effects	Adequacy of randomization	Restricted maximum likelihood	-0.13	0.05	0.014
Study	Tolterodine	Adverse effects	Adequacy of randomization	Empirical Bayes	-0.13	0.05	0.014
Study	Tolterodine	Adverse effects	Adequacy of randomization	Method of moments	-0.13	0.05	0.014
Study	Tolterodine	Adverse effects	Allocation concealment	Restricted maximum likelihood	0.04	0.05	0.385
Study	Tolterodine	Adverse effects	Allocation concealment	Empirical Bayes	0.03	0.07	0.668
Study	Tolterodine	Adverse effects	Allocation concealment	Method of moments	0.04	0.06	0.567
Study	Tolterodine	Adverse effects	Conflict of interest	Restricted maximum likelihood	0.01	0.10	0.952
Study	Tolterodine	Adverse effects	Conflict of interest	Empirical Bayes	-0.01	0.13	0.939

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Tolterodine	Adverse effects	Conflict of interest	Method of moments	0.00	0.11	0.987
Study	Tolterodine	Adverse effects	Intention to treat analyses	Restricted maximum likelihood	0.02	0.05	0.683
Study	Tolterodine	Adverse effects	Intention to treat analyses	Empirical Bayes	0.04	0.06	0.589
Study	Tolterodine	Adverse effects	Intention to treat analyses	Method of moments	0.03	0.06	0.634
Study	Tolterodine	Adverse effects	Justification of sample size	Restricted maximum likelihood	-0.08	0.06	0.186
Study	Tolterodine	Adverse effects	Justification of sample size	Empirical Bayes	-0.05	0.08	0.548
Study	Tolterodine	Adverse effects	Justification of sample size	Method of moments	-0.06	0.07	0.356
Treatment	Tolterodine	Adverse effects	Daily dose	Restricted maximum likelihood	0.12	0.07	0.09
Treatment	Tolterodine	Adverse effects	Daily dose	Empirical Bayes	0.12	0.06	0.071
Treatment	Tolterodine	Adverse effects	Daily dose	Method of moments	0.12	0.06	0.077
Treatment	Tolterodine	Adverse effects	Weeks of treatment	Restricted maximum likelihood	-0.01	0.01	0.716
Treatment	Tolterodine	Adverse effects	Weeks of treatment	Empirical Bayes	-0.01	0.02	0.743
Treatment	Tolterodine	Adverse effects	Weeks of treatment	Method of moments	-0.01	0.01	0.736
Women	Tolterodine	Adverse effects	% women	Restricted maximum likelihood	0.00	0.00	0.59
Women	Tolterodine	Adverse effects	% women	Empirical Bayes	0.00	0.01	0.535
Women	Tolterodine	Adverse effects	% women	Method of moments	0.00	0.01	0.564
Women	Tolterodine	Adverse effects	Control rate	Restricted maximum likelihood	-0.42	0.17	0.024
Women	Tolterodine	Adverse effects	Control rate	Empirical Bayes	-0.44	0.17	0.024
Women	Tolterodine	Adverse effects	Control rate	Method of moments	-0.44	0.17	0.024
Women	Tolterodine	Adverse effects	Country	Restricted maximum likelihood	0.02	0.05	0.719
Women	Tolterodine	Adverse effects	Country	Empirical Bayes	0.02	0.06	0.756
Women	Tolterodine	Adverse effects	Country	Method of moments	0.02	0.05	0.725
Women	Tolterodine	Adverse effects	Daily UI	Restricted maximum likelihood	-0.64	0.35	0.093
Women	Tolterodine	Adverse effects	Daily UI	Empirical Bayes	-0.63	0.33	0.075
Women	Tolterodine	Adverse effects	Daily UI	Method of moments	-0.63	0.33	0.08
Women	Tolterodine	Adverse effects	Inclusion of minorities	Restricted maximum likelihood	-0.03	0.09	0.781
Women	Tolterodine	Adverse effects	Inclusion of minorities	Empirical Bayes	-0.02	0.12	0.85
Women	Tolterodine	Adverse effects	Inclusion of minorities	Method of moments	-0.03	0.11	0.807

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Adverse effects	Inclusion of prior failures	Restricted maximum likelihood	0.03	0.07	0.673
Women	Tolterodine	Adverse effects	Inclusion of prior failures	Empirical Bayes	0.04	0.09	0.65
Women	Tolterodine	Adverse effects	Inclusion of prior failures	Method of moments	0.04	0.08	0.662
Women	Tolterodine	Adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.08	0.08	0.305
Women	Tolterodine	Adverse effects	Inclusion of women with surgical risk factors for UI	Empirical Bayes	-0.09	0.11	0.453
Women	Tolterodine	Adverse effects	Inclusion of women with surgical risk factors for UI	Method of moments	-0.09	0.10	0.392
Study	Tolterodine	Constipation	Adequacy of randomization	Restricted maximum likelihood	0.05	0.12	0.672
Study	Tolterodine	Constipation	Adequacy of randomization	Method of moments	0.05	0.12	0.672
Study	Tolterodine	Constipation	Allocation concealment	Restricted maximum likelihood	0.08	0.15	0.607
Study	Tolterodine	Constipation	Allocation concealment	Method of moments	0.08	0.15	0.607
Study	Tolterodine	Constipation	Conflict of interest	Restricted maximum likelihood	-0.03	0.28	0.923
Study	Tolterodine	Constipation	Conflict of interest	Method of moments	-0.03	0.28	0.923
Study	Tolterodine	Constipation	Intention to treat analyses	Restricted maximum likelihood	0.03	0.17	0.863
Study	Tolterodine	Constipation	Intention to treat analyses	Method of moments	0.03	0.17	0.863
Study	Tolterodine	Constipation	Justification of sample size	Restricted maximum likelihood	0.00	0.12	0.972
Study	Tolterodine	Constipation	Justification of sample size	Method of moments	0.00	0.12	0.972
Treatment	Tolterodine	Constipation	Daily dose	Restricted maximum likelihood	0.01	0.09	0.925
Treatment	Tolterodine	Constipation	Daily dose	Method of moments	0.01	0.09	0.925
Treatment	Tolterodine	Constipation	Weeks of treatment	Restricted maximum likelihood	0.01	0.04	0.811
Treatment	Tolterodine	Constipation	Weeks of treatment	Method of moments	0.01	0.04	0.811
Women	Tolterodine	Constipation	% women	Restricted maximum likelihood	-0.01	0.02	0.529
Women	Tolterodine	Constipation	% women	Restricted maximum likelihood	-0.01	0.02	0.529
Women	Tolterodine	Constipation	Control rate	Restricted maximum likelihood	-13.18	9.62	0.187

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Constipation	Control rate	Method of moments	-13.18	9.62	0.187
Women	Tolterodine	Constipation	Country	Restricted maximum likelihood	0.07	0.10	0.471
Women	Tolterodine	Constipation	Country	Method of moments	0.07	0.10	0.471
Women	Tolterodine	Constipation	Daily UI	Restricted maximum likelihood	-0.07	0.24	0.779
Women	Tolterodine	Constipation	Daily UI	Method of moments	-0.07	0.24	0.779
Women	Tolterodine	Constipation	Inclusion of minorities	Restricted maximum likelihood	0.05	0.26	0.857
Women	Tolterodine	Constipation	Inclusion of minorities	Method of moments	0.05	0.26	0.857
Women	Tolterodine	Constipation	Inclusion of prior failures	Restricted maximum likelihood	0.09	0.24	0.724
Women	Tolterodine	Constipation	Inclusion of prior failures	Method of moments	0.09	0.24	0.724
Women	Tolterodine	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.35	0.62	0.585
Women	Tolterodine	Constipation	Inclusion of women with surgical risk factors for UI	Method of moments	-0.35	0.62	0.585
Study	Tolterodine	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	-0.08	0.09	0.386
Study	Tolterodine	Dry mouth	Adequacy of randomization	Empirical Bayes	-0.12	0.11	0.294
Study	Tolterodine	Dry mouth	Adequacy of randomization	Method of moments	-0.11	0.10	0.316
Study	Tolterodine	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.01	0.11	0.898
Study	Tolterodine	Dry mouth	Allocation concealment	Empirical Bayes	-0.02	0.15	0.892
Study	Tolterodine	Dry mouth	Allocation concealment	Method of moments	-0.02	0.13	0.903
Study	Tolterodine	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.26	0.17	0.14
Study	Tolterodine	Dry mouth	Conflict of interest	Empirical Bayes	-0.26	0.20	0.213
Study	Tolterodine	Dry mouth	Conflict of interest	Method of moments	-0.26	0.18	0.173
Study	Tolterodine	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.10	0.11	0.382
Study	Tolterodine	Dry mouth	Intention to treat analyses	Empirical Bayes	0.11	0.14	0.417
Study	Tolterodine	Dry mouth	Intention to treat analyses	Method of moments	0.11	0.13	0.411
Study	Tolterodine	Dry mouth	Justification of sample size	Restricted maximum likelihood	-0.07	0.10	0.485
Study	Tolterodine	Dry mouth	Justification of sample size	Empirical Bayes	-0.06	0.14	0.682
Study	Tolterodine	Dry mouth	Justification of sample size	Method of moments	-0.06	0.12	0.612

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Tolterodine	Dry mouth	Daily dose	Restricted maximum likelihood	0.08	0.05	0.139
Treatment	Tolterodine	Dry mouth	Daily dose	Empirical Bayes	0.09	0.06	0.139
Treatment	Tolterodine	Dry mouth	Daily dose	Method of moments	0.08	0.05	0.138
Treatment	Tolterodine	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.02	0.03	0.588
Treatment	Tolterodine	Dry mouth	Weeks of treatment	Empirical Bayes	-0.02	0.03	0.651
Treatment	Tolterodine	Dry mouth	Weeks of treatment	Method of moments	-0.02	0.03	0.605
Women	Tolterodine	Dry mouth	% women	Restricted maximum likelihood	-0.01	0.01	0.152
Women	Tolterodine	Dry mouth	% women	Empirical Bayes	-0.02	0.01	0.142
Women	Tolterodine	Dry mouth	% women	Method of moments	-0.02	0.01	0.143
Women	Tolterodine	Dry mouth	Control rate	Restricted maximum likelihood	-2.89	1.89	0.147
Women	Tolterodine	Dry mouth	Control rate	Empirical Bayes	-3.26	2.03	0.129
Women	Tolterodine	Dry mouth	Control rate	Method of moments	-3.11	1.98	0.136
Women	Tolterodine	Dry mouth	Country	Restricted maximum likelihood	-0.07	0.07	0.378
Women	Tolterodine	Dry mouth	Country	Empirical Bayes	-0.09	0.09	0.332
Women	Tolterodine	Dry mouth	Country	Method of moments	-0.08	0.08	0.341
Women	Tolterodine	Dry mouth	Daily UI	Restricted maximum likelihood	-0.23	0.20	0.267
Women	Tolterodine	Dry mouth	Daily UI	Empirical Bayes	-0.27	0.28	0.36
Women	Tolterodine	Dry mouth	Daily UI	Method of moments	-0.25	0.25	0.326
Women	Tolterodine	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.16	0.17	0.355
Women	Tolterodine	Dry mouth	Inclusion of minorities	Empirical Bayes	-0.15	0.22	0.497
Women	Tolterodine	Dry mouth	Inclusion of minorities	Method of moments	-0.16	0.20	0.436
Women	Tolterodine	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.20	0.16	0.242
Women	Tolterodine	Dry mouth	Inclusion of prior failures	Empirical Bayes	0.18	0.21	0.399
Women	Tolterodine	Dry mouth	Inclusion of prior failures	Method of moments	0.19	0.19	0.318
Women	Tolterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.00	0.21	0.994
Women	Tolterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Empirical Bayes	0.00	0.27	0.992

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Method of moments	0.00	0.24	0.996
Study	Tolterodine	Headache	Adequacy of randomization	Restricted maximum likelihood	-0.13	0.15	0.405
Study	Tolterodine	Headache	Adequacy of randomization	Empirical Bayes	-0.13	0.15	0.405
Study	Tolterodine	Headache	Adequacy of randomization	Method of moments	-0.13	0.15	0.405
Study	Tolterodine	Headache	Allocation concealment	Restricted maximum likelihood	0.11	0.13	0.435
Study	Tolterodine	Headache	Allocation concealment	Empirical Bayes	0.11	0.13	0.435
Study	Tolterodine	Headache	Allocation concealment	Method of moments	0.11	0.13	0.435
Study	Tolterodine	Headache	Conflict of interest	Restricted maximum likelihood	0.03	0.26	0.918
Study	Tolterodine	Headache	Conflict of interest	Empirical Bayes	0.03	0.26	0.918
Study	Tolterodine	Headache	Conflict of interest	Method of moments	0.03	0.26	0.918
Study	Tolterodine	Headache	Intention to treat analyses	Restricted maximum likelihood	-0.02	0.16	0.925
Study	Tolterodine	Headache	Intention to treat analyses	Empirical Bayes	-0.02	0.16	0.925
Study	Tolterodine	Headache	Intention to treat analyses	Method of moments	-0.02	0.16	0.925
Study	Tolterodine	Headache	Justification of sample size	Restricted maximum likelihood	0.04	0.13	0.788
Study	Tolterodine	Headache	Justification of sample size	Empirical Bayes	0.04	0.13	0.788
Study	Tolterodine	Headache	Justification of sample size	Method of moments	0.04	0.13	0.788
Treatment	Tolterodine	Headache	Daily dose	Restricted maximum likelihood	-0.13	0.28	0.638
Treatment	Tolterodine	Headache	Daily dose	Empirical Bayes	-0.13	0.28	0.638
Treatment	Tolterodine	Headache	Daily dose	Method of moments	-0.13	0.28	0.638
Treatment	Tolterodine	Headache	Weeks of treatment	Restricted maximum likelihood	-0.03	0.05	0.483
Treatment	Tolterodine	Headache	Weeks of treatment	Empirical Bayes	-0.03	0.05	0.483
Treatment	Tolterodine	Headache	Weeks of treatment	Method of moments	-0.03	0.05	0.483
Women	Tolterodine	Headache	% women	Restricted maximum likelihood	-0.01	0.01	0.348
Women	Tolterodine	Headache	% women	Empirical Bayes	-0.01	0.01	0.348
Women	Tolterodine	Headache	% women	Method of moments	-0.01	0.01	0.348
Women	Tolterodine	Headache	Control rate	Restricted maximum likelihood	-24.03	12.96	0.087

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Headache	Country	Restricted maximum likelihood	-0.10	0.12	0.418
Women	Tolterodine	Headache	Country	Empirical Bayes	-0.10	0.12	0.418
Women	Tolterodine	Headache	Country	Method of moments	-0.10	0.12	0.418
Women	Tolterodine	Headache	Daily UI	Restricted maximum likelihood	0.18	0.26	0.497
Women	Tolterodine	Headache	Daily UI	Empirical Bayes	0.18	0.26	0.497
Women	Tolterodine	Headache	Daily UI	Method of moments	0.18	0.26	0.497
Women	Tolterodine	Headache	Inclusion of minorities	Restricted maximum likelihood	-0.05	0.25	0.842
Women	Tolterodine	Headache	Inclusion of minorities	Empirical Bayes	-0.05	0.25	0.842
Women	Tolterodine	Headache	Inclusion of minorities	Method of moments	-0.05	0.25	0.842
Women	Tolterodine	Headache	Inclusion of prior failures	Restricted maximum likelihood	-0.20	0.30	0.516
Women	Tolterodine	Headache	Inclusion of prior failures	Empirical Bayes	-0.20	0.30	0.516
Women	Tolterodine	Headache	Inclusion of prior failures	Method of moments	-0.20	0.30	0.516
Women	Tolterodine	Headache	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.25	0.39	0.54
Women	Tolterodine	Headache	Inclusion of women with surgical risk factors for UI	Empirical Bayes	0.25	0.39	0.54
Women	Tolterodine	Headache	Inclusion of women with surgical risk factors for UI	Method of moments	0.25	0.39	0.54
Study	Tolterodine	Treatment discontinuation	Adequacy of randomization	Restricted maximum likelihood	-0.02	0.38	0.965
Study	Tolterodine	Treatment discontinuation	Allocation concealment	Restricted maximum likelihood	0.08	0.12	0.533
Study	Tolterodine	Treatment discontinuation	Conflict of interest	Restricted maximum likelihood	0.23	0.22	0.326
Study	Tolterodine	Treatment discontinuation	Intention to treat analyses	Restricted maximum likelihood	-0.19	0.19	0.335
Study	Tolterodine	Treatment discontinuation	Justification of sample size	Restricted maximum likelihood	-0.04	0.13	0.749
Treatment	Tolterodine	Treatment discontinuation	Daily dose	Restricted maximum likelihood	-0.01	0.05	0.875
Treatment	Tolterodine	Treatment discontinuation	Weeks of treatment	Restricted maximum likelihood	-0.01	0.06	0.829

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Treatment discontinuation	% women	Restricted maximum likelihood	0.01	0.01	0.6
Women	Tolterodine	Treatment discontinuation	Control rate	Restricted maximum likelihood	0.79	3.72	0.839
Women	Tolterodine	Treatment discontinuation	Country	Restricted maximum likelihood	0.02	0.08	0.781
Women	Tolterodine	Treatment discontinuation	Daily UI	Restricted maximum likelihood	2.04	1.07	0.097
Women	Tolterodine	Treatment discontinuation	Inclusion of minorities	Restricted maximum likelihood	-0.16	0.51	0.759
Women	Tolterodine	Treatment discontinuation	Inclusion of prior failures	Restricted maximum likelihood	-0.35	0.41	0.422
Women	Tolterodine	Treatment discontinuation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.20	0.26	0.459
Study	Tolterodine	Treatment discontinuation due to adverse effects	Adequacy of randomization	Restricted maximum likelihood	-0.31	0.27	0.278
Study	Tolterodine	Treatment discontinuation due to adverse effects	Allocation concealment	Restricted maximum likelihood	0.36	0.25	0.179
Study	Tolterodine	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	1.01	0.40	0.033
Study	Tolterodine	Treatment discontinuation due to adverse effects	Intention to treat analyses	Restricted maximum likelihood	0.30	0.32	0.379
Study	Tolterodine	Treatment discontinuation due to adverse effects	Justification of sample size	Restricted maximum likelihood	-0.46	0.35	0.22
Treatment	Tolterodine	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	-0.49	0.22	0.054
Treatment	Tolterodine	Treatment discontinuation due to adverse effects	Weeks of treatment	Restricted maximum likelihood	0.06	0.08	0.49
Women	Tolterodine	Treatment discontinuation due to adverse effects	% women	Restricted maximum likelihood	0.00	0.03	0.974

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Treatment discontinuation due to adverse effects	Control rate	Restricted maximum likelihood	-11.32	3.49	0.01
Women	Tolterodine	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	0.02	0.22	0.945
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	0.38	0.59	0.535
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	0.54	0.62	0.404
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.38	0.56	0.514

Appendix Table F49. Severity and quality of life after oxybutynin (individual RCTs)

Reference	Active	Dose	Active N	Control N	Active Mean+/- Standard Deviation	Control Mean+/- Standard Deviation	Mean Difference (95% CI)
Anxiety							
Burgio, 2001236	Oxybutynin	2.5 to 5mg thrice daily	52	46	44.5+/-12.3	45.8+/-12.9	-1.3 (-6.3; 3.7)
Depression							
Burgio, 2001236	Oxybutynin	2.5 to 5mg thrice daily	52	46	50.6+/-10.7	51.4+/-11.2	-0.8 (-5.2; 3.6)
Emotions							
Homma, 2006305	Oxytrol	Transdermal patch 39cm2	164	161	24.9+/-21.6	35.2+/-28.4	-10.3 (-15.8; -4.8)
Homma, 2004306	Oxybutynin IR	3mg thrice daily	122	57	26.7+/-27.9	37.1+/-30.7	-10.4 (-19.8; -1.0)
Homma, 2006305	Oxytrol	Transdermal patch 26cm2	160	161	28.2+/-25.8	35.2+/-28.4	-7.0 (-12.9; -1.1)
Homma, 2006305	Oxytrol	Transdermal patch 52cm2	152	161	29.3+/-26.7	35.2+/-28.4	-5.9 (-12.0; 0.2)
Estimate of percent improvement							
Burgio, 1998238	Oxybutynin	2.5-5mg thrice daily	67	65	66.4+/-35.4	45.1+/-36.6	21.3 (9.0; 33.6)
General health							
Homma, 2006305	Oxytrol	Transdermal patch 39cm2	164	161	30.9+/-22.2	33.0+/-22.7	-2.1 (-7.0; 2.8)
Homma, 2006305	Oxytrol	Transdermal patch 26cm2	160	161	33.4+/-20.3	33.0+/-22.7	0.4 (-4.3; 5.1)
Homma, 2006305	Oxytrol	Transdermal patch 52cm2	152	161	33.9+/-21.6	33.0+/-22.7	0.9 (-4.0; 5.8)
General health perception							
Homma, 2004306	Oxybutynin IR	3mg thrice daily	122	57	34.6+/-20.9	32.9+/-21.2	1.7 (-4.9; 8.3)
Global severity							
Burgio, 2001236	Oxybutynin	2.5 to 5mg thrice daily	52	46	50.4+/-10.0	51.4+/-10.9	-1.0 (-5.2; 3.2)
Hostility							
Burgio, 2001236	Oxybutynin	2.5 to 5mg thrice daily	52	46	44.6+/-10.5	47.3+/-11.2	-2.7 (-7.0; 1.6)
Incontinence impact							
Homma, 2006305	Oxytrol	Transdermal patch 39cm2	164	161	32.7+/-23.6	39.7+/-26.0	-7.0 (-12.4; -1.6)
Homma, 2004306	Oxybutynin-IR	3mg thrice daily	122	57	33.9+/-29.4	46.2+/-28.0	-12.3 (-21.2; -3.4)
Homma, 2006305	Oxytrol	transdermal patch 52cm2	152	161	34.0+/-24.4	39.7+/-26.0	-5.7 (-11.3; -0.1)
Homma, 2006305	Oxytrol	Transdermal patch 26cm2	160	161	34.6+/-23.2	39.7+/-26.0	-5.1 (-10.5; 0.3)
Interpersonal sensitivity							
Burgio, 2001236	Oxybutynin	2.5 to 5mg thrice daily	52	46	48.9+/-11.2	49.2+/-11.3	-0.3 (-4.8; 4.2)
Mean total UDI score							
Dmochowski, 2002271	Oxybutynin TDS	3.9mg	125	132	78.8+/-51.9	94.7+/-50.0	-15.9 (-28.4; -3.4)
Obsessive-compulsive							
Burgio, 2001236	Oxybutynin	2.5 to 5mg thrice daily	52	46	53.9+/-10.9	55.4+/-11.0	-1.5 (-5.8; 2.8)
Paranoid ideation							
Burgio, 2001236	Oxybutynin	2.5 to 5mg thrice daily	52	46	47.2+/-11.6	47.2+/-12.0	0.0 (-4.7; 4.7)

Appendix Table F49. Severity and quality of life after oxybutynin (individual RCTs) (continued)

Reference	Active	Dose	Active N	Control N	Active Mean+/- Standard Deviation	Control Mean+/- Standard Deviation	Mean Difference (95% CI)
Personal relationship							
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 39cm ²	164	161	8.4+/-16.8	12.0+/-20.2	-3.6 (-7.6; 0.4)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 26cm ²	160	161	10.4+/-17.3	12.0+/-20.2	-1.6 (-5.7; 2.5)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 52cm ²	152	161	11.6+/-22.1	12.0+/-20.2	-0.4 (-5.1; 4.3)
Homma, 2004 ³⁰⁶	oxybutynin-IR	3mg thrice daily	122	57	3.5+/-9.6	10.3+/-19.8	-6.8 (-12.2; -1.4)
Phobia							
Burgio, 2001 ²³⁶	Oxybutynin	2.5 to 5mg thrice daily	52	46	45.0+/-8.3	45.1+/-8.5	-0.1 (-3.4; 3.2)
Physical limitation							
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 39cm ²	164	161	26.6+/-22.8	36.5+/-27.5	-9.9 (-15.4; -4.4)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 26cm ²	160	161	29.7+/-25.6	36.5+/-27.5	-6.8 (-12.6; -1.0)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 52cm ²	152	161	29.7+/-27.3	36.5+/-27.5	-6.8 (-12.9; -0.7)
Homma, 2004 ³⁰⁶	Oxybutynin-IR	3mg thrice daily	122	57	20.6+/-24.4	35.7+/-29.3	-15.1 (-23.9; -6.3)
Psychoticism							
Burgio, 2001 ²³⁶	Oxybutynin	2.5 to 5mg thrice daily	52	46	50.4+/-9.7	49.6+/-10.3	0.8 (-3.2; 4.8)
Role limitation							
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 39cm ²	164	161	22.0+/-20.3	31.9+/-24.1	-9.9 (-14.7; -5.1)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 26cm ²	160	161	24.8+/-22.0	31.9+/-24.1	-7.1 (-12.1; -2.1)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 52cm ²	152	161	26.5+/-24.7	31.9+/-24.1	-5.4 (-10.8; 0.0)
Homma, 2004 ³⁰⁶	Oxybutynin IR	3mg thrice daily	122	57	18.6+/-21.0	28.7+/-26.9	-10.1 (-18.0; -2.2)
Severity (coping) measure							
Homma, 2004 ³⁰⁶	Oxybutynin IR	3mg thrice daily	122	57	19.4+/-18.9	29.7+/-21.5	-10.3 (-16.8; -3.8)
Sleep and energy							
Homma, 2004 ³⁰⁶	Oxybutynin IR	3mg thrice daily	122	57	17.2+/-21.4	29.2+/-29.4	-12.0 (-20.5; -3.5)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 39cm ²	164	161	17.9+/-18.9	26.0+/-25.6	-8.1 (-13.0; -3.2)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 26cm ²	160	161	18.2+/-19.2	26.0+/-25.6	-7.8 (-12.7; -2.9)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 52cm ²	152	161	21.1+/-22.8	26.0+/-25.6	-4.9 (-10.3; 0.5)
Social limitation							
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 39cm ²	164	161	13.2+/-17.1	21.6+/-24.2	-8.4 (-13.0; -3.8)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 26cm ²	160	161	16.3+/-21.3	21.6+/-24.2	-5.3 (-10.3; -0.3)
Homma, 2006 ³⁰⁵	Oxytrol	Transdermal patch 52cm ²	152	161	18.4+/-22.8	21.6+/-24.2	-3.2 (-8.4; 2.0)
Homma, 2004 ³⁰⁶	Oxybutynin-IR	3mg thrice daily	122	57	14.0+/-22.1	21.0+/-26.3	-7.0 (-14.9; 0.9)
Summarization							
Burgio, 2001 ²³⁶	Oxybutynin	2.5 to 5mg thrice daily	52	46	51.2+/-9.8	49.8+/-13.0	1.4 (-3.2; 6.0)
Symptom severity							
Homma, 2004 ³⁰⁶	Oxybutynin-IR	3mg thrice daily	122	57	16.4+/-13.6	26.6+/-16.4	-10.2 (-15.1; -5.3)

Appendix Table F50. Domains of quality of life after oxybutynin treatments (individual RCTs)

Reference	Active	Control	Active N	Control N	Active Mean+/- Standard Deviation	Control Mean+/- Standard Deviation	Mean Difference (95%CI)
Personal relationship							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 39cm2	Oxybutynin transdermal patch 52cm2	164	152	8.4+/-16.8	11.6+/-22.1	-3.2 (-7.6; 1.2)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 39cm2	160	164	10.4+/-17.3	8.4+/-16.8	2.0 (-1.7; 5.7)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 52cm2	160	152	10.4+/-17.3	11.6+/-22.1	-1.2 (-5.6; 3.2)
Social limitation							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 39cm2	Oxybutynin transdermal patch 52cm2	164	152	13.2+/-17.1	18.4+/-22.8	-5.2 (-9.7; -0.7)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 39cm2	160	164	16.3+/-21.3	13.2+/-17.1	3.1 (-1.1; 7.3)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 52cm2	160	152	16.3+/-21.3	18.4+/-22.8	-2.1 (-7.0; 2.8)
Sleep/energy							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 39cm2	Oxybutynin transdermal patch 52cm2	164	152	17.9+/-18.9	21.1+/-22.8	-3.2 (-7.8; 1.4)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 39cm2	160	164	18.2+/-19.2	17.9+/-18.9	0.3 (-3.8; 4.4)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 52cm2	160	152	18.2+/-19.2	21.1+/-22.8	-2.9 (-7.6; 1.8)
Role limitation							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 39cm2	Oxybutynin transdermal patch 52cm2	164	152	22.0+/-20.3	26.5+/-24.7	-4.5 (-9.5; 0.5)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 39cm2	160	164	24.8+/-22.0	22.0+/-20.3	2.8 (-1.8; 7.4)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 52cm2	160	152	24.8+/-22.0	26.5+/-24.7	-1.7 (-6.9; 3.5)
Emotions							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 39cm2	Oxybutynin transdermal patch 52cm2	164	152	24.9+/-21.6	29.3+/-26.7	-4.4 (-9.8; 1.0)
Physical limitation							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 39cm2	Oxybutynin transdermal patch 52cm2	164	152	26.6+/-22.8	29.7+/-27.3	-3.1 (-8.7; 2.5)

Appendix Table F50. Domains of quality of life after oxybutynin treatments (individual RCTs) (continued)

Reference	Active	Control	Active N	Control N	Active Mean+/- Standard Deviation	Control Mean+/- Standard Deviation	Mean Difference (95%CI)
Emotions							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 39cm2	160	164	28.2+/-25.8	24.9+/-21.6	3.3 (-1.9; 8.5)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 52cm2	160	152	28.2+/-25.8	29.3+/-26.7	-1.1 (-6.9; 4.7)
Physical limitation							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 39cm2	160	164	29.7+/-25.6	26.6+/-22.8	3.1 (-2.2; 8.4)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 52cm2	160	152	29.7+/-25.6	29.7+/-27.3	0.0 (-5.9; 5.9)
General health							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 39cm2	Oxybutynin transdermal patch 52cm2	164	152	30.9+/-22.2	33.9+/-21.6	-3.0 (-7.8; 1.8)
Incontinence impact							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 39cm2	Oxybutynin transdermal patch 52cm2	164	152	32.7+/-23.6	34.0+/-24.4	-1.3 (-6.6; 4.0)
General health							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 39cm2	160	164	33.4+/-20.3	30.9+/-22.2	2.5 (-2.1; 7.1)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 52cm2	160	152	33.4+/-20.3	33.9+/-21.6	-0.5 (-5.2; 4.2)
Incontinence impact							
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 39cm2	160	164	34.6+/-23.2	32.7+/-23.6	1.9 (-3.2; 7.0)
Homma, 2006 ³⁰⁵	Oxytrol-Oxybutynin transdermal patch 26cm2	Oxybutynin transdermal patch 52cm2	160	152	34.6+/-23.2	34.0+/-24.4	0.6 (-4.7; 5.9)
Mean reduction in IIQ score							
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS, 2.6mg	Oxybutynin TDS3.9mg	133	125	-85.1+/-72.7	-64.2+/-82.9	-20.9 (-40.0; -1.8)

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Continence										
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	8/38	10/38	0.80 (0.35; 1.81)	-0.05 (-0.24; 0.14)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	4/53	7/52	0.56 (0.17; 1.80)	-0.06 (-0.18; 0.06)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	4/53	5/52	0.78 (0.22; 2.76)	-0.02 (-0.13; 0.09)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	2/53	3/52	0.65 (0.11; 3.76)	-0.02 (-0.10; 0.06)		
Adverse events										
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	22/53	21/52	1.03 (0.65; 1.63)	0.01 (-0.18; 0.20)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	22/53	21/52	1.03 (0.65; 1.63)	0.01 (-0.18; 0.20)		
Continence										
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	6/53	4/52	1.47 (0.44; 4.92)	0.04 (-0.08; 0.15)		
Efficacy										
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	22/77	26/77	0.85 (0.53; 1.36)	-0.05 (-0.20; 0.09)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	27/77	28/77	0.96 (0.63; 1.47)	-0.01 (-0.16; 0.14)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	71/77	61/77	1.16 (1.02; 1.33)	0.13 (0.02; 0.24)	8 (4; 47)	130 (21; 238)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	22/77	42/83	0.56 (0.37; 0.85)	-0.22 (-0.37; -0.07)	-5 (-14; -3)	-220 (-368; -73)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	27/77	43/83	0.68 (0.47; 0.98)	-0.17 (-0.32; -0.02)	-6 (-62; -3)	-167 (-319; -16)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	71/77	68/83	1.13 (1.00; 1.27)	0.10 (0.00; 0.20)	10 (5; 1567)	103 (1; 205)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	26/77	42/83	0.67 (0.46; 0.97)	-0.17 (-0.32; -0.02)	-6 (-57; -3)	-168 (-319; -18)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	28/77	43/83	0.70 (0.49; 1.01)	-0.15 (-0.31; 0.00)	-6 (-408; -3)	-154 (-306; -2)

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	61/77	68/83	0.97 (0.83; 1.13)	-0.03 (-0.15; 0.10)		
Adverse effects										
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	25/38	13/38	1.92 (1.17; 3.16)	0.32 (0.10; 0.53)	3 (2; 10)	316 (102; 529)
Gupta, 1999 ²⁹²	OROS oxybutynin chloride	5mg once daily	IR-oxybutynin - Ditropan	5mg thrice daily	6/13	12/13	0.50 (0.27; 0.92)	-0.46 (-0.77; -0.15)	-2 (-6; -1)	-462 (-769; - 154)
Undefined										
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	3/27	4/39	1.08 (0.26; 4.46)	0.01 (-0.14; 0.16)		
Adverse effects										
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	14/38	2/38	7.00 (1.71; 28.72)	0.32 (0.15; 0.48)	3(2; 7)	316 (147; 485)
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	46/53	49/52	0.92 (0.81; 1.04)	-0.07 (-0.19; 0.04)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	46/53	49/52	0.92 (0.81; 1.04)	-0.07 (-0.19; 0.04)		
Discontinuation										
Preik, 2004 ³⁴⁰	CR- oxybutynin	5- 30mg/day	IR-oxybutynin	5-20mg/day	5/53	5/52	0.98 (0.30; 3.19)	0.00 (-0.11; 0.11)		
Withdrawal										
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	3/77	11/77	0.27 (0.08; 0.94)	-0.10 (-0.19; -0.01)	-10 (-69; -5)	-104 (-193; -15)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	4/77	4/77	1.00 (0.26; 3.86)	0.00 (-0.07; 0.07)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	3/77	12/83	0.27 (0.08; 0.92)	-0.11 (-0.19; -0.02)	-9 (-54; -5)	-106 (-193; -18)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	11/77	12/83	0.99 (0.46; 2.11)	0.00 (-0.11; 0.11)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	4/77	2/83	2.16 (0.41; 11.44)	0.03 (-0.03; 0.09)		

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	4/77	2/83	2.16 (0.41; 11.44)	0.03 (-0.03; 0.09)		
Blurred vision		CR- oxybutynin		CR-oxybutynin						
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	1/77	1/77	1.00 (0.06; 15.70)	0.00 (-0.04; 0.04)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	1/77	1/83	1.08 (0.07; 16.94)	0.00 (-0.03; 0.04)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	1/77	1/83	1.08 (0.07; 16.94)	0.00 (-0.03; 0.04)		
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	7/38	9/38	0.78 (0.32; 1.87)	-0.05 (-0.24; 0.13)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	15/53	9/52	1.64 (0.79; 3.40)	0.11 (-0.05; 0.27)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	15/53	9/52	1.64 (0.79; 3.40)	0.11 (-0.05; 0.27)		
Treatment compliance										
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	11/27	11/39	1.44 (0.73; 2.84)	0.13 (-0.11; 0.36)		
Constipation										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	7/130	3/133	2.39 (0.63; 9.03)	0.03 (-0.01; 0.08)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	7/130	1/125	6.73 (0.84; 53.92)	0.05 (0.00; 0.09)	22 (11; 249)	46 (4; 88)
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	3/133	1/125	2.82 (0.30; 26.75)	0.01 (-0.02; 0.04)		
Dmochowski, 2002 ²⁷¹	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	4/77	3/77	1.33 (0.31; 5.76)	0.01 (-0.05; 0.08)		
Dmochowski, 2002 ²⁷¹	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	4/77	4/83	1.08 (0.28; 4.16)	0.00 (-0.06; 0.07)		

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Dmochowski, 2002 ²⁷¹	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	3/77	4/83	0.81 (0.19; 3.50)	-0.01 (-0.07; 0.05)		
Dmochowski, 2002 ²⁷¹	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	8/38	19/38	0.42 (0.21; 0.84)	-0.29 (-0.49; -0.08)	-3 (-12; -2)	-289 (-495; -84)
Dmochowski, 2002 ²⁷¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	16/53	16/52	0.98 (0.55; 1.75)	-0.01 (-0.18; 0.17)		
Constipation										
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	16/53	16/52	0.98 (0.55; 1.75)	-0.01 (-0.18; 0.17)		
Dizziness										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	2/130	5/125	0.38 (0.08; 1.95)	-0.02 (-0.06; 0.02)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	4/133	5/125	0.75 (0.21; 2.74)	-0.01 (-0.05; 0.04)		
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	2/39	0.29 (0.01; 5.73)	-0.05 (-0.14; 0.04)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	5/77	6/77	0.83 (0.27; 2.62)	-0.01 (-0.09; 0.07)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	5/77	6/83	0.90 (0.29; 2.82)	-0.01 (-0.09; 0.07)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	6/77	6/83	1.08 (0.36; 3.20)	0.01 (-0.08; 0.09)		
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	6/38	10/38	0.60 (0.24; 1.49)	-0.11 (-0.29; 0.08)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	15/53	20/52	0.74 (0.42; 1.27)	-0.10 (-0.28; 0.08)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	15/53	20/52	0.74 (0.42; 1.27)	-0.10 (-0.28; 0.08)		
Maximum dosage reached										
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	26/38	12/38	2.17 (1.29; 3.63)	0.37 (0.16; 0.58)	3 (2; 6)	368 (159; 577)

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Dry eyes										
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
Worse dry mouth on completion of treatment										
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	2/38	13/38	0.15 (0.04; 0.64)	-0.29 (-0.46; -0.12)	-3 (-8; -2)	-289 (-456; - 123)
Dry mouth										
Gupta, 1999 ²⁹²	OROS oxybutynin chloride	5mg once daily	IR-oxybutynin	5mg thrice daily	6/13	10/13	0.60 (0.31; 1.16)	-0.31 (-0.66; 0.05)		
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	1/27	4/39	0.36 (0.04; 3.06)	-0.07 (-0.18; 0.05)		
Moderate to severe dry mouth										
Versi, 2000 ⁴²	CR- Oxybutynin	5mg/day	IR-Oxybutynin	5mg/day	4/111	8/115	0.52 (0.16; 1.67)	-0.03 (-0.09; 0.02)		
Dry mouth										
Corcos, 2006 ²⁶⁵	CR- Oxybutynin	5mg/day	CR-Oxybutynin	10mg/day	43/77	52/77	0.83 (0.64; 1.06)	-0.12 (-0.27; 0.04)		
Severe dry mouth										
Corcos, 2006 ²⁶⁵	CR- Oxybutynin	5mg/day	CR-Oxybutynin	10mg/day	2/77	11/77	0.18 (0.04; 0.79)	-0.12 (-0.20; -0.03)	-9 (-32; -5)	-117 (-203; -31)
Dry mouth										
Corcos, 2006 ²⁶⁵	CR- Oxybutynin	5mg/day	CR-Oxybutynin	15mg/day	43/77	58/83	0.80 (0.63; 1.02)	-0.14 (-0.29; 0.01)		
Severe dry mouth										
Corcos, 2006 ²⁶⁵	CR- Oxybutynin	5mg/day	CR-Oxybutynin	15mg/day	2/77	4/83	0.54 (0.10; 2.86)	-0.02 (-0.08; 0.04)		
Dry mouth										
Corcos, 2006 ²⁶⁵	CR- Oxybutynin	10mg/day	CR-Oxybutynin	15mg/day	52/77	58/83	0.97 (0.78; 1.19)	-0.02 (-0.17; 0.12)		
Severe dry mouth										
Corcos, 2006 ²⁶⁵	CR- Oxybutynin	10mg/day	CR-Oxybutynin	15mg/day	11/77	4/83	2.96 (0.99; 8.92)	0.09 (0.00; 0.19)	11 (5; 254)	95 (4; 185)

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Dry mouth of any severity										
Preik, 2004 ³⁴⁰	CR-Oxybutynin	5-30mg/day	IR-Oxybutynin	5-20mg/day	31/53	41/52	0.74 (0.57; 0.97)	-0.20 (-0.38; -0.03)	-5 (-33; -3)	-204 (-377; -31)
Moderate or severe dry mouth										
Preik, 2004 ³⁴⁰	OROS-oxybutynin controlled release	5-30mg/day	IR-Oxybutynin	5-20mg/day	12/53	22/52	0.53 (0.29; 0.95)	-0.20 (-0.38; -0.03)	-5 (-37; -3)	-201 (-375; -27)
Dose titration endpoint-MTD-dry mouth										
Preik, 2004 ³⁴⁰	OROS-oxybutynin controlled release	5-30mg/day	IR-Oxybutynin	5-20mg/day	7/53	13/52	0.53 (0.23; 1.22)	-0.12 (-0.27; 0.03)		
Dose titration endpoint-MED-dry mouth										
Preik, 2004 ³⁴⁰	OROS-oxybutynin controlled release	5-30mg/day	IR-Oxybutynin	5-20mg/day	3/53	7/52	0.42 (0.11; 1.54)	-0.08 (-0.19; 0.03)		
Moderate dry mouth										
Preik, 2004 ³⁴⁰	OROS-oxybutynin controlled release	5-30mg/day	IR-Oxybutynin	5-20mg/day	1/53	4/52	0.25 (0.03; 2.12)	-0.06 (-0.14; 0.02)		
Dose titration endpoint-MAD-dry mouth										
Preik, 2004 ³⁴⁰	OROS-oxybutynin controlled release	5-30mg/day	IR-Oxybutynin	5-20mg/day	1/53	1/52	0.98 (0.06; 15.28)	0.00 (-0.05; 0.05)		
Moderate to severe dry mouth										
Anderson, 1999 ³⁴¹	CR-oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	3/53	11/52	0.27 (0.08; 0.90)	-0.15 (-0.28; -0.03)	-6 (-36; -4)	-155 (-282; -28)
Anderson, 1999 ³⁴¹	CR-oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	5/53	10/52	0.49 (0.18; 1.34)	-0.10 (-0.23; 0.03)		
Anderson, 1999 ³⁴¹	CR-oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	7/53	10/52	0.69 (0.28; 1.67)	-0.06 (-0.20; 0.08)		
Anderson, 1999 ³⁴¹	CR-oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	2/53	4/52	0.49 (0.09; 2.56)	-0.04 (-0.13; 0.05)		

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Dry mouth										
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	15/38	31/38	0.48 (0.32; 0.74)	-0.42 (-0.62; -0.22)	-2 (-4; -2)	-421 (-619; - 223)
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	36/53	45/52	0.78 (0.63; 0.97)	-0.19 (-0.34; -0.03)	-5 (-33; -3)	-186 (-342; -30)
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	36/53	45/52	0.78 (0.63; 0.97)	-0.19 (-0.34; -0.03)	-5 (-33; -3)	-186 (-342; -30)
Moderate to severe dry mouth										
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	24/52	0.53 (0.30; 0.93)	-0.22 (-0.39; -0.04)	-5 (-26; -3)	-216 (-395; -38)
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	24/52	0.53 (0.30; 0.93)	-0.22 (-0.39; -0.04)	-5 (-26; -3)	-216 (-395; -38)
Dry nose										
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
Dry throat										
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	2/27	0/39	7.14 (0.36; 143.14)	0.07 (-0.04; 0.19)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	21/77	32/77	0.66 (0.42; 1.03)	-0.14 (-0.29; 0.01)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	21/77	24/83	0.94 (0.57; 1.55)	-0.02 (-0.16; 0.12)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	32/77	24/83	1.44 (0.94; 2.21)	0.13 (-0.02; 0.27)		
Dyspepsia										
Chancellor, 2001 ²⁴⁹	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	0/36	1/36	0.33 (0.01; 7.92)	-0.03 (-0.10; 0.05)		
Dysuria										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	1/130	3/133	0.34 (0.04; 3.24)	-0.01 (-0.04; 0.01)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	1/130	3/125	0.32 (0.03; 3.04)	-0.02 (-0.05; 0.01)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	3/133	3/125	0.94 (0.19; 4.57)	0.00 (-0.04; 0.04)		

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Erythema absent										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	120/130	108/133	1.14 (1.03; 1.25)	0.11 (0.03; 0.19)	9 (5; 33)	111 (30; 192)
Erythema-mild										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	79/130	92/133	0.88 (0.73; 1.05)	-0.08 (-0.20; 0.03)		
Erythema-moderate										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	46/130	46/133	1.02 (0.74; 1.42)	0.01 (-0.11; 0.12)		
Erythema-severe										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	6/130	8/133	0.77 (0.27; 2.15)	-0.01 (-0.07; 0.04)		
Halitosis										
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	6/77	10/77	0.60 (0.23; 1.57)	-0.05 (-0.15; 0.04)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	6/77	8/83	0.81 (0.29; 2.22)	-0.02 (-0.11; 0.07)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	10/77	8/83	1.35 (0.56; 3.24)	0.03 (-0.06; 0.13)		
Headache										
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
Chancellor, 2001 ²⁴⁹	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	6/36	6/36	1.00 (0.36; 2.81)	0.00 (-0.17; 0.17)		
Impaired urination										
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	15/52	0.85 (0.45; 1.61)	-0.04 (-0.21; 0.13)		
Nausea										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	6/130	5/133	1.23 (0.38; 3.92)	0.01 (-0.04; 0.06)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	6/130	2/125	2.88 (0.59; 14.02)	0.03 (-0.01; 0.07)		

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	5/133	2/125	2.35 (0.46; 11.89)	0.02 (-0.02; 0.06)		
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	4/39	0.16 (0.01; 2.83)	-0.10 (-0.21; 0.01)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	5/77	8/77	0.63 (0.21; 1.83)	-0.04 (-0.13; 0.05)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	5/77	7/83	0.77 (0.26; 2.32)	-0.02 (-0.10; 0.06)		
Chancellor, 2001 ²⁴⁹	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	0/36	1/36	0.33 (0.01; 7.92)	-0.03 (-0.10; 0.05)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	8/77	7/83	1.23 (0.47; 3.24)	0.02 (-0.07; 0.11)		
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	3/38	10/38	0.30 (0.09; 1.01)	-0.18 (-0.35; -0.02)	-5 (-50; -3)	-184 (-348; -20)
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	10/53	9/52	1.09 (0.48; 2.46)	0.02 (-0.13; 0.16)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	10/53	9/52	1.09 (0.48; 2.46)	0.02 (-0.13; 0.16)		
Nervousness										
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	12/52	1.06 (0.54; 2.11)	0.01 (-0.15; 0.18)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	12/52	1.06 (0.54; 2.11)	0.01 (-0.15; 0.18)		
Palpitation										
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	3/38	5/38	0.60 (0.15; 2.34)	-0.05 (-0.19; 0.08)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	1/130	0/133	3.07 (0.13; 74.65)	0.01 (-0.01; 0.03)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	1/130	1/125	0.96 (0.06; 15.21)	0.00 (-0.02; 0.02)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	0/133	1/125	0.31 (0.01; 7.62)	-0.01 (-0.03; 0.01)		

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Urinary retention										
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	2/77	8/77	0.25 (0.05; 1.14)	-0.08 (-0.15; 0.00)	-13 (-938; -6)	-78 (-155; -1)
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	2/77	6/83	0.36 (0.07; 1.73)	-0.05 (-0.11; 0.02)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	8/77	6/83	1.44 (0.52; 3.95)	0.03 (-0.06; 0.12)		
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	9/38	13/38	0.69 (0.34; 1.42)	-0.11 (-0.31; 0.10)		
Impaired urination										
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	9/38	9/38	1.00 (0.45; 2.24)	0.00 (-0.19; 0.19)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	15/52	0.85 (0.45; 1.61)	-0.04 (-0.21; 0.13)		
Somnolence										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	1/130	0/133	3.07 (0.13; 74.65)	0.01 (-0.01; 0.03)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	1/130	2/125	0.48 (0.04; 5.24)	-0.01 (-0.03; 0.02)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	0/133	2/125	0.19 (0.01; 3.88)	-0.02 (-0.04; 0.01)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	4/77	3/77	1.33 (0.31; 5.76)	0.01 (-0.05; 0.08)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	4/77	2/83	2.16 (0.41; 11.44)	0.03 (-0.03; 0.09)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	3/77	2/83	1.62 (0.28; 9.42)	0.01 (-0.04; 0.07)		
Davila, 2001 ²⁶⁷	Oxybutynin transdermal	1.3mg	IR-oxybutynin	5mg twice/thrice daily or 7.5mg thrice daily	7/38	14/38	0.50 (0.23; 1.10)	-0.18 (-0.38; 0.01)		
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	20/53	21/52	0.93 (0.58; 1.51)	-0.03 (-0.21; 0.16)		

Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attrib- utable events (95% CI)
Anderson, 1999 ³⁴¹	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	20/53	21/52	0.93 (0.58; 1.51)	-0.03 (-0.21; 0.16)		
Tachycardia										
Salvatore, 2005 ³⁶⁹	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
Urinary tract infection										
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	10mg/day	8/77	9/77	0.89 (0.36; 2.18)	-0.01 (-0.11; 0.09)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	5mg/day	CR-oxybutynin	15mg/day	8/77	13/83	0.66 (0.29; 1.51)	-0.05 (-0.16; 0.05)		
Corcos, 2006 ²⁶⁵	CR- oxybutynin	10mg/day	CR-oxybutynin	15mg/day	9/77	13/83	0.75 (0.34; 1.65)	-0.04 (-0.15; 0.07)		
Vasodilatation										
Chancellor, 2001 ²⁴⁹	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	0/36	0/36	0.00 (0.00; 0.00)	0.00 (-0.05; 0.05)		
Vision abnormal										
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	3/130	2/133	1.53 (0.26; 9.03)	0.01 (-0.03; 0.04)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	3/130	0/125	6.73 (0.35; 129.03)	0.02 (-0.01; 0.05)		
Dmochowski, 2002 ²⁷¹	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	2/133	0/125	4.70 (0.23; 96.98)	0.02 (-0.01; 0.04)		
Vomiting										
Chancellor, 2001 ²⁴⁹	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	1/36	2/36	0.50 (0.05; 5.27)	-0.03 (-0.12; 0.06)		

Appendix Table F52. Clinical outcomes after tolterodine vs. placebo in secondary data analyses

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Improvement in incontinence								
Improved perceptions of bladder condition	Appell, 1997 ²²²	1mg twice daily	50/121	69/176	1.05 (0.80; 1.40)	0.02 (-0.09; 0.13)		
Improved perceptions of bladder condition	Appell, 1997 ²²²	2mg twice daily	246/474	69/176	1.32 (1.08; 1.62)	0.13 (0.04; 0.21)	8 (5; 24)	127 (42; 212)
Treatment response (primary and secondary efficacy endpoints)	Sand, 2009 ³⁷⁰	4mg daily	140/227	167/430	1.59 (1.36; 1.86)	0.23 (0.15; 0.31)	4 (3; 7)	228 (150; 307)
Perceived improvement in bladder symptoms	Freeman, 2003 ²⁸⁶	4mg once daily	247/398	180/374	1.19 (1.04; 1.37)	0.09 (0.02; 0.16)	11 (6; 48)	89 (21; 156)
Perceived improvement in bladder symptoms in females	Freeman, 2003 ²⁸⁶	4mg once daily	250/398	181/374	1.30 (1.14; 1.48)	0.14 (0.07; 0.21)	7 (5; 13)	144 (75; 214)
Global self-evaluation of treatment: "much benefit"	Freeman, 2003 ²⁸⁶	4mg once daily	171/398	90/374	1.53 (1.24; 1.88)	0.16 (0.09; 0.23)	6 (4; 12)	158 (86; 231)
Global self-evaluation of treatment: much benefit	Freeman, 2003 ²⁸⁶	4mg once daily	172/398	88/374	1.84 (1.48; 2.28)	0.20 (0.13; 0.26)	5 (4; 8)	197 (132; 262)
Treatment failure								
No change in urgency perception scale score	Freeman, 2003 ²⁸⁶	4mg once daily	203/398	212/374	0.90 (0.79; 1.03)	-0.06 (-0.13; 0.01)		
Decrease in urgency perception scale score	Freeman, 2003 ²⁸⁶	4mg once daily	22/398	44/374	0.47 (0.29; 0.77)	-0.06 (-0.10; -0.02)	-16 (-44; -10)	-62 (-102; -23)
Global self-evaluation of treatment: little benefit	Freeman, 2003 ²⁸⁶	4mg once daily	138/398	118/374	1.10 (0.90; 1.34)	0.03 (-0.04; 0.10)		
Global self-evaluation of treatment: no benefit	Freeman, 2003 ²⁸⁶	4mg once daily	88/398	168/374	0.49 (0.40; 0.61)	-0.23 (-0.29; -0.16)	-4 (-6; -3)	-228 (-293; -163)

Appendix Table F52. Clinical outcomes after tolterodine vs. placebo in secondary data analyses (continued)

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Treatment discontinuation								
Withdrawal	Freeman, 2003 ²⁸⁶	4mg once daily	173/398	118/374	1.38 (1.14; 1.66)	0.12 (0.05; 0.19)	8 (5; 19)	119 (51; 187)
Withdrawal	Appell, 1997 ²²²	1mg twice daily	7/121	17/176	0.60 (0.26; 1.40)	-0.04 (-0.10; 0.02)		
Discontinued prematurely	Chapple, 2008 ²⁵⁴	4mg daily	9/290	6/283	1.46 (0.53; 4.06)	0.01 (-0.02; 0.04)		
Withdrawal due to AE	Appell, 1997 ²²²	1mg twice daily	2/121	9/176	0.32 (0.07; 1.47)	-0.03 (-0.07; 0.01)		
Withdrawal due to AE	Appell, 1997 ²²²	2mg twice daily	38/474	9/176	1.57 (0.77; 3.18)	0.03 (-0.01; 0.07)		
Adverse effects								
Abdominal pain	Freeman, 2003 ²⁸⁶	4mg once daily	16/398	6/374	2.51 (0.99; 6.34)	0.02 (0.00; 0.05)	41 (21; 964)	24 (1; 47)
Adverse events	Appell, 1997 ²²²	1mg twice daily	94/121	164/176	0.83 (0.75; 0.92)	-0.15 (-0.24; -0.07)	-6 (-14; -4)	-155 (-238; -72)
Adverse events	Appell, 1997 ²²²	2mg twice daily	351/474	164/176	0.79 (0.74; 0.85)	-0.19 (-0.25; -0.14)	-5 (-7; -4)	-191 (-246; -137)
Autonomic nervous system disorder	Appell, 1997 ²²²	1mg twice daily	35/121	37/176	1.38 (0.92; 2.05)	0.08 (-0.02; 0.18)		
Autonomic nervous system disorder	Appell, 1997 ²²²	2mg twice daily	204/474	37/176	2.05 (1.51; 2.78)	0.22 (0.15; 0.30)	5 (3; 7)	220 (145; 295)
Back pain	Sand, 2009 ³⁷⁰	4mg daily	1/227	1/430	1.89 (0.12; 30.14)	0.00 (-0.01; 0.01)		
Cardiac dysfunction	Appell, 1997 ²²²	2mg twice daily	4/474	3/176	0.50 (0.11; 2.19)	-0.01 (-0.03; 0.01)		
Cardiovascular adverse events	Appell, 1997 ²²²	1mg twice daily	15/121	14/176	1.56 (0.78; 3.11)	0.04 (-0.03; 0.12)		

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Cardiovascular adverse events	Appell, 1997 ²²²	2mg twice daily	20/474	14/176	0.53 (0.27; 1.03)	-0.04 (-0.08; 0.01)		
Constipation	Chapple, 2008 ²⁵⁴	4mg daily	8/290	4/283	1.95 (0.59; 6.41)	0.01 (-0.01; 0.04)		
Constipation	Sand, 2009 ³⁷⁰	4mg daily	6/227	10/430	1.14 (0.42; 3.09)	0.00 (-0.02; 0.03)		
Constipation	Freeman, 2003 ²⁸⁶	4mg once daily	23/398	16/374	1.35 (0.73; 2.52)	0.02 (-0.02; 0.05)		
Cough	Sand, 2009 ³⁷⁰	4mg daily	5/227	3/430	3.16 (0.76; 13.09)	0.02 (-0.01; 0.04)		
Diarrhea	Sand, 2009 ³⁷⁰	4mg daily	3/227	10/430	0.57 (0.16; 2.04)	-0.01 (-0.03; 0.01)		
Diarrhea	Freeman, 2003 ²⁸⁶	4mg once daily	8/398	7/374	1.07 (0.39; 2.93)	0.00 (-0.02; 0.02)		
Dizziness	Sand, 2009 ³⁷⁰	4mg daily	4/227	9/430	0.84 (0.26; 2.70)	0.00 (-0.03; 0.02)		
Dose reduction in case of intolerance	Appell, 1997 ²²²	2mg twice daily	43/474	7/176	2.28 (1.05; 4.98)	0.05 (0.01; 0.09)	20 (11; 82)	51 (12; 90)
Dry eye	Chapple, 2008 ²⁵⁴	4mg daily	1/290	0/283	2.93 (0.12; 71.57)	0.00 (-0.01; 0.01)		
Dry eye	Sand, 2009 ³⁷⁰	4mg daily	1/227	0/430	5.67 (0.23; 138.65)	0.00 (-0.01; 0.02)		
Dry mouth	Chapple, 2008 ²⁵⁴	4mg daily	49/290	20/283	2.39 (1.46; 3.92)	0.10 (0.05; 0.15)	10 (7; 22)	98 (46; 151)
Dry mouth	Sand, 2009 ³⁷⁰	4mg daily	37/227	32/430	2.19 (1.40; 3.42)	0.09 (0.03; 0.14)	11 (7; 29)	89 (35; 143)
Dry mouth	Freeman, 2003 ²⁸⁶	4mg once daily	95/398	28/374	3.19 (2.14; 4.74)	0.16 (0.11; 0.21)	6 (5; 9)	164 (114; 213)
Dry throat	Chapple, 2008 ²⁵⁴	4mg daily	3/290	0/283	6.83 (0.35; 131.66)	0.01 (0.00; 0.02)		
Dry throat	Sand, 2009 ³⁷⁰	4mg daily	2/227	0/430	9.45 (0.46; 196.04)	0.01 (-0.01; 0.02)		

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Fatigue	Chapple, 2008 ²⁵⁴	4mg daily	10/290	1/283	9.76 (1.26; 75.74)	0.03 (0.01; 0.05)	32 (19; 113)	31 (9; 53)
Fatigue	Sand, 2009 ³⁷⁰	4mg daily	7/227	2/430	6.63 (1.39; 31.65)	0.03 (0.00; 0.05)	38 (20; 358)	26 (3; 50)
Gastrointestinal disorder	Appell, 1997 ²²²	1mg twice daily	27/121	48/176	0.82 (0.54; 1.23)	-0.05 (-0.15; 0.05)		
Gastrointestinal disorder	Appell, 1997 ²²²	2mg twice daily	123/474	48/176	0.95 (0.72; 1.27)	-0.01 (-0.09; 0.06)		
Headache	Sand, 2009 ³⁷⁰	4mg daily	13/227	18/430	1.37 (0.68; 2.74)	0.02 (-0.02; 0.05)		
Headache	Freeman, 2003 ²⁸⁶	4mg once daily	23/398	14/374	1.54 (0.81; 2.95)	0.02 (-0.01; 0.05)		
Increased alanine aminotransferase	Chapple, 2008 ²⁵⁴	4mg daily	0/290	1/283	0.33 (0.01; 7.95)	0.00 (-0.01; 0.01)		
Moderate or severe dry mouth	Appell, 1997 ²²²	1mg twice daily	5/121	11/176	0.66 (0.24; 1.85)	-0.02 (-0.07; 0.03)		
Moderate or severe dry mouth	Appell, 1997 ²²²	2mg twice daily	81/474	11/176	2.73 (1.49; 5.01)	0.11 (0.06; 0.16)	9 (6; 17)	108 (59; 158)
Nasopharyngitis	Chapple, 2008 ²⁵⁴	4mg daily	10/290	7/283	1.39 (0.54; 3.61)	0.01 (-0.02; 0.04)		
Nasopharyngitis	Sand, 2009 ³⁷⁰	4mg daily	8/227	12/430	1.26 (0.52; 3.04)	0.01 (-0.02; 0.04)		
Nausea	Chapple, 2008 ²⁵⁴	4mg daily	6/290	1/283	5.86 (0.71; 48.33)	0.02 (0.00; 0.03)		
Nausea	Sand, 2009 ³⁷⁰	4mg daily	3/227	5/430	1.14 (0.27; 4.71)	0.00 (-0.02; 0.02)		
Nausea	Freeman, 2003 ²⁸⁶	4mg once daily	5/398	5/374	0.94 (0.27; 3.22)	0.00 (-0.02; 0.02)		
Palpitations	Appell, 1997 ²²²	1mg twice daily	8/121	4/176	2.91 (0.90; 9.45)	0.04 (-0.01; 0.09)		
Palpitations	Appell, 1997 ²²²	2mg twice daily	2/474	4/176	0.19 (0.03; 1.00)	-0.02 (-0.04; 0.00)		

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Serious adverse events	Appell, 1997 ²²²	2mg twice daily	19/474	5/176	1.41 (0.53; 3.72)	0.01 (-0.02; 0.04)		
URI	Sand, 2009 ³⁷⁰	4mg daily	2/227	9/430	0.42 (0.09; 1.93)	-0.01 (-0.03; 0.01)		
Urinary tract infection	Freeman, 2003 ²⁸⁶	4mg once daily	7/398	12/374	0.55 (0.22; 1.38)	-0.01 (-0.04; 0.01)		
UTI	Sand, 2009 ³⁷⁰	4mg daily	4/227	17/430	0.45 (0.15; 1.31)	-0.02 (-0.05; 0.00)		
Dry mouth	Freeman, 2003 ²⁸⁶	4mg once daily	15/398	7/374	2.01 (0.83; 4.88)	0.02 (0.00; 0.04)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Improvement in UI	Appell, 1997 ²²² Pooled analysis	1mg twice daily vs. 2mg daily	50/121	246/474	0.80 (0.63; 1.00)	-0.11 (-0.20; -0.01)	-9 (-139; -5)	-106 (-204; -7)
Completed the study	Malone-Lee, 2006 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	53/61	64/73	0.99 (0.87; 1.13)	-0.01 (-0.12; 0.11)		
Withdrew from study	Appell, 1997 ²²² Pooled analysis	1mg twice daily vs. 2mg daily	7/121	63/474	0.44 (0.20; 0.93)	-0.08 (-0.13; -0.02)	-13 (-43; -8)	-75 (-127; -23)
Withdrew from study	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg twice daily	27/507	28/514	0.98 (0.58; 1.63)	0.00 (-0.03; 0.03)		
Withdrew due to adverse events	Appell, 1997 ²²² Pooled analysis	1mg twice daily vs. 2mg daily	2/121	38/474	0.21 (0.05; 0.84)	-0.06 (-0.10; -0.03)	-16 (-33; -10)	-64 (-97; -30)
Withdrew due to adverse events	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	15/193	19/399	1.63 (0.85; 3.14)	0.03 (-0.01; 0.07)		
Withdrew due to adverse events	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	4/61	7/73	0.68 (0.21; 2.23)	-0.03 (-0.12; 0.06)		
Withdrew due to adverse events	Jacquetin, 2001 ³¹² RCT	1mg twice daily vs. 2mg twice daily	3/97	2/103	1.59 (0.27; 9.33)	0.01 (-0.03; 0.06)		
All adverse events	Jacquetin, 2001 ³¹² RCT	1mg twice daily vs. 2mg twice daily	78/97	84/103	0.99 (0.86; 1.13)	-0.01 (-0.12; 0.10)		
All adverse events	Jacquetin, 2001 ³¹² RCT	1mg twice daily vs. 2mg twice daily	39/97	55/103	0.75 (0.56; 1.02)	-0.13 (-0.27; 0.01)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
All adverse events	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	34/99	43/99	0.79 (0.56; 1.13)	-0.09 (-0.23; 0.04)		
All adverse events	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	31/99	32/99	0.97 (0.64; 1.46)	-0.01 (-0.14; 0.12)		
At least one adverse event	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	152/193	254/399	1.24 (1.11; 1.37)	0.15 (0.08; 0.23)	7 (4; 13)	151 (76; 226)
At least one adverse event	Millard, 1999 ³⁴⁹ RCT	1mg twice daily vs. 2mg twice daily	8/129	2/123	3.81 (0.83; 17.61)	0.05 (0.00; 0.09)		
At least one adverse event	Appell, 1997 ²²² Pooled analysis	1mg twice daily vs. 2mg daily	94/121	351/474	1.05 (0.94; 1.17)	0.04 (-0.05; 0.12)		
Adverse events of severe intensity	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	5/61	6/73	1.00 (0.32; 3.11)	0.00 (-0.09; 0.09)		
Mild adverse events related to study medication	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	81/193	123/399	1.36 (1.09; 1.70)	0.11 (0.03; 0.19)	9 (5; 35)	111 (28; 194)
Mild adverse events not related to study medication	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	57/193	117/399	1.01 (0.77; 1.31)	0.00 (-0.08; 0.08)		
Moderate adverse events related to study medication	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	46/193	84/399	1.13 (0.83; 1.55)	0.03 (-0.04; 0.10)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Moderate adverse events not related to study medication	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	35/193	40/399	1.81 (1.19; 2.75)	0.08 (0.02; 0.14)	12 (7; 52)	81 (19; 143)
Severe adverse events related to study medication	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	7/193	9/399	1.61 (0.61; 4.25)	0.01 (-0.02; 0.04)		
Severe adverse events not related to study medication	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	5/193	6/399	1.72 (0.53; 5.57)	0.01 (-0.01; 0.04)		
Serious adverse event	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	2/61	1/73	2.39 (0.22; 25.76)	0.02 (-0.03; 0.07)		
Serious adverse event	Millard, 1999 ³⁴⁹ RCT	1mg twice daily vs. 2mg twice daily	5/129	7/123	0.68 (0.22; 2.09)	-0.02 (-0.07; 0.03)		
Serious adverse event	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	7/507	12/514	0.59 (0.23; 1.49)	-0.01 (-0.03; 0.01)		
Abdominal pain	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	18/417	12/408	1.47 (0.72; 3.01)	0.01 (-0.01; 0.04)		
Abdominal pain	Jacquetin, 2007 ³¹² RCT	1mg twice daily vs. 2mg twice daily	6/97	4/103	1.59 (0.46; 5.47)	0.02 (-0.04; 0.08)		
Abdominal pain	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	3/61	6/73	0.60 (0.16; 2.29)	-0.03 (-0.12; 0.05)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Abdominal pain	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	19/507	13/514	1.48 (0.74; 2.97)	0.01 (-0.01; 0.03)		
Abnormal accommodation	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	0/61	3/73	0.17 (0.01; 3.24)	-0.04 (-0.09; 0.01)		
Abnormal accommodation	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	3/99	5/99	0.60 (0.15; 2.44)	-0.02 (-0.07; 0.03)		
Abnormal vision	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	5/417	4/408	1.22 (0.33; 4.52)	0.00 (-0.01; 0.02)		
Abnormal vision	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	6/507	4/514	1.52 (0.43; 5.36)	0.00 (-0.01; 0.02)		
Arthralgia	Takei, 2005 ³⁸³ RCT	4mg/day vs. 4mg/day	1/80	11/74	0.08 (0.01; 0.64)	-0.14 (-0.22; -0.05)	-7 (-19; -5)	-136 (-221; -52)
Arthritis	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	1/417	5/408	0.20 (0.02; 1.67)	-0.01 (-0.02; 0.00)		
Autonomic nervous system	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	11/99	16/99	0.69 (0.34; 1.41)	-0.05 (-0.15; 0.04)		
Autonomic nervous system disorder	Appell, 1997 ²²² Pooled analysis	1mg twice daily vs. 2mg daily	35/121	204/474	0.67 (0.50; 0.91)	-0.14 (-0.23; -0.05)	-7 (-20; -4)	-141 (-233; -49)
Autonomic nervous system disorder	Millard, 1999 ³⁴⁹ RCT	1mg twice daily vs. 2mg twice daily	37/129	53/123	0.67 (0.47; 0.93)	-0.14 (-0.26; -0.03)	-7 (-37; -4)	-144 (-261; -27)

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Back pain	Takei, 2005 ³⁸³ RCT	4mg/day vs. 4mg/day	3/80	11/74	0.25 (0.07; 0.87)	-0.11 (-0.20; -0.02)	-9 (-50; -5)	-111 (-202; -20)
Body disorder as a whole	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	61/193	85/399	1.48 (1.12; 1.96)	0.10 (0.03; 0.18)	10 (6; 38)	103 (26; 180)
Cardiovascular adverse events	Appell, 1997 ²²² Pooled analysis	1mg twice daily vs. 2mg daily	15/121	20/474	2.94 (1.55; 5.57)	0.08 (0.02; 0.14)	12 (7; 49)	82 (20; 143)
Constipation	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	27/417	27/408	0.98 (0.58; 1.64)	0.00 (-0.04; 0.03)		
Constipation	Jacquetin, 2001 ³¹² RCT	1mg twice daily vs. 2mg twice daily	4/97	2/103	2.12 (0.40; 11.33)	0.02 (-0.03; 0.07)		
Constipation	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	2/99	3/99	0.67 (0.11; 3.90)	-0.01 (-0.05; 0.03)		
Constipation	Takei, 2005 ³⁸³ RCT	4mg/day vs. 4mg/day	12/80	16/74	0.69 (0.35; 1.37)	-0.07 (-0.19; 0.06)		
Constipation	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	5/61	0/73	13.13 (0.74; 232.79)	0.08 (0.01; 0.16)	12 (6; 114)	82 (9; 155)
Constipation	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	30/507	35/514	0.87 (0.54; 1.39)	-0.01 (-0.04; 0.02)		
Constipation	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	12/193	31/399	0.80 (0.42; 1.52)	-0.02 (-0.06; 0.03)		
Diarrhea	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	8/61	4/73	2.39 (0.76; 7.57)	0.08 (-0.02; 0.18)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Diarrhea	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	10/507	16/514	0.63 (0.29; 1.38)	-0.01 (-0.03; 0.01)		
Diarrhea	Armstrong, 2007 ²²⁵ pooled analysis	2mg qd vs. 4mg qd	9/193	25/399	0.74 (0.35; 1.56)	-0.02 (-0.05; 0.02)		
Diarrhea	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	10/417	14/408	0.70 (0.31; 1.56)	-0.01 (-0.03; 0.01)		
Diarrhea	Takei, 2005 ³⁸³ RCT	4mg/day vs. 4mg/day	6/80	12/74	0.46 (0.18; 1.17)	-0.09 (-0.19; 0.01)		
Digestive system	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	87/193	145/399	1.24 (1.01; 1.52)	0.09 (0.00; 0.17)	11 (6; 360)	87 (3; 172)
Dizziness	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	7/417	7/408	0.98 (0.35; 2.76)	0.00 (-0.02; 0.02)		
Dizziness	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	5/61	4/73	1.50 (0.42; 5.33)	0.03 (-0.06; 0.11)		
Dizziness	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	11/507	9/514	1.24 (0.52; 2.96)	0.00 (-0.01; 0.02)		
Dry mouth	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	105/417	127/408	0.81 (0.65; 1.01)	-0.06 (-0.12; 0.00)		
Dry mouth	Jacquetin, 2001 ³¹² RCT	1mg twice daily vs. 2mg twice daily	20/97	35/103	0.61 (0.38; 0.97)	-0.13 (-0.26; -0.01)	-7 (-85; -4)	-134 (-255; -12)

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Dry mouth	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	8/99	10/99	0.80 (0.33; 1.94)	-0.02 (-0.10; 0.06)		
Dry mouth	Takei, 2005 ³⁸³ RCT	4mg/day vs. 4mg/day	42/80	63/74	0.62 (0.49; 0.78)	-0.33 (-0.46; -0.19)	-3 (-5; -2)	-326 (-463; -190)
Dry mouth	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	30/61	48/73	0.75 (0.55; 1.01)	-0.17 (-0.33; 0.00)		
Dry mouth	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	118/507	156/514	0.77 (0.62; 0.94)	-0.07 (-0.12; -0.02)	-14 (-60; -8)	-71 (-125; -17)
Dry mouth	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	64/193	89/399	1.49 (1.13; 1.95)	0.11 (0.03; 0.19)	9 (5; 33)	109 (31; 187)
Dry skin	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	2/417	5/408	0.39 (0.08; 2.01)	-0.01 (-0.02; 0.01)		
Dry skin	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	2/507	6/514	0.34 (0.07; 1.67)	-0.01 (-0.02; 0.00)		
Dyspepsia	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	11/417	14/408	0.77 (0.35; 1.67)	-0.01 (-0.03; 0.02)		
Dyspepsia	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	2/61	6/73	0.40 (0.08; 1.91)	-0.05 (-0.13; 0.03)		
Dyspepsia	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	15/507	16/514	0.95 (0.47; 1.90)	0.00 (-0.02; 0.02)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Dyspepsia	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	10/193	11/399	1.88 (0.81; 4.35)	0.02 (-0.01; 0.06)		
Dysuria	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	5/507	8/514	0.63 (0.21; 1.92)	-0.01 (-0.02; 0.01)		
Fatigue	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	11/507	6/514	1.86 (0.69; 4.99)	0.01 (-0.01; 0.03)		
Flatulence	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	8/417	11/408	0.71 (0.29; 1.75)	-0.01 (-0.03; 0.01)		
Flatulence	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	10/507	14/514	0.72 (0.32; 1.62)	-0.01 (-0.03; 0.01)		
Gastrointestinal	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	5/99	6/99	0.83 (0.26; 2.64)	-0.01 (-0.07; 0.05)		
Gastrointestinal disorder	Appell, 1997 ²²² Pooled analysis	1mg twice daily vs. 2mg daily	27/121	123/474	0.86 (0.60; 1.24)	-0.04 (-0.12; 0.05)		
General disorders	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	7/99	6/99	1.17 (0.41; 3.35)	0.01 (-0.06; 0.08)		
Headache	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	29/417	14/408	2.03 (1.09; 3.78)	0.04 (0.01; 0.07)	28 (15; 196)	35 (5; 65)
Headache	Jacquetin, 2001 ³¹² RCT	1mg twice daily vs. 2mg twice daily	3/97	3/103	1.06 (0.22; 5.14)	0.00 (-0.05; 0.05)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Headache	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	3/99	3/99	1.00 (0.21; 4.83)	0.00 (-0.05; 0.05)		
Headache	Takei, 2005 ³⁸³ RCT	4mg/day vs. 4mg/day	6/80	10/74	0.56 (0.21; 1.45)	-0.06 (-0.16; 0.04)		
Headache	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	5/61	7/73	0.85 (0.29; 2.56)	-0.01 (-0.11; 0.08)		
Headache	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	32/507	19/514	1.71 (0.98; 2.97)	0.03 (0.00; 0.05)		
Headache	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	18/193	24/399	1.55 (0.86; 2.79)	0.03 (-0.01; 0.08)		
Hypertension	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	6/417	4/408	1.47 (0.42; 5.16)	0.00 (-0.01; 0.02)		
Insomnia	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	7/417	2/408	3.42 (0.72; 16.39)	0.01 (0.00; 0.03)		
Insomnia	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	7/507	2/514	3.55 (0.74; 17.00)	0.01 (0.00; 0.02)		
Metabolic and nutritional system	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	17/193	21/399	1.67 (0.90; 3.10)	0.04 (-0.01; 0.08)		
Mild to- moderate intensity dry mouth	Jacquetin, 2001 ³¹² RCT	1mg twice daily vs. 2mg twice daily	18/97	30/103	0.64 (0.38; 1.07)	-0.11 (-0.22; 0.01)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Minor noncholinergic and cholinergic adverse events	Millard, 1999 ³⁴⁹ RCT	1mg twice daily vs. 2mg twice daily	95/129	90/123	1.01 (0.87; 1.17)	0.00 (-0.10; 0.11)		
Moderate or severe dry mouth	Appell, 1997 ²²² Pooled analysis	1mg twice daily vs. 2mg daily	5/121	81/474	0.24 (0.10; 0.58)	-0.13 (-0.18; -0.08)	-8 (-12; -6)	-130 (-179; -81)
Nasopharyngitis	Takei, 2005 ³⁸³ RCT	4mg/day vs. 4mg/day	6/80	50/74	0.11 (0.05; 0.24)	-0.60 (-0.72; -0.48)	-2 (-2; -1)	-601 (-722; -479)
Nausea	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	7/417	9/408	0.76 (0.29; 2.02)	-0.01 (-0.02; 0.01)		
Nausea	Malone-Lee, 2001 ³⁴⁶ RCT	1mg twice daily vs. 2mg twice daily	2/61	3/73	0.80 (0.14; 4.62)	-0.01 (-0.07; 0.06)		
Nausea	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	7/507	10/514	0.71 (0.27; 1.85)	-0.01 (-0.02; 0.01)		
Pain	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	15/193	14/399	2.22 (1.09; 4.50)	0.04 (0.00; 0.08)	23 (12; 1303)	43 (1; 84)
Palpitations	Appell, 1997 ²²² Pooled analysis	1mg twice daily vs. 2mg daily	8/121	2/474	15.67 (3.37; 72.84)	0.06 (0.02; 0.11)	16 (9; 58)	62 (17; 107)
Peripheral edema	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	7/507	7/514	1.01 (0.36; 2.87)	0.00 (-0.01; 0.01)		
Peripheral edema	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	11/193	13/399	1.75 (0.80; 3.83)	0.02 (-0.01; 0.06)		
Psychiatric adverse events	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	1/99	1/99	1.00 (0.06; 15.76)	0.00 (-0.03; 0.03)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Respiratory adverse events	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	1/99	3/99	0.33 (0.04; 3.15)	-0.02 (-0.06; 0.02)		
Sinusitis	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	8/417	2/408	3.91 (0.84; 18.32)	0.01 (0.00; 0.03)		
Skin and appendages	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	1/99	1/99	1.00 (0.06; 15.76)	0.00 (-0.03; 0.03)		
Somnolence	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	12/417	11/408	1.07 (0.48; 2.39)	0.00 (-0.02; 0.02)		
Somnolence	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	14/507	13/514	1.09 (0.52; 2.30)	0.00 (-0.02; 0.02)		
Urinary AE	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	6/99	5/99	1.20 (0.38; 3.80)	0.01 (-0.05; 0.07)		
Urinary tract infection	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	15/417	11/408	1.33 (0.62; 2.87)	0.01 (-0.01; 0.03)		
Urinary tract infection	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	16/507	13/514	1.25 (0.61; 2.57)	0.01 (-0.01; 0.03)		
Urinary tract infection	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd	11/193	13/399	1.75 (0.80; 3.83)	0.02 (-0.01; 0.06)		

Appendix Table F53. Clinical outcomes after different doses and clinical formulations of tolterodine (continued)

Outcome	Reference design	Active vs. control	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Urinary tract infection	Jonas, 1997 ³¹⁴ RCT	1mg twice daily vs. 2mg twice daily	5/99	2/99	2.50 (0.50; 12.58)	0.03 (-0.02; 0.08)		
Urogenital system adverse events	Armstrong, 2007 ²²⁵ Pooled analysis	2mg qd vs. 4mg qd campaign	35/193	38/399	1.90 (1.24; 2.91)	0.09 (0.02; 0.15)	12 (7; 41)	86 (25; 148)
Xerophthalmia	Swift, 2003 ³⁸¹ RCT	4mg once daily vs. 2mg twice daily	16/417	8/408	1.96 (0.85; 4.52)	0.02 (0.00; 0.04)		
Xerophthalmia	Van Kerrebroeck, 2001 ³³¹ RCT	4mg once daily vs. 2mg once daily	17/507	12/514	1.44 (0.69; 2.98)	0.01 (-0.01; 0.03)		

Appendix Table F54. Clinical outcomes after tolterodine vs. placebo (results from randomized controlled clinical trials pooled with random effects models)

Drug	Outcome	Publications	Patients	Rate active/control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)
Tolterodine	Continence	4 ^{56,318,365,473}	3,404	53.2/43.7	1.2 (1.1 to 1.4)	0.09 (0.04 to 0.13)	12 (8 to 25)
Tolterodine	Improvement in UI	7 ^{56,286,301,318,323,364,370,470}	6,119	45/37	1.3 (1.1 to 1.4)	0.10(0.04 to 0.15)	10 (7 to 24)
Tolterodine	Treatment failure	6 ^{56, 286, 301, 323, 364, 365, 470}	4,260	9/16	0.7 (0.5 to 1.0)	-0.04 (-0.09 to 0.00)	
Tolterodine	Adverse effects	12 ^{56, 219, 253, 260, 279, 312, 314, 316, 325, 345, 360, 365}	4,162	44.7/38.1	1.2 (1.1 to 1.3)	0.08 (0.05 to 0.11)	13 (9 to 21)
Tolterodine	Serious adverse effects	5 ^{56, 279, 331, 346, 349}	3,550	1.8/3.1	0.6 (0.4 to 0.9)	-0.01 (-0.02 to 0.00)	
Tolterodine	Discontinuation	9 ^{52, 56, 253, 260, 279, 280, 323, 331, 363, 470}	5,384	5.8[6.4]	0.9 (0.8 to 1.2)	-0.01 (-0.01 to 0.00)	
Tolterodine	Discontinuation Adverse effects	10 ^{52, 56, 219, 253, 279, 280, 301, 312, 318, 325, 346, 360, 470}	4,466	4/3	1.0 (0.6 to 1.7)	0.01 (-0.01 to 0.02)	
Tolterodine	Discontinuation Treatment failure	5 ^{52, 56, 301, 325, 470}	4,049	0.7/1.6	0.5 (0.2 to 0.9)	-0.01 (-0.02 to 0.00)	
Tolterodine	Autonomic nervous system disorders	3 ^{279, 314, 349}	831	27.2/15.5	1.8 (1.3 to 2.4)	0.11 (0.03 to 0.19)	9 (5 to 31)
Tolterodine	Blurred vision	2 ^{52, 260}	608	1.3/3.0	0.5 (0.2 to 1.5)	-0.01 (-0.04 to 0.01)	
Tolterodine	Constipation	14 ^{52, 56, 253, 260, 280, 301, 312, 314, 318, 325, 331, 346, 360, 365, 381, 470}	9,592	4/3	1.4 (1.1 to 1.8)	0.01 (0.00 to 0.02)	100 (63 to 333)
Tolterodine	Diarrhea	4 ^{56, 325, 331, 346, 381, 470}	4,056	2/2	1.3 (0.8 to 2.0)	0.01 (0.00 to 0.01)	
Tolterodine	Dizziness	6 ^{56, 253, 301, 325, 331, 346, 381}	5,257	2/2	1.1 (0.7 to 1.7)	0.00 (0.00 to 0.01)	
Tolterodine	Dry mouth	14 ^{52, 56, 219, 253, 260, 301, 312, 316, 318, 331, 345, 360, 365, 470}	7,637	18.4/6.7	2.6 (2.2 to 3.2)	0.13 (0.10 to 0.15)	8 (6 to 10)
Tolterodine	Dyspepsia	6 ^{56, 219, 325, 331, 345, 346, 381}	3,525	3/2	1.8 (0.9 to 3.5)	0.02 (0.001 to 0.03)	67 (34 to 1000)
Tolterodine	Fatigue	4 ^{56, 253, 301, 331}	3,234	1.9/0.7	2.5 (1.2 to 5.2)	0.01 (0.00 to 0.02)	83 (45 to 500)
Tolterodine	General body disorders	2 ^{279, 314}	308	22.3/18.6	1.2 (0.7 to 2.1)	0.02 (-0.10 to 0.15)	
Tolterodine	Headache	11 ^{56, 253, 260, 280, 301, 312, 314, 325, 331, 345, 346, 365, 381, 470}	6,766	4/4	1.2 (1.0 to 1.6)	0.01 (0.00 to 0.02)	91 (1 to 500)

Appendix Table F54. Clinical outcomes after tolterodine vs. placebo (results from randomized controlled clinical trials pooled with random effects models) (continued)

Drug	Outcome	Publications	Patients	Rate active/control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)
Tolterodine	Insomnia	2 ^{331, 365, 381}	1,428	1.7/1.3	2.1 (0.2 to 26.6)	0.01 (-0.02 to 0.04)	
Tolterodine	Nasopharyngitis	5 ^{56, 253, 254, 301, 365, 370}	2,835	3/3	1.2 (0.8 to 1.8)	0.01 (-0.01 to 0.02)	
Tolterodine	Nausea	7 ^{56, 219, 253, 325, 331, 346, 381}	5,642	1.6/2.0	0.8 (0.5 to 1.1)	0.00 (-0.01 to 0.01)	
Tolterodine	Somnolence	2 ^{325, 331, 381}	1,869	1/1	0.9 (0.2 to 4.6)	0.00 (-0.01 to 0.02)	
Tolterodine	Urinary tract infection	5 ^{56, 314, 325, 331, 365, 381, 470}	4,465	2/3	1.0 (0.6 to 1.6)	0.00 (-0.01 to 0.01)	
Tolterodine	Abdominal pain	5 ^{56, 312, 325, 331, 346, 381}	4,637	3/2	1.6 (1.0 to 2.4)	0.01 (0.00 to 0.02)	
Tolterodine	Abnormal vision	2 ^{331, 360, 381}	1,141	2/1	1.3 (0.5 to 3.6)	0.00 (-0.01 to 0.01)	

Appendix Table F55. Clinical outcomes after darifenacin vs. placebo in pooled analyses of individual patient data from RCTs (high level of evidence)

Studies, reference	Dose, mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat 95% CI)	Attributable events (95% CI)
≥7 consecutive dry days							
Chapple, 2005 ²⁵⁶	7.5	19/337	15/388	1.46 (0.75; 2.82)	0.018 (-0.013; 0.049)		
Chapple, 2005 ²⁵⁶	15	24/334	16/388	1.74 (0.94; 3.22)	0.031 (-0.003; 0.065)		
≥3 dry days/week							
Chapple, 2005 ²⁵⁶	7.5	55/337	43/388	1.47 (1.02; 2.13)	0.052 (0.002; 0.103)	19 (10; 486)	52 (2; 103)
Chapple, 2005 ²⁵⁶	15	61/334	48/388	1.48 (1.04; 2.09)	0.059 (0.006; 0.112)	17 (9; 164)	59 (6; 112)
Reduction in incontinence episodes: ≥50%							
Chapple, 2005 ²⁵⁶	7.5	222/337	202/388	1.27 (1.12; 1.43)	0.138 (0.067; 0.209)	7 (5; 15)	138 (67; 209)
Chapple, 2005 ²⁵⁶	15	234/334	217/388	1.25 (1.12; 1.40)	0.141 (0.072; 0.211)	7 (5; 14)	141 (72; 211)
Reduction in incontinence episodes: ≥70%							
Chapple, 2005 ²⁵⁶	7.5	162/337	128/388	1.46 (1.22; 1.74)	0.151 (0.080; 0.222)	7 (5; 13)	151 (80; 222)
Chapple, 2005 ²⁵⁶	15	190/334	151/388	1.46 (1.25; 1.71)	0.180 (0.108; 0.252)	6 (4; 9)	180 (108; 252)
Reduction in incontinence episodes: ≥90%							
Chapple, 2005 ²⁵⁶	7.5	91/337	66/388	1.59 (1.20; 2.10)	0.100 (0.040; 0.160)	10 (6; 25)	100 (40; 160)
Chapple, 2005 ²⁵⁶	15	94/334	66/388	1.65 (1.25; 2.19)	0.111 (0.050; 0.172)	9 (6; 20)	111 (50; 172)
Incontinence impact							
Abrams, 2008 ⁴⁷	7.5	52/337	30/388	2.00 (1.30; 3.05)	0.077 (0.030; 0.124)	13 (8; 33)	77 (30; 124)
Abrams, 2008 ⁴⁷	15	46/334	30/388	1.78 (1.15; 2.75)	0.060 (0.015; 0.106)	17 (9; 67)	60 (15; 106)
Severity measures							
Abrams, 2008 ⁴⁷	7.5	47/337	27/388	2.00 (1.28; 3.14)	0.070 (0.025; 0.115)	14 (9; 40)	70 (25; 115)
Abrams, 2008 ⁴⁷	15	46/334	27/388	1.98 (1.26; 3.11)	0.068 (0.023; 0.113)	15 (9; 43)	68 (23; 113)
Role limitations							
Abrams, 2008 ⁴⁷	7.5	65/337	46/388	1.63 (1.15; 2.30)	0.074 (0.021; 0.127)	13 (8; 47)	74 (21; 127)
Abrams, 2008 ⁴⁷	15	59/334	46/388	1.49 (1.04; 2.13)	0.058 (0.006; 0.110)	17 (9; 165)	58 (6; 110)
Social limitations							
Abrams, 2008 ⁴⁷	7.5	57/337	42/388	1.56 (1.08; 2.26)	0.061 (0.010; 0.111)	16 (9; 97)	61 (10; 111)
Abrams, 2008 ⁴⁷	15	54/334	42/388	1.49 (1.03; 2.17)	0.053 (0.003; 0.104)	19 (10; 305)	53 (3; 104)
Physical limitations							
Abrams, 2008 ⁴⁷	7.5	58/337	49/388	1.36 (0.96; 1.94)	0.046 (-0.006; 0.098)		
Abrams, 2008 ⁴⁷	15	53/334	49/388	1.26 (0.88; 1.80)	0.032 (-0.019; 0.084)		
Emotions							
Abrams, 2008 ⁴⁷	7.5	56/337	44/388	1.47 (1.02; 2.11)	0.053 (0.002; 0.104)	19 (10; 493)	53 (2; 104)
Abrams, 2008 ⁴⁷	15	53/334	44/388	1.40 (0.96; 2.03)	0.045 (-0.005; 0.096)		
Personal relationships							
Abrams, 2008 ⁴⁷	7.5	24/337	20/388	1.38 (0.78; 2.46)	0.020 (-0.016; 0.055)		
Abrams, 2008 ⁴⁷	15	23/334	20/388	1.34 (0.75; 2.39)	0.017 (-0.018; 0.052)		

Appendix Table F55. Clinical outcomes after darifenacin vs. placebo in pooled analyses of individual patient data from RCTs (high level of evidence) (continued)

Studies, reference	Dose, mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat 95% CI)	Attributable events (95% CI)
Sleep/energy							
Abrams, 2008 ⁴⁷	7.5	46/337	37/388	1.43 (0.95; 2.15)	0.041 (-0.006; 0.088)		
Abrams, 2008 ⁴⁷	15	46/334	37/388	1.44 (0.96; 2.17)	0.042 (-0.005; 0.089)		
General health perception							
Abrams, 2008 ⁴⁷	7.5	24/337	19/388	1.45 (0.81; 2.61)	0.022 (-0.013; 0.057)		
Abrams, 2008 ⁴⁷	15	21/334	19/388	1.28 (0.70; 2.35)	0.014 (-0.020; 0.048)		
≥1 adverse effect							
Chapple, 2005 ²⁵⁶	7.5	182/337	189/388	1.11 (0.96; 1.28)	0.053 (-0.020; 0.126)		
Chapple, 2005 ²⁵⁶	15	219/334	189/388	1.35 (1.18; 1.53)	0.169 (0.097; 0.240)	6 (4; 10)	169 (97; 240)
Adverse effects of any cause							
Foote, 2005 ²⁸⁴	15	76/110	56/110	1.36 (1.09; 1.69)	0.182 (0.055; 0.309)	5 (3; 18)	182 (55; 309)
Foote, 2005 ²⁸⁴	7.5	52/97	56/110	1.05 (0.81; 1.37)	0.027 (-0.109; 0.163)		
Discontinued							
Chapple, 2005 ²⁵⁶	7.5	19/337	31/388	0.71 (0.41; 1.23)	-0.024 (-0.060; 0.013)		
Chapple, 2005 ²⁵⁶	15	43/334	31/388	1.61 (1.04; 2.50)	0.049 (0.004; 0.094)	20 (11; 255)	49 (4; 94)
Adverse effects leading to discontinuation							
Chapple, 2005 ²⁵⁶	7.5	5/337	10/388	0.58 (0.20; 1.67)	-0.011 (-0.031; 0.009)		
Chapple, 2005 ²⁵⁶	15	17/334	10/388	1.97 (0.92; 4.25)	0.025 (-0.003; 0.053)		
Foote, 2005 ²⁸⁴	15	10/110	6/110	1.67 (0.63; 4.43)	0.036 (-0.032; 0.105)		
Foote, 2005 ²⁸⁴	7.5	1/97	6/110	0.19 (0.02; 1.54)	-0.044 (-0.091; 0.003)		
Reduction in incontinence episodes: ≥30%							
Chapple, 2005 ²⁵⁶	7.5	259/337	248/388	1.20 (1.09; 1.32)	0.129 (0.064; 0.195)	8 (5; 16)	129 (64; 195)
Chapple, 2005 ²⁵⁶	15	274/334	264/388	1.21 (1.11; 1.31)	0.140 (0.078; 0.202)	7 (5; 13)	140 (78; 202)
Abdominal pain							
Chapple, 2005 ²⁵⁶	7.5	8/337	2/388	4.61 (0.98; 21.54)	0.019 (0.001; 0.036)	54 (28; 1194)	19 (1; 36)
Chapple, 2005 ²⁵⁶	15	13/334	2/388	7.55 (1.72; 33.22)	0.034 (0.012; 0.056)	30 (18; 84)	34 (12; 56)
Back pain							
Chapple, 2005 ²⁵⁶	7.5	8/337	12/388	0.77 (0.32; 1.86)	-0.007 (-0.031; 0.016)		
Chapple, 2005 ²⁵⁶	15	5/334	12/388	0.48 (0.17; 1.36)	-0.016 (-0.038; 0.006)		
Cardiovascular system (total)							
Foote, 2005 ²⁸⁴	7.5	3/97	0/110	7.93 (0.41; 151.59)	0.031 (-0.008; 0.070)		
Foote, 2005 ²⁸⁴	15	1/110	0/110	3.00 (0.12; 72.85)	0.009 (-0.016; 0.034)		
Constipation							
Chapple, 2005 ²⁵⁶	7.5	50/337	24/388	2.40 (1.51; 3.82)	0.087 (0.042; 0.131)	12 (8; 24)	87 (42; 131)
Chapple, 2005 ²⁵⁶	15	71/334	24/388	3.44 (2.22; 5.33)	0.151 (0.101; 0.201)	7 (5; 10)	151 (101; 201)
Foote, 2005 ²⁸⁴	7.5	18/97	7/110	2.92 (1.27; 6.68)	0.122 (0.032; 0.212)	8 (5; 31)	122 (32; 212)
Foote, 2005 ²⁸⁴	15	26/110	7/110	3.71 (1.68; 8.20)	0.173 (0.081; 0.264)	6 (4; 12)	173 (81; 264)
Dry mouth							
Chapple, 2005 ²⁵⁶	7.5	68/337	32/388	2.45 (1.65; 3.63)	0.119 (0.068; 0.170)	8 (6; 15)	119 (68; 170)

Appendix Table F55. Clinical outcomes after darifenacin vs. placebo in pooled analyses of individual patient data from RCTs (high level of evidence) (continued)

Studies, reference	Dose, mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat 95% CI)	Attributable events (95% CI)
Chapple, 2005 ²⁵⁶	15	118/334	32/388	4.28 (2.98; 6.15)	0.271 (0.213; 0.329)	4 (3; 5)	271 (213; 329)
Foote, 2005 ²⁸⁴	7.5	20/97	5/110	4.54 (1.77; 11.63)	0.161 (0.071; 0.250)	6 (4; 14)	161 (71; 250)
Foote, 2005 ²⁸⁴	15	34/110	5/110	6.80 (2.76; 16.74)	0.264 (0.169; 0.358)	4 (3; 6)	264 (169; 358)
Dyspepsia							
Chapple, 2005 ²⁵⁶	7.5	9/337	10/388	1.04 (0.43; 2.52)	0.001 (-0.022; 0.024)		
Chapple, 2005 ²⁵⁶	15	28/334	10/388	3.25 (1.60; 6.60)	0.058 (0.024; 0.092)	17 (11; 41)	58 (24; 92)
Foote, 2005 ²⁸⁴	7.5	2/97	1/110	2.27 (0.21; 24.63)	0.012 (-0.022; 0.045)		
Foote, 2005 ²⁸⁴	15	8/110	1/110	8.00 (1.02; 62.89)	0.064 (0.012; 0.115)	16 (9; 84)	64 (12; 115)
Headache							
Chapple, 2005 ²⁵⁶	7.5	15/337	21/388	0.82 (0.43; 1.57)	-0.010 (-0.041; 0.022)		
Chapple, 2005 ²⁵⁶	15	17/334	21/388	0.94 (0.50; 1.75)	-0.003 (-0.036; 0.029)		
Foote, 2005 ²⁸⁴	7.5	0/97	2/110	0.23 (0.01; 4.66)	-0.018 (-0.049; 0.013)		
Foote, 2005 ²⁸⁴	15	0/110	2/110	0.20 (0.01; 4.12)	-0.018 (-0.048; 0.012)		
Nervous system (total)							
Foote, 2005 ²⁸⁴	7.5	2/97	2/110	1.13 (0.16; 7.90)	0.002 (-0.035; 0.040)		
Foote, 2005 ²⁸⁴	15	2/110	2/110	1.00 (0.14; 6.97)	0.000 (-0.035; 0.035)		
Respiratory tract information							
Chapple, 2005 ²⁵⁶	7.5	9/337	26/388	0.40 (0.19; 0.84)	-0.040 (-0.071; -0.010)	-25 (-99; -14)	-40 (-71; -10)
Chapple, 2005 ²⁵⁶	15	17/334	26/388	0.76 (0.42; 1.38)	-0.016 (-0.050; 0.018)		
UTI							
Chapple, 2005 ²⁵⁶	7.5	16/337	10/388	1.84 (0.85; 4.00)	0.022 (-0.006; 0.049)		
Chapple, 2005 ²⁵⁶	15	15/334	10/388	1.74 (0.79; 3.83)	0.019 (-0.008; 0.046)		

Appendix Table F56. Dose response association between clinical outcomes and darifenacin in pooled analyses of individual patient data from RCTs (high level of evidence)

Studies, reference	Active dose, mg/day	Control dose mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat 95% CI)	Attributable events (95% CI)
≥1 adverse effect Chapple, 2005 ²⁵⁶	7.5	15	182/337	219/334	0.82 (0.73; 0.93)	-0.116 (-0.189; -0.042)	-9 (-24; -5)	-116 (-189; -42)
Adverse effects of any cause Foote, 2005 ²⁸⁴	7.5	15	52/97	76/110	0.78 (0.62; 0.97)	-0.155 (-0.286; -0.023)	-6 (-43; -3)	-155 (-286; -23)
Discontinued Chapple, 2005 ²⁵⁶	7.5	15	19/337	43/334	0.44 (0.26; 0.74)	-0.072 (-0.116; -0.029)	-14 (-35; -9)	-72 (-116; -29)
Adverse effects leading to discontinuation Foote, 2005 ²⁸⁴	7.5	15	1/97	10/110	0.11 (0.01; 0.87)	-0.081 (-0.138; -0.023)	-12 (-43; -7)	-81 (-138; -23)
Adverse effects leading to discontinuation Chapple, 2005 ²⁵⁶	7.5	15	5/337	17/334	0.29 (0.11; 0.78)	-0.036 (-0.063; -0.009)	-28 (-109; -16)	-36 (-63; -9)
Incontinence impact Abrams, 2008 ⁴⁷	7.5	15	52/337	46/334	1.12 (0.78; 1.62)	0.017 (-0.037; 0.070)		
Severity measures Abrams, 2008 ⁴⁷	7.5	15	47/337	46/334	1.01 (0.69; 1.48)	0.002 (-0.051; 0.054)		
Role limitations Abrams, 2008 ⁴⁷	7.5	15	65/337	59/334	1.09 (0.79; 1.50)	0.016 (-0.042; 0.075)		
Social limitations Abrams, 2008 ⁴⁷	7.5	15	57/337	54/334	1.05 (0.74; 1.47)	0.007 (-0.049; 0.064)		
Physical limitations Abrams, 2008 ⁴⁷	7.5	15	58/337	53/334	1.08 (0.77; 1.52)	0.013 (-0.043; 0.070)		
Emotions Abrams, 2008 ⁴⁷	7.5	15	56/337	53/334	1.05 (0.74; 1.48)	0.007 (-0.048; 0.063)		
Personal relationships Abrams, 2008 ⁴⁷	7.5	15	24/337	23/334	1.03 (0.60; 1.80)	0.002 (-0.036; 0.041)		
Sleep/energy Abrams, 2008 ⁴⁷	7.5	15	46/337	46/334	0.99 (0.68; 1.45)	-0.001 (-0.053; 0.051)		
General health perception Abrams, 2008 ⁴⁷	7.5	15	24/337	21/334	1.13 (0.64; 1.99)	0.008 (-0.029; 0.046)		
Dry mouth Chapple, 2005 ²⁵⁶	7.5	15	68/337	118/334	0.57 (0.44; 0.74)	-0.152 (-0.218; -0.085)	-7 (-12; -5)	-152 (-218; -85)
Foote, 2005 ²⁸⁴	7.5	15	20/97	34/110	0.67 (0.41; 1.08)	-0.103 (-0.221; 0.015)		
Abdominal pain Chapple, 2005 ²⁵⁶	7.5	15	8/337	13/334	0.61 (0.26; 1.45)	-0.015 (-0.042; 0.011)		
Back pain Chapple, 2005 ²⁵⁶	7.5	15	8/337	5/334	1.59 (0.52; 4.80)	0.009 (-0.012; 0.030)		
Cardiovascular system (total) Foote, 2005 ²⁸⁴	7.5	15	3/97	1/110	3.40 (0.36; 32.17)	0.022 (-0.017; 0.061)		

Appendix Table F56. Dose response association between clinical outcomes and darifenacin in pooled analyses of individual patient data from RCTs (high level of evidence) (continued)

Studies, reference	Active dose, mg/day	Control dose mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat 95% CI)	Attributable events (95% CI)
Constipation Chapple, 2005 ²⁵⁶ Foote, 2005 ²⁸⁴	7.5 7.5	15 15	50/337 18/97	71/334 26/110	0.70 (0.50; 0.97) 0.79 (0.46; 1.34)	-0.064 (-0.122; -0.006) -0.051 (-0.162; 0.060)	-16 (-161; -8)	-64 (-122; -6)
Dyspepsia Chapple, 2005 ²⁵⁶ Foote, 2005 ²⁸⁴	7.5 7.5	15 15	9/337 2/97	28/334 8/110	0.32 (0.15; 0.66) 0.28 (0.06; 1.30)	-0.057 (-0.091; -0.023) -0.052 (-0.108; 0.004)	-18 (-44; -11)	-57 (-91; -23)
Headache Chapple, 2005 ²⁵⁶ Foote, 2005 ²⁸⁴	7.5 7.5	15 15	15/337 0/97	17/334 0/110	0.87 (0.44; 1.72) 0.00 (0.00; 0.00)	-0.006 (-0.039; 0.026) 0.000 (-0.019; 0.019)		
Nervous system (total) Foote, 2005 ²⁸⁴	7.5	15	2/97	2/110	1.13 (0.16; 7.90)	0.002 (-0.035; 0.040)		
Respiratory tract information Chapple, 2005 ²⁵⁶	7.5	15	9/337	17/334	0.52 (0.24; 1.16)	-0.024 (-0.053; 0.005)		
UTI Chapple, 2005 ²⁵⁶	7.5	15	16/337	15/334	1.06 (0.53; 2.10)	0.003 (-0.029; 0.034)		

Appendix Table F57. Significant dose response association with clinical outcomes after darifenacin (individual RCTs)

Studies, reference	Active dose, mg/day	Control dose mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat 95% CI)	Attributable events (95% CI)
Adverse effects								
Hill, 2006 ⁴²	7.5	30	62/108	92/115	0.72 (0.60; 0.86)	-0.23 (-0.34; -0.11)	-4 (-9; -3)	-226 (-344; -107)
Withdrawals: adverse effects								
Hill, 2006 ⁴²	15	30	73/107	92/115	0.85 (0.73; 1.00)	-0.12 (-0.23; 0.00)	-8 (-314; -4)	-118 (-232; -3)
Hill, 2006 ⁴²	7.5	30	2/108	13/115	0.16 (0.04; 0.71)	-0.09 (-0.16; -0.03)	-11 (-32; -6)	-95 (-158; -31)
Chancellor, 2008 ²⁵⁰	7	15	21/205	6/190	3.24(1.34; 7.86)	0.07(0.02; 0.12)	14(8; 44)	71(22; 119)
Withdrawals due to lack of response								
Hill, 2006 ⁴²	7.5	15	1/108	2/107	0.50 (0.05; 5.38)	-0.01 (-0.04; 0.02)		
Hill, 2006 ⁴²	7.5	30	1/108	1/115	1.06 (0.07; 16.81)	0.00 (-0.02; 0.03)		
Hill, 2006 ⁴²	15	30	2/107	1/115	2.15 (0.20; 23.36)	0.01 (-0.02; 0.04)		
Constipation								
Steers, 2005 ⁴³	7.5	15	32/108	24/160	1.98 (1.24; 3.16)	0.15 (0.04; 0.25)	7 (4; 23)	146 (44; 249)
Hill, 2006 ⁴²	7.5	30	17/108	32/115	0.57 (0.33; 0.96)	-0.12 (-0.23; -0.01)	-8 (-72; -4)	-121 (-228; -14)
Chapple, 2004 ⁴⁷²	15	30	2/53	33/229	0.26 (0.06; 1.06)	-0.11 (-0.17; -0.04)	-9 (-26; -6)	-106 (-175; -38)
Chapple, 2004 ⁴⁷²	15	60	2/53	16/115	0.27 (0.06; 1.14)	-0.10 (-0.18; -0.02)	-10 (-50; -5)	-101 (-183; -20)
Dry mouth								
Steers, 2005 ⁴³	7.5	15	28/108	22/160	1.89 (1.14; 3.12)	0.12 (0.02; 0.22)	8 (5; 43)	122 (23; 220)
Hill, 2006 ⁴²	7.5	15	25/108	43/107	0.58 (0.38; 0.87)	-0.17 (-0.29; -0.05)	-6 (-21; -3)	-170 (-293; -48)
Hill, 2006 ⁴²	7.5	30	25/108	68/115	0.39 (0.27; 0.57)	-0.36 (-0.48; -0.24)	-3 (-4; -2)	-360 (-480; -240)
Hill, 2006 ⁴²	15	30	43/107	68/115	0.68 (0.52; 0.90)	-0.19 (-0.32; -0.06)	-5 (-17; -3)	-189 (-319; -60)
Chapple, 2004 ⁴⁷²	15	60	7/53	36/115	0.42 (0.20; 0.89)	-0.18 (-0.31; -0.06)	-6 (-18; -3)	-181 (-305; -57)
Chapple, 2004 ⁴⁷²	30	60	43/229	36/115	0.60 (0.41; 0.88)	-0.13 (-0.22; -0.03)	-8 (-38; -4)	-125 (-224; -27)
Dyspepsia								
Chapple, 2004 ⁴⁷²	30	60	4/229	9/115	0.22 (0.07; 0.71)	-0.06 (-0.11; -0.01)	-16 (-113; -9)	-61 (-113; -9)
Headache								
Steers, 2005 ⁴³	7.5	15	13/108	5/160	3.85 (1.41; 10.49)	0.09 (0.02; 0.16)	11 (6; 45)	89 (22; 156)
Respiratory tract infection								
Hill, 2006 ⁴²	15	30	6/107	1/115	6.45 (0.79; 52.69)	0.05 (0.00; 0.09)	21 (11; 1665)	47 (1; 94)
Urinary tract disorder								
Hill, 2006 ⁴²	7.5	15	0/108	6/107	0.08 (0.00; 1.34)	-0.06 (-0.10; -0.01)	-18 (-106; -10)	-56 (-103; -9)

Appendix Table F58. Clinical outcomes after solifenacin vs. placebo, pooled individual patient data from RCTs (high level of evidence)

Outcome	Reference	Dose, mg/day	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Complete continence	Cardozo, 2006 ⁴¹²	5.00	1,095	1.50 (1.29; 1.73)	0.17 (0.10; 0.23)	6 (4; 10)	169 (104; 233)
Complete continence	Cardozo, 2006 ⁴¹²	10.00	1,559	1.53 (1.36; 1.72)	0.18 (0.13; 0.23)	6 (4; 8)	180 (132; 228)
Complete continence	Staskin, 2006 ³⁷	5.00	589	1.09 (0.82; 1.43)	0.02 (-0.06; 0.11)		
Complete continence	Staskin, 2006 ³⁷	10.00	882	1.43 (1.19; 1.73)	0.12 (0.06; 0.19)	8 (5; 16)	123 (61; 186)
Discontinued treatment due to adverse effects	Cardozo, 2006 ⁴¹²	5.00	1,095	0.87 (0.48; 1.58)	-0.01 (-0.03; 0.02)		
Discontinued treatment due to adverse effects	Cardozo, 2006 ⁴¹²	10.00	1,559	1.28 (0.86; 1.91)	0.01 (-0.01; 0.04)		
Discontinued treatment due to adverse effects	Staskin, 2006 ³⁷	5.00	589	0.57 (0.20; 1.65)	-0.02 (-0.05; 0.01)		
Discontinued treatment due to adverse effects	Staskin, 2006 ³⁷	10.00	882	1.55 (0.89; 2.71)	0.02 (-0.01; 0.06)		
Blurred vision	Staskin, 2006 ³⁷	5.00	1,794	2.10 (1.17; 3.77)	0.02 (0.00; 0.04)	50 (27; 375)	20 (3; 37)
Blurred vision	Staskin, 2006 ³⁷	10.00	2,449	2.64 (1.63; 4.29)	0.03 (0.02; 0.04)	34 (23; 64)	30 (16; 44)
Blurred vision	Cardozo, 2006 ⁴¹²	5.00	1,095	2.31 (1.10; 4.86)	0.02 (0.00; 0.05)		
Blurred vision	Cardozo, 2006 ⁴¹²	10.00	1,559	2.58 (1.40; 4.75)	0.03 (0.01; 0.05)	35 (22; 92)	28 (11; 46)
Mild blurred vision	Cardozo, 2006 ⁴¹²	5.00	1,150	1.94 (0.86; 4.37)	0.02 (-0.01; 0.04)		
Mild blurred vision	Cardozo, 2006 ⁴¹²	10.00	1,643	2.01 (1.04; 3.88)	0.02 (0.00; 0.03)	63 (33; 833)	16 (1; 31)
Moderate blurred vision	Cardozo, 2006 ⁴¹²	5.00	1,150	2.52 (0.36; 17.79)	0.00 (-0.01; 0.01)		
Moderate blurred vision	Cardozo, 2006 ⁴¹²	10.00	1,643	4.01 (0.86; 18.85)	0.01 (0.00; 0.02)		
Severe blurred vision	Cardozo, 2006 ⁴¹²	5.00	1,150	7.54 (0.31; 184.53)	0.00 (-0.00; 0.01)		
Severe blurred vision	Cardozo, 2006 ⁴¹²	10.00	1,643	9.03 (0.49; 167.51)	0.01 (0.00; 0.01)		
Constipation	Staskin, 2006 ³⁷	5.00	1,794	1.86 (1.16; 2.99)	0.03 (0.00; 0.05)	40 (22; 237)	25 (4; 45)
Constipation	Staskin, 2006 ³⁷	10.00	2,449	4.65 (3.26; 6.64)	0.11 (0.08; 0.13)	10 (8; 12)	105 (84; 126)
Constipation	Cardozo, 2006 ⁴¹²	5.00	1,095	1.78 (1.02; 3.11)	0.03 (-0.00; 0.06)		
Constipation	Cardozo, 2006 ⁴¹²	10.00	1,559	3.91 (2.61; 5.85)	0.10 (0.08; 0.13)	10 (8; 13)	104 (77; 132)
Mild constipation	Cardozo, 2006 ⁴¹²	5.00	1,150	1.99 (1.02; 3.86)	0.02 (-0.00; 0.05)		
Mild constipation	Cardozo, 2006 ⁴¹²	10.00	1,643	2.69 (1.61; 4.52)	0.039 (0.020; 0.059)	26 (17; 51)	39 (20; 59)
Moderate constipation	Cardozo, 2006 ⁴¹²	5.00	1,150	1.14 (0.40; 3.27)	0.00 (-0.01; 0.02)		
Moderate constipation	Cardozo, 2006 ⁴¹²	10.00	1,643	4.84 (2.54; 9.19)	0.05 (0.03; 0.07)	20 (14; 31)	51 (33; 70)
Severe constipation	Cardozo, 2006 ⁴¹²	5.00	1,150	7.54 (0.31; 184.53)	0.00 (-0.00; 0.01)		
Severe constipation	Cardozo, 2006 ⁴¹²	10.00	1,643	23.08 (1.36; 391.08)	0.01 (0.01; 0.02)	75 (46; 192)	13 (5; 22)
Dry mouth	Staskin, 2006 ³⁷	5.00	1,794	2.60 (1.82; 3.71)	0.07 (0.04; 0.10)	15 (11; 25)	67 (39; 95)

Appendix Table F58. Clinical outcomes after solifenacin vs. placebo, pooled individual patient data from RCTs (high level of evidence) (continued)

Outcome	Reference	Dose, mg/day	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Dry mouth	Staskin, 2006 ³⁷	10.00	2,449	6.57 (4.95; 8.73)	0.23 (0.21; 0.26)	4 (4; 5)	234 (206; 261)
Dry mouth	Cardozo, 2006 ⁴¹²	5.00	1,095	2.49 (1.59; 3.90)	0.07 (0.03; 0.10)	15 (10; 35)	67 (29; 104)
Dry mouth	Cardozo, 2006 ⁴¹²	10.00	1,559	6.48 (4.60; 9.12)	0.25 (0.21; 0.28)	4 (4; 5)	246 (211; 281)
Mild dry mouth	Cardozo, 2006 ⁴¹²	5.00	1,150	2.92 (1.74; 4.91)	0.06 (0.03; 0.09)	17 (11; 39)	58 (25; 91)
Mild dry mouth	Cardozo, 2006 ⁴¹²	10.00	1,643	6.18 (4.10; 9.33)	0.16 (0.13; 0.19)	6 (5; 8)	157 (128; 187)
Moderate dry mouth	Cardozo, 2006 ⁴¹²	5.00	1,150	1.60 (0.63; 4.10)	0.01 (-0.01; 0.03)		
Moderate dry mouth	Cardozo, 2006 ⁴¹²	10.00	1,643	6.30 (3.36; 11.81)	0.07 (0.05; 0.09)	14 (11; 20)	71 (50; 91)
Severe dry mouth	Cardozo, 2006 ⁴¹²	5.00	1,150	0.84 (0.03; 20.50)	-0.00 (-0.01; 0.00)		
Severe dry mouth	Cardozo, 2006 ⁴¹²	10.00	1,643	16.06 (2.13; 120.81)	0.02 (0.01; 0.03)	55 (36; 117)	18 (9; 28)

Appendix Table F59. Evidence of dose response association in clinical outcomes after solifenacin 5 vs.10mg/day (pooled individual patient data from RCTs)

Outcome	Reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Continence	Staskin, 2006 ³⁷	611	0.76 (0.58; 0.98)	-0.10 (-0.18; -0.01)	-10 (-71; -5)	-99 (-184; -14)
Continence	Cardozo, 2006 ⁴¹²	1092	0.98 (0.86; 1.11)			
Discontinued treatment due to adverse effects	Cardozo, 2006 ⁴¹²	1092	0.68 (0.38; 1.21)			
Discontinued treatment due to adverse effects	Staskin, 2006 ³⁷	611	0.37 (0.13; 1.02)	-0.04 (-0.08; -0.01)	-23 (-103; -13)	-43 (-77; -10)
Dry mouth	Cardozo, 2006 ⁴¹²	1092	0.38 (0.28; 0.53)	-0.18 (-0.23; -0.13)	-6 (-8; -4)	-179 (-226; -132)
Dry mouth	Staskin, 2006 ³⁷	1811	0.40 (0.31; 0.51)	-0.17 (-0.20; -0.13)	-6 (-8; -5)	-167 (-202; -131)
Mild dry mouth	Cardozo, 2006 ⁴¹²	1147	0.47 (0.32; 0.69)	-0.10 (-0.14; -0.06)	-10 (-17; -7)	-99 (-140; -58)
Moderate dry mouth	Cardozo, 2006 ⁴¹²	1147	0.25 (0.12; 0.55)	-0.06 (-0.09; -0.04)	-16 (-26; -11)	-63 (-87; -38)
Severe dry mouth	Cardozo, 2006 ⁴¹²	1147	0.08 (0.00; 1.26)	-0.02 (-0.03; -0.01)	-51 (-111; -33)	-20 (-30; -9)
Blurred vision	Cardozo, 2006 ⁴¹²	1092	0.89 (0.48; 1.66)			
Blurred vision	Staskin, 2006 ³⁷	1811	0.80 (0.49; 1.28)			
Mild blurred vision	Cardozo, 2006 ⁴¹²	1147	0.96 (0.47; 1.98)			
Moderate blurred vision	Cardozo, 2006 ⁴¹²	1147	0.63 (0.13; 2.94)			
Severe blurred vision	Cardozo, 2006 ⁴¹²	1147	0.63 (0.07; 5.59)			
Constipation	Cardozo, 2006 ⁴¹²	1092	0.45 (0.29; 0.72)	-0.08 (-0.11; -0.04)	-13 (-25; -9)	-76 (-113; -40)
Constipation	Staskin, 2006 ³⁷	1811	0.40 (0.28; 0.58)	-0.08 (-0.11; -0.05)	-12 (-19; -9)	-80 (-107; -54)
Mild constipation	Cardozo, 2006 ⁴¹²	1147	0.74 (0.42; 1.29)	-0.02 (-0.04; 0.01)		
Moderate constipation	Cardozo, 2006 ⁴¹²	1147	0.24 (0.10; 0.59)	-0.05 (-0.07; -0.03)	-20 (-36; -14)	-49 (-71; -28)
Severe constipation	Cardozo, 2006 ⁴¹²	1147	0.23 (0.03; 1.76)	-0.01 (-0.02; 0.00)		

Appendix Table F60. Results from VIBRANT trial³⁹²

Outcome	Dose	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
BSW: benefit-much	5 -10mg daily	1.78 (1.48; 2.14)	0.222 (0.155; 0.290)	4 (3; 6)	222 (155; 290)
BSW: satisfaction-yes	5 -10mg daily	1.42 (1.26; 1.61)	0.207 (0.139; 0.275)	5 (4; 7)	207 (139; 275)
BSW: willingness to continue-yes	5 -10mg daily	1.39 (1.23; 1.57)	0.192 (0.123; 0.260)	5 (4; 8)	192 (123; 260)
PPBC score: None	5 -10mg daily	1.32 (0.88; 1.98)	0.030 (-0.014; 0.074)		
PPBC score: Very minor	5 -10mg daily	1.46 (1.10; 1.94)	0.079 (0.021; 0.136)	13 (7; 47)	79 (21; 136)
Discontinuation	10mg daily	0.84 (0.39; 1.81)	-0.011 (-0.057; 0.036)		
Discontinuation	5mg daily	0.63 (0.27; 1.46)	-0.031 (-0.089; 0.027)		
BSW: benefit-little	5 -10mg daily	0.88 (0.67; 1.15)	-0.028 (-0.087; 0.030)		
BSW: benefit-none	5 -10mg daily	0.46 (0.34; 0.61)	-0.164 (-0.221; -0.106)	-6 (-9; -5)	-164 (-221; -106)
BSW: satisfaction-no	5 -10mg daily	0.51 (0.39; 0.66)	-0.167 (-0.227; -0.106)	-6 (-9; -4)	-167 (-227; -106)
BSW: willingness to continue-no	5 -10mg daily	0.55 (0.43; 0.71)	-0.151 (-0.212; -0.090)	-7 (-11; -5)	-151 (-212; -90)
PPBC score: Severe	5 -10mg daily	0.42 (0.27; 0.64)	-0.095 (-0.140; -0.050)	-11 (-20; -7)	-95 (-140; -50)
PPBC score: Many severe	5 -10mg daily	0.78 (0.36; 1.69)	-0.008 (-0.033; 0.017)		
Dry mouth	5 -10mg daily	5.61 (2.80; 11.23)	0.109 (0.072; 0.146)	9 (7; 14)	109 (72; 146)
Constipation	5 -10mg daily	4.38 (1.95; 9.83)	0.062 (0.032; 0.092)	16 (11; 32)	62 (32; 92)
Dry eye	5 -10mg daily	5.94 (0.72; 49.09)	0.013 (0.000; 0.026)		
Dyspepsia	5 -10mg daily	10.89 (0.60; 196.20)	0.013 (0.001; 0.025)	77 (40; 1616)	13 (1; 25)
Fatigue	5 -10mg daily	2.47 (0.48; 12.67)	0.008 (-0.006; 0.021)		
Nausea	5 -10mg daily	0.66 (0.19; 2.32)	-0.005 (-0.021; 0.011)		
Blurred vision	5 -10mg daily	0.79 (0.21; 2.93)	-0.003 (-0.018; 0.013)		
Headache	5 -10mg daily	0.59 (0.14; 2.47)	-0.005 (-0.020; 0.009)		

Appendix Table F61. Clinical outcomes after fesoterodine vs. placebo, secondary data from post hoc and pooled analyses

Outcome	Reference daily dose mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Response to treatment	Sand, 2009 ³⁷⁰ 4 mg/day	251/434	167/430	1.49 (1.29; 1.72)	0.190 (0.125; 0.255)	5 (4; 8)	190 (125; 255)
Response to treatment	Sand, 2009 ³⁷⁰ 8 mg/day	291/452	167/430	1.66 (1.45; 1.90)	0.255 (0.192; 0.319)	4 (3; 5)	255 (192; 319)
Discontinuation	Sand, 2009 ³⁷⁰ 8 mg/day	14/287	6/283	2.30 (0.90; 5.90)	0.028 (-0.002; 0.058)		
Discontinuation due to adverse effects	Khullar, 2008 ³²⁶ 4 mg/day	27/554	19/554	1.42 (0.80; 2.53)	0.014 (-0.009; 0.038)		
Discontinuation due to adverse effects	Khullar, 2008 ³²⁶ 8 mg/day	41/566	19/554	2.11 (1.24; 3.59)	0.038 (0.012; 0.064)	26 (16; 84)	38 (12; 64)
Back pain	Sand, 2009370mg/day	9/434	1/430	8.92 (1.13; 70.08)	0.018 (0.004; 0.033)	54 (31; 235)	18 (4; 33)
Back pain	Sand, 2009 ³⁷⁰ 8 mg/day	4/421	1/430	4.09 (0.46; 36.40)	0.007 (-0.003; 0.018)		
Constipation	Sand, 2009 ³⁷⁰ 4 mg/day	20/434	10/430	1.98 (0.94; 4.18)	0.023 (-0.002; 0.047)		
Constipation	Khullar, 2008 ³²⁶ 4 mg/day	23/554	11/554	2.09 (1.03; 4.25)	0.022 (0.001; 0.042)	46 (24; 719)	22 (1; 42)
Constipation	Chapple, 2008 ²⁵⁴ 8 mg/day	13/287	4/283	3.20 (1.06; 9.71)	0.031 (0.003; 0.059)	32 (17; 290)	31 (3; 59)
Constipation	Sand, 2009 ³⁷⁰ 4 mg/day	24/421	10/430	2.45 (1.19; 5.06)	0.034 (0.007; 0.060)	30 (17; 135)	34 (7; 60)
Constipation	Khullar, 2008 ³²⁶ 8 mg/day	34/566	11/554	3.03 (1.55; 5.91)	0.040 (0.017; 0.063)	25 (16; 57)	40 (17; 63)
Cough	Sand, 2009 ³⁷⁰ 4 mg/day	7/434	3/430	2.31 (0.60; 8.88)	0.009 (-0.005; 0.023)		
Cough	Sand, 2009 ³⁷⁰ 4 mg/day	5/421	3/430	1.70 (0.41; 7.08)	0.005 (-0.008; 0.018)		
Diarrhea	Sand, 2009 ³⁷⁰ 4 mg/day	7/434	10/430	0.69 (0.27; 1.81)	-0.007 (-0.026; 0.011)		
Diarrhea	Sand, 2009 ³⁷⁰ 4 mg/day	6/421	10/430	0.61 (0.22; 1.67)	-0.009 (-0.027; 0.009)		
Dizziness	Sand, 2009 ³⁷⁰ 4 mg/day	4/434	9/430	0.44 (0.14; 1.42)	-0.012 (-0.028; 0.005)		
Dizziness	Sand, 2009 ³⁷⁰ 4 mg/day	5/421	9/430	0.57 (0.19; 1.68)	-0.009 (-0.026; 0.008)		

Appendix Table F61. Clinical outcomes after fesoterodine vs. placebo, secondary data from post hoc and pooled analyses (continued)

Outcome	Reference daily dose mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Dry eye	Sand, 2009 ³⁷⁰ 4 mg/day	6/434	0/430	12.88 (0.73; 227.94)	0.014 (0.002; 0.026)		
Dry eye	Chapple, 2008 ²⁵⁴ 8 mg/day	12/287	0/283	24.65 (1.47; 414.40)	0.042 (0.018; 0.066)	24 (15; 56)	42 (18; 66)
Dry eye	Sand, 2009 ³⁷⁰ 4 mg/day	10/421	0/430	21.45 (1.26; 364.85)	0.024 (0.009; 0.039)	42 (26; 117)	24 (9; 39)
Dry mouth	Sand, 2009 ³⁷⁰ 4 mg/day	89/434	32/430	2.76 (1.88; 4.03)	0.131 (0.085; 0.176)	8 (6; 12)	131 (85; 176)
Dry mouth	Khullar, 2008 ³²⁶ 4 mg/day	104/554	39/554	2.67 (1.88; 3.78)	0.117 (0.078; 0.156)	9 (6; 13)	117 (78; 156)
Dry mouth	Chapple, 2008 ²⁵⁴ 8 mg/day	97/287	20/283	4.78 (3.04; 7.52)	0.267 (0.205; 0.330)	4 (3; 5)	267 (205; 330)
Dry mouth	Sand, 2009 ³⁷⁰ 4 mg/day	155/421	32/430	4.95 (3.47; 7.06)	0.294 (0.241; 0.346)	3 (3; 4)	294 (241; 346)
Dry mouth	Khullar, 2008 ³²⁶ 8 mg/day	196/566	39/554	4.92 (3.56; 6.80)	0.276 (0.231; 0.321)	4 (3; 4)	276 (231; 321)
Dry throat	Sand, 2009 ³⁷⁰ 4 mg/day	4/434	0/430	8.92 (0.48; 165.12)	0.009 (-0.001; 0.019)		
Dry throat	Khullar, 2008 ³²⁶ 4 mg/day	5/554	2/554	2.50 (0.49; 12.83)	0.005 (-0.004; 0.015)		
Dry throat	Chapple, 2008 ²⁵⁴ 8 mg/day	8/287	0/283	16.76 (0.97; 289.07)	0.028 (0.008; 0.048)	36 (21; 129)	28 (8; 48)
Dry throat	Sand, 2009 ³⁷⁰ 4 mg/day	10/421	0/430	21.45 (1.26; 364.85)	0.024 (0.009; 0.039)	42 (26; 117)	24 (9; 39)
Dry throat	Khullar, 2008 ³²⁶ 8 mg/day	13/566	2/554	6.36 (1.44; 28.06)	0.019 (0.006; 0.033)	52 (31; 165)	19 (6; 33)
Dyspepsia	Khullar, 2008 ³²⁶ 4 mg/day	9/554	3/554	3.00 (0.82; 11.02)	0.011 (-0.001; 0.023)		
Dyspepsia	Khullar, 2008 ³²⁶ 8 mg/day	13/566	3/554	4.24 (1.22; 14.80)	0.018 (0.004; 0.031)		
Fatigue	Sand, 2009 ³⁷⁰ 4 mg/day	5/434	2/430	2.48 (0.48; 12.70)	0.007 (-0.005; 0.019)		
Fatigue	Chapple, 2008 ²⁵⁴ 8 mg/day	1/287	1/283	0.99 (0.06; 15.69)	0.000 (-0.010; 0.010)		
Fatigue	Sand, 2009 ³⁷⁰ 4 mg/day	1/421	2/430	0.51 (0.05; 5.61)	-0.002 (-0.010; 0.006)		
Headache	Sand, 2009 ³⁷⁰ 4 mg/day	21/434	18/430	1.16 (0.62; 2.14)	0.007 (-0.021; 0.034)		

Appendix Table F61. Clinical outcomes after fesoterodine vs. placebo, secondary data from post hoc and pooled analyses (continued)

Outcome	Reference daily dose mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Headache	Khullar, 2008 ³²⁶ 4 mg/day	24/554	23/554	1.04 (0.60; 1.83)	0.002 (-0.022; 0.026)		
Headache	Sand, 2009 ³⁷⁰ 4 mg/day	13/421	18/430	0.74 (0.37; 1.49)	-0.011 (-0.036; 0.014)		
Headache	Khullar, 2008 ³²⁶ 8 mg/day	15/566	23/554	0.64 (0.34; 1.21)	-0.015 (-0.036; 0.006)		
Increased alanine aminotransferase	Chapple, 2008 ²⁵⁴ 8 mg/day	6/287	1/283	5.92 (0.72; 48.83)	0.017 (-0.001; 0.035)		
Lacrimonal disorder	Khullar, 2008 ³²⁶ 4 mg/day	8/554	0/554	17.00 (0.98; 293.82)	0.014 (0.004; 0.025)	69 (40; 255)	14 (4; 25)
Lacrimonal disorder	Khullar, 2008 ³²⁶ 8 mg/day	21/566	0/554	42.09 (2.56; 693.13)	0.037 (0.021; 0.053)	27 (19; 47)	37 (21; 53)
Mild-constipation	Khullar, 2008 ³²⁶ 4 mg/day	8/554	1/554	8.00 (1.00; 63.75)	0.013 (0.002; 0.023)	79 (43; 478)	13 (2; 23)
Mild-constipation	Khullar, 2008 ³²⁶ 4 mg/day	14/554	8/554	1.75 (0.74; 4.14)	0.011 (-0.006; 0.027)		
Mild-constipation	Khullar, 2008 ³²⁶ 8 mg/day	14/566	1/554	13.70 (1.81; 103.86)	0.023 (0.010; 0.036)	44 (28; 104)	23 (10; 36)
Mild-constipation	Khullar, 2008 ³²⁶ 8 mg/day	18/566	8/554	2.20 (0.97; 5.02)	0.017 (0.000; 0.035)		
Mild-dry mouth	Khullar, 2008 ³²⁶ 4 mg/day	16/554	11/554	1.45 (0.68; 3.11)	0.009 (-0.009; 0.027)		
Mild-dry mouth	Khullar, 2008 ³²⁶ 4 mg/day	84/554	27/554	3.11 (2.05; 4.72)	0.103 (0.068; 0.138)	10 (7; 15)	103 (68; 138)
Mild-dry mouth	Khullar, 2008 ³²⁶ 8 mg/day	53/566	11/554	4.72 (2.49; 8.93)	0.074 (0.047; 0.100)	14 (10; 21)	74 (47; 100)
Mild-dry mouth	Khullar, 2008 ³²⁶ 8 mg/day	126/566	27/554	4.57 (3.07; 6.81)	0.174 (0.135; 0.213)	6 (5; 7)	174 (135; 213)
Mild-headache	Khullar, 2008 ³²⁶ 4 mg/day	6/554	3/554	2.00 (0.50; 7.96)	0.005 (-0.005; 0.016)		
Mild-headache	Khullar, 2008 ³²⁶ 4 mg/day	15/554	19/554	0.79 (0.41; 1.54)	-0.007 (-0.028; 0.013)		
Mild-headache	Khullar, 2008 ³²⁶ 8 mg/day	5/566	3/554	1.63 (0.39; 6.79)	0.003 (-0.006; 0.013)		
Mild-headache	Khullar, 2008 ³²⁶ 8 mg/day	9/566	19/554	0.46 (0.21; 1.02)	-0.018 (-0.037; 0.000)		
Mild-urinary tract infection	Khullar, 2008 ³²⁶ 4 mg/day	7/554	5/554	1.40 (0.45; 4.38)	0.004 (-0.009; 0.016)		

Appendix Table F61. Clinical outcomes after fesoterodine vs. placebo, secondary data from post hoc and pooled analyses (continued)

Outcome	Reference daily dose mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Mild-urinary tract infection	Khullar, 2008 ³²⁶ 4 mg/day	11/554	12/554	0.92 (0.41; 2.06)	-0.002 (-0.019; 0.015)		
Mild-urinary tract infection	Khullar, 2008 ³²⁶ 8 mg/day	8/566	5/554	1.57 (0.52; 4.76)	0.005 (-0.007; 0.018)		
Mild-urinary tract infection	Khullar, 2008 ³²⁶ 8 mg/day	15/566	12/554	1.22 (0.58; 2.59)	0.005 (-0.013; 0.023)		
Nasopharyngitis	Sand, Morrow, 2009 ³⁷⁰ 4 mg/day	14/434	12/430	1.16 (0.54; 2.47)	0.004 (-0.018; 0.027)		
Nasopharyngitis	Khullar, 2008 ³²⁶ 4 mg/day	18/554	14/554	1.29 (0.65; 2.56)	0.007 (-0.012; 0.027)		
Nasopharyngitis	Chapple, 2008 ²⁵⁴ 8 mg/day	5/287	7/283	0.70 (0.23; 2.19)	-0.007 (-0.031; 0.016)		
Nasopharyngitis	Sand, 2009 ³⁷⁰ 4 mg/day	6/421	12/430	0.51 (0.19; 1.35)	-0.014 (-0.033; 0.006)		
Nasopharyngitis	Khullar, 2008 ³²⁶ 8 mg/day	7/566	14/554	0.49 (0.20; 1.20)	-0.013 (-0.029; 0.003)		
Nausea	Sand, 2009 ³⁷⁰ 4 mg/day	4/434	5/430	0.79 (0.21; 2.93)	-0.002 (-0.016; 0.011)		
Nausea	Chapple, 2008 ²⁶⁰ 8 mg/day	4/287	1/283	3.94 (0.44; 35.07)	0.010 (-0.005; 0.026)		
Nausea	Sand, 2009 ³⁷⁰ 4 mg/day	11/421	5/430	2.25 (0.79; 6.41)	0.015 (-0.004; 0.033)		
Severe-constipation	Khullar, 2008 ³²⁶ 4 mg/day	1/554	2/554	0.50 (0.05; 5.50)	-0.002 (-0.008; 0.004)		
Severe-constipation	Khullar, 2008 ³²⁶ 8 mg/day	2/566	2/554	0.98 (0.14; 6.92)	0.000 (-0.007; 0.007)		
Severe-dry mouth	Khullar, 2008 ³²⁶ 4 mg/day	4/554	1/554	4.00 (0.45; 35.67)	0.005 (-0.002; 0.013)		
Severe-dry mouth	Khullar, 2008 ³²⁶ 8 mg/day	17/566	1/554	16.64 (2.22; 124.61)	0.028 (0.014; 0.043)	35 (23; 73)	28 (14; 43)
Severe-headache	Khullar, 2008 ³²⁶ 4 mg/day	3/554	1/554	3.00 (0.31; 28.75)	0.004 (-0.003; 0.011)		
Severe-headache	Khullar, 2008 ³²⁶ 8 mg/day	1/566	1/554	0.98 (0.06; 15.61)	0.000 (-0.005; 0.005)		
Severe-urinary tract infection	Khullar, 2008 ³²⁶ 4 mg/day	0/554	0/554	0.00 (0.00; 0.00)	0.000 (-0.004; 0.004)		
Severe-urinary tract infection	Khullar, 2008 ³²⁶ 8 mg/day	1/566	0/554	2.94 (0.12; 71.93)	0.002 (-0.003; 0.007)		

Appendix Table F61. Clinical outcomes after fesoterodine vs. placebo, secondary data from post hoc and pooled analyses (continued)

Outcome	Reference daily dose mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Upper respiratory tract infection	Sand, 2009 ³⁷⁰ 4 mg/day	12/434	9/430	1.32 (0.56; 3.10)	0.007 (-0.014; 0.027)		
Upper respiratory tract infection	Khullar, 2008 ³²⁶ 4 mg/day	14/554	12/554	1.17 (0.54; 2.50)	0.004 (-0.014; 0.021)		
Upper respiratory tract infection	Sand, 2009 ³⁷⁰ 4 mg/day	8/421	9/430	0.91 (0.35; 2.33)	-0.002 (-0.021; 0.017)		
Upper respiratory tract infection	Khullar, 2008 ³²⁶ 8 mg/day	10/566	12/554	0.82 (0.36; 1.87)	-0.004 (-0.020; 0.012)		
Urinary tract infection	Sand, 2009 ³⁷⁰ 4 mg/day	18/434	17/430	1.05 (0.55; 2.01)	0.002 (-0.024; 0.028)		
Urinary tract infection	Khullar, 2008 ³²⁶ 4 mg/day	18/554	17/554	1.06 (0.55; 2.03)	0.002 (-0.019; 0.022)		
Urinary tract infection	Sand, 2009 ³⁷⁰ 4 mg/day	24/421	17/430	1.44 (0.79; 2.64)	0.017 (-0.011; 0.046)		
Urinary tract infection	Khullar, 2008 ³²⁶ 8 mg/day	24/566	17/554	1.38 (0.75; 2.54)	0.012 (-0.010; 0.034)		

Appendix Table F62. Significant dose response effects of fesoterodine

Reference	Dose, mg/day	Outcome	Relative risk 95% CI)	Absolute risk difference 95%CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Chapple, 2007 ²⁵³	8 vs.4	Any adverse event	1.17 (1.00; 1.36)	0.084 (0.001; 0.166)	12 (6; 836)	84 (1; 166)
Nitti, 2007 ³⁵³	8 vs.4	Any adverse event	1.14 (1.01; 1.29)	0.088 (0.009; 0.166)	11 (6;112)	88 (9; 166)
Nitti, 2007 ³⁵³	8 vs.4	Dry eye	4.56 (1.00; 20.94)	0.025 (0.002; 0.048)	40 (21; 439)	25 (2; 48)
Chapple, 2007 ²⁵³	8 vs.4	Dry mouth	1.55 (1.18; 2.05)	0.120 (0.047; 0.193)	8 (5; 21)	120 (47; 193)
Nitti, 2007 ³⁵³	8 vs.4	Dry mouth	2.23 (1.63; 3.05)	0.196 (0.125; 0.266)	5 (4; 8)	196 (125; 266)
Chapple, 2007 ²⁵³	8 vs.4	Dry throat	7.56 (0.95; 60.01)	0.024 (0.004; 0.044)	41 (23; 263)	24 (4; 44)
Nitti, 2007 ³⁵³	8 vs.4	Hypertension	0.07 (0.00; 1.18)	-0.025 (-0.044; -0.005)	-40 (-184; -23)	-25 (-44; -5)
Chapple, 2007 ²⁵³	8 vs.4	Influenza	0.21 (0.05; 0.96)	-0.026 (-0.049; -0.003)	-38 (-354; -20)	-26 (-49; -3)
Nitti, 2007 ³⁵³	8 vs.4	Nasopharyngitis	0.20 (0.04; 0.92)	-0.028 (-0.052; -0.004)	-36 (-223; -19)	-28 (-52; -4)
Sand, 2009 ³⁷⁰ 4 mg/day Pooled analysis	8 vs. 4	Dry mouth	1.67 (1.3; 42.09)	0.138 (0.080; 0.196)	7 (5; 13)	138 (80; 196)
Khullar, 2008 ³²⁶ Pooled analysis	4 vs.8	Dry mouth-total	0.54 (0.44; 0.67)	-0.159 (-0.209; -0.108)	-6 (-9; -5)	-159 (-209; -108)
Khullar, 2008 ³²⁶ Pooled analysis	4 vs.8	Lacrimal disorder	0.39 (0.17; 0.87)	-0.023 (-0.041; -0.004)	-44 (-239; -24)	-23 (-41; -4)
Khullar, 2008 ³²⁶ Pooled analysis	4 vs.8	Moderate dry mouth	0.31 (0.18; 0.53)	-0.065 (-0.093; -0.037)	-15 (-27 -11)	-65 (-93; -37)
Khullar, 2008 ³²⁶ Pooled analysis	4 vs.8	Mild dry mouth	0.68 (0.53; 0.87)	-0.071 (-0.116; -0.026)	-14 (-39 -9)	-71 (-116; -26)
Khullar, 2008 ³²⁶ Pooled analysis	4 vs.8	Nasopharyngitis	2.63 (1.11; 6.24)	0.020 (0.003; 0.037)	50 (27;360)	20 (3; 37)
Khullar, 2008 ³²⁶ Pooled analysis	4 vs.8	Severe dry mouth	0.24 (0.08; 0.71)	-0.023 (-0.039; -0.007)	-44 (-141; -26)	-23 (-39; -7)
Sand, 2009 ³⁷⁰ 4 mg/day Pooled analysis	8 vs. 4	Treatment response	1.11 (1.00; 1.24)	0.065 (0.001; 0.130)	15 (8; 727)	65 (1; 130)

Appendix Table F63. Clinical outcomes after fesoterodine vs. placebo

Reference	Mg/day	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable/100 0 events (95% CI)
Any adverse events						
Cardozo, 2010 ^{474*}	4	867	1.21 (1.07; 1.38)	0.100 (0.033; 0.166)	10 (6; 30)	100 (33; 166)
	8	882	1.39 (1.23; 1.57)	0.181 (0.117; 0.246)	6 (4; 9)	181 (117; 246)
Discontinuations						
Dmochowski, 2010 ⁴⁶⁹	4 to 8	883	0.95 (0.68; 1.33)	-0.007 (-0.052; 0.038)		
Herschorn, 2010 ⁴⁷⁰	4 to 8	1013	1.33 (0.89; 1.98)	0.029 (-0.010; 0.069)		
Adverse events leading to discontinuation						
Dmochowski, 2010 ⁴⁶⁹	4 to 8	883	1.64 (0.97; 2.79)	0.030 (-0.001; 0.062)		
Herschorn, 2010 ⁴⁷⁰	4 to 8	1013	3.61 (1.55; 8.38)	0.047 (0.023; 0.070)	21 (14; 43)	47 (23; 70)
Lack of efficacy leading to discontinuation						
Dmochowski, 2010 ⁴⁶⁹	4 to 8	883	0.32 (0.12; 0.86)	-0.025 (-0.044; -0.005)	-41 (-218; -22)	-25 (-44; -5)
Herschorn, 2010 ⁴⁷⁰	4 to 8	1013	1.28 (0.46; 3.56)	0.004 (-0.012; 0.021)		
Deterioration on the PPBC scale						
Dmochowski, 2010 ⁴⁶⁹	4 to 8	883	0.49 (0.26; 0.92)	-0.033 (-0.061; -0.005)	-30 (-201; -16)	-33 (-61; -5)
Deterioration on the UPS scale						
Dmochowski, 2010 ⁴⁶⁹	4 to 8	883	0.85 (0.51; 1.42)	-0.010 (-0.042; 0.022)		
Deterioration on the PPBC scale from baseline						
Herschorn, 2010 ⁴⁷⁰	4 to 8	1013	0.46 (0.29; 0.74)	-0.055 (-0.091; -0.019)	-18 (-54; -11)	-55 (-91; -19)
Deterioration on the UPS scale from baseline						
Herschorn, 2010 ⁴⁷⁰	4 to 8	1013	0.65 (0.36; 1.16)	-0.020 (-0.049; 0.009)		
≥2-point improvement on the PPBC scale						
Dmochowski, 2010 ⁴⁶⁹	4 to 8	883	1.29 (1.06; 1.57)	0.080 (0.019; 0.141)	13 (7; 54)	80 (19; 141)
improvement on the UPS scale						
Dmochowski, 2010 ⁴⁶⁹	4 to 8	883	1.35 (1.13; 1.61)	0.108 (0.045; 0.171)	9 (6; 22)	108 (45; 171)
≥2-point improvement on the PPBC scale from baseline						
Herschorn, 2010 ⁴⁷⁰	4 to 8	1013	0.94 (0.80; 1.11)	-0.024 (-0.088; 0.040)		
improvement on the UPS scale from baseline						
Herschorn, 2010 ⁴⁷⁰	4 to 8	1013	1.28 (1.07; 1.52)	0.093 (0.030; 0.156)	11 (6; 33)	93 (30; 156)
UTI						
Herschorn, 2010 ⁴⁷⁰	4 to 8	1013	3.69 (0.85; 16.04)	0.016 (0.002; 0.030)	62 (33; 436)	16 (2; 30)
Cardozo, 2010 ^{474*}	4	867	0.89 (0.43; 1.81)	-0.004 (-0.028; 0.020)		
	8	882	1.41 (0.74; 2.66)	0.014 (-0.012; 0.041)		

* pooled analysis

Appendix Table F64. Clinical outcomes after propiverine vs. placebo, individual RCTs

Reference	Dose, mg/day	Outcome	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Dorschner, 2000 ²⁷⁸	45	Urgency symptom free	15/49	7/49	2.14 (0.96; 4.79)	0.163 (0.001; 0.325)	6 (3; 806)	163 (1; 325)
		Incontinence symptom free	24/49	15/49	1.60 (0.96; 2.66)	0.184 (-0.007; 0.374)		
		Urgency improved	29/49	19/49	1.53 (1.00; 2.33)	0.204 (0.010; 0.398)	5 (3; 97)	204 (10; 398)
		Incontinence improved	19/49	11/49	1.73 (0.92; 3.24)	0.163 (-0.016; 0.343)		
		Incontinence unchanged	6/49	23/49	0.26 (0.12; 0.58)	-0.347 (-0.514; -0.180)	-3 (-6; -2)	-347 (-514; -180)
		Urgency unchanged	5/49	23/49	0.22 (0.09; 0.53)	-0.367 (-0.531; -0.204)	-3 (-5; -2)	-367 (-531; -204)
Abrams, 2006 ²²⁰	20	Patients with ≥1 AE	30/38	12/24	1.58 (1.02; 2.43)	0.289 (0.051; 0.528)	3 (2; 20)	289 (51; 528)
	45	Patients with ≥1 AE	34/42	12/24	1.62 (1.06; 2.48)	0.310 (0.077; 0.542)	3 (2; 13)	310 (77; 542)
	20	Patients with ≥1 AE*	30/38	12/24	1.58 (1.02; 2.43)	0.289 (0.051; 0.528)	3 (2; 20)	289 (51; 528)
	45	Patients with ≥1 AE*	34/42	12/24	1.62 (1.06; 2.48)	0.310 (0.077; 0.542)	3 (2; 13)	310 (77; 542)
	45	Abnormal vision	14/42	0/24	16.86 (1.05; 270.62)	0.333 (0.182; 0.485)	3 (2; 6)	333 (182; 485)
	20	Abnormal vision	9/38	0/24	12.18 (0.74; 200.11)	0.237 (0.091; 0.382)	4 (3; 11)	237 (91; 382)
	20	Abnormal vision*	9/38	0/24	12.18 (0.74; 200.11)	0.237 (0.091; 0.382)	4 (3; 11)	237 (91; 382)
	45	Abnormal vision*	14/42	0/24	16.86 (1.05; 270.62)	0.333 (0.182; 0.485)	3 (2; 6)	333 (182; 485)
	20	Constipation	6/38	0/24	8.33 (0.49; 141.53)	0.158 (0.029; 0.287)	6 (3; 35)	158 (29; 287)
	45	Constipation	10/42	0/24	12.21 (0.75; 199.55)	0.238 (0.098; 0.378)	4 (3; 10)	238 (98; 378)
	20	Constipation*	6/38	0/24	8.33 (0.49; 141.53)	0.158 (0.029; 0.287)	6 (3; 35)	158 (29; 287)
	45	Constipation*	10/42	0/24	12.21 (0.75; 199.55)	0.238 (0.098; 0.378)	4 (3; 10)	238 (98; 378)
	20	Dry mouth	13/38	4/24	2.05 (0.76; 5.56)	0.175 (-0.037; 0.388)		
	45	Dry mouth	22/42	4/24	3.14 (1.23; 8.05)	0.357 (0.145; 0.569)	3 (2; 7)	357 (145; 569)
	20	Dry mouth*	13/38	4/24	2.05 (0.76; 5.56)	0.175 (-0.037; 0.388)		
	45	Dry mouth*	22/42	4/24	3.14 (1.23; 8.05)	0.357 (0.145; 0.569)	3 (2; 7)	357 (145; 569)

Appendix Table F55. Significant dose response effects of fesoterodine (continued)

Reference	Dose, mg/day	Outcome	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
	20	Headache	1/38	0/24	1.92 (0.08; 45.37)	0.026 (-0.055; 0.108)		
	45	Headache	3/42	0/24	4.07 (0.22; 75.60)	0.071 (-0.027; 0.170)		
	20	Headache*	1/38	0/24	1.92 (0.08; 45.37)	0.026 (-0.055; 0.108)		
	45	Headache*	3/42	0/24	4.07 (0.22; 75.60)	0.071 (-0.027; 0.170)		

* at followup

Appendix Table F65. Clinical outcomes after botulinum toxin vs. placebo, individual RCTs

Reference sample	Dose	Outcome	Active n/N	Control n/N	Relative risk	Lower 95% CI	Upper 95% CI	Absolute risk difference	Lower 95% CI	Upper 95% CI	Number needed to treat	Attributable events/1000 treated
Brubaker, 2008 ²³³ 84	200U-single dose	>75% decreased number of incontinence episodes	18/28	0/15	20.41	1.32	316.75	0.643	0.448	0.837	2	643
Brubaker, 2008 ²³³ 84	200U-single dose	Serious adverse events	3/28	2/15	0.80	0.15	4.29	-0.026	-0.233	0.180		
Brubaker, 2008 ²³³ 84	200U-single dose	Unexpected adverse events	6/28	0/15	7.17	0.43	119.24	0.214	0.040	0.388	5	214
Brubaker, 2008 ²³³ 84	200U-single dose	Treatment failure	6/28	11/15	0.29	0.14	0.63	-0.519	-0.790	-0.249	-2	-519
Brubaker, 2008 ²³³ 84	200U-single dose	Urinary tract infection	12/28	3/15	2.14	0.71	6.43	0.229	-0.045	0.502		
Brubaker, 2008 ²³³ 84	200U-single dose	Increase in post-void residual volume	12/28	0/15	13.79	0.87	217.93	0.429	0.229	0.628	2	429
Brubaker, 2008 ²³³ 84	200U-single dose	Urinary tract infection without increased PVR	3/28	3/15	0.54	0.12	2.34	-0.093	-0.325	0.140		

Appendix Table F66. Quality of life after botulinum toxin vs. placebo, individual RCTs

Reference	Dose	Outcome	Active N	Control N	Active mean+/- standard deviation	Control mean+/- standard deviation	Mean difference	Lower 95% CI	Upper 95% CI
Ghei, 2005 ²⁸⁸	5000IU	KHQ score: emotional problems	10	10	5.3+/-2.02	7.0+/-2.42	-1.75	-3.70	0.20
Ghei, 2005 ²⁸⁸	5000IU	KHQ score: impact on life	10	10	1.5+/-0.81	2.5+/-0.81	-1	-1.71	-0.29
Ghei, 2005 ²⁸⁸	5000IU	KHQ score: incontinence impact	10	10	4.5+/-3.23	7.0+/-4.03	-2.5	-5.70	0.70
Ghei, 2005 ²⁸⁸	5000IU	KHQ score: incontinence severity measures	10	10	8.5+/-3.23	12.0+/-4.03	-3.5	-6.70	-0.30
Ghei, 2005 ²⁸⁸	5000IU	KHQ score: personal relationships	10	10	2.0+/-4.03	3.5+/-3.23	-1.5	-4.70	1.70
Ghei, 2005 ²⁸⁸	5000IU	KHQ score: physical/social limitations	10	10	5.0+/-2.42	7.5+/-4.03	-2.5	-5.42	0.42
Ghei, 2005 ²⁸⁸	5000IU	KHQ score: present health	10	10	1.0+/-0.81	1.5+/-0.81	-0.5	-1.21	0.21
Ghei, 2005 ²⁸⁸	5000IU	KHQ score: role limitations	10	10	2.5+/-1.61	3.5+/-1.61	-1	-2.41	0.41
Ghei, 2005 ²⁸⁸	5000IU	KHQ score: sleep/energy disturbances	10	10	3.5+/-1.61	5.0+/-0.81	-1.5	-2.62	-0.38

Appendix Table F67. Outcomes after intravesical 100ml of 50nM-single dose injection of resiniferatoxin vs. placebo, individual RCTs

Reference	Active N	Control N	Outcome	Active mean+/- standard deviation	Control mean+/- standard deviation	Mean difference	Lower 95% CI	Upper 95% CI
Rios, 2007 ³⁶²	34	24	General health perception	35.3+/-13.92	44.8+/-23.29	-9.50	-19.93	0.93
Rios, 2007 ³⁶²	34	24	Incontinence impact	61.8+/-33.97	66.7+/-36.78	-4.90	-23.53	13.73
Rios, 2007 ³⁶²	34	24	Role limitations	50.5+/-35.65	51.5+/-35.86	-0.96	-19.65	17.73
Rios, 2007 ³⁶²	34	24	Physical limitations	47.1+/-37.03	46.5+/-38.06	0.53	-19.14	20.20
Rios, 2007 ³⁶²	34	24	Social limitations	24.2+/-29.27	37.9+/-30.83	-13.74	-29.52	2.04
Rios, 2007 ³⁶²	34	24	Personal relationships	32.7+/-45.77	35.4+/-39.85	-2.75	-24.91	19.41
Rios, 2007 ³⁶²	34	24	Emotions	44.4+/-36.60	54.6+/-35.12	-10.19	-28.87	8.49
Rios, 2007 ³⁶²	34	24	Sleep and energy	28.9+/-23.68	38.2+/-31.27	-9.28	-24.11	5.55
Rios, 2007 ³⁶²	34	24	Symptom severity	15.5+/-10.05	10.1+/-10.98	5.39	-0.15	10.93
Reference	Active N	Control N	Outcome	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	
Rios, 2007 ³⁶²	34	24	Hypogastric pain	12/34	4/24	2.12 (0.78;5.78)	0.19 (-0.03;0.41)	
Rios, 2007 ³⁶²	34	24	Dysuria	15/34	6/24	1.76 (0.80;3.89)	0.19 (-0.05;0.43)	
Rios, 2007 ³⁶²	34	24	Minor hematuria	1/34	3/24	0.24 (0.03;2.13)	-0.10 (-0.24;0.05)	

Appendix Table F68. Outcomes after nimodipine, 60mg/day, vs. placebo, individual RCT

Reference	Active N	Control N	Outcome	Active mean+/- standard deviation	Control mean+/- standard deviation	Mean difference	Lower 95% CI	Upper 95% CI
Naglie, 2002 ³⁵²	42	44	Mean IIQ scores(lower better)	15.0+/-13.29	19.4+/-14.82	-4.38	-10.69	1.93
Naglie, 2002 ³⁵²	42	44	AUA symptom scores (lower better)	11.4+/-5.62	13.8+/-6.46	-2.31	-6.26	1.64
Naglie, 2002 ³⁵²	42	44	Incontinent episodes	11.0+/-10.75	18.7+/-20.29	-7.71	-14.56	-0.86
Reference	Active N	Control N	Outcome	Active n/N	Control n/N	Relative Risk (95% CI)	Absolute Risk Difference (95% CI)	
Naglie, 2002 ³⁵²	42	44	Withdrawals	6/42	4/44	1.57(0.48;5.18)	0.05(-0.08;0.19)	

Appendix Table F69. Comparative effectiveness of local estrogen therapy

Active	Control	Reference studies	Subjects	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)	Evidence
Continence								
Estradiol-releasing ring, 7.5mg/day	Estradiol pessaries 0.5 mg every second day	1 ³³⁸	251	Urgency 77.79 (4.84; 1249.40)	0.33 (0.25; 0.41)	3 (2; 4)	328 (248; 409)	Insufficient
Estradiol-releasing ring, 7.5mg/day	Estradiol pessaries 0.5 mg every second day	1 ³³⁸	251	Stress 0.84 (0.61; 1.15)	-0.07 (-0.19; 0.05)			Insufficient
Improved incontinence								
Estradiol-releasing vaginal ring	Estradiol pessary	1 ³³⁸	232	2.69 (1.60; 4.50)	0.26 (0.15; 0.37)	4 (3; 6)	262 (155; 369)	Insufficient

Appendix Table F70. Comparative effectiveness of estrogen topical treatments (individual RCTs)

Reference Sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Continence										
Chompoota weep, 1998 ²⁶² 22/0	Combined contraceptive Intravaginal 1 pill/week at bedtime with 250 mg levonorgestrel +30 microg ethinyl estradiol	Intravaginal conjugated estrogen cream (1g=0.625 mg conjugated equine estrogens) at bedtime	No urinary urgency	10/10	9/85	9/85	1.00 (0.67; 1.48)	0.00 (-0.32; 0.32)		
Lose, 2000 ³³⁸ 251/0	Estradiol-releasing ring, 7.5 mg estradiol	Estradiol pessaries 0.5 mg every second day	No urgency incontinence	134/117	44/33	0/34	77.79 (4.84; 1249.40)	0.33 (0.25; 0.41)	3 (2; 4)	328 (248; 409)
Lose, 2000 ³³⁸ 251/0	Estradiol-releasing ring, 7.5 mg estradiol	Estradiol pessaries 0.5 mg every second day	No stress incontinence	134/117	46/34	48/41	0.84 (0.61; 1.15)	-0.07 (-0.19; 0.05)		
Improved incontinence										
Lose, 2000 ³³⁸ 232/0	Estradiol-releasing vaginal ring	Estradiol pessary	Treatment perception: good	110/101	30/27	34/34	0.80 (0.52; 1.21)	-0.06 (-0.18; 0.05)		
Lose, 2000 ³³⁸ 232/0	Estradiol-releasing vaginal ring	Estradiol Pessary	Treatment perception: excellent	110/101	66/60	14/14	2.69 (1.60; 4.50)	0.26 (0.15; 0.37)	4 (3; 6)	262 (155;369)
Lose, 2000 ³³⁸ 232/0	Estradiol-releasing vaginal ring	Estradiol Pessary	Treatment perception: bad	110/101	2/2	3/3	0.61 (0.10; .59)	-0.01 (-0.05; 0.03)		
Lose, 2000 ³³⁸ 232/0	Estradiol-releasing vaginal ring	Estradiol Pessary	Treatment perception: unacceptable	110/101	3/3	2/2	1.38 (0.23; 8.08)	0.01 (-0.03; 0.05)		

Appendix Table F71. Adverse effects of pharmacological treatments for UI when compared to each other

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Chapple, 2005 ²⁵²	Darifenacin IR	2.5 t.i.d.	Oxybutynin IR	2.5 t.i.d.	5/8	8/8	0.6(0.4; 1.1)	-0.38 (-0.73; -0.02)
Abrams, 1998 ²¹⁹	Tolterodine	2mg twice daily	Oxybutynin	5mg thrice daily	105/118	114/118	0.9 (0.9; 1.0)	-0.08 (-0.14; -0.01)
Madersbacher, 1999 ³⁴³	Propiverine	15mg thrice daily	Oxybutynin	5mg twice daily	95/149	104/145	0.9 (0.8; 1.0)	-0.08 (-0.19; 0.03)
Drutz, 1999 ²⁷⁹	Oxybutynin	5mg thrice a day	Tolterodine	2mg twice a day	101/112	85/109	1.2(1.0; 1.3)	0.12 (0.03; 0.22)
Lee, 2002 ³³²	Oxybutynin	5mg twice daily	Tolterodine	2mg twice daily	94/116	62/112	1.5(1.2; 1.8)	0.26 (0.14; 0.37)
Leung, 2002 ³³⁵	Oxybutynin	5mg twice daily	Tolterodine	2mg twice daily	26/53	32/53	0.8(0.6; 1.2)	-0.11 (-0.30; 0.08)
Halaska, 2003 ²⁹⁸	Trospium	40mg/day	Oxybutynin	10mg/day	103/267	46/90	0.8(0.6; 1.0)	-0.13 (-0.24; -0.01)
Halaska, 2003 ²⁹⁸	Trospium	20mg twice daily	Oxybutynin	5mg twice daily	173/267	69/90	0.8(0.7; 1.0)	-0.12 (-0.22; -0.01)
Dmochowski, 2003 ²⁷⁴	Oxybutynin	3.9mg/day	Tolterodine LA	4mg/day	23/121	29/123	0.8(0.5; 1.3)	-0.05 (-0.15; 0.06)
Homma, 2003 ³⁰⁷	Oxybutynin	3mg thrice daily	Tolterodine ER	4mg/day	42/244	12/239	3.4(1.9; 6.3)	0.12 (0.07; 0.18)
Chapple, 2004 ²⁶⁰	Solifenacin	20mg once daily	Tolterodine	2mg twice daily	21/37	12/37	1.8(1.0; 3.0)	0.24 (0.02; 0.46)
Chapple, 2004 ²⁶⁰	Solifenacin	2.5mg once daily	Tolterodine	2mg twice daily	6/41	12/37	0.5(0.2; 1.1)	-0.18 (-0.36; 0.01)
Chapple, 2004 ²⁶⁰	Solifenacin	5mg once daily	Tolterodine	2mg twice daily	12/37	12/37	1.0(0.5; 1.9)	0.00 (-0.21; 0.21)
Chapple, 2004 ²⁶⁰	Solifenacin	10mg once daily	Tolterodine	2mg twice daily	12/35	12/37	1.1(0.6; 2.0)	0.02 (-0.20; 0.24)
Junemann, 2005 ³¹⁷	Propiverine	15mg twice daily	Tolterodine	2mg twice daily	42/100	43/101	1.0(0.7; 1.4)	-0.01 (-0.14; 0.13)
Armstrong, 2007 ²²⁵	Oxybutynin	10mg qd	Tolterodine ER	4mg qd	404/576	254/399	1.1(1.0; 1.2)	0.06 (0.00; 0.12)

Appendix Table F71. Adverse effects of pharmacological treatments for UI when compared to each other (continued)

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Chapple, 2007 ²⁵³	Tolterodine	4mg daily	Fesoterodine	8mg daily	144/290	167/288	0.9(0.7; 1.0)	-0.08 (-0.16; 0.00)
Chapple, 2007 ²⁵³	Tolterodine	4mg daily	Fesoterodine	4mg daily	144/290	135/272	1.0(0.8; 1.2)	0.00 (-0.08; 0.08)
Herschorn, 2010 ³⁰⁰	Solifenacin	5mg once daily	Oxybutynin IR	5mg 3 times daily	49/68	59/64	0.8(0.7; 0.9)	-0.20 (-0.33; -0.08)
Junemann, 2000 ³¹⁶	Trospium	20mg twice daily	Tolterodine	2mg twice daily	26/76	25/77	1.1(0.7; 1.6)	0.02 (-0.13; 0.17)
U.S. Food and Drug Administration ²⁵⁷	Solifenacin	5mg once daily/5mg twice daily	Tolterodine ER	4mg once daily	282/593	265/607	1.1(1.0; 1.2)	0.04 (-0.02; 0.10)
NCT00444925 ⁵⁶	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	290/685	213/690	1.4(1.2; 1.6)	0.11 (0.06; 0.17)

Appendix Table F72. Dry mouth after pharmacological treatments for UI when compared to each other

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Zinner, 2005 ⁴⁰⁵	Darifenacin ER	15mg/day	Oxybutynin	5 mg 3 times/day	0/19	7/19	0.1(0.0; 1.1)	-0.37 (-0.59; -0.15)
Abrams, 1998 ²¹⁹	Oxybutynin	5mg thrice daily	Tolterodine	2mg twice daily	102/118	59/118	1.7(1.4; 2.1)	0.36 (0.26; 0.47)
Drutz, 1999 ²⁷⁹	Oxybutynin	5mg thrice a day	Tolterodine	2mg twice a day	77/112	33/109	2.3(1.7; 3.1)	0.38 (0.26; 0.51)
Appell, 2001 ²²³	Oxybutynin	10mg/day	Tolterodine LA	2mg twice daily	52/185	64/193	0.8(0.6; 1.2)	-0.05 (-0.14; 0.04)
Lee, 2002 ³³²	Oxybutynin	5mg twice daily	Tolterodine	2mg twice daily	72/116	39/112	1.8(1.3; 2.4)	0.27 (0.15; 0.40)
Halaska, 2003 ²⁹⁸	Trospium	40mg/day	Oxybutynin	10mg/day	87/267	45/90	0.7(0.5; 0.9)	-0.17 (-0.29; -0.06)
Halaska, 2003 ²⁹⁸	Trospium	20mg twice daily	Oxybutynin	5mg twice daily	87/267	45/90	0.7(0.5; 0.9)	-0.17 (-0.29; -0.06)
Diokno, 2003 ²²⁷	Oxybutynin	10mg/d	Tolterodine ER	4mg/d	116/391	89/399	1.3(1.0; 1.7)	0.07 (0.01; 0.13)
Homma, 2003 ³⁰⁷	Oxybutynin	3mg thrice daily	Tolterodine ER	4mg/day	131/244	80/239	1.6(1.3; 2.0)	0.20 (0.12; 0.29)
Chapple, 2004 ²⁶⁰	Solifenacin	2.5mg once daily	Tolterodine	2mg twice daily	0/41	9/37	0.0(0.0; 0.8)	-0.24 (-0.38; -0.10)
Chapple, 2004 ²⁶⁰	Solifenacin	5mg once daily	Tolterodine	2mg twice daily	5/37	9/37	0.6(0.2; 1.5)	-0.11 (-0.28; 0.07)
Chapple, 2004 ²⁶⁰	Solifenacin	10mg once daily	Tolterodine	2mg twice daily	5/35	9/37	0.6(0.2; 1.6)	-0.10 (-0.28; 0.08)
Chapple, 2004 ²⁶⁰	Solifenacin	20mg once daily	Tolterodine	2mg twice daily	14/37	9/37	1.6(0.8; 3.1)	0.14 (-0.07; 0.34)
Chapple, 2004 ⁵²	Solifenacin	5mg daily	Tolterodine	2mg twice daily	39/279	49/266	0.8(0.5; 1.1)	-0.04 (-0.11; 0.02)
Chapple, 2004 ⁵²	Solifenacin	10mg daily	Tolterodine	2mg twice daily	57/269	49/266	1.2(0.8; 1.6)	0.03 (-0.04; 0.10)
Homma, 2004 ³⁰⁶	Oxybutynin	3mg thrice daily	Tolterodine ER	4mg/day	75/122	42/114	1.7(1.3; 2.2)	0.25 (0.12; 0.37)


Appendix Table F72. Dry mouth after pharmacological treatments for UI when compared to each other (continued)

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Sand, 2004 ²²⁶	Oxybutynin	10mg/day	Tolterodine	2mg b.i.d.	43/152	55/163	0.8(0.6; 1.2)	-0.05 (-0.16; 0.05)
Chapple, 2005 ²⁵²	Darifenacin IR	2.5 t.i.d.	Oxybutynin IR	2.5 t.i.d.	4/8	8/8	0.5(0.3; 1.0)	-0.50 (-0.86; -0.14)
Zinner, 2005 ⁴⁰⁵	Darifenacin ER	30mg/day	Oxybutynin	5 mg 3 times/day	7/19	7/19	1.0(0.4; 2.3)	0.00 (-0.31; 0.31)
Armstrong, 2005 ²²⁴	Oxybutynin	10mg/day	Tolterodine ER	4mg daily	110/391	86/399	1.3(1.0; 1.7)	0.07 (0.01; 0.13)
Armstrong, 2007 ²²⁵	Oxybutynin	10mg qd	Tolterodine ER	2mg qd	169/576	64/193	0.9(0.7; 1.1)	-0.04 (-0.11; 0.04)
Armstrong, 2007 ²²⁵	Oxybutynin	10mg qd	Tolterodine ER	4mg qd	169/576	89/399	1.3(1.1; 1.6)	0.07 (0.02; 0.13)
Chapple, 2007 ²⁵³	Solifenacin	5mg daily	Tolterodine	4mg daily	82/578	69/599	1.2(0.9; 1.7)	0.03 (-0.01; 0.06)
Chapple, 2007 ²⁵³	Fesoterodine	8mg daily	Tolterodine	4mg daily	97/288	49/290	2.0(1.5; 2.7)	0.17 (0.10; 0.24)
Chapple, 2007 ²⁵³	Fesoterodine	4mg daily	Tolterodine	4mg daily	59/272	49/290	1.3(0.9; 1.8)	0.05 (-0.02; 0.11)
Yamaguchi, 2007 ⁴⁰³	Solifenacin	5mg daily	Propiverine	20mg daily	67/400	103/402	0.7(0.5; 0.9)	-0.09 (-0.14; -0.03)
Yamaguchi, 2007 ⁴⁰³	Solifenacin	10mg daily	Propiverine	20mg daily	130/385	103/402	1.3(1.1; 1.6)	0.08 (0.02; 0.15)
Chapple, 2008 ²⁵⁴	Fesoterodine	8mg daily	Tolterodine	4mg daily	97/287	49/290	2.0(1.5; 2.7)	0.17 (0.10; 0.24)
Choo, 2008 ²⁶³	Solifenacin	5mg once daily	Tolterodine IR	2mg twice daily	9/120	22/118	0.4(0.2; 0.8)	-0.11 (-0.20; -0.03)
Choo, 2008 ²⁶³	Solifenacin	10mg once daily	Tolterodine IR	2mg twice daily	23/119	22/118	1.0(0.6; 1.8)	0.01 (-0.09; 0.11)
Sand, 2009 ³⁷⁰	Fesoterodine	8mg daily	Tolterodine	4mg daily	155/452	37/227	2.1(1.5; 2.9)	0.18 (0.11; 0.24)
Sand, 2009 ³⁷⁰	Fesoterodine	4mg daily	Tolterodine	4mg daily	89/434	37/227	1.3(0.9; 1.8)	0.04 (-0.02; 0.10)
Herschorn, 2010 ⁴⁷⁰	Fesoterodine	4-8mg once daily	Tolterodine ER	4mg once daily	189/679	112/684	1.7(1.4; 2.1)	0.11 (0.07; 0.16)

Appendix Table F72. Dry mouth after pharmacological treatments for UI when compared to each other (continued)

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Herschorn, 2010 ³⁰⁰	Solifenacin	5mg once daily	Oxybutynin IR	5mg 3 times daily	24/68	53/64	0.4(0.3; 0.6)	-0.48 (-0.62; -0.33)
Junemann, 2000 ³¹⁶	Tropium	20mg twice daily	Tolterodine	2mg twice daily	22/76	21/77	1.1(0.6; 1.8)	0.02 (-0.13; 0.16)
Kaplan, 2010 ³¹⁸	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 mg once daily	270/963	127/974	2.2(1.8; 2.6)	0.15 (0.11; 0.19)
NCT00444925 ^{5b}	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	189/685	112/690	1.7(1.4; 2.1)	0.11 (0.07; 0.16)

Appendix Figure F26. Gain in quality adjusted life years per 1,000 treated patients⁴⁷⁵



Appendix Table F73. Constipation after pharmacological treatments for UI when compared to each other

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Zinner, 2005 ⁴⁰⁵	Darifenacin ER	15mg/day	Oxybutynin	5 mg 3 times/day	2/19	2/19	1.0(0.2; 6.4)	0.00 (-0.20; 0.20)
Halaska, 2003 ²⁹⁸	Trospium	40mg/day	Oxybutynin	10mg/day	18/267	4/90	1.5(0.5; 4.4)	0.02 (-0.03; 0.08)
Halaska, 2003 ²⁹⁸	Trospium	20mg twice daily	Oxybutynin	5mg twice daily	18/267	4/90	1.5(0.5; 4.4)	0.02 (-0.03; 0.08)
Chapple, 2004 ²⁶⁰	Solifenacin	2.5mg once daily	Tolterodine	2mg twice daily	1/41	1/37	0.9(0.1; 13.9)	0.00 (-0.07; 0.07)
Chapple, 2004 ²⁶⁰	Solifenacin	5mg once daily	Tolterodine	2mg twice daily	5/37	1/37	5.0(0.6; 40.8)	0.11 (-0.01; 0.23)
Chapple, 2004 ²⁶⁰	Solifenacin	10mg once daily	Tolterodine	2mg twice daily	2/35	1/37	2.1(0.2; 22.3)	0.03 (-0.06; 0.12)
Chapple, 2004 ²⁶⁰	Solifenacin	20mg once daily	Tolterodine	2mg twice daily	6/37	1/37	6.0(0.8; 47.4)	0.14 (0.01; 0.26)
Chapple, 2004 ⁵²	Solifenacin	5mg daily	Tolterodine	2mg twice daily	20/279	7/266	2.7(1.2; 6.3)	0.05 (0.01; 0.08)
Chapple, 2004 ⁵²	Solifenacin	10mg daily	Tolterodine	2mg twice daily	21/269	7/266	3.0(1.3; 6.9)	0.05 (0.01; 0.09)
Chapple, 2005 ²⁵²	Darifenacin ER	15mg daily	Oxybutynin IR	5mg t.i.d.	8/12	6/12	1.3(0.7; 2.7)	0.17 (-0.22; 0.56)
Chapple, 2005 ²⁵²	Darifenacin ER	30mg daily	Oxybutynin IR	5mg t.i.d.	10/13	2/12	4.6(1.3; 16.9)	0.60 (0.29; 0.91)
Chapple, 2005 ²⁵²	Darifenacin IR	2.5 t.i.d.	Oxybutynin IR	2.5mg t.i.d.	1/8	1/8	1.0(0.1; 13.4)	0.00 (-0.32; 0.32)
Chapple, 2005 ⁵⁸	Solifenacin	5-10mg od	Tolterodine	4mg once daily	3/578	1/599	3.1(0.3; 29.8)	0.00 (0.00; 0.01)
Zinner, 2005 ⁴⁰⁵	Darifenacin ER	30mg/day	Oxybutynin	5 mg 3 times/day	4/19	2/19	2.0(0.4; 9.6)	0.11 (-0.12; 0.33)
Armstrong, 2007 ²²⁵	Oxybutynin	10mg qd	Tolterodine ER	4mg qd	38/576	31/399	0.8(0.5; 1.3)	-0.01 (-0.04; 0.02)
Armstrong, 2007 ²²⁵	Oxybutynin	10mg qd	Tolterodine ER	2mg qd	38/576	12/193	1.1(0.6; 2.0)	0.00 (-0.04; 0.04)
Chapple, 2007 ²⁵⁸	Solifenacin	5mg daily	Tolterodine	4mg daily	12/578	7/599	1.8(0.7; 4.5)	0.01 (-0.01; 0.02)
Chapple, 2007 ²⁵³	Tolterodine	4mg daily	Fesoterodine	8mg daily	8/290	13/288	0.6(0.3; 1.5)	-0.02 (-0.05; 0.01)
Chapple, 2007 ²⁵³	Tolterodine	4mg daily	Fesoterodine	4mg daily	8/290	9/272	0.8(0.3; 2.1)	-0.01 (-0.03; 0.02)

Appendix Table F73. Constipation after pharmacological treatments for UI when compared to each other (continued)

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Yamaguchi, 2007 ⁴⁰³	Solifenacin	5mg daily	Propiverine	20mg daily	42/400	45/402	0.9(0.6; 1.4)	-0.01 (-0.05; 0.04)
Yamaguchi, 2007 ⁴⁰³	Solifenacin	10mg daily	Propiverine	20mg daily	72/385	45/402	1.7(1.2; 2.4)	0.08 (0.03; 0.12)
Chapple, 2008 ²⁵⁴	Tolterodine	4mg daily	Fesoterodine	8mg daily	8/290	13/287	0.6(0.3; 1.4)	-0.02 (-0.05; 0.01)
Choo, 2008 ²⁶³	Solifenacin	5mg once daily	Tolterodine IR	2mg twice daily	8/120	3/118	2.6(0.7; 9.6)	0.04 (-0.01; 0.09)
Choo, 2008 ²⁶³	Solifenacin	10mg once daily	Tolterodine IR	2mg twice daily	17/119	3/118	5.6(1.7; 18.7)	0.12 (0.05; 0.19)
Sand, 2009 ³⁷⁰	Tolterodine	4mg daily	Fesoterodine	8mg daily	6/227	24/452	0.5(0.2; 1.2)	-0.03 (-0.06; 0.00)
Sand, 2009 ³⁷⁰	Tolterodine	4mg daily	Fesoterodine	4mg daily	6/227	20/434	0.6(0.2; 1.4)	-0.02 (-0.05; 0.01)
Zellner, 2009 ⁴⁰⁴	Trospium	15mg to 30mg thrice daily	Oxybutynin	2.5mg to 5mg thrice daily	10/828	1/830	0.1(0.0; 0.8)	0.01 (0.003; 0.02)
Herschorn, 2010 ⁴⁷⁰	Tolterodine ER	4mg once daily	Fesoterodine	4-8mg once daily	28/684	37/679	0.8(0.5; 1.2)	-0.01 (-0.04; 0.01)
Kaplan, 2010 ³¹⁸	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 mg once daily	270/963	29/974	9.4(6.5; 13.7)	0.25 (0.22; 0.28)
Milani, 1993 ³⁴⁸	Flavoxate	400mg t.i.d.	Oxybutynin	5mg t.i.d.	1/50	2/50	0.5(0.0; 5.3)	-0.02 (-0.09; 0.05)
NCT00444925 ⁵⁶	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	37/685	28/690	1.3(0.8; 2.1)	0.01 (-0.01; 0.04)

Appendix Table F74. Discontinuation due to adverse effects after pharmacological treatments for UI when compared to each other

Reference	Active drug	Dose	Control Drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Zinner, 2005 ⁴⁰⁵	Darifenacin ER	15mg/day	Oxybutynin	5 mg 3 times/day	0/19	4/19	0.1(0.0; 1.9)	-0.21 (-0.41; -0.02)
Appell, 1997 ²²²	Oxybutynin	5mg/day	Tolterodine	1mg/day	70/349	2/121	12.1(3.0; 48.7)	0.18 (0.14; 0.23)
Abrams, 1998 ²¹⁹	Tolterodine	2mg twice daily	Oxybutynin	5mg thrice daily	20/118	10/118	2.0(1.0; 4.1)	0.08 (0.00; 0.17)
Drutz, 1999 ²⁷⁹	Oxybutynin	5mg thrice a day	Tolterodine	2mg twice a day	23/112	7/109	3.2(1.4; 7.1)	0.14 (0.05; 0.23)
Appell, 2001 ²²³	Oxybutynin	10mg/day	Tolterodine LA	2mg twice daily	14/185	15/193	1.0(0.5; 2.0)	0.00 (-0.06; 0.05)
Lee, 2002 ³³²	Oxybutynin	5mg twice daily	Tolterodine	2mg twice daily	18/116	11/112	1.6(0.8; 3.2)	0.06 (-0.03; 0.14)
Halaska, 2003 ²⁹⁸	Tropium	20mg twice daily	Oxybutynin	5mg twice daily	10/267	6/90	0.6(0.2; 1.5)	-0.03 (-0.09; 0.03)
Diokno, 2003 ²²⁷	Oxybutynin	10mg/d	Tolterodine ER	4mg/d	20/391	19/399	1.1(0.6; 2.0)	0.00 (-0.03; 0.03)
Chapple, 2004 ⁵²	Solifenacin	5mg daily	Tolterodine	2mg twice daily	9/279	5/266	1.7(0.6; 5.1)	0.01 (-0.01; 0.04)
Chapple, 2004 ⁵²	Solifenacin	10mg daily	Tolterodine	2mg twice daily	7/269	5/266	1.4(0.4; 4.3)	0.01 (-0.02; 0.03)
Homma, 2004 ³⁰⁶	Oxybutynin	3mg thrice daily	Tolterodine ER	4mg/day	21/122	6/114	3.3(1.4; 7.8)	0.12 (0.04; 0.20)
Sand, 2004 ²²⁶	Oxybutynin	10mg/day	Tolterodine	2mg b.i.d.	11/152	12/163	1.0(0.4; 2.2)	0.00 (-0.06; 0.06)
Chapple, 2005 ²⁵²	Darifenacin ER	15mg daily	Oxybutynin IR	5mg t.i.d.	1/12	0/12	3.0(0.1; 67.1)	0.08 (-0.12; 0.29)
Chapple, 2005 ²⁵²	Darifenacin ER	30mg daily	Oxybutynin IR	5mg t.i.d.	1/13	2/12	0.5(0.0; 4.5)	-0.09 (-0.35; 0.17)
Chapple, 2005 ²⁵²	Darifenacin IR	2.5mg t.i.d.	Oxybutynin IR	2.5 t.i.d.	0/8	1/8	0.3(0.0; 7.1)	-0.13 (-0.41; 0.16)
Zinner, 2005 ⁴⁰⁵	Darifenacin ER	30mg/day	Oxybutynin	5 mg 3 times/day	1/19	4/19	0.3(0.0; 2.0)	-0.16 (-0.37; 0.05)
Armstrong, 2005 ²²⁴	Oxybutynin	10mg/day	Tolterodine ER	4mg daily	20/391	19/399	1.1(0.6; 2.0)	0.00 (-0.03; 0.03)
Armstrong, 2007 ²²⁵	Oxybutynin	10mg qd	Tolterodine ER	2mg qd	155/576	61/193	0.9(0.7; 1.1)	-0.05 (-0.12; 0.03)
Armstrong, 2007 ²²⁵	Oxybutynin	10mg qd	Tolterodine IR	2mg bid	35/576	15/193	0.8(0.4; 1.4)	-0.02 (-0.06; 0.03)
Chapple, 2007 ²⁵⁸	Solifenacin	5mg daily	Tolterodine	4mg daily	4/578	7/599	0.6(0.2; 2.0)	0.00 (-0.02; 0.01)
Chapple, 2007 ²⁵³	Tolterodine	4mg daily	Fesoterodine	8mg daily	14/288	9/290	1.6(0.7; 3.6)	0.02 (-0.01; 0.05)
Chapple, 2007 ²⁵³	Tolterodine	4mg daily	Fesoterodine	4mg daily	7/272	9/290	0.8(0.3; 2.2)	-0.01 (-0.03; 0.02)

Appendix Table F74. Discontinuation due to adverse effects after pharmacological treatments for UI when compared to each other (continued)

Reference	Active drug	Dose	Control Drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Yamaguchi, 2007 ⁴⁰³	Solifenacin	5mg daily	Propiverine	20mg daily	20/400	26/402	0.8(0.4; 1.4)	-0.01 (-0.05; 0.02)
Yamaguchi, 2007 ⁴⁰³	Solifenacin	10mg daily	Propiverine	20mg daily	26/385	26/402	1.0(0.6; 1.8)	0.00 (-0.03; 0.04)
Choo, 2008 ²⁶³	Solifenacin	5mg once daily	Tolterodine IR	2mg twice daily	5/120	2/118	2.5(0.5; 12.4)	0.02 (-0.02; 0.07)
Choo, 2008 ²⁶³	Solifenacin	10mg once daily	Tolterodine IR	2mg twice daily	7/119	2/118	3.5(0.7; 16.4)	0.04 (-0.01; 0.09)
Zellner, 2009 ⁴⁰⁴	Trospium	15mg to 30mg thrice daily	Oxybutynin	2.5mg to 5mg thrice daily	47/828	61/830	1.3(0.9; 1.9)	-0.017 (-0.04; 0.007)
Herschorn, 2010 ⁴⁷⁰	Tolterodine ER	4mg once daily	Fesoterodine	4-8mg once daily	44/679	28/684	1.6(1.0; 2.5)	0.02 (0.00; 0.05)
Herschorn, 2010 ³⁰⁰	Solifenacin	5mg once daily	Oxybutynin IR	5mg 3 times daily	7/68	7/64	0.9(0.3; 2.5)	-0.01 (-0.11; 0.10)
U.S. Food and Drug Administration ²⁵⁷	Solifenacin	5mg once daily/5mg twice daily	Tolterodine ER	4mg once daily	25/593	23/607	1.1(0.6; 1.9)	0.00 (-0.02; 0.03)
Kaplan, 2010 ³¹⁸	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 mg once daily	48/963	29/974	1.7(1.1; 2.6)	0.02 (0.00; 0.04)
But, 2010 ²⁴³	Solifenacin	Not reported	Darifenacin	Not reported	8/40	8/37	0.9(0.4; 2.2)	-0.02 (-0.20; 0.17)
NCT00444925 ⁵⁶	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	44/685	28/690	1.6(1.0; 2.5)	0.02 (0.00; 0.05)

Appendix Table F75. Comparative effectiveness of drugs on continence

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Kaplan, 2010 ³¹⁸	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 mg once daily	609/963	566/974	1.1(1.0; 1.2)	0.05 (0.01; 0.09)
NCT00444925 ⁵⁶	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	396/685	358/690	1.1(1.0; 1.2)	0.06 (0.01; 0.11)
Milani, 1993 ³⁴⁸	Flavoxate	1200	Oxybutynin	5mg t.i.d.	14/50	21/50	0.7(0.4; 1.2)	-0.14 (-0.32; 0.04)
Diokno, 2003 ²²⁷	Oxybutynin	10mg/d	Tolterodine	4mg/day	90/391	67/399	1.4(1.0; 1.8)	0.06 (0.01; 0.12)
Chapple, 2005 ⁵⁸	Solifenacin	5-10mg od	Tolterodine	4mg once daily	341/578	294/599	1.2(1.1; 1.3)	0.10 (0.04; 0.16)
Halaska, 2003 ²⁹⁸	Trospium	20mg twice daily	Oxybutynin	5mg twice daily	60/267	11/90	1.8(1.0; 3.3)	0.10 (0.02; 0.19)

Appendix Table F76. Comparative effectiveness of oxybutynin vs. tolterodine (secondary data analyses using individual patient data from RCTs)

Outcomes	Reference	Oxybutynin dose	Tolterodine dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable effects/1000 treated (95% CI)
Improved perceptions of the bladder condition	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	175/349	246/474	0.96 (0.84; 1.10)	-0.02 (-0.09; 0.05)		
Zero episodes of dry mouth	Armstrong, 2005 ²²⁴	10mg/day	4mg daily	281/391	313/399	0.92 (0.85; 0.99)	-0.07 (-0.13; -0.01)	-15 (-176; -8)	-66 (-126; -6)
Adverse events	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	404/576	254/399	1.10 (1.01; 1.21)	0.07 (0.01; 0.13)	15 (8; 218)	65 (5; 125)
Adverse events	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	262/349	351/474	1.01 (0.94; 1.10)	0.01 (-0.05; 0.07)		
Serious adverse events	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	14/349	19/474	1.00 (0.51; 1.97)	0.00 (-0.03; 0.03)		
Serious adverse events	Appell, 1997 ²²²	5mg/day	2mg/day	14/349	19/474	1.00 (0.51; 1.97)	0.00 (-0.027; 0.027)		
Mild adverse events related to treatment	Armstrong, 2007 ²²⁵	10mg qd	2mg bid	217/576	81/193	0.90 (0.74; 1.09)	-0.043 (-0.12; 0.04)		
Moderate adverse events related to treatment	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	103/576	40/399	1.78 (1.27; 2.51)	0.08 (0.04; 0.12)	13 (8; 28)	79 (36; 122)
Moderate adverse events related to treatment	Armstrong, 2007 ²²⁵	10mg qd	2mg bid	103/576	35/193	0.99 (0.70; 1.40)	-0.00 (-0.07; 0.06)		
Severe adverse events related to treatment	Armstrong, 2007 ²²⁵	10mg qd	2mg bid	25/576	5/193	1.68 (0.65; 4.32)	0.02 (-0.01; 0.05)		
Severe adverse events related to treatment	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	25/576	6/399	2.89 (1.20; 6.97)	0.03 (0.01; 0.05)	35 (20; 127)	28 (8; 49)
Withdrawal	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	94/349	63/474	2.03 (1.52; 2.70)	0.14 (0.08; 0.19)		
Withdrawal	Armstrong, 2005 ²²⁴	10mg/day	4mg daily	52/391	42/399	1.26 (0.86; 1.85)	0.03 (-0.02; 0.07)		
Patients with at least one adverse event leading to study drug discontinuation	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	35/576	19/399	1.28 (0.74; 2.20)	0.01 (-0.02; 0.04)		
Patients with at least one adverse event leading to study drug discontinuation	Armstrong, 2007 ²²⁵	10mg qd	2mg bid	35/576	15/193	0.78 (0.44; 1.40)	-0.02 (-0.06; 0.03)		

Appendix Table F76. Comparative effectiveness of oxybutynin vs. tolterodine (secondary data analyses using individual patient data from RCTs) (continued)

Outcomes	Reference	Oxybutynin dose	Tolterodine dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable effects/1000 treated (95% CI)
Withdrawal due to adverse events	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	70/349	38/474	2.50 (1.73; 3.62)	0.12 (0.07; 0.17)	8 (6; 14)	120 (72; 169)
Withdrawal due to adverse events	Armstrong, 2005 ²²⁴	10mg/day	4mg daily	52/391	42/399	1.26 (0.86; 1.85)	0.03 (-0.02; 0.07)		
Withdrawal due to adverse events	Armstrong, 2005 ²²⁴	10mg/day	4mg daily	20/391	19/399	1.07 (0.58; 1.98)	0.00 (-0.03; 0.03)		
Withdrawal due to dry mouth	Armstrong, 2005 ²²⁴	10mg/day	4mg daily	110/391	86/399	1.31 (1.02; 1.67)	0.07 (0.01; 0.13)	15 (8; 176)	66 (6; 126)
Dose reduction in case of intolerance	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	112/349	43/474	3.54 (2.56; 4.89)	0.23 (0.18; 0.29)	4 (4; 6)	230 (175; 286)
Asthenia	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	17/576	0/399	24.26 (1.46; 402.30)	0.03 (0.02; 0.04)	34 (23; 66)	30 (15; 44)
Autonomic nervous system disorder	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	283/349	204/474	1.88 (1.68; 2.11)	0.38 (0.32; 0.44)	3 (2; 3)	381 (320; 441)
Autonomic nervous system disorder	Appell, 1997 ²²²	5mg/day	2mg/day	283/349	204/474	1.88 (1.68; 2.11)	0.38 (0.32; 0.44)	3 (2; 3)	381 (320; 441)
Autonomic nervous system disorder	Appell, 1997 ²²²	5mg/day	1mg/day	283/349	35/121	2.80 (2.11; 3.72)	0.52 (0.43; 0.61)	2 (2; 2)	52 (431; 612)
Discontinuation due to adverse effect on a body as a whole	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	155/576	85/399	1.26 (1.00; 1.59)	0.06 (0.01; 0.11)	18 (9; 507)	5 6(2; 110)
Gastrointestinal disorders	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	140/349	123/474	1.55 (1.27; 1.89)	0.14 (0.08; 0.21)	7 (5; 13)	142 (77; 206)
Dry mouth	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	169/576	92/399	1.27 (1.02; 1.58)	0.06 (0.01; 0.12)	16 (8; 138)	63 (7; 118)
Dry mouth	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	169/576	89/399	1.32 (1.05; 1.64)	0.07 (0.02; 0.13)	14 (8; 66)	70 (15; 126)
Dry mouth	Appell, 1997 ²²²	5mg/day	2mg/day	272/349	190/474	1.94 (1.72; 2.20)	0.379 (0.32; 0.44)	3 (2; 3)	379 (317; 440)
Dry mouth	Appell, 1997 ²²²	5mg/day	1mg/day	272/349	29/121	3.25 (2.36; 4.49)	0.54 (0.45; 0.63)	2 (2; 2)	540 (452; 627)
Dry mouth-onset at 1 month	Armstrong, 2005 ²²⁴	10mg/day	4mg daily	101/391	74/399	1.39 (1.07; 1.82)	0.07 (0.02; 0.13)	14 (8; 66)	73 (15; 131)
Dyspepsia	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	38/349	28/474	1.84 (1.15; 2.94)	0.05 (0.01; 0.09)	20 (11; 92)	50 (11; 89)
Gastrointestinal disorders	Appell, 1997 ²²²	5mg/day	1mg/day	140/349	27/121	1.80 (1.26; 2.57)	0.178 (0.09; 0.27)	6 (4; 11)	178 (88; 268)
Moderate or severe dry mouth	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	209/349	81/474	3.50 (2.82; 4.35)	0.428 (0.37; 0.49)	2 (2; 3)	428 (366; 490)

Appendix Table F76. Comparative effectiveness of oxybutynin vs. tolterodine (secondary data analyses using individual patient data from RCTs) (continued)

Outcomes	Reference	Oxybutynin dose	Tolterodine dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable effects/1000 treated (95% CI)
Nausea	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	14/576	0/399	20.10 (1.20; 336.04)	0.02 (0.01; 0.04)	41 (27; 90)	24 (11; 38)
Pain	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	22/576	0/399	31.20 (1.90; 512.77)	0.04 (0.02; 0.05)	26 (18; 45)	38 (22; 54)
Palpitations	Appell, 1997 ²²²	5mg three times daily	2mg twice daily	8/349	2/474	5.43 (1.16; 25.43)	0.02 (0.00; 0.04)	53 (28; 512)	19 (2; 35)
Rhinitis	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	10/576	0/399	14.56 (0.86; 247.72)	0.02 (0.01; 0.03)	58 (35; 169)	17 (6; 29)
Severe dry mouth	Appell, 1997 ²²²	5mg/day	2mg/day	209/349	81/474	3.50 (2.82; 4.35)	0.43 (0.37; 0.49)	2 (2; 3)	428 (366; 490)
Severe dry mouth	Appell, 1997 ²²²	5mg/day	1mg/day	209/349	5/121	14.49 (6.12; 34.33)	0.56 (0.50; 0.62)	2 (2; 2)	558 (495; 620)
Symptoms associated with urinary emptying	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	55/576	22/399	1.73 (1.07; 2.79)	0.04 (0.01; 0.07)	25 (14; 133)	40 (8; 73)
Urinary tract infection	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	30/576	0/399	42.29 (2.59; 689.54)	0.05 (0.03; 0.07)	19 (14; 30)	52 (34; 71)
Urogenital system adverse effects	Armstrong, 2007 ²²⁵	10mg qd	4mg qd	92/576	38/399	1.68 (1.18; 2.39)	0.06 (0.02; 0.11)	16 (9; 44)	64 (23; 106)

Appendix Table F77. Comparative effectiveness of drugs on improved UI

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Sand, 2009 ³⁷⁰	Fesoterodine	8mg daily	Tolterodine	4mg daily	291/452	140/227	1.0(0.9; 1.2)	0.03 (-0.05; 0.10)
Abrams, 1998 ²¹⁹	Oxybutynin	5mg thrice daily	Tolterodine	2mg twice daily	58/118	59/118	1 (0.8; 1.3)	-0.008 (-0.136; 0.119)
Madersbacher, 1999 ³⁴³	Propiverine	15mg thrice daily	Oxybutynin	5mg twice daily	124/149	115/145	1.0(0.9; 1.2)	0.04 (-0.05; 0.13)
Lee, 2002 ³³²	Oxybutynin	5mg twice daily	Tolterodine	2mg twice daily	53/116	50/112	1.0(0.8; 1.4)	0.01 (-0.12; 0.14)
Homma, 2003 ³⁰⁷	Oxybutynin	3mg thrice daily	Tolterodine ER	4mg/day	129/244	100/239	1.3(1.0; 1.5)	0.11 (0.02; 0.20)
Chapple, 2005 ⁵⁸	Solifenacin	5-10mg od	Tolterodine	4mg once daily	428/578	401/599	1.1(1.0; 1.2)	0.07 (0.02; 0.12)
Sand, 2009 ³⁷⁰	Fesoterodine	4mg daily	Tolterodine	4mg daily	251/434	140/227	0.9(0.8; 1.1)	-0.04 (-0.12; 0.04)
Zellner, 2009 ⁴⁰⁴	Trospium	15mg to 30mg thrice daily	Oxybutynin	2.5mg to 5mg thrice daily	368/828	374/830	1.0(0.9; 1.1)	-0.08 (-0.06; 0.04)
Herschorn, 2010 ⁴⁷⁰	Fesoterodine	4-8mg once daily	Tolterodine ER	4mg once daily	293/679	256/684	1.2(1.0; 1.3)	0.06 (0.01; 0.11)
Kaplan, 2010 ³¹⁸	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 mg once daily	709/963	654/974	1.1(0.9; 1.2)	0.02 (0.02; 0.11)
Milani, 1993 ³⁴⁸	Flavoxate	400mg ti.id.	Oxybutynin	5mg t.i.d.	17/50	9/50	1.9(0.9; 3.8)	0.16 (-0.01; 0.33)
NCT00444925 ⁵⁶	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	256/685	238/690	1.1(0.9; 1.2)	0.03 (-0.02; 0.08)

Appendix Table F78. Comparative effectiveness of tolterodine-ER 4mg/day vs. fesoterodine, evidence from secondary data analysis

Outcome	Reference	Dose of Fesoterodine, mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)	Evidence
Discontinued prematurely	Chapple, 2008 ²⁵⁴	8	9/290	14/287	0.64 (0.28; 1.45)	-0.018 (-0.050; 0.014)			Insufficient
Treatment response	Sand, 2009 ³⁷⁰	8	140/227	291/452	0.96 (0.85; 1.08)	-0.027 (-0.104; 0.050)			Low
		4	140/227	251/434	1.07 (0.94; 1.21)	0.038 (-0.040; 0.117)			Low
Back pain	Sand, 2009 ³⁷⁰	8	1/227	4/452	0.50 (0.06; 4.43)	-0.004 (-0.017; 0.008)			Low
		4	1/227	9/434	0.21 (0.03; 1.67)	-0.016 (-0.032; 0.000)			Low
Constipation	Chapple, 2008 ²⁵⁴	8	8/290	13/287	0.61 (0.26; 1.45)	-0.018 (-0.048; 0.013)			Insufficient
	Sand, 2009 ³⁷⁰	8	6/227	24/452	0.50 (0.21; 1.20)	-0.027 (-0.056; 0.003)			Low
		4	6/227	20/434	0.57 (0.23; 1.41)	-0.020 (-0.048; 0.009)			Low
Cough	Sand, 2009 ³⁷⁰	8	5/227	5/452	1.99 (0.58; 6.81)	0.011 (-0.010; 0.032)			Low
		4	5/227	7/434	1.37 (0.44; 4.25)	0.006 (-0.017; 0.028)			Low
Diarrhea	Sand, 2009 ³⁷⁰	8	3/227	6/452	1.00 (0.25; 3.94)	0.000 (-0.018; 0.018)			Low
		4	3/227	7/434	0.82 (0.21; 3.14)	-0.003 (-0.022; 0.016)			Low
Dizziness	Sand, 2009 ³⁷⁰	8	4/227	5/452	1.59 (0.43; 5.87)	0.007 (-0.013; 0.026)			Low
		4	4/227	4/434	1.91 (0.48; 7.57)	0.008 (-0.011; 0.028)			Low
Dry eye	Chapple, 2008 ²⁵⁴	8	1/290	12/287	0.08 (0.01; 0.63)	-0.038 (-0.062; -0.014)	-26 (-70; -16)	-38 (-62; -14)	Insufficient
	Sand, 2009 ³⁷⁰	8	1/227	10/452	0.20 (0.03; 1.55)	-0.018 (-0.034; -0.002)	-56 (-605; -30)	-18 (-34; -2)	Low
		4	1/227	6/434	0.32 (0.04; 2.63)	-0.009 (-0.023; 0.005)			Low

Appendix Table F78. Comparative effectiveness of tolterodine-ER 4mg/day vs. fesoterodine, evidence from secondary data analysis (continued)

Outcome	Reference	Dose of Fesoterodine, mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)	Evidence
Dry mouth	Chapple, 2008 ²⁵⁴ Sand, 2009 ³⁷⁰	8	49/290	97/287	0.50 (0.37; 0.68)	-0.169 (-0.239; -0.099)	-6 (-10; -4)	-169 (-239; -99)	Insufficient
		8	37/227	155/452	0.48 (0.34; 0.66)	-0.180 (-0.245; -0.115)	-6 (-9; -4)	-180 (-245; -115)	Low
		4	37/227	89/434	0.79 (0.56; 1.13)	-0.042 (-0.103; 0.019)			Low
Dry throat	Chapple, 2008 ²⁵⁴ Sand, 2009 ³⁷⁰	8	3/290	8/287	0.37 (0.10; 1.38)	-0.018 (-0.040; 0.005)			Insufficient
		8	2/227	10/452	0.40 (0.09; 1.80)	-0.013 (-0.032; 0.005)			Low
		4	2/227	4/434	0.96 (0.18; 5.18)	0.000 (-0.016; 0.015)			Low
Fatigue	Chapple, 2008 ²⁵⁴ Sand, 2009 ³⁷⁰	8	10/290	1/287	9.90 (1.28; 76.81)	0.031 (0.009; 0.053)	32 (19;112)	31 (9; 53)	Insufficient
		8	7/227	1/452	13.94 (1.73; 112.60)	0.029 (0.006; 0.052)	35 (19; 175)	29 (6; 52)	Low
		4	7/227	5/434	2.68 (0.86; 8.34)	0.019 (-0.005; 0.044)			Low
Headache	Sand, 2009 ³⁷⁰	8	13/227	13/452	1.99 (0.94; 4.22)	0.029 (-0.005; 0.062)			Low
		4	13/227	21/434	1.18 (0.60; 2.32)	0.009 (-0.027; 0.045)			Low
Increased alanine aminotransferase	Chapple, 2008 ²⁵⁴	8	0/290	6/287	0.08 (0.00; 1.35)	-0.021 (-0.039; -0.003)	-48 (-232; -26)	-21 (-39; -3)	Insufficient
Nasopharyngitis	Chapple, 2008 ²⁵⁴ Sand, 2009 ³⁷⁰	8	10/290	5/287	1.98 (0.69; 5.72)	0.017 (-0.009; 0.043)			Insufficient
		8	8/227	6/452	2.65 (0.93; 7.56)	0.022 (-0.004; 0.048)			Low
		4	8/227	14/434	1.09 (0.47; 2.57)	0.003 (-0.026; 0.032)			Low
Nausea	Sand, 2009 ³⁷⁰	8	3/227	11/452	0.54 (0.15; 1.93)	-0.011 (-0.032; 0.009)			Low
		4	3/227	4/434	1.43 (0.32; 6.35)	0.004 (-0.013; 0.021)			Low
	Chapple, 2008 ²⁵⁴	8	6/290	4/287	1.48 (0.42; 5.21)	0.007 (-0.015; 0.028)			Insufficient

Appendix Table F78. Comparative effectiveness of tolterodine-ER 4mg/day vs. fesoterodine, evidence from secondary data analysis (continued)

Outcome	Reference	Dose of Fesoterodine, mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)	Evidence
URI	Sand, 2009 ³⁷⁰	8	2/227	8/452	0.50 (0.11; 2.32)	-0.009 (-0.026; 0.008)			Low
		4	2/227	12/434	0.32 (0.07; 1.41)	-0.019 (-0.038; 0.001)			Low
UTI	Sand, 2009 ³⁷⁰	8	4/227	24/452	0.33 (0.12; 0.94)	-0.035 (-0.062; -0.009)	-28 (-116; -16)	-35 (-62; -9)	Low
		4	4/227	18/434	0.42 (0.15; 1.24)	-0.024 (-0.049; 0.002)			Low

Appendix Table F79. Improvement in UI after pharmacological treatments for UI

Active	Dose	Control	Dose	Studies	Patients	Rate in active group	Rate in control group	Relative risk (95% CI)	Absolute risk difference (95%CI)	Number needed to treat (95% CI)	Evidence
Fesoterodine	4-8mg once daily	Tolterodine-ER	4mg daily	256, 318, 370, 470	2,703	50	43	1.1 (0.9; 1.2)	0.023 (-0.037; 0.083)		High
Oxybutynin	10mg daily	Tolterodine	4mg/day	3 ^{219, 307, 332}	947	50.3	44.7	1.11 (0.94; 1.31)	0.050 (-0.028; 0.128)		Moderate
Propiverine	15mg thrice daily	Oxybutynin	5mg twice daily	1 ³⁴³	294	83.0	79.0	1.05 (0.94; 1.17)	0.039 (-0.050; 0.128)		Insufficient
Solifenacin succinate	5-10mg once daily	Tolterodine	4mg once daily	1 ⁵⁸	1,177	74.0	67.0	1.11 (1.03; 1.19)	0.071 (0.019; 0.123)	14 (52; 8)	Insufficient
Flavoxate hydrochloride	1200	Oxybutynin	5mg t.i.d.	1 ³⁴⁸	100	34.0	18.0	1.89 (0.93; 3.83)	0.160 (-0.009; 0.329)		Insufficient
Tropium Chloride	15mg to 30mg thrice daily	Oxybutynin Hydrochloride	2.5mg to 5mg thrice daily	1 ⁴⁰⁴	1,658	51	64	0.8 (0.5; 1.1)	-0.017 (-0.04; 0.007)		Insufficient

Appendix Table F80. Blurred vision after pharmacological treatments for UI when compared to each other

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Zinner, 2005 ⁴⁰⁵	Darifenacin ER	15mg/day	Oxybutynin	5 mg 3 times/day	0/19	1/19	0.3(0.01; 7.7)	-0.05 (-0.19; 0.08)
Chapple, 2004 ²⁶⁰	Solifenacin	2.5mg once daily	Tolterodine	2mg twice daily	1/41	0/37	2.7(0.1; 64.6)	0.02 (-0.04; 0.09)
Chapple, 2004 ²⁶⁰	Solifenacin	5mg once daily	Tolterodine	2mg twice daily	1/37	0/37	3.0(0.1; 71.3)	0.03 (-0.04; 0.10)
Chapple, 2004 ²⁶⁰	Solifenacin	10mg once daily	Tolterodine	2mg twice daily	5/35	0/37	11.6(0.7; 202.5)	0.14 (0.02; 0.27)
Chapple, 2004 ²⁶⁰	Solifenacin	20mg once daily	Tolterodine	2mg twice daily	5/37	0/37	11.0(0.6; 192.1)	0.14 (0.02; 0.25)
Chapple, 2004 ⁵²	Solifenacin	5mg daily	Tolterodine	2mg twice daily	10/279	4/266	2.4(0.8; 7.5)	0.02 (-0.01; 0.05)
Chapple, 2004 ⁵²	Solifenacin	10mg daily	Tolterodine	2mg twice daily	15/269	4/266	3.7(1.2; 11.0)	0.04 (0.01; 0.07)
Zinner, 2005 ⁴⁰⁵	Darifenacin ER	30mg/day	Oxybutynin	5 mg 3 times/day	0/19	1/19	0.3(0.0; 7.7)	-0.05 (-0.19; 0.08)
Chapple, 2007 ²⁵⁸	Solifenacin	5mg daily	Tolterodine	4mg daily	1/578	7/599	0.1(0.0; 1.2)	-0.01 (-0.02; 0.00)
Yamaguchi, 2007 ⁴⁰³	Solifenacin	5mg daily	Propiverine	20mg daily	7/400	15/402	0.5(0.2; 1.1)	-0.02 (-0.04; 0.00)
Yamaguchi, 2007 ⁴⁰³	Solifenacin	10mg daily	Propiverine	20mg daily	16/385	15/402	1.1(0.6; 2.2)	0.00 (-0.02; 0.03)
Milani, 1993 ³⁴⁸	Flavoxate	400mg ti.id.	Oxybutynin	5mg t.i.d.	1/50	2/50	0.5(0.0; 5.3)	-0.02 (-0.09; 0.05)
NCT00444925 ⁵⁶	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	12/685	8/690	1.5(0.6; 3.7)	0.01 (-0.01; 0.02)
Armstrong, 2007 ²²⁵	Oxybutynin	10mg qd	Tolterodine ER	4mg qd	10/576	4/399	1.7(0.5; 5.5)	0.01 (-0.01; 0.02)

Bold = significant differences at 95% confidence level

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Aksac, 2003 ⁴⁷⁶ Country: Turkey Aim: The effects of pelvic floor muscle exercises or biofeedback on female urinary stress incontinence	Postmenopausal women with female urinary stress incontinence taking HRT	Not reported	Pelvic floor muscle exercise (contractions for 10 seconds and relaxation for 20 seconds, 10 times/session, 3 sessions/day) via digital palpation at home; pelvic floor muscle exercise (contractions for 10 seconds and relaxation for 20 seconds) via biofeedback	Usual care, hormone replacement therapy
Alewijnse, 2003 ⁴⁷⁷ Country: The Netherlands Aim: The effectiveness of pelvic muscle floor exercise therapy supplemented with a health education program urinary incontinence among women.	Community-dwelling women over 17 years old with urinary incontinence, ability to complete questionnaires in Dutch language.	Continence, neurological conditions, venereal disease, viral infections, using medication that may impact incontinence, pregnancy or 3 months after delivery, after surgical treatment for incontinence, and women with physical impairments. Severe prolapse	Bladder training with voiding frequency of ~7 voidings/day and pelvic floor muscle exercise: 10 slow twitch contractions (10-30 seconds) and 10 fast twitch contractions (2-3 seconds), 5 times/day, each contraction being followed by relaxation	Bladder training and pelvic floor muscle exercise
Amaro, 2005 ⁴⁷⁸ Country: Brazil Aim: The effect of intravaginal electrical stimulation on pelvic floor muscle strength in women with mixed urinary incontinence.	Women with mixed urinary incontinence and predominant urgency incontinence.	Anticholinergic and tricyclic antidepressant medications, pelvic floor exercise, bladder training, vaginal prolapse more than II grade, urinary tract infection, metal implants, and neurological diseases	Intravaginal electrical stimulation with 3 20-minute sessions/week using 4Hz frequency.	Sham stimulation with inactive device
Amaro, 2006 ⁴⁷⁹ Country: Brazil Aim: The effects of intravaginal electrical stimulation in mixed urinary incontinence	Women symptoms of predominant urgency incontinence not taking anticholinergics or tricyclic antidepressants	Use of pelvic floor exercises or bladder training, vaginal prolapse >grade II, retention complaint or obstruction diagnosis during UDS, urinary infection, changes in cutaneous sensitivity, metal implants, and neurological diseases.	Effective intravaginal electrical stimulation using frequency of 4 Hz with 3 20-minute sessions/week	Sham intravaginal electrical stimulation using frequency of 4Hz with 3 20-minute sessions/week

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Andersen, 2002 ⁴⁸⁰ Country: U.S. Aim: The long-term effectiveness of Durasphere vs. Contigen in the treatment of female stress urinary incontinence caused by intrinsic sphincter deficiency	Adult women 21 years of age or older with stress UI caused by intrinsic sphincter deficiency for a period of at least 12 months; positive pad weight test; failure of previous non invasive treatments, post void residual <100 mL and abdominal leak point pressure	Urge primary incontinence, uncontrolled bladder instability, positive urine culture, previous urethral bulking treatments, medication affecting the evaluation of incontinence, pregnancy	Durasphere 4.5 mL injected submucosally between the bladder neck and external sphincter	Contigen 4.2 mL injected submucosally between the bladder neck and external sphincter
Appell, 2006 ⁴⁸¹ Country: U.S. Aim: The effects of transurethral radiofrequency energy collagen micro-remodeling on female stress urinary incontinence	Women with stress urinary incontinence, bladder outlet hypermobility, and leak point pressure >60cm/H2O	Evidence of detrusor overactivity on cystometrogram, post-void residual bladder volumes >50cc, significant pelvic organ prolapse (Stage IV) on physical examination, history of dry or wet overactive bladder, previous surgical or bulking agent therapy	Transurethral radiofrequency energy collagen micro-remodeling	Sham treatment probes lacked needle electrodes and sham treatment of radiofrequency generator
Arvonen, 2001 ⁴⁸² Country: Sweden Aim: The effects of pelvic floor muscle training with and without vaginal balls on females stress urinary incontinence	Women aged 25-65 with stress urinary incontinence, understanding of spoken Swedish	Pregnancy, cysto/rectocele, prolapse, urinary tract infection, altered vaginal tissue, and medication affecting the functioning of the urinary tract or kidneys	Pelvic floor muscle training program with contractions/relaxations for 5 seconds 10 times twice a day	Pelvic floor muscle training program with contractions/relaxations for 20/20 seconds 10 times twice a day using weighted vaginal balls 50-100g.
Aukee, 2002 ⁴⁸³ Country: Finland Aim: The effects of electromyography-assisted biofeedback training and pelvic floor muscle training on female stress urinary incontinence	Women with urodynamically tested stress incontinence ages 31 to 69 years without previous incontinence operations and an abdominal leak point pressure >90.	Genital protrusion beyond the vaginal hymen, an inability to understand instructions for home training, pregnancy, and any severe disease such as malignancy in the abdominal region, multiple sclerosis, and insulin-dependent diabetes.	Pelvic floor muscle exercise after verbal and written instructions for home practice of 20 minutes/day 5 times/week and individual EMG-assisted biofeedback device with vaginal probe and verbal control	Pelvic floor muscle exercise after verbal and written instructions for home practice of 20 minutes/day 5 times per week

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Aukee, 2004 ⁴⁸⁴ Country: Finland Aim: The effectiveness of pelvic floor training with home biofeedback device among women with stress urinary incontinence	Women 21-70 years old with urodynamically confirmed stress incontinent (maximal urethral closure pressure >20cm/H2O and cough leak point pressure >90cm/H2O)	Previous incontinence operations, genital prolapse, inability to understand instructions for home training, pregnancy, severe diseases such as malignancies in the abdominal region, multiple sclerosis and diabetes mellitus requiring insulin	1. Home program with given verbal and written instructions for home practice and advise to practice for 20 minutes/day, 5 times/week. 2. Pelvic floor training by physiotherapist 5 times/12 weeks: 3-5 second contractions with 10 second intervals in supine	Home program with given verbal and written instructions for home practice
Bano, 2005 ⁴⁸⁵ Country: UK Aim: The effects of porcine dermal implant (Permacol) and silicone injection (Macroplastique) on urodynamic stress incontinence in females	Women with urodynamically proven stress incontinence	Not reported	Peri or transurethral porcine dermal implant injection (Permacol)	Transurethral silicone injection (Macroplastique)
Barroso, 2004 ⁴⁸⁶ Country: Brazil Aim: The effects of transvaginal electrical stimulation on urinary incontinence	Women with stress, urge, or mixed urinary incontinence	Prolapse or first degree urogenital prolapse, intrinsic sphincter deficiency, cardiac pacemaker; pregnancy, postmenopausal climacteric with symptoms and signs of urogenital atrophy (they could be included after 3 months of treatment with hormone-replacement therapy)	Transvaginal electrical stimulation at home twice a day (20-minute sessions) with frequency of 20 (urge) or 50Hz (stress UI), a pulse width of 300ms, with asymmetrical biphasic pulses, an adjustable current intensity (0-100mA)	Placebo
Berghmans, 1996 ⁴⁸⁷ Country: The Netherlands Aim: The effects of biofeedback and pelvic floor muscle exercise on female genuine stress incontinence.	Women 18-70 years with mild or moderate stress incontinence (grade 1).	Use of medicine to counteract functional disabilities of the lower urinary tract, pronounced lesions of the pudendus nerve during clinical neurophysiological examination, positive sediment of urine culture, non-compliance in the diagnostic phase, neurogenic urinary incontinence	Pelvic floor muscle exercise 12 treatment sessions, 3 times/week with contractions 3-30 seconds 10-30 times beginning with 4 sets of 10 (5 quick and 5 sustained) and increased by 10 per set until 30 times/set. Biofeedback with EMG vaginal probe and visualization	Pelvic floor muscle exercise 12 treatment sessions, 3 times/week with contractions 3-30 seconds 10-30 times beginning with 4 sets of 10 (5 quick and 5 sustained) and increased by 10 per set until 30 times/set

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Berghmans, 2002⁴⁸⁸ Country: The Netherlands Aim: The effects of physiotherapy in women with proven bladder overactivity</p>	<p>Patients older than 18 years with proven bladder overactivity defined as Detrusor Activity Index ≥ 0.50, able to understand Dutch</p>	<p>Mechanical intravesical obstruction, urinary calculus, urinary tract infection, colpitis, pacemaker, pregnancy, physiotherapy within 3 months, uncontrolled diabetes mellitus</p>	<p>Pelvic floor exercises with contractions for >20 seconds controlled by physiotherapist palpation with relaxation period of 10 seconds. Bladder training to inhibit the sensation of urgency and to postpone voiding, voiding schedule with an interval >2 hours</p>	<p>Usual care</p>
<p>Blowman, 1991⁴⁸⁹ Country: UK Aim: To assess the efficacy of neuromuscular stimulation and pelvic floor exercises, compared with pelvic floor exercises only, in the treatment of genuine stress incontinence</p>	<p>Only patients diagnosed from bladder pressure studies as suffering from genuine stress incontinence were recruited. They all had maximum bladder volumes over 500ml and exhibited no detrusor contraction in lying or standing. All patients demonstrated cough-induced leakage when standing. They were referred to the physiotherapy department gynecology unit and gave informed written consent to take part in the trial.</p>	<p>Not reported</p>	<p>Neurotrophic stimulation</p>	<p>Placebo stimulation</p>
<p>Bo, 1997⁴⁹⁰ Country: Norway Aim: Crossover RCT to examine the effect of voluntary pelvic floor muscle contraction and vaginal electrical stimulation on urethral pressure in women with genuine stress incontinence</p>	<p>Women with genuine stress incontinence participated in pelvic floor exercise program with 8-12 contractions</p>	<p>Not reported</p>	<p>3 voluntary PFM contractions and 2 electrical stimulators Conmax 50Hz – pulse width 0.75ms, 0-90mA Medicon 50Hz - pulse width 0.5ms, 0-100mA</p>	<p>Electrical stimulation with Medicon 50 Hz - pulse width 0.5ms, 0-100mA</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Bo, 1999⁴⁹¹ Country: Norway Aim: The effects of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment on females genuine stress incontinence</p>	<p>Women with clinically and urodynamically proved genuine stress incontinence >4g of leakage measured by pad test with standardized bladder volume.</p>	<p>Urinary incontinence other than genuine stress incontinence, involuntary detrusor contractions >10cm/H2O on cystometry, abnormal bladder function (residual urine >50ml and maximal uroflow <15ml/second), previous surgery for genuine stress incontinence, neurological or psychiatric disease, ongoing urinary tract infections, other diseases that could interfere with participation, use of concomitant treatments during the trial, and inability to understand instructions given in Norwegian</p>	<ol style="list-style-type: none"> 1. Pelvic floor exercise with 8-12 contractions 3 times/day and in groups with skilled physical therapists 1/week. 2. The electrical stimulation using vaginal intermittent stimulation with the MS 106 Twin at 50Hz 30 minutes/day. 3. The vaginal cones of 20, 40, and 70g for 20 minutes/day 	<p>The untreated control group offered the use of a continence guard</p>
<p>Bo, 2000⁴⁹² Country: Norway Aim: The effects of pelvic floor muscle exercise on female genuine stress incontinence</p>	<p>Women with clinically and urodynamically proven genuine stress incontinence >4 grams of leakage measured by the pad test</p>	<p>Urinary incontinence other than GSI, involuntary detrusor contractions exceeding 10cm/H2O on cystometry, residual urine >50ml, maximal uroflow, <15ml/second, previous surgery for GSI, neurological or psychiatric disease, ongoing urinary tract infections, ongoing urinary tract infections, other diseases that could interfere with participation, use of concomitant treatments during the trial, and inability to understand instructions given in Norwegian.</p>	<p>Pelvic floor muscle exercise with 8-12 maximum contractions in 3 series/day and 45 minutes/week group sessions</p>	<p>Untreated control group</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Bo, 2005 ⁴⁹³ Country: Norway Aim: Followup RCT to examine the effects of intensive exercise on stress urinary incontinence.	Women with urodynamic stress urinary incontinence who participated in the original RCT	Not reported	Intensive pelvic floor exercise with 8-12 maximum contractions for 6-8 seconds 3 series/day under the supervision of physical therapist for 6 months	Home exercise groups
Borawski, 2007 ⁴⁹⁴ Country: U.S. Aim: the effects of percutaneous needle electrode technique or a surgical first stage lead placement on implantation of a pulse generator in older urge incontinent women	Women >55 years with refractory urgency incontinence after failure of medical, behavioral, and pelvic floor reeducation management	Not reported	Electrical stimulation with percutaneous needle electrode (22-G spinal needle) placement	Electrical stimulation with surgical first stage lead placement
Borello-France, 2006 ⁴⁹⁵ Country: U.S. Aim: the effects of exercise position during pelvic-floor muscle exercises on females stress urinary incontinence	Women 38 to 70 years old, ambulatory, with symptoms of stress urinary incontinence >1/week	Pregnancy, symptoms of urgency or urge urinary incontinence, prior treatments for stress urinary incontinence (collagen injection, medications affecting bladder tone, pessary, or surgery), practicing pelvic-floor muscle exercises, pacemaker, use of intrauterine device, medical history of pelvic cancer, severe endometriosis, neurologic or metabolic disorders likely to impair bladder or sphincter function	Pelvic floor muscle exercises with EMG biofeedback in the supine position only using maximum 30-60 repetitions of 3-12 second contractions twice daily	Pelvic floor muscle exercises with EMG biofeedback in both supine and upright positions, 1 set (3- and 12-second contractions) in each position with maximum 20 repetitions (2 sets of 10) of the 3-12 second contractions twice daily

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Borello-France, 2008 ⁴⁹⁶ Country: U.S. Aim: Comparative effectiveness of maintenance exercise program either 1 or 4 times per week in women with stress UI	Women 38 to 70 years of age, not pregnant, ambulatory, and recorded at least one SUI episode and no urgency or urge urinary incontinence in a 7-day bladder diary	A medical history that included pelvic cancer, severe endometriosis, use of an intrauterine device, or pacemaker; neurologic or metabolic disorders associated with bladder or sphincter dysfunction; previous medical/surgical treatments for SUI; or prior in instruction in PFM exercise or a prescribed PFM exercise regimen from a physician, nurse, physical therapist, or other health care professional.	High-frequency (4 times per week) maintenance 2 times/day exercise program with 60 repetitions (3 sets of 20 repetitions) of a 3-second PFM contraction and 30 repetitions (3 sets of 10 repetitions) of a 12-second contraction per exercise session	Low-frequency (1 time/week) maintenance 2 times/day exercise program with 60 repetitions (3 sets of 20 repetitions) of a 3-second PFM contraction and 30 repetitions (3 sets of 10 repetitions) of a 12-second contraction per exercise session
Borrie, 2002 ⁴⁹⁷ Country: Canada Aim: The effects of combined lifestyle and behavioral interventions led by nurses in the management of urinary incontinence	Subjects 26 years of age or older with self reported urinary incontinence at least once per week, resided in the community, and communicated in English	Pregnancy, residency of long-term care institutions, dementia	Lifestyle modification sessions every 4 weeks led by trained "nurse continence advisers" with a physician with expertise in continence management	Usual care
Bower, 1998 ⁴⁹⁸ Country: Australia Aim: The effects of surface neuromodulation on cystometric pressure and volume parameters in women with detrusor instability or sensory urgency.	Women with proved detrusor instability or sensory urgency	Urinary tract infection, pregnancy, cardiac pacemaker, impaired cognition, neurogenic bladder dysfunction or cystocele beyond the introitus	Active transcutaneous electrical nerve stimulation with 10Hz. frequency and 200 microsecond pulse width (sacral placement)	1. Sham transcutaneous electrical nerve stimulation with sacral or suprapubic placement 2. Active transcutaneous electrical nerve stimulation with 150Hz. frequency and 200 microsecond pulse with (suprapubic placement)

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Boyington, 2005⁴⁹⁹ Country: U.S. Aim: The effects of computer-based system for continence health promotion that included self-management techniques for women with symptoms of involuntary urine loss, urinary frequency or urgency, or nocturia</p>	<p>Women 50 years or older who lived independently in the community with symptoms of UI, urinary frequency or urgency, or nocturia; minimum of 30 on the Telephone Interview for Cognitive Status-modified (TICS-m); Self-reported ability to read and write English, to ambulate without difficulty, and to toilet independently</p>	<p>Toilet dependently; blood in their urine, recurrent urinary tract infections, persistent difficulty with bladder emptying as evidenced by straining or other efforts to drain the bladder completely, or symptomatic pelvic prolapse</p>	<p>Computer-based system to promote continence health using health clinic visit metaphor that provided fact sheets, testimonials from women who improved with the adoption of behavioral techniques; the expert system advice on Bladder training, PFMT, fluid management, caffeine restriction, and the quick pelvic floor muscle contraction</p>	<p>Alternate computer-based system simulating women's magazine with information about breast self-examination and tips for women traveling alone</p>
<p>Brown, 2006⁵⁰⁰ Country: U.S. Aim: The effects of intensive lifestyle intervention or metformin on prevalence of urinary incontinence among overweight pre-diabetic women</p>	<p>Women in the Diabetes Prevention Program RCT older than 25 years, body mass index ≥ 24kg/m², a fasting plasma glucose level 95-125mg/dl, and a 2-hour post-challenge glucose level 140-199mg/dl.</p>	<p>Taking medications that could affect glucose tolerance or serious medical illness.</p>	<p>Intensive lifestyle therapy to lose and maintain at least 7% of initial body weight through a low-fat diet and to engage in moderate-intensity physical activity for at least 150 minutes each week</p>	<p>Placebo twice daily.</p>
<p>Brubaker, 1997⁵⁰¹ Country: U.S.A. Aim: The effects of transvaginal electrical stimulation for treatment of urinary incontinence in women</p>	<p>Women >25 years of age with either urinary incontinence due to detrusor instability or genuine stress incontinence, or both (mixed incontinence) diagnosed with filling urethrocystometry</p>	<p>Urinary incontinence other than genuine stress incontinence, detrusor instability, or mixed incontinence; leakage episodes <3/week, inadequate genitourinary estrogen (minimum 3 months HRT), inadequate cognitive ability (investigator judgment), urinary tract infection, anatomic defect that precluded use of device, postvoid residual >100ml, implanted electric device, genitourinary surgery, drug treatment for urinary incontinence, anticipated geographic relocation during study.</p>	<p>The transvaginal electric stimulation for 20 minutes 2 times/day using frequency of 20Hz, a 2-second-4-second work-rest cycle with a range of stimulation intensities, from 0-100mA</p>	<p>Sham inactive device</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Bryant, 2002 ⁵⁰² Country: Australia Aim: The effects of caffeine restriction on urinary incontinence symptoms	Adult patients with urinary symptoms with routine intake of caffeine >100mg every 24 hours	Cognitive impairment, pregnancy, urinary tract infection.	Education to reduce caffeine intake to <100mg/day plus bladder training	Bladder training: increasing intervals between voiding; increasing fluid intake to 2 L/day; urinary deferment techniques; ceasing "just in case" voiding
Burgio, 2002 ⁵⁰³ Country: U.S. Aim: The effects of biofeedback as a part of complex behavioral training program for urge incontinence in community-dwelling older women	Ambulatory, nondemented, community-dwelling women ages 55 to 92 years with urgency incontinence or mixed incontinence >2 times/week for at least 3 months, and with urodynamic evidence of bladder dysfunction (detrusor instability during filling or provocation or maximal cystometric capacity of ≤400ml)	Continual leakage, postvoid residual urine volume >150ml, severe uterine prolapse past the vaginal introitus, decompensated congestive heart failure, or impaired mental status (Mini-Mental State Examination score <24)	Biofeedback-assisted behavioral training implemented by nurse practitioners. Abdominal pressure and sphincter responses were measured with 3-balloon probe inserted in rectum. Pelvic floor muscle exercise with 10 second contractions/10 second relaxation for 20-30 minutes	Self-administered behavioral treatment using a self-help booklet to advise pelvic floor exercise and bladder control
Burns, 1990 ⁵⁰⁴ Country: U.S. Aim: The effects of pelvic floor exercises or biofeedback on female stress urinary incontinence	Women with stress or mixed urinary incontinence >3/week with Mini-Mental scores >23	Urinary tract infection	Kegel pelvic floor exercises 4 times/day. Biofeedback with vaginal EMG probe and visual control.	Usual care
Burns, 1993 ⁵⁰⁵ Country: U.S. Aim: The effects of biofeedback and pelvic muscle exercise treatment on stress incontinence in older community-dwelling women	Community-dwelling women older than 55 years with sphincteric incompetence, >3 urine losses/week, urodynamic incontinence, >23 scores in Mini-Mental State exam	Glycosuria, pyuria, residual urine >50cc, peak urine flow <15cc/second	Biofeedback using vaginal EMG probe, contraction for 10 seconds and relaxations for 10 seconds 10 times in each weekly session. Pelvic muscle exercise with 4 sets of 20 increasing by 10/set until maximum 200 sets/day	Usual care
But, 2003 ⁵⁰⁶ Country: Slovenia Aim: The effects of functional magnetic stimulation in the treatment of women with urinary incontinence	Women with urinary incontinence older than 18 years, not pregnant, and not physically or mentally disabled	Implanted electronic equipment (pacemakers), urolithiasis, bladder infection, tumor, recent urethral or continence surgery, use of anticholinergic drugs, beta-blocking agents, and diuretics	Functional magnetic stimulation with Pulsegen device, which produced a pulsating magnetic field of B = 10 microT intensity and a frequency of 10Hz	Placebo treatment with sham not active device

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
But, 2005 ⁵⁰⁷ Country: Slovenia Aim: The effects of functional magnetic stimulation for treating women with mixed urinary incontinence	Women with mixed urinary incontinence and predominant urgency incontinence	Not reported	Functional magnetic stimulation applied continuously at 18.5Hz day and night	Sham inactive device
de Oliveira Camargo, 2009 ⁵⁰⁸ Country: Brazil Aim: Comparative effectiveness of individual vs. group pelvic floor muscle training	Women with confirmed urodynamic SUI, positive cough stress test, and less than 3 g of leakage as measured by a pad test with a standardized bladder volume (200 ml)	Detrusor overactivity, chronic neurological or muscular diseases, abnormal genital bleeding, uterine prolapse, advanced genital prolapse, active genitourinary tract infections, pregnancy, or vaginal atrophy, intrinsic sphincter deficiencies, Valsalva leak point pressure ≤ 60 cm H ₂ O measured in the sitting position with volume of 250 ml in the bladder and/or by urethral closure pressure ≤ 20 cm H ₂ O in the sitting position at maximum cystometric capacity.	Pelvic floor exercises in a group with two weekly sessions of 45 minutes each. In the orthostatic position, patients received oral instructions to perform ten contractions of 5 seconds with 5 seconds of recovery time, 20 contractions of 1 second with 1 second of recovery time	Individual pelvic floor exercises Following PERFECT assessment scheme with contractions in accordance with the endurance, power, and time that the patients could tolerate.
Cammu, 1998 ⁵⁰⁹ Country: Belgium Aim: The effects of pelvic floor exercises and vaginal weight cones in the treatment on female genuine stress incontinence	Ambulatory and fit white women with urodynamic urinary stress incontinence, and vaginal capacity permitting the use of a vaginal probe-EMG biofeedback-or cones post-partum period, and had neither a genital prolapse nor any other associated pathology	Women in the post-partum period; those having genital prolapse or any other associated pathology that warranted surgery. Women with detrusor instability, outflow outflow, and intrinsic urethral sphincter deficiency.	Weekly session of pelvic floor exercises vaginal probe-EMG biofeedback using perineometer	Vaginal weight cones (20, 32, 45, 57, and 70 g) for 15 minutes, twice daily

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Castro, 2008²⁴⁷ Country: Brazil Aim: To compare the effectiveness of pelvic floor exercises, electrical stimulation, vaginal cones, and no active treatment in women with urodynamic stress urinary incontinence.</p>	<p>Women with proven urodynamic stress urinary incontinence were enrolled at the Urogynecology and Reconstructive Pelvic Surgery</p>	<p>Patients with chronic degenerative diseases that would affect muscular and nerve tissues, advanced genital prolapses, pregnancy, active or recurrent urinary tract infections, vulvovaginitis, atrophic vaginitis, continence surgery within one year, and patients with cardiac pacemakers; patients with intrinsic sphincteric deficiencies identified by the Valsalva leak point pressure ≤ 60cm H₂O measurement in the sitting position with a volume of 250 ml in the bladder and/or by the measurement of a urethral closure pressure ≤ 20cm H₂O in the sitting position at maximum cystometric capacity.</p>	<p>Pelvic Floor Muscle Training</p>	<p>Electrical stimulation/weighted vaginal cone/no treatment</p>
<p>Chadha, 2000⁵¹⁰ Country: Australia Aim: The effects of national guidelines and local protocols in improving hospital care for women with UI</p>	<p>Women with urinary incontinence from gynecology units in four district general hospitals across Scotland</p>	<p>Not reported</p>	<p>National evidence based guidelines adapted locally to protocols, which were disseminated at specific local educational meetings and implemented by placing a copy of the appropriate protocol in women's hospital case notes prior to consultation</p>	<p>Usual care</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Coleman, 1999 ⁵¹¹ Country: U.S. Aim: the effect of Chronic Care Clinics on urinary incontinence in frail older adults	Frail older adults were those enrollees at high risk for hospitalization according to the Chronic Disease Score, the patients in the Group Health Cooperative of Puget Sound, a large Health Maintenance Organization located in western Washington State	Severe illness that precluded their participation in the study; moderate to severe dementia; residence in a nursing home, terminal illness; and those who had disenrolled	New model of primary care, Chronic Care Clinics: (1) An extended (30 minutes) visit to the patient's physician and team nurse dedicated to developing a shared treatment plan that emphasized the reduction of disability; (2) A session with the pharmacist	Usual care
Corcos, 2005 ⁵¹² Country: Canada Aim: Noninferiority RCT to examine effects of collagen injection or surgery on female stress urinary incontinence	Women older than 30 years with stress urinary incontinence lasted for >6 months	Contraindications to surgery or collagen injections (allergic reaction), associated conditions (e.g., severe medical disease or indication for hysterectomy) or pelvic prolapse (vault, cystocele, rectocele), neurogenic bladder or interstitial cystitis	Intraurethral collagen submucosal injection 4 injections at 1-month intervals	Surgery (needle bladder neck suspensions, Burch, and slings). The choice of technique was left to the surgeon
Demain, 2001 ⁵¹³ Country: U.S. Aim: Comparative effectiveness of group versus individual management on physical symptoms and quality of life in female urinary incontinence	Women over 18 years of age with clinical symptoms of stress and/or urgency incontinence (median duration of symptoms 3 years 7 months) presenting to physiotherapy	Pregnancy, recent pelvic surgery (3 months), history of pelvic malignancy, fecal incontinence, current urinary infection, grade III prolapse, diseases of central nervous system, acute mental illness and dementia, previous physiotherapy for incontinence	Three educational group sessions with 4-12 women. Women attended 3 1-hour sessions with educational and exercise components	One 45-minute individual treatment, instructions in pelvic floor muscle exercise
Demirturk, 2008 ⁵¹⁴ Country: Turkey Aim: Comparative effectiveness of interferential current and biofeedback applications on incontinence severity in patients with urinary stress incontinence	Women with urodynamic stress UI and moderate intensity of incontinence as determined by a one-hour pad test referred Physical Therapy and Rehabilitation, Women's Health Unit	Urinary tract infections, detrusor over activity, cognitive problems and neoplasm	Interferential current with a frequency of 0-00 Hz 5 minutes per session, three times a week for a total of 5 sessions	Kegel exercises with biofeedback 5 minutes per session, three times a week for a total of 5 sessions

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Diokno, 2004⁵¹⁵ Country: U.S. Aim: The effects of behavioral modification program on incidence of urinary incontinence in older women</p>	<p>Postmenopausal, continent women (0-5 days of incontinent episodes in the previous year) 55 years and older. At baseline 2 groups reported identical 39% absolute continence and zero UI days; 61% of participants reported 1 to 5 UI episodes in year</p>	<p>Neurologic diseases, minimal scores <24, positive paper towel cough test, grade 4 uterine prolapse</p>	<p>1 2-hour classroom presentation on behavioral modification program: pelvic floor muscle training, bladder training, and individualized test of knowledge, adherence, and skills to reinforce the technique as needed</p>	<p>Usual care</p>
<p>Diokno, 2010⁵¹⁶ U.S. Aim: The effectiveness of behavioral modification program vs. standardized protocol taught to adult incontinent women</p>	<p>Adult incontinent ambulatory females from four Michigan counties in the U.S.</p>	<p>1) Women currently under incontinence treatment with medications or previous/current behavioral programs, 2) history of bladder cancer, stroke, multiple sclerosis, Parkinsonism, epilepsy or spinal cord tumor or trauma, 3) pregnancy, 4) MESA questionnaire of 725 or higher on urge score, 70% or higher on stress score, or urge percentage higher than stress percentage to eliminate those with total incontinence and those with urge predominant symptoms, respectively. Previously failed anti-incontinence surgery was not considered for exclusion</p>	<p>Group intervention</p>	<p>No intervention</p>
<p>Dougherty, 2002⁵¹⁷ Country: U.S. Aim: The effects of behavioral management for continence on urinary incontinence in older rural women in their homes</p>	<p>Women 55 years and older, who lived in a private residence in rural area; with involuntary urine loss >2/week of 1g/24 hours or more; without urinary tract infection</p>	<p>Bladder cancer or kidney disease, indwelling urinary catheter, residual urine >100cc, needed caregiver</p>	<p>Behavioral management for continence: Self-monitoring and bladder training to reduce caffeinated beverages to <2 cups/glasses, 1,500 <daily fluid intake <4000cc, no fluid consumption after 6 pm, daytime voiding interval <4 hours, and treatment of const</p>	<p>Usual care</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Dowd, 1996 ⁵¹⁸ Country: U.S. Aim: The effects of hydration on the number of urinary incontinence episodes	Women 50 years old and older with incontinence more than 6 months, independent in self-care, English speakers with >20 scores on Mini-Mental State	Exclusion criteria: not provided	1. Increase fluid intake by 500cc 2. Maintain fluid intake at baseline level	Decrease daily fluid intake by 300cc
Dowd, 2000 ⁵¹⁹ Country: U.S. Aim: The effects of cognitive strategies combined with educational programs in urinary incontinence	Subjects >40 years of age, independent in self-care, with history of incontinence and/or frequency for at least 6 months, able to read and write English, and having hearing adequate for listening to an audiotape	Presence of urinary tract infections or severe neurological disorders	Education about bladder health, recorded incontinence and frequency episodes in a voiding diary, and listening to the audiotape daily	Education about bladder health and recorded incontinence and frequency episodes in the voiding diary
Dumoulin, 2004 ⁵²⁰ Country: Canada Aim: The effectiveness of multimodal supervised physiotherapy programs among women with persistent postnatal stress urinary incontinence	Premenopausal women younger than 45 years presenting symptoms of stress urinary incontinence at least once per week 3 months or more after their last delivery	Current pregnancy, urinary incontinence before pregnancy, previous surgery for stress incontinence, moderate to severe urogenital prolapse, involuntary detrusor contraction on cystometry neurologic or psychiatric disease, or a major medical condition, taking medication that could interfere with their evaluation or treatment, inability to understand French or English instructions.	1. Pelvic floor rehabilitation: 15 minute electrical stimulation of the pelvic floor muscle; then 25 minute pelvic floor muscle exercise program with biofeedback, which included strengthening and motor relearning exercises and a home exercise 5 days/week. 2. Pelvic floor rehabilitation plus abdominal training: in addition to PFE 30 minutes of deep abdominal muscle training consisting of isolation, reeducation, and functional retraining of the transversus abdominis	Relaxation massage for the back and extremities by physiotherapist. They were asked not to exercise their pelvic floor muscles at home.

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Elser, 1999 ⁵²¹ Country: U.S. Aim: The effects of pelvic floor muscle training, bladder training, or both, on urodynamic parameters in women with urinary incontinence	Women 45 years or older, ambulatory, mentally intact with urodynamic genuine stress incontinence or detrusor instability, with or without stress incontinence, experiencing 1–100 episodes of incontinence per week as recorded on the qualifying 7-day diary	Reversible cause of incontinence, uncontrolled metabolic conditions (e.g., diabetes mellitus), postvoid residual of >100ml, persistent urinary tract infection, urinary tract fistula, or indwelling catheterization	Patient education, self-monitoring with treatment logs, compliance assessment, and positive reinforcement techniques administered by trained research nurses. Pelvic floor muscle training with 10 fast (3 second) contractions and 40 sustained (10 second) contractions	Bladder training
Emmons, 2005 ⁵²² Country: U.S. Aim: The effects of acupuncture on overactive bladder in women	Women older than 18 years, with symptoms of overactive bladder with urgency incontinence, >8 voids per day, subjective urgency to void, and urge-associated incontinence at least twice during a 3-day period of time	Pregnancy, taking medications for overactive bladder or receiving acupuncture treatments for any condition, unable to ambulate or unable to complete a 3-day voiding diary, and hematuria or untreated urinary tract infection	Acupuncture treatment expected to improve bladder symptoms	Placebo acupuncture treatment designed to promote relaxation
Engberg, 2002 ⁵²³ Country: U.S. Aim: Cross-over RCT to examine the effects of prompted voiding in cognitively impaired homebound older adults	Adults 60 years and older with urinary incontinence >2 episodes/week for >3 months who met Center for Medicare and Medicaid Services criteria for being homebound, residents in 2 large Medicare-approved home health agencies in a large metropolitan area	Terminal illness; postvoid residual volume >100ml; caregiver was unable or unwilling to provide toileting assistance, complete bladder diaries, or implement the PV protocol	Prompted voiding by caregivers to approach subjects hourly for perceived wet/dry status vs. objective wet checks, feedback and praising for correct response, toilet by request, positive feedback for appropriate toileting	Usual care with attention control (visits by the nurse practitioner every 1-2 weeks to provide social interaction)
Fantl, 1991 ⁵²⁴ Country: U.S. Aim: The effects of bladder training on urinary incontinence in older women	Noninstitutionalized women 55 years and older with clinical and urodynamic urinary incontinence >1 leakage/week; mentally intact (Mini-Mental State Examination score >23), capable of independent toileting	Uncontrolled diabetes, urinary tract infection, urinary obstruction, reversible cause of incontinence, permanent catheterization	Bladder training using 6 weekly visits included patient education; voiding schedule to have micturition from every 30-60 minutes to every 2.5-3 hours; and positive reinforcement	Usual care

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Felicissimo, 2010 ⁵²⁵ Country: Brazil Aim: The effectiveness of intensive supervised PFMT to unsupervised PFMT in the treatment of female stress UI	Women with confirmed urodynamic stress urinary incontinence with Valsalva leak point pressure more than 60 cm/H ₂ O and no detrusor overactivity. All subjects had predominant symptoms of SUI with an average of at least three stress continence episodes per week.	Chronic neurological muscular diseases, abnormal genital bleeding, genital prolapse at stage ≥ 2 of POP-Q (Pelvic Organ Prolapse-Questionnaire), active genitourinary tract infections, pregnancy, and women who preferred surgery. Patients with intrinsic sphincter deficiencies as identified by Valsalva leak point pressure ≤ 60 cm H ₂ O measured in the sitting position with a volume of 250ml in the bladder were also excluded	Supervised Pelvic Floor Muscle Training	Unsupervised Pelvic Floor Muscle Training
Finazzi-Agro, 2005 ⁵²⁶ Country: Italy Aim: Comparative effectiveness of posterior tibial nerve stimulation performed weekly vs. 3 times per week in men and women with overactive bladder syndrome	Men and women with overactive bladder syndrome not responding to antimuscarinic therapy	Not reported	Posterior tibial nerve stimulation 3 times/week	Posterior tibial nerve stimulation 1 time/week

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Finazzi-Agro, 2010⁵²⁷ Country: Italy Aim: To evaluate the efficacy of percutaneous tibial nerve stimulation in female patients with detrusor overactivity incontinence</p>	<p>Urgency incontinence and urodynamically diagnosed detrusor overactivity incontinence; unresponsive to behavioral and rehabilitation therapy or antimuscarinic; able to give written, informed consent; 18 years of age or older; mentally competent and able to understand all study requirements; able to understand the procedures, advantages and possible side effects; willing and able to complete a 3-day voiding diary and I-QoL questionnaire; bladder capacity 100 ml or greater; no signs of neurologic abnormalities at objective examination; no history of neurologic pathology; and no pharmacological treatment or pharmacological treatment unchanged for 30 days before beginning the study</p>	<p>1) Pregnancy or intention to become pregnant during the study; 2) Active urinary tract infection or recurrent urinary tract infections (more than 4 per year); 3) Presence of urinary fistula, bladder or kidney stones, interstitial cystitis, cystoscopic abnormalities that could be malignant; 4) Diabetes mellitus; and Cardiac pacemaker or implanted defibrillator</p>	<p>Percutaneous tibial nerve stimulation</p>	<p>Placebo</p>
<p>Fujishiro, 2000⁵²⁸ Country: Japan Aim: The effects of magnetic stimulation of the sacral roots for the treatment of stress incontinence</p>	<p>Women, 37 to 79 years old with stress incontinence, >1 episode of urinary leakage recorded in a 3-day voiding diary, and 2 gm or more urine loss on a 1-hour pad test</p>	<p>Urinary infection, interstitial cystitis and large uterine myoma, and other treatments for stress incontinence, including pelvic floor exercises, medical treatment and electrical stimulation</p>	<p>Magnetic stimulation of sacral roots with 15Hz. frequency, 50% intensity output for 5 seconds per minute for 30 minutes</p>	<p>Sham stimulation with inactive device</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Fujishiro, 2002⁵²⁹ Country: Japan Aim: The effects of magnetic stimulation of the sacral roots for treating urinary frequency and urge incontinence</p>	<p>Women 43 to 75 years old with the complaint of urinary frequency and/or urgency incontinence, >8 voids daily and/or >1 episode of urgency incontinence on a 3-day voiding diary, and mean of less than 250 ml. urine volume per void on a 3-day voiding diary</p>	<p>Neurological disorders suggesting neurogenic bladder dysfunction, apparent episode of stress incontinence, urinary infection, interstitial cystitis or large uterine myoma , other treatments for urinary frequency or urgency incontinence, including pelvic floor exercises, medical treatment or electrical stimulation</p>	<p>Magnetic stimulation of sacral roots with 15Hz. frequency, 50% intensity output for 5 seconds per minute for 30 minutes</p>	<p>Sham stimulation with inactive device</p>
<p>Gallo, 1997⁵³⁰ Country: U.S. Aim: Comparative effectiveness of external cue to action, an audiocassette tape, to improve pelvic floor muscle exercise compliance in women with stress urinary incontinence</p>	<p>Women aged 20–80 with a history of self-reported stress urinary incontinence and objective genuine stress incontinence during a urodynamic evaluation</p>	<p>Pregnancy and psychological disorders that would make it difficult to follow pelvic floor exercise instruction</p>	<p>The audiotape reinforced pelvic floor exercise instruction with counted aloud 25 consecutive pelvic floor muscle exercise contractions for 10 seconds and then relaxing for 10 seconds; 45-minute appointment with the specialized on UI nurse investigator</p>	<p>45 minute appointment with the specialized on UI nurse investigator with detailed verbal instructions about pelvic floor muscle identification and contraction; proper pelvic floor muscle contraction by the patient measured using a biofeedback computer</p>
<p>Gameiro, 2010⁵³¹ Country: Brazil Aim: To compare the efficacy of the Vaginal Weight Cone and assisted PFMT to treating UI in women.</p>	<p>To be eligible, patients had been referred by a gynecologist as having symptom of predominant SUI, and 50% also presented urgency incontinence. None of the patients had a urodynamic diagnosis of SUI. None of the patients had taken anticholinergics or tricyclic antidepressants or had been treated using pelvic floor exercises or bladder training.</p>	<p>Anterior or posterior vaginal prolapse beyond grade II, urinary infection, neurological or demyelinating condition, and poor comprehension.</p>	<p>Assisted Pelvic Muscle Floor Training</p>	<p>Vaginal weight cone</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Ghoniem, 2009 ⁵³² Country: U.S., Canada Aim: The effectiveness and safety of Macroplastique® as minimally invasive endoscopic treatment for female stress urinary incontinence primarily due to intrinsic sphincter deficiency	Women with a diagnosis of SUI primarily due to ISD that failed behavior modification (biofeedback) or exercise (Kegel)	Not viable mucosal lining, abnormal bladder capacity, urinary tract infection, uncontrolled detrusor overactivity, high post-void residual urine volume, high grade pelvic organ prolapse, confounding bladder pathology, pregnancy or morbid obesity	Transurethral injection of Macroplastique	Transurethral injection of Contigen®
Gilling, 2009 ⁵³³ Country: New Zealand Aim: The efficacy of extracorporeal electromagnetic stimulation of the pelvic floor for treating female stress urinary incontinence	Women >20 years old; symptoms of SUI or mixed UI, genuine SUI confirmed by pad-testing and urodynamics, ambulatory and community-dwelling, neurologically normal, agree not to seek or use any other form of treatment for UI during the study, otherwise healthy	Previous incontinence or pelvic floor surgery, Grade 3 or 4 pelvic prolapse (ICS classification), pregnancy, drugs, e.g. diuretics, alpha-adrenergic antagonists or other medication prescribed for bladder dysfunction, concurrent use of internal medical device	Electromagnetic stimulation 3 times/week using the NeoControl chair (Neotonus Inc., Marietta, GA, USA) with 10-minute stimulation at 10 Hz followed by a 3-minute rest and then a further 10-minute stimulation at 50 Hz. The intensity was adjusted to the maximum level	Sham stimulation with a thin deflective aluminum plate inserted in the chair, which prevented penetration of the magnetic field into the patient, and simulated the noise and sensation produced during active treatment sessions.
Glavind, 1996 ⁵³⁴ Country: Denmark Aim: Effects of biofeedback on continence rates in women with stress UI	Women with self reported incontinence when coughing, laughing, lifting and during physical exercise verified by a positive 1-hour pad-weighing test (>2 g) with a bladder volume of three-quarters of the cystometric capacity	Intravesical obstruction and detrusor instability, previous surgery for urinary incontinence	Physiotherapy 2-3 times with individual instruction combined with biofeedback four times. Biofeedback was performed with a vaginal surface electrode (Dantec 21L20, Skovlunde, Denmark) and a rectal catheter.	physiotherapy 2-3 times with individual instruction alone
Glavind, 1997 ⁵³⁵ Country: Denmark Aim: The effects of vaginal sponge intended to support the urethra during aerobic exercise in women with stress urinary incontinence	Women 44-68 years with stress urinary incontinence lasting from 1 to 11 years, with daily episodes of incontinence.	Intravesical obstruction and detrusor instability	half an hour of aerobic exercises on 2 consecutive days with the vaginal sponge intended to support the urethra	Half an hour of aerobic exercises on 2 consecutive days without the vaginal sponge

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Goode, 2003 ²⁹⁰ Country: U.S. Aim: The effect of biofeedback-assisted behavioral training on urinary incontinence in older women	Ambulatory, non demented, community-dwelling women 55 and older with self-reported urgency incontinence at least twice per week for >3 months with urodynamic evidence of bladder dysfunction	Continual leakage, postvoid residual urine volume greater than 200ml, uterine prolapse past the introitus, narrow-angle glaucoma, unstable angina pectoralis, congestive heart failure, history of malignant arrhythmias, or impaired mental status	Four sessions (over 8 weeks) of biofeedback-assisted behavioral training by nurse practitioners	Placebo control condition, usual care
Goode, 2003 ⁵³⁶ Country: U.S. Aim: Whether pelvic floor electrical stimulation increases efficacy of behavioral training for community-dwelling women with stress incontinence	Ambulatory, nondemented, community-dwelling women ages 40 to 78 years with urinary incontinence (at least 2 stress incontinence episodes per week on the 2-week baseline bladder diary) confirmed during urodynamic testing	Continual leakage, postvoid residual urine volume >150ml, severe uterine prolapse, congestive heart failure, hemoglobin A1C ≥9, or impaired mental status (Mini-Mental State Examination score <24)	Behavioral training (biofeedback-assisted pelvic floor muscle training, home exercises, bladder control strategies, and self-monitoring with bladder diaries). Anorectal biofeedback (~20 minutes) with 3-balloon probe to measure sphincter pressure	Control: self-administered behavioral training administered with a self-help booklet with suggestions for isolating the pelvic floor muscles, progressive home exercise, self monitoring, and bladder control strategies
Gorman, 1995 ⁵³⁷ Country: U.S. Aim: Effectiveness of an expert system for disseminating knowledge to women with urinary incontinence	Ambulatory, alert, community dwelling women with urinary incontinence defined as accidental urine loss at least twice a week	Dependence on a urinary catheter; not successful completion of a mental competency test	1. The expert system-the Urinary Incontinence Consultation System-with the Agency for Health Care Policy and Research (AHCPR) patient guideline for urinary incontinence and research literature for behavioral treatments 2. The educational printed booklet	General health video
Hahn, 1991 ⁵³⁸ Country: Sweden Aim: To compare the effect of two conservative methods and evaluate the long-term results	Women not previously operated upon, with pure stress urinary incontinence, consecutively referred for surgery	Not reported	Pelvic floor training	Intravaginal electrical stimulation

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Harvey, 2002 ⁵³⁹ Country: Not reported Aim: To determine the comparative effectiveness of weighted cones versus biofeedback in women with urodynamic incontinence	Consecutive adult clinic patients with symptoms of mainly stress incontinence and confirmed urodynamic stress incontinence on urodynamics were approached	Age >65 year, detrusor overactivity, past treatment with cones/biofeedback/ electrical stimulation/surgery, POPQ >stage 3.	Biofeedback	Weighted vaginal cones
Hu, 1989 ⁵⁴⁰ Country: U.S. Aim: the effects of behavior therapy program for urinary incontinence on women residents of nursing homes	Women with confirmed stress incontinence in seven nursing homes with ability to recognize her own name.	Hospitalization, insufficient number of wet episodes per day (an average 0.18)	13-week behavior therapy program for urinary incontinence which included hourly checking and prompting of individuals to toilet, praising for successful toileting, and social reinforcement (additional personal service).	Control group received usual incontinence-related care
Huang, 2009 ⁵⁴¹ Country: U.S. Aim: The effects of an intensive behavioral weight reduction intervention on sexual function in overweight and obese women with urinary incontinence	The PRIDE study: at least 30 years old, have a BMI of 25 to 50 kg/m ² and self-report at least 10 episodes of incontinence weekly	Any condition that would prevent safely participating in an intensive diet and exercise program without medical supervision, medical therapy for incontinence, or weight loss in the previous month	Intensive lifestyle and behavior change program modeled after the Diabetes Prevention Program and Look AHEAD (Action for Health in Diabetes) trials designed to produce an average loss of 7% to 9% of initial body weight weekly 1-hour group sessions led by continent nurse	The structured education program: 1-hour group educational sessions at months 1, 2, 3, and 4, providing general information about weight loss, physical activity, healthy eating habits and health promotion
Hui, 2006 ⁵⁴² Country: China Aim: The effects of telemedicine vs. a conventional outpatient continence service in community-dwelling older women with urge or stress incontinence	Community-dwelling older women 60 years or over, with symptoms of urge or stress incontinence, and with one or more incontinence episodes in a week	Active urinary tract infection, a post-void residual volume by bladder ultrasound of more than 150 ml, third-degree uterine prolapse and treatment for urinary symptoms	The nurse specialist provided behavioral training to the group via videoconferencing, with the support of a female registered nurse who helped to run the TCP sessions. Each participant was encouraged to share her experiences with the nurse specialist	Face-to-face consultation the nurse specialist to give digital assessment feedback on pelvic floor contraction + booklet on urge and stress incontinence management

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Hung, 2010 ⁵⁴³ Country: Taiwan Aim: To investigate the effect of treating SUI symptoms in women by retraining diaphragmatic, deep abdominal and PFM coordinated function.	Women aged 18-65 years and had at least one episode of SUI symptom during the previous month	Being pregnant or less than three months postpartum, having systemic neuromuscular disease, having had previous surgery or intensive PFMT for UI, having severe low back pain or pelvic pain, having had a radical hysterectomy or having ongoing urinary tract infections	Diaphragmatic, deep abdominal and pelvic floor retraining	Placebo (Self-monitored PFM exercises)
Janssen, 2001 ⁵⁴⁴ Country: The Netherlands Aim: The effects of individual and group physiotherapy for urinary incontinence in women	Women of all ages with stress, urge, or mixed incontinence	Neurological cause of incontinence, a tumor or infection in the pelvis, severe vaginal prolapse	Individual pelvic floor exercises 5 times/day and bladder training with delay voiding, training with 11 30-minute sessions	Group pelvic floor exercises 5 times/day and bladder training with delay voiding, training with 9 2-hour sessions
Jeyaseelan, 2000 ⁵⁴⁵ Country: UK Aim: Effects of electrical stimulation on women stress incontinence	Women with urodynamically proven stress incontinence	Neurological conditions diagnosed by consultant; Previous electrical stimulation for stress incontinence, prolapse; pregnancy; pacemakers and cardiomyopathy; abnormal urological/gynecological findings; urinary tract/vaginal infection; recent pelvic floor surgery	The electro stimulation technique described by Oldham (International Patent Publication WO98/47357) with a background low frequency (to target slow twitch fibers) and intermediate frequency with an initial doublet (to target fast twitch fibers).	Sham electrical stimulation consisted of one 250- μ s impulse every minute for 60 minutes
Karademir, 2005 ³¹⁹ Country: Turkey Aim: The effects of Stoller afferent neurostimulation with and without a low-dose anticholinergic (oxybutynin hydrochloride) in patients with detrusor overactivity	Patients with symptoms of detrusor overactivity confirmed urodynamically	Urinary tract obstruction, urinary retention, neurologic or metabolic disorder, other treatments for urinary incontinence	Stoller afferent neurostimulation with frequency 20Hz and amplitude 0.5-10mA	Stoller afferent neurostimulation with frequency 20Hz and amplitude 0.5-10mA combined with 5mg of oral oxybutynin hydrochloride

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Kim, 2009 ⁵⁴⁶ Country: Japan Aim: To determine the effects of exercise treatment on reducing urine leakage in Japanese elderly women with stress, urge, and mixed UI	Women aged 70 and older who reported urine leakage one or more times per month.	Not reported	Exercise treatment enhancing PFM and functional fitness	Placebo
Kim, 2001 ⁵⁴⁷ Country: Korea Aim: The effects of continence efficacy intervention program on stress urinary incontinence in Japanese women	Women 20-75 years old with stress or mixed urinary incontinence	Drug or surgery treatment for incontinence	Continence efficacy intervention program: common pelvic floor muscle education, audiovisual tape, calendar, counseling, schedule guideline, assessing self-care methods.	Conventional care
Kim, 2007 ⁵⁴⁸ Country: Japan Aim: the effectiveness of pelvic floor muscle and fitness exercises in reducing urine leakage in elderly women with stress urinary incontinence	Women >70 years old with stress UI >1 per month	Stress UI <1/month; urge or mixed incontinence	Fitness exercises and 60-minute pelvic floor muscle exercise sessions two times per week; 10 fast contractions (3 seconds) and 10 sustained contractions (6–8 seconds) with 10-second relaxation periods between the contractions.	Not described (no active intervention)
Kim, 2008 ⁵⁴⁹ Country: South Korea Aim: The effect of hand acupuncture treatment on the stress urinary incontinence in women	Women diagnosed with stress UI, never treated for UI including estrogen therapy or surgery	Stroke, dementia, Parkinson's disease, multiple sclerosis, spinal cord injury, communication problems, glycosuria or proteinuria	Active hand acupuncture points, ST27, CV4 or SP15	Inactive hand acupuncture points
Kincade, 2007 ⁵⁵⁰ Country: U.S. Aim: The efficacy of self-monitoring techniques to reduce urine loss and increase quality of life for women with urinary incontinence	Community-dwelling women 18 and older living in Wake, Nash, and surrounding counties in North Carolina with involuntary urine loss of >1 g in 24 hours	Involuntary urine loss of less than 1 g in 24 hours, positive urine test for bacteria, diagnosis of bladder cancer or kidney disease, prior treatment of UI with biofeedback, urinary catheter, available to participate for less than 1 year, post void residual	Self-monitoring group with training on self-monitoring techniques at the end of the second visit; individualized counseling about caffeine consumption, amount of and timing of fluid intake, voiding frequency, and constipation; teaching a simple pelvic floor exercise	Wait list group; teaching a simple pelvic floor muscle contraction technique (Quick Kegel)

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Konstantinidou, 2007 ⁵⁵¹ Country: Greece Aim: Comparative effectiveness of group pelvic floor muscle training under intensive supervision to that of individual home therapy in women with stress UI	Women over 18 years with a clinical and urodynamic diagnosis of SUI for more than 3 months, >7 incontinence episodes per week, daytime frequency of less than 8 micturition episodes, nocturia of less than 3 episodes, positive stress test (urine leakage)	Symptoms of urgency and urgency incontinence (excluded by the incontinence-specific history and the absence of detrusor overactivity or increased bladder sensation during standard voiding cystometry), presence of any degree of pelvic organ prolapse	Common weekly session in subgroups of 5, written training instructions for the rest of the week, group instructions for home application of pelvic floor training. Individualized according to the strength and endurance of pelvic floor muscles training program	Group instructions for home application of pelvic floor training and individual followup in hospital every 4 weeks. Individualized according to the strength and endurance of pelvic floor muscles training program included 3 sets of fast contractions.
Kumari, 2008 ⁵⁵² Country: India Aim: Effects of behavioral therapy for urinary incontinence in women	Adult women with urinary incontinence	Continuous urinary drainage catheter, those taking diuretics, diagnosed vesicovaginal fistula, multiple sclerosis, spinal injury, severe uterine prolapse, mental impairment, pregnant women, and women who had delivered a baby in last 6 months	Behavioral treatment with educational materials, pelvic floor exercises with at least 50 pelvic floor contraction exercises each day, bladder retraining, and maintenance of a voiding diary and exercise record	No active therapy
Lagro-Janssen, 1992 ⁵⁵³ Country: The Netherlands Aim: The effects of pelvic floor exercises on stress incontinence and bladder training on urge incontinence	Women with self-reported urinary incontinence confirmed with urodynamic as stress or urge	Not reported	Pelvic floor exercises alone (stress) or bladder training (urge) or its combination (mixed)	Usual care
Lagro-Janssen, 1991 ⁵⁵⁴ Country: The Netherlands Aim: The effects of pelvic floor exercise on urinary incontinence in women	Women ages 20-65 years with genuine stress incontinence	Previously undergone an operation for incontinence; if they suffered from underlying neurological causes for incontinence, from diabetes mellitus or from urinary tract infection; or if there was a temporary cause for their incontinence (for example, pregnancy)	Instructions in pelvic floor exercises 5- 10 sessions of 10 pelvic muscle contractions for 6 seconds each day.	No therapy

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Lamb, 2009 ⁵⁵⁵ Country: UK Aim: To compare the effectiveness of group versus individual sessions of physiotherapy in terms of symptoms, quality of life, and costs, and to investigate the effect of patient preference on uptake and outcome of treatment	Women aged 18 years and over; able and willing to give informed written consent with an interpreter if necessary; clinical symptoms of stress and/or urgency incontinence.	Pregnancy; recent pelvic surgery (less than three months); history of pelvic malignancy; current urinary infection; grade III and IV prolapse; disease of the central nervous system (e.g. multiple sclerosis, cerebrovascular accident) or acute mental illness and dementia; previous physiotherapy for incontinence within the last 12 months.	Group treatment Pelvic Muscle Floor Training	Individual treatment
Lappin, 2003 ⁵⁵⁶ Country: U.S. Aim: Crossover, placebo controlled RCT to examine effects of pulsed electromagnetic fields on bladder control in patients with multiple sclerosis	Patients 18-65 years old with clinically definite multiple sclerosis and light spasticity (>2 in 6 point scale) and bladder control problems	Changes in medication last 2 months, pregnancy, pacemaker, chronic diseases	Daily simulation with low frequency pulsed electromagnetic fields	Sham inactive device
Laycock, 2001 ⁵⁵⁷ Country: UK Aim: The effects of vaginal cones, pressure biofeedback, and pelvic floor exercises on stress urinary incontinence in females	Women 20-64 years old with symptoms of stress urinary incontinence	Moderate or severe urge urinary incontinence, moderate or severe genital prolapse, pregnancy or plans to become pregnant, use of medications that can affect the lower urinary tract, HRT for <3 months, neurological diseases	Pelvic floor exercise with maximum contraction for 1 second and rest for 4 seconds, 10 minutes/day combined with home pressure biofeedback using intra-vaginal perineometer	Pelvic floor exercise for 10 minutes/day
Lee, 2001 ⁵⁵⁸ Country: Canada Aim: The effects of periurethral autologous fat injection on female stress urinary incontinence	Women with stress urinary incontinence determined by history, urinary leakage via the urethra with cough provocation	Detrusor instability on multichannel urodynamic, co-interventions, including hormone replacement, weight reduction, or Kegel exercises, other diagnoses causing incontinence, including bladder instability	Periurethral injections of autologous fat (30cc of fat from the anterior abdominal wall or buttock through a single 2-3mm) with 3 maximum injections depending on outcomes measures	Placebo (saline)

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ Country: Israel Aim: Comparative effectiveness of circular muscle exercises (Paula method) or pelvic floor muscle exercise on stress UI in women	Women at least 1 g urinary leakage in a 1-hour clinic based pad test and with the ability to understand instructions in Hebrew or English	Pregnancy or breastfeeding; 12 weeks of delivery, 6 weeks of abortion, or 6 months of pelvic surgery; cardiac, respiratory, psychiatric, and neurological illnesses that limit physical activity; no demonstrated leakage of >1 g, grade three or higher uterine prolapse	The Paula method of circular muscle exercises. The Paula method was taught by three registered instructors to give weekly individual 45-minute sessions + recommendation to practice daily for 45 minutes at home	Pelvic floor muscle training taught by ten physiotherapists using a structured exercise program in groups of 1–10 people for 30 minutes once weekly for 4 weeks, followed by two more lessons 4 weeks apart each (overall six lessons)
Liebergall-Wischnitzer, 2005 ⁵⁶⁰ Country: Israel Aim: The effects of circular muscle exercises on female urinary stress incontinence	Women, mainly hospital employees with stress or mixed urinary incontinence with urine loss >1g in pad test	Pregnancy, severe cardiac or respiratory diseases, pelvic surgery within 6 months, grade 3 and 4 cystocele, previous pelvic radiation, active mucosal lesion in vagina or perineum	Paula method of circular muscle training 15-45 minutes/day with training sessions of 45 minutes/week	Pelvic floor muscle exercise 15 minutes with 30 minute lesson session/week
Lightner, 2001 ⁵⁶¹ Country: U.S. Aim: the effects of bulking agents on stress urinary incontinence due to intrinsic sphincter deficiency in women	Women diagnosed with stress urinary incontinence due to intrinsic sphincter deficiency, abdominal leak point pressure of less than 90cm/H ₂ O, who failed prior surgical and medical treatment	355 women diagnosed with stress urinary incontinence due to intrinsic sphincter deficiency, abdominal leak point pressure of less than 90cm/H ₂ O, who failed prior surgical and medical treatment	Injection of bulking agent 1.0ml duraspHERE maximum 5 times with a minimum 7 day interval	Injection of bulking agent bovine collagen maximum 5 times with a minimum 7 day interval
Lightner, 2009 ⁵⁶² Country: U.S. Aim: Comparative effectiveness of Zuidex using a non-cystoscopy mid-urethral injection technique vs. Contigen injected endoscopically at the bladder neck in the treatment of urinary stress incontinence secondary to intrinsic sphincter deficiency in adult women	Zuidex Study Group: adult women seeking treatment for stress UI with confirmed urodynamic stress incontinence with abdominal leak point pressures <100 cm H ₂ O, positive pad testing (mean urinary leakage of >10 g during screening)	Previous treatment with bulking agents of any type, pure predominant symptoms, mean voided volumes <200 ml on bladder diary, detrusor overactivity on filling cystometry, postvoid residual volumes >100 ml on 2 occasions, or stage III or IV pelvic floor prolapse	Non-cystoscopy mid-urethral injection of Zuidex	Endoscopical injection of Contigen

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Luber, 1997 ⁵⁶³ Country: U.S. Aim: The effects of functional electrical stimulation for stress incontinence in women	Women with stress urinary incontinence who could adequately retain the vaginal probe and cooperate with the study protocol	Significant pelvic prolapse and detrusor instability, postvoid residual urine >100cc, extra urethral incontinence, history of vaginal intraepithelial neoplasia, urinary tract infection, and a fixed, immobile urethra	Functional electrical stimulation with 15-minute treatment session/day using pulse-width of 2msec scheduled for 2 seconds with 4 seconds rest, frequency of 50Hz, and power 10-100mA.	Sham stimulation with inactive device
MacDiarmid, 2010 ³⁵⁸ Country: U.S. Aim: To assess the sustained effectiveness of PTNS therapy offered at individualized intervals during 1 year in subjects who finished an initial course of 12 consecutive weekly sessions.	Subjects in the OrBIT trial who finished an initial course of 12 consecutive weekly PTNS treatments were offered ongoing sessions of therapy for an additional 9 months to monitor improvement in frequency, nocturia, urgency, urgency incontinence episodes and voided volume. Subjects were required to be OAB drug-free throughout the study.	Not reported	Percutaneous Tibial Nerve Stimulation	Percutaneous Tibial Nerve Stimulation
Majumdar, 2010 ⁵⁶⁴ Country: UK Aim: To evaluate treatment outcomes based on baseline urodynamics vs. symptoms alone	Patients over 18 years of age referred from a primary care with UI and other lower urinary tract symptoms	Patients who were referred for undergoing surgery for significant prolapse (stage2 or more) or had previous consultation and were then referred for surgery for incontinence, cognitive difficulties (consent issue), neurological disorders, previous treatment for incontinence at tertiary level, recurrent dysuria or infection on urine culture	Urodynamics	Conservative treatment based on symptoms and bladder diary
Manganotti, 2007 ⁵⁶⁵ Country: Italy Aim: The short and long-term effects of repetitive magnetic stimulation on the sacral roots	Women with stress UI, >1 episodes of stress UI in 3-day diary, >2g of urine loss in 1 hour pad test	Urinary tract infection, interstitial cystitis, large uterine myoma, severe cardiac or cerebrovascular disorders	Fifteen-Hz repetitive magnetic stimulation of the sacral roots (S2-S4) applied for 15 minutes 3 days a week for 2 weeks (6 times in all)	Sham stimulation

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Manonai, 2006 ⁵⁶⁶ Country: Thailand Aim: Cross-over RCT to examine the effect of a soy-rich diet on urogenital symptoms in peri- and postmenopausal women	Healthy premenopausal and postmenopausal women between 45-70 years old reported at least one type of urinary incontinence	Exclusion criteria: Presence or history of sex hormone dependent malignancies, liver or renal disorders, and pathology of urogenital tract	Self-selected diet with low-fat and low cholesterol foods and soy protein 25g in various forms of soy foods containing more than 50mg/day of isoflavones	Self-selected diet with low fat and low cholesterol foods
Mayer, 2007 ⁵⁶⁷ Country: U.S. Aim: Comparative effectiveness of soft-tissue augmentation of the urethral sphincter with calcium hydroxylapatite vs. glutaraldehyde cross-linked bovine collagen in female stress urinary incontinence due to intrinsic sphincter deficiency and without associated urethral hypermobility	Women age 18 years old or older, stress UI due to intrinsic sphincter deficiency without associated urethral hypermobility (straining urethral angle of 35° or less from horizontal), good bladder function and capacity (more than 250 mL without detrusor instability)	Morbid obesity (more than 100 lb over ideal body weight) and a urethral length of less than 2.5 cm	Transurethral or periurethral soft-tissue augmentation of the urethral sphincter with calcium hydroxylapatite; up to 5 injections during 6 months	Transurethral or periurethral soft-tissue augmentation of the urethral sphincter with glutaraldehyde cross-linked bovine collagen; up to 5 injections during 6 months
McDowell, 2006 ⁵⁶⁸ Country: Northern Ireland Aim: the effects of pelvic floor training and advice, electromyography biofeedback, and neuromuscular electrical stimulation on urinary incontinence in patients with multiple sclerosis	Women >18 years with multiple sclerosis stabilized for the previous 3 months. Expanded Disability Status Scale score <7.5 with at least one of the following: any involuntary leakage of urine, voiding frequency >8/24 hours, nocturia, and/or reported voiding dysfunction such as hesitancy, straining, poor stream, and incomplete emptying demonstrated by uro-flowmetry.	MS relapse necessitating hospitalization 3 months prior to or during the study, symptomatic prolapse, presence of urinary tract infection, current or recent diagnosis of a serious medical condition (other than MS), severe cognitive impairment, contraindications to neuromuscular electrical stimulation.	Pelvic Floor Training and Advice: education with booklet about normal bladder control, lifestyle interventions (weight reduction, relieving constipation, cessation of smoking, caffeine reduction, fluid management, clothing, reducing emotional stress)	Pelvic Floor Training and Advice with EMG Biofeedback and neuromuscular electrical stimulation. Stimulation at clinic (weekly) initially for 5 min 30 minutes using pulse rate 40Hz, pulse width 250msec, with 5sec on and 10 sec off or 10 Hz, 450msec, 10sec

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>McDowell, 1999⁵⁶⁹ Country: U.S. Aim: Cross-over RCT to examine the effects of behavioral therapies of urinary incontinence in homebound older adults.</p>	<p>Adults 60 years and older, homebound (Health Care Financing Administration, cognitively intact (Folstein Mini-Mental State Examination score >24), with urinary incontinence (>2 urinary accidents/week for at least 3 months), who understand and speak English</p>	<p>Folstein MMSE scores <24, severe pelvic prolapse, terminal illness, post-void residual >100ml unable to toilet independently, no caregiver willing and able to assist with toileting, <2 urinary accidents per week, unable to provide satisfactory self-report</p>	<p>Biofeedback-assisted pelvic floor muscle training by nurse practitioners skilled in behavioral therapies for urinary incontinence. Behavioral therapy: 8 weekly sessions at homes with biofeedback-assisted pelvic floor muscle exercises, urge and stress strategies, and bladder training</p>	<p>Usual care with attention control (visits by the nurse practitioner every 1-2 weeks to provide social interaction).</p>
<p>McFall, 2000⁵⁷⁰ Country: U.S. Aim: The effects of group educational intervention for urinary incontinence in elderly women</p>	<p>Women ages 65 or older with self reported urinary incontinence ≥3 months, residing in Oklahoma.</p>	<p>Severe prolapse of uterus, hematuria, diverticulum, fistula, unresolved urinary tract infection, two or more urinary tract infections within 3 months, urinary obstruction, overflow incontinence, a postvoid residual volume of urine (PVR) >100ml, and blood</p>	<p>Community-based intervention with 5 biweekly sessions of education and skill-building, for bladder training, managing the urge to urinate, and performing pelvic muscle exercises. Group support by registered nurses; occupational therapist, and public health professional</p>	<p>Usual care</p>
<p>McFall, 2000⁵⁷¹ Country: U.S. Aim: To report an assessment of a community-based intervention for UI and to summarize the outcomes of the intervention model related to incontinence and other urinary symptoms.</p>	<p>Women 65 years or older and had urinary incontinence for 3 months or more.</p>	<p>Severe prolapse of uterus, hematuria, diverticulum, fistula, unresolved urinary tract infection, two or more urinary tract infections within 3 months, urinary obstruction, overflow incontinence, a postvoid residual volume of urine (PVR) >100 ml, and blood glucose >300 mg/dl on two or more visits in a 3 month period. Functional or disability exclusions were being homebound because of frailty, severe hearing or vision problems, low literacy, and cognitive impairment.</p>	<p>Small group educational approach</p>	<p>Wait control</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Miller, 1998⁵⁷² Country: U.S. Aim: The effects of intentionally contracting the pelvic floor muscles before and during a cough on mild and moderate female stress urinary incontinence.</p>	<p>Women with self reported stress urinary incontinence and demonstrable urine loss during a deep cough with leakage occurring at least weekly and up to 5 times/day.</p>	<p>History of systemic neuromuscular disease, previous bladder surgery, active urinary tract infection, leakage that was delayed after coughing and categorized as detrusor instability, leakage that saturated a paper towel and/or pooled on the floor when coughing in the standing posture, inability to demonstrate any voluntary contraction of the pelvic floor muscles despite detailed instruction during the pelvic exam, and significant coexistent pelvic organ prolapse below the hymenal ring</p>	<p>Immediate intervention group taught intentionally contracting the pelvic floor muscles before and during a cough (Knack)</p>	<p>Wait-listed control group</p>
<p>Moore, 2003⁵⁷³ Country: Australia Aim: The effects of nurse continence advisors and urogynecologists in conservative management of urinary incontinence.</p>	<p>Patients with stress and/or urgency incontinence with idiopathic detrusor instability, sensory urgency, and mild or moderate leakage (urine loss in 1-hour pad test 2-9.9ml/hour or 10-50ml/hour).</p>	<p>Previous pelvic radiotherapy, proven recurrent bacterial cystitis, prolapse beyond the introitus, uterine enlargement or incomplete bladder emptying (postvoid residual >100ml).</p>	<p>2 nurse continence advisors/patient and consulting urogynecologist for 25-35 minutes/week provided bladder training, gradual increase in fluid intake, individual deferment techniques, pelvic floor muscle exercise and examination, transvaginal electro stimulation</p>	<p>Outpatient regimen with 15-20 minute consultation with referral to physiotherapist and bladder training.</p>
<p>Morkved, 2002⁵⁷⁴ Country: Norway Aim: The effects of individual pelvic floor muscle training with and without biofeedback in women with urodynamic stress incontinence.</p>	<p>Women with symptoms of stress incontinence and >2g leakage measured by a pad test with standardized bladder volume.</p>	<p>Involuntary detrusor contractions on cystometry, abnormal bladder function (residual urine >50ml), previous surgery for stress incontinence, neurologic or psychiatric disease, urinary tract infection, other diseases that could interfere with participation</p>	<p>Pelvic floor muscle training with 3 sets of 10 contractions 3 times/day, individually supervised by a physical therapist. At home, 3 sets of 10 high intensity (close to maximum) contractions per day with a biofeedback apparatus</p>	<p>Pelvic floor muscle training with 3 sets of 10 contractions 3 times/day, individually supervised by a physical therapist. At home, 3 sets of 10 high intensity (close to maximum) contractions per day without biofeedback</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Du Moulin, 2007 ⁵⁷⁵ Country: The Netherlands Aim: Effects of a specialized nurse in the care of community-dwelling women with urinary incontinence	Community-dwelling women aged 18 years who attended general practitioner clinic because of urinary incontinence	Urinary tract infection, PVR of 100 mL or more, delivery within 3 months preceding recruitment, bladder cancer, renal disease, or uterine prolapse past the introitus	The continence nurse and multidisciplinary team comprising a GP, urologist, physiotherapist	Standard care provided by the general practitioners
Nager, 2009 ⁵⁷⁶ Country: U.S. Aim: association between successful incontinence pessary fitting or pessary size and specific pelvic organ prolapse measurements in women without advanced pelvic organ prolapse	Pelvic Floor Disorders Network (PFDN): women with stress urinary incontinence (SUI) and POPQ stage ≤ 2	Not reported	Incontinence pessary+ behavioral therapy including pelvic floor muscle training and exercise and bladder control strategies	Incontinence pessary
Ng, 2008 ⁵⁷⁷ Country: Taiwan Aim: The effect of nursing intervention to enhance the efficacy of a home-based pelvic floor muscle exercise on mixed urinary incontinence in community-dwelling women	Women with mixed urinary incontinence interested in behavioral training and potentially available for telephone contact	No educational background, dependent in daily activities	A registered nurse monitoring via telephone checkups twice a week home based PFMT. Education about the pelvic anatomy, the function of the pelvic floor muscle, the bladder and urethra, the use of PFMT, and how to perform PFMT: 1 hour per session, twice weekly, for 4 weeks in total.	Home based PFMT. Education about the pelvic anatomy, the function of the pelvic floor muscle, the bladder and urethra, the use of PFMT, and how to perform PFMT:1 hour per session, twice weekly, for 4 weeks in total.
Nielsen, 1993 ⁵⁷⁸ Country: Denmark Aim: Cross-over RCT to examine effects of urethral plug on female genuine urinary stress incontinence	Women with genuine urinary stress incontinence	Not reported	Urethral plug as oval metal plate, a soft stalk, and 1 sphere along the stalk with fixed distances between the metal plate and the spheres. Inside the stalk is a removable semi-rigid guide pin to ease insertion.	Urethral plug as oval metal plate, a soft stalk, and 2 spheres along the stalk with fixed distances between the metal plate and the spheres. Inside the stalk is a removable semi-rigid guide pin to ease insertion.
Nygaard, 1995 ⁵⁷⁹ Country: U.S. Aim: Crossover RCT to examine the effects of Hodge pessary with support, a super tampon on urinary incontinence during exercise.	Female exercisers ages 33-73 with urinary incontinence during exercise and positive coughing test.	Prolapse of the uterus, stenotic vagina, or pelvic mass.	40-minute standardized aerobics session wearing a Hodge pessary with support 40-minute standardized aerobics sessions wearing a super tampon	40-minute standardized aerobics sessions with no mechanical device

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Nygaard, 1996 ⁵⁸⁰ Country: U.S. Aim: The effects of pelvic floor muscle exercises in combination with specially designed audiotape on stress, urge, and mixed urinary incontinence in women.	Women non pregnant women >21 years old with urinary incontinence.	Genital prolapse past the vaginal introitus, parturition within the preceding 6 months, and deafness	Pelvic floor muscle exercises with 2 5-minute daily sessions, beginning with contractions for 4-8 seconds in combination with specially designed audiotape with 270 minutes of music and verbal instructions of technique tips, reminders, and exercise cues.	Pelvic floor muscle exercises with 2 5-minute daily sessions, beginning with contractions for 4-8 seconds.
O'Brien, 1991 ⁵⁸¹ Country: England Aim: The effects of pelvic floor exercises and bladder retraining supervised by non-specialist nurse on urinary incontinence in adults with regular urinary incontinence.	Adults aged 35 years and older with regular urinary incontinence (two or more leaks in any one month).	Urinary tract infection.	Four sessions of pelvic floor exercises and bladder retraining supervised by non-specialist nurse.	Usual care
O'Brien, 1996 ⁵⁸² Country: UK Aim: Long term (followup of O'Brien, 1991 ⁵⁸¹) effects of behavioral training on urinary incontinence in adult women	Female patients over 35 years from two large Somerset general practices with urinary incontinence two or more leaks in any one month	Reported previously ⁵⁸¹	Nurse-led four sessions of pelvic floor exercises or bladder retraining depending on the dominant symptoms (stress or urge respectively)	Postponed treatment
Oldham, 2010 ⁵⁸³ Country: Canada Aim: Evaluation of a self-contained, fully automated, disposable device (Femestin), with application similar to that of a tampon	Women with urinary incontinence were recruited via a process of self referral through ads placed in local newspapers and on local radio to reflect future practice	Not reported	Pelvic Floor Exercises obtained from Bladder and Bowel Foundation + Femestin device	Pelvic Floor Exercises obtained from Bladder and Bowel Foundation
O'Sullivan, 2003 ⁵⁸⁴ Country: Australia Aim: The effect modification by baseline severity of any urinary incontinence on continence rates after nurse intervention in women with urodynamic UI	Women with urodynamically proven GSI, DI, or Sumild (2-9.9 g) to moderate (10-49.9 g) incontinence (as judged by weight gain on 1-hour pad testing)	Previous pelvic radiotherapy, proven recurrent bacterial cystitis, prolapse beyond the introitus, uterine enlargement of duration more than 12 weeks, or incomplete bladder emptying (residual >100 ml)	Nurse continence adviser with the first visit of 45 minutes with pelvic floor digital testing, verbal biofeedback, bladder training with individual deferment techniques; followup weekly visits of approximately 30 minutes with re-exam of pelvic floor muscle	Routine urogynecology outpatient therapy with a referral note to a physiotherapist (SUI) or educational videotape about bladder training (Urge UI) or anticholinergic therapy (DI)

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Pages, 2001⁵⁸⁵ Country: Germany Aim: The effects of intensive group physical therapy program with individual biofeedback training for female patients with urinary stress incontinence.</p>	<p>51 women, referred by gynecologists for nonoperative treatment of genuine stress incontinence of mild-to-moderate severity.</p>	<p>Not reported</p>	<p>Specific physical therapy program. Group therapy 5 times/week and home pelvic floor exercise with 50 contractions for 10 minutes 2 times/day. Recommendation of weight loss and aerobic sports.</p>	<p>Biofeedback training daily 90-minutes in group and individually for 15 minutes, 5 times/week; Intra vaginal pressure sensor and visual biofeedback in computer monitor</p>
<p>Peters, 2010⁵⁸⁶ Country: U.S. Aim: To compare the efficacy of PTNS to a validated sham</p>	<p>Women and men ≥ 18 years of age; a score of ≥ 4 on the OAB-q short form for urgency; average urinary frequency of ≥ 10 voids per day; self-reported bladder symptoms ≥ 3 months; self-reported failed conservative care; discontinued all antimuscarinic for ≥ 2 weeks; capable of giving informed consent; ambulatory and able to use toilet independently without difficulty; and capable and willing to follow all study-related procedures</p>	<p>Pregnant or planning to become to pregnant during the study; neurogenic bladder; Botox use in bladder or pelvic floor muscles within the past one year; pacemakers or implantable defibrillators; current urinary tract infection; current vaginal infection; use of Interstim; use of Bion; current use of TENS in pelvic region, back or legs; previous PTNS treatment; use of investigational drug/device therapy within past 4 weeks; and participation in any clinical investigation involving or impacting gynecologic, urinary or renal function within past 4 weeks</p>	<p>Percutaneous tibial nerve stimulation</p>	<p>Placebo</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Peters, 2010⁵⁸⁷ Country: U.S. Aim: To compare the efficacy of PTNS to a validated sham in subjects who have previously used OAB pharmacologic therapy</p>	<p>Subjects who previously used OAB pharmacologic therapy prior to their participation in the study. Women and men ≥ 18 years of age; a score of ≥ 4 on the OAB-q short form for urgency; average urinary frequency of ≥ 10 voids per day; self-reported bladder symptoms ≥ 3 months; self-reported failed conservative care; discontinued all antimuscarinic for ≥ 2 weeks; capable of giving informed consent; ambulatory and able to use toilet independently without difficulty; and capable and willing to follow all study-related procedures.</p>	<p>Pregnant or planning to become pregnant during the study; neurogenic bladder; botox use in bladder or pelvic floor muscles within the past one year; pacemakers or implantable defibrillators; current urinary tract infection; current vaginal infection; use of Interstim; use of Bion; current use of TENS in pelvic region, back or legs; previous PTNS treatment; use of investigational drug/device therapy within past 4 weeks; and participation in any clinical investigation involving or impacting gynecologic, urinary or renal function within past 4 weeks</p>	<p>Percutaneous Tibial nerve stimulation</p>	<p>Placebo</p>
<p>Ramsay, 1996⁵⁸⁸ Country: Scotland Aim: Comparative effectiveness of inpatient vs. outpatient behavioral treatment for urinary incontinence in women</p>	<p>Women with urgency, nocturia, urgency incontinence and stress incontinence</p>	<p>Previous treatment for their incontinence, symptoms of hematuria, recurrent dysuria or voiding difficulty, or infection on urine culture</p>	<p>Bladder retraining and physiotherapy as an inpatient 5-day hospital stay</p>	<p>Bladder retraining and physiotherapy as an outpatient with two 2-hour sessions, 1 week apart.</p>
<p>Richter, 2010³⁶¹ Country: U.S. Aim: To compare the effectiveness of a continence pessary to evidence-based behavioral therapy for stress incontinence and to assess whether combined pessary and behavioral therapy is superior to single modality therapy</p>	<p>ATLAS trial: Women at least 18 years old with symptoms of stress only or stress-predominant mixed-incontinence symptoms</p>	<p>Previously reported in Richter, 2007⁵⁸⁹</p>	<p>Behavioral therapy</p>	<p>Pessary + Behavioral therapy/Pessary alone</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Robinson, 2003 ⁵⁸⁹ Country: Canada Aim: The effects of new urethral device or the reliance insert on female urinary incontinence.	Women 30-75 years old with mixed or stress urinary incontinence >2 episodes/week >2g urine loss on baseline pad weight test, with sound mental condition, willing to use >3 devices/week.	Overflow incontinence or neurogenic bladder, type III incontinence, kidney inflammatory diseases, urinary tract infection, use of anticoagulants or incontinence medications, allergy to antibiotics, diabetes mellitus type II, pregnancy, urethral mucosal abnormalities, prosthetic heart valve, HRT last 3 months, collagen injections or other urethral bulking agents last 3 months, detrusor contraction >20cm/H2O.	Urethral device (NEAT) – sterile urethral insert with disposable applicator packaged with device.	Reliance insert sterile balloon type device
Sand, 1995 ⁵⁹⁰ Country: U.S. Aim: The effects of transvaginal electrical stimulation in treating genuine stress incontinence.	Community dwelling women with urodynamically proven genuine stress incontinence, who would comply with visits, not use/seek other treatment for incontinence.	Detrusor instability, pregnancy, pacemaker, prior pelvic floor stimulation, pelvic implanted devices, active vaginal lesions or infections, urinary tract infection, hypermenorrhea or menorrhagia, urinary retention (>100ml), pelvic surgery in past 6 months	Active pelvic floor stimulator with gradually adjusted 60-80mA from 5 seconds on/1 second off for 15 minutes to 5 seconds on/5 seconds off for 30 minutes.	Sham inactive device
Schreiner, 2010 ⁵⁹¹ Country: Brazil Aim: To examine the efficacy of transcutaneous electrical tibial nerve stimulation to treat urge urinary incontinence in older women	Patients from the Urogynecology Section of the Gynecology Department in Sao Lucas Hospital of Pontificia Universidade Catolica do Rio Grande do Sul in the city of Porto Alegre with complaint of urgency incontinence and age of 60 years or more.	Presence of urinary infection during the recruitment process, prior surgery for urinary incontinence, history of genito-urinary cancer, prior pelvic irradiation, pure stress urinary incontinence, genital prolapse above the second degree of Walker, and inability to perform the Kegel exercises.	Transcutaneous electrical tibial nerve stimulation + Bladder training	Bladder training

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Schulz, 2004 ⁵⁹² Country: Canada Aim: The effects of periurethral and transurethral injections of bulking agents on stress urinary incontinence in females.	40 women ages 18-80 years old, with genuine stress incontinence for >12 months, or mixed incontinence with a minor and controlled urge component, who failed 3 months conservative treatments.	Other treatments for incontinence, urinary tract infection, bladder capacity <250ml or postvoid residual volume >100ml, neurogenic bladder, grade 3 cystocele, uterine prolapse or rectocele, radiation of urethra, pregnancy, life expectancy <15 months.	Periurethral route of injection of bulking agent-dextran copolymer	Transurethral route of injection of bulking agent-dextran copolymer
Seo, 2004 ⁵⁹³ Country: South Korea Aim: The effects of vaginal cone with conventional FES-biofeedback therapy for female urinary incontinence.	Patients, who required a non-surgical treatment for urinary incontinence.	Not reported	Pelvic floor exercise (5 second contraction and 10 second relaxation, 3-5 times for >5 minutes/day) and functional electrical stimulation biofeedback (35Hz-50Hz for 24 seconds); 2 training sessions/week.	Vaginal cone, 150g dumbbell-shaped made of fine ceramic material.
Sherman, 1997 ⁵⁹⁴ Country: U.S. Aim: The effects of pelvic muscle exercises with urethral biofeedback on exercise-induced urinary incontinence in female soldiers.	Female active duty soldiers with exercise-induced urinary incontinence (stress or mixed).	Not reported	Pelvic muscle exercises with contractions for 10 seconds and relaxation for 10 seconds 5 times/session, 20 minutes twice/day with urethral biofeedback using vaginal EMG probe.	Pelvic muscle exercises with contractions for 10 seconds and relaxation for 10 seconds 5 times/session 20 minutes twice/day alone.
Smith, 1996 ⁵⁹⁵ Country: U.S. Aim: The effects of intravaginal electrical stimulation on genuine stress urinary incontinence and detrusor instability in women.	Women with urinary incontinence.	Type 3 stress urinary incontinence, pregnancy, urinary retention, vaginal prolapse, cardiac pacemaker, mixed incontinence with no major and minor components.	18 women with stress urinary incontinence: Electrical stimulation using frequency 12.5Hz.-50Hz and amplitude 5-10mA-80mA for 15 to 60 minutes 2/day 38 women with detrusor instability Anticholinergic therapy with Propantheline bromide in dose of 7.5 to 4	Kegel exercise

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Spruijt, 2003⁵⁹⁶ Country: The Netherlands Aim: The effects of intravaginal electrical stimulation of the pelvic floor for urinary incontinence in elderly women.</p>	<p>Women ≥65 years of age, with symptoms of stress, urge or mixed urinary incontinence of >3 months' duration, and with urinary leakage >10cc/24hours.</p>	<p>Persistent urinary tract infection (positive urine culture after antibiotic treatment), recurrent urinary tract infection (within 4 weeks after treatment), bladder pathology or dysfunction because of fistula, tumor, pelvic irradiation, neurological or other chronic conditions (diabetes mellitus, Parkinson's disease), genital, pacemaker, and insufficient mental condition.</p>	<p>Intravaginal electrical stimulation of the pelvic floor using stimulator generated biphasic current pulses with duration of 1ms and a frequency of 50Hz (stress urinary incontinence) or 20Hz (urge urinary incontinence).</p>	<p>Kegel exercise program with verbal instructions on how to exercise at home.</p>
<p>Strasser, 2007⁵⁹⁷ Country: Austria Aim: The effects of ultrasonography-guided injections of autologous cells or endoscopic injections of collagen on stress urinary incontinence.</p>	<p>Females 36-84 years old with intrinsic sphincter insufficiency or stress urinary incontinence with only mild hypermobility of the urethra and the urinary bladder; good state of health who failed pelvic floor muscle exercises.</p>	<p>Urgency incontinence and pronounced hypermobility of the urethra.</p>	<p>Transurethral ultrasonography-guided injections of autologous myoblasts and fibroblasts; regular training of the rhabdosphincter for 12 weeks and trans vaginal electrical stimulation for 4 weeks.</p>	<p>Conventional endoscopic injections of collagen; regular training of the rhabdosphincter for 12 weeks and trans vaginal electrical stimulation for 4 weeks</p>
<p>Subak, 2002⁵⁹⁸ Country: U.S. Aim: The effects of low-intensity behavioral therapy program on urinary incontinence in older women</p>	<p>Women 55 years and older with self reported urinary incontinence, members of health maintenance organization, living independently in the community and functionally capable of independent toileting.</p>	<p>Uncontrolled diabetes mellitus, urinary tract infection, history of urinary obstruction, overflow, functional incontinence, urinary tract anomalies</p>	<p>6 weekly 20-minute group instructional sessions on bladder training by nurse educators and followed individualized voiding schedules.</p>	<p>Usual care</p>
<p>Subak, 2005⁵⁹⁹ Country: U.S. Aim: The effect of weight loss on urinary incontinence in overweight and obese women.</p>	<p>48 women 18 to 80 years old with body mass index between 25 and 45 kg/m², urinary incontinence for at least 3 months and at least 4 incontinent episodes/week, the stable dose of other incontinence therapy .</p>	<p>Exclusion criteria: pregnancy, urinary tract infection, significant medical condition, pelvic cancer, neurological condition possibly associated with incontinence, interstitial cystitis or potential inability to complete the study.</p>	<p>Weight reduction intervention: 3-month standard low calorie liquid diet (800kcal/day or less), increased physical activity to 60 minutes/day, training by a nutritionist, exercise physiologist or behavioral therapist</p>	<p>Usual care</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Subak, 2009 ⁶⁰⁰ Country: U.S. Aim: Effectiveness of weight loss on urinary incontinence in obese women	Women at least 30 years of age, a body-mass index of 25 to 50, >10 urinary-incontinence episodes/week, ability to walk unassisted for two blocks (approximately 270 m) without stopping	Pregnancy, urinary tract infection, significant medical condition, pelvic cancer, neurological condition possibly associated with incontinence, interstitial cystitis or potential inability to complete the study.	Intensive 6-month weight-loss program to produce an average loss of 7 to 9% of initial body weight that included diet, exercise, and behavior modification (AHEAD ,Action for Health in Diabetes) trial	Structured education program: four education sessions at months 1, 2, 3, and 4. During these 1-hour group sessions, which included 10 to 15 women, general information was presented about weight loss, physical activity, and healthful eating habits
Sung, 2000 ⁶⁰¹ Country: Korea Aim: The effects of pelvic floor muscle exercises on female genuine stress incontinence.	Married women with urinary incontinence.	Not reported.	Functional electrical stimulation-biofeedback for 20 minutes/session with frequency 35Hz-50Hz and contractions of 32 seconds, 2 sessions/week Intensive pelvic floor muscle exercises	Control usual care
Sung, 2000 ⁶⁰² Country: South Korea Aim: Comparative effectiveness of pelvic floor muscle exercise and the functional electrical stimulation - biofeedback for female urinary incontinence	Married women diagnosed with genuine stress UI	Not reported	Intensive pelvic floor muscle exercise at home, videotape with instructions to perform exercise, weekly examination of accuracy and intensity of contractions	Functional electrical stimulation (FES)-biofeedback for 20 minutes/session, 2 sessions/week and weekly examination of accuracy and intensity of contractions. Pelvic electrical stimulation for 24 seconds at 35 and 50 Hz simultaneously followed by biofeedback
Swithinbank, 2005 ⁶⁰³ Country: England Aim: Cross-over RCT to examine the effect of caffeine restriction and fluid manipulation in the treatment of patients with urodynamic stress incontinence.	Women with urodynamically proven stress incontinence naive to surgery.	Urinary tract infection, hepatic, cardiac or renal disease and diabetes mellitus, use of antidepressants, anticholinergics or diuretics.	1. Increased decaffeinated fluids to 3 liters daily (20 cups) or decreased decaffeinated fluids to 750ml (5 cups) daily 2. Caffeine restriction and increased fluid intake to 2, 2,673ml/day 3. Caffeine restriction and decreased fluid intake to 872ml/day	Usual care

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
<p>Tibaek, 2007⁶⁰⁴ Country: Denmark Aim: The long term effect of pelvic floor muscle training in women with urinary incontinence after stroke</p>	<p>Women, diagnosed with first ever ischemic stroke according to the definition of World Health Organization and verified by CAT scan, stroke symptoms in at least one month; normal cognitive function (mini-mental state examination a.m. Folstein >25); urinary incontinence according to the definition of ICS that started in close relation to the stroke; independent walking abilities indoors >100 meters with/without aids; independence in toilet visits; and age between 40–85 years.</p>	<p>Urinary tract infection; symptoms of descensus urogenitale; chronic respiration diseases; psychiatric diseases; other neurological diseases; and do not speak Danish.</p>	<p>Systematic, controlled, intensive pelvic floor muscle training program by the specialist physiotherapist: group treatment with 6–8 patients/group for 1 hour/week, vaginal palpation 2-3 times and home exercises 1-2 times daily</p>	<p>Standard program of rehabilitation for patients with stroke without any specific treatment of urinary incontinence</p>
<p>Theofrastous, 2002⁶⁰⁵ Country: U.S. Aim: The efficacy of bladder training and pelvic muscle exercise with biofeedback-assisted instruction on urinary incontinence in women.</p>	<p>Community-dwelling women 45 years and older diagnosed with genuine stress incontinence, (urine loss at least once per week), with urodynamic evidence of genuine stress incontinence, and mentally intact (Mini-Mental State Examination Score >23).</p>	<p>Reversible causes of urinary incontinence, uncontrolled metabolic conditions, residual urine volume after voiding >100ml, urinary tract infection, genitourinary fistula or indwelling catheterization, and inability to correctly perform a pelvic muscle contraction</p>	<p>Pelvic floor muscle training: 4 office biofeedback sessions and home exercise with two sets of 5 quick and 10 sustained contractions with 10-second rest periods increased to 5 quick and 20 sustained contractions 2/day for a total of 50 contractions per day</p>	<p>Bladder training</p>
<p>Thornburn, 1997⁶⁰⁶ Country: UK Aim: The relationship between pad properties (absorption capacity, strike-through, and wetback) and wet comfort in women with light urinary incontinence</p>	<p>Women with light urinary incontinence who used disposable incontinence pads</p>	<p>Not reported</p>	<p>Pad A with the largest wetback</p>	<p>Pad B with the largest strike-through time; Pad F with the largest absorption capacity</p>

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Thyssen, 2001 ⁶⁰⁷ Country: Denmark Aim: Crossover RCT to examine the effects of disposable intravaginal device on stress incontinence in women.	Women with the predominant symptom of stress incontinence, 39 were recruited in Denmark, 28 in England, and 27 in Australia.	Major uterovaginal prolapse	Conveen Continence Guard, CCG made of hydrophilic polyurethane and requires soaking in water before being placed on a handle like applicator for insertion.	Contrelle Continence Tampon, CCT, Coloplast made of hydrophobic polyurethane and supplied ready-assembled within an applicator, allowing insertion directly into the vagina with no manual contact
Tibaek, 2004 ⁶⁰⁸ Country: Denmark Aim: The effect of pelvic floor muscle training in women with urinary incontinence after ischemic stroke	Women diagnosed with first-ever ischemic stroke according to the definition of the World Health Organization and verified by CAT scan; stroke symptoms in at least 1 month; normal cognitive function (Mini-mental state examination a.m. Folstein >25)	Urinary tract infection; symptoms of descensus urogenitale; chronic respiration diseases; psychiatric diseases; other neurological diseases; and do not speak Danish	Systematic, controlled, intensive pelvic floor muscle training program in 12 consecutive weeks by the same specialist physiotherapist. Women received instructions how to perform strength PFM exercise with close to maximum contraction (6 s contraction/6 seconds relaxation	The normal, standard program of rehabilitation without any specific treatment of urinary incontinence
Tibaek, 2005 ⁶⁰⁹ Country: Denmark Aim: The effect of pelvic floor muscle training in women with urinary incontinence after ischemic stroke.	Women 40 and 85 years old with acute ischemic stroke verified by CAT scan lasting >24 hours; stroke symptoms in at least 1 month; normal cognitive function (mini-mental state examination >25); urinary incontinence related to stroke; independent walking	Urinary tract infection; symptom of vaginal prolapse; chronic respiratory diseases; psychiatric diseases; other neurological diseases; does not speak Danish.	Intensive pelvic floor muscle training 1-2 times/day by specialized physiotherapist: group information on incontinence and instruction in self-palpation of PFM, motivation and instruction in home exercises	Usual care
Tsai, 2009 ⁶¹⁰ Country: Taiwan Aim: Comparative effectiveness of interpersonal support and digital vaginal palpation as part of the pelvic floor muscle exercise training compared to pelvic floor muscle exercise training with a printed handout instructions on stress urinary incontinence	Women who presented to the family medicine outpatient clinic without having urine leakage as their chief complaint but with transient UI	Severe uterine prolapse, past the vaginal introitus, heart failure; history of dementia (Mini-Mental State Examination (MMSE) score <24); prior knowledge of PFME prescribed by a physician, a nurse, a physical therapist, or any other health problems	Interpersonal support and digital vaginal palpation as part of the pelvic floor muscle exercise training. The researcher contacted the patients of experimental group by telephone once per week to inquire about any difficulties and/or improvements	Pelvic floor muscle exercise training with a printed handout instruction

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Wang, 2004 ⁶¹¹ Country: Taiwan Aim: The efficacy of pelvic floor muscle training, biofeedback-assisted PFMT, and electrical stimulation in the management of overactive bladder.	Women 16-75 years, symptoms of overactive bladder for more than 6 months, frequency of voiding eight times or more per day, and urgency incontinence one time or more per day.	Pregnancy, deafness, neurologic disorders, diabetes mellitus, pacemaker or intrauterine device use, genital prolapse greater than Stage II of the International Continence Society grading system, residual urine >100ml, and urinary tract infection.	1. Pelvic floor muscle training with submaximal to maximal PFM contractions for 6 seconds 5 times and 10 fast contractions per session at least 3 times/day. 2. Biofeedback-assisted pelvic floor muscle training with an intravaginal electromyogram probe to contract or relax PFMs following the visual EMG signals.	Electrical stimulation in the management of overactive bladder with intravaginal electrode at the physiotherapy unit.
Wells, 1991 ⁶¹² Country: U.S. Aim: The effects of pelvic muscle exercise or pharmacologic treatment of stress urinary incontinence in community-living elderly women	Community-living women, ages 55 to 90 years.	Nursing home residency	Pelvic muscle exercises with contractions for 10 seconds and relaxation for 10 seconds, 90-160 times/day.	Phenylpropanolamine hydrochloride in a dose of 50mg /day, increasing to 50mg 2 times/ day
Williams, 2005 ⁶¹³ Country: England Aim: The effects of continence service provided by specially trained nurses delivering evidence-based interventions using predetermined care pathways in adults.	Men and women aged 40 years and over living in private households reporting incontinence several times per month or more, or several times a year and reported significant impact of symptoms on quality of life.	Pregnancy, urinary fistula, pelvic malignancy, treatment for urinary symptoms.	Continence service that included advice on diet and fluids; bladder training; pelvic floor awareness and lifestyle advice.	Existing primary care including GP and continence advisory services in the area
Williams, 2006 ⁶¹⁴ Country: UK Aim: The efficacy and cost-effectiveness of pelvic floor muscle therapies in women ≥40 years with urodynamic stress incontinence and mixed UI	Women ≥40 years were randomly sampled by household from the Family Health Service Authority registers of participating GP practices and invited if they had urodynamic diagnosis of USI or mixed UI and DO	Pregnant, had urinary fistula, pelvic malignancy, severe prolapse and those currently receiving treatment for urinary symptoms (e.g. on a waiting list for continence surgery).	Pelvic floor muscle training by specially trained nurses, after an initial digital assessment and perineometry to develop individualized exercise regimen.	Standard care: leaflet with information about pelvic floor muscles and three steps in exercising these muscles

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Wing, 2010 ⁶¹⁵ Country: U.S. Aim: To examine the longer term effects of a weight loss intervention on urinary incontinence.	Being at least 30 years old, having a BMI of 25 to 50 kg/m ² , reporting at least 10 UI episodes on a 7-day voiding diary at baseline and agreeing not to initiate new treatments for incontinence or weight reduction during the trial.	Reported Previously in Subak, 2009600	Behavioral weight loss program	Structured education program
Wong, 2001 ⁶¹⁶ Country: China Aim: The efficacy of biofeedback in Chinese women with urinary stress incontinence	Chinese women with genuine stress incontinence	Second or third degree uterine prolapse, previous failure of pelvic floor muscle exercise, continence surgery, pad test with urine loss <2g, neurologic disease.	Biofeedback from the abdominal muscle contractions during pelvic floor exercises with EMG attached over their abdominal muscles	Biofeedback from pelvic floor muscles during pelvic floor exercises
Wyman, 1997 ⁶¹⁷ Country: U.S. Aim: The effects of bladder training on quality of life in older women with urinary incontinence.	Women 55 years and older, ambulatory, mentally intact, independent residents in the community with urodynamic stress urinary incontinence >1 episode/week.	Metabolic decompensation, urinary tract infection, outlet obstruction, fistula, reversible cause of urinary incontinence, permanent indwelling catheter.	Bladder training: patient education, progressive scheduled voiding regimen, positive reinforcement.	Usual care
Wyman, 1998 ⁶¹⁸ Country: U.S. Aim: The efficacy of bladder training, pelvic muscle exercise with biofeedback-assisted instruction, and combination therapy, on urinary incontinence in women.	Community-dwelling women age 45 years and older diagnosed with genuine stress incontinence, (urine loss at least once per week), with urodynamic evidence of genuine stress incontinence, and mentally intact (Mini-Mental State Examination Score >23).	Reversible causes of urinary incontinence, uncontrolled metabolic conditions, residual urine volume after voiding >100ml, urinary tract infection, genitourinary fistula or indwelling catheterization, and inability to correctly perform a pelvic muscle contraction	Structured 12-week program of patient education, self-monitoring of voiding behavior with daily treatment logs, compliance assessment, and positive reinforcement administered by trained registered nurses.	Bladder training

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Yamanishi, 1997 ⁶¹⁹ Country: Japan Aim: CT to examine the effects of electrical pelvic stimulation in stress incontinence.	Patients with stress incontinence.	Persistent urinary infection, uterine or rectal prolapse and cystocele, severe cardiac or cerebrovascular disorders including on-demand heart pacemakers, hepatic disorders and renal dysfunction. Anticholinergics, calcium antagonists, alpha or beta agonists or antagonists, or tricyclic depressants were discontinued 1 week before entry in the study.	Electrical pelvic stimulation with 50Hz. square waves of 1msec. pulse duration and vaginal electrode in women and an anal electrode in men for 15 minutes 2 or 3 times daily	Sham electrical pelvic stimulation with inactive device
Yamanishi, 2000 ⁶²⁰ Country: Japan Aim: The effects of electrical stimulation for urinary incontinence due to detrusor overactivity	Patients with urinary incontinence due to detrusor overactivity urodynamically defined as involuntary detrusor contractions of more than 15cm/H2O during the filling phase.	Use of anticholinergics or tricyclic depressants, pelvic floor exercise, bladder training, or pelvic surgery before entry into the study.	Electrical stimulation 15 minutes twice daily for 4 weeks (vaginal electrode in women and an anal or surface electrode in men to provide alternating pulses of 10Hz square waves of 1-ms pulse duration and a maximum output current of 60mA).	Sham inactive device
Yoon, 2003 ⁶²¹ Country: South Korea Aim: The effectiveness of bladder training versus pelvic muscle exercises in the treatment of urinary incontinence in women.	Parous women 35–55 years old with urine loss of 1.0g or more on a 30 minute pad test and 14 voids or more during a period of 48 hours before the preliminary evaluation.	Urinary tract infection tested by urinalysis and urine culture, previous experience of surgery for urinary incontinence, HRT and other medication for urinary incontinence.	Bladder training with increased interval between voluntary voids ; Pelvic muscle exercise (30 contractions for 15 to 20 minutes/day) with immediate and simultaneous visual feedback of pelvic muscles during a 20 minute weekly biofeedback session	Usual care

Appendix Table F81. Randomized controlled clinical trials of nonpharmacological nonsurgical treatment for UI (continued)

Reference country aim of the Study	Inclusion criteria	Exclusion criteria	Active treatment	Control treatment
Zanetti, 2007 ⁶²² Country: Brazil Aim: Comparative effectiveness of pelvic floor muscle exercises with or without physiotherapist supervision on female stress UI	Women with stress urinary incontinence confirmed by means of urodynamic testing	Topical hormone replacement therapy for less than three months, disorder affecting muscle or nerve tissues, or genital bleeding, pregnancy, urinary tract infection, vulvovaginitis, genital prolapse beyond the hymen, atrophic vaginitis or cardiac pacemaker	Supervised perineal exercises repeated in the orthostatic, sitting and supine positions under guidance from a physiotherapist (twice a week, for 45 minutes).	Unsupervised perineal exercises repeated in the orthostatic, sitting and supine positions performed at home with monthly assessment from a physiotherapist.
Clarke-O'Neill, 2002 ⁶²³ Country: UK Aim: The Continence Product Evaluation Network: comparative survey of washable pants with integral pads for women with light incontinence	The Continence Product Evaluation Network: women 18 years of age and normally used an absorbent product (disposable or reusable) for light incontinence	Not reported	10 pants designed for light incontinence	Cross over evaluation
Tomlinson, 1999 ⁶²⁴ Country: U.S. Aim: The effects of dietary caffeine and fluid intake on urinary incontinence in older rural women	The Behavioral Management for Continence (BMC): women 55 or older living in their own home in one of seven rural counties in northern Florida with involuntary urine loss at least twice a week and of 1 g per day or more	Diagnosis of bladder cancer or kidney disease; use of a urinary catheter; retention of 100 ml or more of urine; need for a caregiver but none was available; and availability for less than 6 months	The Behavioral Management for Continence: self-monitoring (2–4 weeks' duration); bladder training (6–8 weeks' duration); and pelvic muscle exercise with biofeedback (12 weeks' duration). The goal was appropriate intake of 1800–2400 ml/day of fluids	No active treatments; alternative resources within the community

Appendix Table F82. Sponsorship and conflict of interest in studies of nonpharmacological treatments for UI

Reference	Sponsorship	Conflict of Interest
Luber, 1997 ⁵⁶³	Contract grant sponsor: Kaiser Research Foundation; Contract grant number: 01-990-6571.	Not reported
Dougherty, 2002 ⁵¹⁷	Contract grant sponsor: National Institute of Nursing Research, National Institutes of Health (Nursing model: Urinary incontinence for older, rural women); contract grant number: R01 NR 3139. Johnson & Johnson provided absorbent products for the project	Not reported
Hung, 2010 ⁵⁴³	Financial support from the National Science Council of the Republic of China under the grant No. NSC95-2314-B002-226-MY2	Not reported
Tibaek, 2004 ⁶⁰⁸	Financial support provided by The Foundation of Danish Physiotherapists Research, The Foundation of 1870, and Direktor Jacob Madsen og hustrus Fond.	Not reported
Tibaek, 2007 ⁶⁰⁴	Financial support provided by The Foundation of Danish Physiotherapists Research, The Foundation of 1870, and Direktor Jacob Madsen og hustrus Fond.	Not reported
Morkved, 2002 ⁵⁷⁴	Financial support was given by the Norwegian Industrial and Regional Development Fund, Norwegian National Insurance Administration, and by Trondheim Regional Hospital 2000, SINTEF Unimed, Trondheim and Vitacon, Trondheim, Norway	Not reported
Burns, 1993 ⁵⁰⁵	Funded by a cooperative agreement (UOI AG05260) from the National Institute on Aging and the National Center for Nursing Research	Not reported
Mayer, 2007 ⁵⁶⁷	Funded by BioForm Medical.	R. D. Mayer and K. Jacoby are study investigators partially funded by the sponsor, and are paid consultants to the sponsor. R. Dmochowski, R. A. Appell, P. K. Sand, I. Klimberg, C. W. Graham, J. A. Snyder, V. Nitti, and J. C. Winter are study investigators partially funded by the sponsor.
Oldham, 2010 ⁵⁸³	Funded by Femeda	Not reported
Kim, 2001 ⁵⁴⁷	Funded by Sasakawas' Health Science Foundations in Japan and the International Rotarian Scholarship in Japan	Not reported
Williams, 2005 ⁶¹³	Funded by the Medical Research Council (UK) (G9410491). Nicola J Cooper was funded by University Hospitals of Leicester (UHL) NHS Trust. David A Turner was funded by Trent Institute for Health Services Research	None declared
Moore, 2003 ⁵⁷³	Funded by the Health Outcomes Unit of the New South Wales Department of Health of Australia.	Not reported
Borello-France, 2006 ⁴⁹⁵	Funded by the National Institutes of Health/National Institute on Aging grant R15AG15488 to Dr. Borello-France	Not reported

Appendix Table F82. Sponsorship and conflict of interest in studies of nonpharmacological treatments for UI (continued)

Reference	Sponsorship	Conflict of Interest
Bo, 1999 ⁴⁹¹	Funded by the Norwegian Fund for Postgraduate studies in Physiotherapy and Norwegian Research Council. Coloplast AS provided the continence guards and Vitacon S provided the electrical stimulators and cones. They also gave financial support to seminars for the research group	None declared
Bo, 2000 ⁴⁹²	Funded by The Norwegian Fund for Postgraduate Studies in Physiotherapy and The Norwegian Research Council. In addition, Coloplast AS gave financial support to the study	Not reported
Borrie, 2002 ⁴⁹⁷	Funded by the Ontario Ministry of Health Assistive Devices Branch (grant no.M695A2), Parkwood Hospital, London, Ont., and the University of Western Ontario, London, Ont.	None
Peters, 2010 ⁵⁸⁷	Funded by Uroplasty, Inc.	Not reported
Lightner, 2001 ⁵⁶¹	Funded through unrestricted, educational grants by Carbon Medical Technologies.	A. U. Khan and I. Klimberg received research funding from the sponsor of this study.
Jeyaseelan, 2000 ⁵⁴⁵	Funding for this project was provided by University of Manchester Medical Bequest Fund.	Not reported
Gorman, 1995 ⁵³⁷	Funding provided by Florida Nurses Foundation, Sigma Theta Tau, Alpha Theta Chapter, and Rural Women's Health Project (NR3139).	Not reported
Janssen, 2001 ⁵⁴⁴	Funding: Ziekenfondsraad;	None
Kincade, 2007 ⁵⁵⁰	Grant from National Institute of Nursing Research; Grant numbers: R01 NR05071, S1	Not reported
Elser, 1999 ⁵²¹	Grant from National Institute on Aging/National Institutes of Health, Bethesda, MD, grant UO1AG05170-6	Not reported
Chadha, 2000 ⁵¹⁰	Grant support for this study was provided by the Chief Scientist Office of the Scottish Office of Home and Health Department, which also funds the Health Services Research Unit, University of Aberdeen, Scotland.	Not reported
Williams, 2006 ⁶¹⁴	Medical Research Council	None declared
Wyman, 1997 ⁶¹⁷	National Institute of Aging, National Institute for Nursing Research (formerly National Center for Nursing Research), National Institutes of Health, Bethesda, Maryland, Grant Number AG05170.	
Wong, 2001 ⁶¹⁶	None	Not reported
Zanetti, 2007 ⁶²²	None	None
Tsai, 2009 ⁶¹⁰	None	None
Felicissimo, 2010 ⁵²⁵	None	None
Harvey, 2002 ⁵³⁹	Not supported by the Industry	Not reported
Demain, 2001 ⁵¹³	Not reported	The physiotherapy clinical trialist is supported by the West Midlands NHS(E)
O'Brien, 1991 ⁵⁸¹	Not reported	Not reported
Lagro-Janssen, 1991 ⁵⁵⁴	Not reported	Not reported
Smith, 1996 ⁵⁹⁵	Not reported	Not reported
Nielsen, 1993 ⁵⁷⁸	Not reported	Not reported
Nygaard, 1996 ⁵⁸⁰	Not reported	Not reported

Appendix Table F82. Sponsorship and conflict of interest in studies of nonpharmacological treatments for UI (continued)

Reference	Sponsorship	Conflict of Interest
O'Brien, 1996 ⁵⁸²	Not reported	Not reported
Berghmans, 1996 ⁴⁸⁷	Not reported	Not reported
Dowd, 1996 ⁵¹⁸	Not reported	Not reported
Ramsay, 1996 ⁵⁸⁸	Not reported	Not reported
Glavind, 1996 ⁵³⁴	Not reported	Not reported
Bo, 1997 ⁴⁹⁰	Not reported	Not reported
Thornburn, 1997 ⁶⁰⁶	Not reported	Not reported
Brubaker, 1997 ⁵⁰¹	Not reported	Not reported
Sherman, 1997 ⁵⁹⁴	Not reported	Not reported
Cammu, 1998 ⁵⁰⁹	Not reported	Not reported
Glavind, 1997 ⁵³⁵	Not reported	Not reported
Miller, 1998 ⁵⁷²	Not reported	Not reported
Bower, 1998 ⁴⁹⁸	Not reported	Not reported
Yamanishi, 2000 ⁶²⁰	Not reported	Not reported
McFall, 2000 ⁵⁷¹	Not reported	Not reported
Pages, 2001 ⁵⁸⁵	Not reported	None
Clarke-O'Neill, 2002 ⁶²³	Not reported	Not reported
Thyseen, 2001 ⁶⁰⁷	Not reported	Not reported
Bryant, 2002 ⁵⁰²	Not reported	Not reported
Berghmans, 2002 ⁴⁸⁸	Not reported	Not reported
Aukee, 2002 ⁴⁸³	Not reported	Not reported
Yoon, 2003 ⁶²¹	Not reported	Not reported
But, 2003 ⁵⁰⁶	Not reported	Not reported
Aksac, 2003 ⁴⁷⁶	Not reported	Not reported
O'Sullivan, 2003 ⁵⁸⁴	Not reported	Not reported
Robinson, 2003 ⁵⁸⁹	Not reported	Not reported
Diokno, 2004 ⁵¹⁵	Not reported	Not reported
Bano, 2005 ⁴⁸⁵	Not reported	Not reported
Seo, 2004 ⁵⁹³	Not reported	Not reported
Schulz, 2004 ⁵⁹²	Not reported	Not reported
Amaro, 2005 ⁴⁷⁸	Not reported	Not reported
Swithinbank, 2005 ⁶⁰³	Not reported	Not reported
Finazzi Agro, 2005 ⁵²⁶	Not reported	Not reported
Karademir, 2005 ³¹⁹	Not reported	Not reported
Amaro, 2006 ⁴⁷⁹	Not reported	Not reported
Andersen, 2002 ⁴⁸⁰	Not reported	Not reported
Borawski, 2007 ⁴⁹⁴	Not reported	None
Konstantinidou, 2007 ⁵⁵¹	Not reported	None
Manganotti, 2007 ⁵⁶⁵	Not reported	Not reported
Du Moulin, 2007 ⁵⁷⁵	Not reported	Not reported
Demirturk, 2008 ⁵¹⁴	Not reported	None
Castro, 2008 ²⁴⁷	Not reported	Not reported

Appendix Table F82. Sponsorship and conflict of interest in studies of nonpharmacological treatments for UI (continued)

Reference	Sponsorship	Conflict of Interest
Kumari, 2008 ⁵⁵²	Not reported	Not reported
Ghoniem, 2009 ⁵³²	Not reported	Gamal Ghoniem has financial interest and/or other relationship with Astellas, Coloplast, Uroplasty and Bulkamid; Jacques Corcos has financial interest and/or other relationship with Johnson & Johnson, Astellas, Purdue, Triton and Allergan; Craig Comiter has financial interest and/or other relationship with Coloplast and Astellas; O. Lenaine Westney has financial interest and/or other relationship with American Medical Systems; and Sender Herschorn has financial interest and/or other relationship with Pfizer, Astellas, Johnson & Johnson, Allergan and Lilly.
Gilling, 2009 ⁵³³	Not reported	None
de Oliveira Camargo, 2009 ⁵⁰⁸	Not reported	None
Gameiro, 2010 ⁵³¹	Not reported	None
Blowman, 1991 ⁴⁸⁹	Not reported	Not reported
Majumdar, 2010 ⁵⁶⁴	Not Reported	None
Diokno, 2010 ⁵¹⁶	Not Reported	NR
Liebergall-Wischnitzer, 2009 ⁵⁵⁹	Partially funded by The Hadassah Women's Health Research Fund and the Berman Family Foundation	None
Kim, 2009 ⁵⁴⁶	Research grant from the Ministry of Health and Welfare of Japan and a Grant-in-Aid for the Scientific Research B from the Japan Society for the Promotion of Science and Sanitary Products Research Foundation of the KAO Corporation	Not reported
Alewijnse, 2003 ⁴⁷⁷	Sponsored by a grant from Praeventiefonds/ZON (Netherlands Care Research); Grant number: 28-2505.	None
Ng, 2008 ⁵⁷⁷	Sponsored by a grant from The National Science Council in Taiwan (NSC-89-2314-B-040-046)	Not reported
Theofrastous, 2002 ⁶⁰⁵	Sponsored by National Institute on Aging; Contract grant number:UO1-AG-05170.	Not reported
Appell, 2006 ⁴⁸¹	Sponsored by Novasys Medical, Inc. (Newark, CA)	None
McFall, 2000 ⁵⁷⁰	Supported by a co-operative agreement between the Centers for Disease Control & Prevention and the Oklahoma State Department of Health.	Not reported
Goode, 2003 ⁵³⁶	Supported by a grant 1R01DK49472 from the National Institutes of Health	Not reported
Sand, 1995 ⁵⁹⁰	Supported by a grant from Empi, Inc., St.Paul, Minnesota	Not reported
Gallo, 1997 ⁵³⁰	Supported by a grant from Incare Medical Products.	Not reported
Tibaek, 2005 ⁶⁰⁹	Supported by a grant from the Foundation of Danish Physiotherapists Research; Grant sponsor: The Foundation of 1870, Direktor Jacob Madsen og hustrus Fond	Not reported

Appendix Table F82. Sponsorship and conflict of interest in studies of nonpharmacological treatments for UI (continued)

Reference	Sponsorship	Conflict of Interest
Wang, 2004 ⁶¹¹	Supported by a grant from the National Science Council, Taiwan (NSC90-2314-B-182-111).	Not reported
Tomlinson, 1999 ⁶²⁴	Supported by a research grant (R01 NR3139 Nursing Model: Urinary Continence for Older, Rural Women) from the National Institute of Nursing Research, National Institutes of Health (1992–1997). Johnson & Johnson Company. (Milltown, NJ) donated the incontinence products	Not reported
Kim, 2007 ⁵⁴⁸	Supported by a Research Grant of the Ministry of Health and Welfare of Japan and a Grant-in-Aid for Scientific Research B of the Japan Society for the Promotion of Science.	None
Corcos, 2005 ⁵¹²	Supported by a University-Industry grant from the Canadian Institute for Health Research (CIHR) in association with Bard Canada.	All authors are study investigators funded by CIHR and Bard.
Liebergall-Wischnitzer, 2005 ⁵⁶⁰	Supported by an Internal Grant for Paramedical Personnel at Hadassah and the Lillian Silverstein Fund	Not reported
Fantl, 1991 ⁵²⁴	Supported by Cooperative Agreement AG05170 with the National Institute on Aging and National Center on Nursing Research, Bethesda, MD	Not reported
Subak, 2002 ⁵⁹⁸	Supported by Direct Community Benefit Investment, Kaiser Foundation Research Institute	Not reported
Barroso, 2004 ⁴⁸⁶	Supported by Fundação de Amparo à Pesquisa do Rio Grande do Sul (FAPERGS) and the Fundo de Incentivo à Pesquisa (FIPE) of GPPG/HCPA	Not reported
Strasser, 2007 ⁵⁹⁷	Supported by FWF-grant P-12828 (Fonds zur Foerderung der wissenschaftlichen Forschung, Vienna; Institute for Biochemical Pharmacology, Medical University Innsbruck; Austria).	Michael Mitterberger is co-owner of IGOR, and Hannes Strasser and Rainer Marksteiner are founders and co-owners of Innovacell Biotechnologie. Both companies run certified facilities where the autologous cells were grown. Eva Margreiter, an employee of Innovacell, did most cell cultures.
Burgio, 2002 ⁵⁰³	Supported by grant AG RO1 08010 from the National Institute on Aging, National Institutes of Health, Bethesda, MD	Not reported
Manonai, 2006 ⁵⁶⁶	Supported by grant from Thai Health Promotion Foundation	Not reported
But, 2005 ⁵⁰⁷	Supported by Grant L3-4476-0334-02/3.08 from the Ministry of Education, Science and Sport of the Republic of Slovenia	Not reported
Goode, 2002 ²⁹⁰	Supported by Grants AG 08010 and K04 00431 from the National Institute on Aging to Dr. Burgio.	Not reported

Appendix Table F82. Sponsorship and conflict of interest in studies of nonpharmacological treatments for UI (continued)

Reference	Sponsorship	Conflict of Interest
Richter, 2010 ³⁶¹	Supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U10 HD41261, U10 HD 41250, U10 HD54136, U10 HD41249, U10 HD41267, U10 HD41248, U10 HD41268, U10 HD41263, U10 HD54214, U10 HD54241, and U10 HD54215); National Institute of Diabetes and Digestive and Kidney Diseases, and National Institutes of Health Office of Research on Women's Health.	Dr. Burgio is a consultant for Pfizer (New York, NY) and on the advisory board for Astellas (Deerfield, IL). Dr. Brubaker is a Research Consultant for Pfizer (New York, NY) and a Research Investigator for Allergan (Irvine, CA). Dr. Zyczynski has performed contract research for Johnson & Johnson (New Brunswick, NJ). Dr. Lukacz is a consultant for Pfizer (New York, NY), Medtronic (Minneapolis, MN), and Watson Pharmaceuticals (Corona, CA). She has served on the speaker's bureau for Novartis (Basel, Switzerland) and Proctor&Gamble (Cincinnati, OH). She has been a consultant and proctor for Intuitive Surgical Corporation (Sunnyvale, CA), and she has been an editor First Consult. Dr. Schaffer is on the Speaker's Bureau and National Advisory Board of Astellas/GlaxoSmithKline (Deerfield, IL; Philadelphia, PA) and on the Specialty Surgeons Advisory Board of Cadence Pharmaceuticals (San Diego, CA). The other authors did not report any potential conflicts of interest.
Nager, 2009 ⁵⁷⁶	Supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH Office of Research on Women's Health at National Institutes of Health (U10 HD54215, U10 HD41267, U10 HD41250, U10 HD41261, U10 HD54214, U10 HD54241, U10 HD54136, and U01 HD41249).	None
Subak, 2009 ⁶⁰⁰	Supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (U01 DK067860, U01 DK067861, and U01 DK067862) and from the Office of Research on Women's Health.	Dr. Subak reports serving on an advisory board for Pfizer and receiving grant support from Pfizer; Dr. Grady, receiving grant support from Bionovo; Dr. Kusek, owning stock in Eli Lilly, Pfizer, and deCODE Genetics; and Dr. Burgio, serving on an advisory board for Pfizer, receiving grant support from Pfizer, and receiving advisory-board fees from Astellas and GlaxoSmithKline. No other potential conflict of interest relevant to this article was reported.
Wing, 2010 ⁶¹⁵	Supported by Grants U01DK067860, U01DK067861 and U01 DK067862 from the National Institute of Diabetes and Digestive and Kidney Diseases, as well as by the Office of Research on Women's Health.	Delia Smith West has financial interest and/or other relationship with Jenny Craig, Inc.; Holly Richter has financial interest and/or other relationship with Xanodyne, University of California, San Francisco, Pfizer and American Geriatrics Society; and Kathryn Burgio has financial interest and/or other relationship with Pfizer, Astellas and Johnson & Johnson.

Appendix Table F82. Sponsorship and conflict of interest in studies of nonpharmacological treatments for UI (continued)

Reference	Sponsorship	Conflict of Interest
Huang, 2009 ⁵⁴¹	Supported by Grants U01 DK067860, U01 Dk067861 and U01 DK067862, and K24 Dk068389 and K24 Dk080775, from The National Institute of Diabetes and Digestive and Kidney Diseases, and the Office of Research on Women's Health, National Institutes of Health. Alison Huang was supported by Grant KL2RR024130 from the National Center for Research Resources, a component of the National Institutes of Health Clinical Translational Science Award for Medical Research	Alison Huang and Leslee Subak have financial interest and/or other relationship with Pfizer, Inc.
Arvonen, 2001 ⁴⁸²	Supported by Ipex Medical AB	Not reported
Engberg, 2002 ⁵²³	Supported by National Institute for Nursing Research grant No. R01 NR02874.	Not reported
Hahn, 1991 ⁵³⁸	Supported by Neurologiskt handikappades Riksförbund and the LIC hygien	Not reported
McDowell, 1999 ⁵⁶⁹	Supported by NINR RO1 NR02874.	Not reported
Lee, 2001 ⁵⁵⁸	Supported by Physicians Sources, Inc.	Not reported
Lightner, 2009 ⁵⁶²	Supported by Q-Med Ab, Inc., Uppsala, Sweden	Not reported
Subak, 2005 ⁵⁹⁹	Supported by research awards from Mount Zion Health Services, Inc. and the University of California, San Francisco Academic Senate, Committee on Research.	Leslee Subak is a Women's Reproductive Health Research Scholar supported by the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland (K12 HD01262-02). Leslee Subak has financial interest and/or other relationship with Yamanouchi.
Kim, 2008 ⁵⁴⁹	Supported by research funds from Chosun Nursing College, 2006	Not reported
Boyington, 2005 ⁴⁹⁹	Supported by research grant No. 1 K01 NR00125 (A Knowledge-Based System for Continence) from the National Institute for Nursing Research, National Institutes of Health (1999-2003).	Not reported
Laycock, 2001 ⁵⁵⁷	Supported by SSL-International (UK) and Cardio Design (Australia)	Not reported
Dumoulin, 2004 ⁵²⁰	Supported by the Canadian Institutes of Health Research and Laborie Medical Technologies Inc. through a Canadian Institutes of Health Research-Industry grant. C. Dumoulin was supported by studentships from the Canadian Institutes of Health Research and from the Fonds de la Recherche en Santé du Québec.	Not reported

Appendix Table F82. Sponsorship and conflict of interest in studies of nonpharmacological treatments for UI (continued)

Reference	Sponsorship	Conflict of Interest
Brown, 2006 ⁵⁰⁰	Supported by the following: The Diabetes Prevention Program National Institutes of Health/ National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Child Health and Human Development, the National Institute on Aging, the Office of Research on Minority Health and Health Disparities, the Office of Women's Health, the Indian Health Service, the Centers for Disease Control and Prevention, the General Clinical Research Program, the National Center for Research Resources, the American Diabetes Association, Bristol-Myers Squibb, Lipha Pharmaceuticals, and Parke-Davis. LifeScan, Health O Meter, Hoechst Marion Roussel, Merck-Medco Managed Care, Merck, Nike Sports Marketing, Slim Fast Foods, and Quaker Oats donated materials, equipment, or medicines for concomitant conditions.	Not reported
Sung, 2000 ⁶⁰¹	Supported by the Hallym Academy of Science, Hallym University in 1998	Not reported
Sung, 2000 ⁶⁰²	Supported by the Hallym Academy of Sciences, Hallym University in 1998	
Fujishiro, 2002 ⁵²⁹	Supported by the Life Science Foundation of Japan	Not reported
Fujishiro, 2000 ⁵²⁸	Supported by the Life Science Foundation of Japan.	Not reported
Wyman, 1998 ⁶¹⁸	Supported by the National Institute of Aging/National Institutes of Health, Bethesda, Maryland, grant No. UOI AG05170	Not reported
Hu, 1989 ⁵⁴⁰	Supported by the National Institute on Aging and the National Center for Nursing Research, Bethesda, Md.	Not reported
Borello-France, 2008 ⁴⁹⁶	Supported by the National Institutes of Health, National Institute on Aging (grant R15 AG15488-03), and by a Magee-Women's Health Foundation grant	Not reported
Coleman, 1999 ⁵¹¹	Supported by the Robert Wood Johnson Foundation Chronic Care Initiative, Grant No. 024739	Dr Coleman was a Veteran's Affairs Robert Wood Johnson Clinical Scholar during his participation in this study
Dowd, 2000 ⁵¹⁹	Supported by The University of Akron Faculty Grant 1355	Not reported

Appendix Table F82. Sponsorship and conflict of interest in studies of nonpharmacological treatments for UI (continued)

Reference	Sponsorship	Conflict of Interest
MacDiarmid, 2010 ³⁵⁸	Supported by Uroplasty, Inc.	MacDiarmid Scott has financial interest and/or other relationship with Uroplasty, Pfizer, Watson, Astellas and Allergan; Peters Kenneth has financial interest and/or other relationship with Medtronic, Advanced Bionics, Boston Scientific, Allergan, Pfizer, Celgene and Trillium Therapeutics; Wooldridge Leslie has financial interest and/or other relationship with Uroplasty, Astellas and Watson; Rovner Eric has financial interest and/or other relationship with Astellas; Leong Fah Che has financial interest and/or other relationship with Astellas; Siegel Steven has financial interest and/or other relationship with AMS, Medtronic, Uromedica, Uroplasty and QiG; Tate Susan has financial interest and/or other relationship with C.R. Bard; and Feagins Brian has financial interest and/or other relationship with Medtronic, AMS, Novartis, Allergan, Astellas, and Boston Scientific
Yamanishi, 1997 ⁶¹⁹	Supported in part by grants from the National Research and Development for Medical and Welfare Apparatus under Industrial Science and Technology Frontier Program of the Agency of Industrial Science and Technology of the Ministry of International Trade and Industry and the New Energy and Industrial Technology Development Organization of Japan	Not reported
Lamb, 2009 ⁵⁵⁵	The trial was funded by the Physiotherapy Research Foundation	None
Hui, 2006 ⁵⁴²	The telemedicine equipment was supported by the SK Yee Medical Foundation	Not reported
Finazzi-Agro, 2010 ⁵²⁷	Supported by a grant from Uroplasty, Inc.	Enrico Finazzi-Agro has financial interest and/or other relationship with Astellas, Uroplasty and Bioniche.
Schreiner, 2010 ⁵⁹¹	Not reported	None

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
Pelvic floor muscle training (PFMT) and/or other lifestyle interventions	Aksac, 2003 ⁴⁷⁶ Sample: 50 8 weeks	Intention to treat: Intention to treat not stated Allocation concealment not adequate Sample size justified: No	Randomization: Randomization with choosing closed letters (patients had to pick up closed letters)	Randomization: Adequate
PFMT and/or other lifestyle interventions	Alewijnse, 2003 ⁴⁷⁷ Sample: 129 14-22 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: Yes	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Arvonen, 2001 ⁴⁸² Sample: 37 16 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Aukee, 2002 ⁴⁸³ Sample: 30 12 weeks	Intention to treat: Yes Allocation concealment not reported Sample size justified: No	Randomization: Randomization with random numbers table with permuted blocks of four	Randomization: Adequate
PFMT and/or other lifestyle interventions	Aukee, 2004 ⁴⁸⁴ Sample: 35 12 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: No	Randomization: Randomization was performed by a random numbers table, in blocks of four	Randomization: Adequate
PFMT and/or other lifestyle interventions	Berghmans, 1996 ⁴⁸⁷ Sample: 40 12 weeks	Intention to treat: Yes Allocation concealment not adequate Sample size justified: No	Randomization: Computer generated randomization stratified by seriousness of incontinence (grade 1 and 2) and by referral (general practitioner or urologist) with permuted blocks of 4	Randomization: Adequate
PFMT and/or other lifestyle interventions	Bo, 2000 ⁴⁹² Sample: 59 24 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Computer generated randomization stratified by degree of leakage	Randomization: Adequate
PFMT and/or other lifestyle interventions	Bo, 2005 ⁴⁹³ Sample: 52 24 weeks	Intention to treat: Yes Allocation concealment not reported Sample size justified: Yes	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Borello-France, 2006 ⁴⁹⁵ Sample: 44 12 weeks	Intention to treat: Yes Allocation concealment not reported Sample size justified: No	Randomization: Block randomization schedule with a random number table	Randomization: Adequate
PFMT and/or other lifestyle interventions	Borrie, 2002 ⁴⁹⁷ Sample: 421 24 weeks	Intention to treat: Yes Allocation concealment not adequate Sample size justified: No	Randomization: Computer generated randomization with random permuted blocks, block size of 4	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	Boyington, 2005 ⁴⁹⁹ Sample: 71 8 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Quasi-experimental trial with random assignment of participants to intervention and control groups. The minimization technique for balancing age (50-59 years, 60-69 years, and 70 years and older), ethnicity, and presence of the symptom of involuntary urine loss in the 2 groups	Randomization: Adequate
PFMT and/or other lifestyle interventions	Brown, 2006 ⁵⁰⁰ Sample: 2191 2.9 years	Intention to treat: Yes Allocation concealment unclear Sample size justified: Yes	Randomization: Randomization was stratified by clinical center	Randomization: Adequate
PFMT and/or other lifestyle interventions	Bryant, 2002 ⁵⁰² Sample: 95 4 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Burgio, 2002 ⁵⁰³ Sample: 222 8 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: Yes	Randomization: stratified randomization; Randomization stratified by race, type, and severity of incontinence	Randomization: Adequate
PFMT and/or other lifestyle interventions	Burns, 1990 ⁵⁰⁴ Sample: 128 8 weeks	Intention to treat: Not stated Allocation concealment not reported Sample size justified: No	Randomization: Randomization with permuted blocks of 10.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Burns, 1993 ⁵⁰⁵ Sample: 135 24 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate Adjustment for clinical site and study treatment, fluid intake, patient reported diagnosis of congestive heart failure, patient reported diagnosis of diabetes, body mass index, age, urge and stress scores from the medical, epidemiological and social aspects
PFMT and/or other lifestyle interventions	de Oliveira Camargo, 2009 ⁵⁰⁸ Sample: 61 12 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: Yes	Randomization: computer-generated random number table	Randomization: Adequate
PFMT and/or other lifestyle interventions	Cammu, 1998 ⁵⁰⁹ Sample: 60 12 weeks	Intention to treat: Yes Allocation concealment not adequate Sample size justified: No	Randomization: Computerized randomization with random numbers tables	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	Castro, 2008 ²⁴⁷ Sample: 118	Intention to treat: Intention to treat not stated Adequate Sample size justified: No	Randomization: Not reported	Randomization No
PFMT and/or other lifestyle interventions	Chadha, 2000 ⁵¹⁰ Sample: 449 48 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Randomization stratified by hospital size and location. 2 x 2 balanced incomplete block controlled before and after study.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Coleman, 1999 ⁵¹¹ Sample: 169 Length of treatment 48 weeks	Intention to treat: Modified intention-to-treat: patients with followup data were included in the followup analysis irrespective of level of exposure to the intervention Allocation concealment unclear Sample size justified: No	Randomization: Simple random numbers table; The unit of randomization was the physician practice	Randomization: Adequate Possible because the authors modified intention to treat analysis
PFMT and/or other lifestyle interventions	Demain, 2001 ⁵¹³ Sample: 44 12 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Stratified randomization using the method of minimization; Stratification by body mass index and age	Randomization: Adequate
Group intervention	Diokno, 2010 ⁵¹⁶ Sample: 44 6-8 weeks	Intention to treat: NR Allocation concealment NR Sample size justified: No	Randomization: NR	Randomization: Not adequate
PFMT and/or other lifestyle interventions	Diokno, 2004 ⁵¹⁵ Sample: 359 48 weeks	Intention to treat: Not stated Adequate Sample size justified: No	Randomization: Randomizations in blocks of 16 women to provide balanced recruitment between groups	Randomization: Adequate.
PFMT and/or other lifestyle interventions	Dougherty, 2002 ⁵¹⁷ Sample: 218 24 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: No	Randomization: Randomization with minimization to balance by severity, age, bacteriuria ethnicity, and caregiver	Randomization: Adequate
PFMT and/or other lifestyle interventions	Dowd, 1996 ⁵¹⁸ Sample: 58 5 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization Baseline data not provided but some differences at baseline reported.
PFMT and/or other lifestyle interventions	Dowd, 2000 ⁵¹⁹ Sample: 40 6 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	Elser, 1999 ⁵²¹ Sample: 204 Length of treatment 12 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Randomization stratified by severity of urinary incontinence, urodynamic diagnosis, and treatment site randomization.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Engberg, 2002 ⁵²³ Sample: 19 8 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: No	Randomization: Computer-generated stratified by cognitive ability, toileting skills, and severity of urinary incontinence randomization.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Fantl, 1991 ⁵²⁴ Sample: 13 6 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Randomization stratified by urodynamic incontinence. Randomization stratified by urodynamic incontinence.	Randomization: Adequate
Supervised Pelvic Floor Muscle Training	Felicissimo, 2010 ⁵²⁵ Sample: 62 8 weeks	Intention to treat: No Allocation concealment Adequate Sample size justified: Yes	Randomization: Computer generated random number generator	Randomization: Adequate
PFMT and/or other lifestyle interventions	Gallo, 1997 ⁵³⁰ Sample: 86 6 weeks	Intention to treat: Intention to treat not stated Allocation concealment not adequate Sample size justified: Yes	Randomization: Not reported	Randomization: States as adequate, baseline characteristics not reported.
PFMT and/or other lifestyle interventions	Gameiro, 2010 ⁵³¹ Sample: 103	Intention to treat: Intention to treat not stated Allocation concealment not reported Sample size justified: Yes	Randomization: Patients were systematically allocated, in a single-blind study, into two groups. The odd numbers were included in group 1 (n=51) and submitted to VWC associated to standardized general exercise; the even numbers were included in group G2 (n=52) and treated with assisted PFMT	Randomization Adequate
PFMT and/or other lifestyle interventions	Gilling, 2009 ⁵³³ Sample: 70 6 weeks	Intention to treat: Yes Allocation concealment not adequate Sample size justified: Yes	Randomization: Random permuted blocks of 10	Randomization: Adequate
PFMT and/or other lifestyle interventions	Glavind, 1997 ⁵³⁵ Sample: 6 0.5 weeks	Intention to treat: Intention to treat not stated Allocation concealment not adequate Sample size justified: No	Randomization: Not reported	Randomization: Cross over trial
PFMT and/or other lifestyle interventions	Glavind, 1996 ⁵³⁴ Sample: 40 4 weeks	Intention to treat: No Allocation concealment not adequate Sample size justified: No	Randomization: Not reported	Randomization: Stated as adequate, no data provided
PFMT and/or other lifestyle interventions	Goode, 2003 ⁵³⁶ Sample: 200 8 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: Yes	Randomization: Computer-generated stratified by types and severity of incontinence and race randomization with block size of 6.	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	Goode, 2002 ²⁹⁰ Sample: 105 8 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Gorman, 1995 ⁵³⁷ Sample: 60 6 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Hahn, 1991 ⁵³⁸ Sample: 20	Intention to treat: Not reported Allocation concealment Not reported Sample size justified: Not reported	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Harvey, 2002 ⁵³⁹ Sample: 44	Intention to treat: NR Allocation concealment NR Sample size justified: NR	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Hu, 1989 ⁵⁴⁰ Sample: 143 12 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Huang, 2009 ⁵⁴¹ Sample: 338 24 weeks	Intention to treat: Not stated Reported previously Sample size justified: No	Randomization: Random permuted blocks; 2:1 ratio	Randomization: No, women in control group had slightly higher average Beck Depression Inventory score
PFMT and/or other lifestyle interventions	Hui, 2006 ⁵⁴² Sample: 32 8 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Randomization with a table of random numbers	Randomization: Adequate
PFMT and/or other lifestyle interventions	Hung, 2010 ⁵⁴³ Sample: 70 Length of treatment 16 weeks	Intention to treat: No Allocation concealment Not adequate Sample size justified: Yes	Randomization: Block randomization with a maximum of 6 was used	Randomization Adequate
PFMT and/or other lifestyle interventions	Janssen, 2001 ⁵⁴⁴ Sample: 530 12 weeks	Intention to treat: Yes Allocation concealment not adequate Sample size justified: No	Randomization: Randomization stratified by type, severity and duration of incontinence frequency sampling randomization	Randomization: Adequate
PFMT and/or other lifestyle interventions	Kim, 2009 ⁵⁴⁶ Sample: 147	Intention to treat: NR Allocation concealment NR Sample size justified: NR	Randomization: NR	Randomization NR

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	Kim, 2007 ⁵⁴³ Sample: 70 12 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Computer-generated random numbers; randomization was repeated until there was no significant difference between the two groups	Randomization: Adequate unclear because the authors stated that "The participants were divided into two groups based on the frequency of urine leakage and functional fitness measurements"
PFMT and/or other lifestyle interventions	Kim, 2001 ⁵⁴⁷ Sample: 48 12 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Randomization by the order of coming to the clinic.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Kincade, 2007 ⁵⁵⁰ Sample: 224 3 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: Yes	Randomization: The minimization technique; to balance those in the two study groups on age (18–39, 40–64, 65+), estrogen status (pre menopausal/ hormone replacement versus post menopausal/no hormone replacement), severity of urine loss (<50 g vs. more than 50 g), and race	Randomization: Adequate
PFMT and/or other lifestyle interventions	Konstantinidou, 2007 ⁵⁵¹ Sample: 30 12 weeks	Intention to treat: No Allocation concealment not adequate Sample size justified: Yes	Randomization: Unclear consecutive order according to women hospital administration sequence; Not reported	Randomization: Adequate Unclear because described methods of treatment assignment was not random
PFMT and/or other lifestyle interventions	Kumari, 2008 ⁵⁵² Sample: 198 8 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: Yes	Randomization: Block randomization; Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Lagro-Janssen, 1992 ⁵⁵³ Sample: 110 12 weeks	Intention to treat: Not stated Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Lagro-Janssen, 1991 ⁵⁵⁴ Sample: 66 12 weeks	Intention to treat: Not stated Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Lamb, 2009 ⁵⁵⁵ Sample: 174	Intention to treat: Yes Allocation concealment not adequate Sample size justified: Yes	Randomization: Randomized in a ratio of 2:1 (group: individual)	Randomization Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	Liebergall-Wischnitzer, 2009 ⁵⁵⁹ Sample: 245 12 weeks	Intention to treat: Yes Adequate: by a biostatistician and blinded research coordinator Sample size justified: Yes	Randomization: Randomization stratified with a table of random numbers, permuted blocks; block size of 4 and stratified by age (20–50 and 51–65) and place of residence (three towns).	Randomization: No, a significant difference in the prevalence of uterine prolapse
PFMT and/or other lifestyle interventions	Liebergall-Wischnitzer, 2005 ⁵⁶⁰ Sample: 59 12 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Computer generated randomization with block of 4 stratified by age.	Randomization: Adequate
PFMT and/or other lifestyle interventions	MacDiarmid, 2010 ³⁵⁸ Sample: 33	Intention to treat: Intention to treat not stated Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: NA
Urodynamics	Majumdar, 2010 ⁵⁶⁴ Sample: 99 23–26 weeks	Intention to treat: Yes Allocation concealment Adequate Sample size justified: Yes	Randomization: Randomization was done with the help of a Clinical Trial Simulator, a web-based program	Randomization: NR
PFMT and/or other lifestyle interventions	Manonai, 2006 ⁵⁶⁶ Sample: 42 Two 12-week diet periods and two 4-week washout periods.	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Baseline data provided with no analysis for incontinence rate.
PFMT and/or other lifestyle interventions	McDowell, 2006 ⁵⁶⁸ Sample: 30 24 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: No	Randomization: Computer generated randomization list.	Randomization: Adequate
PFMT and/or other lifestyle interventions	McDowell, 1999 ⁵⁶⁹ Sample: 105 8 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Computer-generated stratified by cognitive ability, toileting skills, and severity of urinary incontinence randomization with permuted blocks.	Randomization: Adequate
PFMT and/or other lifestyle interventions	McFall, 2000 ⁵⁷⁰ Sample: 145 Length of treatment 12 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Miller, 1998 ⁵⁷² Sample: 27 1 week	Intention to treat: Not stated Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Baseline data is not reported
PFMT and/or other lifestyle interventions	Moore, 2003 ⁵⁷³ Sample: 145 12 weeks	Intention to treat: Yes Allocation concealment not adequate Sample size justified: Yes	Randomization: Computer-generated randomization stratified with respect to mild and moderate leakage with permuted blocks of 20.	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	Morkved, 2002 ⁵⁷⁴ Sample: 103 24 weeks	Intention to treat: Yes Allocation concealment not adequate Sample size justified: Yes	Randomization: Centralized but no computerized randomization stratified by results of a pad test with standardized bladder volume (20g or less and more than 20g of leakage).	Randomization: Adequate
PFMT and/or other lifestyle interventions	Du Moulin, 2007 ⁵⁷⁵ Sample: 38 24 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Random numbers table; general practitioners were randomized	Randomization No, mixed incontinence was more frequent in the intervention group, whereas stress incontinence was more frequent in the control group. Randomization did not provide balance between treatment groups
PFMT and/or other lifestyle interventions	Nager, 2009 ⁵⁷⁶ Sample: 445 Not reported	Intention to treat: No Previously reported Sample size justified: No	Randomization: Previously reported; Randomization ignored in the article	Randomization: Adequate The outcome - pessary fitting reported in total sample not by randomization status.
PFMT and/or other lifestyle interventions	Ng, 2008 ⁵⁷⁷ Sample: 88 12 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: Yes	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Nygaard, 1996 ⁵⁸⁰ Sample: 71 12 weeks	Intention to treat: Yes Allocation concealment not reported Sample size justified: Yes	Randomization: Randomization with random numbers table, in blocks of 4	Randomization: Baseline data is not reported
PFMT and/or other lifestyle interventions	O'Brien, 1991 ⁵⁸¹ Sample: 561 12 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Computer based randomization.	Randomization: Baseline data is not reported
PFMT and/or other lifestyle interventions	O'Brien, 1996 ⁵⁸² Sample: 292 4 years of followup	Intention to treat: No Reported previously Sample size justified: No	Randomization: Not reported	Randomization Not relevant because the authors reported long term outcomes among all treated. The results reported ignoring randomization as non controlled study.

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	O'Sullivan, 2003 ⁵⁸⁴ Sample: 150 12 weeks	Intention to treat: Yes Adequate Sample size justified:	Randomization: Stratified randomization; randomization was stratified by mild and moderate incontinence	Randomization: Adequate The authors reported outcomes by baseline severity status pooling active and control groups because they did not differ after interventions
PFMT and/or other lifestyle interventions	Pages, 2001 ⁵⁸⁵ Sample: 51 4 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization Baseline data is not reported
PFMT and/or other lifestyle interventions	Richter, 2010 ³⁶¹ Sample: 446	Intention to treat: Yes Adequate Sample size justified: Yes	Randomization: Previously reported	Randomization Adequate
PFMT and/or other lifestyle interventions	Sherman, 1997 ⁵⁹⁴ Sample: 39 8 weeks	Intention to treat: Not stated Allocation concealment not reported Sample size justified: No	Randomization: Randomization stratified by diagnosis of physical stress incontinence or mixed urge/stress incontinence.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Subak, 2005 ⁵⁹⁹ Sample: 48 12 weeks	Intention to treat: Yes Adequate Sample size justified: Yes	Randomization: Randomization was stratified by type of incontinence, with randomly permuted blocks of 4.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Subak, 2009 ⁶⁰⁰ Sample: 338 24 weeks	Intention to treat: Not stated Allocation concealment not adequate Sample size justified: Yes	Randomization: Randomization stratified random permuted blocks; 2:1 ratio with randomly permuted blocks of three or six, stratified according to clinical center	Randomization: Adequate
PFMT and/or other lifestyle interventions	Subak, 2002 ⁵⁹⁸ Sample: 152 6 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Computer based randomization.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Sung, 2000 ⁶⁰² Sample: 60 6 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: The authors stated that they randomly selected patients for treatment. Unclear was it invitation for the study or treatment assignment	Randomization: Baseline data is not reported
PFMT and/or other lifestyle interventions	Swithinbank, 2005 ⁶⁰³ Sample: 69 4 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Not reported	Randomization: Baseline data is not reported
PFMT and/or other lifestyle interventions	Tibaek, 2007 ⁶⁰⁴ Sample: 24 12 weeks	Intention to treat: Not stated Reported previously Sample size justified: No	Randomization: Not reported	Randomization: Stated as adequate (no data provided)
PFMT and/or other lifestyle interventions	Theofrastous, 2002 ⁶⁰⁵ Sample: 137 12 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Not reported	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	Thornburn, 1997 ⁶⁰⁶ Sample: 20 1 week	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization Baseline data is not reported Unclear because baseline characteristics of women were not reported
PFMT and/or other lifestyle interventions	Tibaek, 2004 ⁶⁰⁸ Sample: 26 12 weeks	Intention to treat: No Allocation concealment not adequate Sample size justified: No	Randomization: Simple random numbers table	Randomization: Adequate
PFMT and/or other lifestyle interventions	Tibaek, 2005 ⁶⁰⁹ Sample: 26 12 weeks	Intention to treat: No Allocation concealment not adequate Sample size justified: No	Randomization: Randomization with a table of random numbers; Randomization with a table of random numbers	Randomization: Adequate
PFMT and/or other lifestyle interventions	Tsai, 2009 ⁶¹⁰ Sample: 108 12 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: Yes	Randomization: Random permuted blocks; block size 2	Randomization: Adequate
PFMT and/or other lifestyle interventions	Wang, 2004 ⁶¹¹ Sample: 120 12 weeks	Intention to treat: No Adequate Sample size justified: Yes	Randomization: Central computer-generated randomization in blocks of 6.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Wells, 1991 ⁶¹² Sample: 157 24 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Williams, 2005 ⁶¹³ Sample: 3746 24 weeks	Intention to treat: Yes Adequate Sample size justified: Yes	Randomization: Randomization by household, at a ratio of 4:1 in favor of the continence nurse practitioner.	Randomization: Adequate
PFMT and/or other lifestyle interventions	Williams, 2006 ⁶¹⁴ Sample: 238 12 weeks	Intention to treat: Yes Allocation concealment not adequate Sample size justified: Yes	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Wing, 2010 ⁶¹⁵ Sample: 338	Intention to treat: Yes Reported previously Sample size justified: Yes	Randomization: Randomly allocated in a 2:1 ratio	Randomization Adequate
PFMT and/or other lifestyle interventions	Wong, 2001 ⁶¹⁶ Sample: 38 4 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Permuted block randomization; blocks of 2	Randomization: Adequate
PFMT and/or other lifestyle interventions	Wyman, 1997 ⁶¹⁷ Sample: 131 6 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Stratified by type of incontinence	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
PFMT and/or other lifestyle interventions	Wyman, 1998 ⁶¹⁸ Sample: 204 12 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: Yes	Randomization: Stratified on the basis of their urodynamic diagnostic categorization (genuine stress incontinence or detrusor instability with or without genuine stress incontinence), baseline incontinence severity (1 to 9 incontinent episodes, 10 to 25 episodes, or 26 or greater episodes per week), and treatment site	Randomization: Adequate
PFMT and/or other lifestyle interventions	Yoon, 2003 ⁶²¹ Sample: 50 8 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
PFMT and/or other lifestyle interventions	Zanetti, 2007 ⁶²² Sample: 44 12 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Stratified randomized computer-generated random number table; Stratified by the satisfaction with the previous therapy	Randomization: Adequate
PFMT and/or other lifestyle interventions	Tomlinson, 1999 ⁶²⁴ Sample: 135 12 weeks	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Adequate The results are reported after active treatment only
PFMT and/or other lifestyle interventions	Clarke-O'Neill, 2002 ⁶²³ Sample: 72 1 week	Intention to treat: Yes Allocation concealment unclear Sample size justified: Yes	Randomization: Randomization using Latin squares; Not reported	Randomization Cross over trial differences in quality of life were calculated adjusting for baseline level, number of days practiced the intervention or in wait list group, age, hormone status, and race
Electrostimulation	Finazzi Agro, 2005 ⁵²⁶ Sample: 35 2-8 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Baseline data is not reported
Electrostimulation	Amaro, 2005 ⁴⁷⁸ Sample: 40 4 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Not reported	Randomization: Adequate
Electrostimulation	Amaro, 2006 ⁴⁷⁹ Sample: 40 7 weeks	Intention to treat: Not stated Allocation concealment not reported Sample size justified: Yes	Randomization: Not reported	Randomization: Adequate
Electrostimulation	Barroso, 2004 ⁴⁸⁶ Sample: 36 12 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Randomization before the study by drawing lots	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
Electrostimulation	Berghmans, 2002 ⁴⁸⁸ Sample: 98 9 weeks	Intention to treat: Yes Allocation concealment not adequate Sample size justified: Yes	Randomization: Randomization using blocks of 4.	Randomization: Adequate
Electrostimulation	Blowman, 1991 ⁴⁸⁹ Sample: 14	Intention to treat: Not reported Sample size justified: Not reported	Randomization: Not reported	Randomization: Not reported
Electrostimulation	Bo, 1997 ⁴⁹⁰ Sample: 12 1 day experiment	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization Baseline data is not reported
Electrostimulation	Bo, 1999 ⁴⁹¹ Sample: 122 24 weeks	Intention to treat: Yes Unclear Sample size justified: Yes	Randomization: Computer generated random numbers stratified by baseline leakage	Randomization: Adequate
Electrostimulation	Borawski, 2007 ⁴⁹⁴ Sample: 30 2 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Not reported	Randomization: No
Electrostimulation	Borello-France, 2008 ⁴⁹⁶ Sample: 28 24 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Randomization stratified random permuted blocks Four blocks with 12 assignments each stratified by age (within 5 years) and incontinence severity minimal (<5 urine leakage episodes per week), moderate (5–10 urine leakage episodes per week), or severe (>10 urine leakage episodes per week).	Randomization: Adequate
Electrostimulation	Bower, 1998 ⁴⁹⁸ Sample: 48 Unclear	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Not reported	Randomization: Adequate
Electrostimulation	Brubaker, 1997 ⁵⁰¹ Sample: 121 8 weeks	Intention to treat: No Allocation concealment unclear but centralized data manager blinded for treatment status analyzed the data. Sample size justified: No	Randomization: Computer generated randomization stratified by incontinence type.	Randomization: Adequate
Electrostimulation	But, 2003 ⁵⁰⁶ Sample: 55 Length of treatment 8 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Electrostimulation	But, 2005 ⁵⁰⁷ Sample: 39 8 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Baseline data is not reported
Electrostimulation	Demirturk, 2008 ⁵¹⁴ Sample: 41 5 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization by application order; Not reported	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
Electrostimulation	Dumoulin, 2004 ⁵²⁰ Sample: 64 8 weeks	Intention to treat: Not stated Adequate Sample size justified: Yes	Randomization: Stratified randomization by the results from pad test using a balanced block randomization schedule generated from a table of random numbers.	Randomization: Adequate
Electrostimulation	Emmons, 2005 ⁵²² Sample: 85 4 weeks	Intention to treat: No Allocation concealment not adequate Sample size justified: Yes	Randomization: Computer-generated randomization with random numbers table.	Randomization: Adequate
Electrostimulation	Fujishiro, 2000 ⁵²⁸ Sample: 62 1 week	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Electrostimulation	Fujishiro, 2002 ⁵²⁹ Sample: 37 1 week	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Electrostimulation	Jeyaseelan, 2000 ⁵⁴⁵ Sample: 27 8 weeks	Intention to treat: Not stated Allocation concealment not adequate Sample size justified: Yes	Randomization: computer-generated table of random numbers	Randomization: Adequate
Electrostimulation	Karademir, 2005 ³¹⁹ Sample: 43 8 weeks	Intention to treat: Not stated Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Baseline data reported for age only.
Electrostimulation	Kim, 2008 ⁵⁴⁹ Sample: 52 12 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Electrostimulation	Lappin, 2003 ⁵⁵⁶ Sample: 145 10 weeks, 2 weeks washout period.	Intention to treat: No Adequate Sample size justified: No	Randomization: Central computer generated randomization.	Randomization: Adequate
Electrostimulation	Luber, 1997 ⁵⁶³ Sample: 57 12 weeks	Intention to treat: Not stated Allocation concealment not adequate Sample size justified: Yes	Randomization using the table of random numbers	Randomization: Adequate
Electrostimulation	Manganotti, 2007 ⁵⁶⁵ Sample: 20 2 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Baseline data is not reported
Electrostimulation	Oldham, 2010 ⁵⁸³ Sample: 128	Intention to treat: NR Randomly allocated by a computer-generated randomization list Sample size justified: Yes	Randomization: Not reported	Randomization NR
Electrostimulation	Peters, 2010 ⁵⁸⁷ Sample: 150	Intention to treat: Not reported Sample size justified: Yes	Randomization: Subjects were randomized 1:1 at the first intervention visit to PTNS or sham using a random block design stratified by investigational site	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
Electrostimulation	Ramsay, 1996 ⁵⁸⁸ Sample: 74 1 week	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: computer-generated random number	Randomization: Adequate Multiple-imputation with missing data
Electrostimulation	Sand, 1995 ⁵⁹⁰ Sample: 52 15 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: Yes	Randomization: Computer-generated random numbers with blocks at a 2:1 rate favoring active over placebo devices.	Randomization: Adequate
Electrostimulation	Smith, 1996 ⁵⁹⁵ Sample: 57 16 weeks	Intention to treat: Intention to treat not stated Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Electrostimulation	Spruijt, 2003 ⁵⁹⁶ Sample: 51 8 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Blocked randomization (Pocock).	Randomization: Adequate
Electrostimulation	Sung, 2000 ⁶⁰¹ Sample: 90 6 weeks	Intention to treat: Yes Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Baseline data is not reported
Electrostimulation	Yamanishi, 1997 ⁶¹⁹ Sample: 35 4 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Electrostimulation	Yamanishi, 2000 ⁶²⁰ Sample: 68 4 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Bulking agents or medical devices	Appell, 2006 ⁴⁸¹ Sample: 173 48 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Computer generated randomization with ratio 2:1	Randomization: Adequate
Bulking agents or medical devices	Bano, 2005 ⁴⁸⁵ Sample: 50 Length of treatment 6 months	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Bulking agents or medical devices	Corcos, 2005 ⁵¹² Sample: 133 48 weeks	Intention to treat: Yes Adequate Sample size justified: Yes	Randomization: Centralized randomization stratified by center with randomly distributed blocks 4 and 6 in size.	Randomization: Adequate
Bulking agents or medical devices	Ghoniem, 2009 ⁵³² Sample: 260 24 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: Yes	Randomization: Not reported 1:1 ratio	Randomization: Adequate
Bulking agents or medical devices	Lee, 2001 ⁵⁵⁸ Sample: 68 Duration of followup: 24 months	Intention to treat: No Allocation concealment not reported Sample size justified: Yes	Randomization: Computerized randomization with random number tables	Randomization: Adequate

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
Bulking agents or medical devices	Lightner, 2001 ⁵⁶¹ Sample: 355 48 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Baseline data is not reported
Bulking agents or medical devices	Lightner, 2009 ⁵⁶² Sample: 344 12 weeks	Intention to treat: Not stated Allocation concealment unclear Sample size justified: No	Randomization: Random permuted blocks; 2:1 allocation ratio of Zuidex to Contigen	Randomization: Adequate adjustment for age, race, partner status, parity, hysterectomy, oophorectomy, menopausal status, general health, depression symptoms, systemic estrogen use, SSRI use, clinical severity of incontinence, clinical type of incontinence, BMI and clinical site
Bulking agents or medical devices	Mayer, 2007 ⁵⁶⁷ Sample: 296 24 weeks	Intention to treat: Yes Adequate - central computerized tables generated by Statistical Analysis Systems Sample size justified: Yes	Randomization: Random numbers tables generated by Statistical Analysis Systems	Randomization: Adequate Not relevant
Bulking agents or medical devices	Schulz, 2004 ⁵⁹² Sample: 40 Duration of followup: 12 months	Intention to treat: Yes Allocation concealment not reported Sample size justified: No	Randomization: Computer generated block randomization scheme.	Randomization: Adequate
Bulking agents or medical devices	Strasser, 2007 ⁵⁹⁷ Sample: 63 48 weeks	Intention to treat: Yes Allocation concealment unclear Sample size justified: No	Randomization: Computer-generated randomization list with permuted blocks and ratio of 2:1.	Randomization: Adequate
Bulking agents or medical devices	Andersen, 2002 ⁴⁸⁰ Sample: 52 Single injection	Intention to treat: No Allocation concealment unclear Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Bulking agents or medical devices	Laycock, 2001 ⁵⁵⁷ Sample: 101 12 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Permuted block randomization in ratio 2:2:1	Randomization: Baseline data is not reported
Bulking agents or medical devices	Nielsen, 1993 ⁵⁷⁸ Sample: 40 2 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Baseline data is not reported

Appendix Table 83. Quality of randomized controlled clinical trials of nonpharmacological nonsurgical treatments for UI (continued)

Treatment	Reference sample length of treatment	Intention to treat allocation concealment justification of the sample Size	Randomization	Bias
Bulking agents or medical devices	Nygaard, 1995 ⁵⁷⁹ Sample: 20 Three exercise sessions	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Block randomization	Randomization: Baseline data is not reported
Bulking agents or medical devices	Robinson, 2003 ⁵⁸⁹ Sample: 24 Duration of followup: 4 months	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Adequate
Bulking agents or medical devices	Seo, 2004 ⁵⁹³ Sample: 120 6 weeks	Intention to treat: Not stated Allocation concealment not reported Sample size justified: No	Randomization: Not reported	Randomization: Baseline data is not reported
Bulking agents or medical devices	Thyssen, 2001 ⁶⁰⁷ Sample: 94 5 weeks	Intention to treat: No Allocation concealment not reported Sample size justified: No	Randomization: Block randomization;	Randomization: Baseline data is not reported
Percutaneous tibial nerve stimulation	Finazzi-Agro, 2010 ⁵²⁷ Sample: 35	Intention to treat: No Allocation concealment Not reported Sample size justified: Yes	Randomization: Patients were randomly assigned to PTNS or a placebo group following a computer generated randomization list	Randomization: Adequate
Transcutaneous electrical tibial nerve stimulation + bladder training	Schreiner, 2010 ⁵⁹¹ Sample: 52 12 weeks	Intention to Treat: No Allocation Concealment: Not reported Justification of the Sample Size: No	Randomization: The patients were randomly divided into two groups through simple random number generator	Randomization: Not adequate

Appendix Table F84. Comparative effectiveness of nonpharmacological treatments on improvement of incontinence

Active	Control	Studies reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events 95% CI)	Evidence
Continenence service	Bladder training	1 study ⁵⁸⁸	74	Not significant				Insufficient
Bladder training with audiotape about PFMT	Bladder training	1 study ⁵¹⁹	40	1.72 (1.10; 2.69)	0.38 (0.12; 0.64)	3 (2; 8)	378 (121; 636)	Insufficient
PFMT	Behavioral intervention	1 study ⁶¹⁴	238	Not significant				Insufficient
PFMT+ BT	PFMT	1 study ⁵⁵⁰	224	Inconsistent across definitions benefit				Insufficient
Individual PFMT+ bladder training	Group	1 study ⁵⁴⁴	530	Not significant				Insufficient
Circular muscle exercises (Paula method)	PFMT group	1 study ⁵⁵⁹	240	1.26 (1.02; 1.57)	0.14 (0.01; 0.26)	7 (4; 69)	138 (15; 261)	Insufficient
PFMT+ EMG biofeedback	PFMT	2 studies ^{487, 503, 536}	322	Inconsistent across definition benefit				Low
PFMT	PFMT+ vaginal balls	1 study ⁴⁸²	37	1.49 (0.74; 2.98)	0.19 (-0.13; 0.51)			Insufficient
PFMT	Vaginal cone	1 study ⁶¹⁴	238	Not significant				Insufficient
Physiotherapy + biofeedback	Physiotherapy	1 study ⁵³⁴	40	Not significant				Insufficient
Group physiotherapy	Biofeedback	1 study ⁵⁸⁵	40	Not significant				Insufficient
Vaginal cone therapy	Bladder training	1 study ⁶¹⁴	238	Not significant				Insufficient
Contrelle Continenence Tampon	Conveen Continenence device Guard	1 study ⁶⁰⁷	94	Not significant				Insufficient
Durasphere	Contigen	1 study ⁴⁸⁰	52	1.54 (0.99; 2.38)	0.27 (0.02; 0.52)	4 (2; 56)	269 (18; 521)	Insufficient

Appendix Table F84. Comparative effectiveness of nonpharmacological treatments on improvement of incontinence (continued)

Active	Control	Studies reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events 95% CI)	Evidence
Urethral device (NEAT) packaged with device	Reliance Insert sterile balloon	1 study ⁵⁸⁹	24	Not significant				Low
Durasphere	Bovine collagen	1 study ⁵⁶¹	364	Not significant				
Porcine dermal implant injection (Permacol)	Silicone injection (Macroplastique)	1 study ⁴⁸⁵	50	Not significant				Insufficient
Periurethral dextran copolymer	Transurethral agent-dextran copolymer	1 study ⁵⁹²	40	Not significant				Insufficient
Calcium hydroxylapatite	Bovine Dermal Collagen	1 study ⁵⁶⁷	296	Not significant				Insufficient
Autologous myoblasts and fibroblasts	Collagen	1 study ⁵⁹⁷	63	Not significant				Insufficient
Transurethral injection of Macroplastique	Transurethral injection of Contigen®	1 study ⁵³²	247	Inconsistent across definitions benefit				
Zuidex Implacer	Contigen endoscopic guidance	1 study ⁵⁶²	344	Inconsistent across definitions benefit				Insufficient

Abbreviation: NR = not reported

Appendix Table F85. Effectiveness of nonpharmacological treatments on stress UI in women (results from poorly reported randomized controlled clinical trials)

Reference	Aim	N	% Women	% With UI	Treatment	Duration	Population	Results
Hahn, 1991 ⁶²⁵	To evaluate the function of the pelvic floor and urethral sphincters before and after Contelle device	20	100	100	Pelvic floor training and electrical stimulation with Contelle device (the device was to used for 8-10 hours/night at maximally tolerable intensities)	6 months	Women with genuine stress incontinence	Very few reliable correlations between symptomatic improvement and urodynamic improvement were found
Laycock, 1993 ⁶²⁶	To evaluate the effect of transcutaneous, pre-modulated interferential stimulation on the symptoms of female stress incontinence, by two prospective clinical trials	46 in first trial and 30 in second trial	100	100	Interferential pelvic floor therapy using an Endomed 433 (Enraf Nonius, Delft, Holland) for 15 minutes (on average ten sessions). Instructions: Pelvic Floor Exercises.	6 weeks	Women with urodynamically proven GSI and sterile urine. In the first trial, women were randomized into 2 groups: group 1 received a course of interferential stimulation and group 2 a course of PFMT and weighted vaginal cones therapy. In the second trial, women were randomized into active interferential stimulation and placebo groups.	There was no significant difference in severity of urinary incontinence between the two groups in trial 1 (p=0.4851). In trial 1: 43.5% of patients receiving IFT (n=23) were improved or cured (objectively measured), and 60.9% subjectively classified improved or cured. In trial 2: In the active IFT group: Pad test results showed: 6.7% worse, 6.7% no change, 60% improved, and 13.3% cured, and in the placebo group: 36.4% were worse, 0.7% showed no change, 45.5% improved, and 0% cured. For subjective assessment: in the active IFT group: 6.7% were worse, 60% showed no change, 33.3% improved, and 0% cured and in the placebo group: 54.5% were worse, 18.2% showed no change, 27.3% improved, and 0% cured. For difference in VAS score: in the active IFT group: 26.7% were worse, 0% no change, 73.3% improved, and 0% cured and in the placebo group: 36.4% were worse, 9.1% showed no change, 54.5% improved, and 0% cured

Appendix Table F85. Effectiveness of nonpharmacological treatments on stress UI in women (results from poorly reported randomized controlled clinical trials (continued))

Reference	Aim	N	% Women	% With UI	Treatment	Duration	Population	Results
Borello-France, 2010 ⁶²⁷	To describe adherence to PFMT, barriers, and predictors of exercise adherence in women with urge-predominant UI.	154	100	100	Either tolterodine tartrate extended release capsules 4 mg daily or tolterodine tartrate extended release capsules 4 mg daily combined with a behavioral intervention	10 weeks	BE-DRI trial: Secondary data analysis. Community-dwelling women with pure or predominant UUI , recruited through the investigators' clinical practices, study announcements, advertisements, and referrals, had post-void residual volume of less than 150 mL and the ability to contract their PFM, had to show 7 or more episodes of UI on a 7-day baseline diary, and had to self-report persistent UI for at least 3 months, no current use of antimuscarinic or other medications that could affect UI, and no history of neurologic diseases or conditions (e.g., Parkinson disease, multiple sclerosis, spina bifida, spinal cord injury) or systemic diseases known to affect bladder function.	At 12 months 42% (41) of total women had difficulty to find time to do all of the exercises; 56% (54) had difficulty remembering to exercise; 30% (28) perceived exercises did not help. During the intervention period: Adjusted regression coefficient: Total number of reported barriers to exercise adherence: -2.0 (95% CI=-3.1, -0.9) p-value=0.0007; Barrier: Difficult to find time to do all of the exercises: -7.7 (95% CI=-11.1, -4.4) p-value=<0.001; Barrier: Difficulty remembering to exercise: -7.5 (95% CI=-10.8, -4.2) p-value <0.001; Barrier: Perceived exercises do not help: 4.2 (95% CI=0.4, 8.0) p-value 0.03; Barrier: Other: -4.0 (95% CI=-8.1, -0.03) p-value=0.048. During the followup period: Adjusted Regression Coefficient: Barrier: Difficult to find time to do all of the exercises: -2.5 (95% CI= -4.7, -0.2) p-value=0.03. (Adjusted for age, education, race/ethnicity, Medical, Epidemiological, and Social Aspects of Aging Questionnaire (MESA) urge index, MESA stress index, volume of fluid intake pretreatment, and clinical site. Regression coefficient is the change in contractions per day per unit increase in total barriers or for endorsement of individual barrier versus no endorsement of that barrier)

Appendix Table F85. Effectiveness of nonpharmacological treatments on stress UI in women (results from poorly reported randomized controlled clinical trials (continued))

Reference	Aim	N	% Women	% With UI	Treatment	Duration	Population	Results
Griffiths, 2009 ⁶²⁸	To explore the concerns and expectations of women invited to attend group physiotherapy sessions for the management of female UI and whether the experience changed their views; and to gather recommendations from women attending group sessions on the design and delivery of these sessions	22	100	100	Group treatment	3 weeks	Women who had participated in a randomized clinical trial comparing individual and group treatment, who had stress, urge or mixed incontinence and were recruited to one of five physiotherapy centers in the West Midlands of the UK. Of these women those who had expressed a preference for individual sessions, but were randomized to group sessions and attended at least one session were recruited for an interview study.	It is necessary to consider reducing embarrassment and uncertainty in women who attend group sessions run in physiotherapy departments for urinary incontinence prior to their attendance
Engberg, 2009 ⁶²⁹	To examine the feasibility of recruiting women into a clinical trial designed to examine the efficacy of acupuncture in treating urge and mixed UI and the feasibility of performing the planned study procedures	11	100	100	Acupuncture: 12 treatments over 6 weeks. Control group was given sham acupuncture treatment	6 weeks	Women, aged 40 to 70 years of age, having urge or mixed urge and stress urinary accidents at least twice a week on average and have been incontinent for at least 3 months	Subjects randomized to true acupuncture group had a mean 67.47% (median=75.76%) reduction in daytime accidents/day at 4 weeks post acupuncture, whereas the mean reduction in daytime accidents was 16.67% (median=0%) at 4 weeks post-sham acupuncture. There were no significant group differences in changes in the scores on the quality-of-life measures. Subjects' perceptions about whether they had received the true or sham acupuncture were not significantly better than one would expect by chance.

Appendix Table F85. Effectiveness of nonpharmacological treatments on stress UI in women (results from poorly reported randomized controlled clinical trials (continued))

Reference	Aim	N	% Women	% With UI	Treatment	Duration	Population	Results
MacDiarmid, 2010 ⁶³⁰	To examine percutaneous tibial nerve stimulation on UI (ORBIT trial)	100	90%	Not reported	Weekly 30 minute treatment	12 weeks followed by therapy at tapered intervals for 9 months	Ambulatory adults with OAB symptoms, with or without a history of previous anticholinergic drug use, with at least 8 voids per 24 hours documented by history and physical and voiding diary	Subjects received as low as 1.2 treatments monthly to sustain symptom improvement throughout 12 months. The response to PTNS therapy achieved following 12 weeks of treatment demonstrates excellent durability through 12 months of followup with 94% sustained improvement from 12 weeks. Analysis of number of treatments needed to sustain therapeutic effect appears acceptable
Dunn, 2002 ⁶³¹	To evaluate the short- and medium-term effectiveness of an intraurethral device (FemSoft Insert, Rochester Medical Corporation, Stewartville, Minnesota) in the treatment of exercise-induced incontinence in women	6	100%	100%	Urethral insert	3 months+	Female patients 18 years and older, having stress incontinence during exercise that required pads or clothing changes, being able to perform regular aerobic exercise, and having adequate manual dexterity and intelligence to use the device and complete the subject questionnaires.	This pilot study found that urethral insert is effective and feasible for unsupervised home use. After 3 months, mean satisfaction scores for ease of use were 2.09 for insertion and 1.18 for removal; for comfort, the scores were 2.18 for insertion, 2.05 while wearing, and 1.36 during removal (on a 5-point scale, 1 = very comfortable/satisfied, 5 = very uncomfortable/unsatisfied).
Borello-France, 2010 ⁶²⁷	To examine adherence to exercise therapy and barriers for adherence	154	100%	100%	Behavioral intention: Pelvic floor muscle training, bladder training, and individualized fluid management for those with excessive urine output (>70 oz per day)	10 week study with one-year followup	Adults with OAB	By end of one-year followup period, only 32% of women were exercising at least 5 to 6 days per week. The barriers to exercise adherence were: 42% had difficulty finding time to do all of the exercises; 56% had difficulty remembering to exercise, and 30% perceived exercises did not help.

Appendix Table F86. Subgroup analysis of continence with different nonpharmacological treatments by baseline type of UI (results from individual RCTs were pooled with random effects model)

Treatment	Type of UI	Reference pooled*	Relative risk	Lower 95% CI	Upper 95% CI	Absolute risk difference	Lower 95% CI	Upper 95% CI
PFMT	Not reported	Castro, 2008 ²⁴⁷	3.23	0.98	10.59	0.22	0.03	0.42
PFMT	Not reported	Hung, 2010 ⁵⁴³	5.00	0.62	40.64	0.11	-0.01	0.24
PFMT	Not reported	Pooled	3.59	1.28	10.09	0.15	0.04	0.25
PFMT	Mixed	Kim, 2009 ⁵⁴⁶	3.35	1.79	6.28	0.32	0.18	0.46
PFMT	Mixed	Burns, 1993 ⁵⁰⁵	6.35	0.82	49.32	0.14	0.02	0.26
PFMT	Mixed	Pooled	3.54	1.95	6.45	0.23	0.05	0.41
PFMT	Stress UI	Lagro-Janssen, 1991 ⁵⁵⁴	7.00	0.91	53.78	0.18	0.03	0.33
PFMT	Stress UI	Bo, 1999 ⁴⁹¹	6.07	1.47	25.12	0.32	0.12	0.51
PFMT	Stress UI	Aksac, 2003 ⁴⁷⁶	16.24	1.07	246.51	0.75	0.53	0.98
PFMT	Stress UI	Kim, 2007 ⁵⁴⁸	6.33	2.06	19.49	0.46	0.27	0.65
PFMT	Stress UI	Pooled	6.85	3.15	14.87	0.42	0.19	0.65
PFMT+BT	Not reported	Diokno, 2004 ⁵¹⁵	1.32	0.98	1.78	0.09	-0.01	0.19
PFMT+BT	Mixed	Lagro-Janssen, 1992 ⁵⁵³	10.37	1.37	78.28	0.17	0.06	0.28
PFMT+BT	Mixed	O'Brien, 1991 ⁵⁸¹	15.49	2.13	112.49	0.08	0.05	0.11
PFMT+BT	Mixed	McFall, 2000 ⁵⁷¹	1.69	0.97	2.93	0.14	0.00	0.29
PFMT+BT	Mixed	Kumari, 2008 ⁵⁵²	33.08	4.62	236.86	0.37	0.26	0.48
PFMT+BT	Mixed	Pooled	8.21	1.58	42.53	0.19	0.05	0.32
PFMT+BT	All	Pooled	3.79	1.55	9.27	0.17	0.06	0.27
PEM+EMG BFB	Mixed	Burns, 1993 ⁵⁰⁵	8.78	1.17	66.04	0.20	0.06	0.34
PEM+EMG BFB	Stress UI	Aksac, 2003 ⁴⁷⁶	17.29	1.14	261.69	0.80	0.59	1.01
PEM+EMG BFB	All	Pooled	11.17	2.21	56.44	0.49	-0.10	1.08
Continence service	Mixed	Moore, 2003 ⁵⁷³	1.32	0.90	1.91	0.12	-0.04	0.28
Continence service	Mixed	Williams, 2005 ⁶¹³	1.47	1.26	1.72	0.09	0.06	0.12
Continence service	Mixed	Pooled	1.45	1.25	1.67	0.09	0.06	0.12
Continence service	Stress UI	Kim, 2009 ⁵⁴⁶	6.56	1.78	24.16	0.74	0.51	0.98
Continence service	All	Pooled	1.58	1.07	2.34	0.30	-0.01	0.60
Intravaginal electrical stimulation	Not reported	Yamanishi, 2000 ⁶²⁰	5.87	0.76	45.11	0.16	0.02	0.30
Intravaginal electrical stimulation	Not reported	Castro, 2008 ²⁴⁷	3.67	1.14	11.84	0.27	0.06	0.47
Intravaginal electrical stimulation	Not reported	Pooled	4.12	1.49	11.38	0.19	0.08	0.31
Intravaginal electrical stimulation	Mixed	Yamanishi, 1997 ⁶¹⁹	3.33	0.17	64.33	0.10	-0.07	0.27
Intravaginal electrical stimulation	Stress UI	Sand, 1995 ⁵⁹⁰	1.70	0.40	7.33	0.08	-0.12	0.29

Appendix Table F86. Subgroup analysis of continence with different nonpharmacological treatments by baseline type of UI (results from individual RCTs were pooled with random effects model) (continued)

Treatment	Type of UI	Reference pooled*	Relative risk	Lower 95% CI	Upper 95% CI	Absolute risk difference	Lower 95% CI	Upper 95% CI
Intravaginal electrical stimulation	Stress UI	Luber, 1997 ⁵⁶³	1.20	0.27	5.30	0.03	-0.18	0.23
Intravaginal electrical stimulation	Stress UI	Bo, 1999 ⁴⁹¹	3.50	0.79	15.58	0.16	-0.01	0.32
Intravaginal electrical stimulation	Stress UI	Blowman, 1991 ⁴⁸⁹	5.14	0.84	31.57	0.69	0.30	1.09
Intravaginal electrical stimulation	Stress UI	Pooled	2.30	1.06	4.97	0.18	-0.01	0.37
Intravaginal electrical stimulation	All	Pooled	2.86	1.57	5.23	0.16	0.06	0.26
Magnetic stimulation	Mixed	But, 2005 ⁵⁰⁷	1.08	0.71	1.62	0.05	-0.24	0.34
Magnetic stimulation	Stress UI	Fujishiro, 2000 ⁵²⁸	4.00	0.47	33.80	0.10	-0.04	0.23
Magnetic stimulation	Stress UI	Gilling, 2009 ⁵³³	2.00	0.54	7.37	0.09	-0.07	0.24
Magnetic stimulation	Stress UI	Pooled	2.42	0.79	7.35	0.09	-0.01	0.19
Magnetic stimulation	All	Pooled	1.22	0.78	1.88	0.09	-0.01	0.18
Vaginal Cone	Not reported	Castro, 2008 ²⁴⁷	3.33	1.01	11.05	0.23	0.03	0.44
Vaginal Cone	Stress UI	Bo, 1999 ⁴⁹¹	2.21	0.44	11.17	0.08	-0.08	0.23
Vaginal Cone	All	Pooled	2.88	1.10	7.55	0.14	-0.01	0.29

Abbreviations: PFMT= pelvic floor muscle exercise; BT= bladder training; BFB= biofeedback

* Der Simonian pooled estimate

Appendix Table F87. Clinical outcomes after pelvic floor muscle training compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Continence	Hung, 2010 ⁵⁴³	5/35	1/35	5.00 (0.62; 40.64)	6	0.11 (-0.01; 0.24)	12	Not reported
Continence	Kim, 2009 ⁵⁴⁶	34/74	10/73	3.35 (1.79; 6.28)	19	0.32 (0.18; 0.46)	12	Yes
Continence	Lagro-Janssen, 1991 ⁵⁵⁴	7/33	1/33	7.00 (0.91; 53.78)	6	0.18 (0.03; 0.33)	12	No
Continence	Burns, 1993 ⁵⁰⁵	7/43	1/39	6.35 (0.82; 49.32)	6	0.14 (0.02; 0.26)	13	Yes
Continence	Bo, 1999 ⁴⁹¹	11/29	2/32	6.07 (1.47; 25.12)	10	0.32 (0.12; 0.51)	10	No
Continence	Aksac, 2003 ⁴⁷⁶	15/20	0/10	16.24 (1.07; 246.51)	4	0.75 (0.53; 0.97)	9	No
Continence	Williams, 2006 ⁶¹⁴			1.59 (0.43; 5.87)				Yes
Continence	Kim, 2007 ⁵⁴⁸	19/35	3/35	6.33 (2.06; 19.49)	13	0.46 (0.27; 0.65)	10	No
Continence	Castro, 2008 ²⁴⁷	10/31	3/30	3.23 (0.98; 10.59)	12	0.22 (0.03; 0.42)	10	Not reported
Continence	Hung, 2010 ⁵⁴³	34/35	23/35	1.48 (1.16; 1.89)	23	0.31 (0.15; 0.48)	11	Not reported
Pooled		142/414	45/401	4.35 (2.83; 6.7)	100	0.30 (0.17; 0.42)	100	
Heterogeneity p value I squared				0.90	0	0	79.2	
Improved UI	Aksac, 2003 ⁴⁷⁶	5/20	2/10	1.25 (0.29; 5.35)	18	0.05 (-0.26; 0.36)	14	No
Improved UI	Castro, 2008 ²⁴⁷	12/31	2/30	5.81 (1.42; 23.79)	18	0.32 (0.13; 0.51)	17	Not reported
Improved UI	Burns, 1990 ⁵⁰⁴	21/38	0/40	45.21 (2.83; 720.96)	11	0.55 (0.39; 0.71)	17	Yes
Improved UI	Burns, 1993 ⁵⁰⁵	23/43	2/39	10.43 (2.63; 41.39)	18	0.48 (0.32; 0.65)	17	Yes
Improved UI	Hung, 2010 ⁵⁴³	25/35	21/35	1.19 (0.85; 1.68)	23	0.11 (-0.11; 0.34)	16	Not reported
Improved UI	Lagro-Janssen, 1991 ⁵⁵⁴	28/33	0/33	57.00 (3.62; 896.38)	11	0.85 (0.718; 0.98)	18	No
Pooled		114/200	27/187	5.44 (1.57; 18.83)	100	0.41 (0.17; 0.65)	100	
Heterogeneity p value I squared				0.00	80.00	0.00	90.00	
Treatment failure	Hung, 2010 ⁵⁴³	0/35	1/35	0.33 (0.01; 7.91)	12	-0.03 (-0.10; 0.05)	39	Not reported
Treatment failure	Bo, 2000 ⁴⁹²	1/29	12/30	0.09 (0.01; 0.62)	24	-0.37 (-0.55; -0.18)	32	
Treatment failure	Castro, 2008 ²⁴⁷	11/31	19/30	0.56 (0.32; 0.97)	64	-0.28 (-0.52; -0.04)	29	Not reported
Pooled		12/95	32/95	0.33 (0.102; 1.10)	100	-0.21 (-0.45; 0.02)	100	
Heterogeneity p value I squared				0.20	39.00	0.00	84.80	

Appendix Table F88. Quality of life after pelvic floor muscle training compared to no active treatment (individual RCTs)

Reference sample/men	Active	Definition of quality of life	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Bo, 2000 ⁴⁹² 59/0	8-12 maximum contractions in 3 series/day and 45 minutes/week group sessions	Dissatisfaction from spending the rest of the life with symptoms as now	29/30	1/4	11/38	0.09 (0.01; 0.68)	-0.33 (-0.52; -0.15)	-3 (-7; -2)	-332 (-517;-147)
Bo, 2000 ⁴⁹² 59/0	8-12 maximum contractions in 3 series/day and 45 minutes/week group sessions	Problem with intercourse	29/30	3/11	10/33	0.31 (0.09; 1.01)	-0.23 (-0.43; -0.03)	-4 (-36; -2)	-230 (-432;-28)
Bo, 2000 ⁴⁹² 59/0	8-12 maximum contractions in 3 series/day and 45 minutes/week group sessions	Problem with sex-life spoiled by urinary symptoms	29/30	3/11	15/50	0.21 (0.07; 0.64)	-0.40 (-0.61; -0.19)	-3 (-5; -2)	-397 (-607;-186)
Bo, 2000 ⁴⁹² 59/0	8-12 maximum contractions in 3 series/day and 45 minutes/week group sessions	Sex-life spoiled by urinary symptoms	29/30	5/17	15/50	0.34 (0.14; 0.83)	-0.33 (-0.55; -0.10)	-3 (-10; -2)	-328 (-553;-102)
Bo, 2000 ⁴⁹² 59/0	8-12 maximum contractions in 3 series/day and 45 minutes/week group sessions	Overall interference with life	29/30	16/56	25/82	0.66 (0.46; 0.95)	-0.28 (-0.51; -0.06)	-4 (-18; -2)	-282 (-506;-57)
Lagro-Janssen, 1991 ⁵⁵⁴ 66/0	5- 10 sessions of 10 pelvic muscle contractions held for 6 seconds daily	Improvement in psychological impact of urinary incontinence	33/33	23/70	0/0	47.00 (2.97; 742.97)	0.70 (0.54; 0.86)	1 (1; 2)	697 (536;857)
Lagro-Janssen, 1991 ⁵⁵⁴ 66/0	5- 10 sessions of 10 pelvic muscle contractions held for 6 seconds daily	Improvement in restrictions of activities	33/33	25/75	2/6	12.50 (3.22; 48.56)	0.70 (0.53; 0.86)	1 (1; 2)	697 (530;864)

Appendix Table F89. Scoring of quality of life after pelvic floor muscle training compared to no active treatment (individual RCTs)

Reference	Active	Definition of quality of life	Randomized active/control	Active mean standard deviation	Control mean standard deviation	Mean difference (95% CI)
Sung, 2000 ⁶⁰¹	Intensive pelvic floor muscle exercises	Frequency of incontinence (0-5-very serious problem)	30/30	2.00/0.50	2.20/0.40	-0.20 (-0.43; 0.03)
Sung, 2000 ⁶⁰¹	Intensive pelvic floor muscle exercises	Quantity of urine leakage	30/30	2.10/0.50	2.20/0.50	-0.10 (-0.35; 0.15)
Sung, 2000 ⁶⁰¹	Intensive pelvic floor muscle exercises	Severity of incontinence	30/30	2.10/0.70	2.30/0.50	-0.20 (-0.51; 0.11)
Sung, 2000 ⁶⁰¹	Intensive pelvic floor muscle exercises	Discomfort due to incontinence	30/30	2.00/0.70	2.20/0.60	-0.20 (-0.53; 0.13)
Sung, 2000 ⁶⁰¹	Intensive pelvic floor muscle exercises	Wearing protection	30/30	1.40/0.60	1.50/0.60	-0.10 (-0.40; 0.20)
Sung, 2000 ⁶⁰¹	Intensive pelvic floor muscle exercises	Discomfort due to wearing protection	30/30	1.20/0.40	1.30/0.50	-0.10 (-0.33; 0.13)
Sung, 2000 ⁶⁰¹	Intensive pelvic floor muscle exercises	Avoidance of places and situations	30/30	1.40/0.70	1.50/0.80	-0.10 (-0.48; 0.28)
Bo, 2000 ⁴⁹²	8-12 maximum contractions in 3 series/day	Quality of Life Scale	29/30	90.10/10.23	85.20/12.05	4.90 (-0.80; 10.60)
Aksac, 2003 ⁴⁷⁶	Contractions for 10 seconds and relaxation for 20 seconds, 10 times/session, 3 sessions/day	Visual analog scale based social activity index: 0=cannot undertake any social activity, 10=does not have any problem.	20/10	7.50/1.20	3.60/0.60	3.90 (3.26; 4.54)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Total health perception	14/12	629.00/39.50	656.00/40.33	-27.00 (-57.80; 3.80)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Physical functioning (SF-36 0 worse to 100)	14/12	60.00/6.83	67.00/6.67	-7.00 (-12.20; -1.80)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Role limitation due to physical problems (SF-36 0 worse to 100)	14/12	75.00/8.33	88.00/14.50	-13.00 (-22.29; -3.71)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Body pain (SF-36 0 worse to 100)	14/12	76.00/9.33	76.00/8.00	0.00 (-6.66; 6.66)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	General health perceptions (SF-36 0 worse to 100)	14/12	60.00/7.33	64.00/8.00	-4.00 (-9.94; 1.94)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Vitality (SF-36 0 worse to 100)	14/12	55.00/5.50	83.00/4.83	-28.00 (-31.97; -24.03)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Social functioning (SF-36 0 worse to 100)	14/12	100.00/2.00	100.00/0.00	0.00 (0.00; 0.00)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Role limitation due to mental problems (SF-36 0 worse to 100)	14/12	100.00/11.17	100.00/4.17	0.00 (-6.31; 6.31)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Mental health (SF-36 0 worse to 100)	14/12	82.00/5.33	86.00/5.33	-4.00 (-8.11; 0.11)

Appendix Table F89. Scoring of quality of life after pelvic floor muscle training compared to no active treatment (individual RCTs) (continued)

Reference	Active	Definition of quality of life	Randomized active/control	Active mean standard deviation	Control mean standard deviation	Mean difference (95% CI)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At followup: Total quality of life	14/12	29.00/10.83	18.00/18.67	11.00 (-0.99; 22.99)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At followup: Physical activity	14/12	6.00/2.50	0.00/3.50	6.00 (3.63; 8.37)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At followup: Travel	14/12	8.00/4.00	0.00/4.83	8.00 (4.55; 11.45)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At followup: Social relationships	14/12	3.00/1.50	2.00/2.17	1.00 (-0.46; 2.46)
Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At followup: Emotional health	14/12	8.00/3.17	13.00/2.83	-5.00 (-7.31; -2.69)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Physical functioning (SF-36 0 worse to 100)	12/12	60.00/7.33	70.00/9.00	-10.00 (-16.57; -3.43)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Role limitation due to physical problems (SF-36 0 worse to 100)	12/12	75.00/11.50	87.00/10.50	-12.00 (-20.81; -3.19)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	General health perceptions (SF-36 0 worse to 100)	12/12	57.00/7.83	54.00/6.83	3.00 (-2.88; 8.88)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Vitality (SF-36 0 worse to 100)	12/12	52.00/5.83	70.00/6.33	-18.00 (-22.87; -13.13)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Social functioning (SF-36 0 worse to 100)	12/12	100.00/5.67	100.00/1.67	0.00 (-3.34; 3.34)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Role limitation due to mental problems (SF-36 0 worse to 100)	12/12	100.00/5.67	100.00/0.00	0.00 (0.00; 0.00)

Appendix Table F89. Scoring of quality of life after pelvic floor muscle training compared to no active treatment (individual RCTs) (continued)

Reference	Active	Definition of quality of life	Randomized active/control	Active mean standard deviation	Control mean standard deviation	Mean difference (95% CI)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Mental health (SF-36 0 worse to 100)	12/12	82.00/4.67	84.00/2.67	-2.00 (-5.04; 1.04)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	physical functioning at followup (SF-36 0 worse to 100)	12/12	60.00/7.00	65.00/8.33	-5.00 (-11.16; 1.16)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	Role limitation due to physical problems at followup (SF-36 0 worse to 100)	12/12	75.00/11.50	75.00/12.50	0.00 (-9.61; 9.61)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At 6 month followup: Physical activity	12/12	0.00/3.00	6.00/1.83	-6.00 (-7.99; -4.01)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At 6 month followup: Travel	12/12	8.00/1.83	6.00/3.67	2.00 (-0.32; 4.32)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At 6 month followup: Social relationships	12/12	0.00/0.33	3.00/1.50	-3.00 (-3.87; -2.13)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At 6 month followup: Emotional health	12/12	4.00/2.67	13.00/4.83	-9.00 (-12.12; -5.88)
Tibaek, 2007 ⁶⁰⁴ followup of Tibaek, 2004 ⁶⁰⁸	Pelvic floor muscle therapy	IIQ (0 best to 100) At 6 month followup: Total quality of life	12/12	20.00/8.17	27.00/14.50	-7.00 (-16.42; 2.42)

Appendix Table F90. Clinical outcomes after vaginal cones compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CII)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Continence	Bo, 1999 ⁴⁹¹	4/29	2/32	2.21 (0.44; 11.17)	35	0.08 (-0.08; 0.23)	61	No
Continence	Castro, 2008 ²⁴⁷	9/27	3/30	3.33 (1.01; 11.05)	65	0.23 (0.03; 0.44)	39	Not reported
Pooled		13/56	5/62	2.88 (1.10; 7.55)	100	0.14 (-0.01; 0.29)	100	
Heterogeneity p value, I squared				0.69	0.00	0.23	31.20	
Improved UI- negative pad test	Castro, 2008 ²⁴⁷	11/27	2/30	6.11 (1.49; 25.13)		0.34 (0.14; 0.55)		Not reported
Improved UI- pad weight<2g	Castro, 2008 ²⁴⁷	11/27	3/30	4.07 (1.27; 13.07)		0.31 (0.09; 0.52)		Not reported
Improved UI- satisfied	Castro, 2008 ²⁴⁷	13/27	5/30	2.89 (1.19; 7.04)		0.32 (0.08; 0.55)		Not reported
Treatment discontinuation Treatment failure	Castro, 2008 ²⁴⁷	4/27	2/30	2.22 (0.44; 11.18)		0.08 (-0.08; 0.24)		Not reported
Treatment failure	Castro, 2008 ²⁴⁷	11/27	19/30	0.64 (0.38; 1.09)		-0.23 (-0.48; 0.03)		Not reported

Appendix Table F91. Scoring of quality of life after vaginal cones compared to no active treatment (results from individual RCT)

Reference	Active	Definition of quality of life	Randomized active/ control	Active mean standard deviation	Control mean standard deviation	Mean difference (95% CI)
Bo, 1999 ⁴⁹¹	Vaginal cones of 20, 40, and 70g worn for 20 minutes/day	Change from baseline in leakage index	29/32	-0.30/0.53	0.10/0.58	-0.40 (-0.68; -0.12)
Bo, 1999 ⁴⁹¹	Vaginal cones of 20, 40, and 70g worn for 20 minutes/day	Change from baseline in social activity index	29/32	0.10/1.06	-0.20/1.73	0.30 (-0.41; 1.01)

Appendix Table F92. Clinical outcomes after pelvic floor muscle training combined with biofeedback compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CII)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Continence	Burns, 1993 ⁵⁰⁵	9/40	1/39	8.78 (1.17; 66.04)	64	0.20 (0.06; 0.34)	51	Yes
Continence	Aksac, 2003 ⁴⁷⁶	16/20	0/10	17.29 (1.14; 261.69)	36	0.80 (0.59; 1.01)	49	No
Pooled		25/60	1/49	11.17 (2.21; 56.44)	100	0.49 (-0.10; 1.08)	100	
Heterogeneity p value I squared				0.70	0.00	0.00	95.30	
Improved UI	Aksac, 2003 ⁴⁷⁶	4/20	2/10	1.00 (0.22; 4.56)	25	0.00 (-0.30; 0.30)	20	No
Improved UI	Burns, 1990 ⁵⁰⁴	24/40	0/40	49.00 (3.08; 779.07)	15	0.60 (0.45; 0.75)	28	Yes
Improved UI	Burns, 1993 ⁵⁰⁵	24/40	2/39	11.70 (2.96; 46.20)	26	0.55 (0.38; 0.72)	27	Yes
Improved UI	Goode, 2002 ²⁹⁰	27/33	19/37	1.59 (1.12; 2.27)	35	0.31 (0.10; 0.51)	25	Yes
Pooled		80/133	23/126	3.93 (0.10; 15.49)	100	0.39 (0.17; 0.61)	100	
Heterogeneity p value I squared				0.00	78.00	0.00	80.30	

Appendix Table F93. Scoring of quality of life after pelvic floor muscle training with biofeedback using vaginal EMG probe compared to no active treatment (individual RCT)

Reference	Active	Definition of quality of life	Randomized active/ control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Aksac, 2003 ⁴⁷⁶	Contractions for 10 seconds and relaxation for 20 seconds) via biofeedback (vaginal probe in EMG) 3 times/ week	Visual analog scale based social activity index: 0=cannot undertake any social activity, 10=does not have any problem	20/10	8.10/0.80	3.60/0.60	4.50 (3.99; 5.01)

Appendix Table F94. Continence after supervised pelvic floor muscle training when compared to no active treatment, individual RCTs

Reference sample/men	Active	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Bo, 1999 ⁴⁹¹ 61/0	Pelvic floor exercise with 8-12 contractions 3 times/day and in groups with skilled physical therapists 1/week	29/32	12/41	1/3	13.24 (1.83; 95.63)	0.38 (0.19; 0.57)	3 (2; 5)	383 (193; 572)

Appendix Table F95. Scoring of quality of life after supervised pelvic floor muscle training compared to no active treatment (individual RCTs)

Reference	Active	Definition of quality of life	Randomized active/ control	Active mean/ standard deviation	Control mean standard deviation	Mean difference (95% CI)
Bo, 1999 ⁴⁹¹	Pelvic floor exercise with 8-12 contractions 3 times/day and in groups with skilled physical therapists 1/week	Change from baseline in leakage index	29/32	-0.90/0.51	0.10/0.58	-1.00 (-1.27; -0.73)
Bo, 1999 ⁴⁹¹	Pelvic floor exercise with 8-12 contractions 3 times/day and in groups with skilled physical therapists 1/week	Change from baseline in Social activity index	29/32	0.60/1.02	-0.20/1.73	0.80 (0.09; 1.51)

Appendix Table F96. Clinical outcomes after electrical intravaginal stimulation compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CII)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Continence	Yamanishi, 1997 ⁶¹⁹	2/20	0/13	3.33 (0.17; 64.33)	4	0.10 (-0.07; 0.27)	17	Yes
Continence	Luber, 1997 ⁵⁶³	3/20	3/24	1.20 (0.27; 5.30)	16	0.03 (-0.18; 0.23)	14	No
Continence	Blowman, 1991 ⁴⁸⁹	6/7	1/6	5.14 (0.84; 31.57)	11	0.69 (0.30; 1.09)	5	No
Continence	Sand, 1995 ⁵⁹⁰	7/35	2/17	1.70 (0.39; 7.33)	17	0.08 (-0.12; 0.28)	14	No
Continence	Bo, 1999 ⁴⁹¹	7/32	2/32	3.50 (0.79; 15.58)	16	0.16 (-0.01; 0.32)	17	No
Continence	Yamanishi, 2000 ⁶²⁰	7/37	1/31	5.86 (0.76; 45.11)	9	0.16 (0.02; 0.30)	20	Not reported
Continence	Castro, 2008 ²⁴⁷	11/30	3/30	3.67 (1.14; 11.84)	26	0.27 (0.04; 0.47)	14	Not reported
Continence				4.38 (1.02; 18.84)				No
Pooled		43/188	12/159	2.86 (1.57; 5.23)	100	0.16 (0.06; 0.26)	100	
Heterogeneity p value, I squared				0.82	0.00	0.100	43.70	
Improved UI	Sand, 1995 ⁵⁹⁰	13/35	2/17	3.16 (0.80; 12.44)	9	0.25 (0.03; 0.48)	9	No
Improved UI	Brubaker, 1997 ⁵⁰¹	21/60	10/61	2.14 (1.10; 4.14)	23	0.19 (0.03; 0.34)	16	Yes
Improved UI	Luber, 1997 ⁵⁶³	3/20	3/24	1.20 (0.27; 5.30)	8	0.03 (-0.18; 0.23)	10	No
Improved UI	Yamanishi, 1997 ⁶¹⁹	3/20	0/13	4.67 (0.26; 83.55)	2	0.15 (-0.04; 0.34)	12	Yes
Improved UI	Bo, 1999 ⁴⁹¹	3/32	1/32	3.00 (0.33; 27.33)	4	0.06 (-0.06; 0.18)	22	No
Improved UI	Yamanishi, 2000 ⁶²⁰	8/37	2/31	3.35 (0.77; 14.64)	8	0.15 (-0.01; 0.31)	15	Not reported
Improved UI	Amaro, 2006 ⁴⁷⁹	17/20	14/20	1.21 (0.86; 1.71)	38	0.15 (-0.11; 0.40)	7	Yes
Improved UI	Castro, 2008 ²⁴⁷	13/30	2/30	6.50 (1.60; 26.36)	9	0.37 (0.17; 0.57)	10	Not reported
Pooled		81/254	34/228	2.01 (1.28; 3.15)	100	0.16 (0.08; 0.23)	100	
Heterogeneity p value, I squared				0.19	30.00	0.239	23.800	
Treatment discontinuation	Jeyaseelan, 2000 ⁵⁴⁵	1/13	2/14	0.54 (0.06; 5.26)	46	-0.07 (-0.30; 0.17)	43	
Treatment discontinuation	Sand, 1995 ⁵⁹⁰	7/35	1/17	3.40 (0.45; 25.47)	54	0.14 (-0.03; 0.31)	57	No
Pooled		8/48	3/31	1.47 (0.24; 8.86)	100	0.05 (-0.15; 0.25)	100	

Appendix Table F96. Clinical outcomes after electrical intravaginal stimulation compared to no active treatment (results from RCTs pooled with random effects models) (continued)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CII)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Heterogeneity p value, I squared				0.24	29.00	0.16	48.60	
Treatment failure		2/7	1/6	1.71 (0.20; 14.55)	6	0.12 (-0.33; 0.57)	35	No
Treatment failure	Castro, 2008 ²⁴⁷	12/30	19/30	0.63 (0.38; 1.06)	95	-0.23 (-0.48; 0.01)	65	Not reported
Pooled		14/37	20/36	0.67 (0.40; 1.10)	100	-0.11 (-0.44; 0.22)	100	
Heterogeneity p value, I squared				0.37	0.00	0.18	45.20	
Adherence	Sand, 1995 ⁵⁹⁰	28/35	15/17	0.91 (0.71; 1.15)		-0.08 (-0.29; 0.12)		No
Adverse effects	Sand, 1995 ⁵⁹⁰	1/35	2/17	0.24 (0.02; 2.49)		-0.09 (-0.25; 0.07)		No
Adverse effects	Sand, 1995 ⁵⁹⁰	3/35	1/17	1.46 (0.16; 12.99)		0.03 (-0.12; 0.17)		No
Adverse effects	Sand, 1995 ⁵⁹⁰	4/35	2/17	0.97 (0.20; 4.79)		-0.00 (-0.19; 0.18)		No
Adverse effects	Sand, 1995 ⁵⁹⁰	5/35	2/17	1.21 (0.26; 5.63)		0.03 (-0.17; 0.22)		No
Treatment discontinuation Adverse effects	Sand, 1995 ⁵⁹⁰	2/35	0/17	2.50 (0.13; 49.38)		0.06 (-0.06; 0.17)		No
Treatment discontinuation Treatment failure	Castro, 2008 ²⁴⁷	1/30	2/30	0.50 (0.05; 5.22)		-0.03 (-0.14; 0.08)		Not reported

Appendix Table F97. Improvement in UI after nonpharmacological treatments compared to no active treatment

Treatment	Studies/ patients	Rate in active/ control	Relative risk (95% CI)	Absolute risk difference 95% CI)	Number needed to treat (95% CI)	Attributable Events (95% CI)	Bayesian odds ratio median (2.5%; 97.5%)	Level of evidence
Continence Service	2 ^{582, 613} /4038	62.6/53.5	1.33 (1.06; 1.68)	0.20 (-0.01; 0.41)				Low
Bladder Training	2 ^{524, 598} /283	61.4/19.2	3.22 (2.25; 4.60)	0.43 (0.28; 0.59)	2 (2; 4)	430 (275; 585)	8 (3; 20)	Low
Pelvic Floor Muscle Training	6 ^{247, 476, 504, 505, 543, 554} /510	56.9/14.7	5.44 (1.57; 18.83)	0.41 (0.17; 0.65)	2 (2; 6)	412 (174; 649)	14 (3; 69)	High
Pelvic Floor Muscle Training + Bladder Training	4 ^{515, 553, 571, 581} /1171	53.3/22.5	4.13 (1.58; 10.78)	0.39 (0.17; 0.60)	3 (2; 6)	387 (171; 603)	8 (2; 41)	High
Pelvic Floor Muscle Training with Biofeedback	4 ^{290, 476, 504, 505} /383	60.1/18.6	3.93 (1.00; 15.49)	0.39 (0.17; 0.61)	3 (2; 6)			High
Electrical Stimulation	8 ^{247, 479, 491, 501, 563, 590, 619, 620} /582	31.7/15.1	2.01 (1.28; 3.15)	0.16 (0.04; 0.23)	6 (4; 12)	156 (84; 228)	3 (2; 6)	High
Percutaneous Electrical Stimulation	3 ^{527, 586, 587} /405	40/20	1.9(1.1;3.2)	0.31(0.04;0.58)	3(2;25)	308(40;577)	3.1(1.4;8.8)	Moderate
Magnetic Stimulation	3 ^{506, 507, 528} /153	46.8/21.2	2.30 (1.43; 3.71)	0.27 (0.11; 0.42)	4 (2; 9)	265 (112; 417)	4 (2; 12)	Moderate
Weight Loss	2 ^{599, 600} /386	42.8/20.8	2.17 (1.26; 3.76)	0.27 (0.06; 0.49)	4 (2; 18)	273 (57; 490)	3 (1; 10)	Moderate
Bulking Agents	2 ^{481, 558} /241		Not significant					Low

Appendix Table F98. Scoring of quality of life after electrical stimulation compared to no active treatment (results from individual RCTs)

Reference	Active	Definition of Quality of life	Randomized active/ control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Yamanishi, 1997 ⁶¹⁹ 14 men	Electrical pelvic stimulation with 50 Hz. square waves of 1 ms. pulse duration using vaginal electrode in women for 15 minutes 2 or 3 times daily	Disturbance in daily activities: 0-not at all, 3-very disturbed	20/13	1.00/1.20	2.10/1.00	-1.10 (-1.86; -0.34)
Bo, 1999 ⁴⁹¹	Electrical stimulation using vaginal intermittent stimulation with the MS 106 Twin at 50 Hz 30 minutes/day	Change from baseline in leakage index	32/32	-0.20/0.51	0.10/0.58	-0.30 (-0.57; -0.03)
Bo, 1999 ⁴⁹¹	Electrical stimulation using vaginal intermittent stimulation with the MS 106 Twin at 50 Hz 30 minutes/day	Change from baseline in social activity index	32/32	0.60/1.02	-0.20/1.73	0.80 (0.10; 1.50)
Sung, 2000 ⁶⁰¹	Functional electrical stimulation for 20 minutes/session with frequency 35Hz-50Hz	Frequency of incontinence (0/5-very serious problem)	30/30	1.70/1.00	2.20/0.40	-0.50 (-0.89; -0.11)
Sung, 2000 ⁶⁰¹	Functional electrical stimulation for 20 minutes/session with frequency 35Hz	Quantity of urine leakage	30/30	1.80/0.90	2.20/0.50	-0.40 (-0.77; -0.03)
Sung, 2000 ⁶⁰¹	Functional electrical stimulation for 20 minutes/session with frequency 35Hz	Severity of incontinence	30/30	1.80/0.80	2.30/0.50	-0.50 (-0.84; -0.16)
Sung, 2000 ⁶⁰¹	Functional electrical stimulation for 20 minutes/session with frequency 35Hz	Discomfort due to incontinence	30/30	1.80/0.80	2.20/0.60	-0.40(-0.76; -0.04)
Sung, 2000 ⁶⁰¹	Functional electrical stimulation for 20 minutes/session with frequency 35Hz	Wearing protection	30/30	1.60/1.10	1.50/0.60	0.10 (-0.35; 0.55)
Sung, 2000 ⁶⁰¹	Functional electrical stimulation for 20 minutes/session with frequency 35Hz	Discomfort due to wearing protection	30/30	1.30/0.60	1.30/0.50	0.00 (-0.28; 0.28)
Sung, 2000 ⁶⁰¹	Functional electrical stimulation for 20 minutes/session with frequency 35Hz-50Hz	Avoidance of places and situations	30/30	1.40/0.90	1.50/0.80	-0.10 (-0.53; 0.33)
Jeyaseelan, 2000 ⁵⁴⁵	Electrostimulation technique described by Oldham (International Patent Publication WO98/47357) with a background low frequency (to target slow twitch fibers) and intermediate frequency with an initial doublet (to target fast twitch fibers)	Change in incontinence impact questionnaire (IIQ)	13/14	-4.10/16.40	-9.10/17.10	5.00 (-7.64; 17.64)

Appendix Table F98. Scoring of quality of life after electrical stimulation compared to no active treatment (results from individual RCTs) (continued)

Reference	Active	Definition of Quality of life	Randomized active/ control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Jeyaseelan, 2000 ⁵⁴⁵	Electrostimulation technique described by Oldham (International Patent Publication WO98/47357) with a background low frequency (to target slow twitch fibers) and intermediate frequency with an initial doublet (to target fast twitch fibers)	Change in Urogenital Distress Inventory (UDI)	13/14	-11.80/15.90	-3.30/8.30	-8.50 (-18.18; 1.18)

Appendix Table F99. Clinical outcomes after electrical stimulation compared to no active treatments (results from individual RCTs)

Reference sample/men	Active	Definition of improvement	Randomized active/control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)
Amaro, 2006 ⁴⁷⁹ 40/0	Effective Intravaginal electrical stimulation using frequency of 4 Hz with 3 20-minute sessions/week	Self reported urgency incontinence	20/20	3/15	6/32	0.50 (0.14; 1.73)	-0.15 (-0.40; 0.10)
Amaro, 2005 ⁴⁷⁸ 40/0	Intravaginal electrical stimulation with 3 20 minute sessions/week using 4 Hz frequency	Urge urinary incontinence at 1 month followup	20/20	3/15	6/32	0.50 (0.14; 1.73)	-0.15 (-0.40; 0.10)
Jeyaseelan, 2000 ⁵⁴⁵ 27/0	New stimulation pattern by Oldham	Withdrawal of the treatment	13/14	1/8	2/14	0.54 (0.06; 5.26)	-0.07 (-0.30; 0.17)
Brubaker, 1997 ⁵⁰¹ 121/0	Transvaginal electric stimulation for 20 minutes 2 times/day using frequency of 20 Hz, a 2-second-4-second work-rest cycle with a range of stimulation intensities, from 0 to 100 mA	Final urodynamic diagnosis of Detrusor over activity	61/60	16/27	25/41	0.63 (0.38; 1.06)	-0.15 (-0.32; 0.01)

Appendix Table F100. Clinical outcomes after nonpharmacological treatments compared to no active treatment

Studies reference	Number of subjects	Pooled relative risk (95% CI)	Pooled absolute risk difference (95% CI)	Number needed to treat (95%CI)	Attributable events/1000 treated (95% CI)	Evidence
SEVERITY OF UI						
Continence service (1 study) Williams, 2005 ⁶¹³	3,746	0.94 (0.89; 1.00)	-0.04 (-0.08; 0.00)	-25 (-452; -13)	-40 (-78; -2)	Insufficient
PFMT+BT (2 studies) Lagro-Janssen, 1992 ⁵⁵³ McFall, 2000 ⁵⁷⁰	245	Significant reduction in severity and pad utilization				Low
Discontinuation/adherence						
PFMT (1 study) Williams, 2006 ⁶¹⁴	158	NS differences				Insufficient
PFMT+BT (1 study) Yang, 1995 ⁵³²	108	NS differences				Insufficient
Electrical stimulation (1 study) Jeyaseelan, 2000 ⁵⁴⁵	27	NS differences				Insufficient
Vaginal cones (1 study) Williams, 2006 ⁶¹⁴ adherence	159	0.63 (0.49; 0.80)	-0.30 (-0.44; -0.16)	-3 (-6; -2)	-297 (-438; -157)	Insufficient
Weight loss (1 study) Subak, 2009 ⁶⁰⁰ Huang, 2009 ⁵⁴¹	338	0.17 (0.06; 0.44)	-0.11 (-0.18; -0.05)	-9 (-22; -6)	-112 (-178; -46)	Insufficient
Prevalence of UI						
PFMT (1 study) Williams, 2006 ⁶¹⁴	158	NS differences in UI				Insufficient
PFMT+BT (1 study) Kumari, 2008 ⁵⁵²	164	Significant reduction in stress, urgency, but not mixed UI				Insufficient
Acupuncture (1 study) Emmons, 2005 ⁵²²	85	NS differences in UUI				Insufficient

Appendix Table F100. Clinical outcomes after nonpharmacological treatments compared to no active treatment (continued)

Studies reference	Number of subjects	Pooled relative risk (95% CI)	Pooled absolute risk difference (95% CI)	Number needed to treat (95%CI)	Attributable events/1000 treated (95% CI)	Evidence
Electrical stimulation (3 studies) Brubaker, 1997 ⁵⁰¹ Amaro, 2005 ⁴⁷⁸ Amaro, 2006 ⁴⁷⁹	201	NS differences in UUI				Low
Vaginal cones (1 study) Williams, 2006 ⁵¹⁴	159	NS differences				Insufficient
Weight loss (1 study) Brown, 2006 ⁵⁰⁰	1319 NS change in urgency UI	0.85 (0.73; 0.99)	-0.05 (-0.11; 0.00)	-18 (-329; -10)	-54 (-105; -3)	Insufficient
Diet high in soy protein (1 study) Manonai, 2006 ⁵⁶⁶	36 Significant increase in stress UI, NS changes in urgency UI					Insufficient
Adverse effects						
Macroplastique (1 study) Ghoniem, 2009 ⁵³²	240	NS differences				Insufficient

Abbreviation: NS = Not significant

Appendix Table F101. Clinical outcomes after magnetic stimulation compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CII)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Continence	Fujishiro, 2000 ⁵²⁸	4/31	1/31	4.00 (0.47; 33.79)	4	0.10 (-0.04; 0.23)	51	No
Continence	Gilling, 2009 ⁵³³	6/35	3/35	2.00 (0.54; 7.37)	11	0.09 (-0.07; 0.24)	38	No
Continence	But, 2005 ⁵⁰⁷	17/23	11/16	1.08 (0.71; 1.62)	85	0.05 (-0.24; 0.34)	11	Yes
Pooled		27/89	15/82	1.22 (0.78; 1.88)	100	0.09 (-0.01; 0.18)	100	
Heterogeneity p value, I squared				0.35	4.00	0.96	0.00	
Improved UI	But, 2003 ⁵⁰⁶	7/30	1/22	5.13 (0.68; 38.77)	6	0.19 (0.01; 0.36)	46	Not reported
Improved UI	But, 2005 ⁵⁰⁷	11/26	3/13	1.83 (0.62; 5.45)	19	0.19 (-0.11; 0.49)	21	Yes
Improved UI	Fujishiro, 2000 ⁵²⁸	23/31	10/31	2.30 (1.33; 3.99)	75	0.42 (0.19; 0.64)	33	No
Pooled		41/87	14/66	2.30 (1.43; 3.71)	100	0.27 (0.11; 0.42)	100	
Heterogeneity p value, I squared				0.68	0.00	0.25	27.90	

Appendix Table F102. Pooled analysis of improvement in incontinence after magnetic stimulation when compared to no active treatment, random effects model

Reference	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk differences (95% CI)	Weight for relative risk	Weight for absolute risk differences
Fujishiro, 2000 ⁵²⁸	23/31	10/31	2.30 (1.33; 3.99)	0.42 (0.19; 0.64)	75.2	32.73
But, 2003 ⁵⁰⁸	7/30	1/22	5.13 (0.68; 38.77)	0.19 (0.01; 0.36)	5.58	45.92
But, 2005 ⁵⁰⁷	11/26	3/13	1.83 (0.62; 5.45)	0.19 (-0.11; 0.49)	19.22	21.35
Studies: 3	Patients: 153		2.30 (1.43; 3.71)	0.27 (0.11; 0.42)	100	100
I-squared (variation attributable to heterogeneity)			0	27.9		

Appendix Table F103. Scoring of quality of life after magnetic stimulation compared to no active treatment (results from RCTs)

Reference	Active	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean/standard deviation	Mean difference (95% CI)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	General health perception, 1 week (T2)	10/10	37.50/13.10	42.50/16.80	-5.00 (-18.20; 8.20)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Incontinence impact, 1 week (T2)	10/10	39.90/26.20	56.60/22.40	-16.70 (-38.06; 4.66)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Role limitation, 1 week (T2)	10/10	33.30/30.40	33.30/22.20	0.00 (-23.33; 23.33)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Physical limitation, 1 week (T2)	10/10	43.20/27.40	46.60/24.60	-3.40 (-26.22; 19.42)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Social limitation, 1 week (T2)	10/10	14.90/19.50	32.10/21.20	-17.20 (-35.05; 0.65)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Personal relationships, 1 week (T2)	10/10	6.60/11.60	31.60/39.60	-25.00 (-50.58; 0.58)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Emotions, 1 week (T2)	10/10	41.00/29.10	42.10/29.00	-1.10 (-26.56; 24.36)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Sleep/energy, 1 week (T2)	10/10	29.90/20.40	19.90/13.10	10.00 (-5.03; 25.03)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	SEAPI-QMM, 1 week (T2)	10/10	1.70/0.80	1.80/0.60	-0.10 (-0.72; 0.52)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	General health perception, 1 month (T3)	10/10	52.30/25.90	57.50/28.90	-5.20 (-29.25; 18.85)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Incontinence impact, 1 month (T3)	10/10	49.60/22.20	64.90/16.50	-15.30 (-32.44; 1.84)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Role limitation, 1 month (T3)	10/10	39.90/29.60	53.30/23.30	-13.40 (-36.75; 9.95)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Physical limitation, 1 month (T3)	10/10	47.90/28.80	58.20/26.30	-10.30 (-34.47; 13.87)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Social limitation, 1 month (T3)	10/10	27.20/33.00	44.40/28.60	-17.20 (-44.27; 9.87)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Personal relationships, 1 month (T3)	10/10	13.80/14.60	34.90/34.60	-21.10 (-44.38; 2.18)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Emotions, 1 month (T3)	10/10	46.30/30.90	48.80/35.10	-2.50 (-31.48; 26.48)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	Sleep/energy, 1 month (T3)	10/10	29.90/17.20	33.30/13.60	-3.40 (-16.99; 10.19)
Manganotti, 2007 ⁵⁶⁵	Active magnetic stimulation	SEAPI-QMM, 1 month (T3)	10/10	2.30/0.80	2.10/0.30	0.20 (-0.33; 0.73)
Gilling, 2009 ⁵³³	Electromagnetic stimulation	I-QOL score	35/35	71.20/3.30	67.30/4.40	3.90 (2.08; 5.72)
Gilling, 2009 ⁵³³	Electromagnetic stimulation	KHQ score	35/35	6.90/0.70	8.60/1.00	-1.70 (-2.10; -1.30)
Gilling, 2009 ⁵³³	Electromagnetic stimulation	I-QOL score at 6 months of followup	35/35	73.60/3.00	68.90/4.50	4.70 (2.91; 6.49)
Gilling, 2009 ⁵³³	Electromagnetic stimulation	KHQ score at 6 months of followup	35/35	7.70/0.70	8.50/1.00	-0.80 (-1.20; -0.40)

Appendix Table F104. Improvement in incontinence after injection of bulking agents when compared to no active treatment (results from individual RCTs)

Reference sample	Active	Definition of outcomes	Randomized active/control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)
Lee, 2001 ⁵⁵⁸ 68	Periurethral injections of autologous fat with 3 max injections depending on outcomes measures	Cured or improved	35/33	6/17	6/18	0.94 (0.34; 2.63)	-0.01 (-0.19 ;0.17)
Appell, 2006 ⁴⁸¹ 173	Transurethral radiofrequency energy collagen micro-remodeling	Improvement >10 point I-QOL score	110/63	53/48	28/44	1.08 (0.77; 1.52)	0.04 (-0.12; 0.19)

Appendix Table F105. Scoring of quality of life after bulking agent when compared to no active treatment (results from individual RCT)

Reference	Active	Definition of quality of life	Randomized active/ control	Active mean standard deviation	Control mean standard deviation	Mean difference (95% CI)
Lee, 2001 ⁵⁵⁸	Periurethral injections of autologous fat (30 cc of fat from the anterior abdominal wall or buttock through a single 2 to 3 mm) with 3 max injections depending on outcomes measures	Mean incontinence score	35/33	10.90/4.50	12.20/4.60	-1.30 (-3.46; 0.86)

Appendix Table F106. Clinical outcomes after bladder training compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Continence	Fantl, 1991 ⁵²⁴	8/65	2/66	4.06 (0.90; 18.41)		0.09 (0.00; 0.18)		Yes
Treatment failure	Fantl, 1991 ⁵²⁴	5/65	28/66	0.18 (0.07; 0.44)		-0.35 (-0.48; -0.21)		Yes
Improved UI	Subak, 2002 ⁵⁹⁸	39/77	11/75	3.41 (1.89; 6.15)	37	0.35 (0.22; 0.49)	52	Yes
Improved UI	Fantl, 1991 ⁵²⁴	49/65	16/66	3.11 (1.99; 4.87)	63	0.51 (0.36; 0.66)	48	Yes
Pooled		87	27	3.22 (2.25; 4.60)	100	0.43 (0.28; 0.59)	100	
Heterogeneity p value				0.81	0.00	0.12	58	
I squared								

Appendix Table F107. Scoring of quality of life after bladder training compared to no active treatment (individual RCT)

Reference	Active	Definition of quality of life	Randomized active/ control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Wyman, 1997 ⁶¹⁷	Bladder training: patient education, progressive scheduled voiding regimen, positive reinforcement	Self reported quality of life measures (Incontinence Impact Questionnaire (IIQ))	65/66	32.00/41.00	60.00/65.00	-28.00 (-46.58; -9.42)

Appendix Table F108. Clinical outcomes after percutaneous electrical stimulation compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Improved UI	Peters, 2010 ⁵⁸⁶	39/110	23/110	1.70 (1.09; 2.64)	46.28	0.15 (0.03; 0.26)	34.31	Not reported
Improved UI	Peters, 2010 ⁵⁸⁷	29/73	18/77	1.70 (1.04; 2.78)	49.95	0.16 (0.02; 0.31)	35.63	
Improved UI	Finazzi-Agro, 2010 ⁵²⁷	12/18	0/17	23.7 (1.5; 371.3)	3.77	0.67 (0.44; 0.89)	30.05	
Pooled		6880/201	41/204	1.9 (1.1; 3.2)	100	0.31 (0.04; 0.58)	100	
Heterogeneity p value, I squared		0.14/49%				0/89%		
Adverse effects	Peters, 2010 ⁵⁸⁶	6/110	0/110	13.00 (0.74; 228.00)		0.06 (0.01; 0.10)		Not reported

Appendix Table F109. Clinical outcomes after pelvic floor muscle training combined with bladder training compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CII)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Continence	Lagro-Janssen, 1992 ⁵⁵³	10/54	1/56	10.37 (1.37; 78.28)	12	0.17 (0.06; 0.28)	19	Yes
Continence	McFall, 2000 ⁵⁷¹	25/72	15/73	1.69 (0.97; 2.93)	30	0.14 (-0.00; 0.29)	17	Yes
Continence	Kumari, 2008 ⁵⁵²	30/78	1/86	33.08 (4.62; 236.86)	13	0.37 (0.26; 0.48)	19	Yes
Continence	O'Brien, 1991 ⁵⁸¹	32/378	1/183	15.49 (2.13; 112.49)	13	0.08 (0.045; 0.11)	24	Yes
Continence	Diokno, 2004 ⁵¹⁵	61/164	55/195	1.32 (0.98; 1.78)	32	0.09 (-0.01; 0.19)	20	Not reported
Pooled		158/746	72/593	3.79 (1.55; 9.27)	100	0.166 (0.06; 0.27)	100	
Heterogeneity p value			<0.05	79		<0.05	85.2	
I squared								
Improved UI	McFall, 2000 ⁵⁷¹	30/49	22/59	1.64 (1.10; 2.45)	28	0.24 (0.055; 0.42)	23	Yes
Improved UI	Lagro-Janssen, 1992 ⁵⁵³	40/54	2/56	20.74 (5.27; 81.63)	18	0.71 (0.58; 0.83)	25	Yes
Improved UI	Diokno, 2004 ⁵¹⁵	92/164	80/195	1.37 (1.10; 1.70)	29	0.15 (0.05; 0.25)	26	Not reported
Improved UI	O'Brien, 1991 ⁵⁸¹	182/378	7/183	12.59 (6.04; 26.22)	25	0.44 (0.39; 0.50)	27	Yes
Pooled		344/645	111/493	4.13 (1.58; 10.78)	100	0.39 (0.17; 0.60)	100	
Heterogeneity p value				0.00	93.00	0.00	0.94	
I squared								
Treatment failure	Lagro-Janssen, 1992 ⁵⁵³	1/54	2/56	0.52 (0.05; 5.55)	8	-0.02 (-0.08; 0.04)	87	Yes
Treatment failure	McFall, 2000 ⁵⁷⁰	10/49	15/59	0.80 (0.40; 1.62)	92	-0.05 (-0.21; 0.11)	13	Yes
Pooled		11/103	17/115	0.78 (0.39; 1.52)	100	-0.02 (-0.78; 0.04)	100	
Heterogeneity p value				0.7	0	0.7	0	
I squared								
Treatment discontinuation	McFall, 2000 ⁵⁷⁰	7/49	5/59	1.69 (0.57; 4.98)	38	0.06 (-0.06; 0.18)	40	Yes
Treatment discontinuation	Kumari, 2008 ⁵⁵²	9/78	10/86	0.99 (0.43; 2.31)	62	-0.00 (-0.10; 0.10)	60	Yes
Pooled		16/127	15/145	1.21 (0.62; 2.36)	100	0.02 (-0.05; 0.10)	100	
Heterogeneity p value				0.45	0.00	0.46	0.00	
I squared								

Appendix Table F110. Clinical outcomes after pelvic floor muscle training combined with bladder training when compared to no active treatment (individual RCTs)

Reference sample/men	Active	Definition of outcome	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Lagro-Janssen, 1992 ⁵⁵³ 110/0	PFMT alone (stress) or bladder training (urge) or its combination (mixed)	Self reported severe urinary incontinence	54/56	4/7	23/41	0.18 (0.07; 0.49)	-0.34 (-0.48; -0.19)	-3 (-5; -2)	-337 (-483; -190)
		Self reported deterioration in urinary incontinence	54/56	1/2	2/3	0.52 (0.05; 5.55)	-0.02 (-0.08; 0.04)		
McFall, 2000 ⁵⁷⁰ 108/0	Community based small group educational intervention: PFMT + bladder training	Withdraw	49/59	7/14	5/8	1.69 (0.57; 4.98)	0.06 (-0.06; 0.18)		
		No reduction in number of incontinence episodes	49/59	10/20	15/25	0.80 (0.40; 1.62)	-0.05 (-0.21; 0.11)		
		Self reported bothersomeness of urinary incontinence	72/73	42/59	62/85	0.69 (0.55; 0.85)	-0.27 (-0.41; -0.13)	-4 (-8; -2)	-266 (-406; -126)
McFall, 2000 ⁵⁷⁰ 145/0	Community-based intervention: bladder training, and PFMT	Use absorbent pads for urinary incontinence	72/73	39/54	56/77	0.71 (0.55; 0.90)	-0.23 (-0.38; -0.07)	-4 (-13; -3)	-225 (-376; -75)

Appendix Table F110. Clinical outcomes after pelvic floor muscle training combined with bladder training when compared to no active treatment, individual RCTs (continued)

Reference sample/men	Active	Definition of outcome	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Kumari, 2008 ⁵⁵² 164/0	Behavioral treatment with PFMT + bladder retraining	Death	78/86	2/3	1/1	2.21 (0.20; 23.85)	0.01 (-0.03; 0.06)		
		Stress incontinence 3 months after intervention	78/86	11/14	27/31	0.45 (0.24; 0.84)	-0.17 (-0.30; -0.05)	-6 (-21; -3)	-173 (-298; -48)
		Stress incontinence 6 months after intervention	78/86	9/12	22/26	0.45 (0.22; 0.92)	-0.14 (-0.26; -0.02)	-7 (-41; -4)	-140 (-257; -24)
		Stress incontinence	78/86	15/19	28/33	0.59 (0.34; 1.02)	-0.13 (-0.27; 0.00)	-8 (-873; -4)	-133 (-265; -1)
		Mixed incontinence 6 months after intervention	78/86	17/22	28/33	0.67 (0.40; 1.12)	-0.11 (-0.24; 0.03)		
		Mixed incontinence 3 months after intervention	78/86	23/30	32/37	0.79 (0.51; 1.23)	-0.08 (-0.22; 0.07)		
		Mixed incontinence	78/86	25/32	34/40	0.81 (0.54; 1.23)	-0.07 (-0.22; 0.07)		
		Urgency incontinence 6 months after intervention	78/86	2/3	15/17	0.15 (0.03; 0.62)	-0.15 (-0.24; -0.06)	-7 (-16; -4)	-149 (-236; -61)
		Urgency incontinence 3 months after intervention	78/86	6/8	19/22	0.35 (0.15; 0.83)	-0.14 (-0.25; -0.04)	-7 (-26; -4)	-144 (-250; -38)
		Urgency incontinence	78/86	8/10	23/27	0.38 (0.18; 0.81)	-0.16 (-0.28; -0.05)	-6 (-20; -4)	-165 (-280; -50)

Appendix Table F111. Scoring of quality of life after pelvic floor muscle training combined with bladder training compared to no active treatment (individual RCT)

Reference	Active	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean/standard deviation	Mean difference (95% CI)
Kumari, 2008 ⁵⁵²	Behavioral treatment with PFMT+ bladder training	IIQ score	78/86	4.60/6.80	12.03/9.42	-7.43 (-9.93; -4.93)
Kumari, 2008 ⁵⁵²	Behavioral treatment with PFMT+ bladder training	IIQ score 6 month after intervention	78/86	2.57/8.16	9.54/10.88	-6.97 (-9.90; -4.04)

Appendix Table F112. Clinical outcomes after continence service compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CII)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Continence	Kim, 2001 ⁵⁴⁷	14/16	2/15	6.56 (1.78; 24.16)	8	0.72 (0.51; 0.98)	30	No
Continence	Moore, 2003 ⁵⁷³	37/74	27/71	1.31 (0.90; 1.91)	38	0.12 (-0.04; 0.28)	33	Yes
Continence	Williams, 2005 ⁶¹³	828/2958	150/788	1.47 (1.26; 1.72)	54	0.09 (0.06; 0.12)	37	Yes
Pooled		879/3048	179/874	1.58 (1.07; 2.34)	100	0.30 (-0.01; 0.60)	100	
Heterogeneity p value				0.07	63	0	93	
I squared								
Improved UI	O'Brien, 1996 ⁵⁸²	56/61	102/168	3.11 (1.99; 4.87)	47	0.311 (0.21; 0.41)	47	Yes
Improved UI	Williams, 2005 ⁶¹³	1834/2958	410/788	1.19 (1.11; 1.28)	53	0.100 (0.06; 0.14)	53	Yes
Pooled		1890/3019	512/956	1.33 (1.06; 1.68)	100	0.2 (-0.01; 0.41)	100	
Heterogeneity p value				0.00	88.10	0.00	93.20	
I squared								

Appendix Table F113. Improvement in urinary incontinence after interventions that were implemented by continence specialists when compared to no active treatment (individual RCTs)

Reference sample/men	Active	Control	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
O'Brien, 1996 ⁵⁸² /0	Followup after nurse-led continence interventions	Postponed treatment	146	19/13					
			in cured patients	124/85					
			in those with improved UI	15/10					
	Adherence to PFMT for more than year	No adherence	61/168	56/92	102/61	1.51 (1.31; 1.74)	0.31 (0.21; 0.41)	3 (2; 5)	311 (210; 412)
Williams, 2005 ⁶¹³ 3746/1498	Continence service	Existing primary care	2958/788	1834/62	410/52	1.19 (1.11; 1.28)	0.10 (0.06; 0.14)	10 (7; 16)	100 (61; 139)

Appendix Table F114. Quality of life after interventions that were implemented by continence specialists when compared to no active treatment (individual RCTs)

Reference sample/men	Active	Control	Definition of quality of life	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/ 1000 treated (95% CI)
Du Moulin, 2007 ⁵⁷⁵ 101/0	Continence nurse and multi-disciplinary team	Standard care	No problem in pain/discomfort at 1 year of followup	50/51	19/38	5/10	3.88 (1.57; 9.58)	0.28 (0.12; 0.44)	4 (2; 8)	282 (125;439)
			No problem in usual activities at 1 year of followup	50/51	22/44	6/12	3.74 (1.66; 8.44)	0.32 (0.16; 0.49)	3 (2; 6)	322 (159;486)
			No problem in mobility at 1 year of followup	50/51	25/50	8/16	3.19 (1.59; 6.38)	0.34 (0.17; 0.51)	3 (2; 6)	343 (172;514)
			No problem in anxiety/depression at 1 year of followup	50/51	26/52	6/12	4.42 (1.99; 9.81)	0.40 (0.24; 0.57)	2 (2; 4)	402 (238;567)
			No problem in self-care at 1 year of followup	50/51	31/62	10/20	3.16 (1.74; 5.74)	0.42 (0.25; 0.60)	2 (2; 4)	424 (251;597)
Williams, 2005 ⁶¹³ 3746/1498	Continence service	Existing primary care	% satisfied with current urinary symptoms for rest of life	2958/788	1893/64	418/53	1.21 (1.12; 1.30)	0.11 (0.07; 0.15)	9 (7; 14)	110 (71;148)
Williams, 2005 ⁶¹³ 3,746/1,498			% of mild or no problem	2958/788	2337/79	552/70	1.13 (1.07; 1.18)	0.09 (0.05; 0.12)	11 (8; 8)	90 (54;125)

Appendix Table F115. Scoring of quality of life after interventions that were implemented by continence specialists when compared to no active treatment (individual RCTs)

Reference	Active	Control	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Du Moulin, 2007 ⁵⁷⁵	Continence nurse and multidisciplinary team	Standard care	IIQ (impact) mobility (0 to 100 worse)	50/51	21.00/25.30	17.60/20.40	3.40 (-5.57; 12.37)
			IIQ emotional (0 to 100 worse)	50/51	13.90/25.10	14.00/17.90	-0.10 (-8.62; 8.42)
			IIQ social (0 to 100 worse)	50/51	9.80/18.80	3.70/7.90	6.10 (0.46; 11.74)
			IIQ embarrassment (0 to 100 worse)	50/51	17.90/26.50	17.60/23.00	0.30 (-9.38; 9.98)
			IIQ physical (0 to 100 worse)	50/51	13.50/21.60	11.70/17.70	1.80 (-5.91; 9.51)
			1 year of followup IIQ (impact) mobility (0 to 100 worse)	50/51	18.40/25.00	14.70/18.40	3.70 (-4.87; 12.27)
			1 year of followup IIQ emotional (0 to 100 worse)	50/51	12.40/20.70	12.90/12.70	-0.50 (-7.21; 6.21)
			1 year of followup IIQ social (0 to 100 worse)	50/51	7.80/21.80	5.60/9.40	2.20 (-4.37; 8.77)
			1 year of followup IIQ embarrassment (0 to 100 worse)	50/51	15.40/26.60	13.30/16.30	2.10 (-6.52; 10.72)
			1 year of followup IIQ physical (0 to 100 worse)	50/51	10.40/19.50	9.30/12.40	1.10 (-5.29; 7.49)
			1 year of followup EQ-5D (0 worse to 100)	50/51	73.50/18.30	71.50/8.10	2.00 (-3.54; 7.54)
			Patient satisfaction (1 worse to 10)	50/51	8.20/1.20	7.40/1.10	0.80 (0.35; 1.25)
			Patient satisfaction (1 worse to 10) at 1 year of followup	50/51	8.70/1.00	7.50/1.00	1.20 (0.81; 1.59)
Chadha, 2000 ⁵¹⁰	National evidence based guidelines	Pre-guidelines levels	Self-reported perception of urinary incontinence, scores	449/449	15.50/20.30	13.90/20.70	1.60 (-1.08; 4.28)
Kim, 2001 ⁵⁴⁷	Continence Efficacy Intervention Program	Conventional care	Improved scores (from 0 to 100)	16/17	37.80/23.90	23.60/18.90	14.20 (-0.56; 28.96)

Appendix Table F115. Scoring of quality of life after interventions that were implemented by continence specialists when compared to no active treatment (individual RCTs) (continued)

Reference	Active	Control	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Moore, 2003 ⁵⁷³	2 nurse continence advisors/patient and consulting urogynecologist	Outpatient regimen	Incontinence score	74/71	4.00/1.83	3.00/2.00	1.00 (0.37; 1.63)
			Quality of life Urogenital distress inventory	74/71	18.00/6.17	15.50/5.00	2.50 (0.68; 4.32)
			Short Urogenital distress inventory	74/71	8.00/1.50	6.00/2.50	2.00 (1.33; 2.67)
			Quality of life incontinence impact questionnaire	74/71	36.00/9.33	37.50/3.67	-1.50 (-3.79; 0.79)
			Short incontinence impact questionnaire 7	74/71	11.00/1.33	10.00/2.33	1.00 (0.38; 1.62)
Kim, 2001 ⁵⁴⁷	Continence Efficacy Intervention Program	Conventional care	Continence self-efficacy (16 worse 160)	16/15	140.20/14.60	107.70/34.70	32.50 (13.54; 51.46)
			Score of Improvement by subjective evaluation (0 to 100)	16/15	37.80/23.90	20.00/17.30	17.80 (3.18; 32.42)
Borrie 2002 ⁴⁹⁷ 120 men	Lifestyle modification by nurse continence advisers	Usual care	Control over urinary incontinence	210/211			1.20 (0.70; 1.60)
			Acceptance of urinary incontinence	210/211			0.50 (0.00; 0.90)
			Coping with urinary incontinence	210/211			0.60 (0.30; 1.00)
			Knowledge about incontinence	210/211			2.30 (1.90; 2.70)
			IIQ-short form	210/211			3.10 (1.90; 4.30)
			Change in bladder control	210/211			1.70 (1.40; 1.90)
			Change in amount leaked	210/211			1.70 (1.50; 2.00)
Change in quality of life	210/211			1.50 (1.20; 1.70)			

Bold = Significant differences at 95% confidence level

Appendix Table F116. Clinical outcomes after weight loss program compared to no active treatment (results from RCTs pooled with random effects models)

Outcome	Reference	Active events/ randomized	Control events/ randomized	Relative risk (95% CII)	Weight, %	Absolute risk difference (95% CI)	Weight %	Inclusion of mixed UI
Continence	Subak, 2009 ⁶⁰⁰	16/226	4/112	1.98 (0.68; 5.79)		0.04 (-0.01; 0.08)		Yes
Improved UI	Subak, 2005 ⁵⁹⁹	14/24	4/24	3.50 (1.35; 9.11)	26	0.42 (0.17; 0.66)	37	Yes
Improved UI	Subak, 2009 ⁶⁰⁰	93/226	25/112	1.84 (1.26; 2.69)	74	0.19 (0.09; 0.29)	63	Yes
Pooled		107/250	28/136	2.17 (1.26; 3.76)	100	0.27 (0.06; 0.49)	100	
Heterogeneity p value, I squared				0.22	33.00	0.09	64.50	
Treatment discontinuation	Subak, 2009 ⁶⁰⁰	5/226	15/112	0.17 (0.06; 0.44)		-0.11 (-0.18; - 0.05)		Yes
Treatment discontinuation	Huang, 2009 ⁵⁴¹	5/226	15/112	0.17 (0.06; 0.44)		-0.11 (-0.18; - 0.05)		Not reported

Appendix Table F117. Quality of life after intensive weight loss programs when compared to no active treatment (individual RCTs)

Reference sample	Active	Control	Definition of improvement	Randomized active/control	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Subak, 2009 ⁶⁰⁰ 313	Intensive 6-month weight-loss program (7 to 9% of initial body weight)	Structured education program	Incontinence somewhat or much less of a problem	219/94	1.40 (1.14; 1.71)	0.22 (0.10; 0.33)	5 (3; 10)	215 (100;331)
Huang, 2009 ⁵⁴¹	Intensive lifestyle and behavior change program— an average loss of 7% to 9% of initial body weight	Structured education program	Odds ratio of frequency of sexual activity	226/112	1.34 (0.99; 1.81)			
Huang, 2009 ⁵⁴¹	Intensive lifestyle and behavior change program— an average loss of 7% to 9% of initial body weight	Structured education program	Odds ratio of overall sexual satisfaction	226/112	1.28 (0.83; 1.99)			
Huang, 2009 ⁵⁴¹	Intensive lifestyle and behavior change program— an average loss of 7% to 9% of initial body weight	Structured education program	Odds ratio of level of sexual desire	226/112	1.12 (0.79; 1.61)			

Appendix Table F118. Urinary incontinence, treatment failure and discontinuation after intensive weight loss programs when compared to no active treatment (individual RCTs)

Reference sample/ men	Active	Control	Definition of Outcome	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Subak, 2009 ⁶⁰⁰ Huang, 2009 ⁵⁴¹ 338/0	Intensive 6-month weight-loss program (7 to 9% of initial body weight)	Structured education program	Discontinued the intervention	226/112	5/2	15/13	0.17 (0.06; 0.44)	-0.11 (-0.18; -0.05)	-9 (-22; -6)	-112 (-178; -46)
Brown, 2006 ⁵⁰⁰ 1319/0	Intensive lifestyle therapy to lose and maintain at least 7% of initial body weight and physical activity for at least 150 minutes each week	Placebo twice daily.	Prevalence of stress incontinence after the treatment	659/660	206/31	242/37	0.85 (0.73; 0.99)	-0.05 (-0.11; 0.00)	-18 (-329; -10)	-54 (-105; -3)
			Prevalence of urgency incontinence after the treatment	659/660	156/24	169/26	0.92 (0.77; 1.12)	-0.02 (-0.07; 0.03)		

Appendix Table F119. Urinary incontinence after a diet high in soy protein (individual RCT)

Reference	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Manonai, 2006 ⁵⁶⁶	Self-selected diet with low-fat and low-cholesterol foods and soy protein 25 g in various forms of soy foods containing more than 50 mg/day of isoflavones	Self-selected diet with low-fat and low-cholesterol foods	% of women reported stress incontinence after treatments	36/36	18/51	0/0	37.00 (2.31; 591.54)	0.50 (0.33; 0.67)	2 (2; 3)	500 (335; 665)
Manonai, 2006 ⁵⁶⁶	Self-selected diet with low-fat and low-cholesterol foods and soy protein 25 g in various forms of soy foods containing more than 50 mg/day of isoflavones	Self-selected diet with low-fat and low-cholesterol foods	% of women reported urgency incontinence after treatments	36/36	6/17	8/22	0.75 (0.29; 1.94)	-0.06 (-0.24; 0.13)		

Appendix Table F120. Urinary incontinence after acupuncture compared to no active treatment (results from individual RCTs)

Reference sample	Active	Definition of incontinence	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)
Kim, 2005 ⁵²² 85	Acupuncture treatment expected to improve bladder symptoms	Proportion of subjects with detrusor contractions during cystometry	44/41	7/16	11/28	0.59 (0.25; 1.38)	-0.11 (-0.28; 0.06)

Appendix Table F121. Scoring of quality of life after acupuncture compared to no active treatment (results from individual RCTs)

Reference	Active	Definition of quality of life	Randomized active/ control	Active mean/ standard deviation	Control mean standard deviation	Mean difference (95% CI)
Emmons, 2005 ⁵²²	Acupuncture treatment expected to improve bladder symptoms	Urinary distress inventory score	44/41	3.60/3.20	5.80/4.80	-2.20 (-3.95; -0.45)
Emmons, 2005 ⁵²²	Acupuncture treatment expected to improve bladder symptoms	Incontinence impact questionnaire score	44/41	4.30/2.70	7.00/3.50	-2.70 (-4.04; -1.36)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	How much inconvenience do you have due to urinary incontinence during daily life? (score 0 worse to 4)	25/27	1.70/0.66	1.70/0.08	0.00 (-0.26; 0.26)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Affecting physical hobbies such as exercise and mountain climbing? (score 0 worse to 4)	25/27	1.70/0.59	1.80/0.07	-0.10 (-0.33; 0.13)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Affecting social communities such as cinema and weddings (score 0 worse to 4)	25/27	1.80/0.70	1.30/0.09	0.50 (0.22; 0.78)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Affecting keeping friendships (score 0 worse to 4)	25/27	1.90/0.64	1.70/0.08	0.20 (-0.05; 0.45)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Affecting business with colleagues (score 0 worse to 4)	25/27	1.90/0.67	1.80/0.09	0.10 (-0.16; 0.36)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Affecting sexual life (score 0 worse to 4)	25/27	1.80/0.70	1.40/0.09	0.40 (0.12; 0.68)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Affecting making new friends (score 0 worse to 4)	25/27	1.90/0.53	1.40/0.09	0.50 (0.29; 0.71)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Financial loss (score 0 worse to 4)	25/27	1.50/0.51	1.60/0.09	-0.10 (-0.30; 0.10)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Damage to general health (score 0 worse to 4)	25/27	1.80/0.55	1.50/0.09	0.30 (0.08; 0.52)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Getting easily angry or nervous (score 0 worse to 4)	25/27	1.80/0.57	1.50/0.09	0.30 (0.07; 0.53)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Influence general activity (score 0 worse to 4)	25/27	1.70/0.45	1.50/0.09	0.20 (0.02; 0.38)
Kim, 2008 ⁵⁴⁹	Hand acupuncture	Useless person than before (score 0 worse to 4)	25/27	1.70/0.52	1.50/0.09	0.20 (-0.01; 0.41)

Appendix Table F122. Clinical outcomes after supervised PFMT combined with bladder training compared to self administered PFMT (results from RCTs pooled with random effects models)

Outcome	Reference	Active n/N	Control n/N	Rate active/control	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Continence	Bo, 2005 ⁴⁹³	13/21	4/26	60/17	4.02 (1.54; 10.53)	17.48	0.465 (0.215; 0.715)	18.61
Continence	de Oliveira Camargo, 2009 ⁵⁰⁸	14/30	16/30	47/53	0.88 (0.53; 1.46)	22.04	-0.067 (-0.319; 0.186)	24.66
Continence	Zanetti, 2007 ⁶²²	11/23	2/21	48/10	5.02 (1.26; 20.07)	11.75	0.383 (0.143; 0.623)	19.09
Continence	Burgio, 2002 ⁵⁰³	15/74	11/75	20/15	1.38 (0.68; 2.81)	25.95	0.056 (-0.066; 0.178)	18.48
Continence	Felicissimo, 2010 ⁵²⁵	11/31	11/31	37/35	1 (0.5; 1.9)	22.77	0 (-0.24; 0.24)	19.16
Pooled		64/179	44/183	36/24	1.6 (0.88; 2.9)	100	0.16 (-0.03; 0.35)	100
Heterogeneity					0.018	66.4%	0.003	75.1%
P value, I squared,%								
Improved UI	Zanetti, 2007 ⁶²²	15/23	5/21	67/24	2.74 (1.21; 6.23)	28.6	0.414 (0.147; 0.681)	24.5
Improved UI	Burgio, 2002 ⁵⁰³	36/74	20/75	49/27	1.82 (1.17; 2.84)	17.1	0.22 (0.068; 0.371)	16.59
Improved UI	Konstantinidou, 2007 ⁵⁵¹	1/15	1/15	7/7	1 (0.07; 14.55)	2.65	0 (-0.179; 0.179)	22.52
Improved UI	de Oliveira Camargo, 2009 ⁵⁰⁸	18/30	20/30	60/67	0.9 (0.61; 1.33)	30.59	-0.067 (-0.31; 0.177)	18.03
Improved UI	Felicissimo, 2010 ⁵²⁵	11/31	11/31	37/35	1 (0.51; 1.96)	21.06	0 (-0.24; 0.24)	18.36
Pooled		82/173	57/172	47/33	1.37 (0.87; 2.2)	100	0.11 (-0.05; 0.27)	100
Heterogeneity					0.05	57.9%	0.023	64.6%
P value, I squared,%								
Treatment failure	Konstantinidou, 2007 ⁵⁵¹	4/15	7/15	27/47	0.86 (0.32; 2.30)	39.55	-0.056 (-0.405; 0.294)	26.35
Treatment failure	Bo, 2005 ⁴⁹³	1/21	7/26	5/27	0.18 (0.02; 1.33)	16.43	-0.222 (-0.415; -0.028)	44.5
Treatment failure	Aukee, 2004 ⁴⁸⁴	9/19	5/16	47/31	1.52 (0.64; 3.61)	44.03	0.161 (-0.158; 0.481)	29.15
Pooled		14/55	19/57	25/33	0.85 (0.34; 2.16)	100	-0.066 (-0.3; 0.167)	100
Heterogeneity					0.15	47.60%	0.126	51.70%
P value, I squared,%								
Treatment discontinuation	Tsai, 2009 ⁶¹⁰	4/54	5/54	7/9	0.8 (0.23; 2.82)	49.05	-0.019 (-0.123; 0.086)	90.15
Treatment discontinuation	Konstantinidou, 2007 ⁵⁵¹	3/15	5/15	20/33	0.79 (0.23; 2.7)	50.95	-0.063 (-0.379; 0.252)	9.85
Pooled		7/69	10/69	10/14	0.79 (0.33; 1.91)	100	-0.023 (-0.122; 0.076)	100

Appendix Table F113. Clinical outcomes after supervised PFMT combined with bladder training compared to self administered PFMT (results from RCTs pooled with random effects models) (continued)

Outcome	Reference	Active n/N	Control n/N	Rate active/control	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Heterogeneity P value, I squared,%					0.98	0.00%	0.791	0.00%

Appendix Table F123. Improvement in UI rates compared between nonpharmacological treatments

Active treatment	Control treatment	Studies	Patients	Rate active/ control, %	Relative risk (95% CI)	Absolute risk difference (95%CI)	Level of evidence
Pelvic floor muscle training+ bladder training	Bladder training	1 ⁶¹⁸	272	21/15	1.40 (0.83; 2.36)	0.06 (-0.03; 0.15)	Insufficient
Supervised pelvic floor muscle training	Pelvic floor muscle training	4 ^{503, 508, 551, 622}	283	50/33	1.51 (0.85; 2.67)	0.14 (-0.05; 0.32)	Moderate
Pelvic floor muscle training	Electrical stimulation	4 ^{247, 538, 595, 596}	136	31/45	0.97 (0.62; 1.51)	-0.01 (-0.17; 0.16)	Moderate
Pelvic floor muscle training	Vaginal cone	4 ^{247, 531, 593, 614}	440	41/41	1.02 (0.91; 1.14)	0.01 (-0.08; 0.09)	Moderate

Appendix Table F124. Clinical outcomes after PFMT combined with biofeedback compared to PFMT alone (results from RCTs pooled with random effects models)

Outcome	Reference	Active n/N	Control n/N	Rate active/control	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Continence	Berghmans, 1996 ⁴⁸⁷	5/20	3/20	25/15	1.67 (0.46; 6.06)	7.05	0.1 (-0.146; 0.346)	12.53
Continence	Glavind, 1996 ⁵³⁴	11/20	3/20	55/15	3.67 (1.20; 11.19)	8.95	0.4 (0.132; 0.668)	11.19
Continence	Morkved, 2002 ⁵⁷⁴	19/53	14/50	36/28	1.28 (0.72; 2.27)	21.85	0.078 (-0.101; 0.258)	17.73
Continence	Burgio, 2002 ⁵⁰³	15/73	11/75	20/15	1.40 (0.69; 2.84)	17.15	0.059 (-0.064; 0.181)	23.68
Continence UD	Goode, 2003 ⁵³⁶	18/66	25/67	28/38	0.73 (0.44; 1.21)	24.8	-0.1 (-0.258; 0.058)	19.82
Continence	Wang, 2004 ⁶¹¹	15/38	12/40	38/30	1.32 (0.71; 2.44)	20.2	0.095 (-0.116; 0.305)	15.05
Pooled		82/270	68/272	30/25	1.27 (0.88; 1.85)	100	0.079 (-0.031; 0.189)	100
Heterogeneity					0.147	38.80%	0.065	51.80%
P value, I squared,%								
Treatment failure	Morkved, 2002 ⁵⁷⁴	1/53	3/50	2/6	0.31 (0.03; 2.92)	66.52	-0.041 (-0.116; 0.034)	74.27
Treatment failure	Glavind, 1996 ⁵³⁴	0/20	1/20	0/5	0.33 (0.01; 7.72)	33.48	-0.05 (-0.178; 0.078)	25.73
Pooled		1/73	4/70	1/6	0.32 (0.05; 1.98)	100	-0.043 (-0.108; 0.022)	100
Heterogeneity					0.98	0.00%	0.907	0.00%
P value, I squared,%								

Appendix Table F125. Quality of life after supervised vs. self-administered PFMT programs (individual RCTs)

Reference sample/men	Active	Definition of quality of life	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Ng, 2008 ⁵⁷⁷ /0	A registered nurse monitoring via telephone checkups twice a week home based PFMT	Affect on family life	44/44			0.96 (0.50; 1.83)			
Ng, 2008 ⁵⁷⁷ /0	A registered nurse monitoring via telephone checkups twice a week home based PFMT	Affect on holidays/recreation	44/44			0.92 (0.57; 1.50)			
Ng, 2008 ⁵⁷⁷ /0	A registered nurse monitoring via telephone checkups twice a week home based PFMT	Affect on interests/hobbies	44/44			0.85 (0.53; 1.37)			
Ng, 2008 ⁵⁷⁷ /0	A registered nurse monitoring via telephone checkups twice a week home based PFMT	Affect on social activities	44/44			0.79 (0.48; 1.30)			
Ng, 2008 ⁵⁷⁷ /0	A registered nurse monitoring via telephone checkups twice a week home based PFMT	Worried about smell of urine	44/44			0.67 (0.44; 1.04)			
Ng, 2008 ⁵⁷⁷ /0	A registered nurse monitoring via telephone checkups twice a week home based PFMT	Affect on sexual life	44/44			0.62 (0.34; 1.13)			
Ng, 2008 ⁵⁷⁷ /0	A registered nurse monitoring via telephone checkups twice a week home based PFMT	Affect on sexual quality	44/44			0.52 (0.29; 0.95)			
Zanetti, 2007 ⁶²² 44/0	Supervised PMFT	Patient satisfaction	23/21	15/67	5/24	2.74 (1.20; 6.23)	0.41 (0.15; 0.68)	2 (1; 7)	414 (147;681)

Appendix Table F126. Scoring of quality of life after supervised vs. self-administered PFMT programs (individual RCTs)

Reference sample/men	Definition of quality of life	randomized active/control	Active mean/standard deviation	Control mean/standard deviation	Mean difference (95% CI)
de Oliveira Camargo, 2009 ⁵⁰⁸ /0	Final general health (KHQ 0 best to 100)	30/30	39.20/21.50	37.50/20.50	1.70 (-8.93; 12.33)
de Oliveira Camargo, 2009 ⁵⁰⁸ /0	Final incontinence impact (KHQ 0 best to 100)	30/30	20.00/25.70	13.30/24.10	6.70 (-5.91; 19.31)
de Oliveira Camargo, 2009 ⁵⁰⁸ /0	Final physical activities limitations (KHQ 0 best to 100)	30/30	3.30/8.10	10.60/17.80	-7.30 (-14.30; -0.30)
de Oliveira Camargo, 2009 ⁵⁰⁸ /0	Final physical limitations (KHQ 0 best to 100)	30/30	4.40/11.50	10.60/11.50	-6.20 (-12.02; -0.38)
de Oliveira Camargo, 2009 ⁵⁰⁸ /0	Final social limitations (KHQ 0 best to 100)	30/30	0.70/2.80	3.70/10.20	-3.00 (-6.78; 0.78)
de Oliveira Camargo, 2009 ⁵⁰⁸ /0	Final personal relationships (KHQ 0 best to 100)	30/30		2.30/7.80	
de Oliveira Camargo, 2009 ⁵⁰⁸ /0	Final emotions (KHQ 0 best to 100)	30/30	5.60/19.30	4.80/11.60	0.80 (-7.26; 8.86)
de Oliveira Camargo, 2009 ⁵⁰⁸ /0	Final sleep/disposition (KHQ 0 best to 100)	30/30	7.20/17.90	4.40/10.70	2.80 (-4.66; 10.26)
de Oliveira Camargo, 2009 ⁵⁰⁸ /0	Final gravity (KHQ 0 best to 100)	30/30	15.30/20.30	14.40/20.30	0.90 (-9.37; 11.17)

Appendix Table F127. Continence and improvement in incontinence after complex group and individual pelvic floor muscle training programs (individual RCTs)

Outcome	Reference	Active	Control	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Continence	Pages, 2001 ⁵⁸⁵ 40/0	Specific physical therapy program: group therapy 5 times/week and home pelvic floor exercise with 50 contractions for 10 minutes 2 times/day; recommendation of weight loss and aerobic sports.	Biofeedback training daily 90-minutes in group and individually for 15 minutes, 5 times/week Intra vaginal pressure sensor and visual biofeedback in computer monitor	27/13	6/22	4/28	0.72 (0.25; 2.12)	-0.09 (-0.38; 0.21)		
Continence	Janssen, 2001 ⁵⁴⁴ 530/0	Individual pelvic floor exercises 5 times/day and bladder training with delay voiding, training with 11 30-minute sessions.	Group pelvic floor exercises 5 times/day and bladder training with delay voiding, training with 9 2-hour sessions	126/404	25/20	53/13	1.51 (0.98; 2.33)	0.07 (-0.01; 0.14)		
				126/404	28/22	57/14	1.58 (1.05; 2.36)	0.08 (0.00; 0.16)	12 (6; 1003)	81 (1; 161)
Improvement in incontinence	Janssen, 2001 ⁵⁴⁴ 530/0	Individual pelvic floor exercises 5 times/day and bladder training with delay voiding, training with 11 30-minute sessions.	Group pelvic floor exercises 5 times/day and bladder training with delay voiding, training with 9 2-hour sessions at 3 months	126/404	118/94	347/86	1.09 (1.03; 1.16)	0.08 (0.02; 0.13)	13 (8; 43)	78 (23; 132)
			at 9 months	126/404	107/85	315/78	1.09 (1.00; 1.19)	0.07 (0.00; 0.14)		

Appendix Table F127. Continence and improvement in incontinence after complex group and individual pelvic floor muscle training programs, individual RCTs (continued)

Outcome	Reference	Active	Control	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Improvement in incontinence	Pages, 2001 ⁵⁸⁵ 40/0	Specific physical therapy program: group therapy 5 times/week and home pelvic floor exercise with 50 contractions for 10 minutes 2 times/day; recommendation of weight loss and aerobic sports.	Biofeedback training daily 90-minutes in group and individually for 15 minutes, 5 times/week Intra vaginal pressure sensor and visual biofeedback in computer monitor	27/13	20/74	9/68	1.07 (0.70; 1.64)	0.05 (-0.25; 0.35)		

Appendix Table F128. Scoring of quality of life after PFMT with biofeedback using vaginal EMG probe when compared to PFMT (individual RCTs)

Reference sample/men	Active	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean/standard deviation	Mean difference (95% CI)
Morkved, 2002 ⁵⁷⁴ /0	PFMT with biofeedback	Leakage index	53/50	1.90/0.74	1.90/0.72	0.00 (-0.28; 0.28)
Morkved, 2002 ⁵⁷⁴ /0	PFMT with biofeedback	Social activity index	53/50	9.50/0.74	9.40/1.08	0.10 (-0.26; 0.46)
Aukee, 2002 ⁴⁸³ /0	Pelvic floor muscle exercise of and individual EMG-assisted biofeedback	Leakage index	15/15	34.90/10.40	38.10/10.50	-3.20 (-10.68; 4.28)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and Advice and EMG biofeedback	Incontinence Impact Questionnaire Scores: Total score	10/10	62.50/44.20	101.60/46.10	-39.10 (-78.68; 0.48)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and Advice and EMG biofeedback	Incontinence Impact Questionnaire Scores: Physical activity	10/10	32.90/37.10	35.60/25.70	-2.70 (-30.67; 25.27)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG Biofeedback	Incontinence Impact Questionnaire Scores: Emotional health	10/10	28.70/39.20	28.70/26.00	0.00 (-29.15; 29.15)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Incontinence Impact Questionnaire Scores: Travel	10/10	32.90/37.10	46.40/28.00	-13.50 (-42.31; 15.31)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Incontinence Impact Questionnaire Scores: Social relationships	10/10	28.80/39.30	14.90/12.40	13.90 (-11.64; 3 9.44)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Urogenital Distress Inventory Scores: Total score	10/10	77.90/33.50	139.60/66.50	-61.70 (-107.85; -15.55)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Urogenital Distress Inventory Scores: Irritative symptoms	10/10	40.00/18.12	56.60/28.80	-16.60 (-37.69; 4.49)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Urogenital Distress Inventory Scores: Obstructive/discomfort	10/10	23.70/18.20	49.10/36.10	-25.40 (-50.46; -0.34)

Appendix Table F128. Scoring of quality of life after PFMT with biofeedback using vaginal EMG probe when compared to PFMT (individual RCTs) (continued)

Reference sample/men	Active	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean/standard deviation	Mean difference (95% CI)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Urogenital Distress Inventory Scores: Stress symptoms	10/10	19.90/23.30	47.50/34.70	-27.60 (-53.51; -1.69)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Incontinence Impact Questionnaire (Scores: Total score	10/10	78.90/55.70	101.60/46.10	-22.70 (-67.51; 22.11)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Incontinence Impact Questionnaire Scores: Physical activity	10/10	27.00/30.50	35.60/25.70	-8.60 (-33.32; 16.12)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Incontinence Impact Questionnaire Scores: Emotional health	10/10	28.50/29.50	28.70/26.00	-0.20 (-24.57; 24.17)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Incontinence Impact Questionnaire Scores: Travel	10/10	32.70/30.90	46.40/28.00	-13.70 (-39.54; 12.14)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Incontinence Impact Questionnaire Scores: Social relationships	10/10	25.00/30.60	14.90/12.40	10.10 (-10.36; 30.56)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Urogenital Distress Inventory Scores: Total score	10/10	100.50/43.10	139.60/66.50	-39.10 (-88.22; 10.02)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Urogenital Distress Inventory Scores: Irritative symptoms	10/10	47.60/12.00	56.60/28.80	-9.00 (-28.34; 10.34)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Urogenital Distress Inventory Scores: Obstructive/discomfort	10/10	31.50/22.80	49.10/36.10	-17.60 (-44.06; 8.86)
McDowell, 2006 ⁵⁶⁸ /0	PFMT and advice and EMG biofeedback	Urogenital Distress Inventory Scores: Stress symptoms	10/10	23.20/26.20	47.50/34.70	-24.30 (-51.25; 2.65)
Wong, 2001 ⁶¹⁶ /0	Pelvic floor exercises with EMG	IIQ-7 (1 to 100 worse)	19/19	14.29	14.29	0.00
Sung, 2000 ⁶⁰² /0	Pelvic floor exercises with EMG	Discomfort due to incontinence (0 to 5 worse)	30/30	1.80/0.80	2.00/0.70	-0.20 (-0.58; 0.18)
Sung, 2000 ⁶⁰² /0	Pelvic floor exercises with EMG	Discomfort due to fluid intake restriction (0 to 5 worse)	30/30	1.40/0.70	1.10/0.30	0.30 (0.03; 0.57)
Sung, 2000 ⁶⁰² /0	Pelvic floor exercises with EMG	Problems on daily tasks (0 to 5 worse)	30/30	1.40/0.70	1.10/0.30	0.30 (0.03; 0.57)
Sung, 2000 ⁶⁰² /0	Pelvic floor exercises with EMG	Avoidance of places & situations (0 to 5 worse)	30/30	1.40/0.90	1.40/0.70	0.00 (-0.41; 0.41)

Appendix Table F128. Scoring of quality of life after PFMT with biofeedback using vaginal EMG probe when compared to PFMT (individual RCTs) (continued)

Reference sample/men	Active	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean/standard deviation	Mean difference (95% CI)
Sung, 2000 ⁶⁰² /0	Pelvic floor exercises with EMG	Discomfort due to avoidance of places & situations (0 to 5 worse)	30/30	1.30/0.70	1.20/0.40	0.10 (-0.19; 0.39)
Sung, 2000 ⁶⁰² /0	Pelvic floor exercises with EMG	Interference in physical activity (0 to 5 worse)	30/30	1.60/0.80	1.30/0.40	0.30 (-0.02; 0.62)
Sung, 2000 ⁶⁰² /0	Pelvic floor exercises with EMG	Interference in relations with other people (0 to 5 worse)	30/30	1.20/0.70	1.10/0.30	0.10 (-0.17; 0.37)

Appendix Table F129. Clinical outcomes after pelvic floor muscle training with biofeedback using vaginal EMG probe when compared to pelvic floor muscle training, individual RCT

Reference sample	Active	Outcome	Randomized active/control	Active events /rate, %	Control events/ rate, %	Relative risk (95%CI)	Absolute risk differences (95% CI)
Morkved, 2002 ⁵⁷⁴ 103	Pelvic floor muscle training with biofeedback apparatus	Urinary incontinence is problematic	53/50	3/6	6/12	0.47(0.12;1.79)	-0.06(-0.17;0.05)
Morkved, 2002 ⁵⁷⁴ 103	Pelvic floor muscle training with biofeedback apparatus	Urinary incontinence is minor problem	53/50	17/32	18/36	0.89(0.52;1.53)	-0.04(-0.22;0.14)
Morkved, 2002 ⁵⁷⁴ 103	Pelvic floor muscle training with biofeedback apparatus	Urinary incontinence is moderate problem	53/50	8/15	5/10	1.51(0.53;4.31)	0.05(-0.08;0.18)

Appendix Table F130. Clinical outcomes after PFMT compared to electrical stimulation (results from RCTs pooled with random effects models)

Outcome	Reference	Active n/N	Control n/N	Rate active/control	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Continence	Castro, 2008 ²⁴⁷	10/31	11/30	32/37	0.88 (0.44; 1.76)	85.64	-0.044 (-0.282; 0.194)	43.26
Continence	Hahn, 1991 ⁵³⁸	1/10	1/10	10/10	1 (0.07; 13.87)	5.96	0 (-0.263; 0.263)	35.54
Continence	Smith, 1996 ⁵⁹⁵	1/9	2/9	11/22	0.5 (0.06; 4.58)	8.4	-0.111 (-0.452; 0.229)	21.2
Pooled		12/50	14/49	24/29	0.85 (0.45; 1.61)	100	-0.043 (-0.199; 0.114)	100
Heterogeneity							0.88	0.00%
P value, I squared,%								
Improved Urinary incontinence	Smith, 1996 ⁵⁹⁵	3/9	4/9	33/44	0.75 (0.23; 2.44)	14.09	-0.111 (-0.559; 0.336)	13.49
Improved Urinary incontinence	Spruijt, 2003 ⁵⁹⁶	4/25	7/12	36/29	1.19 (0.43; 3.29)	18.88	0.053 (-0.266; 0.373)	26.46
Improved Urinary incontinence	Castro, 2008 ²⁴⁷	12/31	13/30	39/43	0.89 (0.49; 1.63)	53.75	-0.046 (-0.293; 0.2)	44.41
Improved Urinary incontinence	Hahn, 1991 ⁵³⁸	4/10	3/10	40/30	1.33 (0.40; 4.49)	13.27	0.1 (-0.316; 0.516)	15.63
Pooled		23/75	27/61	31/45	0.97 (0.62; 1.51)	100	-0.006 (-0.17; 0.159)	100
Heterogeneity					0.88	0.00%	0.874	0.00%
P value, I squared,%								
Treatment failure	Castro, 2008 ²⁴⁷	11/31	12/30	35/40	0.89 (0.47; 1.69)	53.82	-0.045 (-0.288; 0.198)	54.03
Treatment failure	Spruijt, 2003 ⁵⁹⁶	7/25	6/12	55/25	2.43 (1.04; 5.66)	46.18	0.343 (0.018; 0.669)	45.97
Pooled		18/56	18/42	31/43	1.41 (0.53; 3.78)	100	0.133 (-0.246; 0.513)	100
Heterogeneity					0.06	71.00%	0.061	71.60%
P value, I squared,%								

Appendix Table F131. Clinical outcomes compared after different nonpharmacological treatments (results from individual RCTs)

Active	Control	Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)
Bladder training	PFMT	Continence	Morkved, 2002 ⁵⁷⁴	28/53	21/50	1.26 (0.83; 1.90)	0.108 (-0.083; 0.300)	
Bladder training with audiotape	Bladder training	Improved UI	Dowd, 2000 ⁵¹⁹	19/21	10/19	1.72 (1.10; 2.69)	0.378 (0.121; 0.636)	3 (2; 8)
Bladder training with audiotape	Bladder training	Improved UI	Dowd, 2000 ⁵¹⁹	19/21	13/19	1.32 (0.95; 1.85)	0.221 (-0.023; 0.464)	
Cone	Bladder training	Continence	Williams, 2006 ⁶¹⁴	0/80	0/79	0.88 (0.28; 2.76)		
Continence service	Bladder training	Continence	Ramsay, 1996 ⁵⁸⁸	19/35	23/39	0.92 (0.62; 1.37)	-0.047 (-0.273; 0.179)	
Continence service	Bladder training	Improved UI	Ramsay, 1996 ⁵⁸⁸	17/35	19/39	1.00 (0.62; 1.59)	-0.001 (-0.230; 0.227)	
Continence service	PFMT	Continence	Kim, 2001 ⁵⁴⁷	14/16	2/17	7.44 (2.00; 27.70)	0.757 (0.534; 0.980)	1 (1; 2)
Electrical stimulation	PFMT+ biofeedback	Treatment discontinuation	Demirturk, 2008 ⁵¹⁴	0/20	1/21	0.35 (0.02; 8.10)	-0.048 (-0.171; 0.076)	
Electrical stimulation	cone	Treatment discontinuation due to treatment failure	Castro, 2008 ²⁴⁷	1/30	4/27	0.23 (0.03; 1.89)	-0.115 (-0.263; 0.034)	
Electrical stimulation	cone	Continence	Castro, 2008 ²⁴⁷	13/30	11/27	1.06 (0.58; 1.96)	0.026 (-0.231; 0.282)	
Electrical stimulation	cone	Treatment failure	Castro, 2008 ²⁴⁷	12/30	11/27	0.98 (0.52; 1.85)	-0.007 (-0.263; 0.248)	
Electrical stimulation	cone	Improved UI	Castro, 2008 ²⁴⁷	13/30	11/27	1.06 (0.58; 1.96)	0.026 (-0.231; 0.282)	
Pessary	PFMT+ ring	Treatment discontinuation	Richter, 2010 ³⁶¹	39/149	18/151	2.20 (1.32; 3.66)	0.143 (0.055; 0.230)	7 (4; 18)
Pessary	PFMT+ ring	Treatment discontinuation due to adverse effects	Richter, 2010 ³⁶¹	1/149	0/151	3.04 (0.12; 74.03)	0.007 (-0.012; 0.025)	
Pessary	PFMT+ ring	Treatment discontinuation due to treatment failure	Richter, 2010 ³⁶¹	6/149	4/151	1.52 (0.44; 5.28)	0.014 (-0.027; 0.054)	
Pessary	PFMT+ ring	Improved UI	Richter, 2010 ³⁶¹	59/149	80/151	0.75 (0.58; 0.96)	-0.134 (-0.246; -0.022)	-7 (-45; -4)
Pessary	PFMT+ ring	Improved UI	Richter, 2010 ³⁶¹	94/149	118/151	0.81 (0.70; 0.94)	-0.151 (-0.252; -0.049)	-7 (-20; -4)

**Appendix Table F131. Clinical outcomes compared after different nonpharmacological treatments (results from individual RCTs)
(continued)**

Active	Control	Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)
PFMT	Balls	Treatment failure	Arvonen, 2001 ⁴⁸²	1/19	1/18	0.95 (0.06; 14.04)	-0.003 (-0.149; 0.143)	
PFMT	Balls	Improved UI	Arvonen, 2001 ⁴⁸²	11/19	7/18	1.49 (0.74; 2.98)	0.190 (-0.126; 0.506)	
PFMT	Bladder training	Improved UI	Williams, 2006 ⁶¹⁴	0/79	0/79	0.68 (0.35; 1.38)	0.000 (0.000; 0.000)	
PFMT	Bladder training	Improved UI	Williams, 2006 ⁶¹⁴	0/79	0/79	0.77 (0.40; 1.47)	0.000 (0.000; 0.000)	
PFMT	Pessary	Treatment discontinuation	Richter, 2010 ³⁶¹	22/146	39/149	0.58 (0.36; 0.92)	-0.111 (-0.202; -0.020)	-9 (-51; -5)
PFMT	Pessary	Treatment discontinuation due to adverse effects	Richter, 2010 ³⁶¹	0/146	1/149	0.34 (0.01; 8.28)	-0.007 (-0.025; 0.012)	
PFMT	Pessary	Treatment discontinuation due to treatment failure	Richter, 2010 ³⁶¹	2/146	1/149	2.04 (0.19; 22.27)	0.007 (-0.016; 0.030)	
PFMT	Pessary	Treatment failure	Richter, 2010 ³⁶¹	6/146	6/149	1.02 (0.34; 3.09)	0.001 (-0.044; 0.046)	
PFMT	Pessary	Improved UI	Richter, 2010 ³⁶¹	110/146	94/149	1.19 (1.02; 1.39)	0.123 (0.018; 0.227)	8 (4; 55)
PFMT	Pessary	Improved UI	Richter, 2010 ³⁶¹	72/146	59/149	1.25 (0.96; 1.61)	0.097 (-0.016; 0.210)	
PFMT	Pessary	Improved UI	Richter, 2010 ³⁶¹	71/146	49/149	1.48 (1.11; 1.96)	0.157 (0.047; 0.268)	6 (4; 21)
PFMT	PFMT+ ring	Treatment discontinuation	Richter, 2010 ³⁶¹	22/146	18/151	1.26 (0.71; 2.26)	0.031 (-0.046; 0.109)	
PFMT	PFMT+ ring	Treatment discontinuation due to adverse effects	Richter, 2010 ³⁶¹	0/146	0/151	0.00 (0.00; 0.00)	0.000 (-0.013; 0.013)	
PFMT	PFMT+ ring	Treatment discontinuation Treatment failure	Richter, 2010 ³⁶¹	6/146	4/151	1.55 (0.45; 5.39)	0.015 (-0.027; 0.056)	
PFMT	PFMT+ ring	Improved UI	Richter, 2010 ³⁶¹	72/146	80/151	0.93 (0.74; 1.16)	-0.037 (-0.150; 0.077)	
PFMT+ biofeedback	Bladder training	Continence	Wyman, 1998 ⁶¹⁸	8/69	12/68	0.66 (0.29; 1.51)	-0.061 (-0.178; 0.057)	
PFMT+ biofeedback	Bladder training	Continence	Wyman, 1998 ⁶¹⁸	14/69	11/68	1.25 (0.61; 2.56)	0.041 (-0.088; 0.170)	
PFMT+ biofeedback	Bladder training	Continence 3 months	Wyman, 1998 ⁶¹⁸	13/69	10/68	1.28 (0.60; 2.72)	0.041 (-0.084; 0.166)	

Appendix Table F131. Clinical outcomes compared after different nonpharmacological treatments (results from individual RCTs) (continued)

Active	Control	Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)
PFMT+ biofeedback	Bladder training	Treatment failure	Wyman, 1998 ⁶¹⁸	13/69	14/68	0.92 (0.47; 1.80)	-0.017 (-0.151; 0.116)	
PFMT+ biofeedback	Bladder training	Improved UI	Wyman, 1998 ⁶¹⁸	8/69	11/68	0.72 (0.31; 1.67)	-0.046 (-0.161; 0.070)	
PFMT+ biofeedback	Cone	Treatment discontinuation	Harvey, 2002 ⁵³⁹	12/19	18/25	0.88 (0.58; 1.34)	-0.088 (-0.368; 0.191)	
PFMT+ biofeedback	Cone	Continence UD	Harvey, 2002 ⁵³⁹	1/19	1/25	1.32 (0.09; 19.71)	0.013 (-0.114; 0.139)	
PFMT+ biofeedback	Cone	Continence (negative pad test)	Harvey, 2002 ⁵³⁹	2/19	2/25	1.32 (0.20; 8.51)	0.025 (-0.149; 0.199)	
PFMT+ bladder training	PFMT+ biofeedback	Adherence to treatment	Wyman, 1998 ⁶¹⁸	39/67	44/69	0.91 (0.70; 1.20)	-0.056 (-0.219; 0.108)	
PFMT+ bladder training	PFMT+ biofeedback	Continence 3 months	Wyman, 1998 ⁶¹⁸	16/67	13/69	1.27 (0.66; 2.43)	0.050 (-0.087; 0.188)	
PFMT+ bladder training	PFMT+ biofeedback	Continence	Wyman, 1998 ⁶¹⁸	19/67	8/69	2.45 (1.15; 5.20)	0.168 (0.036; 0.299)	6 (3; 28)
PFMT+ bladder training	PFMT+ biofeedback	Treatment failure	Wyman, 1998 ⁶¹⁸	4/67	13/69	0.32 (0.11; 0.92)	-0.129 (-0.237; -0.020)	-8 (-49; -4)
PFMT+ bladder training	PFMT+ biofeedback	Improved UI	Wyman, 1998 ⁶¹⁸	10/67	20/69	0.51 (0.26; 1.02)	-0.141 (-0.277; -0.004)	-7 (-270; -4)
PFMT+ bladder training	PFMT+ biofeedback	Improved UI 3 months	Wyman, 1998 ⁶¹⁸	6/67	9/69	0.69 (0.26; 1.82)	-0.041 (-0.146; 0.064)	
PFMT+ bladder training	PFMT+ biofeedback	Improved UI	Wyman, 1998 ⁶¹⁸	32/67	19/69	1.73 (1.10; 2.74)	0.202 (0.043; 0.362)	5 (3; 23)
PFMT+ bladder training	PFMT+ biofeedback	Improved UI	Wyman, 1998 ⁶¹⁸	14/67	8/69	1.80 (0.81; 4.01)	0.093 (-0.030; 0.216)	
PFMT+ electrical stimulation	PFMT	Improvement in ICIQ-UI score	Oldham, 2010 ⁵⁸³	32/64	16/64	2.00 (1.23; 3.26)	0.250 (0.088; 0.412)	4 (2; 11)
PFMT+ electrical stimulation	PFMT	Improvement in leak frequency	Oldham, 2010 ⁵⁸³	43/64	21/64	2.05 (1.39; 3.02)	0.344 (0.181; 0.506)	3 (2; 6)
PFMT+ electrical stimulation	PFMT	Improvement in terms of leak interference with life	Oldham, 2010 ⁵⁸³	32/64	21/64	1.52 (0.99; 2.34)	0.172 (0.004; 0.340)	6 (3; 261)
PFMT+ electrical stimulation	PFMT	Reduction in severity of symptoms: Condition mild or normal post treatment	Oldham, 2010 ⁵⁸³	54/64	45/64	1.20 (0.99; 1.45)	0.141 (-0.002; 0.284)	

Appendix Table F131. Clinical outcomes compared after different nonpharmacological treatments (results from individual RCTs) (continued)

Active	Control	Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)
PFMT+ reminder	PFMT+ Bladder training	Continence	Alenijnse, 2003 ⁴⁷⁷	17/52	21/51	0.79 (0.48; 1.32)	-0.085 (-0.271; 0.101)	
PFMT+ video tape	PFMT	“Routine” pelvic floor exercises, response=yes	Gallo, 1997 ⁵³⁰	41/43	22/43	1.86 (1.38; 2.51)	0.442 (0.280; 0.604)	2 (2; 4)
PFMT+ video tape	PFMT	Number of times per day patient performed pelvic floor exercises, response=two	Gallo, 1997 ⁵³⁰	34/43	4/43	8.50 (3.30; 21.89)	0.698 (0.548; 0.847)	1 (1; 2)
Face to face training	Telemedicine	Urinary incontinence	Hui, 2006 ⁵⁴²	2/27	4/31	0.57 (0.11; 2.89)	-0.055 (-0.209; 0.099)	
Weight loss	Education	≥70% improvement in weekly UI episodes: urge: 18 months	Wing, 2010 ⁶¹⁵	106/226	38/112	1.38 (1.03; 1.85)	0.130 (0.021; 0.239)	8 (4; 49)
Weight loss	Education	≥70% improvement in weekly UI episodes: Total: 12 months	Wing, 2010 ⁶¹⁵	104/226	35/112	1.47 (1.08; 2.01)	0.148 (0.040; 0.255)	7 (4; 25)
Weight loss	Education	≥70% improvement in weekly UI episodes: stress:12 months	Wing, 2010 ⁶¹⁵	145/226	54/112	1.33 (1.07; 1.65)	0.159 (0.048; 0.271)	6 (4; 21)
Weight loss	Education	≥70% improvement in weekly UI episodes: urge: 12 months	Wing, 2010 ⁶¹⁵	106/226	39/112	1.35 (1.01; 1.80)	0.121 (0.011; 0.230)	8 (4; 89)
Weight loss	Education	Reduction in weekly stress urinary incontinence episodes at 12 months	Wing, 2010 ⁶¹⁵	147/226	53/112	1.37 (1.11; 1.71)	0.177 (0.066; 0.289)	6 (3; 15)

Appendix Table F132. Clinical outcomes after PFMT compared to vaginal cones (results from RCTs pooled with random effects models)

Outcome	Reference	Active n/N	Control n/N	Rate active/control	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Continence	Castro, 2008 ²⁴⁷	10/31	9/27	32/33	0.97 (0.46; 2.02)	16.99	-0.011 (-0.253; 0.232)	37.49
Continence	Williams, 2006 ⁶¹⁴	0/79	0/80	0/0				
Continence	Gameiro, 2010 ⁵³¹	26/52	34/51	50/67	0.75 (0.54; 1.05)	83.01	-0.167 (-0.354; 0.021)	62.51
Pooled		36/162	43/158	22/27	0.78 (0.58; 1.06)	100	-0.108 (-0.257; 0.04)	100
Heterogeneity P value, I squared,%					0.54	0.00%	0.319	0.00%
Improved Urinary incontinence	Seo, 2004 ⁵⁹³	55/60	53/60	92/88	1.04 (0.92; 1.17)	89.16	0.033 (-0.074; 0.141)	67.1
Improved Urinary incontinence	Castro, 2008 ²⁴⁷	12/31	11/27	39/41	0.95 (0.50; 1.79)	3.16	-0.02 (-0.273; 0.232)	12.09
Improved Urinary incontinence	Williams, 2006 ⁶¹⁴	0/79	0/80					
Improved Urinary incontinence	Gameiro, 2010 ⁵³¹	23/52	26/51	44/51	0.87 (0.58; 1.30)	7.69	-0.067 (-0.26; 0.125)	20.81
Pooled		0/222	0/218	0/0	1.02 (0.91; 1.14)	100	0.006 (-0.082; 0.094)	100
Heterogeneity P value, I squared,%					0.69	0.00%	0.653	0.00%

Appendix Table F133. Scoring of quality of life after PFMT with biofeedback vs. vaginal cones (individual RCTs)

Reference sample/men	Active	Control	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Seo, 2004 ⁵⁹³ /0	Pelvic floor exercise (5 second contraction and 10 second relaxation, 3-5 times for >5 minutes/day) and functional Electrical Stimulation Biofeedback (35Hz-50Hz for 24 seconds); 2 training sessions/week	Vaginal cone, 150-gram dumbbell-shaped made of fine ceramic material	Changes in sexual life	60/60	-0.19/0.12		
Seo, 2004 ⁵⁹³ /0	Pelvic floor exercise (5 second contraction and 10 second relaxation, 3-5 times for >5 minutes/day) and functional Electrical Stimulation Biofeedback (35Hz-50Hz for 24 seconds); 2 training sessions/week	Vaginal cone, 150-gram dumbbell-shaped made of fine ceramic material	Changes in daily life	60/60	-0.27/0.11		
Seo, 2004 ⁵⁹³ /0	Pelvic floor exercise (5 second contraction and 10 second relaxation, 3-5 times for >5 minutes/day) and functional Electrical Stimulation Biofeedback (35Hz-50Hz for 24 seconds); 2 training sessions/week	Vaginal cone, 150-gram dumbbell-shaped made of fine ceramic material	Changes in difficulty in personal relationships	60/60	-0.29/0.14		

Appendix Table F133. Scoring of quality of life after PFMT with biofeedback vs. medical devices (individual RCTs) (continued)

Reference sample/men	Active	Control	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Seo, 2004 ⁵⁹³ /0	Pelvic floor exercise (5 second contraction and 10 second relaxation, 3-5 times for >5 minutes/day) and functional Electrical Stimulation Biofeedback (35Hz-50Hz for 24 seconds); 2 training sessions/week	Vaginal cone, 150-gram dumbbell-shaped made of fine ceramic material	Changes in quality of life	60/60	-0.27/0.13		
Cammu, 1998 ⁵⁰⁹ /0	Weekly session of pelvic floor exercises vaginal probe-EMG biofeedback using perineometer	Vaginal weight cones	Visual analogue scale (0–10)	30/30	2.60/2.10	2.90/2.40	-0.30 (-1.44;0.84)
Cammu, 1998 ⁵⁰⁹ /0	Weekly session of pelvic floor exercises vaginal probe-EMG biofeedback using perineometer	Vaginal weight cones	Visual analogue scale (0–10)Severity of incontinence	30/30	2.10/2.10	3.40/3.30	-1.30 (-2.70;0.10)

Appendix Table F134. Comparative effectiveness of circular muscle exercises (Paula method) vs. PFMT (individual RCT)

Reference sample/men	Outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ 241/0	Improved (pad test <1g)	117/123	76/65	62/50	1.30 (1.04; 1.62)	0.15 (0.03; 0.27)	7 (4; 38)	150 (26; 273)
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ 241/0	Percent cured	117/123	60/51	42/34	1.50 (1.11; 2.03)	0.17 (0.05; 0.29)	6 (3; 21)	171 (48; 295)
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ 241/0	No feelings of bladder fullness	117/123	77/66	64/52	1.26 (1.02; 1.57)	0.14 (0.01; 0.26)	7 (4; 69)	138 (15; 261)

Appendix Table F135. Scoring of quality of life after circular muscle exercises (Paula method) vs. PFMT (individual RCTs)

Reference sample/men	Outcome	Randomized active/control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ /0	Mean I-QOL improvement	117/123	10.80/18.76	9.80/20.37	1.00 (-3.95; 5.95)
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ /0	I-QOL overall score	117/123	83.10/5.10	78.10/17.60	5.00 (1.76; 8.24)
Liebergall-Wischnitzer, 2005 ⁵⁶⁰ /0	Change from baseline in quality of life-avoidance, limiting behaviors scores (8 items)	31/32	9.80/17.30	9.50/27.40	0.30 (-11.66; 11.06)
Liebergall-Wischnitzer, 2005 ⁵⁶⁰ /0	Change from baseline in quality of life-avoidance, social embarrassment scores (5 items)	31/32	14.00/23.00	9.30/13.00	4.70 (-13.89; 4.49)

Appendix Table F136. Clinical outcomes after circular muscle exercises (Paula method) vs. PFMT (individual RCTs)

Reference sample/men	Outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95%CI)
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ 240/0	Leakage annoyance often/very often	117/123	14/12	29/24	0.51 (0.28; 0.91)	-0.12 (-0.21; -0.02)	-9 (-48; -5)	-116 (-211 ; -21)
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ 240/0	Leakage amount moderate/very large	117/123	17/15	25/20	0.71 (0.41; 1.25)	-0.06 (-0.15; 0.04)		
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ 240/0	Feelings of bladder fullness	117/123	16/14	22/18	0.76 (0.42; 1.38)	-0.04 (-0.13; 0.05)		
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ 240/0	Leakage frequency monthly or once in several months	117/123	26/22	25/20	1.09 (0.67; 1.78)	0.02 (-0.08 ; 0.12)		
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ 240/0	Daily-weekly	117/123	65/56	61/50	1.12 (0.88; 1.43)	0.06 (-0.07; 0.19)		

Appendix Table F137. Comparative effectiveness on quality of life after PFMT vs. active controls (individual RCTs)

Reference sample/men	Active	Control	Definitions of the outcomes	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Liebergall-Wischnitzer, 2009 ⁵⁵⁹ 240/0	Circular muscle exercises (Paula method)	PFMT group	Leakage annoyance not at all/seldom/sometime	117/123	81/69	59/48	1.44 (1.16; 1.80)	0.21 (0.09; 0.33)	5 (3; 11)	213 (91;334)
Morkved, 2002 ⁵⁷⁴ 103/0	Pelvic floor muscle training with a biofeedback apparatus	Pelvic floor muscle training without biofeedback	Urinary incontinence is very problematic	53/50	1/2	3/6	0.31 (0.03; 2.92)	-0.04 (-0.12; 0.03)		
Sherman, 1997 ⁵⁹⁴ 39/0	Pelvic muscle exercises with vaginal EMG probe.	Pelvic muscle	Best activity level	23/16	4/0	5/0	0.56 (0.18; 1.76)	-0.14 (-0.41; 0.14)		
Williams, 2006 ⁶¹⁴ /0	Pelvic floor muscle therapies	Vaginal cone therapy	Odds ratio of satisfaction with current urinary symptoms for rest of life	79/80			1.02 (0.54;1.95)			
Williams, 2006 ⁶¹⁴ /0	Pelvic floor muscle therapies	Behavioral intervention	Odds ratio of satisfaction with current urinary symptoms for rest of life	79/79			0.77 (0.40;1.47)			
Glavind, 1996 ⁵³⁴ 40/0	Physiotherapy in combination with biofeedback	Physiotherapy	Acceptance of degree of incontinence	20/20	15/75	10/50	1.50 (0.90; 2.49)	0.25 (-0.04; 0.54)		

Appendix Table F138. Scoring of quality of life after PFMT (individual RCTs)

Reference sample/men	Active	Control	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean/standard deviation	Mean difference (95% CI)
Borello-France, 2008 ⁴⁹⁶ /0	High-frequency (4 times per week)	Low-frequency (1 time per week)	Change in incontinence impact questionnaire score	22/22	-4.00/10.60	-6.00/27.00	2.00 (-10.12; 14.12)
Borello-France, 2008 ⁴⁹⁶ /0	High-frequency (4 times per week)	Low-frequency (1 time per week)	Change in Brink score	22/22	0.00/0.97	0.00/1.00	0.00 (-0.58; 0.58)
Demain, 2001 ⁵¹³ /0	Three educational group sessions, PFMT	One 45-minute individual instruction in PFMT	Incontinence impact questionnaire score (0 to 100 worse)	22/22	14.30/22.73	7.10/28.72	7.20 (-8.10; 22.50)
Williams, 2006 ⁶¹⁴ /0	Pelvic floor muscle therapies	Vaginal cone therapy	Median (interquartile range) impact score	79/80			-0.46 (-3.09; 2.18)
Williams, 2006 ⁶¹⁴ /0	Pelvic floor muscle therapies	Primary behavioral intervention	Median (interquartile range) impact score	79/79			-0.02 (-2.78; 2.75)
Kincade, 2007 ⁵⁵⁰ /0	Self-monitoring group with training on fluid intake, voiding frequency, and PFMT	Quick Kegel	Quality of life using Incontinence impact questionnaire with scores 0-400 (worse)	117/107	99.30/96.60	112.10/89.90	-12.80 (-37.22; 11.62)

Appendix Table F139. Continence after PFMT with personal reminders and self-help guides or different positions during exercise (individual RCTs)

Reference sample/men	Active	Control	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)
Alewiinse, 2003 ⁴⁷⁷ 103/0	Pelvic floor muscle exercise with reminder and Self-Help Guide	Bladder training and pelvic floor muscle exercise	52/51	17/33	21/41	0.79 (0.48; 1.32)	-0.08 (-0.27; 0.10)
Borello-France, 2006 ⁴⁹⁵ 44/0	Pelvic-floor muscle exercises with EMG biofeedback in the supine position only using max 30-60 repetitions of 3-12 second contractions twice daily	Pelvic-floor muscle exercises with EMG biofeedback in both supine and upright positions, 1 set (3- and 12-second contractions) in each position with max of 20 repetitions (2 sets of 10) of the 3-12 second contractions twice daily	22/22	13/59	13/59	1.00 (0.61; 1.64)	0.00 (-0.29; 0.29)

Appendix Table F140. Comparative effectiveness of medical devices (individual RCTs)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/ 1000 treated (95% CI)
Williams, 2006 ⁶¹⁴ /0	Vaginal cone therapy	Primary behavioral intervention	Odds ratio of no symptoms (cure)	80/79			0.88 (0.28; 2.76)			
Williams, 2006 ⁶¹⁴ /0	Vaginal cone therapy	Primary behavioral intervention	Odds ratio of mild or no problem	80/79			0.88 (0.44; 1.77)			
Thyssen, 2001 ⁶⁰⁷ 124/0	Contrelle Continenace Tampon	Conveen Continenace disposable Intravaginal device guard	Subjectively continent	62/62	30/48	22/35	1.36 (0.89; 2.08)	0.13 (-0.04; 0.30)		
Thyssen, 2001 ⁶⁰⁷ 188/0	Conveen Continenace disposable Intravaginal device guard	Contrelle Continenace Tampon	Cured from stress urinary incontinence	94/94	34/36	45/48	0.76 (0.54; 1.06)	-0.12 (-0.26; 0.02)		
Nygaard, 1995 ⁵⁷⁹ 40/0	Hodge pessary with support	40-minute standardized aerobics sessions wearing a super tampon	Continent during exercise	20/20	7/36	12/58	0.58 (0.29; 1.17)	-0.25 (-0.55; 0.05)		
Andersen, 2002 ⁴⁸⁰ 52/0	Durasphere	Contigen [®]	Dry	26/26	10/38	3/12	3.33 (1.03; 10.74)	0.27 (0.05; 0.49)	4 (2; 22)	269 (46; 493)
Robinson, 2003 ⁵⁸⁹ 24/0	Urethral device (NEAT) –sterile urethral insert with disposable applicator packaged with device.	Reliance Insert sterile balloon type device	Success as negative pad weight test	13/11	9/73	7/62	1.09 (0.61; 1.93)	0.06 (-0.32; 0.44)		
Improvement in incontinence										
Thyssen, 2001 ⁶⁰⁷ 124/0	Contrelle Continenace Tampon	Conveen Continenace disposable Intravaginal device guard	Improvement in UI	62/62	22/35	25/40	0.88 (0.56; 1.38)	-0.05 (-0.22; 0.12)		

Appendix Table F140. Comparative effectiveness of medical devices (individual RCTs) (continued)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/ 1000 treated (95% CI)
Thyssen, 2001 ⁶⁰⁷ 188/0	Conveen Continence disposable Intravaginal device guard	Contrelle Continence Tampon	Self reported Improvement in stress urinary incontinence	94/94	38/40	34/36	1.12 (0.78; 1.61)	0.04 (-0.10; 0.18)		
Andersen, 2002 ⁴⁸⁰ 52/0	Durasphere	Contigen®	Improvement of 1 or more continence grades	26/26	20/77	13/50	1.54 (0.99; 2.38)	0.27 (0.02; 0.52)	4 (2; 56)	269 (18; 521)
Seo, 2004 ⁵⁹³ 120/0	Pelvic floor exercise (5 sec contraction and 10 sec relaxation, 3-5 times for >5 min/day) and functional Electrical Stimulation Biofeedback (35Hz-50Hz for 24 sec); 2 training sessions/week	Vaginal cone, 150-gram dumbbell- shaped made of fine ceramic material	Self reported improvement in urinary incontinence	60/60	55/92	53/88	1.04 (0.92; 1.17)	0.03 (-0.07; 0.14)		
Robinson, 2003 ⁵⁸⁹ 24/0	Urethral device (NEAT) –sterile urethral insert with disposable applicator packaged with device.	Reliance Insert sterile balloon type device	Success as a 50% or greater reduction in urine loss	13/11	9/67	6/58	1.27 (0.66; 2.43)	0.15 (-0.24; 0.53)		

Appendix Table F141. Scoring of quality of life after medical devices compared to active controls (individual RCTs)

Reference sample	Active	Control	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean/standard deviation	Mean difference (95% CI)
Seo, 2004 ⁵⁹³ /0	Pelvic floor exercise with Electrical Stimulation Biofeedback	Vaginal cone	Changes in scores Restriction in exercise due to incontinence	60/60	-0.59/0.18	-0.36/0.17	-0.23 (-0.29; -0.17)
Seo, 2004 ⁵⁹³ /0	Pelvic floor exercise with Electrical Stimulation Biofeedback	Vaginal cone	Changes in scores Avoiding places due to urinary incontinence	60/60	-0.29/0.14	-0.13/0.15	-0.16 (-0.21; -0.11)
Andersen, 2002 ⁴⁸⁰ /0	Durasphere	Contigen®	Change in continence grade	26/26	1.28/0.84	0.86/1.01	0.42 (-0.08; 0.92)
Williams, 2006 ⁶¹⁴ /0	Vaginal cone	Primary behavioral intervention	Median (interquartile range) impact score	80/79			-0.48 (-2.60; 1.66)

Appendix Table F142. Comparative effectiveness of medical devices on quality of life (individual RCT)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Thyssen, 2001 ⁶⁰⁷ 124/0	CCT	CCG	preference of the device	62/62	39/63	16/26	2.44 (1.53; 3.87)	0.37 (0.21; 0.53)	3 (2; 5)	371 (209;533)
Thyssen, 2001 ⁶⁰⁷ 124/0	CCT	CCG	No bother from UI	62/62	54/87	45/72	1.20 (1.00; 1.44)	0.15 (0.01; 0.28)	7 (4; 160)	145 (6;284)
Williams, 2006 ⁶¹⁴ /0	Vaginal cone therapy	Behavioral intervention	OR of satisfaction with current urinary symptoms for rest of life	80/79			0.75 (0.40; 1.44)			

Abbreviations: CCG=Conveen Continence disposable Intravaginal device guard, CCT=Contrelle Continence Tampon

Appendix Table F143. Comparative comfort in using different pads for urinary incontinence (individual RCT)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)
Thornburn, 1997 ⁶⁰⁶ 514/0	Pad C	Pad F	Good wet comfort	258/255	116/45	128/50	0.90 (0.75; 1.08)	-0.05 (-0.14; 0.04)
Thornburn, 1997 ⁶⁰⁶ 514/0	Pad A	Pad C	Good wet comfort	247/258	124/50	116/45	1.11 (0.93; 1.34)	0.05 (-0.04; 0.14)
Thornburn, 1997 ⁶⁰⁶ 514/0	Pad A	Pad F	Good wet comfort	247/255	124/50	128/50	1.00 (0.84; 1.19)	0.00 (-0.09; 0.09)
Thornburn, 1997 ⁶⁰⁶ 514/0	Pad C	Pad F	Good absorbency	258/255	134/52	153/60	0.87 (0.74; 1.01)	-0.08 (-0.17; 0.01)
Thornburn, 1997 ⁶⁰⁶ 514/0	Pad A	Pad C	Good leakage performance	247/258	136/55	155/60	0.92 (0.79; 1.07)	-0.05 (-0.14; 0.04)
Thornburn, 1997 ⁶⁰⁶ 514/0	Pad A	Pad F	Good leakage performance	247/255	136/55	153/60	0.92 (0.79; 1.07)	-0.05 (-0.14; 0.04)
Thornburn, 1997 ⁶⁰⁶ 514/0	Pad A	Pad C	Good absorbency	247/258	143/58	134/52	1.11 (0.95; 1.31)	0.06 (-0.03; 0.15)
Thornburn, 1997 ⁶⁰⁶ 514/0	Pad A	Pad F	Good absorbency	247/255	143/58	153/60	0.96 (0.83; 1.12)	-0.02 (-0.11; 0.07)
Thornburn, 1997 ⁶⁰⁶ 514/0	Pad C	Pad F	Good leakage performance	258/255	155/60	153/60	1.00 (0.87; 1.15)	0.00 (-0.08; 0.09)

Appendix Table F144. Comparative effectiveness of bulking agents (individual RCTs)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Continence										
Mayer, 2007 ⁵⁶⁷ 296/0	Calcium hydroxylapatite	Bovine Dermal Collagen	Cure rate or Stamey grade 0 at 12 months	158/138	51/32	37/27	1.20 (0.84; 1.72)	0.05 (-0.05; 0.16)		
Bano, 2005 ⁴⁸⁵ 50/0	Peri or transurethral porcine dermal implant injection (Permacol)	Transurethral silicone injection (Macroplastique)	Urinary continence (negative pad test)	25/25	15/60	9/36	1.67 (0.90; 3.08)	0.24 (-0.03; 0.51)		
Schulz, 2004 ⁵⁹² 40/0	Periurethral route of injection of bulking agent-dextran copolymer	Transurethral route of injection of bulking agent-dextran copolymer	Objective urinary continence (dry in pad test)	20/20	1/5	3/15	0.33 (0.04; 2.94)	-0.10 (-0.28; 0.08)		
Ghoniem, 2009 ⁵³² 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Number of Stamey grade dry	122/125	45/37	31/25	1.49 (1.01; 2.18)	0.12 (0.01; 0.24)	8 (4; 152)	121 (7; 235)
Ghoniem, 2009 ⁵³² 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Patient assessment - dry	122/125	34/28	25/20	1.39 (0.89; 2.19)	0.08 (-0.03; 0.18)		
Ghoniem, 2009 ⁵³² 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Physician assessment - dry	122/125	43/35	32/26	1.38 (0.94; 2.02)	0.10 (-0.02; 0.21)		
Strasser, 2007 ⁵⁹⁷ 63/0	Transurethral ultra-sonography-guided injections of autologous myoblasts and fibroblasts	Conventional endoscopic injections of collagen	Continence	42/21	38/90	2/10	9.50 (2.53; 35.63)	0.81 (0.66; 0.96)	1 (1; 2)	810 (656; 963)
Lightner, 2009 ⁵⁶² 344/0	Zuidex Implacer	Contigen® endoscopic guidance	Dry rates	227/117	83/37	52/44	0.82 (0.63; 1.07)	-0.08 (-0.19; 0.03)		

Appendix Table F144. Comparative effectiveness of bulking agents (individual RCTs) (continued)

Reference sample	Active	Control	Definition of outcome	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Improvement in Incontinence										
Lightner, 2001 ⁵⁶¹ 364/0	Injection of bulking agent 1.0 mL Durasphere max 5 times with a minimum 7-day interval	Injection of bulking agent bovine collagen max 5 times with a minimum 7-day interval	Improvement of 1 or more continence grades	176/188	76/43	79/42	1.03 (0.81; 1.30)	0.01 (-0.09; 0.11)		
Bano, 2005 ⁴⁸⁵ 50/0	Peri or transurethral porcine dermal implant injection (Permacol)	Transurethral silicone injection (Macroplastique)	Improvement in urinary incontinence (pad test)	25/25	15/60	10/40	1.50 (0.84; 2.67)	0.20 (-0.07 ;0.47)		
Bano, 2005 ⁴⁸⁵ 50/0	Peri or transurethral porcine dermal implant injection (Permacol)	Transurethral silicone injection (Macroplastique)	Improved urinary incontinence scores (Stamey)	25/25	14/56	10/40	1.40 (0.77; 2.53)	0.16 (-0.11; 0.43)		
Bano, 2005 ⁴⁸⁵ 50/0	Peri or transurethral porcine dermal implant injection (Permacol)	Transurethral silicone injection (Macroplastique)	Improved urinary incontinence scores (Kings College Hospital Quality of Health Questionnaire)	25/25	14/56	7/28	2.00 (0.98; 4.10)	0.28 (0.02; 0.54)	4 (2; 57)	280 (18; 542)
Schulz, 2004 ⁵⁹² 40/0	Periurethral route of injection of bulking agent-dextran copolymer	Transurethral route of injection of bulking agent-dextran copolymer	Subjective improvement in urinary incontinence	20/20	6/30	7/35	0.86 (0.35; 2.10)	-0.05 (-0.34; 0.24)		
Mayer, 2007 ⁵⁶⁷ 296/0	Calcium hydroxylapatite	Bovine Dermal Collagen	Improved by one Stamey grade at 6 months	158/138	97/61	71/51	1.19 (0.97; 1.46)	0.10 (-0.01; 0.21)		
Mayer, 2007 ⁵⁶⁷ 296/0	Calcium hydroxylapatite	Bovine Dermal Collagen	Improved by one Stamey grade at 12 months	158/138	83/53	57/41	1.27 (0.99; 1.63)	0.11 (0.00; 0.23)		
Mayer, 2007 ⁵⁶⁷ 296/0	Calcium hydroxylapatite	Bovine Dermal Collagen	Improvement of two Stamey scale units or being dry	158/138	66/41	46/33	1.25 (0.92; 1.68)	0.08 (-0.03; 0.19)		

Appendix Table F144. Comparative effectiveness of bulking agents (individual RCTs) (continued)

Reference sample	Active	Control	Definition of outcome	Randomized active/ control	Active events/ rate	Control events/ rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Mayer, 2007 ⁵⁶⁷ / 296/0	Calcium hydroxylapatite	Bovine Dermal Collagen	50% or more decline in 24-hour pad weight test at 12 months	158/138	81/51	54/39	1.31 (1.01; 1.70)	0.12 (0.01; 0.23)	8 (4; 116)	121 (9; 234)
Strasser, 2007 ⁵⁹⁷ / 63/0	Transurethral ultra-sonography-guided injections of autologous myoblasts and fibroblasts	Conventional endoscopic injections of collagen	Substantial improvement in urinary incontinence	42/21	3/7	1/5	1.50 (0.17; 13.56)	0.02 (-0.10 ;0.14)		
Strasser, 2007 ⁵⁹⁷ / 63/0	Transurethral ultra-sonography-guided injections of autologous myoblasts and fibroblasts	Conventional endoscopic injections of collagen	Slight improvement in urinary incontinence	42/21	1/2	6/29	0.08 (0.01; 0.65)	-0.26 (-0.46; -0.06)	-4 (-16; -2)	-262 (-461; -63)
Ghoniem, 2009 ⁵³² / 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Improvement of at least 1 Stamey grade at 12 months	122/125	75/61	60/48	1.28 (1.02; 1.61)	0.13 (0.01; 0.26)	7 (4; 85)	135 (12; 258)
Ghoniem, 2009 ⁵³² / 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Patient assessment - improved	122/125	45/37	39/31	1.18 (0.83; 1.68)	0.06 (-0.06; 0.17)		
Ghoniem, 2009 ⁵³² / 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Physician assessment - marked improvement	122/125	39/32	38/30	1.05 (0.73; 1.52)	0.02 (-0.10; 0.13)		
Ghoniem, 2009 ⁵³² / 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	With a Stamey grade of 0 or dry outcome	122/125	45/37	31/25	1.49 (1.01; 2.18)	0.12 (0.01; 0.24)	8 (4; 152)	121 (7; 235)
Lightner, 2009 ⁵⁶² / 344/0	Zuidex Implacer	Contigen® Endoscopic guidance	Reduction in urine leakage at least 50% on provocation tests	227/117	148/65	98/84	0.78 (0.69; 0.88)	-0.19 (-0.28; -0.09)	-5 (-11; -4)	-186 (-277; -94)

Appendix Table F144. Comparative effectiveness of bulking agents (individual RCTs) (continued)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Lightner, 2009 ⁵⁶² 344/0	Zuidex Implacer	Contigen [®] Endoscopic guidance	Responder rate based on >50% reduction in incontinent episodes	227/117	122/54	78/67	0.81 (0.68 ;0.96)	-0.13 (-0.24; -0.02)	-8 (-46; -4)	-129 (-236; -22)
Lightner, 2009 ⁵⁶² 344/0	Zuidex Implacer	Contigen [®] Endoscopic guidance	One-grade improvement on Stamey score at 12 months	227/117	116/51	64/55	0.93 (0.76; 1.15)	-0.04 (-0.15; 0.08)		
Lightner, 2009 ⁵⁶² 344/0	Zuidex Implacer	Contigen [®] Endoscopic guidance	3 treatments needed for clinical effect	227/117	67/30	38/33	0.91 (0.65; 1.26)	-0.03 (-0.13; 0.07)		

Appendix Table F145. Quality of life scores after bulking agents (individual RCTs)

Reference sample/men	Active	Control	Definition of quality of life	Randomized active/control	Active mean/standard deviation	Control mean/standard deviation	Mean difference (95% CI)
Ghoniem, 2009 ⁵³² /0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	I-QOL improvement	122/125	28.70/20.70	26.40/24.00	2.30 (-3.29; 7.89)
Strasser, 2007 ⁵⁹⁷ /0	Transurethral ultrasonography-guided injections of autologous myoblasts and fibroblasts	Conventional endoscopic injections of collagen	Quality of life score	42/21	108.00/0.67	64.00/17.33	44.00 (36.58; 51.42))

Appendix Table F146. Clinical outcomes after bulking agents (individual RCTs)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Lightner, 2009 ⁵⁶² 344/0	Zuidex Implanter	Contigen® Endoscopic guidance	Withdraw due to adverse events	227/117	8/4	2/2	2.06 (0.44; 9.55)	0.02 (-0.02; 0.05)		
Lightner, 2009 ⁵⁶² 344/0	Zuidex Implanter	Contigen® Endoscopic guidance	Lack of effect	227/117	43/19	11/9	2.01 (1.08; 3.76)	0.10 (0.02; 0.17)	10 (6; 46)	95 (22; 169)
Lightner, 2009 ⁵⁶² 344/0	Zuidex Implanter	Contigen® Endoscopic guidance	Worsened incontinence at 12 months	227/117	32/14	8/7	2.06 (0.98; 4.33)	0.07 (0.01; 0.14)	14 (7; 121)	73 (8; 137)
Ghoniem, 2009 ⁵³² 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Discontinued due to loss to followup	122/125	20/16	31/25	0.66 (0.40; 1.09)	-0.08 (-0.18; 0.02)		
Ghoniem, 2009 ⁵³² 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Withdrew	122/125	8/7	4/3	2.05 (0.63; 6.63)	0.03 (-0.02; 0.09)		
Ghoniem, 2009 ⁵³² 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Physician assessment - unchanged	122/125	6/5	10/8	0.61 (0.23; 1.64)	-0.03 (-0.09; 0.03)		
Ghoniem, 2009 ⁵³² 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Patient assessment - unchanged	122/125	8/7	11/9	0.75 (0.31; 1.79)	-0.02 (-0.09; 0.04)		
Ghoniem, 2009 ⁵³² 247/0	Transurethral injection of Macroplastique	Transurethral injection of Contigen®	Urgency incontinence	122/125	6/5	5/4	1.23 (0.39; 3.92)	0.0 (-0.04; 0.06)		
Strasser, 2007 ⁵⁹⁷ 63/0	Transurethral ultra-sonography-guided injections of autologous myoblasts and fibroblasts	Conventional endoscopic injections of collagen	Number of incontinent patients	42/21	4/10	19/90	0.11 (0.04; 0.27)	-0.81 (-0.96; -0.66)	-1 (-2; -1)	-810 (-963; -656)
Mayer, 2007 ⁵⁶⁷ 296/0	Calcium hydroxylapatite (CaHA)	Bovine Dermal Collagen	Urgency incontinence after treatment	158/138	7/5	12/9	0.51 (0.21; 1.26)	-0.04 (-0.10; 0.01)		

Appendix Table F146. Clinical outcomes after bulking agents (individual RCTs) (continued)

Reference sample	Active	Control	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Lightner, 2001 ⁵⁶¹ 364/0	Injection of bulking agent 1.0 mL Durasphere max 5 times with a minimum 7-day interval	Injection of bulking agent bovine collagen max 5 times with a minimum 7-day interval	Incidence of urgency	176/188	43/25	22/12	2.09 (1.30; 3.34)	0.13 (0.05; 0.21)	8 (5; 20)	127 (49; 206)

Appendix Table F147. Comparative effectiveness of nonpharmacological treatments on continence (insufficient evidence)

Active	Control	Studies reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events 95% CI)	Evidence
Continence service	Bladder training	1 study ⁵⁸⁸	74	Not significant				Insufficient
Continence service	PFMT	1 study ⁵⁴⁷	33	7.44 (2.00; 27.70)	0.76 (0.53; 0.98)	1 (1; 2)	757 (534; 980)	Insufficient
Continence service	Tele continence service	1 study ⁵⁴²	58	Not significant				Insufficient
PFMT+ reminder	PFMT+ bladder training	1 study ⁴⁷⁷	103	Not significant				Insufficient
PFMT in the supine position	PFMT in both supine and upright positions	1 study ⁴⁹⁵	44	Not significant				Insufficient
Group physiotherapy	Biofeedback	1 study ⁵⁸⁵	40	Not significant				Insufficient
Individual PFMT+BT	Group PFMT	1 study ⁵⁴⁴	530	1.58 (1.05; 2.36)	0.08 (0.00; 0.16)	12 (6; 1003)	81 (1; 161)	Insufficient
Circular muscle exercises (Paula method)	PFMT	1 study ⁵⁵⁹	245	1.50 (1.11; 2.03)	0.17 (0.05; 0.29)	6 (3; 21)	171 (48; 295)	Insufficient
PFMT	PFMT+ Balls	1 study ⁴⁸²	37	0.11 (0.01; 1.83)	-0.22 (-0.43; -0.02)	-5 (-52; -2)	-222 (-425; -19)	Insufficient
Physiotherapy in combination with biofeedback	Physiotherapy	1 study ⁵³⁴	40	3.67 (1.20; 11.19)	0.40 (0.13; 0.67)	3 (1; 8)	400 (132; 668)	Insufficient
Weekly posterior tibial nerve simulation	Posterior tibial nerve simulation three times per week	1 study ⁵²⁶	35	Not significant				Insufficient
Vaginal cone	behavioral intervention	1 study ⁶¹⁴	238	Not significant				Insufficient
Conveen Continence device Guard	Contrelle Continence Tampon	1 study ⁶⁰⁷	94	Not significant				Insufficient
Hodge pessary with support	Super tampon	1 study ⁵⁷⁹	40	Not significant				Insufficient
Durasphere	Contigen	1 study ⁴⁸⁰	52	3.33 (1.03; 10.74)	0.27 (0.05; 0.49)	4 (2; 22)	269 (46; 493)	Insufficient

Appendix Table F147. Comparative effectiveness of nonpharmacological treatments on continence (insufficient evidence) (continued)

Active	Control	Studies reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events 95% CI)	Evidence
Urethral device (NEAT)	Reliance insert sterile balloon	1 study ⁵⁸⁹	24	Not significant				Insufficient
Calcium hydroxylapatite	Bovine Dermal Collagen	1 study ⁵⁶⁷	296	Not significant				Insufficient
Peri or transurethral porcine dermal implant injection (Permacol)	Transurethral silicone injection (Macroplastique)	1 study ⁴⁸⁵		Not significant				Insufficient
Periurethral route of injection of bulking agent-dextran copolymer	Transurethral route of injection of bulking agent-dextran copolymer	1 study ⁵⁹²		Not significant				Insufficient
Macroplastique	Contigen®	1 study ⁵³²	247	1.49 (1.01; 2.18) NS for self reported continence	0.12 (0.01; 0.24)	8 (4; 152)	121 (7; 235)	Insufficient
Autologous myoblasts and fibroblasts	Collagen	1 study ⁵⁹⁷	63	9.50 (2.53; 35.63)	0.81 (0.66; 0.96)	1 (1; 2)	810 (656; 963)	Insufficient
Zuidex Implacer	Contigen Endoscopic guidance	1 study ⁵⁶²	344	Not significant				Insufficient

Appendix Table F148. Clinical outcomes after PFMT combined with bladder training with or without transcutaneous tibial nerve (results from individual RCTs)⁵⁹¹

Outcome	Active n/N	Control n/N	Rate active/control	Relative risk (95% CI)	Absolute risk difference (95% CI)
Retained some urge urinary incontinence	11/26	21/26	44/81	0.5 (0.3;0.9)	-0.38 (-0.63;-0.14)
Reduction of at least 50% of the number of incontinence episodes	20/26	7/26	76/27	2.9 (1.5;5.6)	0.50 (0.26;0.74)
Reported cure or improvement	18/26	9/26	68/35	2.0 (1.1;3.6)	0.35 (0.09;0.60)

Appendix Table F149. Clinical outcomes after PFMT combined with bladder training compared to bladder training alone (results from RCTs pooled with random effects models)

Outcome	Reference	Active n/N	Control n/N	Rate active/control	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Continence	Elser, 1999521	10/68	17/68	15/25	0.59 (0.29; 1.19)	49.42	-0.103 (-0.236; 0.03)	50.37
Continence	Wyman, 1998618	18/67	11/68	27/16	1.66 (0.85; 3.25)	50.58	0.107 (-0.031; 0.244)	49.63
		28/135	28/136	21/21	1 (0.4; 2.8)		0.001 (-0.2; 0.21)	
					0.064	63.70%	0.053	66.00%
Improved UI	Wyman, 1998618	14/69	9/68	20/13	1.53 (0.71; 3.30)	46.39	0.071 (-0.054; 0.195)	52.52

Appendix Table F150. Quality of life scoring after continence program vs. PFMT (individual RCT)

Reference sample/men	Active	Control	Outcome	Randomized active/control	Active mean/standard deviation	Control mean standard deviation	Mean difference (95% CI)
Kim, 2001 ⁵⁴ /0	Continence Efficacy Intervention Program	PFMT	Score of Improvement by subjective evaluation (0 to 100)	16/17	37.80/23.90	23.60/18.90	14.20 (-0.56;2 8.96)

Appendix Table F151. Nonsignificant differences in comparative effectiveness of oxybutynin when compared to nonpharmacological treatments (results from individual randomized controlled clinical trials)

Reference	Outcome	Active treatment	Control treatment	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)
Karademir, 2005 ³¹⁹	Cured from urgency incontinence	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA combined with 5 mg of oral oxybutynin hydrochloride	3/21	3/23	1.10 (0.25; 4.84)	0.01 (-0.19; 0.22)
Karademir, 2005 ³¹⁹	Decrease in symptoms of frequency	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA combined with 5 mg of oral oxybutynin hydrochloride	8/21	10/22	0.84 (0.41; 1.71)	-0.07 (-0.37;0.22)
Karademir, 2005 ³¹⁹	Decrease in symptoms of urgency	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA combined with 5 mg of oral oxybutynin hydrochloride	10/21	13/22	0.81 (0.46; 1.42)	-0.12 (-0.41 ;0.18)
Karademir, 2005 ³¹⁹	Decrease in symptoms of urgency incontinence	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA combined with 5 mg of oral oxybutynin hydrochloride	15/21	20/22	0.79 (0.58; 1.06)	-0.20 (-0.42; 0.03)
Burgio, 2010 ²⁴²	Completely satisfied with treatment progress	Pelvic Floor Muscle training + Urge suppression techniques + Oxybutynin	Oxybutynin	25/32	28/32	0.89 (0.71;1.12)	-0.09 (-0.28; 0.10)
Burgio, 2010 ²⁴²	Perceived improvement: much better	Pelvic Floor Muscle training + Urge suppression techniques + Oxybutynin	Oxybutynin	25/32	29/32	0.86 (0.70; 1.07)	-0.13 (-0.30;0.05)
Goode, 2002 ²⁹⁰	Self reported improvement in UI	Four sessions (over 8 weeks) of biofeedback-assisted behavioral training by nurse practitioners.	2.5 mg of oxybutynin chloride 3 times/day, dose adjustments from minimum 2.5 mg/ day to a maximum 5.0 mg 3 times/day	27/33	27/35	1.06 (0.83; 1.35)	0.05 (-0.15; 0.24)

Appendix Table F152. Comparative effectiveness of combined therapy with tolterodine ER, 4 mg daily and behavioral intervention with pelvic floor muscle training vs. tolterodine ER, 4 mg daily monotherapy. Urinary Incontinence Treatment Network: behavior enhances drug reduction of incontinence, (BE-DRI) randomized controlled clinical trial

Reference	Outcome	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Burgio, 2008 ²³⁹	Totally dry	32/154	26/153	1.22 (0.77; 1.95)	0.038 (-0.050; 0.125)		
Burgio, 2008 ²³⁹	At least 70% reduction in incontinence episodes	106/154	89/153	1.18 (1.00; 1.40)	0.107 (0.000; 0.214)		
Burgio, 2008 ²³⁹	Success as not receiving drugs or any other therapy for urgency incontinence and a 70% or greater reduction in frequency of incontinence episodes	43/154	41/153	1.04 (0.72; 1.50)	0.011 (-0.088; 0.111)		
Burgio, 2008 ²³⁹	Completely satisfied with their progress at the end of stage 1	82/154	61/153	1.34 (1.05; 1.71)	0.134 (0.023; 0.244)	7 (43; 4)	134 (23;244)
Burgio, 2008 ²³⁹	Completely satisfied with their progress at 8 months	51/154	31/153	1.63 (1.11; 2.41)	0.129 (0.031 ;0.226)	8 (33; 4)	129 (31; 226)
Burgio, 2008 ²³⁹	Improvement with treatment as "better" or "much better" at stage 1	139/154	118/153	1.17 (1.06; 1.29)	0.131 (0.050 ;0.213)	8 (20; 5)	131 (50; 213)
Burgio, 2008 ²³⁹	Improvement with treatment as "better" or "much better" at 8 months	106/154	66/153	1.60 (1.29; 1.97)	0.257 (0.150; 0.364)	4 (7; 3)	257 (150; 364)
Zimmern, 2010 ²⁴¹	Much better	63/154	46/153	1.36 (1.00; 1.85)	0.108 (0.002; 0.215)	9 (478; 5)	108 (2; 215)
Zimmern, 2010 ²⁴¹	Blurriness	14/154	15/153	0.93 (0.46; 1.85)	-0.007 (-0.073; 0.058)		
Zimmern, 2010 ²⁴¹	Confusion	14/154	16/153	0.8 (0.44; 1.72)	-0.014 (-0.080 ;0.053)		
Zimmern, 2010 ²⁴¹	Constipation	63/154	64/153	0.98 (0.75; 1.28)	-0.009 (-0.119; 0.101)		
Zimmern, 2010 ²⁴¹	Dry mouth	103/154	114/153	0.90 (0.78; 1.04)	-0.076 (-0.178; 0.025)		
Burgio, 2008 ²³⁹	Failure	75/154	49/153	1.52 (1.15; 2.02)	0.167 (0.059; 0.275)	6 (17; 4)	167 (59; 275)
Zimmern, 2010 ²⁴¹	Much worse	0/154	0/153	0.00 (0.00; 0.00)	0.000 (-0.013; 0.013)		

Appendix Table F153 Comparative effectiveness of percutaneous tibial nerve stimulation vs. extended-release tolterodine (results from overactive bladder innovative therapy trial)³⁵⁷

Outcome	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Subject assessment: cured	1/50	2/50	0.50 (0.05; 5.34)	-0.020 (-0.087; 0.047)		
Investigator assessment : cured	2/50	2/50	1.00 (0.15; 6.82)	0.000 (-0.077; 0.077)		
Subject assessment: improved	34/50	21/50	1.62 (1.11; 2.36)	0.260 (0.072; 0.448)	4 (2; 14)	260 (72; 448)
Subject assessment: cured or improved	35/50	23/50	1.52 (1.07; 2.16)	0.240 (0.052; 0.428)	4 (2; 19)	240 (52; 428)
Investigator assessment: improved	33/50	24/50	1.38 (0.97; 1.95)	0.180 (-0.011; 0.371)		
investigator assessment: cured or improved	35/50	26/50	1.35 (0.98; 1.86)	0.180 (-0.008 ;0.368)		
Withdrawn because treatment unsuccessful	0/50	3/50	0.14 (0.01; 2.70)	-0.060 (-0.134 ;0.014)		
Subject assessment no improvement/worsening	9/50	19/50	0.47 (0.24; 0.94)	-0.200 (-0.372; -0.028)	-5 (-35; -3)	-200 (-372; -28)
Investigator assessment no improvement/worsening	9/50	17/50	0.53 (0.26; 1.07)	-0.160 (-0.329; 0.009)		

Appendix Table F154. Nonsignificant differences in comparative effectiveness of flexible-dose solifenacin 5/10 mg with and without simplified bladder training in patients with overactive bladder syndrome (results from individual randomized controlled trial)⁶¹

Outcome	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)
Mild adverse effects	66/323	71/320	0.92 (0.68; 1.24)	-0.018 (-0.081; 0.046)
Moderate adverse effects	68/323	66/320	1.02 (0.76; 1.38)	0.004 (-0.059; 0.067)
Serious adverse effects	6/323	6/320	0.99 (0.32; 3.04)	0.000 (-0.021; 0.021)
Severe adverse effects	16/323	12/320	1.32 (0.64; 2.75)	0.012 (-0.019; 0.044)
Treatment-related adverse effects	83/323	81/320	1.02 (0.78; 1.32)	0.004 (-0.064; 0.071)
Constipation	14/323	24/320	0.58 (0.30; 1.10)	-0.032 (-0.068; 0.005)
Dry mouth	52/323	45/320	1.14 (0.79; 1.65)	0.020 (-0.035; 0.076)
Dyspepsia	6/323	8/320	0.74 (0.26; 2.12)	-0.006 (-0.029; 0.016)
Eye disorders	15/323	14/320	1.06 (0.52; 2.16)	0.003 (-0.029; 0.035)
Gastrointestinal disorders	77/323	85/320	0.90 (0.69; 1.17)	-0.027 (-0.094; 0.040)
General disorders and administration site	13/323	12/320	1.07 (0.50; 2.32)	0.003 (-0.027; 0.033)
Influenza and infections	52/323	45/320	1.14 (0.79; 1.65)	0.020 (-0.035; 0.076)
Musculoskeletal and connective tissue disorders	15/323	15/320	0.99 (0.49; 1.99)	0.000 (-0.033; 0.032)
Nervous system disorders	19/323	15/320	1.25 (0.65; 2.43)	0.012 (-0.023 ;0.047)
Psychiatric disorders	8/323	4/320	1.98 (0.60; 6.51)	0.012 (-0.009; 0.033)
Renal and urinary disorders	9/323	7/320	1.27 (0.48; 3.38)	0.006 (-0.018; 0.030)
Respiratory, thoracic, and mediastinal disorders	7/323	8/320	0.87 (0.32; 2.36)	-0.003 (-0.027 ;0.020)
Skin/subcutaneous disorders	11/323	5/320	2.18 (0.77; 6.20)	0.018 (-0.006; 0.042)

Appendix Table F155. Comparative effectiveness of intravaginal electrical stimulation and tiroprium hydrochloride in women with overactive bladder syndrome (results from individual randomized controlled clinical trial)³⁵⁶

Outcome	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Very satisfied or satisfied with the treatment	16/17	16/18	1.06 (0.87; 1.30)	0.05 (-0.13; 0.24)		
Experienced side-effects	8/17	5/18	1.69 (0.69; 4.16)	0.19 (-0.12; 0.51)		
Constipation	1/17	0/18	3.17 (0.14; 72.80)	0.06 (-0.09; 0.21)		
Hematuria secondary to nephrolithiasis	1/17	0/18	3.17 (0.14; 72.80)	0.06 (-0.09; 0.21)		
Urinary tract infection	1/17	2/18	0.53 (0.05; 5.32)	-0.05 (-0.24; 0.13)		
Vaginal discomfort	0/17	2/18	0.21 (0.01; 4.10)	-0.11 (-0.28; 0.06)		
Vaginal hemorrhage	0/17	1/18	0.35 (0.02; 8.09)	-0.06 (-0.20; 0.09)		
Xerostomia	5/17	0/18	11.61 (0.69; 195.26)	0.29 (0.07; 0.52)	3 (14; 2)	294 (69; 519)

References for Appendix F

1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for Pelvex hometrainer. 2001. www.accessdata.fda.gov/cdrh_docs/pdf/K002043.pdf. Accessed June 25, 2010.
2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary for Vitala(tm) continence Control Device. 2008. www.accessdata.fda.gov/cdrh_docs/pdf8/K083785.pdf. Accessed June 25, 2010.
3. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for ureau Pessary. 2008. www.accessdata.fda.gov/cdrh_docs/pdf8/K083769.pdf. Accessed June 25, 2010.
4. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for PelvicFlexer. 2001. www.accessdata.fda.gov/cdrh_docs/pdf/K011688.pdf. Accessed June 25, 2010.
5. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for Hollister Contimed Pressure Biofeedback device. 1996. www.accessdata.fda.gov/cdrh_docs/pdf/K960311.pdf. Accessed June 25, 2010.
6. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary of pathway vaginal emg/stimulation perineometer sensor. 2000. www.accessdata.fda.gov/cdrh_docs/pdf/K993976.pdf. Accessed June 25, 2010.
7. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 501(k) summary for UroMed Alternative Bladder Control Continence Device. 1997. www.accessdata.fda.gov/cdrh_docs/pdf/K971992.pdf. Accessed June 25, 2010.
8. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for InCare Pelvic Floor Therapy System with Desktop Computer. 1996. www.accessdata.fda.gov/cdrh_docs/pdf/K961872.pdf. Accessed June 25, 2010.
9. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary review for perineometer and vaginal probe. 1997. www.accessdata.fda.gov/cdrh_docs/pdf/K970145.pdf. Accessed June 25, 2010.
10. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary for vaginal stimulation/emg probe-tampon. 1997. www.accessdata.fda.gov/cdrh_docs/pdf/K971541.pdf. Accessed June 25, 2010.
11. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for innoSense pelvic floor stimulation and electromyography system. 1997. www.accessdata.fda.gov/cdrh_docs/pdf/K971527.pdf. Accessed June 25, 2010.
12. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary for vaginal stimulation/emg probe - small. 1997. www.accessdata.fda.gov/cdrh_docs/pdf/K970602.pdf. Accessed June 25, 2010.
13. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary for perform perineometric probe and pelvic floor contraction indicator. 1998. www.accessdata.fda.gov/cdrh_docs/pdf/K981277.pdf. Accessed June 25, 2010.
14. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary review for peritron perineometer. 1998. www.accessdata.fda.gov/cdrh_docs/pdf/K983052.pdf. Accessed June 25, 2010.
15. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary for reflex treatment system. 1999. www.accessdata.fda.gov/cdrh_docs/pdf/K994079.pdf. Accessed June 25, 2010.
16. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for Mentor EvaCare Vaginal Pessaries. 1999. www.accessdata.fda.gov/cdrh_docs/pdf/K993308.pdf. Accessed June 25, 2010.

17. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Summary for pelvic muscle therapy. 2000. www.accessdata.fda.gov/cdrh_docs/pdf/K002830.pdf. Accessed June 25, 2010.
18. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary accuset sensor. 2000. www.accessdata.fda.gov/cdrh_docs/pdf/K001386.pdf. Accessed June 25, 2010.
19. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary for femiscan clinic system and personal system. 2000. www.accessdata.fda.gov/cdrh_docs/pdf/K993411.pdf. Accessed June 25, 2010.
20. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Summary Review for InCare Pelvic Floor Therapy System. 2001. www.accessdata.fda.gov/cdrh_docs/pdf/K013612.pdf. Accessed June 25, 2010.
21. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for InCare Pressure Biofeedback Vaginal and Anal Pressure Probes. 2001. www.accessdata.fda.gov/cdrh_docs/pdf/K013653.pdf. Accessed June 25, 2010.
22. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for MTI ST#1 Silicone Pessary. 2002. www.accessdata.fda.gov/cdrh_docs/pdf2/K020512.pdf. Accessed June 25, 2010.
23. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for Portex Ring Pessary. 2002. www.accessdata.fda.gov/cdrh_docs/pdf/K012277.pdf. Accessed June 25, 2010.
24. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for marina Medical Silicone Pessary. 2003. www.accessdata.fda.gov/cdrh_docs/pdf3/K031463.pdf. Accessed June 25, 2010.
25. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for Kolpexin Sphere. 2004. www.accessdata.fda.gov/cdrh_docs/pdf3/K032644.pdf. Accessed June 25, 2010.
26. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for Intra-vaginal stress incontinence device. 2006. www.accessdata.fda.gov/cdrh_docs/pdf6/K060526.pdf. Accessed June 25, 2010.
27. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) Summary for pathway vaginal/rectal perineometer probe. www.accessdata.fda.gov/cdrh_docs/pdf/K974036.pdf. Accessed June 25, 2010.
28. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary for anal stimulation/emg probe - w/Stop. 1999. www.accessdata.fda.gov/cdrh_docs/pdf/K990456.pdf. Accessed June 25, 2010.
29. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 510(k) summary for liberty plus system pfs-300. 1997. www.accessdata.fda.gov/cdrh_docs/pdf/K970077.pdf. Accessed June 25, 2010.
30. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for Gelnique (oxybutynin chloride) 10% gel. 2009. www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022204s000_gelnique_toc.cfm. Accessed June 25, 2010.
31. Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. *J Urol*. 2009 Apr;181(4):1764-72. PMID: 19233423.
32. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for PAMELOR (Brand Name Drug). 2001. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/018012_s024_PAMELOR%20CAPSULES.pdf. Accessed June 25, 2010.
33. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for Sanctura (Trospium Chloride) Tablets. 2004. www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-595_Sanctura.cfm. Accessed June 25, 2010.

34. Rudy D, Cline K, Harris R, et al. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. *BJU Int.* 2006 Mar;97(3):540-6. PMID: 16469022.
35. Zinner N, Gittelman M, Harris R, et al. Trosipium chloride improves overactive bladder symptoms: a multicenter phase III trial. *J Urol.* 2004 Jun;171(6 Pt 1):2311-5, quiz 435. PMID: 15126811.
36. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for VesiCare (Solifenacin Succinate) Tablets. 2004. www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VesiCare.cfm. Accessed June 25, 2010.
37. Staskin DR, Te AE. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. *BJU Int.* 2006 Jun;97(6):1256-61. PMID: 16686722.
38. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for Sanctura XR (Trosipium Chloride) Extended Release Capsules. 2007. www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022103s000TOC.cfm. Accessed June 25, 2010.
39. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for Ditropan XL (Oxybutinin Chloride) Tablets. 1998. http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20897.cfm. Accessed June 25, 2010.
40. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. *Obstet Gynecol.* 2000 May;95(5):718-21. PMID: 10775736.
41. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Medical Review for Enablex (Clarifenacin) Extended Release Tablets. 2004. www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex.cfm. Accessed June 25, 2010.
42. Hill S, Khullar V, Wyndaele JJ, et al. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006 May;17(3):239-47. PMID: 15999217.
43. Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. *BJU Int.* 2005 Mar;95(4):580-6. PMID: 15705084.
44. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Statistical Review for Sanctura XR (Trosipium Chloride) Extended Release Capsules. 2007. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022103s000TOC.cfm. Accessed June 25, 2010.
45. Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. *J Urol.* 2007 Sep;178(3 Pt 1):978-83; discussion 83-4. PMID: 17632131.
46. Health Canada. Product Monograph for ENABLEX. 2006. <http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=75871>. Accessed June 25, 2010.
47. Abrams P, Kelleher C, Huels J, et al. Clinical relevance of health-related quality of life outcomes with darifenacin. *BJU Int.* 2008 Jul;102(2):208-13. PMID: 18325056.
48. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Product Monograph for SANCTURA XR. 2010. <http://webprod.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng>. Accessed June 25, 2010.
49. Staskin DR, Rosenberg MT, Sand PK, et al. Trosipium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. *Int J Clin Pract.* 2009 Dec;63(12):1715-23. PMID: 19930332.

50. Canada H. Product Monograph for VESICARE. 2006. <http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=76292>. Accessed June 25, 2010.
51. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. *J Urol*. 2004 Nov;172(5 Pt 1):1919-24. PMID: 15540755.
52. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. *BJU Int*. 2004 Feb;93(3):303-10. PMID: 14764127.
53. NCT00168454. A Research Study for Patients With Overactive Bladder. 2008. <http://clinicaltrials.gov/ct2/show/NCT00168454>.
54. NCT00178191. Randomized Trial for Botox Urinary Incontinence. <http://www.clinicaltrials.gov/ct2/show/NCT00178191?term=NCT00178191&rank=1>.
55. NCT00269750. A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. 2005. <http://clinicaltrials.gov/show/NCT00269750>. Accessed June 25, 2010.
56. NCT00444925. Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB). <http://www.clinicaltrials.gov/ct2/show/NCT00444925?term=NCT00444925&rank=1>.
57. NCT00536484. Fesoterodine Flexible Dose Study. <http://www.clinicaltrials.gov/ct2/show/NCT00536484?term=NCT00536484&rank=1>.
58. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. *Eur Urol*. 2005 Sep;48(3):464-70. PMID: 15990220.
59. Pharmaceutical Research and Manufacturers of America. Solifenacin in the treatment of urgency symptoms of overactive bladder in a rising dose, randomized, placebo-controlled, double-blind trial (SUNRISE). www.clinicalstudyresults.org/documents/company-study_8351_0.pdf. Accessed June 25, 2010.
60. Cardozo L, Hessdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. *BJU Int*. 2008 Nov;102(9):1120-7. PMID: 18990175.
61. Mattiasson A, Masala A, Morton R, et al. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study. *BJU Int*. 2009 Oct 10; PMID: 19818077.
62. Pharmaceutical Research and Manufacturers of America. Solifenacin succinate in a flexible dose regimen with simplified bladder training versus solifenacin succinate in a flexible dose regimen alone in a prospective, randomized, parallel group, overactive bladder symptom study. http://www.clinicalstudyresults.org/documents/company-study_8352_0.pdf. Accessed June 25, 2010.
63. Digesu GA, Khullar V, Cardozo L, et al. Overactive bladder symptoms: do we need urodynamics? *Neurourol Urodyn*. 2003;22(2):105-8. PMID: 12579626.
64. Khan MS, Chaliha C, Leskova L, et al. The relationship between urinary symptom questionnaires and urodynamic diagnoses: an analysis of two methods of questionnaire administration. *BJOG*. 2004 May;111(5):468-74. PMID: 15104612.
65. Versi E, Orrego G, Hardy E, et al. Evaluation of the home pad test in the investigation of female urinary incontinence. *Br J Obstet Gynaecol*. 1996 Feb;103(2):162-7. PMID: 8616134.
66. Sandvik H, Hunskaar S, Vanvik A, et al. Diagnostic classification of female urinary incontinence: an epidemiological survey corrected for validity. *J Clin Epidemiol*. 1995 Mar;48(3):339-43. PMID: 7897455.

67. Clarke B. The role of urodynamic assessment in the diagnosis of lower urinary tract disorders. *Int Urogynecol J Pelvic Floor Dysfunct.* 1997;8(4):196-9. PMID: 9449295.
68. Jarvis GJ, Hall S, Stamp S, et al. An assessment of urodynamic examination in incontinent women. *Br J Obstet Gynaecol.* 1980 Oct;87(10):893-6. PMID: 7426486.
69. Hilton P, Stanton SL. Algorithmic method for assessing urinary incontinence in elderly women. *Br Med J (Clin Res Ed).* 1981 Mar 21;282(6268):940-2. PMID: 6781660.
70. Cundiff GW, Harris RL, Coates KW, et al. Clinical predictors of urinary incontinence in women. *Am J Obstet Gynecol.* 1997 Aug;177(2):262-6; discussion 6-7. PMID: 9290438.
71. Brown JS, Bradley CS, Subak LL, et al. The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. *Ann Intern Med.* 2006 May 16;144(10):715-23. PMID: 16702587.
72. Costantini E, Lazzeri M, Bini V, et al. Sensitivity and specificity of one-hour pad test as a predictive value for female urinary incontinence. *Urol Int.* 2008;81(2):153-9. PMID: 18758212.
73. Ishiko O, Hirai K, Sumi T, et al. The urinary incontinence score in the diagnosis of female urinary incontinence. *Int J Gynaecol Obstet.* 2000 Feb;68(2):131-7. PMID: 10717817.
74. Shepherd AM, Powell PH, Ball AJ. The place of urodynamic studies in the investigation and treatment of female urinary tract symptoms. *J Obstet Gynaecol.* 1982;3:123-5.
75. Versi E, L. C, Anand D. The use of pad tests in the investigation of female urinary incontinence. *J Obstet Gynecol.* 1988;8:270-3. PMID: no-2.
76. Bradley CS, Rovner ES, Morgan MA, et al. A new questionnaire for urinary incontinence diagnosis in women: development and testing. *Am J Obstet Gynecol.* 2005 Jan;192(1):66-73. PMID: 15672005.
77. FitzGerald MP, Brubaker L. Urinary incontinence symptom scores and urodynamic diagnoses. *Neurourol Urodyn.* 2002;21(1):30-5. PMID: 11835421.
78. Sand PK, Hill RC, Ostergard DR. Incontinence history as a predictor of detrusor stability. *Obstet Gynecol.* 1988 Feb;71(2):257-60. PMID: 3336562.
79. Cantor TJ, Bates CP. A comparative study of symptoms and objective urodynamic findings in 214 incontinent women. *Br J Obstet Gynaecol.* 1980 Oct;87(10):889-92. PMID: 7191720.
80. Valente S. The usefulness of urodynamics in urogynaecological disorders. *Clin Exp Obstet Gynecol.* 1988;15(3):102-7. PMID: 3402082.
81. Hastie KJ, Moisey CU. Are urodynamics necessary in female patients presenting with stress incontinence? *Br J Urol.* 1989 Feb;63(2):155-6. PMID: 2702401.
82. Bent AE, Richardson DA, Ostergard DR. Diagnosis of lower urinary tract disorders in postmenopausal patients. *Am J Obstet Gynecol.* 1983 Jan 15;145(2):218-22. PMID: 6849357.
83. De Muylder X, Claes H, Neven P, et al. Usefulness of urodynamic investigations in female incontinence. *Eur J Obstet Gynecol Reprod Biol.* 1992 May 13;44(3):205-8. PMID: 1607060.
84. Farrar DJ, Whiteside CG, Osborne JL, et al. A urosynamic analysis of micturition symptoms in the female. *Surg Gynecol Obstet.* 1975 Dec;141(6):875-81. PMID: 1188564.
85. Lagro-Janssen AL, Debruyne FM, van Weel C. Value of the patient's case history in diagnosing urinary incontinence in general practice. *Br J Urol.* 1991 Jun;67(6):569-72. PMID: 2070199.
86. Ouslander J, Staskin D, Raz S, et al. Clinical versus urodynamic diagnosis in an incontinent geriatric female population. *J Urol.* 1987 Jan;137(1):68-71. PMID: 3795368.
87. Bergman A, Bader K. Reliability of the patient's history in the diagnosis of urinary incontinence. *Int J Gynaecol Obstet.* 1990 Jul;32(3):255-9. PMID: 1972118.

88. Haylen BT, Sutherst JR, Frazer MI. Is the investigation of most stress incontinence really necessary? *Br J Urol*. 1989 Aug;64(2):147-9. PMID: 2765780.
89. Versi E, Cardozo LD. Perineal pad weighing versus videographic analysis in genuine stress incontinence. *Br J Obstet Gynaecol*. 1986 Apr;93(4):364-6. PMID: 3964613.
90. Bates CP, Loose H, Stanton SL. The objective study of incontinence after repair operations. *Surg Gynecol Obstet*. 1973 Jan;136(1):17-22. PMID: 4682258.
91. Arnold EP, Webster JR, Loose H, et al. Urodynamics of female incontinence: factors influencing the results of surgery. *Am J Obstet Gynecol*. 1973 Nov 15;117(6):805-13. PMID: 4795646.
92. Moolgaoker AS, Ardran GM, Smith JC, et al. The diagnosis and management of urinary incontinence in the female. *J Obstet Gynaecol Br Commonw*. 1972 Jun;79(6):481-97. PMID: 5064185.
93. Warrell DW. Investigation and Treatment of Incontinence of Urine in Women Who Have Had a Prolapse Repair Operation. *Br J Urol*. 1965 Apr;37:233-9. PMID: 14282088.
94. Klingele CJ, Carley ME, Hill RF. Patient characteristics that are associated with urodynamically diagnosed detrusor instability and genuine stress incontinence. *Am J Obstet Gynecol*. 2002 May;186(5):866-8. PMID: 12015497.
95. Niecestro RM, Wheeler JS, Jr., Nanninga J, et al. Use of stresscath for diagnosing stress incontinence. *Urology*. 1992 Mar;39(3):266-9. PMID: 1546422.
96. Diokno AC, Normolle DP, Brown MB, et al. Urodynamic tests for female geriatric urinary incontinence. *Urology*. 1990 Nov;36(5):431-9. PMID: 2238302.
97. Tyagi V, Hamoodi I, Yousef M, et al. How reliable is history taking in diagnosing type of urinary incontinence? *Neurourology and Urodynamics*. 2010;29:1134-5.
98. Thiede HA, Saini VD. Urogynecology: comments and caveats. *Am J Obstet Gynecol*. 1987 Sep;157(3):563-8. PMID: 3631157.
99. Awad SA, McGinnis RH. Factors that influence the incidence of detrusor instability in women. *J Urol*. 1983 Jul;130(1):114-5. PMID: 6683325.
100. Glezerman M, Glasner M, Rikover M, et al. Evaluation of reliability of history in women complaining of urinary stress incontinence. *Eur J Obstet Gynecol Reprod Biol*. 1986 Mar;21(3):159-64. PMID: 3956835.
101. Walters MD, Shields LE. The diagnostic value of history, physical examination, and the Q-tip cotton swab test in women with urinary incontinence. *Am J Obstet Gynecol*. 1988 Jul;159(1):145-9. PMID: 3394734.
102. Versi E, Cardozo L, Anand D, et al. Symptoms analysis for the diagnosis of genuine stress incontinence. *Br J Obstet Gynaecol*. 1991 Aug;98(8):815-9. PMID: 1911591.
103. Bump RC, Norton PA, Zinner NR, et al. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. *Obstet Gynecol*. 2003 Jul;102(1):76-83. PMID: 12850610.
104. Yalcin I, Versi E, Benson JT, et al. Validation of a clinical algorithm to diagnose stress urinary incontinence for large studies. *J Urol*. 2004 Jun;171(6 Pt 1):2321-5. PMID: 15126813.
105. Videla FL, Wall LL. Stress incontinence diagnosed without multichannel urodynamic studies. *Obstet Gynecol*. 1998 Jun;91(6):965-8. PMID: 9611005.
106. Dinokno AC, Dimaculangan RR, Lim EU, et al. Office based criteria for predicting type II stress incontinence without further evaluation studies. *J Urol*. 1999 Apr;161(4):1263-7. PMID: 10081882.
107. Lemack GE, Zimmern PE. Predictability of urodynamic findings based on the Urogenital Distress Inventory-6 questionnaire. *Urology*. 1999 Sep;54(3):461-6. PMID: 10475355.
108. Ramsay N, Ali HM, Heslington K. Can scoring the severity of symptoms help to predict the urodynamic diagnosis? . *Int Urogynecol J* 1995;6:267-70.

109. Ramsay IN, Hilton P, Rice N. The symptomatic characterization of patients with detrusor instability and those with genuine stress incontinence. *Int Urogynecol J*. 1993;4:23-6. PMID: No-4.
110. Montz FJ, Stanton SL. Q-Tip test in female urinary incontinence. *Obstet Gynecol*. 1986 Feb;67(2):258-60. PMID: 3945436.
111. Haeusler G, Hanzal E, Joura E, et al. Differential diagnosis of detrusor instability and stress-incontinence by patient history: the Gaudenz-Incontinence-Questionnaire revisited. *Acta Obstet Gynecol Scand*. 1995 Sep;74(8):635-7. PMID: 7660771.
112. Nager CW, Albo ME, Fitzgerald MP, et al. Reference urodynamic values for stress incontinent women. *Neurourol Urodyn*. 2007;26(3):333-40. PMID: 17315221.
113. Matharu G, Donaldson MM, McGrother CW, et al. Relationship between urinary symptoms reported in a postal questionnaire and urodynamic diagnosis. *Neurourol Urodyn*. 2005;24(2):100-5. PMID: 15605372.
114. Coyne KS, Zyczynski T, Margolis MK, et al. Validation of an overactive bladder awareness tool for use in primary care settings. *Adv Ther*. 2005 Jul-Aug;22(4):381-94. PMID: 16418145.
115. Lukacz ES, Lawrence JM, Buckwalter JG, et al. Epidemiology of prolapse and incontinence questionnaire: validation of a new epidemiologic survey. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Jul-Aug;16(4):272-84. PMID: 15856132.
116. Fischer-Rasmussen W, Hansen RI, Stage P. Predictive values of diagnostic tests in the evaluation of female urinary stress incontinence. *Acta Obstet Gynecol Scand*. 1986;65(4):291-4. PMID: 3739640.
117. Summitt RL, Jr., Stovall TG, Bent AE, et al. Urinary incontinence: correlation of history and brief office evaluation with multichannel urodynamic testing. *Am J Obstet Gynecol*. 1992 Jun;166(6 Pt 1):1835-40; discussion 40-4. PMID: 1615993.
118. Griffiths DJ, McCracken PN, Harrison GM, et al. Characteristics of urinary incontinence in elderly patients studied by 24-hour monitoring and urodynamic testing. *Age Ageing*. 1992 May;21(3):195-201. PMID: 1615782.
119. Chen GD, Su TH, Lin LY. Applicability of perineal sonography in anatomical evaluation of bladder neck in women with and without genuine stress incontinence. *J Clin Ultrasound*. 1997 May;25(4):189-94. PMID: 9142618.
120. Kiilholma PJ, Makinen JI, Pitkanen YA, et al. Perineal ultrasound: an alternative for radiography for evaluating stress urinary incontinence in females. *Ann Chir Gynaecol Suppl*. 1994;208:43-5. PMID: 8092770.
121. Contreras Ortiz O, Lombardo RJ, Pellicari A. Non-invasive diagnosis of bladder instability using the Bladder Instability Discriminant Index (BIDI). *Zentralbl Gynakol*. 1993;115(10):446-9. PMID: 8273434.
122. Bergman A, Ballard CA, Platt LD. Ultrasonic evaluation of urethrovesical junction in women with stress urinary incontinence. *J Clin Ultrasound*. 1988 Jun;16(5):295-300. PMID: 3152386.
123. Bergman A, McKenzie CJ, Richmond J, et al. Transrectal ultrasound versus cystography in the evaluation of anatomical stress urinary incontinence. *Br J Urol*. 1988 Sep;62(3):228-34. PMID: 3056562.
124. Bergman A, McCarthy TA, Ballard CA, et al. Role of the Q-tip test in evaluating stress urinary incontinence. *J Reprod Med*. 1987 Apr;32(4):273-5. PMID: 3585870.
125. Klovning A, Hunnskaar S, Eriksen BC. Validity of a scored urological history in detecting detrusor instability in female urinary incontinence. *Acta Obstet Gynecol Scand*. 1996 Nov;75(10):941-5. PMID: 9003097.
126. Sunshine T, J., Glowacki GA. Clinical correlation of urodynamic testing in patients with urinary incontinence. *Journal of Gynecologic Surgery* 1989;5:93-8. PMID: 131.

127. Kujansuu E, Kauppila A. Scored urological history and urethrocytometry in the differential diagnosis of female urinary incontinence. *Ann Chir Gynaecol.* 1982;71(4):197-202. PMID: 6889831.
128. Diokno AC, Wells TJ, Brink CA. Urinary incontinence in elderly women: urodynamic evaluation. *J Am Geriatr Soc.* 1987 Oct;35(10):940-6. PMID: 3655177.
129. Korda A, Krieger M, Hunter P, et al. The value of clinical symptoms in the diagnosis of urinary incontinence in the female. *Aust N Z J Obstet Gynaecol.* 1987 May;27(2):149-51. PMID: 3675441.
130. Quinn MJ, Fansworth BA, Pollard WJ, et al. Vaginal ultrasound in the diagnosis of stress incontinence: a prospective comparison to urodynamic investigations. *Neurourol Urodyn* 1989;8:8:302-3.
131. Abdel-fattah M, Barrington JW, Youssef M. The standard 1-hour pad test: does it have any value in clinical practice? *Eur Urol.* 2004 Sep;46(3):377-80. PMID: 15306111.
132. Amarenco G, Arnould B, Carita P, et al. European psychometric validation of the CONTILIFE: a Quality of Life questionnaire for urinary incontinence. *Eur Urol.* 2003 Apr;43(4):391-404. PMID: 12667721.
133. Amundsen C, Lau M, English SF, et al. Do urinary symptoms correlate with urodynamic findings? *J Urol.* 1999 Jun;161(6):1871-4. PMID: 10332456.
134. Bent AE, Gousse AE, Hendrix SL, et al. Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence. *Obstet Gynecol.* 2005 Oct;106(4):767-73. PMID: 16199634.
135. Borup K, Hvidman L, Nielsen JB, et al. Validity of a self-administered questionnaire, with reference to a clinical stress urinary incontinence test. *Scand J Urol Nephrol.* 2008;42(2):148-53. PMID: 17853006.
136. Byrne DJ, Stewart PA, Gray BK. The role of urodynamics in female urinary stress incontinence. *Br J Urol.* 1987 Mar;59(3):228-9. PMID: 3567483.
137. Caputo RM, Benson JT. The Q-tip test and urethrovesical junction mobility. *Obstet Gynecol.* 1993 Dec;82(6):892-6. PMID: 8233260.
138. Cardozo LD, Stanton SL. Genuine stress incontinence and detrusor instability--a review of 200 patients. *Br J Obstet Gynaecol.* 1980 Mar;87(3):184-90. PMID: 7387918.
139. Chiarelli P, Brown W, McElduff P. Leaking urine: prevalence and associated factors in Australian women. *Neurourol Urodyn.* 1999;18(6):567-77. PMID: 10529705.
140. Drutz HP, Mandel F. Urodynamic analysis of urinary incontinence symptoms in women. *Am J Obstet Gynecol.* 1979 Aug 1;134(7):789-92. PMID: 463981.
141. Eastwood HD, Warrell R. Urinary incontinence in the elderly female: prediction in diagnosis and outcome of management. *Age Ageing.* 1984 Jul;13(4):230-4. PMID: 6475652.
142. Eastwood HD. Urodynamic studies in the management of urinary incontinence in the elderly. *Age Ageing.* 1979 Feb;8(1):41-8. PMID: 443110.
143. Gunthorpe W, Brown W, Redman S. The development and evaluation of an incontinence screening questionnaire for female primary care. *Neurourol Urodyn.* 2000;19(5):595-607. PMID: 11002302.
144. Harvey MA, Kristjansson B, Griffith D, et al. The Incontinence Impact Questionnaire and the Urogenital Distress Inventory: a revisit of their validity in women without a urodynamic diagnosis. *Am J Obstet Gynecol.* 2001 Jul;185(1):25-31. PMID: 11483899.
145. Homma Y, Uemura S. Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder. *BJU Int.* 2004 May;93(7):1009-13. PMID: 15142153.
146. Jackson S, Donovan J, Brookes S, et al. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. *Br J Urol.* 1996 Jun;77(6):805-12. PMID: 8705212.

147. James M, Jackson S, Shepherd A, et al. Pure stress leakage symptomatology: is it safe to discount detrusor instability? *Br J Obstet Gynaecol.* 1999 Dec;106(12):1255-8. PMID: 10609718.
148. Kinchen KS, Lee J, Fireman B, et al. The prevalence, burden, and treatment of urinary incontinence among women in a managed care plan. *J Womens Health (Larchmt).* 2007 Apr;16(3):415-22. PMID: 17439386.
149. Kulseng-Hanssen S, Borstad E. The development of a questionnaire to measure the severity of symptoms and the quality of life before and after surgery for stress incontinence. *BJOG.* 2003 Nov;110(11):983-8. PMID: 14592582.
150. Lagro-Janssen TL, Smits AJ, Van Weel C. Women with urinary incontinence: self-perceived worries and general practitioners' knowledge of problem. *Br J Gen Pract.* 1990 Aug;40(337):331-4. PMID: 2121179.
151. Lemack GE, Zimmern PE. Identifying patients who require urodynamic testing before surgery for stress incontinence based on questionnaire information and surgical history. *Urology.* 2000 Apr;55(4):506-11. PMID: 10736492.
152. Lin LY, Yeh NH, Lin CY, et al. Comparisons of urodynamic characteristics between female patients with overactive bladder and overactive bladder plus stress urinary incontinence. *Urology.* 2004 Nov;64(5):945-9. PMID: 15533483.
153. Lowenstein L, Kenton K, FitzGerald MP, et al. Clinically useful measures in women with mixed urinary incontinence. *Am J Obstet Gynecol.* 2008 Jun;198(6):664 e1-3; discussion e3-4. PMID: 18538148.
154. Massolt ET, Groen J, Vierhout ME. Application of the Blaivas-Groutz bladder outlet obstruction nomogram in women with urinary incontinence. *Neurourol Urodyn.* 2005;24(3):237-42. PMID: 15747342.
155. Miller JM, Ashton-Miller JA, Carchidi LT, et al. On the lack of correlation between self-report and urine loss measured with standing provocation test in older stress-incontinent women. *J Womens Health.* 1999 Mar;8(2):157-62. PMID: 10100129.
156. Morkved S, Bo K. Prevalence of urinary incontinence during pregnancy and postpartum. *Int Urogynecol J Pelvic Floor Dysfunct.* 1999;10(6):394-8. PMID: 10614977.
157. Oh SJ, Ku JH, Hong SK, et al. Factors influencing self-perceived disease severity in women with stress urinary incontinence combined with or without urge incontinence. *Neurourol Urodyn.* 2005;24(4):341-7. PMID: 15791635.
158. Phua SM, Shields LE. The role of urodynamics in evaluation of incontinent females. *Singapore Med J.* 1992;33:139-42.
159. Rosenzweig BA, Pushkin S, Blumenfeld D, et al. Prevalence of abnormal urodynamic test results in continent women with severe genitourinary prolapse. *Obstet Gynecol.* 1992 Apr;79(4):539-42. PMID: 1553172.
160. Sand PK, Brubaker LT, Novak T. Simple standing incremental cystometry as a screening method for detrusor instability. *Obstet Gynecol.* 1991 Mar;77(3):453-7. PMID: 1992416.
161. Scarpero HM, Fiske J, Xue X, et al. American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life. *Urology.* 2003 Jun;61(6):1118-22. PMID: 12809877.
162. Shimabukuro T, Takahashi Y, Naito K. Lower urinary tract symptoms in 1,912 apparently healthy persons of both sexes. *Hinyokika Kyo.* 2006 Mar;52(3):189-95. PMID: 16617872.
163. Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. *Continence Program in Women (CPW) Research Group. Qual Life Res.* 1994 Oct;3(5):291-306. PMID: 7841963.
164. Stach-Lempinen B, Kujansuu E, Laippala P, et al. Visual analogue scale, urinary incontinence severity score and 15 D--psychometric testing of three different health-related quality-of-life instruments for urinary incontinent women. *Scand J Urol Nephrol.* 2001 Dec;35(6):476-83. PMID: 11848427.

165. Stav K, Dwyer PL, Rosamilia A. Women overestimate daytime urinary frequency: the importance of the bladder diary. *J Urol*. 2009 May;181(5):2176-80. PMID: 19296975.
166. Sutherst JR, Brown MC. Comparison of single and multichannel cystometry in diagnosing bladder instability. *Br Med J (Clin Res Ed)*. 1984 Jun 9;288(6432):1720-2. PMID: 6428513.
167. Swift SE, Ostergard DR. Evaluation of current urodynamic testing methods in the diagnosis of genuine stress incontinence. *Obstet Gynecol*. 1995 Jul;86(1):85-91. PMID: 7784028.
168. Swithinbank LV, Donovan JL, du Heaume JC, et al. Urinary symptoms and incontinence in women: relationships between occurrence, age, and perceived impact. *Br J Gen Pract*. 1999 Nov;49(448):897-900. PMID: 10818656.
169. Theofrastous JP, Cundiff GW, Harris RL, et al. The effect of vesical volume on Valsalva leak-point pressures in women with genuine stress urinary incontinence. *Obstet Gynecol*. 1996 May;87(5 Pt 1):711-4. PMID: 8677072.
170. Weidner AC, Myers ER, Visco AG, et al. Which women with stress incontinence require urodynamic evaluation? *Am J Obstet Gynecol*. 2001 Jan;184(2):20-7. PMID: 11174474.
171. Wyman JF, Choi SC, Harkins SW, et al. The urinary diary in evaluation of incontinent women: a test-retest analysis. *Obstet Gynecol*. 1988 Jun;71(6 Pt 1):812-7. PMID: 3368165.
172. Wyman JF, Harkins SW, Choi SC, et al. Psychosocial impact of urinary incontinence in women. *Obstet Gynecol*. 1987 Sep;70(3 Pt 1):378-81. PMID: 3627585.
173. Yoon E, Swift S. A comparison of maximum cystometric bladder capacity with maximum environmental voided volumes. *Int Urogynecol J Pelvic Floor Dysfunct*. 1998;9(2):78-82. PMID: 9694135.
174. Nitti VW, Rovner ES, Bavendam T. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. *BJU Int*. 2010 May;105(9):1268-75. PMID: 19889062.
175. Auwad W, Steggles P, Bombieri L, et al. Moderate weight loss in obese women with urinary incontinence: a prospective longitudinal study. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Sep;19(9):1251-9. PMID: 18421406.
176. Wing RR, Creasman JM, West DS, et al. Improving urinary incontinence in overweight and obese women through modest weight loss. *Obstet Gynecol*. 2010 Aug;116(2 Pt 1):284-92. PMID: 20664387.
177. Hines SH, Seng JS, Messer KL, et al. Adherence to a behavioral program to prevent incontinence. *West J Nurs Res*. 2007 Feb;29(1):36-56; discussion 7-64. PMID: 17228060.
178. Sugaya K, Owan T, Hatano T, et al. Device to promote pelvic floor muscle training for stress incontinence. *Int J Urol*. 2003 Aug;10(8):416-22. PMID: 12887362.
179. Brubaker L, Shott S, Tomezsko J, et al. Pelvic floor fitness using lay instructors. *Obstet Gynecol*. 2008 Jun;111(6):1298-304. PMID: 18515512.
180. Wang AC. Bladder-sphincter biofeedback as treatment of detrusor instability in women who failed to respond to oxybutynin. *Chang Gung Med J*. 2000 Oct;23(10):590-9. PMID: 11126150.
181. Bellin P, Smith J, Poll W, et al. Results of a multicenter trial of the CapSure (Re/Stor) Continence shield on women with stress urinary incontinence. *Urology*. 1998 May;51(5):697-706. PMID: 9610582.
182. Crivellaro S, Tosco L, Martinez Bustamante L, et al. Long term results of the adjustable continence therapy (ACT) for recurrent female stress urinary incontinence. *Neurourology and Urodynamics*. 2010;29:1161.

183. Morris AR, Moore KH. The Contiform incontinence device - efficacy and patient acceptability. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Dec;14(6):412-7. PMID: 14677003.
184. Allen WA, Leek H, Izurieta A, et al. Update: the "Contiform" intravaginal device in four sizes for the treatment of stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Jun;19(6):757-61. PMID: 18183342.
185. Sander P, Thyssen H, Lose G, et al. Effect of a vaginal device on quality of life with urinary stress incontinence. *Obstet Gynecol.* 1999 Mar;93(3):407-11. PMID: 10074989.
186. Nilsson CG. Effectiveness of the convene continence guard (a disposable vaginal device) in the treatment of complicated female stress incontinence. *Acta Obstet Gynecol Scand.* 2000 Dec;79(12):1052-5. PMID: 11130086.
187. Pieper B, Cleland V. An external urine-collection device for women: a clinical trial. *J ET Nurs.* 1993 Mar-Apr;20(2):51-5. PMID: 8507726.
188. Versi E, Harvey MA. Efficacy of an external urethral device in women with genuine stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 1998;9(5):271-4. PMID: 9849759.
189. Versi E, Griffiths DJ, Harvey MA. A new external urethral occlusive device for female urinary incontinence. *Obstet Gynecol.* 1998 Aug;92(2):286-91. PMID: 9699768.
190. Sirls LT, Foote JE, Kaufman JM, et al. Long-term results of the FemSoft urethral insert for the management of female stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2002;13(2):88-95; discussion PMID: 12054188.
191. Macaulay M, van den Heuvel E, Jowitt F, et al. A noninvasive continence management system: development and evaluation of a novel toileting device for women. *J Wound Ostomy Continence Nurs.* 2007 Nov-Dec;34(6):641-8. PMID: 18030103.
192. Donnelly MJ, Powell-Morgan S, Olsen AL, et al. Vaginal pessaries for the management of stress and mixed urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 Sep-Oct;15(5):302-7. PMID: 15300365.
193. Brincat C, Kenton K, Pat Fitzgerald M, et al. Sexual activity predicts continued pessary use. *Am J Obstet Gynecol.* 2004 Jul;191(1):198-200. PMID: 15295365.
194. Maito JM, Quam ZA, Craig E, et al. Predictors of successful pessary fitting and continued use in a nurse-midwifery pessary clinic. *J Midwifery Womens Health.* 2006 Mar-Apr;51(2):78-84. PMID: 16504903.
195. Sulak PJ, Kuehl TJ, Shull BL. Vaginal pessaries and their use in pelvic relaxation. *J Reprod Med.* 1993 Dec;38(12):919-23. PMID: 8120847.
196. Clemons JL, Aguilar VC, Tillinghast TA, et al. Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. *Am J Obstet Gynecol.* 2004 Apr;190(4):1025-9. PMID: 15118635.
197. Farrell SA, Baydock S, Amir B, et al. Effectiveness of a new self-positioning pessary for the management of urinary incontinence in women. *Am J Obstet Gynecol.* 2007 May;196(5):474 e1-8. PMID: 17466709.
198. Nguyen JN, Jones CR. Pessary treatment of pelvic relaxation: factors affecting successful fitting and continued use. *J Wound Ostomy Continence Nurs.* 2005 Jul-Aug;32(4):255-61; quiz 62-3. PMID: 16030465.
199. Staskin D, Bavendam T, Miller J, et al. Effectiveness of a urinary control insert in the management of stress urinary incontinence: early results of a multicenter study. *Urology.* 1996 May;47(5):629-36. PMID: 8650857.
200. Kocjancic E, Crivellaro S, Smith JJ, 3rd, et al. Adjustable continence therapy for treatment of recurrent female urinary incontinence. *J Endourol.* 2008 Jul;22(7):1403-7. PMID: 18613782.
201. Brubaker L, Harris T, Gleason D, et al. The external urethral barrier for stress incontinence: a multicenter trial of safety and efficacy. *Miniguard Investigators Group. Obstet Gynecol.* 1999 Jun;93(6):932-7. PMID: 10362157.

202. Moore KH, Simons A, Dowell C, et al. Efficacy and user acceptability of the urethral occlusive device in women with urinary incontinence. *J Urol*. 1999 Aug;162(2):464-8. PMID: 10411058.
203. Sand PK, Staskin D, Miller J, et al. Effect of a urinary control insert on quality of life in incontinent women. *Int Urogynecol J Pelvic Floor Dysfunct*. 1999;10(2):100-5. PMID: 10384971.
204. Aboseif SR, Franke EI, Nash SD, et al. The adjustable continence therapy system for recurrent female stress urinary incontinence: 1-year results of the North America Clinical Study Group. *J Urol*. 2009 May;181(5):2187-91. PMID: 19296967.
205. Indrekvam S, Sandvik H, Hunskaar S. A Norwegian national cohort of 3198 women treated with home-managed electrical stimulation for urinary incontinence--effectiveness and treatment results. *Scand J Urol Nephrol*. 2001 Feb;35(1):32-9. PMID: 11291684.
206. Galloway NT, El-Galley RE, Sand PK, et al. Update on extracorporeal magnetic innervation (EXMI) therapy for stress urinary incontinence. *Urology*. 2000 Dec 4;56(6 Suppl 1):82-6. PMID: 11114568.
207. Bergstrom K, Carlsson CP, Lindholm C, et al. Improvement of urge- and mixed-type incontinence after acupuncture treatment among elderly women - a pilot study. *J Auton Nerv Syst*. 2000 Mar 15;79(2-3):173-80. PMID: 10699649.
208. Nuhoglu B, Fidan V, Ayyildiz A, et al. Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up. *Int Urogynecol J Pelvic Floor Dysfunct*. 2006 May;17(3):204-7. PMID: 16049624.
209. van Kerrebroeck P, ter Meulen F, Larsson G, et al. Treatment of stress urinary incontinence using a copolymer system: impact on quality of life. *BJU Int*. 2004 Nov;94(7):1040-3. PMID: 15541124.
210. van Kerrebroeck P, ter Meulen F, Larsson G, et al. Efficacy and safety of a novel system (NASHA/Dx copolymer using the Implacer device) for treatment of stress urinary incontinence. *Urology*. 2004 Aug;64(2):276-81. PMID: 15302478.
211. Chapple CR, Haab F, Cervigni M, et al. An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence. *Eur Urol*. 2005 Sep;48(3):488-94. PMID: 15967568.
212. Tannenbaum C, Straus SE, Thorped K, et al. Effectiveness of a new evidence-based self-management tool for incontinent older women. *Neurourology and Urodynamics*. 2010;29:1046-7.
213. Vandoninck V, van Balken MR, Finazzi Agro E, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. *NeuroUrol Urodyn*. 2003;22(3):227-32. PMID: 12707873.
214. Vandoninck V, Van Balken MR, Finazzi Agro E, et al. Posterior tibial nerve stimulation in the treatment of urge incontinence. *NeuroUrol Urodyn*. 2003;22(1):17-23. PMID: 12478596.
215. Govier FE, Litwiller S, Nitti V, et al. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. *J Urol*. 2001 Apr;165(4):1193-8. PMID: 11257669.
216. Wooldridge LS. Percutaneous tibial nerve stimulation for the treatment of urinary frequency, urinary urgency, and urge incontinence: results from a community-based clinic. *Urol Nurs*. 2009 May-Jun;29(3):177-85. PMID: 19579411.
217. Vandoninck V, van Balken MR, Finazzi Agro E, et al. Posterior tibial nerve stimulation in the treatment of voiding dysfunction: urodynamic data. *NeuroUrol Urodyn*. 2004;23(3):246-51. PMID: 15098221.
218. Surwit E, Campbell JD, Karaszewski K. Neuromodulation of the pudendal, hypogastric, and tibial nerves with pelvic floor muscle rehabilitation in the treatment of urinary urge incontinence. *Neuromodulation: Technology at the Neural Interface*. 2009 2009;12(3):175-9.
219. Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. *Br J Urol*. 1998 Jun;81(6):801-10. PMID: 9666761.

220. Abrams P, Cardozo L, Chapple C, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. *Int J Urol*. 2006 Jun;13(6):692-8. PMID: 16834644.
221. Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, et al. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. *Br J Clin Pharmacol*. 2005 May;59(5):588-92. PMID: 15842558.
222. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. *Urology*. 1997 Dec;50(6A Suppl):90-6; discussion 7-9. PMID: 9426760.
223. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. *Mayo Clin Proc*. 2001 Apr;76(4):358-63. PMID: 11322350.
224. Armstrong RB, Lubner KM, Peters KM. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. *Int Urol Nephrol*. 2005;37(2):247-52. PMID: 16142551.
225. Armstrong RB, Dmochowski RR, Sand PK, et al. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. *Int Urol Nephrol*. 2007;39(4):1069-77. PMID: 17333521.
226. Sand PK, Miklos J, Ritter H, et al. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. *Int Urogynecol J Pelvic Floor Dysfunct*. 2004 Jul-Aug;15(4):243-8. PMID: 15517668.
227. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. *Mayo Clin Proc*. 2003 Jun;78(6):687-95. PMID: 12934777.
228. Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. *Clin Ther*. 2004 Jul;26(7):1026-36. PMID: 15336467.
229. Bent AE, Gousse AE, Hendrix SL, et al. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. *Neurourol Urodyn*. 2008;27(3):212-21. PMID: 17580357.
230. Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. *BJU Int*. 2000 May;85(7):793-8. PMID: 10792154.
231. Blom MW, Sommers DK. The effects of an estradiol transdermal therapeutic system, alone and in combination with naproxen, on urge incontinence in elderly women: a pilot study. *Current Therapeutic Research*. 1995;56(10):1100-4. PMID: 10.1013/0011-393.
232. Bodeker RH, Madersbacher H, Neumeister C, et al. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of tiroprium chloride in patients with urinary urge incontinence. *BMC Urol*. 2010;10:15. PMID: 20840754.
233. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. *J Urol*. 2008 Jul;180(1):217-22. PMID: 18499184.
234. Brunton S, Wang F, Edwards SB, et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. *Drug Saf*. 2010 May 1;33(5):393-407. PMID: 20397739.
235. Bump RC, Voss S, Beardsworth A, et al. Long-term efficacy of duloxetine in women with stress urinary incontinence. *BJU Int*. 2008 Jul;102(2):214-8. PMID: 18422764.

236. Burgio KL, Locher JL, Roth DL, et al. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. *J Gerontol B Psychol Sci Soc Sci.* 2001 Jan;56(1):P46-51. PMID: 11192337.
237. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. *J Am Geriatr Soc.* 2000 Apr;48(4):370-4. PMID: 10798461.
238. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. *JAMA.* 1998 Dec 16;280(23):1995-2000. PMID: 9863850.
239. Burgio KL, Kraus SR, Menefee S, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. *Ann Intern Med.* 2008 Aug 5;149(3):161-9. PMID: 18678843.
240. Fitzgerald MP, Lemack G, Wheeler T, et al. Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 Nov;19(11):1545-50. PMID: 18704249.
241. Zimmern P, Litman HJ, Mueller E, et al. Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. *BJU Int.* 2010 Jun;105(12):1680-5. PMID: 19912207.
242. Burgio KL, Goode PS, Richter HE, et al. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. *J Urol.* 2010 Aug;184(2):598-603. PMID: 20639023.
243. But I, Pakiz M, Hlebic G, et al. Comparison of efficacy and tolerability of two selective M3 receptor antagonists Solifenacin and Darifenacin in women with overactive bladder- the Solidar study. *Neurourology and Urodynamics.* 2010;29:1217-9.
244. Cardozo L, Lange R, Voss S, et al. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence. *Curr Med Res Opin.* 2010 Feb;26(2):253-61. PMID: 19929591.
245. Cardozo L, Drutz HP, Baygani SK, et al. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. *Obstet Gynecol.* 2004 Sep;104(3):511-9. PMID: 15339761.
246. Cartwright R, Srikrishna S, Cardozo L, et al. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. *BJU Int.* 2011 Jan;107(1):70-6. PMID: 20626389.
247. Castro RA, Arruda RM, Zanetti MR, et al. Single-blind, randomized, controlled trial of pelvic floor muscle training, electrical stimulation, vaginal cones, and no active treatment in the management of stress urinary incontinence. *Clinics (Sao Paulo).* 2008 Aug;63(4):465-72. PMID: 18719756.
248. Castro-Diaz D, Palma PC, Bouchard C, et al. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Aug;18(8):919-29. PMID: 17160693.
249. Chancellor MB, Appell RA, Sathyan G, et al. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. *Clin Ther.* 2001 May;23(5):753-60. PMID: 11394733.
250. Chancellor MB, Kianifard F, Beamer E, et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. *Int J Clin Pract.* 2008 Apr;62(4):606-13. PMID: 18324952.
251. Chancellor MB, Oefelein MG, Vasavada S. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. *Neurourol Urodyn.* 2010 Apr;29(4):551-4. PMID: 19634167.
252. Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. *Eur Urol.* 2005 Jul;48(1):102-9. PMID: 15936869

253. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. *Eur Urol.* 2007 Oct;52(4):1204-12. PMID: 17651893.
254. Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. *BJU Int.* 2008 Nov;102(9):1128-32. PMID: 18647298.
255. Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients \geq 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. *Curr Med Res Opin.* 2007 Oct;23(10):2347-58. PMID: 17706004.
256. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. *BJU Int.* 2005 May;95(7):993-1001. PMID: 15839920.
257. Pharmaceutical Research and Manufacturers of America. Solifenacin in a flexible dose regimen with tolterodine as an active comparator in a double-blind, double-dummy, randomized overactive bladder symptom trial (STAR). http://www.clinicalstudyresults.org/documents/company-study_8350_0.pdf. Accessed June 25, 2010.
258. Chapple CR, Fianu-Jonsson A, Indig M, et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. *Eur Urol.* 2007 Oct;52(4):1195-203. PMID: 17574730.
259. Chapple CR, Cardozo L, Steers WD, et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. *Int J Clin Pract.* 2006 Aug;60(8):959-66. PMID: 16893438.
260. Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. *BJU Int.* 2004 Jan;93(1):71-7. PMID: 14678372.
261. Chapple C. Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study. 2004 Congress of the International Continence Society; August 25-27, 2004; Paris, France. Abstract 142. 2004.
262. Chompootaweep S, Nunthapisud P, Trivijitsilp P, et al. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. *Clin Pharmacol Ther.* 1998 Aug;64(2):204-10. PMID: 9728901.
263. Choo MS, Lee JZ, Lee JB, et al. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. *Int J Clin Pract.* 2008 Nov;62(11):1675-83. PMID: 19143854.
264. Chu F, Smith N, Uchida T. Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. *Current Therapeutic Research.* 2009 December;70(6):405-20. PMID: 10.1016/j.curtheres.2009.11.001.
265. Corcos J, Casey R, Patrick A, et al. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. *BJU Int.* 2006 Mar;97(3):520-7. PMID: 16469019.
266. Corcos J, Angulo JC, Garely AD, et al. Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. *Curr Med Res Opin.* 2011 May;27(5):1059-65. PMID: 21428726.
267. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. *J Urol.* 2001 Jul;166(1):140-5. PMID: 11435842.

268. Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. *Menopause*. 2004 Jan-Feb;11(1):49-56. PMID: 14716182.
269. Chu FM, Dmochowski RR, Lama DJ, et al. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. *Am J Obstet Gynecol*. 2005 Jun;192(6):1849-54; discussion 54-5. PMID: 15970828.
270. Anderson RU, MacDiarmid S, Kell S, et al. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct*. 2006 Sep;17(5):502-11. PMID: 16724169.
271. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. *J Urol*. 2002 Aug;168(2):580-6. PMID: 12131314.
272. Dmochowski RR, Sand PK, Zinner NR, et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. *Urology*. 2008 Mar;71(3):449-54. PMID: 18342185.
273. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. *World J Urol*. 2005 Sep;23(4):263-70. PMID: 16151816.
274. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. *Urology*. 2003 Aug;62(2):237-42. PMID: 12893326.
275. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. *J Urol*. 2003 Oct;170(4 Pt 1):1259-63. PMID: 14501737.
276. Dmochowski R, Kreder K, MacDiarmid S, et al. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. *BJU Int*. 2007 Jul;100(1):107-10. PMID: 17552957.
277. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. *J Urol*. 2010 Oct 16PMID: 20952013.
278. Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. *Eur Urol*. 2000 Jun;37(6):702-8. PMID: 10828671.
279. Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct*. 1999;10(5):283-9. PMID: 10543335.
280. DuBeau CE, Khullar V, Versi E. "Unblinding" in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. *Neurourol Urodyn*. 2005;24(1):13-20. PMID: 15570576.
281. Duckett JR, Vella M, Kavalakuntla G, et al. Tolerability and efficacy of duloxetine in a nontrial situation. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2007 May;114(5):543-7. PMID: 17355360.
282. Enzelsberger H, Helmer H, Kurz C. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. *Br J Obstet Gynaecol*. 1995 Nov;102(11):929-30. PMID: 8534633.
283. Flynn MK, Amundsen CL, Pervich M, et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. *J Urol*. 2009 Jun;181(6):2608-15. PMID: 19375091.
284. Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. *Eur Urol*. 2005 Sep;48(3):471-7. PMID: 15990219.

285. Franzen K, Johansson JE, Lauridsen I, et al. Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women--a randomized controlled trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2010 Dec;21(12):1517-24. PMID: 20585755.
286. Freeman R, Hill S, Millard R, et al. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. *Obstet Gynecol.* 2003 Sep;102(3):605-11. PMID: 12962951.
287. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. *Curr Med Res Opin.* 2007 Jan;23(1):175-84. PMID: 17257478.
288. Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. *J Urol.* 2005 Nov;174(5):1873-7; discussion 7. PMID: 16217327.
289. Ghoniem GM, Van Leeuwen JS, Elser DM, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. *J Urol.* 2005 May;173(5):1647-53. PMID: 15821528.
290. Goode PS, Burgio KL, Locher JL, et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. *J Am Geriatr Soc.* 2002 May;50(5):808-16. PMID: 12028165.
291. Goode PS. Behavioral and drug therapy for urinary incontinence. *Urology.* 2004 Mar;63(3 Suppl 1):58-64. PMID: 15013654.
292. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. *J Clin Pharmacol.* 1999 Mar;39(3):289-96. PMID: 10073329.
293. Gupta SK, Sathyan G, Lindemulder EA, et al. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. *Clin Pharmacol Ther.* 1999 Jun;65(6):672-84. PMID: 10391673.
294. Gousse A, Kanagarajah P, Ayyathurai R, et al. A single center, prospective, randomized study to evaluate the effect of repeat intradetrusor injections of botulinum toxin-A for refractory idiopathic overactive bladder patients: Dose difference between 100U and 150U. *Neurourology and Urodynamics.* 2010;29:902-3.
295. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. *BJU Int.* 2006 Nov;98(5):1025-32. PMID: 16879437.
296. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. *Eur Urol.* 2004 Apr;45(4):420-9; discussion 9. PMID: 15041104.
297. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. *Eur Urol.* 2005 Mar;47(3):376-84. PMID: 15716204.
298. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. *World J Urol.* 2003 May;20(6):392-9. PMID: 12811500.
299. Herschorn S, Becker D, Miller E, et al. Impact of a health education intervention in overactive bladder patients. *Can J Urol.* 2004 Dec;11(6):2430-7. PMID: 15636668.
300. Herschorn S, Stothers L, Carlson K, et al. Tolerability of 5 mg Solifenacin Once Daily Versus 5 mg Oxybutynin Immediate Release 3 Times Daily: Results of the VECTOR Trial. *J Urol.* 2010 Mar 17PMID: 20303119.
301. Herschorn S, Heesakkers J, Castro-Diaz D, et al. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. *Curr Med Res Opin.* 2008 Dec;24(12):3513-21. PMID: 19032133.
302. Ho CH, Chang TC, Lin HH, et al. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. *J Formos Med Assoc.* 2010 Oct;109(10):702-8. PMID: 20970066.

303. Høltedahl K, Verelst M, Schiefloe A, et al. Usefulness of urodynamic examination in female urinary incontinence--lessons from a population-based, randomized, controlled study of conservative treatment. *Scand J Urol Nephrol.* 2000 Jun;34(3):169-74. PMID: 10961470.
304. Høltedahl K, Verelst M, Schiefloe A. A population based, randomized, controlled trial of conservative treatment for urinary incontinence in women. *Acta Obstet Gynecol Scand.* 1998 Jul;77(6):671-7. PMID: 9688247.
305. Homma Y, Koyama N. Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. *Neurourol Urodyn.* 2006;25(3):228-35. PMID: 16532466.
306. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. *World J Urol.* 2004 Oct;22(4):251-6. PMID: 15455256.
307. Homma Y, Paick JS, Lee JG, et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. *BJU Int.* 2003 Nov;92(7):741-7. PMID: 14616458.
308. Hurley DJ, Turner CL, Yalcin I, et al. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. *Eur J Obstet Gynecol Reprod Biol.* 2006 Mar 1;125(1):120-8. PMID: 16188367.
309. Viktrup L, Yalcin I. Duloxetine treatment of stress urinary incontinence in women: effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus, and depression on efficacy. *Eur J Obstet Gynecol Reprod Biol.* 2007 Jul;133(1):105-13. PMID: 16769171.
310. Ishiko O, Hirai K, Sumi T, et al. Hormone replacement therapy plus pelvic floor muscle exercise for postmenopausal stress incontinence. A randomized, controlled trial. *J Reprod Med.* 2001 Mar;46(3):213-20. PMID: 11304861.
311. Jackson S, Shepherd A, Brookes S, et al. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind placebo-controlled trial. *Br J Obstet Gynaecol.* 1999 Jul;106(7):711-8. PMID: 10428529.
312. Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. *Eur J Obstet Gynecol Reprod Biol.* 2001 Sep;98(1):97-102. PMID: 11516807.
313. Johnson TM, 2nd, Burgio KL, Redden DT, et al. Effects of behavioral and drug therapy on nocturia in older incontinent women. *J Am Geriatr Soc.* 2005 May;53(5):846-50. PMID: 15877562.
314. Jonas U, Hofner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. *World J Urol.* 1997;15(2):144-51. PMID: 9144906.
315. Junemann KP, Hessdorfer E, Unamba-Oparah I, et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. *Urol Int.* 2006;77(4):334-9. PMID: 17135784.
316. Junemann KP, Al-Shukri S. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge syndrome: a double-blinded, placebo-controlled, multicentre clinical trial. *Neurourol Urodyn.* 2000;19:488-90. PMID: 85B.
317. Junemann KP, Halaska M, Rittstein T, et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. *Eur Urol.* 2005 Sep;48(3):478-82. PMID: 15967567.
318. Kaplan SA, Schneider T, Foote J, et al. Superior efficacy of fesoterodine over tolterodine with rapid onset: A prospective, head-to-head, placebo-controlled trial. *Neurourology and Urodynamics.* 2010;29:905-7.

319. Karademir K, Baykal K, Sen B, et al. A peripheral neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. *Scand J Urol Nephrol*. 2005;39(3):230-3. PMID: 16118096.
320. Karram MM, Toglia MR, Serels SR, et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. *Urology*. 2009 Jan;73(1):14-8. PMID: 18995887.
321. Toglia MR, Serels SR, Laramee C, et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. *Postgrad Med*. 2009 Sep;121(5):151-8. PMID: 19820284.
322. Kelleher C, Cardozo L, Kobashi K, et al. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2006 Jun;17(4):382-8. PMID: 16283422.
323. Kelleher CJ, Reese PR, Pleil AM, et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. *The American journal of managed care*; 2002. p. S608-15.
324. Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. *BJU Int*. 2008 Jul;102(1):56-61. PMID: 18564231.
325. Khullar V, Hill S, Laval KU, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. *Urology*. 2004 Aug;64(2):269-74; discussion 74-5. PMID: 15302476.
326. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. *Urology*. 2008 May;71(5):839-43. PMID: 18342923.
327. Kinchen KS, Obenchain R, Swindle R. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Sep-Oct;16(5):337-44. PMID: 15662490.
328. Kreder KJ, Jr., Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. *BJU Int*. 2003 Sep;92(4):418-21. PMID: 12930432.
329. Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. *J Am Geriatr Soc*. 2008 May;56(5):862-70. PMID: 18410326.
330. Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. *J Urol*. 2004 Feb;171(2 Pt 1):752-6. PMID: 14713803.
331. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. *Urology*. 2001 Mar;57(3):414-21. PMID: 11248608.
332. Lee JG, Hong JY, Choo MS, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. *Int J Urol*. 2002 May;9(5):247-52. PMID: 12060436.
333. Lee KS, Lee HW, Choo MS, et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. *BJU Int*. 2010 Jun;105(11):1565-70. PMID: 19912183.
334. Lehtoranta K, Tainio H, Lukkari-Lax E, et al. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. *Scand J Urol Nephrol*. 2002 Feb;36(1):18-24. PMID: 12002352.
335. Leung HY, Yip SK, Cheon C, et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. *BJU Int*. 2002 Sep;90(4):375-80. PMID: 12175392.
336. Lin AT, Sun MJ, Tai HL, et al. Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial. *BMC Urol*. 2008;8:2. PMID: 18221532.

337. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. *J Urol.* 2005 Feb;173(2):493-8. PMID: 15643227.
338. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. *BJOG.* 2000 Aug;107(8):1029-34. PMID: 10955437.
339. MacDiarmid SA, Anderson RU, Armstrong RB, et al. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. *J Urol.* 2005 Oct;174(4 Pt 1):1301-5; discussion 5. PMID: 16145407.
340. Preik M, Albrecht D, O'Connell M, et al. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. *BJU Int.* 2004 Oct;94(6):821-7. PMID: 15476516.
341. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. *J Urol.* 1999 Jun;161(6):1809-12. PMID: 10332441.
342. Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. *Urology.* 1999 Sep;54(3):420-3. PMID: 10475346.
343. Madersbacher H, Halaska M, Voigt R, et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. *BJU Int.* 1999 Oct;84(6):646-51. PMID: 10510109.
344. Malhotra B, Wood N, Sachse R, et al. Thorough QT study of the effect of fesoterodine on cardiac repolarization. *Int J Clin Pharmacol Ther.* 2010 May;48(5):309-18. PMID: 20420787.
345. Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. *BJU Int.* 2009 Apr;103(7):931-7. PMID: 19281469.
346. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. *J Am Geriatr Soc.* 2001 Jun;49(6):700-5. PMID: 11454106.
347. Mattiasson A, Blaakaer J, Hoyer K, et al. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. *BJU Int.* 2003 Jan;91(1):54-60. PMID: 12614251.
348. Milani R, Scalabrino S, Milia R, et al. Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. *Int Urogynecol J;* 1993. p. 3-8.
349. Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. *J Urol.* 1999 May;161(5):1551-5. PMID: 10210394.
350. Millard RJ, Moore K, Rencken R, et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. *BJU Int.* 2004 Feb;93(3):311-8. PMID: 14764128.
351. Moore KH, Hay DM, Imrie AE, et al. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. *Br J Urol.* 1990 Nov;66(5):479-85. PMID: 2249115.
352. Naglie G, Radomski SB, Brymer C, et al. A randomized, double-blind, placebo controlled crossover trial of nimodipine in older persons with detrusor instability and urge incontinence. *J Urol.* 2002 Feb;167(2 Pt 1):586-90. PMID: 11792923.
353. Nitti CVW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. *J Urol.* 2007 Dec;178(6):2488-94. PMID: 17937959.
354. Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. *Am J Obstet Gynecol.* 2002 Jul;187(1):40-8. PMID: 12114886.
355. Sahai A, Kalsi V, Khan MS, et al. Techniques for the intradetrusor administration of botulinum toxin. *BJU Int.* 2006 Apr;97(4):675-8. PMID: 16536751.

356. Ozdedeli S, Karapolat H, Akkoc Y. Comparison of intravaginal electrical stimulation and tiroprium hydrochloride in women with overactive bladder syndrome: a randomized controlled study. *Clin Rehabil*. 2010 Apr;24(4):342-51. PMID: 20212061.
357. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. *J Urol*. 2009 Sep;182(3):1055-61. PMID: 19616802.
358. MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. *J Urol*. 2010 Jan;183(1):234-40. PMID: 19913821.
359. Pontari MA, Mohamed FB, Lebovitch S, et al. Central nervous system findings on functional magnetic resonance imaging in patients before and after treatment with anticholinergic medication. *J Urol*. 2010 May;183(5):1899-905. PMID: 20303095.
360. Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. *Br J Urol*. 1998 Jan;81(1):42-8. PMID: 9467475.
361. Richter HE, Burgio KL, Brubaker L, et al. Continence pessary compared with behavioral therapy or combined therapy for stress incontinence: a randomized controlled trial. *Obstet Gynecol*. 2010 Mar;115(3):609-17. PMID: 20177294.
362. Rios LA, Panhoca R, Mattos D, Jr., et al. Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: A single dose, 4 weeks, double-blind, randomized, placebo controlled trial. *Neurourol Urodyn*. 2007;26(6):773-8. PMID: 17638305.
363. Robinson D, Cardozo L, Terpstra G, et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. *BJU Int*. 2007 Oct;100(4):840-5. PMID: 17822465.
364. Rogers RG, Bachmann G, Scarpero H, et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. *Curr Med Res Opin*. 2009 Sep;25(9):2159-65. PMID: 19601704.
365. Rogers R, Bachmann G, Jumadilova Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Nov;19(11):1551-7. PMID: 18685795.
366. Rogers RG, Omotosho T, Bachmann G, et al. Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Apr;20(4):381-5. PMID: 19132285.
367. Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying tiroprium chloride in patients with overactive bladder. *Urology*. 2006 Feb;67(2):275-80. PMID: 16461077.
368. Rufford J, Hextall A, Cardozo L, et al. A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. *Int Urogynecol J Pelvic Floor Dysfunct*. 2003 Jun;14(2):78-83. PMID: 12851747.
369. Salvatore S, Khullar V, Cardozo L, et al. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. *Eur J Obstet Gynecol Reprod Biol*. 2005 Apr 1;119(2):237-41. PMID: 15808387.
370. Sand PK, Morrow JD, Bavendam T, et al. Efficacy and tolerability of fesoterodine in women with overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Jul;20(7):827-35. PMID: 19495545.
371. Sand PK, Dmochowski RR, Zinner NR, et al. Tiroprium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Aug 29. PMID: 19727537.

372. Dmochowski RR, Rosenberg MT, Zinner NR, et al. Extended-release trospium chloride improves quality of life in overactive bladder. *Value Health*. 2010 Mar;13(2):251-7. PMID: 19818062.
373. Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. *Am J Obstet Gynecol*. 2006 Dec;195(6):1730-5. PMID: 17132474.
374. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. *BJU Int*. 2007 Apr;99(4):836-44. PMID: 17187655.
375. Sand PK, Johnson Ii TM, Rovner ES, et al. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged \geq 75 years) with overactive bladder syndrome. *BJU Int*. 2011 Feb;107(4):612-20. PMID: 20707790.
376. Scarpero H, Sand PK, Kelleher CJ, et al. Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. *Curr Med Res Opin*. 2011 May;27(5):921-30. PMID: 21355814.
377. Schagen van Leeuwen JH, Lange RR, Jonasson AF, et al. Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. *Maturitas*. 2008 Jun 20;60(2):138-47. PMID: 18547757.
378. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. *Curr Urol Rep*. 2004 Dec;5(6):423-6. PMID: 15541209.
379. Staskin DR, Cardozo L. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. *Int J Clin Pract*. 2009 Jun;63(6):973-6. PMID: 19459997.
380. Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. *BJU Int*. 2007 Aug;100(2):337-45. PMID: 17511767.
381. Swift S, Garely A, Dimpfl T, et al. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct*. 2003 Feb;14(1):50-4; discussion 4-5. PMID: 12601517.
382. Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. *Age Ageing*. 1995/07/01 ed; 1995. p. 287-91.
383. Takei M, Homma Y. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. *Int J Urol*. 2005 May;12(5):456-64. PMID: 15948744.
384. Tapp AJ, Cardozo LD, Versi E, et al. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. *Br J Obstet Gynaecol*. 1990 Jun;97(6):521-6. PMID: 2198921.
385. Tincello DG, Adams EJ, Sutherst JR, et al. Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. *BJU Int*. 2000 Mar;85(4):416-20. PMID: 10691817.
386. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. *J Urol*. 1991 Apr;145(4):813-6; discussion 6-7. PMID: 2005707.
387. Togli MR, Ostergard DR, Appell RA, et al. Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. *Int Urogynecol J Pelvic Floor Dysfunct*. 2010 Jul;21(7):847-54. PMID: 20339833.

388. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Solifenacin in the treatment of urgency symptoms of overactive bladder in a rising dose, randomized, placebo-controlled, double-blind trial (SUNRISE). www.clinicalstudyresults.org/documents/company-study_8351_0.pdf. Accessed June 25, 2010.
389. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Statistical Review for Sanctura (Trospium Chloride) Tablets. 2004. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-595_Sanctura.cfm. Accessed June 25, 2010.
390. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Statistical Review for Enablex (Darifenacin Hydrobromide) Extended Release Tablets. 2004. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex.cfm. Accessed June 25, 2010.
391. Van Kerrebroeck PE, Heesakkers J, Berriman S, et al. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. *Int J Clin Pract*. 2010 Feb 19;PMID: 20201992.
392. Vardy MD, Mitcheson HD, Samuels TA, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. *Int J Clin Pract*. 2009 Dec;63(12):1702-14. PMID: 19930331.
393. Vella M, Duckett J, Basu M. Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008 Jul;19(7):961-4. PMID: 18231697.
394. von Holst T, Salbach B. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints. *Maturitas*. 2000/03/14 ed; 2000. p. 143-53.
395. Waetjen LE, Brown JS, Vittinghoff E, et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. *Obstet Gynecol*. 2005 Nov;106(5 Pt 1):946-52. PMID: 16260511.
396. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. *Am J Geriatr Pharmacother*. 2006 Mar;4(1):14-24. PMID: 16730617.
397. Wang AC, Chen MC, Kuo WY, et al. Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Jul;20(7):819-25. PMID: 19495544.
398. Mazur D, Wehnert J, Dorschner W, et al. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study. *Scand J Urol Nephrol*. 1995 Sep;29(3):289-94. PMID: 8578271.
399. Wein AJ, Khullar V, Wang JT, et al. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. *BJU Int*. 2007 Feb;99(2):360-3. PMID: 17155987.
400. Weinstein DL, Cohen JS, Liu C, et al. Duloxetine in the treatment of women with stress urinary incontinence: results from DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations). *Curr Med Res Opin*. 2006 Nov;22(11):2121-9. PMID: 17076972.
401. Yalcin I, Patrick DL, Summers K, et al. Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence. *Urology*. 2006 Jun;67(6):1304-8. PMID: 16750246.
402. Yalcin I, Bump RC. The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. *Am J Obstet Gynecol*. 2004 Jul;191(1):194-7. PMID: 15295364.

403. Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. *BJU Int*. 2007 Sep;100(3):579-87. PMID: 17669143.
404. Zellner M, Madersbacher H, Palmtag H, et al. Trosipium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. *Clin Ther*. 2009 Nov;31(11):2519-39. PMID: 20109997.
405. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. *World J Urol*. 2005 Sep;23(4):248-52. PMID: 16096831.
406. Zinner N, Kobashi KC, Ebinger U, et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. *Int J Clin Pract*. 2008 Nov;62(11):1664-74. PMID: 18811599.
407. Zinner N, Susset J, Gittelman M, et al. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. *Int J Clin Pract*. 2006 Jan;60(1):119-26. PMID: 16409440.
408. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. *J Am Geriatr Soc*. 2002 May;50(5):799-807. PMID: 12028164.
409. Zinner N, Harnett M, Sabounjian L, et al. The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. *J Urol*. 2005 May;173(5):1639-43. PMID: 15821526.
410. Zinner NR, Dmochowski RR, Staskin DR, et al. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. *Neurourol Urodyn*. 2011 Sep;30(7):1214-9. PMID: 21462240.
411. van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. *BJOG*. 2004 Mar;111(3):249-57. PMID: 14961887.
412. Cardozo L, Castro-Diaz D, Gittelman M, et al. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. *Int Urogynecol J Pelvic Floor Dysfunct*. 2006 Sep;17(5):512-9. PMID: 16625311.
413. Wang AC, Chih SY, Chen MC. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. *Urology*. 2006 Nov;68(5):999-1004. PMID: 17113893.
414. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. *J Manag Care Pharm*. 2009 Nov-Dec;15(9):728-40. PMID: 19954264.
415. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. *Expert Opin Pharmacother*. 2008 Jul;9(10):1787-96. PMID: 18570610.
416. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. *Drugs of the Future*. 2004;29(7):715-20.
417. Kelleher C, Snedecor S, Lee R, et al. Evaluating pharmacologic treatment of overactive bladder: The economic costs and benefits of fesoterodine. *UroToday International Journal*. 2008;1(0).
418. Kelleher CJ, Kreder KJ, Pleil AM, et al. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. *Am J Manag Care*. 2002 Dec;8(19 Suppl):S616-30. PMID: 12516956.
419. Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). *Clin Ther*. 2002 Apr;24(4):616-28. PMID: 12017406.

420. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. *Eur Urol.* 2002 Jun;41(6):588-95. PMID: 12074774.
421. Wernick JE, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. *Drug Saf.* 2007;30(5):437-55. PMID: 17472422.
422. Michel MC, Methfessel D, Minarzyk A, et al. Safety and tolerability of duloxetine in the treatment of female stress urinary incontinence (SUI) in general practice in Germany: Results from a large observational study. *International Continence Society.* 2009.
423. Serati M, Salvatore S, Uccella S, et al. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? *Eur Urol.* 2009 Mar;55(3):713-9. PMID: 18584946.
424. Ghei M, Miller R, Malone-Lee J. Case series data to encourage randomized trials of bladder retraining compared to antimuscarinic agents. *J Urol.* 2006 Apr;175(4):1411-5; discussion 5-6. PMID: 16516010.
425. Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESICare Open-Label Trial (VOLT). *Clin Ther.* 2006 Nov;28(11):1935-46. PMID: 17213014.
426. Capo JP, Jr., Laramée C, Lucente V, et al. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESICare Open-Label Trial. *Int J Clin Pract.* 2008 Jan;62(1):39-46. PMID: 18036164.
427. Sand PK, Steers WD, Dmochowski R, et al. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009 Jun;20(6):667-75. PMID: 19434385.
428. Mallett V, Burks D, Garely AD, et al. Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes. *Curr Med Res Opin.* 2007 Apr;23(4):821-31. PMID: 17407639.
429. Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. *Clin Ther.* 2008 Oct;30(10):1766-81. PMID: 19014833.
430. Swift SE, Siami P, Forero-Schwanhaeuser S. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study. *Clin Drug Investig.* 2009;29(5):305-16. PMID: 19366272.
431. Zinner N, Noe L, Rasouliyan L, et al. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. *Am J Geriatr Pharmacother.* 2009 Dec;7(6):373-82. PMID: 20129258.
432. Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. *Am J Manag Care.* 2009 Mar;15(4 Suppl):S98-S107. PMID: 19355804.
433. Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. *BJU Int.* 2006 Jan;97(1):96-100. PMID: 16336336.
434. Wu EQ, Birnbaum H, Marynchenko M, et al. Employees with overactive bladder: work loss burden. *J Occup Environ Med.* 2005 May;47(5):439-46. PMID: 15891521.
435. Pelletier EM, Vats V, Clemens JQ. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. *Am J Manag Care.* 2009 Mar;15(4 Suppl):S108-14. PMID: 19355799.

436. Schabert VF, Bavendam T, Goldberg EL, et al. Challenges for managing overactive bladder and guidance for patient support. *Am J Manag Care*. 2009 Mar;15(4 Suppl):S118-22. PMID: 19355801.
437. Bolge S. Impact of successful treatment of overactive bladder on health care resource use and productivity. *Drug Benefits Trends*. 2006;18:244-55.
438. Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. *Curr Med Res Opin*. 2007 Jan;23(1):65-76. PMID: 17257467.
439. Zhou Z, Jensen G. Insurance claims costs for overactive bladder disorder. *Drug Benefits Trends*. 2001;13(4):45-8; 53-8.
440. Brubaker L, Fanning K, Goldberg EL, et al. Predictors of discontinuing overactive bladder medications. *BJU Int*. 2010 May;105(9):1283-90. PMID: 19912189.
441. Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. *BJU Int*. 2010 May;105(9):1276-82. PMID: 19912188.
442. Coyne KS, Elinoff V, Gordon DA, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. *Int J Clin Pract*. 2008 Jun;62(6):925-31. PMID: 18479285.
443. Elinoff V, Bavendam T, Glasser DB, et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. *Int J Clin Pract*. 2006 Jun;60(6):745-51. PMID: 16805763.
444. Michel MC, Oelke M, Goepel M, et al. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. *Neurourol Urodyn*. 2007;26(2):190-5. PMID: 17096320.
445. Michel MC, de la Rosette JJ, Piro M, et al. Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? *J Urol*. 2004 Aug;172(2):601-4. PMID: 15247741.
446. Michel MC, Schneider T, Kregge S, et al. Does gender or age affect the efficacy and safety of tolterodine? *J Urol*. 2002 Sep;168(3):1027-31. PMID: 12187215.
447. Roberts R, Bavendam T, Glasser DB, et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. *Int J Clin Pract*. 2006 Jun;60(6):752-8. PMID: 16805764.
448. Sussman DO, Kraus SR, Carlsson M, et al. Onset of efficacy of tolterodine extended release in patients with overactive bladder. *Curr Med Res Opin*. 2007 Apr;23(4):777-81. PMID: 17407634.
449. Lawrence M, Guay DR, Benson SR, et al. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. *Pharmacotherapy*. 2000 Apr;20(4):470-5. PMID: 10772377.
450. Shaya FT, Blume S, Gu A, et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. *Am J Manag Care*. 2005 Jul;11(4 Suppl):S121-9. PMID: 16161385.
451. Hussain RM, Hartigan-Go K, Thomas SH, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. *Br J Clin Pharmacol*. 1996 Jan;41(1):73-5. PMID: 8824696.
452. Nilsson CG, Lukkari E, Haarala M, et al. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. *Neurourol Urodyn*. 1997;16(6):533-42. PMID: 9353802.
453. Bemelmans BL, Kiemeny LA, Debruyne FM. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. *Eur Urol*. 2000 Jun;37(6):709-13. PMID: 10828672.
454. Radomski SB, Caley B, Reiz JL, et al. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence. *Curr Med Res Opin*. 2004;20(2):249-53. PMID: 15006020.
455. Wang PS, Levin R, Zhao SZ, et al. Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients. *J Am Geriatr Soc*. 2002 Jan;50(1):117-24. PMID: 12028256.

456. Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. *Int Urol Nephrol*. 2002;34(1):43-9. PMID: 12549638.
457. Pizzi LT, Talati A, Gemmen E, et al. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. *Pharmacoeconomics*. 2009;27(4):329-39. PMID: 19485428.
458. Newman DK. The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin. *Director*. 2008 Winter;16(1):22-5. PMID: 19343871.
459. Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. *Int J Clin Pract*. 2009 Apr;63(4):560-7. PMID: 19348029.
460. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. *Am J Obstet Gynecol*. 2005 May;192(5):1735-40. PMID: 15902187.
461. Balkrishnan R, Bhosle MJ, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. *J Urol*. 2006 Mar;175(3 Pt 1):1067-71; discussion 71-2. PMID: 16469620.
462. Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. *Value Health*. 2005 Jul-Aug;8(4):495-505. PMID: 16091027.
463. Perfetto EM, Subedi P, Jumadilova Z. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. *Am J Manag Care*. 2005 Jul;11(4 Suppl):S150-7. PMID: 16161388.
464. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. *Pharmacoeconomics*. 2004;22(16):1047-59. PMID: 15524493.
465. O'Brien BJ, Goeree R, Bernard L, et al. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. *Clin Ther*. 2001 Dec;23(12):2038-49. PMID: 11813937.
466. Varadharajan S, Jumadilova Z, Girase P, et al. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. *Am J Manag Care*. 2005 Jul;11(4 Suppl):S140-9. PMID: 16161387.
467. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. *Pharmacotherapy*. 2006 Dec;26(12):1694-702. PMID: 17125433.
468. Norton P, Karram M, Wall LL, et al. Randomized double-blind trial of terodiline in the treatment of urge incontinence in women. *Obstet Gynecol*. 1994 Sep;84(3):386-91. PMID: 8058236.
469. Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. *Urology*. 2010 Jan;75(1):62-8. PMID: 19931895.
470. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. *BJU Int*. 2010 Jan;105(1):58-66. PMID: 20132103.
471. Herschorn S, Heesakkers J, Castro-Diaz D, et al. Tolterodine Extended Release (TER) Improves Objective and Subjective Outcomes After 1 Week of Treatment in Patients with Overactive Bladder (OAB). *Proceedings of the 32nd Annual IUGA Meeting, Cancún, Mexico*. 2007;12-16, June 2007

472. Chapple CR. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. *Expert Opin Investig Drugs*. 2004 Nov;13(11):1493-500. PMID: 15500396.
473. Malone-Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. *BJU Int*. 2003 Sep;92(4):415-7. PMID: 12930431.
474. Cardozo L, Khullar V, Wang JT, et al. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? *BJU Int*. 2010 Feb 11; PMID: 20151972.
475. Cardozo L, Thorpe A, Warner J, et al. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. *BJU Int*. 2010 Feb 3; PMID: 20132203.
476. Aksac B, Aki S, Karan A, et al. Biofeedback and pelvic floor exercises for the rehabilitation of urinary stress incontinence. *Gynecol Obstet Invest*. 2003;56(1):23-7. PMID: 12867764.
477. Alewijnse D, Metsemakers JF, Mesters IE, et al. Effectiveness of pelvic floor muscle exercise therapy supplemented with a health education program to promote long-term adherence among women with urinary incontinence. *Neurourol Urodyn*. 2003;22(4):284-95. PMID: 12808702.
478. Amaro JL, Gameiro MO, Padovani CR. Effect of intravaginal electrical stimulation on pelvic floor muscle strength. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Sep-Oct;16(5):355-8. PMID: 15647885.
479. Amaro JL, Gameiro MO, Kawano PR, et al. Intravaginal electrical stimulation: a randomized, double-blind study on the treatment of mixed urinary incontinence. *Acta Obstet Gynecol Scand*. 2006;85(5):619-22. PMID: 16752244.
480. Andersen RC. Long-term follow-up comparison of Durasphere and Contigen in the treatment of stress urinary incontinence. *Journal of Lower Genital Tract Disease*. 2002(4):239-43. PMID: 17051030
481. Appell RA, Juma S, Wells WG, et al. Transurethral radiofrequency energy collagen micro-remodeling for the treatment of female stress urinary incontinence. *Neurourol Urodyn*. 2006;25(4):331-6. PMID: 16673379.
482. Arvonen T, Fianu-Jonasson A, Tyni-Lenne R. Effectiveness of two conservative modes of physical therapy in women with urinary stress incontinence. *Neurourol Urodyn*. 2001;20(5):591-9. PMID: 11574936.
483. Aukee P, Immonen P, Penttinen J, et al. Increase in pelvic floor muscle activity after 12 weeks' training: a randomized prospective pilot study. *Urology*. 2002 Dec;60(6):1020-3; discussion 3-4. PMID: 12475661.
484. Aukee P, Immonen P, Laaksonen DE, et al. The effect of home biofeedback training on stress incontinence. *Acta Obstet Gynecol Scand*. 2004 Oct;83(10):973-7. PMID: 15453897.
485. Bano F, Barrington JW, Dyer R. Comparison between porcine dermal implant (Permacol) and silicone injection (Macroplastique) for urodynamic stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005 Mar-Apr;16(2):147-50; discussion 50. PMID: 15378234.
486. Barroso JC, Ramos JG, Martins-Costa S, et al. Transvaginal electrical stimulation in the treatment of urinary incontinence. *BJU Int*. 2004 Feb;93(3):319-23. PMID: 14764129.
487. Berghmans LC, Frederiks CM, de Bie RA, et al. Efficacy of biofeedback, when included with pelvic floor muscle exercise treatment, for genuine stress incontinence. *Neurourol Urodyn*. 1996;15(1):37-52. PMID: 8696355.
488. Berghmans B, van Waalwijk van Doorn E, Nieman F, et al. Efficacy of physical therapeutic modalities in women with proven bladder overactivity. *Eur Urol*. 2002 Jun;41(6):581-7. PMID: 12074773.
489. Blowman C, Pickles c, Emery S, et al. Prospective double blind controlled trial of intensive physiotherapy with and without stimulation of the pelvic floor in treatment of genuine stress incontinence. *Physiotherapy*. 1991 October;77(10):661-4.

490. Bo K, Talseth T. Change in urethral pressure during voluntary pelvic floor muscle contraction and vaginal electrical stimulation. *Int Urogynecol J Pelvic Floor Dysfunct.* 1997;8(1):3-6; discussion -7. PMID: 9260089.
491. Bo K, Talseth T, Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. *BMJ.* 1999 Feb 20;318(7182):487-93. PMID: 10024253.
492. Bo K, Talseth T, Vinsnes A. Randomized controlled trial on the effect of pelvic floor muscle training on quality of life and sexual problems in genuine stress incontinent women. *Acta Obstet Gynecol Scand.* 2000 Jul;79(7):598-603. PMID: 10929962.
493. Bo K, Kvarstein B, Nygaard I. Lower urinary tract symptoms and pelvic floor muscle exercise adherence after 15 years. *Obstet Gynecol.* 2005 May;105(5 Pt 1):999-1005. PMID: 15863536.
494. Borawski KM, Foster RT, Webster GD, et al. Predicting implantation with a neuromodulator using two different test stimulation techniques: A prospective randomized study in urge incontinent women. *Neurourol Urodyn.* 2007;26(1):14-8. PMID: 17123297.
495. Borello-France DF, Zyczynski HM, Downey PA, et al. Effect of pelvic-floor muscle exercise position on continence and quality-of-life outcomes in women with stress urinary incontinence. *Phys Ther.* 2006 Jul;86(7):974-86. PMID: 16813477.
496. Borello-France DF, Downey PA, Zyczynski HM, et al. Continence and quality-of-life outcomes 6 months following an intensive pelvic-floor muscle exercise program for female stress urinary incontinence: a randomized trial comparing low- and high-frequency maintenance exercise. *Phys Ther.* 2008 Dec;88(12):1545-53. PMID: 18820095.
497. Borrie MJ, Bawden M, Speechley M, et al. Interventions led by nurse continence advisers in the management of urinary incontinence: a randomized controlled trial. *CMAJ.* 2002 May 14;166(10):1267-73. PMID: 12041843.
498. Bower WF, Moore KH, Adams RD, et al. A urodynamic study of surface neuromodulation versus sham in detrusor instability and sensory urgency. *J Urol.* 1998 Dec;160(6 Pt 1):2133-6. PMID: 9817339.
499. Boyington AR, Dougherty MC, Phetrasuwan S. Effectiveness of a computer-based system to deliver a continence health promotion intervention. *J Wound Ostomy Continence Nurs.* 2005 Jul-Aug;32(4):246-54. PMID: 16030464.
500. Brown JS, Wing R, Barrett-Connor E, et al. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. *Diabetes Care.* 2006 Feb;29(2):385-90. PMID: 16443892.
501. Brubaker L, Benson JT, Bent A, et al. Transvaginal electrical stimulation for female urinary incontinence. *Am J Obstet Gynecol.* 1997 Sep;177(3):536-40. PMID: 9322620.
502. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. *Br J Nurs.* 2002 Apr 25-May 8;11(8):560-5. PMID: 11979209.
503. Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. *JAMA.* 2002 Nov 13;288(18):2293-9. PMID: 12425706.
504. Burns PA, Pranikoff K, Nochajski T, et al. Treatment of stress incontinence with pelvic floor exercises and biofeedback. *J Am Geriatr Soc.* 1990 Mar;38(3):341-4. PMID: 2179379.
505. Burns PA, Pranikoff K, Nochajski TH, et al. A comparison of effectiveness of biofeedback and pelvic muscle exercise treatment of stress incontinence in older community-dwelling women. *J Gerontol.* 1993 Jul;48(4):M167-74. PMID: 8315230.
506. But I. Conservative treatment of female urinary incontinence with functional magnetic stimulation. *Urology.* 2003 Mar;61(3):558-61. PMID: 12639647.
507. But I, Faganelj M, Sostaric A. Functional magnetic stimulation for mixed urinary incontinence. *J Urol.* 2005 May;173(5):1644-6. PMID: 15821527.

508. de Oliveira Camargo F, Rodrigues AM, Arruda RM, et al. Pelvic floor muscle training in female stress urinary incontinence: comparison between group training and individual treatment using PERFECT assessment scheme. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009 Aug 19;PMID: 19690792.
509. Cammu H, Van Nysten M. Pelvic floor exercises versus vaginal weight cones in genuine stress incontinence. *Eur J Obstet Gynecol Reprod Biol.* 1998 Mar;77(1):89-93. PMID: 9550207.
510. Chadha Y, Mollison J, Howie F, et al. Guidelines in gynaecology: evaluation in menorrhagia and in urinary incontinence. *BJOG.* 2000 Apr;107(4):535-43. PMID: 10759275.
511. Coleman EA, Grothaus LC, Sandhu N, et al. Chronic care clinics: a randomized controlled trial of a new model of primary care for frail older adults. *J Am Geriatr Soc.* 1999 Jul;47(7):775-83. PMID: 10404919.
512. Corcos J, Collet JP, Shapiro S, et al. Multicenter randomized clinical trial comparing surgery and collagen injections for treatment of female stress urinary incontinence. *Urology.* 2005 May;65(5):898-904. PMID: 15882720.
513. Demain S, Smith JF, Hiller L, et al. Comparison of group and individual physiotherapy for female urinary incontinence in primary care. *Physiotherapy;* 2001. p. 235-42.
514. Demirturk F, Akbayrak T, Karakaya IC, et al. Interferential current versus biofeedback results in urinary stress incontinence. *Swiss Medical Weekly.* 2008 May 31;138(21-22):317-21. PMID: 18516753.
515. Diokno AC, Sampsel CM, Herzog AR, et al. Prevention of urinary incontinence by behavioral modification program: a randomized, controlled trial among older women in the community. *J Urol.* 2004 Mar;171(3):1165-71. PMID: 14767293.
516. Diokno AC, Ocampo MS, Jr., Ibrahim IA, et al. Group session teaching of behavioral modification program (BMP) for urinary incontinence: a randomized controlled trial among incontinent women. *Int Urol Nephrol.* 2010 Jun;42(2):375-81. PMID: 19701691.
517. Dougherty MC, Dwyer JW, Pendergast JF, et al. A randomized trial of behavioral management for continence with older rural women. *Res Nurs Health.* 2002 Feb;25(1):3-13. PMID: 11807915.
518. Dowd TT, Campbell JM, Jones JA. Fluid intake and urinary incontinence in older community-dwelling women. *J Community Health Nurs.* 1996;13(3):179-86. PMID: 8916607.
519. Dowd T, Kolcaba K, Steiner R. Using cognitive strategies to enhance bladder control and comfort. *Holist Nurs Pract.* 2000 Jan;14(2):91-103. PMID: 12119974.
520. Dumoulin C, Lemieux MC, Bourbonnais D, et al. Physiotherapy for persistent postnatal stress urinary incontinence: a randomized controlled trial. *Obstet Gynecol.* 2004 Sep;104(3):504-10. PMID: 15339760.
521. Elser DM, Wyman JF, McClish DK, et al. The effect of bladder training, pelvic floor muscle training, or combination training on urodynamic parameters in women with urinary incontinence. *Continence Program for Women Research Group. Neurourol Urodyn.* 1999;18(5):427-36. PMID: 10494113.
522. Emmons SL, Otto L. Acupuncture for overactive bladder: a randomized controlled trial. *Obstet Gynecol.* 2005 Jul;106(1):138-43. PMID: 15994629.
523. Engberg S, Sereika SM, McDowell BJ, et al. Effectiveness of prompted voiding in treating urinary incontinence in cognitively impaired homebound older adults. *J Wound Ostomy Continence Nurs.* 2002 Sep;29(5):252-65. PMID: 12510471.
524. Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. *JAMA.* 1991 Feb 6;265(5):609-13. PMID: 1987410.
525. Felicissimo MF, Carneiro MM, Saleme CS, et al. Intensive supervised versus unsupervised pelvic floor muscle training for the treatment of stress urinary incontinence: a randomized comparative trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2010 Jul;21(7):835-40. PMID: 20179901.

526. Finazzi Agro E, Campagna A, Sciobica F, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? *Minerva Urol Nefrol.* 2005 Jun;57(2):119-23. PMID: 15951736.
527. Finazzi-Agro E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *J Urol.* 2010 Nov;184(5):2001-6. PMID: 20850833.
528. Fujishiro T, Enomoto H, Ugawa Y, et al. Magnetic stimulation of the sacral roots for the treatment of stress incontinence: an investigational study and placebo controlled trial. *J Urol.* 2000 Oct;164(4):1277-9. PMID: 10992380.
529. Fujishiro T, Takahashi S, Enomoto H, et al. Magnetic stimulation of the sacral roots for the treatment of urinary frequency and urge incontinence: an investigational study and placebo controlled trial. *J Urol.* 2002 Sep;168(3):1036-9. PMID: 12187217.
530. Gallo ML, Staskin DR. Cues to action: pelvic floor muscle exercise compliance in women with stress urinary incontinence. *Neurourol Urodyn.* 1997;16(3):167-77. PMID: 9136139.
531. Gameiro MO, Moreira EH, Gameiro FO, et al. Vaginal weight cone versus assisted pelvic floor muscle training in the treatment of female urinary incontinence. A prospective, single-blind, randomized trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2010 Apr;21(4):395-9. PMID: 20052573.
532. Ghoniem G, Corcos J, Comiter C, et al. Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. *J Urol.* 2009 Jan;181(1):204-10. PMID: 19013613.
533. Gilling PJ, Wilson LC, Westenberg AM, et al. A double-blind randomized controlled trial of electromagnetic stimulation of the pelvic floor vs sham therapy in the treatment of women with stress urinary incontinence. *BJU Int.* 2009 May;103(10):1386-90. PMID: 19154474.
534. Glavind K, Nohr SB, Walter S. Biofeedback and physiotherapy versus physiotherapy alone in the treatment of genuine stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 1996;7(6):339-43. PMID: 9203484.
535. Glavind K. Use of a vaginal sponge during aerobic exercises in patients with stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 1997;8(6):351-3. PMID: 9609334.
536. Goode PS, Burgio KL, Locher JL, et al. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. *JAMA.* 2003 Jul 16;290(3):345-52. PMID: 12865375.
537. Gorman R. Expert system for management of urinary incontinence in women. *Proc Annu Symp Comput Appl Med Care.* 1995:527-31. PMID: 8563340.
538. Hahn I, Sommar S, Fall M. A comparative study of pelvic floor training and electrical stimulation for the treatment of genuine female stress urinary incontinence. *Neurourology and Urodynamics.* 1991;10(6):545-54.
539. Harvey CA. A Randomised, Single-Blind Comparison of Pelvic Floor Muscle Exercises With Biofeedback Versus Weighted Vaginal Cones in the Management of Genuine Stress Incontinence: A Pilot Study. 2002.
540. Hu TW, Igou JF, Kaltreider DL, et al. A clinical trial of a behavioral therapy to reduce urinary incontinence in nursing homes. Outcome and implications. *JAMA.* 1989 May 12;261(18):2656-62. PMID: 2496240.
541. Huang AJ, Stewart AL, Hernandez AL, et al. Sexual function among overweight and obese women with urinary incontinence in a randomized controlled trial of an intensive behavioral weight loss intervention. *J Urol.* 2009 May;181(5):2235-42. PMID: 19296980.
542. Hui E, Lee PS, Woo J. Management of urinary incontinence in older women using videoconferencing versus conventional management: a randomized controlled trial. *J Telemed Telecare.* 2006;12(7):343-7. PMID: 17059650.

543. Hung HC, Hsiao SM, Chih SY, et al. An alternative intervention for urinary incontinence: retraining diaphragmatic, deep abdominal and pelvic floor muscle coordinated function. *Man Ther.* 2010 Jun;15(3):273-9. PMID: 20185357.
544. Janssen CC, Lagro-Janssen AL, Felling AJ. The effects of physiotherapy for female urinary incontinence: individual compared with group treatment. *BJU Int.* 2001 Feb;87(3):201-6. PMID: 11167642.
545. Jeyaseelan SM, Haslam EJ, Winstanley J, et al. An evaluation of a new pattern of electrical stimulation as a treatment for urinary stress incontinence: a randomized, double-blind, controlled trial. *Clin Rehabil.* 2000 Dec;14(6):631-40. PMID: 11128739.
546. Kim H, Yoshida H, Suzuki T. Exercises treatment to reduce the urine leakage in elderly community-dwelling Japanese women with stress, urge, and mixed urinary incontinence. 39th Annual Meeting of the International Continence Society (ICS 2009), Moscone West, San Francisco, 29 Sep - 3 Oct 2009. 2009.
547. Kim JI. Continence efficacy intervention program for community residing women with stress urinary incontinence in Japan. *Public Health Nurs.* 2001 Jan-Feb;18(1):64-72. PMID: 11251875.
548. Kim H, Suzuki T, Yoshida Y, et al. Effectiveness of multidimensional exercises for the treatment of stress urinary incontinence in elderly community-dwelling Japanese women: a randomized, controlled, crossover trial. *J Am Geriatr Soc.* 2007 Dec;55(12):1932-9. PMID: 17944890.
549. Kim JH, Nam D, Park MK, et al. Randomized control trial of hand acupuncture for female stress urinary incontinence. *Acupunct Electrother Res.* 2008;33(3-4):179-92. PMID: 19301628.
550. Kincade JE, Dougherty MC, Carlson JR, et al. Randomized clinical trial of efficacy of self-monitoring techniques to treat urinary incontinence in women. *Neurourol Urodyn.* 2007;26(4):507-11. PMID: 17366526.
551. Konstantinidou E, Apostolidis A, Kondelidis N, et al. Short-term efficacy of group pelvic floor training under intensive supervision versus unsupervised home training for female stress urinary incontinence: a randomized pilot study. *Neurourol Urodyn.* 2007;26(4):486-91. PMID: 17245777.
552. Kumari S, Jain V, Mandal AK, et al. Behavioral therapy for urinary incontinence in India. *Int J Gynaecol Obstet.* 2008 Nov;103(2):125-30. PMID: 18755458.
553. Lagro-Janssen AL, Debruyne FM, Smits AJ, et al. The effects of treatment of urinary incontinence in general practice. *Fam Pract.* 1992 Sep;9(3):284-9. PMID: 1459383.
554. Lagro-Janssen TL, Debruyne FM, Smits AJ, et al. Controlled trial of pelvic floor exercises in the treatment of urinary stress incontinence in general practice. *Br J Gen Pract.* 1991 Nov;41(352):445-9. PMID: 1807303.
555. Lamb SE, Pepper J, Lall R, et al. Group treatments for sensitive health care problems: a randomised controlled trial of group versus individual physiotherapy sessions for female urinary incontinence. *BMC Womens Health.* 2009;9:26. PMID: 19751517.
556. Lappin MS, Lawrie FW, Richards TL, et al. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial. *Altern Ther Health Med.* 2003 Jul-Aug;9(4):38-48. PMID: 12868251.
557. Laycock J, Brown J, Cusack C, et al. Pelvic floor reeducation for stress incontinence: comparing three methods. *Br J Community Nurs.* 2001 May;6(5):230-7. PMID: 11893948.
558. Lee PE, Kung RC, Drutz HP. Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial. *J Urol.* 2001 Jan;165(1):153-8. PMID: 11125386.
559. Liebergall-Wischnitzer M, Hochner-Celnikier D, Lavy Y, et al. Randomized trial of circular muscle versus pelvic floor training for stress urinary incontinence in women. *J Womens Health (Larchmt).* 2009 Mar;18(3):377-85. PMID: 19281321.

560. Liebergall-Wischnitzer M, Hochner-Celnikier D, Lavy Y, et al. Paula method of circular muscle exercises for urinary stress incontinence--a clinical trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005 Sep-Oct;16(5):345-51. PMID: 15660184.
561. Lightner D, Calvosa C, Andersen R, et al. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. *Urology.* 2001 Jul;58(1):12-5. PMID: 11445471.
562. Lightner D, Rovner E, Corcos J, et al. Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. *Urology.* 2009 Oct;74(4):771-5. PMID: 19660800.
563. Luber KM, Wolde-Tsadik G. Efficacy of functional electrical stimulation in treating genuine stress incontinence: a randomized clinical trial. *Neurourol Urodyn.* 1997;16(6):543-51. PMID: 9353803.
564. Majumdar A, Latthe P, Toozs-Hobson P. Urodynamics prior to treatment as an intervention: a pilot study. *Neurourol Urodyn.* 2010 Apr;29(4):522-6. PMID: 19731310.
565. Manganotti P, Zaina F, Vedovi E, et al. Repetitive magnetic stimulation of the sacral roots for the treatment of stress incontinence: a brief report. *Eura Medicophys.* 2007 Sep;43(3):339-44. PMID: 17259914.
566. Manonai J, Songchitsomboon S, Chanda K, et al. The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial. *Maturitas.* 2006 May 20;54(2):135-40. PMID: 16297576.
567. Mayer RD, Dmochowski RR, Appell RA, et al. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. *Urology.* 2007 May;69(5):876-80. PMID: 17482925.
568. McDowell D, Ashe RG, Marshall K, et al. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. *Neurourol Urodyn.* 2006;25(4):337-48. PMID: 16637070.
569. McDowell BJ, Engberg S, Sereika S, et al. Effectiveness of behavioral therapy to treat incontinence in homebound older adults. *J Am Geriatr Soc.* 1999 Mar;47(3):309-18. PMID: 10078893.
570. McFall SL, Yerkes AM, Cowan LD. Outcomes of a small group educational intervention for urinary incontinence: health-related quality of life. *J Aging Health.* 2000 Aug;12(3):301-17. PMID: 11067699.
571. McFall SL, Yerkes AM, Cowan LD. Outcomes of a small group educational intervention for urinary incontinence: episodes of incontinence and other urinary symptoms. *J Aging Health.* 2000 May;12(2):250-67. PMID: 11010699.
572. Miller JM, Ashton-Miller JA, DeLancey JO. A pelvic muscle precontraction can reduce cough-related urine loss in selected women with mild SUI. *J Am Geriatr Soc.* 1998 Jul;46(7):870-4. PMID: 9670874.
573. Moore KH, O'Sullivan RJ, Simons A, et al. Randomised controlled trial of nurse continence advisor therapy compared with standard urogynaecology regimen for conservative incontinence treatment: efficacy, costs and two year follow up. *BJOG.* 2003 Jul;110(7):649-57. PMID: 12842055.
574. Morkved S, Bo K, Fjortoft T. Effect of adding biofeedback to pelvic floor muscle training to treat urodynamic stress incontinence. *Obstet Gynecol.* 2002 Oct;100(4):730-9. PMID: 12383542.
575. Du Moulin MF, Hamers JP, Paulus A, et al. Effects of introducing a specialized nurse in the care of community-dwelling women suffering from urinary incontinence: a randomized controlled trial. *J Wound Ostomy Continence Nurs.* 2007 Nov-Dec;34(6):631-40. PMID: 18030102.

576. Nager CW, Richter HE, Nygaard I, et al. Incontinence pessaries: size, POPQ measures, and successful fitting. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009 Sep;20(9):1023-8. PMID: 19533009.
577. Ng SC, Lin TL, Chang SJ, et al. Nursing intervention to enhance efficacy of home practice of pelvic floor muscle exercises in treating mixed urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008 May;19(5):637-42. PMID: 18004495.
578. Nielsen KK, Walter S, Maegaard E, et al. The urethral plug II: an alternative treatment in women with genuine urinary stress incontinence. *Br J Urol.* 1993 Oct;72(4):428-32. PMID: 8261298.
579. Nygaard I. Prevention of exercise incontinence with mechanical devices. *J Reprod Med.* 1995 Feb;40(2):89-94. PMID: 7738934.
580. Nygaard IE, Kreder KJ, Lopic MM, et al. Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence. *Am J Obstet Gynecol.* 1996 Jan;174(1 Pt 1):120-5. PMID: 8571994.
581. O'Brien J, Austin M, Sethi P, et al. Urinary incontinence: prevalence, need for treatment, and effectiveness of intervention by nurse. *BMJ.* 1991 Nov 23;303(6813):1308-12. PMID: 1747675.
582. O'Brien J. Evaluating primary care interventions for incontinence. *Nurs Stand.* 1996 Feb 28;10(23):40-3. PMID: 8695463.
583. Oldham J, McBride K, Herbert J. Evaluation of a new electrostim technology for the treatment of urinary incontinence in women: a randomised controlled trial. *Neurourology and Urodynamics.* 2010;29:1067.
584. O'Sullivan R, Simons A, Prashar S, et al. Is objective cure of mild undifferentiated incontinence more readily achieved than that of moderate incontinence? Costs and 2-year outcome. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Aug;14(3):193-8; discussion 8. PMID: 12955342.
585. Pages IH, Jahr S, Schaufele MK, et al. Comparative analysis of biofeedback and physical therapy for treatment of urinary stress incontinence in women. *Am J Phys Med Rehabil.* 2001 Jul;80(7):494-502. PMID: 11421517.
586. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUMiT trial. *J Urol.* 2010 Apr;183(4):1438-43. PMID: 20171677.
587. Peters K, Carrico DJ, Perez-Marrero RA, et al. 12 week results from the Sumit trial: Percutaneous tibial nerve stimulation vs validated sham in those exposed to pharmacologic therapy. *Neurourology and Urodynamics.* 2010;29:988-9.
588. Ramsay IN, Ali HM, Hunter M, et al. A prospective, randomized controlled trial of inpatient versus outpatient continence programs in the treatment of urinary incontinence in the female. *Int Urogynecol J Pelvic Floor Dysfunct.* 1996;7(5):260-3. PMID: 9127183.
589. Robinson H, Schulz J, Flood C, et al. A randomized controlled trial of the NEAT expandable tip continence device. *Int Urogynecol J Pelvic Floor Dysfunct.* 2003 Aug;14(3):199-203; discussion PMID: 12955343.
590. Sand PK, Richardson DA, Staskin DR, et al. Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: a multicenter, placebo-controlled trial. *Am J Obstet Gynecol.* 1995 Jul;173(1):72-9. PMID: 7631730.
591. Schreiner L, dos Santos TG, Knorst MR, et al. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. *Int Urogynecol J Pelvic Floor Dysfunct.* 2010 Sep;21(9):1065-70. PMID: 20458465.
592. Schulz JA, Nager CW, Stanton SL, et al. Bulking agents for stress urinary incontinence: short-term results and complications in a randomized comparison of periurethral and transurethral injections. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 Jul-Aug;15(4):261-5. PMID: 15517671.
593. Seo JT, Yoon H, Kim YH. A randomized prospective study comparing new vaginal cone and FES-Biofeedback. *Yonsei Med J.* 2004 Oct 31;45(5):879-84. PMID: 15515199.

594. Sherman RA, Davis GD, Wong MF. Behavioral treatment of exercise-induced urinary incontinence among female soldiers. *Mil Med.* 1997 Oct;162(10):690-4. PMID: 9339085.
595. Smith JJ, 3rd. Intravaginal stimulation randomized trial. *J Urol.* 1996 Jan;155(1):127-30. PMID: 7490809.
596. Spruijt J, Vierhout M, Verstraeten R, et al. Vaginal electrical stimulation of the pelvic floor: a randomized feasibility study in urinary incontinent elderly women. *Acta Obstet Gynecol Scand.* 2003 Nov;82(11):1043-8. PMID: 14616279.
597. Strasser H, Marksteiner R, Margreiter E, et al. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. *Lancet.* 2007 Jun 30;369(9580):2179-86. PMID: 17604800.
598. Subak LL, Quesenberry CP, Posner SF, et al. The effect of behavioral therapy on urinary incontinence: a randomized controlled trial. *Obstet Gynecol.* 2002 Jul;100(1):72-8. PMID: 12100806.
599. Subak LL, Whitcomb E, Shen H, et al. Weight loss: a novel and effective treatment for urinary incontinence. *J Urol.* 2005 Jul;174(1):190-5. PMID: 15947625.
600. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. *N Engl J Med.* 2009 Jan 29;360(5):481-90. PMID: 19179316.
601. Sung MS, Choi YH, Back SH, et al. The effect of pelvic floor muscle exercises on genuine stress incontinence among Korean women--focusing on its effects on the quality of life. *Yonsei Med J.* 2000 Apr;41(2):237-51. PMID: 10817026.
602. Sung MS, Hong JY, Choi YH, et al. FES-biofeedback versus intensive pelvic floor muscle exercise for the prevention and treatment of genuine stress incontinence. *J Korean Med Sci.* 2000 Jun;15(3):303-8. PMID: 10895973.
603. Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. *J Urol.* 2005 Jul;174(1):187-9. PMID: 15947624.
604. Tibaek S, Gard G, Jensen R. Is there a long-lasting effect of pelvic floor muscle training in women with urinary incontinence after ischemic stroke? A 6-month follow-up study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007 Mar;18(3):281-7. PMID: 16673051.
605. Theofrastous JP, Wyman JF, Bump RC, et al. Effects of pelvic floor muscle training on strength and predictors of response in the treatment of urinary incontinence. *Neurourol Urodyn.* 2002;21(5):486-90. PMID: 12232886.
606. Thornburn P, Fader M, Dean G, et al. Improving the performance of small incontinence pads: a study of "wet comfort". *J Wound Ostomy Continence Nurs.* 1997 Jul;24(4):219-25. PMID: 9274279.
607. Thyssen H, Bidmead J, Lose G, et al. A new intravaginal device for stress incontinence in women. *BJU Int.* 2001 Dec;88(9):889-92. PMID: 11851609.
608. Tibaek S, Jensen R, Lindskov G, et al. Can quality of life be improved by pelvic floor muscle training in women with urinary incontinence after ischemic stroke? A randomised, controlled and blinded study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004 Mar-Apr;15(2):117-23; discussion 23. PMID: 15014939.
609. Tibaek S, Gard G, Jensen R. Pelvic floor muscle training is effective in women with urinary incontinence after stroke: a randomised, controlled and blinded study. *Neurourol Urodyn.* 2005;24(4):348-57. PMID: 15791633.
610. Tsai YC, Liu CH. The effectiveness of pelvic floor exercises, digital vaginal palpation and interpersonal support on stress urinary incontinence: an experimental study. *Int J Nurs Stud.* 2009 Sep;46(9):1181-6. PMID: 19361800.
611. Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. *Urology.* 2004 Jan;63(1):61-6. PMID: 14751349.

612. Wells TJ, Brink CA, Diokno AC, et al. Pelvic muscle exercise for stress urinary incontinence in elderly women. *J Am Geriatr Soc.* 1991 Aug;39(8):785-91. PMID: 2071809.
613. Williams KS, Assassa RP, Cooper NJ, et al. Clinical and cost-effectiveness of a new nurse-led continence service: a randomised controlled trial. *Br J Gen Pract.* 2005 Sep;55(518):696-703. PMID: 16176737.
614. Williams KS, Assassa RP, Gillies CL, et al. A randomized controlled trial of the effectiveness of pelvic floor therapies for urodynamic stress and mixed incontinence. *BJU Int.* 2006 Nov;98(5):1043-50. PMID: 17034605.
615. Wing RR, West DS, Grady D, et al. Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months. *J Urol.* 2010 Sep;184(3):1005-10. PMID: 20643425.
616. Wong KS, Fung KY, Fung SM, et al. Biofeedback of pelvic floor muscles in the management of genuine stress incontinence in Chinese women. *Physiotherapy*; 2001. p. 644-8.
617. Wyman JF, Fantl JA, McClish DK, et al. Quality of life following bladder training in older women with urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 1997;8(4):223-9. PMID: 9449301.
618. Wyman JF, Fantl JA, McClish DK, et al. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. *Am J Obstet Gynecol.* 1998 Oct;179(4):999-1007. PMID: 9790388.
619. Yamanishi T, Yasuda K, Sakakibara R, et al. Pelvic floor electrical stimulation in the treatment of stress incontinence: an investigational study and a placebo controlled double-blind trial. *The Journal of urology*; 1997. p. 2127-31.
620. Yamanishi T, Yasuda K, Sakakibara R, et al. Randomized, double-blind study of electrical stimulation for urinary incontinence due to detrusor overactivity. *Urology.* 2000 Mar;55(3):353-7. PMID: 10699609.
621. Yoon HS, Song HH, Ro YJ. A comparison of effectiveness of bladder training and pelvic muscle exercise on female urinary incontinence. *Int J Nurs Stud.* 2003 Jan;40(1):45-50. PMID: 12550149.
622. Zanetti MR, Castro Rde A, Rotta AL, et al. Impact of supervised physiotherapeutic pelvic floor exercises for treating female stress urinary incontinence. *Sao Paulo Med J.* 2007 Sep 6;125(5):265-9. PMID: 18094892.
623. Clarke-O'Neill S, Pettersson L, Fader M, et al. A multicentre comparative evaluation: washable pants with an integral pad for light incontinence. *J Clin Nurs.* 2002 Jan;11(1):79-89. PMID: 11845759.
624. Tomlinson BU, Dougherty MC, Pendergast JF, et al. Dietary caffeine, fluid intake and urinary incontinence in older rural women. *Int Urogynecol J Pelvic Floor Dysfunct.* 1999;10(1):22-8. PMID: 10207763.
625. Hahn I, Naucler J, Sommar S, et al. Urodynamic assessment of pelvic floor training. *World Journal of Urology.* 1991;9(3):162-6.
626. Laycock J, Jerwood D. Does pre-modulated interferential therapy cure genuine stress incontinence? *Physiotherapy.* 1993 10 August;79(8):553-60.
627. Borello-France D, Burgio KL, Goode PS, et al. Adherence to Behavioral Interventions for Urge Incontinence When Combined With Drug Therapy: Adherence Rates, Barriers, and Predictors. *Phys Ther.* 2010 Jul 29; PMID: 20671098.
628. Griffiths F, Pepper J, Jorstad-Stein EC, et al. Group versus individual sessions delivered by a physiotherapist for female urinary incontinence: an interview study with women attending group sessions nested within a randomised controlled trial. *BMC Womens Health.* 2009;9:25. PMID: 19744315.
629. Engberg S, Cohen S, Sereika SM. The efficacy of acupuncture in treating urge and mixed incontinence in women: a pilot study. *J Wound Ostomy Continence Nurs.* 2009 Nov-Dec;36(6):661-70. PMID: 19920749.

630. MacDiarmid S, Peters KM, Wooldridge L. 12 month percutaneous tibial nerve stimulation treatment interval results: Outcomes from the Orbit trial. *Neurourology and Urodynamics*. 2010;29:1179-80.
631. Dunn M, Brandt D, Nygaard I. Treatment of exercise incontinence with a urethral insert: a pilot study in women. *Phys Sportsmed*. 2002 Jan;30(1):45-8. PMID: 20086499.
632. Yang SC, Park DS, Lee JM, et al. Laparoscopic extraperitoneal bladder neck suspension (LEBNS) for stress urinary incontinence. *J Korean Med Sci*. 1995 Dec;10(6):426-30. PMID: 8924227.